[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "The efficacy of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay was assessed by analyzing nasal swabs and swabs from other body sites for the presence of MRSA in a low-prevalence area. From 681 patients with a high risk for MRSA carriage, 1,601 specimens were collected and transported in Amies agar. After discordant analysis, the sensitivity, specificity, positive predictive value, and negative predictive value of the BD GeneOhm MRSA assay were 84.3%, 99.2%, 88.4%, and 98.9%, respectively, compared to culture.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "746d6125a1ae4b47b8868da9703ff04b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[81, 81], [47, 47], [12, 12], [31, 31]], "char_spans": [[457, 460], [248, 251], [76, 79], [178, 181]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["the", 16], ["BD", 20], ["GeneOhm", 23], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["assay", 82], ["was", 88], ["assessed", 92], ["by", 101], ["analyzing", 104], ["nasal", 114], ["swabs", 120], ["and", 126], ["swabs", 130], ["from", 136], ["other", 141], ["body", 147], ["sites", 152], ["for", 158], ["the", 162], ["presence", 166], ["of", 175], ["MRSA", 178], ["in", 183], ["a", 186], ["low", 188], ["-", 191], ["prevalence", 192], ["area", 203], [".", 207], ["From", 209], ["681", 214], ["patients", 218], ["with", 227], ["a", 232], ["high", 234], ["risk", 239], ["for", 244], ["MRSA", 248], ["carriage", 253], [",", 261], ["1,601", 263], ["specimens", 269], ["were", 279], ["collected", 284], ["and", 294], ["transported", 298], ["in", 310], ["Amies", 313], ["agar", 319], [".", 323], ["After", 325], ["discordant", 331], ["analysis", 342], [",", 350], ["the", 352], ["sensitivity", 356], [",", 367], ["specificity", 369], [",", 380], ["positive", 382], ["predictive", 391], ["value", 402], [",", 407], ["and", 409], ["negative", 413], ["predictive", 422], ["value", 433], ["of", 439], ["the", 442], ["BD", 446], ["GeneOhm", 449], ["MRSA", 457], ["assay", 462], ["were", 468], ["84.3", 473], ["%", 477], [",", 478], ["99.2", 480], ["%", 484], [",", 485], ["88.4", 487], ["%", 491], [",", 492], ["and", 494], ["98.9", 498], ["%", 502], [",", 503], ["respectively", 505], [",", 517], ["compared", 519], ["to", 528], ["culture", 531], [".", 538]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway. ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects. We compared the distribution of ZFHX1B transcripts during mouse and human embryogenesis as well as in adult mice and humans. This showed that this gene is strongly transcribed at an early stage in the developing peripheral and central nervous systems of both mice and humans, in all neuronal regions of the brains of 25-week human fetuses and adult mice, and at varying levels in numerous nonneural tissues. Northern blot analysis suggested that ZFHX1B undergoes tissue-specific alternative splicing in both species. These results strongly suggest that ZFHX1B determines the transcriptional levels of target genes in various tissues through the combinatorial interactions of its isoforms with different Smad proteins. Thus, as well as causing neural defects, ZFHX1B mutations may also cause other malformations.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "8870a7ba64174735af9856e72fd82aaa", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[0, 0], [24, 24], [120, 120], [136, 136], [168, 168], [49, 49]], "char_spans": [[0, 5], [151, 156], [735, 740], [842, 847], [1048, 1053], [321, 326]]}]}], "context_tokens": [["ZFHX1B", 0], ["encodes", 7], ["Smad", 15], ["-", 19], ["interacting", 20], ["protein", 32], ["1", 40], [",", 41], ["a", 43], ["transcriptional", 45], ["corepressor", 61], ["involved", 73], ["in", 82], ["the", 85], ["transforming", 89], ["growth", 102], ["factors", 109], ["beta", 117], ["(", 122], ["TGFbeta", 123], [")", 130], ["signaling", 132], ["pathway", 142], [".", 149], ["ZFHX1B", 151], ["mutations", 158], ["cause", 168], ["a", 174], ["complex", 176], ["developmental", 184], ["phenotype", 198], ["characterized", 208], ["by", 222], ["severe", 225], ["mental", 232], ["retardation", 239], ["(", 251], ["MR", 252], [")", 254], ["and", 256], ["multiple", 260], ["congenital", 269], ["defects", 280], [".", 287], ["We", 289], ["compared", 292], ["the", 301], ["distribution", 305], ["of", 318], ["ZFHX1B", 321], ["transcripts", 328], ["during", 340], ["mouse", 347], ["and", 353], ["human", 357], ["embryogenesis", 363], ["as", 377], ["well", 380], ["as", 385], ["in", 388], ["adult", 391], ["mice", 397], ["and", 402], ["humans", 406], [".", 412], ["This", 414], ["showed", 419], ["that", 426], ["this", 431], ["gene", 436], ["is", 441], ["strongly", 444], ["transcribed", 453], ["at", 465], ["an", 468], ["early", 471], ["stage", 477], ["in", 483], ["the", 486], ["developing", 490], ["peripheral", 501], ["and", 512], ["central", 516], ["nervous", 524], ["systems", 532], ["of", 540], ["both", 543], ["mice", 548], ["and", 553], ["humans", 557], [",", 563], ["in", 565], ["all", 568], ["neuronal", 572], ["regions", 581], ["of", 589], ["the", 592], ["brains", 596], ["of", 603], ["25-week", 606], ["human", 614], ["fetuses", 620], ["and", 628], ["adult", 632], ["mice", 638], [",", 642], ["and", 644], ["at", 648], ["varying", 651], ["levels", 659], ["in", 666], ["numerous", 669], ["nonneural", 678], ["tissues", 688], [".", 695], ["Northern", 697], ["blot", 706], ["analysis", 711], ["suggested", 720], ["that", 730], ["ZFHX1B", 735], ["undergoes", 742], ["tissue", 752], ["-", 758], ["specific", 759], ["alternative", 768], ["splicing", 780], ["in", 789], ["both", 792], ["species", 797], [".", 804], ["These", 806], ["results", 812], ["strongly", 820], ["suggest", 829], ["that", 837], ["ZFHX1B", 842], ["determines", 849], ["the", 860], ["transcriptional", 864], ["levels", 880], ["of", 887], ["target", 890], ["genes", 897], ["in", 903], ["various", 906], ["tissues", 914], ["through", 922], ["the", 930], ["combinatorial", 934], ["interactions", 948], ["of", 961], ["its", 964], ["isoforms", 968], ["with", 977], ["different", 982], ["Smad", 992], ["proteins", 997], [".", 1005], ["Thus", 1007], [",", 1011], ["as", 1013], ["well", 1016], ["as", 1021], ["causing", 1024], ["neural", 1032], ["defects", 1039], [",", 1046], ["ZFHX1B", 1048], ["mutations", 1055], ["may", 1065], ["also", 1069], ["cause", 1074], ["other", 1080], ["malformations", 1086], [".", 1099]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "While Clostridium difficile epidemiology is well documented in many European countries, data are largely missing for South Eastern European region. Here we report the PCR ribotype distribution of 249 C.\u00a0difficile isolates received for typing from six hospital settings from Croatia, Bosnia and Herzegovina, Republic of Macedonia and Serbia in time period from 2008 to 2015. Twenty-four PCR ribotypes were detected. The majority of strains from Bosnia and Herzegovina and Serbia belonged to PCR ribotype 027 (65.8%). Other three dominating PCR ribotypes were 176 (18 strains; Croatia), 001/072 (15 strains; all countries) and 014/020 (15 strains; all countries).", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "7bfea0506db945dca07567f46a77be7c", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[82, 83]], "char_spans": [[494, 505]]}]}], "context_tokens": [["While", 0], ["Clostridium", 6], ["difficile", 18], ["epidemiology", 28], ["is", 41], ["well", 44], ["documented", 49], ["in", 60], ["many", 63], ["European", 68], ["countries", 77], [",", 86], ["data", 88], ["are", 93], ["largely", 97], ["missing", 105], ["for", 113], ["South", 117], ["Eastern", 123], ["European", 131], ["region", 140], [".", 146], ["Here", 148], ["we", 153], ["report", 156], ["the", 163], ["PCR", 167], ["ribotype", 171], ["distribution", 180], ["of", 193], ["249", 196], ["C.", 200], ["difficile", 203], ["isolates", 213], ["received", 222], ["for", 231], ["typing", 235], ["from", 242], ["six", 247], ["hospital", 251], ["settings", 260], ["from", 269], ["Croatia", 274], [",", 281], ["Bosnia", 283], ["and", 290], ["Herzegovina", 294], [",", 305], ["Republic", 307], ["of", 316], ["Macedonia", 319], ["and", 329], ["Serbia", 333], ["in", 340], ["time", 343], ["period", 348], ["from", 355], ["2008", 360], ["to", 365], ["2015", 368], [".", 372], ["Twenty", 374], ["-", 380], ["four", 381], ["PCR", 386], ["ribotypes", 390], ["were", 400], ["detected", 405], [".", 413], ["The", 415], ["majority", 419], ["of", 428], ["strains", 431], ["from", 439], ["Bosnia", 444], ["and", 451], ["Herzegovina", 455], ["and", 467], ["Serbia", 471], ["belonged", 478], ["to", 487], ["PCR", 490], ["ribotype", 494], ["027", 503], ["(", 507], ["65.8", 508], ["%", 512], [")", 513], [".", 514], ["Other", 516], ["three", 522], ["dominating", 528], ["PCR", 539], ["ribotypes", 543], ["were", 553], ["176", 558], ["(", 562], ["18", 563], ["strains", 566], [";", 573], ["Croatia", 575], [")", 582], [",", 583], ["001/072", 585], ["(", 593], ["15", 594], ["strains", 597], [";", 604], ["all", 606], ["countries", 610], [")", 619], ["and", 621], ["014/020", 625], ["(", 633], ["15", 634], ["strains", 637], [";", 644], ["all", 646], ["countries", 650], [")", 659], [".", 660]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Restless legs syndrome/Willis-Ekbom disease (RLS/WED) is commonly seen in patients with end-stage renal disease (ESRD), but this condition has not been properly recognized. The prevalence of RLS/WED in ESRD shows the ethnic variation (7%-68%), with the similar tendency of primary RLS/WED. Although RLS/WED in ESRD is defined in secondary RLS/WED, the factors of ESRD that are involved in the genesis of RLS/WED remain unknown. Even after renal transplantation, RLS/WED symptoms do not completely disappear, and genetic predisposition to RLS/WED may play an important role in causing RLS/WED. Long-term intervention for RLS/WED and ESRD will be necessary.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "bad640c274d449bc9a202b19f0948118", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["commonly", 57], ["seen", 66], ["in", 71], ["patients", 74], ["with", 83], ["end", 88], ["-", 91], ["stage", 92], ["renal", 98], ["disease", 104], ["(", 112], ["ESRD", 113], [")", 117], [",", 118], ["but", 120], ["this", 124], ["condition", 129], ["has", 139], ["not", 143], ["been", 147], ["properly", 152], ["recognized", 161], [".", 171], ["The", 173], ["prevalence", 177], ["of", 188], ["RLS", 191], ["/", 194], ["WED", 195], ["in", 199], ["ESRD", 202], ["shows", 207], ["the", 213], ["ethnic", 217], ["variation", 224], ["(", 234], ["7%-68", 235], ["%", 240], [")", 241], [",", 242], ["with", 244], ["the", 249], ["similar", 253], ["tendency", 261], ["of", 270], ["primary", 273], ["RLS", 281], ["/", 284], ["WED", 285], [".", 288], ["Although", 290], ["RLS", 299], ["/", 302], ["WED", 303], ["in", 307], ["ESRD", 310], ["is", 315], ["defined", 318], ["in", 326], ["secondary", 329], ["RLS", 339], ["/", 342], ["WED", 343], [",", 346], ["the", 348], ["factors", 352], ["of", 360], ["ESRD", 363], ["that", 368], ["are", 373], ["involved", 377], ["in", 386], ["the", 389], ["genesis", 393], ["of", 401], ["RLS", 404], ["/", 407], ["WED", 408], ["remain", 412], ["unknown", 419], [".", 426], ["Even", 428], ["after", 433], ["renal", 439], ["transplantation", 445], [",", 460], ["RLS", 462], ["/", 465], ["WED", 466], ["symptoms", 470], ["do", 479], ["not", 482], ["completely", 486], ["disappear", 497], [",", 506], ["and", 508], ["genetic", 512], ["predisposition", 520], ["to", 535], ["RLS", 538], ["/", 541], ["WED", 542], ["may", 546], ["play", 550], ["an", 555], ["important", 558], ["role", 568], ["in", 573], ["causing", 576], ["RLS", 584], ["/", 587], ["WED", 588], [".", 591], ["Long", 593], ["-", 597], ["term", 598], ["intervention", 603], ["for", 616], ["RLS", 620], ["/", 623], ["WED", 624], ["and", 628], ["ESRD", 632], ["will", 637], ["be", 642], ["necessary", 645], [".", 654]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "Although alpha-synuclein (alpha-syn) has been implicated as a major component of the abnormal filaments that form glial cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA), it is uncertain if GCIs are homogenous and contain full-length alpha-syn. Since this has implications for hypotheses about the pathogenesis of GCIs, we used a novel panel of antibodies to defined regions throughout alpha-syn in immunohistochemical epitope mapping studies of GCIs in MSA brains. Although the immunostaining profile of GCIs with these antibodies was similar for all MSA brains, there were significant differences in the immunoreactivity of the alpha-syn epitopes detected in GCIs. Notably, carboxy-terminal alpha-syn epitopes were immunodominant in GCIs, but the entire panel of antibodies immunostained cortical Lewy bodies (LBs) in dementia with LBs brain with similar intensity. While the distribution of alpha-syn labeled GCIs paralleled that previously reported using silver stains, antibodies to carboxy-terminal alpha-syn epitopes revealed a previously undescribed burden of GCIs in the MSA hippocampal formation. Finally, Western blots demonstrated detergent insoluble monomeric and high-molecular weight alpha-syn species in GCI rich MSA cerebellar white matter. Collectively, these data indicate that alpha-syn is a prominent component of GCIs in MSA, and that GCIs and LBs may result from cell type specific conformational or post-translational permutations in alpha-syn.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "6bb8ed04d3334d21be1d6007dec1ca83", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[1, 3]], "char_spans": [[9, 23]]}]}], "context_tokens": [["Although", 0], ["alpha", 9], ["-", 14], ["synuclein", 15], ["(", 25], ["alpha", 26], ["-", 31], ["syn", 32], [")", 35], ["has", 37], ["been", 41], ["implicated", 46], ["as", 57], ["a", 60], ["major", 62], ["component", 68], ["of", 78], ["the", 81], ["abnormal", 85], ["filaments", 94], ["that", 104], ["form", 109], ["glial", 114], ["cytoplasmic", 120], ["inclusions", 132], ["(", 143], ["GCIs", 144], [")", 148], ["in", 150], ["multiple", 153], ["system", 162], ["atrophy", 169], ["(", 177], ["MSA", 178], [")", 181], [",", 182], ["it", 184], ["is", 187], ["uncertain", 190], ["if", 200], ["GCIs", 203], ["are", 208], ["homogenous", 212], ["and", 223], ["contain", 227], ["full", 235], ["-", 239], ["length", 240], ["alpha", 247], ["-", 252], ["syn", 253], [".", 256], ["Since", 258], ["this", 264], ["has", 269], ["implications", 273], ["for", 286], ["hypotheses", 290], ["about", 301], ["the", 307], ["pathogenesis", 311], ["of", 324], ["GCIs", 327], [",", 331], ["we", 333], ["used", 336], ["a", 341], ["novel", 343], ["panel", 349], ["of", 355], ["antibodies", 358], ["to", 369], ["defined", 372], ["regions", 380], ["throughout", 388], ["alpha", 399], ["-", 404], ["syn", 405], ["in", 409], ["immunohistochemical", 412], ["epitope", 432], ["mapping", 440], ["studies", 448], ["of", 456], ["GCIs", 459], ["in", 464], ["MSA", 467], ["brains", 471], [".", 477], ["Although", 479], ["the", 488], ["immunostaining", 492], ["profile", 507], ["of", 515], ["GCIs", 518], ["with", 523], ["these", 528], ["antibodies", 534], ["was", 545], ["similar", 549], ["for", 557], ["all", 561], ["MSA", 565], ["brains", 569], [",", 575], ["there", 577], ["were", 583], ["significant", 588], ["differences", 600], ["in", 612], ["the", 615], ["immunoreactivity", 619], ["of", 636], ["the", 639], ["alpha", 643], ["-", 648], ["syn", 649], ["epitopes", 653], ["detected", 662], ["in", 671], ["GCIs", 674], [".", 678], ["Notably", 680], [",", 687], ["carboxy", 689], ["-", 696], ["terminal", 697], ["alpha", 706], ["-", 711], ["syn", 712], ["epitopes", 716], ["were", 725], ["immunodominant", 730], ["in", 745], ["GCIs", 748], [",", 752], ["but", 754], ["the", 758], ["entire", 762], ["panel", 769], ["of", 775], ["antibodies", 778], ["immunostained", 789], ["cortical", 803], ["Lewy", 812], ["bodies", 817], ["(", 824], ["LBs", 825], [")", 828], ["in", 830], ["dementia", 833], ["with", 842], ["LBs", 847], ["brain", 851], ["with", 857], ["similar", 862], ["intensity", 870], [".", 879], ["While", 881], ["the", 887], ["distribution", 891], ["of", 904], ["alpha", 907], ["-", 912], ["syn", 913], ["labeled", 917], ["GCIs", 925], ["paralleled", 930], ["that", 941], ["previously", 946], ["reported", 957], ["using", 966], ["silver", 972], ["stains", 979], [",", 985], ["antibodies", 987], ["to", 998], ["carboxy", 1001], ["-", 1008], ["terminal", 1009], ["alpha", 1018], ["-", 1023], ["syn", 1024], ["epitopes", 1028], ["revealed", 1037], ["a", 1046], ["previously", 1048], ["undescribed", 1059], ["burden", 1071], ["of", 1078], ["GCIs", 1081], ["in", 1086], ["the", 1089], ["MSA", 1093], ["hippocampal", 1097], ["formation", 1109], [".", 1118], ["Finally", 1120], [",", 1127], ["Western", 1129], ["blots", 1137], ["demonstrated", 1143], ["detergent", 1156], ["insoluble", 1166], ["monomeric", 1176], ["and", 1186], ["high", 1190], ["-", 1194], ["molecular", 1195], ["weight", 1205], ["alpha", 1212], ["-", 1217], ["syn", 1218], ["species", 1222], ["in", 1230], ["GCI", 1233], ["rich", 1237], ["MSA", 1242], ["cerebellar", 1246], ["white", 1257], ["matter", 1263], [".", 1269], ["Collectively", 1271], [",", 1283], ["these", 1285], ["data", 1291], ["indicate", 1296], ["that", 1305], ["alpha", 1310], ["-", 1315], ["syn", 1316], ["is", 1320], ["a", 1323], ["prominent", 1325], ["component", 1335], ["of", 1345], ["GCIs", 1348], ["in", 1353], ["MSA", 1356], [",", 1359], ["and", 1361], ["that", 1365], ["GCIs", 1370], ["and", 1375], ["LBs", 1379], ["may", 1383], ["result", 1387], ["from", 1394], ["cell", 1399], ["type", 1404], ["specific", 1409], ["conformational", 1418], ["or", 1433], ["post", 1436], ["-", 1440], ["translational", 1441], ["permutations", 1455], ["in", 1468], ["alpha", 1471], ["-", 1476], ["syn", 1477], [".", 1480]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental defect in this disorder. In the majority of cases, FSHD is caused by contraction of the D4Z4 repeat array (FSHD1). This results in local chromatin relaxation and stable expression of the DUX4 retrogene in skeletal muscle, but only when a polymorphic DUX4 polyadenylation signal is present. In some cases (FSHD2), D4Z4 chromatin relaxation and stable DUX4 expression occur in the absence of D4Z4 array contraction. DUX4 is a germline transcription factor and its expression in skeletal muscle leads to activation of early stem cell and germline programs and transcriptional activation of retroelements. Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4. The genes regulated by DUX4 suggest several mechanisms of muscle damage, and provide potential biomarkers and therapeutic targets that should be investigated in future studies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "942b79bc7d384edd901fe2769f46512d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[65, 65], [167, 167], [21, 21], [170, 170]], "char_spans": [[403, 406], [1017, 1020], [147, 150], [1031, 1034]]}]}], "context_tokens": [["In", 0], ["recent", 3], ["years", 10], [",", 15], ["we", 17], ["have", 20], ["seen", 25], ["remarkable", 30], ["progress", 41], ["in", 50], ["our", 53], ["understanding", 57], ["of", 71], ["the", 74], ["disease", 78], ["mechanism", 86], ["underlying", 96], ["facioscapulohumeral", 107], ["muscular", 127], ["dystrophy", 136], ["(", 146], ["FSHD", 147], [")", 151], [".", 152], ["The", 154], ["purpose", 158], ["of", 166], ["this", 169], ["review", 174], ["is", 181], ["to", 184], ["provide", 187], ["a", 195], ["comprehensive", 197], ["overview", 211], ["of", 220], ["our", 223], ["current", 227], ["understanding", 235], ["of", 249], ["the", 252], ["disease", 256], ["mechanism", 264], ["and", 274], ["to", 278], ["discuss", 281], ["the", 289], ["observations", 293], ["supporting", 306], ["the", 317], ["possibility", 321], ["of", 333], ["a", 336], ["developmental", 338], ["defect", 352], ["in", 359], ["this", 362], ["disorder", 367], [".", 375], ["In", 377], ["the", 380], ["majority", 384], ["of", 393], ["cases", 396], [",", 401], ["FSHD", 403], ["is", 408], ["caused", 411], ["by", 418], ["contraction", 421], ["of", 433], ["the", 436], ["D4Z4", 440], ["repeat", 445], ["array", 452], ["(", 458], ["FSHD1", 459], [")", 464], [".", 465], ["This", 467], ["results", 472], ["in", 480], ["local", 483], ["chromatin", 489], ["relaxation", 499], ["and", 510], ["stable", 514], ["expression", 521], ["of", 532], ["the", 535], ["DUX4", 539], ["retrogene", 544], ["in", 554], ["skeletal", 557], ["muscle", 566], [",", 572], ["but", 574], ["only", 578], ["when", 583], ["a", 588], ["polymorphic", 590], ["DUX4", 602], ["polyadenylation", 607], ["signal", 623], ["is", 630], ["present", 633], [".", 640], ["In", 642], ["some", 645], ["cases", 650], ["(", 656], ["FSHD2", 657], [")", 662], [",", 663], ["D4Z4", 665], ["chromatin", 670], ["relaxation", 680], ["and", 691], ["stable", 695], ["DUX4", 702], ["expression", 707], ["occur", 718], ["in", 724], ["the", 727], ["absence", 731], ["of", 739], ["D4Z4", 742], ["array", 747], ["contraction", 753], [".", 764], ["DUX4", 766], ["is", 771], ["a", 774], ["germline", 776], ["transcription", 785], ["factor", 799], ["and", 806], ["its", 810], ["expression", 814], ["in", 825], ["skeletal", 828], ["muscle", 837], ["leads", 844], ["to", 850], ["activation", 853], ["of", 864], ["early", 867], ["stem", 873], ["cell", 878], ["and", 883], ["germline", 887], ["programs", 896], ["and", 905], ["transcriptional", 909], ["activation", 925], ["of", 936], ["retroelements", 939], [".", 952], ["Recent", 954], ["studies", 961], ["have", 969], ["provided", 974], ["a", 983], ["plausible", 985], ["disease", 995], ["mechanism", 1003], ["for", 1013], ["FSHD", 1017], ["in", 1022], ["which", 1025], ["FSHD", 1031], ["results", 1036], ["from", 1044], ["inappropriate", 1049], ["expression", 1063], ["of", 1074], ["the", 1077], ["germline", 1081], ["transcription", 1090], ["factor", 1104], ["DUX4", 1111], [".", 1115], ["The", 1117], ["genes", 1121], ["regulated", 1127], ["by", 1137], ["DUX4", 1140], ["suggest", 1145], ["several", 1153], ["mechanisms", 1161], ["of", 1172], ["muscle", 1175], ["damage", 1182], [",", 1188], ["and", 1190], ["provide", 1194], ["potential", 1202], ["biomarkers", 1212], ["and", 1223], ["therapeutic", 1227], ["targets", 1239], ["that", 1247], ["should", 1252], ["be", 1259], ["investigated", 1262], ["in", 1275], ["future", 1278], ["studies", 1285], [".", 1292]]}
{"context": "A study was carried out on 200 patients of ages 20-40 years suffering from acute viral hepatitis. Sera were tested for markers of hepatitis B (HBsAg, and IgM anti-HBc) and hepatitis A (IgM-anti-HAV) by the ELISA technique. Sera negative for the markers of both viruses: Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV) infection. Non-A, non-B hepatitis (NANB) was diagnosed by exclusion. The results of the study showed that 133 (66.5%) patients had evidence of HBV infection, while only 9(4.5%) were diagnosed as HAV infection. EBV and CMV were the possible etiological agents of acute viral hepatitis in (3.5%) and 1%) respectively. Accordingly the Non-A, non-B hepatitis in this study amounts to (24.5%) of the acute viral hepatitis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "c5f3d85f9a094b98b72b423fbde816d2", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[80, 83]], "char_spans": [[373, 390]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["carried", 12], ["out", 20], ["on", 24], ["200", 27], ["patients", 31], ["of", 40], ["ages", 43], ["20", 48], ["-", 50], ["40", 51], ["years", 54], ["suffering", 60], ["from", 70], ["acute", 75], ["viral", 81], ["hepatitis", 87], [".", 96], ["Sera", 98], ["were", 103], ["tested", 108], ["for", 115], ["markers", 119], ["of", 127], ["hepatitis", 130], ["B", 140], ["(", 142], ["HBsAg", 143], [",", 148], ["and", 150], ["IgM", 154], ["anti", 158], ["-", 162], ["HBc", 163], [")", 166], ["and", 168], ["hepatitis", 172], ["A", 182], ["(", 184], ["IgM", 185], ["-", 188], ["anti", 189], ["-", 193], ["HAV", 194], [")", 197], ["by", 199], ["the", 202], ["ELISA", 206], ["technique", 212], [".", 221], ["Sera", 223], ["negative", 228], ["for", 237], ["the", 241], ["markers", 245], ["of", 253], ["both", 256], ["viruses", 261], [":", 268], ["Hepatitis", 270], ["A", 280], ["(", 282], ["HAV", 283], [")", 286], ["and", 288], ["Hepatitis", 292], ["B", 302], ["(", 304], ["HBV", 305], [")", 308], ["were", 310], ["subsequently", 315], ["tested", 328], ["for", 335], ["IGM", 339], ["Heterophil", 343], ["antibodies", 354], ["against", 365], ["Epstein", 373], ["-", 380], ["Barr", 381], ["virus", 386], ["(", 392], ["EBV", 393], [")", 396], ["by", 398], ["the", 401], ["Monospot", 405], ["slide", 414], ["test", 420], ["to", 425], ["diagnose", 428], ["acute", 437], ["infectious", 443], ["mononucleosis", 454], ["and", 468], ["tested", 472], ["for", 479], ["anti", 483], ["-", 487], ["CMV", 488], ["(", 492], ["IgM", 493], [")", 496], ["by", 498], ["ELISA", 501], ["technique", 507], ["for", 517], ["the", 521], ["diagnosis", 525], ["of", 535], ["acute", 538], ["Cytomegalovirus", 544], ["(", 560], ["CMV", 561], [")", 564], ["infection", 566], [".", 575], ["Non", 577], ["-", 580], ["A", 581], [",", 582], ["non", 584], ["-", 587], ["B", 588], ["hepatitis", 590], ["(", 600], ["NANB", 601], [")", 605], ["was", 607], ["diagnosed", 611], ["by", 621], ["exclusion", 624], [".", 633], ["The", 635], ["results", 639], ["of", 647], ["the", 650], ["study", 654], ["showed", 660], ["that", 667], ["133", 672], ["(", 676], ["66.5", 677], ["%", 681], [")", 682], ["patients", 684], ["had", 693], ["evidence", 697], ["of", 706], ["HBV", 709], ["infection", 713], [",", 722], ["while", 724], ["only", 730], ["9(4.5", 735], ["%", 740], [")", 741], ["were", 743], ["diagnosed", 748], ["as", 758], ["HAV", 761], ["infection", 765], [".", 774], ["EBV", 776], ["and", 780], ["CMV", 784], ["were", 788], ["the", 793], ["possible", 797], ["etiological", 806], ["agents", 818], ["of", 825], ["acute", 828], ["viral", 834], ["hepatitis", 840], ["in", 850], ["(", 853], ["3.5", 854], ["%", 857], [")", 858], ["and", 860], ["1", 864], ["%", 865], [")", 866], ["respectively", 868], [".", 880], ["Accordingly", 882], ["the", 894], ["Non", 898], ["-", 901], ["A", 902], [",", 903], ["non", 905], ["-", 908], ["B", 909], ["hepatitis", 911], ["in", 921], ["this", 924], ["study", 929], ["amounts", 935], ["to", 943], ["(", 946], ["24.5", 947], ["%", 951], [")", 952], ["of", 954], ["the", 957], ["acute", 961], ["viral", 967], ["hepatitis", 973], [".", 982]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells. The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012. SNP increased Ca(2+) influx and intracellular Ca(2+) levels. In addition, SNP increased ERK and p38 MAPK phosphorylation, and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. These effects of SNP were prevented by SEA0400. SNP-induced cytotoxicity was not affected by inhibitors of the Ca(2+), Na(+) and store-operated/capacitative channels. Moreover, SNP-induced increase in intracellular Ca(2+) levels, ROS production and decrease in cell viability were blocked by a cGMP-dependent protein kinase (PKG) inhibitor. These results suggest that Ca(2+) influx via the reverse of NCX is involved in the cascade of NO-induced neuronal apoptosis and NO activates the NCX through guanylate cyclase/PKG pathway.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "78c14f714e4744988b69ad994964895d", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[1, 4]], "char_spans": [[4, 25]]}, {"text": "NCX", "token_spans": [[291, 291], [307, 307], [6, 6], [63, 63], [88, 88], [95, 95]], "char_spans": [[1572, 1574], [1657, 1659], [28, 30], [333, 335], [471, 473], [562, 564]]}]}], "context_tokens": [["The", 0], ["Na(+)/Ca(2", 4], ["+", 14], [")", 15], ["exchanger", 17], ["(", 27], ["NCX", 28], [")", 31], ["plays", 33], ["a", 39], ["role", 41], ["in", 46], ["the", 49], ["regulation", 53], ["of", 64], ["intracellular", 67], ["Ca(2", 81], ["+", 85], [")", 86], ["levels", 88], [",", 94], ["and", 96], ["nitric", 100], ["oxide", 107], ["(", 113], ["NO", 114], [")", 116], ["is", 118], ["involved", 121], ["in", 130], ["many", 133], ["pathological", 138], ["conditions", 151], ["including", 162], ["neurodegenerative", 172], ["disorders", 190], [".", 199], ["We", 201], ["have", 204], ["previously", 209], ["found", 220], ["that", 226], ["sodium", 231], ["nitroprusside", 238], ["(", 252], ["SNP", 253], [")", 256], [",", 257], ["an", 259], ["NO", 262], ["donor", 265], [",", 270], ["causes", 272], ["apoptotic", 279], ["-", 288], ["like", 289], ["cell", 294], ["death", 299], ["in", 305], ["cultured", 308], ["glial", 317], ["cells", 323], ["via", 329], ["NCX", 333], ["-", 336], ["mediated", 337], ["pathways", 346], ["and", 355], ["the", 359], ["mechanism", 363], ["for", 373], ["NO", 377], ["-", 379], ["induced", 380], ["cytotoxicity", 388], ["is", 401], ["cell", 404], ["type", 409], ["-", 413], ["dependent", 414], [".", 423], ["The", 425], ["present", 429], ["study", 437], ["examined", 443], ["using", 452], ["the", 458], ["specific", 462], ["NCX", 471], ["inhibitor", 475], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 485], ["(", 544], ["SEA0400", 545], [")", 552], ["whether", 554], ["NCX", 562], ["is", 566], ["involved", 569], ["in", 578], ["NO", 581], ["-", 583], ["induced", 584], ["injury", 592], ["in", 599], ["cultured", 602], ["neuronal", 611], ["cells", 620], [".", 625], ["The", 627], ["treatment", 631], ["of", 641], ["neuroblastoma", 644], ["SH", 658], ["-", 660], ["SY5Y", 661], ["cells", 666], ["with", 672], ["SNP", 677], ["resulted", 681], ["in", 690], ["apoptosis", 693], ["and", 703], ["the", 707], ["cytotoxicity", 711], ["was", 724], ["blocked", 728], ["by", 736], ["the", 739], ["mitogen", 743], ["-", 750], ["activated", 751], ["protein", 761], ["(", 769], ["MAP)/extracellular", 770], ["signal", 789], ["-", 795], ["regulated", 796], ["kinase", 806], ["(", 813], ["ERK", 814], [")", 817], ["kinase", 819], ["inhibitor", 826], ["U0126", 836], ["and", 842], ["the", 846], ["p38", 850], ["MAP", 854], ["kinase", 858], ["(", 865], ["MAPK", 866], [")", 870], ["inhibitor", 872], ["SB203580", 882], [",", 890], ["but", 892], ["not", 896], ["by", 900], ["the", 903], ["c", 907], ["-", 908], ["Jun", 909], ["N", 913], ["-", 914], ["terminal", 915], ["kinase", 924], ["(", 931], ["JNK", 932], [")", 935], ["inhibitor", 937], ["SP60012", 947], [".", 954], ["SNP", 956], ["increased", 960], ["Ca(2", 970], ["+", 974], [")", 975], ["influx", 977], ["and", 984], ["intracellular", 988], ["Ca(2", 1002], ["+", 1006], [")", 1007], ["levels", 1009], [".", 1015], ["In", 1017], ["addition", 1020], [",", 1028], ["SNP", 1030], ["increased", 1034], ["ERK", 1044], ["and", 1048], ["p38", 1052], ["MAPK", 1056], ["phosphorylation", 1061], [",", 1076], ["and", 1078], ["production", 1082], ["of", 1093], ["reactive", 1096], ["oxygen", 1105], ["species", 1112], ["(", 1120], ["ROS", 1121], [")", 1124], ["in", 1126], ["an", 1129], ["extracellular", 1132], ["Ca(2+)-dependent", 1146], ["manner", 1163], [".", 1169], ["These", 1171], ["effects", 1177], ["of", 1185], ["SNP", 1188], ["were", 1192], ["prevented", 1197], ["by", 1207], ["SEA0400", 1210], [".", 1217], ["SNP", 1219], ["-", 1222], ["induced", 1223], ["cytotoxicity", 1231], ["was", 1244], ["not", 1248], ["affected", 1252], ["by", 1261], ["inhibitors", 1264], ["of", 1275], ["the", 1278], ["Ca(2", 1282], ["+", 1286], [")", 1287], [",", 1288], ["Na(+", 1290], [")", 1294], ["and", 1296], ["store", 1300], ["-", 1305], ["operated", 1306], ["/", 1314], ["capacitative", 1315], ["channels", 1328], [".", 1336], ["Moreover", 1338], [",", 1346], ["SNP", 1348], ["-", 1351], ["induced", 1352], ["increase", 1360], ["in", 1369], ["intracellular", 1372], ["Ca(2", 1386], ["+", 1390], [")", 1391], ["levels", 1393], [",", 1399], ["ROS", 1401], ["production", 1405], ["and", 1416], ["decrease", 1420], ["in", 1429], ["cell", 1432], ["viability", 1437], ["were", 1447], ["blocked", 1452], ["by", 1460], ["a", 1463], ["cGMP", 1465], ["-", 1469], ["dependent", 1470], ["protein", 1480], ["kinase", 1488], ["(", 1495], ["PKG", 1496], [")", 1499], ["inhibitor", 1501], [".", 1510], ["These", 1512], ["results", 1518], ["suggest", 1526], ["that", 1534], ["Ca(2", 1539], ["+", 1543], [")", 1544], ["influx", 1546], ["via", 1553], ["the", 1557], ["reverse", 1561], ["of", 1569], ["NCX", 1572], ["is", 1576], ["involved", 1579], ["in", 1588], ["the", 1591], ["cascade", 1595], ["of", 1603], ["NO", 1606], ["-", 1608], ["induced", 1609], ["neuronal", 1617], ["apoptosis", 1626], ["and", 1636], ["NO", 1640], ["activates", 1643], ["the", 1653], ["NCX", 1657], ["through", 1661], ["guanylate", 1669], ["cyclase", 1679], ["/", 1686], ["PKG", 1687], ["pathway", 1691], [".", 1698]]}
{"context": "Both non-Group A streptococcal (non-GAS) pharyngitis and Group A streptococcal (GAS) pharyngitis are commonly found in patients with sore throat. It is not known whether or not they present with similar signs and symptoms compared to patients with non-streptococcal pharyngitis. MEDLINE was searched for prospective studies that reported throat culture for both GAS and non-GAS as a reference standard, and reported at least one sign, symptom, or the Centor score. Summary estimates of sensitivity, specificity, likelihood ratios (LR+ and LR-), and diagnostic odds ratios (DOR) were calculated using a bivariate random effects model. Summary receiver operating characteristic (ROC) curves were created for key signs and symptoms. Eight studies met our inclusion criteria. Tonsillar exudate had the highest LR+ for both GAS and non-GAS pharyngitis (1.53 versus 1.71). The confidence intervals of sensitivity, LR+, LR-, and DOR for all signs, symptoms, and the Centor score between two groups overlapped, with the relative difference between sensitivities within 15% for arthralgia or myalgia, fever, injected throat, tonsillar enlargement, and tonsillar exudate. Larger differences in sensitivities were observed for sore throat, cervical adenopathy, and lack of a cough, although the difference for lack of a cough largely due to a single outlier. Signs and symptoms of patients with GAS and non-GAS pharyngitis are generally similar. No signs or symptoms clearly distinguish GAS from non-GAS infection. Further work is needed to determine whether Group C streptococcus is a pathogen that should be treated.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "6952c83e31114a20b979dc5962329901", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[49, 50]], "char_spans": [[252, 276]]}]}], "context_tokens": [["Both", 0], ["non", 5], ["-", 8], ["Group", 9], ["A", 15], ["streptococcal", 17], ["(", 31], ["non", 32], ["-", 35], ["GAS", 36], [")", 39], ["pharyngitis", 41], ["and", 53], ["Group", 57], ["A", 63], ["streptococcal", 65], ["(", 79], ["GAS", 80], [")", 83], ["pharyngitis", 85], ["are", 97], ["commonly", 101], ["found", 110], ["in", 116], ["patients", 119], ["with", 128], ["sore", 133], ["throat", 138], [".", 144], ["It", 146], ["is", 149], ["not", 152], ["known", 156], ["whether", 162], ["or", 170], ["not", 173], ["they", 177], ["present", 182], ["with", 190], ["similar", 195], ["signs", 203], ["and", 209], ["symptoms", 213], ["compared", 222], ["to", 231], ["patients", 234], ["with", 243], ["non", 248], ["-", 251], ["streptococcal", 252], ["pharyngitis", 266], [".", 277], ["MEDLINE", 279], ["was", 287], ["searched", 291], ["for", 300], ["prospective", 304], ["studies", 316], ["that", 324], ["reported", 329], ["throat", 338], ["culture", 345], ["for", 353], ["both", 357], ["GAS", 362], ["and", 366], ["non", 370], ["-", 373], ["GAS", 374], ["as", 378], ["a", 381], ["reference", 383], ["standard", 393], [",", 401], ["and", 403], ["reported", 407], ["at", 416], ["least", 419], ["one", 425], ["sign", 429], [",", 433], ["symptom", 435], [",", 442], ["or", 444], ["the", 447], ["Centor", 451], ["score", 458], [".", 463], ["Summary", 465], ["estimates", 473], ["of", 483], ["sensitivity", 486], [",", 497], ["specificity", 499], [",", 510], ["likelihood", 512], ["ratios", 523], ["(", 530], ["LR+", 531], ["and", 535], ["LR-", 539], [")", 542], [",", 543], ["and", 545], ["diagnostic", 549], ["odds", 560], ["ratios", 565], ["(", 572], ["DOR", 573], [")", 576], ["were", 578], ["calculated", 583], ["using", 594], ["a", 600], ["bivariate", 602], ["random", 612], ["effects", 619], ["model", 627], [".", 632], ["Summary", 634], ["receiver", 642], ["operating", 651], ["characteristic", 661], ["(", 676], ["ROC", 677], [")", 680], ["curves", 682], ["were", 689], ["created", 694], ["for", 702], ["key", 706], ["signs", 710], ["and", 716], ["symptoms", 720], [".", 728], ["Eight", 730], ["studies", 736], ["met", 744], ["our", 748], ["inclusion", 752], ["criteria", 762], [".", 770], ["Tonsillar", 772], ["exudate", 782], ["had", 790], ["the", 794], ["highest", 798], ["LR+", 806], ["for", 810], ["both", 814], ["GAS", 819], ["and", 823], ["non", 827], ["-", 830], ["GAS", 831], ["pharyngitis", 835], ["(", 847], ["1.53", 848], ["versus", 853], ["1.71", 860], [")", 864], [".", 865], ["The", 867], ["confidence", 871], ["intervals", 882], ["of", 892], ["sensitivity", 895], [",", 906], ["LR+", 908], [",", 911], ["LR-", 913], [",", 916], ["and", 918], ["DOR", 922], ["for", 926], ["all", 930], ["signs", 934], [",", 939], ["symptoms", 941], [",", 949], ["and", 951], ["the", 955], ["Centor", 959], ["score", 966], ["between", 972], ["two", 980], ["groups", 984], ["overlapped", 991], [",", 1001], ["with", 1003], ["the", 1008], ["relative", 1012], ["difference", 1021], ["between", 1032], ["sensitivities", 1040], ["within", 1054], ["15", 1061], ["%", 1063], ["for", 1065], ["arthralgia", 1069], ["or", 1080], ["myalgia", 1083], [",", 1090], ["fever", 1092], [",", 1097], ["injected", 1099], ["throat", 1108], [",", 1114], ["tonsillar", 1116], ["enlargement", 1126], [",", 1137], ["and", 1139], ["tonsillar", 1143], ["exudate", 1153], [".", 1160], ["Larger", 1162], ["differences", 1169], ["in", 1181], ["sensitivities", 1184], ["were", 1198], ["observed", 1203], ["for", 1212], ["sore", 1216], ["throat", 1221], [",", 1227], ["cervical", 1229], ["adenopathy", 1238], [",", 1248], ["and", 1250], ["lack", 1254], ["of", 1259], ["a", 1262], ["cough", 1264], [",", 1269], ["although", 1271], ["the", 1280], ["difference", 1284], ["for", 1295], ["lack", 1299], ["of", 1304], ["a", 1307], ["cough", 1309], ["largely", 1315], ["due", 1323], ["to", 1327], ["a", 1330], ["single", 1332], ["outlier", 1339], [".", 1346], ["Signs", 1348], ["and", 1354], ["symptoms", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["GAS", 1384], ["and", 1388], ["non", 1392], ["-", 1395], ["GAS", 1396], ["pharyngitis", 1400], ["are", 1412], ["generally", 1416], ["similar", 1426], [".", 1433], ["No", 1435], ["signs", 1438], ["or", 1444], ["symptoms", 1447], ["clearly", 1456], ["distinguish", 1464], ["GAS", 1476], ["from", 1480], ["non", 1485], ["-", 1488], ["GAS", 1489], ["infection", 1493], [".", 1502], ["Further", 1504], ["work", 1512], ["is", 1517], ["needed", 1520], ["to", 1527], ["determine", 1530], ["whether", 1540], ["Group", 1548], ["C", 1554], ["streptococcus", 1556], ["is", 1570], ["a", 1573], ["pathogen", 1575], ["that", 1584], ["should", 1589], ["be", 1596], ["treated", 1599], [".", 1606]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Understanding the pathogenesis of CLL has uncovered a plethora of novel targets for human application of monoclonal antibodies, engineered T cells, or inhibitors of signal transduction pathways. The B-cell receptor signaling pathway is being actively explored as a therapeutic target in CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy. Other key components of the BCR pathway, namely PI3K-\u03b4, are also being targeted with novel therapies with promising results as well. Future trials would likely evaluate ibrutinib in the front-line setting. Moreover, improvements in allogeneic HCT mostly by continuing to reduce associated toxicity as well as incorporating cellular therapies such as autologous CLL tumor vaccines, among others, will continue to expand. This is also the case for the next generation of chimeric antigen receptor therapy for CLL once genetically modified T cells are available at broad scale and with improved efficacy. As our ability to further refine and integrate these therapies continues to improve, and we gain further knowledge from gene sequencing, we anticipate that treatment algorithms will continue to be revised to a more personalized approach to treat this disease with improved efficacy and devoid of unnecessary toxicity.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "e34cd287534b4fd788442be110013bba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[48, 48], [112, 112]], "char_spans": [[292, 300], [643, 651]]}]}], "context_tokens": [["Understanding", 0], ["the", 14], ["pathogenesis", 18], ["of", 31], ["CLL", 34], ["has", 38], ["uncovered", 42], ["a", 52], ["plethora", 54], ["of", 63], ["novel", 66], ["targets", 72], ["for", 80], ["human", 84], ["application", 90], ["of", 102], ["monoclonal", 105], ["antibodies", 116], [",", 126], ["engineered", 128], ["T", 139], ["cells", 141], [",", 146], ["or", 148], ["inhibitors", 151], ["of", 162], ["signal", 165], ["transduction", 172], ["pathways", 185], [".", 193], ["The", 195], ["B", 199], ["-", 200], ["cell", 201], ["receptor", 206], ["signaling", 215], ["pathway", 225], ["is", 233], ["being", 236], ["actively", 242], ["explored", 251], ["as", 260], ["a", 263], ["therapeutic", 265], ["target", 277], ["in", 284], ["CLL", 287], [".", 290], ["Ibrutinib", 292], [",", 301], ["an", 303], ["inhibitor", 306], ["of", 316], ["Bruton", 319], ["'s", 325], ["tyrosine", 328], ["kinase", 337], ["is", 344], ["showing", 347], ["impressive", 355], ["responses", 366], ["in", 376], ["heavily", 379], ["pre", 387], ["-", 390], ["treated", 391], ["high", 399], ["-", 403], ["risk", 404], ["CLL", 409], [",", 412], ["whether", 414], ["alone", 422], ["or", 428], ["in", 431], ["combination", 434], ["with", 446], ["MoAbs", 451], ["or", 457], ["chemotherapy", 460], [".", 472], ["Other", 474], ["key", 480], ["components", 484], ["of", 495], ["the", 498], ["BCR", 502], ["pathway", 506], [",", 513], ["namely", 515], ["PI3K", 522], ["-", 526], ["\u03b4", 527], [",", 528], ["are", 530], ["also", 534], ["being", 539], ["targeted", 545], ["with", 554], ["novel", 559], ["therapies", 565], ["with", 575], ["promising", 580], ["results", 590], ["as", 598], ["well", 601], [".", 605], ["Future", 607], ["trials", 614], ["would", 621], ["likely", 627], ["evaluate", 634], ["ibrutinib", 643], ["in", 653], ["the", 656], ["front", 660], ["-", 665], ["line", 666], ["setting", 671], [".", 678], ["Moreover", 680], [",", 688], ["improvements", 690], ["in", 703], ["allogeneic", 706], ["HCT", 717], ["mostly", 721], ["by", 728], ["continuing", 731], ["to", 742], ["reduce", 745], ["associated", 752], ["toxicity", 763], ["as", 772], ["well", 775], ["as", 780], ["incorporating", 783], ["cellular", 797], ["therapies", 806], ["such", 816], ["as", 821], ["autologous", 824], ["CLL", 835], ["tumor", 839], ["vaccines", 845], [",", 853], ["among", 855], ["others", 861], [",", 867], ["will", 869], ["continue", 874], ["to", 883], ["expand", 886], [".", 892], ["This", 894], ["is", 899], ["also", 902], ["the", 907], ["case", 911], ["for", 916], ["the", 920], ["next", 924], ["generation", 929], ["of", 940], ["chimeric", 943], ["antigen", 952], ["receptor", 960], ["therapy", 969], ["for", 977], ["CLL", 981], ["once", 985], ["genetically", 990], ["modified", 1002], ["T", 1011], ["cells", 1013], ["are", 1019], ["available", 1023], ["at", 1033], ["broad", 1036], ["scale", 1042], ["and", 1048], ["with", 1052], ["improved", 1057], ["efficacy", 1066], [".", 1074], ["As", 1076], ["our", 1079], ["ability", 1083], ["to", 1091], ["further", 1094], ["refine", 1102], ["and", 1109], ["integrate", 1113], ["these", 1123], ["therapies", 1129], ["continues", 1139], ["to", 1149], ["improve", 1152], [",", 1159], ["and", 1161], ["we", 1165], ["gain", 1168], ["further", 1173], ["knowledge", 1181], ["from", 1191], ["gene", 1196], ["sequencing", 1201], [",", 1211], ["we", 1213], ["anticipate", 1216], ["that", 1227], ["treatment", 1232], ["algorithms", 1242], ["will", 1253], ["continue", 1258], ["to", 1267], ["be", 1270], ["revised", 1273], ["to", 1281], ["a", 1284], ["more", 1286], ["personalized", 1291], ["approach", 1304], ["to", 1313], ["treat", 1316], ["this", 1322], ["disease", 1327], ["with", 1335], ["improved", 1340], ["efficacy", 1349], ["and", 1358], ["devoid", 1362], ["of", 1369], ["unnecessary", 1372], ["toxicity", 1384], [".", 1392]]}
{"context": "Chronic lymphocytic leukemia (CLL) is characterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable responsiveness of the BCR to antigen ligation. Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL. Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising, however, raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL. To determine the role of BTK in CLL, we used patient samples and the E\u03bc-TCL1 (TCL1) transgenic mouse model of CLL, which results in spontaneous leukemia development. Inhibition of BTK in primary human CLL cells by small interfering RNA promotes apoptosis. Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL, demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib. Collectively, our data confirm the importance of kinase-functional BTK in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "6696f9c425644649871fb87ff9a6ff0d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[196, 196], [100, 100], [53, 53], [166, 166]], "char_spans": [[1141, 1149], [593, 601], [301, 309], [958, 966]]}]}], "context_tokens": [["Chronic", 0], ["lymphocytic", 8], ["leukemia", 20], ["(", 29], ["CLL", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["constitutive", 55], ["activation", 68], ["of", 79], ["the", 82], ["B", 86], ["-", 87], ["cell", 88], ["receptor", 93], ["(", 102], ["BCR", 103], [")", 106], ["signaling", 108], ["pathway", 118], [",", 125], ["but", 127], ["variable", 131], ["responsiveness", 140], ["of", 155], ["the", 158], ["BCR", 162], ["to", 166], ["antigen", 169], ["ligation", 177], [".", 185], ["Bruton", 187], ["'s", 193], ["tyrosine", 196], ["kinase", 205], ["(", 212], ["BTK", 213], [")", 216], ["shows", 218], ["constitutive", 224], ["activity", 237], ["in", 246], ["CLL", 249], ["and", 253], ["is", 257], ["the", 260], ["target", 264], ["of", 271], ["irreversible", 274], ["inhibition", 287], ["by", 298], ["ibrutinib", 301], [",", 310], ["an", 312], ["orally", 315], ["bioavailable", 322], ["kinase", 335], ["inhibitor", 342], ["that", 352], ["has", 357], ["shown", 361], ["outstanding", 367], ["activity", 379], ["in", 388], ["CLL", 391], [".", 394], ["Early", 396], ["clinical", 402], ["results", 411], ["in", 419], ["CLL", 422], ["with", 426], ["other", 431], ["reversible", 437], ["and", 448], ["irreversible", 452], ["BTK", 465], ["inhibitors", 469], ["have", 480], ["been", 485], ["less", 490], ["promising", 495], [",", 504], ["however", 506], [",", 513], ["raising", 515], ["the", 523], ["question", 527], ["of", 536], ["whether", 539], ["BTK", 547], ["kinase", 551], ["activity", 558], ["is", 567], ["an", 570], ["important", 573], ["target", 583], ["of", 590], ["ibrutinib", 593], ["and", 603], ["also", 607], ["in", 612], ["CLL", 615], [".", 618], ["To", 620], ["determine", 623], ["the", 633], ["role", 637], ["of", 642], ["BTK", 645], ["in", 649], ["CLL", 652], [",", 655], ["we", 657], ["used", 660], ["patient", 665], ["samples", 673], ["and", 681], ["the", 685], ["E\u03bc", 689], ["-", 691], ["TCL1", 692], ["(", 697], ["TCL1", 698], [")", 702], ["transgenic", 704], ["mouse", 715], ["model", 721], ["of", 727], ["CLL", 730], [",", 733], ["which", 735], ["results", 741], ["in", 749], ["spontaneous", 752], ["leukemia", 764], ["development", 773], [".", 784], ["Inhibition", 786], ["of", 797], ["BTK", 800], ["in", 804], ["primary", 807], ["human", 815], ["CLL", 821], ["cells", 825], ["by", 831], ["small", 834], ["interfering", 840], ["RNA", 852], ["promotes", 856], ["apoptosis", 865], [".", 874], ["Inhibition", 876], ["of", 887], ["BTK", 890], ["kinase", 894], ["activity", 901], ["through", 910], ["either", 918], ["targeted", 925], ["genetic", 934], ["inactivation", 942], ["or", 955], ["ibrutinib", 958], ["in", 968], ["the", 971], ["TCL1", 975], ["mouse", 980], ["significantly", 986], ["delays", 1000], ["the", 1007], ["development", 1011], ["of", 1023], ["CLL", 1026], [",", 1029], ["demonstrating", 1031], ["that", 1045], ["BTK", 1050], ["is", 1054], ["a", 1057], ["critical", 1059], ["kinase", 1068], ["for", 1075], ["CLL", 1079], ["development", 1083], ["and", 1095], ["expansion", 1099], ["and", 1109], ["thus", 1113], ["an", 1118], ["important", 1121], ["target", 1131], ["of", 1138], ["ibrutinib", 1141], [".", 1150], ["Collectively", 1152], [",", 1164], ["our", 1166], ["data", 1170], ["confirm", 1175], ["the", 1183], ["importance", 1187], ["of", 1198], ["kinase", 1201], ["-", 1207], ["functional", 1208], ["BTK", 1219], ["in", 1223], ["CLL", 1226], [".", 1229]]}
{"context": "Mutations in the ribosomal protein (RP)S19 gene have been found in about 25% of the cases of Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. Various mutations have been identified in the RPS19 gene, but no investigations regarding the effect of these alterations on RPS19 mRNA levels have been performed. It is well established that mutated mRNA containing a premature stop codon (PTC) or lacking a stop codon can be rapidly degraded by specific mechanisms called nonsense mediated decay (NMD) and nonstop decay. To study the involvement of such mechanisms in DBA, we analyzed immortalized lymphoblastoid cells and primary fibroblasts from patients presenting different kinds of mutations in the RPS19 gene, generating allelic deletion, missense, nonsense, and nonstop messengers. We found that RPS19 mRNA levels are decreased in the cells with allelic deletion and, to a variable extent, also in all the cell lines with PTC or nonstop mutations. Further analysis showed that translation inhibition causes a stabilization of the mutated RPS19 mRNA. Our findings indicate that NMD and nonstop decay affect the expression of mutated RPS19 genes; this may help to clarify genotype-phenotype correlations in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "141cca4558cd4f99b00b0fe5066754ca", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[19, 22]], "char_spans": [[93, 115]]}, {"text": "DBA", "token_spans": [[219, 219], [24, 24], [111, 111]], "char_spans": [[1271, 1273], [118, 120], [627, 629]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["(", 35], ["RP)S19", 36], ["gene", 43], ["have", 48], ["been", 53], ["found", 58], ["in", 64], ["about", 67], ["25", 73], ["%", 75], ["of", 77], ["the", 80], ["cases", 84], ["of", 90], ["Diamond", 93], ["-", 100], ["Blackfan", 101], ["anemia", 110], ["(", 117], ["DBA", 118], [")", 121], [",", 122], ["a", 124], ["rare", 126], ["congenital", 131], ["hypoplastic", 142], ["anemia", 154], ["that", 161], ["includes", 166], ["variable", 175], ["physical", 184], ["malformations", 193], [".", 206], ["Various", 208], ["mutations", 216], ["have", 226], ["been", 231], ["identified", 236], ["in", 247], ["the", 250], ["RPS19", 254], ["gene", 260], [",", 264], ["but", 266], ["no", 270], ["investigations", 273], ["regarding", 288], ["the", 298], ["effect", 302], ["of", 309], ["these", 312], ["alterations", 318], ["on", 330], ["RPS19", 333], ["mRNA", 339], ["levels", 344], ["have", 351], ["been", 356], ["performed", 361], [".", 370], ["It", 372], ["is", 375], ["well", 378], ["established", 383], ["that", 395], ["mutated", 400], ["mRNA", 408], ["containing", 413], ["a", 424], ["premature", 426], ["stop", 436], ["codon", 441], ["(", 447], ["PTC", 448], [")", 451], ["or", 453], ["lacking", 456], ["a", 464], ["stop", 466], ["codon", 471], ["can", 477], ["be", 481], ["rapidly", 484], ["degraded", 492], ["by", 501], ["specific", 504], ["mechanisms", 513], ["called", 524], ["nonsense", 531], ["mediated", 540], ["decay", 549], ["(", 555], ["NMD", 556], [")", 559], ["and", 561], ["nonstop", 565], ["decay", 573], [".", 578], ["To", 580], ["study", 583], ["the", 589], ["involvement", 593], ["of", 605], ["such", 608], ["mechanisms", 613], ["in", 624], ["DBA", 627], [",", 630], ["we", 632], ["analyzed", 635], ["immortalized", 644], ["lymphoblastoid", 657], ["cells", 672], ["and", 678], ["primary", 682], ["fibroblasts", 690], ["from", 702], ["patients", 707], ["presenting", 716], ["different", 727], ["kinds", 737], ["of", 743], ["mutations", 746], ["in", 756], ["the", 759], ["RPS19", 763], ["gene", 769], [",", 773], ["generating", 775], ["allelic", 786], ["deletion", 794], [",", 802], ["missense", 804], [",", 812], ["nonsense", 814], [",", 822], ["and", 824], ["nonstop", 828], ["messengers", 836], [".", 846], ["We", 848], ["found", 851], ["that", 857], ["RPS19", 862], ["mRNA", 868], ["levels", 873], ["are", 880], ["decreased", 884], ["in", 894], ["the", 897], ["cells", 901], ["with", 907], ["allelic", 912], ["deletion", 920], ["and", 929], [",", 932], ["to", 934], ["a", 937], ["variable", 939], ["extent", 948], [",", 954], ["also", 956], ["in", 961], ["all", 964], ["the", 968], ["cell", 972], ["lines", 977], ["with", 983], ["PTC", 988], ["or", 992], ["nonstop", 995], ["mutations", 1003], [".", 1012], ["Further", 1014], ["analysis", 1022], ["showed", 1031], ["that", 1038], ["translation", 1043], ["inhibition", 1055], ["causes", 1066], ["a", 1073], ["stabilization", 1075], ["of", 1089], ["the", 1092], ["mutated", 1096], ["RPS19", 1104], ["mRNA", 1110], [".", 1114], ["Our", 1116], ["findings", 1120], ["indicate", 1129], ["that", 1138], ["NMD", 1143], ["and", 1147], ["nonstop", 1151], ["decay", 1159], ["affect", 1165], ["the", 1172], ["expression", 1176], ["of", 1187], ["mutated", 1190], ["RPS19", 1198], ["genes", 1204], [";", 1209], ["this", 1211], ["may", 1216], ["help", 1220], ["to", 1225], ["clarify", 1228], ["genotype", 1236], ["-", 1244], ["phenotype", 1245], ["correlations", 1255], ["in", 1268], ["DBA", 1271], [".", 1274]]}
{"context": "Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7887f12a541643aebe9893f82a5f0c28", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[86, 88], [36, 38], [100, 102], [8, 10], [57, 59], [79, 81]], "char_spans": [[505, 511], [213, 219], [582, 588], [36, 42], [337, 343], [464, 470]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["IM", 19], [")", 21], ["binds", 23], ["to", 29], ["the", 32], ["BCR", 36], ["-", 39], ["ABL", 40], ["protein", 44], [",", 51], ["inhibiting", 53], ["its", 64], ["kinase", 68], ["activity", 75], ["and", 84], ["effectively", 88], ["controlling", 100], ["diseases", 112], ["driven", 121], ["by", 128], ["this", 131], ["kinase", 136], [".", 142], ["IM", 144], ["resistance", 147], ["has", 158], ["been", 162], ["associated", 167], ["with", 178], ["kinase", 183], ["mutations", 190], ["or", 200], ["increased", 203], ["BCR", 213], ["-", 216], ["ABL", 217], ["expression", 221], [".", 231], ["However", 233], [",", 240], ["disease", 242], ["progression", 250], ["may", 262], ["be", 266], ["mediated", 269], ["by", 278], ["other", 281], ["mechanisms", 287], ["that", 298], ["render", 303], ["tumor", 310], ["cells", 316], ["independent", 322], ["of", 334], ["BCR", 337], ["-", 340], ["ABL", 341], [".", 344], ["To", 346], ["demonstrate", 349], ["this", 361], ["potential", 366], [",", 375], ["IM", 377], ["-", 379], ["resistant", 380], ["cells", 390], ["were", 396], ["found", 401], ["in", 407], ["chronic", 410], ["myelogenous", 418], ["leukemia", 430], ["patients", 439], ["with", 448], ["continuous", 453], ["BCR", 464], ["-", 467], ["ABL", 468], ["gene", 472], ["expression", 477], ["but", 488], ["undetectable", 492], ["BCR", 505], ["-", 508], ["ABL", 509], ["protein", 513], ["expression", 521], [".", 531], ["These", 533], ["cells", 539], ["were", 545], ["unresponsive", 550], ["to", 563], ["IM", 566], ["and", 569], ["acquired", 573], ["BCR", 582], ["-", 585], ["ABL", 586], ["-", 589], ["independent", 590], ["signaling", 602], ["characteristics", 612], [".", 627], ["IM", 629], ["resistance", 632], ["in", 643], ["some", 646], ["patients", 651], ["may", 660], ["be", 664], ["mediated", 667], ["through", 676], ["loss", 684], ["of", 689], ["kinase", 692], ["target", 699], ["dependence", 706], [".", 716]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. To provide an evidence-based update of new treatments published since 2005 for the management of RLS. First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "de513d59252e439c8c943b250eba9f14", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[128, 149]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["publication", 10], ["of", 22], ["the", 25], ["first", 29], ["European", 35], ["Federation", 44], ["of", 55], ["Neurological", 58], ["Societies", 71], ["(", 81], ["EFNS", 82], [")", 86], ["guidelines", 88], ["in", 99], ["2005", 102], ["on", 107], ["the", 110], ["management", 114], ["of", 125], ["restless", 128], ["legs", 137], ["syndrome", 142], ["(", 151], ["RLS", 152], [";", 155], ["also", 157], ["known", 162], ["as", 168], ["Willis", 171], ["-", 177], ["Ekbom", 178], ["disease", 184], [")", 191], [",", 192], ["there", 194], ["have", 200], ["been", 205], ["major", 210], ["therapeutic", 216], ["advances", 228], ["in", 237], ["the", 240], ["field", 244], [".", 249], ["Furthermore", 251], [",", 262], ["the", 264], ["management", 268], ["of", 279], ["RLS", 282], ["is", 286], ["now", 289], ["a", 293], ["part", 295], ["of", 300], ["routine", 303], ["neurological", 311], ["practice", 324], ["in", 333], ["Europe", 336], [".", 342], ["New", 344], ["drugs", 348], ["have", 354], ["also", 359], ["become", 364], ["available", 371], [",", 380], ["and", 382], ["further", 386], ["randomized", 394], ["controlled", 405], ["trials", 416], ["have", 423], ["been", 428], ["undertaken", 433], [".", 443], ["These", 445], ["guidelines", 451], ["were", 462], ["undertaken", 467], ["by", 478], ["the", 481], ["EFNS", 485], ["in", 490], ["collaboration", 493], ["with", 507], ["the", 512], ["European", 516], ["Neurological", 525], ["Society", 538], ["and", 546], ["the", 550], ["European", 554], ["Sleep", 563], ["Research", 569], ["Society", 578], [".", 585], ["To", 587], ["provide", 590], ["an", 598], ["evidence", 601], ["-", 609], ["based", 610], ["update", 616], ["of", 623], ["new", 626], ["treatments", 630], ["published", 641], ["since", 651], ["2005", 657], ["for", 662], ["the", 666], ["management", 670], ["of", 681], ["RLS", 684], [".", 687], ["First", 689], [",", 694], ["we", 696], ["determined", 699], ["what", 710], ["the", 715], ["objectives", 719], ["of", 730], ["management", 733], ["of", 744], ["primary", 747], ["and", 755], ["secondary", 759], ["RLS", 769], ["should", 773], ["be", 780], [".", 782], ["We", 784], ["developed", 787], ["the", 797], ["search", 801], ["strategy", 808], ["and", 817], ["conducted", 821], ["a", 831], ["review", 833], ["of", 840], ["the", 843], ["scientific", 847], ["literature", 858], ["up", 869], ["to", 872], ["31", 875], ["December", 878], ["2011", 887], ["(", 892], ["print", 893], ["and", 899], ["electronic", 903], ["publications", 914], [")", 926], ["for", 928], ["the", 932], ["drug", 936], ["classes", 941], ["and", 949], ["interventions", 953], ["employed", 967], ["in", 976], ["RLS", 979], ["treatment", 983], [".", 992], ["Previous", 994], ["guidelines", 1003], ["were", 1014], ["consulted", 1019], [".", 1028], ["All", 1030], ["trials", 1034], ["were", 1041], ["analysed", 1046], ["according", 1055], ["to", 1065], ["class", 1068], ["of", 1074], ["evidence", 1077], [",", 1085], ["and", 1087], ["recommendations", 1091], ["made", 1107], ["according", 1112], ["to", 1122], ["the", 1125], ["2004", 1129], ["EFNS", 1134], ["criteria", 1139], ["for", 1148], ["rating", 1152], [".", 1158], ["Level", 1160], ["A", 1166], ["recommendations", 1168], ["can", 1184], ["be", 1188], ["made", 1191], ["for", 1196], ["rotigotine", 1200], [",", 1210], ["ropinirole", 1212], [",", 1222], ["pramipexole", 1224], [",", 1235], ["gabapentin", 1237], ["enacarbil", 1248], [",", 1257], ["gabapentin", 1259], ["and", 1270], ["pregabalin", 1274], [",", 1284], ["which", 1286], ["are", 1292], ["all", 1296], ["considered", 1300], ["effective", 1311], ["for", 1321], ["the", 1325], ["short", 1329], ["-", 1334], ["term", 1335], ["treatment", 1340], ["for", 1350], ["RLS", 1354], [".", 1357], ["However", 1359], [",", 1366], ["for", 1368], ["the", 1372], ["long", 1376], ["-", 1380], ["term", 1381], ["treatment", 1386], ["for", 1396], ["RLS", 1400], [",", 1403], ["rotigotine", 1405], ["is", 1416], ["considered", 1419], ["effective", 1430], [",", 1439], ["gabapentin", 1441], ["enacarbil", 1452], ["is", 1462], ["probably", 1465], ["effective", 1474], [",", 1483], ["and", 1485], ["ropinirole", 1489], [",", 1499], ["pramipexole", 1501], ["and", 1513], ["gabapentin", 1517], ["are", 1528], ["considered", 1532], ["possibly", 1543], ["effective", 1552], [".", 1561], ["Cabergoline", 1563], ["has", 1575], ["according", 1579], ["to", 1589], ["our", 1592], ["criteria", 1596], ["a", 1605], ["level", 1607], ["A", 1613], ["recommendation", 1615], [",", 1629], ["but", 1631], ["the", 1635], ["taskforce", 1639], ["can", 1649], ["not", 1652], ["recommend", 1656], ["this", 1666], ["drug", 1671], ["because", 1676], ["of", 1684], ["its", 1687], ["serious", 1691], ["adverse", 1699], ["events", 1707], [".", 1713]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7d7dfb5ece1846bc8fab1c8af7bcce92", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[256, 256], [115, 115], [325, 325], [282, 282], [341, 341], [196, 196], [4, 4], [174, 174], [402, 402], [94, 94]], "char_spans": [[1517, 1520], [695, 698], [1926, 1929], [1662, 1665], [2006, 2009], [1147, 1150], [40, 43], [1011, 1014], [2397, 2400], [553, 556]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contraction", 78], ["of", 90], ["an", 93], ["array", 96], ["of", 102], ["tandem", 105], ["3.3-kb", 112], ["repeats", 119], ["(", 127], ["D4Z4", 128], [")", 132], ["at", 134], ["4q35", 137], [".", 141], ["Within", 143], ["each", 150], ["repeat", 155], ["unit", 162], ["is", 167], ["a", 170], ["gene", 172], [",", 176], ["DUX4", 178], [",", 182], ["that", 184], ["can", 189], ["encode", 193], ["a", 200], ["protein", 202], ["containing", 210], ["two", 221], ["homeodomains", 225], [".", 237], ["A", 239], ["DUX4", 241], ["transcript", 246], ["derived", 257], ["from", 265], ["the", 270], ["last", 274], ["repeat", 279], ["unit", 286], ["in", 291], ["a", 294], ["contracted", 296], ["array", 307], ["is", 313], ["associated", 316], ["with", 327], ["pathogenesis", 332], ["but", 345], ["it", 349], ["is", 352], ["unclear", 355], ["how", 363], [".", 366], ["Using", 368], ["exon", 374], ["-", 378], ["based", 379], ["microarrays", 385], [",", 396], ["the", 398], ["expression", 402], ["profiles", 413], ["of", 422], ["myogenic", 425], ["precursor", 434], ["cells", 444], ["were", 450], ["determined", 455], [".", 465], ["Both", 467], ["undifferentiated", 472], ["myoblasts", 489], ["and", 499], ["myoblasts", 503], ["differentiated", 513], ["to", 528], ["myotubes", 531], ["derived", 540], ["from", 548], ["FSHD", 553], ["patients", 558], ["and", 567], ["controls", 571], ["were", 580], ["studied", 585], ["after", 593], ["immunocytochemical", 599], ["verification", 618], ["of", 631], ["the", 634], ["quality", 638], ["of", 646], ["the", 649], ["cultures", 653], [".", 661], ["To", 663], ["further", 666], ["our", 674], ["understanding", 678], ["of", 692], ["FSHD", 695], ["and", 700], ["normal", 704], ["myogenesis", 711], [",", 721], ["the", 723], ["expression", 727], ["profiles", 738], ["obtained", 747], ["were", 756], ["compared", 761], ["to", 770], ["those", 773], ["of", 779], ["19", 782], ["non", 785], ["-", 788], ["muscle", 789], ["cell", 796], ["types", 801], ["analyzed", 807], ["by", 816], ["identical", 819], ["methods", 829], [".", 836], ["Many", 838], ["of", 843], ["the", 846], ["~17,000", 850], ["examined", 858], ["genes", 867], ["were", 873], ["differentially", 878], ["expressed", 893], ["(", 903], [">", 904], ["2-fold", 905], [",", 911], ["p<0.01", 913], [")", 919], ["in", 921], ["control", 924], ["myoblasts", 932], ["or", 942], ["myotubes", 945], ["vs.", 954], ["non", 958], ["-", 961], ["muscle", 962], ["cells", 969], ["(", 975], ["2185", 976], ["and", 981], ["3006", 985], [",", 989], ["respectively", 991], [")", 1003], ["or", 1005], ["in", 1008], ["FSHD", 1011], ["vs.", 1016], ["control", 1020], ["myoblasts", 1028], ["or", 1038], ["myotubes", 1041], ["(", 1050], ["295", 1051], ["and", 1055], ["797", 1059], [",", 1062], ["respectively", 1064], [")", 1076], [".", 1077], ["Surprisingly", 1079], [",", 1091], ["despite", 1093], ["the", 1101], ["morphologically", 1105], ["normal", 1121], ["differentiation", 1128], ["of", 1144], ["FSHD", 1147], ["myoblasts", 1152], ["to", 1162], ["myotubes", 1165], [",", 1173], ["most", 1175], ["of", 1180], ["the", 1183], ["disease", 1187], ["-", 1194], ["related", 1195], ["dysregulation", 1203], ["was", 1217], ["seen", 1221], ["as", 1226], ["dampening", 1229], ["of", 1239], ["normal", 1242], ["myogenesis", 1249], ["-", 1259], ["specific", 1260], ["expression", 1269], ["changes", 1280], [",", 1287], ["including", 1289], ["in", 1299], ["genes", 1302], ["for", 1308], ["muscle", 1312], ["structure", 1319], [",", 1328], ["mitochondrial", 1330], ["function", 1344], [",", 1352], ["stress", 1354], ["responses", 1361], [",", 1370], ["and", 1372], ["signal", 1376], ["transduction", 1383], [".", 1395], ["Other", 1397], ["classes", 1403], ["of", 1411], ["genes", 1414], [",", 1419], ["including", 1421], ["those", 1431], ["encoding", 1437], ["extracellular", 1446], ["matrix", 1460], ["or", 1467], ["pro", 1470], ["-", 1473], ["inflammatory", 1474], ["proteins", 1487], [",", 1495], ["were", 1497], ["upregulated", 1502], ["in", 1514], ["FSHD", 1517], ["myogenic", 1522], ["cells", 1531], ["independent", 1537], ["of", 1549], ["an", 1552], ["inverse", 1555], ["myogenesis", 1563], ["association", 1574], [".", 1585], ["Importantly", 1587], [",", 1598], ["the", 1600], ["disease", 1604], ["-", 1611], ["linked", 1612], ["DUX4", 1619], ["RNA", 1624], ["isoform", 1628], ["was", 1636], ["detected", 1640], ["by", 1649], ["RT", 1652], ["-", 1654], ["PCR", 1655], ["in", 1659], ["FSHD", 1662], ["myoblast", 1667], ["and", 1676], ["myotube", 1680], ["preparations", 1688], ["only", 1701], ["at", 1706], ["extremely", 1709], ["low", 1719], ["levels", 1723], [".", 1729], ["Unique", 1731], ["insights", 1738], ["into", 1747], ["myogenesis", 1752], ["-", 1762], ["specific", 1763], ["gene", 1772], ["expression", 1777], ["were", 1788], ["also", 1793], ["obtained", 1798], [".", 1806], ["For", 1808], ["example", 1812], [",", 1819], ["all", 1821], ["four", 1825], ["Argonaute", 1830], ["genes", 1840], ["involved", 1846], ["in", 1855], ["RNA", 1858], ["-", 1861], ["silencing", 1862], ["were", 1872], ["significantly", 1877], ["upregulated", 1891], ["during", 1903], ["normal", 1910], ["(", 1917], ["but", 1918], ["not", 1922], ["FSHD", 1926], [")", 1930], ["myogenesis", 1932], ["relative", 1943], ["to", 1952], ["non", 1955], ["-", 1958], ["muscle", 1959], ["cell", 1966], ["types", 1971], [".", 1976], ["DUX4", 1978], ["'s", 1982], ["pathogenic", 1985], ["effect", 1996], ["in", 2003], ["FSHD", 2006], ["may", 2011], ["occur", 2015], ["transiently", 2021], ["at", 2033], ["or", 2036], ["before", 2039], ["the", 2046], ["stage", 2050], ["of", 2056], ["myoblast", 2059], ["formation", 2068], ["to", 2078], ["establish", 2081], ["a", 2091], ["cascade", 2093], ["of", 2101], ["gene", 2104], ["dysregulation", 2109], [".", 2122], ["This", 2124], ["contrasts", 2129], ["with", 2139], ["the", 2144], ["current", 2148], ["emphasis", 2156], ["on", 2165], ["toxic", 2168], ["effects", 2174], ["of", 2182], ["experimentally", 2185], ["upregulated", 2200], ["DUX4", 2212], ["expression", 2217], ["at", 2228], ["the", 2231], ["myoblast", 2235], ["or", 2244], ["myotube", 2247], ["stages", 2255], [".", 2261], ["Our", 2263], ["model", 2267], ["could", 2273], ["explain", 2279], ["why", 2287], ["DUX4", 2291], ["'s", 2295], ["inappropriate", 2298], ["expression", 2312], ["was", 2323], ["barely", 2327], ["detectable", 2334], ["in", 2345], ["myoblasts", 2348], ["and", 2358], ["myotubes", 2362], ["but", 2371], ["nonetheless", 2375], ["linked", 2387], ["to", 2394], ["FSHD", 2397], [".", 2401]]}
{"context": "{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag. The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). Selexipag and ACT-333679 evoked full relaxation of pulmonary artery from control and monocrotaline (MCT)-PAH rats, and ACT-333679 relaxed normal pulmonary artery contracted with either endothelin-1 (ET-1) or phenylephrine. In contrast, treprostinil evoked weaker relaxation than ACT-333679 of control pulmonary artery and failed to induce relaxation of pulmonary artery from MCT-PAH rats. Treprostinil did not evoke relaxation of normal pulmonary artery contracted with either ET-1 or phenylephrine. Expression of prostaglandin E(3) (EP(3)) receptor mRNA was increased in pulmonary artery from MCT-PAH rats. In contraction experiments, the selective EP(3) receptor agonist sulprostone evoked significantly greater contraction of pulmonary artery from MCT-PAH rats compared with control rats. The presence of a threshold concentration of ET-1 significantly augmented the contractile response to sulprostone in normal pulmonary artery. ACT-333679 did not evoke direct contraction of rat pulmonary artery, whereas treprostinil evoked concentration-dependent contraction that was inhibited by the EP(3) receptor antagonist (2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. Antagonism of EP(3) receptors also revealed a relaxant response to treprostinil in normal pulmonary artery contracted with ET-1. These data demonstrate that the relaxant efficacy of the selective IP receptor agonist selexipag and its metabolite ACT-333679 is not modified under conditions associated with PAH, whereas relaxation to treprostinil may be limited in the presence of mediators of disease.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "69acbdb73b2c414cb48a711bb6da31f1", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[59, 61]], "char_spans": [[395, 425]]}]}], "context_tokens": [["{", 0], ["4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic", 1], ["acid", 61], ["(", 66], ["ACT-333679", 67], [")", 77], ["is", 79], ["the", 82], ["main", 86], ["metabolite", 91], ["of", 102], ["the", 105], ["selective", 109], ["prostacyclin", 119], ["(", 132], ["PGI(2", 133], [")", 138], [")", 139], ["receptor", 141], ["(", 150], ["IP", 151], ["receptor", 154], [")", 162], ["agonist", 164], ["selexipag", 172], [".", 181], ["The", 183], ["goal", 187], ["of", 192], ["this", 195], ["study", 200], ["was", 206], ["to", 210], ["determine", 213], ["the", 223], ["influence", 227], ["of", 237], ["IP", 240], ["receptor", 243], ["selectivity", 252], ["on", 264], ["the", 267], ["vasorelaxant", 271], ["efficacy", 284], ["of", 293], ["ACT-333679", 296], ["and", 307], ["the", 311], ["PGI(2", 315], [")", 320], ["analog", 322], ["treprostinil", 329], ["in", 342], ["pulmonary", 345], ["artery", 355], ["under", 362], ["conditions", 368], ["associated", 379], ["with", 390], ["pulmonary", 395], ["arterial", 405], ["hypertension", 414], ["(", 427], ["PAH", 428], [")", 431], [".", 432], ["Selexipag", 434], ["and", 444], ["ACT-333679", 448], ["evoked", 459], ["full", 466], ["relaxation", 471], ["of", 482], ["pulmonary", 485], ["artery", 495], ["from", 502], ["control", 507], ["and", 515], ["monocrotaline", 519], ["(", 533], ["MCT)-PAH", 534], ["rats", 543], [",", 547], ["and", 549], ["ACT-333679", 553], ["relaxed", 564], ["normal", 572], ["pulmonary", 579], ["artery", 589], ["contracted", 596], ["with", 607], ["either", 612], ["endothelin-1", 619], ["(", 632], ["ET-1", 633], [")", 637], ["or", 639], ["phenylephrine", 642], [".", 655], ["In", 657], ["contrast", 660], [",", 668], ["treprostinil", 670], ["evoked", 683], ["weaker", 690], ["relaxation", 697], ["than", 708], ["ACT-333679", 713], ["of", 724], ["control", 727], ["pulmonary", 735], ["artery", 745], ["and", 752], ["failed", 756], ["to", 763], ["induce", 766], ["relaxation", 773], ["of", 784], ["pulmonary", 787], ["artery", 797], ["from", 804], ["MCT", 809], ["-", 812], ["PAH", 813], ["rats", 817], [".", 821], ["Treprostinil", 823], ["did", 836], ["not", 840], ["evoke", 844], ["relaxation", 850], ["of", 861], ["normal", 864], ["pulmonary", 871], ["artery", 881], ["contracted", 888], ["with", 899], ["either", 904], ["ET-1", 911], ["or", 916], ["phenylephrine", 919], [".", 932], ["Expression", 934], ["of", 945], ["prostaglandin", 948], ["E(3", 962], [")", 965], ["(", 967], ["EP(3", 968], [")", 972], [")", 973], ["receptor", 975], ["mRNA", 984], ["was", 989], ["increased", 993], ["in", 1003], ["pulmonary", 1006], ["artery", 1016], ["from", 1023], ["MCT", 1028], ["-", 1031], ["PAH", 1032], ["rats", 1036], [".", 1040], ["In", 1042], ["contraction", 1045], ["experiments", 1057], [",", 1068], ["the", 1070], ["selective", 1074], ["EP(3", 1084], [")", 1088], ["receptor", 1090], ["agonist", 1099], ["sulprostone", 1107], ["evoked", 1119], ["significantly", 1126], ["greater", 1140], ["contraction", 1148], ["of", 1160], ["pulmonary", 1163], ["artery", 1173], ["from", 1180], ["MCT", 1185], ["-", 1188], ["PAH", 1189], ["rats", 1193], ["compared", 1198], ["with", 1207], ["control", 1212], ["rats", 1220], [".", 1224], ["The", 1226], ["presence", 1230], ["of", 1239], ["a", 1242], ["threshold", 1244], ["concentration", 1254], ["of", 1268], ["ET-1", 1271], ["significantly", 1276], ["augmented", 1290], ["the", 1300], ["contractile", 1304], ["response", 1316], ["to", 1325], ["sulprostone", 1328], ["in", 1340], ["normal", 1343], ["pulmonary", 1350], ["artery", 1360], [".", 1366], ["ACT-333679", 1368], ["did", 1379], ["not", 1383], ["evoke", 1387], ["direct", 1393], ["contraction", 1400], ["of", 1412], ["rat", 1415], ["pulmonary", 1419], ["artery", 1429], [",", 1435], ["whereas", 1437], ["treprostinil", 1445], ["evoked", 1458], ["concentration", 1465], ["-", 1478], ["dependent", 1479], ["contraction", 1489], ["that", 1501], ["was", 1506], ["inhibited", 1510], ["by", 1520], ["the", 1523], ["EP(3", 1527], [")", 1531], ["receptor", 1533], ["antagonist", 1542], ["(", 1553], ["2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide", 1554], [".", 1621], ["Antagonism", 1623], ["of", 1634], ["EP(3", 1637], [")", 1641], ["receptors", 1643], ["also", 1653], ["revealed", 1658], ["a", 1667], ["relaxant", 1669], ["response", 1678], ["to", 1687], ["treprostinil", 1690], ["in", 1703], ["normal", 1706], ["pulmonary", 1713], ["artery", 1723], ["contracted", 1730], ["with", 1741], ["ET-1", 1746], [".", 1750], ["These", 1752], ["data", 1758], ["demonstrate", 1763], ["that", 1775], ["the", 1780], ["relaxant", 1784], ["efficacy", 1793], ["of", 1802], ["the", 1805], ["selective", 1809], ["IP", 1819], ["receptor", 1822], ["agonist", 1831], ["selexipag", 1839], ["and", 1849], ["its", 1853], ["metabolite", 1857], ["ACT-333679", 1868], ["is", 1879], ["not", 1882], ["modified", 1886], ["under", 1895], ["conditions", 1901], ["associated", 1912], ["with", 1923], ["PAH", 1928], [",", 1931], ["whereas", 1933], ["relaxation", 1941], ["to", 1952], ["treprostinil", 1955], ["may", 1968], ["be", 1972], ["limited", 1975], ["in", 1983], ["the", 1986], ["presence", 1990], ["of", 1999], ["mediators", 2002], ["of", 2012], ["disease", 2015], [".", 2022]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Spectrins comprise \u03b1- and \u03b2-subunits made up predominantly of a series of homologous repeating units of about 106 amino acids; the \u03b1- and \u03b2-chains form antiparallel dimers by lateral association, and tetramers through head-to-head contacts between the dimers. Here we consider the first of these interactions. (1) We confirm earlier observations, showing that the first two paired repeats (\u03b2IR1 with \u03b1IR21, and \u03b2IR2 with \u03b1RI20) at one end of the erythroid spectrin (\u03b1I\u03b2I) dimer are necessary and sufficient to unite the chains; (2) we resolve a conflict in published reports by showing that the strength of the interaction is considerably increased on adding the adjoining pair of repeats (\u03b2IR3-\u03b1IR19); (3) in brain (\u03b1II\u03b2II) spectrin the first two pairs of repeats are similarly essential and sufficient for heterodimer formation; (4) this interaction is ~60-fold stronger than that in the erythroid counterpart, but no enhancement can be detected on addition of three further pairs of repeats; (5) formation of a tight \u03b1I\u03b2I dimer probably depends on structural coupling of the first two repeats in each chain; (6) an analysis of the sequences of the strongly interacting repeats, \u03b2IR1, \u03b2IIR1, \u03b1IR21 and \u03b1IIR20 and repeats in \u03b1-actinin, which also interact very strongly in forming an antiparallel dimer, affords a possible explanation for the different properties of the two spectrin isoforms in respect of the stability of the inter-chain interactions, and also suggests the evolutionary path by which the erythroid and non-erythroid sequences diverged.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "0cf3e09ca48743ab8afcd531f7b306e9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[248, 248], [30, 30]], "char_spans": [[1285, 1296], [152, 163]]}]}], "context_tokens": [["Spectrins", 0], ["comprise", 10], ["\u03b1-", 19], ["and", 22], ["\u03b2", 26], ["-", 27], ["subunits", 28], ["made", 37], ["up", 42], ["predominantly", 45], ["of", 59], ["a", 62], ["series", 64], ["of", 71], ["homologous", 74], ["repeating", 85], ["units", 95], ["of", 101], ["about", 104], ["106", 110], ["amino", 114], ["acids", 120], [";", 125], ["the", 127], ["\u03b1-", 131], ["and", 134], ["\u03b2", 138], ["-", 139], ["chains", 140], ["form", 147], ["antiparallel", 152], ["dimers", 165], ["by", 172], ["lateral", 175], ["association", 183], [",", 194], ["and", 196], ["tetramers", 200], ["through", 210], ["head", 218], ["-", 222], ["to", 223], ["-", 225], ["head", 226], ["contacts", 231], ["between", 240], ["the", 248], ["dimers", 252], [".", 258], ["Here", 260], ["we", 265], ["consider", 268], ["the", 277], ["first", 281], ["of", 287], ["these", 290], ["interactions", 296], [".", 308], ["(", 310], ["1", 311], [")", 312], ["We", 314], ["confirm", 317], ["earlier", 325], ["observations", 333], [",", 345], ["showing", 347], ["that", 355], ["the", 360], ["first", 364], ["two", 370], ["paired", 374], ["repeats", 381], ["(", 389], ["\u03b2IR1", 390], ["with", 395], ["\u03b1IR21", 400], [",", 405], ["and", 407], ["\u03b2IR2", 411], ["with", 416], ["\u03b1RI20", 421], [")", 426], ["at", 428], ["one", 431], ["end", 435], ["of", 439], ["the", 442], ["erythroid", 446], ["spectrin", 456], ["(", 465], ["\u03b1I\u03b2I", 466], [")", 470], ["dimer", 472], ["are", 478], ["necessary", 482], ["and", 492], ["sufficient", 496], ["to", 507], ["unite", 510], ["the", 516], ["chains", 520], [";", 526], ["(", 528], ["2", 529], [")", 530], ["we", 532], ["resolve", 535], ["a", 543], ["conflict", 545], ["in", 554], ["published", 557], ["reports", 567], ["by", 575], ["showing", 578], ["that", 586], ["the", 591], ["strength", 595], ["of", 604], ["the", 607], ["interaction", 611], ["is", 623], ["considerably", 626], ["increased", 639], ["on", 649], ["adding", 652], ["the", 659], ["adjoining", 663], ["pair", 673], ["of", 678], ["repeats", 681], ["(", 689], ["\u03b2IR3-\u03b1IR19", 690], [")", 700], [";", 701], ["(", 703], ["3", 704], [")", 705], ["in", 707], ["brain", 710], ["(", 716], ["\u03b1II\u03b2II", 717], [")", 723], ["spectrin", 725], ["the", 734], ["first", 738], ["two", 744], ["pairs", 748], ["of", 754], ["repeats", 757], ["are", 765], ["similarly", 769], ["essential", 779], ["and", 789], ["sufficient", 793], ["for", 804], ["heterodimer", 808], ["formation", 820], [";", 829], ["(", 831], ["4", 832], [")", 833], ["this", 835], ["interaction", 840], ["is", 852], ["~60-fold", 855], ["stronger", 864], ["than", 873], ["that", 878], ["in", 883], ["the", 886], ["erythroid", 890], ["counterpart", 900], [",", 911], ["but", 913], ["no", 917], ["enhancement", 920], ["can", 932], ["be", 936], ["detected", 939], ["on", 948], ["addition", 951], ["of", 960], ["three", 963], ["further", 969], ["pairs", 977], ["of", 983], ["repeats", 986], [";", 993], ["(", 995], ["5", 996], [")", 997], ["formation", 999], ["of", 1009], ["a", 1012], ["tight", 1014], ["\u03b1I\u03b2I", 1020], ["dimer", 1025], ["probably", 1031], ["depends", 1040], ["on", 1048], ["structural", 1051], ["coupling", 1062], ["of", 1071], ["the", 1074], ["first", 1078], ["two", 1084], ["repeats", 1088], ["in", 1096], ["each", 1099], ["chain", 1104], [";", 1109], ["(", 1111], ["6", 1112], [")", 1113], ["an", 1115], ["analysis", 1118], ["of", 1127], ["the", 1130], ["sequences", 1134], ["of", 1144], ["the", 1147], ["strongly", 1151], ["interacting", 1160], ["repeats", 1172], [",", 1179], ["\u03b2IR1", 1181], [",", 1185], ["\u03b2IIR1", 1187], [",", 1192], ["\u03b1IR21", 1194], ["and", 1200], ["\u03b1IIR20", 1204], ["and", 1211], ["repeats", 1215], ["in", 1223], ["\u03b1", 1226], ["-", 1227], ["actinin", 1228], [",", 1235], ["which", 1237], ["also", 1243], ["interact", 1248], ["very", 1257], ["strongly", 1262], ["in", 1271], ["forming", 1274], ["an", 1282], ["antiparallel", 1285], ["dimer", 1298], [",", 1303], ["affords", 1305], ["a", 1313], ["possible", 1315], ["explanation", 1324], ["for", 1336], ["the", 1340], ["different", 1344], ["properties", 1354], ["of", 1365], ["the", 1368], ["two", 1372], ["spectrin", 1376], ["isoforms", 1385], ["in", 1394], ["respect", 1397], ["of", 1405], ["the", 1408], ["stability", 1412], ["of", 1422], ["the", 1425], ["inter", 1429], ["-", 1434], ["chain", 1435], ["interactions", 1441], [",", 1453], ["and", 1455], ["also", 1459], ["suggests", 1464], ["the", 1473], ["evolutionary", 1477], ["path", 1490], ["by", 1495], ["which", 1498], ["the", 1504], ["erythroid", 1508], ["and", 1518], ["non", 1522], ["-", 1525], ["erythroid", 1526], ["sequences", 1536], ["diverged", 1546], [".", 1554]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies are common disorders of the aging population and characterized by the progressive accumulation of \u03b1-synuclein (\u03b1-syn) in the central nervous system. Aggregation of \u03b1-syn into oligomers with a ring-like appearance has been proposed to play a role in toxicity. However, the molecular mechanisms and the potential sequence of events involved in the formation of pore-like structures are unclear. We utilized computer modeling and cell-based studies to investigate the process of oligomerization of wild-type and A53T mutant \u03b1-syn in membranes. The studies suggest that \u03b1-syn penetrates the membrane rapidly, changing its conformation from \u03b1-helical towards a coiled structure. This penetration facilitates the incorporation of additional \u03b1-syn monomers in the complex, and the subsequent displacement of phospholipids and the formation of oligomers in the membrane. This process occurred more rapidly, and with a more favorable energy of interaction, for mutant A53T compared with wild-type \u03b1-syn. After 4 ns of simulation of the protein-membrane model, \u03b1-syn had penetrated through two-thirds of the membrane. By 9 ns, the penetration of the annular \u03b1-syn oligomers can result in the formation of pore-like structures that fully perforate the lipid bilayer. Experimental incubation of recombinant \u03b1-syn in synthetic membranes resulted in the formation of similar pore-like complexes. Moreover, mutant (A53T) \u03b1-syn had a greater tendency to accumulate in neuronal membrane fractions in cell cultures, resulting in greater neuronal permeability, as demonstrated with the calcein efflux assay. These studies provide a sequential molecular explanation for the process of \u03b1-syn oligomerization in the membrane, and support the role of formation of pore-like structures in the pathogenesis of the neurodegenerative process in PD.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "c042537f3aac4a97a4633fcf4c88fc5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["are", 55], ["common", 59], ["disorders", 66], ["of", 76], ["the", 79], ["aging", 83], ["population", 89], ["and", 100], ["characterized", 104], ["by", 118], ["the", 121], ["progressive", 125], ["accumulation", 137], ["of", 150], ["\u03b1", 153], ["-", 154], ["synuclein", 155], ["(", 165], ["\u03b1", 166], ["-", 167], ["syn", 168], [")", 171], ["in", 173], ["the", 176], ["central", 180], ["nervous", 188], ["system", 196], [".", 202], ["Aggregation", 204], ["of", 216], ["\u03b1", 219], ["-", 220], ["syn", 221], ["into", 225], ["oligomers", 230], ["with", 240], ["a", 245], ["ring", 247], ["-", 251], ["like", 252], ["appearance", 257], ["has", 268], ["been", 272], ["proposed", 277], ["to", 286], ["play", 289], ["a", 294], ["role", 296], ["in", 301], ["toxicity", 304], [".", 312], ["However", 314], [",", 321], ["the", 323], ["molecular", 327], ["mechanisms", 337], ["and", 348], ["the", 352], ["potential", 356], ["sequence", 366], ["of", 375], ["events", 378], ["involved", 385], ["in", 394], ["the", 397], ["formation", 401], ["of", 411], ["pore", 414], ["-", 418], ["like", 419], ["structures", 424], ["are", 435], ["unclear", 439], [".", 446], ["We", 448], ["utilized", 451], ["computer", 460], ["modeling", 469], ["and", 478], ["cell", 482], ["-", 486], ["based", 487], ["studies", 493], ["to", 501], ["investigate", 504], ["the", 516], ["process", 520], ["of", 528], ["oligomerization", 531], ["of", 547], ["wild", 550], ["-", 554], ["type", 555], ["and", 560], ["A53", 564], ["T", 567], ["mutant", 569], ["\u03b1", 576], ["-", 577], ["syn", 578], ["in", 582], ["membranes", 585], [".", 594], ["The", 596], ["studies", 600], ["suggest", 608], ["that", 616], ["\u03b1", 621], ["-", 622], ["syn", 623], ["penetrates", 627], ["the", 638], ["membrane", 642], ["rapidly", 651], [",", 658], ["changing", 660], ["its", 669], ["conformation", 673], ["from", 686], ["\u03b1", 691], ["-", 692], ["helical", 693], ["towards", 701], ["a", 709], ["coiled", 711], ["structure", 718], [".", 727], ["This", 729], ["penetration", 734], ["facilitates", 746], ["the", 758], ["incorporation", 762], ["of", 776], ["additional", 779], ["\u03b1", 790], ["-", 791], ["syn", 792], ["monomers", 796], ["in", 805], ["the", 808], ["complex", 812], [",", 819], ["and", 821], ["the", 825], ["subsequent", 829], ["displacement", 840], ["of", 853], ["phospholipids", 856], ["and", 870], ["the", 874], ["formation", 878], ["of", 888], ["oligomers", 891], ["in", 901], ["the", 904], ["membrane", 908], [".", 916], ["This", 918], ["process", 923], ["occurred", 931], ["more", 940], ["rapidly", 945], [",", 952], ["and", 954], ["with", 958], ["a", 963], ["more", 965], ["favorable", 970], ["energy", 980], ["of", 987], ["interaction", 990], [",", 1001], ["for", 1003], ["mutant", 1007], ["A53", 1014], ["T", 1017], ["compared", 1019], ["with", 1028], ["wild", 1033], ["-", 1037], ["type", 1038], ["\u03b1", 1043], ["-", 1044], ["syn", 1045], [".", 1048], ["After", 1050], ["4", 1056], ["ns", 1058], ["of", 1061], ["simulation", 1064], ["of", 1075], ["the", 1078], ["protein", 1082], ["-", 1089], ["membrane", 1090], ["model", 1099], [",", 1104], ["\u03b1", 1106], ["-", 1107], ["syn", 1108], ["had", 1112], ["penetrated", 1116], ["through", 1127], ["two", 1135], ["-", 1138], ["thirds", 1139], ["of", 1146], ["the", 1149], ["membrane", 1153], [".", 1161], ["By", 1163], ["9", 1166], ["ns", 1168], [",", 1170], ["the", 1172], ["penetration", 1176], ["of", 1188], ["the", 1191], ["annular", 1195], ["\u03b1", 1203], ["-", 1204], ["syn", 1205], ["oligomers", 1209], ["can", 1219], ["result", 1223], ["in", 1230], ["the", 1233], ["formation", 1237], ["of", 1247], ["pore", 1250], ["-", 1254], ["like", 1255], ["structures", 1260], ["that", 1271], ["fully", 1276], ["perforate", 1282], ["the", 1292], ["lipid", 1296], ["bilayer", 1302], [".", 1309], ["Experimental", 1311], ["incubation", 1324], ["of", 1335], ["recombinant", 1338], ["\u03b1", 1350], ["-", 1351], ["syn", 1352], ["in", 1356], ["synthetic", 1359], ["membranes", 1369], ["resulted", 1379], ["in", 1388], ["the", 1391], ["formation", 1395], ["of", 1405], ["similar", 1408], ["pore", 1416], ["-", 1420], ["like", 1421], ["complexes", 1426], [".", 1435], ["Moreover", 1437], [",", 1445], ["mutant", 1447], ["(", 1454], ["A53", 1455], ["T", 1458], [")", 1459], ["\u03b1", 1461], ["-", 1462], ["syn", 1463], ["had", 1467], ["a", 1471], ["greater", 1473], ["tendency", 1481], ["to", 1490], ["accumulate", 1493], ["in", 1504], ["neuronal", 1507], ["membrane", 1516], ["fractions", 1525], ["in", 1535], ["cell", 1538], ["cultures", 1543], [",", 1551], ["resulting", 1553], ["in", 1563], ["greater", 1566], ["neuronal", 1574], ["permeability", 1583], [",", 1595], ["as", 1597], ["demonstrated", 1600], ["with", 1613], ["the", 1618], ["calcein", 1622], ["efflux", 1630], ["assay", 1637], [".", 1642], ["These", 1644], ["studies", 1650], ["provide", 1658], ["a", 1666], ["sequential", 1668], ["molecular", 1679], ["explanation", 1689], ["for", 1701], ["the", 1705], ["process", 1709], ["of", 1717], ["\u03b1", 1720], ["-", 1721], ["syn", 1722], ["oligomerization", 1726], ["in", 1742], ["the", 1745], ["membrane", 1749], [",", 1757], ["and", 1759], ["support", 1763], ["the", 1771], ["role", 1775], ["of", 1780], ["formation", 1783], ["of", 1793], ["pore", 1796], ["-", 1800], ["like", 1801], ["structures", 1806], ["in", 1817], ["the", 1820], ["pathogenesis", 1824], ["of", 1837], ["the", 1840], ["neurodegenerative", 1844], ["process", 1862], ["in", 1870], ["PD", 1873], [".", 1875]]}
{"context": "To develop a clinical prediction rule to identify patients who can be safely discharged one hour after the administration of naloxone for presumed opioid overdose. Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. Patients were classified into two groups: those with adverse events within 24 hours and those without. Using classification and regression tree methodology, a decision rule was developed to predict safe discharge. Clinical findings from 573 patients allowed us to develop a clinical prediction rule with a sensitivity of 99% (95% CI = 96% to 100%) and a specificity of 40% (95% CI = 36% to 45%). Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration if they: 1) can mobilize as usual; 2) have oxygen saturation on room air of >92%; 3) have a respiratory rate >10 breaths/min and <20 breaths/min; 4) have a temperature of >35.0 degrees C and <37.5 degrees C; 5) have a heart rate >50 beats/min and <100 beats/min; and 6) have a Glasgow Coma Scale score of 15. This prediction rule for safe early discharge of patients with presumed opioid overdose performs well in this derivation set but requires validation followed by confirmation of safe implementation.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "70d7878277804532b313a72e5e20e286", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[20, 20], [29, 29], [143, 143]], "char_spans": [[125, 132], [186, 193], [791, 798]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["a", 11], ["clinical", 13], ["prediction", 22], ["rule", 33], ["to", 38], ["identify", 41], ["patients", 50], ["who", 59], ["can", 63], ["be", 67], ["safely", 70], ["discharged", 77], ["one", 88], ["hour", 92], ["after", 97], ["the", 103], ["administration", 107], ["of", 122], ["naloxone", 125], ["for", 134], ["presumed", 138], ["opioid", 147], ["overdose", 154], [".", 162], ["Patients", 164], ["who", 173], ["received", 177], ["naloxone", 186], ["for", 195], ["known", 199], ["or", 205], ["presumed", 208], ["opioid", 217], ["overdose", 224], ["were", 233], ["formally", 238], ["evaluated", 247], ["one", 257], ["hour", 261], ["later", 266], ["for", 272], ["multiple", 276], ["potential", 285], ["predictor", 295], ["variables", 305], [".", 314], ["Patients", 316], ["were", 325], ["classified", 330], ["into", 341], ["two", 346], ["groups", 350], [":", 356], ["those", 358], ["with", 364], ["adverse", 369], ["events", 377], ["within", 384], ["24", 391], ["hours", 394], ["and", 400], ["those", 404], ["without", 410], [".", 417], ["Using", 419], ["classification", 425], ["and", 440], ["regression", 444], ["tree", 455], ["methodology", 460], [",", 471], ["a", 473], ["decision", 475], ["rule", 484], ["was", 489], ["developed", 493], ["to", 503], ["predict", 506], ["safe", 514], ["discharge", 519], [".", 528], ["Clinical", 530], ["findings", 539], ["from", 548], ["573", 553], ["patients", 557], ["allowed", 566], ["us", 574], ["to", 577], ["develop", 580], ["a", 588], ["clinical", 590], ["prediction", 599], ["rule", 610], ["with", 615], ["a", 620], ["sensitivity", 622], ["of", 634], ["99", 637], ["%", 639], ["(", 641], ["95", 642], ["%", 644], ["CI", 646], ["=", 649], ["96", 651], ["%", 653], ["to", 655], ["100", 658], ["%", 661], [")", 662], ["and", 664], ["a", 668], ["specificity", 670], ["of", 682], ["40", 685], ["%", 687], ["(", 689], ["95", 690], ["%", 692], ["CI", 694], ["=", 697], ["36", 699], ["%", 701], ["to", 703], ["45", 706], ["%", 708], [")", 709], [".", 710], ["Patients", 712], ["with", 721], ["presumed", 726], ["opioid", 735], ["overdose", 742], ["can", 751], ["be", 755], ["safely", 758], ["discharged", 765], ["one", 776], ["hour", 780], ["after", 785], ["naloxone", 791], ["administration", 800], ["if", 815], ["they", 818], [":", 822], ["1", 824], [")", 825], ["can", 827], ["mobilize", 831], ["as", 840], ["usual", 843], [";", 848], ["2", 850], [")", 851], ["have", 853], ["oxygen", 858], ["saturation", 865], ["on", 876], ["room", 879], ["air", 884], ["of", 888], [">", 891], ["92", 892], ["%", 894], [";", 895], ["3", 897], [")", 898], ["have", 900], ["a", 905], ["respiratory", 907], ["rate", 919], [">", 924], ["10", 925], ["breaths", 928], ["/", 935], ["min", 936], ["and", 940], ["<", 944], ["20", 945], ["breaths", 948], ["/", 955], ["min", 956], [";", 959], ["4", 961], [")", 962], ["have", 964], ["a", 969], ["temperature", 971], ["of", 983], [">", 986], ["35.0", 987], ["degrees", 992], ["C", 1000], ["and", 1002], ["<", 1006], ["37.5", 1007], ["degrees", 1012], ["C", 1020], [";", 1021], ["5", 1023], [")", 1024], ["have", 1026], ["a", 1031], ["heart", 1033], ["rate", 1039], [">", 1044], ["50", 1045], ["beats", 1048], ["/", 1053], ["min", 1054], ["and", 1058], ["<", 1062], ["100", 1063], ["beats", 1067], ["/", 1072], ["min", 1073], [";", 1076], ["and", 1078], ["6", 1082], [")", 1083], ["have", 1085], ["a", 1090], ["Glasgow", 1092], ["Coma", 1100], ["Scale", 1105], ["score", 1111], ["of", 1117], ["15", 1120], [".", 1122], ["This", 1124], ["prediction", 1129], ["rule", 1140], ["for", 1145], ["safe", 1149], ["early", 1154], ["discharge", 1160], ["of", 1170], ["patients", 1173], ["with", 1182], ["presumed", 1187], ["opioid", 1196], ["overdose", 1203], ["performs", 1212], ["well", 1221], ["in", 1226], ["this", 1229], ["derivation", 1234], ["set", 1245], ["but", 1249], ["requires", 1253], ["validation", 1262], ["followed", 1273], ["by", 1282], ["confirmation", 1285], ["of", 1298], ["safe", 1301], ["implementation", 1306], [".", 1320]]}
{"context": "The carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved. Its presentation is characteristic in females about 40 years of age. The diagnosis is mainly based on clinical features and is confirmed by electrical criteria. In the anamnesis it is important to consider systemic diseases as causing the abnormality. Treatment depends on the etiology. It may be medical or surgical. In the present article we report three cases with different etiology and treatment. We also review the syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "944fef283f4a45c0b0e909cc2f35bb32", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[29, 29]], "char_spans": [[138, 143]]}]}], "context_tokens": [["The", 0], ["carpal", 4], ["tunnel", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["neuropathy", 32], ["due", 43], ["to", 47], ["trapping", 50], ["(", 59], ["focal", 60], ["lesion", 66], ["of", 73], ["the", 76], ["peripheral", 80], ["nerve", 91], ["due", 97], ["to", 101], ["a", 104], ["local", 106], ["cause", 112], [")", 117], [";", 118], ["in", 120], ["this", 123], ["case", 128], [",", 132], ["the", 134], ["median", 138], ["nerve", 145], ["is", 151], ["the", 154], ["most", 158], ["commonly", 163], ["involved", 172], [".", 180], ["Its", 182], ["presentation", 186], ["is", 199], ["characteristic", 202], ["in", 217], ["females", 220], ["about", 228], ["40", 234], ["years", 237], ["of", 243], ["age", 246], [".", 249], ["The", 251], ["diagnosis", 255], ["is", 265], ["mainly", 268], ["based", 275], ["on", 281], ["clinical", 284], ["features", 293], ["and", 302], ["is", 306], ["confirmed", 309], ["by", 319], ["electrical", 322], ["criteria", 333], [".", 341], ["In", 343], ["the", 346], ["anamnesis", 350], ["it", 360], ["is", 363], ["important", 366], ["to", 376], ["consider", 379], ["systemic", 388], ["diseases", 397], ["as", 406], ["causing", 409], ["the", 417], ["abnormality", 421], [".", 432], ["Treatment", 434], ["depends", 444], ["on", 452], ["the", 455], ["etiology", 459], [".", 467], ["It", 469], ["may", 472], ["be", 476], ["medical", 479], ["or", 487], ["surgical", 490], [".", 498], ["In", 500], ["the", 503], ["present", 507], ["article", 515], ["we", 523], ["report", 526], ["three", 533], ["cases", 539], ["with", 545], ["different", 550], ["etiology", 560], ["and", 569], ["treatment", 573], [".", 582], ["We", 584], ["also", 587], ["review", 592], ["the", 599], ["syndrome", 603], [".", 611]]}
{"context": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice. MPTP treatment (10 mg/kg, four times at 2-h intervals) decreased dopamine levels in the midbrain and impaired motor coordination, and these effects were counteracted by S-methylthiocitrulline, a selective neuronal NO synthase inhibitor. SEA0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in MPTP-treated mice. SEA0400 had no radical-scavenging activity. SEA0400 did not affect MPTP metabolism and MPTP-induced NO production and microglial activation, while it attenuated MPTP-induced increases in extracellular signal-regulated kinase (ERK) phosphorylation and lipid peroxidation product, thiobarbituric acid reactive substance. These findings suggest that SEA0400 protects against MPTP-induced neurotoxicity probably by blocking ERK phosphorylation and lipid peroxidation which are downstream of NCX-mediated Ca(2+) influx.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "da32f12980d845719c03c2c03494afe1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9]], "char_spans": [[32, 53]]}, {"text": "NCX", "token_spans": [[72, 72], [39, 39], [11, 11], [250, 250]], "char_spans": [[420, 422], [212, 214], [56, 58], [1563, 1565]]}]}], "context_tokens": [["We", 0], ["have", 3], ["recently", 8], ["shown", 17], ["that", 23], ["the", 28], ["Na(+)/Ca(2", 32], ["+", 42], [")", 43], ["exchanger", 45], ["(", 55], ["NCX", 56], [")", 59], ["is", 61], ["involved", 64], ["in", 73], ["nitric", 76], ["oxide", 83], ["(", 89], ["NO)-induced", 90], ["cytotoxicity", 102], ["in", 115], ["cultured", 118], ["astrocytes", 127], ["and", 138], ["neurons", 142], [".", 149], ["However", 151], [",", 158], ["there", 160], ["is", 166], ["no", 169], ["in", 172], ["vivo", 175], ["evidence", 180], ["suggesting", 189], ["the", 200], ["role", 204], ["of", 209], ["NCX", 212], ["in", 216], ["neurodegenerative", 219], ["disorders", 237], ["associated", 247], ["with", 258], ["NO", 263], [".", 265], ["NO", 267], ["is", 270], ["implicated", 273], ["in", 284], ["the", 287], ["pathogenesis", 291], ["of", 304], ["neurodegenerative", 307], ["disorders", 325], ["such", 335], ["as", 340], ["Parkinson", 343], ["'s", 352], ["disease", 355], [".", 362], ["This", 364], ["study", 369], ["examined", 375], ["the", 384], ["effect", 388], ["of", 395], ["SEA0400", 398], [",", 405], ["the", 407], ["specific", 411], ["NCX", 420], ["inhibitor", 424], [",", 433], ["on", 435], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 438], ["(", 483], ["MPTP)-induced", 484], ["dopaminergic", 498], ["neurotoxicity", 511], [",", 524], ["a", 526], ["model", 528], ["of", 534], ["Parkinson", 537], ["'s", 546], ["disease", 549], [",", 556], ["in", 558], ["C57BL/6J", 561], ["mice", 570], [".", 574], ["MPTP", 576], ["treatment", 581], ["(", 591], ["10", 592], ["mg", 595], ["/", 597], ["kg", 598], [",", 600], ["four", 602], ["times", 607], ["at", 613], ["2-h", 616], ["intervals", 620], [")", 629], ["decreased", 631], ["dopamine", 641], ["levels", 650], ["in", 657], ["the", 660], ["midbrain", 664], ["and", 673], ["impaired", 677], ["motor", 686], ["coordination", 692], [",", 704], ["and", 706], ["these", 710], ["effects", 716], ["were", 724], ["counteracted", 729], ["by", 742], ["S", 745], ["-", 746], ["methylthiocitrulline", 747], [",", 767], ["a", 769], ["selective", 771], ["neuronal", 781], ["NO", 790], ["synthase", 793], ["inhibitor", 802], [".", 811], ["SEA0400", 813], ["protected", 821], ["against", 831], ["the", 839], ["dopaminergic", 843], ["neurotoxicity", 856], ["(", 870], ["determined", 871], ["by", 882], ["dopamine", 885], ["levels", 894], ["in", 901], ["the", 904], ["midbrain", 908], ["and", 917], ["striatum", 921], [",", 929], ["tyrosine", 931], ["hydroxylase", 940], ["immunoreactivity", 952], ["in", 969], ["the", 972], ["substantia", 976], ["nigra", 987], ["and", 993], ["striatum", 997], [",", 1005], ["striatal", 1007], ["dopamine", 1016], ["release", 1025], [",", 1032], ["and", 1034], ["motor", 1038], ["deficits", 1044], [")", 1052], ["in", 1054], ["MPTP", 1057], ["-", 1061], ["treated", 1062], ["mice", 1070], [".", 1074], ["SEA0400", 1076], ["had", 1084], ["no", 1088], ["radical", 1091], ["-", 1098], ["scavenging", 1099], ["activity", 1110], [".", 1118], ["SEA0400", 1120], ["did", 1128], ["not", 1132], ["affect", 1136], ["MPTP", 1143], ["metabolism", 1148], ["and", 1159], ["MPTP", 1163], ["-", 1167], ["induced", 1168], ["NO", 1176], ["production", 1179], ["and", 1190], ["microglial", 1194], ["activation", 1205], [",", 1215], ["while", 1217], ["it", 1223], ["attenuated", 1226], ["MPTP", 1237], ["-", 1241], ["induced", 1242], ["increases", 1250], ["in", 1260], ["extracellular", 1263], ["signal", 1277], ["-", 1283], ["regulated", 1284], ["kinase", 1294], ["(", 1301], ["ERK", 1302], [")", 1305], ["phosphorylation", 1307], ["and", 1323], ["lipid", 1327], ["peroxidation", 1333], ["product", 1346], [",", 1353], ["thiobarbituric", 1355], ["acid", 1370], ["reactive", 1375], ["substance", 1384], [".", 1393], ["These", 1395], ["findings", 1401], ["suggest", 1410], ["that", 1418], ["SEA0400", 1423], ["protects", 1431], ["against", 1440], ["MPTP", 1448], ["-", 1452], ["induced", 1453], ["neurotoxicity", 1461], ["probably", 1475], ["by", 1484], ["blocking", 1487], ["ERK", 1496], ["phosphorylation", 1500], ["and", 1516], ["lipid", 1520], ["peroxidation", 1526], ["which", 1539], ["are", 1545], ["downstream", 1549], ["of", 1560], ["NCX", 1563], ["-", 1566], ["mediated", 1567], ["Ca(2", 1576], ["+", 1580], [")", 1581], ["influx", 1583], [".", 1589]]}
{"context": "The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer. In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha20-21/beta1-2; alpha18-21/beta1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha20 and beta2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta2 motif opposite negative potential on the AB face of the alpha20 motif and vise versa. Protease protection analysis of the alpha20-21/beta1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta2 and alpha21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha21-beta1 and alpha20-beta2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "341b721c73f64225b0bb8a8e9b4fdbef", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[7, 7]], "char_spans": [[42, 53]]}]}], "context_tokens": [["The", 0], ["spectrin", 4], ["heterodimer", 13], ["is", 25], ["formed", 28], ["by", 35], ["the", 38], ["antiparallel", 42], ["lateral", 55], ["association", 63], ["of", 75], ["an", 78], ["alpha", 81], ["and", 87], ["a", 91], ["beta", 93], ["subunit", 98], [",", 105], ["each", 107], ["of", 112], ["which", 115], ["comprises", 121], ["largely", 131], ["a", 139], ["series", 141], ["of", 148], ["homologous", 151], ["triple", 162], ["-", 168], ["helical", 169], ["motifs", 177], [".", 183], ["Initiation", 185], ["of", 196], ["dimer", 199], ["assembly", 205], ["involves", 214], ["strong", 223], ["binding", 230], ["between", 238], ["complementary", 246], ["motifs", 260], ["near", 267], ["the", 272], ["actin", 276], ["-", 281], ["binding", 282], ["end", 290], ["of", 294], ["the", 297], ["dimer", 301], [".", 306], ["In", 308], ["this", 311], ["study", 316], [",", 321], ["the", 323], ["mechanism", 327], ["of", 337], ["lateral", 340], ["spectrin", 348], ["association", 357], ["at", 369], ["this", 372], ["dimer", 377], ["nucleation", 383], ["site", 394], ["was", 399], ["investigated", 403], ["using", 416], ["the", 422], ["analytical", 426], ["ultracentrifuge", 437], ["to", 453], ["analyze", 456], ["heterodimers", 464], ["formed", 477], ["from", 484], ["recombinant", 489], ["peptides", 501], ["containing", 510], ["two", 521], ["or", 525], ["four", 528], ["homologous", 533], ["motifs", 544], ["from", 551], ["each", 556], ["subunit", 561], ["(", 569], ["alpha20", 570], ["-", 577], ["21/beta1", 578], ["-", 586], ["2", 587], [";", 588], ["alpha18", 590], ["-", 597], ["21/beta1", 598], ["-", 606], ["4", 607], [")", 608], [".", 609], ["Both", 611], ["the", 616], ["two", 620], ["-", 623], ["motif", 624], ["and", 630], ["four", 634], ["-", 638], ["motif", 639], ["dimer", 645], ["associations", 651], ["were", 664], ["weakened", 669], ["substantially", 678], ["with", 692], ["increasing", 697], ["salt", 708], ["concentration", 713], [",", 726], ["indicating", 728], ["that", 739], ["electrostatic", 744], ["interactions", 758], ["are", 771], ["important", 775], ["for", 785], ["the", 789], ["dimer", 793], ["initiation", 799], ["process", 810], [".", 817], ["Modeling", 819], ["of", 828], ["the", 831], ["electrostatic", 835], ["potential", 849], ["on", 859], ["the", 862], ["surface", 866], ["of", 874], ["the", 877], ["alpha20", 881], ["and", 889], ["beta2", 893], ["motifs", 899], ["showed", 906], ["that", 913], ["the", 918], ["side", 922], ["of", 927], ["the", 930], ["motifs", 934], ["comprising", 941], ["the", 952], ["A", 956], ["and", 958], ["B", 962], ["helices", 964], ["is", 972], ["the", 975], ["most", 979], ["favorable", 984], ["for", 994], ["association", 998], [",", 1009], ["with", 1011], ["an", 1016], ["area", 1019], ["of", 1024], ["positive", 1027], ["electrostatic", 1036], ["potential", 1050], ["on", 1060], ["the", 1063], ["AB", 1067], ["face", 1070], ["of", 1075], ["the", 1078], ["beta2", 1082], ["motif", 1088], ["opposite", 1094], ["negative", 1103], ["potential", 1112], ["on", 1122], ["the", 1125], ["AB", 1129], ["face", 1132], ["of", 1137], ["the", 1140], ["alpha20", 1144], ["motif", 1152], ["and", 1158], ["vise", 1162], ["versa", 1167], [".", 1172], ["Protease", 1174], ["protection", 1183], ["analysis", 1194], ["of", 1203], ["the", 1206], ["alpha20", 1210], ["-", 1217], ["21/beta1", 1218], ["-", 1226], ["2", 1227], ["dimer", 1229], ["showed", 1235], ["that", 1242], ["multiple", 1247], ["trypsin", 1256], ["and", 1264], ["proteinase", 1268], ["K", 1279], ["sites", 1281], ["in", 1287], ["the", 1290], ["A", 1294], ["helices", 1296], ["of", 1304], ["the", 1307], ["beta2", 1311], ["and", 1317], ["alpha21", 1321], ["motifs", 1329], ["become", 1336], ["buried", 1343], ["upon", 1350], ["dimer", 1355], ["formation", 1361], [".", 1370], ["Together", 1372], [",", 1380], ["these", 1382], ["data", 1388], ["support", 1393], ["a", 1401], ["model", 1403], ["where", 1409], ["complementary", 1415], ["long", 1429], ["range", 1434], ["electrostatic", 1440], ["interactions", 1454], ["on", 1467], ["the", 1470], ["AB", 1474], ["faces", 1477], ["of", 1483], ["the", 1486], ["triple", 1490], ["-", 1496], ["helical", 1497], ["motifs", 1505], ["in", 1512], ["the", 1515], ["dimer", 1519], ["nucleation", 1525], ["site", 1536], ["initiate", 1541], ["the", 1550], ["correct", 1554], ["pairing", 1562], ["of", 1570], ["motifs", 1573], [",", 1579], ["i.e.", 1581], ["alpha21-beta1", 1586], ["and", 1600], ["alpha20-beta2", 1604], [".", 1617], ["After", 1619], ["initial", 1625], ["docking", 1633], ["of", 1641], ["these", 1644], ["complementary", 1650], ["triple", 1664], ["-", 1670], ["helical", 1671], ["motifs", 1679], [",", 1685], ["this", 1687], ["association", 1692], ["is", 1704], ["probably", 1707], ["stabilized", 1716], ["by", 1727], ["subsequent", 1730], ["formation", 1741], ["of", 1751], ["stronger", 1754], ["hydrophobic", 1763], ["interactions", 1775], ["in", 1788], ["a", 1791], ["complex", 1793], ["involving", 1801], ["the", 1811], ["A", 1815], ["helices", 1817], ["of", 1825], ["both", 1828], ["subunits", 1833], ["and", 1842], ["possibly", 1846], ["most", 1855], ["of", 1860], ["the", 1863], ["AB", 1867], ["faces", 1870], [".", 1875], ["The", 1877], ["beta", 1881], ["subunit", 1886], ["A", 1894], ["helix", 1896], ["in", 1902], ["particular", 1905], ["appears", 1916], ["to", 1924], ["be", 1927], ["buried", 1930], ["in", 1937], ["the", 1940], ["dimer", 1944], ["interface", 1950], [".", 1959]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes. A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n\u2009=\u20092572) or placebo (n\u2009=\u20092573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P\u2009=\u2009.08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P\u2009=\u2009.005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P\u2009=\u2009.04). In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. clinicaltrials.gov Identifier: NCT01130246.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9b9bcd725a354906b933c55de76f23a8", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], ["generates", 35], ["bioactive", 45], ["phospholipid", 55], ["products", 68], ["implicated", 77], ["in", 88], ["atherosclerosis", 91], [".", 106], ["The", 108], ["sPLA2", 112], ["inhibitor", 118], ["varespladib", 128], ["has", 140], ["favorable", 144], ["effects", 154], ["on", 162], ["lipid", 165], ["and", 171], ["inflammatory", 175], ["markers", 188], [";", 195], ["however", 197], [",", 204], ["its", 206], ["effect", 210], ["on", 217], ["cardiovascular", 220], ["outcomes", 235], ["is", 244], ["unknown", 247], [".", 254], ["To", 256], ["determine", 259], ["the", 269], ["effects", 273], ["of", 281], ["sPLA2", 284], ["inhibition", 290], ["with", 301], ["varespladib", 306], ["on", 318], ["cardiovascular", 321], ["outcomes", 336], [".", 344], ["A", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["randomized", 362], [",", 372], ["multicenter", 374], ["trial", 386], ["at", 392], ["362", 395], ["academic", 399], ["and", 408], ["community", 412], ["hospitals", 422], ["in", 432], ["Europe", 435], [",", 441], ["Australia", 443], [",", 452], ["New", 454], ["Zealand", 458], [",", 465], ["India", 467], [",", 472], ["and", 474], ["North", 478], ["America", 484], ["of", 492], ["5145", 495], ["patients", 500], ["randomized", 509], ["within", 520], ["96", 527], ["hours", 530], ["of", 536], ["presentation", 539], ["of", 552], ["an", 555], ["acute", 558], ["coronary", 564], ["syndrome", 573], ["(", 582], ["ACS", 583], [")", 586], ["to", 588], ["either", 591], ["varespladib", 598], ["(", 610], ["n", 611], ["=", 613], ["2572", 615], [")", 619], ["or", 621], ["placebo", 624], ["(", 632], ["n", 633], ["=", 635], ["2573", 637], [")", 641], ["with", 643], ["enrollment", 648], ["between", 659], ["June", 667], ["1", 672], [",", 673], ["2010", 675], [",", 679], ["and", 681], ["March", 685], ["7", 691], [",", 692], ["2012", 694], ["(", 699], ["study", 700], ["termination", 706], ["on", 718], ["March", 721], ["9", 727], [",", 728], ["2012", 730], [")", 734], [".", 735], ["Participants", 737], ["were", 750], ["randomized", 755], ["to", 766], ["receive", 769], ["varespladib", 777], ["(", 789], ["500", 790], ["mg", 794], [")", 796], ["or", 798], ["placebo", 801], ["daily", 809], ["for", 815], ["16", 819], ["weeks", 822], [",", 827], ["in", 829], ["addition", 832], ["to", 841], ["atorvastatin", 844], ["and", 857], ["other", 861], ["established", 867], ["therapies", 879], [".", 888], ["The", 890], ["primary", 894], ["efficacy", 902], ["measure", 911], ["was", 919], ["a", 923], ["composite", 925], ["of", 935], ["cardiovascular", 938], ["mortality", 953], [",", 962], ["nonfatal", 964], ["myocardial", 973], ["infarction", 984], ["(", 995], ["MI", 996], [")", 998], [",", 999], ["nonfatal", 1001], ["stroke", 1010], [",", 1016], ["or", 1018], ["unstable", 1021], ["angina", 1030], ["with", 1037], ["evidence", 1042], ["of", 1051], ["ischemia", 1054], ["requiring", 1063], ["hospitalization", 1073], ["at", 1089], ["16", 1092], ["weeks", 1095], [".", 1100], ["Six", 1102], ["-", 1105], ["month", 1106], ["survival", 1112], ["status", 1121], ["was", 1128], ["also", 1132], ["evaluated", 1137], [".", 1146], ["At", 1148], ["a", 1151], ["prespecified", 1153], ["interim", 1166], ["analysis", 1174], [",", 1182], ["including", 1184], ["212", 1194], ["primary", 1198], ["end", 1206], ["point", 1210], ["events", 1216], [",", 1222], ["the", 1224], ["independent", 1228], ["data", 1240], ["and", 1245], ["safety", 1249], ["monitoring", 1256], ["board", 1267], ["recommended", 1273], ["termination", 1285], ["of", 1297], ["the", 1300], ["trial", 1304], ["for", 1310], ["futility", 1314], ["and", 1323], ["possible", 1327], ["harm", 1336], [".", 1340], ["The", 1342], ["primary", 1346], ["end", 1354], ["point", 1358], ["occurred", 1364], ["in", 1373], ["136", 1376], ["patients", 1380], ["(", 1389], ["6.1", 1390], ["%", 1393], [")", 1394], ["treated", 1396], ["with", 1404], ["varespladib", 1409], ["compared", 1421], ["with", 1430], ["109", 1435], ["patients", 1439], ["(", 1448], ["5.1", 1449], ["%", 1452], [")", 1453], ["treated", 1455], ["with", 1463], ["placebo", 1468], ["(", 1476], ["hazard", 1477], ["ratio", 1484], ["[", 1490], ["HR", 1491], ["]", 1493], [",", 1494], ["1.25", 1496], [";", 1500], ["95", 1502], ["%", 1504], ["CI", 1506], [",", 1508], ["0.97", 1510], ["-", 1514], ["1.61", 1515], [";", 1519], ["log", 1521], ["-", 1524], ["rank", 1525], ["P", 1530], ["=", 1532], [".08", 1534], [")", 1537], [".", 1538], ["Varespladib", 1540], ["was", 1552], ["associated", 1556], ["with", 1567], ["a", 1572], ["greater", 1574], ["risk", 1582], ["of", 1587], ["MI", 1590], ["(", 1593], ["78", 1594], ["[", 1597], ["3.4", 1598], ["%", 1601], ["]", 1602], ["vs", 1604], ["47", 1607], ["[", 1610], ["2.2", 1611], ["%", 1614], ["]", 1615], [";", 1616], ["HR", 1618], [",", 1620], ["1.66", 1622], [";", 1626], ["95", 1628], ["%", 1630], ["CI", 1632], [",", 1634], ["1.16", 1636], ["-", 1640], ["2.39", 1641], [";", 1645], ["log", 1647], ["-", 1650], ["rank", 1651], ["P", 1656], ["=", 1658], [".005", 1660], [")", 1664], [".", 1665], ["The", 1667], ["composite", 1671], ["secondary", 1681], ["end", 1691], ["point", 1695], ["of", 1701], ["cardiovascular", 1704], ["mortality", 1719], [",", 1728], ["MI", 1730], [",", 1732], ["and", 1734], ["stroke", 1738], ["was", 1745], ["observed", 1749], ["in", 1758], ["107", 1761], ["patients", 1765], ["(", 1774], ["4.6", 1775], ["%", 1778], [")", 1779], ["in", 1781], ["the", 1784], ["varespladib", 1788], ["group", 1800], ["and", 1806], ["79", 1810], ["patients", 1813], ["(", 1822], ["3.8", 1823], ["%", 1826], [")", 1827], ["in", 1829], ["the", 1832], ["placebo", 1836], ["group", 1844], ["(", 1850], ["HR", 1851], [",", 1853], ["1.36", 1855], [";", 1859], ["95", 1861], ["%", 1863], ["CI", 1865], [",", 1867], ["1.02", 1869], ["-", 1873], ["1.82", 1874], [";", 1878], ["P", 1880], ["=", 1882], [".04", 1884], [")", 1887], [".", 1888], ["In", 1890], ["patients", 1893], ["with", 1902], ["recent", 1907], ["ACS", 1914], [",", 1917], ["varespladib", 1919], ["did", 1931], ["not", 1935], ["reduce", 1939], ["the", 1946], ["risk", 1950], ["of", 1955], ["recurrent", 1958], ["cardiovascular", 1968], ["events", 1983], ["and", 1990], ["significantly", 1994], ["increased", 2008], ["the", 2018], ["risk", 2022], ["of", 2027], ["MI", 2030], [".", 2032], ["The", 2034], ["sPLA2", 2038], ["inhibition", 2044], ["with", 2055], ["varespladib", 2060], ["may", 2072], ["be", 2076], ["harmful", 2079], ["and", 2087], ["is", 2091], ["not", 2094], ["a", 2098], ["useful", 2100], ["strategy", 2107], ["to", 2116], ["reduce", 2119], ["adverse", 2126], ["cardiovascular", 2134], ["outcomes", 2149], ["after", 2158], ["ACS", 2164], [".", 2167], ["clinicaltrials.gov", 2169], ["Identifier", 2188], [":", 2198], ["NCT01130246", 2200], [".", 2211]]}
{"context": "Selenoprotein S (SelS) is a 189 amino acid trans-membrane protein that plays an important yet undefined role in the unfolded protein response. It has been proposed that SelS may function as a reductase, with the penultimate selenocysteine (Sec(188)) residue participating in a selenosulfide bond with cysteine (Cys(174)). Cotranslational incorporation of Sec into SelS depends on the recoding of the UGA codon, which requires a Selenocysteine Insertion Sequence (SECIS) element in the 3'UTR of the transcript. Here we identify multiple mechanisms that regulate the expression of SelS. The human SelS gene encodes two transcripts (variants 1 and 2), which differ in their 3'UTR sequences due to an alternative splicing event that removes the SECIS element from the variant 1 transcript. Both transcripts are widely expressed in human cell lines, with the SECIS-containing variant 2 mRNA being more abundant. In vitro experiments demonstrate that the variant 1 3'UTR does not allow readthrough of the UGA/Sec codon. Thus, this transcript would produce a truncated protein that does not contain Sec and cannot make the selenosulfide bond. While the variant 2 3'UTR does support Sec insertion, its activity is weak. Bioinformatic analysis revealed two highly conserved stem-loop structures, one in the proximal part of the variant 2 3'UTR and the other immediately downstream of the SECIS element. The proximal stem-loop promotes Sec insertion in the native context but not when positioned far from the UGA/Sec codon in a heterologous mRNA. In contrast, the 140 nucleotides downstream of the SECIS element inhibit Sec insertion. We also show that endogenous SelS is enriched at perinuclear speckles, in addition to its known localization in the endoplasmic reticulum. Our results suggest the expression of endogenous SelS is more complex than previously appreciated, which has implications for past and future studies on the function of this protein.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "a90edaed7fbb4491a6476503ca82d435", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[132, 132], [247, 247], [152, 152], [82, 82], [287, 287]], "char_spans": [[741, 745], [1379, 1383], [854, 858], [463, 467], [1588, 1592]]}]}], "context_tokens": [["Selenoprotein", 0], ["S", 14], ["(", 16], ["SelS", 17], [")", 21], ["is", 23], ["a", 26], ["189", 28], ["amino", 32], ["acid", 38], ["trans", 43], ["-", 48], ["membrane", 49], ["protein", 58], ["that", 66], ["plays", 71], ["an", 77], ["important", 80], ["yet", 90], ["undefined", 94], ["role", 104], ["in", 109], ["the", 112], ["unfolded", 116], ["protein", 125], ["response", 133], [".", 141], ["It", 143], ["has", 146], ["been", 150], ["proposed", 155], ["that", 164], ["SelS", 169], ["may", 174], ["function", 178], ["as", 187], ["a", 190], ["reductase", 192], [",", 201], ["with", 203], ["the", 208], ["penultimate", 212], ["selenocysteine", 224], ["(", 239], ["Sec(188", 240], [")", 247], [")", 248], ["residue", 250], ["participating", 258], ["in", 272], ["a", 275], ["selenosulfide", 277], ["bond", 291], ["with", 296], ["cysteine", 301], ["(", 310], ["Cys(174", 311], [")", 318], [")", 319], [".", 320], ["Cotranslational", 322], ["incorporation", 338], ["of", 352], ["Sec", 355], ["into", 359], ["SelS", 364], ["depends", 369], ["on", 377], ["the", 380], ["recoding", 384], ["of", 393], ["the", 396], ["UGA", 400], ["codon", 404], [",", 409], ["which", 411], ["requires", 417], ["a", 426], ["Selenocysteine", 428], ["Insertion", 443], ["Sequence", 453], ["(", 462], ["SECIS", 463], [")", 468], ["element", 470], ["in", 478], ["the", 481], ["3'UTR", 485], ["of", 491], ["the", 494], ["transcript", 498], [".", 508], ["Here", 510], ["we", 515], ["identify", 518], ["multiple", 527], ["mechanisms", 536], ["that", 547], ["regulate", 552], ["the", 561], ["expression", 565], ["of", 576], ["SelS.", 579], ["The", 585], ["human", 589], ["SelS", 595], ["gene", 600], ["encodes", 605], ["two", 613], ["transcripts", 617], ["(", 629], ["variants", 630], ["1", 639], ["and", 641], ["2", 645], [")", 646], [",", 647], ["which", 649], ["differ", 655], ["in", 662], ["their", 665], ["3'UTR", 671], ["sequences", 677], ["due", 687], ["to", 691], ["an", 694], ["alternative", 697], ["splicing", 709], ["event", 718], ["that", 724], ["removes", 729], ["the", 737], ["SECIS", 741], ["element", 747], ["from", 755], ["the", 760], ["variant", 764], ["1", 772], ["transcript", 774], [".", 784], ["Both", 786], ["transcripts", 791], ["are", 803], ["widely", 807], ["expressed", 814], ["in", 824], ["human", 827], ["cell", 833], ["lines", 838], [",", 843], ["with", 845], ["the", 850], ["SECIS", 854], ["-", 859], ["containing", 860], ["variant", 871], ["2", 879], ["mRNA", 881], ["being", 886], ["more", 892], ["abundant", 897], [".", 905], ["In", 907], ["vitro", 910], ["experiments", 916], ["demonstrate", 928], ["that", 940], ["the", 945], ["variant", 949], ["1", 957], ["3'UTR", 959], ["does", 965], ["not", 970], ["allow", 974], ["readthrough", 980], ["of", 992], ["the", 995], ["UGA", 999], ["/", 1002], ["Sec", 1003], ["codon", 1007], [".", 1012], ["Thus", 1014], [",", 1018], ["this", 1020], ["transcript", 1025], ["would", 1036], ["produce", 1042], ["a", 1050], ["truncated", 1052], ["protein", 1062], ["that", 1070], ["does", 1075], ["not", 1080], ["contain", 1084], ["Sec", 1092], ["and", 1096], ["can", 1100], ["not", 1103], ["make", 1107], ["the", 1112], ["selenosulfide", 1116], ["bond", 1130], [".", 1134], ["While", 1136], ["the", 1142], ["variant", 1146], ["2", 1154], ["3'UTR", 1156], ["does", 1162], ["support", 1167], ["Sec", 1175], ["insertion", 1179], [",", 1188], ["its", 1190], ["activity", 1194], ["is", 1203], ["weak", 1206], [".", 1210], ["Bioinformatic", 1212], ["analysis", 1226], ["revealed", 1235], ["two", 1244], ["highly", 1248], ["conserved", 1255], ["stem", 1265], ["-", 1269], ["loop", 1270], ["structures", 1275], [",", 1285], ["one", 1287], ["in", 1291], ["the", 1294], ["proximal", 1298], ["part", 1307], ["of", 1312], ["the", 1315], ["variant", 1319], ["2", 1327], ["3'UTR", 1329], ["and", 1335], ["the", 1339], ["other", 1343], ["immediately", 1349], ["downstream", 1361], ["of", 1372], ["the", 1375], ["SECIS", 1379], ["element", 1385], [".", 1392], ["The", 1394], ["proximal", 1398], ["stem", 1407], ["-", 1411], ["loop", 1412], ["promotes", 1417], ["Sec", 1426], ["insertion", 1430], ["in", 1440], ["the", 1443], ["native", 1447], ["context", 1454], ["but", 1462], ["not", 1466], ["when", 1470], ["positioned", 1475], ["far", 1486], ["from", 1490], ["the", 1495], ["UGA", 1499], ["/", 1502], ["Sec", 1503], ["codon", 1507], ["in", 1513], ["a", 1516], ["heterologous", 1518], ["mRNA", 1531], [".", 1535], ["In", 1537], ["contrast", 1540], [",", 1548], ["the", 1550], ["140", 1554], ["nucleotides", 1558], ["downstream", 1570], ["of", 1581], ["the", 1584], ["SECIS", 1588], ["element", 1594], ["inhibit", 1602], ["Sec", 1610], ["insertion", 1614], [".", 1623], ["We", 1625], ["also", 1628], ["show", 1633], ["that", 1638], ["endogenous", 1643], ["SelS", 1654], ["is", 1659], ["enriched", 1662], ["at", 1671], ["perinuclear", 1674], ["speckles", 1686], [",", 1694], ["in", 1696], ["addition", 1699], ["to", 1708], ["its", 1711], ["known", 1715], ["localization", 1721], ["in", 1734], ["the", 1737], ["endoplasmic", 1741], ["reticulum", 1753], [".", 1762], ["Our", 1764], ["results", 1768], ["suggest", 1776], ["the", 1784], ["expression", 1788], ["of", 1799], ["endogenous", 1802], ["SelS", 1813], ["is", 1818], ["more", 1821], ["complex", 1826], ["than", 1834], ["previously", 1839], ["appreciated", 1850], [",", 1861], ["which", 1863], ["has", 1869], ["implications", 1873], ["for", 1886], ["past", 1890], ["and", 1895], ["future", 1899], ["studies", 1906], ["on", 1914], ["the", 1917], ["function", 1921], ["of", 1930], ["this", 1933], ["protein", 1938], [".", 1945]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disorder characterized by the appearance of intracytoplasmic inclusions called Lewy bodies (LB) in dopamine neurons in the substantia nigra and the progressive loss of these neurons. Recently, mutations in the alpha-synuclein gene have been identified in early-onset familial PD, and alpha-synuclein has been shown to be a major component of LB in all patients. Yet, the pathophysiological function of alpha-synuclein remains unknown. In this report, we have investigated the toxic effects of adenovirus-mediated alpha-synuclein overexpression on dopamine neurons in rat primary mesencephalic cultures and in a rat dopaminergic cell line - the large T-antigen immortalized, mesencephalon-derived 1RB3AN27 (N27). Adenovirus-transduced cultures showed high-level expression of alpha-synuclein within the cells. Overexpression of human mutant alpha-synuclein (Ala(53)Thr) selectively induced apoptotic programmed cell death of primary dopamine neurons as well as N27 cells. The mutant protein also potentiated the neurotoxicity of 6-hydroxydopamine (6-OHDA). By contrast, overexpression of wild-type human alpha-synuclein was not directly neurotoxic but did increase cell death after 6-OHDA. Overexpression of wild-type rat alpha-synuclein had no effect on dopamine cell survival or 6-OHDA neurotoxicity. These results indicate that overexpression of human mutant alpha-synuclein directly leads to dopamine neuron death, and overexpression of either human mutant or human wild-type alpha-synuclein renders dopamine neurons more vulnerable to neurotoxic insults.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d46479c4ece34bc181a6026e994a86e9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[81, 83], [222, 224], [244, 246], [101, 103], [157, 159], [58, 60], [201, 203], [265, 267], [146, 148], [43, 45]], "char_spans": [[450, 464], [1269, 1283], [1409, 1423], [561, 575], [888, 902], [332, 346], [1151, 1165], [1527, 1541], [823, 837], [258, 272]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disorder", 48], ["characterized", 57], ["by", 71], ["the", 74], ["appearance", 78], ["of", 89], ["intracytoplasmic", 92], ["inclusions", 109], ["called", 120], ["Lewy", 127], ["bodies", 132], ["(", 139], ["LB", 140], [")", 142], ["in", 144], ["dopamine", 147], ["neurons", 156], ["in", 164], ["the", 167], ["substantia", 171], ["nigra", 182], ["and", 188], ["the", 192], ["progressive", 196], ["loss", 208], ["of", 213], ["these", 216], ["neurons", 222], [".", 229], ["Recently", 231], [",", 239], ["mutations", 241], ["in", 251], ["the", 254], ["alpha", 258], ["-", 263], ["synuclein", 264], ["gene", 274], ["have", 279], ["been", 284], ["identified", 289], ["in", 300], ["early", 303], ["-", 308], ["onset", 309], ["familial", 315], ["PD", 324], [",", 326], ["and", 328], ["alpha", 332], ["-", 337], ["synuclein", 338], ["has", 348], ["been", 352], ["shown", 357], ["to", 363], ["be", 366], ["a", 369], ["major", 371], ["component", 377], ["of", 387], ["LB", 390], ["in", 393], ["all", 396], ["patients", 400], [".", 408], ["Yet", 410], [",", 413], ["the", 415], ["pathophysiological", 419], ["function", 438], ["of", 447], ["alpha", 450], ["-", 455], ["synuclein", 456], ["remains", 466], ["unknown", 474], [".", 481], ["In", 483], ["this", 486], ["report", 491], [",", 497], ["we", 499], ["have", 502], ["investigated", 507], ["the", 520], ["toxic", 524], ["effects", 530], ["of", 538], ["adenovirus", 541], ["-", 551], ["mediated", 552], ["alpha", 561], ["-", 566], ["synuclein", 567], ["overexpression", 577], ["on", 592], ["dopamine", 595], ["neurons", 604], ["in", 612], ["rat", 615], ["primary", 619], ["mesencephalic", 627], ["cultures", 641], ["and", 650], ["in", 654], ["a", 657], ["rat", 659], ["dopaminergic", 663], ["cell", 676], ["line", 681], ["-", 686], ["the", 688], ["large", 692], ["T", 698], ["-", 699], ["antigen", 700], ["immortalized", 708], [",", 720], ["mesencephalon", 722], ["-", 735], ["derived", 736], ["1RB3AN27", 744], ["(", 753], ["N27", 754], [")", 757], [".", 758], ["Adenovirus", 760], ["-", 770], ["transduced", 771], ["cultures", 782], ["showed", 791], ["high", 798], ["-", 802], ["level", 803], ["expression", 809], ["of", 820], ["alpha", 823], ["-", 828], ["synuclein", 829], ["within", 839], ["the", 846], ["cells", 850], [".", 855], ["Overexpression", 857], ["of", 872], ["human", 875], ["mutant", 881], ["alpha", 888], ["-", 893], ["synuclein", 894], ["(", 904], ["Ala(53)Thr", 905], [")", 915], ["selectively", 917], ["induced", 929], ["apoptotic", 937], ["programmed", 947], ["cell", 958], ["death", 963], ["of", 969], ["primary", 972], ["dopamine", 980], ["neurons", 989], ["as", 997], ["well", 1000], ["as", 1005], ["N27", 1008], ["cells", 1012], [".", 1017], ["The", 1019], ["mutant", 1023], ["protein", 1030], ["also", 1038], ["potentiated", 1043], ["the", 1055], ["neurotoxicity", 1059], ["of", 1073], ["6-hydroxydopamine", 1076], ["(", 1094], ["6-OHDA", 1095], [")", 1101], [".", 1102], ["By", 1104], ["contrast", 1107], [",", 1115], ["overexpression", 1117], ["of", 1132], ["wild", 1135], ["-", 1139], ["type", 1140], ["human", 1145], ["alpha", 1151], ["-", 1156], ["synuclein", 1157], ["was", 1167], ["not", 1171], ["directly", 1175], ["neurotoxic", 1184], ["but", 1195], ["did", 1199], ["increase", 1203], ["cell", 1212], ["death", 1217], ["after", 1223], ["6-OHDA", 1229], [".", 1235], ["Overexpression", 1237], ["of", 1252], ["wild", 1255], ["-", 1259], ["type", 1260], ["rat", 1265], ["alpha", 1269], ["-", 1274], ["synuclein", 1275], ["had", 1285], ["no", 1289], ["effect", 1292], ["on", 1299], ["dopamine", 1302], ["cell", 1311], ["survival", 1316], ["or", 1325], ["6-OHDA", 1328], ["neurotoxicity", 1335], [".", 1348], ["These", 1350], ["results", 1356], ["indicate", 1364], ["that", 1373], ["overexpression", 1378], ["of", 1393], ["human", 1396], ["mutant", 1402], ["alpha", 1409], ["-", 1414], ["synuclein", 1415], ["directly", 1425], ["leads", 1434], ["to", 1440], ["dopamine", 1443], ["neuron", 1452], ["death", 1459], [",", 1464], ["and", 1466], ["overexpression", 1470], ["of", 1485], ["either", 1488], ["human", 1495], ["mutant", 1501], ["or", 1508], ["human", 1511], ["wild", 1517], ["-", 1521], ["type", 1522], ["alpha", 1527], ["-", 1532], ["synuclein", 1533], ["renders", 1543], ["dopamine", 1551], ["neurons", 1560], ["more", 1568], ["vulnerable", 1573], ["to", 1584], ["neurotoxic", 1587], ["insults", 1598], [".", 1605]]}
{"context": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined. Patients undergoing diagnostic upper endoscopy who received sedation with either diazepam or midazolam alone were given flumazenil 0.2 mg incrementally immediately following the procedure until awake. They were then asked to repeat three psychomotor tests measuring cognitive and motor skills, with their baseline scores compared with postprocedure scores over a 3-hour period. Full psychomotor function was restored to baseline values within 30 minutes after flumazenil in 79% of patients, with no differences in the reversal of psychomotor skill impairment observed between diazepam and midazolam sedation. There was no evidence of rebound sedation seen for up to 3 hours. No significant anterograde amnesia was evident in 78% of individuals. These results demonstrate that flumazenil's effects on reversing psychomotor impairment are similar when midazolam or diazepam are used for conscious sedation. However, the potential usefulness of routine flumazenil reversal of conscious sedation will require further evaluation of specific psychomotor performance skills (such as driving a car) before we lift the admonition against leaving the endoscopic suite unattended, driving a vehicle, or operating complicated machinery for several hours.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "8c08be9367e44a248f7e98941e6d911d", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [163, 163], [189, 189], [109, 109], [58, 58]], "char_spans": [[0, 9], [1042, 1051], [1216, 1225], [726, 735], [386, 395]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["competitive", 16], ["benzodiazepine", 28], ["antagonist", 43], ["that", 54], ["acts", 59], ["to", 64], ["reverse", 67], ["their", 75], ["sedative", 81], ["and", 90], ["hypnotic", 94], ["effects", 103], [".", 110], ["It", 112], ["is", 115], ["indicated", 118], ["in", 128], ["the", 131], ["management", 135], ["of", 146], ["benzodiazepine", 149], ["overdose", 164], [",", 172], ["but", 174], ["its", 178], ["role", 182], ["in", 187], ["the", 190], ["routine", 194], ["reversal", 202], ["of", 211], ["endoscopic", 214], ["conscious", 225], ["sedation", 235], ["has", 244], ["not", 248], ["been", 252], ["defined", 257], [".", 264], ["Patients", 266], ["undergoing", 275], ["diagnostic", 286], ["upper", 297], ["endoscopy", 303], ["who", 313], ["received", 317], ["sedation", 326], ["with", 335], ["either", 340], ["diazepam", 347], ["or", 356], ["midazolam", 359], ["alone", 369], ["were", 375], ["given", 380], ["flumazenil", 386], ["0.2", 397], ["mg", 401], ["incrementally", 404], ["immediately", 418], ["following", 430], ["the", 440], ["procedure", 444], ["until", 454], ["awake", 460], [".", 465], ["They", 467], ["were", 472], ["then", 477], ["asked", 482], ["to", 488], ["repeat", 491], ["three", 498], ["psychomotor", 504], ["tests", 516], ["measuring", 522], ["cognitive", 532], ["and", 542], ["motor", 546], ["skills", 552], [",", 558], ["with", 560], ["their", 565], ["baseline", 571], ["scores", 580], ["compared", 587], ["with", 596], ["postprocedure", 601], ["scores", 615], ["over", 622], ["a", 627], ["3-hour", 629], ["period", 636], [".", 642], ["Full", 644], ["psychomotor", 649], ["function", 661], ["was", 670], ["restored", 674], ["to", 683], ["baseline", 686], ["values", 695], ["within", 702], ["30", 709], ["minutes", 712], ["after", 720], ["flumazenil", 726], ["in", 737], ["79", 740], ["%", 742], ["of", 744], ["patients", 747], [",", 755], ["with", 757], ["no", 762], ["differences", 765], ["in", 777], ["the", 780], ["reversal", 784], ["of", 793], ["psychomotor", 796], ["skill", 808], ["impairment", 814], ["observed", 825], ["between", 834], ["diazepam", 842], ["and", 851], ["midazolam", 855], ["sedation", 865], [".", 873], ["There", 875], ["was", 881], ["no", 885], ["evidence", 888], ["of", 897], ["rebound", 900], ["sedation", 908], ["seen", 917], ["for", 922], ["up", 926], ["to", 929], ["3", 932], ["hours", 934], [".", 939], ["No", 941], ["significant", 944], ["anterograde", 956], ["amnesia", 968], ["was", 976], ["evident", 980], ["in", 988], ["78", 991], ["%", 993], ["of", 995], ["individuals", 998], [".", 1009], ["These", 1011], ["results", 1017], ["demonstrate", 1025], ["that", 1037], ["flumazenil", 1042], ["'s", 1052], ["effects", 1055], ["on", 1063], ["reversing", 1066], ["psychomotor", 1076], ["impairment", 1088], ["are", 1099], ["similar", 1103], ["when", 1111], ["midazolam", 1116], ["or", 1126], ["diazepam", 1129], ["are", 1138], ["used", 1142], ["for", 1147], ["conscious", 1151], ["sedation", 1161], [".", 1169], ["However", 1171], [",", 1178], ["the", 1180], ["potential", 1184], ["usefulness", 1194], ["of", 1205], ["routine", 1208], ["flumazenil", 1216], ["reversal", 1227], ["of", 1236], ["conscious", 1239], ["sedation", 1249], ["will", 1258], ["require", 1263], ["further", 1271], ["evaluation", 1279], ["of", 1290], ["specific", 1293], ["psychomotor", 1302], ["performance", 1314], ["skills", 1326], ["(", 1333], ["such", 1334], ["as", 1339], ["driving", 1342], ["a", 1350], ["car", 1352], [")", 1355], ["before", 1357], ["we", 1364], ["lift", 1367], ["the", 1372], ["admonition", 1376], ["against", 1387], ["leaving", 1395], ["the", 1403], ["endoscopic", 1407], ["suite", 1418], ["unattended", 1424], [",", 1434], ["driving", 1436], ["a", 1444], ["vehicle", 1446], [",", 1453], ["or", 1455], ["operating", 1458], ["complicated", 1468], ["machinery", 1480], ["for", 1490], ["several", 1494], ["hours", 1502], [".", 1507]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We characterize 13 patients with DVD--5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role for differential parent-of-origin expression of FOXP2 in human speech development.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a5597097671740739398b8d4cab19549", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[32, 32], [93, 93], [181, 181], [211, 211], [148, 148], [103, 103], [40, 40], [168, 168], [2, 2]], "char_spans": [[193, 197], [502, 506], [1058, 1062], [1203, 1207], [858, 862], [571, 575], [241, 245], [970, 974], [13, 17]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["FOXP2", 13], ["cause", 19], ["developmental", 25], ["verbal", 39], ["dyspraxia", 46], ["(", 56], ["DVD", 57], [")", 60], [",", 61], ["but", 63], ["only", 67], ["a", 72], ["few", 74], ["cases", 78], ["have", 84], ["been", 89], ["described", 94], [".", 103], ["We", 105], ["characterize", 108], ["13", 121], ["patients", 124], ["with", 133], ["DVD--5", 138], ["with", 145], ["hemizygous", 150], ["paternal", 161], ["deletions", 170], ["spanning", 180], ["the", 189], ["FOXP2", 193], ["gene", 199], [",", 203], ["1", 205], ["with", 207], ["a", 212], ["translocation", 214], ["interrupting", 228], ["FOXP2", 241], [",", 246], ["and", 248], ["the", 252], ["remaining", 256], ["7", 266], ["with", 268], ["maternal", 273], ["uniparental", 282], ["disomy", 294], ["of", 301], ["chromosome", 304], ["7", 315], ["(", 317], ["UPD7", 318], [")", 322], [",", 323], ["who", 325], ["were", 329], ["also", 334], ["given", 339], ["a", 345], ["diagnosis", 347], ["of", 357], ["Silver", 360], ["-", 366], ["Russell", 367], ["Syndrome", 375], ["(", 384], ["SRS", 385], [")", 388], [".", 389], ["Of", 391], ["these", 394], ["individuals", 400], ["with", 412], ["DVD", 417], [",", 420], ["all", 422], ["12", 426], ["for", 429], ["whom", 433], ["parental", 438], ["DNA", 447], ["was", 451], ["available", 455], ["showed", 465], ["absence", 472], ["of", 480], ["a", 483], ["paternal", 485], ["copy", 494], ["of", 499], ["FOXP2", 502], [".", 507], ["Five", 509], ["other", 514], ["individuals", 520], ["with", 532], ["deletions", 537], ["of", 547], ["paternally", 550], ["inherited", 561], ["FOXP2", 571], ["but", 577], ["with", 581], ["incomplete", 586], ["clinical", 597], ["information", 606], ["or", 618], ["phenotypes", 621], ["too", 632], ["complex", 636], ["to", 644], ["properly", 647], ["assess", 656], ["are", 663], ["also", 667], ["described", 672], [".", 681], ["Four", 683], ["of", 688], ["the", 691], ["patients", 695], ["with", 704], ["DVD", 709], ["also", 713], ["meet", 718], ["criteria", 723], ["for", 732], ["autism", 736], ["spectrum", 743], ["disorder", 752], [".", 760], ["Individuals", 762], ["with", 774], ["paternal", 779], ["UPD7", 788], ["or", 793], ["with", 796], ["partial", 801], ["maternal", 809], ["UPD7", 818], ["or", 823], ["deletion", 826], ["starting", 835], ["downstream", 844], ["of", 855], ["FOXP2", 858], ["do", 864], ["not", 867], ["have", 871], ["DVD", 876], [".", 879], ["Using", 881], ["quantitative", 887], ["real", 900], ["-", 904], ["time", 905], ["polymerase", 910], ["chain", 921], ["reaction", 927], [",", 935], ["we", 937], ["show", 940], ["the", 945], ["maternally", 949], ["inherited", 960], ["FOXP2", 970], ["to", 976], ["be", 979], ["comparatively", 982], ["underexpressed", 996], [".", 1010], ["Our", 1012], ["results", 1016], ["indicate", 1024], ["that", 1033], ["absence", 1038], ["of", 1046], ["paternal", 1049], ["FOXP2", 1058], ["is", 1064], ["the", 1067], ["cause", 1071], ["of", 1077], ["DVD", 1080], ["in", 1084], ["patients", 1087], ["with", 1096], ["SRS", 1101], ["with", 1105], ["maternal", 1110], ["UPD7", 1119], [".", 1123], ["The", 1125], ["data", 1129], ["also", 1134], ["point", 1139], ["to", 1145], ["a", 1148], ["role", 1150], ["for", 1155], ["differential", 1159], ["parent", 1172], ["-", 1178], ["of", 1179], ["-", 1181], ["origin", 1182], ["expression", 1189], ["of", 1200], ["FOXP2", 1203], ["in", 1209], ["human", 1212], ["speech", 1218], ["development", 1225], [".", 1236]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.", "qas": [{"question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answers": ["Intravenous"], "qid": "b281754e18ae429e9ea7345319018381", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["administration", 12], ["route", 27], ["of", 33], ["IVIG", 36], ["in", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Intravenous", "token_spans": [[0, 0]], "char_spans": [[0, 10]]}]}], "context_tokens": [["Intravenous", 0], ["immunoglobulin", 12], ["(", 27], ["IVIG", 28], [")", 32], ["has", 34], ["shown", 38], ["limited", 44], ["promise", 52], ["so", 60], ["far", 63], ["in", 67], ["human", 70], ["clinical", 76], ["studies", 85], ["on", 93], ["Alzheimer", 96], ["'s", 105], ["disease", 108], ["(", 116], ["AD", 117], [")", 119], [",", 120], ["yet", 122], ["overwhelmingly", 126], ["positive", 141], ["preclinical", 150], ["work", 162], ["in", 167], ["animals", 170], ["and", 178], ["human", 182], ["brain", 188], ["cultures", 194], ["support", 203], ["the", 211], ["notion", 215], ["that", 222], ["the", 227], ["therapy", 231], ["remains", 239], ["potentially", 247], ["efficacious", 259], [".", 270], ["Here", 272], [",", 276], ["we", 278], ["elaborate", 281], ["on", 291], ["IVIG", 294], ["neuropreservation", 299], ["by", 317], ["demonstrating", 320], ["that", 334], ["IVIG", 339], ["protects", 344], ["human", 353], ["primary", 359], ["neurons", 367], ["against", 375], ["oxidative", 383], ["stress", 393], ["in", 400], ["vitro", 403], ["and", 409], ["that", 413], ["IVIG", 418], ["preserves", 423], ["antioxidant", 433], ["defense", 445], ["mechanisms", 453], ["in", 464], ["vivo", 467], [".", 471], ["Based", 473], ["on", 479], ["these", 482], ["results", 488], [",", 495], ["we", 497], ["propose", 500], ["the", 508], ["following", 512], ["translational", 522], ["impact", 536], [":", 542], ["If", 544], ["the", 547], ["dosage", 551], ["and", 558], ["treatment", 562], ["conditions", 572], ["are", 583], ["adequately", 587], ["optimized", 598], [",", 607], ["then", 609], ["IVIG", 614], ["treatment", 619], ["could", 629], ["play", 635], ["a", 640], ["significant", 642], ["role", 654], ["in", 659], ["preventing", 662], ["and/or", 673], ["delaying", 680], ["the", 689], ["progression", 693], ["of", 705], ["neurodegenerative", 708], ["diseases", 726], [",", 734], ["such", 736], ["as", 741], ["AD", 744], [".", 746], ["We", 748], ["suggest", 751], ["that", 759], ["IVIG", 764], ["warrants", 769], ["further", 778], ["investigation", 786], ["to", 800], ["fully", 803], ["exploit", 809], ["its", 817], ["potential", 821], ["as", 831], ["an", 834], ["anti", 837], ["-", 841], ["oxidant", 842], [",", 849], ["neuroprotective", 851], ["and", 867], ["synapto", 871], ["-", 878], ["protecting", 879], ["agent", 890], [".", 895]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) carrying pvl is an emerging problem worldwide. CA-MRSA tends to harbor staphylococcal cassette chromosome mec type IV (SCCmec IV), to be non-multiantibiotic resistant, and to have different genotypes from the local hospital-acquired MRSA (HA-MRSA). However, in Ireland, 80% of HA-MRSA isolates have the non-multiantibiotic-resistant genotype ST22-MRSA-IV. This study investigated MRSA isolates from Ireland (CA-MRSA, health care-associated MRSA, and HA-MRSA) for the carriage of pvl and determined the genotypic characteristics of all pvl-positive isolates identified. All 1,389 MRSA isolates were investigated by antibiogram-resistogram typing and SmaI DNA macrorestriction analysis. pvl-positive isolates were further characterized by multilocus sequence typing and SCCmec, agr, and toxin gene typing. Twenty-five (1.8%) MRSA isolates belonging to six genotypes (ST30, ST8, ST22, ST80, ST5, and ST154) harbored pvl. Nineteen of these (76%) were CA-MRSA isolates, but a prospective study of MRSA isolates from 401 patients showed that only 6.7% (2/30) of patients with CA-MRSA yielded pvl-positive isolates. Thus, pvl cannot be used as a sole marker for CA-MRSA. Fifty-two percent of pvl-positive MRSA isolates were recovered from patients with skin and soft tissue infections; thirty-six percent were from patients of non-Irish ethnic origin, reflecting the increasing heterogeneity of the Irish population due to immigration. All 25 pvl-positive isolates carried SCCmec IV; 14 (56%) harbored SCCmec IV.1 or IV.3, and the remaining 11 isolates could not be subtyped. This study demonstrates that pvl is not a reliable marker for CA-MRSA in Ireland and reveals the emergence and importation of diverse genotypes of pvl-positive MRSA in Ireland.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f981f754748548ed8b74416b9b29aedd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[362, 362], [11, 11], [173, 173], [90, 90], [214, 214], [253, 253], [346, 346], [60, 60], [108, 108], [73, 73], [23, 23], [103, 103], [263, 263], [56, 56], [232, 232], [206, 206], [130, 130], [97, 97]], "char_spans": [[1802, 1805], [67, 70], [896, 899], [453, 456], [1065, 1068], [1231, 1234], [1707, 1710], [315, 318], [526, 529], [353, 356], [123, 126], [513, 516], [1271, 1274], [306, 309], [1146, 1149], [1023, 1026], [652, 655], [484, 487]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["methicillin", 19], ["-", 30], ["resistant", 31], ["Staphylococcus", 41], ["aureus", 56], ["(", 63], ["CA", 64], ["-", 66], ["MRSA", 67], [")", 71], ["carrying", 73], ["pvl", 82], ["is", 86], ["an", 89], ["emerging", 92], ["problem", 101], ["worldwide", 109], [".", 118], ["CA", 120], ["-", 122], ["MRSA", 123], ["tends", 128], ["to", 134], ["harbor", 137], ["staphylococcal", 144], ["cassette", 159], ["chromosome", 168], ["mec", 179], ["type", 183], ["IV", 188], ["(", 191], ["SCCmec", 192], ["IV", 199], [")", 201], [",", 202], ["to", 204], ["be", 207], ["non", 210], ["-", 213], ["multiantibiotic", 214], ["resistant", 230], [",", 239], ["and", 241], ["to", 245], ["have", 248], ["different", 253], ["genotypes", 263], ["from", 273], ["the", 278], ["local", 282], ["hospital", 288], ["-", 296], ["acquired", 297], ["MRSA", 306], ["(", 311], ["HA", 312], ["-", 314], ["MRSA", 315], [")", 319], [".", 320], ["However", 322], [",", 329], ["in", 331], ["Ireland", 334], [",", 341], ["80", 343], ["%", 345], ["of", 347], ["HA", 350], ["-", 352], ["MRSA", 353], ["isolates", 358], ["have", 367], ["the", 372], ["non", 376], ["-", 379], ["multiantibiotic", 380], ["-", 395], ["resistant", 396], ["genotype", 406], ["ST22-MRSA", 415], ["-", 424], ["IV", 425], [".", 427], ["This", 429], ["study", 434], ["investigated", 440], ["MRSA", 453], ["isolates", 458], ["from", 467], ["Ireland", 472], ["(", 480], ["CA", 481], ["-", 483], ["MRSA", 484], [",", 488], ["health", 490], ["care", 497], ["-", 501], ["associated", 502], ["MRSA", 513], [",", 517], ["and", 519], ["HA", 523], ["-", 525], ["MRSA", 526], [")", 530], ["for", 532], ["the", 536], ["carriage", 540], ["of", 549], ["pvl", 552], ["and", 556], ["determined", 560], ["the", 571], ["genotypic", 575], ["characteristics", 585], ["of", 601], ["all", 604], ["pvl", 608], ["-", 611], ["positive", 612], ["isolates", 621], ["identified", 630], [".", 640], ["All", 642], ["1,389", 646], ["MRSA", 652], ["isolates", 657], ["were", 666], ["investigated", 671], ["by", 684], ["antibiogram", 687], ["-", 698], ["resistogram", 699], ["typing", 711], ["and", 718], ["SmaI", 722], ["DNA", 727], ["macrorestriction", 731], ["analysis", 748], [".", 756], ["pvl", 758], ["-", 761], ["positive", 762], ["isolates", 771], ["were", 780], ["further", 785], ["characterized", 793], ["by", 807], ["multilocus", 810], ["sequence", 821], ["typing", 830], ["and", 837], ["SCCmec", 841], [",", 847], ["agr", 849], [",", 852], ["and", 854], ["toxin", 858], ["gene", 864], ["typing", 869], [".", 875], ["Twenty", 877], ["-", 883], ["five", 884], ["(", 889], ["1.8", 890], ["%", 893], [")", 894], ["MRSA", 896], ["isolates", 901], ["belonging", 910], ["to", 920], ["six", 923], ["genotypes", 927], ["(", 937], ["ST30", 938], [",", 942], ["ST8", 944], [",", 947], ["ST22", 949], [",", 953], ["ST80", 955], [",", 959], ["ST5", 961], [",", 964], ["and", 966], ["ST154", 970], [")", 975], ["harbored", 977], ["pvl", 986], [".", 989], ["Nineteen", 991], ["of", 1000], ["these", 1003], ["(", 1009], ["76", 1010], ["%", 1012], [")", 1013], ["were", 1015], ["CA", 1020], ["-", 1022], ["MRSA", 1023], ["isolates", 1028], [",", 1036], ["but", 1038], ["a", 1042], ["prospective", 1044], ["study", 1056], ["of", 1062], ["MRSA", 1065], ["isolates", 1070], ["from", 1079], ["401", 1084], ["patients", 1088], ["showed", 1097], ["that", 1104], ["only", 1109], ["6.7", 1114], ["%", 1117], ["(", 1119], ["2/30", 1120], [")", 1124], ["of", 1126], ["patients", 1129], ["with", 1138], ["CA", 1143], ["-", 1145], ["MRSA", 1146], ["yielded", 1151], ["pvl", 1159], ["-", 1162], ["positive", 1163], ["isolates", 1172], [".", 1180], ["Thus", 1182], [",", 1186], ["pvl", 1188], ["can", 1192], ["not", 1195], ["be", 1199], ["used", 1202], ["as", 1207], ["a", 1210], ["sole", 1212], ["marker", 1217], ["for", 1224], ["CA", 1228], ["-", 1230], ["MRSA", 1231], [".", 1235], ["Fifty", 1237], ["-", 1242], ["two", 1243], ["percent", 1247], ["of", 1255], ["pvl", 1258], ["-", 1261], ["positive", 1262], ["MRSA", 1271], ["isolates", 1276], ["were", 1285], ["recovered", 1290], ["from", 1300], ["patients", 1305], ["with", 1314], ["skin", 1319], ["and", 1324], ["soft", 1328], ["tissue", 1333], ["infections", 1340], [";", 1350], ["thirty", 1352], ["-", 1358], ["six", 1359], ["percent", 1363], ["were", 1371], ["from", 1376], ["patients", 1381], ["of", 1390], ["non", 1393], ["-", 1396], ["Irish", 1397], ["ethnic", 1403], ["origin", 1410], [",", 1416], ["reflecting", 1418], ["the", 1429], ["increasing", 1433], ["heterogeneity", 1444], ["of", 1458], ["the", 1461], ["Irish", 1465], ["population", 1471], ["due", 1482], ["to", 1486], ["immigration", 1489], [".", 1500], ["All", 1502], ["25", 1506], ["pvl", 1509], ["-", 1512], ["positive", 1513], ["isolates", 1522], ["carried", 1531], ["SCCmec", 1539], ["IV", 1546], [";", 1548], ["14", 1550], ["(", 1553], ["56", 1554], ["%", 1556], [")", 1557], ["harbored", 1559], ["SCCmec", 1568], ["IV.1", 1575], ["or", 1580], ["IV.3", 1583], [",", 1587], ["and", 1589], ["the", 1593], ["remaining", 1597], ["11", 1607], ["isolates", 1610], ["could", 1619], ["not", 1625], ["be", 1629], ["subtyped", 1632], [".", 1640], ["This", 1642], ["study", 1647], ["demonstrates", 1653], ["that", 1666], ["pvl", 1671], ["is", 1675], ["not", 1678], ["a", 1682], ["reliable", 1684], ["marker", 1693], ["for", 1700], ["CA", 1704], ["-", 1706], ["MRSA", 1707], ["in", 1712], ["Ireland", 1715], ["and", 1723], ["reveals", 1727], ["the", 1735], ["emergence", 1739], ["and", 1749], ["importation", 1753], ["of", 1765], ["diverse", 1768], ["genotypes", 1776], ["of", 1786], ["pvl", 1789], ["-", 1792], ["positive", 1793], ["MRSA", 1802], ["in", 1807], ["Ireland", 1810], [".", 1817]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex (Lee, J.-H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a approximately 450 kDa complex that contains all five non-catalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "7b483c4cbcd8422c8a975ae0c76fa06c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[56, 57], [201, 202]], "char_spans": [[300, 309], [1159, 1168]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["identified", 14], ["a", 25], ["mammalian", 27], ["Set1A", 37], ["complex", 43], ["analogous", 51], ["to", 61], ["the", 64], ["yeast", 68], ["Set1/COMPASS", 74], ["histone", 87], ["H3-Lys4", 95], ["methyltransferase", 103], ["complex", 121], ["(", 129], ["Lee", 130], [",", 133], ["J.-H.", 135], [",", 140], ["and", 142], ["Skalnik", 146], [",", 153], ["D.", 155], ["G.", 158], ["(", 161], ["2005", 162], [")", 166], ["J.", 168], ["Biol", 171], [".", 175], ["Chem", 177], [".", 181], ["280", 183], [",", 186], ["41725", 188], ["-", 193], ["41731", 194], [")", 199], [".", 200], ["Data", 202], ["base", 207], ["analysis", 212], ["indicates", 221], ["that", 231], ["human", 236], ["Set1A", 242], ["protein", 248], ["shares", 256], ["39", 263], ["%", 265], ["identity", 267], ["with", 276], ["an", 281], ["uncharacterized", 284], ["SET", 300], ["domain", 304], ["protein", 311], [",", 318], ["KIAA1076", 320], [",", 328], ["hereafter", 330], ["denoted", 340], ["Set1B.", 348], ["Immunoprecipitation", 355], ["and", 375], ["mass", 379], ["spectrometry", 384], ["reveal", 397], ["that", 404], ["Set1B", 409], ["associates", 415], ["with", 426], ["a", 431], ["approximately", 433], ["450", 447], ["kDa", 451], ["complex", 455], ["that", 463], ["contains", 468], ["all", 477], ["five", 481], ["non", 486], ["-", 489], ["catalytic", 490], ["components", 500], ["of", 511], ["the", 514], ["Set1A", 518], ["complex", 524], [",", 531], ["including", 533], ["CFP1", 543], [",", 547], ["Rbbp5", 549], [",", 554], ["Ash2", 556], [",", 560], ["Wdr5", 562], [",", 566], ["and", 568], ["Wdr82", 572], [".", 577], ["These", 579], ["data", 585], ["reveal", 590], ["two", 597], ["human", 601], ["protein", 607], ["complexes", 615], ["that", 625], ["differ", 630], ["only", 637], ["in", 642], ["the", 645], ["identity", 649], ["of", 658], ["the", 661], ["catalytic", 665], ["histone", 675], ["methyltransferase", 683], [".", 700], ["In", 702], ["vitro", 705], ["assays", 711], ["demonstrate", 718], ["that", 730], ["the", 735], ["Set1B", 739], ["complex", 745], ["is", 753], ["a", 756], ["histone", 758], ["methyltransferase", 766], ["that", 784], ["produces", 789], ["trimethylated", 798], ["histone", 812], ["H3", 820], ["at", 823], ["Lys(4", 826], [")", 831], [".", 832], ["Both", 834], ["Set1A", 839], ["and", 845], ["Set1B", 849], ["are", 855], ["widely", 859], ["expressed", 866], [".", 875], ["Inducible", 877], ["expression", 887], ["of", 898], ["the", 901], ["carboxyl", 905], ["terminus", 914], ["of", 923], ["either", 926], ["Set1A", 933], ["or", 939], ["Set1B", 942], ["decreases", 948], ["steady", 958], ["-", 964], ["state", 965], ["levels", 971], ["of", 978], ["both", 981], ["endogenous", 986], ["Set1A", 997], ["and", 1003], ["Set1B", 1007], ["protein", 1013], [",", 1020], ["but", 1022], ["does", 1026], ["not", 1031], ["alter", 1035], ["the", 1041], ["expression", 1045], ["of", 1056], ["the", 1059], ["non", 1063], ["-", 1066], ["catalytic", 1067], ["components", 1077], ["of", 1088], ["the", 1091], ["Set1", 1095], ["complexes", 1100], [".", 1109], ["A", 1111], ["123-amino", 1113], ["acid", 1123], ["fragment", 1128], ["upstream", 1137], ["of", 1146], ["the", 1149], ["Set1A", 1153], ["SET", 1159], ["domain", 1163], ["is", 1170], ["necessary", 1173], ["for", 1183], ["interaction", 1187], ["with", 1199], ["CFP1", 1204], [",", 1208], ["Ash2", 1210], [",", 1214], ["Rbbp5", 1216], [",", 1221], ["and", 1223], ["Wdr5", 1227], [".", 1231], ["This", 1233], ["protein", 1238], ["domain", 1246], ["is", 1253], ["also", 1256], ["required", 1261], ["to", 1270], ["mediate", 1273], ["feedback", 1281], ["inhibition", 1290], ["of", 1301], ["Set1A", 1304], ["and", 1310], ["Set1B", 1314], ["expression", 1320], [",", 1330], ["which", 1332], ["is", 1338], ["a", 1341], ["consequence", 1343], ["of", 1355], ["reduced", 1358], ["Set1A", 1366], ["and", 1372], ["Set1B", 1376], ["stability", 1382], ["when", 1392], ["not", 1397], ["associated", 1401], ["with", 1412], ["the", 1417], ["methyltransferase", 1421], ["complex", 1439], [".", 1446], ["Confocal", 1448], ["microscopy", 1457], ["reveals", 1468], ["that", 1476], ["Set1A", 1481], ["and", 1487], ["Set1B", 1491], ["each", 1497], ["localize", 1502], ["to", 1511], ["a", 1514], ["largely", 1516], ["non", 1524], ["-", 1527], ["overlapping", 1528], ["set", 1540], ["of", 1544], ["euchromatic", 1547], ["nuclear", 1559], ["speckles", 1567], [",", 1575], ["suggesting", 1577], ["that", 1588], ["Set1A", 1593], ["and", 1599], ["Set1B", 1603], ["each", 1609], ["bind", 1614], ["to", 1619], ["a", 1622], ["unique", 1624], ["set", 1631], ["of", 1635], ["target", 1638], ["genes", 1645], ["and", 1651], ["thus", 1655], ["make", 1660], ["non", 1665], ["-", 1668], ["redundant", 1669], ["contributions", 1679], ["to", 1693], ["the", 1696], ["epigenetic", 1700], ["control", 1711], ["of", 1719], ["chromatin", 1722], ["structure", 1732], ["and", 1742], ["gene", 1746], ["expression", 1751], [".", 1761]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. The under-expression of PRDX2 observed in DS samples was confirmed by real-time PCR (0.73-fold). To test whether decreased expression is associated with enhanced sensitivity of DS neurons to reactive oxygen species, we down-regulated PRDX2 through stable transfections of SH-SY5Y neuroblastoma cells with antisense contructs of the complete PRDX2 coding sequence. In addition, we over-expressed SOD1 and compared the effects of the two genes on cell viability. Cells transfected with either construct showed similar sensitivity to oxidative stress in addition to increased apoptosis under basal conditions and after treatment with oxidative cytotoxic agents. This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "733e977ad4f14caf9148b8dbb151fd8c", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[30, 30]], "char_spans": [[195, 205]]}]}], "context_tokens": [["Suppression", 0], ["subtractive", 12], ["hybridization", 24], ["performed", 38], ["on", 48], ["Down", 51], ["syndrome", 56], ["(", 65], ["DS", 66], [")", 68], ["versus", 70], ["control", 77], ["fetal", 85], ["brains", 91], ["revealed", 98], ["differential", 107], ["expression", 120], ["of", 131], ["peroxiredoxin", 134], ["2", 148], ["(", 150], ["PRDX2", 151], [")", 156], [",", 157], ["mapped", 159], ["at", 166], ["13q12", 169], [".", 174], ["Peroxiredoxins", 176], ["are", 191], ["antioxidant", 195], ["enzymes", 207], ["involved", 215], ["in", 224], ["protein", 227], ["and", 235], ["lipid", 239], ["protection", 245], ["against", 256], ["oxidative", 264], ["injury", 274], ["and", 281], ["in", 285], ["cellular", 288], ["signalling", 297], ["pathways", 308], ["regulating", 317], ["apoptosis", 328], [".", 337], ["The", 339], ["under", 343], ["-", 348], ["expression", 349], ["of", 360], ["PRDX2", 363], ["observed", 369], ["in", 378], ["DS", 381], ["samples", 384], ["was", 392], ["confirmed", 396], ["by", 406], ["real", 409], ["-", 413], ["time", 414], ["PCR", 419], ["(", 423], ["0.73-fold", 424], [")", 433], [".", 434], ["To", 436], ["test", 439], ["whether", 444], ["decreased", 452], ["expression", 462], ["is", 473], ["associated", 476], ["with", 487], ["enhanced", 492], ["sensitivity", 501], ["of", 513], ["DS", 516], ["neurons", 519], ["to", 527], ["reactive", 530], ["oxygen", 539], ["species", 546], [",", 553], ["we", 555], ["down", 558], ["-", 562], ["regulated", 563], ["PRDX2", 573], ["through", 579], ["stable", 587], ["transfections", 594], ["of", 608], ["SH", 611], ["-", 613], ["SY5Y", 614], ["neuroblastoma", 619], ["cells", 633], ["with", 639], ["antisense", 644], ["contructs", 654], ["of", 664], ["the", 667], ["complete", 671], ["PRDX2", 680], ["coding", 686], ["sequence", 693], [".", 701], ["In", 703], ["addition", 706], [",", 714], ["we", 716], ["over", 719], ["-", 723], ["expressed", 724], ["SOD1", 734], ["and", 739], ["compared", 743], ["the", 752], ["effects", 756], ["of", 764], ["the", 767], ["two", 771], ["genes", 775], ["on", 781], ["cell", 784], ["viability", 789], [".", 798], ["Cells", 800], ["transfected", 806], ["with", 818], ["either", 823], ["construct", 830], ["showed", 840], ["similar", 847], ["sensitivity", 855], ["to", 867], ["oxidative", 870], ["stress", 880], ["in", 887], ["addition", 890], ["to", 899], ["increased", 902], ["apoptosis", 912], ["under", 922], ["basal", 928], ["conditions", 934], ["and", 945], ["after", 949], ["treatment", 955], ["with", 965], ["oxidative", 970], ["cytotoxic", 980], ["agents", 990], [".", 996], ["This", 998], ["suggests", 1003], ["that", 1012], ["the", 1017], ["decreased", 1021], ["expression", 1031], ["of", 1042], ["PRDX2", 1045], ["may", 1051], ["contribute", 1055], ["to", 1066], ["the", 1069], ["altered", 1073], ["redox", 1081], ["state", 1087], ["in", 1093], ["DS", 1096], ["at", 1099], ["levels", 1102], ["comparable", 1109], ["to", 1120], ["that", 1123], ["of", 1128], ["the", 1131], ["increased", 1135], ["expression", 1145], ["of", 1156], ["SOD1", 1159], [".", 1163]]}
{"context": "Systemic autoinflammatory diseases are caused by mutations in genes that function in innate immunity. Here, we report an autoinflammatory disease caused by loss-of-function mutations in OTULIN (FAM105B), encoding a deubiquitinase with linear linkage specificity. We identified two missense and one frameshift mutations in one Pakistani and two Turkish families with four affected patients. Patients presented with neonatal-onset fever, neutrophilic dermatitis/panniculitis, and failure to thrive, but without obvious primary immunodeficiency. HEK293 cells transfected with mutated OTULIN had decreased enzyme activity relative to cells transfected with WT OTULIN, and showed a substantial defect in the linear deubiquitination of target molecules. Stimulated patients' fibroblasts and peripheral blood mononuclear cells showed evidence for increased signaling in the canonical NF-\u03baB pathway and accumulated linear ubiquitin aggregates. Levels of proinflammatory cytokines were significantly increased in the supernatants of stimulated primary cells and serum samples. This discovery adds to the emerging spectrum of human diseases caused by defects in the ubiquitin pathway and suggests a role for targeted cytokine therapies.", "qas": [{"question": "Which is the enzymatic activity of OTULIN?", "answers": ["deubiquitination"], "qid": "f85c2449871b49c598f41e1f233256be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["OTULIN", 35], ["?", 41]], "detected_answers": [{"text": "deubiquitination", "token_spans": [[114, 114]], "char_spans": [[710, 725]]}]}], "context_tokens": [["Systemic", 0], ["autoinflammatory", 9], ["diseases", 26], ["are", 35], ["caused", 39], ["by", 46], ["mutations", 49], ["in", 59], ["genes", 62], ["that", 68], ["function", 73], ["in", 82], ["innate", 85], ["immunity", 92], [".", 100], ["Here", 102], [",", 106], ["we", 108], ["report", 111], ["an", 118], ["autoinflammatory", 121], ["disease", 138], ["caused", 146], ["by", 153], ["loss", 156], ["-", 160], ["of", 161], ["-", 163], ["function", 164], ["mutations", 173], ["in", 183], ["OTULIN", 186], ["(", 193], ["FAM105B", 194], [")", 201], [",", 202], ["encoding", 204], ["a", 213], ["deubiquitinase", 215], ["with", 230], ["linear", 235], ["linkage", 242], ["specificity", 250], [".", 261], ["We", 263], ["identified", 266], ["two", 277], ["missense", 281], ["and", 290], ["one", 294], ["frameshift", 298], ["mutations", 309], ["in", 319], ["one", 322], ["Pakistani", 326], ["and", 336], ["two", 340], ["Turkish", 344], ["families", 352], ["with", 361], ["four", 366], ["affected", 371], ["patients", 380], [".", 388], ["Patients", 390], ["presented", 399], ["with", 409], ["neonatal", 414], ["-", 422], ["onset", 423], ["fever", 429], [",", 434], ["neutrophilic", 436], ["dermatitis", 449], ["/", 459], ["panniculitis", 460], [",", 472], ["and", 474], ["failure", 478], ["to", 486], ["thrive", 489], [",", 495], ["but", 497], ["without", 501], ["obvious", 509], ["primary", 517], ["immunodeficiency", 525], [".", 541], ["HEK293", 543], ["cells", 550], ["transfected", 556], ["with", 568], ["mutated", 573], ["OTULIN", 581], ["had", 588], ["decreased", 592], ["enzyme", 602], ["activity", 609], ["relative", 618], ["to", 627], ["cells", 630], ["transfected", 636], ["with", 648], ["WT", 653], ["OTULIN", 656], [",", 662], ["and", 664], ["showed", 668], ["a", 675], ["substantial", 677], ["defect", 689], ["in", 696], ["the", 699], ["linear", 703], ["deubiquitination", 710], ["of", 727], ["target", 730], ["molecules", 737], [".", 746], ["Stimulated", 748], ["patients", 759], ["'", 767], ["fibroblasts", 769], ["and", 781], ["peripheral", 785], ["blood", 796], ["mononuclear", 802], ["cells", 814], ["showed", 820], ["evidence", 827], ["for", 836], ["increased", 840], ["signaling", 850], ["in", 860], ["the", 863], ["canonical", 867], ["NF", 877], ["-", 879], ["\u03baB", 880], ["pathway", 883], ["and", 891], ["accumulated", 895], ["linear", 907], ["ubiquitin", 914], ["aggregates", 924], [".", 934], ["Levels", 936], ["of", 943], ["proinflammatory", 946], ["cytokines", 962], ["were", 972], ["significantly", 977], ["increased", 991], ["in", 1001], ["the", 1004], ["supernatants", 1008], ["of", 1021], ["stimulated", 1024], ["primary", 1035], ["cells", 1043], ["and", 1049], ["serum", 1053], ["samples", 1059], [".", 1066], ["This", 1068], ["discovery", 1073], ["adds", 1083], ["to", 1088], ["the", 1091], ["emerging", 1095], ["spectrum", 1104], ["of", 1113], ["human", 1116], ["diseases", 1122], ["caused", 1131], ["by", 1138], ["defects", 1141], ["in", 1149], ["the", 1152], ["ubiquitin", 1156], ["pathway", 1166], ["and", 1174], ["suggests", 1178], ["a", 1187], ["role", 1189], ["for", 1194], ["targeted", 1198], ["cytokine", 1207], ["therapies", 1216], [".", 1225]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "The identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase. Incorporating the use of markers of BCR-ABL kinase inhibition into clinical trials led to the realization that imatinib-resistant kinase domain mutations are the major cause of relapse during imatinib therapy and the subsequent development of new inhibitors to treat CML patients. The development of imatinib validates an emerging paradigm in cancer, in which a tumor is defined by genetic abnormalities and effective therapies are developed that target events critical to the growth and survival of a specific tumor.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "773d0b65b19340d59e18c9cf74fe8c94", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [59, 61], [23, 25]], "char_spans": [[283, 289], [335, 341], [148, 154]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["Philadelphia", 26], ["chromosome", 39], ["in", 50], ["cells", 53], ["from", 59], ["individuals", 64], ["with", 76], ["chronic", 81], ["myelogenous", 89], ["leukemia", 101], ["(", 110], ["CML", 111], [")", 114], ["led", 116], ["to", 120], ["the", 123], ["recognition", 127], ["that", 139], ["the", 144], ["BCR", 148], ["-", 151], ["ABL", 152], ["tyrosine", 156], ["kinase", 165], ["causes", 172], ["CML", 179], [".", 182], ["This", 184], ["in", 189], ["turn", 192], ["led", 197], ["to", 201], ["the", 204], ["development", 208], ["of", 220], ["imatinib", 223], ["mesylate", 232], [",", 240], ["a", 242], ["clinically", 244], ["successful", 255], ["inhibitor", 266], ["of", 276], ["the", 279], ["BCR", 283], ["-", 286], ["ABL", 287], ["kinase", 291], [".", 297], ["Incorporating", 299], ["the", 313], ["use", 317], ["of", 321], ["markers", 324], ["of", 332], ["BCR", 335], ["-", 338], ["ABL", 339], ["kinase", 343], ["inhibition", 350], ["into", 361], ["clinical", 366], ["trials", 375], ["led", 382], ["to", 386], ["the", 389], ["realization", 393], ["that", 405], ["imatinib", 410], ["-", 418], ["resistant", 419], ["kinase", 429], ["domain", 436], ["mutations", 443], ["are", 453], ["the", 457], ["major", 461], ["cause", 467], ["of", 473], ["relapse", 476], ["during", 484], ["imatinib", 491], ["therapy", 500], ["and", 508], ["the", 512], ["subsequent", 516], ["development", 527], ["of", 539], ["new", 542], ["inhibitors", 546], ["to", 557], ["treat", 560], ["CML", 566], ["patients", 570], [".", 578], ["The", 580], ["development", 584], ["of", 596], ["imatinib", 599], ["validates", 608], ["an", 618], ["emerging", 621], ["paradigm", 630], ["in", 639], ["cancer", 642], [",", 648], ["in", 650], ["which", 653], ["a", 659], ["tumor", 661], ["is", 667], ["defined", 670], ["by", 678], ["genetic", 681], ["abnormalities", 689], ["and", 703], ["effective", 707], ["therapies", 717], ["are", 727], ["developed", 731], ["that", 741], ["target", 746], ["events", 753], ["critical", 760], ["to", 769], ["the", 772], ["growth", 776], ["and", 783], ["survival", 787], ["of", 796], ["a", 799], ["specific", 801], ["tumor", 810], [".", 815]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "We immunohistochemically investigated the degeneration processes of the nigro-striatal and nigro-amygdaloid pathways and the relationship between the loss of dopaminergic neurons and Lewy bodies (LB) formation in the substantia nigra using 15 autopsied cases of dementia with Lewy bodies (DLB). The number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra and TH-positive axonal terminals in the putamen decreased with a specific pattern. The substantia nigra possessed alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining. Most of the granular stains were positive for anti-phosphorylated alpha-synuclein antibody, whereas the diffuse stains were negative. These findings suggest that the axonal terminals in the putamen undergo abnormal alpha-synuclein accumulation, but may not always originate from LB-bearing neurons in the substantia nigra. The central amygdaloid nucleus contained anti-alpha-synuclein- and -phosphorylated alpha-synuclein-positive dystrophic axonal terminals, the degree of which was greater for cases with granular staining in the putamen, and which was proportional to the number of alpha-synuclein-positive neurons in the substantia nigra. Thus, the axonal terminals in the central amygdaloid nucleus may have originated from LB-bearing neurons in the substantia nigra. The results of the present study indicate that the nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in DLB, and suggest that the degeneration of the nigro-amygdaloid pathway more strongly reflects LB formation in dopaminergic neurons of the substantia nigra than that of the nigro-striatal pathway. In addition, they indicate that there is no direct relationship between the loss of dopaminergic neurons and LB formation in the substantia nigra.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "838f259cf3d94ed1a4628e26a79fa183", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[102, 104], [170, 172], [175, 177], [119, 121], [207, 209], [80, 82], [143, 145]], "char_spans": [[619, 633], [1020, 1035], [1057, 1071], [717, 731], [1236, 1250], [490, 504], [866, 880]]}]}], "context_tokens": [["We", 0], ["immunohistochemically", 3], ["investigated", 25], ["the", 38], ["degeneration", 42], ["processes", 55], ["of", 65], ["the", 68], ["nigro", 72], ["-", 77], ["striatal", 78], ["and", 87], ["nigro", 91], ["-", 96], ["amygdaloid", 97], ["pathways", 108], ["and", 117], ["the", 121], ["relationship", 125], ["between", 138], ["the", 146], ["loss", 150], ["of", 155], ["dopaminergic", 158], ["neurons", 171], ["and", 179], ["Lewy", 183], ["bodies", 188], ["(", 195], ["LB", 196], [")", 198], ["formation", 200], ["in", 210], ["the", 213], ["substantia", 217], ["nigra", 228], ["using", 234], ["15", 240], ["autopsied", 243], ["cases", 253], ["of", 259], ["dementia", 262], ["with", 271], ["Lewy", 276], ["bodies", 281], ["(", 288], ["DLB", 289], [")", 292], [".", 293], ["The", 295], ["number", 299], ["of", 306], ["tyrosine", 309], ["hydroxylase", 318], ["(", 330], ["TH)-positive", 331], ["neurons", 344], ["in", 352], ["the", 355], ["substantia", 359], ["nigra", 370], ["and", 376], ["TH", 380], ["-", 382], ["positive", 383], ["axonal", 392], ["terminals", 399], ["in", 409], ["the", 412], ["putamen", 416], ["decreased", 424], ["with", 434], ["a", 439], ["specific", 441], ["pattern", 450], [".", 457], ["The", 459], ["substantia", 463], ["nigra", 474], ["possessed", 480], ["alpha", 490], ["-", 495], ["synuclein", 496], ["-", 505], ["positive", 506], ["LB", 515], ["-", 517], ["bearing", 518], ["neurons", 526], ["that", 534], ["were", 539], ["almost", 544], ["evenly", 551], ["distributed", 558], [",", 569], ["while", 571], ["the", 577], ["putamen", 581], ["exhibited", 589], ["diffuse", 599], ["or", 607], ["granular", 610], ["alpha", 619], ["-", 624], ["synuclein", 625], ["-", 634], ["immunostaining", 635], [".", 649], ["Most", 651], ["of", 656], ["the", 659], ["granular", 663], ["stains", 672], ["were", 679], ["positive", 684], ["for", 693], ["anti", 697], ["-", 701], ["phosphorylated", 702], ["alpha", 717], ["-", 722], ["synuclein", 723], ["antibody", 733], [",", 741], ["whereas", 743], ["the", 751], ["diffuse", 755], ["stains", 763], ["were", 770], ["negative", 775], [".", 783], ["These", 785], ["findings", 791], ["suggest", 800], ["that", 808], ["the", 813], ["axonal", 817], ["terminals", 824], ["in", 834], ["the", 837], ["putamen", 841], ["undergo", 849], ["abnormal", 857], ["alpha", 866], ["-", 871], ["synuclein", 872], ["accumulation", 882], [",", 894], ["but", 896], ["may", 900], ["not", 904], ["always", 908], ["originate", 915], ["from", 925], ["LB", 930], ["-", 932], ["bearing", 933], ["neurons", 941], ["in", 949], ["the", 952], ["substantia", 956], ["nigra", 967], [".", 972], ["The", 974], ["central", 978], ["amygdaloid", 986], ["nucleus", 997], ["contained", 1005], ["anti", 1015], ["-", 1019], ["alpha", 1020], ["-", 1025], ["synuclein-", 1026], ["and", 1037], ["-phosphorylated", 1041], ["alpha", 1057], ["-", 1062], ["synuclein", 1063], ["-", 1072], ["positive", 1073], ["dystrophic", 1082], ["axonal", 1093], ["terminals", 1100], [",", 1109], ["the", 1111], ["degree", 1115], ["of", 1122], ["which", 1125], ["was", 1131], ["greater", 1135], ["for", 1143], ["cases", 1147], ["with", 1153], ["granular", 1158], ["staining", 1167], ["in", 1176], ["the", 1179], ["putamen", 1183], [",", 1190], ["and", 1192], ["which", 1196], ["was", 1202], ["proportional", 1206], ["to", 1219], ["the", 1222], ["number", 1226], ["of", 1233], ["alpha", 1236], ["-", 1241], ["synuclein", 1242], ["-", 1251], ["positive", 1252], ["neurons", 1261], ["in", 1269], ["the", 1272], ["substantia", 1276], ["nigra", 1287], [".", 1292], ["Thus", 1294], [",", 1298], ["the", 1300], ["axonal", 1304], ["terminals", 1311], ["in", 1321], ["the", 1324], ["central", 1328], ["amygdaloid", 1336], ["nucleus", 1347], ["may", 1355], ["have", 1359], ["originated", 1364], ["from", 1375], ["LB", 1380], ["-", 1382], ["bearing", 1383], ["neurons", 1391], ["in", 1399], ["the", 1402], ["substantia", 1406], ["nigra", 1417], [".", 1422], ["The", 1424], ["results", 1428], ["of", 1436], ["the", 1439], ["present", 1443], ["study", 1451], ["indicate", 1457], ["that", 1466], ["the", 1471], ["nigro", 1475], ["-", 1480], ["striatal", 1481], ["and", 1490], ["nigro", 1494], ["-", 1499], ["amygdaloid", 1500], ["pathways", 1511], ["undergo", 1520], ["different", 1528], ["degeneration", 1538], ["processes", 1551], ["in", 1561], ["DLB", 1564], [",", 1567], ["and", 1569], ["suggest", 1573], ["that", 1581], ["the", 1586], ["degeneration", 1590], ["of", 1603], ["the", 1606], ["nigro", 1610], ["-", 1615], ["amygdaloid", 1616], ["pathway", 1627], ["more", 1635], ["strongly", 1640], ["reflects", 1649], ["LB", 1658], ["formation", 1661], ["in", 1671], ["dopaminergic", 1674], ["neurons", 1687], ["of", 1695], ["the", 1698], ["substantia", 1702], ["nigra", 1713], ["than", 1719], ["that", 1724], ["of", 1729], ["the", 1732], ["nigro", 1736], ["-", 1741], ["striatal", 1742], ["pathway", 1751], [".", 1758], ["In", 1760], ["addition", 1763], [",", 1771], ["they", 1773], ["indicate", 1778], ["that", 1787], ["there", 1792], ["is", 1798], ["no", 1801], ["direct", 1804], ["relationship", 1811], ["between", 1824], ["the", 1832], ["loss", 1836], ["of", 1841], ["dopaminergic", 1844], ["neurons", 1857], ["and", 1865], ["LB", 1869], ["formation", 1872], ["in", 1882], ["the", 1885], ["substantia", 1889], ["nigra", 1900], [".", 1905]]}
{"context": "To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. An 800-bed, teaching, university-affiliated hospital. Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant \"waking\" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "703c26f6e3614fc3ad84fedea34fc7ed", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[416, 416], [213, 213], [363, 363], [134, 134], [294, 294], [605, 605], [12, 12], [564, 564], [105, 105], [233, 233], [505, 505], [585, 585], [15, 15]], "char_spans": [[2297, 2306], [1230, 1239], [1959, 1968], [704, 713], [1667, 1676], [3464, 3473], [59, 68], [3188, 3197], [539, 548], [1317, 1326], [2830, 2839], [3319, 3328], [84, 93]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], [",", 22], ["usefulness", 24], [",", 34], ["safety", 36], [",", 42], ["and", 44], ["dosages", 48], ["of", 56], ["flumazenil", 59], ["required", 70], ["when", 79], ["flumazenil", 84], ["is", 95], ["used", 98], ["in", 103], ["the", 106], ["diagnosis", 110], ["of", 120], ["benzodiazepine", 123], ["-", 137], ["induced", 138], ["coma", 146], ["(", 151], ["vs.", 152], ["other", 156], ["drug", 162], ["-", 166], ["induced", 167], ["coma", 175], [")", 179], [",", 180], ["and", 182], ["to", 186], ["reverse", 189], ["or", 197], ["prevent", 200], ["the", 208], ["recurrence", 212], ["of", 223], ["unconsciousness", 226], [".", 241], ["A", 243], ["two", 245], ["-", 248], ["phase", 249], ["study", 255], [":", 260], ["a", 262], ["controlled", 264], [",", 274], ["randomized", 276], [",", 286], ["double", 288], ["-", 294], ["blind", 295], ["study", 301], ["followed", 307], ["by", 316], ["a", 319], ["prospective", 321], [",", 332], ["open", 334], ["study", 339], [".", 344], ["An", 346], ["800-bed", 349], [",", 356], ["teaching", 358], [",", 366], ["university", 368], ["-", 378], ["affiliated", 379], ["hospital", 390], [".", 398], ["Unconscious", 400], ["patients", 412], ["(", 421], ["n", 422], ["=", 424], ["110", 426], [")", 429], ["suspected", 431], ["of", 441], ["benzodiazepine", 444], ["overdose", 459], [",", 467], ["graded", 469], ["2", 476], ["to", 478], ["4", 481], ["on", 483], ["the", 486], ["Matthew", 490], ["and", 498], ["Lawson", 502], ["coma", 509], ["scale", 514], [",", 519], ["were", 521], ["treated", 526], ["with", 534], ["flumazenil", 539], [",", 549], ["the", 551], ["specific", 555], ["benzodiazepine", 564], ["receptor", 579], ["antagonist", 588], [".", 598], ["The", 600], ["first", 604], ["31", 610], ["patients", 613], ["were", 622], ["studied", 627], ["in", 635], ["a", 638], ["double", 640], ["-", 646], ["blind", 647], ["fashion", 653], [",", 660], ["while", 662], ["the", 668], ["rest", 672], ["of", 677], ["the", 680], ["patients", 684], ["were", 693], ["given", 698], ["flumazenil", 704], ["according", 715], ["to", 725], ["an", 728], ["open", 731], ["protocol", 736], [".", 744], ["INTERVENTIONS", 746], [";", 759], ["All", 761], ["patients", 765], ["received", 774], ["supplemental", 783], ["oxygen", 796], [";", 802], ["endotracheal", 804], ["intubation", 817], ["was", 828], ["performed", 832], [",", 841], ["and", 843], ["synchronized", 847], ["intermittent", 860], ["mandatory", 873], ["ventilation", 883], ["was", 895], ["initiated", 899], ["whenever", 909], ["it", 918], ["was", 921], ["deemed", 925], ["necessary", 932], [".", 941], ["A", 943], ["peripheral", 945], ["intravenous", 956], ["cannula", 968], ["was", 976], ["inserted", 980], [",", 988], ["as", 990], ["were", 993], ["indwelling", 998], ["arterial", 1009], ["and", 1018], ["urinary", 1022], ["bladder", 1030], ["catheters", 1038], [".", 1047], ["Blood", 1049], ["pressure", 1055], [",", 1063], ["electrocardiogram", 1065], [",", 1082], ["respiratory", 1084], ["rate", 1096], [",", 1100], ["end", 1102], ["-", 1105], ["tidal", 1106], ["CO2", 1112], [",", 1115], ["and", 1117], ["core", 1121], ["temperature", 1126], ["were", 1138], ["continuously", 1143], ["monitored", 1156], [".", 1165], ["The", 1167], ["first", 1171], ["31", 1177], ["double", 1180], ["-", 1186], ["blind", 1187], ["patients", 1193], ["received", 1202], ["either", 1211], ["intravenous", 1218], ["flumazenil", 1230], ["(", 1241], ["to", 1242], ["a", 1245], ["maximum", 1247], ["of", 1255], ["1", 1258], ["mg", 1260], [")", 1262], ["or", 1264], ["saline", 1267], [",", 1273], ["while", 1275], ["the", 1281], ["rest", 1285], ["of", 1290], ["the", 1293], ["patients", 1297], ["were", 1306], ["given", 1311], ["flumazenil", 1317], ["until", 1328], ["either", 1334], ["regaining", 1341], ["consciousness", 1351], ["or", 1365], ["a", 1368], ["maximum", 1370], ["of", 1378], ["2.5", 1381], ["mg", 1385], ["was", 1388], ["injected", 1392], [".", 1400], ["Patients", 1402], ["remaining", 1411], ["unconscious", 1421], ["among", 1433], ["double", 1439], ["-", 1445], ["blind", 1446], ["patients", 1452], ["or", 1461], ["those", 1464], ["patients", 1470], ["relapsing", 1479], ["into", 1489], ["coma", 1494], ["after", 1499], ["the", 1505], ["first", 1509], ["dose", 1515], ["were", 1520], ["later", 1525], ["treated", 1531], ["in", 1539], ["the", 1542], ["open", 1546], ["phase", 1551], ["of", 1557], ["the", 1560], ["study", 1564], [".", 1569], ["Treatment", 1571], ["continued", 1581], ["by", 1591], ["boluses", 1594], ["or", 1602], ["infusion", 1605], ["as", 1614], ["long", 1617], ["as", 1622], ["efficacious", 1625], [".", 1636], ["Fourteen", 1638], ["of", 1647], ["17", 1650], ["double", 1653], ["-", 1659], ["blind", 1660], [",", 1665], ["flumazenil", 1667], ["-", 1677], ["treated", 1678], ["patients", 1686], ["woke", 1695], ["after", 1700], ["a", 1706], ["mean", 1708], ["of", 1713], ["0.8", 1716], ["+", 1720], ["/-", 1721], ["0.3", 1724], ["(", 1728], ["SD", 1729], [")", 1731], ["mg", 1733], ["vs.", 1736], ["one", 1740], ["of", 1744], ["14", 1747], ["placebo", 1750], ["patients", 1758], ["(", 1767], ["p", 1768], ["<", 1770], [".001", 1772], [")", 1776], [".", 1777], ["Seventy", 1779], ["-", 1786], ["five", 1787], ["percent", 1792], ["of", 1800], ["the", 1803], ["aggregated", 1807], ["controlled", 1818], ["and", 1829], ["uncontrolled", 1833], ["patients", 1846], ["awoke", 1855], ["from", 1861], ["coma", 1866], ["scores", 1871], ["of", 1878], ["3.1", 1881], ["+", 1885], ["/-", 1886], ["0.6", 1889], ["to", 1893], ["0.4", 1896], ["+", 1900], ["/-", 1901], ["0.5", 1904], ["(", 1908], ["p", 1909], ["<", 1911], [".01", 1913], [")", 1916], ["after", 1918], ["the", 1924], ["injection", 1928], ["of", 1938], ["0.7", 1941], ["+", 1945], ["/-", 1946], ["0.3", 1949], ["mg", 1953], ["of", 1956], ["flumazenil", 1959], [".", 1969], ["These", 1971], ["patients", 1977], ["had", 1986], ["high", 1990], ["benzodiazepine", 1995], ["serum", 2010], ["blood", 2016], ["concentrations", 2022], [".", 2036], ["Twenty", 2038], ["-", 2044], ["five", 2045], ["percent", 2050], ["of", 2058], ["the", 2061], ["patients", 2065], ["did", 2074], ["not", 2078], ["regain", 2082], ["consciousness", 2089], [".", 2102], ["These", 2104], ["patients", 2110], ["had", 2119], ["very", 2123], ["high", 2128], ["serum", 2133], ["concentrations", 2139], ["of", 2154], ["nonbenzodiazepine", 2157], ["drugs", 2175], [".", 2180], ["Sixty", 2182], ["percent", 2188], ["of", 2196], ["the", 2199], ["responders", 2203], ["who", 2214], ["had", 2218], ["primarily", 2222], ["ingested", 2232], ["benzodiazepines", 2241], ["remained", 2257], ["awake", 2266], ["for", 2272], ["72", 2276], ["+", 2279], ["/-", 2280], ["37", 2283], ["mins", 2286], ["after", 2291], ["flumazenil", 2297], ["administration", 2308], [";", 2322], ["40", 2324], ["%", 2326], ["relapsed", 2328], ["into", 2337], ["coma", 2342], ["after", 2347], ["18", 2353], ["+", 2356], ["/-", 2357], ["7", 2360], ["mins", 2362], ["and", 2367], ["various", 2371], ["central", 2379], ["nervous", 2387], ["system", 2395], ["depressant", 2402], ["drugs", 2413], ["were", 2419], ["detected", 2424], ["in", 2433], ["their", 2436], ["blood", 2442], ["in", 2448], ["addition", 2451], ["to", 2460], ["benzodiazepines", 2463], [".", 2478], ["Seventy", 2480], ["-", 2487], ["one", 2488], ["percent", 2492], ["of", 2500], ["the", 2503], ["patients", 2507], ["had", 2516], ["ingested", 2520], ["tricyclic", 2529], ["antidepressants", 2539], [".", 2554], ["Seventy", 2556], ["-", 2563], ["eight", 2564], ["percent", 2570], ["of", 2578], ["the", 2581], ["responders", 2585], ["were", 2596], ["continually", 2601], ["and", 2613], ["efficaciously", 2617], ["treated", 2631], ["for", 2639], ["<", 2643], ["or", 2645], ["=", 2648], ["8", 2650], ["days", 2652], [".", 2656], ["Fourteen", 2658], ["(", 2667], ["25", 2668], ["%", 2670], [")", 2671], ["of", 2673], ["the", 2676], ["intubated", 2680], ["patients", 2690], ["were", 2699], ["extubated", 2704], ["safely", 2714], ["while", 2721], ["12", 2727], ["patients", 2730], [",", 2738], ["who", 2740], ["had", 2744], ["shown", 2748], ["increased", 2754], ["respiratory", 2764], ["insufficiency", 2776], [",", 2789], ["resumed", 2791], ["satisfactory", 2799], ["respiration", 2812], ["after", 2824], ["flumazenil", 2830], ["injection", 2841], [".", 2850], ["Five", 2852], ["cases", 2857], ["of", 2863], ["transient", 2866], ["increase", 2876], ["in", 2885], ["blood", 2888], ["pressure", 2894], ["and", 2903], ["heart", 2907], ["rate", 2913], ["were", 2918], ["encountered", 2923], [".", 2934], ["There", 2936], ["were", 2942], ["27", 2947], ["mildly", 2950], ["unpleasant", 2957], ["\"", 2968], ["waking", 2969], ["\"", 2975], ["episodes", 2977], [",", 2985], ["such", 2987], ["as", 2992], ["anxiety", 2995], [",", 3002], ["restlessness", 3004], [",", 3016], ["and", 3018], ["aggression", 3022], [",", 3032], ["but", 3034], ["no", 3038], ["patient", 3041], ["had", 3049], ["benzodiazepine", 3053], ["withdrawal", 3068], ["signs", 3079], [",", 3084], ["convulsions", 3086], [",", 3097], ["or", 3099], ["dysrhythmia", 3102], [",", 3113], ["most", 3115], ["noticeably", 3120], ["absent", 3131], ["in", 3138], ["tricyclic", 3141], ["antidepressant", 3151], ["-", 3165], ["intoxicated", 3166], ["patients", 3178], [".", 3186], ["Flumazenil", 3188], ["is", 3199], ["a", 3202], ["valid", 3204], ["diagnostic", 3210], ["tool", 3221], ["for", 3226], ["distinguishing", 3230], ["pure", 3245], ["benzodiazepine", 3250], ["from", 3265], ["mixed", 3270], ["-", 3275], ["drug", 3276], ["intoxication", 3281], ["or", 3294], ["nondrug", 3297], ["-", 3304], ["induced", 3305], ["coma", 3313], [".", 3317], ["Flumazenil", 3319], ["is", 3330], ["effective", 3333], ["in", 3343], ["preventing", 3346], ["recurrence", 3357], ["of", 3368], ["benzodiazepine", 3371], ["-", 3385], ["induced", 3386], ["coma", 3394], [".", 3398], ["Respiratory", 3400], ["insufficiency", 3412], ["is", 3426], ["reversed", 3429], ["after", 3438], ["its", 3444], ["administration", 3448], [".", 3462], ["Flumazenil", 3464], ["is", 3475], ["safe", 3478], ["when", 3483], ["administered", 3488], ["cautiously", 3501], [",", 3511], ["even", 3513], ["in", 3518], ["patients", 3521], ["with", 3530], ["coma", 3535], ["caused", 3540], ["by", 3547], ["a", 3550], ["mixed", 3552], ["overdose", 3558], ["of", 3567], ["benzodiazepine", 3570], ["plus", 3585], ["tricyclic", 3590], ["antidepressants", 3600], [".", 3615]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-\u03baB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor-\u03baB ligand", "RANKL"], "qid": "ce4f694e2894496cb11f3d96bd206a41", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[79, 86]], "char_spans": [[432, 477]]}, {"text": "RANKL", "token_spans": [[88, 88], [112, 112]], "char_spans": [[480, 484], [601, 605]]}]}], "context_tokens": [["Giant", 0], ["-", 5], ["cell", 6], ["tumor", 11], ["of", 17], ["bone", 20], ["is", 25], ["a", 28], ["rare", 30], [",", 34], ["locally", 36], ["aggressive", 44], ["tumor", 55], ["that", 61], ["typically", 66], ["occurs", 76], ["in", 83], ["the", 86], ["bones", 90], ["of", 96], ["skeletally", 99], ["mature", 110], ["young", 117], ["adults", 123], ["in", 130], ["their", 133], ["second", 139], ["to", 146], ["fourth", 149], ["decades", 156], [".", 163], ["Traditionally", 165], [",", 178], ["surgery", 180], ["has", 188], ["been", 192], ["the", 197], ["mainstay", 201], ["of", 210], ["therapy", 213], ["for", 221], ["this", 225], ["disease", 230], [",", 237], ["but", 239], ["the", 243], ["disease", 247], ["can", 255], ["recur", 259], ["even", 265], ["with", 270], ["optimal", 275], ["procedures", 283], [".", 293], ["Furthermore", 295], [",", 306], ["it", 308], ["may", 311], ["occur", 315], ["in", 321], ["locations", 324], ["where", 334], ["a", 340], ["surgical", 342], ["approach", 351], ["would", 360], ["be", 366], ["morbid", 369], [".", 375], ["The", 377], ["maturation", 381], ["of", 392], ["the", 395], ["understanding", 399], ["of", 413], ["the", 416], ["role", 420], ["of", 425], ["the", 428], ["receptor", 432], ["activator", 441], ["of", 451], ["nuclear", 454], ["factor", 462], ["-", 468], ["\u03baB", 469], ["ligand", 472], ["(", 479], ["RANKL", 480], [")", 485], ["in", 487], ["the", 490], ["pathophysiology", 494], ["of", 510], ["giant", 513], ["-", 518], ["cell", 519], ["tumor", 524], ["of", 530], ["bone", 533], ["has", 538], ["led", 542], ["to", 546], ["the", 549], ["use", 553], ["of", 557], ["denosumab", 560], [",", 569], ["a", 571], ["monoclonal", 573], ["antibody", 584], ["against", 593], ["RANKL", 601], [",", 606], ["in", 608], ["this", 611], ["disease", 616], [".", 623], ["In", 625], ["2013", 628], [",", 632], ["the", 634], ["US", 638], ["Food", 641], ["and", 646], ["Drug", 650], ["Administration", 655], ["approved", 670], ["denosumab", 679], ["for", 689], ["use", 693], ["in", 697], ["patients", 700], ["with", 709], ["recurrent", 714], ["/", 723], ["unresectable", 724], ["/", 736], ["metastatic", 737], ["giant", 748], ["-", 753], ["cell", 754], ["tumor", 759], ["of", 765], ["bone", 768], ["or", 773], ["for", 776], ["patients", 780], ["in", 789], ["whom", 792], ["surgery", 797], ["would", 805], ["be", 811], ["morbid", 814], [".", 820]]}
{"context": "Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a neurodegenerative disorder caused by defective function of the lysosomal membrane glycoprotein CLN3. The activity of the lysosomal acid phosphatase (LAP/ACP2) was found to be significantly increased in the cerebellum and brain stem of Cln3-targeted mice during the early stages of postnatal life. Histochemical localization studies revealed an increased LAP/ACP2 staining intensity in neurons of the cerebral cortex of 48-week-old Cln3-targeted mice as compared with controls. Additionally, the expression of another lysosomal membrane protein LAMP-2 was increased in all brain areas. Knockdown of CLN3 expression in HeLa cells by RNA interference also resulted in increased LAP/ACP2 and LAMP-2 expression. Finally in fibroblasts of two juvenile neuronal ceroid lipofuscinosis patients elevated levels of LAP/ACP2 were found. Both activation of gene transcription and increased protein half-life appear to contribute to increased LAP/ACP2 protein expression in CLN3-deficient cells. The data suggest that lysosomal dysfunction and accumulation of storage material require increased biogenesis of LAP/ACP2 and LAMP-2 positive membranes which makes LAP/ACP2 suitable as biomarker of Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "5af94115175949a3aa6007921a11d0a1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[5, 6], [199, 200]], "char_spans": [[41, 54], [1243, 1256]]}]}], "context_tokens": [["Juvenile", 0], ["neuronal", 9], ["ceroid", 18], ["lipofuscinosis", 25], ["(", 40], ["Batten", 41], ["disease", 48], [")", 55], ["is", 57], ["a", 60], ["neurodegenerative", 62], ["disorder", 80], ["caused", 89], ["by", 96], ["defective", 99], ["function", 109], ["of", 118], ["the", 121], ["lysosomal", 125], ["membrane", 135], ["glycoprotein", 144], ["CLN3", 157], [".", 161], ["The", 163], ["activity", 167], ["of", 176], ["the", 179], ["lysosomal", 183], ["acid", 193], ["phosphatase", 198], ["(", 210], ["LAP", 211], ["/", 214], ["ACP2", 215], [")", 219], ["was", 221], ["found", 225], ["to", 231], ["be", 234], ["significantly", 237], ["increased", 251], ["in", 261], ["the", 264], ["cerebellum", 268], ["and", 279], ["brain", 283], ["stem", 289], ["of", 294], ["Cln3-targeted", 297], ["mice", 311], ["during", 316], ["the", 323], ["early", 327], ["stages", 333], ["of", 340], ["postnatal", 343], ["life", 353], [".", 357], ["Histochemical", 359], ["localization", 373], ["studies", 386], ["revealed", 394], ["an", 403], ["increased", 406], ["LAP", 416], ["/", 419], ["ACP2", 420], ["staining", 425], ["intensity", 434], ["in", 444], ["neurons", 447], ["of", 455], ["the", 458], ["cerebral", 462], ["cortex", 471], ["of", 478], ["48-week", 481], ["-", 488], ["old", 489], ["Cln3-targeted", 493], ["mice", 507], ["as", 512], ["compared", 515], ["with", 524], ["controls", 529], [".", 537], ["Additionally", 539], [",", 551], ["the", 553], ["expression", 557], ["of", 568], ["another", 571], ["lysosomal", 579], ["membrane", 589], ["protein", 598], ["LAMP-2", 606], ["was", 613], ["increased", 617], ["in", 627], ["all", 630], ["brain", 634], ["areas", 640], [".", 645], ["Knockdown", 647], ["of", 657], ["CLN3", 660], ["expression", 665], ["in", 676], ["HeLa", 679], ["cells", 684], ["by", 690], ["RNA", 693], ["interference", 697], ["also", 710], ["resulted", 715], ["in", 724], ["increased", 727], ["LAP", 737], ["/", 740], ["ACP2", 741], ["and", 746], ["LAMP-2", 750], ["expression", 757], [".", 767], ["Finally", 769], ["in", 777], ["fibroblasts", 780], ["of", 792], ["two", 795], ["juvenile", 799], ["neuronal", 808], ["ceroid", 817], ["lipofuscinosis", 824], ["patients", 839], ["elevated", 848], ["levels", 857], ["of", 864], ["LAP", 867], ["/", 870], ["ACP2", 871], ["were", 876], ["found", 881], [".", 886], ["Both", 888], ["activation", 893], ["of", 904], ["gene", 907], ["transcription", 912], ["and", 926], ["increased", 930], ["protein", 940], ["half", 948], ["-", 952], ["life", 953], ["appear", 958], ["to", 965], ["contribute", 968], ["to", 979], ["increased", 982], ["LAP", 992], ["/", 995], ["ACP2", 996], ["protein", 1001], ["expression", 1009], ["in", 1020], ["CLN3-deficient", 1023], ["cells", 1038], [".", 1043], ["The", 1045], ["data", 1049], ["suggest", 1054], ["that", 1062], ["lysosomal", 1067], ["dysfunction", 1077], ["and", 1089], ["accumulation", 1093], ["of", 1106], ["storage", 1109], ["material", 1117], ["require", 1126], ["increased", 1134], ["biogenesis", 1144], ["of", 1155], ["LAP", 1158], ["/", 1161], ["ACP2", 1162], ["and", 1167], ["LAMP-2", 1171], ["positive", 1178], ["membranes", 1187], ["which", 1197], ["makes", 1203], ["LAP", 1209], ["/", 1212], ["ACP2", 1213], ["suitable", 1218], ["as", 1227], ["biomarker", 1230], ["of", 1240], ["Batten", 1243], ["disease", 1250], [".", 1257]]}
{"context": "Cells respond to stresses such as osmotic shock and heat shock by activating stress-activated protein kinases (SAPKs), including c-Jun N-terminal kinase (JNK) [1]. Activation of JNK requires phosphorylation of threonine and tyrosine residues in the TPY activation loop motif [2, 3] and can be reversed by the removal of either phosphate group. Numerous JNK phosphatases including dual-specificity phosphatases [4, 5], have been identified. Many stimuli activate JNK by increasing its rate of phosphorylation; however, JNK dephosphorylation is inhibited in cells after heat shock [6], suggesting that a JNK phosphatase(s) is inactivated. M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. We have previously expressed M3/6 in the mouse bone marrow cell line BAF3 in order to show that JNK activation by IL-3 is necessary for cell survival and proliferation [9]. Here we report that M3/6 dissociates from JNK and appears in an insoluble fraction after heat shock. These data identify M3/6 as a JNK phosphatase that is inactivated by heat shock and provide a molecular mechanism for the activation of JNK by heat shock.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "902996f009de41b18ed94ad607438522", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[37, 37], [69, 69], [99, 99], [115, 115], [173, 173], [89, 89], [153, 153], [190, 190], [130, 130], [31, 31], [207, 207]], "char_spans": [[178, 180], [353, 355], [518, 520], [602, 604], [917, 919], [462, 464], [798, 800], [1006, 1008], [690, 692], [154, 156], [1112, 1114]]}]}], "context_tokens": [["Cells", 0], ["respond", 6], ["to", 14], ["stresses", 17], ["such", 26], ["as", 31], ["osmotic", 34], ["shock", 42], ["and", 48], ["heat", 52], ["shock", 57], ["by", 63], ["activating", 66], ["stress", 77], ["-", 83], ["activated", 84], ["protein", 94], ["kinases", 102], ["(", 110], ["SAPKs", 111], [")", 116], [",", 117], ["including", 119], ["c", 129], ["-", 130], ["Jun", 131], ["N", 135], ["-", 136], ["terminal", 137], ["kinase", 146], ["(", 153], ["JNK", 154], [")", 157], ["[", 159], ["1].", 160], ["Activation", 164], ["of", 175], ["JNK", 178], ["requires", 182], ["phosphorylation", 191], ["of", 207], ["threonine", 210], ["and", 220], ["tyrosine", 224], ["residues", 233], ["in", 242], ["the", 245], ["TPY", 249], ["activation", 253], ["loop", 264], ["motif", 269], ["[", 275], ["2", 276], [",", 277], ["3", 279], ["]", 280], ["and", 282], ["can", 286], ["be", 290], ["reversed", 293], ["by", 302], ["the", 305], ["removal", 309], ["of", 317], ["either", 320], ["phosphate", 327], ["group", 337], [".", 342], ["Numerous", 344], ["JNK", 353], ["phosphatases", 357], ["including", 370], ["dual", 380], ["-", 384], ["specificity", 385], ["phosphatases", 397], ["[", 410], ["4", 411], [",", 412], ["5", 414], ["]", 415], [",", 416], ["have", 418], ["been", 423], ["identified", 428], [".", 438], ["Many", 440], ["stimuli", 445], ["activate", 453], ["JNK", 462], ["by", 466], ["increasing", 469], ["its", 480], ["rate", 484], ["of", 489], ["phosphorylation", 492], [";", 507], ["however", 509], [",", 516], ["JNK", 518], ["dephosphorylation", 522], ["is", 540], ["inhibited", 543], ["in", 553], ["cells", 556], ["after", 562], ["heat", 568], ["shock", 573], ["[", 579], ["6", 580], ["]", 581], [",", 582], ["suggesting", 584], ["that", 595], ["a", 600], ["JNK", 602], ["phosphatase(s", 606], [")", 619], ["is", 621], ["inactivated", 624], [".", 635], ["M3/6", 637], ["is", 642], ["a", 645], ["dual", 647], ["-", 651], ["specificity", 652], ["phosphatase", 664], ["selective", 676], ["for", 686], ["JNK", 690], ["[", 694], ["7", 695], [",", 696], ["8].", 698], ["We", 702], ["have", 705], ["previously", 710], ["expressed", 721], ["M3/6", 731], ["in", 736], ["the", 739], ["mouse", 743], ["bone", 749], ["marrow", 754], ["cell", 761], ["line", 766], ["BAF3", 771], ["in", 776], ["order", 779], ["to", 785], ["show", 788], ["that", 793], ["JNK", 798], ["activation", 802], ["by", 813], ["IL-3", 816], ["is", 821], ["necessary", 824], ["for", 834], ["cell", 838], ["survival", 843], ["and", 852], ["proliferation", 856], ["[", 870], ["9].", 871], ["Here", 875], ["we", 880], ["report", 883], ["that", 890], ["M3/6", 895], ["dissociates", 900], ["from", 912], ["JNK", 917], ["and", 921], ["appears", 925], ["in", 933], ["an", 936], ["insoluble", 939], ["fraction", 949], ["after", 958], ["heat", 964], ["shock", 969], [".", 974], ["These", 976], ["data", 982], ["identify", 987], ["M3/6", 996], ["as", 1001], ["a", 1004], ["JNK", 1006], ["phosphatase", 1010], ["that", 1022], ["is", 1027], ["inactivated", 1030], ["by", 1042], ["heat", 1045], ["shock", 1050], ["and", 1056], ["provide", 1060], ["a", 1068], ["molecular", 1070], ["mechanism", 1080], ["for", 1090], ["the", 1094], ["activation", 1098], ["of", 1109], ["JNK", 1112], ["by", 1116], ["heat", 1119], ["shock", 1124], [".", 1129]]}
{"context": "Diabetic foot osteomyelitis (DFO) is the most common infection associated to diabetic foot ulcers (DFU). This review is designed to provide an update on the diagnosis and treatment of DFO based on an analysis of MEDLINE through PubMed using as search criterion \"Diabetic Foot Osteomyelitis\". Authors have included in this review the most relevant manuscripts regarding diagnosis and treatment of DFO. After review and critical analysis of publications, it may be concluded that diagnosis of DFO is not simple because of its heterogeneous presentation. Clinical inflammatory signs, probe-to-bone test, and plain X-rays are postulated as the basic tests for clinical diagnosis when DFO is suspected. Diagnosis should be supported by laboratory tests, of which ESR (>70mm/h) has been shown to be most precise. MRI is the most accurate imaging test, especially for differential diagnosis with Charcot foot. Pathogen isolation by bone culture is essential when the patient is treated with ATB only. Medical or surgical treatment should be based on the clinical characteristics of the patient and the lesion. Surgery should always be an option if medical treatment fails.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "4a19f71a111a4c8383421715c8506878", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[48, 50], [0, 2]], "char_spans": [[262, 288], [0, 26]]}]}], "context_tokens": [["Diabetic", 0], ["foot", 9], ["osteomyelitis", 14], ["(", 28], ["DFO", 29], [")", 32], ["is", 34], ["the", 37], ["most", 41], ["common", 46], ["infection", 53], ["associated", 63], ["to", 74], ["diabetic", 77], ["foot", 86], ["ulcers", 91], ["(", 98], ["DFU", 99], [")", 102], [".", 103], ["This", 105], ["review", 110], ["is", 117], ["designed", 120], ["to", 129], ["provide", 132], ["an", 140], ["update", 143], ["on", 150], ["the", 153], ["diagnosis", 157], ["and", 167], ["treatment", 171], ["of", 181], ["DFO", 184], ["based", 188], ["on", 194], ["an", 197], ["analysis", 200], ["of", 209], ["MEDLINE", 212], ["through", 220], ["PubMed", 228], ["using", 235], ["as", 241], ["search", 244], ["criterion", 251], ["\"", 261], ["Diabetic", 262], ["Foot", 271], ["Osteomyelitis", 276], ["\"", 289], [".", 290], ["Authors", 292], ["have", 300], ["included", 305], ["in", 314], ["this", 317], ["review", 322], ["the", 329], ["most", 333], ["relevant", 338], ["manuscripts", 347], ["regarding", 359], ["diagnosis", 369], ["and", 379], ["treatment", 383], ["of", 393], ["DFO", 396], [".", 399], ["After", 401], ["review", 407], ["and", 414], ["critical", 418], ["analysis", 427], ["of", 436], ["publications", 439], [",", 451], ["it", 453], ["may", 456], ["be", 460], ["concluded", 463], ["that", 473], ["diagnosis", 478], ["of", 488], ["DFO", 491], ["is", 495], ["not", 498], ["simple", 502], ["because", 509], ["of", 517], ["its", 520], ["heterogeneous", 524], ["presentation", 538], [".", 550], ["Clinical", 552], ["inflammatory", 561], ["signs", 574], [",", 579], ["probe", 581], ["-", 586], ["to", 587], ["-", 589], ["bone", 590], ["test", 595], [",", 599], ["and", 601], ["plain", 605], ["X", 611], ["-", 612], ["rays", 613], ["are", 618], ["postulated", 622], ["as", 633], ["the", 636], ["basic", 640], ["tests", 646], ["for", 652], ["clinical", 656], ["diagnosis", 665], ["when", 675], ["DFO", 680], ["is", 684], ["suspected", 687], [".", 696], ["Diagnosis", 698], ["should", 708], ["be", 715], ["supported", 718], ["by", 728], ["laboratory", 731], ["tests", 742], [",", 747], ["of", 749], ["which", 752], ["ESR", 758], ["(", 762], [">", 763], ["70mm", 764], ["/", 768], ["h", 769], [")", 770], ["has", 772], ["been", 776], ["shown", 781], ["to", 787], ["be", 790], ["most", 793], ["precise", 798], [".", 805], ["MRI", 807], ["is", 811], ["the", 814], ["most", 818], ["accurate", 823], ["imaging", 832], ["test", 840], [",", 844], ["especially", 846], ["for", 857], ["differential", 861], ["diagnosis", 874], ["with", 884], ["Charcot", 889], ["foot", 897], [".", 901], ["Pathogen", 903], ["isolation", 912], ["by", 922], ["bone", 925], ["culture", 930], ["is", 938], ["essential", 941], ["when", 951], ["the", 956], ["patient", 960], ["is", 968], ["treated", 971], ["with", 979], ["ATB", 984], ["only", 988], [".", 992], ["Medical", 994], ["or", 1002], ["surgical", 1005], ["treatment", 1014], ["should", 1024], ["be", 1031], ["based", 1034], ["on", 1040], ["the", 1043], ["clinical", 1047], ["characteristics", 1056], ["of", 1072], ["the", 1075], ["patient", 1079], ["and", 1087], ["the", 1091], ["lesion", 1095], [".", 1101], ["Surgery", 1103], ["should", 1111], ["always", 1118], ["be", 1125], ["an", 1128], ["option", 1131], ["if", 1138], ["medical", 1141], ["treatment", 1149], ["fails", 1159], [".", 1164]]}
{"context": "Restless legs syndrome is a neurological disorder characterized by an urgency to move the legs during periods of rest. Data from a variety of sources provide a compelling argument that the amount of iron in the brain is lower in individuals with restless legs syndrome compared with neurologically normal individuals. Moreover, a significant percentage of patients with restless legs syndrome are responsive to intravenous iron therapy. The mechanism underlying the decreased iron concentrations in restless legs syndrome brains is unknown. We hypothesize that the source of the brain iron deficit is at the blood-brain interface. Thus we analysed the expression of iron management proteins in the epithelial cells of the choroid plexus and the brain microvasculature in post-mortem tissues. The choroid plexus, obtained at autopsy, from 18 neurologically normal controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical staining for iron and immunostaining for iron management proteins. Iron and heavy chain ferritin staining was reduced in the epithelial cells of choroid plexus in restless legs syndrome. Divalent metal transporter, ferroportin, transferrin and its receptor were upregulated in the choroid plexus in restless legs syndrome. Microvessels were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at autopsy and quantitative immunoblot analyses was performed. Expression of heavy chain ferritin, transferrin and its receptor in the microvessels from restless legs syndrome was significantly decreased compared with the controls but divalent metal protein 1, ferroportin, prohepcidin, mitochondrial ferritin and light-chain ferritin remained unchanged. The presence of an iron regulatory protein was demonstrated in the brain microvasculature and the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier report in neuromelanin cells from the substantia nigra of restless legs syndrome brains. This study reveals that there are alterations in the iron management protein profile in restless legs syndrome compared with controls at the site of blood-brain interface suggesting fundamental differences in brain iron acquisition in individuals with restless legs syndrome. Furthermore, the decrease in transferrin receptor expression in the microvasculature in the presence of relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems associated with brain iron acquisition in restless legs syndrome. The consistent finding of loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates this protein as a factor in the underlying cause of the iron deficiency in the restless legs syndrome brain. The data herein provide evidence for regulation of iron uptake and storage within brain microvessels that challenge the existing paradigm that the blood-brain barrier is merely a transport system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "240a062b131041ab863a237c0c0a8a73", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[158, 158], [93, 93], [75, 75], [109, 109], [67, 67], [166, 166], [397, 397], [332, 332], [356, 356], [281, 281], [410, 410], [450, 450], [34, 34], [382, 382], [433, 433], [162, 162]], "char_spans": [[974, 977], [585, 588], [476, 479], [666, 669], [423, 426], [1028, 1031], [2534, 2537], [2086, 2089], [2248, 2251], [1767, 1770], [2612, 2615], [2863, 2866], [199, 202], [2428, 2431], [2759, 2762], [1002, 1005]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["is", 23], ["a", 26], ["neurological", 28], ["disorder", 41], ["characterized", 50], ["by", 64], ["an", 67], ["urgency", 70], ["to", 78], ["move", 81], ["the", 86], ["legs", 90], ["during", 95], ["periods", 102], ["of", 110], ["rest", 113], [".", 117], ["Data", 119], ["from", 124], ["a", 129], ["variety", 131], ["of", 139], ["sources", 142], ["provide", 150], ["a", 158], ["compelling", 160], ["argument", 171], ["that", 180], ["the", 185], ["amount", 189], ["of", 196], ["iron", 199], ["in", 204], ["the", 207], ["brain", 211], ["is", 217], ["lower", 220], ["in", 226], ["individuals", 229], ["with", 241], ["restless", 246], ["legs", 255], ["syndrome", 260], ["compared", 269], ["with", 278], ["neurologically", 283], ["normal", 298], ["individuals", 305], [".", 316], ["Moreover", 318], [",", 326], ["a", 328], ["significant", 330], ["percentage", 342], ["of", 353], ["patients", 356], ["with", 365], ["restless", 370], ["legs", 379], ["syndrome", 384], ["are", 393], ["responsive", 397], ["to", 408], ["intravenous", 411], ["iron", 423], ["therapy", 428], [".", 435], ["The", 437], ["mechanism", 441], ["underlying", 451], ["the", 462], ["decreased", 466], ["iron", 476], ["concentrations", 481], ["in", 496], ["restless", 499], ["legs", 508], ["syndrome", 513], ["brains", 522], ["is", 529], ["unknown", 532], [".", 539], ["We", 541], ["hypothesize", 544], ["that", 556], ["the", 561], ["source", 565], ["of", 572], ["the", 575], ["brain", 579], ["iron", 585], ["deficit", 590], ["is", 598], ["at", 601], ["the", 604], ["blood", 608], ["-", 613], ["brain", 614], ["interface", 620], [".", 629], ["Thus", 631], ["we", 636], ["analysed", 639], ["the", 648], ["expression", 652], ["of", 663], ["iron", 666], ["management", 671], ["proteins", 682], ["in", 691], ["the", 694], ["epithelial", 698], ["cells", 709], ["of", 715], ["the", 718], ["choroid", 722], ["plexus", 730], ["and", 737], ["the", 741], ["brain", 745], ["microvasculature", 751], ["in", 768], ["post", 771], ["-", 775], ["mortem", 776], ["tissues", 783], [".", 790], ["The", 792], ["choroid", 796], ["plexus", 804], [",", 810], ["obtained", 812], ["at", 821], ["autopsy", 824], [",", 831], ["from", 833], ["18", 838], ["neurologically", 841], ["normal", 856], ["controls", 863], ["and", 872], ["14", 876], ["individuals", 879], ["who", 891], ["had", 895], ["primary", 899], ["restless", 907], ["legs", 916], ["syndrome", 921], ["was", 930], ["subjected", 934], ["to", 944], ["histochemical", 947], ["staining", 961], ["for", 970], ["iron", 974], ["and", 979], ["immunostaining", 983], ["for", 998], ["iron", 1002], ["management", 1007], ["proteins", 1018], [".", 1026], ["Iron", 1028], ["and", 1033], ["heavy", 1037], ["chain", 1043], ["ferritin", 1049], ["staining", 1058], ["was", 1067], ["reduced", 1071], ["in", 1079], ["the", 1082], ["epithelial", 1086], ["cells", 1097], ["of", 1103], ["choroid", 1106], ["plexus", 1114], ["in", 1121], ["restless", 1124], ["legs", 1133], ["syndrome", 1138], [".", 1146], ["Divalent", 1148], ["metal", 1157], ["transporter", 1163], [",", 1174], ["ferroportin", 1176], [",", 1187], ["transferrin", 1189], ["and", 1201], ["its", 1205], ["receptor", 1209], ["were", 1218], ["upregulated", 1223], ["in", 1235], ["the", 1238], ["choroid", 1242], ["plexus", 1250], ["in", 1257], ["restless", 1260], ["legs", 1269], ["syndrome", 1274], [".", 1282], ["Microvessels", 1284], ["were", 1297], ["isolated", 1302], ["from", 1311], ["the", 1316], ["motor", 1320], ["cortex", 1326], ["of", 1333], ["11", 1336], ["restless", 1339], ["legs", 1348], ["syndrome", 1353], ["and", 1362], ["14", 1366], ["control", 1369], ["brains", 1377], ["obtained", 1384], ["at", 1393], ["autopsy", 1396], ["and", 1404], ["quantitative", 1408], ["immunoblot", 1421], ["analyses", 1432], ["was", 1441], ["performed", 1445], [".", 1454], ["Expression", 1456], ["of", 1467], ["heavy", 1470], ["chain", 1476], ["ferritin", 1482], [",", 1490], ["transferrin", 1492], ["and", 1504], ["its", 1508], ["receptor", 1512], ["in", 1521], ["the", 1524], ["microvessels", 1528], ["from", 1541], ["restless", 1546], ["legs", 1555], ["syndrome", 1560], ["was", 1569], ["significantly", 1573], ["decreased", 1587], ["compared", 1597], ["with", 1606], ["the", 1611], ["controls", 1615], ["but", 1624], ["divalent", 1628], ["metal", 1637], ["protein", 1643], ["1", 1651], [",", 1652], ["ferroportin", 1654], [",", 1665], ["prohepcidin", 1667], [",", 1678], ["mitochondrial", 1680], ["ferritin", 1694], ["and", 1703], ["light", 1707], ["-", 1712], ["chain", 1713], ["ferritin", 1719], ["remained", 1728], ["unchanged", 1737], [".", 1746], ["The", 1748], ["presence", 1752], ["of", 1761], ["an", 1764], ["iron", 1767], ["regulatory", 1772], ["protein", 1783], ["was", 1791], ["demonstrated", 1795], ["in", 1808], ["the", 1811], ["brain", 1815], ["microvasculature", 1821], ["and", 1838], ["the", 1842], ["activity", 1846], ["of", 1855], ["this", 1858], ["protein", 1863], ["is", 1871], ["decreased", 1874], ["in", 1884], ["restless", 1887], ["legs", 1896], ["syndrome", 1901], [";", 1909], ["a", 1911], ["finding", 1913], ["similar", 1921], ["to", 1929], ["our", 1932], ["earlier", 1936], ["report", 1944], ["in", 1951], ["neuromelanin", 1954], ["cells", 1967], ["from", 1973], ["the", 1978], ["substantia", 1982], ["nigra", 1993], ["of", 1999], ["restless", 2002], ["legs", 2011], ["syndrome", 2016], ["brains", 2025], [".", 2031], ["This", 2033], ["study", 2038], ["reveals", 2044], ["that", 2052], ["there", 2057], ["are", 2063], ["alterations", 2067], ["in", 2079], ["the", 2082], ["iron", 2086], ["management", 2091], ["protein", 2102], ["profile", 2110], ["in", 2118], ["restless", 2121], ["legs", 2130], ["syndrome", 2135], ["compared", 2144], ["with", 2153], ["controls", 2158], ["at", 2167], ["the", 2170], ["site", 2174], ["of", 2179], ["blood", 2182], ["-", 2187], ["brain", 2188], ["interface", 2194], ["suggesting", 2204], ["fundamental", 2215], ["differences", 2227], ["in", 2239], ["brain", 2242], ["iron", 2248], ["acquisition", 2253], ["in", 2265], ["individuals", 2268], ["with", 2280], ["restless", 2285], ["legs", 2294], ["syndrome", 2299], [".", 2307], ["Furthermore", 2309], [",", 2320], ["the", 2322], ["decrease", 2326], ["in", 2335], ["transferrin", 2338], ["receptor", 2350], ["expression", 2359], ["in", 2370], ["the", 2373], ["microvasculature", 2377], ["in", 2394], ["the", 2397], ["presence", 2401], ["of", 2410], ["relative", 2413], ["brain", 2422], ["iron", 2428], ["deficiency", 2433], ["reported", 2444], ["in", 2453], ["restless", 2456], ["legs", 2465], ["syndrome", 2470], ["brains", 2479], ["may", 2486], ["underlie", 2490], ["the", 2499], ["problems", 2503], ["associated", 2512], ["with", 2523], ["brain", 2528], ["iron", 2534], ["acquisition", 2539], ["in", 2551], ["restless", 2554], ["legs", 2563], ["syndrome", 2568], [".", 2576], ["The", 2578], ["consistent", 2582], ["finding", 2593], ["of", 2601], ["loss", 2604], ["of", 2609], ["iron", 2612], ["regulatory", 2617], ["protein", 2628], ["activity", 2636], ["in", 2645], ["restless", 2648], ["legs", 2657], ["syndrome", 2662], ["brain", 2671], ["tissue", 2677], ["further", 2684], ["implicates", 2692], ["this", 2703], ["protein", 2708], ["as", 2716], ["a", 2719], ["factor", 2721], ["in", 2728], ["the", 2731], ["underlying", 2735], ["cause", 2746], ["of", 2752], ["the", 2755], ["iron", 2759], ["deficiency", 2764], ["in", 2775], ["the", 2778], ["restless", 2782], ["legs", 2791], ["syndrome", 2796], ["brain", 2805], [".", 2810], ["The", 2812], ["data", 2816], ["herein", 2821], ["provide", 2828], ["evidence", 2836], ["for", 2845], ["regulation", 2849], ["of", 2860], ["iron", 2863], ["uptake", 2868], ["and", 2875], ["storage", 2879], ["within", 2887], ["brain", 2894], ["microvessels", 2900], ["that", 2913], ["challenge", 2918], ["the", 2928], ["existing", 2932], ["paradigm", 2941], ["that", 2950], ["the", 2955], ["blood", 2959], ["-", 2964], ["brain", 2965], ["barrier", 2971], ["is", 2979], ["merely", 2982], ["a", 2989], ["transport", 2991], ["system", 3001], [".", 3007]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "To evaluate the long-term impact of successive interventions on rates of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection and MRSA bacteremia in an endemic hospital-wide situation. Quasi-experimental, interrupted time-series analysis. The impact of the interventions was analyzed by use of segmented regression. Representative MRSA isolates were typed by use of pulsed-field gel electrophoresis. A 950-bed teaching hospital in Seville, Spain. All patients admitted to the hospital during the period from 1995 through 2008. Three successive interventions were studied: (1) contact precautions, with no active surveillance for MRSA; (2) targeted active surveillance for MRSA in patients and healthcare workers in specific wards, prioritized according to clinical epidemiology data; and (3) targeted active surveillance for MRSA in patients admitted from other medical centers. Neither the preintervention rate of MRSA colonization or infection (0.56 cases per 1,000 patient-days [95% confidence interval {CI}, 0.49-0.62 cases per 1,000 patient-days]) nor the slope for the rate of MRSA colonization or infection changed significantly after the first intervention. The rate decreased significantly to 0.28 cases per 1,000 patient-days (95% CI, 0.17-0.40 cases per 1,000 patient-days) after the second intervention and to 0.07 cases per 1,000 patient-days (95% CI, 0.06-0.08 cases per 1,000 patient-days) after the third intervention, and the rate remained at a similar level for 8 years. The MRSA bacteremia rate decreased by 80%, whereas the rate of bacteremia due to methicillin-susceptible S. aureus did not change. Eighty-three percent of the MRSA isolates identified were clonally related. All MRSA isolates obtained from healthcare workers were clonally related to those recovered from patients who were in their care. Our data indicate that long-term control of endemic MRSA is feasible in tertiary care centers. The use of targeted active surveillance for MRSA in patients and healthcare workers in specific wards (identified by means of analysis of clinical epidemiology data) and the use of decolonization were key to the success of the program.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "195e202a3f16414ebfc5916fde09ab66", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[351, 351], [112, 112], [160, 160], [59, 59], [19, 19], [283, 283], [25, 25], [121, 121], [199, 199], [313, 313], [146, 146], [321, 321], [366, 366]], "char_spans": [[1902, 1905], [653, 656], [939, 942], [355, 358], [118, 121], [1517, 1520], [154, 157], [696, 699], [1107, 1110], [1672, 1675], [849, 852], [1724, 1727], [1989, 1992]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["long", 16], ["-", 20], ["term", 21], ["impact", 26], ["of", 33], ["successive", 36], ["interventions", 47], ["on", 61], ["rates", 64], ["of", 70], ["methicillin", 73], ["-", 84], ["resistant", 85], ["Staphylococcus", 95], ["aureus", 110], ["(", 117], ["MRSA", 118], [")", 122], ["colonization", 124], ["or", 137], ["infection", 140], ["and", 150], ["MRSA", 154], ["bacteremia", 159], ["in", 170], ["an", 173], ["endemic", 176], ["hospital", 184], ["-", 192], ["wide", 193], ["situation", 198], [".", 207], ["Quasi", 209], ["-", 214], ["experimental", 215], [",", 227], ["interrupted", 229], ["time", 241], ["-", 245], ["series", 246], ["analysis", 253], [".", 261], ["The", 263], ["impact", 267], ["of", 274], ["the", 277], ["interventions", 281], ["was", 295], ["analyzed", 299], ["by", 308], ["use", 311], ["of", 315], ["segmented", 318], ["regression", 328], [".", 338], ["Representative", 340], ["MRSA", 355], ["isolates", 360], ["were", 369], ["typed", 374], ["by", 380], ["use", 383], ["of", 387], ["pulsed", 390], ["-", 396], ["field", 397], ["gel", 403], ["electrophoresis", 407], [".", 422], ["A", 424], ["950-bed", 426], ["teaching", 434], ["hospital", 443], ["in", 452], ["Seville", 455], [",", 462], ["Spain", 464], [".", 469], ["All", 471], ["patients", 475], ["admitted", 484], ["to", 493], ["the", 496], ["hospital", 500], ["during", 509], ["the", 516], ["period", 520], ["from", 527], ["1995", 532], ["through", 537], ["2008", 545], [".", 549], ["Three", 551], ["successive", 557], ["interventions", 568], ["were", 582], ["studied", 587], [":", 594], ["(", 596], ["1", 597], [")", 598], ["contact", 600], ["precautions", 608], [",", 619], ["with", 621], ["no", 626], ["active", 629], ["surveillance", 636], ["for", 649], ["MRSA", 653], [";", 657], ["(", 659], ["2", 660], [")", 661], ["targeted", 663], ["active", 672], ["surveillance", 679], ["for", 692], ["MRSA", 696], ["in", 701], ["patients", 704], ["and", 713], ["healthcare", 717], ["workers", 728], ["in", 736], ["specific", 739], ["wards", 748], [",", 753], ["prioritized", 755], ["according", 767], ["to", 777], ["clinical", 780], ["epidemiology", 789], ["data", 802], [";", 806], ["and", 808], ["(", 812], ["3", 813], [")", 814], ["targeted", 816], ["active", 825], ["surveillance", 832], ["for", 845], ["MRSA", 849], ["in", 854], ["patients", 857], ["admitted", 866], ["from", 875], ["other", 880], ["medical", 886], ["centers", 894], [".", 901], ["Neither", 903], ["the", 911], ["preintervention", 915], ["rate", 931], ["of", 936], ["MRSA", 939], ["colonization", 944], ["or", 957], ["infection", 960], ["(", 970], ["0.56", 971], ["cases", 976], ["per", 982], ["1,000", 986], ["patient", 992], ["-", 999], ["days", 1000], ["[", 1005], ["95", 1006], ["%", 1008], ["confidence", 1010], ["interval", 1021], ["{", 1030], ["CI", 1031], ["}", 1033], [",", 1034], ["0.49", 1036], ["-", 1040], ["0.62", 1041], ["cases", 1046], ["per", 1052], ["1,000", 1056], ["patient", 1062], ["-", 1069], ["days", 1070], ["]", 1074], [")", 1075], ["nor", 1077], ["the", 1081], ["slope", 1085], ["for", 1091], ["the", 1095], ["rate", 1099], ["of", 1104], ["MRSA", 1107], ["colonization", 1112], ["or", 1125], ["infection", 1128], ["changed", 1138], ["significantly", 1146], ["after", 1160], ["the", 1166], ["first", 1170], ["intervention", 1176], [".", 1188], ["The", 1190], ["rate", 1194], ["decreased", 1199], ["significantly", 1209], ["to", 1223], ["0.28", 1226], ["cases", 1231], ["per", 1237], ["1,000", 1241], ["patient", 1247], ["-", 1254], ["days", 1255], ["(", 1260], ["95", 1261], ["%", 1263], ["CI", 1265], [",", 1267], ["0.17", 1269], ["-", 1273], ["0.40", 1274], ["cases", 1279], ["per", 1285], ["1,000", 1289], ["patient", 1295], ["-", 1302], ["days", 1303], [")", 1307], ["after", 1309], ["the", 1315], ["second", 1319], ["intervention", 1326], ["and", 1339], ["to", 1343], ["0.07", 1346], ["cases", 1351], ["per", 1357], ["1,000", 1361], ["patient", 1367], ["-", 1374], ["days", 1375], ["(", 1380], ["95", 1381], ["%", 1383], ["CI", 1385], [",", 1387], ["0.06", 1389], ["-", 1393], ["0.08", 1394], ["cases", 1399], ["per", 1405], ["1,000", 1409], ["patient", 1415], ["-", 1422], ["days", 1423], [")", 1427], ["after", 1429], ["the", 1435], ["third", 1439], ["intervention", 1445], [",", 1457], ["and", 1459], ["the", 1463], ["rate", 1467], ["remained", 1472], ["at", 1481], ["a", 1484], ["similar", 1486], ["level", 1494], ["for", 1500], ["8", 1504], ["years", 1506], [".", 1511], ["The", 1513], ["MRSA", 1517], ["bacteremia", 1522], ["rate", 1533], ["decreased", 1538], ["by", 1548], ["80", 1551], ["%", 1553], [",", 1554], ["whereas", 1556], ["the", 1564], ["rate", 1568], ["of", 1573], ["bacteremia", 1576], ["due", 1587], ["to", 1591], ["methicillin", 1594], ["-", 1605], ["susceptible", 1606], ["S.", 1618], ["aureus", 1621], ["did", 1628], ["not", 1632], ["change", 1636], [".", 1642], ["Eighty", 1644], ["-", 1650], ["three", 1651], ["percent", 1657], ["of", 1665], ["the", 1668], ["MRSA", 1672], ["isolates", 1677], ["identified", 1686], ["were", 1697], ["clonally", 1702], ["related", 1711], [".", 1718], ["All", 1720], ["MRSA", 1724], ["isolates", 1729], ["obtained", 1738], ["from", 1747], ["healthcare", 1752], ["workers", 1763], ["were", 1771], ["clonally", 1776], ["related", 1785], ["to", 1793], ["those", 1796], ["recovered", 1802], ["from", 1812], ["patients", 1817], ["who", 1826], ["were", 1830], ["in", 1835], ["their", 1838], ["care", 1844], [".", 1848], ["Our", 1850], ["data", 1854], ["indicate", 1859], ["that", 1868], ["long", 1873], ["-", 1877], ["term", 1878], ["control", 1883], ["of", 1891], ["endemic", 1894], ["MRSA", 1902], ["is", 1907], ["feasible", 1910], ["in", 1919], ["tertiary", 1922], ["care", 1931], ["centers", 1936], [".", 1943], ["The", 1945], ["use", 1949], ["of", 1953], ["targeted", 1956], ["active", 1965], ["surveillance", 1972], ["for", 1985], ["MRSA", 1989], ["in", 1994], ["patients", 1997], ["and", 2006], ["healthcare", 2010], ["workers", 2021], ["in", 2029], ["specific", 2032], ["wards", 2041], ["(", 2047], ["identified", 2048], ["by", 2059], ["means", 2062], ["of", 2068], ["analysis", 2071], ["of", 2080], ["clinical", 2083], ["epidemiology", 2092], ["data", 2105], [")", 2109], ["and", 2111], ["the", 2115], ["use", 2119], ["of", 2123], ["decolonization", 2126], ["were", 2141], ["key", 2146], ["to", 2150], ["the", 2153], ["success", 2157], ["of", 2165], ["the", 2168], ["program", 2172], [".", 2179]]}
{"context": "The effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a newly synthesized Na(+)-Ca(2+) exchanger (NCX) inhibitor, on the NCX current and other membrane currents were examined in isolated guinea-pig ventricular myocytes and compared with those of 2-[2-[4-(4-nitrobenzyloxy) phenyl]ethyl]isothiourea (KB-R7943). SEA0400 concentration-dependently inhibited the NCX current with a 10 fold higher potency than that of KB-R7943; 1 microM SEA0400 and 10 microM KB-R7943 inhibited the NCX current by more than 80%. KB-R7943, at 10 microM, inhibited the sodium current, L-type calcium current, delayed rectifier potassium current and inwardly rectifying potassium current by more than 50%, but SEA0400 (1 microM) had no significant effect on these currents. These results indicate that SEA0400 is a potent and highly selective inhibitor of NCX, and would be a powerful tool for further studies on the role of NCX in the heart and the therapeutic potential of its inhibition.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "3c5acbfea860401088f0e789580bf84b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[59, 59], [85, 85], [154, 154], [169, 169], [24, 24], [18, 18]], "char_spans": [[390, 392], [509, 511], [863, 865], [932, 934], [153, 155], [130, 132]]}]}], "context_tokens": [["The", 0], ["effects", 4], ["of", 12], ["2-[4-[(2,5-difluorophenyl", 15], [")", 40], ["methoxy]phenoxy]-5-ethoxyaniline", 42], ["(", 75], ["SEA0400", 76], [")", 83], [",", 84], ["a", 86], ["newly", 88], ["synthesized", 94], ["Na(+)-Ca(2", 106], ["+", 116], [")", 117], ["exchanger", 119], ["(", 129], ["NCX", 130], [")", 133], ["inhibitor", 135], [",", 144], ["on", 146], ["the", 149], ["NCX", 153], ["current", 157], ["and", 165], ["other", 169], ["membrane", 175], ["currents", 184], ["were", 193], ["examined", 198], ["in", 207], ["isolated", 210], ["guinea", 219], ["-", 225], ["pig", 226], ["ventricular", 230], ["myocytes", 242], ["and", 251], ["compared", 255], ["with", 264], ["those", 269], ["of", 275], ["2-[2-[4-(4-nitrobenzyloxy", 278], [")", 303], ["phenyl]ethyl]isothiourea", 305], ["(", 330], ["KB", 331], ["-", 333], ["R7943", 334], [")", 339], [".", 340], ["SEA0400", 342], ["concentration", 350], ["-", 363], ["dependently", 364], ["inhibited", 376], ["the", 386], ["NCX", 390], ["current", 394], ["with", 402], ["a", 407], ["10", 409], ["fold", 412], ["higher", 417], ["potency", 424], ["than", 432], ["that", 437], ["of", 442], ["KB", 445], ["-", 447], ["R7943", 448], [";", 453], ["1", 455], ["microM", 457], ["SEA0400", 464], ["and", 472], ["10", 476], ["microM", 479], ["KB", 486], ["-", 488], ["R7943", 489], ["inhibited", 495], ["the", 505], ["NCX", 509], ["current", 513], ["by", 521], ["more", 524], ["than", 529], ["80", 534], ["%", 536], [".", 537], ["KB", 539], ["-", 541], ["R7943", 542], [",", 547], ["at", 549], ["10", 552], ["microM", 555], [",", 561], ["inhibited", 563], ["the", 573], ["sodium", 577], ["current", 584], [",", 591], ["L", 593], ["-", 594], ["type", 595], ["calcium", 600], ["current", 608], [",", 615], ["delayed", 617], ["rectifier", 625], ["potassium", 635], ["current", 645], ["and", 653], ["inwardly", 657], ["rectifying", 666], ["potassium", 677], ["current", 687], ["by", 695], ["more", 698], ["than", 703], ["50", 708], ["%", 710], [",", 711], ["but", 713], ["SEA0400", 717], ["(", 725], ["1", 726], ["microM", 728], [")", 734], ["had", 736], ["no", 740], ["significant", 743], ["effect", 755], ["on", 762], ["these", 765], ["currents", 771], [".", 779], ["These", 781], ["results", 787], ["indicate", 795], ["that", 804], ["SEA0400", 809], ["is", 817], ["a", 820], ["potent", 822], ["and", 829], ["highly", 833], ["selective", 840], ["inhibitor", 850], ["of", 860], ["NCX", 863], [",", 866], ["and", 868], ["would", 872], ["be", 878], ["a", 881], ["powerful", 883], ["tool", 892], ["for", 897], ["further", 901], ["studies", 909], ["on", 917], ["the", 920], ["role", 924], ["of", 929], ["NCX", 932], ["in", 936], ["the", 939], ["heart", 943], ["and", 949], ["the", 953], ["therapeutic", 957], ["potential", 969], ["of", 979], ["its", 982], ["inhibition", 986], [".", 996]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "Understanding gene regulation in Plasmodium, the causative agent of malaria, is an important step in deciphering its complex life cycle as well as leading to possible new targets for therapeutic applications. Very little is known about gene regulation in Plasmodium, and in particular, few regulatory elements have been identified. Such discovery has been significantly hampered by the high A-T content of some of the genomes of Plasmodium species, as well as the challenge in associating discovered regulatory elements to gene regulatory cascades due to Plasmodium's complex life cycle. We report a new method of using comparative genomics to systematically discover motifs in Plasmodium without requiring any functional data. Different from previous methods, our method does not depend on sequence alignments, and thus is particularly suitable for highly divergent genomes. We applied our method to discovering regulatory motifs between the human parasite, P.falciparum, and its rodent-infectious relative, P.yoelii. We also tested our procedure against comparisons between P.falciparum and the primate-infectious, P.knowlesi. Our computational effort leads to an initial catalog of 38 distinct motifs, corresponding to over 16 200 sites in the Plasmodium genome. The functionality of these motifs was further supported by their defined distribution within the genome as well as a correlation with gene expression patterns. This initial map provides a systematic view of gene regulation in Plasmodium, which can be refined as additional genomes become available. The new algorithm, named motif discovery using orthologous sequences (MDOS), is available at http://www.ics.uci.edu/ approximately xhx/project/mdos/.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "1a5db1bc1c094524a9cf3fcac627a7f9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[74, 75]], "char_spans": [[429, 446]]}]}], "context_tokens": [["Understanding", 0], ["gene", 14], ["regulation", 19], ["in", 30], ["Plasmodium", 33], [",", 43], ["the", 45], ["causative", 49], ["agent", 59], ["of", 65], ["malaria", 68], [",", 75], ["is", 77], ["an", 80], ["important", 83], ["step", 93], ["in", 98], ["deciphering", 101], ["its", 113], ["complex", 117], ["life", 125], ["cycle", 130], ["as", 136], ["well", 139], ["as", 144], ["leading", 147], ["to", 155], ["possible", 158], ["new", 167], ["targets", 171], ["for", 179], ["therapeutic", 183], ["applications", 195], [".", 207], ["Very", 209], ["little", 214], ["is", 221], ["known", 224], ["about", 230], ["gene", 236], ["regulation", 241], ["in", 252], ["Plasmodium", 255], [",", 265], ["and", 267], ["in", 271], ["particular", 274], [",", 284], ["few", 286], ["regulatory", 290], ["elements", 301], ["have", 310], ["been", 315], ["identified", 320], [".", 330], ["Such", 332], ["discovery", 337], ["has", 347], ["been", 351], ["significantly", 356], ["hampered", 370], ["by", 379], ["the", 382], ["high", 386], ["A", 391], ["-", 392], ["T", 393], ["content", 395], ["of", 403], ["some", 406], ["of", 411], ["the", 414], ["genomes", 418], ["of", 426], ["Plasmodium", 429], ["species", 440], [",", 447], ["as", 449], ["well", 452], ["as", 457], ["the", 460], ["challenge", 464], ["in", 474], ["associating", 477], ["discovered", 489], ["regulatory", 500], ["elements", 511], ["to", 520], ["gene", 523], ["regulatory", 528], ["cascades", 539], ["due", 548], ["to", 552], ["Plasmodium", 555], ["'s", 565], ["complex", 568], ["life", 576], ["cycle", 581], [".", 586], ["We", 588], ["report", 591], ["a", 598], ["new", 600], ["method", 604], ["of", 611], ["using", 614], ["comparative", 620], ["genomics", 632], ["to", 641], ["systematically", 644], ["discover", 659], ["motifs", 668], ["in", 675], ["Plasmodium", 678], ["without", 689], ["requiring", 697], ["any", 707], ["functional", 711], ["data", 722], [".", 726], ["Different", 728], ["from", 738], ["previous", 743], ["methods", 752], [",", 759], ["our", 761], ["method", 765], ["does", 772], ["not", 777], ["depend", 781], ["on", 788], ["sequence", 791], ["alignments", 800], [",", 810], ["and", 812], ["thus", 816], ["is", 821], ["particularly", 824], ["suitable", 837], ["for", 846], ["highly", 850], ["divergent", 857], ["genomes", 867], [".", 874], ["We", 876], ["applied", 879], ["our", 887], ["method", 891], ["to", 898], ["discovering", 901], ["regulatory", 913], ["motifs", 924], ["between", 931], ["the", 939], ["human", 943], ["parasite", 949], [",", 957], ["P.falciparum", 959], [",", 971], ["and", 973], ["its", 977], ["rodent", 981], ["-", 987], ["infectious", 988], ["relative", 999], [",", 1007], ["P.yoelii", 1009], [".", 1017], ["We", 1019], ["also", 1022], ["tested", 1027], ["our", 1034], ["procedure", 1038], ["against", 1048], ["comparisons", 1056], ["between", 1068], ["P.falciparum", 1076], ["and", 1089], ["the", 1093], ["primate", 1097], ["-", 1104], ["infectious", 1105], [",", 1115], ["P.knowlesi", 1117], [".", 1127], ["Our", 1129], ["computational", 1133], ["effort", 1147], ["leads", 1154], ["to", 1160], ["an", 1163], ["initial", 1166], ["catalog", 1174], ["of", 1182], ["38", 1185], ["distinct", 1188], ["motifs", 1197], [",", 1203], ["corresponding", 1205], ["to", 1219], ["over", 1222], ["16", 1227], ["200", 1230], ["sites", 1234], ["in", 1240], ["the", 1243], ["Plasmodium", 1247], ["genome", 1258], [".", 1264], ["The", 1266], ["functionality", 1270], ["of", 1284], ["these", 1287], ["motifs", 1293], ["was", 1300], ["further", 1304], ["supported", 1312], ["by", 1322], ["their", 1325], ["defined", 1331], ["distribution", 1339], ["within", 1352], ["the", 1359], ["genome", 1363], ["as", 1370], ["well", 1373], ["as", 1378], ["a", 1381], ["correlation", 1383], ["with", 1395], ["gene", 1400], ["expression", 1405], ["patterns", 1416], [".", 1424], ["This", 1426], ["initial", 1431], ["map", 1439], ["provides", 1443], ["a", 1452], ["systematic", 1454], ["view", 1465], ["of", 1470], ["gene", 1473], ["regulation", 1478], ["in", 1489], ["Plasmodium", 1492], [",", 1502], ["which", 1504], ["can", 1510], ["be", 1514], ["refined", 1517], ["as", 1525], ["additional", 1528], ["genomes", 1539], ["become", 1547], ["available", 1554], [".", 1563], ["The", 1565], ["new", 1569], ["algorithm", 1573], [",", 1582], ["named", 1584], ["motif", 1590], ["discovery", 1596], ["using", 1606], ["orthologous", 1612], ["sequences", 1624], ["(", 1634], ["MDOS", 1635], [")", 1639], [",", 1640], ["is", 1642], ["available", 1645], ["at", 1655], ["http://www.ics.uci.edu/", 1658], ["approximately", 1682], ["xhx", 1696], ["/", 1699], ["project", 1700], ["/", 1707], ["mdos/.", 1708]]}
{"context": "Riociguat (Adempas(\u00ae)), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). It has been designated an orphan medicine by the European Medicines Agency and the US FDA. This article reviews the available pharmacological properties of oral riociguat and its clinical efficacy and tolerability in adults with CTEPH or PAH. Riociguat is effective and well tolerated in patients with inoperable CTEPH or persistent/recurrent CTEPH following pulmonary endarterectomy, and in patients with PAH. It has a positive result on exercise capacity and pulmonary haemodynamics, and improves WHO functional class. Most adverse events can be attributed to the vasodilatory mechanism of riociguat; however, there is a potential for serious bleeding and fetal harm, and riociguat use is contraindicated in pregnant patients. Pulmonary endarterectomy remains the first treatment of choice for CTEPH, as it is potentially curative. Head-to-head trials comparing riociguat with the approved phosphodiesterase type 5 inhibitors in patients with PAH would be of value for the placement of riociguat in the management of this disease. Riociguat is a promising addition to the treatment options for patients with CTEPH or PAH.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "1c213ca20e164591b8e737b5184e9108", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[0, 0], [81, 81], [166, 166], [150, 150], [198, 198], [218, 218], [226, 226], [95, 95]], "char_spans": [[0, 8], [450, 458], [963, 971], [881, 889], [1153, 1161], [1277, 1285], [1322, 1330], [532, 540]]}]}], "context_tokens": [["Riociguat", 0], ["(", 10], ["Adempas", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["soluble", 26], ["guanylate", 34], ["cyclase", 44], ["stimulator", 52], [",", 62], ["is", 64], ["a", 67], ["new", 69], [",", 72], ["first", 74], ["-", 79], ["in", 80], ["-", 82], ["class", 83], ["drug", 89], ["approved", 94], ["for", 103], ["the", 107], ["treatment", 111], ["of", 121], ["patients", 124], ["with", 133], ["chronic", 138], ["thromboembolic", 146], ["pulmonary", 161], ["hypertension", 171], ["(", 184], ["CTEPH", 185], [")", 190], ["[", 192], ["inoperable", 193], ["or", 204], ["persistent", 207], ["/", 217], ["recurrent", 218], ["following", 228], ["surgery", 238], ["]", 245], ["or", 247], ["pulmonary", 250], ["arterial", 260], ["hypertension", 269], ["(", 282], ["PAH", 283], [")", 286], [".", 287], ["It", 289], ["has", 292], ["been", 296], ["designated", 301], ["an", 312], ["orphan", 315], ["medicine", 322], ["by", 331], ["the", 334], ["European", 338], ["Medicines", 347], ["Agency", 357], ["and", 364], ["the", 368], ["US", 372], ["FDA", 375], [".", 378], ["This", 380], ["article", 385], ["reviews", 393], ["the", 401], ["available", 405], ["pharmacological", 415], ["properties", 431], ["of", 442], ["oral", 445], ["riociguat", 450], ["and", 460], ["its", 464], ["clinical", 468], ["efficacy", 477], ["and", 486], ["tolerability", 490], ["in", 503], ["adults", 506], ["with", 513], ["CTEPH", 518], ["or", 524], ["PAH", 527], [".", 530], ["Riociguat", 532], ["is", 542], ["effective", 545], ["and", 555], ["well", 559], ["tolerated", 564], ["in", 574], ["patients", 577], ["with", 586], ["inoperable", 591], ["CTEPH", 602], ["or", 608], ["persistent", 611], ["/", 621], ["recurrent", 622], ["CTEPH", 632], ["following", 638], ["pulmonary", 648], ["endarterectomy", 658], [",", 672], ["and", 674], ["in", 678], ["patients", 681], ["with", 690], ["PAH", 695], [".", 698], ["It", 700], ["has", 703], ["a", 707], ["positive", 709], ["result", 718], ["on", 725], ["exercise", 728], ["capacity", 737], ["and", 746], ["pulmonary", 750], ["haemodynamics", 760], [",", 773], ["and", 775], ["improves", 779], ["WHO", 788], ["functional", 792], ["class", 803], [".", 808], ["Most", 810], ["adverse", 815], ["events", 823], ["can", 830], ["be", 834], ["attributed", 837], ["to", 848], ["the", 851], ["vasodilatory", 855], ["mechanism", 868], ["of", 878], ["riociguat", 881], [";", 890], ["however", 892], [",", 899], ["there", 901], ["is", 907], ["a", 910], ["potential", 912], ["for", 922], ["serious", 926], ["bleeding", 934], ["and", 943], ["fetal", 947], ["harm", 953], [",", 957], ["and", 959], ["riociguat", 963], ["use", 973], ["is", 977], ["contraindicated", 980], ["in", 996], ["pregnant", 999], ["patients", 1008], [".", 1016], ["Pulmonary", 1018], ["endarterectomy", 1028], ["remains", 1043], ["the", 1051], ["first", 1055], ["treatment", 1061], ["of", 1071], ["choice", 1074], ["for", 1081], ["CTEPH", 1085], [",", 1090], ["as", 1092], ["it", 1095], ["is", 1098], ["potentially", 1101], ["curative", 1113], [".", 1121], ["Head", 1123], ["-", 1127], ["to", 1128], ["-", 1130], ["head", 1131], ["trials", 1136], ["comparing", 1143], ["riociguat", 1153], ["with", 1163], ["the", 1168], ["approved", 1172], ["phosphodiesterase", 1181], ["type", 1199], ["5", 1204], ["inhibitors", 1206], ["in", 1217], ["patients", 1220], ["with", 1229], ["PAH", 1234], ["would", 1238], ["be", 1244], ["of", 1247], ["value", 1250], ["for", 1256], ["the", 1260], ["placement", 1264], ["of", 1274], ["riociguat", 1277], ["in", 1287], ["the", 1290], ["management", 1294], ["of", 1305], ["this", 1308], ["disease", 1313], [".", 1320], ["Riociguat", 1322], ["is", 1332], ["a", 1335], ["promising", 1337], ["addition", 1347], ["to", 1356], ["the", 1359], ["treatment", 1363], ["options", 1373], ["for", 1381], ["patients", 1385], ["with", 1394], ["CTEPH", 1399], ["or", 1405], ["PAH", 1408], [".", 1411]]}
{"context": "Iron deficiency is the most common nutritional disorder affecting at least one third of world's population. Though anemia is common manifestation of iron deficiency, other effects of iron deficiency on various tissues, organs and systems are usually under recognized. Impaired brain development and cognitive, behavioural and psychomotor impairment are most worrisome manifestations of iron deficiency. Studies have demonstrated that some of these changes occurring during period of brain growth spurt (<2 years age) may be irreversible. Association of iron deficiency with febrile seizures, pica, breath holding spells, restless leg syndrome and thrombosis is increasingly being recognized. Impaired cell-mediated immunity and bactericidal function are generally noted in iron-deficient persons; however, the findings are inconsistent. Despite proven reversible functional immunological defects in vitro studies, a clinically important relationship between states of iron deficiency and susceptibility to infections remains controversial. Studies from malaria endemic regions have reported increased incidence of malaria in association with iron supplementation. These and some other aspects of iron deficiency are reviewed in this article.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "012f50f15b46427a95f71bd22cb9066f", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [59, 59], [123, 123], [89, 89], [24, 24], [152, 152], [184, 184], [30, 30], [175, 175]], "char_spans": [[0, 3], [386, 389], [773, 776], [553, 556], [149, 152], [968, 971], [1196, 1199], [183, 186], [1142, 1145]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["nutritional", 35], ["disorder", 47], ["affecting", 56], ["at", 66], ["least", 69], ["one", 75], ["third", 79], ["of", 85], ["world", 88], ["'s", 93], ["population", 96], [".", 106], ["Though", 108], ["anemia", 115], ["is", 122], ["common", 125], ["manifestation", 132], ["of", 146], ["iron", 149], ["deficiency", 154], [",", 164], ["other", 166], ["effects", 172], ["of", 180], ["iron", 183], ["deficiency", 188], ["on", 199], ["various", 202], ["tissues", 210], [",", 217], ["organs", 219], ["and", 226], ["systems", 230], ["are", 238], ["usually", 242], ["under", 250], ["recognized", 256], [".", 266], ["Impaired", 268], ["brain", 277], ["development", 283], ["and", 295], ["cognitive", 299], [",", 308], ["behavioural", 310], ["and", 322], ["psychomotor", 326], ["impairment", 338], ["are", 349], ["most", 353], ["worrisome", 358], ["manifestations", 368], ["of", 383], ["iron", 386], ["deficiency", 391], [".", 401], ["Studies", 403], ["have", 411], ["demonstrated", 416], ["that", 429], ["some", 434], ["of", 439], ["these", 442], ["changes", 448], ["occurring", 456], ["during", 466], ["period", 473], ["of", 480], ["brain", 483], ["growth", 489], ["spurt", 496], ["(", 502], ["<", 503], ["2", 504], ["years", 506], ["age", 512], [")", 515], ["may", 517], ["be", 521], ["irreversible", 524], [".", 536], ["Association", 538], ["of", 550], ["iron", 553], ["deficiency", 558], ["with", 569], ["febrile", 574], ["seizures", 582], [",", 590], ["pica", 592], [",", 596], ["breath", 598], ["holding", 605], ["spells", 613], [",", 619], ["restless", 621], ["leg", 630], ["syndrome", 634], ["and", 643], ["thrombosis", 647], ["is", 658], ["increasingly", 661], ["being", 674], ["recognized", 680], [".", 690], ["Impaired", 692], ["cell", 701], ["-", 705], ["mediated", 706], ["immunity", 715], ["and", 724], ["bactericidal", 728], ["function", 741], ["are", 750], ["generally", 754], ["noted", 764], ["in", 770], ["iron", 773], ["-", 777], ["deficient", 778], ["persons", 788], [";", 795], ["however", 797], [",", 804], ["the", 806], ["findings", 810], ["are", 819], ["inconsistent", 823], [".", 835], ["Despite", 837], ["proven", 845], ["reversible", 852], ["functional", 863], ["immunological", 874], ["defects", 888], ["in", 896], ["vitro", 899], ["studies", 905], [",", 912], ["a", 914], ["clinically", 916], ["important", 927], ["relationship", 937], ["between", 950], ["states", 958], ["of", 965], ["iron", 968], ["deficiency", 973], ["and", 984], ["susceptibility", 988], ["to", 1003], ["infections", 1006], ["remains", 1017], ["controversial", 1025], [".", 1038], ["Studies", 1040], ["from", 1048], ["malaria", 1053], ["endemic", 1061], ["regions", 1069], ["have", 1077], ["reported", 1082], ["increased", 1091], ["incidence", 1101], ["of", 1111], ["malaria", 1114], ["in", 1122], ["association", 1125], ["with", 1137], ["iron", 1142], ["supplementation", 1147], [".", 1162], ["These", 1164], ["and", 1170], ["some", 1174], ["other", 1179], ["aspects", 1185], ["of", 1193], ["iron", 1196], ["deficiency", 1201], ["are", 1212], ["reviewed", 1216], ["in", 1225], ["this", 1228], ["article", 1233], [".", 1240]]}
{"context": "In the previous study, we generated a rat model of dilated cardiomyopathy (DCM) induced by adriamycin and found that the expression of lncRNA H19 was significantly upregulated in myocardial tissue. The present study was aimed to investigate the potential role of H19 in the pathogenesis of adriamycin-induced DCM. H19 knockdown in the myocardium of DCM rats attenuated cardiomyocyte apoptosis and improved left ventricular structure and function. Adriamycin treatment was associated with elevated H19 and miR-675 expression and increased apoptosis in neonatal cardiomyocytes. Enforced expression of miR-675 was found to induce apoptosis in cardiomyocytes with adriamycin treatment and H19-siRNA transfection. The 3'-untranslated region of PA2G4 was cloned downstream of a luciferase reporter construct and cotransfected into HEK293 cells with miR-675 mimic. The results of luciferase assay showed that PA2G4 was a direct target of miR-675. The expression of PA2G4 was reduced in cardiomyocytes transfected with miR-675 mimic. Moreover, H19 knockdown was found to increase PA2G4 expression and suppress apoptosis in cardiomyocytes exposed to adriamycin. In conclusion, our study suggests that H19/miR-675 axis is involved in the promotion of cardiomyocyte apoptosis by targeting PA2G4, which may provide a new therapeutic strategy for the treatment of adriamycin-induced DCM.", "qas": [{"question": "Name an lncRNA associated with dilated cardiomyopathy.", "answers": ["lncRNA H19"], "qid": "3c81cb4513234032a3bb15f1165ca927", "question_tokens": [["Name", 0], ["an", 5], ["lncRNA", 8], ["associated", 15], ["with", 26], ["dilated", 31], ["cardiomyopathy", 39], [".", 53]], "detected_answers": [{"text": "lncRNA H19", "token_spans": [[25, 26]], "char_spans": [[135, 144]]}]}], "context_tokens": [["In", 0], ["the", 3], ["previous", 7], ["study", 16], [",", 21], ["we", 23], ["generated", 26], ["a", 36], ["rat", 38], ["model", 42], ["of", 48], ["dilated", 51], ["cardiomyopathy", 59], ["(", 74], ["DCM", 75], [")", 78], ["induced", 80], ["by", 88], ["adriamycin", 91], ["and", 102], ["found", 106], ["that", 112], ["the", 117], ["expression", 121], ["of", 132], ["lncRNA", 135], ["H19", 142], ["was", 146], ["significantly", 150], ["upregulated", 164], ["in", 176], ["myocardial", 179], ["tissue", 190], [".", 196], ["The", 198], ["present", 202], ["study", 210], ["was", 216], ["aimed", 220], ["to", 226], ["investigate", 229], ["the", 241], ["potential", 245], ["role", 255], ["of", 260], ["H19", 263], ["in", 267], ["the", 270], ["pathogenesis", 274], ["of", 287], ["adriamycin", 290], ["-", 300], ["induced", 301], ["DCM", 309], [".", 312], ["H19", 314], ["knockdown", 318], ["in", 328], ["the", 331], ["myocardium", 335], ["of", 346], ["DCM", 349], ["rats", 353], ["attenuated", 358], ["cardiomyocyte", 369], ["apoptosis", 383], ["and", 393], ["improved", 397], ["left", 406], ["ventricular", 411], ["structure", 423], ["and", 433], ["function", 437], [".", 445], ["Adriamycin", 447], ["treatment", 458], ["was", 468], ["associated", 472], ["with", 483], ["elevated", 488], ["H19", 497], ["and", 501], ["miR-675", 505], ["expression", 513], ["and", 524], ["increased", 528], ["apoptosis", 538], ["in", 548], ["neonatal", 551], ["cardiomyocytes", 560], [".", 574], ["Enforced", 576], ["expression", 585], ["of", 596], ["miR-675", 599], ["was", 607], ["found", 611], ["to", 617], ["induce", 620], ["apoptosis", 627], ["in", 637], ["cardiomyocytes", 640], ["with", 655], ["adriamycin", 660], ["treatment", 671], ["and", 681], ["H19-siRNA", 685], ["transfection", 695], [".", 707], ["The", 709], ["3'-untranslated", 713], ["region", 729], ["of", 736], ["PA2G4", 739], ["was", 745], ["cloned", 749], ["downstream", 756], ["of", 767], ["a", 770], ["luciferase", 772], ["reporter", 783], ["construct", 792], ["and", 802], ["cotransfected", 806], ["into", 820], ["HEK293", 825], ["cells", 832], ["with", 838], ["miR-675", 843], ["mimic", 851], [".", 856], ["The", 858], ["results", 862], ["of", 870], ["luciferase", 873], ["assay", 884], ["showed", 890], ["that", 897], ["PA2G4", 902], ["was", 908], ["a", 912], ["direct", 914], ["target", 921], ["of", 928], ["miR-675", 931], [".", 938], ["The", 940], ["expression", 944], ["of", 955], ["PA2G4", 958], ["was", 964], ["reduced", 968], ["in", 976], ["cardiomyocytes", 979], ["transfected", 994], ["with", 1006], ["miR-675", 1011], ["mimic", 1019], [".", 1024], ["Moreover", 1026], [",", 1034], ["H19", 1036], ["knockdown", 1040], ["was", 1050], ["found", 1054], ["to", 1060], ["increase", 1063], ["PA2G4", 1072], ["expression", 1078], ["and", 1089], ["suppress", 1093], ["apoptosis", 1102], ["in", 1112], ["cardiomyocytes", 1115], ["exposed", 1130], ["to", 1138], ["adriamycin", 1141], [".", 1151], ["In", 1153], ["conclusion", 1156], [",", 1166], ["our", 1168], ["study", 1172], ["suggests", 1178], ["that", 1187], ["H19/miR-675", 1192], ["axis", 1204], ["is", 1209], ["involved", 1212], ["in", 1221], ["the", 1224], ["promotion", 1228], ["of", 1238], ["cardiomyocyte", 1241], ["apoptosis", 1255], ["by", 1265], ["targeting", 1268], ["PA2G4", 1278], [",", 1283], ["which", 1285], ["may", 1291], ["provide", 1295], ["a", 1303], ["new", 1305], ["therapeutic", 1309], ["strategy", 1321], ["for", 1330], ["the", 1334], ["treatment", 1338], ["of", 1348], ["adriamycin", 1351], ["-", 1361], ["induced", 1362], ["DCM", 1370], [".", 1373]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "Although first described as early as 1898 and long considered a vestigial organelle of little functional importance, the primary cilium has become one of the hottest research topics in modern cell biology and physiology. Primary cilia are nonmotile sensory organelles present in a single copy on the surface of most growth-arrested or differentiated mammalian cells, and defects in their assembly or function are tightly coupled to many developmental defects, diseases and disorders. In normal tissues, the primary cilium coordinates a series of signal transduction pathways, including Hedgehog, Wnt, PDGFRalpha and integrin signaling. In the kidney, the primary cilium may function as a mechano-, chemo- and osmosensing unit that probes the extracellular environment and transmits signals to the cell via, e.g., polycystins, which depend on ciliary localization for appropriate function. Indeed, hypomorphic mutations in the mouse ift88 (previously called Tg737) gene, which encodes a ciliogenic intraflagellar transport protein, result in malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD). While PKD was one of the first diseases to be linked to dysfunctional primary cilia, defects in this organelle have subsequently been associated with many other phenotypes, including cancer, obesity, diabetes as well as a number of developmental defects. Collectively, these disorders of the cilium are now referred to as the ciliopathies. In this review, we provide a brief overview of the structure and function of primary cilia and some of their roles in coordinating signal transduction pathways in mammalian development, health and disease.", "qas": [{"question": "Which is the most common disease attributed to malfunction or absence of primary cilia?", "answers": ["Polycystic kidney disease (PKD)"], "qid": "f11dbef10d7344129874377bdcfdef01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["disease", 25], ["attributed", 33], ["to", 44], ["malfunction", 47], ["or", 59], ["absence", 62], ["of", 70], ["primary", 73], ["cilia", 81], ["?", 86]], "detected_answers": [{"text": "Polycystic kidney disease (PKD)", "token_spans": [[193, 197]], "char_spans": [[1176, 1205]]}]}], "context_tokens": [["Although", 0], ["first", 9], ["described", 15], ["as", 25], ["early", 28], ["as", 34], ["1898", 37], ["and", 42], ["long", 46], ["considered", 51], ["a", 62], ["vestigial", 64], ["organelle", 74], ["of", 84], ["little", 87], ["functional", 94], ["importance", 105], [",", 115], ["the", 117], ["primary", 121], ["cilium", 129], ["has", 136], ["become", 140], ["one", 147], ["of", 151], ["the", 154], ["hottest", 158], ["research", 166], ["topics", 175], ["in", 182], ["modern", 185], ["cell", 192], ["biology", 197], ["and", 205], ["physiology", 209], [".", 219], ["Primary", 221], ["cilia", 229], ["are", 235], ["nonmotile", 239], ["sensory", 249], ["organelles", 257], ["present", 268], ["in", 276], ["a", 279], ["single", 281], ["copy", 288], ["on", 293], ["the", 296], ["surface", 300], ["of", 308], ["most", 311], ["growth", 316], ["-", 322], ["arrested", 323], ["or", 332], ["differentiated", 335], ["mammalian", 350], ["cells", 360], [",", 365], ["and", 367], ["defects", 371], ["in", 379], ["their", 382], ["assembly", 388], ["or", 397], ["function", 400], ["are", 409], ["tightly", 413], ["coupled", 421], ["to", 429], ["many", 432], ["developmental", 437], ["defects", 451], [",", 458], ["diseases", 460], ["and", 469], ["disorders", 473], [".", 482], ["In", 484], ["normal", 487], ["tissues", 494], [",", 501], ["the", 503], ["primary", 507], ["cilium", 515], ["coordinates", 522], ["a", 534], ["series", 536], ["of", 543], ["signal", 546], ["transduction", 553], ["pathways", 566], [",", 574], ["including", 576], ["Hedgehog", 586], [",", 594], ["Wnt", 596], [",", 599], ["PDGFRalpha", 601], ["and", 612], ["integrin", 616], ["signaling", 625], [".", 634], ["In", 636], ["the", 639], ["kidney", 643], [",", 649], ["the", 651], ["primary", 655], ["cilium", 663], ["may", 670], ["function", 674], ["as", 683], ["a", 686], ["mechano-", 688], [",", 696], ["chemo-", 698], ["and", 705], ["osmosensing", 709], ["unit", 721], ["that", 726], ["probes", 731], ["the", 738], ["extracellular", 742], ["environment", 756], ["and", 768], ["transmits", 772], ["signals", 782], ["to", 790], ["the", 793], ["cell", 797], ["via", 802], [",", 805], ["e.g.", 807], [",", 811], ["polycystins", 813], [",", 824], ["which", 826], ["depend", 832], ["on", 839], ["ciliary", 842], ["localization", 850], ["for", 863], ["appropriate", 867], ["function", 879], [".", 887], ["Indeed", 889], [",", 895], ["hypomorphic", 897], ["mutations", 909], ["in", 919], ["the", 922], ["mouse", 926], ["ift88", 932], ["(", 938], ["previously", 939], ["called", 950], ["Tg737", 957], [")", 962], ["gene", 964], [",", 968], ["which", 970], ["encodes", 976], ["a", 984], ["ciliogenic", 986], ["intraflagellar", 997], ["transport", 1012], ["protein", 1022], [",", 1029], ["result", 1031], ["in", 1038], ["malformation", 1041], ["of", 1054], ["primary", 1057], ["cilia", 1065], [",", 1070], ["and", 1072], ["in", 1076], ["the", 1079], ["collecting", 1083], ["ducts", 1094], ["of", 1100], ["kidney", 1103], ["tubules", 1110], ["this", 1118], ["is", 1123], ["accompanied", 1126], ["by", 1138], ["development", 1141], ["of", 1153], ["autosomal", 1156], ["recessive", 1166], ["polycystic", 1176], ["kidney", 1187], ["disease", 1194], ["(", 1202], ["PKD", 1203], [")", 1206], [".", 1207], ["While", 1209], ["PKD", 1215], ["was", 1219], ["one", 1223], ["of", 1227], ["the", 1230], ["first", 1234], ["diseases", 1240], ["to", 1249], ["be", 1252], ["linked", 1255], ["to", 1262], ["dysfunctional", 1265], ["primary", 1279], ["cilia", 1287], [",", 1292], ["defects", 1294], ["in", 1302], ["this", 1305], ["organelle", 1310], ["have", 1320], ["subsequently", 1325], ["been", 1338], ["associated", 1343], ["with", 1354], ["many", 1359], ["other", 1364], ["phenotypes", 1370], [",", 1380], ["including", 1382], ["cancer", 1392], [",", 1398], ["obesity", 1400], [",", 1407], ["diabetes", 1409], ["as", 1418], ["well", 1421], ["as", 1426], ["a", 1429], ["number", 1431], ["of", 1438], ["developmental", 1441], ["defects", 1455], [".", 1462], ["Collectively", 1464], [",", 1476], ["these", 1478], ["disorders", 1484], ["of", 1494], ["the", 1497], ["cilium", 1501], ["are", 1508], ["now", 1512], ["referred", 1516], ["to", 1525], ["as", 1528], ["the", 1531], ["ciliopathies", 1535], [".", 1547], ["In", 1549], ["this", 1552], ["review", 1557], [",", 1563], ["we", 1565], ["provide", 1568], ["a", 1576], ["brief", 1578], ["overview", 1584], ["of", 1593], ["the", 1596], ["structure", 1600], ["and", 1610], ["function", 1614], ["of", 1623], ["primary", 1626], ["cilia", 1634], ["and", 1640], ["some", 1644], ["of", 1649], ["their", 1652], ["roles", 1658], ["in", 1664], ["coordinating", 1667], ["signal", 1680], ["transduction", 1687], ["pathways", 1700], ["in", 1709], ["mammalian", 1712], ["development", 1722], [",", 1733], ["health", 1735], ["and", 1742], ["disease", 1746], [".", 1753]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "db311c7e2115419da83e01e6c5610862", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[6, 9]], "char_spans": [[41, 68]]}]}], "context_tokens": [["Selective", 0], ["degradation", 10], ["of", 22], ["proteins", 25], ["by", 34], ["the", 37], ["ubiquitin", 41], ["-", 50], ["proteasome", 51], ["pathway", 62], ["is", 70], ["a", 73], ["critical", 75], ["determinant", 84], ["for", 96], ["maintaining", 100], ["cellular", 112], ["homeostasis", 121], [".", 132], ["Most", 134], ["intracellular", 139], ["proteins", 153], ["are", 162], ["degraded", 166], ["by", 175], ["the", 178], ["proteasome", 182], [",", 192], ["a", 194], ["multicatalytic", 196], ["enzyme", 211], ["complex", 218], ["containing", 226], ["a", 237], ["20S", 239], ["catalytic", 243], ["core", 253], ["and", 258], ["two", 262], ["19S", 266], ["regulatory", 270], ["complexes", 281], [".", 290], ["Many", 292], ["proteasome", 297], ["target", 308], ["proteins", 315], ["are", 324], ["involved", 328], ["in", 337], ["the", 340], ["regulation", 344], ["of", 355], ["important", 358], ["processes", 368], ["of", 378], ["carcinogenesis", 381], ["and", 396], ["cancer", 400], ["cell", 407], ["survival", 412], [",", 420], ["such", 422], ["as", 427], ["cell", 430], ["cycle", 435], ["progression", 441], [",", 452], ["cell", 454], ["proliferation", 459], [",", 472], ["differentiation", 474], ["and", 490], ["apoptosis", 494], [".", 503], ["Indeed", 505], [",", 511], ["the", 513], ["ubiquitin", 517], ["-", 526], ["proteasome", 527], ["-", 537], ["dependent", 538], ["degradation", 548], ["pathway", 560], ["plays", 568], ["an", 574], ["essential", 577], ["role", 587], ["in", 592], ["both", 595], ["the", 600], ["up", 604], ["-", 606], ["regulation", 607], ["of", 618], ["cell", 621], ["proliferation", 626], ["and", 640], ["down", 644], ["-", 648], ["regulation", 649], ["of", 660], ["cell", 663], ["death", 668], ["in", 674], ["human", 677], ["cancer", 683], ["cells", 690], [".", 695], ["Both", 697], ["in", 702], ["vitro", 705], ["and", 711], ["in", 715], ["vivo", 718], ["experimental", 723], ["and", 736], ["clinical", 740], ["results", 749], ["have", 757], ["demonstrated", 762], ["the", 775], ["potential", 779], ["use", 789], ["of", 793], ["proteasome", 796], ["inhibitors", 807], ["as", 818], ["novel", 821], ["anticancer", 827], ["drugs", 838], [".", 843], ["Proteasome", 845], ["inhibition", 856], ["in", 867], ["cancer", 870], ["cells", 877], ["leads", 883], ["to", 889], ["accumulation", 892], ["of", 905], ["pro", 908], ["-", 911], ["apoptotic", 912], ["target", 922], ["proteins", 929], ["followed", 938], ["by", 947], ["induction", 950], ["of", 960], ["cell", 963], ["death", 968], [".", 973], ["The", 975], ["clinical", 979], ["efficacy", 988], ["of", 997], ["the", 1000], ["proteasome", 1004], ["inhibitor", 1015], ["bortezomib", 1025], ["toward", 1036], ["multiple", 1043], ["myeloma", 1052], ["and", 1060], ["other", 1064], ["hematologic", 1070], ["malignancies", 1082], ["provides", 1095], ["the", 1104], ["\"", 1108], ["proof", 1109], ["of", 1115], ["concept", 1118], ["\"", 1125], ["that", 1127], ["targeting", 1132], ["the", 1142], ["proteasome", 1146], ["is", 1157], ["a", 1160], ["promising", 1162], ["strategy", 1172], ["for", 1181], ["cancer", 1185], ["treatment", 1192], [".", 1201], ["Several", 1203], ["other", 1211], ["proteasome", 1217], ["inhibitors", 1228], ["have", 1239], ["also", 1244], ["been", 1249], ["identified", 1254], ["from", 1265], ["natural", 1270], ["resources", 1278], [",", 1287], ["such", 1289], ["as", 1294], ["marine", 1297], ["microbial", 1304], ["metabolites", 1314], [",", 1325], ["green", 1327], ["tea", 1333], ["polyphenols", 1337], [",", 1348], ["flavonoids", 1350], [",", 1360], ["and", 1362], ["medicinal", 1366], ["compounds", 1376], [".", 1385], ["Additionally", 1387], [",", 1399], ["the", 1401], ["use", 1405], ["of", 1409], ["metal", 1412], ["complexes", 1418], ["as", 1428], ["proteasome", 1431], ["inhibitors", 1442], ["has", 1453], ["also", 1457], ["been", 1462], ["investigated", 1467], ["as", 1480], ["a", 1483], ["potential", 1485], ["anticancer", 1495], ["strategy", 1506], [".", 1514], ["The", 1516], ["clinical", 1520], ["significance", 1529], ["of", 1542], ["targeting", 1545], ["the", 1555], ["tumor", 1559], ["survival", 1565], ["-", 1573], ["associated", 1574], ["proteasome", 1585], ["pathway", 1596], ["for", 1604], ["cancer", 1608], ["treatment", 1615], [",", 1624], ["intervention", 1626], ["and", 1639], ["prevention", 1643], ["will", 1654], ["be", 1659], ["discussed", 1662], [".", 1671]]}
{"context": "The FOXP2 gene is important for the development of proper speech motor control in humans. However, the role of the gene in general vocal behavior in other mammals, including mice, is unclear. Here, we track the vocal development of Foxp2 heterozygous knockout (Foxp2+/-) mice and their wildtype (WT) littermates from juvenile to adult ages, and observe severe abnormalities in the courtship song of Foxp2+/- mice. In comparison to their WT littermates, Foxp2+/- mice vocalized less, produced shorter syllable sequences, and possessed an abnormal syllable inventory. In addition, Foxp2+/- song also exhibited irregular rhythmic structure, and its development did not follow the consistent trajectories observed in WT vocalizations. These results demonstrate that the Foxp2 gene is critical for normal vocal behavior in juvenile and adult mice, and that Foxp2 mutant mice may provide a tractable model system for the study of the gene's role in general vocal motor control.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "9d3f3ba44ee44d29bc6fd1b262200ffb", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[45, 45], [131, 131], [74, 74], [147, 147], [84, 84], [104, 104], [1, 1], [49, 49]], "char_spans": [[232, 236], [766, 770], [399, 406], [852, 856], [453, 460], [579, 586], [4, 8], [261, 268]]}]}], "context_tokens": [["The", 0], ["FOXP2", 4], ["gene", 10], ["is", 15], ["important", 18], ["for", 28], ["the", 32], ["development", 36], ["of", 48], ["proper", 51], ["speech", 58], ["motor", 65], ["control", 71], ["in", 79], ["humans", 82], [".", 88], ["However", 90], [",", 97], ["the", 99], ["role", 103], ["of", 108], ["the", 111], ["gene", 115], ["in", 120], ["general", 123], ["vocal", 131], ["behavior", 137], ["in", 146], ["other", 149], ["mammals", 155], [",", 162], ["including", 164], ["mice", 174], [",", 178], ["is", 180], ["unclear", 183], [".", 190], ["Here", 192], [",", 196], ["we", 198], ["track", 201], ["the", 207], ["vocal", 211], ["development", 217], ["of", 229], ["Foxp2", 232], ["heterozygous", 238], ["knockout", 251], ["(", 260], ["Foxp2+/-", 261], [")", 269], ["mice", 271], ["and", 276], ["their", 280], ["wildtype", 286], ["(", 295], ["WT", 296], [")", 298], ["littermates", 300], ["from", 312], ["juvenile", 317], ["to", 326], ["adult", 329], ["ages", 335], [",", 339], ["and", 341], ["observe", 345], ["severe", 353], ["abnormalities", 360], ["in", 374], ["the", 377], ["courtship", 381], ["song", 391], ["of", 396], ["Foxp2+/-", 399], ["mice", 408], [".", 412], ["In", 414], ["comparison", 417], ["to", 428], ["their", 431], ["WT", 437], ["littermates", 440], [",", 451], ["Foxp2+/-", 453], ["mice", 462], ["vocalized", 467], ["less", 477], [",", 481], ["produced", 483], ["shorter", 492], ["syllable", 500], ["sequences", 509], [",", 518], ["and", 520], ["possessed", 524], ["an", 534], ["abnormal", 537], ["syllable", 546], ["inventory", 555], [".", 564], ["In", 566], ["addition", 569], [",", 577], ["Foxp2+/-", 579], ["song", 588], ["also", 593], ["exhibited", 598], ["irregular", 608], ["rhythmic", 618], ["structure", 627], [",", 636], ["and", 638], ["its", 642], ["development", 646], ["did", 658], ["not", 662], ["follow", 666], ["the", 673], ["consistent", 677], ["trajectories", 688], ["observed", 701], ["in", 710], ["WT", 713], ["vocalizations", 716], [".", 729], ["These", 731], ["results", 737], ["demonstrate", 745], ["that", 757], ["the", 762], ["Foxp2", 766], ["gene", 772], ["is", 777], ["critical", 780], ["for", 789], ["normal", 793], ["vocal", 800], ["behavior", 806], ["in", 815], ["juvenile", 818], ["and", 827], ["adult", 831], ["mice", 837], [",", 841], ["and", 843], ["that", 847], ["Foxp2", 852], ["mutant", 858], ["mice", 865], ["may", 870], ["provide", 874], ["a", 882], ["tractable", 884], ["model", 894], ["system", 900], ["for", 907], ["the", 911], ["study", 915], ["of", 921], ["the", 924], ["gene", 928], ["'s", 932], ["role", 935], ["in", 940], ["general", 943], ["vocal", 951], ["motor", 957], ["control", 963], [".", 970]]}
{"context": "Histone variant H2A.Z-containing nucleosomes exist at most eukaryotic promoters and play important roles in gene transcription and genome stability. The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. How SWR1 catalyzes the replacement reaction is largely unknown. Here, we determined the crystal structure of the N-terminal region (599-627) of the catalytic subunit Swr1, termed Swr1-Z domain, in complex with the H2A.Z-H2B dimer at 1.78 \u00c5 resolution. The Swr1-Z domain forms a 310 helix and an irregular chain. A conserved LxxLF motif in the Swr1-Z 310 helix specifically recognizes the \u03b1C helix of H2A.Z. Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "fd3253087bbd4003b295d765450a9097", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[83, 83], [52, 52], [29, 29]], "char_spans": [[500, 503], [338, 341], [203, 206]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["exist", 45], ["at", 51], ["most", 54], ["eukaryotic", 59], ["promoters", 70], ["and", 80], ["play", 84], ["important", 89], ["roles", 99], ["in", 105], ["gene", 108], ["transcription", 113], ["and", 127], ["genome", 131], ["stability", 138], [".", 147], ["The", 149], ["multisubunit", 153], ["nucleosome", 166], ["-", 176], ["remodeling", 177], ["enzyme", 188], ["complex", 195], ["SWR1", 203], [",", 207], ["conserved", 209], ["from", 219], ["yeast", 224], ["to", 230], ["mammals", 233], [",", 240], ["catalyzes", 242], ["the", 252], ["ATP", 256], ["-", 259], ["dependent", 260], ["replacement", 270], ["of", 282], ["histone", 285], ["H2A", 293], ["in", 297], ["canonical", 300], ["nucleosomes", 310], ["with", 322], ["H2A.Z.", 327], ["How", 334], ["SWR1", 338], ["catalyzes", 343], ["the", 353], ["replacement", 357], ["reaction", 369], ["is", 378], ["largely", 381], ["unknown", 389], [".", 396], ["Here", 398], [",", 402], ["we", 404], ["determined", 407], ["the", 418], ["crystal", 422], ["structure", 430], ["of", 440], ["the", 443], ["N", 447], ["-", 448], ["terminal", 449], ["region", 458], ["(", 465], ["599", 466], ["-", 469], ["627", 470], [")", 473], ["of", 475], ["the", 478], ["catalytic", 482], ["subunit", 492], ["Swr1", 500], [",", 504], ["termed", 506], ["Swr1-Z", 513], ["domain", 520], [",", 526], ["in", 528], ["complex", 531], ["with", 539], ["the", 544], ["H2A.Z", 548], ["-", 553], ["H2B", 554], ["dimer", 558], ["at", 564], ["1.78", 567], ["\u00c5", 572], ["resolution", 574], [".", 584], ["The", 586], ["Swr1-Z", 590], ["domain", 597], ["forms", 604], ["a", 610], ["310", 612], ["helix", 616], ["and", 622], ["an", 626], ["irregular", 629], ["chain", 639], [".", 644], ["A", 646], ["conserved", 648], ["LxxLF", 658], ["motif", 664], ["in", 670], ["the", 673], ["Swr1-Z", 677], ["310", 684], ["helix", 688], ["specifically", 694], ["recognizes", 707], ["the", 718], ["\u03b1C", 722], ["helix", 725], ["of", 731], ["H2A.Z.", 734], ["Our", 741], ["results", 745], ["show", 753], ["that", 758], ["the", 763], ["Swr1-Z", 767], ["domain", 774], ["can", 781], ["deliver", 785], ["the", 793], ["H2A.Z", 797], ["-", 802], ["H2B", 803], ["dimer", 807], ["to", 813], ["the", 816], ["DNA-(H3-H4)2", 820], ["tetrasome", 833], ["to", 843], ["form", 846], ["the", 851], ["nucleosome", 855], ["by", 866], ["a", 869], ["histone", 871], ["chaperone", 879], ["mechanism", 889], [".", 898]]}
{"context": "Oxidatively damaged proteins accumulate with age in almost all cell types and tissues. The activity of chaperone-mediated autophagy (CMA), a selective pathway for the degradation of cytosolic proteins in lysosomes, decreases with age. We have analyzed the possible participation of CMA in the removal of oxidized proteins in rat liver and cultured mouse fibroblasts. Added to the fact that CMA substrates, when oxidized, are more efficiently internalized into lysosomes, we have found a constitutive activation of CMA during oxidative stress. Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway. In contrast with the well characterized mechanism of CMA activation during nutritional stress, which does not require de novo synthesis of the receptor, oxidation-induced activation of CMA is attained through transcriptional up-regulation of lamp2a. We conclude that CMA is activated during oxidative stress and that the higher activity of this pathway under these conditions, along with the higher susceptibility of the oxidized proteins to be taken up by lysosomes, both contribute to the efficient removal of oxidized proteins.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "231d54cde09548338f239c48ff1fd357", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[185, 185]], "char_spans": [[1096, 1101]]}]}], "context_tokens": [["Oxidatively", 0], ["damaged", 12], ["proteins", 20], ["accumulate", 29], ["with", 40], ["age", 45], ["in", 49], ["almost", 52], ["all", 59], ["cell", 63], ["types", 68], ["and", 74], ["tissues", 78], [".", 85], ["The", 87], ["activity", 91], ["of", 100], ["chaperone", 103], ["-", 112], ["mediated", 113], ["autophagy", 122], ["(", 132], ["CMA", 133], [")", 136], [",", 137], ["a", 139], ["selective", 141], ["pathway", 151], ["for", 159], ["the", 163], ["degradation", 167], ["of", 179], ["cytosolic", 182], ["proteins", 192], ["in", 201], ["lysosomes", 204], [",", 213], ["decreases", 215], ["with", 225], ["age", 230], [".", 233], ["We", 235], ["have", 238], ["analyzed", 243], ["the", 252], ["possible", 256], ["participation", 265], ["of", 279], ["CMA", 282], ["in", 286], ["the", 289], ["removal", 293], ["of", 301], ["oxidized", 304], ["proteins", 313], ["in", 322], ["rat", 325], ["liver", 329], ["and", 335], ["cultured", 339], ["mouse", 348], ["fibroblasts", 354], [".", 365], ["Added", 367], ["to", 373], ["the", 376], ["fact", 380], ["that", 385], ["CMA", 390], ["substrates", 394], [",", 404], ["when", 406], ["oxidized", 411], [",", 419], ["are", 421], ["more", 425], ["efficiently", 430], ["internalized", 442], ["into", 455], ["lysosomes", 460], [",", 469], ["we", 471], ["have", 474], ["found", 479], ["a", 485], ["constitutive", 487], ["activation", 500], ["of", 511], ["CMA", 514], ["during", 518], ["oxidative", 525], ["stress", 535], [".", 541], ["Oxidation", 543], ["-", 552], ["induced", 553], ["activation", 561], ["of", 572], ["CMA", 575], ["correlates", 579], ["with", 590], ["higher", 595], ["levels", 602], ["of", 609], ["several", 612], ["components", 620], ["of", 631], ["the", 634], ["lysosomal", 638], ["translocation", 648], ["complex", 662], [",", 669], ["but", 671], ["in", 675], ["particular", 678], ["of", 689], ["the", 692], ["lumenal", 696], ["chaperone", 704], [",", 713], ["required", 715], ["for", 724], ["substrate", 728], ["uptake", 738], [",", 744], ["and", 746], ["of", 750], ["the", 753], ["lysosomal", 757], ["membrane", 767], ["protein", 776], ["(", 784], ["lamp", 785], [")", 789], ["type", 791], ["2a", 796], [",", 798], ["previously", 800], ["identified", 811], ["as", 822], ["a", 825], ["receptor", 827], ["for", 836], ["this", 840], ["pathway", 845], [".", 852], ["In", 854], ["contrast", 857], ["with", 866], ["the", 871], ["well", 875], ["characterized", 880], ["mechanism", 894], ["of", 904], ["CMA", 907], ["activation", 911], ["during", 922], ["nutritional", 929], ["stress", 941], [",", 947], ["which", 949], ["does", 955], ["not", 960], ["require", 964], ["de", 972], ["novo", 975], ["synthesis", 980], ["of", 990], ["the", 993], ["receptor", 997], [",", 1005], ["oxidation", 1007], ["-", 1016], ["induced", 1017], ["activation", 1025], ["of", 1036], ["CMA", 1039], ["is", 1043], ["attained", 1046], ["through", 1055], ["transcriptional", 1063], ["up", 1079], ["-", 1081], ["regulation", 1082], ["of", 1093], ["lamp2a", 1096], [".", 1102], ["We", 1104], ["conclude", 1107], ["that", 1116], ["CMA", 1121], ["is", 1125], ["activated", 1128], ["during", 1138], ["oxidative", 1145], ["stress", 1155], ["and", 1162], ["that", 1166], ["the", 1171], ["higher", 1175], ["activity", 1182], ["of", 1191], ["this", 1194], ["pathway", 1199], ["under", 1207], ["these", 1213], ["conditions", 1219], [",", 1229], ["along", 1231], ["with", 1237], ["the", 1242], ["higher", 1246], ["susceptibility", 1253], ["of", 1268], ["the", 1271], ["oxidized", 1275], ["proteins", 1284], ["to", 1293], ["be", 1296], ["taken", 1299], ["up", 1305], ["by", 1308], ["lysosomes", 1311], [",", 1320], ["both", 1322], ["contribute", 1327], ["to", 1338], ["the", 1341], ["efficient", 1345], ["removal", 1355], ["of", 1363], ["oxidized", 1366], ["proteins", 1375], [".", 1383]]}
{"context": "Malformation of cortical development (MCD) is a well-known cause of drug-resistant epilepsy and focal cortical dysplasia (FCD) is the most common neuropathological finding in surgical specimens from drug-resistant epilepsy patients. Palmini's classification proposed in 2004 is now widely used to categorize FCD. Recently, however, Blumcke et al. recommended a new system for classifying FCD in 2011. We applied the new classification system in practical diagnosis of a sample of 117 patients who underwent neurosurgical operations due to drug-resistant epilepsy at Severance Hospital in Seoul, Korea. Among 117 cases, a total of 16 cases were shifted to other FCD subtypes under the new classification system. Five cases were reclassified to type IIIa and five cases were categorized as dual pathology. The other six cases were changed within the type I category. The most remarkable changes in the new classification system are the advent of dual pathology and FCD type III. Thus, it will be very important for pathologists and clinicians to discriminate between these new categories. More large-scale research needs to be conducted to elucidate the clinical influence of the alterations within the classification of type I disease. Although the new FCD classification system has several advantages compared to the former, the correlation with clinical characteristics is not yet clear.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "fcc71128ce954ca0aaa995650ab41118", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[19, 21]], "char_spans": [[96, 119]]}]}], "context_tokens": [["Malformation", 0], ["of", 13], ["cortical", 16], ["development", 25], ["(", 37], ["MCD", 38], [")", 41], ["is", 43], ["a", 46], ["well", 48], ["-", 52], ["known", 53], ["cause", 59], ["of", 65], ["drug", 68], ["-", 72], ["resistant", 73], ["epilepsy", 83], ["and", 92], ["focal", 96], ["cortical", 102], ["dysplasia", 111], ["(", 121], ["FCD", 122], [")", 125], ["is", 127], ["the", 130], ["most", 134], ["common", 139], ["neuropathological", 146], ["finding", 164], ["in", 172], ["surgical", 175], ["specimens", 184], ["from", 194], ["drug", 199], ["-", 203], ["resistant", 204], ["epilepsy", 214], ["patients", 223], [".", 231], ["Palmini", 233], ["'s", 240], ["classification", 243], ["proposed", 258], ["in", 267], ["2004", 270], ["is", 275], ["now", 278], ["widely", 282], ["used", 289], ["to", 294], ["categorize", 297], ["FCD", 308], [".", 311], ["Recently", 313], [",", 321], ["however", 323], [",", 330], ["Blumcke", 332], ["et", 340], ["al", 343], [".", 345], ["recommended", 347], ["a", 359], ["new", 361], ["system", 365], ["for", 372], ["classifying", 376], ["FCD", 388], ["in", 392], ["2011", 395], [".", 399], ["We", 401], ["applied", 404], ["the", 412], ["new", 416], ["classification", 420], ["system", 435], ["in", 442], ["practical", 445], ["diagnosis", 455], ["of", 465], ["a", 468], ["sample", 470], ["of", 477], ["117", 480], ["patients", 484], ["who", 493], ["underwent", 497], ["neurosurgical", 507], ["operations", 521], ["due", 532], ["to", 536], ["drug", 539], ["-", 543], ["resistant", 544], ["epilepsy", 554], ["at", 563], ["Severance", 566], ["Hospital", 576], ["in", 585], ["Seoul", 588], [",", 593], ["Korea", 595], [".", 600], ["Among", 602], ["117", 608], ["cases", 612], [",", 617], ["a", 619], ["total", 621], ["of", 627], ["16", 630], ["cases", 633], ["were", 639], ["shifted", 644], ["to", 652], ["other", 655], ["FCD", 661], ["subtypes", 665], ["under", 674], ["the", 680], ["new", 684], ["classification", 688], ["system", 703], [".", 709], ["Five", 711], ["cases", 716], ["were", 722], ["reclassified", 727], ["to", 740], ["type", 743], ["IIIa", 748], ["and", 753], ["five", 757], ["cases", 762], ["were", 768], ["categorized", 773], ["as", 785], ["dual", 788], ["pathology", 793], [".", 802], ["The", 804], ["other", 808], ["six", 814], ["cases", 818], ["were", 824], ["changed", 829], ["within", 837], ["the", 844], ["type", 848], ["I", 853], ["category", 855], [".", 863], ["The", 865], ["most", 869], ["remarkable", 874], ["changes", 885], ["in", 893], ["the", 896], ["new", 900], ["classification", 904], ["system", 919], ["are", 926], ["the", 930], ["advent", 934], ["of", 941], ["dual", 944], ["pathology", 949], ["and", 959], ["FCD", 963], ["type", 967], ["III", 972], [".", 975], ["Thus", 977], [",", 981], ["it", 983], ["will", 986], ["be", 991], ["very", 994], ["important", 999], ["for", 1009], ["pathologists", 1013], ["and", 1026], ["clinicians", 1030], ["to", 1041], ["discriminate", 1044], ["between", 1057], ["these", 1065], ["new", 1071], ["categories", 1075], [".", 1085], ["More", 1087], ["large", 1092], ["-", 1097], ["scale", 1098], ["research", 1104], ["needs", 1113], ["to", 1119], ["be", 1122], ["conducted", 1125], ["to", 1135], ["elucidate", 1138], ["the", 1148], ["clinical", 1152], ["influence", 1161], ["of", 1171], ["the", 1174], ["alterations", 1178], ["within", 1190], ["the", 1197], ["classification", 1201], ["of", 1216], ["type", 1219], ["I", 1224], ["disease", 1226], [".", 1233], ["Although", 1235], ["the", 1244], ["new", 1248], ["FCD", 1252], ["classification", 1256], ["system", 1271], ["has", 1278], ["several", 1282], ["advantages", 1290], ["compared", 1301], ["to", 1310], ["the", 1313], ["former", 1317], [",", 1323], ["the", 1325], ["correlation", 1329], ["with", 1341], ["clinical", 1346], ["characteristics", 1355], ["is", 1371], ["not", 1374], ["yet", 1378], ["clear", 1382], [".", 1387]]}
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "The clear connection between ribosome biogenesis dysfunction and specific hematopoiesis-related disorders prompted us to examine the role of critical lineage-specific transcription factors in the transcriptional regulation of ribosomal protein (RP) genes during terminal erythroid differentiation. By applying EMSA and ChIP methodologies in mouse erythroleukemia cells we show that GATA1 and PU.1 bind in vitro and in vivo the proximal promoter region of the RPS19 gene which is frequently mutated in Diamond-Blackfan Anemia. Moreover, ChIPseq data analysis also demonstrates that several RP genes are enriched as potential GATA1 and PU.1 gene targets in mouse and human erythroid cells, with GATA1 binding showing an association with higher ribosomal protein gene expression levels during terminal erythroid differentiation in human and mouse. Our results suggest that RP gene expression and hence balanced ribosome biosynthesis may be specifically and selectively regulated by lineage specific transcription factors during hematopoiesis, a finding which may be clinically relevant to ribosomopathies.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "35f2d4aeaa304a9d9c6fb6f5340d5589", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[77, 80]], "char_spans": [[501, 523]]}]}], "context_tokens": [["The", 0], ["clear", 4], ["connection", 10], ["between", 21], ["ribosome", 29], ["biogenesis", 38], ["dysfunction", 49], ["and", 61], ["specific", 65], ["hematopoiesis", 74], ["-", 87], ["related", 88], ["disorders", 96], ["prompted", 106], ["us", 115], ["to", 118], ["examine", 121], ["the", 129], ["role", 133], ["of", 138], ["critical", 141], ["lineage", 150], ["-", 157], ["specific", 158], ["transcription", 167], ["factors", 181], ["in", 189], ["the", 192], ["transcriptional", 196], ["regulation", 212], ["of", 223], ["ribosomal", 226], ["protein", 236], ["(", 244], ["RP", 245], [")", 247], ["genes", 249], ["during", 255], ["terminal", 262], ["erythroid", 271], ["differentiation", 281], [".", 296], ["By", 298], ["applying", 301], ["EMSA", 310], ["and", 315], ["ChIP", 319], ["methodologies", 324], ["in", 338], ["mouse", 341], ["erythroleukemia", 347], ["cells", 363], ["we", 369], ["show", 372], ["that", 377], ["GATA1", 382], ["and", 388], ["PU.1", 392], ["bind", 397], ["in", 402], ["vitro", 405], ["and", 411], ["in", 415], ["vivo", 418], ["the", 423], ["proximal", 427], ["promoter", 436], ["region", 445], ["of", 452], ["the", 455], ["RPS19", 459], ["gene", 465], ["which", 470], ["is", 476], ["frequently", 479], ["mutated", 490], ["in", 498], ["Diamond", 501], ["-", 508], ["Blackfan", 509], ["Anemia", 518], [".", 524], ["Moreover", 526], [",", 534], ["ChIPseq", 536], ["data", 544], ["analysis", 549], ["also", 558], ["demonstrates", 563], ["that", 576], ["several", 581], ["RP", 589], ["genes", 592], ["are", 598], ["enriched", 602], ["as", 611], ["potential", 614], ["GATA1", 624], ["and", 630], ["PU.1", 634], ["gene", 639], ["targets", 644], ["in", 652], ["mouse", 655], ["and", 661], ["human", 665], ["erythroid", 671], ["cells", 681], [",", 686], ["with", 688], ["GATA1", 693], ["binding", 699], ["showing", 707], ["an", 715], ["association", 718], ["with", 730], ["higher", 735], ["ribosomal", 742], ["protein", 752], ["gene", 760], ["expression", 765], ["levels", 776], ["during", 783], ["terminal", 790], ["erythroid", 799], ["differentiation", 809], ["in", 825], ["human", 828], ["and", 834], ["mouse", 838], [".", 843], ["Our", 845], ["results", 849], ["suggest", 857], ["that", 865], ["RP", 870], ["gene", 873], ["expression", 878], ["and", 889], ["hence", 893], ["balanced", 899], ["ribosome", 908], ["biosynthesis", 917], ["may", 930], ["be", 934], ["specifically", 937], ["and", 950], ["selectively", 954], ["regulated", 966], ["by", 976], ["lineage", 979], ["specific", 987], ["transcription", 996], ["factors", 1010], ["during", 1018], ["hematopoiesis", 1025], [",", 1038], ["a", 1040], ["finding", 1042], ["which", 1050], ["may", 1056], ["be", 1060], ["clinically", 1063], ["relevant", 1074], ["to", 1083], ["ribosomopathies", 1086], [".", 1101]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65\u2003=\u2003one point each for Confusion, Urea\u2003>\u20037 mmol/L, Respiratory rate\u2003\u2265\u200330/min, low Blood pressure, age\u2003\u2265\u200365 years. 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30\u2003days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "930ebd41e49942059fff966207ce5c03", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[288, 288], [46, 46]], "char_spans": [[1588, 1596], [282, 290]]}]}], "context_tokens": [["Hospitalization", 0], ["for", 16], ["exacerbation", 20], ["of", 33], ["COPD", 36], ["is", 41], ["associated", 44], ["with", 55], ["a", 60], ["high", 62], ["risk", 67], ["of", 72], ["mortality", 75], [".", 84], ["A", 86], ["risk", 88], ["-", 92], ["prediction", 93], ["model", 104], ["using", 110], ["information", 116], ["easily", 128], ["obtained", 135], ["on", 144], ["admission", 147], ["could", 157], ["help", 163], ["to", 168], ["identify", 171], ["high", 180], ["-", 184], ["risk", 185], ["individuals", 190], [".", 201], ["The", 203], ["CURB65", 207], ["score", 214], ["was", 220], ["developed", 224], ["to", 234], ["predict", 237], ["mortality", 245], ["risk", 255], ["in", 260], ["community", 263], ["acquired", 273], ["pneumonia", 282], [".", 291], ["A", 293], ["retrospective", 295], ["study", 309], ["found", 315], ["that", 321], ["this", 326], ["score", 331], ["was", 337], ["also", 341], ["associated", 346], ["with", 357], ["mortality", 362], ["in", 372], ["COPD", 375], ["exacerbations", 380], [".", 393], ["We", 395], ["conducted", 398], ["a", 408], ["prospective", 410], ["study", 422], ["to", 428], ["assess", 431], ["the", 438], ["utility", 442], ["of", 450], ["the", 453], ["CURB65", 457], ["score", 464], ["in", 470], ["acute", 473], ["COPD", 479], ["exacerbations", 484], [".", 497], ["Consecutive", 499], ["patients", 511], ["with", 520], ["physician", 525], ["diagnosed", 535], ["COPD", 545], ["exacerbations", 550], ["admitted", 564], ["to", 573], ["a", 576], ["public", 578], ["hospital", 585], ["during", 594], ["a", 601], ["1-year", 603], ["period", 610], ["were", 617], ["studied", 622], ["prospectively", 630], [".", 643], ["The", 645], ["CURB65", 649], ["scores", 656], ["were", 663], ["calculated", 668], ["from", 679], ["information", 684], ["obtained", 696], ["at", 705], ["initial", 708], ["hospital", 716], ["presentation", 725], [".", 737], ["CURB65", 739], ["=", 746], ["one", 748], ["point", 752], ["each", 758], ["for", 763], ["Confusion", 767], [",", 776], ["Urea", 778], [">", 783], ["7", 785], ["mmol", 787], ["/", 791], ["L", 792], [",", 793], ["Respiratory", 795], ["rate", 807], ["\u2265", 812], ["30/min", 814], [",", 820], ["low", 822], ["Blood", 826], ["pressure", 832], [",", 840], ["age", 842], ["\u2265", 846], ["65", 848], ["years", 851], [".", 856], ["30-day", 858], ["mortality", 865], ["data", 875], ["were", 880], ["available", 885], ["for", 895], ["249", 899], ["of", 903], ["252", 906], ["patients", 910], [".", 918], ["CURB65", 920], ["scores", 927], ["on", 934], ["admission", 937], ["significantly", 947], ["predicted", 961], ["risk", 971], ["of", 976], ["death", 979], ["during", 985], ["the", 992], ["hospital", 996], ["admission", 1005], ["and", 1015], ["at", 1019], ["30", 1022], ["days", 1025], [".", 1029], ["The", 1031], ["30-day", 1035], ["mortality", 1042], ["by", 1052], ["score", 1055], ["groups", 1061], ["were", 1068], [":", 1072], ["low", 1074], ["risk", 1078], ["(", 1083], ["scores", 1084], ["0", 1091], ["-", 1092], ["1", 1093], [")", 1094], ["2.0", 1096], ["%", 1099], ["(", 1101], ["2/98", 1102], [")", 1106], [",", 1107], ["moderate", 1109], ["risk", 1118], ["(", 1123], ["score", 1124], ["2", 1130], [")", 1131], ["6.7", 1133], ["%", 1136], ["(", 1138], ["6/90", 1139], [")", 1143], ["and", 1145], ["high", 1149], ["risk", 1154], ["(", 1159], ["scores", 1160], ["3", 1167], ["-", 1168], ["5", 1169], [")", 1170], ["21.3", 1172], ["%", 1176], ["(", 1178], ["13/61", 1179], [")", 1184], [".", 1185], ["CURB65", 1187], ["scores", 1194], ["were", 1201], ["not", 1206], ["predictive", 1210], ["of", 1221], ["1-year", 1224], ["mortality", 1231], [".", 1240], ["A", 1242], ["simple", 1244], ["6-point", 1251], ["score", 1259], ["based", 1265], ["on", 1271], ["confusion", 1274], [",", 1283], ["blood", 1285], ["urea", 1291], [",", 1295], ["respiratory", 1297], ["rate", 1309], [",", 1313], ["blood", 1315], ["pressure", 1321], ["and", 1330], ["age", 1334], ["can", 1338], ["be", 1342], ["used", 1345], ["to", 1350], ["stratify", 1353], ["patients", 1362], ["with", 1371], ["COPD", 1376], ["exacerbation", 1381], ["into", 1394], ["different", 1399], ["management", 1409], ["groups", 1420], [".", 1426], ["The", 1428], ["CURB65", 1432], ["score", 1439], ["was", 1445], ["as", 1449], ["effective", 1452], ["in", 1462], ["predicting", 1465], ["early", 1476], ["mortality", 1482], ["in", 1492], ["our", 1495], ["cohort", 1499], ["of", 1506], ["acute", 1509], ["COPD", 1515], ["exacerbations", 1520], ["as", 1534], ["it", 1537], ["was", 1540], ["in", 1544], ["previous", 1547], ["cohorts", 1556], ["with", 1564], ["community", 1569], ["acquired", 1579], ["pneumonia", 1588], [".", 1597], ["Our", 1599], ["findings", 1603], ["suggest", 1612], ["that", 1620], ["CURB65", 1625], ["scores", 1632], ["can", 1639], ["help", 1643], ["clinicians", 1648], ["to", 1659], ["assess", 1662], ["patients", 1669], ["with", 1678], ["exacerbation", 1683], ["of", 1696], ["COPD", 1699], [".", 1703]]}
{"context": "Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the condition. Recently approved anti-Tb drugs (bedaquiline and delamanid) have the potential to induce arrhythmia and are recommended in patients with MDR-Tb when other alternatives fail. The goal of elimination of Tb by 2050 will not be achieved without an effective new vaccine. The recent advancement in the development of Tb vaccines is the keen focus of this review. To date, Bacille Calmette Guerin (BCG) is the only licensed Tb vaccine in use, however its efficacy in pulmonary Tb is variable in adolescents and adults. There are nearly 15 vaccine candidates in various phases of clinical trials, includes five protein or adjuvant vaccines, four viral-vectored vaccines, three mycobacterial whole cell or extract vaccines, and one each of the recombinant live and the attenuated Mycobacterium tuberculosis (Mtb) vaccine.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "70def1204d7c4c8eacdf2cc36356ec55", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [180, 180]], "char_spans": [[0, 11], [975, 986]]}]}], "context_tokens": [["Tuberculosis", 0], ["(", 13], ["Tb", 14], [")", 16], ["continues", 18], ["to", 28], ["be", 31], ["a", 34], ["dreadful", 36], ["infection", 45], ["worldwide", 55], ["with", 65], ["nearly", 70], ["1.5", 77], ["million", 81], ["deaths", 89], ["in", 96], ["2013", 99], [".", 103], ["Furthermore", 105], ["multi", 117], ["/", 122], ["extensively", 123], ["drug", 135], ["-", 139], ["resistant", 140], ["Tb", 150], ["(", 153], ["MDR", 154], ["/", 157], ["XDR", 158], ["-", 161], ["Tb", 162], [")", 164], ["worsens", 166], ["the", 174], ["condition", 178], [".", 187], ["Recently", 189], ["approved", 198], ["anti", 207], ["-", 211], ["Tb", 212], ["drugs", 215], ["(", 221], ["bedaquiline", 222], ["and", 234], ["delamanid", 238], [")", 247], ["have", 249], ["the", 254], ["potential", 258], ["to", 268], ["induce", 271], ["arrhythmia", 278], ["and", 289], ["are", 293], ["recommended", 297], ["in", 309], ["patients", 312], ["with", 321], ["MDR", 326], ["-", 329], ["Tb", 330], ["when", 333], ["other", 338], ["alternatives", 344], ["fail", 357], [".", 361], ["The", 363], ["goal", 367], ["of", 372], ["elimination", 375], ["of", 387], ["Tb", 390], ["by", 393], ["2050", 396], ["will", 401], ["not", 406], ["be", 410], ["achieved", 413], ["without", 422], ["an", 430], ["effective", 433], ["new", 443], ["vaccine", 447], [".", 454], ["The", 456], ["recent", 460], ["advancement", 467], ["in", 479], ["the", 482], ["development", 486], ["of", 498], ["Tb", 501], ["vaccines", 504], ["is", 513], ["the", 516], ["keen", 520], ["focus", 525], ["of", 531], ["this", 534], ["review", 539], [".", 545], ["To", 547], ["date", 550], [",", 554], ["Bacille", 556], ["Calmette", 564], ["Guerin", 573], ["(", 580], ["BCG", 581], [")", 584], ["is", 586], ["the", 589], ["only", 593], ["licensed", 598], ["Tb", 607], ["vaccine", 610], ["in", 618], ["use", 621], [",", 624], ["however", 626], ["its", 634], ["efficacy", 638], ["in", 647], ["pulmonary", 650], ["Tb", 660], ["is", 663], ["variable", 666], ["in", 675], ["adolescents", 678], ["and", 690], ["adults", 694], [".", 700], ["There", 702], ["are", 708], ["nearly", 712], ["15", 719], ["vaccine", 722], ["candidates", 730], ["in", 741], ["various", 744], ["phases", 752], ["of", 759], ["clinical", 762], ["trials", 771], [",", 777], ["includes", 779], ["five", 788], ["protein", 793], ["or", 801], ["adjuvant", 804], ["vaccines", 813], [",", 821], ["four", 823], ["viral", 828], ["-", 833], ["vectored", 834], ["vaccines", 843], [",", 851], ["three", 853], ["mycobacterial", 859], ["whole", 873], ["cell", 879], ["or", 884], ["extract", 887], ["vaccines", 895], [",", 903], ["and", 905], ["one", 909], ["each", 913], ["of", 918], ["the", 921], ["recombinant", 925], ["live", 937], ["and", 942], ["the", 946], ["attenuated", 950], ["Mycobacterium", 961], ["tuberculosis", 975], ["(", 988], ["Mtb", 989], [")", 992], ["vaccine", 994], [".", 1001]]}
{"context": "Reactive oxygen species (ROS) have been known for a long time to play important roles in host defense against microbial infections. In addition, it has become apparent that they also perform regulatory roles in signal transduction and cell proliferation. The source of these chemicals are members of the NOX family of NADPH oxidases that are found in a variety of tissues. NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity. Unlike NOX2, the phagocytic NADPH oxidase whose activity is tightly repressed in the resting state, NOX1 produces superoxide constitutively at low levels. These levels can be further increased in a stimulus-dependent manner, yet the molecular details regulating this activity are not fully understood. Here we present the first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22(phox). Using isothermal titration calorimetry we show that the isolated tandem SH3 domains of NOXO1 bind to p22(phox) with high affinity, most likely adopting a superSH3 domain conformation. In contrast, complex formation is severely inhibited in the presence of the C-terminal tail of NOXO1, suggesting that this region competes for binding to p22(phox) and thereby contributes to the regulation of superoxide production. Furthermore, we provide data indicating that the molecular details of the interaction between NOXO1 and NOXA1 is significantly different from that between the homologous proteins of the phagocytic oxidase, suggesting that there are important functional differences between the two systems. Taken together, this study provides clear evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "976535f8681e45c9881400b1e940a908", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[316, 316], [132, 132], [67, 67]], "char_spans": [[1888, 1891], [744, 747], [373, 376]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["have", 30], ["been", 35], ["known", 40], ["for", 46], ["a", 50], ["long", 52], ["time", 57], ["to", 62], ["play", 65], ["important", 70], ["roles", 80], ["in", 86], ["host", 89], ["defense", 94], ["against", 102], ["microbial", 110], ["infections", 120], [".", 130], ["In", 132], ["addition", 135], [",", 143], ["it", 145], ["has", 148], ["become", 152], ["apparent", 159], ["that", 168], ["they", 173], ["also", 178], ["perform", 183], ["regulatory", 191], ["roles", 202], ["in", 208], ["signal", 211], ["transduction", 218], ["and", 231], ["cell", 235], ["proliferation", 240], [".", 253], ["The", 255], ["source", 259], ["of", 266], ["these", 269], ["chemicals", 275], ["are", 285], ["members", 289], ["of", 297], ["the", 300], ["NOX", 304], ["family", 308], ["of", 315], ["NADPH", 318], ["oxidases", 324], ["that", 333], ["are", 338], ["found", 342], ["in", 348], ["a", 351], ["variety", 353], ["of", 361], ["tissues", 364], [".", 371], ["NOX1", 373], [",", 377], ["an", 379], ["NADPH", 382], ["oxidase", 388], ["homologue", 396], ["that", 406], ["is", 411], ["most", 414], ["abundantly", 419], ["expressed", 430], ["in", 440], ["colon", 443], ["epithelial", 449], ["cells", 460], [",", 465], ["requires", 467], ["the", 476], ["regulatory", 480], ["subunits", 491], ["NOXO1", 500], ["(", 506], ["NOX", 507], ["organizing", 511], ["protein", 522], ["1", 530], [")", 531], ["and", 533], ["NOXA1", 537], ["(", 543], ["NOX", 544], ["activating", 548], ["protein", 559], ["1", 567], [")", 568], [",", 569], ["as", 571], ["well", 574], ["as", 579], ["the", 582], ["flavocytochrome", 586], ["component", 602], ["p22(phox", 612], [")", 620], ["for", 622], ["maximal", 626], ["activity", 634], [".", 642], ["Unlike", 644], ["NOX2", 651], [",", 655], ["the", 657], ["phagocytic", 661], ["NADPH", 672], ["oxidase", 678], ["whose", 686], ["activity", 692], ["is", 701], ["tightly", 704], ["repressed", 712], ["in", 722], ["the", 725], ["resting", 729], ["state", 737], [",", 742], ["NOX1", 744], ["produces", 749], ["superoxide", 758], ["constitutively", 769], ["at", 784], ["low", 787], ["levels", 791], [".", 797], ["These", 799], ["levels", 805], ["can", 812], ["be", 816], ["further", 819], ["increased", 827], ["in", 837], ["a", 840], ["stimulus", 842], ["-", 850], ["dependent", 851], ["manner", 861], [",", 867], ["yet", 869], ["the", 873], ["molecular", 877], ["details", 887], ["regulating", 895], ["this", 906], ["activity", 911], ["are", 920], ["not", 924], ["fully", 928], ["understood", 934], [".", 944], ["Here", 946], ["we", 951], ["present", 954], ["the", 962], ["first", 966], ["quantitative", 972], ["characterization", 985], ["of", 1002], ["the", 1005], ["interactions", 1009], ["made", 1022], ["between", 1027], ["the", 1035], ["cytosolic", 1039], ["regulators", 1049], ["NOXO1", 1060], ["and", 1066], ["NOXA1", 1070], ["and", 1076], ["membrane", 1080], ["-", 1088], ["bound", 1089], ["p22(phox", 1095], [")", 1103], [".", 1104], ["Using", 1106], ["isothermal", 1112], ["titration", 1123], ["calorimetry", 1133], ["we", 1145], ["show", 1148], ["that", 1153], ["the", 1158], ["isolated", 1162], ["tandem", 1171], ["SH3", 1178], ["domains", 1182], ["of", 1190], ["NOXO1", 1193], ["bind", 1199], ["to", 1204], ["p22(phox", 1207], [")", 1215], ["with", 1217], ["high", 1222], ["affinity", 1227], [",", 1235], ["most", 1237], ["likely", 1242], ["adopting", 1249], ["a", 1258], ["superSH3", 1260], ["domain", 1269], ["conformation", 1276], [".", 1288], ["In", 1290], ["contrast", 1293], [",", 1301], ["complex", 1303], ["formation", 1311], ["is", 1321], ["severely", 1324], ["inhibited", 1333], ["in", 1343], ["the", 1346], ["presence", 1350], ["of", 1359], ["the", 1362], ["C", 1366], ["-", 1367], ["terminal", 1368], ["tail", 1377], ["of", 1382], ["NOXO1", 1385], [",", 1390], ["suggesting", 1392], ["that", 1403], ["this", 1408], ["region", 1413], ["competes", 1420], ["for", 1429], ["binding", 1433], ["to", 1441], ["p22(phox", 1444], [")", 1452], ["and", 1454], ["thereby", 1458], ["contributes", 1466], ["to", 1478], ["the", 1481], ["regulation", 1485], ["of", 1496], ["superoxide", 1499], ["production", 1510], [".", 1520], ["Furthermore", 1522], [",", 1533], ["we", 1535], ["provide", 1538], ["data", 1546], ["indicating", 1551], ["that", 1562], ["the", 1567], ["molecular", 1571], ["details", 1581], ["of", 1589], ["the", 1592], ["interaction", 1596], ["between", 1608], ["NOXO1", 1616], ["and", 1622], ["NOXA1", 1626], ["is", 1632], ["significantly", 1635], ["different", 1649], ["from", 1659], ["that", 1664], ["between", 1669], ["the", 1677], ["homologous", 1681], ["proteins", 1692], ["of", 1701], ["the", 1704], ["phagocytic", 1708], ["oxidase", 1719], [",", 1726], ["suggesting", 1728], ["that", 1739], ["there", 1744], ["are", 1750], ["important", 1754], ["functional", 1764], ["differences", 1775], ["between", 1787], ["the", 1795], ["two", 1799], ["systems", 1803], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["study", 1833], ["provides", 1839], ["clear", 1848], ["evidence", 1854], ["that", 1863], ["the", 1868], ["assembly", 1872], ["of", 1881], ["the", 1884], ["NOX1", 1888], ["oxidase", 1893], ["complex", 1901], ["can", 1909], ["be", 1913], ["regulated", 1916], ["through", 1926], ["reversible", 1934], ["protein", 1945], ["-", 1952], ["protein", 1953], ["interactions", 1961], [".", 1973]]}
{"context": "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem. White matter pathology is generally less severe and thought to occur in the brainstem, spinal cord, and cerebellar white matter. Here, we investigated both grey and white matter pathology in a group of 12 SCA3 patients and matched controls. We used voxel-based morphometry for analysis of tissue loss, and tract-based spatial statistics (TBSS) on diffusion magnetic resonance imaging to investigate microstructural pathology. We analysed correlations between microstructural properties of the brain and ataxia severity, as measured by the Scale for the Assessment and Rating of Ataxia (SARA) score. SCA3 patients exhibited significant loss of both grey and white matter in the cerebellar hemispheres, brainstem including pons and in lateral thalamus. On between-group analysis, TBSS detected widespread microstructural white matter pathology in the cerebellum, brainstem, and bilaterally in thalamus and the cerebral hemispheres. Furthermore, fractional anisotropy in a white matter network comprising frontal, thalamic, brainstem and left cerebellar white matter strongly and negatively correlated with SARA ataxia scores. Tractography identified the thalamic white matter thus implicated as belonging to ventrolateral thalamus. Disruption of white matter integrity in patients suffering from SCA3 is more widespread than previously thought. Moreover, our data provide evidence that microstructural white matter changes in SCA3 are strongly related to the clinical severity of ataxia symptoms.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "3b79b6f68f774f36a9a24a3a0960be22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[35, 35]], "char_spans": [[206, 213]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["(", 30], ["SCA3", 31], [")", 35], ["is", 37], ["the", 40], ["most", 44], ["frequent", 49], ["inherited", 58], ["cerebellar", 68], ["ataxia", 79], ["in", 86], ["Europe", 89], [",", 95], ["the", 97], ["US", 101], ["and", 104], ["Japan", 108], [",", 113], ["leading", 115], ["to", 123], ["disability", 126], ["and", 137], ["death", 141], ["through", 147], ["motor", 155], ["complications", 161], [".", 174], ["Although", 176], ["the", 185], ["affected", 189], ["protein", 198], ["ataxin-3", 206], ["is", 215], ["found", 218], ["ubiquitously", 224], ["in", 237], ["the", 240], ["brain", 244], [",", 249], ["grey", 251], ["matter", 256], ["atrophy", 263], ["is", 271], ["predominant", 274], ["in", 286], ["the", 289], ["cerebellum", 293], ["and", 304], ["the", 308], ["brainstem", 312], [".", 321], ["White", 323], ["matter", 329], ["pathology", 336], ["is", 346], ["generally", 349], ["less", 359], ["severe", 364], ["and", 371], ["thought", 375], ["to", 383], ["occur", 386], ["in", 392], ["the", 395], ["brainstem", 399], [",", 408], ["spinal", 410], ["cord", 417], [",", 421], ["and", 423], ["cerebellar", 427], ["white", 438], ["matter", 444], [".", 450], ["Here", 452], [",", 456], ["we", 458], ["investigated", 461], ["both", 474], ["grey", 479], ["and", 484], ["white", 488], ["matter", 494], ["pathology", 501], ["in", 511], ["a", 514], ["group", 516], ["of", 522], ["12", 525], ["SCA3", 528], ["patients", 533], ["and", 542], ["matched", 546], ["controls", 554], [".", 562], ["We", 564], ["used", 567], ["voxel", 572], ["-", 577], ["based", 578], ["morphometry", 584], ["for", 596], ["analysis", 600], ["of", 609], ["tissue", 612], ["loss", 619], [",", 623], ["and", 625], ["tract", 629], ["-", 634], ["based", 635], ["spatial", 641], ["statistics", 649], ["(", 660], ["TBSS", 661], [")", 665], ["on", 667], ["diffusion", 670], ["magnetic", 680], ["resonance", 689], ["imaging", 699], ["to", 707], ["investigate", 710], ["microstructural", 722], ["pathology", 738], [".", 747], ["We", 749], ["analysed", 752], ["correlations", 761], ["between", 774], ["microstructural", 782], ["properties", 798], ["of", 809], ["the", 812], ["brain", 816], ["and", 822], ["ataxia", 826], ["severity", 833], [",", 841], ["as", 843], ["measured", 846], ["by", 855], ["the", 858], ["Scale", 862], ["for", 868], ["the", 872], ["Assessment", 876], ["and", 887], ["Rating", 891], ["of", 898], ["Ataxia", 901], ["(", 908], ["SARA", 909], [")", 913], ["score", 915], [".", 920], ["SCA3", 922], ["patients", 927], ["exhibited", 936], ["significant", 946], ["loss", 958], ["of", 963], ["both", 966], ["grey", 971], ["and", 976], ["white", 980], ["matter", 986], ["in", 993], ["the", 996], ["cerebellar", 1000], ["hemispheres", 1011], [",", 1022], ["brainstem", 1024], ["including", 1034], ["pons", 1044], ["and", 1049], ["in", 1053], ["lateral", 1056], ["thalamus", 1064], [".", 1072], ["On", 1074], ["between", 1077], ["-", 1084], ["group", 1085], ["analysis", 1091], [",", 1099], ["TBSS", 1101], ["detected", 1106], ["widespread", 1115], ["microstructural", 1126], ["white", 1142], ["matter", 1148], ["pathology", 1155], ["in", 1165], ["the", 1168], ["cerebellum", 1172], [",", 1182], ["brainstem", 1184], [",", 1193], ["and", 1195], ["bilaterally", 1199], ["in", 1211], ["thalamus", 1214], ["and", 1223], ["the", 1227], ["cerebral", 1231], ["hemispheres", 1240], [".", 1251], ["Furthermore", 1253], [",", 1264], ["fractional", 1266], ["anisotropy", 1277], ["in", 1288], ["a", 1291], ["white", 1293], ["matter", 1299], ["network", 1306], ["comprising", 1314], ["frontal", 1325], [",", 1332], ["thalamic", 1334], [",", 1342], ["brainstem", 1344], ["and", 1354], ["left", 1358], ["cerebellar", 1363], ["white", 1374], ["matter", 1380], ["strongly", 1387], ["and", 1396], ["negatively", 1400], ["correlated", 1411], ["with", 1422], ["SARA", 1427], ["ataxia", 1432], ["scores", 1439], [".", 1445], ["Tractography", 1447], ["identified", 1460], ["the", 1471], ["thalamic", 1475], ["white", 1484], ["matter", 1490], ["thus", 1497], ["implicated", 1502], ["as", 1513], ["belonging", 1516], ["to", 1526], ["ventrolateral", 1529], ["thalamus", 1543], [".", 1551], ["Disruption", 1553], ["of", 1564], ["white", 1567], ["matter", 1573], ["integrity", 1580], ["in", 1590], ["patients", 1593], ["suffering", 1602], ["from", 1612], ["SCA3", 1617], ["is", 1622], ["more", 1625], ["widespread", 1630], ["than", 1641], ["previously", 1646], ["thought", 1657], [".", 1664], ["Moreover", 1666], [",", 1674], ["our", 1676], ["data", 1680], ["provide", 1685], ["evidence", 1693], ["that", 1702], ["microstructural", 1707], ["white", 1723], ["matter", 1729], ["changes", 1736], ["in", 1744], ["SCA3", 1747], ["are", 1752], ["strongly", 1756], ["related", 1765], ["to", 1773], ["the", 1776], ["clinical", 1780], ["severity", 1789], ["of", 1798], ["ataxia", 1801], ["symptoms", 1808], [".", 1816]]}
{"context": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome, a highly complex and dynamic macromolecular machine composed of RNA and protein. Because of its complexity, biochemical analysis of the spliceosome has been previously limited to bulk assays in largely unfractionated cell extracts. We now report development of methodologies for studying the splicing of isolated single pre-mRNA molecules in real time. In this system, a fluorescently tagged pre-mRNA is tethered to a glass surface via its 3'-end. Splicing can be observed in Saccharomyces cerevisiae whole cell extract by monitoring loss of intron-specific fluorescence with a multi-wavelength total internal reflection fluorescence (TIRF) microscope. To prolong fluorophore lifetime, two enzyme-based O2 scavenging systems compatible with splicing were also developed. This work provides a powerful new approach for elucidating the mechanisms of spliceosome function and demonstrates the feasibility of utilizing TIRF microscopy for biochemical studies of single molecules in highly complex environments.", "qas": [{"question": "What is the function of the spliceosome complex?", "answers": ["The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome."], "qid": "59b8dc15064f45a0b670dacf91a6101a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["the", 24], ["spliceosome", 28], ["complex", 40], ["?", 47]], "detected_answers": [{"text": "The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome.", "token_spans": [[1, 12]], "char_spans": [[4, 90]]}]}], "context_tokens": [["The", 0], ["excision", 4], ["of", 13], ["introns", 16], ["from", 24], ["nascent", 29], ["eukaryotic", 37], ["transcripts", 48], ["is", 60], ["catalyzed", 63], ["by", 73], ["the", 76], ["spliceosome", 80], [",", 91], ["a", 93], ["highly", 95], ["complex", 102], ["and", 110], ["dynamic", 114], ["macromolecular", 122], ["machine", 137], ["composed", 145], ["of", 154], ["RNA", 157], ["and", 161], ["protein", 165], [".", 172], ["Because", 174], ["of", 182], ["its", 185], ["complexity", 189], [",", 199], ["biochemical", 201], ["analysis", 213], ["of", 222], ["the", 225], ["spliceosome", 229], ["has", 241], ["been", 245], ["previously", 250], ["limited", 261], ["to", 269], ["bulk", 272], ["assays", 277], ["in", 284], ["largely", 287], ["unfractionated", 295], ["cell", 310], ["extracts", 315], [".", 323], ["We", 325], ["now", 328], ["report", 332], ["development", 339], ["of", 351], ["methodologies", 354], ["for", 368], ["studying", 372], ["the", 381], ["splicing", 385], ["of", 394], ["isolated", 397], ["single", 406], ["pre", 413], ["-", 416], ["mRNA", 417], ["molecules", 422], ["in", 432], ["real", 435], ["time", 440], [".", 444], ["In", 446], ["this", 449], ["system", 454], [",", 460], ["a", 462], ["fluorescently", 464], ["tagged", 478], ["pre", 485], ["-", 488], ["mRNA", 489], ["is", 494], ["tethered", 497], ["to", 506], ["a", 509], ["glass", 511], ["surface", 517], ["via", 525], ["its", 529], ["3'-end", 533], [".", 539], ["Splicing", 541], ["can", 550], ["be", 554], ["observed", 557], ["in", 566], ["Saccharomyces", 569], ["cerevisiae", 583], ["whole", 594], ["cell", 600], ["extract", 605], ["by", 613], ["monitoring", 616], ["loss", 627], ["of", 632], ["intron", 635], ["-", 641], ["specific", 642], ["fluorescence", 651], ["with", 664], ["a", 669], ["multi", 671], ["-", 676], ["wavelength", 677], ["total", 688], ["internal", 694], ["reflection", 703], ["fluorescence", 714], ["(", 727], ["TIRF", 728], [")", 732], ["microscope", 734], [".", 744], ["To", 746], ["prolong", 749], ["fluorophore", 757], ["lifetime", 769], [",", 777], ["two", 779], ["enzyme", 783], ["-", 789], ["based", 790], ["O2", 796], ["scavenging", 799], ["systems", 810], ["compatible", 818], ["with", 829], ["splicing", 834], ["were", 843], ["also", 848], ["developed", 853], [".", 862], ["This", 864], ["work", 869], ["provides", 874], ["a", 883], ["powerful", 885], ["new", 894], ["approach", 898], ["for", 907], ["elucidating", 911], ["the", 923], ["mechanisms", 927], ["of", 938], ["spliceosome", 941], ["function", 953], ["and", 962], ["demonstrates", 966], ["the", 979], ["feasibility", 983], ["of", 995], ["utilizing", 998], ["TIRF", 1008], ["microscopy", 1013], ["for", 1024], ["biochemical", 1028], ["studies", 1040], ["of", 1048], ["single", 1051], ["molecules", 1058], ["in", 1068], ["highly", 1071], ["complex", 1078], ["environments", 1086], [".", 1098]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2'-O-methyl phosphorothioate has demonstrated the capability to induce dystrophin expression in Duchenne muscular dystrophy (DMD) patients in phase II-III clinical trials with benefit in muscle functions. However, potential of the therapy for DMD at different stages of the disease progression is not understood. In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis. Biweekly intravenous (i.v.) administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. This was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. However, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started. The PPMO treatment alleviated the disease pathology and significantly prolonged the life span of the mice receiving treatment at younger age with mild phenotype. However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage. The results could be critical for design of clinical trials with antisense therapy to DMD.", "qas": [{"question": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "answers": ["100%"], "qid": "d6fb14e3be8245baaf66693d4b546e8f", "question_tokens": [["In", 0], ["what", 3], ["percentage", 8], ["of", 19], ["skeletal", 22], ["muscle", 31], ["fibers", 38], ["is", 45], ["dystrophin", 48], ["expression", 59], ["restored", 70], ["after", 79], ["PPMO-", 85], ["mediated", 91], ["exon", 100], ["skipping", 105], ["?", 113]], "detected_answers": [{"text": "100%", "token_spans": [[145, 145]], "char_spans": [[802, 804]]}]}], "context_tokens": [["Antisense", 0], ["therapy", 10], ["with", 18], ["both", 23], ["chemistries", 28], ["of", 40], ["phosphorodiamidate", 43], ["morpholino", 62], ["oligomers", 73], ["(", 83], ["PMOs", 84], [")", 88], ["and", 90], ["2'-O", 94], ["-", 98], ["methyl", 99], ["phosphorothioate", 106], ["has", 123], ["demonstrated", 127], ["the", 140], ["capability", 144], ["to", 155], ["induce", 158], ["dystrophin", 165], ["expression", 176], ["in", 187], ["Duchenne", 190], ["muscular", 199], ["dystrophy", 208], ["(", 218], ["DMD", 219], [")", 222], ["patients", 224], ["in", 233], ["phase", 236], ["II", 242], ["-", 244], ["III", 245], ["clinical", 249], ["trials", 258], ["with", 265], ["benefit", 270], ["in", 278], ["muscle", 281], ["functions", 288], [".", 297], ["However", 299], [",", 306], ["potential", 308], ["of", 318], ["the", 321], ["therapy", 325], ["for", 333], ["DMD", 337], ["at", 341], ["different", 344], ["stages", 354], ["of", 361], ["the", 364], ["disease", 368], ["progression", 376], ["is", 388], ["not", 391], ["understood", 395], [".", 405], ["In", 407], ["this", 410], ["study", 415], [",", 420], ["we", 422], ["examined", 425], ["the", 434], ["effect", 438], ["of", 445], ["peptide", 448], ["-", 455], ["conjugated", 456], ["PMO", 467], ["(", 471], ["PPMO)-mediated", 472], ["exon", 487], ["skipping", 492], ["on", 501], ["disease", 504], ["progression", 512], ["of", 524], ["utrophin", 527], ["-", 535], ["dystrophin", 536], ["-", 546], ["deficient", 547], ["mice", 557], ["(", 562], ["dko", 563], [")", 566], ["of", 568], ["four", 571], ["age", 576], ["groups", 580], ["(", 587], ["21", 588], ["-", 590], ["29", 591], [",", 593], ["30", 595], ["-", 597], ["39", 598], [",", 600], ["40", 602], ["-", 604], ["49", 605], ["and", 608], ["50", 612], ["+", 614], ["days", 616], [")", 620], [",", 621], ["representing", 623], ["diseases", 636], ["from", 645], ["early", 650], ["stage", 656], ["to", 662], ["advanced", 665], ["stage", 674], ["with", 680], ["severe", 685], ["kyphosis", 692], [".", 700], ["Biweekly", 702], ["intravenous", 711], ["(", 723], ["i.v", 724], [".", 727], [")", 728], ["administration", 730], ["of", 745], ["the", 748], ["PPMO", 752], ["restored", 757], ["the", 766], ["dystrophin", 770], ["expression", 781], ["in", 792], ["nearly", 795], ["100", 802], ["%", 805], ["skeletal", 807], ["muscle", 816], ["fibers", 823], ["in", 830], ["all", 833], ["age", 837], ["groups", 841], [".", 847], ["This", 849], ["was", 854], ["associated", 858], ["with", 869], ["the", 874], ["restoration", 878], ["of", 890], ["dystrophin", 893], ["-", 903], ["associated", 904], ["proteins", 915], ["including", 924], ["functional", 934], ["glycosylated", 945], ["dystroglycan", 958], ["and", 971], ["neuronal", 975], ["nitric", 984], ["synthase", 991], [".", 999], ["However", 1001], [",", 1008], ["therapeutic", 1010], ["outcomes", 1022], ["clearly", 1031], ["depended", 1039], ["on", 1048], ["severity", 1051], ["of", 1060], ["the", 1063], ["disease", 1067], ["at", 1075], ["the", 1078], ["time", 1082], ["the", 1087], ["treatment", 1091], ["started", 1101], [".", 1108], ["The", 1110], ["PPMO", 1114], ["treatment", 1119], ["alleviated", 1129], ["the", 1140], ["disease", 1144], ["pathology", 1152], ["and", 1162], ["significantly", 1166], ["prolonged", 1180], ["the", 1190], ["life", 1194], ["span", 1199], ["of", 1204], ["the", 1207], ["mice", 1211], ["receiving", 1216], ["treatment", 1226], ["at", 1236], ["younger", 1239], ["age", 1247], ["with", 1251], ["mild", 1256], ["phenotype", 1261], [".", 1270], ["However", 1272], [",", 1279], ["restoration", 1281], ["of", 1293], ["high", 1296], ["levels", 1301], ["of", 1308], ["dystrophin", 1311], ["expression", 1322], ["failed", 1333], ["to", 1340], ["prevent", 1343], ["disease", 1351], ["progression", 1359], ["to", 1371], ["the", 1374], ["mice", 1378], ["receiving", 1383], ["treatment", 1393], ["when", 1403], ["disease", 1408], ["was", 1416], ["already", 1420], ["at", 1428], ["advanced", 1431], ["stage", 1440], [".", 1445], ["The", 1447], ["results", 1451], ["could", 1459], ["be", 1465], ["critical", 1468], ["for", 1477], ["design", 1481], ["of", 1488], ["clinical", 1491], ["trials", 1500], ["with", 1507], ["antisense", 1512], ["therapy", 1522], ["to", 1530], ["DMD", 1533], [".", 1536]]}
{"context": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation of Na(+) in one direction with that of Ca(2+) in the opposite direction. This system contributes to the regulation of intracellular Ca(2+) concentration via the forward mode (Ca(2+) efflux) or the reverse mode (Ca(2+) influx). We have previously demonstrated that the Ca(2+) paradox, an in vitro reperfusion model, causes the sustained activation of the reverse mode of the NCX, the disruption of Ca(2+) homeostasis, and subsequent delayed apoptotic-like death in astrocytes. In addition, we found that the nitric oxide (NO)-cyclic GMP signaling pathway inhibits Ca(2+) paradox-mediated astrocyte apoptosis, while a high concentration of NO induces cytotoxicity. In this way, Ca(2+) and NO may work together in the pathogenesis of several cells in the central nervous system. Concerning the role of NCX in NO cytotoxicity, we have found, using the specific inhibitor of NCX 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), that NCX is involved in NO-induced cytotoxicity in cultured microglia, astrocytes, and neuronal cells. This review summarizes the pathological roles of the NCX as a new target for NO-mediated cellular toxicity, based on our studies on NO-NCX-mediated glial toxicity.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "5658da3cc5b84d219d6f6991552febf0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[3, 6]], "char_spans": [[20, 41]]}, {"text": "NCX", "token_spans": [[96, 96], [224, 224], [243, 243], [177, 177], [198, 198], [8, 8], [191, 191]], "char_spans": [[489, 491], [1215, 1217], [1297, 1299], [914, 916], [1064, 1066], [44, 46], [985, 987]]}]}], "context_tokens": [["The", 0], ["plasma", 4], ["membrane", 11], ["Na(+)/Ca(2", 20], ["+", 30], [")", 31], ["exchanger", 33], ["(", 43], ["NCX", 44], [")", 47], ["is", 49], ["a", 52], ["bidirectional", 54], ["ion", 68], ["transporter", 72], ["that", 84], ["couples", 89], ["the", 97], ["translocation", 101], ["of", 115], ["Na(+", 118], [")", 122], ["in", 124], ["one", 127], ["direction", 131], ["with", 141], ["that", 146], ["of", 151], ["Ca(2", 154], ["+", 158], [")", 159], ["in", 161], ["the", 164], ["opposite", 168], ["direction", 177], [".", 186], ["This", 188], ["system", 193], ["contributes", 200], ["to", 212], ["the", 215], ["regulation", 219], ["of", 230], ["intracellular", 233], ["Ca(2", 247], ["+", 251], [")", 252], ["concentration", 254], ["via", 268], ["the", 272], ["forward", 276], ["mode", 284], ["(", 289], ["Ca(2", 290], ["+", 294], [")", 295], ["efflux", 297], [")", 303], ["or", 305], ["the", 308], ["reverse", 312], ["mode", 320], ["(", 325], ["Ca(2", 326], ["+", 330], [")", 331], ["influx", 333], [")", 339], [".", 340], ["We", 342], ["have", 345], ["previously", 350], ["demonstrated", 361], ["that", 374], ["the", 379], ["Ca(2", 383], ["+", 387], [")", 388], ["paradox", 390], [",", 397], ["an", 399], ["in", 402], ["vitro", 405], ["reperfusion", 411], ["model", 423], [",", 428], ["causes", 430], ["the", 437], ["sustained", 441], ["activation", 451], ["of", 462], ["the", 465], ["reverse", 469], ["mode", 477], ["of", 482], ["the", 485], ["NCX", 489], [",", 492], ["the", 494], ["disruption", 498], ["of", 509], ["Ca(2", 512], ["+", 516], [")", 517], ["homeostasis", 519], [",", 530], ["and", 532], ["subsequent", 536], ["delayed", 547], ["apoptotic", 555], ["-", 564], ["like", 565], ["death", 570], ["in", 576], ["astrocytes", 579], [".", 589], ["In", 591], ["addition", 594], [",", 602], ["we", 604], ["found", 607], ["that", 613], ["the", 618], ["nitric", 622], ["oxide", 629], ["(", 635], ["NO)-cyclic", 636], ["GMP", 647], ["signaling", 651], ["pathway", 661], ["inhibits", 669], ["Ca(2", 678], ["+", 682], [")", 683], ["paradox", 685], ["-", 692], ["mediated", 693], ["astrocyte", 702], ["apoptosis", 712], [",", 721], ["while", 723], ["a", 729], ["high", 731], ["concentration", 736], ["of", 750], ["NO", 753], ["induces", 756], ["cytotoxicity", 764], [".", 776], ["In", 778], ["this", 781], ["way", 786], [",", 789], ["Ca(2", 791], ["+", 795], [")", 796], ["and", 798], ["NO", 802], ["may", 805], ["work", 809], ["together", 814], ["in", 823], ["the", 826], ["pathogenesis", 830], ["of", 843], ["several", 846], ["cells", 854], ["in", 860], ["the", 863], ["central", 867], ["nervous", 875], ["system", 883], [".", 889], ["Concerning", 891], ["the", 902], ["role", 906], ["of", 911], ["NCX", 914], ["in", 918], ["NO", 921], ["cytotoxicity", 924], [",", 936], ["we", 938], ["have", 941], ["found", 946], [",", 951], ["using", 953], ["the", 959], ["specific", 963], ["inhibitor", 972], ["of", 982], ["NCX", 985], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 989], ["(", 1048], ["SEA0400", 1049], [")", 1056], [",", 1057], ["that", 1059], ["NCX", 1064], ["is", 1068], ["involved", 1071], ["in", 1080], ["NO", 1083], ["-", 1085], ["induced", 1086], ["cytotoxicity", 1094], ["in", 1107], ["cultured", 1110], ["microglia", 1119], [",", 1128], ["astrocytes", 1130], [",", 1140], ["and", 1142], ["neuronal", 1146], ["cells", 1155], [".", 1160], ["This", 1162], ["review", 1167], ["summarizes", 1174], ["the", 1185], ["pathological", 1189], ["roles", 1202], ["of", 1208], ["the", 1211], ["NCX", 1215], ["as", 1219], ["a", 1222], ["new", 1224], ["target", 1228], ["for", 1235], ["NO", 1239], ["-", 1241], ["mediated", 1242], ["cellular", 1251], ["toxicity", 1260], [",", 1268], ["based", 1270], ["on", 1276], ["our", 1279], ["studies", 1283], ["on", 1291], ["NO", 1294], ["-", 1296], ["NCX", 1297], ["-", 1300], ["mediated", 1301], ["glial", 1310], ["toxicity", 1316], [".", 1324]]}
{"context": "This case report is about an elderly man who presented with a long-standing history of high-grade fever and weight loss. He initially had only hepatosplenomegaly, but then developed jaundice. He also had pancytopenia and raised liver enzymes. His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus. The liver biopsy showed sinusoidal phagocytosis and the subsequent bone marrow aspiration and biopsy showed significant hemophagocytosis, hence Hemophagocytic syndrome was diagnosed. The fever was refractory to antibiotic and anti-tuberculosis therapy, but it responded only partially to steroids. Full response was only noticed following anti-viral treatment in the form of intravenous Ganciclovir. The patient's general condition, liver enzymes, bilirubin, hematological parameters and even the weight returned back to their normal range 2 weeks after Ganciclovir therapy. Cessation of this drug resulted in relapse of his symptoms and oral antivirals did not help. Splenectomy, steroid pulse therapy and immunosuppressive treatment were only partially helpful. Reintroduction of Ganciclovir did help for a short period. We conclude that our patient had virus-associated hemophagocytic syndrome most likely related to Epstein-Barr virus infection, which was then confirmed by the splenic biopsy, and that Ganciclovir can be of great help in eradicating the virus and treating the disease, provided that it is given for a long enough period.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "27f01386fc37446ab4eaa091c48db4f9", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[62, 65], [212, 215]], "char_spans": [[336, 353], [1276, 1293]]}]}], "context_tokens": [["This", 0], ["case", 5], ["report", 10], ["is", 17], ["about", 20], ["an", 26], ["elderly", 29], ["man", 37], ["who", 41], ["presented", 45], ["with", 55], ["a", 60], ["long", 62], ["-", 66], ["standing", 67], ["history", 76], ["of", 84], ["high", 87], ["-", 91], ["grade", 92], ["fever", 98], ["and", 104], ["weight", 108], ["loss", 115], [".", 119], ["He", 121], ["initially", 124], ["had", 134], ["only", 138], ["hepatosplenomegaly", 143], [",", 161], ["but", 163], ["then", 167], ["developed", 172], ["jaundice", 182], [".", 190], ["He", 192], ["also", 195], ["had", 200], ["pancytopenia", 204], ["and", 217], ["raised", 221], ["liver", 228], ["enzymes", 234], [".", 241], ["His", 243], ["septic", 247], ["screen", 254], ["was", 261], ["negative", 265], [",", 273], ["but", 275], ["he", 279], ["had", 282], ["a", 286], ["positive", 288], ["Monospot", 297], ["test", 306], ["and", 311], ["immunoglobulin", 315], ["G", 330], ["for", 332], ["Epstein", 336], ["-", 343], ["Barr", 344], ["virus", 349], [".", 354], ["The", 356], ["liver", 360], ["biopsy", 366], ["showed", 373], ["sinusoidal", 380], ["phagocytosis", 391], ["and", 404], ["the", 408], ["subsequent", 412], ["bone", 423], ["marrow", 428], ["aspiration", 435], ["and", 446], ["biopsy", 450], ["showed", 457], ["significant", 464], ["hemophagocytosis", 476], [",", 492], ["hence", 494], ["Hemophagocytic", 500], ["syndrome", 515], ["was", 524], ["diagnosed", 528], [".", 537], ["The", 539], ["fever", 543], ["was", 549], ["refractory", 553], ["to", 564], ["antibiotic", 567], ["and", 578], ["anti", 582], ["-", 586], ["tuberculosis", 587], ["therapy", 600], [",", 607], ["but", 609], ["it", 613], ["responded", 616], ["only", 626], ["partially", 631], ["to", 641], ["steroids", 644], [".", 652], ["Full", 654], ["response", 659], ["was", 668], ["only", 672], ["noticed", 677], ["following", 685], ["anti", 695], ["-", 699], ["viral", 700], ["treatment", 706], ["in", 716], ["the", 719], ["form", 723], ["of", 728], ["intravenous", 731], ["Ganciclovir", 743], [".", 754], ["The", 756], ["patient", 760], ["'s", 767], ["general", 770], ["condition", 778], [",", 787], ["liver", 789], ["enzymes", 795], [",", 802], ["bilirubin", 804], [",", 813], ["hematological", 815], ["parameters", 829], ["and", 840], ["even", 844], ["the", 849], ["weight", 853], ["returned", 860], ["back", 869], ["to", 874], ["their", 877], ["normal", 883], ["range", 890], ["2", 896], ["weeks", 898], ["after", 904], ["Ganciclovir", 910], ["therapy", 922], [".", 929], ["Cessation", 931], ["of", 941], ["this", 944], ["drug", 949], ["resulted", 954], ["in", 963], ["relapse", 966], ["of", 974], ["his", 977], ["symptoms", 981], ["and", 990], ["oral", 994], ["antivirals", 999], ["did", 1010], ["not", 1014], ["help", 1018], [".", 1022], ["Splenectomy", 1024], [",", 1035], ["steroid", 1037], ["pulse", 1045], ["therapy", 1051], ["and", 1059], ["immunosuppressive", 1063], ["treatment", 1081], ["were", 1091], ["only", 1096], ["partially", 1101], ["helpful", 1111], [".", 1118], ["Reintroduction", 1120], ["of", 1135], ["Ganciclovir", 1138], ["did", 1150], ["help", 1154], ["for", 1159], ["a", 1163], ["short", 1165], ["period", 1171], [".", 1177], ["We", 1179], ["conclude", 1182], ["that", 1191], ["our", 1196], ["patient", 1200], ["had", 1208], ["virus", 1212], ["-", 1217], ["associated", 1218], ["hemophagocytic", 1229], ["syndrome", 1244], ["most", 1253], ["likely", 1258], ["related", 1265], ["to", 1273], ["Epstein", 1276], ["-", 1283], ["Barr", 1284], ["virus", 1289], ["infection", 1295], [",", 1304], ["which", 1306], ["was", 1312], ["then", 1316], ["confirmed", 1321], ["by", 1331], ["the", 1334], ["splenic", 1338], ["biopsy", 1346], [",", 1352], ["and", 1354], ["that", 1358], ["Ganciclovir", 1363], ["can", 1375], ["be", 1379], ["of", 1382], ["great", 1385], ["help", 1391], ["in", 1396], ["eradicating", 1399], ["the", 1411], ["virus", 1415], ["and", 1421], ["treating", 1425], ["the", 1434], ["disease", 1438], [",", 1445], ["provided", 1447], ["that", 1456], ["it", 1461], ["is", 1464], ["given", 1467], ["for", 1473], ["a", 1477], ["long", 1479], ["enough", 1484], ["period", 1491], [".", 1497]]}
{"context": "Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib. Dasatinib also inhibits many Src-family tyrosine kinases. We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clinically relevant concentrations. T-cell functions including proliferation, activation and cytokine production were all uniformly inhibited in the presence of dasatinib. We also demonstrated inhibition of TCR signalling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signalling by dasatinib is responsible for the suppression of T-cell function. These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "5b937d99df5342ca8ffb9a12ec8714ce", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[50, 50]], "char_spans": [[300, 307]]}]}], "context_tokens": [["Dasatinib", 0], ["(", 10], ["BMS-354825", 11], [")", 21], ["is", 23], ["a", 26], ["Src", 28], ["/", 31], ["ABL", 32], ["tyrosine", 36], ["kinase", 45], ["inhibitor", 52], ["currently", 62], ["approved", 72], ["for", 81], ["the", 85], ["treatment", 89], ["of", 99], ["chronic", 102], ["myeloid", 110], ["leukemia", 118], [".", 126], ["Dasatinib", 128], ["has", 138], ["increased", 142], ["potency", 152], ["against", 160], ["ABL", 168], ["compared", 172], ["to", 181], ["the", 184], ["current", 188], ["therapy", 196], ["imatinib", 204], [",", 212], ["and", 214], ["is", 218], ["effective", 221], ["in", 231], ["many", 234], ["cases", 239], ["where", 245], ["disease", 251], ["is", 259], ["resistant", 262], ["to", 272], ["imatinib", 275], [".", 283], ["Dasatinib", 285], ["also", 295], ["inhibits", 300], ["many", 309], ["Src", 314], ["-", 317], ["family", 318], ["tyrosine", 325], ["kinases", 334], [".", 341], ["We", 343], ["have", 346], ["demonstrated", 351], ["in", 364], ["this", 367], ["study", 372], ["that", 378], ["dasatinib", 383], ["is", 393], ["able", 396], ["to", 401], ["block", 404], ["the", 410], ["function", 414], ["of", 423], ["normal", 426], ["human", 433], ["T", 439], ["-", 440], ["lymphocytes", 441], ["in", 453], ["vitro", 456], ["at", 462], ["clinically", 465], ["relevant", 476], ["concentrations", 485], [".", 499], ["T", 501], ["-", 502], ["cell", 503], ["functions", 508], ["including", 518], ["proliferation", 528], [",", 541], ["activation", 543], ["and", 554], ["cytokine", 558], ["production", 567], ["were", 578], ["all", 583], ["uniformly", 587], ["inhibited", 597], ["in", 607], ["the", 610], ["presence", 614], ["of", 623], ["dasatinib", 626], [".", 635], ["We", 637], ["also", 640], ["demonstrated", 645], ["inhibition", 658], ["of", 669], ["TCR", 672], ["signalling", 676], ["through", 687], ["Src", 695], ["-", 698], ["family", 699], ["kinase", 706], ["LCK", 713], [",", 716], ["and", 718], ["predicted", 722], ["that", 732], ["inhibition", 737], ["of", 748], ["LCK", 751], ["and", 755], ["other", 759], ["kinases", 765], ["involved", 773], ["in", 782], ["T", 785], ["-", 786], ["cell", 787], ["signalling", 792], ["by", 803], ["dasatinib", 806], ["is", 816], ["responsible", 819], ["for", 831], ["the", 835], ["suppression", 839], ["of", 851], ["T", 854], ["-", 855], ["cell", 856], ["function", 861], [".", 869], ["These", 871], ["findings", 877], ["raise", 886], ["the", 892], ["concern", 896], ["about", 904], ["potential", 910], ["T", 920], ["-", 921], ["cell", 922], ["inhibition", 927], ["in", 938], ["patients", 941], ["taking", 950], ["dasatinib", 957], [",", 966], ["and", 968], ["suggest", 972], ["a", 980], ["possible", 982], ["application", 991], ["for", 1003], ["the", 1007], ["treatment", 1011], ["of", 1021], ["T", 1024], ["-", 1025], ["cell", 1026], ["mediated", 1031], ["immune", 1040], ["disorders", 1047], [".", 1056]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "Spleen tyrosine kinase (Syk) is an important modulator of immune signaling. The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy. We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-month, double-blind, placebo-controlled trial. The primary outcome was the American College of Rheumatology (ACR) 20 response (which indicates at least a 20% reduction in the number of both tender and swollen joints and improvement in at least three of five other criteria) at month 6. R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, respectively, vs. 35%; P<0.001 for the comparison of both doses with placebo). It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.007 for the comparison of the 150-mg dose with placebo) and ACR 70 (28% and 14% vs. 10%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.34 for the comparison of the 150-mg dose with placebo). A clinically significant effect was noted by the end of the first week of treatment. Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (6% vs. 1%). R788 was associated with an increase in systolic blood pressure of approximately 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy. In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.)", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "f793e627a2a246e4bdb80b8e39f246c4", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["an", 32], ["important", 35], ["modulator", 45], ["of", 55], ["immune", 58], ["signaling", 65], [".", 74], ["The", 76], ["objective", 80], ["of", 90], ["this", 93], ["phase", 98], ["2", 104], ["study", 106], ["was", 112], ["to", 116], ["evaluate", 119], ["the", 128], ["efficacy", 132], ["and", 141], ["safety", 145], ["of", 152], ["R788", 155], [",", 159], ["an", 161], ["oral", 164], ["inhibitor", 169], ["of", 179], ["Syk", 182], [",", 185], ["in", 187], ["patients", 190], ["with", 199], ["active", 204], ["rheumatoid", 211], ["arthritis", 222], ["despite", 232], ["methotrexate", 240], ["therapy", 253], [".", 260], ["We", 262], ["enrolled", 265], ["457", 274], ["patients", 278], ["who", 287], ["had", 291], ["active", 295], ["rheumatoid", 302], ["arthritis", 313], ["despite", 323], ["long", 331], ["-", 335], ["term", 336], ["methotrexate", 341], ["therapy", 354], ["in", 362], ["a", 365], ["6-month", 367], [",", 374], ["double", 376], ["-", 382], ["blind", 383], [",", 388], ["placebo", 390], ["-", 397], ["controlled", 398], ["trial", 409], [".", 414], ["The", 416], ["primary", 420], ["outcome", 428], ["was", 436], ["the", 440], ["American", 444], ["College", 453], ["of", 461], ["Rheumatology", 464], ["(", 477], ["ACR", 478], [")", 481], ["20", 483], ["response", 486], ["(", 495], ["which", 496], ["indicates", 502], ["at", 512], ["least", 515], ["a", 521], ["20", 523], ["%", 525], ["reduction", 527], ["in", 537], ["the", 540], ["number", 544], ["of", 551], ["both", 554], ["tender", 559], ["and", 566], ["swollen", 570], ["joints", 578], ["and", 585], ["improvement", 589], ["in", 601], ["at", 604], ["least", 607], ["three", 613], ["of", 619], ["five", 622], ["other", 627], ["criteria", 633], [")", 641], ["at", 643], ["month", 646], ["6", 652], [".", 653], ["R788", 655], [",", 659], ["at", 661], ["a", 664], ["dose", 666], ["of", 671], ["100", 674], ["mg", 678], ["twice", 681], ["daily", 687], ["and", 693], ["at", 697], ["a", 700], ["dose", 702], ["of", 707], ["150", 710], ["mg", 714], ["once", 717], ["daily", 722], [",", 727], ["was", 729], ["significantly", 733], ["superior", 747], ["to", 756], ["placebo", 759], ["at", 767], ["month", 770], ["6", 776], ["(", 778], ["ACR", 779], ["20", 783], ["response", 786], ["rates", 795], ["of", 801], ["67", 804], ["%", 806], ["and", 808], ["57", 812], ["%", 814], [",", 815], ["respectively", 817], [",", 829], ["vs.", 831], ["35", 835], ["%", 837], [";", 838], ["P<0.001", 840], ["for", 848], ["the", 852], ["comparison", 856], ["of", 867], ["both", 870], ["doses", 875], ["with", 881], ["placebo", 886], [")", 893], [".", 894], ["It", 896], ["was", 899], ["also", 903], ["significantly", 908], ["superior", 922], ["with", 931], ["respect", 936], ["to", 944], ["ACR", 947], ["50", 951], [",", 953], ["which", 955], ["indicates", 961], ["at", 971], ["least", 974], ["a", 980], ["50", 982], ["%", 984], ["improvement", 986], ["(", 998], ["43", 999], ["%", 1001], ["and", 1003], ["32", 1007], ["%", 1009], ["vs.", 1011], ["19", 1015], ["%", 1017], [";", 1018], ["P<0.001", 1020], ["for", 1028], ["the", 1032], ["comparison", 1036], ["of", 1047], ["the", 1050], ["100-mg", 1054], ["dose", 1061], ["with", 1066], ["placebo", 1071], [",", 1078], ["P=0.007", 1080], ["for", 1088], ["the", 1092], ["comparison", 1096], ["of", 1107], ["the", 1110], ["150-mg", 1114], ["dose", 1121], ["with", 1126], ["placebo", 1131], [")", 1138], ["and", 1140], ["ACR", 1144], ["70", 1148], ["(", 1151], ["28", 1152], ["%", 1154], ["and", 1156], ["14", 1160], ["%", 1162], ["vs.", 1164], ["10", 1168], ["%", 1170], [";", 1171], ["P<0.001", 1173], ["for", 1181], ["the", 1185], ["comparison", 1189], ["of", 1200], ["the", 1203], ["100-mg", 1207], ["dose", 1214], ["with", 1219], ["placebo", 1224], [",", 1231], ["P=0.34", 1233], ["for", 1240], ["the", 1244], ["comparison", 1248], ["of", 1259], ["the", 1262], ["150-mg", 1266], ["dose", 1273], ["with", 1278], ["placebo", 1283], [")", 1290], [".", 1291], ["A", 1293], ["clinically", 1295], ["significant", 1306], ["effect", 1318], ["was", 1325], ["noted", 1329], ["by", 1335], ["the", 1338], ["end", 1342], ["of", 1346], ["the", 1349], ["first", 1353], ["week", 1359], ["of", 1364], ["treatment", 1367], [".", 1376], ["Adverse", 1378], ["effects", 1386], ["included", 1394], ["diarrhea", 1403], ["(", 1412], ["in", 1413], ["19", 1416], ["%", 1418], ["of", 1420], ["subjects", 1423], ["taking", 1432], ["the", 1439], ["100-mg", 1443], ["dose", 1450], ["of", 1455], ["R788", 1458], ["vs.", 1463], ["3", 1467], ["%", 1468], ["of", 1470], ["those", 1473], ["taking", 1479], ["placebo", 1486], [")", 1493], [",", 1494], ["upper", 1496], ["respiratory", 1502], ["infections", 1514], ["(", 1525], ["14", 1526], ["%", 1528], ["vs.", 1530], ["7", 1534], ["%", 1535], [")", 1536], [",", 1537], ["and", 1539], ["neutropenia", 1543], ["(", 1555], ["6", 1556], ["%", 1557], ["vs.", 1559], ["1", 1563], ["%", 1564], [")", 1565], [".", 1566], ["R788", 1568], ["was", 1573], ["associated", 1577], ["with", 1588], ["an", 1593], ["increase", 1596], ["in", 1605], ["systolic", 1608], ["blood", 1617], ["pressure", 1623], ["of", 1632], ["approximately", 1635], ["3", 1649], ["mm", 1651], ["Hg", 1654], ["between", 1657], ["baseline", 1665], ["and", 1674], ["month", 1678], ["1", 1684], [",", 1685], ["as", 1687], ["compared", 1690], ["with", 1699], ["a", 1704], ["decrease", 1706], ["of", 1715], ["2", 1718], ["mm", 1720], ["Hg", 1723], ["with", 1726], ["placebo", 1731], [";", 1738], ["23", 1740], ["%", 1742], ["of", 1744], ["the", 1747], ["patients", 1751], ["taking", 1760], ["R788", 1767], ["vs.", 1772], ["7", 1776], ["%", 1777], ["of", 1779], ["the", 1782], ["patients", 1786], ["receiving", 1795], ["placebo", 1805], ["required", 1813], ["the", 1822], ["initiation", 1826], ["of", 1837], ["or", 1840], ["a", 1843], ["change", 1845], ["in", 1852], ["antihypertensive", 1855], ["therapy", 1872], [".", 1879], ["In", 1881], ["this", 1884], ["phase", 1889], ["2", 1895], ["study", 1897], [",", 1902], ["a", 1904], ["Syk", 1906], ["inhibitor", 1910], ["reduced", 1920], ["disease", 1928], ["activity", 1936], ["in", 1945], ["patients", 1948], ["with", 1957], ["rheumatoid", 1962], ["arthritis", 1973], [";", 1982], ["adverse", 1984], ["events", 1992], ["included", 1999], ["diarrhea", 2008], [",", 2016], ["hypertension", 2018], [",", 2030], ["and", 2032], ["neutropenia", 2036], [".", 2047], ["Additional", 2049], ["studies", 2060], ["will", 2068], ["be", 2073], ["needed", 2076], ["to", 2083], ["further", 2086], ["assess", 2094], ["the", 2101], ["safety", 2105], ["and", 2112], ["efficacy", 2116], ["of", 2125], ["Syk", 2128], ["-", 2131], ["inhibition", 2132], ["therapy", 2143], ["in", 2151], ["patients", 2154], ["with", 2163], ["rheumatoid", 2168], ["arthritis", 2179], [".", 2188], ["(", 2190], ["Funded", 2191], ["by", 2198], ["Rigel", 2201], [";", 2206], ["ClinicalTrials.gov", 2208], ["number", 2227], [",", 2233], ["NCT00665925", 2235], [".", 2246], [")", 2247]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Neurobiology of speech and language has previously been studied in the KE family, in which half of the members have severe impairment in both speech and language. The gene responsible for the phenotype was mapped to chromosome 7q31 and identified as the FOXP2 gene, coding for a transcription factor containing a polyglutamine tract and a forkhead DNA-binding domain. Because of linkage studies implicating 7q31 in autism, where language impairment is a component of the disorder, and in specific language impairment, FOXP2 has also been considered as a potential susceptibility locus for the language deficits in autism and/or specific language impairment. In this study, we characterized mice with a disruption in the murine Foxp2 gene. Disruption of both copies of the Foxp2 gene caused severe motor impairment, premature death, and an absence of ultrasonic vocalizations that are elicited when pups are removed from their mothers. Disruption of a single copy of the gene led to modest developmental delay but a significant alteration in ultrasonic vocalization in response to such separation. Learning and memory appear normal in the heterozygous animals. Cerebellar abnormalities were observed in mice with disruptions in Foxp2, with Purkinje cells particularly affected. Our findings support a role for Foxp2 in cerebellar development and in a developmental process that subsumes social communication functions in diverse organisms.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "7dd09d57cc444e8eb573053076049159", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[123, 123], [218, 218], [132, 132], [44, 44], [204, 204], [89, 89]], "char_spans": [[727, 731], [1309, 1313], [772, 776], [254, 258], [1227, 1231], [518, 522]]}]}], "context_tokens": [["Neurobiology", 0], ["of", 13], ["speech", 16], ["and", 23], ["language", 27], ["has", 36], ["previously", 40], ["been", 51], ["studied", 56], ["in", 64], ["the", 67], ["KE", 71], ["family", 74], [",", 80], ["in", 82], ["which", 85], ["half", 91], ["of", 96], ["the", 99], ["members", 103], ["have", 111], ["severe", 116], ["impairment", 123], ["in", 134], ["both", 137], ["speech", 142], ["and", 149], ["language", 153], [".", 161], ["The", 163], ["gene", 167], ["responsible", 172], ["for", 184], ["the", 188], ["phenotype", 192], ["was", 202], ["mapped", 206], ["to", 213], ["chromosome", 216], ["7q31", 227], ["and", 232], ["identified", 236], ["as", 247], ["the", 250], ["FOXP2", 254], ["gene", 260], [",", 264], ["coding", 266], ["for", 273], ["a", 277], ["transcription", 279], ["factor", 293], ["containing", 300], ["a", 311], ["polyglutamine", 313], ["tract", 327], ["and", 333], ["a", 337], ["forkhead", 339], ["DNA", 348], ["-", 351], ["binding", 352], ["domain", 360], [".", 366], ["Because", 368], ["of", 376], ["linkage", 379], ["studies", 387], ["implicating", 395], ["7q31", 407], ["in", 412], ["autism", 415], [",", 421], ["where", 423], ["language", 429], ["impairment", 438], ["is", 449], ["a", 452], ["component", 454], ["of", 464], ["the", 467], ["disorder", 471], [",", 479], ["and", 481], ["in", 485], ["specific", 488], ["language", 497], ["impairment", 506], [",", 516], ["FOXP2", 518], ["has", 524], ["also", 528], ["been", 533], ["considered", 538], ["as", 549], ["a", 552], ["potential", 554], ["susceptibility", 564], ["locus", 579], ["for", 585], ["the", 589], ["language", 593], ["deficits", 602], ["in", 611], ["autism", 614], ["and/or", 621], ["specific", 628], ["language", 637], ["impairment", 646], [".", 656], ["In", 658], ["this", 661], ["study", 666], [",", 671], ["we", 673], ["characterized", 676], ["mice", 690], ["with", 695], ["a", 700], ["disruption", 702], ["in", 713], ["the", 716], ["murine", 720], ["Foxp2", 727], ["gene", 733], [".", 737], ["Disruption", 739], ["of", 750], ["both", 753], ["copies", 758], ["of", 765], ["the", 768], ["Foxp2", 772], ["gene", 778], ["caused", 783], ["severe", 790], ["motor", 797], ["impairment", 803], [",", 813], ["premature", 815], ["death", 825], [",", 830], ["and", 832], ["an", 836], ["absence", 839], ["of", 847], ["ultrasonic", 850], ["vocalizations", 861], ["that", 875], ["are", 880], ["elicited", 884], ["when", 893], ["pups", 898], ["are", 903], ["removed", 907], ["from", 915], ["their", 920], ["mothers", 926], [".", 933], ["Disruption", 935], ["of", 946], ["a", 949], ["single", 951], ["copy", 958], ["of", 963], ["the", 966], ["gene", 970], ["led", 975], ["to", 979], ["modest", 982], ["developmental", 989], ["delay", 1003], ["but", 1009], ["a", 1013], ["significant", 1015], ["alteration", 1027], ["in", 1038], ["ultrasonic", 1041], ["vocalization", 1052], ["in", 1065], ["response", 1068], ["to", 1077], ["such", 1080], ["separation", 1085], [".", 1095], ["Learning", 1097], ["and", 1106], ["memory", 1110], ["appear", 1117], ["normal", 1124], ["in", 1131], ["the", 1134], ["heterozygous", 1138], ["animals", 1151], [".", 1158], ["Cerebellar", 1160], ["abnormalities", 1171], ["were", 1185], ["observed", 1190], ["in", 1199], ["mice", 1202], ["with", 1207], ["disruptions", 1212], ["in", 1224], ["Foxp2", 1227], [",", 1232], ["with", 1234], ["Purkinje", 1239], ["cells", 1248], ["particularly", 1254], ["affected", 1267], [".", 1275], ["Our", 1277], ["findings", 1281], ["support", 1290], ["a", 1298], ["role", 1300], ["for", 1305], ["Foxp2", 1309], ["in", 1315], ["cerebellar", 1318], ["development", 1329], ["and", 1341], ["in", 1345], ["a", 1348], ["developmental", 1350], ["process", 1364], ["that", 1372], ["subsumes", 1377], ["social", 1386], ["communication", 1393], ["functions", 1407], ["in", 1417], ["diverse", 1420], ["organisms", 1428], [".", 1437]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "We report a novel mutation in the XK gene (XK) in a Japanese patient with McLeod syndrome. A 50-year-old man showed progressive muscular atrophy, choreic movement, elevated level of serum creatinine kinase, and acanthocytosis. The expression level of all the Kell antigens in erythrocyte was decreased and molecular analysis revealed a single-base (T) deletion at the nucleotide position 1095 in XK. This deletion caused a frameshift in translation, leading to a premature stop codon at the amino acid position 408. We conclude this single-base deletion causes defective Kx protein, which is responsible for the McLeod phenotype in this patient.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "682f059c5e1247ec92d678ce3cc5a4cc", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[7, 7], [73, 73], [10, 10]], "char_spans": [[34, 35], [396, 397], [43, 44]]}]}], "context_tokens": [["We", 0], ["report", 3], ["a", 10], ["novel", 12], ["mutation", 18], ["in", 27], ["the", 30], ["XK", 34], ["gene", 37], ["(", 42], ["XK", 43], [")", 45], ["in", 47], ["a", 50], ["Japanese", 52], ["patient", 61], ["with", 69], ["McLeod", 74], ["syndrome", 81], [".", 89], ["A", 91], ["50-year", 93], ["-", 100], ["old", 101], ["man", 105], ["showed", 109], ["progressive", 116], ["muscular", 128], ["atrophy", 137], [",", 144], ["choreic", 146], ["movement", 154], [",", 162], ["elevated", 164], ["level", 173], ["of", 179], ["serum", 182], ["creatinine", 188], ["kinase", 199], [",", 205], ["and", 207], ["acanthocytosis", 211], [".", 225], ["The", 227], ["expression", 231], ["level", 242], ["of", 248], ["all", 251], ["the", 255], ["Kell", 259], ["antigens", 264], ["in", 273], ["erythrocyte", 276], ["was", 288], ["decreased", 292], ["and", 302], ["molecular", 306], ["analysis", 316], ["revealed", 325], ["a", 334], ["single", 336], ["-", 342], ["base", 343], ["(", 348], ["T", 349], [")", 350], ["deletion", 352], ["at", 361], ["the", 364], ["nucleotide", 368], ["position", 379], ["1095", 388], ["in", 393], ["XK", 396], [".", 398], ["This", 400], ["deletion", 405], ["caused", 414], ["a", 421], ["frameshift", 423], ["in", 434], ["translation", 437], [",", 448], ["leading", 450], ["to", 458], ["a", 461], ["premature", 463], ["stop", 473], ["codon", 478], ["at", 484], ["the", 487], ["amino", 491], ["acid", 497], ["position", 502], ["408", 511], [".", 514], ["We", 516], ["conclude", 519], ["this", 528], ["single", 533], ["-", 539], ["base", 540], ["deletion", 545], ["causes", 554], ["defective", 561], ["Kx", 571], ["protein", 574], [",", 581], ["which", 583], ["is", 589], ["responsible", 592], ["for", 604], ["the", 608], ["McLeod", 612], ["phenotype", 619], ["in", 629], ["this", 632], ["patient", 637], [".", 644]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "Spleen tyrosine kinase (Syk) has been identified as an important modulator of immune signaling in B cells and cells bearing Fcgamma-activating receptors. R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro and in vivo models, suggesting potential activity in the treatment of rheumatoid arthritis (RA). We enrolled 189 patients with active RA despite methotrexate therapy in a 3-month, multicenter, ascending-dose, double-blind, placebo-controlled trial. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Twice-daily oral doses of 100 mg and 150 mg of R788 were significantly superior to placebo or twice-daily oral doses of 50 mg at week 12 (ACR20 achieved in 65% and 72% versus 38% and 32% of patients, respectively [P < 0.01]). ACR50 (achieved in 49% and 57% versus 19% and 17% of patients, respectively) and ACR70 (achieved in 33% and 40% versus 4% and 2% of patients, respectively) scores showed a similar pattern. Clinical effect was noted as early as 1 week after initiation of therapy. Reductions in serum interleukin-6 and matrix metalloproteinase 3 levels also occurred as early as week 1 in the groups receiving 100 mg and 150 mg R788. The major adverse effects were gastrointestinal side effects (predominantly diarrhea) and neutropenia (<1,500/mm3), both of which were dose related. These results indicate that an inhibitor of Syk kinase produces significant clinical benefits at 12 weeks in a population of patients with active RA receiving methotrexate therapy. Syk kinase may be an important new therapeutic target in RA and related autoimmune conditions.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "782a069dddc14cda828565a5f8c628ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["has", 29], ["been", 33], ["identified", 38], ["as", 49], ["an", 52], ["important", 55], ["modulator", 65], ["of", 75], ["immune", 78], ["signaling", 85], ["in", 95], ["B", 98], ["cells", 100], ["and", 106], ["cells", 110], ["bearing", 116], ["Fcgamma", 124], ["-", 131], ["activating", 132], ["receptors", 143], [".", 152], ["R788", 154], [",", 158], ["a", 160], ["prodrug", 162], ["of", 170], ["active", 173], ["metabolite", 180], ["R406", 191], [",", 195], ["has", 197], ["been", 201], ["shown", 206], ["to", 212], ["be", 215], ["an", 218], ["inhibitor", 221], ["of", 231], ["Syk", 234], ["kinase", 238], [",", 244], ["active", 246], ["in", 253], ["a", 256], ["variety", 258], ["of", 266], ["in", 269], ["vitro", 272], ["and", 278], ["in", 282], ["vivo", 285], ["models", 290], [",", 296], ["suggesting", 298], ["potential", 309], ["activity", 319], ["in", 328], ["the", 331], ["treatment", 335], ["of", 345], ["rheumatoid", 348], ["arthritis", 359], ["(", 369], ["RA", 370], [")", 372], [".", 373], ["We", 375], ["enrolled", 378], ["189", 387], ["patients", 391], ["with", 400], ["active", 405], ["RA", 412], ["despite", 415], ["methotrexate", 423], ["therapy", 436], ["in", 444], ["a", 447], ["3-month", 449], [",", 456], ["multicenter", 458], [",", 469], ["ascending", 471], ["-", 480], ["dose", 481], [",", 485], ["double", 487], ["-", 493], ["blind", 494], [",", 499], ["placebo", 501], ["-", 508], ["controlled", 509], ["trial", 520], [".", 525], ["The", 527], ["primary", 531], ["end", 539], ["point", 543], ["was", 549], ["the", 553], ["American", 557], ["College", 566], ["of", 574], ["Rheumatology", 577], ["20", 590], ["%", 592], ["improvement", 594], ["criteria", 606], ["(", 615], ["ACR20", 616], [")", 621], ["response", 623], ["rate", 632], ["at", 637], ["week", 640], ["12", 645], [".", 647], ["Twice", 649], ["-", 654], ["daily", 655], ["oral", 661], ["doses", 666], ["of", 672], ["100", 675], ["mg", 679], ["and", 682], ["150", 686], ["mg", 690], ["of", 693], ["R788", 696], ["were", 701], ["significantly", 706], ["superior", 720], ["to", 729], ["placebo", 732], ["or", 740], ["twice", 743], ["-", 748], ["daily", 749], ["oral", 755], ["doses", 760], ["of", 766], ["50", 769], ["mg", 772], ["at", 775], ["week", 778], ["12", 783], ["(", 786], ["ACR20", 787], ["achieved", 793], ["in", 802], ["65", 805], ["%", 807], ["and", 809], ["72", 813], ["%", 815], ["versus", 817], ["38", 824], ["%", 826], ["and", 828], ["32", 832], ["%", 834], ["of", 836], ["patients", 839], [",", 847], ["respectively", 849], ["[", 862], ["P", 863], ["<", 865], ["0.01", 867], ["]", 871], [")", 872], [".", 873], ["ACR50", 875], ["(", 881], ["achieved", 882], ["in", 891], ["49", 894], ["%", 896], ["and", 898], ["57", 902], ["%", 904], ["versus", 906], ["19", 913], ["%", 915], ["and", 917], ["17", 921], ["%", 923], ["of", 925], ["patients", 928], [",", 936], ["respectively", 938], [")", 950], ["and", 952], ["ACR70", 956], ["(", 962], ["achieved", 963], ["in", 972], ["33", 975], ["%", 977], ["and", 979], ["40", 983], ["%", 985], ["versus", 987], ["4", 994], ["%", 995], ["and", 997], ["2", 1001], ["%", 1002], ["of", 1004], ["patients", 1007], [",", 1015], ["respectively", 1017], [")", 1029], ["scores", 1031], ["showed", 1038], ["a", 1045], ["similar", 1047], ["pattern", 1055], [".", 1062], ["Clinical", 1064], ["effect", 1073], ["was", 1080], ["noted", 1084], ["as", 1090], ["early", 1093], ["as", 1099], ["1", 1102], ["week", 1104], ["after", 1109], ["initiation", 1115], ["of", 1126], ["therapy", 1129], [".", 1136], ["Reductions", 1138], ["in", 1149], ["serum", 1152], ["interleukin-6", 1158], ["and", 1172], ["matrix", 1176], ["metalloproteinase", 1183], ["3", 1201], ["levels", 1203], ["also", 1210], ["occurred", 1215], ["as", 1224], ["early", 1227], ["as", 1233], ["week", 1236], ["1", 1241], ["in", 1243], ["the", 1246], ["groups", 1250], ["receiving", 1257], ["100", 1267], ["mg", 1271], ["and", 1274], ["150", 1278], ["mg", 1282], ["R788", 1285], [".", 1289], ["The", 1291], ["major", 1295], ["adverse", 1301], ["effects", 1309], ["were", 1317], ["gastrointestinal", 1322], ["side", 1339], ["effects", 1344], ["(", 1352], ["predominantly", 1353], ["diarrhea", 1367], [")", 1375], ["and", 1377], ["neutropenia", 1381], ["(", 1393], ["<", 1394], ["1,500/mm3", 1395], [")", 1404], [",", 1405], ["both", 1407], ["of", 1412], ["which", 1415], ["were", 1421], ["dose", 1426], ["related", 1431], [".", 1438], ["These", 1440], ["results", 1446], ["indicate", 1454], ["that", 1463], ["an", 1468], ["inhibitor", 1471], ["of", 1481], ["Syk", 1484], ["kinase", 1488], ["produces", 1495], ["significant", 1504], ["clinical", 1516], ["benefits", 1525], ["at", 1534], ["12", 1537], ["weeks", 1540], ["in", 1546], ["a", 1549], ["population", 1551], ["of", 1562], ["patients", 1565], ["with", 1574], ["active", 1579], ["RA", 1586], ["receiving", 1589], ["methotrexate", 1599], ["therapy", 1612], [".", 1619], ["Syk", 1621], ["kinase", 1625], ["may", 1632], ["be", 1636], ["an", 1639], ["important", 1642], ["new", 1652], ["therapeutic", 1656], ["target", 1668], ["in", 1675], ["RA", 1678], ["and", 1681], ["related", 1685], ["autoimmune", 1693], ["conditions", 1704], [".", 1714]]}
{"context": "Since reports that precursor cells in the adult subventricular zone (SVZ) contribute to regenerative neuro- and gliogenesis in CA1, we wondered whether a similar route of migration might also exist under physiological conditions. Permanent labeling of SVZ precursor cells with a lentiviral vector for green fluorescent protein did not reveal any migration from the SVZ into CA1 in the intact murine brain. However, in a nestin-GFP reporter mouse we found proliferating cells within the corpus callosum/alveus region expressing nestin and glial fibrillary acidic protein similar to precursor cells in the neighboring neurogenic region of the adult dentate gyrus. Within 3 weeks of BrdU administration, BrdU-positive nestin-GFP-expressing protoplasmic astrocytes emerged in CA1. Similar to precursor cells isolated from the dentate gyrus and the SVZ, nestin-GFP-expressing cells from corpus callosum/alveus were self-renewing and multipotent in vitro, whereas cells isolated from CA1 were not. Nestin-GFP-expressing cells in CA1 differentiated into postmitotic astrocytes characterized by S100beta expression. No new neurons were found in CA1. The number of nestin-GFP-expressing astrocytes in CA1 was increased by environmental enrichment. We conclude that astrogenesis in CA1 is influenced by environmental conditions. However, SVZ precursor cells do not contribute to physiological cellular plasticity in CA1.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "030fff89fcaf4f7a8d31056a6f48f949", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[171, 171], [119, 119], [71, 71], [199, 199], [88, 88], [143, 143]], "char_spans": [[992, 997], [715, 720], [420, 425], [1156, 1161], [527, 532], [849, 854]]}]}], "context_tokens": [["Since", 0], ["reports", 6], ["that", 14], ["precursor", 19], ["cells", 29], ["in", 35], ["the", 38], ["adult", 42], ["subventricular", 48], ["zone", 63], ["(", 68], ["SVZ", 69], [")", 72], ["contribute", 74], ["to", 85], ["regenerative", 88], ["neuro-", 101], ["and", 108], ["gliogenesis", 112], ["in", 124], ["CA1", 127], [",", 130], ["we", 132], ["wondered", 135], ["whether", 144], ["a", 152], ["similar", 154], ["route", 162], ["of", 168], ["migration", 171], ["might", 181], ["also", 187], ["exist", 192], ["under", 198], ["physiological", 204], ["conditions", 218], [".", 228], ["Permanent", 230], ["labeling", 240], ["of", 249], ["SVZ", 252], ["precursor", 256], ["cells", 266], ["with", 272], ["a", 277], ["lentiviral", 279], ["vector", 290], ["for", 297], ["green", 301], ["fluorescent", 307], ["protein", 319], ["did", 327], ["not", 331], ["reveal", 335], ["any", 342], ["migration", 346], ["from", 356], ["the", 361], ["SVZ", 365], ["into", 369], ["CA1", 374], ["in", 378], ["the", 381], ["intact", 385], ["murine", 392], ["brain", 399], [".", 404], ["However", 406], [",", 413], ["in", 415], ["a", 418], ["nestin", 420], ["-", 426], ["GFP", 427], ["reporter", 431], ["mouse", 440], ["we", 446], ["found", 449], ["proliferating", 455], ["cells", 469], ["within", 475], ["the", 482], ["corpus", 486], ["callosum", 493], ["/", 501], ["alveus", 502], ["region", 509], ["expressing", 516], ["nestin", 527], ["and", 534], ["glial", 538], ["fibrillary", 544], ["acidic", 555], ["protein", 562], ["similar", 570], ["to", 578], ["precursor", 581], ["cells", 591], ["in", 597], ["the", 600], ["neighboring", 604], ["neurogenic", 616], ["region", 627], ["of", 634], ["the", 637], ["adult", 641], ["dentate", 647], ["gyrus", 655], [".", 660], ["Within", 662], ["3", 669], ["weeks", 671], ["of", 677], ["BrdU", 680], ["administration", 685], [",", 699], ["BrdU", 701], ["-", 705], ["positive", 706], ["nestin", 715], ["-", 721], ["GFP", 722], ["-", 725], ["expressing", 726], ["protoplasmic", 737], ["astrocytes", 750], ["emerged", 761], ["in", 769], ["CA1", 772], [".", 775], ["Similar", 777], ["to", 785], ["precursor", 788], ["cells", 798], ["isolated", 804], ["from", 813], ["the", 818], ["dentate", 822], ["gyrus", 830], ["and", 836], ["the", 840], ["SVZ", 844], [",", 847], ["nestin", 849], ["-", 855], ["GFP", 856], ["-", 859], ["expressing", 860], ["cells", 871], ["from", 877], ["corpus", 882], ["callosum", 889], ["/", 897], ["alveus", 898], ["were", 905], ["self", 910], ["-", 914], ["renewing", 915], ["and", 924], ["multipotent", 928], ["in", 940], ["vitro", 943], [",", 948], ["whereas", 950], ["cells", 958], ["isolated", 964], ["from", 973], ["CA1", 978], ["were", 982], ["not", 987], [".", 990], ["Nestin", 992], ["-", 998], ["GFP", 999], ["-", 1002], ["expressing", 1003], ["cells", 1014], ["in", 1020], ["CA1", 1023], ["differentiated", 1027], ["into", 1042], ["postmitotic", 1047], ["astrocytes", 1059], ["characterized", 1070], ["by", 1084], ["S100beta", 1087], ["expression", 1096], [".", 1106], ["No", 1108], ["new", 1111], ["neurons", 1115], ["were", 1123], ["found", 1128], ["in", 1134], ["CA1", 1137], [".", 1140], ["The", 1142], ["number", 1146], ["of", 1153], ["nestin", 1156], ["-", 1162], ["GFP", 1163], ["-", 1166], ["expressing", 1167], ["astrocytes", 1178], ["in", 1189], ["CA1", 1192], ["was", 1196], ["increased", 1200], ["by", 1210], ["environmental", 1213], ["enrichment", 1227], [".", 1237], ["We", 1239], ["conclude", 1242], ["that", 1251], ["astrogenesis", 1256], ["in", 1269], ["CA1", 1272], ["is", 1276], ["influenced", 1279], ["by", 1290], ["environmental", 1293], ["conditions", 1307], [".", 1317], ["However", 1319], [",", 1326], ["SVZ", 1328], ["precursor", 1332], ["cells", 1342], ["do", 1348], ["not", 1351], ["contribute", 1355], ["to", 1366], ["physiological", 1369], ["cellular", 1383], ["plasticity", 1392], ["in", 1403], ["CA1", 1406], [".", 1409]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "For the first time a causal treatment of hepatic encephalopathy may be possible by the benzodiazepine antagonist flumazenil. In contrast to all other treatments used so far by flumazenil hepatic encephalopathy improves within minutes. Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose. For treatment of hepatic encephalopathy development of a new antagonist with a longer half-life is desirable. However, ut should be stressed that the current experience with flumazenil is limited and that the effects of flumazenil on hepatic encephalopathy is not proven by randomized controlled studies. Therefore, this drug should only be used in clinical studies.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "fc13d80c19934d369960cc64e8a7ed87", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[29, 29], [97, 97], [36, 36], [89, 89], [17, 17]], "char_spans": [[176, 185], [601, 610], [235, 244], [555, 564], [113, 122]]}]}], "context_tokens": [["For", 0], ["the", 4], ["first", 8], ["time", 14], ["a", 19], ["causal", 21], ["treatment", 28], ["of", 38], ["hepatic", 41], ["encephalopathy", 49], ["may", 64], ["be", 68], ["possible", 71], ["by", 80], ["the", 83], ["benzodiazepine", 87], ["antagonist", 102], ["flumazenil", 113], [".", 123], ["In", 125], ["contrast", 128], ["to", 137], ["all", 140], ["other", 144], ["treatments", 150], ["used", 161], ["so", 166], ["far", 169], ["by", 173], ["flumazenil", 176], ["hepatic", 187], ["encephalopathy", 195], ["improves", 210], ["within", 219], ["minutes", 226], [".", 233], ["Flumazenil", 235], ["is", 246], ["the", 249], ["first", 253], ["benzodiazepine", 259], ["antagonist", 274], ["which", 285], ["can", 291], ["be", 295], ["used", 298], ["in", 303], ["humans", 306], ["and", 313], ["is", 317], ["a", 320], ["well", 322], ["established", 327], ["for", 339], ["treatment", 343], ["of", 353], ["benzodiazepine", 356], ["overdose", 371], [".", 379], ["For", 381], ["treatment", 385], ["of", 395], ["hepatic", 398], ["encephalopathy", 406], ["development", 421], ["of", 433], ["a", 436], ["new", 438], ["antagonist", 442], ["with", 453], ["a", 458], ["longer", 460], ["half", 467], ["-", 471], ["life", 472], ["is", 477], ["desirable", 480], [".", 489], ["However", 491], [",", 498], ["ut", 500], ["should", 503], ["be", 510], ["stressed", 513], ["that", 522], ["the", 527], ["current", 531], ["experience", 539], ["with", 550], ["flumazenil", 555], ["is", 566], ["limited", 569], ["and", 577], ["that", 581], ["the", 586], ["effects", 590], ["of", 598], ["flumazenil", 601], ["on", 612], ["hepatic", 615], ["encephalopathy", 623], ["is", 638], ["not", 641], ["proven", 645], ["by", 652], ["randomized", 655], ["controlled", 666], ["studies", 677], [".", 684], ["Therefore", 686], [",", 695], ["this", 697], ["drug", 702], ["should", 707], ["only", 714], ["be", 719], ["used", 722], ["in", 727], ["clinical", 730], ["studies", 739], [".", 746]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "Heat shock proteins (Hsp) are known to enhance cell survival under various stress conditions. In the heart, the small Hsp20 has emerged as a key mediator of protection against apoptosis, remodeling, and ischemia/reperfusion injury. Moreover, Hsp20 has been implicated in modulation of cardiac contractility ex vivo. The objective of this study was to determine the in vivo role of Hsp20 in the heart and the mechanisms underlying its regulatory effects in calcium (Ca) cycling. Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN. Furthermore, recombinant protein studies confirmed a physical interaction between AA 73 to 160 in Hsp20 and AA 163 to 330 in PP1. Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", "qas": [{"question": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", "answers": ["Protein phosphatase 1", "PP1"], "qid": "04c9df99ae544e2a96f40f77fd2378b2", "question_tokens": [["Which", 0], ["protein", 6], ["phosphatase", 14], ["has", 26], ["been", 30], ["found", 35], ["to", 41], ["interact", 44], ["with", 53], ["the", 58], ["heat", 62], ["shock", 67], ["protein", 73], [",", 80], ["HSP20", 82], ["?", 87]], "detected_answers": [{"text": "PP1", "token_spans": [[227, 227], [175, 175], [254, 254]], "char_spans": [[1374, 1376], [1031, 1033], [1513, 1515]]}]}], "context_tokens": [["Heat", 0], ["shock", 5], ["proteins", 11], ["(", 20], ["Hsp", 21], [")", 24], ["are", 26], ["known", 30], ["to", 36], ["enhance", 39], ["cell", 47], ["survival", 52], ["under", 61], ["various", 67], ["stress", 75], ["conditions", 82], [".", 92], ["In", 94], ["the", 97], ["heart", 101], [",", 106], ["the", 108], ["small", 112], ["Hsp20", 118], ["has", 124], ["emerged", 128], ["as", 136], ["a", 139], ["key", 141], ["mediator", 145], ["of", 154], ["protection", 157], ["against", 168], ["apoptosis", 176], [",", 185], ["remodeling", 187], [",", 197], ["and", 199], ["ischemia", 203], ["/", 211], ["reperfusion", 212], ["injury", 224], [".", 230], ["Moreover", 232], [",", 240], ["Hsp20", 242], ["has", 248], ["been", 252], ["implicated", 257], ["in", 268], ["modulation", 271], ["of", 282], ["cardiac", 285], ["contractility", 293], ["ex", 307], ["vivo", 310], [".", 314], ["The", 316], ["objective", 320], ["of", 330], ["this", 333], ["study", 338], ["was", 344], ["to", 348], ["determine", 351], ["the", 361], ["in", 365], ["vivo", 368], ["role", 373], ["of", 378], ["Hsp20", 381], ["in", 387], ["the", 390], ["heart", 394], ["and", 400], ["the", 404], ["mechanisms", 408], ["underlying", 419], ["its", 430], ["regulatory", 434], ["effects", 445], ["in", 453], ["calcium", 456], ["(", 464], ["Ca", 465], [")", 467], ["cycling", 469], [".", 476], ["Hsp20", 478], ["overexpression", 484], ["in", 499], ["intact", 502], ["animals", 509], ["resulted", 517], ["in", 526], ["significant", 529], ["enhancement", 541], ["of", 553], ["cardiac", 556], ["function", 564], [",", 572], ["coupled", 574], ["with", 582], ["augmented", 587], ["Ca", 597], ["cycling", 600], ["and", 608], ["sarcoplasmic", 612], ["reticulum", 625], ["Ca", 635], ["load", 638], ["in", 643], ["isolated", 646], ["cardiomyocytes", 655], [".", 669], ["This", 671], ["was", 676], ["associated", 680], ["with", 691], ["specific", 696], ["increases", 705], ["in", 715], ["phosphorylation", 718], ["of", 734], ["phospholamban", 737], ["(", 751], ["PLN", 752], [")", 755], ["at", 757], ["both", 760], ["Ser16", 765], ["and", 771], ["Thr17", 775], [",", 780], ["relieving", 782], ["its", 792], ["inhibition", 796], ["of", 807], ["the", 810], ["apparent", 814], ["Ca", 823], ["affinity", 826], ["of", 835], ["SERCA2a", 838], [".", 845], ["Accordingly", 847], [",", 858], ["the", 860], ["inotropic", 864], ["effects", 874], ["of", 882], ["Hsp20", 885], ["were", 891], ["abrogated", 896], ["in", 906], ["cardiomyocytes", 909], ["expressing", 924], ["nonphosphorylatable", 935], ["PLN", 955], ["(", 959], ["S16A", 960], ["/", 964], ["T17A", 965], [")", 969], [".", 970], ["Interestingly", 972], [",", 985], ["the", 987], ["activity", 991], ["of", 1000], ["type", 1003], ["1", 1008], ["protein", 1010], ["phosphatase", 1018], ["(", 1030], ["PP1", 1031], [")", 1034], [",", 1035], ["a", 1037], ["known", 1039], ["regulator", 1045], ["of", 1055], ["PLN", 1058], ["signaling", 1062], [",", 1071], ["was", 1073], ["significantly", 1077], ["reduced", 1091], ["by", 1099], ["Hsp20", 1102], ["overexpression", 1108], [",", 1122], ["suggesting", 1124], ["that", 1135], ["the", 1140], ["Hsp20", 1144], ["stimulatory", 1150], ["effects", 1162], ["are", 1170], ["partially", 1174], ["mediated", 1184], ["through", 1193], ["the", 1201], ["PP1-PLN", 1205], ["axis", 1213], [".", 1217], ["This", 1219], ["hypothesis", 1224], ["was", 1235], ["supported", 1239], ["by", 1249], ["cell", 1252], ["fractionation", 1257], [",", 1270], ["coimmunoprecipitation", 1272], [",", 1293], ["and", 1295], ["coimmunolocalization", 1299], ["studies", 1320], [",", 1327], ["which", 1329], ["revealed", 1335], ["an", 1344], ["association", 1347], ["between", 1359], ["Hsp20", 1367], [",", 1372], ["PP1", 1374], [",", 1377], ["and", 1379], ["PLN", 1383], [".", 1386], ["Furthermore", 1388], [",", 1399], ["recombinant", 1401], ["protein", 1413], ["studies", 1421], ["confirmed", 1429], ["a", 1439], ["physical", 1441], ["interaction", 1450], ["between", 1462], ["AA", 1470], ["73", 1473], ["to", 1476], ["160", 1479], ["in", 1483], ["Hsp20", 1486], ["and", 1492], ["AA", 1496], ["163", 1499], ["to", 1503], ["330", 1506], ["in", 1510], ["PP1", 1513], [".", 1516], ["Hsp20", 1518], ["is", 1524], ["a", 1527], ["novel", 1529], ["regulator", 1535], ["of", 1545], ["sarcoplasmic", 1548], ["reticulum", 1561], ["Ca", 1571], ["cycling", 1574], ["by", 1582], ["targeting", 1585], ["the", 1595], ["PP1-PLN", 1599], ["axis", 1607], [".", 1611], ["These", 1613], ["findings", 1619], [",", 1627], ["coupled", 1629], ["with", 1637], ["the", 1642], ["well", 1646], ["-", 1650], ["recognized", 1651], ["cardioprotective", 1662], ["role", 1679], ["of", 1684], ["Hsp20", 1687], [",", 1692], ["suggest", 1694], ["a", 1702], ["dual", 1704], ["benefit", 1709], ["of", 1717], ["targeting", 1720], ["Hsp20", 1730], ["in", 1736], ["heart", 1739], ["disease", 1745], [".", 1752]]}
{"context": "Autonomic failure with Lewy bodies (AF-LB) was first described by Fichefet et al. in 1965, and more than ten cases have been reported to date. AF-LB and Parkinson's disease (PD) share the neuropathological findings characterized by widely distributed Lewy bodies in the central nervous system including the substantia nigra and locus coeruleus. However, clinical manifestations of AF-LB are far different from PD in which autonomic dysfunction, if present, is not a predominant feature. In the present study, clinical features were comparatively analysed in AF-LB and PD to investigate the nosological relation between PD and AF-LB. The subjects were 94 patients with PD and 11 reported cases of AF-LB in the literature. A test of 70 degrees passive head-up tilt was performed upon the patients with PD in our laboratory. Based on the results in tilting test, the patients with PD were divided into two groups; PD-I (69 cases) with an orthostatic fall of systolic blood pressure less than 30 mmHg, and PD-II (25 cases) with a fall of 30 mmHg or more. Autonomic dysfunctions were more extent in PD-II than in PD-I, because the incidences of anhidrosis, impotence, neurogenic bladder and constipation were higher in PD-II. All of the cases of AF-LB were contained in the previous literatures with reasonably full clinical descriptions. Mean age at onset of the disease was 62.1 +/- 8.7 (mean +/- SD) years old in PD-I, 64.5 +/- 7.5 years old in PD-II and 63.9 +/- 9.0 years old in AF-LB, and no significant differences were found among the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "fe5cca28fd2c430ca12e90e27e78ad75", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[36, 40]], "char_spans": [[153, 175]]}]}], "context_tokens": [["Autonomic", 0], ["failure", 10], ["with", 18], ["Lewy", 23], ["bodies", 28], ["(", 35], ["AF", 36], ["-", 38], ["LB", 39], [")", 41], ["was", 43], ["first", 47], ["described", 53], ["by", 63], ["Fichefet", 66], ["et", 75], ["al", 78], [".", 80], ["in", 82], ["1965", 85], [",", 89], ["and", 91], ["more", 95], ["than", 100], ["ten", 105], ["cases", 109], ["have", 115], ["been", 120], ["reported", 125], ["to", 134], ["date", 137], [".", 141], ["AF", 143], ["-", 145], ["LB", 146], ["and", 149], ["Parkinson", 153], ["'s", 162], ["disease", 165], ["(", 173], ["PD", 174], [")", 176], ["share", 178], ["the", 184], ["neuropathological", 188], ["findings", 206], ["characterized", 215], ["by", 229], ["widely", 232], ["distributed", 239], ["Lewy", 251], ["bodies", 256], ["in", 263], ["the", 266], ["central", 270], ["nervous", 278], ["system", 286], ["including", 293], ["the", 303], ["substantia", 307], ["nigra", 318], ["and", 324], ["locus", 328], ["coeruleus", 334], [".", 343], ["However", 345], [",", 352], ["clinical", 354], ["manifestations", 363], ["of", 378], ["AF", 381], ["-", 383], ["LB", 384], ["are", 387], ["far", 391], ["different", 395], ["from", 405], ["PD", 410], ["in", 413], ["which", 416], ["autonomic", 422], ["dysfunction", 432], [",", 443], ["if", 445], ["present", 448], [",", 455], ["is", 457], ["not", 460], ["a", 464], ["predominant", 466], ["feature", 478], [".", 485], ["In", 487], ["the", 490], ["present", 494], ["study", 502], [",", 507], ["clinical", 509], ["features", 518], ["were", 527], ["comparatively", 532], ["analysed", 546], ["in", 555], ["AF", 558], ["-", 560], ["LB", 561], ["and", 564], ["PD", 568], ["to", 571], ["investigate", 574], ["the", 586], ["nosological", 590], ["relation", 602], ["between", 611], ["PD", 619], ["and", 622], ["AF", 626], ["-", 628], ["LB", 629], [".", 631], ["The", 633], ["subjects", 637], ["were", 646], ["94", 651], ["patients", 654], ["with", 663], ["PD", 668], ["and", 671], ["11", 675], ["reported", 678], ["cases", 687], ["of", 693], ["AF", 696], ["-", 698], ["LB", 699], ["in", 702], ["the", 705], ["literature", 709], [".", 719], ["A", 721], ["test", 723], ["of", 728], ["70", 731], ["degrees", 734], ["passive", 742], ["head", 750], ["-", 754], ["up", 755], ["tilt", 758], ["was", 763], ["performed", 767], ["upon", 777], ["the", 782], ["patients", 786], ["with", 795], ["PD", 800], ["in", 803], ["our", 806], ["laboratory", 810], [".", 820], ["Based", 822], ["on", 828], ["the", 831], ["results", 835], ["in", 843], ["tilting", 846], ["test", 854], [",", 858], ["the", 860], ["patients", 864], ["with", 873], ["PD", 878], ["were", 881], ["divided", 886], ["into", 894], ["two", 899], ["groups", 903], [";", 909], ["PD", 911], ["-", 913], ["I", 914], ["(", 916], ["69", 917], ["cases", 920], [")", 925], ["with", 927], ["an", 932], ["orthostatic", 935], ["fall", 947], ["of", 952], ["systolic", 955], ["blood", 964], ["pressure", 970], ["less", 979], ["than", 984], ["30", 989], ["mmHg", 992], [",", 996], ["and", 998], ["PD", 1002], ["-", 1004], ["II", 1005], ["(", 1008], ["25", 1009], ["cases", 1012], [")", 1017], ["with", 1019], ["a", 1024], ["fall", 1026], ["of", 1031], ["30", 1034], ["mmHg", 1037], ["or", 1042], ["more", 1045], [".", 1049], ["Autonomic", 1051], ["dysfunctions", 1061], ["were", 1074], ["more", 1079], ["extent", 1084], ["in", 1091], ["PD", 1094], ["-", 1096], ["II", 1097], ["than", 1100], ["in", 1105], ["PD", 1108], ["-", 1110], ["I", 1111], [",", 1112], ["because", 1114], ["the", 1122], ["incidences", 1126], ["of", 1137], ["anhidrosis", 1140], [",", 1150], ["impotence", 1152], [",", 1161], ["neurogenic", 1163], ["bladder", 1174], ["and", 1182], ["constipation", 1186], ["were", 1199], ["higher", 1204], ["in", 1211], ["PD", 1214], ["-", 1216], ["II", 1217], [".", 1219], ["All", 1221], ["of", 1225], ["the", 1228], ["cases", 1232], ["of", 1238], ["AF", 1241], ["-", 1243], ["LB", 1244], ["were", 1247], ["contained", 1252], ["in", 1262], ["the", 1265], ["previous", 1269], ["literatures", 1278], ["with", 1290], ["reasonably", 1295], ["full", 1306], ["clinical", 1311], ["descriptions", 1320], [".", 1332], ["Mean", 1334], ["age", 1339], ["at", 1343], ["onset", 1346], ["of", 1352], ["the", 1355], ["disease", 1359], ["was", 1367], ["62.1", 1371], ["+", 1376], ["/-", 1377], ["8.7", 1380], ["(", 1384], ["mean", 1385], ["+", 1390], ["/-", 1391], ["SD", 1394], [")", 1396], ["years", 1398], ["old", 1404], ["in", 1408], ["PD", 1411], ["-", 1413], ["I", 1414], [",", 1415], ["64.5", 1417], ["+", 1422], ["/-", 1423], ["7.5", 1426], ["years", 1430], ["old", 1436], ["in", 1440], ["PD", 1443], ["-", 1445], ["II", 1446], ["and", 1449], ["63.9", 1453], ["+", 1458], ["/-", 1459], ["9.0", 1462], ["years", 1466], ["old", 1472], ["in", 1476], ["AF", 1479], ["-", 1481], ["LB", 1482], [",", 1484], ["and", 1486], ["no", 1490], ["significant", 1493], ["differences", 1505], ["were", 1517], ["found", 1522], ["among", 1528], ["the", 1534], ["three", 1538], ["groups.(ABSTRACT", 1544], ["TRUNCATED", 1561], ["AT", 1571], ["250", 1574], ["WORDS", 1578], [")", 1583]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "This study aimed to explore retrospective childhood ADHD symptomatology, psychiatric comorbidity, rates of substance-use disorders (SUD), as well as their association with high-risk health behaviors in prison and adverse health outcomes. A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors. Wald \u03c7(2) tests revealed significant associations of ADHD with MDD and PTSD, as well as increased risk for overdosing and intravenous drug use in prison. A logistic regression model adjusted for mood and anxiety comorbidity predicted lifetime SUD diagnosis (odds ratio = 2.38; 95% confidence interval = [1.15, 4.94]). Our results provide further evidence on the association of drug dependence and ADHD symptoms, and their overrepresentation among prison inmates.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "cb4d005ff43d41c896f0469ab1363b38", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[144, 144], [115, 115]], "char_spans": [[768, 771], [640, 643]]}]}], "context_tokens": [["This", 0], ["study", 5], ["aimed", 11], ["to", 17], ["explore", 20], ["retrospective", 28], ["childhood", 42], ["ADHD", 52], ["symptomatology", 57], [",", 71], ["psychiatric", 73], ["comorbidity", 85], [",", 96], ["rates", 98], ["of", 104], ["substance", 107], ["-", 116], ["use", 117], ["disorders", 121], ["(", 131], ["SUD", 132], [")", 135], [",", 136], ["as", 138], ["well", 141], ["as", 146], ["their", 149], ["association", 155], ["with", 167], ["high", 172], ["-", 176], ["risk", 177], ["health", 182], ["behaviors", 189], ["in", 199], ["prison", 202], ["and", 209], ["adverse", 213], ["health", 221], ["outcomes", 228], [".", 236], ["A", 238], ["randomly", 240], ["selected", 249], ["representative", 258], ["sample", 273], ["of", 280], ["inmates", 283], ["in", 291], ["the", 294], ["Puerto", 298], ["Rico", 305], ["correctional", 310], ["system", 323], ["(", 330], ["N", 331], ["=", 333], ["1,179", 335], [")", 340], ["was", 342], ["assessed", 346], ["with", 355], ["the", 360], ["Spanish", 364], ["-", 371], ["language", 372], ["Wender", 381], ["Utah", 388], ["Rating", 393], ["Scale", 400], ["(", 406], ["WURS", 407], [")", 411], [";", 412], ["the", 414], ["Composite", 418], ["International", 428], ["Diagnostic", 442], ["Interview", 453], ["(", 463], ["CIDI", 464], [")", 468], ["modules", 470], ["for", 478], ["lifetime", 482], ["/", 490], ["current", 491], ["major", 499], ["depression", 505], ["disorder", 516], ["(", 525], ["MDD", 526], [")", 529], [",", 530], ["generalized", 532], ["anxiety", 544], ["disorder", 552], ["(", 561], ["GAD", 562], [")", 565], [",", 566], ["and", 568], ["SUD", 572], [";", 575], ["the", 577], ["Davidson", 581], ["Trauma", 590], ["Scale", 597], ["(", 603], ["DTS", 604], [";", 607], ["posttraumatic", 609], ["stress", 623], ["disorder", 630], ["[", 639], ["PTSD", 640], ["]", 644], [")", 645], [";", 646], ["and", 648], ["self", 652], ["-", 656], ["reports", 657], ["of", 665], ["in", 668], ["-", 670], ["site", 671], ["high", 676], ["-", 680], ["risk", 681], ["behaviors", 686], [".", 695], ["Wald", 697], ["\u03c7(2", 702], [")", 705], ["tests", 707], ["revealed", 713], ["significant", 722], ["associations", 734], ["of", 747], ["ADHD", 750], ["with", 755], ["MDD", 760], ["and", 764], ["PTSD", 768], [",", 772], ["as", 774], ["well", 777], ["as", 782], ["increased", 785], ["risk", 795], ["for", 800], ["overdosing", 804], ["and", 815], ["intravenous", 819], ["drug", 831], ["use", 836], ["in", 840], ["prison", 843], [".", 849], ["A", 851], ["logistic", 853], ["regression", 862], ["model", 873], ["adjusted", 879], ["for", 888], ["mood", 892], ["and", 897], ["anxiety", 901], ["comorbidity", 909], ["predicted", 921], ["lifetime", 931], ["SUD", 940], ["diagnosis", 944], ["(", 954], ["odds", 955], ["ratio", 960], ["=", 966], ["2.38", 968], [";", 972], ["95", 974], ["%", 976], ["confidence", 978], ["interval", 989], ["=", 998], ["[", 1000], ["1.15", 1001], [",", 1005], ["4.94", 1007], ["]", 1011], [")", 1012], [".", 1013], ["Our", 1015], ["results", 1019], ["provide", 1027], ["further", 1035], ["evidence", 1043], ["on", 1052], ["the", 1055], ["association", 1059], ["of", 1071], ["drug", 1074], ["dependence", 1079], ["and", 1090], ["ADHD", 1094], ["symptoms", 1099], [",", 1107], ["and", 1109], ["their", 1113], ["overrepresentation", 1119], ["among", 1138], ["prison", 1144], ["inmates", 1151], [".", 1158]]}
{"context": "Mutant ataxin-3 is aberrantly folded and proteolytically cleaved in spinocerebellar ataxia type 3. The C-terminal region of the protein includes a polyglutamine stretch that is expanded in spinocerebellar ataxia type 3. Here, we report on the analysis of an ataxin-3 mutant mouse that has been obtained by gene trap integration. The ataxin-3 fusion protein encompasses 259\u2009N-terminal amino acids including the Josephin domain and an ubiquitin-interacting motif but lacks the C-terminus with the polyglutamine stretch, the valosin-containing protein binding region and part of the ubiquitin-interacting motif 2. Homozygous ataxin-3 mutant mice were viable and showed no apparent anatomical defects at birth. However, at the age of 9 months, homozygous and heterozygous mutant mice revealed significantly altered behaviour and progressing deficits of motor coordination followed by premature death at \u223c12 months. At this time, prominent extranuclear protein aggregates and neuronal cell death was found in mutant mice. This was associated with disturbances of the endoplasmic reticulum-mediated unfolded protein response, consistent with the normal role of ataxin-3 in endoplasmic reticulum homeostasis. Thus, the ataxin-3 gene trap model provides evidence for a contribution of the non-polyglutamine containing ataxin-3\u2009N-terminus, which mimics a calpain fragment that has been observed in spinocerebellar ataxia type 3. Consistent with the disease in humans, gene trap mice develop cytoplasmic inclusion bodies and implicate impaired unfolded protein response in the pathogenesis of spinocerebellar ataxia type 3.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "b4fcd51ad7b44e5b973a0b67bc523ce8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[106, 106], [44, 44], [57, 57], [215, 215], [1, 1], [200, 200], [191, 191]], "char_spans": [[622, 629], [258, 265], [333, 340], [1310, 1317], [7, 14], [1212, 1219], [1155, 1162]]}]}], "context_tokens": [["Mutant", 0], ["ataxin-3", 7], ["is", 16], ["aberrantly", 19], ["folded", 30], ["and", 37], ["proteolytically", 41], ["cleaved", 57], ["in", 65], ["spinocerebellar", 68], ["ataxia", 84], ["type", 91], ["3", 96], [".", 97], ["The", 99], ["C", 103], ["-", 104], ["terminal", 105], ["region", 114], ["of", 121], ["the", 124], ["protein", 128], ["includes", 136], ["a", 145], ["polyglutamine", 147], ["stretch", 161], ["that", 169], ["is", 174], ["expanded", 177], ["in", 186], ["spinocerebellar", 189], ["ataxia", 205], ["type", 212], ["3", 217], [".", 218], ["Here", 220], [",", 224], ["we", 226], ["report", 229], ["on", 236], ["the", 239], ["analysis", 243], ["of", 252], ["an", 255], ["ataxin-3", 258], ["mutant", 267], ["mouse", 274], ["that", 280], ["has", 285], ["been", 289], ["obtained", 294], ["by", 303], ["gene", 306], ["trap", 311], ["integration", 316], [".", 327], ["The", 329], ["ataxin-3", 333], ["fusion", 342], ["protein", 349], ["encompasses", 357], ["259", 369], ["N", 373], ["-", 374], ["terminal", 375], ["amino", 384], ["acids", 390], ["including", 396], ["the", 406], ["Josephin", 410], ["domain", 419], ["and", 426], ["an", 430], ["ubiquitin", 433], ["-", 442], ["interacting", 443], ["motif", 455], ["but", 461], ["lacks", 465], ["the", 471], ["C", 475], ["-", 476], ["terminus", 477], ["with", 486], ["the", 491], ["polyglutamine", 495], ["stretch", 509], [",", 516], ["the", 518], ["valosin", 522], ["-", 529], ["containing", 530], ["protein", 541], ["binding", 549], ["region", 557], ["and", 564], ["part", 568], ["of", 573], ["the", 576], ["ubiquitin", 580], ["-", 589], ["interacting", 590], ["motif", 602], ["2", 608], [".", 609], ["Homozygous", 611], ["ataxin-3", 622], ["mutant", 631], ["mice", 638], ["were", 643], ["viable", 648], ["and", 655], ["showed", 659], ["no", 666], ["apparent", 669], ["anatomical", 678], ["defects", 689], ["at", 697], ["birth", 700], [".", 705], ["However", 707], [",", 714], ["at", 716], ["the", 719], ["age", 723], ["of", 727], ["9", 730], ["months", 732], [",", 738], ["homozygous", 740], ["and", 751], ["heterozygous", 755], ["mutant", 768], ["mice", 775], ["revealed", 780], ["significantly", 789], ["altered", 803], ["behaviour", 811], ["and", 821], ["progressing", 825], ["deficits", 837], ["of", 846], ["motor", 849], ["coordination", 855], ["followed", 868], ["by", 877], ["premature", 880], ["death", 890], ["at", 896], ["\u223c12", 899], ["months", 903], [".", 909], ["At", 911], ["this", 914], ["time", 919], [",", 923], ["prominent", 925], ["extranuclear", 935], ["protein", 948], ["aggregates", 956], ["and", 967], ["neuronal", 971], ["cell", 980], ["death", 985], ["was", 991], ["found", 995], ["in", 1001], ["mutant", 1004], ["mice", 1011], [".", 1015], ["This", 1017], ["was", 1022], ["associated", 1026], ["with", 1037], ["disturbances", 1042], ["of", 1055], ["the", 1058], ["endoplasmic", 1062], ["reticulum", 1074], ["-", 1083], ["mediated", 1084], ["unfolded", 1093], ["protein", 1102], ["response", 1110], [",", 1118], ["consistent", 1120], ["with", 1131], ["the", 1136], ["normal", 1140], ["role", 1147], ["of", 1152], ["ataxin-3", 1155], ["in", 1164], ["endoplasmic", 1167], ["reticulum", 1179], ["homeostasis", 1189], [".", 1200], ["Thus", 1202], [",", 1206], ["the", 1208], ["ataxin-3", 1212], ["gene", 1221], ["trap", 1226], ["model", 1231], ["provides", 1237], ["evidence", 1246], ["for", 1255], ["a", 1259], ["contribution", 1261], ["of", 1274], ["the", 1277], ["non", 1281], ["-", 1284], ["polyglutamine", 1285], ["containing", 1299], ["ataxin-3", 1310], ["N", 1319], ["-", 1320], ["terminus", 1321], [",", 1329], ["which", 1331], ["mimics", 1337], ["a", 1344], ["calpain", 1346], ["fragment", 1354], ["that", 1363], ["has", 1368], ["been", 1372], ["observed", 1377], ["in", 1386], ["spinocerebellar", 1389], ["ataxia", 1405], ["type", 1412], ["3", 1417], [".", 1418], ["Consistent", 1420], ["with", 1431], ["the", 1436], ["disease", 1440], ["in", 1448], ["humans", 1451], [",", 1457], ["gene", 1459], ["trap", 1464], ["mice", 1469], ["develop", 1474], ["cytoplasmic", 1482], ["inclusion", 1494], ["bodies", 1504], ["and", 1511], ["implicate", 1515], ["impaired", 1525], ["unfolded", 1534], ["protein", 1543], ["response", 1551], ["in", 1560], ["the", 1563], ["pathogenesis", 1567], ["of", 1580], ["spinocerebellar", 1583], ["ataxia", 1599], ["type", 1606], ["3", 1611], [".", 1612]]}
{"context": "This study was performed to understand the epidemiology of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections in southern New England children. A retrospective review was conducted of the medical records of children 0 to 18 years old with MRSA isolated by the Rhode Island Hospital microbiology laboratory (Providence, RI) between 1997 and 2001. A case was classified as either health care-associated MRSA (HCA-MRSA) or CA-MRSA based on time of culture and other strict criteria. The spectrum of illness of the HCA-MRSA and CA-MRSA cases was compared, as were the antibiotic-susceptibility patterns of their isolates. Risk factors for CA-MRSA acquisition were identified, and molecular subtyping of selected isolates was performed. Between 1997 and 2001, S aureus was isolated from 1063 children. Of these children, 57 had MRSA. During this period, both the absolute number of MRSA cases and the proportion of S aureus cases due to MRSA rose more than threefold due to increases in both CA-MRSA and HCA-MRSA infections. Of the 57 MRSA cases, 23 (40%) were CA-MRSA. CA-MRSA patients were more likely to have skin/soft-tissue infections than HCA-MRSA patients (83% vs 38%). Risk factors for acquisition of MRSA including intrafamilial spread, frequent antibiotic exposure, and child-care attendance were identified in 8 of the 23 (35%) CA-MRSA patients. CA-MRSA isolates were more likely to be susceptible to non-beta-lactam antibiotics than HCA-MRSA isolates. All isolates were vancomycin susceptible. MRSA accounts for an increasing proportion of all pediatric S aureus infections in southern New England. A significant percentage of these cases are due to CA-MRSA. Pediatricians should have heightened suspicion for CA-MRSA in children with presumed S aureus infections, especially if they have skin/soft-tissue infections or risk factors for MRSA acquisition.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "8a35ad57cdec42baa86b8aa65906ba8e", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[75, 75], [107, 107], [205, 205], [301, 301], [371, 371], [84, 84], [20, 20], [172, 172], [199, 199], [236, 236], [195, 195], [251, 251], [79, 79], [128, 128], [103, 103], [216, 216], [338, 338], [283, 283], [278, 278], [310, 310], [220, 220], [348, 348], [183, 183], [46, 46], [161, 161]], "char_spans": [[434, 437], [560, 563], [1063, 1066], [1477, 1480], [1877, 1880], [456, 459], [126, 129], [910, 913], [1036, 1039], [1177, 1180], [1023, 1026], [1237, 1240], [444, 447], [671, 674], [548, 551], [1092, 1095], [1693, 1696], [1388, 1391], [1370, 1373], [1534, 1537], [1101, 1104], [1753, 1756], [965, 968], [272, 275], [856, 859]]}]}], "context_tokens": [["This", 0], ["study", 5], ["was", 11], ["performed", 15], ["to", 25], ["understand", 28], ["the", 39], ["epidemiology", 43], ["of", 56], ["community", 59], ["-", 68], ["acquired", 69], ["methicillin", 78], ["-", 89], ["resistant", 90], ["Staphylococcus", 100], ["aureus", 115], ["(", 122], ["CA", 123], ["-", 125], ["MRSA", 126], [")", 130], ["infections", 132], ["in", 143], ["southern", 146], ["New", 155], ["England", 159], ["children", 167], [".", 175], ["A", 177], ["retrospective", 179], ["review", 193], ["was", 200], ["conducted", 204], ["of", 214], ["the", 217], ["medical", 221], ["records", 229], ["of", 237], ["children", 240], ["0", 249], ["to", 251], ["18", 254], ["years", 257], ["old", 263], ["with", 267], ["MRSA", 272], ["isolated", 277], ["by", 286], ["the", 289], ["Rhode", 293], ["Island", 299], ["Hospital", 306], ["microbiology", 315], ["laboratory", 328], ["(", 339], ["Providence", 340], [",", 350], ["RI", 352], [")", 354], ["between", 356], ["1997", 364], ["and", 369], ["2001", 373], [".", 377], ["A", 379], ["case", 381], ["was", 386], ["classified", 390], ["as", 401], ["either", 404], ["health", 411], ["care", 418], ["-", 422], ["associated", 423], ["MRSA", 434], ["(", 439], ["HCA", 440], ["-", 443], ["MRSA", 444], [")", 448], ["or", 450], ["CA", 453], ["-", 455], ["MRSA", 456], ["based", 461], ["on", 467], ["time", 470], ["of", 475], ["culture", 478], ["and", 486], ["other", 490], ["strict", 496], ["criteria", 503], [".", 511], ["The", 513], ["spectrum", 517], ["of", 526], ["illness", 529], ["of", 537], ["the", 540], ["HCA", 544], ["-", 547], ["MRSA", 548], ["and", 553], ["CA", 557], ["-", 559], ["MRSA", 560], ["cases", 565], ["was", 571], ["compared", 575], [",", 583], ["as", 585], ["were", 588], ["the", 593], ["antibiotic", 597], ["-", 607], ["susceptibility", 608], ["patterns", 623], ["of", 632], ["their", 635], ["isolates", 641], [".", 649], ["Risk", 651], ["factors", 656], ["for", 664], ["CA", 668], ["-", 670], ["MRSA", 671], ["acquisition", 676], ["were", 688], ["identified", 693], [",", 703], ["and", 705], ["molecular", 709], ["subtyping", 719], ["of", 729], ["selected", 732], ["isolates", 741], ["was", 750], ["performed", 754], [".", 763], ["Between", 765], ["1997", 773], ["and", 778], ["2001", 782], [",", 786], ["S", 788], ["aureus", 790], ["was", 797], ["isolated", 801], ["from", 810], ["1063", 815], ["children", 820], [".", 828], ["Of", 830], ["these", 833], ["children", 839], [",", 847], ["57", 849], ["had", 852], ["MRSA", 856], [".", 860], ["During", 862], ["this", 869], ["period", 874], [",", 880], ["both", 882], ["the", 887], ["absolute", 891], ["number", 900], ["of", 907], ["MRSA", 910], ["cases", 915], ["and", 921], ["the", 925], ["proportion", 929], ["of", 940], ["S", 943], ["aureus", 945], ["cases", 952], ["due", 958], ["to", 962], ["MRSA", 965], ["rose", 970], ["more", 975], ["than", 980], ["threefold", 985], ["due", 995], ["to", 999], ["increases", 1002], ["in", 1012], ["both", 1015], ["CA", 1020], ["-", 1022], ["MRSA", 1023], ["and", 1028], ["HCA", 1032], ["-", 1035], ["MRSA", 1036], ["infections", 1041], [".", 1051], ["Of", 1053], ["the", 1056], ["57", 1060], ["MRSA", 1063], ["cases", 1068], [",", 1073], ["23", 1075], ["(", 1078], ["40", 1079], ["%", 1081], [")", 1082], ["were", 1084], ["CA", 1089], ["-", 1091], ["MRSA", 1092], [".", 1096], ["CA", 1098], ["-", 1100], ["MRSA", 1101], ["patients", 1106], ["were", 1115], ["more", 1120], ["likely", 1125], ["to", 1132], ["have", 1135], ["skin", 1140], ["/", 1144], ["soft", 1145], ["-", 1149], ["tissue", 1150], ["infections", 1157], ["than", 1168], ["HCA", 1173], ["-", 1176], ["MRSA", 1177], ["patients", 1182], ["(", 1191], ["83", 1192], ["%", 1194], ["vs", 1196], ["38", 1199], ["%", 1201], [")", 1202], [".", 1203], ["Risk", 1205], ["factors", 1210], ["for", 1218], ["acquisition", 1222], ["of", 1234], ["MRSA", 1237], ["including", 1242], ["intrafamilial", 1252], ["spread", 1266], [",", 1272], ["frequent", 1274], ["antibiotic", 1283], ["exposure", 1294], [",", 1302], ["and", 1304], ["child", 1308], ["-", 1313], ["care", 1314], ["attendance", 1319], ["were", 1330], ["identified", 1335], ["in", 1346], ["8", 1349], ["of", 1351], ["the", 1354], ["23", 1358], ["(", 1361], ["35", 1362], ["%", 1364], [")", 1365], ["CA", 1367], ["-", 1369], ["MRSA", 1370], ["patients", 1375], [".", 1383], ["CA", 1385], ["-", 1387], ["MRSA", 1388], ["isolates", 1393], ["were", 1402], ["more", 1407], ["likely", 1412], ["to", 1419], ["be", 1422], ["susceptible", 1425], ["to", 1437], ["non", 1440], ["-", 1443], ["beta", 1444], ["-", 1448], ["lactam", 1449], ["antibiotics", 1456], ["than", 1468], ["HCA", 1473], ["-", 1476], ["MRSA", 1477], ["isolates", 1482], [".", 1490], ["All", 1492], ["isolates", 1496], ["were", 1505], ["vancomycin", 1510], ["susceptible", 1521], [".", 1532], ["MRSA", 1534], ["accounts", 1539], ["for", 1548], ["an", 1552], ["increasing", 1555], ["proportion", 1566], ["of", 1577], ["all", 1580], ["pediatric", 1584], ["S", 1594], ["aureus", 1596], ["infections", 1603], ["in", 1614], ["southern", 1617], ["New", 1626], ["England", 1630], [".", 1637], ["A", 1639], ["significant", 1641], ["percentage", 1653], ["of", 1664], ["these", 1667], ["cases", 1673], ["are", 1679], ["due", 1683], ["to", 1687], ["CA", 1690], ["-", 1692], ["MRSA", 1693], [".", 1697], ["Pediatricians", 1699], ["should", 1713], ["have", 1720], ["heightened", 1725], ["suspicion", 1736], ["for", 1746], ["CA", 1750], ["-", 1752], ["MRSA", 1753], ["in", 1758], ["children", 1761], ["with", 1770], ["presumed", 1775], ["S", 1784], ["aureus", 1786], ["infections", 1793], [",", 1803], ["especially", 1805], ["if", 1816], ["they", 1819], ["have", 1824], ["skin", 1829], ["/", 1833], ["soft", 1834], ["-", 1838], ["tissue", 1839], ["infections", 1846], ["or", 1857], ["risk", 1860], ["factors", 1865], ["for", 1873], ["MRSA", 1877], ["acquisition", 1882], [".", 1893]]}
{"context": "Protection and replenishment of a functional pancreatic \u03b2-cell mass (BCM) are key goals of all diabetes therapies. Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor. The apelin-APJ signaling system is expressed in rodent and human islet cells. Apelin exposure has been shown to inhibit and to stimulate insulin secretion. Our aim was to assess the influence of a selective APJ deletion in pancreatic islet cells on islet homeostasis and glucose tolerance in mice. Cre-LoxP strategy was utilized to mediate islet APJ deletion. APJ deletion in islet cells (APJ(\u0394islet)) resulted in a significantly reduced islet size, density and BCM. An ip glucose tolerance test showed significantly impaired glucose clearance in APJ(\u0394islet) mice. APJ(\u0394islet) mice were not insulin resistant and in vivo glucose-stimulated insulin secretion was reduced modestly. In vitro glucose-stimulated insulin secretion showed a significantly reduced insulin secretion by islets from APJ(\u0394islet) mice. Glucose clearance in response to ip glucose tolerance test in obese APJ(\u0394islet) mice fed a chronic high-fat (HF) diet, but not pregnant APJ(\u0394islet) mice, was impaired significantly. In addition, the obesity-induced adaptive elevations in mean islet size and fractional islet area were reduced significantly in obese APJ(\u0394islet) mice when compared with wild-type mice. Together, these findings demonstrate a stimulatory role for the islet cell apelin-APJ signaling axis in regulation of pancreatic islet homeostasis and in metabolic induced \u03b2-cell hyperplasia. The results indicate the apelin-APJ system can be exploited for replenishment of BCM.", "qas": [{"question": "What is apelin?", "answers": ["Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor."], "qid": "22b639b52f25417c920ceec18fc765f2", "question_tokens": [["What", 0], ["is", 5], ["apelin", 8], ["?", 14]], "detected_answers": [{"text": "Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor.", "token_spans": [[22, 40]], "char_spans": [[115, 213]]}]}], "context_tokens": [["Protection", 0], ["and", 11], ["replenishment", 15], ["of", 29], ["a", 32], ["functional", 34], ["pancreatic", 45], ["\u03b2", 56], ["-", 57], ["cell", 58], ["mass", 63], ["(", 68], ["BCM", 69], [")", 72], ["are", 74], ["key", 78], ["goals", 82], ["of", 88], ["all", 91], ["diabetes", 95], ["therapies", 104], [".", 113], ["Apelin", 115], [",", 121], ["a", 123], ["small", 125], ["regulatory", 131], ["peptide", 142], [",", 149], ["is", 151], ["the", 154], ["endogenous", 158], ["ligand", 169], ["for", 176], ["the", 180], ["apelin", 184], ["receptor", 191], ["(", 200], ["APJ", 201], [")", 204], ["receptor", 206], [".", 214], ["The", 216], ["apelin", 220], ["-", 226], ["APJ", 227], ["signaling", 231], ["system", 241], ["is", 248], ["expressed", 251], ["in", 261], ["rodent", 264], ["and", 271], ["human", 275], ["islet", 281], ["cells", 287], [".", 292], ["Apelin", 294], ["exposure", 301], ["has", 310], ["been", 314], ["shown", 319], ["to", 325], ["inhibit", 328], ["and", 336], ["to", 340], ["stimulate", 343], ["insulin", 353], ["secretion", 361], [".", 370], ["Our", 372], ["aim", 376], ["was", 380], ["to", 384], ["assess", 387], ["the", 394], ["influence", 398], ["of", 408], ["a", 411], ["selective", 413], ["APJ", 423], ["deletion", 427], ["in", 436], ["pancreatic", 439], ["islet", 450], ["cells", 456], ["on", 462], ["islet", 465], ["homeostasis", 471], ["and", 483], ["glucose", 487], ["tolerance", 495], ["in", 505], ["mice", 508], [".", 512], ["Cre", 514], ["-", 517], ["LoxP", 518], ["strategy", 523], ["was", 532], ["utilized", 536], ["to", 545], ["mediate", 548], ["islet", 556], ["APJ", 562], ["deletion", 566], [".", 574], ["APJ", 576], ["deletion", 580], ["in", 589], ["islet", 592], ["cells", 598], ["(", 604], ["APJ(\u0394islet", 605], [")", 615], [")", 616], ["resulted", 618], ["in", 627], ["a", 630], ["significantly", 632], ["reduced", 646], ["islet", 654], ["size", 660], [",", 664], ["density", 666], ["and", 674], ["BCM", 678], [".", 681], ["An", 683], ["ip", 686], ["glucose", 689], ["tolerance", 697], ["test", 707], ["showed", 712], ["significantly", 719], ["impaired", 733], ["glucose", 742], ["clearance", 750], ["in", 760], ["APJ(\u0394islet", 763], [")", 773], ["mice", 775], [".", 779], ["APJ(\u0394islet", 781], [")", 791], ["mice", 793], ["were", 798], ["not", 803], ["insulin", 807], ["resistant", 815], ["and", 825], ["in", 829], ["vivo", 832], ["glucose", 837], ["-", 844], ["stimulated", 845], ["insulin", 856], ["secretion", 864], ["was", 874], ["reduced", 878], ["modestly", 886], [".", 894], ["In", 896], ["vitro", 899], ["glucose", 905], ["-", 912], ["stimulated", 913], ["insulin", 924], ["secretion", 932], ["showed", 942], ["a", 949], ["significantly", 951], ["reduced", 965], ["insulin", 973], ["secretion", 981], ["by", 991], ["islets", 994], ["from", 1001], ["APJ(\u0394islet", 1006], [")", 1016], ["mice", 1018], [".", 1022], ["Glucose", 1024], ["clearance", 1032], ["in", 1042], ["response", 1045], ["to", 1054], ["ip", 1057], ["glucose", 1060], ["tolerance", 1068], ["test", 1078], ["in", 1083], ["obese", 1086], ["APJ(\u0394islet", 1092], [")", 1102], ["mice", 1104], ["fed", 1109], ["a", 1113], ["chronic", 1115], ["high", 1123], ["-", 1127], ["fat", 1128], ["(", 1132], ["HF", 1133], [")", 1135], ["diet", 1137], [",", 1141], ["but", 1143], ["not", 1147], ["pregnant", 1151], ["APJ(\u0394islet", 1160], [")", 1170], ["mice", 1172], [",", 1176], ["was", 1178], ["impaired", 1182], ["significantly", 1191], [".", 1204], ["In", 1206], ["addition", 1209], [",", 1217], ["the", 1219], ["obesity", 1223], ["-", 1230], ["induced", 1231], ["adaptive", 1239], ["elevations", 1248], ["in", 1259], ["mean", 1262], ["islet", 1267], ["size", 1273], ["and", 1278], ["fractional", 1282], ["islet", 1293], ["area", 1299], ["were", 1304], ["reduced", 1309], ["significantly", 1317], ["in", 1331], ["obese", 1334], ["APJ(\u0394islet", 1340], [")", 1350], ["mice", 1352], ["when", 1357], ["compared", 1362], ["with", 1371], ["wild", 1376], ["-", 1380], ["type", 1381], ["mice", 1386], [".", 1390], ["Together", 1392], [",", 1400], ["these", 1402], ["findings", 1408], ["demonstrate", 1417], ["a", 1429], ["stimulatory", 1431], ["role", 1443], ["for", 1448], ["the", 1452], ["islet", 1456], ["cell", 1462], ["apelin", 1467], ["-", 1473], ["APJ", 1474], ["signaling", 1478], ["axis", 1488], ["in", 1493], ["regulation", 1496], ["of", 1507], ["pancreatic", 1510], ["islet", 1521], ["homeostasis", 1527], ["and", 1539], ["in", 1543], ["metabolic", 1546], ["induced", 1556], ["\u03b2", 1564], ["-", 1565], ["cell", 1566], ["hyperplasia", 1571], [".", 1582], ["The", 1584], ["results", 1588], ["indicate", 1596], ["the", 1605], ["apelin", 1609], ["-", 1615], ["APJ", 1616], ["system", 1620], ["can", 1627], ["be", 1631], ["exploited", 1634], ["for", 1644], ["replenishment", 1648], ["of", 1662], ["BCM", 1665], [".", 1668]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.- and mosquito bite\u2013delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "bff1390d69824f58b4c462e5805f90f1", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[0, 0], [35, 35], [58, 58]], "char_spans": [[0, 6], [196, 202], [314, 320]]}]}], "context_tokens": [["Malaria", 0], [",", 7], ["which", 9], ["is", 15], ["the", 18], ["result", 22], ["of", 29], ["Plasmodium", 32], ["falciparum", 43], ["infection", 54], [",", 63], ["is", 65], ["a", 68], ["global", 70], ["health", 77], ["threat", 84], ["that", 91], ["resulted", 96], ["in", 105], ["655,000", 108], ["deaths", 116], ["and", 123], ["216", 127], ["million", 131], ["clinical", 139], ["cases", 148], ["in", 154], ["2010", 157], ["alone", 162], [".", 167], ["Recent", 169], ["phase", 176], ["3", 182], ["trials", 184], ["with", 191], ["malaria", 196], ["vaccine", 204], ["candidate", 212], ["RTS", 222], [",", 225], ["S", 226], ["/", 227], ["AS01", 228], ["(", 233], ["RTS", 234], [",", 237], ["S", 238], [")", 239], ["in", 241], ["children", 244], ["has", 253], ["demonstrated", 257], ["modest", 270], ["efficacy", 277], ["against", 286], ["clinical", 294], ["and", 303], ["severe", 307], ["malaria", 314], [".", 321], ["RTS", 323], [",", 326], ["S", 327], ["targets", 329], ["the", 337], ["pre", 341], ["-", 344], ["erythrocytic", 345], ["phase", 358], ["of", 364], ["the", 367], ["disease", 371], ["and", 379], ["induces", 383], ["high", 391], ["antibody", 396], ["titers", 405], ["against", 412], ["the", 420], ["P.", 424], ["falciparum", 427], ["circumsporozoite", 438], ["protein", 455], ["(", 463], ["CSP", 464], [")", 467], ["and", 469], ["a", 473], ["moderate", 475], ["CD4(+", 484], [")", 489], ["T", 491], ["cell", 493], ["response", 498], [".", 506], ["The", 508], ["individual", 512], ["contribution", 523], ["of", 536], ["these", 539], ["adaptive", 545], ["immune", 554], ["responses", 561], ["to", 571], ["protection", 574], ["from", 585], ["infection", 590], ["remains", 600], ["unknown", 608], [".", 615], ["Here", 617], [",", 621], ["we", 623], ["found", 626], ["that", 632], ["prophylactic", 637], ["administration", 650], ["of", 665], ["anti", 668], ["-", 672], ["CSP", 673], ["mAbs", 677], ["derived", 682], ["from", 690], ["an", 695], ["RTS", 698], [",", 701], ["S", 702], ["-", 703], ["vaccinated", 704], ["recipient", 715], ["fully", 725], ["protected", 731], ["mice", 741], ["with", 746], ["humanized", 751], ["livers", 761], ["from", 768], ["i.v.-", 773], ["and", 779], ["mosquito", 783], ["bite", 792], ["\u2013", 796], ["delivered", 797], ["P.", 807], ["falciparum", 810], ["sporozoite", 821], ["challenge", 832], [".", 841], ["Titers", 843], ["of", 850], ["anti", 853], ["-", 857], ["CSP", 858], ["that", 862], ["conveyed", 867], ["full", 876], ["protection", 881], ["were", 892], ["within", 897], ["the", 904], ["range", 908], ["observed", 914], ["in", 923], ["human", 926], ["RTS", 932], [",", 935], ["S", 936], ["vaccine", 938], ["recipients", 946], [".", 956], ["Increasing", 958], ["anti", 969], ["-", 973], ["CSP", 974], ["titers", 978], ["resulted", 985], ["in", 994], ["a", 997], ["dose", 999], ["-", 1003], ["dependent", 1004], ["reduction", 1014], ["of", 1024], ["the", 1027], ["liver", 1031], ["parasite", 1037], ["burden", 1046], [".", 1052], ["These", 1054], ["data", 1060], ["indicate", 1065], ["that", 1074], ["RTS", 1079], [",", 1082], ["S", 1083], ["-", 1084], ["induced", 1085], ["antibodies", 1093], ["are", 1104], ["protective", 1108], ["and", 1119], ["provide", 1123], ["sterilizing", 1131], ["immunity", 1143], ["against", 1152], ["P.", 1160], ["falciparum", 1163], ["infection", 1174], ["when", 1184], ["reaching", 1189], ["or", 1198], ["exceeding", 1201], ["a", 1211], ["critical", 1213], ["plasma", 1222], ["concentration", 1229], [".", 1242]]}
{"context": "Autosomal-recessive hereditary spastic paraplegias (AR-HSP) consist of a genetically diverse group of neurodegenerative diseases characterised by pyramidal tracts dysfunction. The causative genes for many types of AR-HSP remain elusive. We tried to identify the gene mutation for AR-HSP with cerebellar ataxia and neuropathy. This study included two patients in a Japanese family with their parents who are first cousins. Neurological examination and gene analysis were conducted in the two patients and two normal family members. We undertook genome-wide linkage analysis employing single nucleotide polymorphism arrays using the two patients' DNAs and exome sequencing using one patient's sample. We detected a homozygous missense mutation (c.4189T>G, p.F1397V) in the lysosomal trafficking regulator (LYST) gene, which is described as the causative gene for Ch\u00e9diak-Higashi syndrome (CHS). CHS is a rare autosomal-recessive syndrome characterised by hypopigmentation, severe immune deficiency, a bleeding tendency and progressive neurological dysfunction. This mutation was co-segregated with the disease in the family and was located at well-conserved amino acid. This LYST mutation was not found in 200 Japanese control DNAs. Microscopic observation of peripheral blood in the two patients disclosed large peroxidase-positive granules in both patients' granulocytes, although they had no symptoms of immune deficiency or bleeding tendency. We diagnosed these patients as having adult CHS presenting spastic paraplegia with cerebellar ataxia and neuropathy. The clinical spectrum of CHS is broader than previously recognised. Adult CHS must be considered in the differential diagnosis of AR-HSP.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "25cc4073015c444db3084d4edbb2c04f", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[138, 140]], "char_spans": [[804, 813]]}]}], "context_tokens": [["Autosomal", 0], ["-", 9], ["recessive", 10], ["hereditary", 20], ["spastic", 31], ["paraplegias", 39], ["(", 51], ["AR", 52], ["-", 54], ["HSP", 55], [")", 58], ["consist", 60], ["of", 68], ["a", 71], ["genetically", 73], ["diverse", 85], ["group", 93], ["of", 99], ["neurodegenerative", 102], ["diseases", 120], ["characterised", 129], ["by", 143], ["pyramidal", 146], ["tracts", 156], ["dysfunction", 163], [".", 174], ["The", 176], ["causative", 180], ["genes", 190], ["for", 196], ["many", 200], ["types", 205], ["of", 211], ["AR", 214], ["-", 216], ["HSP", 217], ["remain", 221], ["elusive", 228], [".", 235], ["We", 237], ["tried", 240], ["to", 246], ["identify", 249], ["the", 258], ["gene", 262], ["mutation", 267], ["for", 276], ["AR", 280], ["-", 282], ["HSP", 283], ["with", 287], ["cerebellar", 292], ["ataxia", 303], ["and", 310], ["neuropathy", 314], [".", 324], ["This", 326], ["study", 331], ["included", 337], ["two", 346], ["patients", 350], ["in", 359], ["a", 362], ["Japanese", 364], ["family", 373], ["with", 380], ["their", 385], ["parents", 391], ["who", 399], ["are", 403], ["first", 407], ["cousins", 413], [".", 420], ["Neurological", 422], ["examination", 435], ["and", 447], ["gene", 451], ["analysis", 456], ["were", 465], ["conducted", 470], ["in", 480], ["the", 483], ["two", 487], ["patients", 491], ["and", 500], ["two", 504], ["normal", 508], ["family", 515], ["members", 522], [".", 529], ["We", 531], ["undertook", 534], ["genome", 544], ["-", 550], ["wide", 551], ["linkage", 556], ["analysis", 564], ["employing", 573], ["single", 583], ["nucleotide", 590], ["polymorphism", 601], ["arrays", 614], ["using", 621], ["the", 627], ["two", 631], ["patients", 635], ["'", 643], ["DNAs", 645], ["and", 650], ["exome", 654], ["sequencing", 660], ["using", 671], ["one", 677], ["patient", 681], ["'s", 688], ["sample", 691], [".", 697], ["We", 699], ["detected", 702], ["a", 711], ["homozygous", 713], ["missense", 724], ["mutation", 733], ["(", 742], ["c.4189T", 743], [">", 750], ["G", 751], [",", 752], ["p", 754], [".", 755], ["F1397V", 756], [")", 762], ["in", 764], ["the", 767], ["lysosomal", 771], ["trafficking", 781], ["regulator", 793], ["(", 803], ["LYST", 804], [")", 808], ["gene", 810], [",", 814], ["which", 816], ["is", 822], ["described", 825], ["as", 835], ["the", 838], ["causative", 842], ["gene", 852], ["for", 857], ["Ch\u00e9diak", 861], ["-", 868], ["Higashi", 869], ["syndrome", 877], ["(", 886], ["CHS", 887], [")", 890], [".", 891], ["CHS", 893], ["is", 897], ["a", 900], ["rare", 902], ["autosomal", 907], ["-", 916], ["recessive", 917], ["syndrome", 927], ["characterised", 936], ["by", 950], ["hypopigmentation", 953], [",", 969], ["severe", 971], ["immune", 978], ["deficiency", 985], [",", 995], ["a", 997], ["bleeding", 999], ["tendency", 1008], ["and", 1017], ["progressive", 1021], ["neurological", 1033], ["dysfunction", 1046], [".", 1057], ["This", 1059], ["mutation", 1064], ["was", 1073], ["co", 1077], ["-", 1079], ["segregated", 1080], ["with", 1091], ["the", 1096], ["disease", 1100], ["in", 1108], ["the", 1111], ["family", 1115], ["and", 1122], ["was", 1126], ["located", 1130], ["at", 1138], ["well", 1141], ["-", 1145], ["conserved", 1146], ["amino", 1156], ["acid", 1162], [".", 1166], ["This", 1168], ["LYST", 1173], ["mutation", 1178], ["was", 1187], ["not", 1191], ["found", 1195], ["in", 1201], ["200", 1204], ["Japanese", 1208], ["control", 1217], ["DNAs", 1225], [".", 1229], ["Microscopic", 1231], ["observation", 1243], ["of", 1255], ["peripheral", 1258], ["blood", 1269], ["in", 1275], ["the", 1278], ["two", 1282], ["patients", 1286], ["disclosed", 1295], ["large", 1305], ["peroxidase", 1311], ["-", 1321], ["positive", 1322], ["granules", 1331], ["in", 1340], ["both", 1343], ["patients", 1348], ["'", 1356], ["granulocytes", 1358], [",", 1370], ["although", 1372], ["they", 1381], ["had", 1386], ["no", 1390], ["symptoms", 1393], ["of", 1402], ["immune", 1405], ["deficiency", 1412], ["or", 1423], ["bleeding", 1426], ["tendency", 1435], [".", 1443], ["We", 1445], ["diagnosed", 1448], ["these", 1458], ["patients", 1464], ["as", 1473], ["having", 1476], ["adult", 1483], ["CHS", 1489], ["presenting", 1493], ["spastic", 1504], ["paraplegia", 1512], ["with", 1523], ["cerebellar", 1528], ["ataxia", 1539], ["and", 1546], ["neuropathy", 1550], [".", 1560], ["The", 1562], ["clinical", 1566], ["spectrum", 1575], ["of", 1584], ["CHS", 1587], ["is", 1591], ["broader", 1594], ["than", 1602], ["previously", 1607], ["recognised", 1618], [".", 1628], ["Adult", 1630], ["CHS", 1636], ["must", 1640], ["be", 1645], ["considered", 1648], ["in", 1659], ["the", 1662], ["differential", 1666], ["diagnosis", 1679], ["of", 1689], ["AR", 1692], ["-", 1694], ["HSP", 1695], [".", 1698]]}
{"context": "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane. We determined the structure of supercomplex I", "qas": [{"question": "Where is the respirasome located?", "answers": ["In the inner mitochondrial membrane"], "qid": "33ef66d3e9fc40e58b68c9f3044a109b", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["respirasome", 13], ["located", 25], ["?", 32]], "detected_answers": [{"text": "In the inner mitochondrial membrane", "token_spans": [[14, 18]], "char_spans": [[92, 126]]}]}], "context_tokens": [["Respirasomes", 0], ["are", 13], ["macromolecular", 17], ["assemblies", 32], ["of", 43], ["the", 46], ["respiratory", 50], ["chain", 62], ["complexes", 68], ["I", 78], [",", 79], ["III", 81], ["and", 85], ["IV", 89], ["in", 92], ["the", 95], ["inner", 99], ["mitochondrial", 105], ["membrane", 119], [".", 127], ["We", 129], ["determined", 132], ["the", 143], ["structure", 147], ["of", 157], ["supercomplex", 160], ["I", 173]]}
{"context": "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR (Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent M. tuberculosis infection. In silico analysis of the DosR regulon in BCG and M. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens. Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding selected latency antigens. Since immune responses to TB latency antigens have been associated with control of latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating DosR regulon antigens to complement and improve the current BCG vaccine.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "f40c5ca38b964c3fbfd353444320a3b9", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[116, 117]], "char_spans": [[695, 702]]}]}], "context_tokens": [["Mycobacterium", 0], ["bovis", 14], ["BCG", 20], ["is", 24], ["widely", 27], ["used", 34], ["as", 39], ["a", 42], ["vaccine", 44], ["against", 52], ["tuberculosis", 60], ["(", 73], ["TB", 74], [")", 76], [",", 77], ["despite", 79], ["its", 87], ["variable", 91], ["protective", 100], ["efficacy", 111], [".", 119], ["Relatively", 121], ["little", 132], ["is", 139], ["known", 142], ["about", 148], ["the", 154], ["immune", 158], ["response", 165], ["profiles", 174], ["following", 183], ["BCG", 193], ["vaccination", 197], ["in", 209], ["relation", 212], ["to", 221], ["protection", 224], ["against", 235], ["TB", 243], [".", 245], ["Here", 247], ["we", 252], ["tested", 255], ["whether", 262], ["BCG", 270], ["vaccination", 274], ["results", 286], ["in", 294], ["immune", 297], ["responses", 304], ["to", 314], ["DosR", 317], ["(", 322], ["Rv3133c", 323], [")", 330], ["regulon", 332], ["-", 339], ["encoded", 340], ["proteins", 348], [".", 356], ["These", 358], ["so", 364], ["-", 366], ["called", 367], ["TB", 374], ["latency", 377], ["antigens", 385], ["are", 394], ["targeted", 398], ["by", 407], ["the", 410], ["immune", 414], ["system", 421], ["during", 428], ["persistent", 435], ["Mycobacterium", 446], ["tuberculosis", 460], ["infection", 473], ["and", 483], ["have", 487], ["been", 492], ["associated", 497], ["with", 508], ["immunity", 513], ["against", 522], ["latent", 530], ["M.", 537], ["tuberculosis", 540], ["infection", 553], [".", 562], ["In", 564], ["silico", 567], ["analysis", 574], ["of", 583], ["the", 586], ["DosR", 590], ["regulon", 595], ["in", 603], ["BCG", 606], ["and", 610], ["M.", 614], ["tuberculosis", 617], ["showed", 630], ["at", 637], ["least", 640], ["97", 646], ["%", 648], ["amino", 650], ["acid", 656], ["sequence", 661], ["homology", 670], [",", 678], ["with", 680], ["41", 685], ["out", 688], ["of", 692], ["48", 695], ["genes", 698], ["being", 704], ["identical", 710], [".", 719], ["Transcriptional", 721], ["profiling", 737], ["of", 747], ["14", 750], ["different", 753], ["BCG", 763], ["strains", 767], [",", 774], ["under", 776], ["hypoxia", 782], ["and", 790], ["nitric", 794], ["oxide", 801], ["exposure", 807], ["in", 816], ["vitro", 819], [",", 824], ["revealed", 826], ["a", 835], ["functional", 837], ["DosR", 848], ["regulon", 853], ["similar", 861], ["to", 869], ["that", 872], ["observed", 877], ["in", 886], ["M.", 889], ["tuberculosis", 892], [".", 904], ["Next", 906], [",", 910], ["we", 912], ["assessed", 915], ["human", 924], ["immune", 930], ["responses", 937], ["to", 947], ["a", 950], ["series", 952], ["of", 959], ["immunodominant", 962], ["TB", 977], ["latency", 980], ["antigens", 988], ["and", 997], ["found", 1001], ["that", 1007], ["BCG", 1012], ["vaccination", 1016], ["fails", 1028], ["to", 1034], ["induce", 1037], ["significant", 1044], ["responses", 1056], ["to", 1066], ["latency", 1069], ["antigens", 1077], [".", 1085], ["Similar", 1087], ["results", 1095], ["were", 1103], ["obtained", 1108], ["with", 1117], ["BCG", 1122], ["-", 1125], ["vaccinated", 1126], ["BALB", 1137], ["/", 1141], ["c", 1142], ["mice", 1144], [".", 1148], ["In", 1150], ["contrast", 1153], [",", 1161], ["responses", 1163], ["to", 1173], ["latency", 1176], ["antigens", 1184], ["were", 1193], ["observed", 1198], ["in", 1207], ["individuals", 1210], ["with", 1222], ["suspected", 1227], ["exposure", 1237], ["to", 1246], ["TB", 1249], ["(", 1252], ["as", 1253], ["indicated", 1256], ["by", 1266], ["positive", 1269], ["gamma", 1278], ["interferon", 1284], ["responses", 1295], ["to", 1305], ["TB", 1308], ["-", 1310], ["specific", 1311], ["antigens", 1320], ["ESAT-6", 1329], ["and", 1336], ["CFP-10", 1340], [")", 1346], ["and", 1348], ["in", 1352], ["mice", 1355], ["vaccinated", 1360], ["with", 1371], ["plasmid", 1376], ["DNA", 1384], ["encoding", 1388], ["selected", 1397], ["latency", 1406], ["antigens", 1414], [".", 1422], ["Since", 1424], ["immune", 1430], ["responses", 1437], ["to", 1447], ["TB", 1450], ["latency", 1453], ["antigens", 1461], ["have", 1470], ["been", 1475], ["associated", 1480], ["with", 1491], ["control", 1496], ["of", 1504], ["latent", 1507], ["M.", 1514], ["tuberculosis", 1517], ["infection", 1530], [",", 1539], ["our", 1541], ["findings", 1545], ["support", 1554], ["the", 1562], ["development", 1566], ["of", 1578], ["vaccination", 1581], ["strategies", 1593], ["incorporating", 1604], ["DosR", 1618], ["regulon", 1623], ["antigens", 1631], ["to", 1640], ["complement", 1643], ["and", 1654], ["improve", 1658], ["the", 1666], ["current", 1670], ["BCG", 1678], ["vaccine", 1682], [".", 1689]]}
{"context": "Identifying and tackling the social determinants of infectious diseases has become a public health priority following the recognition that individuals with lower socioeconomic status are disproportionately affected by infectious diseases. In many parts of the world, epidemiologically and genotypically defined community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged to become frequent causes of hospital infection. The aim of this study was to use spatial models with adjustment for area-level hospital attendance to determine the transmission niche of genotypically defined CA- and health-care-associated (HA)-MRSA strains across a diverse region of South East London and to explore a potential link between MRSA carriage and markers of social and material deprivation. This study involved spatial analysis of cross-sectional data linked with all MRSA isolates identified by three National Health Service (NHS) microbiology laboratories between 1 November 2011 and 29 February 2012. The cohort of hospital-based NHS microbiology diagnostic services serves 867,254 usual residents in the Lambeth, Southwark, and Lewisham boroughs in South East London, United Kingdom (UK). Isolates were classified as HA- or CA-MRSA based on whole genome sequencing. All MRSA cases identified over 4 mo within the three-borough catchment area (n = 471) were mapped to small geographies and linked to area-level aggregated socioeconomic and demographic data. Disease mapping and ecological regression models were used to infer the most likely transmission niches for each MRSA genetic classification and to describe the spatial epidemiology of MRSA in relation to social determinants. Specifically, we aimed to identify demographic and socioeconomic population traits that explain cross-area extra variation in HA- and CA-MRSA relative risks following adjustment for hospital attendance data. We explored the potential for associations with the English Indices of Deprivation 2010 (including the Index of Multiple Deprivation and several deprivation domains and subdomains) and the 2011 England and Wales census demographic and socioeconomic indicators (including numbers of households by deprivation dimension) and indicators of population health. Both CA-and HA-MRSA were associated with household deprivation (CA-MRSA relative risk [RR]: 1.72 [1.03-2.94]; HA-MRSA RR: 1.57 [1.06-2.33]), which was correlated with hospital attendance (Pearson correlation coefficient [PCC] = 0.76). HA-MRSA was also associated with poor health (RR: 1.10 [1.01-1.19]) and residence in communal care homes (RR: 1.24 [1.12-1.37]), whereas CA-MRSA was linked with household overcrowding (RR: 1.58 [1.04-2.41]) and wider barriers, which represent a combined score for household overcrowding, low income, and homelessness (RR: 1.76 [1.16-2.70]). CA-MRSA was also associated with recent immigration to the UK (RR: 1.77 [1.19-2.66]). For the area-level variation in RR for CA-MRSA, 28.67% was attributable to the spatial arrangement of target geographies, compared with only 0.09% for HA-MRSA. An advantage to our study is that it provided a representative sample of usual residents receiving care in the catchment areas. A limitation is that relationships apparent in aggregated data analyses cannot be assumed to operate at the individual level. There was no evidence of community transmission of HA-MRSA strains, implying that HA-MRSA cases identified in the community originate from the hospital reservoir and are maintained by frequent attendance at health care facilities. In contrast, there was a high risk of CA-MRSA in deprived areas linked with overcrowding, homelessness, low income, and recent immigration to the UK, which was not explainable by health care exposure. Furthermore, areas adjacent to these deprived areas were themselves at greater risk of CA-MRSA, indicating community transmission of CA-MRSA. This ongoing community transmission could lead to CA-MRSA becoming the dominant strain types carried by patients admitted to hospital, particularly if successful hospital-based MRSA infection control programmes are maintained. These results suggest that community infection control programmes targeting transmission of CA-MRSA will be required to control MRSA in both the community and hospital. These epidemiological changes will also have implications for effectiveness of risk-factor-based hospital admission MRSA screening programmes.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c8be4f51b2ab4a5381c642b0ef7213c6", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[213, 213], [141, 141], [205, 205], [275, 275], [429, 429], [629, 629], [715, 715], [622, 622], [707, 707], [765, 765], [771, 771], [383, 383], [513, 513], [399, 399], [305, 305], [118, 118], [54, 54], [374, 374], [662, 662], [726, 726], [796, 796], [265, 265], [567, 567], [745, 745], [466, 466], [545, 545]], "char_spans": [[1297, 1300], [891, 894], [1254, 1257], [1669, 1672], [2512, 2515], [3435, 3438], [3918, 3921], [3404, 3407], [3872, 3875], [4246, 4249], [4279, 4282], [2341, 2344], [2853, 2856], [2387, 2390], [1847, 1850], [752, 755], [382, 385], [2289, 2292], [3622, 3625], [3977, 3980], [4436, 4439], [1597, 1600], [3090, 3093], [4101, 4104], [2649, 2652], [2978, 2981]]}]}], "context_tokens": [["Identifying", 0], ["and", 12], ["tackling", 16], ["the", 25], ["social", 29], ["determinants", 36], ["of", 49], ["infectious", 52], ["diseases", 63], ["has", 72], ["become", 76], ["a", 83], ["public", 85], ["health", 92], ["priority", 99], ["following", 108], ["the", 118], ["recognition", 122], ["that", 134], ["individuals", 139], ["with", 151], ["lower", 156], ["socioeconomic", 162], ["status", 176], ["are", 183], ["disproportionately", 187], ["affected", 206], ["by", 215], ["infectious", 218], ["diseases", 229], [".", 237], ["In", 239], ["many", 242], ["parts", 247], ["of", 253], ["the", 256], ["world", 260], [",", 265], ["epidemiologically", 267], ["and", 285], ["genotypically", 289], ["defined", 303], ["community", 311], ["-", 320], ["associated", 321], ["(", 332], ["CA", 333], [")", 335], ["methicillin", 337], ["-", 348], ["resistant", 349], ["Staphylococcus", 359], ["aureus", 374], ["(", 381], ["MRSA", 382], [")", 386], ["strains", 388], ["have", 396], ["emerged", 401], ["to", 409], ["become", 412], ["frequent", 419], ["causes", 428], ["of", 435], ["hospital", 438], ["infection", 447], [".", 456], ["The", 458], ["aim", 462], ["of", 466], ["this", 469], ["study", 474], ["was", 480], ["to", 484], ["use", 487], ["spatial", 491], ["models", 499], ["with", 506], ["adjustment", 511], ["for", 522], ["area", 526], ["-", 530], ["level", 531], ["hospital", 537], ["attendance", 546], ["to", 557], ["determine", 560], ["the", 570], ["transmission", 574], ["niche", 587], ["of", 593], ["genotypically", 596], ["defined", 610], ["CA-", 618], ["and", 622], ["health", 626], ["-", 632], ["care", 633], ["-", 637], ["associated", 638], ["(", 649], ["HA)-MRSA", 650], ["strains", 659], ["across", 667], ["a", 674], ["diverse", 676], ["region", 684], ["of", 691], ["South", 694], ["East", 700], ["London", 705], ["and", 712], ["to", 716], ["explore", 719], ["a", 727], ["potential", 729], ["link", 739], ["between", 744], ["MRSA", 752], ["carriage", 757], ["and", 766], ["markers", 770], ["of", 778], ["social", 781], ["and", 788], ["material", 792], ["deprivation", 801], [".", 812], ["This", 814], ["study", 819], ["involved", 825], ["spatial", 834], ["analysis", 842], ["of", 851], ["cross", 854], ["-", 859], ["sectional", 860], ["data", 870], ["linked", 875], ["with", 882], ["all", 887], ["MRSA", 891], ["isolates", 896], ["identified", 905], ["by", 916], ["three", 919], ["National", 925], ["Health", 934], ["Service", 941], ["(", 949], ["NHS", 950], [")", 953], ["microbiology", 955], ["laboratories", 968], ["between", 981], ["1", 989], ["November", 991], ["2011", 1000], ["and", 1005], ["29", 1009], ["February", 1012], ["2012", 1021], [".", 1025], ["The", 1027], ["cohort", 1031], ["of", 1038], ["hospital", 1041], ["-", 1049], ["based", 1050], ["NHS", 1056], ["microbiology", 1060], ["diagnostic", 1073], ["services", 1084], ["serves", 1093], ["867,254", 1100], ["usual", 1108], ["residents", 1114], ["in", 1124], ["the", 1127], ["Lambeth", 1131], [",", 1138], ["Southwark", 1140], [",", 1149], ["and", 1151], ["Lewisham", 1155], ["boroughs", 1164], ["in", 1173], ["South", 1176], ["East", 1182], ["London", 1187], [",", 1193], ["United", 1195], ["Kingdom", 1202], ["(", 1210], ["UK", 1211], [")", 1213], [".", 1214], ["Isolates", 1216], ["were", 1225], ["classified", 1230], ["as", 1241], ["HA-", 1244], ["or", 1248], ["CA", 1251], ["-", 1253], ["MRSA", 1254], ["based", 1259], ["on", 1265], ["whole", 1268], ["genome", 1274], ["sequencing", 1281], [".", 1291], ["All", 1293], ["MRSA", 1297], ["cases", 1302], ["identified", 1308], ["over", 1319], ["4", 1324], ["mo", 1326], ["within", 1329], ["the", 1336], ["three", 1340], ["-", 1345], ["borough", 1346], ["catchment", 1354], ["area", 1364], ["(", 1369], ["n", 1370], ["=", 1372], ["471", 1374], [")", 1377], ["were", 1379], ["mapped", 1384], ["to", 1391], ["small", 1394], ["geographies", 1400], ["and", 1412], ["linked", 1416], ["to", 1423], ["area", 1426], ["-", 1430], ["level", 1431], ["aggregated", 1437], ["socioeconomic", 1448], ["and", 1462], ["demographic", 1466], ["data", 1478], [".", 1482], ["Disease", 1484], ["mapping", 1492], ["and", 1500], ["ecological", 1504], ["regression", 1515], ["models", 1526], ["were", 1533], ["used", 1538], ["to", 1543], ["infer", 1546], ["the", 1552], ["most", 1556], ["likely", 1561], ["transmission", 1568], ["niches", 1581], ["for", 1588], ["each", 1592], ["MRSA", 1597], ["genetic", 1602], ["classification", 1610], ["and", 1625], ["to", 1629], ["describe", 1632], ["the", 1641], ["spatial", 1645], ["epidemiology", 1653], ["of", 1666], ["MRSA", 1669], ["in", 1674], ["relation", 1677], ["to", 1686], ["social", 1689], ["determinants", 1696], [".", 1708], ["Specifically", 1710], [",", 1722], ["we", 1724], ["aimed", 1727], ["to", 1733], ["identify", 1736], ["demographic", 1745], ["and", 1757], ["socioeconomic", 1761], ["population", 1775], ["traits", 1786], ["that", 1793], ["explain", 1798], ["cross", 1806], ["-", 1811], ["area", 1812], ["extra", 1817], ["variation", 1823], ["in", 1833], ["HA-", 1836], ["and", 1840], ["CA", 1844], ["-", 1846], ["MRSA", 1847], ["relative", 1852], ["risks", 1861], ["following", 1867], ["adjustment", 1877], ["for", 1888], ["hospital", 1892], ["attendance", 1901], ["data", 1912], [".", 1916], ["We", 1918], ["explored", 1921], ["the", 1930], ["potential", 1934], ["for", 1944], ["associations", 1948], ["with", 1961], ["the", 1966], ["English", 1970], ["Indices", 1978], ["of", 1986], ["Deprivation", 1989], ["2010", 2001], ["(", 2006], ["including", 2007], ["the", 2017], ["Index", 2021], ["of", 2027], ["Multiple", 2030], ["Deprivation", 2039], ["and", 2051], ["several", 2055], ["deprivation", 2063], ["domains", 2075], ["and", 2083], ["subdomains", 2087], [")", 2097], ["and", 2099], ["the", 2103], ["2011", 2107], ["England", 2112], ["and", 2120], ["Wales", 2124], ["census", 2130], ["demographic", 2137], ["and", 2149], ["socioeconomic", 2153], ["indicators", 2167], ["(", 2178], ["including", 2179], ["numbers", 2189], ["of", 2197], ["households", 2200], ["by", 2211], ["deprivation", 2214], ["dimension", 2226], [")", 2235], ["and", 2237], ["indicators", 2241], ["of", 2252], ["population", 2255], ["health", 2266], [".", 2272], ["Both", 2274], ["CA", 2279], ["-", 2281], ["and", 2282], ["HA", 2286], ["-", 2288], ["MRSA", 2289], ["were", 2294], ["associated", 2299], ["with", 2310], ["household", 2315], ["deprivation", 2325], ["(", 2337], ["CA", 2338], ["-", 2340], ["MRSA", 2341], ["relative", 2346], ["risk", 2355], ["[", 2360], ["RR", 2361], ["]", 2363], [":", 2364], ["1.72", 2366], ["[", 2371], ["1.03", 2372], ["-", 2376], ["2.94", 2377], ["]", 2381], [";", 2382], ["HA", 2384], ["-", 2386], ["MRSA", 2387], ["RR", 2392], [":", 2394], ["1.57", 2396], ["[", 2401], ["1.06", 2402], ["-", 2406], ["2.33", 2407], ["]", 2411], [")", 2412], [",", 2413], ["which", 2415], ["was", 2421], ["correlated", 2425], ["with", 2436], ["hospital", 2441], ["attendance", 2450], ["(", 2461], ["Pearson", 2462], ["correlation", 2470], ["coefficient", 2482], ["[", 2494], ["PCC", 2495], ["]", 2498], ["=", 2500], ["0.76", 2502], [")", 2506], [".", 2507], ["HA", 2509], ["-", 2511], ["MRSA", 2512], ["was", 2517], ["also", 2521], ["associated", 2526], ["with", 2537], ["poor", 2542], ["health", 2547], ["(", 2554], ["RR", 2555], [":", 2557], ["1.10", 2559], ["[", 2564], ["1.01", 2565], ["-", 2569], ["1.19", 2570], ["]", 2574], [")", 2575], ["and", 2577], ["residence", 2581], ["in", 2591], ["communal", 2594], ["care", 2603], ["homes", 2608], ["(", 2614], ["RR", 2615], [":", 2617], ["1.24", 2619], ["[", 2624], ["1.12", 2625], ["-", 2629], ["1.37", 2630], ["]", 2634], [")", 2635], [",", 2636], ["whereas", 2638], ["CA", 2646], ["-", 2648], ["MRSA", 2649], ["was", 2654], ["linked", 2658], ["with", 2665], ["household", 2670], ["overcrowding", 2680], ["(", 2693], ["RR", 2694], [":", 2696], ["1.58", 2698], ["[", 2703], ["1.04", 2704], ["-", 2708], ["2.41", 2709], ["]", 2713], [")", 2714], ["and", 2716], ["wider", 2720], ["barriers", 2726], [",", 2734], ["which", 2736], ["represent", 2742], ["a", 2752], ["combined", 2754], ["score", 2763], ["for", 2769], ["household", 2773], ["overcrowding", 2783], [",", 2795], ["low", 2797], ["income", 2801], [",", 2807], ["and", 2809], ["homelessness", 2813], ["(", 2826], ["RR", 2827], [":", 2829], ["1.76", 2831], ["[", 2836], ["1.16", 2837], ["-", 2841], ["2.70", 2842], ["]", 2846], [")", 2847], [".", 2848], ["CA", 2850], ["-", 2852], ["MRSA", 2853], ["was", 2858], ["also", 2862], ["associated", 2867], ["with", 2878], ["recent", 2883], ["immigration", 2890], ["to", 2902], ["the", 2905], ["UK", 2909], ["(", 2912], ["RR", 2913], [":", 2915], ["1.77", 2917], ["[", 2922], ["1.19", 2923], ["-", 2927], ["2.66", 2928], ["]", 2932], [")", 2933], [".", 2934], ["For", 2936], ["the", 2940], ["area", 2944], ["-", 2948], ["level", 2949], ["variation", 2955], ["in", 2965], ["RR", 2968], ["for", 2971], ["CA", 2975], ["-", 2977], ["MRSA", 2978], [",", 2982], ["28.67", 2984], ["%", 2989], ["was", 2991], ["attributable", 2995], ["to", 3008], ["the", 3011], ["spatial", 3015], ["arrangement", 3023], ["of", 3035], ["target", 3038], ["geographies", 3045], [",", 3056], ["compared", 3058], ["with", 3067], ["only", 3072], ["0.09", 3077], ["%", 3081], ["for", 3083], ["HA", 3087], ["-", 3089], ["MRSA", 3090], [".", 3094], ["An", 3096], ["advantage", 3099], ["to", 3109], ["our", 3112], ["study", 3116], ["is", 3122], ["that", 3125], ["it", 3130], ["provided", 3133], ["a", 3142], ["representative", 3144], ["sample", 3159], ["of", 3166], ["usual", 3169], ["residents", 3175], ["receiving", 3185], ["care", 3195], ["in", 3200], ["the", 3203], ["catchment", 3207], ["areas", 3217], [".", 3222], ["A", 3224], ["limitation", 3226], ["is", 3237], ["that", 3240], ["relationships", 3245], ["apparent", 3259], ["in", 3268], ["aggregated", 3271], ["data", 3282], ["analyses", 3287], ["can", 3296], ["not", 3299], ["be", 3303], ["assumed", 3306], ["to", 3314], ["operate", 3317], ["at", 3325], ["the", 3328], ["individual", 3332], ["level", 3343], [".", 3348], ["There", 3350], ["was", 3356], ["no", 3360], ["evidence", 3363], ["of", 3372], ["community", 3375], ["transmission", 3385], ["of", 3398], ["HA", 3401], ["-", 3403], ["MRSA", 3404], ["strains", 3409], [",", 3416], ["implying", 3418], ["that", 3427], ["HA", 3432], ["-", 3434], ["MRSA", 3435], ["cases", 3440], ["identified", 3446], ["in", 3457], ["the", 3460], ["community", 3464], ["originate", 3474], ["from", 3484], ["the", 3489], ["hospital", 3493], ["reservoir", 3502], ["and", 3512], ["are", 3516], ["maintained", 3520], ["by", 3531], ["frequent", 3534], ["attendance", 3543], ["at", 3554], ["health", 3557], ["care", 3564], ["facilities", 3569], [".", 3579], ["In", 3581], ["contrast", 3584], [",", 3592], ["there", 3594], ["was", 3600], ["a", 3604], ["high", 3606], ["risk", 3611], ["of", 3616], ["CA", 3619], ["-", 3621], ["MRSA", 3622], ["in", 3627], ["deprived", 3630], ["areas", 3639], ["linked", 3645], ["with", 3652], ["overcrowding", 3657], [",", 3669], ["homelessness", 3671], [",", 3683], ["low", 3685], ["income", 3689], [",", 3695], ["and", 3697], ["recent", 3701], ["immigration", 3708], ["to", 3720], ["the", 3723], ["UK", 3727], [",", 3729], ["which", 3731], ["was", 3737], ["not", 3741], ["explainable", 3745], ["by", 3757], ["health", 3760], ["care", 3767], ["exposure", 3772], [".", 3780], ["Furthermore", 3782], [",", 3793], ["areas", 3795], ["adjacent", 3801], ["to", 3810], ["these", 3813], ["deprived", 3819], ["areas", 3828], ["were", 3834], ["themselves", 3839], ["at", 3850], ["greater", 3853], ["risk", 3861], ["of", 3866], ["CA", 3869], ["-", 3871], ["MRSA", 3872], [",", 3876], ["indicating", 3878], ["community", 3889], ["transmission", 3899], ["of", 3912], ["CA", 3915], ["-", 3917], ["MRSA", 3918], [".", 3922], ["This", 3924], ["ongoing", 3929], ["community", 3937], ["transmission", 3947], ["could", 3960], ["lead", 3966], ["to", 3971], ["CA", 3974], ["-", 3976], ["MRSA", 3977], ["becoming", 3982], ["the", 3991], ["dominant", 3995], ["strain", 4004], ["types", 4011], ["carried", 4017], ["by", 4025], ["patients", 4028], ["admitted", 4037], ["to", 4046], ["hospital", 4049], [",", 4057], ["particularly", 4059], ["if", 4072], ["successful", 4075], ["hospital", 4086], ["-", 4094], ["based", 4095], ["MRSA", 4101], ["infection", 4106], ["control", 4116], ["programmes", 4124], ["are", 4135], ["maintained", 4139], [".", 4149], ["These", 4151], ["results", 4157], ["suggest", 4165], ["that", 4173], ["community", 4178], ["infection", 4188], ["control", 4198], ["programmes", 4206], ["targeting", 4217], ["transmission", 4227], ["of", 4240], ["CA", 4243], ["-", 4245], ["MRSA", 4246], ["will", 4251], ["be", 4256], ["required", 4259], ["to", 4268], ["control", 4271], ["MRSA", 4279], ["in", 4284], ["both", 4287], ["the", 4292], ["community", 4296], ["and", 4306], ["hospital", 4310], [".", 4318], ["These", 4320], ["epidemiological", 4326], ["changes", 4342], ["will", 4350], ["also", 4355], ["have", 4360], ["implications", 4365], ["for", 4378], ["effectiveness", 4382], ["of", 4396], ["risk", 4399], ["-", 4403], ["factor", 4404], ["-", 4410], ["based", 4411], ["hospital", 4417], ["admission", 4426], ["MRSA", 4436], ["screening", 4441], ["programmes", 4451], [".", 4461]]}
{"context": "Nerve growth factor (NGF) antagonism has long been proposed as a chronic pain treatment. In 2010, the FDA suspended clinical trials using tanezumab, a humanized monoclonal anti-NGF antibody, to treat osteoarthritis due to worsening joint damage in 16 patients. Increased physical activity in the absence of acute pain which normally prevents self-harm was purported as a potential cause. Such an adverse effect is consistent with an extension of tanezumab's primary mechanism of action by decreasing pain sensitivity below baseline levels. In animal inflammatory pain models, NGF antagonism decreases intraepidermal nerve fiber (IENF) density and attenuates increases in expression of nociception-related proteins, such as calcitonin gene-related peptide (CGRP) and substance P (SP). Little is known of the effects of NGF antagonism in noninflamed animals and the hypoalgesia that ensues. In the current study, we immunized rats with NGF or cytochrome C (cytC) and examined (1) nocifensive behaviors with thermal latencies, mechanical thresholds, the hot plate test, and the tail flick test, (2) IENF density, and (3) expression of CGRP, SP, voltage-gated sodium channel 1.8 (Nav1.8), and glutaminase in subpopulations of dorsal root ganglion (DRG) neurons separated by size and isolectin B4 (IB4) labeling. Rats with high anti-NGF titers had delayed responses on the hot plate test but no other behavioral abnormalities. Delayed hot plate responses correlated with lower IENF density. CGRP and SP expression was decreased principally in medium (400-800 \u03bcm(2)) and small neurons (<400 \u03bcm(2)), respectively, regardless of IB4 labeling. Expression of Nav1.8 was only decreased in small and medium IB4 negative neurons. NGF immunization appears to result in a more profound antagonism of NGF than tanezumab therapy, but we hypothesize that decreases in IENF density and nociception-related protein expression are potential mechanisms for tanezumab-induced hypoalgesia.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "589de266ea4f4f239030a2ea5f61bf8b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[165, 165], [251, 251], [335, 335], [100, 100], [4, 4], [324, 324], [33, 33], [145, 145]], "char_spans": [[934, 936], [1328, 1330], [1785, 1787], [576, 578], [21, 23], [1717, 1719], [177, 179], [818, 820]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["antagonism", 26], ["has", 37], ["long", 41], ["been", 46], ["proposed", 51], ["as", 60], ["a", 63], ["chronic", 65], ["pain", 73], ["treatment", 78], [".", 87], ["In", 89], ["2010", 92], [",", 96], ["the", 98], ["FDA", 102], ["suspended", 106], ["clinical", 116], ["trials", 125], ["using", 132], ["tanezumab", 138], [",", 147], ["a", 149], ["humanized", 151], ["monoclonal", 161], ["anti", 172], ["-", 176], ["NGF", 177], ["antibody", 181], [",", 189], ["to", 191], ["treat", 194], ["osteoarthritis", 200], ["due", 215], ["to", 219], ["worsening", 222], ["joint", 232], ["damage", 238], ["in", 245], ["16", 248], ["patients", 251], [".", 259], ["Increased", 261], ["physical", 271], ["activity", 280], ["in", 289], ["the", 292], ["absence", 296], ["of", 304], ["acute", 307], ["pain", 313], ["which", 318], ["normally", 324], ["prevents", 333], ["self", 342], ["-", 346], ["harm", 347], ["was", 352], ["purported", 356], ["as", 366], ["a", 369], ["potential", 371], ["cause", 381], [".", 386], ["Such", 388], ["an", 393], ["adverse", 396], ["effect", 404], ["is", 411], ["consistent", 414], ["with", 425], ["an", 430], ["extension", 433], ["of", 443], ["tanezumab", 446], ["'s", 455], ["primary", 458], ["mechanism", 466], ["of", 476], ["action", 479], ["by", 486], ["decreasing", 489], ["pain", 500], ["sensitivity", 505], ["below", 517], ["baseline", 523], ["levels", 532], [".", 538], ["In", 540], ["animal", 543], ["inflammatory", 550], ["pain", 563], ["models", 568], [",", 574], ["NGF", 576], ["antagonism", 580], ["decreases", 591], ["intraepidermal", 601], ["nerve", 616], ["fiber", 622], ["(", 628], ["IENF", 629], [")", 633], ["density", 635], ["and", 643], ["attenuates", 647], ["increases", 658], ["in", 668], ["expression", 671], ["of", 682], ["nociception", 685], ["-", 696], ["related", 697], ["proteins", 705], [",", 713], ["such", 715], ["as", 720], ["calcitonin", 723], ["gene", 734], ["-", 738], ["related", 739], ["peptide", 747], ["(", 755], ["CGRP", 756], [")", 760], ["and", 762], ["substance", 766], ["P", 776], ["(", 778], ["SP", 779], [")", 781], [".", 782], ["Little", 784], ["is", 791], ["known", 794], ["of", 800], ["the", 803], ["effects", 807], ["of", 815], ["NGF", 818], ["antagonism", 822], ["in", 833], ["noninflamed", 836], ["animals", 848], ["and", 856], ["the", 860], ["hypoalgesia", 864], ["that", 876], ["ensues", 881], [".", 887], ["In", 889], ["the", 892], ["current", 896], ["study", 904], [",", 909], ["we", 911], ["immunized", 914], ["rats", 924], ["with", 929], ["NGF", 934], ["or", 938], ["cytochrome", 941], ["C", 952], ["(", 954], ["cytC", 955], [")", 959], ["and", 961], ["examined", 965], ["(", 974], ["1", 975], [")", 976], ["nocifensive", 978], ["behaviors", 990], ["with", 1000], ["thermal", 1005], ["latencies", 1013], [",", 1022], ["mechanical", 1024], ["thresholds", 1035], [",", 1045], ["the", 1047], ["hot", 1051], ["plate", 1055], ["test", 1061], [",", 1065], ["and", 1067], ["the", 1071], ["tail", 1075], ["flick", 1080], ["test", 1086], [",", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["IENF", 1096], ["density", 1101], [",", 1108], ["and", 1110], ["(", 1114], ["3", 1115], [")", 1116], ["expression", 1118], ["of", 1129], ["CGRP", 1132], [",", 1136], ["SP", 1138], [",", 1140], ["voltage", 1142], ["-", 1149], ["gated", 1150], ["sodium", 1156], ["channel", 1163], ["1.8", 1171], ["(", 1175], ["Nav1.8", 1176], [")", 1182], [",", 1183], ["and", 1185], ["glutaminase", 1189], ["in", 1201], ["subpopulations", 1204], ["of", 1219], ["dorsal", 1222], ["root", 1229], ["ganglion", 1234], ["(", 1243], ["DRG", 1244], [")", 1247], ["neurons", 1249], ["separated", 1257], ["by", 1267], ["size", 1270], ["and", 1275], ["isolectin", 1279], ["B4", 1289], ["(", 1292], ["IB4", 1293], [")", 1296], ["labeling", 1298], [".", 1306], ["Rats", 1308], ["with", 1313], ["high", 1318], ["anti", 1323], ["-", 1327], ["NGF", 1328], ["titers", 1332], ["had", 1339], ["delayed", 1343], ["responses", 1351], ["on", 1361], ["the", 1364], ["hot", 1368], ["plate", 1372], ["test", 1378], ["but", 1383], ["no", 1387], ["other", 1390], ["behavioral", 1396], ["abnormalities", 1407], [".", 1420], ["Delayed", 1422], ["hot", 1430], ["plate", 1434], ["responses", 1440], ["correlated", 1450], ["with", 1461], ["lower", 1466], ["IENF", 1472], ["density", 1477], [".", 1484], ["CGRP", 1486], ["and", 1491], ["SP", 1495], ["expression", 1498], ["was", 1509], ["decreased", 1513], ["principally", 1523], ["in", 1535], ["medium", 1538], ["(", 1545], ["400", 1546], ["-", 1549], ["800", 1550], ["\u03bcm(2", 1554], [")", 1558], [")", 1559], ["and", 1561], ["small", 1565], ["neurons", 1571], ["(", 1579], ["<", 1580], ["400", 1581], ["\u03bcm(2", 1585], [")", 1589], [")", 1590], [",", 1591], ["respectively", 1593], [",", 1605], ["regardless", 1607], ["of", 1618], ["IB4", 1621], ["labeling", 1625], [".", 1633], ["Expression", 1635], ["of", 1646], ["Nav1.8", 1649], ["was", 1656], ["only", 1660], ["decreased", 1665], ["in", 1675], ["small", 1678], ["and", 1684], ["medium", 1688], ["IB4", 1695], ["negative", 1699], ["neurons", 1708], [".", 1715], ["NGF", 1717], ["immunization", 1721], ["appears", 1734], ["to", 1742], ["result", 1745], ["in", 1752], ["a", 1755], ["more", 1757], ["profound", 1762], ["antagonism", 1771], ["of", 1782], ["NGF", 1785], ["than", 1789], ["tanezumab", 1794], ["therapy", 1804], [",", 1811], ["but", 1813], ["we", 1817], ["hypothesize", 1820], ["that", 1832], ["decreases", 1837], ["in", 1847], ["IENF", 1850], ["density", 1855], ["and", 1863], ["nociception", 1867], ["-", 1878], ["related", 1879], ["protein", 1887], ["expression", 1895], ["are", 1906], ["potential", 1910], ["mechanisms", 1920], ["for", 1931], ["tanezumab", 1935], ["-", 1944], ["induced", 1945], ["hypoalgesia", 1953], [".", 1964]]}
{"context": "We generated a genome-wide replication profile in the genome of Lachancea kluyveri and assessed the relationship between replication and base composition. This species diverged from Saccharomyces cerevisiae before the ancestral whole genome duplication. The genome comprises eight chromosomes among which a chromosomal arm of 1 Mb has a G + C-content much higher than the rest of the genome. We identified 252 active replication origins in L. kluyveri and found considerable divergence in origin location with S. cerevisiae and with Lachancea waltii. Although some global features of S. cerevisiae replication are conserved: Centromeres replicate early, whereas telomeres replicate late, we found that replication origins both in L. kluyveri and L. waltii do not behave as evolutionary fragile sites. In L. kluyveri, replication timing along chromosomes alternates between regions of early and late activating origins, except for the 1 Mb GC-rich chromosomal arm. This chromosomal arm contains an origin consensus motif different from other chromosomes and is replicated early during S-phase. We showed that precocious replication results from the specific absence of late firing origins in this chromosomal arm. In addition, we found a correlation between GC-content and distance from replication origins as well as a lack of replication-associated compositional skew between leading and lagging strands specifically in this GC-rich chromosomal arm. These findings suggest that the unusual base composition in the genome of L. kluyveri could be linked to replication.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "d8b6714eca6845d68ff4a83b405e4a77", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[174, 174], [103, 103], [142, 142]], "char_spans": [[1071, 1075], [647, 651], [884, 888]]}]}], "context_tokens": [["We", 0], ["generated", 3], ["a", 13], ["genome", 15], ["-", 21], ["wide", 22], ["replication", 27], ["profile", 39], ["in", 47], ["the", 50], ["genome", 54], ["of", 61], ["Lachancea", 64], ["kluyveri", 74], ["and", 83], ["assessed", 87], ["the", 96], ["relationship", 100], ["between", 113], ["replication", 121], ["and", 133], ["base", 137], ["composition", 142], [".", 153], ["This", 155], ["species", 160], ["diverged", 168], ["from", 177], ["Saccharomyces", 182], ["cerevisiae", 196], ["before", 207], ["the", 214], ["ancestral", 218], ["whole", 228], ["genome", 234], ["duplication", 241], [".", 252], ["The", 254], ["genome", 258], ["comprises", 265], ["eight", 275], ["chromosomes", 281], ["among", 293], ["which", 299], ["a", 305], ["chromosomal", 307], ["arm", 319], ["of", 323], ["1", 326], ["Mb", 328], ["has", 331], ["a", 335], ["G", 337], ["+", 339], ["C", 341], ["-", 342], ["content", 343], ["much", 351], ["higher", 356], ["than", 363], ["the", 368], ["rest", 372], ["of", 377], ["the", 380], ["genome", 384], [".", 390], ["We", 392], ["identified", 395], ["252", 406], ["active", 410], ["replication", 417], ["origins", 429], ["in", 437], ["L.", 440], ["kluyveri", 443], ["and", 452], ["found", 456], ["considerable", 462], ["divergence", 475], ["in", 486], ["origin", 489], ["location", 496], ["with", 505], ["S.", 510], ["cerevisiae", 513], ["and", 524], ["with", 528], ["Lachancea", 533], ["waltii", 543], [".", 549], ["Although", 551], ["some", 560], ["global", 565], ["features", 572], ["of", 581], ["S.", 584], ["cerevisiae", 587], ["replication", 598], ["are", 610], ["conserved", 614], [":", 623], ["Centromeres", 625], ["replicate", 637], ["early", 647], [",", 652], ["whereas", 654], ["telomeres", 662], ["replicate", 672], ["late", 682], [",", 686], ["we", 688], ["found", 691], ["that", 697], ["replication", 702], ["origins", 714], ["both", 722], ["in", 727], ["L.", 730], ["kluyveri", 733], ["and", 742], ["L.", 746], ["waltii", 749], ["do", 756], ["not", 759], ["behave", 763], ["as", 770], ["evolutionary", 773], ["fragile", 786], ["sites", 794], [".", 799], ["In", 801], ["L.", 804], ["kluyveri", 807], [",", 815], ["replication", 817], ["timing", 829], ["along", 836], ["chromosomes", 842], ["alternates", 854], ["between", 865], ["regions", 873], ["of", 881], ["early", 884], ["and", 890], ["late", 894], ["activating", 899], ["origins", 910], [",", 917], ["except", 919], ["for", 926], ["the", 930], ["1", 934], ["Mb", 936], ["GC", 939], ["-", 941], ["rich", 942], ["chromosomal", 947], ["arm", 959], [".", 962], ["This", 964], ["chromosomal", 969], ["arm", 981], ["contains", 985], ["an", 994], ["origin", 997], ["consensus", 1004], ["motif", 1014], ["different", 1020], ["from", 1030], ["other", 1035], ["chromosomes", 1041], ["and", 1053], ["is", 1057], ["replicated", 1060], ["early", 1071], ["during", 1077], ["S", 1084], ["-", 1085], ["phase", 1086], [".", 1091], ["We", 1093], ["showed", 1096], ["that", 1103], ["precocious", 1108], ["replication", 1119], ["results", 1131], ["from", 1139], ["the", 1144], ["specific", 1148], ["absence", 1157], ["of", 1165], ["late", 1168], ["firing", 1173], ["origins", 1180], ["in", 1188], ["this", 1191], ["chromosomal", 1196], ["arm", 1208], [".", 1211], ["In", 1213], ["addition", 1216], [",", 1224], ["we", 1226], ["found", 1229], ["a", 1235], ["correlation", 1237], ["between", 1249], ["GC", 1257], ["-", 1259], ["content", 1260], ["and", 1268], ["distance", 1272], ["from", 1281], ["replication", 1286], ["origins", 1298], ["as", 1306], ["well", 1309], ["as", 1314], ["a", 1317], ["lack", 1319], ["of", 1324], ["replication", 1327], ["-", 1338], ["associated", 1339], ["compositional", 1350], ["skew", 1364], ["between", 1369], ["leading", 1377], ["and", 1385], ["lagging", 1389], ["strands", 1397], ["specifically", 1405], ["in", 1418], ["this", 1421], ["GC", 1426], ["-", 1428], ["rich", 1429], ["chromosomal", 1434], ["arm", 1446], [".", 1449], ["These", 1451], ["findings", 1457], ["suggest", 1466], ["that", 1474], ["the", 1479], ["unusual", 1483], ["base", 1491], ["composition", 1496], ["in", 1508], ["the", 1511], ["genome", 1515], ["of", 1522], ["L.", 1525], ["kluyveri", 1528], ["could", 1537], ["be", 1543], ["linked", 1546], ["to", 1553], ["replication", 1556], [".", 1567]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "2b04e73544f7459d9232316ec0e13a4a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[57, 83]]}]}], "context_tokens": [["Nivolumab", 0], ["was", 10], ["developed", 14], ["as", 24], ["a", 27], ["monoclonal", 29], ["antibody", 40], ["against", 49], ["programmed", 57], ["death", 68], ["receptor-1", 74], [",", 84], ["an", 86], ["immune", 89], ["checkpoint", 96], ["inhibitor", 107], ["which", 117], ["negatively", 123], ["regulates", 134], ["T", 144], ["-", 145], ["cell", 146], ["proliferation", 151], ["and", 165], ["activation", 169], [".", 179], ["Intravenous", 181], ["administration", 193], ["of", 208], ["nivolumab", 211], ["was", 221], ["approved", 225], ["for", 234], ["the", 238], ["treatment", 242], ["of", 252], ["unresectable", 255], ["malignant", 268], ["melanoma", 278], ["in", 287], ["2014", 290], ["in", 295], ["Japan", 298], [".", 303], ["When", 305], ["advanced", 310], ["melanoma", 319], ["patients", 328], ["were", 337], ["treated", 342], ["with", 350], ["nivolumab", 355], [",", 364], ["median", 366], ["overall", 373], ["survival", 381], ["became", 390], ["longer", 397], [".", 403], ["Overall", 405], ["survival", 413], ["rate", 422], ["was", 427], ["significantly", 431], ["better", 445], ["in", 452], ["nivolumab", 455], ["-", 464], ["treated", 465], ["melanoma", 473], ["patients", 482], ["than", 491], ["dacarbazine", 496], ["-", 507], ["treated", 508], ["melanoma", 516], ["patients", 525], [".", 533], ["Nivolumab", 535], ["had", 545], ["an", 549], ["acceptable", 552], ["long", 563], ["-", 567], ["term", 568], ["tolerability", 573], ["profile", 586], [",", 593], ["with", 595], ["22", 600], ["%", 602], ["of", 604], ["patients", 607], ["experiencing", 616], ["grade", 629], ["3", 635], ["or", 637], ["4", 640], ["adverse", 642], ["events", 650], ["related", 657], ["to", 665], ["the", 668], ["drug", 672], [".", 676], ["Therefore", 678], [",", 687], ["nivolumab", 689], ["can", 699], ["become", 703], ["an", 710], ["alternative", 713], ["therapy", 725], ["for", 733], ["advanced", 737], ["malignant", 746], ["melanoma", 756], [".", 764]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "Protective protein/cathepsin A (PPCA) has a serine carboxypeptidase activity of unknown physiological function. We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA). Degradation of lamp2a is important because its level in the lysosomal membrane is a rate-limiting step of CMA. Cells defective in PPCA show reduced rates of lamp2a degradation, higher levels of lamp2a and higher rates of CMA. Restoration of PPCA protease activity increases rates of lamp2a degradation, reduces levels of lysosomal lamp2a and reduces rates of CMA. PPCA associates with lamp2a on the lysosomal membrane and cleaves lamp2a near the boundary between the luminal and transmembrane domains. In addition to the well-studied role of PPCA in targeting and protecting two lysosomal glycosidases, we have defined a role for the proteolytic activity of this multifunctional protein.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "a636a925df634cada0c2d6964688e93a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[109, 109], [54, 54], [102, 102], [38, 38], [87, 87], [119, 119], [126, 126], [81, 81]], "char_spans": [[628, 633], [312, 317], [580, 585], [237, 242], [491, 496], [682, 687], [727, 732], [454, 459]]}]}], "context_tokens": [["Protective", 0], ["protein", 11], ["/", 18], ["cathepsin", 19], ["A", 29], ["(", 31], ["PPCA", 32], [")", 36], ["has", 38], ["a", 42], ["serine", 44], ["carboxypeptidase", 51], ["activity", 68], ["of", 77], ["unknown", 80], ["physiological", 88], ["function", 102], [".", 110], ["We", 112], ["now", 115], ["demonstrate", 119], ["that", 131], ["this", 136], ["protease", 141], ["activity", 150], ["triggers", 159], ["the", 168], ["degradation", 172], ["of", 184], ["the", 187], ["lysosome", 191], ["-", 199], ["associated", 200], ["membrane", 211], ["protein", 220], ["type", 228], ["2a", 233], ["(", 236], ["lamp2a", 237], [")", 243], [",", 244], ["a", 246], ["receptor", 248], ["for", 257], ["chaperone", 261], ["-", 270], ["mediated", 271], ["autophagy", 280], ["(", 290], ["CMA", 291], [")", 294], [".", 295], ["Degradation", 297], ["of", 309], ["lamp2a", 312], ["is", 319], ["important", 322], ["because", 332], ["its", 340], ["level", 344], ["in", 350], ["the", 353], ["lysosomal", 357], ["membrane", 367], ["is", 376], ["a", 379], ["rate", 381], ["-", 385], ["limiting", 386], ["step", 395], ["of", 400], ["CMA", 403], [".", 406], ["Cells", 408], ["defective", 414], ["in", 424], ["PPCA", 427], ["show", 432], ["reduced", 437], ["rates", 445], ["of", 451], ["lamp2a", 454], ["degradation", 461], [",", 472], ["higher", 474], ["levels", 481], ["of", 488], ["lamp2a", 491], ["and", 498], ["higher", 502], ["rates", 509], ["of", 515], ["CMA", 518], [".", 521], ["Restoration", 523], ["of", 535], ["PPCA", 538], ["protease", 543], ["activity", 552], ["increases", 561], ["rates", 571], ["of", 577], ["lamp2a", 580], ["degradation", 587], [",", 598], ["reduces", 600], ["levels", 608], ["of", 615], ["lysosomal", 618], ["lamp2a", 628], ["and", 635], ["reduces", 639], ["rates", 647], ["of", 653], ["CMA", 656], [".", 659], ["PPCA", 661], ["associates", 666], ["with", 677], ["lamp2a", 682], ["on", 689], ["the", 692], ["lysosomal", 696], ["membrane", 706], ["and", 715], ["cleaves", 719], ["lamp2a", 727], ["near", 734], ["the", 739], ["boundary", 743], ["between", 752], ["the", 760], ["luminal", 764], ["and", 772], ["transmembrane", 776], ["domains", 790], [".", 797], ["In", 799], ["addition", 802], ["to", 811], ["the", 814], ["well", 818], ["-", 822], ["studied", 823], ["role", 831], ["of", 836], ["PPCA", 839], ["in", 844], ["targeting", 847], ["and", 857], ["protecting", 861], ["two", 872], ["lysosomal", 876], ["glycosidases", 886], [",", 898], ["we", 900], ["have", 903], ["defined", 908], ["a", 916], ["role", 918], ["for", 923], ["the", 927], ["proteolytic", 931], ["activity", 943], ["of", 952], ["this", 955], ["multifunctional", 960], ["protein", 976], [".", 983]]}
{"context": "Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for posttraumatic stress disorder (PTSD). Serotonergic (5HT) attenuation of stress sensitivity is postulated from SSRIs' effects in other anxiety disorders, and we studied this in PTSD. Ten patients with PTSD fully recovered on SSRIs (Clinical Global Impression Scale-I 1 and 2) were enrolled in the study. Patients were tested on two occasions 1 week apart; in each session, they received a drink containing large neutral amino acids (LNAAs) either with (sham tryptophan depletion [STD], control) or without (acute tryptophan depletion [ATD]) tryptophan. At 5.5 hours after the drink, subjects were exposed to a trauma-related exposure challenge. Self-reports of PTSD (visual analogue scales [VAS] and the Davidson Trauma Scale [DTS]), anxiety (Spielberger State Inventory [STAI] Form Y-1), and mood (Profile of Mood States [POMS]) were obtained. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were also measured. The trauma-related exposure challenge induced anxiety on both days, with more marked responses on the ATD day according to VAS, DTS, POMS, and DBP (p < .05). A trend of significance (.1 > p > .05) was observed for STAI Form Y-1, HR, and SBP. These data demonstrate that ATD accentuates responses to trauma-related stimuli in SSRI-recovered PTSD. They also suggest that SSRI-induced increases in serotonin function restrain PTSD symptoms, especially under provocation, supporting a role for serotonin in mediating stress resilience.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "a197452996814e96bc9331b41b870709", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[283, 283], [44, 44], [297, 297], [17, 17], [143, 143], [49, 49]], "char_spans": [[1349, 1352], [254, 257], [1432, 1435], [109, 112], [738, 741], [278, 281]]}]}], "context_tokens": [["Selective", 0], ["serotonin", 10], ["reuptake", 20], ["inhibitors", 29], ["(", 40], ["SSRIs", 41], [")", 46], ["are", 48], ["first", 52], ["-", 57], ["line", 58], ["treatments", 63], ["for", 74], ["posttraumatic", 78], ["stress", 92], ["disorder", 99], ["(", 108], ["PTSD", 109], [")", 113], [".", 114], ["Serotonergic", 116], ["(", 129], ["5HT", 130], [")", 133], ["attenuation", 135], ["of", 147], ["stress", 150], ["sensitivity", 157], ["is", 169], ["postulated", 172], ["from", 183], ["SSRIs", 188], ["'", 193], ["effects", 195], ["in", 203], ["other", 206], ["anxiety", 212], ["disorders", 220], [",", 229], ["and", 231], ["we", 235], ["studied", 238], ["this", 246], ["in", 251], ["PTSD", 254], [".", 258], ["Ten", 260], ["patients", 264], ["with", 273], ["PTSD", 278], ["fully", 283], ["recovered", 289], ["on", 299], ["SSRIs", 302], ["(", 308], ["Clinical", 309], ["Global", 318], ["Impression", 325], ["Scale", 336], ["-", 341], ["I", 342], ["1", 344], ["and", 346], ["2", 350], [")", 351], ["were", 353], ["enrolled", 358], ["in", 367], ["the", 370], ["study", 374], [".", 379], ["Patients", 381], ["were", 390], ["tested", 395], ["on", 402], ["two", 405], ["occasions", 409], ["1", 419], ["week", 421], ["apart", 426], [";", 431], ["in", 433], ["each", 436], ["session", 441], [",", 448], ["they", 450], ["received", 455], ["a", 464], ["drink", 466], ["containing", 472], ["large", 483], ["neutral", 489], ["amino", 497], ["acids", 503], ["(", 509], ["LNAAs", 510], [")", 515], ["either", 517], ["with", 524], ["(", 529], ["sham", 530], ["tryptophan", 535], ["depletion", 546], ["[", 556], ["STD", 557], ["]", 560], [",", 561], ["control", 563], [")", 570], ["or", 572], ["without", 575], ["(", 583], ["acute", 584], ["tryptophan", 590], ["depletion", 601], ["[", 611], ["ATD", 612], ["]", 615], [")", 616], ["tryptophan", 618], [".", 628], ["At", 630], ["5.5", 633], ["hours", 637], ["after", 643], ["the", 649], ["drink", 653], [",", 658], ["subjects", 660], ["were", 669], ["exposed", 674], ["to", 682], ["a", 685], ["trauma", 687], ["-", 693], ["related", 694], ["exposure", 702], ["challenge", 711], [".", 720], ["Self", 722], ["-", 726], ["reports", 727], ["of", 735], ["PTSD", 738], ["(", 743], ["visual", 744], ["analogue", 751], ["scales", 760], ["[", 767], ["VAS", 768], ["]", 771], ["and", 773], ["the", 777], ["Davidson", 781], ["Trauma", 790], ["Scale", 797], ["[", 803], ["DTS", 804], ["]", 807], [")", 808], [",", 809], ["anxiety", 811], ["(", 819], ["Spielberger", 820], ["State", 832], ["Inventory", 838], ["[", 848], ["STAI", 849], ["]", 853], ["Form", 855], ["Y-1", 860], [")", 863], [",", 864], ["and", 866], ["mood", 870], ["(", 875], ["Profile", 876], ["of", 884], ["Mood", 887], ["States", 892], ["[", 899], ["POMS", 900], ["]", 904], [")", 905], ["were", 907], ["obtained", 912], [".", 920], ["Heart", 922], ["rate", 928], ["(", 933], ["HR", 934], [")", 936], [",", 937], ["systolic", 939], ["(", 948], ["SBP", 949], [")", 952], ["and", 954], ["diastolic", 958], ["(", 968], ["DBP", 969], [")", 972], ["blood", 974], ["pressure", 980], ["were", 989], ["also", 994], ["measured", 999], [".", 1007], ["The", 1009], ["trauma", 1013], ["-", 1019], ["related", 1020], ["exposure", 1028], ["challenge", 1037], ["induced", 1047], ["anxiety", 1055], ["on", 1063], ["both", 1066], ["days", 1071], [",", 1075], ["with", 1077], ["more", 1082], ["marked", 1087], ["responses", 1094], ["on", 1104], ["the", 1107], ["ATD", 1111], ["day", 1115], ["according", 1119], ["to", 1129], ["VAS", 1132], [",", 1135], ["DTS", 1137], [",", 1140], ["POMS", 1142], [",", 1146], ["and", 1148], ["DBP", 1152], ["(", 1156], ["p", 1157], ["<", 1159], [".05", 1161], [")", 1164], [".", 1165], ["A", 1167], ["trend", 1169], ["of", 1175], ["significance", 1178], ["(", 1191], [".1", 1192], [">", 1195], ["p", 1197], [">", 1199], [".05", 1201], [")", 1204], ["was", 1206], ["observed", 1210], ["for", 1219], ["STAI", 1223], ["Form", 1228], ["Y-1", 1233], [",", 1236], ["HR", 1238], [",", 1240], ["and", 1242], ["SBP", 1246], [".", 1249], ["These", 1251], ["data", 1257], ["demonstrate", 1262], ["that", 1274], ["ATD", 1279], ["accentuates", 1283], ["responses", 1295], ["to", 1305], ["trauma", 1308], ["-", 1314], ["related", 1315], ["stimuli", 1323], ["in", 1331], ["SSRI", 1334], ["-", 1338], ["recovered", 1339], ["PTSD", 1349], [".", 1353], ["They", 1355], ["also", 1360], ["suggest", 1365], ["that", 1373], ["SSRI", 1378], ["-", 1382], ["induced", 1383], ["increases", 1391], ["in", 1401], ["serotonin", 1404], ["function", 1414], ["restrain", 1423], ["PTSD", 1432], ["symptoms", 1437], [",", 1445], ["especially", 1447], ["under", 1458], ["provocation", 1464], [",", 1475], ["supporting", 1477], ["a", 1488], ["role", 1490], ["for", 1495], ["serotonin", 1499], ["in", 1509], ["mediating", 1512], ["stress", 1522], ["resilience", 1529], [".", 1539]]}
{"context": "Two spontaneous mutant beige rats, with phenotypes resembling human Chediak- Higashi syndrome (CHS), were found independently in two inbred strains. Both beige mutations were identified to be recessive alleles in the Lyst locus on rat chromosome 17 and the alleles were denoted Lyst(bg) and Lyst(bg-Kyo). As it is almost impossible to discriminate these mutations phenotypically, we developed an allele-specific genotyping method for the Lyst gene. The nested PCR amplification was followed by restriction fragment length polymorphism (RFLP) analysis. By this method, we could discriminate the mutant Lyst(bg), Lyst(bg-Kyo) alleles, and the normal Lyst allele, easily and accurately.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome", "Chediak- Higashi syndrome"], "qid": "23bd86de677a400e8ee3c4a56c6f39e1", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[10, 12]], "char_spans": [[68, 92]]}]}], "context_tokens": [["Two", 0], ["spontaneous", 4], ["mutant", 16], ["beige", 23], ["rats", 29], [",", 33], ["with", 35], ["phenotypes", 40], ["resembling", 51], ["human", 62], ["Chediak-", 68], ["Higashi", 77], ["syndrome", 85], ["(", 94], ["CHS", 95], [")", 98], [",", 99], ["were", 101], ["found", 106], ["independently", 112], ["in", 126], ["two", 129], ["inbred", 133], ["strains", 140], [".", 147], ["Both", 149], ["beige", 154], ["mutations", 160], ["were", 170], ["identified", 175], ["to", 186], ["be", 189], ["recessive", 192], ["alleles", 202], ["in", 210], ["the", 213], ["Lyst", 217], ["locus", 222], ["on", 228], ["rat", 231], ["chromosome", 235], ["17", 246], ["and", 249], ["the", 253], ["alleles", 257], ["were", 265], ["denoted", 270], ["Lyst(bg", 278], [")", 285], ["and", 287], ["Lyst(bg", 291], ["-", 298], ["Kyo", 299], [")", 302], [".", 303], ["As", 305], ["it", 308], ["is", 311], ["almost", 314], ["impossible", 321], ["to", 332], ["discriminate", 335], ["these", 348], ["mutations", 354], ["phenotypically", 364], [",", 378], ["we", 380], ["developed", 383], ["an", 393], ["allele", 396], ["-", 402], ["specific", 403], ["genotyping", 412], ["method", 423], ["for", 430], ["the", 434], ["Lyst", 438], ["gene", 443], [".", 447], ["The", 449], ["nested", 453], ["PCR", 460], ["amplification", 464], ["was", 478], ["followed", 482], ["by", 491], ["restriction", 494], ["fragment", 506], ["length", 515], ["polymorphism", 522], ["(", 535], ["RFLP", 536], [")", 540], ["analysis", 542], [".", 550], ["By", 552], ["this", 555], ["method", 560], [",", 566], ["we", 568], ["could", 571], ["discriminate", 577], ["the", 590], ["mutant", 594], ["Lyst(bg", 601], [")", 608], [",", 609], ["Lyst(bg", 611], ["-", 618], ["Kyo", 619], [")", 622], ["alleles", 624], [",", 631], ["and", 633], ["the", 637], ["normal", 641], ["Lyst", 648], ["allele", 653], [",", 659], ["easily", 661], ["and", 668], ["accurately", 672], [".", 682]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "Batten disease (juvenile-onset neuronal ceroid lipofuscinosis, JNCL), the most common neurodegenerative disorder of childhood, is caused by mutations in a recently identified gene ( CLN3 ) localized to chromosome 16p11.2-12.1. To elucidate the biosynthesis and localization of the CLN3 protein, we expressed CLN3 cDNA in COS-1 and HeLa cell lines. In vitro translation, immunoprecipitation and Western blotting analyses detected an approximately 43 kDa polypeptide. Pulse-chase experiments indicated that the CLN3 protein is synthesized as an N -glycosylated single-chain polypeptide, which was not detected in growth medium. Confocal immunofluorescence microscopy revealed that the CLN3 protein is localized to the lysosomal compartment. These results provide evidence that Batten disease can be classified as a member of lysosomal diseases.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "4a70e96cd685482787d78a9a40f450ca", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [126, 127]], "char_spans": [[0, 13], [775, 788]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[10, 10]], "char_spans": [[63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["(", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], [",", 61], ["JNCL", 63], [")", 67], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["neurodegenerative", 86], ["disorder", 104], ["of", 113], ["childhood", 116], [",", 125], ["is", 127], ["caused", 130], ["by", 137], ["mutations", 140], ["in", 150], ["a", 153], ["recently", 155], ["identified", 164], ["gene", 175], ["(", 180], ["CLN3", 182], [")", 187], ["localized", 189], ["to", 199], ["chromosome", 202], ["16p11.2", 213], ["-", 220], ["12.1", 221], [".", 225], ["To", 227], ["elucidate", 230], ["the", 240], ["biosynthesis", 244], ["and", 257], ["localization", 261], ["of", 274], ["the", 277], ["CLN3", 281], ["protein", 286], [",", 293], ["we", 295], ["expressed", 298], ["CLN3", 308], ["cDNA", 313], ["in", 318], ["COS-1", 321], ["and", 327], ["HeLa", 331], ["cell", 336], ["lines", 341], [".", 346], ["In", 348], ["vitro", 351], ["translation", 357], [",", 368], ["immunoprecipitation", 370], ["and", 390], ["Western", 394], ["blotting", 402], ["analyses", 411], ["detected", 420], ["an", 429], ["approximately", 432], ["43", 446], ["kDa", 449], ["polypeptide", 453], [".", 464], ["Pulse", 466], ["-", 471], ["chase", 472], ["experiments", 478], ["indicated", 490], ["that", 500], ["the", 505], ["CLN3", 509], ["protein", 514], ["is", 522], ["synthesized", 525], ["as", 537], ["an", 540], ["N", 543], ["-glycosylated", 545], ["single", 559], ["-", 565], ["chain", 566], ["polypeptide", 572], [",", 583], ["which", 585], ["was", 591], ["not", 595], ["detected", 599], ["in", 608], ["growth", 611], ["medium", 618], [".", 624], ["Confocal", 626], ["immunofluorescence", 635], ["microscopy", 654], ["revealed", 665], ["that", 674], ["the", 679], ["CLN3", 683], ["protein", 688], ["is", 696], ["localized", 699], ["to", 709], ["the", 712], ["lysosomal", 716], ["compartment", 726], [".", 737], ["These", 739], ["results", 745], ["provide", 753], ["evidence", 761], ["that", 770], ["Batten", 775], ["disease", 782], ["can", 790], ["be", 794], ["classified", 797], ["as", 808], ["a", 811], ["member", 813], ["of", 820], ["lysosomal", 823], ["diseases", 833], [".", 841]]}
{"context": "Neutrophil elastase gene (ELANE) mutations are responsible for the majority of cases of severe congenital neutropenia (CN) and cyclic neutropenia (CyN). We screened CN (n\u00a0=\u00a0395) or CyN (n\u00a0=\u00a092) patients for ELANE mutations and investigated the impact of mutations on mRNA expression, protein expression, and activity. We found 116 different mutations in 162 (41%) CN patients and 26 in 51 (55%) CyN patients, 69 of them were novel. CyN-associated mutations were predicted to be more benign than CN-associated mutations, but the mutation severity largely overlapped. The frequency of acquired CSF3R mutations, malignant transformation, and the need for hematopoietic stem cell transplantation was significantly higher in CN patients with ELANE mutation than in ELANE mutation negative patients. Cellular elastase activity was reduced in neutrophils from CN/CyN patients, irrespective of the mutation status. In CN, enzymatic activity was significantly lower in patients with ELANE mutations compared with those with wild-type ELANE. Despite differences in the spectrum of mutations in CN or CyN, type or localization of mutation only partially determine the clinical phenotype. Specific ELANE mutations have limited predictive value for leukemogenesis; the risk for leukemia was correlated with disease severity rather than with occurrence of an ELANE mutation.", "qas": [{"question": "Which gene is most commonly associated with severe congenital and cyclic neutropenia?", "answers": ["The neutrophil elastase gene (ELANE)"], "qid": "2cf03749226444fea30c672c678b3d63", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["most", 14], ["commonly", 19], ["associated", 28], ["with", 39], ["severe", 44], ["congenital", 51], ["and", 62], ["cyclic", 66], ["neutropenia", 73], ["?", 84]], "detected_answers": [{"text": "The neutrophil elastase gene (ELANE)", "token_spans": [[0, 4]], "char_spans": [[0, 30]]}]}], "context_tokens": [["Neutrophil", 0], ["elastase", 11], ["gene", 20], ["(", 25], ["ELANE", 26], [")", 31], ["mutations", 33], ["are", 43], ["responsible", 47], ["for", 59], ["the", 63], ["majority", 67], ["of", 76], ["cases", 79], ["of", 85], ["severe", 88], ["congenital", 95], ["neutropenia", 106], ["(", 118], ["CN", 119], [")", 121], ["and", 123], ["cyclic", 127], ["neutropenia", 134], ["(", 146], ["CyN", 147], [")", 150], [".", 151], ["We", 153], ["screened", 156], ["CN", 165], ["(", 168], ["n", 169], ["=", 171], ["395", 173], [")", 176], ["or", 178], ["CyN", 181], ["(", 185], ["n", 186], ["=", 188], ["92", 190], [")", 192], ["patients", 194], ["for", 203], ["ELANE", 207], ["mutations", 213], ["and", 223], ["investigated", 227], ["the", 240], ["impact", 244], ["of", 251], ["mutations", 254], ["on", 264], ["mRNA", 267], ["expression", 272], [",", 282], ["protein", 284], ["expression", 292], [",", 302], ["and", 304], ["activity", 308], [".", 316], ["We", 318], ["found", 321], ["116", 327], ["different", 331], ["mutations", 341], ["in", 351], ["162", 354], ["(", 358], ["41", 359], ["%", 361], [")", 362], ["CN", 364], ["patients", 367], ["and", 376], ["26", 380], ["in", 383], ["51", 386], ["(", 389], ["55", 390], ["%", 392], [")", 393], ["CyN", 395], ["patients", 399], [",", 407], ["69", 409], ["of", 412], ["them", 415], ["were", 420], ["novel", 425], [".", 430], ["CyN", 432], ["-", 435], ["associated", 436], ["mutations", 447], ["were", 457], ["predicted", 462], ["to", 472], ["be", 475], ["more", 478], ["benign", 483], ["than", 490], ["CN", 495], ["-", 497], ["associated", 498], ["mutations", 509], [",", 518], ["but", 520], ["the", 524], ["mutation", 528], ["severity", 537], ["largely", 546], ["overlapped", 554], [".", 564], ["The", 566], ["frequency", 570], ["of", 580], ["acquired", 583], ["CSF3R", 592], ["mutations", 598], [",", 607], ["malignant", 609], ["transformation", 619], [",", 633], ["and", 635], ["the", 639], ["need", 643], ["for", 648], ["hematopoietic", 652], ["stem", 666], ["cell", 671], ["transplantation", 676], ["was", 692], ["significantly", 696], ["higher", 710], ["in", 717], ["CN", 720], ["patients", 723], ["with", 732], ["ELANE", 737], ["mutation", 743], ["than", 752], ["in", 757], ["ELANE", 760], ["mutation", 766], ["negative", 775], ["patients", 784], [".", 792], ["Cellular", 794], ["elastase", 803], ["activity", 812], ["was", 821], ["reduced", 825], ["in", 833], ["neutrophils", 836], ["from", 848], ["CN", 853], ["/", 855], ["CyN", 856], ["patients", 860], [",", 868], ["irrespective", 870], ["of", 883], ["the", 886], ["mutation", 890], ["status", 899], [".", 905], ["In", 907], ["CN", 910], [",", 912], ["enzymatic", 914], ["activity", 924], ["was", 933], ["significantly", 937], ["lower", 951], ["in", 957], ["patients", 960], ["with", 969], ["ELANE", 974], ["mutations", 980], ["compared", 990], ["with", 999], ["those", 1004], ["with", 1010], ["wild", 1015], ["-", 1019], ["type", 1020], ["ELANE", 1025], [".", 1030], ["Despite", 1032], ["differences", 1040], ["in", 1052], ["the", 1055], ["spectrum", 1059], ["of", 1068], ["mutations", 1071], ["in", 1081], ["CN", 1084], ["or", 1087], ["CyN", 1090], [",", 1093], ["type", 1095], ["or", 1100], ["localization", 1103], ["of", 1116], ["mutation", 1119], ["only", 1128], ["partially", 1133], ["determine", 1143], ["the", 1153], ["clinical", 1157], ["phenotype", 1166], [".", 1175], ["Specific", 1177], ["ELANE", 1186], ["mutations", 1192], ["have", 1202], ["limited", 1207], ["predictive", 1215], ["value", 1226], ["for", 1232], ["leukemogenesis", 1236], [";", 1250], ["the", 1252], ["risk", 1256], ["for", 1261], ["leukemia", 1265], ["was", 1274], ["correlated", 1278], ["with", 1289], ["disease", 1294], ["severity", 1302], ["rather", 1311], ["than", 1318], ["with", 1323], ["occurrence", 1328], ["of", 1339], ["an", 1342], ["ELANE", 1345], ["mutation", 1351], [".", 1359]]}
{"context": "Probe-to-bone test and simple X-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. This study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "117440db7a2441f29ff04ebe978b490f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[56, 58], [19, 21]], "char_spans": [[312, 338], [82, 108]]}]}], "context_tokens": [["Probe", 0], ["-", 5], ["to", 6], ["-", 8], ["bone", 9], ["test", 14], ["and", 19], ["simple", 23], ["X", 30], ["-", 31], ["rays", 32], ["are", 37], ["both", 41], ["standard", 46], ["tests", 55], ["for", 61], ["the", 65], ["diagnosis", 69], ["of", 79], ["diabetic", 82], ["foot", 91], ["osteomyelitis", 96], [".", 109], ["This", 111], ["study", 116], ["demonstrates", 122], ["the", 135], ["importance", 139], ["of", 150], ["considering", 153], ["jointly", 165], ["clinical", 173], ["information", 182], ["(", 194], ["probe", 195], ["-", 200], ["to", 201], ["-", 203], ["bone", 204], ["test", 209], [")", 213], ["and", 215], ["diagnostic", 219], ["tests", 230], ["(", 236], ["simple", 237], ["radiography", 244], [")", 255], ["to", 257], ["increase", 260], ["agreement", 269], ["among", 279], ["clinicians", 285], ["on", 296], ["diagnosis", 299], ["of", 309], ["diabetic", 312], ["foot", 321], ["osteomyelitis", 326], [".", 339]]}
{"context": "The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase (c-Abl) that has been implicated in processes of cell differentiation, cell division, cell adhesion and stress response. Alterations of ABL1 by chromosomal rearrangement or viral transduction can lead to malignant transformation. Activity of the c-Abl protein is negatively regulated by its SH3 domain through an unknown mechanism, and deletion of the SH3 domain turns ABL1 into an oncogene. We present evidence for an intramolecular inhibitory interaction of the SH3 domain with the catalytic domain and with the linker between the SH2 and catalytic domain (SH2-CD linker). Site-directed mutations in each of these three elements activate c-Abl. Mutations in the linker cause a conformational change of the molecule and increase binding of the SH3 domain to peptide ligands. Individual mutation of two charged residues in the SH3 and catalytic domain activates c-Abl, while inhibition is restored in the double reciprocal mutant. We propose that regulators of c-Abl will have opposite effects on its activity depending on their ability to favour or disrupt these intramolecular interactions.", "qas": [{"question": "What kind of enzyme is encoded by the proto-oncogene ABL1?", "answers": ["Nonreceptor tyrosine kinase", "Protein-Tyrosine Kinase", "protein tyrosine kinase"], "qid": "0e43309febce41e0bc84f3276562043b", "question_tokens": [["What", 0], ["kind", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["encoded", 23], ["by", 31], ["the", 34], ["proto", 38], ["-", 43], ["oncogene", 44], ["ABL1", 53], ["?", 57]], "detected_answers": [{"text": "Protein-Tyrosine Kinase", "token_spans": [[10, 12]], "char_spans": [[58, 80]]}]}], "context_tokens": [["The", 0], ["ABL1", 4], ["proto", 9], ["-", 14], ["oncogene", 15], ["encodes", 24], ["a", 32], ["cytoplasmic", 34], ["and", 46], ["nuclear", 50], ["protein", 58], ["tyrosine", 66], ["kinase", 75], ["(", 82], ["c", 83], ["-", 84], ["Abl", 85], [")", 88], ["that", 90], ["has", 95], ["been", 99], ["implicated", 104], ["in", 115], ["processes", 118], ["of", 128], ["cell", 131], ["differentiation", 136], [",", 151], ["cell", 153], ["division", 158], [",", 166], ["cell", 168], ["adhesion", 173], ["and", 182], ["stress", 186], ["response", 193], [".", 201], ["Alterations", 203], ["of", 215], ["ABL1", 218], ["by", 223], ["chromosomal", 226], ["rearrangement", 238], ["or", 252], ["viral", 255], ["transduction", 261], ["can", 274], ["lead", 278], ["to", 283], ["malignant", 286], ["transformation", 296], [".", 310], ["Activity", 312], ["of", 321], ["the", 324], ["c", 328], ["-", 329], ["Abl", 330], ["protein", 334], ["is", 342], ["negatively", 345], ["regulated", 356], ["by", 366], ["its", 369], ["SH3", 373], ["domain", 377], ["through", 384], ["an", 392], ["unknown", 395], ["mechanism", 403], [",", 412], ["and", 414], ["deletion", 418], ["of", 427], ["the", 430], ["SH3", 434], ["domain", 438], ["turns", 445], ["ABL1", 451], ["into", 456], ["an", 461], ["oncogene", 464], [".", 472], ["We", 474], ["present", 477], ["evidence", 485], ["for", 494], ["an", 498], ["intramolecular", 501], ["inhibitory", 516], ["interaction", 527], ["of", 539], ["the", 542], ["SH3", 546], ["domain", 550], ["with", 557], ["the", 562], ["catalytic", 566], ["domain", 576], ["and", 583], ["with", 587], ["the", 592], ["linker", 596], ["between", 603], ["the", 611], ["SH2", 615], ["and", 619], ["catalytic", 623], ["domain", 633], ["(", 640], ["SH2-CD", 641], ["linker", 648], [")", 654], [".", 655], ["Site", 657], ["-", 661], ["directed", 662], ["mutations", 671], ["in", 681], ["each", 684], ["of", 689], ["these", 692], ["three", 698], ["elements", 704], ["activate", 713], ["c", 722], ["-", 723], ["Abl", 724], [".", 727], ["Mutations", 729], ["in", 739], ["the", 742], ["linker", 746], ["cause", 753], ["a", 759], ["conformational", 761], ["change", 776], ["of", 783], ["the", 786], ["molecule", 790], ["and", 799], ["increase", 803], ["binding", 812], ["of", 820], ["the", 823], ["SH3", 827], ["domain", 831], ["to", 838], ["peptide", 841], ["ligands", 849], [".", 856], ["Individual", 858], ["mutation", 869], ["of", 878], ["two", 881], ["charged", 885], ["residues", 893], ["in", 902], ["the", 905], ["SH3", 909], ["and", 913], ["catalytic", 917], ["domain", 927], ["activates", 934], ["c", 944], ["-", 945], ["Abl", 946], [",", 949], ["while", 951], ["inhibition", 957], ["is", 968], ["restored", 971], ["in", 980], ["the", 983], ["double", 987], ["reciprocal", 994], ["mutant", 1005], [".", 1011], ["We", 1013], ["propose", 1016], ["that", 1024], ["regulators", 1029], ["of", 1040], ["c", 1043], ["-", 1044], ["Abl", 1045], ["will", 1049], ["have", 1054], ["opposite", 1059], ["effects", 1068], ["on", 1076], ["its", 1079], ["activity", 1083], ["depending", 1092], ["on", 1102], ["their", 1105], ["ability", 1111], ["to", 1119], ["favour", 1122], ["or", 1129], ["disrupt", 1132], ["these", 1140], ["intramolecular", 1146], ["interactions", 1161], [".", 1173]]}
{"context": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. Here, we report on a 14-month-old boy with a reverse phenotype of Sotos syndrome due to the reciprocal duplication of the 5q35.3 region, including the NSD1 gene, detected by array CGH. The phenotype includes delayed bone age, microcephaly, seizures, and failure to thrive. Our case suggests that the gene dosage effect of the NSD1 gene is the likely cause for the reversed phenotype of Sotos syndrome in this patient.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "4dacfcd587cf4e6f8eed4e508e7a454e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[109, 110], [75, 76], [3, 4]], "char_spans": [[630, 638], [455, 463], [26, 34]]}]}], "context_tokens": [["Haploinsufficiency", 0], ["of", 19], ["the", 22], ["NSD1", 26], ["gene", 31], ["due", 36], ["to", 40], ["5q35", 43], ["microdeletions", 48], ["or", 63], ["intragenic", 66], ["mutations", 77], ["is", 87], ["the", 90], ["major", 94], ["cause", 100], ["of", 106], ["Sotos", 109], ["syndrome", 115], ["characterized", 124], ["by", 138], ["generalized", 141], ["overgrowth", 153], [",", 163], ["large", 165], ["hands", 171], ["and", 177], ["feet", 181], ["with", 186], ["advanced", 191], ["bone", 200], ["age", 205], [",", 208], ["craniofacial", 210], ["dysmorphic", 223], ["features", 234], [",", 242], ["learning", 244], ["disability", 253], [",", 263], ["and", 265], ["possible", 269], ["susceptibility", 278], ["to", 293], ["tumors", 296], [".", 302], ["Here", 304], [",", 308], ["we", 310], ["report", 313], ["on", 320], ["a", 323], ["14-month", 325], ["-", 333], ["old", 334], ["boy", 338], ["with", 342], ["a", 347], ["reverse", 349], ["phenotype", 357], ["of", 367], ["Sotos", 370], ["syndrome", 376], ["due", 385], ["to", 389], ["the", 392], ["reciprocal", 396], ["duplication", 407], ["of", 419], ["the", 422], ["5q35.3", 426], ["region", 433], [",", 439], ["including", 441], ["the", 451], ["NSD1", 455], ["gene", 460], [",", 464], ["detected", 466], ["by", 475], ["array", 478], ["CGH", 484], [".", 487], ["The", 489], ["phenotype", 493], ["includes", 503], ["delayed", 512], ["bone", 520], ["age", 525], [",", 528], ["microcephaly", 530], [",", 542], ["seizures", 544], [",", 552], ["and", 554], ["failure", 558], ["to", 566], ["thrive", 569], [".", 575], ["Our", 577], ["case", 581], ["suggests", 586], ["that", 595], ["the", 600], ["gene", 604], ["dosage", 609], ["effect", 616], ["of", 623], ["the", 626], ["NSD1", 630], ["gene", 635], ["is", 640], ["the", 643], ["likely", 647], ["cause", 654], ["for", 660], ["the", 664], ["reversed", 668], ["phenotype", 677], ["of", 687], ["Sotos", 690], ["syndrome", 696], ["in", 705], ["this", 708], ["patient", 713], [".", 720]]}
{"context": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib is also known to inhibit the tyrosine kinase of the stem cell factor receptor, c-Kit. Nilotinib is 30 times more potent than imatinib towards BCR-ABL in vitro. Studies in healthy volunteers and patients with chronic myelogenous leukemia or gastrointestinal stromal tumors have shown that therapeutic doses of nilotinib deliver drug levels similar to those of imatinib. The aim of this study was to compare the inhibitory effects of imatinib and nilotinib on proliferation, differentiation, adhesion, migration and engraftment capacities of human cord blood CD34(+) cells. After a 48-hour cell culture with or without TKIs, CFC, LTC-IC, migration, adhesion and cell cycle analysis were performed. In a second time, the impact of these TKIs on engraftment was assessed in a xenotransplantation model using NOD/SCID/IL-2R\u03b3 (null) mice. TKIs did not affect LTC-IC frequencies despite in vitro inhibition of CFC formation due to inhibition of CD34(+) cell cycle entry. Adhesion of CD34(+) cells to retronectin was reduced in the presence of either imatinib or nilotinib but only at high concentrations. Migration through a SDF-1\u03b1 gradient was not changed by cell culture in the presence of TKIs. Finally, bone marrow cellularity and human chimerism were not affected by daily doses of imatinib and nilotinib in a xenogenic transplantation model. No significant difference was seen between TKIs given the equivalent affinity of imatinib and nilotinib for KIT. These data suggest that combining non-myeloablative conditioning regimen with TKIs starting the day of the transplantation could be safe.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "345ca0bfb3974062abd3ec10a6cbc84a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[21, 23], [54, 56]], "char_spans": [[144, 150], [313, 319]]}]}], "context_tokens": [["The", 0], ["availability", 4], ["of", 17], ["tyrosine", 20], ["kinase", 29], ["inhibitors", 36], ["(", 47], ["TKIs", 48], [")", 52], ["has", 54], ["considerably", 58], ["changed", 71], ["the", 79], ["management", 83], ["of", 94], ["Philadelphia", 97], ["chromosome", 110], ["positive", 121], ["leukemia", 130], [".", 138], ["The", 140], ["BCR", 144], ["-", 147], ["ABL", 148], ["inhibitor", 152], ["imatinib", 162], ["is", 171], ["also", 174], ["known", 179], ["to", 185], ["inhibit", 188], ["the", 196], ["tyrosine", 200], ["kinase", 209], ["of", 216], ["the", 219], ["stem", 223], ["cell", 228], ["factor", 233], ["receptor", 240], [",", 248], ["c", 250], ["-", 251], ["Kit", 252], [".", 255], ["Nilotinib", 257], ["is", 267], ["30", 270], ["times", 273], ["more", 279], ["potent", 284], ["than", 291], ["imatinib", 296], ["towards", 305], ["BCR", 313], ["-", 316], ["ABL", 317], ["in", 321], ["vitro", 324], [".", 329], ["Studies", 331], ["in", 339], ["healthy", 342], ["volunteers", 350], ["and", 361], ["patients", 365], ["with", 374], ["chronic", 379], ["myelogenous", 387], ["leukemia", 399], ["or", 408], ["gastrointestinal", 411], ["stromal", 428], ["tumors", 436], ["have", 443], ["shown", 448], ["that", 454], ["therapeutic", 459], ["doses", 471], ["of", 477], ["nilotinib", 480], ["deliver", 490], ["drug", 498], ["levels", 503], ["similar", 510], ["to", 518], ["those", 521], ["of", 527], ["imatinib", 530], [".", 538], ["The", 540], ["aim", 544], ["of", 548], ["this", 551], ["study", 556], ["was", 562], ["to", 566], ["compare", 569], ["the", 577], ["inhibitory", 581], ["effects", 592], ["of", 600], ["imatinib", 603], ["and", 612], ["nilotinib", 616], ["on", 626], ["proliferation", 629], [",", 642], ["differentiation", 644], [",", 659], ["adhesion", 661], [",", 669], ["migration", 671], ["and", 681], ["engraftment", 685], ["capacities", 697], ["of", 708], ["human", 711], ["cord", 717], ["blood", 722], ["CD34(+", 728], [")", 734], ["cells", 736], [".", 741], ["After", 743], ["a", 749], ["48-hour", 751], ["cell", 759], ["culture", 764], ["with", 772], ["or", 777], ["without", 780], ["TKIs", 788], [",", 792], ["CFC", 794], [",", 797], ["LTC", 799], ["-", 802], ["IC", 803], [",", 805], ["migration", 807], [",", 816], ["adhesion", 818], ["and", 827], ["cell", 831], ["cycle", 836], ["analysis", 842], ["were", 851], ["performed", 856], [".", 865], ["In", 867], ["a", 870], ["second", 872], ["time", 879], [",", 883], ["the", 885], ["impact", 889], ["of", 896], ["these", 899], ["TKIs", 905], ["on", 910], ["engraftment", 913], ["was", 925], ["assessed", 929], ["in", 938], ["a", 941], ["xenotransplantation", 943], ["model", 963], ["using", 969], ["NOD", 975], ["/", 978], ["SCID", 979], ["/", 983], ["IL-2R\u03b3", 984], ["(", 991], ["null", 992], [")", 996], ["mice", 998], [".", 1002], ["TKIs", 1004], ["did", 1009], ["not", 1013], ["affect", 1017], ["LTC", 1024], ["-", 1027], ["IC", 1028], ["frequencies", 1031], ["despite", 1043], ["in", 1051], ["vitro", 1054], ["inhibition", 1060], ["of", 1071], ["CFC", 1074], ["formation", 1078], ["due", 1088], ["to", 1092], ["inhibition", 1095], ["of", 1106], ["CD34(+", 1109], [")", 1115], ["cell", 1117], ["cycle", 1122], ["entry", 1128], [".", 1133], ["Adhesion", 1135], ["of", 1144], ["CD34(+", 1147], [")", 1153], ["cells", 1155], ["to", 1161], ["retronectin", 1164], ["was", 1176], ["reduced", 1180], ["in", 1188], ["the", 1191], ["presence", 1195], ["of", 1204], ["either", 1207], ["imatinib", 1214], ["or", 1223], ["nilotinib", 1226], ["but", 1236], ["only", 1240], ["at", 1245], ["high", 1248], ["concentrations", 1253], [".", 1267], ["Migration", 1269], ["through", 1279], ["a", 1287], ["SDF-1\u03b1", 1289], ["gradient", 1296], ["was", 1305], ["not", 1309], ["changed", 1313], ["by", 1321], ["cell", 1324], ["culture", 1329], ["in", 1337], ["the", 1340], ["presence", 1344], ["of", 1353], ["TKIs", 1356], [".", 1360], ["Finally", 1362], [",", 1369], ["bone", 1371], ["marrow", 1376], ["cellularity", 1383], ["and", 1395], ["human", 1399], ["chimerism", 1405], ["were", 1415], ["not", 1420], ["affected", 1424], ["by", 1433], ["daily", 1436], ["doses", 1442], ["of", 1448], ["imatinib", 1451], ["and", 1460], ["nilotinib", 1464], ["in", 1474], ["a", 1477], ["xenogenic", 1479], ["transplantation", 1489], ["model", 1505], [".", 1510], ["No", 1512], ["significant", 1515], ["difference", 1527], ["was", 1538], ["seen", 1542], ["between", 1547], ["TKIs", 1555], ["given", 1560], ["the", 1566], ["equivalent", 1570], ["affinity", 1581], ["of", 1590], ["imatinib", 1593], ["and", 1602], ["nilotinib", 1606], ["for", 1616], ["KIT", 1620], [".", 1623], ["These", 1625], ["data", 1631], ["suggest", 1636], ["that", 1644], ["combining", 1649], ["non", 1659], ["-", 1662], ["myeloablative", 1663], ["conditioning", 1677], ["regimen", 1690], ["with", 1698], ["TKIs", 1703], ["starting", 1708], ["the", 1717], ["day", 1721], ["of", 1725], ["the", 1728], ["transplantation", 1732], ["could", 1748], ["be", 1754], ["safe", 1757], [".", 1761]]}
{"context": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene. Detection of apoptotic nuclei in temporal lobe, brain stem, medulla oblongata, hippocampus and basal ganglia from one young CADASIL patient was performed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL). Our results showed a great involvement of glial cells in apoptotic cell death in the majority of the brain regions examined; neuronal apoptosis was significantly present only in the brain stem region. We hypothesized that in the early stages of the disease neuronal involvement of apoptosis is limited to the cells of the brain stem, sparing the cortical area which is involved in neuronal apoptosis and cognitive decline later.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "63bd935131b94b97a6120e16b7ff3249", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[41, 42]], "char_spans": [[275, 285]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["apoptosis", 24], ["in", 34], ["the", 37], ["pathogenesis", 41], ["of", 54], ["brain", 57], ["lesions", 63], ["in", 71], ["cerebral", 74], ["autosomal", 83], ["dominant", 93], ["arteriopathy", 102], ["with", 115], ["subcortical", 120], ["infarcts", 132], ["and", 141], ["leukoencephalopathy", 145], ["(", 165], ["CADASIL", 166], [")", 173], [",", 174], ["a", 176], ["hereditary", 178], ["microangiopathy", 189], ["leading", 205], ["to", 213], ["cognitive", 216], ["decline", 226], ["and", 234], ["dementia", 238], [",", 246], ["caused", 248], ["by", 255], ["mutations", 258], ["in", 268], ["the", 271], ["NOTCH3", 275], ["gene", 282], [".", 286], ["Detection", 288], ["of", 298], ["apoptotic", 301], ["nuclei", 311], ["in", 318], ["temporal", 321], ["lobe", 330], [",", 334], ["brain", 336], ["stem", 342], [",", 346], ["medulla", 348], ["oblongata", 356], [",", 365], ["hippocampus", 367], ["and", 379], ["basal", 383], ["ganglia", 389], ["from", 397], ["one", 402], ["young", 406], ["CADASIL", 412], ["patient", 420], ["was", 428], ["performed", 432], ["by", 442], ["terminal", 445], ["deoxynucleotidyl", 454], ["transferase", 471], ["(", 483], ["TdT)-mediated", 484], ["dUTP", 498], ["nick", 503], ["end", 508], ["-", 511], ["labeling", 512], ["(", 521], ["TUNEL", 522], [")", 527], [".", 528], ["Our", 530], ["results", 534], ["showed", 542], ["a", 549], ["great", 551], ["involvement", 557], ["of", 569], ["glial", 572], ["cells", 578], ["in", 584], ["apoptotic", 587], ["cell", 597], ["death", 602], ["in", 608], ["the", 611], ["majority", 615], ["of", 624], ["the", 627], ["brain", 631], ["regions", 637], ["examined", 645], [";", 653], ["neuronal", 655], ["apoptosis", 664], ["was", 674], ["significantly", 678], ["present", 692], ["only", 700], ["in", 705], ["the", 708], ["brain", 712], ["stem", 718], ["region", 723], [".", 729], ["We", 731], ["hypothesized", 734], ["that", 747], ["in", 752], ["the", 755], ["early", 759], ["stages", 765], ["of", 772], ["the", 775], ["disease", 779], ["neuronal", 787], ["involvement", 796], ["of", 808], ["apoptosis", 811], ["is", 821], ["limited", 824], ["to", 832], ["the", 835], ["cells", 839], ["of", 845], ["the", 848], ["brain", 852], ["stem", 858], [",", 862], ["sparing", 864], ["the", 872], ["cortical", 876], ["area", 885], ["which", 890], ["is", 896], ["involved", 899], ["in", 908], ["neuronal", 911], ["apoptosis", 920], ["and", 930], ["cognitive", 934], ["decline", 944], ["later", 952], [".", 957]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "Interleukin-6 (IL-6) can activate downstream signaling pathways in lung cancer cells, such as the STAT3 pathway, and is reported to be produced by tumor cells with activating EGFR mutations. We examined IL-6/STAT3 in lung cancer tumor tissues and the effects of siltuximab, a neutralizing antibody to human IL-6, in mouse models of lung cancer. IL-6 and STAT3 activation levels were compared with tumor histology and presence of KRAS mutations in snap-frozen, non-small-cell lung cancer tumors. The effects of siltuximab alone or in combination with erlotinib were examined in mouse xenograft models constructed using three cell line xenograft models and one primary explant mouse model. We examined the influence of cancer-associated fibroblasts (CAFs) on tumor growth and siltuximab effects. IL-6 levels were higher in tumors of squamous cell versus adenocarcinoma histology and were not associated with presence of KRAS mutations. Tyrosine phosphorylation status of STAT3 did not correlate with tumor IL-6 levels. Serine phosphorylation of STAT3 was correlated with KRAS mutation status. Both tumor and stromal cells contributed to total IL-6 within tumors. Siltuximab had minimal effect as a single agent in xenografts with tumor cells alone; however, in models coadministered with CAFs, siltuximab had more potent effects on tumor inhibition. We observed no effects of combined erlotinib and siltuximab. IL-6 is elevated in subsets of human NSCLCs, especially with squamous cell histology. Tumors supported by stromal production of IL-6 seem to be the most vulnerable to tumor growth inhibition by siltuximab.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "3e577b5a3ecf46909b53f1b6b6403b89", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["can", 21], ["activate", 25], ["downstream", 34], ["signaling", 45], ["pathways", 55], ["in", 64], ["lung", 67], ["cancer", 72], ["cells", 79], [",", 84], ["such", 86], ["as", 91], ["the", 94], ["STAT3", 98], ["pathway", 104], [",", 111], ["and", 113], ["is", 117], ["reported", 120], ["to", 129], ["be", 132], ["produced", 135], ["by", 144], ["tumor", 147], ["cells", 153], ["with", 159], ["activating", 164], ["EGFR", 175], ["mutations", 180], [".", 189], ["We", 191], ["examined", 194], ["IL-6/STAT3", 203], ["in", 214], ["lung", 217], ["cancer", 222], ["tumor", 229], ["tissues", 235], ["and", 243], ["the", 247], ["effects", 251], ["of", 259], ["siltuximab", 262], [",", 272], ["a", 274], ["neutralizing", 276], ["antibody", 289], ["to", 298], ["human", 301], ["IL-6", 307], [",", 311], ["in", 313], ["mouse", 316], ["models", 322], ["of", 329], ["lung", 332], ["cancer", 337], [".", 343], ["IL-6", 345], ["and", 350], ["STAT3", 354], ["activation", 360], ["levels", 371], ["were", 378], ["compared", 383], ["with", 392], ["tumor", 397], ["histology", 403], ["and", 413], ["presence", 417], ["of", 426], ["KRAS", 429], ["mutations", 434], ["in", 444], ["snap", 447], ["-", 451], ["frozen", 452], [",", 458], ["non", 460], ["-", 463], ["small", 464], ["-", 469], ["cell", 470], ["lung", 475], ["cancer", 480], ["tumors", 487], [".", 493], ["The", 495], ["effects", 499], ["of", 507], ["siltuximab", 510], ["alone", 521], ["or", 527], ["in", 530], ["combination", 533], ["with", 545], ["erlotinib", 550], ["were", 560], ["examined", 565], ["in", 574], ["mouse", 577], ["xenograft", 583], ["models", 593], ["constructed", 600], ["using", 612], ["three", 618], ["cell", 624], ["line", 629], ["xenograft", 634], ["models", 644], ["and", 651], ["one", 655], ["primary", 659], ["explant", 667], ["mouse", 675], ["model", 681], [".", 686], ["We", 688], ["examined", 691], ["the", 700], ["influence", 704], ["of", 714], ["cancer", 717], ["-", 723], ["associated", 724], ["fibroblasts", 735], ["(", 747], ["CAFs", 748], [")", 752], ["on", 754], ["tumor", 757], ["growth", 763], ["and", 770], ["siltuximab", 774], ["effects", 785], [".", 792], ["IL-6", 794], ["levels", 799], ["were", 806], ["higher", 811], ["in", 818], ["tumors", 821], ["of", 828], ["squamous", 831], ["cell", 840], ["versus", 845], ["adenocarcinoma", 852], ["histology", 867], ["and", 877], ["were", 881], ["not", 886], ["associated", 890], ["with", 901], ["presence", 906], ["of", 915], ["KRAS", 918], ["mutations", 923], [".", 932], ["Tyrosine", 934], ["phosphorylation", 943], ["status", 959], ["of", 966], ["STAT3", 969], ["did", 975], ["not", 979], ["correlate", 983], ["with", 993], ["tumor", 998], ["IL-6", 1004], ["levels", 1009], [".", 1015], ["Serine", 1017], ["phosphorylation", 1024], ["of", 1040], ["STAT3", 1043], ["was", 1049], ["correlated", 1053], ["with", 1064], ["KRAS", 1069], ["mutation", 1074], ["status", 1083], [".", 1089], ["Both", 1091], ["tumor", 1096], ["and", 1102], ["stromal", 1106], ["cells", 1114], ["contributed", 1120], ["to", 1132], ["total", 1135], ["IL-6", 1141], ["within", 1146], ["tumors", 1153], [".", 1159], ["Siltuximab", 1161], ["had", 1172], ["minimal", 1176], ["effect", 1184], ["as", 1191], ["a", 1194], ["single", 1196], ["agent", 1203], ["in", 1209], ["xenografts", 1212], ["with", 1223], ["tumor", 1228], ["cells", 1234], ["alone", 1240], [";", 1245], ["however", 1247], [",", 1254], ["in", 1256], ["models", 1259], ["coadministered", 1266], ["with", 1281], ["CAFs", 1286], [",", 1290], ["siltuximab", 1292], ["had", 1303], ["more", 1307], ["potent", 1312], ["effects", 1319], ["on", 1327], ["tumor", 1330], ["inhibition", 1336], [".", 1346], ["We", 1348], ["observed", 1351], ["no", 1360], ["effects", 1363], ["of", 1371], ["combined", 1374], ["erlotinib", 1383], ["and", 1393], ["siltuximab", 1397], [".", 1407], ["IL-6", 1409], ["is", 1414], ["elevated", 1417], ["in", 1426], ["subsets", 1429], ["of", 1437], ["human", 1440], ["NSCLCs", 1446], [",", 1452], ["especially", 1454], ["with", 1465], ["squamous", 1470], ["cell", 1479], ["histology", 1484], [".", 1493], ["Tumors", 1495], ["supported", 1502], ["by", 1512], ["stromal", 1515], ["production", 1523], ["of", 1534], ["IL-6", 1537], ["seem", 1542], ["to", 1547], ["be", 1550], ["the", 1553], ["most", 1557], ["vulnerable", 1562], ["to", 1573], ["tumor", 1576], ["growth", 1582], ["inhibition", 1589], ["by", 1600], ["siltuximab", 1603], [".", 1613]]}
{"context": "Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 \u03bcg per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P\u22640.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.).", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "cf8660626db24842b789111d454df139", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[44, 46], [3, 5]], "char_spans": [[269, 287], [24, 42]]}]}], "context_tokens": [["Increased", 0], ["expression", 10], ["of", 21], ["nerve", 24], ["growth", 30], ["factor", 37], ["in", 44], ["injured", 47], ["or", 55], ["inflamed", 58], ["tissue", 67], ["is", 74], ["associated", 77], ["with", 88], ["increased", 93], ["pain", 103], [".", 107], ["This", 109], ["proof", 114], ["-", 119], ["of", 120], ["-", 122], ["concept", 123], ["study", 131], ["was", 137], ["designed", 141], ["to", 150], ["investigate", 153], ["the", 165], ["safety", 169], ["and", 176], ["analgesic", 180], ["efficacy", 190], ["of", 199], ["tanezumab", 202], [",", 211], ["a", 213], ["humanized", 215], ["monoclonal", 225], ["antibody", 236], ["that", 245], ["binds", 250], ["and", 256], ["inhibits", 260], ["nerve", 269], ["growth", 275], ["factor", 282], [".", 288], ["We", 290], ["randomly", 293], ["assigned", 302], ["450", 311], ["patients", 315], ["with", 324], ["osteoarthritis", 329], ["of", 344], ["the", 347], ["knee", 351], ["to", 356], ["receive", 359], ["tanezumab", 367], ["(", 377], ["administered", 378], ["at", 391], ["a", 394], ["dose", 396], ["of", 401], ["10", 404], [",", 406], ["25", 408], [",", 410], ["50", 412], [",", 414], ["100", 416], [",", 419], ["or", 421], ["200", 424], ["\u03bcg", 428], ["per", 431], ["kilogram", 435], ["of", 444], ["body", 447], ["weight", 452], [")", 458], ["or", 460], ["placebo", 463], ["on", 471], ["days", 474], ["1", 479], ["and", 481], ["56", 485], [".", 487], ["The", 489], ["primary", 493], ["efficacy", 501], ["measures", 510], ["were", 519], ["knee", 524], ["pain", 529], ["while", 534], ["walking", 540], ["and", 548], ["the", 552], ["patient", 556], ["'s", 563], ["global", 566], ["assessment", 573], ["of", 584], ["response", 587], ["to", 596], ["therapy", 599], [".", 606], ["We", 608], ["also", 611], ["assessed", 616], ["pain", 625], [",", 629], ["stiffness", 631], [",", 640], ["and", 642], ["physical", 646], ["function", 655], ["using", 664], ["the", 670], ["Western", 674], ["Ontario", 682], ["and", 690], ["McMaster", 694], ["Universities", 703], ["Osteoarthritis", 716], ["Index", 731], ["(", 737], ["WOMAC", 738], [")", 743], [";", 744], ["the", 746], ["rate", 750], ["of", 755], ["response", 758], ["using", 767], ["the", 773], ["criteria", 777], ["of", 786], ["the", 789], ["Outcome", 793], ["Measures", 801], ["for", 810], ["Rheumatology", 814], ["Committee", 827], ["and", 837], ["Osteoarthritis", 841], ["Research", 856], ["Society", 865], ["International", 873], ["Standing", 887], ["Committee", 896], ["for", 906], ["Clinical", 910], ["Trials", 919], ["Response", 926], ["Criteria", 935], ["Initiative", 944], ["(", 955], ["OMERACT", 956], ["-", 963], ["OARSI", 964], [")", 969], [";", 970], ["and", 972], ["safety", 976], [".", 982], ["When", 984], ["averaged", 989], ["over", 998], ["weeks", 1003], ["1", 1009], ["through", 1011], ["16", 1019], [",", 1021], ["the", 1023], ["mean", 1027], ["reductions", 1032], ["from", 1043], ["baseline", 1048], ["in", 1057], ["knee", 1060], ["pain", 1065], ["while", 1070], ["walking", 1076], ["ranged", 1084], ["from", 1091], ["45", 1096], ["to", 1099], ["62", 1102], ["%", 1104], ["with", 1106], ["various", 1111], ["doses", 1119], ["of", 1125], ["tanezumab", 1128], [",", 1137], ["as", 1139], ["compared", 1142], ["with", 1151], ["22", 1156], ["%", 1158], ["with", 1160], ["placebo", 1165], ["(", 1173], ["P<0.001", 1174], [")", 1181], [".", 1182], ["Tanezumab", 1184], [",", 1193], ["as", 1195], ["compared", 1198], ["with", 1207], ["placebo", 1212], [",", 1219], ["was", 1221], ["also", 1225], ["associated", 1230], ["with", 1241], ["significantly", 1246], ["greater", 1260], ["improvements", 1268], ["in", 1281], ["the", 1284], ["response", 1288], ["to", 1297], ["therapy", 1300], ["as", 1308], ["assessed", 1311], ["with", 1320], ["the", 1325], ["use", 1329], ["of", 1333], ["the", 1336], ["patients", 1340], ["'", 1348], ["global", 1350], ["assessment", 1357], ["measure", 1368], ["(", 1376], ["mean", 1377], ["increases", 1382], ["in", 1392], ["score", 1395], ["of", 1401], ["29", 1404], ["to", 1407], ["47", 1410], ["%", 1412], ["with", 1414], ["various", 1419], ["doses", 1427], ["of", 1433], ["tanezumab", 1436], [",", 1445], ["as", 1447], ["compared", 1450], ["with", 1459], ["19", 1464], ["%", 1466], ["with", 1468], ["placebo", 1473], [";", 1480], ["P\u22640.001", 1482], [")", 1489], [".", 1490], ["The", 1492], ["rate", 1496], ["of", 1501], ["response", 1504], ["according", 1513], ["to", 1523], ["the", 1526], ["OMERACT", 1530], ["-", 1537], ["OARSI", 1538], ["criteria", 1544], ["ranged", 1553], ["from", 1560], ["74", 1565], ["to", 1568], ["93", 1571], ["%", 1573], ["with", 1575], ["tanezumab", 1580], ["treatment", 1590], [",", 1599], ["as", 1601], ["compared", 1604], ["with", 1613], ["44", 1618], ["%", 1620], ["with", 1622], ["placebo", 1627], ["(", 1635], ["P<0.001", 1636], [")", 1643], [".", 1644], ["The", 1646], ["rates", 1650], ["of", 1656], ["adverse", 1659], ["events", 1667], ["were", 1674], ["68", 1679], ["%", 1681], ["and", 1683], ["55", 1687], ["%", 1689], ["in", 1691], ["the", 1694], ["tanezumab", 1698], ["and", 1708], ["placebo", 1712], ["groups", 1720], [",", 1726], ["respectively", 1728], [".", 1740], ["The", 1742], ["most", 1746], ["common", 1751], ["adverse", 1758], ["events", 1766], ["among", 1773], ["tanezumab", 1779], ["-", 1788], ["treated", 1789], ["patients", 1797], ["were", 1806], ["headache", 1811], ["(", 1820], ["9", 1821], ["%", 1822], ["of", 1824], ["the", 1827], ["patients", 1831], [")", 1839], [",", 1840], ["upper", 1842], ["respiratory", 1848], ["tract", 1860], ["infection", 1866], ["(", 1876], ["7", 1877], ["%", 1878], [")", 1879], [",", 1880], ["and", 1882], ["paresthesia", 1886], ["(", 1898], ["7", 1899], ["%", 1900], [")", 1901], [".", 1902], ["In", 1904], ["this", 1907], ["proof", 1912], ["-", 1917], ["of", 1918], ["-", 1920], ["concept", 1921], ["study", 1929], [",", 1934], ["treatment", 1936], ["with", 1946], ["tanezumab", 1951], ["was", 1961], ["associated", 1965], ["with", 1976], ["a", 1981], ["reduction", 1983], ["in", 1993], ["joint", 1996], ["pain", 2002], ["and", 2007], ["improvement", 2011], ["in", 2023], ["function", 2026], [",", 2034], ["with", 2036], ["mild", 2041], ["and", 2046], ["moderate", 2050], ["adverse", 2059], ["events", 2067], [",", 2073], ["among", 2075], ["patients", 2081], ["with", 2090], ["moderate", 2095], ["-", 2103], ["to", 2104], ["-", 2106], ["severe", 2107], ["osteoarthritis", 2114], ["of", 2129], ["the", 2132], ["knee", 2136], [".", 2140], ["(", 2142], ["Funded", 2143], ["by", 2150], ["Rinat", 2153], ["Neuroscience", 2159], [";", 2171], ["ClinicalTrials.gov", 2173], ["number", 2192], [",", 2198], ["NCT00394563", 2200], [".", 2211], [")", 2212], [".", 2213]]}
{"context": "An intervention trial found a trend for shorter length of stay (LOS) in patients with community-acquired pneumonia (CAP) when the CURB65 score was combined with the prognostic biomarker proadrenomedullin (ProADM) (CURB65-A). However, the efficacy and safety of CURB65-A in real life situations remains unclear. From September, 2011, until April, 2012, we performed a post-study prospective observational quality control survey at the cantonal Hospital of Aarau, Switzerland of consecutive adults with CAP. The primary endpoint was length of stay (LOS) during the index hospitalization and within 30 days. We compared the results with two well-defined historic cohorts of CAP patients hospitalized in the same hospital with the use of multivariate regression, namely 83 patients in the observation study without ProADM (OPTIMA I) and the 169 patients in the intervention study (OPTIMA II RCT). A total of 89 patients with confirmed CAP were included. As compared to patients with CURB65 only observed in the OPTIMA I study, adjusted regression analysis showed a significant shorter initial LOS (7.5 vs. 10.4 days; -2.32; 95% CI, -4.51 to -0.13; p = 0.04) when CURB65-A was used in clinical routine. No significant differences were found for LOS within 30 days. There were no significant differences in safety outcomes in regard to mortality and ICU admission between the cohorts. This post-study survey provides evidence that the use of ProADM in combination with CURB65 (CURB65-A) in \"real life\" situations reduces initial LOS compared to the CURB65 score alone without apparent negative effects on patient safety.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "071541cdeb9e4d6c9a4b372f6a11c778", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[20, 20]], "char_spans": [[105, 113]]}]}], "context_tokens": [["An", 0], ["intervention", 3], ["trial", 16], ["found", 22], ["a", 28], ["trend", 30], ["for", 36], ["shorter", 40], ["length", 48], ["of", 55], ["stay", 58], ["(", 63], ["LOS", 64], [")", 67], ["in", 69], ["patients", 72], ["with", 81], ["community", 86], ["-", 95], ["acquired", 96], ["pneumonia", 105], ["(", 115], ["CAP", 116], [")", 119], ["when", 121], ["the", 126], ["CURB65", 130], ["score", 137], ["was", 143], ["combined", 147], ["with", 156], ["the", 161], ["prognostic", 165], ["biomarker", 176], ["proadrenomedullin", 186], ["(", 204], ["ProADM", 205], [")", 211], ["(", 213], ["CURB65-A", 214], [")", 222], [".", 223], ["However", 225], [",", 232], ["the", 234], ["efficacy", 238], ["and", 247], ["safety", 251], ["of", 258], ["CURB65-A", 261], ["in", 270], ["real", 273], ["life", 278], ["situations", 283], ["remains", 294], ["unclear", 302], [".", 309], ["From", 311], ["September", 316], [",", 325], ["2011", 327], [",", 331], ["until", 333], ["April", 339], [",", 344], ["2012", 346], [",", 350], ["we", 352], ["performed", 355], ["a", 365], ["post", 367], ["-", 371], ["study", 372], ["prospective", 378], ["observational", 390], ["quality", 404], ["control", 412], ["survey", 420], ["at", 427], ["the", 430], ["cantonal", 434], ["Hospital", 443], ["of", 452], ["Aarau", 455], [",", 460], ["Switzerland", 462], ["of", 474], ["consecutive", 477], ["adults", 489], ["with", 496], ["CAP", 501], [".", 504], ["The", 506], ["primary", 510], ["endpoint", 518], ["was", 527], ["length", 531], ["of", 538], ["stay", 541], ["(", 546], ["LOS", 547], [")", 550], ["during", 552], ["the", 559], ["index", 563], ["hospitalization", 569], ["and", 585], ["within", 589], ["30", 596], ["days", 599], [".", 603], ["We", 605], ["compared", 608], ["the", 617], ["results", 621], ["with", 629], ["two", 634], ["well", 638], ["-", 642], ["defined", 643], ["historic", 651], ["cohorts", 660], ["of", 668], ["CAP", 671], ["patients", 675], ["hospitalized", 684], ["in", 697], ["the", 700], ["same", 704], ["hospital", 709], ["with", 718], ["the", 723], ["use", 727], ["of", 731], ["multivariate", 734], ["regression", 747], [",", 757], ["namely", 759], ["83", 766], ["patients", 769], ["in", 778], ["the", 781], ["observation", 785], ["study", 797], ["without", 803], ["ProADM", 811], ["(", 818], ["OPTIMA", 819], ["I", 826], [")", 827], ["and", 829], ["the", 833], ["169", 837], ["patients", 841], ["in", 850], ["the", 853], ["intervention", 857], ["study", 870], ["(", 876], ["OPTIMA", 877], ["II", 884], ["RCT", 887], [")", 890], [".", 891], ["A", 893], ["total", 895], ["of", 901], ["89", 904], ["patients", 907], ["with", 916], ["confirmed", 921], ["CAP", 931], ["were", 935], ["included", 940], [".", 948], ["As", 950], ["compared", 953], ["to", 962], ["patients", 965], ["with", 974], ["CURB65", 979], ["only", 986], ["observed", 991], ["in", 1000], ["the", 1003], ["OPTIMA", 1007], ["I", 1014], ["study", 1016], [",", 1021], ["adjusted", 1023], ["regression", 1032], ["analysis", 1043], ["showed", 1052], ["a", 1059], ["significant", 1061], ["shorter", 1073], ["initial", 1081], ["LOS", 1089], ["(", 1093], ["7.5", 1094], ["vs.", 1098], ["10.4", 1102], ["days", 1107], [";", 1111], ["-2.32", 1113], [";", 1118], ["95", 1120], ["%", 1122], ["CI", 1124], [",", 1126], ["-4.51", 1128], ["to", 1134], ["-0.13", 1137], [";", 1142], ["p", 1144], ["=", 1146], ["0.04", 1148], [")", 1152], ["when", 1154], ["CURB65-A", 1159], ["was", 1168], ["used", 1172], ["in", 1177], ["clinical", 1180], ["routine", 1189], [".", 1196], ["No", 1198], ["significant", 1201], ["differences", 1213], ["were", 1225], ["found", 1230], ["for", 1236], ["LOS", 1240], ["within", 1244], ["30", 1251], ["days", 1254], [".", 1258], ["There", 1260], ["were", 1266], ["no", 1271], ["significant", 1274], ["differences", 1286], ["in", 1298], ["safety", 1301], ["outcomes", 1308], ["in", 1317], ["regard", 1320], ["to", 1327], ["mortality", 1330], ["and", 1340], ["ICU", 1344], ["admission", 1348], ["between", 1358], ["the", 1366], ["cohorts", 1370], [".", 1377], ["This", 1379], ["post", 1384], ["-", 1388], ["study", 1389], ["survey", 1395], ["provides", 1402], ["evidence", 1411], ["that", 1420], ["the", 1425], ["use", 1429], ["of", 1433], ["ProADM", 1436], ["in", 1443], ["combination", 1446], ["with", 1458], ["CURB65", 1463], ["(", 1470], ["CURB65-A", 1471], [")", 1479], ["in", 1481], ["\"", 1484], ["real", 1485], ["life", 1490], ["\"", 1494], ["situations", 1496], ["reduces", 1507], ["initial", 1515], ["LOS", 1523], ["compared", 1527], ["to", 1536], ["the", 1539], ["CURB65", 1543], ["score", 1550], ["alone", 1556], ["without", 1562], ["apparent", 1570], ["negative", 1579], ["effects", 1588], ["on", 1596], ["patient", 1599], ["safety", 1607], [".", 1613]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "Alterations in GABAergic mRNA expression play a key role for prefrontal dysfunction in schizophrenia and other neurodevelopmental disease. Here, we show that histone H3-lysine 4 methylation, a chromatin mark associated with the transcriptional process, progressively increased at GAD1 and other GABAergic gene promoters (GAD2, NPY, SST) in human prefrontal cortex (PFC) from prenatal to peripubertal ages and throughout adulthood. Alterations in schizophrenia included decreased GAD1 expression and H3K4-trimethylation, predominantly in females and in conjunction with a risk haplotype at the 5' end of GAD1. Heterozygosity for a truncated, lacZ knock-in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4 methylation at GABAergic gene promoters. In contrast, Gad1 H3K4 (tri)methylation and Mll1 occupancy was increased in cerebral cortex of mice after treatment with the atypical antipsychotic, clozapine. These effects were not mimicked by haloperidol or genetic ablation of dopamine D2 and D3 receptors, suggesting that blockade of D2-like signaling is not sufficient for clozapine-induced histone methylation. Therefore, chromatin remodeling mechanisms at GABAergic gene promoters, including MLL1-mediated histone methylation, operate throughout an extended period of normal human PFC development and play a role in the neurobiology of schizophrenia.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "e6d3491bc82b418c870a7d4356305e46", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[132, 132], [143, 143]], "char_spans": [[799, 802], [863, 866]]}]}], "context_tokens": [["Alterations", 0], ["in", 12], ["GABAergic", 15], ["mRNA", 25], ["expression", 30], ["play", 41], ["a", 46], ["key", 48], ["role", 52], ["for", 57], ["prefrontal", 61], ["dysfunction", 72], ["in", 84], ["schizophrenia", 87], ["and", 101], ["other", 105], ["neurodevelopmental", 111], ["disease", 130], [".", 137], ["Here", 139], [",", 143], ["we", 145], ["show", 148], ["that", 153], ["histone", 158], ["H3-lysine", 166], ["4", 176], ["methylation", 178], [",", 189], ["a", 191], ["chromatin", 193], ["mark", 203], ["associated", 208], ["with", 219], ["the", 224], ["transcriptional", 228], ["process", 244], [",", 251], ["progressively", 253], ["increased", 267], ["at", 277], ["GAD1", 280], ["and", 285], ["other", 289], ["GABAergic", 295], ["gene", 305], ["promoters", 310], ["(", 320], ["GAD2", 321], [",", 325], ["NPY", 327], [",", 330], ["SST", 332], [")", 335], ["in", 337], ["human", 340], ["prefrontal", 346], ["cortex", 357], ["(", 364], ["PFC", 365], [")", 368], ["from", 370], ["prenatal", 375], ["to", 384], ["peripubertal", 387], ["ages", 400], ["and", 405], ["throughout", 409], ["adulthood", 420], [".", 429], ["Alterations", 431], ["in", 443], ["schizophrenia", 446], ["included", 460], ["decreased", 469], ["GAD1", 479], ["expression", 484], ["and", 495], ["H3K4-trimethylation", 499], [",", 518], ["predominantly", 520], ["in", 534], ["females", 537], ["and", 545], ["in", 549], ["conjunction", 552], ["with", 564], ["a", 569], ["risk", 571], ["haplotype", 576], ["at", 586], ["the", 589], ["5", 593], ["'", 594], ["end", 596], ["of", 600], ["GAD1", 603], [".", 607], ["Heterozygosity", 609], ["for", 624], ["a", 628], ["truncated", 630], [",", 639], ["lacZ", 641], ["knock", 646], ["-", 651], ["in", 652], ["allele", 655], ["of", 662], ["mixed", 665], ["-", 670], ["lineage", 671], ["leukemia", 679], ["1", 688], ["(", 690], ["Mll1", 691], [")", 695], [",", 696], ["a", 698], ["histone", 700], ["methyltransferase", 708], ["expressed", 726], ["in", 736], ["GABAergic", 739], ["and", 749], ["other", 753], ["cortical", 759], ["neurons", 768], [",", 775], ["resulted", 777], ["in", 786], ["decreased", 789], ["H3K4", 799], ["methylation", 804], ["at", 816], ["GABAergic", 819], ["gene", 829], ["promoters", 834], [".", 843], ["In", 845], ["contrast", 848], [",", 856], ["Gad1", 858], ["H3K4", 863], ["(", 868], ["tri)methylation", 869], ["and", 885], ["Mll1", 889], ["occupancy", 894], ["was", 904], ["increased", 908], ["in", 918], ["cerebral", 921], ["cortex", 930], ["of", 937], ["mice", 940], ["after", 945], ["treatment", 951], ["with", 961], ["the", 966], ["atypical", 970], ["antipsychotic", 979], [",", 992], ["clozapine", 994], [".", 1003], ["These", 1005], ["effects", 1011], ["were", 1019], ["not", 1024], ["mimicked", 1028], ["by", 1037], ["haloperidol", 1040], ["or", 1052], ["genetic", 1055], ["ablation", 1063], ["of", 1072], ["dopamine", 1075], ["D2", 1084], ["and", 1087], ["D3", 1091], ["receptors", 1094], [",", 1103], ["suggesting", 1105], ["that", 1116], ["blockade", 1121], ["of", 1130], ["D2-like", 1133], ["signaling", 1141], ["is", 1151], ["not", 1154], ["sufficient", 1158], ["for", 1169], ["clozapine", 1173], ["-", 1182], ["induced", 1183], ["histone", 1191], ["methylation", 1199], [".", 1210], ["Therefore", 1212], [",", 1221], ["chromatin", 1223], ["remodeling", 1233], ["mechanisms", 1244], ["at", 1255], ["GABAergic", 1258], ["gene", 1268], ["promoters", 1273], [",", 1282], ["including", 1284], ["MLL1-mediated", 1294], ["histone", 1308], ["methylation", 1316], [",", 1327], ["operate", 1329], ["throughout", 1337], ["an", 1348], ["extended", 1351], ["period", 1360], ["of", 1367], ["normal", 1370], ["human", 1377], ["PFC", 1383], ["development", 1387], ["and", 1399], ["play", 1403], ["a", 1408], ["role", 1410], ["in", 1415], ["the", 1418], ["neurobiology", 1422], ["of", 1435], ["schizophrenia", 1438], [".", 1451]]}
{"context": "The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "708d81adb4e44a03ab3e302e8165cec5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[197, 197]], "char_spans": [[1138, 1147]]}]}], "context_tokens": [["The", 0], ["vitamin", 4], ["K", 12], ["antagonists", 14], ["(", 26], ["VKAs", 27], [")", 31], ["have", 33], ["been", 38], ["the", 43], ["standard", 47], ["(", 56], ["and", 57], ["only", 61], [")", 65], ["oral", 67], ["anticoagulants", 72], ["used", 87], ["for", 92], ["the", 96], ["long", 100], ["-", 104], ["term", 105], ["treatment", 110], ["or", 120], ["prevention", 123], ["of", 134], ["venous", 137], ["thromboembolism", 144], ["or", 160], ["stroke", 163], ["in", 170], ["patients", 173], ["with", 182], ["atrial", 187], ["fibrillation", 194], [".", 206], ["The", 208], ["coagulopathy", 212], ["induced", 225], ["by", 233], ["VKAs", 236], ["can", 241], ["be", 245], ["reversed", 248], ["with", 257], ["vitamin", 262], ["K", 270], [",", 271], ["and", 273], ["in", 277], ["urgent", 280], ["situations", 287], [",", 297], ["the", 299], ["vitamin", 303], ["K", 311], ["-", 312], ["dependent", 313], ["coagulation", 323], ["factors", 335], ["can", 343], ["be", 347], ["replaced", 350], ["by", 359], ["transfusion", 362], [".", 373], ["In", 375], ["the", 378], ["last", 382], ["decade", 387], [",", 393], ["a", 395], ["new", 397], ["class", 401], ["of", 407], ["oral", 410], ["anticoagulants", 415], ["has", 430], ["been", 434], ["developed", 439], [",", 448], ["direct", 450], ["oral", 457], ["anticoagulants", 462], ["that", 477], ["bind", 482], ["to", 487], ["a", 490], ["specific", 492], ["coagulation", 501], ["factor", 513], ["and", 520], ["neutralize", 524], ["it", 535], [".", 537], ["These", 539], ["compounds", 545], ["were", 555], ["shown", 560], ["to", 566], ["be", 569], ["effective", 572], ["and", 582], ["safe", 586], ["compared", 591], ["with", 600], ["the", 605], ["VKAs", 609], ["and", 614], ["were", 618], ["licensed", 623], ["for", 632], ["specific", 636], ["indications", 645], [",", 656], ["but", 658], ["without", 662], ["a", 670], ["specific", 672], ["reversal", 681], ["agent", 690], [".", 695], ["The", 697], ["absence", 701], ["of", 709], ["a", 712], ["reversal", 714], ["agent", 723], ["is", 729], ["a", 732], ["barrier", 734], ["to", 742], ["more", 745], ["widespread", 750], ["use", 761], ["of", 765], ["these", 768], ["agents", 774], [".", 780], ["Currently", 782], [",", 791], ["for", 793], ["the", 797], ["management", 801], ["of", 812], ["major", 815], ["life", 821], ["-", 825], ["threatening", 826], ["bleeding", 838], ["with", 847], ["the", 852], ["direct", 856], ["oral", 863], ["anticoagulants", 868], [",", 882], ["most", 884], ["authorities", 889], ["recommend", 901], ["the", 911], ["use", 915], ["of", 919], ["four", 922], ["factor", 927], ["prothrombin", 934], ["complex", 946], ["concentrates", 954], [".", 966], ["There", 968], ["are", 974], ["now", 978], ["three", 982], ["reversal", 988], ["agents", 997], ["in", 1004], ["development", 1007], ["and", 1019], ["poised", 1023], ["to", 1030], ["enter", 1033], ["the", 1039], ["market", 1043], [".", 1049], ["Idarucizumab", 1051], ["is", 1064], ["a", 1067], ["specific", 1069], ["antidote", 1078], ["targeted", 1087], ["to", 1096], ["reverse", 1099], ["the", 1107], ["direct", 1111], ["thrombin", 1118], ["inhibitor", 1127], [",", 1136], ["dabigatran", 1138], [",", 1148], ["which", 1150], ["was", 1156], ["recently", 1160], ["approved", 1169], ["for", 1178], ["use", 1182], ["in", 1186], ["the", 1189], ["USA", 1193], [".", 1196], ["Andexanet", 1198], ["alfa", 1208], ["is", 1213], ["an", 1216], ["antidote", 1219], ["targeted", 1228], ["to", 1237], ["reverse", 1240], ["the", 1248], ["oral", 1252], ["direct", 1257], ["factor", 1264], ["Xa", 1271], ["inhibitors", 1274], ["as", 1285], ["well", 1288], ["as", 1293], ["the", 1296], ["indirect", 1300], ["inhibitor", 1309], ["enoxaparin", 1319], [".", 1329], ["Ciraparantag", 1331], ["is", 1344], ["an", 1347], ["antidote", 1350], ["targeted", 1359], ["to", 1368], ["reverse", 1371], ["the", 1379], ["direct", 1383], ["thrombin", 1390], ["and", 1399], ["factor", 1403], ["Xa", 1410], ["inhibitors", 1413], ["as", 1424], ["well", 1427], ["as", 1432], ["the", 1435], ["indirect", 1439], ["inhibitor", 1448], ["enoxaparin", 1458], [".", 1468]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "9366db61286b41f79e9e069494d2c271", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most frequent neurocutaneous disorder with autosomal dominant inheritance. Phenotype variability is high ranging from merely several caf\u00e9-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas. Identification of genetic factors that modify the NF1 phenotype would contribute to the understanding of NF1 pathophysiology and improve patient counselling. As even monozygotic (MZ) twins with NF1 may differ phenotypically, we wondered whether these variations might be inherited in a non-Mendelian fashion. Mitochondrial DNA (mtDNA) is inherited extrachromosomally through the cytoplasm of the oocyte and often harbours heteroplasmic sequence variations. At the time of blastomere separation, these variants may be skewedly distributed and effect phenotypic differences. Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation. MtDNA was extracted from nucleated blood cells of four pairs of discordant MZ twins with NF1 and from cutaneous neurofibromas of one twin pair. We sequenced the entire mitochondrial genome and determined the state of heteroplasmy by investigating a microsatellite region of the mitochondrial D-loop (D310-tract). The clinical diagnosis was confirmed in all patients by detection of pathogenic mutations in the NF1 gene. Monozygosity was verified by genotyping. However, we did not detect evidence for mtDNA sequence differences or for different degrees of heteroplasmy between individuals of the same twin pair. The phenotypic discordance of MZ twins with NF1 cannot be explained by skewed distribution of mtDNA mutations or polymorphisms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1c8a233817e24aaf970974c3d66dfce4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[59, 59], [51, 51], [150, 150], [74, 74], [227, 227], [4, 4], [268, 268], [175, 175]], "char_spans": [[396, 398], [341, 343], [966, 968], [485, 487], [1451, 1453], [26, 28], [1697, 1699], [1130, 1132]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["frequent", 43], ["neurocutaneous", 52], ["disorder", 67], ["with", 76], ["autosomal", 81], ["dominant", 91], ["inheritance", 100], [".", 111], ["Phenotype", 113], ["variability", 123], ["is", 135], ["high", 138], ["ranging", 143], ["from", 151], ["merely", 156], ["several", 163], ["caf\u00e9", 171], ["-", 175], ["au", 176], ["-", 178], ["lait", 179], ["spots", 184], ["to", 190], ["malignant", 193], ["peripheral", 203], ["nerve", 214], ["sheath", 220], ["tumors", 227], ["or", 234], ["severe", 237], ["disfigurement", 244], ["through", 258], ["plexiform", 266], ["neurofibromas", 276], [".", 289], ["Identification", 291], ["of", 306], ["genetic", 309], ["factors", 317], ["that", 325], ["modify", 330], ["the", 337], ["NF1", 341], ["phenotype", 345], ["would", 355], ["contribute", 361], ["to", 372], ["the", 375], ["understanding", 379], ["of", 393], ["NF1", 396], ["pathophysiology", 400], ["and", 416], ["improve", 420], ["patient", 428], ["counselling", 436], [".", 447], ["As", 449], ["even", 452], ["monozygotic", 457], ["(", 469], ["MZ", 470], [")", 472], ["twins", 474], ["with", 480], ["NF1", 485], ["may", 489], ["differ", 493], ["phenotypically", 500], [",", 514], ["we", 516], ["wondered", 519], ["whether", 528], ["these", 536], ["variations", 542], ["might", 553], ["be", 559], ["inherited", 562], ["in", 572], ["a", 575], ["non", 577], ["-", 580], ["Mendelian", 581], ["fashion", 591], [".", 598], ["Mitochondrial", 600], ["DNA", 614], ["(", 618], ["mtDNA", 619], [")", 624], ["is", 626], ["inherited", 629], ["extrachromosomally", 639], ["through", 658], ["the", 666], ["cytoplasm", 670], ["of", 680], ["the", 683], ["oocyte", 687], ["and", 694], ["often", 698], ["harbours", 704], ["heteroplasmic", 713], ["sequence", 727], ["variations", 736], [".", 746], ["At", 748], ["the", 751], ["time", 755], ["of", 760], ["blastomere", 763], ["separation", 774], [",", 784], ["these", 786], ["variants", 792], ["may", 801], ["be", 805], ["skewedly", 808], ["distributed", 817], ["and", 829], ["effect", 833], ["phenotypic", 840], ["differences", 851], [".", 862], ["Because", 864], ["of", 872], ["their", 875], ["co", 881], ["-", 883], ["localization", 884], ["with", 897], ["the", 902], ["tumor", 906], ["suppressor", 912], ["protein", 923], ["neurofibromin", 931], [",", 944], ["which", 946], ["is", 952], ["mutated", 955], ["in", 963], ["NF1", 966], [",", 969], ["mitochondria", 971], ["were", 984], ["particular", 989], ["attractive", 1000], ["candidates", 1011], ["for", 1022], ["investigation", 1026], [".", 1039], ["MtDNA", 1041], ["was", 1047], ["extracted", 1051], ["from", 1061], ["nucleated", 1066], ["blood", 1076], ["cells", 1082], ["of", 1088], ["four", 1091], ["pairs", 1096], ["of", 1102], ["discordant", 1105], ["MZ", 1116], ["twins", 1119], ["with", 1125], ["NF1", 1130], ["and", 1134], ["from", 1138], ["cutaneous", 1143], ["neurofibromas", 1153], ["of", 1167], ["one", 1170], ["twin", 1174], ["pair", 1179], [".", 1183], ["We", 1185], ["sequenced", 1188], ["the", 1198], ["entire", 1202], ["mitochondrial", 1209], ["genome", 1223], ["and", 1230], ["determined", 1234], ["the", 1245], ["state", 1249], ["of", 1255], ["heteroplasmy", 1258], ["by", 1271], ["investigating", 1274], ["a", 1288], ["microsatellite", 1290], ["region", 1305], ["of", 1312], ["the", 1315], ["mitochondrial", 1319], ["D", 1333], ["-", 1334], ["loop", 1335], ["(", 1340], ["D310-tract", 1341], [")", 1351], [".", 1352], ["The", 1354], ["clinical", 1358], ["diagnosis", 1367], ["was", 1377], ["confirmed", 1381], ["in", 1391], ["all", 1394], ["patients", 1398], ["by", 1407], ["detection", 1410], ["of", 1420], ["pathogenic", 1423], ["mutations", 1434], ["in", 1444], ["the", 1447], ["NF1", 1451], ["gene", 1455], [".", 1459], ["Monozygosity", 1461], ["was", 1474], ["verified", 1478], ["by", 1487], ["genotyping", 1490], [".", 1500], ["However", 1502], [",", 1509], ["we", 1511], ["did", 1514], ["not", 1518], ["detect", 1522], ["evidence", 1529], ["for", 1538], ["mtDNA", 1542], ["sequence", 1548], ["differences", 1557], ["or", 1569], ["for", 1572], ["different", 1576], ["degrees", 1586], ["of", 1594], ["heteroplasmy", 1597], ["between", 1610], ["individuals", 1618], ["of", 1630], ["the", 1633], ["same", 1637], ["twin", 1642], ["pair", 1647], [".", 1651], ["The", 1653], ["phenotypic", 1657], ["discordance", 1668], ["of", 1680], ["MZ", 1683], ["twins", 1686], ["with", 1692], ["NF1", 1697], ["can", 1701], ["not", 1704], ["be", 1708], ["explained", 1711], ["by", 1721], ["skewed", 1724], ["distribution", 1731], ["of", 1744], ["mtDNA", 1747], ["mutations", 1753], ["or", 1763], ["polymorphisms", 1766], [".", 1779]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. The purpose of this study was to evaluate the effect of moderate liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD; effect on COMT activity) of OPC. An open-label, parallel-group study in patients (n\u2009=\u20098) with moderate liver impairment (Child-Pugh category B, score of 7 to 9) and matched healthy subjects (n\u2009=\u20098, control) with normal liver function. All subjects received a single 50-mg oral dose of OPC, with plasma and urine concentrations of opicapone and its metabolites measured up to 72\u00a0h post-dose, including soluble COMT (S-COMT) activity. A one-way analysis of variance (ANOVA) was used to compare the main PK and PD parameters between groups. Point estimates (PE) of geometric mean ratios (GMR) and corresponding 90\u00a0% confidence intervals (90%CI) for the ratio hepatic/control subjects of each parameter were calculated and compared with the reference interval (80-125\u00a0%). Exposure to opicapone (AUC and Cmax) increased significantly in patients with moderate hepatic impairment (PE [90%CI]: AUC0-\u221e, 184\u00a0% [135-250\u00a0%]; Cmax, 189\u00a0% [144-249\u00a0%]). Although apparent total clearance (CL/F) of opicapone was decreased by \u223c35\u00a0%, similar elimination half-life and unbound/bound fractions of opicapone were observed between the two groups. Both rate and extent of exposure to BIA 9-1103 were higher in the hepatically impaired group, but not statistically significant compared with the control group. Similar to the parent (opicapone), the observed increase in exposure to BIA 9-1106 was statistically significant in the hepatically impaired group over the control group. BIA 9-1106 was the only metabolite detected in urine and its urine PK parameters were in accordance with plasma data. Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100\u00a0% and 91.2\u00a0% for the hepatically impaired and control groups respectively. Both Emax and AUEC for the hepatically impaired group reached statistical significance over the control group. OPC was well tolerated in both hepatically impaired and control groups. The bioavailability of an orally administered single dose of 50\u00a0mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect. As the tolerability profile of OPC was favourable under the conditions of this study and its exposure is completely purged from systemic circulation before the subsequent dose administration, no OPC dose adjustment is needed in patients with mild to moderate chronic hepatic impairment. However, as OPC is under clinical development for use as adjunctive therapy in levodopa-treated patients with Parkinson's disease, an adjustment of levodopa and/or OPC regimens in patients should be carefully considered based on a potentially enhanced levodopa dopaminergic response and the associated tolerability.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "6bedca90e5b9429482c8374aa747b8c4", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[7, 11]], "char_spans": [[27, 54]]}]}], "context_tokens": [["Opicapone", 0], ["(", 10], ["OPC", 11], [")", 14], ["is", 16], ["a", 19], ["novel", 21], ["catechol", 27], ["-", 35], ["O", 36], ["-", 37], ["methyltransferase", 38], ["(", 56], ["COMT", 57], [")", 61], ["inhibitor", 63], ["to", 73], ["be", 76], ["used", 79], ["as", 84], ["adjunctive", 87], ["therapy", 98], ["in", 106], ["levodopa", 109], ["-", 117], ["treated", 118], ["patients", 126], ["with", 135], ["Parkinson", 140], ["'s", 149], ["disease", 152], [".", 159], ["The", 161], ["purpose", 165], ["of", 173], ["this", 176], ["study", 181], ["was", 187], ["to", 191], ["evaluate", 194], ["the", 203], ["effect", 207], ["of", 214], ["moderate", 217], ["liver", 226], ["impairment", 232], ["on", 243], ["the", 246], ["pharmacokinetics", 250], ["(", 267], ["PK", 268], [")", 270], ["and", 272], ["pharmacodynamics", 276], ["(", 293], ["PD", 294], [";", 296], ["effect", 298], ["on", 305], ["COMT", 308], ["activity", 313], [")", 321], ["of", 323], ["OPC", 326], [".", 329], ["An", 331], ["open", 334], ["-", 338], ["label", 339], [",", 344], ["parallel", 346], ["-", 354], ["group", 355], ["study", 361], ["in", 367], ["patients", 370], ["(", 379], ["n", 380], ["=", 382], ["8)", 384], ["with", 387], ["moderate", 392], ["liver", 401], ["impairment", 407], ["(", 418], ["Child", 419], ["-", 424], ["Pugh", 425], ["category", 430], ["B", 439], [",", 440], ["score", 442], ["of", 448], ["7", 451], ["to", 453], ["9", 456], [")", 457], ["and", 459], ["matched", 463], ["healthy", 471], ["subjects", 479], ["(", 488], ["n", 489], ["=", 491], ["8", 493], [",", 494], ["control", 496], [")", 503], ["with", 505], ["normal", 510], ["liver", 517], ["function", 523], [".", 531], ["All", 533], ["subjects", 537], ["received", 546], ["a", 555], ["single", 557], ["50-mg", 564], ["oral", 570], ["dose", 575], ["of", 580], ["OPC", 583], [",", 586], ["with", 588], ["plasma", 593], ["and", 600], ["urine", 604], ["concentrations", 610], ["of", 625], ["opicapone", 628], ["and", 638], ["its", 642], ["metabolites", 646], ["measured", 658], ["up", 667], ["to", 670], ["72", 673], ["h", 676], ["post", 678], ["-", 682], ["dose", 683], [",", 687], ["including", 689], ["soluble", 699], ["COMT", 707], ["(", 712], ["S", 713], ["-", 714], ["COMT", 715], [")", 719], ["activity", 721], [".", 729], ["A", 731], ["one", 733], ["-", 736], ["way", 737], ["analysis", 741], ["of", 750], ["variance", 753], ["(", 762], ["ANOVA", 763], [")", 768], ["was", 770], ["used", 774], ["to", 779], ["compare", 782], ["the", 790], ["main", 794], ["PK", 799], ["and", 802], ["PD", 806], ["parameters", 809], ["between", 820], ["groups", 828], [".", 834], ["Point", 836], ["estimates", 842], ["(", 852], ["PE", 853], [")", 855], ["of", 857], ["geometric", 860], ["mean", 870], ["ratios", 875], ["(", 882], ["GMR", 883], [")", 886], ["and", 888], ["corresponding", 892], ["90", 906], ["%", 909], ["confidence", 911], ["intervals", 922], ["(", 932], ["90%CI", 933], [")", 938], ["for", 940], ["the", 944], ["ratio", 948], ["hepatic", 954], ["/", 961], ["control", 962], ["subjects", 970], ["of", 979], ["each", 982], ["parameter", 987], ["were", 997], ["calculated", 1002], ["and", 1013], ["compared", 1017], ["with", 1026], ["the", 1031], ["reference", 1035], ["interval", 1045], ["(", 1054], ["80", 1055], ["-", 1057], ["125", 1058], ["%", 1062], [")", 1063], [".", 1064], ["Exposure", 1066], ["to", 1075], ["opicapone", 1078], ["(", 1088], ["AUC", 1089], ["and", 1093], ["Cmax", 1097], [")", 1101], ["increased", 1103], ["significantly", 1113], ["in", 1127], ["patients", 1130], ["with", 1139], ["moderate", 1144], ["hepatic", 1153], ["impairment", 1161], ["(", 1172], ["PE", 1173], ["[", 1176], ["90%CI", 1177], ["]", 1182], [":", 1183], ["AUC0-\u221e", 1185], [",", 1191], ["184", 1193], ["%", 1197], ["[", 1199], ["135", 1200], ["-", 1203], ["250", 1204], ["%", 1208], ["]", 1209], [";", 1210], ["Cmax", 1212], [",", 1216], ["189", 1218], ["%", 1222], ["[", 1224], ["144", 1225], ["-", 1228], ["249", 1229], ["%", 1233], ["]", 1234], [")", 1235], [".", 1236], ["Although", 1238], ["apparent", 1247], ["total", 1256], ["clearance", 1262], ["(", 1272], ["CL", 1273], ["/", 1275], ["F", 1276], [")", 1277], ["of", 1279], ["opicapone", 1282], ["was", 1292], ["decreased", 1296], ["by", 1306], ["\u223c35", 1309], ["%", 1313], [",", 1314], ["similar", 1316], ["elimination", 1324], ["half", 1336], ["-", 1340], ["life", 1341], ["and", 1346], ["unbound", 1350], ["/", 1357], ["bound", 1358], ["fractions", 1364], ["of", 1374], ["opicapone", 1377], ["were", 1387], ["observed", 1392], ["between", 1401], ["the", 1409], ["two", 1413], ["groups", 1417], [".", 1423], ["Both", 1425], ["rate", 1430], ["and", 1435], ["extent", 1439], ["of", 1446], ["exposure", 1449], ["to", 1458], ["BIA", 1461], ["9", 1465], ["-", 1466], ["1103", 1467], ["were", 1472], ["higher", 1477], ["in", 1484], ["the", 1487], ["hepatically", 1491], ["impaired", 1503], ["group", 1512], [",", 1517], ["but", 1519], ["not", 1523], ["statistically", 1527], ["significant", 1541], ["compared", 1553], ["with", 1562], ["the", 1567], ["control", 1571], ["group", 1579], [".", 1584], ["Similar", 1586], ["to", 1594], ["the", 1597], ["parent", 1601], ["(", 1608], ["opicapone", 1609], [")", 1618], [",", 1619], ["the", 1621], ["observed", 1625], ["increase", 1634], ["in", 1643], ["exposure", 1646], ["to", 1655], ["BIA", 1658], ["9", 1662], ["-", 1663], ["1106", 1664], ["was", 1669], ["statistically", 1673], ["significant", 1687], ["in", 1699], ["the", 1702], ["hepatically", 1706], ["impaired", 1718], ["group", 1727], ["over", 1733], ["the", 1738], ["control", 1742], ["group", 1750], [".", 1755], ["BIA", 1757], ["9", 1761], ["-", 1762], ["1106", 1763], ["was", 1768], ["the", 1772], ["only", 1776], ["metabolite", 1781], ["detected", 1792], ["in", 1801], ["urine", 1804], ["and", 1810], ["its", 1814], ["urine", 1818], ["PK", 1824], ["parameters", 1827], ["were", 1838], ["in", 1843], ["accordance", 1846], ["with", 1857], ["plasma", 1862], ["data", 1869], [".", 1873], ["Maximum", 1875], ["S", 1883], ["-", 1884], ["COMT", 1885], ["inhibition", 1890], ["(", 1901], ["Emax", 1902], [")", 1906], ["occurred", 1908], ["earlier", 1917], ["for", 1925], ["the", 1929], ["hepatically", 1933], ["impaired", 1945], ["group", 1954], ["with", 1960], ["values", 1965], ["of", 1972], ["100", 1975], ["%", 1979], ["and", 1981], ["91.2", 1985], ["%", 1990], ["for", 1992], ["the", 1996], ["hepatically", 2000], ["impaired", 2012], ["and", 2021], ["control", 2025], ["groups", 2033], ["respectively", 2040], [".", 2052], ["Both", 2054], ["Emax", 2059], ["and", 2064], ["AUEC", 2068], ["for", 2073], ["the", 2077], ["hepatically", 2081], ["impaired", 2093], ["group", 2102], ["reached", 2108], ["statistical", 2116], ["significance", 2128], ["over", 2141], ["the", 2146], ["control", 2150], ["group", 2158], [".", 2163], ["OPC", 2165], ["was", 2169], ["well", 2173], ["tolerated", 2178], ["in", 2188], ["both", 2191], ["hepatically", 2196], ["impaired", 2208], ["and", 2217], ["control", 2221], ["groups", 2229], [".", 2235], ["The", 2237], ["bioavailability", 2241], ["of", 2257], ["an", 2260], ["orally", 2263], ["administered", 2270], ["single", 2283], ["dose", 2290], ["of", 2295], ["50", 2298], ["mg", 2301], ["OPC", 2304], ["was", 2308], ["significantly", 2312], ["higher", 2326], ["in", 2333], ["patients", 2336], ["with", 2345], ["moderate", 2350], ["chronic", 2359], ["hepatic", 2367], ["impairment", 2375], [",", 2385], ["perhaps", 2387], ["by", 2395], ["a", 2398], ["reduced", 2400], ["first", 2408], ["-", 2413], ["pass", 2414], ["effect", 2419], [".", 2425], ["As", 2427], ["the", 2430], ["tolerability", 2434], ["profile", 2447], ["of", 2455], ["OPC", 2458], ["was", 2462], ["favourable", 2466], ["under", 2477], ["the", 2483], ["conditions", 2487], ["of", 2498], ["this", 2501], ["study", 2506], ["and", 2512], ["its", 2516], ["exposure", 2520], ["is", 2529], ["completely", 2532], ["purged", 2543], ["from", 2550], ["systemic", 2555], ["circulation", 2564], ["before", 2576], ["the", 2583], ["subsequent", 2587], ["dose", 2598], ["administration", 2603], [",", 2617], ["no", 2619], ["OPC", 2622], ["dose", 2626], ["adjustment", 2631], ["is", 2642], ["needed", 2645], ["in", 2652], ["patients", 2655], ["with", 2664], ["mild", 2669], ["to", 2674], ["moderate", 2677], ["chronic", 2686], ["hepatic", 2694], ["impairment", 2702], [".", 2712], ["However", 2714], [",", 2721], ["as", 2723], ["OPC", 2726], ["is", 2730], ["under", 2733], ["clinical", 2739], ["development", 2748], ["for", 2760], ["use", 2764], ["as", 2768], ["adjunctive", 2771], ["therapy", 2782], ["in", 2790], ["levodopa", 2793], ["-", 2801], ["treated", 2802], ["patients", 2810], ["with", 2819], ["Parkinson", 2824], ["'s", 2833], ["disease", 2836], [",", 2843], ["an", 2845], ["adjustment", 2848], ["of", 2859], ["levodopa", 2862], ["and/or", 2871], ["OPC", 2878], ["regimens", 2882], ["in", 2891], ["patients", 2894], ["should", 2903], ["be", 2910], ["carefully", 2913], ["considered", 2923], ["based", 2934], ["on", 2940], ["a", 2943], ["potentially", 2945], ["enhanced", 2957], ["levodopa", 2966], ["dopaminergic", 2975], ["response", 2988], ["and", 2997], ["the", 3001], ["associated", 3005], ["tolerability", 3016], [".", 3028]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike. CA-MRSA may express virulence factors such as Panton-Valentine leukocidin, which makes soft-tissue and hard-tissue infections due to such organisms challenging to treat. We report a case of osteomyelitis of the proximal tibia in a 10-year-old boy and discuss its management in what is to the authors' knowledge the first case report of Panton-Valentine leukocidin-positive CA-MRSA osteomyelitis in a child in the UK.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "aee842a768df4abebce2612c194f1e62", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[33, 33], [104, 104], [11, 11]], "char_spans": [[191, 194], [564, 567], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["is", 75], ["increasing", 78], ["in", 89], ["prevalence", 92], ["among", 103], ["asymptomatic", 109], ["carriers", 122], ["and", 131], ["in", 135], ["cases", 138], ["of", 144], ["paediatric", 147], ["soft", 158], ["-", 162], ["tissue", 163], ["infections", 170], ["alike", 181], [".", 186], ["CA", 188], ["-", 190], ["MRSA", 191], ["may", 196], ["express", 200], ["virulence", 208], ["factors", 218], ["such", 226], ["as", 231], ["Panton", 234], ["-", 240], ["Valentine", 241], ["leukocidin", 251], [",", 261], ["which", 263], ["makes", 269], ["soft", 275], ["-", 279], ["tissue", 280], ["and", 287], ["hard", 291], ["-", 295], ["tissue", 296], ["infections", 303], ["due", 314], ["to", 318], ["such", 321], ["organisms", 326], ["challenging", 336], ["to", 348], ["treat", 351], [".", 356], ["We", 358], ["report", 361], ["a", 368], ["case", 370], ["of", 375], ["osteomyelitis", 378], ["of", 392], ["the", 395], ["proximal", 399], ["tibia", 408], ["in", 414], ["a", 417], ["10-year", 419], ["-", 426], ["old", 427], ["boy", 431], ["and", 435], ["discuss", 439], ["its", 447], ["management", 451], ["in", 462], ["what", 465], ["is", 470], ["to", 473], ["the", 476], ["authors", 480], ["'", 487], ["knowledge", 489], ["the", 499], ["first", 503], ["case", 509], ["report", 514], ["of", 521], ["Panton", 524], ["-", 530], ["Valentine", 531], ["leukocidin", 541], ["-", 551], ["positive", 552], ["CA", 561], ["-", 563], ["MRSA", 564], ["osteomyelitis", 569], ["in", 583], ["a", 586], ["child", 588], ["in", 594], ["the", 597], ["UK", 601], [".", 603]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "We investigated the requirements for selenocysteine insertion at single or multiple UGA codons in eukaryotic selenoproteins. Two functional SECIS elements were identified in the 3' untranslated region of the rat selenoprotein P mRNA, with predicted stem-loops and critical nucleotides similar to those in the SECIS elements in the type I iodothyronine 5' deiodinase (5'DI) and glutathione peroxidase selenoprotein mRNAs. Site-directed mutational analyses of three SECIS elements confirmed that conserved nucleotides in the loop and in unpaired regions of the stem are critical for activity. This indicates that multiple contact sites are required for SECIS function. Stop codon function at any of five out-of-context UGA codons in the 5'DI mRNA was suppressed by SECIS elements from the 5'DI or selenoprotein P genes linked downstream. Thus, the presence of SECIS elements in eukaryotic selenoprotein mRNAs permits complete flexibility in UGA codon position.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "03e383d3bf6142a5983cf58fc309b81d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[75, 75], [19, 19], [105, 105], [146, 146], [129, 129], [49, 49]], "char_spans": [[464, 468], [140, 144], [651, 655], [858, 862], [763, 767], [309, 313]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["requirements", 20], ["for", 33], ["selenocysteine", 37], ["insertion", 52], ["at", 62], ["single", 65], ["or", 72], ["multiple", 75], ["UGA", 84], ["codons", 88], ["in", 95], ["eukaryotic", 98], ["selenoproteins", 109], [".", 123], ["Two", 125], ["functional", 129], ["SECIS", 140], ["elements", 146], ["were", 155], ["identified", 160], ["in", 171], ["the", 174], ["3", 178], ["'", 179], ["untranslated", 181], ["region", 194], ["of", 201], ["the", 204], ["rat", 208], ["selenoprotein", 212], ["P", 226], ["mRNA", 228], [",", 232], ["with", 234], ["predicted", 239], ["stem", 249], ["-", 253], ["loops", 254], ["and", 260], ["critical", 264], ["nucleotides", 273], ["similar", 285], ["to", 293], ["those", 296], ["in", 302], ["the", 305], ["SECIS", 309], ["elements", 315], ["in", 324], ["the", 327], ["type", 331], ["I", 336], ["iodothyronine", 338], ["5", 352], ["'", 353], ["deiodinase", 355], ["(", 366], ["5'DI", 367], [")", 371], ["and", 373], ["glutathione", 377], ["peroxidase", 389], ["selenoprotein", 400], ["mRNAs", 414], [".", 419], ["Site", 421], ["-", 425], ["directed", 426], ["mutational", 435], ["analyses", 446], ["of", 455], ["three", 458], ["SECIS", 464], ["elements", 470], ["confirmed", 479], ["that", 489], ["conserved", 494], ["nucleotides", 504], ["in", 516], ["the", 519], ["loop", 523], ["and", 528], ["in", 532], ["unpaired", 535], ["regions", 544], ["of", 552], ["the", 555], ["stem", 559], ["are", 564], ["critical", 568], ["for", 577], ["activity", 581], [".", 589], ["This", 591], ["indicates", 596], ["that", 606], ["multiple", 611], ["contact", 620], ["sites", 628], ["are", 634], ["required", 638], ["for", 647], ["SECIS", 651], ["function", 657], [".", 665], ["Stop", 667], ["codon", 672], ["function", 678], ["at", 687], ["any", 690], ["of", 694], ["five", 697], ["out", 702], ["-", 705], ["of", 706], ["-", 708], ["context", 709], ["UGA", 717], ["codons", 721], ["in", 728], ["the", 731], ["5'DI", 735], ["mRNA", 740], ["was", 745], ["suppressed", 749], ["by", 760], ["SECIS", 763], ["elements", 769], ["from", 778], ["the", 783], ["5'DI", 787], ["or", 792], ["selenoprotein", 795], ["P", 809], ["genes", 811], ["linked", 817], ["downstream", 824], [".", 834], ["Thus", 836], [",", 840], ["the", 842], ["presence", 846], ["of", 855], ["SECIS", 858], ["elements", 864], ["in", 873], ["eukaryotic", 876], ["selenoprotein", 887], ["mRNAs", 901], ["permits", 907], ["complete", 915], ["flexibility", 924], ["in", 936], ["UGA", 939], ["codon", 943], ["position", 949], [".", 957]]}
{"context": "Infections generally occur in intravenous drug abuse (IVDA) patients, most commonly affecting the spine and proximal joints. Numerous serious musculoskeletal complications of IVDA may involve the upper extremity, however. Soft-tissue complications in the upper extremity of IVDA patients include cellulitis, ulceration, abscess, pyomyositis, septic bursitis, tenosynovitis, and necrotizing fasciitis. Foreign bodies in soft tissue due to needle fragments are common findings. Primary bone and joint IVDA complications include osteomyelitis (acute and chronic) and septic arthritis. Other IVDA complications in the upper extremity affecting blood vessels and lymphatics include hematoma, arterial aneurysm and pseudoaneurysm, thrombosis, thrombophlebitis, \"puffy hand\" syndrome, and lymphadenopathy. These complications usually present as urgent issues requiring prompt and accurate evaluation in the acute setting. Diagnostic imaging not only aids in making the correct diagnosis but also permits precise definition of the location and extent of these abnormalities. We review the imaging findings and illustrate a wide range of disabling and even life-threatening complications affecting the upper extremity of IVDA patients that require early diagnosis for optimal outcome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "b303b77c66f64d6c905ec9262e272043", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[4, 6]], "char_spans": [[30, 51]]}]}], "context_tokens": [["Infections", 0], ["generally", 11], ["occur", 21], ["in", 27], ["intravenous", 30], ["drug", 42], ["abuse", 47], ["(", 53], ["IVDA", 54], [")", 58], ["patients", 60], [",", 68], ["most", 70], ["commonly", 75], ["affecting", 84], ["the", 94], ["spine", 98], ["and", 104], ["proximal", 108], ["joints", 117], [".", 123], ["Numerous", 125], ["serious", 134], ["musculoskeletal", 142], ["complications", 158], ["of", 172], ["IVDA", 175], ["may", 180], ["involve", 184], ["the", 192], ["upper", 196], ["extremity", 202], [",", 211], ["however", 213], [".", 220], ["Soft", 222], ["-", 226], ["tissue", 227], ["complications", 234], ["in", 248], ["the", 251], ["upper", 255], ["extremity", 261], ["of", 271], ["IVDA", 274], ["patients", 279], ["include", 288], ["cellulitis", 296], [",", 306], ["ulceration", 308], [",", 318], ["abscess", 320], [",", 327], ["pyomyositis", 329], [",", 340], ["septic", 342], ["bursitis", 349], [",", 357], ["tenosynovitis", 359], [",", 372], ["and", 374], ["necrotizing", 378], ["fasciitis", 390], [".", 399], ["Foreign", 401], ["bodies", 409], ["in", 416], ["soft", 419], ["tissue", 424], ["due", 431], ["to", 435], ["needle", 438], ["fragments", 445], ["are", 455], ["common", 459], ["findings", 466], [".", 474], ["Primary", 476], ["bone", 484], ["and", 489], ["joint", 493], ["IVDA", 499], ["complications", 504], ["include", 518], ["osteomyelitis", 526], ["(", 540], ["acute", 541], ["and", 547], ["chronic", 551], [")", 558], ["and", 560], ["septic", 564], ["arthritis", 571], [".", 580], ["Other", 582], ["IVDA", 588], ["complications", 593], ["in", 607], ["the", 610], ["upper", 614], ["extremity", 620], ["affecting", 630], ["blood", 640], ["vessels", 646], ["and", 654], ["lymphatics", 658], ["include", 669], ["hematoma", 677], [",", 685], ["arterial", 687], ["aneurysm", 696], ["and", 705], ["pseudoaneurysm", 709], [",", 723], ["thrombosis", 725], [",", 735], ["thrombophlebitis", 737], [",", 753], ["\"", 755], ["puffy", 756], ["hand", 762], ["\"", 766], ["syndrome", 768], [",", 776], ["and", 778], ["lymphadenopathy", 782], [".", 797], ["These", 799], ["complications", 805], ["usually", 819], ["present", 827], ["as", 835], ["urgent", 838], ["issues", 845], ["requiring", 852], ["prompt", 862], ["and", 869], ["accurate", 873], ["evaluation", 882], ["in", 893], ["the", 896], ["acute", 900], ["setting", 906], [".", 913], ["Diagnostic", 915], ["imaging", 926], ["not", 934], ["only", 938], ["aids", 943], ["in", 948], ["making", 951], ["the", 958], ["correct", 962], ["diagnosis", 970], ["but", 980], ["also", 984], ["permits", 989], ["precise", 997], ["definition", 1005], ["of", 1016], ["the", 1019], ["location", 1023], ["and", 1032], ["extent", 1036], ["of", 1043], ["these", 1046], ["abnormalities", 1052], [".", 1065], ["We", 1067], ["review", 1070], ["the", 1077], ["imaging", 1081], ["findings", 1089], ["and", 1098], ["illustrate", 1102], ["a", 1113], ["wide", 1115], ["range", 1120], ["of", 1126], ["disabling", 1129], ["and", 1139], ["even", 1143], ["life", 1148], ["-", 1152], ["threatening", 1153], ["complications", 1165], ["affecting", 1179], ["the", 1189], ["upper", 1193], ["extremity", 1199], ["of", 1209], ["IVDA", 1212], ["patients", 1217], ["that", 1226], ["require", 1231], ["early", 1239], ["diagnosis", 1245], ["for", 1255], ["optimal", 1259], ["outcome", 1267], [".", 1274]]}
{"context": "Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib. However, the effect of EGFR-TKI treatment on the prolongation of overall survival (OS) of these patients remains uncertain, although several recent studies have shown prolongation of progression free survival compared with cytotoxic chemotherapy. A total of 304 patients with lung adenocarcinoma who had postoperative recurrent disease were studied. To eliminate potential biases as possible, the matching of four potential predictive factors of responsiveness to EGFR-TKI led to the identification of 81 pairs of patients (those who were treated with gefitinib and those who were not). A deletion mutation in exon 19 and a point mutation (L858R) in exon 21 of the EGFR gene were also analyzed. We compared the OS between the two groups. OS in the gefitinib group was significantly longer than in the control group (median, 63 vs. 41 months; p\u00a0=\u00a00.015). EGFR mutations were detected in 65 out of 129 patients (50%) in the whole sample. EGFR mutational status was not an independent prognostic factor of gefitinib benefit; rather, it was a predictive factor. This study strongly suggested that gefitinib treatment improved OS of lung adenocarcinoma patients who had postoperative recurrence, especially those carrying EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "4c43e1cef300429f95de389403fe64ce", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[6, 13]], "char_spans": [[44, 87]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["lung", 14], ["adenocarcinoma", 19], ["who", 34], ["carry", 38], ["epidermal", 44], ["growth", 54], ["factor", 61], ["receptor", 68], ["(", 77], ["EGFR", 78], [")", 82], ["gene", 84], ["mutations", 89], ["respond", 99], ["remarkably", 107], ["well", 118], ["to", 123], ["EGFR", 126], ["tyrosine", 131], ["kinase", 140], ["inhibitor", 147], ["(", 157], ["EGFR", 158], ["-", 162], ["TKI", 163], [")", 166], [",", 167], ["gefitinib", 169], [",", 178], ["or", 180], ["erlotinib", 183], [".", 192], ["However", 194], [",", 201], ["the", 203], ["effect", 207], ["of", 214], ["EGFR", 217], ["-", 221], ["TKI", 222], ["treatment", 226], ["on", 236], ["the", 239], ["prolongation", 243], ["of", 256], ["overall", 259], ["survival", 267], ["(", 276], ["OS", 277], [")", 279], ["of", 281], ["these", 284], ["patients", 290], ["remains", 299], ["uncertain", 307], [",", 316], ["although", 318], ["several", 327], ["recent", 335], ["studies", 342], ["have", 350], ["shown", 355], ["prolongation", 361], ["of", 374], ["progression", 377], ["free", 389], ["survival", 394], ["compared", 403], ["with", 412], ["cytotoxic", 417], ["chemotherapy", 427], [".", 439], ["A", 441], ["total", 443], ["of", 449], ["304", 452], ["patients", 456], ["with", 465], ["lung", 470], ["adenocarcinoma", 475], ["who", 490], ["had", 494], ["postoperative", 498], ["recurrent", 512], ["disease", 522], ["were", 530], ["studied", 535], [".", 542], ["To", 544], ["eliminate", 547], ["potential", 557], ["biases", 567], ["as", 574], ["possible", 577], [",", 585], ["the", 587], ["matching", 591], ["of", 600], ["four", 603], ["potential", 608], ["predictive", 618], ["factors", 629], ["of", 637], ["responsiveness", 640], ["to", 655], ["EGFR", 658], ["-", 662], ["TKI", 663], ["led", 667], ["to", 671], ["the", 674], ["identification", 678], ["of", 693], ["81", 696], ["pairs", 699], ["of", 705], ["patients", 708], ["(", 717], ["those", 718], ["who", 724], ["were", 728], ["treated", 733], ["with", 741], ["gefitinib", 746], ["and", 756], ["those", 760], ["who", 766], ["were", 770], ["not", 775], [")", 778], [".", 779], ["A", 781], ["deletion", 783], ["mutation", 792], ["in", 801], ["exon", 804], ["19", 809], ["and", 812], ["a", 816], ["point", 818], ["mutation", 824], ["(", 833], ["L858R", 834], [")", 839], ["in", 841], ["exon", 844], ["21", 849], ["of", 852], ["the", 855], ["EGFR", 859], ["gene", 864], ["were", 869], ["also", 874], ["analyzed", 879], [".", 887], ["We", 889], ["compared", 892], ["the", 901], ["OS", 905], ["between", 908], ["the", 916], ["two", 920], ["groups", 924], [".", 930], ["OS", 932], ["in", 935], ["the", 938], ["gefitinib", 942], ["group", 952], ["was", 958], ["significantly", 962], ["longer", 976], ["than", 983], ["in", 988], ["the", 991], ["control", 995], ["group", 1003], ["(", 1009], ["median", 1010], [",", 1016], ["63", 1018], ["vs.", 1021], ["41", 1025], ["months", 1028], [";", 1034], ["p", 1036], ["=", 1038], ["0.015", 1040], [")", 1045], [".", 1046], ["EGFR", 1048], ["mutations", 1053], ["were", 1063], ["detected", 1068], ["in", 1077], ["65", 1080], ["out", 1083], ["of", 1087], ["129", 1090], ["patients", 1094], ["(", 1103], ["50", 1104], ["%", 1106], [")", 1107], ["in", 1109], ["the", 1112], ["whole", 1116], ["sample", 1122], [".", 1128], ["EGFR", 1130], ["mutational", 1135], ["status", 1146], ["was", 1153], ["not", 1157], ["an", 1161], ["independent", 1164], ["prognostic", 1176], ["factor", 1187], ["of", 1194], ["gefitinib", 1197], ["benefit", 1207], [";", 1214], ["rather", 1216], [",", 1222], ["it", 1224], ["was", 1227], ["a", 1231], ["predictive", 1233], ["factor", 1244], [".", 1250], ["This", 1252], ["study", 1257], ["strongly", 1263], ["suggested", 1272], ["that", 1282], ["gefitinib", 1287], ["treatment", 1297], ["improved", 1307], ["OS", 1316], ["of", 1319], ["lung", 1322], ["adenocarcinoma", 1327], ["patients", 1342], ["who", 1351], ["had", 1355], ["postoperative", 1359], ["recurrence", 1373], [",", 1383], ["especially", 1385], ["those", 1396], ["carrying", 1402], ["EGFR", 1411], ["mutations", 1416], [".", 1425]]}
{"context": "Although chronic stress is known to be linked with memory and other neurological disorders, little is known about the relationship between chronic stress and the onset or development of Alzheimer's disease (AD). In this study, we investigated the effects of long-term stress on the onset and severity of cognitive deficits and pathological changes in APPV717I-CT100 mice overexpressing human APP-CT100 containing the London mutation (V717I) after exposure to immobilization stress. We found that chronic immobilization stress accelerated cognitive impairments, as accessed by the Passive avoidance and the Social Transfer of Food Preference (STFP) tests. Moreover, the numbers and densities of vascular and extracellular deposits containing amyloid beta peptide (Abeta) and carboxyl-terminal fragments of amyloid precursor protein (APP-CTFs), which are pathologic markers of AD, were significantly elevated in stressed animals, especially in the hippocampus. Moreover, stressed animals, also showed highly elevated levels of neurodegeneration and tau phosphorylation and increased intraneuronal Abeta and APP-CTFs immunoreactivities in the hippocampus and in the entorhinal and piriform cortex. This study provides the first evidence that chronic stress accelerates the onset and severity of cognitive deficits and that these are highly correlated with pathological changes, which thus indicates that chronic stress may be an important contributor to the onset and development of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b1ad29199ed6423184843a3ceb0c058c", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[30, 32]], "char_spans": [[186, 204]]}, {"text": "AD", "token_spans": [[150, 150], [243, 243], [34, 34]], "char_spans": [[875, 876], [1480, 1481], [207, 208]]}]}], "context_tokens": [["Although", 0], ["chronic", 9], ["stress", 17], ["is", 24], ["known", 27], ["to", 33], ["be", 36], ["linked", 39], ["with", 46], ["memory", 51], ["and", 58], ["other", 62], ["neurological", 68], ["disorders", 81], [",", 90], ["little", 92], ["is", 99], ["known", 102], ["about", 108], ["the", 114], ["relationship", 118], ["between", 131], ["chronic", 139], ["stress", 147], ["and", 154], ["the", 158], ["onset", 162], ["or", 168], ["development", 171], ["of", 183], ["Alzheimer", 186], ["'s", 195], ["disease", 198], ["(", 206], ["AD", 207], [")", 209], [".", 210], ["In", 212], ["this", 215], ["study", 220], [",", 225], ["we", 227], ["investigated", 230], ["the", 243], ["effects", 247], ["of", 255], ["long", 258], ["-", 262], ["term", 263], ["stress", 268], ["on", 275], ["the", 278], ["onset", 282], ["and", 288], ["severity", 292], ["of", 301], ["cognitive", 304], ["deficits", 314], ["and", 323], ["pathological", 327], ["changes", 340], ["in", 348], ["APPV717I", 351], ["-", 359], ["CT100", 360], ["mice", 366], ["overexpressing", 371], ["human", 386], ["APP", 392], ["-", 395], ["CT100", 396], ["containing", 402], ["the", 413], ["London", 417], ["mutation", 424], ["(", 433], ["V717I", 434], [")", 439], ["after", 441], ["exposure", 447], ["to", 456], ["immobilization", 459], ["stress", 474], [".", 480], ["We", 482], ["found", 485], ["that", 491], ["chronic", 496], ["immobilization", 504], ["stress", 519], ["accelerated", 526], ["cognitive", 538], ["impairments", 548], [",", 559], ["as", 561], ["accessed", 564], ["by", 573], ["the", 576], ["Passive", 580], ["avoidance", 588], ["and", 598], ["the", 602], ["Social", 606], ["Transfer", 613], ["of", 622], ["Food", 625], ["Preference", 630], ["(", 641], ["STFP", 642], [")", 646], ["tests", 648], [".", 653], ["Moreover", 655], [",", 663], ["the", 665], ["numbers", 669], ["and", 677], ["densities", 681], ["of", 691], ["vascular", 694], ["and", 703], ["extracellular", 707], ["deposits", 721], ["containing", 730], ["amyloid", 741], ["beta", 749], ["peptide", 754], ["(", 762], ["Abeta", 763], [")", 768], ["and", 770], ["carboxyl", 774], ["-", 782], ["terminal", 783], ["fragments", 792], ["of", 802], ["amyloid", 805], ["precursor", 813], ["protein", 823], ["(", 831], ["APP", 832], ["-", 835], ["CTFs", 836], [")", 840], [",", 841], ["which", 843], ["are", 849], ["pathologic", 853], ["markers", 864], ["of", 872], ["AD", 875], [",", 877], ["were", 879], ["significantly", 884], ["elevated", 898], ["in", 907], ["stressed", 910], ["animals", 919], [",", 926], ["especially", 928], ["in", 939], ["the", 942], ["hippocampus", 946], [".", 957], ["Moreover", 959], [",", 967], ["stressed", 969], ["animals", 978], [",", 985], ["also", 987], ["showed", 992], ["highly", 999], ["elevated", 1006], ["levels", 1015], ["of", 1022], ["neurodegeneration", 1025], ["and", 1043], ["tau", 1047], ["phosphorylation", 1051], ["and", 1067], ["increased", 1071], ["intraneuronal", 1081], ["Abeta", 1095], ["and", 1101], ["APP", 1105], ["-", 1108], ["CTFs", 1109], ["immunoreactivities", 1114], ["in", 1133], ["the", 1136], ["hippocampus", 1140], ["and", 1152], ["in", 1156], ["the", 1159], ["entorhinal", 1163], ["and", 1174], ["piriform", 1178], ["cortex", 1187], [".", 1193], ["This", 1195], ["study", 1200], ["provides", 1206], ["the", 1215], ["first", 1219], ["evidence", 1225], ["that", 1234], ["chronic", 1239], ["stress", 1247], ["accelerates", 1254], ["the", 1266], ["onset", 1270], ["and", 1276], ["severity", 1280], ["of", 1289], ["cognitive", 1292], ["deficits", 1302], ["and", 1311], ["that", 1315], ["these", 1320], ["are", 1326], ["highly", 1330], ["correlated", 1337], ["with", 1348], ["pathological", 1353], ["changes", 1366], [",", 1373], ["which", 1375], ["thus", 1381], ["indicates", 1386], ["that", 1396], ["chronic", 1401], ["stress", 1409], ["may", 1416], ["be", 1420], ["an", 1423], ["important", 1426], ["contributor", 1436], ["to", 1448], ["the", 1451], ["onset", 1455], ["and", 1461], ["development", 1465], ["of", 1477], ["AD", 1480], [".", 1482]]}
{"context": "Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "d6448dc3be2e45b2be46a0805cc13200", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[0, 0], [21, 21], [478, 478]], "char_spans": [[0, 14], [123, 137], [2400, 2414]]}]}], "context_tokens": [["Interleukin-17A", 0], ["is", 16], ["considered", 19], ["to", 30], ["be", 33], ["central", 36], ["to", 44], ["the", 47], ["pathogenesis", 51], ["of", 64], ["psoriasis", 67], [".", 76], ["We", 78], ["evaluated", 81], ["secukinumab", 91], [",", 102], ["a", 104], ["fully", 106], ["human", 112], ["anti", 118], ["-", 122], ["interleukin-17A", 123], ["monoclonal", 139], ["antibody", 150], [",", 158], ["in", 160], ["patients", 163], ["with", 172], ["moderate", 177], ["-", 185], ["to", 186], ["-", 188], ["severe", 189], ["plaque", 196], ["psoriasis", 203], [".", 212], ["In", 214], ["two", 217], ["phase", 221], ["3", 227], [",", 228], ["double", 230], ["-", 236], ["blind", 237], [",", 242], ["52-week", 244], ["trials", 252], [",", 258], ["ERASURE", 260], ["(", 268], ["Efficacy", 269], ["of", 278], ["Response", 281], ["and", 290], ["Safety", 294], ["of", 301], ["Two", 304], ["Fixed", 308], ["Secukinumab", 314], ["Regimens", 326], ["in", 335], ["Psoriasis", 338], [")", 347], ["and", 349], ["FIXTURE", 353], ["(", 361], ["Full", 362], ["Year", 367], ["Investigative", 372], ["Examination", 386], ["of", 398], ["Secukinumab", 401], ["vs.", 413], ["Etanercept", 417], ["Using", 428], ["Two", 434], ["Dosing", 438], ["Regimens", 445], ["to", 454], ["Determine", 457], ["Efficacy", 467], ["in", 476], ["Psoriasis", 479], [")", 488], [",", 489], ["we", 491], ["randomly", 494], ["assigned", 503], ["738", 512], ["patients", 516], ["(", 525], ["in", 526], ["the", 529], ["ERASURE", 533], ["study", 541], [")", 546], ["and", 548], ["1306", 552], ["patients", 557], ["(", 566], ["in", 567], ["the", 570], ["FIXTURE", 574], ["study", 582], [")", 587], ["to", 589], ["subcutaneous", 592], ["secukinumab", 605], ["at", 617], ["a", 620], ["dose", 622], ["of", 627], ["300", 630], ["mg", 634], ["or", 637], ["150", 640], ["mg", 644], ["(", 647], ["administered", 648], ["once", 661], ["weekly", 666], ["for", 673], ["5", 677], ["weeks", 679], [",", 684], ["then", 686], ["every", 691], ["4", 697], ["weeks", 699], [")", 704], [",", 705], ["placebo", 707], [",", 714], ["or", 716], ["(", 719], ["in", 720], ["the", 723], ["FIXTURE", 727], ["study", 735], ["only", 741], [")", 745], ["etanercept", 747], ["at", 758], ["a", 761], ["dose", 763], ["of", 768], ["50", 771], ["mg", 774], ["(", 777], ["administered", 778], ["twice", 791], ["weekly", 797], ["for", 804], ["12", 808], ["weeks", 811], [",", 816], ["then", 818], ["once", 823], ["weekly", 828], [")", 834], [".", 835], ["The", 837], ["objective", 841], ["of", 851], ["each", 854], ["study", 859], ["was", 865], ["to", 869], ["show", 872], ["the", 877], ["superiority", 881], ["of", 893], ["secukinumab", 896], ["over", 908], ["placebo", 913], ["at", 921], ["week", 924], ["12", 929], ["with", 932], ["respect", 937], ["to", 945], ["the", 948], ["proportion", 952], ["of", 963], ["patients", 966], ["who", 975], ["had", 979], ["a", 983], ["reduction", 985], ["of", 995], ["75", 998], ["%", 1000], ["or", 1002], ["more", 1005], ["from", 1010], ["baseline", 1015], ["in", 1024], ["the", 1027], ["psoriasis", 1031], ["area", 1041], ["-", 1045], ["and", 1046], ["-", 1049], ["severity", 1050], ["index", 1059], ["score", 1065], ["(", 1071], ["PASI", 1072], ["75", 1077], [")", 1079], ["and", 1081], ["a", 1085], ["score", 1087], ["of", 1093], ["0", 1096], ["(", 1098], ["clear", 1099], [")", 1104], ["or", 1106], ["1", 1109], ["(", 1111], ["almost", 1112], ["clear", 1119], [")", 1124], ["on", 1126], ["a", 1129], ["5-point", 1131], ["modified", 1139], ["investigator", 1148], ["'s", 1160], ["global", 1163], ["assessment", 1170], ["(", 1181], ["coprimary", 1182], ["end", 1192], ["points", 1196], [")", 1202], [".", 1203], ["The", 1205], ["proportion", 1209], ["of", 1220], ["patients", 1223], ["who", 1232], ["met", 1236], ["the", 1240], ["criterion", 1244], ["for", 1254], ["PASI", 1258], ["75", 1263], ["at", 1266], ["week", 1269], ["12", 1274], ["was", 1277], ["higher", 1281], ["with", 1288], ["each", 1293], ["secukinumab", 1298], ["dose", 1310], ["than", 1315], ["with", 1320], ["placebo", 1325], ["or", 1333], ["etanercept", 1336], [":", 1346], ["in", 1348], ["the", 1351], ["ERASURE", 1355], ["study", 1363], [",", 1368], ["the", 1370], ["rates", 1374], ["were", 1380], ["81.6", 1385], ["%", 1389], ["with", 1391], ["300", 1396], ["mg", 1400], ["of", 1403], ["secukinumab", 1406], [",", 1417], ["71.6", 1419], ["%", 1423], ["with", 1425], ["150", 1430], ["mg", 1434], ["of", 1437], ["secukinumab", 1440], [",", 1451], ["and", 1453], ["4.5", 1457], ["%", 1460], ["with", 1462], ["placebo", 1467], [";", 1474], ["in", 1476], ["the", 1479], ["FIXTURE", 1483], ["study", 1491], [",", 1496], ["the", 1498], ["rates", 1502], ["were", 1508], ["77.1", 1513], ["%", 1517], ["with", 1519], ["300", 1524], ["mg", 1528], ["of", 1531], ["secukinumab", 1534], [",", 1545], ["67.0", 1547], ["%", 1551], ["with", 1553], ["150", 1558], ["mg", 1562], ["of", 1565], ["secukinumab", 1568], [",", 1579], ["44.0", 1581], ["%", 1585], ["with", 1587], ["etanercept", 1592], [",", 1602], ["and", 1604], ["4.9", 1608], ["%", 1611], ["with", 1613], ["placebo", 1618], ["(", 1626], ["P<0.001", 1627], ["for", 1635], ["each", 1639], ["secukinumab", 1644], ["dose", 1656], ["vs.", 1661], ["comparators", 1665], [")", 1676], [".", 1677], ["The", 1679], ["proportion", 1683], ["of", 1694], ["patients", 1697], ["with", 1706], ["a", 1711], ["response", 1713], ["of", 1722], ["0", 1725], ["or", 1727], ["1", 1730], ["on", 1732], ["the", 1735], ["modified", 1739], ["investigator", 1748], ["'s", 1760], ["global", 1763], ["assessment", 1770], ["at", 1781], ["week", 1784], ["12", 1789], ["was", 1792], ["higher", 1796], ["with", 1803], ["each", 1808], ["secukinumab", 1813], ["dose", 1825], ["than", 1830], ["with", 1835], ["placebo", 1840], ["or", 1848], ["etanercept", 1851], [":", 1861], ["in", 1863], ["the", 1866], ["ERASURE", 1870], ["study", 1878], [",", 1883], ["the", 1885], ["rates", 1889], ["were", 1895], ["65.3", 1900], ["%", 1904], ["with", 1906], ["300", 1911], ["mg", 1915], ["of", 1918], ["secukinumab", 1921], [",", 1932], ["51.2", 1934], ["%", 1938], ["with", 1940], ["150", 1945], ["mg", 1949], ["of", 1952], ["secukinumab", 1955], [",", 1966], ["and", 1968], ["2.4", 1972], ["%", 1975], ["with", 1977], ["placebo", 1982], [";", 1989], ["in", 1991], ["the", 1994], ["FIXTURE", 1998], ["study", 2006], [",", 2011], ["the", 2013], ["rates", 2017], ["were", 2023], ["62.5", 2028], ["%", 2032], ["with", 2034], ["300", 2039], ["mg", 2043], ["of", 2046], ["secukinumab", 2049], [",", 2060], ["51.1", 2062], ["%", 2066], ["with", 2068], ["150", 2073], ["mg", 2077], ["of", 2080], ["secukinumab", 2083], [",", 2094], ["27.2", 2096], ["%", 2100], ["with", 2102], ["etanercept", 2107], [",", 2117], ["and", 2119], ["2.8", 2123], ["%", 2126], ["with", 2128], ["placebo", 2133], ["(", 2141], ["P<0.001", 2142], ["for", 2150], ["each", 2154], ["secukinumab", 2159], ["dose", 2171], ["vs.", 2176], ["comparators", 2180], [")", 2191], [".", 2192], ["The", 2194], ["rates", 2198], ["of", 2204], ["infection", 2207], ["were", 2217], ["higher", 2222], ["with", 2229], ["secukinumab", 2234], ["than", 2246], ["with", 2251], ["placebo", 2256], ["in", 2264], ["both", 2267], ["studies", 2272], ["and", 2280], ["were", 2284], ["similar", 2289], ["to", 2297], ["those", 2300], ["with", 2306], ["etanercept", 2311], [".", 2321], ["Secukinumab", 2323], ["was", 2335], ["effective", 2339], ["for", 2349], ["psoriasis", 2353], ["in", 2363], ["two", 2366], ["randomized", 2370], ["trials", 2381], [",", 2387], ["validating", 2389], ["interleukin-17A", 2400], ["as", 2416], ["a", 2419], ["therapeutic", 2421], ["target", 2433], [".", 2439], ["(", 2441], ["Funded", 2442], ["by", 2449], ["Novartis", 2452], ["Pharmaceuticals", 2461], [";", 2476], ["ERASURE", 2478], ["and", 2486], ["FIXTURE", 2490], ["ClinicalTrials.gov", 2498], ["numbers", 2517], [",", 2524], ["NCT01365455", 2526], ["and", 2538], ["NCT01358578", 2542], [",", 2553], ["respectively", 2555], [".", 2567], [")", 2568], [".", 2569]]}
{"context": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK. It explores the different strains of MRSA and points out the main ways to control their spread. It is intended to be a reference source for all nurses.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2227001cc02f46f4b3d6c776d15071cd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[37, 37], [10, 10]], "char_spans": [[203, 206], [72, 75]]}]}], "context_tokens": [["This", 0], ["article", 5], ["explains", 13], ["what", 22], ["methicillin", 27], ["-", 38], ["resistant", 39], ["Staphylococcus", 49], ["aureus", 64], ["(", 71], ["MRSA", 72], [")", 76], ["is", 78], [",", 80], ["how", 82], ["it", 86], ["is", 89], ["spread", 92], ["and", 99], ["what", 103], ["the", 108], ["real", 112], ["challenges", 117], ["are", 128], ["in", 132], ["healthcare", 135], ["settings", 146], ["in", 155], ["the", 158], ["UK", 162], [".", 164], ["It", 166], ["explores", 169], ["the", 178], ["different", 182], ["strains", 192], ["of", 200], ["MRSA", 203], ["and", 208], ["points", 212], ["out", 219], ["the", 223], ["main", 227], ["ways", 232], ["to", 237], ["control", 240], ["their", 248], ["spread", 254], [".", 260], ["It", 262], ["is", 265], ["intended", 268], ["to", 277], ["be", 280], ["a", 283], ["reference", 285], ["source", 295], ["for", 302], ["all", 306], ["nurses", 310], [".", 316]]}
{"context": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML). Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients. Twelve chronic-phase patients initially receiving 400 mg/day and 4 patients with accelerated phase initially receiving either 400 mg/day (two patients) or 600 mg/day (two patients) had their dose increased (14 to 800 mg/day and 2 to 600 mg/day) because of progressive disease (usually clonal evolution) or inadequate cytogenetic response after at least 1 year of therapy. Six patients had major cytogenetic responses after dose increase (3 complete and 3 partial). Two others had minor cytogenetic responses. Two patients with clonal evolution transiently lost the additional clonal aberrations. Almost all of the responses occurred within 6 months, and were typically 3-6 months in duration. However, 3 patients have continuing major cytogenetic responses of >18 months duration. Dose increase was well tolerated, with thrombocytopenia, mild leukopenia, and exacerbation of prior edema being the most common adverse events. Although increasing the dose of imatinib can benefit a subgroup of patients with CML with either an inadequate cytogenetic response or disease progression, our results suggest the majority will not have a sustained meaningful response, and that other options, such as allogeneic stem cell transplant or investigational therapies, also need to be considered at the time of dose increase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "52dc16109e66480083c5d9ca84eb049e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[12, 14]], "char_spans": [[76, 82]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["tyrosine", 23], ["kinase", 32], ["inhibitor", 39], ["with", 49], ["high", 54], ["affinity", 59], ["for", 68], ["the", 72], ["BCR", 76], ["-", 79], ["ABL", 80], ["fusion", 84], ["protein", 91], ["expressed", 99], ["by", 109], ["the", 112], ["hematopoietic", 116], ["cells", 130], ["in", 136], ["chronic", 139], ["myelogenous", 147], ["leukemia", 159], ["(", 168], ["CML", 169], [")", 172], [".", 173], ["Some", 175], ["patients", 180], ["with", 189], ["chronic", 194], ["-", 201], ["phase", 202], ["or", 208], ["accelerated", 211], ["-", 222], ["phase", 223], ["CML", 229], ["either", 233], ["relapse", 240], ["after", 248], ["an", 254], ["initial", 257], ["response", 265], ["or", 274], ["are", 277], ["refractory", 281], ["to", 292], ["imatinib", 295], [",", 303], ["prompting", 305], ["us", 315], ["to", 318], ["evaluate", 321], ["the", 330], ["efficacy", 334], ["of", 343], ["dose", 346], ["increase", 351], ["in", 360], ["such", 363], ["patients", 368], [".", 376], ["Twelve", 378], ["chronic", 385], ["-", 392], ["phase", 393], ["patients", 399], ["initially", 408], ["receiving", 418], ["400", 428], ["mg", 432], ["/", 434], ["day", 435], ["and", 439], ["4", 443], ["patients", 445], ["with", 454], ["accelerated", 459], ["phase", 471], ["initially", 477], ["receiving", 487], ["either", 497], ["400", 504], ["mg", 508], ["/", 510], ["day", 511], ["(", 515], ["two", 516], ["patients", 520], [")", 528], ["or", 530], ["600", 533], ["mg", 537], ["/", 539], ["day", 540], ["(", 544], ["two", 545], ["patients", 549], [")", 557], ["had", 559], ["their", 563], ["dose", 569], ["increased", 574], ["(", 584], ["14", 585], ["to", 588], ["800", 591], ["mg", 595], ["/", 597], ["day", 598], ["and", 602], ["2", 606], ["to", 608], ["600", 611], ["mg", 615], ["/", 617], ["day", 618], [")", 621], ["because", 623], ["of", 631], ["progressive", 634], ["disease", 646], ["(", 654], ["usually", 655], ["clonal", 663], ["evolution", 670], [")", 679], ["or", 681], ["inadequate", 684], ["cytogenetic", 695], ["response", 707], ["after", 716], ["at", 722], ["least", 725], ["1", 731], ["year", 733], ["of", 738], ["therapy", 741], [".", 748], ["Six", 750], ["patients", 754], ["had", 763], ["major", 767], ["cytogenetic", 773], ["responses", 785], ["after", 795], ["dose", 801], ["increase", 806], ["(", 815], ["3", 816], ["complete", 818], ["and", 827], ["3", 831], ["partial", 833], [")", 840], [".", 841], ["Two", 843], ["others", 847], ["had", 854], ["minor", 858], ["cytogenetic", 864], ["responses", 876], [".", 885], ["Two", 887], ["patients", 891], ["with", 900], ["clonal", 905], ["evolution", 912], ["transiently", 922], ["lost", 934], ["the", 939], ["additional", 943], ["clonal", 954], ["aberrations", 961], [".", 972], ["Almost", 974], ["all", 981], ["of", 985], ["the", 988], ["responses", 992], ["occurred", 1002], ["within", 1011], ["6", 1018], ["months", 1020], [",", 1026], ["and", 1028], ["were", 1032], ["typically", 1037], ["3", 1047], ["-", 1048], ["6", 1049], ["months", 1051], ["in", 1058], ["duration", 1061], [".", 1069], ["However", 1071], [",", 1078], ["3", 1080], ["patients", 1082], ["have", 1091], ["continuing", 1096], ["major", 1107], ["cytogenetic", 1113], ["responses", 1125], ["of", 1135], [">", 1138], ["18", 1139], ["months", 1142], ["duration", 1149], [".", 1157], ["Dose", 1159], ["increase", 1164], ["was", 1173], ["well", 1177], ["tolerated", 1182], [",", 1191], ["with", 1193], ["thrombocytopenia", 1198], [",", 1214], ["mild", 1216], ["leukopenia", 1221], [",", 1231], ["and", 1233], ["exacerbation", 1237], ["of", 1250], ["prior", 1253], ["edema", 1259], ["being", 1265], ["the", 1271], ["most", 1275], ["common", 1280], ["adverse", 1287], ["events", 1295], [".", 1301], ["Although", 1303], ["increasing", 1312], ["the", 1323], ["dose", 1327], ["of", 1332], ["imatinib", 1335], ["can", 1344], ["benefit", 1348], ["a", 1356], ["subgroup", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["CML", 1384], ["with", 1388], ["either", 1393], ["an", 1400], ["inadequate", 1403], ["cytogenetic", 1414], ["response", 1426], ["or", 1435], ["disease", 1438], ["progression", 1446], [",", 1457], ["our", 1459], ["results", 1463], ["suggest", 1471], ["the", 1479], ["majority", 1483], ["will", 1492], ["not", 1497], ["have", 1501], ["a", 1506], ["sustained", 1508], ["meaningful", 1518], ["response", 1529], [",", 1537], ["and", 1539], ["that", 1543], ["other", 1548], ["options", 1554], [",", 1561], ["such", 1563], ["as", 1568], ["allogeneic", 1571], ["stem", 1582], ["cell", 1587], ["transplant", 1592], ["or", 1603], ["investigational", 1606], ["therapies", 1622], [",", 1631], ["also", 1633], ["need", 1638], ["to", 1643], ["be", 1646], ["considered", 1649], ["at", 1660], ["the", 1663], ["time", 1667], ["of", 1672], ["dose", 1675], ["increase", 1680], [".", 1688]]}
{"context": "The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. From March 27, 2009, until Jan 31, 2011, children (age 5-17 months) and young infants (age 6-12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical malaria was analysed by negative binomial regression and against severe malaria by relative risk reduction. This trial is registered with ClinicalTrials.gov, number NCT00866619. 8922 children and 6537 young infants were included in the modified intention-to-treat analyses. Children were followed up for a median of 48 months (IQR 39-50) and young infants for 38 months (34-41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C group, 6616 episodes occurred in the R3R group (VE 36\u00b73%, 95% CI 31\u00b78-40\u00b75) and 7396 occurred in the R3C group (28\u00b73%, 23\u00b73-32\u00b79); compared with 171 children who experienced at least one episode of severe malaria in the C3C group, 116 children experienced at least one episode of severe malaria in the R3R group (32\u00b72%, 13\u00b77 to 46\u00b79) and 169 in the R3C group (1\u00b71%, -23\u00b70 to 20\u00b75). In young infants, compared with 6170 episodes of clinical malaria that met the primary case definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25\u00b79%, 95% CI 19\u00b79-31\u00b75) and 5444 occurred in the R3C group (18\u00b73%, 11\u00b77-24\u00b74); and compared with 116 infants who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced at least one episode of severe malaria in the R3R group (17\u00b73%, 95% CI -9\u00b74 to 37\u00b75) and 104 in the R3C group (10\u00b73%, -17\u00b79 to 31\u00b78). In children, 1774 cases of clinical malaria were averted per 1000 children (95% CI 1387-2186) in the R3R group and 1363 per 1000 children (995-1797) in the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592-1337) in the R3R group and 558 (158-926) in the R3C group. The frequency of SAEs overall was balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\u00b72 per 1000 doses in young infants and 2\u00b75 per 1000 doses in children. RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e339e78113964de2b3b0f21b5a8d959d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[261, 261], [419, 419], [358, 358], [547, 547], [739, 739], [789, 789], [196, 196], [12, 12], [231, 231], [434, 434], [532, 532], [585, 585], [280, 280], [472, 472], [270, 270]], "char_spans": [[1217, 1223], [2000, 2006], [1727, 1733], [2579, 2585], [3391, 3397], [3662, 3668], [857, 863], [52, 58], [1066, 1072], [2082, 2088], [2499, 2505], [2718, 2724], [1337, 1343], [2235, 2241], [1265, 1271]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["the", 27], ["RTS", 31], [",", 34], ["S", 35], ["/", 36], ["AS01", 37], ["candidate", 42], ["malaria", 52], ["vaccine", 60], ["during", 68], ["18", 75], ["months", 78], ["of", 85], ["follow", 88], ["-", 94], ["up", 95], ["have", 98], ["been", 103], ["published", 108], ["previously", 118], [".", 128], ["Herein", 130], [",", 136], ["we", 138], ["report", 141], ["the", 148], ["final", 152], ["results", 158], ["from", 166], ["the", 171], ["same", 175], ["trial", 180], [",", 185], ["including", 187], ["the", 197], ["efficacy", 201], ["of", 210], ["a", 213], ["booster", 215], ["dose", 223], [".", 227], ["From", 229], ["March", 234], ["27", 240], [",", 242], ["2009", 244], [",", 248], ["until", 250], ["Jan", 256], ["31", 260], [",", 262], ["2011", 264], [",", 268], ["children", 270], ["(", 279], ["age", 280], ["5", 284], ["-", 285], ["17", 286], ["months", 289], [")", 295], ["and", 297], ["young", 301], ["infants", 307], ["(", 315], ["age", 316], ["6", 320], ["-", 321], ["12", 322], ["weeks", 325], [")", 330], ["were", 332], ["enrolled", 337], ["at", 346], ["11", 349], ["centres", 352], ["in", 360], ["seven", 363], ["countries", 369], ["in", 379], ["sub", 382], ["-", 385], ["Saharan", 386], ["Africa", 394], [".", 400], ["Participants", 402], ["were", 415], ["randomly", 420], ["assigned", 429], ["(", 438], ["1:1:1", 439], [")", 444], ["at", 446], ["first", 449], ["vaccination", 455], ["by", 467], ["block", 470], ["randomisation", 476], ["with", 490], ["minimisation", 495], ["by", 508], ["centre", 511], ["to", 518], ["receive", 521], ["three", 529], ["doses", 535], ["of", 541], ["RTS", 544], [",", 547], ["S", 548], ["/", 549], ["AS01", 550], ["at", 555], ["months", 558], ["0", 565], [",", 566], ["1", 568], [",", 569], ["and", 571], ["2", 575], ["and", 577], ["a", 581], ["booster", 583], ["dose", 591], ["at", 596], ["month", 599], ["20", 605], ["(", 608], ["R3R", 609], ["group", 613], [")", 618], [";", 619], ["three", 621], ["doses", 627], ["of", 633], ["RTS", 636], [",", 639], ["S", 640], ["/", 641], ["AS01", 642], ["and", 647], ["a", 651], ["dose", 653], ["of", 658], ["comparator", 661], ["vaccine", 672], ["at", 680], ["month", 683], ["20", 689], ["(", 692], ["R3C", 693], ["group", 697], [")", 702], [";", 703], ["or", 705], ["a", 708], ["comparator", 710], ["vaccine", 721], ["at", 729], ["months", 732], ["0", 739], [",", 740], ["1", 742], [",", 743], ["2", 745], [",", 746], ["and", 748], ["20", 752], ["(", 755], ["C3C", 756], ["[", 760], ["control", 761], ["group", 769], ["]", 774], [")", 775], [".", 776], ["Participants", 778], ["were", 791], ["followed", 796], ["up", 805], ["until", 808], ["Jan", 814], ["31", 818], [",", 820], ["2014", 822], [".", 826], ["Cases", 828], ["of", 834], ["clinical", 837], ["and", 846], ["severe", 850], ["malaria", 857], ["were", 865], ["captured", 870], ["through", 879], ["passive", 887], ["case", 895], ["detection", 900], [".", 909], ["Serious", 911], ["adverse", 919], ["events", 927], ["(", 934], ["SAEs", 935], [")", 939], ["were", 941], ["recorded", 946], [".", 954], ["Analyses", 956], ["were", 965], ["by", 970], ["modified", 973], ["intention", 982], ["to", 992], ["treat", 995], ["and", 1001], ["per", 1005], ["protocol", 1009], [".", 1017], ["The", 1019], ["coprimary", 1023], ["endpoints", 1033], ["were", 1043], ["the", 1048], ["occurrence", 1052], ["of", 1063], ["malaria", 1066], ["over", 1074], ["12", 1079], ["months", 1082], ["after", 1089], ["dose", 1095], ["3", 1100], ["in", 1102], ["each", 1105], ["age", 1110], ["category", 1114], [".", 1122], ["In", 1124], ["this", 1127], ["final", 1132], ["analysis", 1138], [",", 1146], ["we", 1148], ["present", 1151], ["data", 1159], ["for", 1164], ["the", 1168], ["efficacy", 1172], ["of", 1181], ["the", 1184], ["booster", 1188], ["on", 1196], ["the", 1199], ["occurrence", 1203], ["of", 1214], ["malaria", 1217], [".", 1224], ["Vaccine", 1226], ["efficacy", 1234], ["(", 1243], ["VE", 1244], [")", 1246], ["against", 1248], ["clinical", 1256], ["malaria", 1265], ["was", 1273], ["analysed", 1277], ["by", 1286], ["negative", 1289], ["binomial", 1298], ["regression", 1307], ["and", 1318], ["against", 1322], ["severe", 1330], ["malaria", 1337], ["by", 1345], ["relative", 1348], ["risk", 1357], ["reduction", 1362], [".", 1371], ["This", 1373], ["trial", 1378], ["is", 1384], ["registered", 1387], ["with", 1398], ["ClinicalTrials.gov", 1403], [",", 1421], ["number", 1423], ["NCT00866619", 1430], [".", 1441], ["8922", 1443], ["children", 1448], ["and", 1457], ["6537", 1461], ["young", 1466], ["infants", 1472], ["were", 1480], ["included", 1485], ["in", 1494], ["the", 1497], ["modified", 1501], ["intention", 1510], ["-", 1519], ["to", 1520], ["-", 1522], ["treat", 1523], ["analyses", 1529], [".", 1537], ["Children", 1539], ["were", 1548], ["followed", 1553], ["up", 1562], ["for", 1565], ["a", 1569], ["median", 1571], ["of", 1578], ["48", 1581], ["months", 1584], ["(", 1591], ["IQR", 1592], ["39", 1596], ["-", 1598], ["50", 1599], [")", 1601], ["and", 1603], ["young", 1607], ["infants", 1613], ["for", 1621], ["38", 1625], ["months", 1628], ["(", 1635], ["34", 1636], ["-", 1638], ["41", 1639], [")", 1641], ["after", 1643], ["dose", 1649], ["1", 1654], [".", 1655], ["From", 1657], ["month", 1662], ["0", 1668], ["until", 1670], ["study", 1676], ["end", 1682], [",", 1685], ["compared", 1687], ["with", 1696], ["9585", 1701], ["episodes", 1706], ["of", 1715], ["clinical", 1718], ["malaria", 1727], ["that", 1735], ["met", 1740], ["the", 1744], ["primary", 1748], ["case", 1756], ["definition", 1761], ["in", 1772], ["children", 1775], ["in", 1784], ["the", 1787], ["C3C", 1791], ["group", 1795], [",", 1800], ["6616", 1802], ["episodes", 1807], ["occurred", 1816], ["in", 1825], ["the", 1828], ["R3R", 1832], ["group", 1836], ["(", 1842], ["VE", 1843], ["36\u00b73", 1846], ["%", 1850], [",", 1851], ["95", 1853], ["%", 1855], ["CI", 1857], ["31\u00b78", 1860], ["-", 1864], ["40\u00b75", 1865], [")", 1869], ["and", 1871], ["7396", 1875], ["occurred", 1880], ["in", 1889], ["the", 1892], ["R3C", 1896], ["group", 1900], ["(", 1906], ["28\u00b73", 1907], ["%", 1911], [",", 1912], ["23\u00b73", 1914], ["-", 1918], ["32\u00b79", 1919], [")", 1923], [";", 1924], ["compared", 1926], ["with", 1935], ["171", 1940], ["children", 1944], ["who", 1953], ["experienced", 1957], ["at", 1969], ["least", 1972], ["one", 1978], ["episode", 1982], ["of", 1990], ["severe", 1993], ["malaria", 2000], ["in", 2008], ["the", 2011], ["C3C", 2015], ["group", 2019], [",", 2024], ["116", 2026], ["children", 2030], ["experienced", 2039], ["at", 2051], ["least", 2054], ["one", 2060], ["episode", 2064], ["of", 2072], ["severe", 2075], ["malaria", 2082], ["in", 2090], ["the", 2093], ["R3R", 2097], ["group", 2101], ["(", 2107], ["32\u00b72", 2108], ["%", 2112], [",", 2113], ["13\u00b77", 2115], ["to", 2120], ["46\u00b79", 2123], [")", 2127], ["and", 2129], ["169", 2133], ["in", 2137], ["the", 2140], ["R3C", 2144], ["group", 2148], ["(", 2154], ["1\u00b71", 2155], ["%", 2158], [",", 2159], ["-23\u00b70", 2161], ["to", 2167], ["20\u00b75", 2170], [")", 2174], [".", 2175], ["In", 2177], ["young", 2180], ["infants", 2186], [",", 2193], ["compared", 2195], ["with", 2204], ["6170", 2209], ["episodes", 2214], ["of", 2223], ["clinical", 2226], ["malaria", 2235], ["that", 2243], ["met", 2248], ["the", 2252], ["primary", 2256], ["case", 2264], ["definition", 2269], ["in", 2280], ["the", 2283], ["C3C", 2287], ["group", 2291], [",", 2296], ["4993", 2298], ["episodes", 2303], ["occurred", 2312], ["in", 2321], ["the", 2324], ["R3R", 2328], ["group", 2332], ["(", 2338], ["VE", 2339], ["25\u00b79", 2342], ["%", 2346], [",", 2347], ["95", 2349], ["%", 2351], ["CI", 2353], ["19\u00b79", 2356], ["-", 2360], ["31\u00b75", 2361], [")", 2365], ["and", 2367], ["5444", 2371], ["occurred", 2376], ["in", 2385], ["the", 2388], ["R3C", 2392], ["group", 2396], ["(", 2402], ["18\u00b73", 2403], ["%", 2407], [",", 2408], ["11\u00b77", 2410], ["-", 2414], ["24\u00b74", 2415], [")", 2419], [";", 2420], ["and", 2422], ["compared", 2426], ["with", 2435], ["116", 2440], ["infants", 2444], ["who", 2452], ["experienced", 2456], ["at", 2468], ["least", 2471], ["one", 2477], ["episode", 2481], ["of", 2489], ["severe", 2492], ["malaria", 2499], ["in", 2507], ["the", 2510], ["C3C", 2514], ["group", 2518], [",", 2523], ["96", 2525], ["infants", 2528], ["experienced", 2536], ["at", 2548], ["least", 2551], ["one", 2557], ["episode", 2561], ["of", 2569], ["severe", 2572], ["malaria", 2579], ["in", 2587], ["the", 2590], ["R3R", 2594], ["group", 2598], ["(", 2604], ["17\u00b73", 2605], ["%", 2609], [",", 2610], ["95", 2612], ["%", 2614], ["CI", 2616], ["-9\u00b74", 2619], ["to", 2624], ["37\u00b75", 2627], [")", 2631], ["and", 2633], ["104", 2637], ["in", 2641], ["the", 2644], ["R3C", 2648], ["group", 2652], ["(", 2658], ["10\u00b73", 2659], ["%", 2663], [",", 2664], ["-17\u00b79", 2666], ["to", 2672], ["31\u00b78", 2675], [")", 2679], [".", 2680], ["In", 2682], ["children", 2685], [",", 2693], ["1774", 2695], ["cases", 2700], ["of", 2706], ["clinical", 2709], ["malaria", 2718], ["were", 2726], ["averted", 2731], ["per", 2739], ["1000", 2743], ["children", 2748], ["(", 2757], ["95", 2758], ["%", 2760], ["CI", 2762], ["1387", 2765], ["-", 2769], ["2186", 2770], [")", 2774], ["in", 2776], ["the", 2779], ["R3R", 2783], ["group", 2787], ["and", 2793], ["1363", 2797], ["per", 2802], ["1000", 2806], ["children", 2811], ["(", 2820], ["995", 2821], ["-", 2824], ["1797", 2825], [")", 2829], ["in", 2831], ["the", 2834], ["R3C", 2838], ["group", 2842], [".", 2847], ["The", 2849], ["numbers", 2853], ["of", 2861], ["cases", 2864], ["averted", 2870], ["per", 2878], ["1000", 2882], ["young", 2887], ["infants", 2893], ["were", 2901], ["983", 2906], ["(", 2910], ["95", 2911], ["%", 2913], ["CI", 2915], ["592", 2918], ["-", 2921], ["1337", 2922], [")", 2926], ["in", 2928], ["the", 2931], ["R3R", 2935], ["group", 2939], ["and", 2945], ["558", 2949], ["(", 2953], ["158", 2954], ["-", 2957], ["926", 2958], [")", 2961], ["in", 2963], ["the", 2966], ["R3C", 2970], ["group", 2974], [".", 2979], ["The", 2981], ["frequency", 2985], ["of", 2995], ["SAEs", 2998], ["overall", 3003], ["was", 3011], ["balanced", 3015], ["between", 3024], ["groups", 3032], [".", 3038], ["However", 3040], [",", 3047], ["meningitis", 3049], ["was", 3060], ["reported", 3064], ["as", 3073], ["a", 3076], ["SAE", 3078], ["in", 3082], ["22", 3085], ["children", 3088], [":", 3096], ["11", 3098], ["in", 3101], ["the", 3104], ["R3R", 3108], ["group", 3112], [",", 3117], ["ten", 3119], ["in", 3123], ["the", 3126], ["R3C", 3130], ["group", 3134], [",", 3139], ["and", 3141], ["one", 3145], ["in", 3149], ["the", 3152], ["C3C", 3156], ["group", 3160], [".", 3165], ["The", 3167], ["incidence", 3171], ["of", 3181], ["generalised", 3184], ["convulsive", 3196], ["seizures", 3207], ["within", 3216], ["7", 3223], ["days", 3225], ["of", 3230], ["RTS", 3233], [",", 3236], ["S", 3237], ["/", 3238], ["AS01", 3239], ["booster", 3244], ["was", 3252], ["2\u00b72", 3256], ["per", 3260], ["1000", 3264], ["doses", 3269], ["in", 3275], ["young", 3278], ["infants", 3284], ["and", 3292], ["2\u00b75", 3296], ["per", 3300], ["1000", 3304], ["doses", 3309], ["in", 3315], ["children", 3318], [".", 3326], ["RTS", 3328], [",", 3331], ["S", 3332], ["/", 3333], ["AS01", 3334], ["prevented", 3339], ["a", 3349], ["substantial", 3351], ["number", 3363], ["of", 3370], ["cases", 3373], ["of", 3379], ["clinical", 3382], ["malaria", 3391], ["over", 3399], ["a", 3404], ["3", 3406], ["-", 3407], ["4", 3408], ["year", 3410], ["period", 3415], ["in", 3422], ["young", 3425], ["infants", 3431], ["and", 3439], ["children", 3443], ["when", 3452], ["administered", 3457], ["with", 3470], ["or", 3475], ["without", 3478], ["a", 3486], ["booster", 3488], ["dose", 3496], [".", 3500], ["Efficacy", 3502], ["was", 3511], ["enhanced", 3515], ["by", 3524], ["the", 3527], ["administration", 3531], ["of", 3546], ["a", 3549], ["booster", 3551], ["dose", 3559], ["in", 3564], ["both", 3567], ["age", 3572], ["categories", 3576], [".", 3586], ["Thus", 3588], [",", 3592], ["the", 3594], ["vaccine", 3598], ["has", 3606], ["the", 3610], ["potential", 3614], ["to", 3624], ["make", 3627], ["a", 3632], ["substantial", 3634], ["contribution", 3646], ["to", 3659], ["malaria", 3662], ["control", 3670], ["when", 3678], ["used", 3683], ["in", 3688], ["combination", 3691], ["with", 3703], ["other", 3708], ["effective", 3714], ["control", 3724], ["measures", 3732]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell aplasia characterized by normochromic macrocytic anemia, reticulocytopenia, and normocellular bone marrow with a selective deficiency of erythroid precursors. Ribosomal protein S19 (RPS19), currently the only gene associated with DBA, is mutated in 25% of DBA patients, but its role in erythropoiesis is unknown. We attempted to elucidate the importance of RPS19 in translation in relation to the pathogenesis of DBA. We measured translation and proliferation rates in unstimulated and phytohemagglutinin (PHA)-stimulated lymphocytes isolated from DBA patients, as well as in K562 cells expressing several RPS19 mutants to directly test the effect of RPS19 mutations on translation. The effect of leucine on overall translation was also studied. We found that the level of translation was on average 48-73% of controls in both unstimulated and PHA-activated DBA lymphocytes irrespective of mutations in RPS19. The addition of leucine increased the translational level in RPS19-non-mutated DBA cells, but not in cells with an RPS19 mutation. In unstimulated DBA cells, proliferation was significantly impaired in both RPS19-mutated and non-mutated cells, but in both groups could be efficiently activated by PHA. Studies on K562 cells showed that RPS19 mutations affecting RPS19 conserved arginines R56Q and R62Q could significantly inhibit the rate of protein synthesis, indicating the importance of RPS19 in translation. Our results indicate that inefficient translation may be the main cause of DBA, and administration of leucine may be beneficial for at least some DBA patients.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f06fc76bb7624c4ba8baf1c01fb0c0a8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[48, 48], [192, 192], [83, 83], [5, 5], [100, 100], [276, 276], [263, 263], [56, 56], [158, 158], [178, 178]], "char_spans": [[295, 297], [1122, 1124], [478, 480], [25, 27], [613, 615], [1633, 1635], [1562, 1564], [321, 323], [923, 925], [1054, 1056]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["pure", 51], ["red", 56], ["cell", 60], ["aplasia", 65], ["characterized", 73], ["by", 87], ["normochromic", 90], ["macrocytic", 103], ["anemia", 114], [",", 120], ["reticulocytopenia", 122], [",", 139], ["and", 141], ["normocellular", 145], ["bone", 159], ["marrow", 164], ["with", 171], ["a", 176], ["selective", 178], ["deficiency", 188], ["of", 199], ["erythroid", 202], ["precursors", 212], [".", 222], ["Ribosomal", 224], ["protein", 234], ["S19", 242], ["(", 246], ["RPS19", 247], [")", 252], [",", 253], ["currently", 255], ["the", 265], ["only", 269], ["gene", 274], ["associated", 279], ["with", 290], ["DBA", 295], [",", 298], ["is", 300], ["mutated", 303], ["in", 311], ["25", 314], ["%", 316], ["of", 318], ["DBA", 321], ["patients", 325], [",", 333], ["but", 335], ["its", 339], ["role", 343], ["in", 348], ["erythropoiesis", 351], ["is", 366], ["unknown", 369], [".", 376], ["We", 378], ["attempted", 381], ["to", 391], ["elucidate", 394], ["the", 404], ["importance", 408], ["of", 419], ["RPS19", 422], ["in", 428], ["translation", 431], ["in", 443], ["relation", 446], ["to", 455], ["the", 458], ["pathogenesis", 462], ["of", 475], ["DBA", 478], [".", 481], ["We", 483], ["measured", 486], ["translation", 495], ["and", 507], ["proliferation", 511], ["rates", 525], ["in", 531], ["unstimulated", 534], ["and", 547], ["phytohemagglutinin", 551], ["(", 570], ["PHA)-stimulated", 571], ["lymphocytes", 587], ["isolated", 599], ["from", 608], ["DBA", 613], ["patients", 617], [",", 625], ["as", 627], ["well", 630], ["as", 635], ["in", 638], ["K562", 641], ["cells", 646], ["expressing", 652], ["several", 663], ["RPS19", 671], ["mutants", 677], ["to", 685], ["directly", 688], ["test", 697], ["the", 702], ["effect", 706], ["of", 713], ["RPS19", 716], ["mutations", 722], ["on", 732], ["translation", 735], [".", 746], ["The", 748], ["effect", 752], ["of", 759], ["leucine", 762], ["on", 770], ["overall", 773], ["translation", 781], ["was", 793], ["also", 797], ["studied", 802], [".", 809], ["We", 811], ["found", 814], ["that", 820], ["the", 825], ["level", 829], ["of", 835], ["translation", 838], ["was", 850], ["on", 854], ["average", 857], ["48", 865], ["-", 867], ["73", 868], ["%", 870], ["of", 872], ["controls", 875], ["in", 884], ["both", 887], ["unstimulated", 892], ["and", 905], ["PHA", 909], ["-", 912], ["activated", 913], ["DBA", 923], ["lymphocytes", 927], ["irrespective", 939], ["of", 952], ["mutations", 955], ["in", 965], ["RPS19", 968], [".", 973], ["The", 975], ["addition", 979], ["of", 988], ["leucine", 991], ["increased", 999], ["the", 1009], ["translational", 1013], ["level", 1027], ["in", 1033], ["RPS19-non", 1036], ["-", 1045], ["mutated", 1046], ["DBA", 1054], ["cells", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["in", 1073], ["cells", 1076], ["with", 1082], ["an", 1087], ["RPS19", 1090], ["mutation", 1096], [".", 1104], ["In", 1106], ["unstimulated", 1109], ["DBA", 1122], ["cells", 1126], [",", 1131], ["proliferation", 1133], ["was", 1147], ["significantly", 1151], ["impaired", 1165], ["in", 1174], ["both", 1177], ["RPS19-mutated", 1182], ["and", 1196], ["non", 1200], ["-", 1203], ["mutated", 1204], ["cells", 1212], [",", 1217], ["but", 1219], ["in", 1223], ["both", 1226], ["groups", 1231], ["could", 1238], ["be", 1244], ["efficiently", 1247], ["activated", 1259], ["by", 1269], ["PHA", 1272], [".", 1275], ["Studies", 1277], ["on", 1285], ["K562", 1288], ["cells", 1293], ["showed", 1299], ["that", 1306], ["RPS19", 1311], ["mutations", 1317], ["affecting", 1327], ["RPS19", 1337], ["conserved", 1343], ["arginines", 1353], ["R56Q", 1363], ["and", 1368], ["R62Q", 1372], ["could", 1377], ["significantly", 1383], ["inhibit", 1397], ["the", 1405], ["rate", 1409], ["of", 1414], ["protein", 1417], ["synthesis", 1425], [",", 1434], ["indicating", 1436], ["the", 1447], ["importance", 1451], ["of", 1462], ["RPS19", 1465], ["in", 1471], ["translation", 1474], [".", 1485], ["Our", 1487], ["results", 1491], ["indicate", 1499], ["that", 1508], ["inefficient", 1513], ["translation", 1525], ["may", 1537], ["be", 1541], ["the", 1544], ["main", 1548], ["cause", 1553], ["of", 1559], ["DBA", 1562], [",", 1565], ["and", 1567], ["administration", 1571], ["of", 1586], ["leucine", 1589], ["may", 1597], ["be", 1601], ["beneficial", 1604], ["for", 1615], ["at", 1619], ["least", 1622], ["some", 1628], ["DBA", 1633], ["patients", 1637], [".", 1645]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established. The mice transcribed a sufficient amount of alpha-galactosidase mRNA, but the steady-state levels of the enzyme protein were decreased in liver, kidney and heart, only residual activity being detected in these tissues. The mice will be useful for the clarification of the defective regulation of the structurally altered enzyme protein expressed by the mutant gene at the organ or individual level as well as for the evaluation of drugs that stabilize and/or activate the mutant alpha-galactosidase.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "0b96af4f05454584acfec3b094cb01bf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[114, 116], [38, 40], [6, 8]], "char_spans": [[654, 672], [219, 237], [42, 60]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["expressing", 16], ["a", 27], ["human", 29], ["mutant", 35], ["alpha", 42], ["-", 47], ["galactosidase", 48], ["with", 62], ["an", 67], ["R301Q", 70], ["substitution", 76], [",", 88], ["which", 90], ["was", 96], ["found", 100], ["in", 106], ["a", 109], ["patient", 111], ["with", 119], ["a", 124], ["variant", 126], ["form", 134], ["of", 139], ["Fabry", 142], ["disease", 148], [",", 155], ["were", 157], ["established", 162], [".", 173], ["The", 175], ["mice", 179], ["transcribed", 184], ["a", 196], ["sufficient", 198], ["amount", 209], ["of", 216], ["alpha", 219], ["-", 224], ["galactosidase", 225], ["mRNA", 239], [",", 243], ["but", 245], ["the", 249], ["steady", 253], ["-", 259], ["state", 260], ["levels", 266], ["of", 273], ["the", 276], ["enzyme", 280], ["protein", 287], ["were", 295], ["decreased", 300], ["in", 310], ["liver", 313], [",", 318], ["kidney", 320], ["and", 327], ["heart", 331], [",", 336], ["only", 338], ["residual", 343], ["activity", 352], ["being", 361], ["detected", 367], ["in", 376], ["these", 379], ["tissues", 385], [".", 392], ["The", 394], ["mice", 398], ["will", 403], ["be", 408], ["useful", 411], ["for", 418], ["the", 422], ["clarification", 426], ["of", 440], ["the", 443], ["defective", 447], ["regulation", 457], ["of", 468], ["the", 471], ["structurally", 475], ["altered", 488], ["enzyme", 496], ["protein", 503], ["expressed", 511], ["by", 521], ["the", 524], ["mutant", 528], ["gene", 535], ["at", 540], ["the", 543], ["organ", 547], ["or", 553], ["individual", 556], ["level", 567], ["as", 573], ["well", 576], ["as", 581], ["for", 584], ["the", 588], ["evaluation", 592], ["of", 603], ["drugs", 606], ["that", 612], ["stabilize", 617], ["and/or", 627], ["activate", 634], ["the", 643], ["mutant", 647], ["alpha", 654], ["-", 659], ["galactosidase", 660], [".", 673]]}
{"context": "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10\u00a0days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p\u00a0\u2264\u00a00.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p\u00a0=\u00a00.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "38addabed56946b49d470b639537d475", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[11, 12]], "char_spans": [[63, 74]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["infection", 37], ["(", 47], ["CDI", 48], [")", 51], ["caused", 53], ["by", 60], ["ribotype", 63], ["027", 72], ["(", 76], ["B1/NAP1", 77], [")", 84], ["began", 86], ["in", 92], ["our", 95], ["hospital", 99], ["in", 108], ["November", 111], ["2014", 120], [",", 124], ["and", 126], ["produced", 130], ["141", 139], ["episodes", 143], ["in", 152], ["the", 155], ["following", 159], ["months", 169], [".", 175], ["The", 177], ["aim", 181], ["of", 185], ["this", 188], ["study", 193], ["is", 199], ["to", 202], ["describe", 205], ["this", 214], ["outbreak", 219], [",", 227], ["assess", 229], ["risk", 236], ["factors", 241], ["for", 249], ["recurrence", 253], ["of", 264], ["CDI-027", 267], ["and", 275], ["to", 279], ["analyze", 282], ["the", 290], ["implementation", 294], ["of", 309], ["a", 312], ["novel", 314], ["treatment", 320], ["strategy", 330], [".", 338], ["This", 340], ["is", 345], ["a", 348], ["prospective", 350], ["study", 362], ["of", 368], ["all", 371], ["patients", 375], ["with", 384], ["CDI-027", 389], [",", 396], ["from", 398], ["November", 403], ["2014", 412], ["to", 417], ["November", 420], ["2015", 429], [".", 433], ["The", 435], ["epidemiological", 439], ["data", 455], ["were", 460], ["collected", 465], ["daily", 475], ["for", 481], ["each", 485], ["patient", 490], [".", 497], ["We", 499], ["compared", 502], ["clinical", 511], ["characteristics", 520], ["and", 536], ["treatment", 540], ["between", 550], ["patients", 558], ["with", 567], ["and", 572], ["without", 576], ["recurrence", 584], ["of", 595], ["CDI-027", 598], [".", 605], ["Interestingly", 607], [",", 620], ["liver", 622], ["cirrhosis", 628], ["was", 638], ["present", 642], ["in", 650], ["22", 653], ["%", 655], ["of", 657], ["the", 660], ["patients", 664], [",", 672], ["and", 674], ["most", 678], ["of", 683], ["them", 686], ["received", 691], ["prophylaxis", 700], ["for", 712], ["hepatic", 716], ["encephalopathy", 724], ["with", 739], ["rifaximin", 744], [".", 753], ["Patients", 755], ["were", 764], ["also", 769], ["taking", 774], ["antimicrobial", 781], ["drugs", 795], ["(", 801], ["93.6", 802], ["%", 806], [")", 807], ["and", 809], ["proton", 813], ["pump", 820], ["inhibitors", 825], ["(", 836], ["80.1", 837], ["%", 841], [")", 842], [".", 843], ["Overall", 845], [",", 852], ["27", 854], ["(", 857], ["23.5", 858], ["%", 862], [")", 863], ["patients", 865], ["had", 874], ["a", 878], ["first", 880], ["recurrence", 886], ["of", 897], ["CDI-027", 900], [".", 907], ["Liver", 909], ["cirrhosis", 915], ["increased", 925], ["the", 935], ["risk", 939], ["of", 944], ["recurrence", 947], ["(", 958], ["44.4", 959], ["%", 963], ["vs", 965], ["14.8", 968], ["%", 972], [")", 973], [".", 974], ["Patients", 976], ["treated", 985], ["with", 993], ["a", 998], ["prolonged", 1000], ["oral", 1010], ["vancomycin", 1015], ["regimen", 1026], ["vs", 1034], ["the", 1037], ["conventional", 1041], ["regimen", 1054], ["(", 1062], ["oral", 1063], ["metronidazole", 1068], ["or", 1082], ["10", 1085], ["days", 1088], ["of", 1093], ["vancomycin", 1096], [")", 1106], ["had", 1108], ["fewer", 1112], ["recurrences", 1118], ["(", 1130], ["8.6", 1131], ["versus", 1135], ["44.7", 1142], ["%", 1146], ["[", 1148], ["p", 1149], ["\u2264", 1151], ["0.01", 1153], ["]", 1157], [";", 1158], ["OR", 1160], [",", 1162], ["0.91", 1164], [";", 1168], ["95", 1170], ["%", 1172], ["CI", 1174], [",", 1176], ["0.028", 1178], ["-", 1183], ["0.294", 1184], [")", 1189], ["and", 1191], ["less", 1195], ["attributable", 1200], ["mortality", 1213], ["(", 1223], ["0", 1224], ["%", 1225], ["versus", 1227], ["7.1", 1234], ["%", 1237], [";", 1238], ["p", 1240], ["=", 1242], ["0.058", 1244], [")", 1249], [".", 1250], ["We", 1252], ["report", 1255], ["an", 1262], ["outbreak", 1265], ["of", 1274], ["CDI-027", 1277], [",", 1284], ["mainly", 1286], ["in", 1293], ["patients", 1296], ["with", 1305], ["liver", 1310], ["cirrhosis", 1316], [".", 1325], ["Recurrence", 1327], ["of", 1338], ["CDI-027", 1341], ["was", 1349], ["more", 1353], ["common", 1358], ["in", 1365], ["those", 1368], ["patients", 1374], [".", 1382], ["A", 1384], ["novel", 1386], ["approach", 1392], ["involving", 1401], ["high", 1411], ["-", 1415], ["dose", 1416], ["prolonged", 1421], ["vancomycin", 1431], ["taper", 1442], ["as", 1448], ["a", 1451], ["first", 1453], ["-", 1458], ["line", 1459], ["treatment", 1464], [",", 1473], ["together", 1475], ["with", 1484], ["a", 1489], ["bundle", 1491], ["of", 1498], ["outbreak", 1501], ["measures", 1510], [",", 1518], ["seemed", 1520], ["to", 1527], ["reduce", 1530], ["the", 1537], ["number", 1541], ["of", 1548], ["cases", 1551], ["of", 1557], ["CDI-027", 1560], [",", 1567], ["recurrences", 1569], [",", 1580], ["and", 1582], ["attributable", 1586], ["mortality", 1599], [".", 1608], ["Nevertheless", 1610], [",", 1622], ["this", 1624], ["approach", 1629], ["warrants", 1638], ["further", 1647], ["investigation", 1655], [".", 1668]]}
{"context": "Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD. Although carbidopa and trihydroxybenzylhydrazine (the in vivo hydrolysis product of benserazide) are both powerful irreversible DDC inhibitors, they are not selective because they irreversibly bind to free PLP and PLP-enzymes, thus inducing diverse side effects. Therefore, the main goals of this study were (a) to use virtual screening to identify potential human DDC inhibitors and (b) to evaluate the reliability of our virtual-screening (VS) protocol by experimentally testing the \"in vitro\" activity of selected molecules. Starting from the crystal structure of the DDC-carbidopa complex, a new VS protocol, integrating pharmacophore searches and molecular docking, was developed. Analysis of 15 selected compounds, obtained by filtering the public ZINC database, yielded two molecules that bind to the active site of human DDC and behave as competitive inhibitors with K(i) values \u226510 \u00b5M. By performing in silico similarity search on the latter compounds followed by a substructure search using the core of the most active compound we identified several competitive inhibitors of human DDC with K(i) values in the low micromolar range, unable to bind free PLP, and predicted to not cross the blood-brain barrier. The most potent inhibitor with a K(i) value of 500 nM represents a new lead compound, targeting human DDC, that may be the basis for lead optimization in the development of new DDC inhibitors. To our knowledge, a similar approach has not been reported yet in the field of DDC inhibitors discovery.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "d11256fd28f844698bd688152f464ae5", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[56, 58]], "char_spans": [[298, 303]]}]}], "context_tokens": [["Dopa", 0], ["decarboxylase", 5], ["(", 19], ["DDC", 20], [")", 23], [",", 24], ["a", 26], ["pyridoxal", 28], ["5'-phosphate", 38], ["(", 51], ["PLP", 52], [")", 55], ["enzyme", 57], ["responsible", 64], ["for", 76], ["the", 80], ["biosynthesis", 84], ["of", 97], ["dopamine", 100], ["and", 109], ["serotonin", 113], [",", 122], ["is", 124], ["involved", 127], ["in", 136], ["Parkinson", 139], ["'s", 148], ["disease", 151], ["(", 159], ["PD", 160], [")", 162], [".", 163], ["PD", 165], ["is", 168], ["a", 171], ["neurodegenerative", 173], ["disease", 191], ["mainly", 199], ["due", 206], ["to", 210], ["a", 213], ["progressive", 215], ["loss", 227], ["of", 232], ["dopamine", 235], ["-", 243], ["producing", 244], ["cells", 254], ["in", 260], ["the", 263], ["midbrain", 267], [".", 275], ["Co", 277], ["-", 279], ["administration", 280], ["of", 295], ["L", 298], ["-", 299], ["Dopa", 300], ["with", 305], ["peripheral", 310], ["DDC", 321], ["inhibitors", 325], ["(", 336], ["carbidopa", 337], ["or", 347], ["benserazide", 350], [")", 361], ["is", 363], ["the", 366], ["most", 370], ["effective", 375], ["symptomatic", 385], ["treatment", 397], ["for", 407], ["PD", 411], [".", 413], ["Although", 415], ["carbidopa", 424], ["and", 434], ["trihydroxybenzylhydrazine", 438], ["(", 464], ["the", 465], ["in", 469], ["vivo", 472], ["hydrolysis", 477], ["product", 488], ["of", 496], ["benserazide", 499], [")", 510], ["are", 512], ["both", 516], ["powerful", 521], ["irreversible", 530], ["DDC", 543], ["inhibitors", 547], [",", 557], ["they", 559], ["are", 564], ["not", 568], ["selective", 572], ["because", 582], ["they", 590], ["irreversibly", 595], ["bind", 608], ["to", 613], ["free", 616], ["PLP", 621], ["and", 625], ["PLP", 629], ["-", 632], ["enzymes", 633], [",", 640], ["thus", 642], ["inducing", 647], ["diverse", 656], ["side", 664], ["effects", 669], [".", 676], ["Therefore", 678], [",", 687], ["the", 689], ["main", 693], ["goals", 698], ["of", 704], ["this", 707], ["study", 712], ["were", 718], ["(", 723], ["a", 724], [")", 725], ["to", 727], ["use", 730], ["virtual", 734], ["screening", 742], ["to", 752], ["identify", 755], ["potential", 764], ["human", 774], ["DDC", 780], ["inhibitors", 784], ["and", 795], ["(", 799], ["b", 800], [")", 801], ["to", 803], ["evaluate", 806], ["the", 815], ["reliability", 819], ["of", 831], ["our", 834], ["virtual", 838], ["-", 845], ["screening", 846], ["(", 856], ["VS", 857], [")", 859], ["protocol", 861], ["by", 870], ["experimentally", 873], ["testing", 888], ["the", 896], ["\"", 900], ["in", 901], ["vitro", 904], ["\"", 909], ["activity", 911], ["of", 920], ["selected", 923], ["molecules", 932], [".", 941], ["Starting", 943], ["from", 952], ["the", 957], ["crystal", 961], ["structure", 969], ["of", 979], ["the", 982], ["DDC", 986], ["-", 989], ["carbidopa", 990], ["complex", 1000], [",", 1007], ["a", 1009], ["new", 1011], ["VS", 1015], ["protocol", 1018], [",", 1026], ["integrating", 1028], ["pharmacophore", 1040], ["searches", 1054], ["and", 1063], ["molecular", 1067], ["docking", 1077], [",", 1084], ["was", 1086], ["developed", 1090], [".", 1099], ["Analysis", 1101], ["of", 1110], ["15", 1113], ["selected", 1116], ["compounds", 1125], [",", 1134], ["obtained", 1136], ["by", 1145], ["filtering", 1148], ["the", 1158], ["public", 1162], ["ZINC", 1169], ["database", 1174], [",", 1182], ["yielded", 1184], ["two", 1192], ["molecules", 1196], ["that", 1206], ["bind", 1211], ["to", 1216], ["the", 1219], ["active", 1223], ["site", 1230], ["of", 1235], ["human", 1238], ["DDC", 1244], ["and", 1248], ["behave", 1252], ["as", 1259], ["competitive", 1262], ["inhibitors", 1274], ["with", 1285], ["K(i", 1290], [")", 1293], ["values", 1295], ["\u226510", 1302], ["\u00b5M.", 1306], ["By", 1310], ["performing", 1313], ["in", 1324], ["silico", 1327], ["similarity", 1334], ["search", 1345], ["on", 1352], ["the", 1355], ["latter", 1359], ["compounds", 1366], ["followed", 1376], ["by", 1385], ["a", 1388], ["substructure", 1390], ["search", 1403], ["using", 1410], ["the", 1416], ["core", 1420], ["of", 1425], ["the", 1428], ["most", 1432], ["active", 1437], ["compound", 1444], ["we", 1453], ["identified", 1456], ["several", 1467], ["competitive", 1475], ["inhibitors", 1487], ["of", 1498], ["human", 1501], ["DDC", 1507], ["with", 1511], ["K(i", 1516], [")", 1519], ["values", 1521], ["in", 1528], ["the", 1531], ["low", 1535], ["micromolar", 1539], ["range", 1550], [",", 1555], ["unable", 1557], ["to", 1564], ["bind", 1567], ["free", 1572], ["PLP", 1577], [",", 1580], ["and", 1582], ["predicted", 1586], ["to", 1596], ["not", 1599], ["cross", 1603], ["the", 1609], ["blood", 1613], ["-", 1618], ["brain", 1619], ["barrier", 1625], [".", 1632], ["The", 1634], ["most", 1638], ["potent", 1643], ["inhibitor", 1650], ["with", 1660], ["a", 1665], ["K(i", 1667], [")", 1670], ["value", 1672], ["of", 1678], ["500", 1681], ["nM", 1685], ["represents", 1688], ["a", 1699], ["new", 1701], ["lead", 1705], ["compound", 1710], [",", 1718], ["targeting", 1720], ["human", 1730], ["DDC", 1736], [",", 1739], ["that", 1741], ["may", 1746], ["be", 1750], ["the", 1753], ["basis", 1757], ["for", 1763], ["lead", 1767], ["optimization", 1772], ["in", 1785], ["the", 1788], ["development", 1792], ["of", 1804], ["new", 1807], ["DDC", 1811], ["inhibitors", 1815], [".", 1825], ["To", 1827], ["our", 1830], ["knowledge", 1834], [",", 1843], ["a", 1845], ["similar", 1847], ["approach", 1855], ["has", 1864], ["not", 1868], ["been", 1872], ["reported", 1877], ["yet", 1886], ["in", 1890], ["the", 1893], ["field", 1897], ["of", 1903], ["DDC", 1906], ["inhibitors", 1910], ["discovery", 1921], [".", 1930]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They account for the activations of multiple growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR and STAT5 pathways. The BCR-ABL tyrosine kinase inhibitor imatinib is the standard treatment for Ph+ leukemia and plays efficacious role in CML. However, imatinib has few inhibitory effects on SRC tyrosine kinase with response rate of Ph+ ALL lower and relapse more frequent and quicker compared with CML. Previous studies showed that oridonin inhibits proliferation and induces apoptosis in many tumor cells. However, the anticancer activity and mechanism of oridonin in Ph+ ALL is unknown. To investigate the anticancer activity of oridonin, we examined its role in constitutively activated Akt/mTOR, Raf/MEK/ERK, STAT5 and SRC pathway, mRNA level of bcr/abl gene, cell viability and apoptosis in Ph+ ALL SUP-B15 cells. Furthermore, we detected synergetic effect of oridonin plus imatinib. Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. Oridonin plus imatinib exerted synergetic effects by overcoming imatinib defect of upregulating Akt/mTOR and LYN signaling. Additionally, we examined the effect of oridonin on the signaling pathways in the primary specimens from Ph+ ALL patients. Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "86cf7cabdc464986812d7f76361ff136", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[52, 54], [16, 18], [164, 166]], "char_spans": [[281, 287], [113, 119], [910, 916]]}]}], "context_tokens": [["Philadelphia", 0], ["chromosome", 13], ["-", 23], ["positive", 24], ["acute", 33], ["lymphoblastic", 39], ["leukemia", 53], ["(", 62], ["Ph+", 63], ["ALL", 67], [")", 70], ["is", 72], ["triggered", 75], ["by", 85], ["constitutively", 88], ["activated", 103], ["BCR", 113], ["-", 116], ["ABL", 117], ["and", 121], ["SRC", 125], ["family", 129], ["tyrosine", 136], ["kinases", 145], [".", 152], ["They", 153], ["account", 158], ["for", 166], ["the", 170], ["activations", 174], ["of", 186], ["multiple", 189], ["growth", 198], ["-", 204], ["signaling", 205], ["pathways", 215], [",", 223], ["including", 225], ["Raf", 235], ["/", 238], ["MEK", 239], ["/", 242], ["ERK", 243], [",", 246], ["Akt", 248], ["/", 251], ["mTOR", 252], ["and", 257], ["STAT5", 261], ["pathways", 267], [".", 275], ["The", 277], ["BCR", 281], ["-", 284], ["ABL", 285], ["tyrosine", 289], ["kinase", 298], ["inhibitor", 305], ["imatinib", 315], ["is", 324], ["the", 327], ["standard", 331], ["treatment", 340], ["for", 350], ["Ph+", 354], ["leukemia", 358], ["and", 367], ["plays", 371], ["efficacious", 377], ["role", 389], ["in", 394], ["CML", 397], [".", 400], ["However", 402], [",", 409], ["imatinib", 411], ["has", 420], ["few", 424], ["inhibitory", 428], ["effects", 439], ["on", 447], ["SRC", 450], ["tyrosine", 454], ["kinase", 463], ["with", 470], ["response", 475], ["rate", 484], ["of", 489], ["Ph+", 492], ["ALL", 496], ["lower", 500], ["and", 506], ["relapse", 510], ["more", 518], ["frequent", 523], ["and", 532], ["quicker", 536], ["compared", 544], ["with", 553], ["CML", 558], [".", 561], ["Previous", 563], ["studies", 572], ["showed", 580], ["that", 587], ["oridonin", 592], ["inhibits", 601], ["proliferation", 610], ["and", 624], ["induces", 628], ["apoptosis", 636], ["in", 646], ["many", 649], ["tumor", 654], ["cells", 660], [".", 665], ["However", 667], [",", 674], ["the", 676], ["anticancer", 680], ["activity", 691], ["and", 700], ["mechanism", 704], ["of", 714], ["oridonin", 717], ["in", 726], ["Ph+", 729], ["ALL", 733], ["is", 737], ["unknown", 740], [".", 747], ["To", 749], ["investigate", 752], ["the", 764], ["anticancer", 768], ["activity", 779], ["of", 788], ["oridonin", 791], [",", 799], ["we", 801], ["examined", 804], ["its", 813], ["role", 817], ["in", 822], ["constitutively", 825], ["activated", 840], ["Akt", 850], ["/", 853], ["mTOR", 854], [",", 858], ["Raf", 860], ["/", 863], ["MEK", 864], ["/", 867], ["ERK", 868], [",", 871], ["STAT5", 873], ["and", 879], ["SRC", 883], ["pathway", 887], [",", 894], ["mRNA", 896], ["level", 901], ["of", 907], ["bcr", 910], ["/", 913], ["abl", 914], ["gene", 918], [",", 922], ["cell", 924], ["viability", 929], ["and", 939], ["apoptosis", 943], ["in", 953], ["Ph+", 956], ["ALL", 960], ["SUP", 964], ["-", 967], ["B15", 968], ["cells", 972], [".", 977], ["Furthermore", 979], [",", 990], ["we", 992], ["detected", 995], ["synergetic", 1004], ["effect", 1015], ["of", 1022], ["oridonin", 1025], ["plus", 1034], ["imatinib", 1039], [".", 1047], ["Our", 1049], ["results", 1053], ["showed", 1061], ["that", 1068], ["oridonin", 1073], ["inhibiting", 1082], ["activations", 1093], ["of", 1105], ["LYN", 1108], ["(", 1112], ["one", 1113], ["of", 1117], ["SRC", 1120], ["family", 1124], ["kinases", 1131], [")", 1138], ["and", 1140], ["ABL", 1144], ["and", 1148], ["their", 1152], ["downstream", 1158], ["Akt", 1169], ["/", 1172], ["mTOR", 1173], [",", 1177], ["Raf", 1179], ["/", 1182], ["MEK", 1183], ["/", 1186], ["ERK", 1187], ["and", 1191], ["STAT5", 1195], ["pathways", 1201], [",", 1209], ["downregulated", 1211], ["Bcl-2", 1225], ["but", 1231], ["upregulated", 1235], ["Bax", 1247], ["protein", 1251], ["and", 1259], ["then", 1263], ["induced", 1268], ["apoptosis", 1276], ["in", 1286], ["Ph+", 1289], ["ALL", 1293], ["cells", 1297], [".", 1302], ["Oridonin", 1304], ["plus", 1313], ["imatinib", 1318], ["exerted", 1327], ["synergetic", 1335], ["effects", 1346], ["by", 1354], ["overcoming", 1357], ["imatinib", 1368], ["defect", 1377], ["of", 1384], ["upregulating", 1387], ["Akt", 1400], ["/", 1403], ["mTOR", 1404], ["and", 1409], ["LYN", 1413], ["signaling", 1417], [".", 1426], ["Additionally", 1428], [",", 1440], ["we", 1442], ["examined", 1445], ["the", 1454], ["effect", 1458], ["of", 1465], ["oridonin", 1468], ["on", 1477], ["the", 1480], ["signaling", 1484], ["pathways", 1494], ["in", 1503], ["the", 1506], ["primary", 1510], ["specimens", 1518], ["from", 1528], ["Ph+", 1533], ["ALL", 1537], ["patients", 1541], [".", 1549], ["Our", 1551], ["data", 1555], ["showed", 1560], ["that", 1567], ["oridonin", 1572], ["remarkably", 1581], ["suppressed", 1592], ["activations", 1603], ["of", 1615], ["Akt", 1618], ["/", 1621], ["mTOR", 1622], [",", 1626], ["Raf", 1628], ["/", 1631], ["MEK", 1632], ["and", 1636], ["STAT5", 1640], ["pathway", 1646], ["in", 1654], ["these", 1657], ["primary", 1663], ["specimens", 1671], ["and", 1681], ["oridonin", 1685], ["with", 1694], ["imatinib", 1699], ["exerted", 1708], ["synergetic", 1716], ["suppressive", 1727], ["effects", 1739], ["on", 1747], ["mTOR", 1750], [",", 1754], ["STAT5", 1756], ["and", 1762], ["LYN", 1766], ["signaling", 1770], ["in", 1780], ["one", 1783], ["imatinib", 1787], ["resistant", 1796], ["patient", 1806], ["specimen", 1814], [".", 1822], ["Additional", 1824], ["evaluation", 1835], ["of", 1846], ["oridonin", 1849], ["as", 1858], ["a", 1861], ["potential", 1863], ["therapeutic", 1873], ["agent", 1885], ["for", 1891], ["Ph+", 1895], ["ALL", 1899], ["seems", 1903], ["warranted", 1909], [".", 1918]]}
{"context": "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "db97a187c75442e883f177344a687937", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[243, 243]], "char_spans": [[1399, 1408]]}]}], "context_tokens": [["Venous", 0], ["thromboembolism", 7], ["(", 23], ["VTE", 24], [")", 27], ["is", 29], ["associated", 32], ["with", 43], ["significant", 48], ["morbidity", 60], ["and", 70], ["mortality", 74], [".", 83], ["Factors", 85], ["such", 93], ["as", 98], ["the", 101], ["presence", 105], ["of", 114], ["transient", 117], ["risk", 127], ["factors", 132], ["for", 140], ["VTE", 144], [",", 147], ["risk", 149], ["of", 154], ["bleeding", 157], [",", 165], ["and", 167], ["location", 171], ["of", 180], ["deep", 183], ["vein", 188], ["thrombosis", 193], ["(", 204], ["DVT", 205], [")", 208], ["determine", 210], ["the", 220], ["duration", 224], ["of", 233], ["anticoagulation", 236], [".", 251], ["Extended", 253], ["anticoagulation", 262], ["is", 278], ["offered", 281], ["to", 289], ["patients", 292], ["with", 301], ["unprovoked", 306], ["pulmonary", 317], ["embolism", 327], ["(", 336], ["PE", 337], [")", 339], ["or", 341], ["proximal", 344], ["DVT", 353], ["and", 357], ["a", 361], ["low", 363], ["risk", 367], ["of", 372], ["bleeding", 375], [".", 383], ["Anticoagulation", 385], ["for", 401], ["3", 405], ["months", 407], ["is", 414], ["advised", 417], ["in", 425], ["patients", 428], ["with", 437], ["provoked", 442], ["DVT", 451], ["or", 455], ["PE", 458], [",", 460], ["high", 462], ["risk", 467], ["of", 472], ["bleeding", 475], [",", 483], ["and", 485], ["isolated", 489], ["distal", 498], ["or", 505], ["upper", 508], ["extremity", 514], ["DVT", 524], [".", 527], ["In", 529], ["patients", 532], ["with", 541], ["unprovoked", 546], ["PE", 557], ["or", 560], ["proximal", 563], ["DVT", 572], ["and", 576], ["a", 580], ["low", 582], ["risk", 586], ["of", 591], ["bleeding", 594], [",", 602], ["who", 604], ["want", 608], ["to", 613], ["stop", 616], ["anticoagulation", 621], ["after", 637], ["3", 643], ["months", 645], [",", 651], ["further", 653], ["risk", 661], ["stratification", 666], ["is", 681], ["necessary", 684], [".", 693], ["Clinical", 695], ["scoring", 704], ["system", 712], [",", 718], ["and", 720], ["thrombophilia", 724], ["testing", 738], ["otherwise", 746], ["not", 756], ["routinely", 760], ["performed", 770], [",", 779], ["may", 781], ["be", 785], ["considered", 788], ["to", 799], ["measure", 802], ["risk", 810], ["of", 815], ["annual", 818], ["recurrence", 825], ["in", 836], ["such", 839], ["cases", 844], [".", 849], ["Short", 851], ["-", 856], ["term", 857], ["anticoagulation", 862], ["may", 878], ["be", 882], ["considered", 885], ["in", 896], ["subsegmental", 899], ["PE", 912], ["and", 915], ["superficial", 919], ["vein", 931], ["thrombosis", 936], [",", 946], ["particularly", 948], ["if", 961], ["patients", 964], ["are", 973], ["at", 977], ["low", 980], ["risk", 984], ["of", 989], ["bleeding", 992], ["and", 1001], ["have", 1005], ["persistent", 1010], ["risk", 1021], ["factors", 1026], ["for", 1034], ["recurrent", 1038], ["VTE", 1048], [".", 1051], ["In", 1053], ["cases", 1056], ["of", 1062], ["catheter", 1065], ["-", 1073], ["associated", 1074], ["thrombosis", 1085], [",", 1095], ["the", 1097], ["catheter", 1101], ["need", 1110], ["not", 1115], ["be", 1119], ["removed", 1122], ["routinely", 1130], [",", 1139], ["and", 1141], ["the", 1145], ["patient", 1149], ["may", 1157], ["be", 1161], ["anticoagulated", 1164], ["for", 1179], ["3", 1183], ["months", 1185], ["or", 1192], ["longer", 1195], ["if", 1202], ["the", 1205], ["catheter", 1209], ["is", 1218], ["maintained", 1221], ["in", 1232], ["patients", 1235], ["with", 1244], ["cancer", 1249], [".", 1255], ["Extensive", 1257], ["screening", 1267], ["for", 1277], ["occult", 1281], ["cancer", 1288], ["in", 1295], ["cases", 1298], ["of", 1304], ["unprovoked", 1307], ["VTE", 1318], ["is", 1322], ["not", 1325], ["beneficial", 1329], [".", 1339], ["New", 1341], ["oral", 1345], ["anticoagulants", 1350], ["such", 1365], ["as", 1370], ["apixaban", 1373], [",", 1381], ["rivaroxaban", 1383], [",", 1394], ["or", 1396], ["dabigatran", 1399], ["may", 1410], ["be", 1414], ["preferred", 1417], ["to", 1427], ["vitamin", 1430], ["K", 1438], ["antagonists", 1440], ["in", 1452], ["patients", 1455], ["without", 1464], ["cancer", 1472], ["or", 1479], ["renal", 1482], ["failure", 1488], [",", 1495], ["more", 1497], ["so", 1502], ["after", 1505], ["the", 1511], ["development", 1515], ["of", 1527], ["reversal", 1530], ["agents", 1539], ["such", 1546], ["as", 1551], ["idarucizumab", 1554], ["and", 1567], ["andexanet", 1571], ["alfa", 1581], [".", 1585]]}
{"context": "The worldwide expansion in the use of benzodiazepines has led to their frequent, and often inappropriate, use and to increase in their involvement in self-induced poisoning and iatrogenic overdosing. Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions. Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma. Intravenous flumazenil 10 to 20 micrograms/kg is effective in neonates and small children. Intramuscular, oral (20 to 25 mg 3 times daily or as required) and rectal administration may be used as alternatives in long term regimens. Patients with mixed-drug overdose require higher doses (up to 2 mg bolus, approximately equal to 1 mg/h infusion) to regain consciousness. Children and the elderly, chronically ill patients, and pregnant women and their fetuses all respond satisfactorily to flumazenil, but the usefulness of the drug in patients with hepatic encephalopathy and alcohol overdose is debatable. The use of flumazenil results in complete awakening with restoration of upper airway protective reflexes, thus enabling gastric lavage to be performed and transfer of the patient from the emergency room to another hospital department. Resumption of effective spontaneous respiration allows for expeditious extubation, weaning off mechanical ventilation or the avoidance of endotracheal intubation. While flumazenil is not associated with haemodynamic adverse effects, caution should be exercised when using this agent in patients who have co-ingested chloral hydrate to carbamazepine or whose ECG shows abnormalities typical to those seen after overdose with tricyclic antidepressants (TCAs); the use of flumazenil in the presence of these drugs can sometimes induce treatable cardiac dysrrhythmia. Flumazenil per se does not induce adverse effects. Coma reversal by flumazenil may cause mild, short-lived reactions caused by sudden awakening. Withdrawal symptoms in long term benzodiazepine users and seizures in patients who have taken an overdose of TCA or carbamazepine and a benzodiazepine can occur with flumazenil; these symptoms are avoidable by utilising slow flumazenil dose titration.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "369cc5a5643045aebe426287af31c52b", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[64, 64], [224, 224], [355, 355], [395, 395], [202, 202], [404, 404], [329, 329], [343, 343], [280, 280], [34, 34], [111, 111]], "char_spans": [[435, 444], [1295, 1304], [2151, 2160], [2394, 2403], [1166, 1175], [2453, 2462], [1988, 1997], [2083, 2092], [1688, 1697], [200, 209], [689, 698]]}]}], "context_tokens": [["The", 0], ["worldwide", 4], ["expansion", 14], ["in", 24], ["the", 27], ["use", 31], ["of", 35], ["benzodiazepines", 38], ["has", 54], ["led", 58], ["to", 62], ["their", 65], ["frequent", 71], [",", 79], ["and", 81], ["often", 85], ["inappropriate", 91], [",", 104], ["use", 106], ["and", 110], ["to", 114], ["increase", 117], ["in", 126], ["their", 129], ["involvement", 135], ["in", 147], ["self", 150], ["-", 154], ["induced", 155], ["poisoning", 163], ["and", 173], ["iatrogenic", 177], ["overdosing", 188], [".", 198], ["Flumazenil", 200], ["is", 211], ["a", 214], ["specific", 216], ["and", 225], ["competitive", 229], ["antagonist", 241], ["at", 252], ["the", 255], ["central", 259], ["benzodiazepine", 267], ["receptor", 282], [",", 290], ["reversing", 292], ["all", 302], ["effects", 306], ["of", 314], ["benzodiazepine", 317], ["agonists", 332], ["without", 341], ["tranquillising", 349], ["or", 364], ["anticonvulsant", 367], ["actions", 382], [".", 389], ["Incremental", 391], ["intravenous", 403], ["bolus", 415], ["injections", 421], ["of", 432], ["flumazenil", 435], ["0.1", 446], ["to", 450], ["0.3", 453], ["mg", 457], ["are", 460], ["the", 464], ["most", 468], ["effective", 473], ["and", 483], ["well", 487], ["tolerated", 492], ["in", 502], ["the", 505], ["diagnosis", 509], ["and", 519], ["treatment", 523], ["of", 533], ["pure", 536], ["benzodiazepine", 541], ["overdose", 556], [";", 564], ["additional", 566], ["boluses", 577], ["or", 585], ["an", 588], ["infusion", 591], ["(", 600], ["0.3", 601], ["to", 605], ["0.5", 608], ["mg", 612], ["/", 614], ["h", 615], [")", 616], ["can", 618], ["be", 622], ["given", 625], ["to", 631], ["prevent", 634], ["patients", 642], ["from", 651], ["relapsing", 656], ["into", 666], ["coma", 671], [".", 675], ["Intravenous", 677], ["flumazenil", 689], ["10", 700], ["to", 703], ["20", 706], ["micrograms", 709], ["/", 719], ["kg", 720], ["is", 723], ["effective", 726], ["in", 736], ["neonates", 739], ["and", 748], ["small", 752], ["children", 758], [".", 766], ["Intramuscular", 768], [",", 781], ["oral", 783], ["(", 788], ["20", 789], ["to", 792], ["25", 795], ["mg", 798], ["3", 801], ["times", 803], ["daily", 809], ["or", 815], ["as", 818], ["required", 821], [")", 829], ["and", 831], ["rectal", 835], ["administration", 842], ["may", 857], ["be", 861], ["used", 864], ["as", 869], ["alternatives", 872], ["in", 885], ["long", 888], ["term", 893], ["regimens", 898], [".", 906], ["Patients", 908], ["with", 917], ["mixed", 922], ["-", 927], ["drug", 928], ["overdose", 933], ["require", 942], ["higher", 950], ["doses", 957], ["(", 963], ["up", 964], ["to", 967], ["2", 970], ["mg", 972], ["bolus", 975], [",", 980], ["approximately", 982], ["equal", 996], ["to", 1002], ["1", 1005], ["mg", 1007], ["/", 1009], ["h", 1010], ["infusion", 1012], [")", 1020], ["to", 1022], ["regain", 1025], ["consciousness", 1032], [".", 1045], ["Children", 1047], ["and", 1056], ["the", 1060], ["elderly", 1064], [",", 1071], ["chronically", 1073], ["ill", 1085], ["patients", 1089], [",", 1097], ["and", 1099], ["pregnant", 1103], ["women", 1112], ["and", 1118], ["their", 1122], ["fetuses", 1128], ["all", 1136], ["respond", 1140], ["satisfactorily", 1148], ["to", 1163], ["flumazenil", 1166], [",", 1176], ["but", 1178], ["the", 1182], ["usefulness", 1186], ["of", 1197], ["the", 1200], ["drug", 1204], ["in", 1209], ["patients", 1212], ["with", 1221], ["hepatic", 1226], ["encephalopathy", 1234], ["and", 1249], ["alcohol", 1253], ["overdose", 1261], ["is", 1270], ["debatable", 1273], [".", 1282], ["The", 1284], ["use", 1288], ["of", 1292], ["flumazenil", 1295], ["results", 1306], ["in", 1314], ["complete", 1317], ["awakening", 1326], ["with", 1336], ["restoration", 1341], ["of", 1353], ["upper", 1356], ["airway", 1362], ["protective", 1369], ["reflexes", 1380], [",", 1388], ["thus", 1390], ["enabling", 1395], ["gastric", 1404], ["lavage", 1412], ["to", 1419], ["be", 1422], ["performed", 1425], ["and", 1435], ["transfer", 1439], ["of", 1448], ["the", 1451], ["patient", 1455], ["from", 1463], ["the", 1468], ["emergency", 1472], ["room", 1482], ["to", 1487], ["another", 1490], ["hospital", 1498], ["department", 1507], [".", 1517], ["Resumption", 1519], ["of", 1530], ["effective", 1533], ["spontaneous", 1543], ["respiration", 1555], ["allows", 1567], ["for", 1574], ["expeditious", 1578], ["extubation", 1590], [",", 1600], ["weaning", 1602], ["off", 1610], ["mechanical", 1614], ["ventilation", 1625], ["or", 1637], ["the", 1640], ["avoidance", 1644], ["of", 1654], ["endotracheal", 1657], ["intubation", 1670], [".", 1680], ["While", 1682], ["flumazenil", 1688], ["is", 1699], ["not", 1702], ["associated", 1706], ["with", 1717], ["haemodynamic", 1722], ["adverse", 1735], ["effects", 1743], [",", 1750], ["caution", 1752], ["should", 1760], ["be", 1767], ["exercised", 1770], ["when", 1780], ["using", 1785], ["this", 1791], ["agent", 1796], ["in", 1802], ["patients", 1805], ["who", 1814], ["have", 1818], ["co", 1823], ["-", 1825], ["ingested", 1826], ["chloral", 1835], ["hydrate", 1843], ["to", 1851], ["carbamazepine", 1854], ["or", 1868], ["whose", 1871], ["ECG", 1877], ["shows", 1881], ["abnormalities", 1887], ["typical", 1901], ["to", 1909], ["those", 1912], ["seen", 1918], ["after", 1923], ["overdose", 1929], ["with", 1938], ["tricyclic", 1943], ["antidepressants", 1953], ["(", 1969], ["TCAs", 1970], [")", 1974], [";", 1975], ["the", 1977], ["use", 1981], ["of", 1985], ["flumazenil", 1988], ["in", 1999], ["the", 2002], ["presence", 2006], ["of", 2015], ["these", 2018], ["drugs", 2024], ["can", 2030], ["sometimes", 2034], ["induce", 2044], ["treatable", 2051], ["cardiac", 2061], ["dysrrhythmia", 2069], [".", 2081], ["Flumazenil", 2083], ["per", 2094], ["se", 2098], ["does", 2101], ["not", 2106], ["induce", 2110], ["adverse", 2117], ["effects", 2125], [".", 2132], ["Coma", 2134], ["reversal", 2139], ["by", 2148], ["flumazenil", 2151], ["may", 2162], ["cause", 2166], ["mild", 2172], [",", 2176], ["short", 2178], ["-", 2183], ["lived", 2184], ["reactions", 2190], ["caused", 2200], ["by", 2207], ["sudden", 2210], ["awakening", 2217], [".", 2226], ["Withdrawal", 2228], ["symptoms", 2239], ["in", 2248], ["long", 2251], ["term", 2256], ["benzodiazepine", 2261], ["users", 2276], ["and", 2282], ["seizures", 2286], ["in", 2295], ["patients", 2298], ["who", 2307], ["have", 2311], ["taken", 2316], ["an", 2322], ["overdose", 2325], ["of", 2334], ["TCA", 2337], ["or", 2341], ["carbamazepine", 2344], ["and", 2358], ["a", 2362], ["benzodiazepine", 2364], ["can", 2379], ["occur", 2383], ["with", 2389], ["flumazenil", 2394], [";", 2404], ["these", 2406], ["symptoms", 2412], ["are", 2421], ["avoidable", 2425], ["by", 2435], ["utilising", 2438], ["slow", 2448], ["flumazenil", 2453], ["dose", 2464], ["titration", 2469], [".", 2478]]}
{"context": "The protein alpha-synuclein (ASYN) is thought to be involved in the development of dementia with Lewy bodies (DLB). Overexpression of ASYN has been linked to cellular toxicity and human disease, and in experimental models, chaperones such as heat shock proteins (HSPs) are protective against ASYN toxicity. We have assessed the abundance of mRNA for ASYN and chaperones and the abundance and solubility of the encoded proteins in temporal cortex from sporadic human DLB. We found a reduction of ASYN mRNA in DLB (44.9% of control). The abundance of the Triton-soluble fraction (bioavailable protein) was not altered, but there was an increase of the Triton-insoluble component (likely representing aggregates). We evaluated 3 chaperones: HSP70, HSP90, and HDJ1. HSP70 mRNA was increased in DLB, whereas the mRNAs for HSP90 and HDJ1 were unchanged. HSP70 accumulated in the Triton-soluble fraction, whereas HSP90 and HDJ1 proteins accumulated in the Triton-insoluble fraction. These observations suggest that sporadic DLB is not associated with overexpression of ASYN. Rather, the persistence of normal soluble ASYN protein levels, despite the reduction of its mRNA, suggests a primary defect in clearance of the protein. However, this reduced clearance cannot be attributed to a failure of chaperone expression, because their mRNA is unchanged or increased in the DLB brain.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "91fa2b5f1bc346b9a724636caadd7ff3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[2, 4]], "char_spans": [[12, 26]]}]}], "context_tokens": [["The", 0], ["protein", 4], ["alpha", 12], ["-", 17], ["synuclein", 18], ["(", 28], ["ASYN", 29], [")", 33], ["is", 35], ["thought", 38], ["to", 46], ["be", 49], ["involved", 52], ["in", 61], ["the", 64], ["development", 68], ["of", 80], ["dementia", 83], ["with", 92], ["Lewy", 97], ["bodies", 102], ["(", 109], ["DLB", 110], [")", 113], [".", 114], ["Overexpression", 116], ["of", 131], ["ASYN", 134], ["has", 139], ["been", 143], ["linked", 148], ["to", 155], ["cellular", 158], ["toxicity", 167], ["and", 176], ["human", 180], ["disease", 186], [",", 193], ["and", 195], ["in", 199], ["experimental", 202], ["models", 215], [",", 221], ["chaperones", 223], ["such", 234], ["as", 239], ["heat", 242], ["shock", 247], ["proteins", 253], ["(", 262], ["HSPs", 263], [")", 267], ["are", 269], ["protective", 273], ["against", 284], ["ASYN", 292], ["toxicity", 297], [".", 305], ["We", 307], ["have", 310], ["assessed", 315], ["the", 324], ["abundance", 328], ["of", 338], ["mRNA", 341], ["for", 346], ["ASYN", 350], ["and", 355], ["chaperones", 359], ["and", 370], ["the", 374], ["abundance", 378], ["and", 388], ["solubility", 392], ["of", 403], ["the", 406], ["encoded", 410], ["proteins", 418], ["in", 427], ["temporal", 430], ["cortex", 439], ["from", 446], ["sporadic", 451], ["human", 460], ["DLB", 466], [".", 469], ["We", 471], ["found", 474], ["a", 480], ["reduction", 482], ["of", 492], ["ASYN", 495], ["mRNA", 500], ["in", 505], ["DLB", 508], ["(", 512], ["44.9", 513], ["%", 517], ["of", 519], ["control", 522], [")", 529], [".", 530], ["The", 532], ["abundance", 536], ["of", 546], ["the", 549], ["Triton", 553], ["-", 559], ["soluble", 560], ["fraction", 568], ["(", 577], ["bioavailable", 578], ["protein", 591], [")", 598], ["was", 600], ["not", 604], ["altered", 608], [",", 615], ["but", 617], ["there", 621], ["was", 627], ["an", 631], ["increase", 634], ["of", 643], ["the", 646], ["Triton", 650], ["-", 656], ["insoluble", 657], ["component", 667], ["(", 677], ["likely", 678], ["representing", 685], ["aggregates", 698], [")", 708], [".", 709], ["We", 711], ["evaluated", 714], ["3", 724], ["chaperones", 726], [":", 736], ["HSP70", 738], [",", 743], ["HSP90", 745], [",", 750], ["and", 752], ["HDJ1", 756], [".", 760], ["HSP70", 762], ["mRNA", 768], ["was", 773], ["increased", 777], ["in", 787], ["DLB", 790], [",", 793], ["whereas", 795], ["the", 803], ["mRNAs", 807], ["for", 813], ["HSP90", 817], ["and", 823], ["HDJ1", 827], ["were", 832], ["unchanged", 837], [".", 846], ["HSP70", 848], ["accumulated", 854], ["in", 866], ["the", 869], ["Triton", 873], ["-", 879], ["soluble", 880], ["fraction", 888], [",", 896], ["whereas", 898], ["HSP90", 906], ["and", 912], ["HDJ1", 916], ["proteins", 921], ["accumulated", 930], ["in", 942], ["the", 945], ["Triton", 949], ["-", 955], ["insoluble", 956], ["fraction", 966], [".", 974], ["These", 976], ["observations", 982], ["suggest", 995], ["that", 1003], ["sporadic", 1008], ["DLB", 1017], ["is", 1021], ["not", 1024], ["associated", 1028], ["with", 1039], ["overexpression", 1044], ["of", 1059], ["ASYN", 1062], [".", 1066], ["Rather", 1068], [",", 1074], ["the", 1076], ["persistence", 1080], ["of", 1092], ["normal", 1095], ["soluble", 1102], ["ASYN", 1110], ["protein", 1115], ["levels", 1123], [",", 1129], ["despite", 1131], ["the", 1139], ["reduction", 1143], ["of", 1153], ["its", 1156], ["mRNA", 1160], [",", 1164], ["suggests", 1166], ["a", 1175], ["primary", 1177], ["defect", 1185], ["in", 1192], ["clearance", 1195], ["of", 1205], ["the", 1208], ["protein", 1212], [".", 1219], ["However", 1221], [",", 1228], ["this", 1230], ["reduced", 1235], ["clearance", 1243], ["can", 1253], ["not", 1256], ["be", 1260], ["attributed", 1263], ["to", 1274], ["a", 1277], ["failure", 1279], ["of", 1287], ["chaperone", 1290], ["expression", 1300], [",", 1310], ["because", 1312], ["their", 1320], ["mRNA", 1326], ["is", 1331], ["unchanged", 1334], ["or", 1344], ["increased", 1347], ["in", 1357], ["the", 1360], ["DLB", 1364], ["brain", 1368], [".", 1373]]}
{"context": "We transplanted adult whole bone marrow prelabeled with bromodeoxyuridine (BrdU) into the ischemic boundary zone of the adult rat brain at 1 day after 2 h of middle cerebral artery occlusion (MCAo). Approximately 3.3% of 10(6) transplanted bone marrow cells were BrdU reactive at 14 days after MCAo. BrdU-reactive cells expressed neuronal and astrocytic proteins, neuronal nuclei protein (NeuN, 1%), and glial fibrillary acidic protein (GFAP, 5%) immunoreactivities, respectively. In addition, bone marrow transplantation promoted proliferation of ependymal and subependymal cells, identified by nestin (a neuroepithelial stem cell marker), within the ventricular zone and subventricular zone (VZ/SVZ). These data suggest that intracerebral transplantation of bone marrow could potentially be used to induce plasticity in ischemic brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "69369bb8e0cf4025bff67e3552f85dad", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[107, 107]], "char_spans": [[596, 601]]}]}], "context_tokens": [["We", 0], ["transplanted", 3], ["adult", 16], ["whole", 22], ["bone", 28], ["marrow", 33], ["prelabeled", 40], ["with", 51], ["bromodeoxyuridine", 56], ["(", 74], ["BrdU", 75], [")", 79], ["into", 81], ["the", 86], ["ischemic", 90], ["boundary", 99], ["zone", 108], ["of", 113], ["the", 116], ["adult", 120], ["rat", 126], ["brain", 130], ["at", 136], ["1", 139], ["day", 141], ["after", 145], ["2", 151], ["h", 153], ["of", 155], ["middle", 158], ["cerebral", 165], ["artery", 174], ["occlusion", 181], ["(", 191], ["MCAo", 192], [")", 196], [".", 197], ["Approximately", 199], ["3.3", 213], ["%", 216], ["of", 218], ["10(6", 221], [")", 225], ["transplanted", 227], ["bone", 240], ["marrow", 245], ["cells", 252], ["were", 258], ["BrdU", 263], ["reactive", 268], ["at", 277], ["14", 280], ["days", 283], ["after", 288], ["MCAo", 294], [".", 298], ["BrdU", 300], ["-", 304], ["reactive", 305], ["cells", 314], ["expressed", 320], ["neuronal", 330], ["and", 339], ["astrocytic", 343], ["proteins", 354], [",", 362], ["neuronal", 364], ["nuclei", 373], ["protein", 380], ["(", 388], ["NeuN", 389], [",", 393], ["1", 395], ["%", 396], [")", 397], [",", 398], ["and", 400], ["glial", 404], ["fibrillary", 410], ["acidic", 421], ["protein", 428], ["(", 436], ["GFAP", 437], [",", 441], ["5", 443], ["%", 444], [")", 445], ["immunoreactivities", 447], [",", 465], ["respectively", 467], [".", 479], ["In", 481], ["addition", 484], [",", 492], ["bone", 494], ["marrow", 499], ["transplantation", 506], ["promoted", 522], ["proliferation", 531], ["of", 545], ["ependymal", 548], ["and", 558], ["subependymal", 562], ["cells", 575], [",", 580], ["identified", 582], ["by", 593], ["nestin", 596], ["(", 603], ["a", 604], ["neuroepithelial", 606], ["stem", 622], ["cell", 627], ["marker", 632], [")", 638], [",", 639], ["within", 641], ["the", 648], ["ventricular", 652], ["zone", 664], ["and", 669], ["subventricular", 673], ["zone", 688], ["(", 693], ["VZ", 694], ["/", 696], ["SVZ", 697], [")", 700], [".", 701], ["These", 703], ["data", 709], ["suggest", 714], ["that", 722], ["intracerebral", 727], ["transplantation", 741], ["of", 757], ["bone", 760], ["marrow", 765], ["could", 772], ["potentially", 778], ["be", 790], ["used", 793], ["to", 798], ["induce", 801], ["plasticity", 808], ["in", 819], ["ischemic", 822], ["brain", 831], [".", 836]]}
{"context": "Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran. Dabigatran reversal with idarucizumab before administration of IV-tPA might reduce the risk of sICH. We report a case of a 69-year-old stroke patient on dabigatran for paroxysmal atrial fibrillation who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 12. There was no early evidence of ischemic stroke or hemorrhage on head computed tomography, and coagulation studies implied therapeutic dabigatran levels. After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197\u2009minutes after he was last seen at his baseline. Subsequent brain magnetic resonance imaging showed 2 punctate infarcts in the left temporal lobe and occipital lobe with no evidence of hemorrhage. The patient was discharged with an NIHSS of 1. Telephone follow-up 2 months later indicated that he was at his prestroke baseline, except for a complaint of worsened short-term memory. Idarucizumab reversal of dabigatran may reduce the risk of sICH and should be considered for acute stroke patients arriving in the IV-tPA time window.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "f9c27593e5f743369c33b2e1ea8791ae", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[0, 0], [176, 176], [97, 97], [29, 29], [71, 71], [263, 263], [168, 168], [126, 126], [95, 95]], "char_spans": [[0, 9], [1049, 1058], [575, 584], [180, 189], [408, 417], [1541, 1550], [996, 1005], [728, 737], [563, 572]]}]}], "context_tokens": [["Dabigatran", 0], ["is", 11], ["a", 14], ["direct", 16], ["thrombin", 23], ["inhibitor", 32], ["used", 42], ["to", 47], ["reduce", 50], ["the", 57], ["risk", 61], ["of", 66], ["stroke", 69], ["in", 76], ["patients", 79], ["with", 88], ["nonvalvular", 93], ["atrial", 105], ["fibrillation", 112], [".", 124], ["For", 126], ["patients", 130], ["who", 139], ["present", 143], ["with", 151], ["an", 156], ["acute", 159], ["stroke", 165], ["despite", 172], ["dabigatran", 180], ["therapy", 191], [",", 198], ["clinical", 200], ["data", 209], ["on", 214], ["the", 217], ["use", 221], ["of", 225], ["intravenous", 228], ["tissue", 240], ["plasminogen", 247], ["activator", 259], ["(", 269], ["IV", 270], ["-", 272], ["tPA", 273], [")", 276], ["is", 278], ["limited", 281], [".", 288], ["There", 290], ["is", 296], ["an", 299], ["anticipated", 302], ["increased", 314], ["risk", 324], ["of", 329], ["symptomatic", 332], ["intracranial", 344], ["hemorrhage", 357], ["(", 368], ["sICH", 369], [")", 373], ["when", 375], ["using", 380], ["IV", 386], ["-", 388], ["tPA", 389], ["in", 393], ["patients", 396], ["on", 405], ["dabigatran", 408], ["therapy", 419], [".", 426], ["In", 428], ["2015", 431], [",", 435], ["the", 437], ["humanized", 441], ["monoclonal", 451], ["antibody", 462], ["fragment", 471], ["idarucizumab", 480], ["was", 493], ["approved", 497], ["for", 506], ["rapid", 510], ["(", 516], ["minutes", 517], [")", 524], ["reversal", 526], ["of", 535], ["anticoagulant", 538], ["effects", 552], ["of", 560], ["dabigatran", 563], [".", 573], ["Dabigatran", 575], ["reversal", 586], ["with", 595], ["idarucizumab", 600], ["before", 613], ["administration", 620], ["of", 635], ["IV", 638], ["-", 640], ["tPA", 641], ["might", 645], ["reduce", 651], ["the", 658], ["risk", 662], ["of", 667], ["sICH", 670], [".", 674], ["We", 676], ["report", 679], ["a", 686], ["case", 688], ["of", 693], ["a", 696], ["69-year", 698], ["-", 705], ["old", 706], ["stroke", 710], ["patient", 717], ["on", 725], ["dabigatran", 728], ["for", 739], ["paroxysmal", 743], ["atrial", 754], ["fibrillation", 761], ["who", 774], ["presented", 778], ["with", 788], ["an", 793], ["initial", 796], ["National", 804], ["Institutes", 813], ["of", 824], ["Health", 827], ["Stroke", 834], ["Scale", 841], ["(", 847], ["NIHSS", 848], [")", 853], ["of", 855], ["12", 858], [".", 860], ["There", 862], ["was", 868], ["no", 872], ["early", 875], ["evidence", 881], ["of", 890], ["ischemic", 893], ["stroke", 902], ["or", 909], ["hemorrhage", 912], ["on", 923], ["head", 926], ["computed", 931], ["tomography", 940], [",", 950], ["and", 952], ["coagulation", 956], ["studies", 968], ["implied", 976], ["therapeutic", 984], ["dabigatran", 996], ["levels", 1007], [".", 1013], ["After", 1015], ["controlling", 1021], ["blood", 1033], ["pressure", 1039], [",", 1047], ["dabigatran", 1049], ["was", 1060], ["reversed", 1064], ["with", 1073], ["idarucizumab", 1078], [",", 1090], ["and", 1092], ["IV", 1096], ["-", 1098], ["tPA", 1099], ["was", 1103], ["administrated", 1107], ["beginning", 1121], ["197", 1131], ["minutes", 1135], ["after", 1143], ["he", 1149], ["was", 1152], ["last", 1156], ["seen", 1161], ["at", 1166], ["his", 1169], ["baseline", 1173], [".", 1181], ["Subsequent", 1183], ["brain", 1194], ["magnetic", 1200], ["resonance", 1209], ["imaging", 1219], ["showed", 1227], ["2", 1234], ["punctate", 1236], ["infarcts", 1245], ["in", 1254], ["the", 1257], ["left", 1261], ["temporal", 1266], ["lobe", 1275], ["and", 1280], ["occipital", 1284], ["lobe", 1294], ["with", 1299], ["no", 1304], ["evidence", 1307], ["of", 1316], ["hemorrhage", 1319], [".", 1329], ["The", 1331], ["patient", 1335], ["was", 1343], ["discharged", 1347], ["with", 1358], ["an", 1363], ["NIHSS", 1366], ["of", 1372], ["1", 1375], [".", 1376], ["Telephone", 1378], ["follow", 1388], ["-", 1394], ["up", 1395], ["2", 1398], ["months", 1400], ["later", 1407], ["indicated", 1413], ["that", 1423], ["he", 1428], ["was", 1431], ["at", 1435], ["his", 1438], ["prestroke", 1442], ["baseline", 1452], [",", 1460], ["except", 1462], ["for", 1469], ["a", 1473], ["complaint", 1475], ["of", 1485], ["worsened", 1488], ["short", 1497], ["-", 1502], ["term", 1503], ["memory", 1508], [".", 1514], ["Idarucizumab", 1516], ["reversal", 1529], ["of", 1538], ["dabigatran", 1541], ["may", 1552], ["reduce", 1556], ["the", 1563], ["risk", 1567], ["of", 1572], ["sICH", 1575], ["and", 1580], ["should", 1584], ["be", 1591], ["considered", 1594], ["for", 1605], ["acute", 1609], ["stroke", 1615], ["patients", 1622], ["arriving", 1631], ["in", 1640], ["the", 1643], ["IV", 1647], ["-", 1649], ["tPA", 1650], ["time", 1654], ["window", 1659], [".", 1665]]}
{"context": "The effect of the newly synthesized compound 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) on the Na+-Ca2+ exchanger (NCX) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (KB-R7943). In addition, the effects of SEA0400 on reperfusion injury in vitro and in vivo were examined. SEA0400 was extremely more potent than KB-R7943 in inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia: IC50s of SEA0400 and KB-R7943 were 5 to 33 nM and 2 to 4 microM, respectively. SEA0400 at the concentration range that inhibited NCX exhibited negligible affinities for the Ca2+ channels, Na+ channels, K+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the Na+/H+ exchanger, Na+,K+-ATPase, Ca2+-ATPase, and five enzymes. SEA0400, unlike KB-R7943, did not inhibit the store-operated Ca2+ entry in cultured astrocytes. SEA0400 attenuated dose- dependently paradoxical Ca2+ challenge-induced production of reactive oxygen species, DNA ladder formation, and nuclear condensation in cultured astrocytes, whereas it did not affect thapsigargin-induced cell injury. Furthermore, administration of SEA0400 reduced infarct volumes after a transient middle cerebral artery occlusion in rat cerebral cortex and striatum. These results indicate that SEA0400 is the most potent and selective inhibitor of NCX, and suggest that the compound may exert protective effects on postischemic brain damage.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e77f03a3c71044b98123b465164c6cc7", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[240, 240], [17, 17], [102, 102]], "char_spans": [[1422, 1424], [141, 143], [614, 616]]}]}], "context_tokens": [["The", 0], ["effect", 4], ["of", 11], ["the", 14], ["newly", 18], ["synthesized", 24], ["compound", 36], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 45], ["(", 104], ["SEA0400", 105], [")", 112], ["on", 114], ["the", 117], ["Na+-Ca2", 121], ["+", 128], ["exchanger", 130], ["(", 140], ["NCX", 141], [")", 144], ["was", 146], ["investigated", 150], ["and", 163], ["compared", 167], ["against", 176], ["that", 184], ["of", 189], ["2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea", 192], ["(", 243], ["KB", 244], ["-", 246], ["R7943", 247], [")", 252], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["the", 268], ["effects", 272], ["of", 280], ["SEA0400", 283], ["on", 291], ["reperfusion", 294], ["injury", 306], ["in", 313], ["vitro", 316], ["and", 322], ["in", 326], ["vivo", 329], ["were", 334], ["examined", 339], [".", 347], ["SEA0400", 349], ["was", 357], ["extremely", 361], ["more", 371], ["potent", 376], ["than", 383], ["KB", 388], ["-", 390], ["R7943", 391], ["in", 397], ["inhibiting", 400], ["Na+-dependent", 411], ["Ca2", 425], ["+", 428], ["uptake", 430], ["in", 437], ["cultured", 440], ["neurons", 449], [",", 456], ["astrocytes", 458], [",", 468], ["and", 470], ["microglia", 474], [":", 483], ["IC50s", 485], ["of", 491], ["SEA0400", 494], ["and", 502], ["KB", 506], ["-", 508], ["R7943", 509], ["were", 515], ["5", 520], ["to", 522], ["33", 525], ["nM", 528], ["and", 531], ["2", 535], ["to", 537], ["4", 540], ["microM", 542], [",", 548], ["respectively", 550], [".", 562], ["SEA0400", 564], ["at", 572], ["the", 575], ["concentration", 579], ["range", 593], ["that", 599], ["inhibited", 604], ["NCX", 614], ["exhibited", 618], ["negligible", 628], ["affinities", 639], ["for", 650], ["the", 654], ["Ca2", 658], ["+", 661], ["channels", 663], [",", 671], ["Na+", 673], ["channels", 677], [",", 685], ["K+", 687], ["channels", 690], [",", 698], ["norepinephrine", 700], ["transporter", 715], [",", 726], ["and", 728], ["14", 732], ["receptors", 735], [",", 744], ["and", 746], ["did", 750], ["not", 754], ["affect", 758], ["the", 765], ["activities", 769], ["of", 780], ["the", 783], ["Na+/H+", 787], ["exchanger", 794], [",", 803], ["Na+,K+-ATPase", 805], [",", 818], ["Ca2", 820], ["+", 823], ["-ATPase", 824], [",", 831], ["and", 833], ["five", 837], ["enzymes", 842], [".", 849], ["SEA0400", 851], [",", 858], ["unlike", 860], ["KB", 867], ["-", 869], ["R7943", 870], [",", 875], ["did", 877], ["not", 881], ["inhibit", 885], ["the", 893], ["store", 897], ["-", 902], ["operated", 903], ["Ca2", 912], ["+", 915], ["entry", 917], ["in", 923], ["cultured", 926], ["astrocytes", 935], [".", 945], ["SEA0400", 947], ["attenuated", 955], ["dose-", 966], ["dependently", 972], ["paradoxical", 984], ["Ca2", 996], ["+", 999], ["challenge", 1001], ["-", 1010], ["induced", 1011], ["production", 1019], ["of", 1030], ["reactive", 1033], ["oxygen", 1042], ["species", 1049], [",", 1056], ["DNA", 1058], ["ladder", 1062], ["formation", 1069], [",", 1078], ["and", 1080], ["nuclear", 1084], ["condensation", 1092], ["in", 1105], ["cultured", 1108], ["astrocytes", 1117], [",", 1127], ["whereas", 1129], ["it", 1137], ["did", 1140], ["not", 1144], ["affect", 1148], ["thapsigargin", 1155], ["-", 1167], ["induced", 1168], ["cell", 1176], ["injury", 1181], [".", 1187], ["Furthermore", 1189], [",", 1200], ["administration", 1202], ["of", 1217], ["SEA0400", 1220], ["reduced", 1228], ["infarct", 1236], ["volumes", 1244], ["after", 1252], ["a", 1258], ["transient", 1260], ["middle", 1270], ["cerebral", 1277], ["artery", 1286], ["occlusion", 1293], ["in", 1303], ["rat", 1306], ["cerebral", 1310], ["cortex", 1319], ["and", 1326], ["striatum", 1330], [".", 1338], ["These", 1340], ["results", 1346], ["indicate", 1354], ["that", 1363], ["SEA0400", 1368], ["is", 1376], ["the", 1379], ["most", 1383], ["potent", 1388], ["and", 1395], ["selective", 1399], ["inhibitor", 1409], ["of", 1419], ["NCX", 1422], [",", 1425], ["and", 1427], ["suggest", 1431], ["that", 1439], ["the", 1444], ["compound", 1448], ["may", 1457], ["exert", 1461], ["protective", 1467], ["effects", 1478], ["on", 1486], ["postischemic", 1489], ["brain", 1502], ["damage", 1508], [".", 1514]]}
{"context": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues and play a major role in epigenetic regulation of gene transcription. We solved the structures of the catalytic domains of GLP, G9a, Suv39H2 and PRDM2, four of the eight known human H3K9 methyltransferases in their apo conformation or in complex with the methyl donating cofactor, and peptide substrates. We analyzed the structural determinants for methylation state specificity, and designed a G9a mutant able to tri-methylate H3K9. We show that the I-SET domain acts as a rigid docking platform, while induced-fit of the Post-SET domain is necessary to achieve a catalytically competent conformation. We also propose a model where long-range electrostatics bring enzyme and histone substrate together, while the presence of an arginine upstream of the target lysine is critical for binding and specificity. This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "2a976c6394c14d34bced70aaed51880b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [111, 112], [94, 95]], "char_spans": [[0, 9], [620, 629], [545, 554]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["methyltransferases", 11], ["deposit", 30], ["methyl", 38], ["marks", 45], ["on", 51], ["specific", 54], ["histone", 63], ["tail", 71], ["lysine", 76], ["residues", 83], ["and", 92], ["play", 96], ["a", 101], ["major", 103], ["role", 109], ["in", 114], ["epigenetic", 117], ["regulation", 128], ["of", 139], ["gene", 142], ["transcription", 147], [".", 160], ["We", 162], ["solved", 165], ["the", 172], ["structures", 176], ["of", 187], ["the", 190], ["catalytic", 194], ["domains", 204], ["of", 212], ["GLP", 215], [",", 218], ["G9a", 220], [",", 223], ["Suv39H2", 225], ["and", 233], ["PRDM2", 237], [",", 242], ["four", 244], ["of", 249], ["the", 252], ["eight", 256], ["known", 262], ["human", 268], ["H3K9", 274], ["methyltransferases", 279], ["in", 298], ["their", 301], ["apo", 307], ["conformation", 311], ["or", 324], ["in", 327], ["complex", 330], ["with", 338], ["the", 343], ["methyl", 347], ["donating", 354], ["cofactor", 363], [",", 371], ["and", 373], ["peptide", 377], ["substrates", 385], [".", 395], ["We", 397], ["analyzed", 400], ["the", 409], ["structural", 413], ["determinants", 424], ["for", 437], ["methylation", 441], ["state", 453], ["specificity", 459], [",", 470], ["and", 472], ["designed", 476], ["a", 485], ["G9a", 487], ["mutant", 491], ["able", 498], ["to", 503], ["tri", 506], ["-", 509], ["methylate", 510], ["H3K9", 520], [".", 524], ["We", 526], ["show", 529], ["that", 534], ["the", 539], ["I", 543], ["-", 544], ["SET", 545], ["domain", 549], ["acts", 556], ["as", 561], ["a", 564], ["rigid", 566], ["docking", 572], ["platform", 580], [",", 588], ["while", 590], ["induced", 596], ["-", 603], ["fit", 604], ["of", 608], ["the", 611], ["Post", 615], ["-", 619], ["SET", 620], ["domain", 624], ["is", 631], ["necessary", 634], ["to", 644], ["achieve", 647], ["a", 655], ["catalytically", 657], ["competent", 671], ["conformation", 681], [".", 693], ["We", 695], ["also", 698], ["propose", 703], ["a", 711], ["model", 713], ["where", 719], ["long", 725], ["-", 729], ["range", 730], ["electrostatics", 736], ["bring", 751], ["enzyme", 757], ["and", 764], ["histone", 768], ["substrate", 776], ["together", 786], [",", 794], ["while", 796], ["the", 802], ["presence", 806], ["of", 815], ["an", 818], ["arginine", 821], ["upstream", 830], ["of", 839], ["the", 842], ["target", 846], ["lysine", 853], ["is", 860], ["critical", 863], ["for", 872], ["binding", 876], ["and", 884], ["specificity", 888], [".", 899], ["This", 901], ["article", 906], ["can", 914], ["also", 918], ["be", 923], ["viewed", 926], ["as", 933], ["an", 936], ["enhanced", 939], ["version", 948], ["in", 956], ["which", 959], ["the", 965], ["text", 969], ["of", 974], ["the", 977], ["article", 981], ["is", 989], ["integrated", 992], ["with", 1003], ["interactive", 1008], ["3D", 1020], ["representations", 1023], ["and", 1039], ["animated", 1043], ["transitions", 1052], [".", 1063], ["Please", 1065], ["note", 1072], ["that", 1077], ["a", 1082], ["web", 1084], ["plugin", 1088], ["is", 1095], ["required", 1098], ["to", 1107], ["access", 1110], ["this", 1117], ["enhanced", 1122], ["functionality", 1131], [".", 1144], ["Instructions", 1146], ["for", 1159], ["the", 1163], ["installation", 1167], ["and", 1180], ["use", 1184], ["of", 1188], ["the", 1191], ["web", 1195], ["plugin", 1199], ["are", 1206], ["available", 1210], ["in", 1220], ["Text", 1223], ["S1", 1228], [".", 1230]]}
{"context": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. Present experiments were designed to study the effect of partial blockade of Na(+)/Ca(2+) exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Intracellular Ca(2+) transient and cell shortening were measured in ventricular myocytes loaded with Fura-2-AM fluorescent dye. Partial blockade of Na(+)/Ca(2+) exchanger was induced by superfusion of the cells with SEA0400 at a concentration of 0.3 microM. Amplitude of the intracellular Ca(2+) transient and cell shortening was significantly increased by SEA0400 in both field stimulated and voltage clamped myocytes, without significant elevation of diastolic Ca(2+) level and the decay time constant of the Ca(2+) transient. In patch clamped myocytes the SEA0400 induced increase in the Ca(2+) transient and cell shortening was accompanied by significant reduction of peak L-type Ca(2+) current. These effects can be explained by the autoregulative nature of cardiac Ca(2+) handling, as the reduced Ca(2+) efflux from the cell results in an increased Ca(2+) load to the sarcoplasmic reticulum leading to increased Ca(2+) release, which in turn may decrease the L-type Ca(2+) current by accelaration of Ca(2+) dependent inactivation of L-type Ca(2+) current. Our results suggest that complex changes in the Ca(2+) cycling can occur after selective pharmacological inhibition of the Na(+)/Ca(2+) exchanger.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "4fe2e279a8224262a6918b198e8b0ed1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[42, 45], [79, 82], [7, 10], [272, 275], [25, 28]], "char_spans": [[250, 271], [478, 499], [40, 61], [1515, 1536], [149, 170]]}]}], "context_tokens": [["SEA0400", 0], ["is", 8], ["a", 11], ["selective", 13], ["inhibitor", 23], ["of", 33], ["the", 36], ["Na(+)/Ca(2", 40], ["+", 50], [")", 51], ["exchanger", 53], ["having", 63], ["equal", 70], ["potencies", 76], ["to", 86], ["suppress", 89], ["both", 98], ["the", 103], ["forward", 107], ["and", 115], ["reverse", 119], ["mode", 127], ["operation", 132], ["of", 142], ["the", 145], ["Na(+)/Ca(2", 149], ["+", 159], [")", 160], ["exchanger", 162], [".", 171], ["Present", 173], ["experiments", 181], ["were", 193], ["designed", 198], ["to", 207], ["study", 210], ["the", 216], ["effect", 220], ["of", 227], ["partial", 230], ["blockade", 238], ["of", 247], ["Na(+)/Ca(2", 250], ["+", 260], [")", 261], ["exchanger", 263], ["on", 273], ["Ca(2", 276], ["+", 280], [")", 281], ["handling", 283], ["in", 292], ["isolated", 295], ["rat", 304], ["ventricular", 308], ["myocytes", 320], [".", 328], ["Intracellular", 330], ["Ca(2", 344], ["+", 348], [")", 349], ["transient", 351], ["and", 361], ["cell", 365], ["shortening", 370], ["were", 381], ["measured", 386], ["in", 395], ["ventricular", 398], ["myocytes", 410], ["loaded", 419], ["with", 426], ["Fura-2-AM", 431], ["fluorescent", 441], ["dye", 453], [".", 456], ["Partial", 458], ["blockade", 466], ["of", 475], ["Na(+)/Ca(2", 478], ["+", 488], [")", 489], ["exchanger", 491], ["was", 501], ["induced", 505], ["by", 513], ["superfusion", 516], ["of", 528], ["the", 531], ["cells", 535], ["with", 541], ["SEA0400", 546], ["at", 554], ["a", 557], ["concentration", 559], ["of", 573], ["0.3", 576], ["microM.", 580], ["Amplitude", 588], ["of", 598], ["the", 601], ["intracellular", 605], ["Ca(2", 619], ["+", 623], [")", 624], ["transient", 626], ["and", 636], ["cell", 640], ["shortening", 645], ["was", 656], ["significantly", 660], ["increased", 674], ["by", 684], ["SEA0400", 687], ["in", 695], ["both", 698], ["field", 703], ["stimulated", 709], ["and", 720], ["voltage", 724], ["clamped", 732], ["myocytes", 740], [",", 748], ["without", 750], ["significant", 758], ["elevation", 770], ["of", 780], ["diastolic", 783], ["Ca(2", 793], ["+", 797], [")", 798], ["level", 800], ["and", 806], ["the", 810], ["decay", 814], ["time", 820], ["constant", 825], ["of", 834], ["the", 837], ["Ca(2", 841], ["+", 845], [")", 846], ["transient", 848], [".", 857], ["In", 859], ["patch", 862], ["clamped", 868], ["myocytes", 876], ["the", 885], ["SEA0400", 889], ["induced", 897], ["increase", 905], ["in", 914], ["the", 917], ["Ca(2", 921], ["+", 925], [")", 926], ["transient", 928], ["and", 938], ["cell", 942], ["shortening", 947], ["was", 958], ["accompanied", 962], ["by", 974], ["significant", 977], ["reduction", 989], ["of", 999], ["peak", 1002], ["L", 1007], ["-", 1008], ["type", 1009], ["Ca(2", 1014], ["+", 1018], [")", 1019], ["current", 1021], [".", 1028], ["These", 1030], ["effects", 1036], ["can", 1044], ["be", 1048], ["explained", 1051], ["by", 1061], ["the", 1064], ["autoregulative", 1068], ["nature", 1083], ["of", 1090], ["cardiac", 1093], ["Ca(2", 1101], ["+", 1105], [")", 1106], ["handling", 1108], [",", 1116], ["as", 1118], ["the", 1121], ["reduced", 1125], ["Ca(2", 1133], ["+", 1137], [")", 1138], ["efflux", 1140], ["from", 1147], ["the", 1152], ["cell", 1156], ["results", 1161], ["in", 1169], ["an", 1172], ["increased", 1175], ["Ca(2", 1185], ["+", 1189], [")", 1190], ["load", 1192], ["to", 1197], ["the", 1200], ["sarcoplasmic", 1204], ["reticulum", 1217], ["leading", 1227], ["to", 1235], ["increased", 1238], ["Ca(2", 1248], ["+", 1252], [")", 1253], ["release", 1255], [",", 1262], ["which", 1264], ["in", 1270], ["turn", 1273], ["may", 1278], ["decrease", 1282], ["the", 1291], ["L", 1295], ["-", 1296], ["type", 1297], ["Ca(2", 1302], ["+", 1306], [")", 1307], ["current", 1309], ["by", 1317], ["accelaration", 1320], ["of", 1333], ["Ca(2", 1336], ["+", 1340], [")", 1341], ["dependent", 1343], ["inactivation", 1353], ["of", 1366], ["L", 1369], ["-", 1370], ["type", 1371], ["Ca(2", 1376], ["+", 1380], [")", 1381], ["current", 1383], [".", 1390], ["Our", 1392], ["results", 1396], ["suggest", 1404], ["that", 1412], ["complex", 1417], ["changes", 1425], ["in", 1433], ["the", 1436], ["Ca(2", 1440], ["+", 1444], [")", 1445], ["cycling", 1447], ["can", 1455], ["occur", 1459], ["after", 1465], ["selective", 1471], ["pharmacological", 1481], ["inhibition", 1497], ["of", 1508], ["the", 1511], ["Na(+)/Ca(2", 1515], ["+", 1525], [")", 1526], ["exchanger", 1528], [".", 1537]]}
{"context": "MicroRNAs (miRNAs) are non-coding, short (21-23nt) regulators of protein-coding genes that are generally transcribed first into primary miRNA (pri-miR), followed by the generation of precursor miRNA (pre-miR). This finally leads to the production of the mature miRNA. A large amount of information is available on the pre- and mature miRNAs. However, very little is known about the pri-miRs, due to a lack of knowledge about their transcription start sites (TSSs). Based on the genomic loci, miRNAs can be categorized into two types --intragenic (intra-miR) and intergenic (inter-miR). While it is already an established fact that intra-miRs are commonly transcribed in conjunction with their host genes, the transcription machinery of inter-miRs is poorly understood. Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs. In this paper, we concentrate on the problem of TSS prediction for miRNAs. The present study begins with the identification of positive and negative promoter samples from recently published data stemming from RNA-sequencing studies. From these samples of experimentally validated miRNA TSSs, a number of standard sequence features are extracted. Furthermore, to account for potential footprints related to promoter regulation by CpG dinucleotide targeted DNA methylation, a number of novel features are defined. We develop a support vector machine (SVM) with RBF kernel for the prediction of miRNA TSSs trained on human miRNA promoters. A novel feature reduction technique based on archived multi-objective simulated annealing (AMOSA) identifies the final set of features. The resulting model trained on miRNA promoters shows improved performance over the one trained on protein-coding gene promoters in terms of classification accuracy, sensitivity and specificity. Results are also reported for a completely independent biologically validated test set. In a part of the investigation, the proposed approach is used to predict protein-coding gene TSSs. It shows a significantly improved performance when compared to previously published gene TSS prediction methods.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cdd96acd2fc94e268b146391bc401383", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[179, 181]], "char_spans": [[887, 903]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["short", 35], ["(", 41], ["21", 42], ["-", 44], ["23nt", 45], [")", 49], ["regulators", 51], ["of", 62], ["protein", 65], ["-", 72], ["coding", 73], ["genes", 80], ["that", 86], ["are", 91], ["generally", 95], ["transcribed", 105], ["first", 117], ["into", 123], ["primary", 128], ["miRNA", 136], ["(", 142], ["pri", 143], ["-", 146], ["miR", 147], [")", 150], [",", 151], ["followed", 153], ["by", 162], ["the", 165], ["generation", 169], ["of", 180], ["precursor", 183], ["miRNA", 193], ["(", 199], ["pre", 200], ["-", 203], ["miR", 204], [")", 207], [".", 208], ["This", 210], ["finally", 215], ["leads", 223], ["to", 229], ["the", 232], ["production", 236], ["of", 247], ["the", 250], ["mature", 254], ["miRNA", 261], [".", 266], ["A", 268], ["large", 270], ["amount", 276], ["of", 283], ["information", 286], ["is", 298], ["available", 301], ["on", 311], ["the", 314], ["pre-", 318], ["and", 323], ["mature", 327], ["miRNAs", 334], [".", 340], ["However", 342], [",", 349], ["very", 351], ["little", 356], ["is", 363], ["known", 366], ["about", 372], ["the", 378], ["pri", 382], ["-", 385], ["miRs", 386], [",", 390], ["due", 392], ["to", 396], ["a", 399], ["lack", 401], ["of", 406], ["knowledge", 409], ["about", 419], ["their", 425], ["transcription", 431], ["start", 445], ["sites", 451], ["(", 457], ["TSSs", 458], [")", 462], [".", 463], ["Based", 465], ["on", 471], ["the", 474], ["genomic", 478], ["loci", 486], [",", 490], ["miRNAs", 492], ["can", 499], ["be", 503], ["categorized", 506], ["into", 518], ["two", 523], ["types", 527], ["--intragenic", 533], ["(", 546], ["intra", 547], ["-", 552], ["miR", 553], [")", 556], ["and", 558], ["intergenic", 562], ["(", 573], ["inter", 574], ["-", 579], ["miR", 580], [")", 583], [".", 584], ["While", 586], ["it", 592], ["is", 595], ["already", 598], ["an", 606], ["established", 609], ["fact", 621], ["that", 626], ["intra", 631], ["-", 636], ["miRs", 637], ["are", 642], ["commonly", 646], ["transcribed", 655], ["in", 667], ["conjunction", 670], ["with", 682], ["their", 687], ["host", 693], ["genes", 698], [",", 703], ["the", 705], ["transcription", 709], ["machinery", 723], ["of", 733], ["inter", 736], ["-", 741], ["miRs", 742], ["is", 747], ["poorly", 750], ["understood", 757], [".", 767], ["Although", 769], ["it", 778], ["is", 781], ["assumed", 784], ["that", 792], ["miRNA", 797], ["promoters", 803], ["are", 813], ["similar", 817], ["in", 825], ["structure", 828], ["to", 838], ["gene", 841], ["promoters", 846], [",", 855], ["since", 857], ["both", 863], ["are", 868], ["transcribed", 872], ["by", 884], ["RNA", 887], ["polymerase", 891], ["II", 902], ["(", 905], ["Pol", 906], ["II", 910], [")", 912], [",", 913], ["computational", 915], ["validations", 929], ["exhibit", 941], ["poor", 949], ["performance", 954], ["of", 966], ["gene", 969], ["promoter", 974], ["prediction", 983], ["methods", 994], ["on", 1002], ["miRNAs", 1005], [".", 1011], ["In", 1013], ["this", 1016], ["paper", 1021], [",", 1026], ["we", 1028], ["concentrate", 1031], ["on", 1043], ["the", 1046], ["problem", 1050], ["of", 1058], ["TSS", 1061], ["prediction", 1065], ["for", 1076], ["miRNAs", 1080], [".", 1086], ["The", 1088], ["present", 1092], ["study", 1100], ["begins", 1106], ["with", 1113], ["the", 1118], ["identification", 1122], ["of", 1137], ["positive", 1140], ["and", 1149], ["negative", 1153], ["promoter", 1162], ["samples", 1171], ["from", 1179], ["recently", 1184], ["published", 1193], ["data", 1203], ["stemming", 1208], ["from", 1217], ["RNA", 1222], ["-", 1225], ["sequencing", 1226], ["studies", 1237], [".", 1244], ["From", 1246], ["these", 1251], ["samples", 1257], ["of", 1265], ["experimentally", 1268], ["validated", 1283], ["miRNA", 1293], ["TSSs", 1299], [",", 1303], ["a", 1305], ["number", 1307], ["of", 1314], ["standard", 1317], ["sequence", 1326], ["features", 1335], ["are", 1344], ["extracted", 1348], [".", 1357], ["Furthermore", 1359], [",", 1370], ["to", 1372], ["account", 1375], ["for", 1383], ["potential", 1387], ["footprints", 1397], ["related", 1408], ["to", 1416], ["promoter", 1419], ["regulation", 1428], ["by", 1439], ["CpG", 1442], ["dinucleotide", 1446], ["targeted", 1459], ["DNA", 1468], ["methylation", 1472], [",", 1483], ["a", 1485], ["number", 1487], ["of", 1494], ["novel", 1497], ["features", 1503], ["are", 1512], ["defined", 1516], [".", 1523], ["We", 1525], ["develop", 1528], ["a", 1536], ["support", 1538], ["vector", 1546], ["machine", 1553], ["(", 1561], ["SVM", 1562], [")", 1565], ["with", 1567], ["RBF", 1572], ["kernel", 1576], ["for", 1583], ["the", 1587], ["prediction", 1591], ["of", 1602], ["miRNA", 1605], ["TSSs", 1611], ["trained", 1616], ["on", 1624], ["human", 1627], ["miRNA", 1633], ["promoters", 1639], [".", 1648], ["A", 1650], ["novel", 1652], ["feature", 1658], ["reduction", 1666], ["technique", 1676], ["based", 1686], ["on", 1692], ["archived", 1695], ["multi", 1704], ["-", 1709], ["objective", 1710], ["simulated", 1720], ["annealing", 1730], ["(", 1740], ["AMOSA", 1741], [")", 1746], ["identifies", 1748], ["the", 1759], ["final", 1763], ["set", 1769], ["of", 1773], ["features", 1776], [".", 1784], ["The", 1786], ["resulting", 1790], ["model", 1800], ["trained", 1806], ["on", 1814], ["miRNA", 1817], ["promoters", 1823], ["shows", 1833], ["improved", 1839], ["performance", 1848], ["over", 1860], ["the", 1865], ["one", 1869], ["trained", 1873], ["on", 1881], ["protein", 1884], ["-", 1891], ["coding", 1892], ["gene", 1899], ["promoters", 1904], ["in", 1914], ["terms", 1917], ["of", 1923], ["classification", 1926], ["accuracy", 1941], [",", 1949], ["sensitivity", 1951], ["and", 1963], ["specificity", 1967], [".", 1978], ["Results", 1980], ["are", 1988], ["also", 1992], ["reported", 1997], ["for", 2006], ["a", 2010], ["completely", 2012], ["independent", 2023], ["biologically", 2035], ["validated", 2048], ["test", 2058], ["set", 2063], [".", 2066], ["In", 2068], ["a", 2071], ["part", 2073], ["of", 2078], ["the", 2081], ["investigation", 2085], [",", 2098], ["the", 2100], ["proposed", 2104], ["approach", 2113], ["is", 2122], ["used", 2125], ["to", 2130], ["predict", 2133], ["protein", 2141], ["-", 2148], ["coding", 2149], ["gene", 2156], ["TSSs", 2161], [".", 2165], ["It", 2167], ["shows", 2170], ["a", 2176], ["significantly", 2178], ["improved", 2192], ["performance", 2201], ["when", 2213], ["compared", 2218], ["to", 2227], ["previously", 2230], ["published", 2241], ["gene", 2251], ["TSS", 2256], ["prediction", 2260], ["methods", 2271], [".", 2278]]}
{"context": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients. In order to investigate a possible phenotype-genotype correlation and to further define the predictive value of NSD1 mutations, we performed mutational analysis of the NSD1 gene in 20 patients and one familial case with Sotos syndrome, five patients with Weaver syndrome, six patients with unclassified overgrowth/mental retardation, and six patients with macrocephaly/mental retardation. We were able to identify mutations within the NSD1 gene in 18 patients and the familial case with Sotos syndrome (90%). The mutations (six nonsense, eight frame shifts, three splice site, one missense, one in-frame deletion) are expected to result in an impairment of NSD1 function. The best correlation between clinical assessment and molecular results was obtained for the Sotos facial gestalt in conjunction with overgrowth, macrocephaly, and developmental delay. In contrast to the high mutation detection rate in Sotos syndrome, none of the patients with Weaver syndrome, unclassified overgrowth/mental retardation and macrocephaly/mental retardation, harbored NSD1 mutations. We tested for large deletions by FISH analysis but were not able to identify any deletion cases. The results indicate that the great majority of patients with Sotos syndrome are caused by mutations in NSD1. Deletions covering the NSD1 locus were not found in the patients analyzed here.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "c0eee31746d343f19dcd03ff0c8496b2", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[73, 74], [13, 15], [118, 119]], "char_spans": [[438, 446], [76, 85], [705, 713]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["deletions", 10], ["encompassing", 20], ["the", 33], ["nuclear", 37], ["receptor", 45], ["binding", 54], ["SET", 62], ["-", 65], ["Domain", 66], ["1", 73], ["(", 75], ["NSD1", 76], [")", 80], ["gene", 82], ["have", 87], ["been", 92], ["described", 97], ["as", 107], ["the", 110], ["major", 114], ["cause", 120], ["of", 126], ["Japanese", 129], ["patients", 138], ["with", 147], ["the", 152], ["Sotos", 156], ["syndrome", 162], [",", 170], ["whereas", 172], ["point", 180], ["mutations", 186], ["have", 196], ["been", 201], ["identified", 206], ["in", 217], ["the", 220], ["majority", 224], ["of", 233], ["European", 236], ["Sotos", 245], ["syndrome", 251], ["patients", 260], [".", 268], ["In", 270], ["order", 273], ["to", 279], ["investigate", 282], ["a", 294], ["possible", 296], ["phenotype", 305], ["-", 314], ["genotype", 315], ["correlation", 324], ["and", 336], ["to", 340], ["further", 343], ["define", 351], ["the", 358], ["predictive", 362], ["value", 373], ["of", 379], ["NSD1", 382], ["mutations", 387], [",", 396], ["we", 398], ["performed", 401], ["mutational", 411], ["analysis", 422], ["of", 431], ["the", 434], ["NSD1", 438], ["gene", 443], ["in", 448], ["20", 451], ["patients", 454], ["and", 463], ["one", 467], ["familial", 471], ["case", 480], ["with", 485], ["Sotos", 490], ["syndrome", 496], [",", 504], ["five", 506], ["patients", 511], ["with", 520], ["Weaver", 525], ["syndrome", 532], [",", 540], ["six", 542], ["patients", 546], ["with", 555], ["unclassified", 560], ["overgrowth", 573], ["/", 583], ["mental", 584], ["retardation", 591], [",", 602], ["and", 604], ["six", 608], ["patients", 612], ["with", 621], ["macrocephaly", 626], ["/", 638], ["mental", 639], ["retardation", 646], [".", 657], ["We", 659], ["were", 662], ["able", 667], ["to", 672], ["identify", 675], ["mutations", 684], ["within", 694], ["the", 701], ["NSD1", 705], ["gene", 710], ["in", 715], ["18", 718], ["patients", 721], ["and", 730], ["the", 734], ["familial", 738], ["case", 747], ["with", 752], ["Sotos", 757], ["syndrome", 763], ["(", 772], ["90", 773], ["%", 775], [")", 776], [".", 777], ["The", 779], ["mutations", 783], ["(", 793], ["six", 794], ["nonsense", 798], [",", 806], ["eight", 808], ["frame", 814], ["shifts", 820], [",", 826], ["three", 828], ["splice", 834], ["site", 841], [",", 845], ["one", 847], ["missense", 851], [",", 859], ["one", 861], ["in", 865], ["-", 867], ["frame", 868], ["deletion", 874], [")", 882], ["are", 884], ["expected", 888], ["to", 897], ["result", 900], ["in", 907], ["an", 910], ["impairment", 913], ["of", 924], ["NSD1", 927], ["function", 932], [".", 940], ["The", 942], ["best", 946], ["correlation", 951], ["between", 963], ["clinical", 971], ["assessment", 980], ["and", 991], ["molecular", 995], ["results", 1005], ["was", 1013], ["obtained", 1017], ["for", 1026], ["the", 1030], ["Sotos", 1034], ["facial", 1040], ["gestalt", 1047], ["in", 1055], ["conjunction", 1058], ["with", 1070], ["overgrowth", 1075], [",", 1085], ["macrocephaly", 1087], [",", 1099], ["and", 1101], ["developmental", 1105], ["delay", 1119], [".", 1124], ["In", 1126], ["contrast", 1129], ["to", 1138], ["the", 1141], ["high", 1145], ["mutation", 1150], ["detection", 1159], ["rate", 1169], ["in", 1174], ["Sotos", 1177], ["syndrome", 1183], [",", 1191], ["none", 1193], ["of", 1198], ["the", 1201], ["patients", 1205], ["with", 1214], ["Weaver", 1219], ["syndrome", 1226], [",", 1234], ["unclassified", 1236], ["overgrowth", 1249], ["/", 1259], ["mental", 1260], ["retardation", 1267], ["and", 1279], ["macrocephaly", 1283], ["/", 1295], ["mental", 1296], ["retardation", 1303], [",", 1314], ["harbored", 1316], ["NSD1", 1325], ["mutations", 1330], [".", 1339], ["We", 1341], ["tested", 1344], ["for", 1351], ["large", 1355], ["deletions", 1361], ["by", 1371], ["FISH", 1374], ["analysis", 1379], ["but", 1388], ["were", 1392], ["not", 1397], ["able", 1401], ["to", 1406], ["identify", 1409], ["any", 1418], ["deletion", 1422], ["cases", 1431], [".", 1436], ["The", 1438], ["results", 1442], ["indicate", 1450], ["that", 1459], ["the", 1464], ["great", 1468], ["majority", 1474], ["of", 1483], ["patients", 1486], ["with", 1495], ["Sotos", 1500], ["syndrome", 1506], ["are", 1515], ["caused", 1519], ["by", 1526], ["mutations", 1529], ["in", 1539], ["NSD1", 1542], [".", 1546], ["Deletions", 1548], ["covering", 1558], ["the", 1567], ["NSD1", 1571], ["locus", 1576], ["were", 1582], ["not", 1587], ["found", 1591], ["in", 1597], ["the", 1600], ["patients", 1604], ["analyzed", 1613], ["here", 1622], [".", 1626]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract. We report a 58-year-old female with a history of a pigmented rash on her extremities, thick keratotic plaques on her hands, and brittle nails. Chest imaging revealed a right upper lobe mass that was proven to be small cell lung carcinoma. While Bazex syndrome has been described in the dermatology literature, it is also important for the radiologist to be aware of this entity and its common presentations.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "17fe85e739194ecda4e790b9d6224dc0", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[84, 85], [3, 4]], "char_spans": [[497, 510], [30, 43]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastic", 14], ["(", 29], ["Bazex", 30], ["syndrome", 36], [")", 44], ["is", 46], ["a", 49], ["rare", 51], [",", 55], ["but", 57], ["distinctive", 61], ["paraneoplastic", 73], ["dermatosis", 88], ["characterized", 99], ["by", 113], ["erythematosquamous", 116], ["lesions", 135], ["located", 143], ["at", 151], ["the", 154], ["acral", 158], ["sites", 164], ["and", 170], ["is", 174], ["most", 177], ["commonly", 182], ["associated", 191], ["with", 202], ["carcinomas", 207], ["of", 218], ["the", 221], ["upper", 225], ["aerodigestive", 231], ["tract", 245], [".", 250], ["We", 252], ["report", 255], ["a", 262], ["58-year", 264], ["-", 271], ["old", 272], ["female", 276], ["with", 283], ["a", 288], ["history", 290], ["of", 298], ["a", 301], ["pigmented", 303], ["rash", 313], ["on", 318], ["her", 321], ["extremities", 325], [",", 336], ["thick", 338], ["keratotic", 344], ["plaques", 354], ["on", 362], ["her", 365], ["hands", 369], [",", 374], ["and", 376], ["brittle", 380], ["nails", 388], [".", 393], ["Chest", 395], ["imaging", 401], ["revealed", 409], ["a", 418], ["right", 420], ["upper", 426], ["lobe", 432], ["mass", 437], ["that", 442], ["was", 447], ["proven", 451], ["to", 458], ["be", 461], ["small", 464], ["cell", 470], ["lung", 475], ["carcinoma", 480], [".", 489], ["While", 491], ["Bazex", 497], ["syndrome", 503], ["has", 512], ["been", 516], ["described", 521], ["in", 531], ["the", 534], ["dermatology", 538], ["literature", 550], [",", 560], ["it", 562], ["is", 565], ["also", 568], ["important", 573], ["for", 583], ["the", 587], ["radiologist", 591], ["to", 603], ["be", 606], ["aware", 609], ["of", 615], ["this", 618], ["entity", 623], ["and", 630], ["its", 634], ["common", 638], ["presentations", 645], [".", 658]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "Na\u00efve and primed pluripotent states retain distinct molecular properties, yet limited knowledge exists on how their state transitions are regulated. Here, we identify Mettl3, an N(6)-methyladenosine (m(6)A) transferase, as a regulator for terminating murine na\u00efve pluripotency. Mettl3 knockout preimplantation epiblasts and na\u00efve embryonic stem cells are depleted for m(6)A in mRNAs, yet are viable. However, they fail to adequately terminate their na\u00efve state and, subsequently, undergo aberrant and restricted lineage priming at the postimplantation stage, which leads to early embryonic lethality. m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. This study highlights a critical role for an mRNA epigenetic modification in vivo and identifies regulatory modules that functionally influence na\u00efve and primed pluripotency in an opposing manner.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "e2dccc6fa3a84b67a72cd87b03a0db2e", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[101, 102]], "char_spans": [[642, 655]]}]}], "context_tokens": [["Na\u00efve", 0], ["and", 6], ["primed", 10], ["pluripotent", 17], ["states", 29], ["retain", 36], ["distinct", 43], ["molecular", 52], ["properties", 62], [",", 72], ["yet", 74], ["limited", 78], ["knowledge", 86], ["exists", 96], ["on", 103], ["how", 106], ["their", 110], ["state", 116], ["transitions", 122], ["are", 134], ["regulated", 138], [".", 147], ["Here", 149], [",", 153], ["we", 155], ["identify", 158], ["Mettl3", 167], [",", 173], ["an", 175], ["N(6)-methyladenosine", 178], ["(", 199], ["m(6)A", 200], [")", 205], ["transferase", 207], [",", 218], ["as", 220], ["a", 223], ["regulator", 225], ["for", 235], ["terminating", 239], ["murine", 251], ["na\u00efve", 258], ["pluripotency", 264], [".", 276], ["Mettl3", 278], ["knockout", 285], ["preimplantation", 294], ["epiblasts", 310], ["and", 320], ["na\u00efve", 324], ["embryonic", 330], ["stem", 340], ["cells", 345], ["are", 351], ["depleted", 355], ["for", 364], ["m(6)A", 368], ["in", 374], ["mRNAs", 377], [",", 382], ["yet", 384], ["are", 388], ["viable", 392], [".", 398], ["However", 400], [",", 407], ["they", 409], ["fail", 414], ["to", 419], ["adequately", 422], ["terminate", 433], ["their", 443], ["na\u00efve", 449], ["state", 455], ["and", 461], [",", 464], ["subsequently", 466], [",", 478], ["undergo", 480], ["aberrant", 488], ["and", 497], ["restricted", 501], ["lineage", 512], ["priming", 520], ["at", 528], ["the", 531], ["postimplantation", 535], ["stage", 552], [",", 557], ["which", 559], ["leads", 565], ["to", 571], ["early", 574], ["embryonic", 580], ["lethality", 590], [".", 599], ["m(6)A", 601], ["predominantly", 607], ["and", 621], ["directly", 625], ["reduces", 634], ["mRNA", 642], ["stability", 647], [",", 656], ["including", 658], ["that", 668], ["of", 673], ["key", 676], ["na\u00efve", 680], ["pluripotency", 686], ["-", 698], ["promoting", 699], ["transcripts", 709], [".", 720], ["This", 722], ["study", 727], ["highlights", 733], ["a", 744], ["critical", 746], ["role", 755], ["for", 760], ["an", 764], ["mRNA", 767], ["epigenetic", 772], ["modification", 783], ["in", 796], ["vivo", 799], ["and", 804], ["identifies", 808], ["regulatory", 819], ["modules", 830], ["that", 838], ["functionally", 843], ["influence", 856], ["na\u00efve", 866], ["and", 872], ["primed", 876], ["pluripotency", 883], ["in", 896], ["an", 899], ["opposing", 902], ["manner", 911], [".", 917]]}
{"context": "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. Here we explore natural genetic variation affecting editing levels of particular sites in 81 natural strains of Drosophila melanogaster. The analysis of associations between editing levels and single-nucleotide polymorphisms allows us to map putative cis-regulatory regions affecting editing of 16 A-to-I editing sites (cis-RNA editing quantitative trait loci or cis-edQTLs, P\u00a0<\u00a010(-8)). The observed changes in editing levels are validated by independent molecular technique. All identified regulatory variants are located in close proximity of modulated editing sites. Moreover, colocalized editing sites are often regulated by same loci. Similar to expression and splicing QTL studies, the characterization of edQTLs will greatly expand our understanding of cis-regulatory evolution of gene expression.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "d56d38b84b684192b16ecad81b0152c7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[22, 22]], "char_spans": [[130, 133]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[24, 29]], "char_spans": [[136, 168]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["usually", 12], ["affects", 20], ["only", 28], ["a", 33], ["fraction", 35], ["of", 44], ["expressed", 47], ["transcripts", 57], ["and", 69], ["there", 73], ["is", 79], ["a", 82], ["vast", 84], ["amount", 89], ["of", 96], ["variation", 99], ["in", 109], ["editing", 112], ["levels", 120], ["of", 127], ["ADAR", 130], ["(", 135], ["adenosine", 136], ["deaminase", 146], [",", 155], ["RNA", 157], ["-", 160], ["specific", 161], [")", 169], ["targets", 171], [".", 178], ["Here", 180], ["we", 185], ["explore", 188], ["natural", 196], ["genetic", 204], ["variation", 212], ["affecting", 222], ["editing", 232], ["levels", 240], ["of", 247], ["particular", 250], ["sites", 261], ["in", 267], ["81", 270], ["natural", 273], ["strains", 281], ["of", 289], ["Drosophila", 292], ["melanogaster", 303], [".", 315], ["The", 317], ["analysis", 321], ["of", 330], ["associations", 333], ["between", 346], ["editing", 354], ["levels", 362], ["and", 369], ["single", 373], ["-", 379], ["nucleotide", 380], ["polymorphisms", 391], ["allows", 405], ["us", 412], ["to", 415], ["map", 418], ["putative", 422], ["cis", 431], ["-", 434], ["regulatory", 435], ["regions", 446], ["affecting", 454], ["editing", 464], ["of", 472], ["16", 475], ["A", 478], ["-", 479], ["to", 480], ["-", 482], ["I", 483], ["editing", 485], ["sites", 493], ["(", 499], ["cis", 500], ["-", 503], ["RNA", 504], ["editing", 508], ["quantitative", 516], ["trait", 529], ["loci", 535], ["or", 540], ["cis", 543], ["-", 546], ["edQTLs", 547], [",", 553], ["P", 555], ["<", 557], ["10(-8", 559], [")", 564], [")", 565], [".", 566], ["The", 568], ["observed", 572], ["changes", 581], ["in", 589], ["editing", 592], ["levels", 600], ["are", 607], ["validated", 611], ["by", 621], ["independent", 624], ["molecular", 636], ["technique", 646], [".", 655], ["All", 657], ["identified", 661], ["regulatory", 672], ["variants", 683], ["are", 692], ["located", 696], ["in", 704], ["close", 707], ["proximity", 713], ["of", 723], ["modulated", 726], ["editing", 736], ["sites", 744], [".", 749], ["Moreover", 751], [",", 759], ["colocalized", 761], ["editing", 773], ["sites", 781], ["are", 787], ["often", 791], ["regulated", 797], ["by", 807], ["same", 810], ["loci", 815], [".", 819], ["Similar", 821], ["to", 829], ["expression", 832], ["and", 843], ["splicing", 847], ["QTL", 856], ["studies", 860], [",", 867], ["the", 869], ["characterization", 873], ["of", 890], ["edQTLs", 893], ["will", 900], ["greatly", 905], ["expand", 913], ["our", 920], ["understanding", 924], ["of", 938], ["cis", 941], ["-", 944], ["regulatory", 945], ["evolution", 956], ["of", 966], ["gene", 969], ["expression", 974], [".", 984]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common familial tumour syndrome with multiple clinical features such as neurofibromas, caf\u00e9-au-lait spots (CLS), iris Lisch nodules, axillary freckling, optic glioma, specific bone lesions and an increased risk of malignant tumours. It is caused by a wide spectrum of mutations affecting the NF1 gene. Most mutations result in the loss of one allele at the DNA, mRNA or protein level and thus in the loss of any function of the gene product neurofibromin. The idea of the simultaneous loss of several different neurofibromin functions has been postulated to explain the pleiotropic effects of its loss. However, we have identified a novel missense mutation in a family with a classical multi-symptomatic NF1 phenotype, including a malignant schwannoma, that specifically abolishes the Ras-GTPase-activating function of neurofibromin. In this family, Arg1276 had mutated into proline. Based on complex biochemical studies as well as the analysis of the crystal structure of the GTPase-activating protein (GAP) domain of p120GAP in the presence of Ras, we unequivocally identified this amino acid as the arginine finger of the neurofibromin GAP-related domain (GRD)-the most essential catalytic element for RasGAP activity. Here, we present data demonstrating that the mutation R1276P, unlike previously reported missense mutations of the GRD region, does not impair the secondary and tertiary protein structure. It neither reduces the level of cellular neurofibromin nor influences its binding to Ras substantially, but it does completely disable GAP activity. Our findings provide direct evidence that failure of neurofibromin GAP activity is the critical element of NF1 pathogenesis. Thus, therapeutic approaches aimed at the reduction of Ras.GTP levels in neural crest-derived cells can be expected to relieve most of the NF1 symptoms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "6f4df195db2e4569b74922aec8abb058", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[298, 298], [4, 4], [137, 137], [328, 328], [62, 62]], "char_spans": [[1703, 1705], [26, 28], [740, 742], [1860, 1862], [328, 330]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["familial", 43], ["tumour", 52], ["syndrome", 59], ["with", 68], ["multiple", 73], ["clinical", 82], ["features", 91], ["such", 100], ["as", 105], ["neurofibromas", 108], [",", 121], ["caf\u00e9", 123], ["-", 127], ["au", 128], ["-", 130], ["lait", 131], ["spots", 136], ["(", 142], ["CLS", 143], [")", 146], [",", 147], ["iris", 149], ["Lisch", 154], ["nodules", 160], [",", 167], ["axillary", 169], ["freckling", 178], [",", 187], ["optic", 189], ["glioma", 195], [",", 201], ["specific", 203], ["bone", 212], ["lesions", 217], ["and", 225], ["an", 229], ["increased", 232], ["risk", 242], ["of", 247], ["malignant", 250], ["tumours", 260], [".", 267], ["It", 269], ["is", 272], ["caused", 275], ["by", 282], ["a", 285], ["wide", 287], ["spectrum", 292], ["of", 301], ["mutations", 304], ["affecting", 314], ["the", 324], ["NF1", 328], ["gene", 332], [".", 336], ["Most", 338], ["mutations", 343], ["result", 353], ["in", 360], ["the", 363], ["loss", 367], ["of", 372], ["one", 375], ["allele", 379], ["at", 386], ["the", 389], ["DNA", 393], [",", 396], ["mRNA", 398], ["or", 403], ["protein", 406], ["level", 414], ["and", 420], ["thus", 424], ["in", 429], ["the", 432], ["loss", 436], ["of", 441], ["any", 444], ["function", 448], ["of", 457], ["the", 460], ["gene", 464], ["product", 469], ["neurofibromin", 477], [".", 490], ["The", 492], ["idea", 496], ["of", 501], ["the", 504], ["simultaneous", 508], ["loss", 521], ["of", 526], ["several", 529], ["different", 537], ["neurofibromin", 547], ["functions", 561], ["has", 571], ["been", 575], ["postulated", 580], ["to", 591], ["explain", 594], ["the", 602], ["pleiotropic", 606], ["effects", 618], ["of", 626], ["its", 629], ["loss", 633], [".", 637], ["However", 639], [",", 646], ["we", 648], ["have", 651], ["identified", 656], ["a", 667], ["novel", 669], ["missense", 675], ["mutation", 684], ["in", 693], ["a", 696], ["family", 698], ["with", 705], ["a", 710], ["classical", 712], ["multi", 722], ["-", 727], ["symptomatic", 728], ["NF1", 740], ["phenotype", 744], [",", 753], ["including", 755], ["a", 765], ["malignant", 767], ["schwannoma", 777], [",", 787], ["that", 789], ["specifically", 794], ["abolishes", 807], ["the", 817], ["Ras", 821], ["-", 824], ["GTPase", 825], ["-", 831], ["activating", 832], ["function", 843], ["of", 852], ["neurofibromin", 855], [".", 868], ["In", 870], ["this", 873], ["family", 878], [",", 884], ["Arg1276", 886], ["had", 894], ["mutated", 898], ["into", 906], ["proline", 911], [".", 918], ["Based", 920], ["on", 926], ["complex", 929], ["biochemical", 937], ["studies", 949], ["as", 957], ["well", 960], ["as", 965], ["the", 968], ["analysis", 972], ["of", 981], ["the", 984], ["crystal", 988], ["structure", 996], ["of", 1006], ["the", 1009], ["GTPase", 1013], ["-", 1019], ["activating", 1020], ["protein", 1031], ["(", 1039], ["GAP", 1040], [")", 1043], ["domain", 1045], ["of", 1052], ["p120GAP", 1055], ["in", 1063], ["the", 1066], ["presence", 1070], ["of", 1079], ["Ras", 1082], [",", 1085], ["we", 1087], ["unequivocally", 1090], ["identified", 1104], ["this", 1115], ["amino", 1120], ["acid", 1126], ["as", 1131], ["the", 1134], ["arginine", 1138], ["finger", 1147], ["of", 1154], ["the", 1157], ["neurofibromin", 1161], ["GAP", 1175], ["-", 1178], ["related", 1179], ["domain", 1187], ["(", 1194], ["GRD)-the", 1195], ["most", 1204], ["essential", 1209], ["catalytic", 1219], ["element", 1229], ["for", 1237], ["RasGAP", 1241], ["activity", 1248], [".", 1256], ["Here", 1258], [",", 1262], ["we", 1264], ["present", 1267], ["data", 1275], ["demonstrating", 1280], ["that", 1294], ["the", 1299], ["mutation", 1303], ["R1276P", 1312], [",", 1318], ["unlike", 1320], ["previously", 1327], ["reported", 1338], ["missense", 1347], ["mutations", 1356], ["of", 1366], ["the", 1369], ["GRD", 1373], ["region", 1377], [",", 1383], ["does", 1385], ["not", 1390], ["impair", 1394], ["the", 1401], ["secondary", 1405], ["and", 1415], ["tertiary", 1419], ["protein", 1428], ["structure", 1436], [".", 1445], ["It", 1447], ["neither", 1450], ["reduces", 1458], ["the", 1466], ["level", 1470], ["of", 1476], ["cellular", 1479], ["neurofibromin", 1488], ["nor", 1502], ["influences", 1506], ["its", 1517], ["binding", 1521], ["to", 1529], ["Ras", 1532], ["substantially", 1536], [",", 1549], ["but", 1551], ["it", 1555], ["does", 1558], ["completely", 1563], ["disable", 1574], ["GAP", 1582], ["activity", 1586], [".", 1594], ["Our", 1596], ["findings", 1600], ["provide", 1609], ["direct", 1617], ["evidence", 1624], ["that", 1633], ["failure", 1638], ["of", 1646], ["neurofibromin", 1649], ["GAP", 1663], ["activity", 1667], ["is", 1676], ["the", 1679], ["critical", 1683], ["element", 1692], ["of", 1700], ["NF1", 1703], ["pathogenesis", 1707], [".", 1719], ["Thus", 1721], [",", 1725], ["therapeutic", 1727], ["approaches", 1739], ["aimed", 1750], ["at", 1756], ["the", 1759], ["reduction", 1763], ["of", 1773], ["Ras", 1776], [".", 1779], ["GTP", 1780], ["levels", 1784], ["in", 1791], ["neural", 1794], ["crest", 1801], ["-", 1806], ["derived", 1807], ["cells", 1815], ["can", 1821], ["be", 1825], ["expected", 1828], ["to", 1837], ["relieve", 1840], ["most", 1848], ["of", 1853], ["the", 1856], ["NF1", 1860], ["symptoms", 1864], [".", 1872]]}
{"context": "Two missense mutations (Ala-30 --> Pro and Ala-53 --> Thr) in the gene encoding alpha-synuclein are associated with rare autosomal dominant forms of familial Parkinson's disease. In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease. However, the normal conformation of alpha-synuclein, its cellular localization in neurons, and the effects of the mutations remain to be determined. In the present study, we examine these questions using sensitive fluorescence resonance energy transfer techniques. Transient transfection of alpha-synuclein expression constructs into primary cortical neurons and counterstaining with the lipophilic fluorescent marker, DiI, demonstrates a close association between alpha-synuclein and cellular membranes. Both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes. A weak interaction also occurs between the N and C termini themselves. The Parkinson's disease-associated mutations have no effect on membrane interaction; however, the Ala-30 --> Pro mutation alters the three-dimensional conformation of alpha-synuclein, as measured by significantly increased fluorescence resonance energy transfer between the N and C termini.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "9cf91c000cf144009e50440635f148d1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[129, 131], [145, 147], [196, 198], [37, 39], [105, 107], [64, 66], [18, 20]], "char_spans": [[776, 790], [854, 868], [1147, 1161], [192, 206], [602, 616], [347, 361], [80, 94]]}]}], "context_tokens": [["Two", 0], ["missense", 4], ["mutations", 13], ["(", 23], ["Ala-30", 24], ["--", 31], [">", 33], ["Pro", 35], ["and", 39], ["Ala-53", 43], ["--", 50], [">", 52], ["Thr", 54], [")", 57], ["in", 59], ["the", 62], ["gene", 66], ["encoding", 71], ["alpha", 80], ["-", 85], ["synuclein", 86], ["are", 96], ["associated", 100], ["with", 111], ["rare", 116], ["autosomal", 121], ["dominant", 131], ["forms", 140], ["of", 146], ["familial", 149], ["Parkinson", 158], ["'s", 167], ["disease", 170], [".", 177], ["In", 179], ["addition", 182], [",", 190], ["alpha", 192], ["-", 197], ["synuclein", 198], ["is", 208], ["an", 211], ["abundant", 214], ["component", 223], ["of", 233], ["Lewy", 236], ["bodies", 241], ["in", 248], ["sporadic", 251], ["Parkinson", 260], ["'s", 269], ["disease", 272], ["and", 280], ["diffuse", 284], ["Lewy", 292], ["body", 297], ["disease", 302], [".", 309], ["However", 311], [",", 318], ["the", 320], ["normal", 324], ["conformation", 331], ["of", 344], ["alpha", 347], ["-", 352], ["synuclein", 353], [",", 362], ["its", 364], ["cellular", 368], ["localization", 377], ["in", 390], ["neurons", 393], [",", 400], ["and", 402], ["the", 406], ["effects", 410], ["of", 418], ["the", 421], ["mutations", 425], ["remain", 435], ["to", 442], ["be", 445], ["determined", 448], [".", 458], ["In", 460], ["the", 463], ["present", 467], ["study", 475], [",", 480], ["we", 482], ["examine", 485], ["these", 493], ["questions", 499], ["using", 509], ["sensitive", 515], ["fluorescence", 525], ["resonance", 538], ["energy", 548], ["transfer", 555], ["techniques", 564], [".", 574], ["Transient", 576], ["transfection", 586], ["of", 599], ["alpha", 602], ["-", 607], ["synuclein", 608], ["expression", 618], ["constructs", 629], ["into", 640], ["primary", 645], ["cortical", 653], ["neurons", 662], ["and", 670], ["counterstaining", 674], ["with", 690], ["the", 695], ["lipophilic", 699], ["fluorescent", 710], ["marker", 722], [",", 728], ["DiI", 730], [",", 733], ["demonstrates", 735], ["a", 748], ["close", 750], ["association", 756], ["between", 768], ["alpha", 776], ["-", 781], ["synuclein", 782], ["and", 792], ["cellular", 796], ["membranes", 805], [".", 814], ["Both", 816], ["the", 821], ["N-", 825], ["and", 828], ["C", 832], ["-", 833], ["terminal", 834], ["regions", 843], ["of", 851], ["alpha", 854], ["-", 859], ["synuclein", 860], ["are", 870], ["tightly", 874], ["associated", 882], ["with", 893], ["membranes", 898], [".", 907], ["A", 909], ["weak", 911], ["interaction", 916], ["also", 928], ["occurs", 933], ["between", 940], ["the", 948], ["N", 952], ["and", 954], ["C", 958], ["termini", 960], ["themselves", 968], [".", 978], ["The", 980], ["Parkinson", 984], ["'s", 993], ["disease", 996], ["-", 1003], ["associated", 1004], ["mutations", 1015], ["have", 1025], ["no", 1030], ["effect", 1033], ["on", 1040], ["membrane", 1043], ["interaction", 1052], [";", 1063], ["however", 1065], [",", 1072], ["the", 1074], ["Ala-30", 1078], ["--", 1085], [">", 1087], ["Pro", 1089], ["mutation", 1093], ["alters", 1102], ["the", 1109], ["three", 1113], ["-", 1118], ["dimensional", 1119], ["conformation", 1131], ["of", 1144], ["alpha", 1147], ["-", 1152], ["synuclein", 1153], [",", 1162], ["as", 1164], ["measured", 1167], ["by", 1176], ["significantly", 1179], ["increased", 1193], ["fluorescence", 1203], ["resonance", 1216], ["energy", 1226], ["transfer", 1233], ["between", 1242], ["the", 1250], ["N", 1254], ["and", 1256], ["C", 1260], ["termini", 1262], [".", 1269]]}
{"context": "Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for \u223c15% of newly diagnosed cases of leukemia in adults. CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein. Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP). Clinical trials with 2nd generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be determined. For patients who fail standard-dose imatinib therapy, imatinib dose escalation is a second-line option. Alternative second-line options include 2nd generation TKIs. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. Patients who develop the T315I \"gatekeeper\" mutation display resistance to all currently available TKIs and are candidate for clinical trials. Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e71892e90a214ef1be0a9cb61da4dd09", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[217, 219], [93, 95], [105, 107], [243, 245]], "char_spans": [[1199, 1205], [536, 542], [593, 599], [1372, 1378]]}]}], "context_tokens": [["Chronic", 0], ["Myeloid", 8], ["Leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["myeloproliferative", 36], ["neoplasm", 55], ["with", 64], ["an", 69], ["incidence", 72], ["of", 82], ["one", 85], ["-", 88], ["two", 89], ["cases", 93], ["per", 99], ["100,000", 103], ["adults", 111], ["and", 118], ["accounts", 122], ["for", 131], ["\u223c15", 135], ["%", 138], ["of", 140], ["newly", 143], ["diagnosed", 149], ["cases", 159], ["of", 165], ["leukemia", 168], ["in", 177], ["adults", 180], [".", 186], ["CML", 188], ["is", 192], ["characterized", 195], ["by", 209], ["a", 212], ["balanced", 214], ["genetic", 223], ["translocation", 231], [",", 244], ["t(9;22)(q34;q11.2", 246], [")", 263], [",", 264], ["involving", 266], ["a", 276], ["fusion", 278], ["of", 285], ["the", 288], ["Abelson", 292], ["oncogene", 300], ["(", 309], ["ABL", 310], [")", 313], ["from", 315], ["chromosome", 320], ["9q34", 331], ["with", 336], ["the", 341], ["breakpoint", 345], ["cluster", 356], ["region", 364], ["(", 371], ["BCR", 372], [")", 375], ["gene", 377], ["on", 382], ["chromosome", 385], ["22q11.2", 396], [".", 403], ["This", 405], ["rearrangement", 410], ["is", 424], ["known", 427], ["as", 433], ["the", 436], ["Philadelphia", 440], ["chromosome", 453], [".", 463], ["The", 465], ["molecular", 469], ["consequence", 479], ["of", 491], ["this", 494], ["translocation", 499], ["is", 513], ["the", 516], ["generation", 520], ["of", 531], ["a", 534], ["BCR", 536], ["-", 539], ["ABL", 540], ["fusion", 544], ["oncogene", 551], [",", 559], ["which", 561], ["in", 567], ["turn", 570], ["translates", 575], ["into", 586], ["a", 591], ["Bcr", 593], ["-", 596], ["Abl", 597], ["oncoprotein", 601], [".", 612], ["Three", 614], ["tyrosine", 620], ["kinase", 629], ["inhibitors", 636], ["(", 647], ["TKIs", 648], [")", 652], [",", 653], ["imatinib", 655], [",", 663], ["nilotinib", 665], [",", 674], ["and", 676], ["dasatinib", 680], [",", 689], ["have", 691], ["been", 696], ["approved", 701], ["by", 710], ["the", 713], ["US", 717], ["Food", 720], ["and", 725], ["Drug", 729], ["Administration", 734], ["for", 749], ["the", 753], ["first", 757], ["-", 762], ["line", 763], ["treatment", 768], ["of", 778], ["patients", 781], ["with", 790], ["newly", 795], ["diagnosed", 801], ["CML", 811], ["in", 815], ["chronic", 818], ["phase", 826], ["(", 832], ["CML", 833], ["-", 836], ["CP", 837], [")", 839], [".", 840], ["Clinical", 842], ["trials", 851], ["with", 858], ["2nd", 863], ["generation", 867], ["TKIs", 878], ["reported", 883], ["significantly", 892], ["deeper", 906], ["and", 913], ["faster", 917], ["responses", 924], [";", 933], ["their", 935], ["impact", 941], ["on", 948], ["long", 951], ["-", 955], ["term", 956], ["survival", 961], ["remains", 970], ["to", 978], ["be", 981], ["determined", 984], [".", 994], ["For", 996], ["patients", 1000], ["who", 1009], ["fail", 1013], ["standard", 1018], ["-", 1026], ["dose", 1027], ["imatinib", 1032], ["therapy", 1041], [",", 1048], ["imatinib", 1050], ["dose", 1059], ["escalation", 1064], ["is", 1075], ["a", 1078], ["second", 1080], ["-", 1086], ["line", 1087], ["option", 1092], [".", 1098], ["Alternative", 1100], ["second", 1112], ["-", 1118], ["line", 1119], ["options", 1124], ["include", 1132], ["2nd", 1140], ["generation", 1144], ["TKIs", 1155], [".", 1159], ["Although", 1161], ["both", 1170], ["are", 1175], ["potent", 1179], ["and", 1186], ["specific", 1190], ["BCR", 1199], ["-", 1202], ["ABL", 1203], ["TKIs", 1207], [",", 1211], ["dasatinib", 1213], ["and", 1223], ["nilotinib", 1227], ["exhibit", 1237], ["unique", 1245], ["pharmacological", 1252], ["profiles", 1268], ["and", 1277], ["response", 1281], ["patterns", 1290], ["relative", 1299], ["to", 1308], ["different", 1311], ["patient", 1321], ["characteristics", 1329], [",", 1344], ["such", 1346], ["as", 1351], ["disease", 1354], ["stage", 1362], ["and", 1368], ["BCR", 1372], ["-", 1375], ["ABL", 1376], ["mutational", 1380], ["status", 1391], [".", 1397], ["Patients", 1399], ["who", 1408], ["develop", 1412], ["the", 1420], ["T315I", 1424], ["\"", 1430], ["gatekeeper", 1431], ["\"", 1441], ["mutation", 1443], ["display", 1452], ["resistance", 1460], ["to", 1471], ["all", 1474], ["currently", 1478], ["available", 1488], ["TKIs", 1498], ["and", 1503], ["are", 1507], ["candidate", 1511], ["for", 1521], ["clinical", 1525], ["trials", 1534], [".", 1540], ["Allogeneic", 1542], ["transplantation", 1553], ["remains", 1569], ["an", 1577], ["important", 1580], ["therapeutic", 1590], ["option", 1602], ["for", 1609], ["CML", 1613], ["-", 1616], ["CP", 1617], ["harboring", 1620], ["the", 1630], ["T315I", 1634], ["mutation", 1640], [",", 1648], ["patients", 1650], ["who", 1659], ["fail", 1663], ["2nd", 1668], ["generation", 1672], ["TKIs", 1683], [",", 1687], ["and", 1689], ["for", 1693], ["all", 1697], ["patients", 1701], ["in", 1710], ["advanced", 1713], ["phase", 1722], ["disease", 1728], [".", 1735]]}
{"context": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. A 182-kb plasmid, pXO1, carries the anthrax toxin genes and the genes responsible for their regulation of transcription, namely atxA and, pagR, the second gene of the pag operon. AtxA has major effects on the physiology of B. anthracis. It coordinates the transcription activation of the toxin genes with that of the capsule biosynthetic enzyme operon, located on the second virulence plasmid, pXO2. In rich medium, B. anthracis synthesises alternatively two S-layer proteins (Sap and EA1). An exponential phase \"Sap-layer\" is subsequently replaced by a stationary phase \"EA1-layer\". S-layer gene transcription is controlled by alternative sigma factors and by Sap acting as a transcriptional repressor of eag. Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. Only eag is significantly expressed in these conditions and this is due to AtxA activating eag and repressing sap transcription. PagR, and not AtxA itself, is the direct effector of this regulation by binding to sap and eag promoter regions. Therefore, PagR mediates the effect of AtxA on eag and sap and is the most downstream element of a signalling cascade initiated by AtxA. Taken together, these results indicate that the B. anthracis transcriptional regulator AtxA is controlling the synthesis of the three toxin components and of the surface elements (capsule and S-layer). Thus, AtxA is a master regulator that coordinates the response to host signals by orchestrating positive and negative controls over genes located on all genetic elements.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "877eabc12fb54287bc30ec4db7f37e8a", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[160, 160], [11, 11]], "char_spans": [[872, 874], [78, 80]]}]}], "context_tokens": [["Transcription", 0], ["of", 14], ["the", 17], ["major", 21], ["Bacillus", 27], ["anthracis", 36], ["virulence", 46], ["genes", 56], ["is", 62], ["triggered", 65], ["by", 75], ["CO2", 78], [",", 81], ["a", 83], ["signal", 85], ["mimicking", 92], ["the", 102], ["host", 106], ["environment", 111], [".", 122], ["A", 124], ["182-kb", 126], ["plasmid", 133], [",", 140], ["pXO1", 142], [",", 146], ["carries", 148], ["the", 156], ["anthrax", 160], ["toxin", 168], ["genes", 174], ["and", 180], ["the", 184], ["genes", 188], ["responsible", 194], ["for", 206], ["their", 210], ["regulation", 216], ["of", 227], ["transcription", 230], [",", 243], ["namely", 245], ["atxA", 252], ["and", 257], [",", 260], ["pagR", 262], [",", 266], ["the", 268], ["second", 272], ["gene", 279], ["of", 284], ["the", 287], ["pag", 291], ["operon", 295], [".", 301], ["AtxA", 303], ["has", 308], ["major", 312], ["effects", 318], ["on", 326], ["the", 329], ["physiology", 333], ["of", 344], ["B.", 347], ["anthracis", 350], [".", 359], ["It", 361], ["coordinates", 364], ["the", 376], ["transcription", 380], ["activation", 394], ["of", 405], ["the", 408], ["toxin", 412], ["genes", 418], ["with", 424], ["that", 429], ["of", 434], ["the", 437], ["capsule", 441], ["biosynthetic", 449], ["enzyme", 462], ["operon", 469], [",", 475], ["located", 477], ["on", 485], ["the", 488], ["second", 492], ["virulence", 499], ["plasmid", 509], [",", 516], ["pXO2", 518], [".", 522], ["In", 524], ["rich", 527], ["medium", 532], [",", 538], ["B.", 540], ["anthracis", 543], ["synthesises", 553], ["alternatively", 565], ["two", 579], ["S", 583], ["-", 584], ["layer", 585], ["proteins", 591], ["(", 600], ["Sap", 601], ["and", 605], ["EA1", 609], [")", 612], [".", 613], ["An", 615], ["exponential", 618], ["phase", 630], ["\"", 636], ["Sap", 637], ["-", 640], ["layer", 641], ["\"", 646], ["is", 648], ["subsequently", 651], ["replaced", 664], ["by", 673], ["a", 676], ["stationary", 678], ["phase", 689], ["\"", 695], ["EA1-layer", 696], ["\"", 705], [".", 706], ["S", 708], ["-", 709], ["layer", 710], ["gene", 716], ["transcription", 721], ["is", 735], ["controlled", 738], ["by", 749], ["alternative", 752], ["sigma", 764], ["factors", 770], ["and", 778], ["by", 782], ["Sap", 785], ["acting", 789], ["as", 796], ["a", 799], ["transcriptional", 801], ["repressor", 817], ["of", 827], ["eag", 830], [".", 833], ["Furthermore", 835], [",", 846], ["in", 848], ["vitro", 851], ["in", 857], ["presence", 860], ["of", 869], ["CO2", 872], ["and", 876], ["in", 880], ["vivo", 883], [",", 887], ["AtxA", 889], ["is", 894], ["part", 897], ["of", 902], ["the", 905], ["sap", 909], ["and", 913], ["eag", 917], ["regulatory", 921], ["network", 932], [".", 939], ["Only", 941], ["eag", 946], ["is", 950], ["significantly", 953], ["expressed", 967], ["in", 977], ["these", 980], ["conditions", 986], ["and", 997], ["this", 1001], ["is", 1006], ["due", 1009], ["to", 1013], ["AtxA", 1016], ["activating", 1021], ["eag", 1032], ["and", 1036], ["repressing", 1040], ["sap", 1051], ["transcription", 1055], [".", 1068], ["PagR", 1070], [",", 1074], ["and", 1076], ["not", 1080], ["AtxA", 1084], ["itself", 1089], [",", 1095], ["is", 1097], ["the", 1100], ["direct", 1104], ["effector", 1111], ["of", 1120], ["this", 1123], ["regulation", 1128], ["by", 1139], ["binding", 1142], ["to", 1150], ["sap", 1153], ["and", 1157], ["eag", 1161], ["promoter", 1165], ["regions", 1174], [".", 1181], ["Therefore", 1183], [",", 1192], ["PagR", 1194], ["mediates", 1199], ["the", 1208], ["effect", 1212], ["of", 1219], ["AtxA", 1222], ["on", 1227], ["eag", 1230], ["and", 1234], ["sap", 1238], ["and", 1242], ["is", 1246], ["the", 1249], ["most", 1253], ["downstream", 1258], ["element", 1269], ["of", 1277], ["a", 1280], ["signalling", 1282], ["cascade", 1293], ["initiated", 1301], ["by", 1311], ["AtxA.", 1314], ["Taken", 1320], ["together", 1326], [",", 1334], ["these", 1336], ["results", 1342], ["indicate", 1350], ["that", 1359], ["the", 1364], ["B.", 1368], ["anthracis", 1371], ["transcriptional", 1381], ["regulator", 1397], ["AtxA", 1407], ["is", 1412], ["controlling", 1415], ["the", 1427], ["synthesis", 1431], ["of", 1441], ["the", 1444], ["three", 1448], ["toxin", 1454], ["components", 1460], ["and", 1471], ["of", 1475], ["the", 1478], ["surface", 1482], ["elements", 1490], ["(", 1499], ["capsule", 1500], ["and", 1508], ["S", 1512], ["-", 1513], ["layer", 1514], [")", 1519], [".", 1520], ["Thus", 1522], [",", 1526], ["AtxA", 1528], ["is", 1533], ["a", 1536], ["master", 1538], ["regulator", 1545], ["that", 1555], ["coordinates", 1560], ["the", 1572], ["response", 1576], ["to", 1585], ["host", 1588], ["signals", 1593], ["by", 1601], ["orchestrating", 1604], ["positive", 1618], ["and", 1627], ["negative", 1631], ["controls", 1640], ["over", 1649], ["genes", 1654], ["located", 1660], ["on", 1668], ["all", 1671], ["genetic", 1675], ["elements", 1683], [".", 1691]]}
{"context": "Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML. Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported. Only a few cases so far have been reported in the literature and almost all were in females. We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes. The case described here suggests that imatinib may also induce immune hepatitis, in some patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "1db96bcfd90d49b5af28e24058364cb1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[44, 46], [67, 69]], "char_spans": [[242, 248], [391, 397]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["one", 12], ["of", 16], ["the", 19], ["most", 23], ["recent", 28], ["medications", 35], ["used", 47], ["for", 52], ["the", 56], ["treatment", 60], ["of", 70], ["chronic", 73], ["myeloid", 81], ["leukemia", 89], ["(", 98], ["CML", 99], [")", 102], ["and", 104], ["gastrointestinal", 108], ["stromal", 125], ["tumor", 133], ["(", 139], ["GIST", 140], [")", 144], [".", 145], ["It", 147], ["is", 150], ["an", 153], ["orally", 156], ["administered", 163], ["protein", 176], ["-", 183], ["tyrosine", 184], ["kinase", 193], ["inhibitor", 200], [",", 209], ["an", 211], ["enzyme", 214], ["which", 221], ["is", 227], ["produced", 230], ["by", 239], ["BCR", 242], ["-", 245], ["ABL", 246], ["fusion", 250], ["which", 257], ["results", 263], ["from", 271], ["translocation", 276], ["of", 290], ["9:22", 293], ["chromosome", 298], ["(", 309], ["Philadelphia", 310], ["chromosome", 323], [")", 333], [".", 334], ["Imatinib", 336], ["blocks", 345], ["proliferation", 352], ["and", 366], ["induces", 370], ["apoptosis", 378], ["of", 388], ["BCR", 391], ["-", 394], ["ABL", 395], ["-", 398], ["expression", 399], ["in", 410], ["CML", 413], [".", 416], ["Many", 418], ["side", 423], ["effects", 428], ["produced", 436], ["by", 445], ["imatinib", 448], ["have", 457], ["been", 462], ["documented", 467], ["but", 478], ["its", 482], ["induction", 486], ["of", 496], ["hepatotoxcity", 499], ["has", 513], ["been", 517], ["rarely", 522], ["reported", 529], [".", 537], ["Only", 539], ["a", 544], ["few", 546], ["cases", 550], ["so", 556], ["far", 559], ["have", 563], ["been", 568], ["reported", 573], ["in", 582], ["the", 585], ["literature", 589], ["and", 600], ["almost", 604], ["all", 611], ["were", 615], ["in", 620], ["females", 623], [".", 630], ["We", 632], ["describe", 635], ["another", 644], ["case", 652], ["of", 657], ["hepatotoxicity", 660], ["due", 675], ["to", 679], ["imatinib", 682], ["in", 691], ["a", 694], ["17-year", 696], ["old", 704], ["female", 708], ["with", 715], ["clinical", 720], [",", 728], ["laboratory", 730], ["and", 741], ["histopathological", 745], ["changes", 763], [".", 770], ["The", 772], ["case", 776], ["described", 781], ["here", 791], ["suggests", 796], ["that", 805], ["imatinib", 810], ["may", 819], ["also", 823], ["induce", 828], ["immune", 835], ["hepatitis", 842], [",", 851], ["in", 853], ["some", 856], ["patients", 861], [".", 869]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "The calcium-regulated protein phosphatase calcineurin (PP2B) functions as a regulator of gene expression in diverse tissues through the dephosphorylation and activation of a family of transcription factors known as nuclear factor of activated T cells (NFAT). Here we show that NFATc3, in addition to being calcium responsive, is regulated through an indirect recruitment of class II histone deacetylases (HDACs). Specifically, yeast two-hybrid screening with the rel homology domain of NFATc3 identified the chaperone mammalian relative of DnaJ (Mrj) as a specific interacting factor. Mrj and NFATc3 were shown to directly associate with one another in mammalian cells and in vitro. Mrj served as a potent inhibitor of NFAT transcriptional activity within the nucleus through a mechanism involving histone deacetylase recruitment in conjunction with heat shock stimulation. Indeed, Mrj was determined to interact with class II histone deacetylases, each of which translocated to the nucleus following heat shock stimulation. Mrj also decreased NFATc3 occupancy of the tumor necrosis factor-alpha promoter in cardiomyocytes in an HDAC-dependent manner, and Mrj blocked calcineurin-induced cardiomyocyte hypertrophic growth. Conversely, small-interfering-RNA-mediated reduction of Mrj augmented NFAT transcriptional activity and spontaneously induced cardiac myocyte growth. Collectively, our results define a novel response pathway whereby NFATc3 is negatively regulated by class II histone deacetylases through the DnaJ (heat shock protein-40) superfamily member Mrj.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "ed2c56657551418794065dae4cc3bb3c", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[196, 196], [6, 6]], "char_spans": [[1168, 1178], [42, 52]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["regulated", 12], ["protein", 22], ["phosphatase", 30], ["calcineurin", 42], ["(", 54], ["PP2B", 55], [")", 59], ["functions", 61], ["as", 71], ["a", 74], ["regulator", 76], ["of", 86], ["gene", 89], ["expression", 94], ["in", 105], ["diverse", 108], ["tissues", 116], ["through", 124], ["the", 132], ["dephosphorylation", 136], ["and", 154], ["activation", 158], ["of", 169], ["a", 172], ["family", 174], ["of", 181], ["transcription", 184], ["factors", 198], ["known", 206], ["as", 212], ["nuclear", 215], ["factor", 223], ["of", 230], ["activated", 233], ["T", 243], ["cells", 245], ["(", 251], ["NFAT", 252], [")", 256], [".", 257], ["Here", 259], ["we", 264], ["show", 267], ["that", 272], ["NFATc3", 277], [",", 283], ["in", 285], ["addition", 288], ["to", 297], ["being", 300], ["calcium", 306], ["responsive", 314], [",", 324], ["is", 326], ["regulated", 329], ["through", 339], ["an", 347], ["indirect", 350], ["recruitment", 359], ["of", 371], ["class", 374], ["II", 380], ["histone", 383], ["deacetylases", 391], ["(", 404], ["HDACs", 405], [")", 410], [".", 411], ["Specifically", 413], [",", 425], ["yeast", 427], ["two", 433], ["-", 436], ["hybrid", 437], ["screening", 444], ["with", 454], ["the", 459], ["rel", 463], ["homology", 467], ["domain", 476], ["of", 483], ["NFATc3", 486], ["identified", 493], ["the", 504], ["chaperone", 508], ["mammalian", 518], ["relative", 528], ["of", 537], ["DnaJ", 540], ["(", 545], ["Mrj", 546], [")", 549], ["as", 551], ["a", 554], ["specific", 556], ["interacting", 565], ["factor", 577], [".", 583], ["Mrj", 585], ["and", 589], ["NFATc3", 593], ["were", 600], ["shown", 605], ["to", 611], ["directly", 614], ["associate", 623], ["with", 633], ["one", 638], ["another", 642], ["in", 650], ["mammalian", 653], ["cells", 663], ["and", 669], ["in", 673], ["vitro", 676], [".", 681], ["Mrj", 683], ["served", 687], ["as", 694], ["a", 697], ["potent", 699], ["inhibitor", 706], ["of", 716], ["NFAT", 719], ["transcriptional", 724], ["activity", 740], ["within", 749], ["the", 756], ["nucleus", 760], ["through", 768], ["a", 776], ["mechanism", 778], ["involving", 788], ["histone", 798], ["deacetylase", 806], ["recruitment", 818], ["in", 830], ["conjunction", 833], ["with", 845], ["heat", 850], ["shock", 855], ["stimulation", 861], [".", 872], ["Indeed", 874], [",", 880], ["Mrj", 882], ["was", 886], ["determined", 890], ["to", 901], ["interact", 904], ["with", 913], ["class", 918], ["II", 924], ["histone", 927], ["deacetylases", 935], [",", 947], ["each", 949], ["of", 954], ["which", 957], ["translocated", 963], ["to", 976], ["the", 979], ["nucleus", 983], ["following", 991], ["heat", 1001], ["shock", 1006], ["stimulation", 1012], [".", 1023], ["Mrj", 1025], ["also", 1029], ["decreased", 1034], ["NFATc3", 1044], ["occupancy", 1051], ["of", 1061], ["the", 1064], ["tumor", 1068], ["necrosis", 1074], ["factor", 1083], ["-", 1089], ["alpha", 1090], ["promoter", 1096], ["in", 1105], ["cardiomyocytes", 1108], ["in", 1123], ["an", 1126], ["HDAC", 1129], ["-", 1133], ["dependent", 1134], ["manner", 1144], [",", 1150], ["and", 1152], ["Mrj", 1156], ["blocked", 1160], ["calcineurin", 1168], ["-", 1179], ["induced", 1180], ["cardiomyocyte", 1188], ["hypertrophic", 1202], ["growth", 1215], [".", 1221], ["Conversely", 1223], [",", 1233], ["small", 1235], ["-", 1240], ["interfering", 1241], ["-", 1252], ["RNA", 1253], ["-", 1256], ["mediated", 1257], ["reduction", 1266], ["of", 1276], ["Mrj", 1279], ["augmented", 1283], ["NFAT", 1293], ["transcriptional", 1298], ["activity", 1314], ["and", 1323], ["spontaneously", 1327], ["induced", 1341], ["cardiac", 1349], ["myocyte", 1357], ["growth", 1365], [".", 1371], ["Collectively", 1373], [",", 1385], ["our", 1387], ["results", 1391], ["define", 1399], ["a", 1406], ["novel", 1408], ["response", 1414], ["pathway", 1423], ["whereby", 1431], ["NFATc3", 1439], ["is", 1446], ["negatively", 1449], ["regulated", 1460], ["by", 1470], ["class", 1473], ["II", 1479], ["histone", 1482], ["deacetylases", 1490], ["through", 1503], ["the", 1511], ["DnaJ", 1515], ["(", 1520], ["heat", 1521], ["shock", 1526], ["protein-40", 1532], [")", 1542], ["superfamily", 1544], ["member", 1556], ["Mrj", 1563], [".", 1566]]}
{"context": "When cDNA containing proteins enriched in the bovine cerebellar cortex were cloned, a clone which seemed to encode a selenoprotein P-like protein was isolated. The coding nucleotide sequence of its cDNA insert displayed high homology to rat and human selenoprotein P cDNA but contained 12 rather than 10 TGAs (12 rather than 10 selenocysteines in deduced amino acids), a tandem repeat of one CACTCC (His-Ser) and seven CATCCCs (His-Pro), and a 3' untranslated region approximately 890 bases shorter than that of rat liver selenoprotein P. RT-PCR using a set of primers flanking to the repeat displayed the existence of mRNA without the repeat. The tandem repeat and its adjacent region consisted of a similar motif of CAC/TCC/AC/T. Thus, these proteins included a (His-Pro) rich domain with a slightly negative free energy change irrespective of having the tandem repeat or not. Such His-Pro repeats reportedly exist in the segmentation gene paired or homeobox protein Om(1D) of Drosophila. Moreover, both this selenoprotein P-like protein mRNA and selenoprotein P mRNA were expressed in all the areas of the brain but most prominently in the cerebellar cortex, hippocampus, and olfactory bulb. These findings suggest the possibility that these selenoproteins are major selenium carriers in the brain and play a role in the morphological response of nerve or glial cells.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "ac71a6d1dc574af19a94520c1b63208d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[20, 21], [100, 101], [196, 197], [43, 44], [203, 204]], "char_spans": [[117, 131], [522, 537], [1011, 1025], [251, 265], [1049, 1063]]}]}], "context_tokens": [["When", 0], ["cDNA", 5], ["containing", 10], ["proteins", 21], ["enriched", 30], ["in", 39], ["the", 42], ["bovine", 46], ["cerebellar", 53], ["cortex", 64], ["were", 71], ["cloned", 76], [",", 82], ["a", 84], ["clone", 86], ["which", 92], ["seemed", 98], ["to", 105], ["encode", 108], ["a", 115], ["selenoprotein", 117], ["P", 131], ["-", 132], ["like", 133], ["protein", 138], ["was", 146], ["isolated", 150], [".", 158], ["The", 160], ["coding", 164], ["nucleotide", 171], ["sequence", 182], ["of", 191], ["its", 194], ["cDNA", 198], ["insert", 203], ["displayed", 210], ["high", 220], ["homology", 225], ["to", 234], ["rat", 237], ["and", 241], ["human", 245], ["selenoprotein", 251], ["P", 265], ["cDNA", 267], ["but", 272], ["contained", 276], ["12", 286], ["rather", 289], ["than", 296], ["10", 301], ["TGAs", 304], ["(", 309], ["12", 310], ["rather", 313], ["than", 320], ["10", 325], ["selenocysteines", 328], ["in", 344], ["deduced", 347], ["amino", 355], ["acids", 361], [")", 366], [",", 367], ["a", 369], ["tandem", 371], ["repeat", 378], ["of", 385], ["one", 388], ["CACTCC", 392], ["(", 399], ["His", 400], ["-", 403], ["Ser", 404], [")", 407], ["and", 409], ["seven", 413], ["CATCCCs", 419], ["(", 427], ["His", 428], ["-", 431], ["Pro", 432], [")", 435], [",", 436], ["and", 438], ["a", 442], ["3", 444], ["'", 445], ["untranslated", 447], ["region", 460], ["approximately", 467], ["890", 481], ["bases", 485], ["shorter", 491], ["than", 499], ["that", 504], ["of", 509], ["rat", 512], ["liver", 516], ["selenoprotein", 522], ["P.", 536], ["RT", 539], ["-", 541], ["PCR", 542], ["using", 546], ["a", 552], ["set", 554], ["of", 558], ["primers", 561], ["flanking", 569], ["to", 578], ["the", 581], ["repeat", 585], ["displayed", 592], ["the", 602], ["existence", 606], ["of", 616], ["mRNA", 619], ["without", 624], ["the", 632], ["repeat", 636], [".", 642], ["The", 644], ["tandem", 648], ["repeat", 655], ["and", 662], ["its", 666], ["adjacent", 670], ["region", 679], ["consisted", 686], ["of", 696], ["a", 699], ["similar", 701], ["motif", 709], ["of", 715], ["CAC", 718], ["/", 721], ["TCC", 722], ["/", 725], ["AC", 726], ["/", 728], ["T.", 729], ["Thus", 732], [",", 736], ["these", 738], ["proteins", 744], ["included", 753], ["a", 762], ["(", 764], ["His", 765], ["-", 768], ["Pro", 769], [")", 772], ["rich", 774], ["domain", 779], ["with", 786], ["a", 791], ["slightly", 793], ["negative", 802], ["free", 811], ["energy", 816], ["change", 823], ["irrespective", 830], ["of", 843], ["having", 846], ["the", 853], ["tandem", 857], ["repeat", 864], ["or", 871], ["not", 874], [".", 877], ["Such", 879], ["His", 884], ["-", 887], ["Pro", 888], ["repeats", 892], ["reportedly", 900], ["exist", 911], ["in", 917], ["the", 920], ["segmentation", 924], ["gene", 937], ["paired", 942], ["or", 949], ["homeobox", 952], ["protein", 961], ["Om(1D", 969], [")", 974], ["of", 976], ["Drosophila", 979], [".", 989], ["Moreover", 991], [",", 999], ["both", 1001], ["this", 1006], ["selenoprotein", 1011], ["P", 1025], ["-", 1026], ["like", 1027], ["protein", 1032], ["mRNA", 1040], ["and", 1045], ["selenoprotein", 1049], ["P", 1063], ["mRNA", 1065], ["were", 1070], ["expressed", 1075], ["in", 1085], ["all", 1088], ["the", 1092], ["areas", 1096], ["of", 1102], ["the", 1105], ["brain", 1109], ["but", 1115], ["most", 1119], ["prominently", 1124], ["in", 1136], ["the", 1139], ["cerebellar", 1143], ["cortex", 1154], [",", 1160], ["hippocampus", 1162], [",", 1173], ["and", 1175], ["olfactory", 1179], ["bulb", 1189], [".", 1193], ["These", 1195], ["findings", 1201], ["suggest", 1210], ["the", 1218], ["possibility", 1222], ["that", 1234], ["these", 1239], ["selenoproteins", 1245], ["are", 1260], ["major", 1264], ["selenium", 1270], ["carriers", 1279], ["in", 1288], ["the", 1291], ["brain", 1295], ["and", 1301], ["play", 1305], ["a", 1310], ["role", 1312], ["in", 1317], ["the", 1320], ["morphological", 1324], ["response", 1338], ["of", 1347], ["nerve", 1350], ["or", 1356], ["glial", 1359], ["cells", 1365], [".", 1370]]}
{"context": "During the recent cloning of the mouse Lyst gene we developed both a high-resolution genetic map and a complete YAC and BAC contig of the Lyst critical region on mouse Chromosome 13. We also report the mapping of the human homologue of the mouse Lyst gene (LYST) to 1q43. These data are consistent with LYST being the gene for the human Chediak-Higashi Syndrome and strengthen the synteny relationship between MMU13 and human 1q43.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "d77f93b7ab7a49efbb741987986a7418", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[67, 70]], "char_spans": [[337, 360]]}]}], "context_tokens": [["During", 0], ["the", 7], ["recent", 11], ["cloning", 18], ["of", 26], ["the", 29], ["mouse", 33], ["Lyst", 39], ["gene", 44], ["we", 49], ["developed", 52], ["both", 62], ["a", 67], ["high", 69], ["-", 73], ["resolution", 74], ["genetic", 85], ["map", 93], ["and", 97], ["a", 101], ["complete", 103], ["YAC", 112], ["and", 116], ["BAC", 120], ["contig", 124], ["of", 131], ["the", 134], ["Lyst", 138], ["critical", 143], ["region", 152], ["on", 159], ["mouse", 162], ["Chromosome", 168], ["13", 179], [".", 181], ["We", 183], ["also", 186], ["report", 191], ["the", 198], ["mapping", 202], ["of", 210], ["the", 213], ["human", 217], ["homologue", 223], ["of", 233], ["the", 236], ["mouse", 240], ["Lyst", 246], ["gene", 251], ["(", 256], ["LYST", 257], [")", 261], ["to", 263], ["1q43", 266], [".", 270], ["These", 272], ["data", 278], ["are", 283], ["consistent", 287], ["with", 298], ["LYST", 303], ["being", 308], ["the", 314], ["gene", 318], ["for", 323], ["the", 327], ["human", 331], ["Chediak", 337], ["-", 344], ["Higashi", 345], ["Syndrome", 353], ["and", 362], ["strengthen", 366], ["the", 377], ["synteny", 381], ["relationship", 389], ["between", 402], ["MMU13", 410], ["and", 416], ["human", 420], ["1q43", 426], [".", 430]]}
{"context": "The members of the NOX family of enzymes are expressed in a variety of tissues and serve a number of functions. There is a high level of conservation of primary protein sequence, as well as functional features, although specialized responses are beginning to emerge. In this context, our data demonstrate that the NOX1 cytoplasmic domains interact efficiently with the cytoplasmic subunits of the phagocyte NADPH oxidase and identify the second cytoplasmic loop of NOX electron transporters as a crucial domain for enzyme function. Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1. Finally, we have provided the first example of how alternative splicing of a NOX co-factor may be involved in the regulation of NADPH oxidase function.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d9e22d6ebaa441090217077e2711e57", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[104, 104], [57, 57]], "char_spans": [[613, 616], [314, 317]]}]}], "context_tokens": [["The", 0], ["members", 4], ["of", 12], ["the", 15], ["NOX", 19], ["family", 23], ["of", 30], ["enzymes", 33], ["are", 41], ["expressed", 45], ["in", 55], ["a", 58], ["variety", 60], ["of", 68], ["tissues", 71], ["and", 79], ["serve", 83], ["a", 89], ["number", 91], ["of", 98], ["functions", 101], [".", 110], ["There", 112], ["is", 118], ["a", 121], ["high", 123], ["level", 128], ["of", 134], ["conservation", 137], ["of", 150], ["primary", 153], ["protein", 161], ["sequence", 169], [",", 177], ["as", 179], ["well", 182], ["as", 187], ["functional", 190], ["features", 201], [",", 209], ["although", 211], ["specialized", 220], ["responses", 232], ["are", 242], ["beginning", 246], ["to", 256], ["emerge", 259], [".", 265], ["In", 267], ["this", 270], ["context", 275], [",", 282], ["our", 284], ["data", 288], ["demonstrate", 293], ["that", 305], ["the", 310], ["NOX1", 314], ["cytoplasmic", 319], ["domains", 331], ["interact", 339], ["efficiently", 348], ["with", 360], ["the", 365], ["cytoplasmic", 369], ["subunits", 381], ["of", 390], ["the", 393], ["phagocyte", 397], ["NADPH", 407], ["oxidase", 413], ["and", 421], ["identify", 425], ["the", 434], ["second", 438], ["cytoplasmic", 445], ["loop", 457], ["of", 462], ["NOX", 465], ["electron", 469], ["transporters", 478], ["as", 491], ["a", 494], ["crucial", 496], ["domain", 504], ["for", 511], ["enzyme", 515], ["function", 522], [".", 530], ["Studies", 532], ["of", 540], ["cytosolic", 543], ["co", 553], ["-", 555], ["factors", 556], ["showed", 564], ["that", 571], ["the", 576], ["C", 580], ["-", 581], ["terminal", 582], ["cytoplasmic", 591], ["domain", 603], ["of", 610], ["NOX1", 613], ["was", 618], ["absolutely", 622], ["required", 633], ["for", 642], ["activation", 646], ["with", 657], ["NOXO1", 662], ["and", 668], ["NOXA1", 672], ["and", 678], ["that", 682], ["this", 687], ["activity", 692], ["required", 701], ["interaction", 710], ["of", 722], ["the", 725], ["putative", 729], ["NADPH", 738], ["-", 743], ["binding", 744], ["region", 752], ["of", 759], ["this", 762], ["domain", 767], ["with", 774], ["NOXA1", 779], [".", 784], ["Finally", 786], [",", 793], ["we", 795], ["have", 798], ["provided", 803], ["the", 812], ["first", 816], ["example", 822], ["of", 830], ["how", 833], ["alternative", 837], ["splicing", 849], ["of", 858], ["a", 861], ["NOX", 863], ["co", 867], ["-", 869], ["factor", 870], ["may", 877], ["be", 881], ["involved", 884], ["in", 893], ["the", 896], ["regulation", 900], ["of", 911], ["NADPH", 914], ["oxidase", 920], ["function", 928], [".", 936]]}
{"context": "The identification of the alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein as a component of Lewy bodies has heralded a new era in the study of Parkinson's disease. We have identified a large family with Lewy body parkinsonism linked to a novel locus on chromosome 4p15 that does not have a mutation in the alpha-synuclein gene. Here we report the clinical and neuropathological findings in an individual from this family and describe unusual high molecular weight alpha-synuclein-immunoreactive proteins in brain homogenates from brain regions with the most marked neuropathology. Distinctive histopathology was revealed with alpha-synuclein immunostaining, including pleomorphic Lewy bodies, synuclein-positive glial inclusions and widespread, severe neuritic dystrophy. We also discuss the relationship of this familial disorder to a Lewy body disease clinical spectrum, ranging from Parkinson's disease to dementia with psychosis.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "89d94b385eb34bc8ba92ccfb2605442f", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[22, 24], [70, 72], [118, 120], [4, 6], [95, 97]], "char_spans": [[118, 132], [366, 380], [686, 700], [26, 40], [524, 538]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["alpha", 26], ["-", 31], ["synuclein", 32], ["gene", 42], ["on", 47], ["chromosome", 50], ["4q", 61], ["as", 64], ["a", 67], ["locus", 69], ["for", 75], ["familial", 79], ["Lewy", 88], ["-", 92], ["body", 93], ["parkinsonism", 98], ["and", 111], ["of", 115], ["alpha", 118], ["-", 123], ["synuclein", 124], ["as", 134], ["a", 137], ["component", 139], ["of", 149], ["Lewy", 152], ["bodies", 157], ["has", 164], ["heralded", 168], ["a", 177], ["new", 179], ["era", 183], ["in", 187], ["the", 190], ["study", 194], ["of", 200], ["Parkinson", 203], ["'s", 212], ["disease", 215], [".", 222], ["We", 224], ["have", 227], ["identified", 232], ["a", 243], ["large", 245], ["family", 251], ["with", 258], ["Lewy", 263], ["body", 268], ["parkinsonism", 273], ["linked", 286], ["to", 293], ["a", 296], ["novel", 298], ["locus", 304], ["on", 310], ["chromosome", 313], ["4p15", 324], ["that", 329], ["does", 334], ["not", 339], ["have", 343], ["a", 348], ["mutation", 350], ["in", 359], ["the", 362], ["alpha", 366], ["-", 371], ["synuclein", 372], ["gene", 382], [".", 386], ["Here", 388], ["we", 393], ["report", 396], ["the", 403], ["clinical", 407], ["and", 416], ["neuropathological", 420], ["findings", 438], ["in", 447], ["an", 450], ["individual", 453], ["from", 464], ["this", 469], ["family", 474], ["and", 481], ["describe", 485], ["unusual", 494], ["high", 502], ["molecular", 507], ["weight", 517], ["alpha", 524], ["-", 529], ["synuclein", 530], ["-", 539], ["immunoreactive", 540], ["proteins", 555], ["in", 564], ["brain", 567], ["homogenates", 573], ["from", 585], ["brain", 590], ["regions", 596], ["with", 604], ["the", 609], ["most", 613], ["marked", 618], ["neuropathology", 625], [".", 639], ["Distinctive", 641], ["histopathology", 653], ["was", 668], ["revealed", 672], ["with", 681], ["alpha", 686], ["-", 691], ["synuclein", 692], ["immunostaining", 702], [",", 716], ["including", 718], ["pleomorphic", 728], ["Lewy", 740], ["bodies", 745], [",", 751], ["synuclein", 753], ["-", 762], ["positive", 763], ["glial", 772], ["inclusions", 778], ["and", 789], ["widespread", 793], [",", 803], ["severe", 805], ["neuritic", 812], ["dystrophy", 821], [".", 830], ["We", 832], ["also", 835], ["discuss", 840], ["the", 848], ["relationship", 852], ["of", 865], ["this", 868], ["familial", 873], ["disorder", 882], ["to", 891], ["a", 894], ["Lewy", 896], ["body", 901], ["disease", 906], ["clinical", 914], ["spectrum", 923], [",", 931], ["ranging", 933], ["from", 941], ["Parkinson", 946], ["'s", 955], ["disease", 958], ["to", 966], ["dementia", 969], ["with", 978], ["psychosis", 983], [".", 992]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "db82e6a831de4a5e9ce53368a088128a", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[0, 7]], "char_spans": [[0, 43]]}]}], "context_tokens": [["Epidermal", 0], ["growth", 10], ["factor", 17], ["receptor", 24], ["(", 33], ["EGFR", 34], [")", 38], ["gene", 40], ["mutations", 45], ["have", 55], ["been", 60], ["found", 65], ["in", 71], ["a", 74], ["subset", 76], ["of", 83], ["non", 86], ["-", 89], ["small", 90], ["cell", 96], ["lung", 101], ["cancer", 106], ["(", 113], ["NSCLC", 114], [")", 119], ["with", 121], ["good", 126], ["clinical", 131], ["response", 140], ["to", 149], ["gefitinib", 152], ["therapy", 162], [".", 169], ["A", 171], ["quick", 173], ["and", 179], ["sensitive", 183], ["method", 193], ["with", 200], ["large", 205], ["throughput", 211], ["is", 222], ["required", 225], ["to", 234], ["utilize", 237], ["the", 245], ["information", 249], ["to", 261], ["determine", 264], ["whether", 274], ["the", 282], ["molecular", 286], ["targeted", 296], ["therapy", 305], ["should", 313], ["be", 320], ["applied", 323], ["for", 331], ["the", 335], ["particular", 339], ["NSCLC", 350], ["patients", 356], [".", 364], ["Using", 366], ["probes", 372], ["for", 379], ["the", 383], ["13", 387], ["different", 390], ["mutations", 400], ["including", 410], ["11", 420], ["that", 423], ["have", 428], ["already", 433], ["been", 441], ["reported", 446], [",", 454], ["we", 456], ["have", 459], ["genotyped", 464], ["the", 474], ["EGFR", 478], ["mutation", 483], ["status", 492], ["in", 499], ["94", 502], ["NSCLC", 505], ["patients", 511], ["using", 520], ["the", 526], ["TaqMan", 530], ["PCR", 537], ["assay", 541], [".", 546], ["We", 548], ["have", 551], ["also", 556], ["genotyped", 561], ["the", 571], ["EGFR", 575], ["mutations", 580], ["status", 590], ["in", 597], ["additional", 600], ["182", 611], ["NSCLC", 615], ["patients", 621], [",", 629], ["as", 631], ["well", 634], ["as", 639], ["63", 642], ["gastric", 645], [",", 652], ["95", 654], ["esophagus", 657], ["and", 667], ["70", 671], ["colon", 674], ["carcinoma", 680], ["patients", 690], [".", 698], ["In", 700], ["94", 703], ["NSCLC", 706], ["samples", 712], [",", 719], ["the", 721], ["result", 725], ["of", 732], ["the", 735], ["TaqMan", 739], ["PCR", 746], ["assay", 750], ["perfectly", 756], ["matched", 766], ["with", 774], ["that", 779], ["of", 784], ["the", 787], ["sequencing", 791], ["excluding", 802], ["one", 812], ["patient", 816], [".", 823], ["In", 825], ["one", 828], ["sample", 832], ["in", 839], ["which", 842], ["no", 848], ["EGFR", 851], ["mutation", 856], ["was", 865], ["detected", 869], ["by", 878], ["direct", 881], ["sequencing", 888], [",", 898], ["the", 900], ["TaqMan", 904], ["PCR", 911], ["assay", 915], ["detected", 921], ["a", 930], ["mutation", 932], [".", 940], ["This", 942], ["patient", 947], ["was", 955], ["a", 959], ["gefitinib", 961], ["responder", 971], [".", 980], ["In", 982], ["a", 985], ["serial", 987], ["dilution", 994], ["study", 1003], [",", 1008], ["the", 1010], ["assay", 1014], ["could", 1020], ["detect", 1026], ["a", 1033], ["mutant", 1035], ["sample", 1042], ["diluted", 1049], ["in", 1057], ["1/10", 1060], ["with", 1065], ["a", 1070], ["wild", 1072], ["-", 1076], ["type", 1077], ["sample", 1082], [".", 1088], ["Of", 1090], ["182", 1093], ["NSCLC", 1097], ["samples", 1103], [",", 1110], ["46", 1112], ["mutations", 1115], ["were", 1125], ["detected", 1130], [".", 1138], ["EGFR", 1140], ["mutation", 1145], ["was", 1154], ["significantly", 1158], ["correlated", 1172], ["with", 1183], ["gender", 1188], [",", 1194], ["smoking", 1196], ["status", 1204], [",", 1210], ["pathological", 1212], ["subtypes", 1225], [",", 1233], ["and", 1235], ["differentiation", 1239], ["of", 1255], ["lung", 1258], ["cancers", 1263], [".", 1270], ["There", 1272], ["was", 1278], ["no", 1282], ["mutation", 1285], ["detected", 1294], ["by", 1303], ["the", 1306], ["TaqMan", 1310], ["PCR", 1317], ["assay", 1321], ["in", 1327], ["gastric", 1330], [",", 1337], ["esophagus", 1339], ["and", 1349], ["colon", 1353], ["carcinomas", 1359], [".", 1369], ["TaqMan", 1371], ["PCR", 1378], ["assay", 1382], ["is", 1388], ["a", 1391], ["rapid", 1393], ["and", 1399], ["sensitive", 1403], ["method", 1413], ["of", 1420], ["detection", 1423], ["of", 1433], ["EGFR", 1436], ["mutations", 1441], ["with", 1451], ["high", 1456], ["throughput", 1461], [",", 1471], ["and", 1473], ["may", 1477], ["be", 1481], ["useful", 1484], ["to", 1491], ["determine", 1494], ["whether", 1504], ["gefitinib", 1512], ["should", 1522], ["be", 1529], ["offered", 1532], ["for", 1540], ["the", 1544], ["treatment", 1548], ["of", 1558], ["NSCLC", 1561], ["patients", 1567], [".", 1575], ["The", 1577], ["TaqMan", 1581], ["PCR", 1588], ["assay", 1592], ["can", 1598], ["offer", 1602], ["us", 1608], ["a", 1611], ["complementary", 1613], ["and", 1627], ["confirmative", 1631], ["test", 1644], [".", 1648]]}
{"context": "McLeod syndrome is caused by mutations of XK, an X-chromosomal gene of unknown function. Originally defined as a peculiar Kell blood group variant, the disease affects multiple organs, including the nervous system, but is certainly underdiagnosed. We analyzed the mutations and clinical findings of 22 affected men, aged 27 to 72 years. Fifteen different XK mutations were found, nine of which were novel, including the one of the eponymous case McLeod. Their common result is predicted absence or truncation of the XK protein. All patients showed elevated levels of muscle creatine phosphokinase, but clinical myopathy was less common. A peripheral neuropathy with areflexia was found in all but 2 patients. The central nervous system was affected in 15 patients, as obvious from the occurrence of seizures, cognitive impairment, psychopathology, and choreatic movements. Neuroimaging emphasized the particular involvement of the basal ganglia, which was also detected in 1 asymptomatic young patient. Most features develop with age, mainly after the fourth decade. The resemblance of McLeod syndrome with Huntington's disease and with autosomal recessive chorea-acanthocytosis suggests that the corresponding proteins--XK, huntingtin, and chorein--might belong to a common pathway, the dysfunction of which causes degeneration of the basal ganglia.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "8f600aec47fb4b109b628824fc85d81f", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[64, 64], [208, 208], [7, 7], [94, 94]], "char_spans": [[355, 356], [1221, 1222], [42, 43], [516, 517]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["caused", 19], ["by", 26], ["mutations", 29], ["of", 39], ["XK", 42], [",", 44], ["an", 46], ["X", 49], ["-", 50], ["chromosomal", 51], ["gene", 63], ["of", 68], ["unknown", 71], ["function", 79], [".", 87], ["Originally", 89], ["defined", 100], ["as", 108], ["a", 111], ["peculiar", 113], ["Kell", 122], ["blood", 127], ["group", 133], ["variant", 139], [",", 146], ["the", 148], ["disease", 152], ["affects", 160], ["multiple", 168], ["organs", 177], [",", 183], ["including", 185], ["the", 195], ["nervous", 199], ["system", 207], [",", 213], ["but", 215], ["is", 219], ["certainly", 222], ["underdiagnosed", 232], [".", 246], ["We", 248], ["analyzed", 251], ["the", 260], ["mutations", 264], ["and", 274], ["clinical", 278], ["findings", 287], ["of", 296], ["22", 299], ["affected", 302], ["men", 311], [",", 314], ["aged", 316], ["27", 321], ["to", 324], ["72", 327], ["years", 330], [".", 335], ["Fifteen", 337], ["different", 345], ["XK", 355], ["mutations", 358], ["were", 368], ["found", 373], [",", 378], ["nine", 380], ["of", 385], ["which", 388], ["were", 394], ["novel", 399], [",", 404], ["including", 406], ["the", 416], ["one", 420], ["of", 424], ["the", 427], ["eponymous", 431], ["case", 441], ["McLeod", 446], [".", 452], ["Their", 454], ["common", 460], ["result", 467], ["is", 474], ["predicted", 477], ["absence", 487], ["or", 495], ["truncation", 498], ["of", 509], ["the", 512], ["XK", 516], ["protein", 519], [".", 526], ["All", 528], ["patients", 532], ["showed", 541], ["elevated", 548], ["levels", 557], ["of", 564], ["muscle", 567], ["creatine", 574], ["phosphokinase", 583], [",", 596], ["but", 598], ["clinical", 602], ["myopathy", 611], ["was", 620], ["less", 624], ["common", 629], [".", 635], ["A", 637], ["peripheral", 639], ["neuropathy", 650], ["with", 661], ["areflexia", 666], ["was", 676], ["found", 680], ["in", 686], ["all", 689], ["but", 693], ["2", 697], ["patients", 699], [".", 707], ["The", 709], ["central", 713], ["nervous", 721], ["system", 729], ["was", 736], ["affected", 740], ["in", 749], ["15", 752], ["patients", 755], [",", 763], ["as", 765], ["obvious", 768], ["from", 776], ["the", 781], ["occurrence", 785], ["of", 796], ["seizures", 799], [",", 807], ["cognitive", 809], ["impairment", 819], [",", 829], ["psychopathology", 831], [",", 846], ["and", 848], ["choreatic", 852], ["movements", 862], [".", 871], ["Neuroimaging", 873], ["emphasized", 886], ["the", 897], ["particular", 901], ["involvement", 912], ["of", 924], ["the", 927], ["basal", 931], ["ganglia", 937], [",", 944], ["which", 946], ["was", 952], ["also", 956], ["detected", 961], ["in", 970], ["1", 973], ["asymptomatic", 975], ["young", 988], ["patient", 994], [".", 1001], ["Most", 1003], ["features", 1008], ["develop", 1017], ["with", 1025], ["age", 1030], [",", 1033], ["mainly", 1035], ["after", 1042], ["the", 1048], ["fourth", 1052], ["decade", 1059], [".", 1065], ["The", 1067], ["resemblance", 1071], ["of", 1083], ["McLeod", 1086], ["syndrome", 1093], ["with", 1102], ["Huntington", 1107], ["'s", 1117], ["disease", 1120], ["and", 1128], ["with", 1132], ["autosomal", 1137], ["recessive", 1147], ["chorea", 1157], ["-", 1163], ["acanthocytosis", 1164], ["suggests", 1179], ["that", 1188], ["the", 1193], ["corresponding", 1197], ["proteins", 1211], ["--", 1219], ["XK", 1221], [",", 1223], ["huntingtin", 1225], [",", 1235], ["and", 1237], ["chorein", 1241], ["--", 1248], ["might", 1250], ["belong", 1256], ["to", 1263], ["a", 1266], ["common", 1268], ["pathway", 1275], [",", 1282], ["the", 1284], ["dysfunction", 1288], ["of", 1300], ["which", 1303], ["causes", 1309], ["degeneration", 1316], ["of", 1329], ["the", 1332], ["basal", 1336], ["ganglia", 1342], [".", 1349]]}
{"context": "A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission. 6,537 infants aged 6-12 wk and 8,923 children aged 5-17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from -1 to 49, respectively; corresponding ranges among infants were -10 to 1,402 and -13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively. RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa. www.ClinicalTrials.gov NCT00866619 Please see later in the article for the Editors' Summary.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "83bbfe9e1ba04ab5b0d56e7dbde01a22", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[157, 157], [259, 259], [42, 42], [325, 325], [451, 451], [469, 469], [428, 428], [409, 409], [1, 1], [216, 216], [159, 159], [257, 257], [79, 79]], "char_spans": [[663, 669], [997, 1003], [221, 227], [1336, 1342], [1977, 1983], [2069, 2075], [1868, 1874], [1772, 1778], [2, 8], [850, 856], [672, 678], [988, 994], [398, 404]]}]}], "context_tokens": [["A", 0], ["malaria", 2], ["vaccine", 10], ["could", 18], ["be", 24], ["an", 27], ["important", 30], ["addition", 40], ["to", 49], ["current", 52], ["control", 60], ["strategies", 68], [".", 78], ["We", 80], ["report", 83], ["the", 90], ["safety", 94], ["and", 101], ["vaccine", 105], ["efficacy", 113], ["(", 122], ["VE", 123], [")", 125], ["of", 127], ["the", 130], ["RTS", 134], [",", 137], ["S", 138], ["/", 139], ["AS01", 140], ["vaccine", 145], ["during", 153], ["18", 160], ["mo", 163], ["following", 166], ["vaccination", 176], ["at", 188], ["11", 191], ["African", 194], ["sites", 202], ["with", 208], ["varying", 213], ["malaria", 221], ["transmission", 229], [".", 241], ["6,537", 243], ["infants", 249], ["aged", 257], ["6", 262], ["-", 263], ["12", 264], ["wk", 267], ["and", 270], ["8,923", 274], ["children", 280], ["aged", 289], ["5", 294], ["-", 295], ["17", 296], ["mo", 299], ["were", 302], ["randomized", 307], ["to", 318], ["receive", 321], ["three", 329], ["doses", 335], ["of", 341], ["RTS", 344], [",", 347], ["S", 348], ["/", 349], ["AS01", 350], ["or", 355], ["comparator", 358], ["vaccine", 369], [".", 376], ["VE", 378], ["against", 381], ["clinical", 389], ["malaria", 398], ["in", 406], ["children", 409], ["during", 418], ["the", 425], ["18", 429], ["mo", 432], ["after", 435], ["vaccine", 441], ["dose", 449], ["3", 454], ["(", 456], ["per", 457], ["protocol", 461], [")", 469], ["was", 471], ["46", 475], ["%", 477], ["(", 479], ["95", 480], ["%", 482], ["CI", 484], ["42", 487], ["%", 489], ["to", 491], ["50", 494], ["%", 496], [")", 497], ["(", 499], ["range", 500], ["40", 506], ["%", 508], ["to", 510], ["77", 513], ["%", 515], [";", 516], ["VE", 518], [",", 520], ["p<0.01", 522], ["across", 529], ["all", 536], ["sites", 540], [")", 545], [".", 546], ["VE", 548], ["during", 551], ["the", 558], ["20", 562], ["mo", 565], ["after", 568], ["vaccine", 574], ["dose", 582], ["1", 587], ["(", 589], ["intention", 590], ["to", 600], ["treat", 603], ["[", 609], ["ITT", 610], ["]", 613], [")", 614], ["was", 616], ["45", 620], ["%", 622], ["(", 624], ["95", 625], ["%", 627], ["CI", 629], ["41", 632], ["%", 634], ["to", 636], ["49", 639], ["%", 641], [")", 642], [".", 643], ["VE", 645], ["against", 648], ["severe", 656], ["malaria", 663], [",", 670], ["malaria", 672], ["hospitalization", 680], [",", 695], ["and", 697], ["all", 701], ["-", 704], ["cause", 705], ["hospitalization", 711], ["was", 727], ["34", 731], ["%", 733], ["(", 735], ["95", 736], ["%", 738], ["CI", 740], ["15", 743], ["%", 745], ["to", 747], ["48", 750], ["%", 752], [")", 753], [",", 754], ["41", 756], ["%", 758], ["(", 760], ["95", 761], ["%", 763], ["CI", 765], ["30", 768], ["%", 770], ["to", 772], ["50", 775], ["%", 777], [")", 778], [",", 779], ["and", 781], ["19", 785], ["%", 787], ["(", 789], ["95", 790], ["%", 792], ["CI", 794], ["11", 797], ["%", 799], ["to", 801], ["27", 804], ["%", 806], [")", 807], [",", 808], ["respectively", 810], ["(", 823], ["ITT", 824], [")", 827], [".", 828], ["VE", 830], ["against", 833], ["clinical", 841], ["malaria", 850], ["in", 858], ["infants", 861], ["was", 869], ["27", 873], ["%", 875], ["(", 877], ["95", 878], ["%", 880], ["CI", 882], ["20", 885], ["%", 887], ["to", 889], ["32", 892], ["%", 894], [",", 895], ["per", 897], ["protocol", 901], [";", 909], ["27", 911], ["%", 913], ["[", 915], ["95", 916], ["%", 918], ["CI", 920], ["21", 923], ["%", 925], ["to", 927], ["33", 930], ["%", 932], ["]", 933], [",", 934], ["ITT", 936], [")", 939], [",", 940], ["with", 942], ["no", 947], ["significant", 950], ["protection", 962], ["against", 973], ["severe", 981], ["malaria", 988], [",", 995], ["malaria", 997], ["hospitalization", 1005], [",", 1020], ["or", 1022], ["all", 1025], ["-", 1028], ["cause", 1029], ["hospitalization", 1035], [".", 1050], ["Post", 1052], ["-", 1056], ["vaccination", 1057], ["anti", 1069], ["-", 1073], ["circumsporozoite", 1074], ["antibody", 1091], ["geometric", 1100], ["mean", 1110], ["titer", 1115], ["varied", 1121], ["from", 1128], ["348", 1133], ["to", 1137], ["787", 1140], ["EU", 1144], ["/", 1146], ["ml", 1147], ["across", 1150], ["sites", 1157], ["in", 1163], ["children", 1166], ["and", 1175], ["from", 1179], ["117", 1184], ["to", 1188], ["335", 1191], ["EU", 1195], ["/", 1197], ["ml", 1198], ["in", 1201], ["infants", 1204], ["(", 1212], ["per", 1213], ["protocol", 1217], [")", 1225], [".", 1226], ["VE", 1228], ["waned", 1231], ["over", 1237], ["time", 1242], ["in", 1247], ["both", 1250], ["age", 1255], ["categories", 1259], ["(", 1270], ["Schoenfeld", 1271], ["residuals", 1282], ["p<0.001", 1292], [")", 1299], [".", 1300], ["The", 1302], ["number", 1306], ["of", 1313], ["clinical", 1316], ["and", 1325], ["severe", 1329], ["malaria", 1336], ["cases", 1344], ["averted", 1350], ["per", 1358], ["1,000", 1362], ["children", 1368], ["vaccinated", 1377], ["ranged", 1388], ["across", 1395], ["sites", 1402], ["from", 1408], ["37", 1413], ["to", 1416], ["2,365", 1419], ["and", 1425], ["from", 1429], ["-1", 1434], ["to", 1437], ["49", 1440], [",", 1442], ["respectively", 1444], [";", 1456], ["corresponding", 1458], ["ranges", 1472], ["among", 1479], ["infants", 1485], ["were", 1493], ["-10", 1498], ["to", 1502], ["1,402", 1505], ["and", 1511], ["-13", 1515], ["to", 1519], ["37", 1522], [",", 1524], ["respectively", 1526], ["(", 1539], ["ITT", 1540], [")", 1543], [".", 1544], ["Meningitis", 1546], ["was", 1557], ["reported", 1561], ["as", 1570], ["a", 1573], ["serious", 1575], ["adverse", 1583], ["event", 1591], ["in", 1597], ["16/5,949", 1600], ["and", 1609], ["1/2,974", 1613], ["children", 1621], ["and", 1630], ["in", 1634], ["9/4,358", 1637], ["and", 1645], ["3/2,179", 1649], ["infants", 1657], ["in", 1665], ["the", 1668], ["RTS", 1672], [",", 1675], ["S", 1676], ["/", 1677], ["AS01", 1678], ["and", 1683], ["control", 1687], ["groups", 1695], [",", 1701], ["respectively", 1703], [".", 1715], ["RTS", 1717], [",", 1720], ["S", 1721], ["/", 1722], ["AS01", 1723], ["prevented", 1728], ["many", 1738], ["cases", 1743], ["of", 1749], ["clinical", 1752], ["and", 1761], ["severe", 1765], ["malaria", 1772], ["over", 1780], ["the", 1785], ["18", 1789], ["mo", 1792], ["after", 1795], ["vaccine", 1801], ["dose", 1809], ["3", 1814], [",", 1815], ["with", 1817], ["the", 1822], ["highest", 1826], ["impact", 1834], ["in", 1841], ["areas", 1844], ["with", 1850], ["the", 1855], ["greatest", 1859], ["malaria", 1868], ["incidence", 1876], [".", 1885], ["VE", 1887], ["was", 1890], ["higher", 1894], ["in", 1901], ["children", 1904], ["than", 1913], ["in", 1918], ["infants", 1921], [",", 1928], ["but", 1930], ["even", 1934], ["at", 1939], ["modest", 1942], ["levels", 1949], ["of", 1956], ["VE", 1959], [",", 1961], ["the", 1963], ["number", 1967], ["of", 1974], ["malaria", 1977], ["cases", 1985], ["averted", 1991], ["was", 1999], ["substantial", 2003], [".", 2014], ["RTS", 2016], [",", 2019], ["S", 2020], ["/", 2021], ["AS01", 2022], ["could", 2027], ["be", 2033], ["an", 2036], ["important", 2039], ["addition", 2049], ["to", 2058], ["current", 2061], ["malaria", 2069], ["control", 2077], ["in", 2085], ["Africa", 2088], [".", 2094], ["www", 2096], [".", 2099], ["ClinicalTrials.gov", 2100], ["NCT00866619", 2119], ["Please", 2131], ["see", 2138], ["later", 2142], ["in", 2148], ["the", 2151], ["article", 2155], ["for", 2163], ["the", 2167], ["Editors", 2171], ["'", 2178], ["Summary", 2180], [".", 2187]]}
{"context": "Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups IIa, V and X, which play a pivotal role in atherosclerotic disease and inflammation. Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis, whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). At the time of publication, phase II trials were ongoing in patients with acute coronary syndrome and in patients undergoing elective percutaneous coronary intervention, and a phase III trial in patients with acute coronary syndrome was planned. Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "206aa6a2af2042ff92e09f48ea2bde5f", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[5, 7]], "char_spans": [[30, 55]]}]}], "context_tokens": [["Varespladib", 0], ["methyl", 12], ["is", 19], ["an", 22], ["oral", 25], ["secretory", 30], ["phospholipase", 40], ["A2", 54], ["inhibitor", 57], ["that", 67], ["is", 72], ["being", 75], ["developed", 81], ["by", 91], ["Anthera", 94], ["Pharmaceuticals", 102], ["Inc", 118], ["for", 122], ["the", 126], ["potential", 130], ["treatment", 140], ["of", 150], ["coronary", 153], ["artery", 162], ["disease", 169], [",", 176], ["acute", 178], ["coronary", 184], ["syndrome", 193], ["and", 202], ["inflammation", 206], [".", 218], ["Varespladib", 220], ["methyl", 232], ["is", 239], ["a", 242], ["prodrug", 244], ["that", 252], ["is", 257], ["rapidly", 260], ["metabolized", 268], ["to", 280], ["varespladib", 283], [",", 294], ["and", 296], ["both", 300], ["compounds", 305], ["are", 315], ["able", 319], ["to", 324], ["potently", 327], ["inhibit", 336], ["the", 344], ["enzymes", 348], ["of", 356], ["the", 359], ["human", 363], ["secretory", 369], ["phospholipase", 379], ["groups", 393], ["IIa", 400], [",", 403], ["V", 405], ["and", 407], ["X", 411], [",", 412], ["which", 414], ["play", 420], ["a", 425], ["pivotal", 427], ["role", 435], ["in", 440], ["atherosclerotic", 443], ["disease", 459], ["and", 467], ["inflammation", 471], [".", 483], ["Phase", 485], ["II", 491], ["clinical", 494], ["trials", 503], ["of", 510], ["varespladib", 513], ["methyl", 525], ["in", 532], ["patients", 535], ["with", 544], ["coronary", 549], ["artery", 558], ["disease", 565], [",", 572], ["rheumatoid", 574], ["arthritis", 585], [",", 594], ["asthma", 596], ["and", 603], ["ulcerative", 607], ["colitis", 618], ["revealed", 626], ["that", 635], ["the", 640], ["drug", 644], ["was", 649], ["well", 653], ["tolerated", 658], [".", 667], ["Varespladib", 669], ["methyl", 681], ["did", 688], ["not", 692], ["demonstrate", 696], ["a", 708], ["good", 710], ["efficacy", 715], ["profile", 724], ["in", 732], ["patients", 735], ["with", 744], ["rheumatoid", 749], ["arthritis", 760], [",", 769], ["asthma", 771], ["and", 778], ["ulcerative", 782], ["colitis", 793], [",", 800], ["whereas", 802], ["in", 810], ["patients", 813], ["with", 822], ["coronary", 827], ["artery", 836], ["disease", 843], [",", 850], ["varespladib", 852], ["methyl", 864], ["consistently", 871], ["reduced", 884], ["LDL", 892], ["-", 895], ["cholesterol", 896], ["levels", 908], ["(", 915], ["elevated", 916], ["LDL", 925], ["-", 928], ["cholesterol", 929], ["levels", 941], ["are", 948], ["a", 952], ["marker", 954], ["of", 961], ["increased", 964], ["cardiovascular", 974], ["risk", 989], [")", 993], [".", 994], ["At", 996], ["the", 999], ["time", 1003], ["of", 1008], ["publication", 1011], [",", 1022], ["phase", 1024], ["II", 1030], ["trials", 1033], ["were", 1040], ["ongoing", 1045], ["in", 1053], ["patients", 1056], ["with", 1065], ["acute", 1070], ["coronary", 1076], ["syndrome", 1085], ["and", 1094], ["in", 1098], ["patients", 1101], ["undergoing", 1110], ["elective", 1121], ["percutaneous", 1130], ["coronary", 1143], ["intervention", 1152], [",", 1164], ["and", 1166], ["a", 1170], ["phase", 1172], ["III", 1178], ["trial", 1182], ["in", 1188], ["patients", 1191], ["with", 1200], ["acute", 1205], ["coronary", 1211], ["syndrome", 1220], ["was", 1229], ["planned", 1233], [".", 1240], ["Varespladib", 1242], ["methyl", 1254], ["could", 1261], ["represent", 1267], ["a", 1277], ["novel", 1279], ["therapy", 1285], ["for", 1293], ["the", 1297], ["treatment", 1301], ["of", 1311], ["cardiovascular", 1314], ["disease", 1329], [",", 1336], ["although", 1338], ["the", 1347], ["efficacy", 1351], [",", 1359], ["safety", 1361], ["profile", 1368], ["and", 1376], ["advantages", 1380], ["of", 1391], ["this", 1394], ["drug", 1399], ["compared", 1404], ["with", 1413], ["existing", 1418], ["therapeutic", 1427], ["options", 1439], ["would", 1447], ["need", 1453], ["to", 1458], ["be", 1461], ["established", 1464], ["in", 1476], ["upcoming", 1479], ["phase", 1488], ["III", 1494], ["trials", 1498], [".", 1504]]}
{"context": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. The index case presented with an exacerbation of torsades de pointes ventricular tachycardia from diuretic induced hypokalaemia, and responded to diuretic withdrawal and beta blocker therapy.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "f3e0556321574bc9984f02992df32320", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[193, 210]]}]}], "context_tokens": [["A", 0], ["family", 2], ["with", 9], ["the", 14], ["Romano", 18], ["-", 24], ["Ward", 25], ["syndrome", 30], ["is", 39], ["presented", 42], [".", 51], ["This", 53], ["family", 58], ["showed", 65], ["typical", 72], ["features", 80], ["of", 89], ["this", 92], ["syndrome", 97], ["with", 106], ["QT", 111], ["prolongation", 114], [",", 126], ["torsades", 128], ["de", 137], ["pointes", 140], ["ventricular", 148], ["tachycardia", 160], [",", 171], ["sudden", 173], ["death", 180], ["and", 186], ["an", 190], ["autosomal", 193], ["dominant", 203], ["inheritance", 212], ["pattern", 224], [".", 231], ["The", 233], ["index", 237], ["case", 243], ["presented", 248], ["with", 258], ["an", 263], ["exacerbation", 266], ["of", 279], ["torsades", 282], ["de", 291], ["pointes", 294], ["ventricular", 302], ["tachycardia", 314], ["from", 326], ["diuretic", 331], ["induced", 340], ["hypokalaemia", 348], [",", 360], ["and", 362], ["responded", 366], ["to", 376], ["diuretic", 379], ["withdrawal", 388], ["and", 399], ["beta", 403], ["blocker", 408], ["therapy", 416], [".", 423]]}
{"context": "Phosphorylation of cytoplasmic polyadenylation element binding protein (CPEB) regulates protein synthesis in hippocampal dendrites. CPEB binds the 3' untranslated region (UTR) of cytoplasmic mRNAs and, when phosphorylated, initiates mRNA polyadenylation and translation. We report that, of the protein kinases activated in the hippocampus during synaptic plasticity, calcium/calmodulin-dependent protein kinase II (CaMKII) robustly phosphorylated the regulatory site (threonine 171) in CPEB in vitro. In postsynaptic density fractions or hippocampal neurons, CPEB phosphorylation increased when CaMKII was activated. These increases in CPEB phosphorylation were attenuated by a specific peptide inhibitor of CaMKII and by the general CaM-kinase inhibitor KN-93. Inhibitors of protein phosphatase 1 increased basal CPEB phosphorylation in neurons; this was also attenuated by a CaM-kinase inhibitor. To determine whether CaM-kinase activity regulates CPEB-dependent mRNA translation, hippocampal neurons were transfected with luciferase fused to a 3' UTR containing CPE-binding elements. Depolarization of neurons stimulated synthesis of luciferase; this was abrogated by inhibitors of protein synthesis, mRNA polyadenylation, and CaMKII. These results demonstrate that CPEB phosphorylation and translation are regulated by CaMKII activity and provide a possible mechanism for how dendritic protein synthesis in the hippocampus may be stimulated during synaptic plasticity.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "7d3d225c01ba4d0daa3bfa2341e0caf8", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[57, 64]], "char_spans": [[367, 412]]}]}], "context_tokens": [["Phosphorylation", 0], ["of", 16], ["cytoplasmic", 19], ["polyadenylation", 31], ["element", 47], ["binding", 55], ["protein", 63], ["(", 71], ["CPEB", 72], [")", 76], ["regulates", 78], ["protein", 88], ["synthesis", 96], ["in", 106], ["hippocampal", 109], ["dendrites", 121], [".", 130], ["CPEB", 132], ["binds", 137], ["the", 143], ["3", 147], ["'", 148], ["untranslated", 150], ["region", 163], ["(", 170], ["UTR", 171], [")", 174], ["of", 176], ["cytoplasmic", 179], ["mRNAs", 191], ["and", 197], [",", 200], ["when", 202], ["phosphorylated", 207], [",", 221], ["initiates", 223], ["mRNA", 233], ["polyadenylation", 238], ["and", 254], ["translation", 258], [".", 269], ["We", 271], ["report", 274], ["that", 281], [",", 285], ["of", 287], ["the", 290], ["protein", 294], ["kinases", 302], ["activated", 310], ["in", 320], ["the", 323], ["hippocampus", 327], ["during", 339], ["synaptic", 346], ["plasticity", 355], [",", 365], ["calcium", 367], ["/", 374], ["calmodulin", 375], ["-", 385], ["dependent", 386], ["protein", 396], ["kinase", 404], ["II", 411], ["(", 414], ["CaMKII", 415], [")", 421], ["robustly", 423], ["phosphorylated", 432], ["the", 447], ["regulatory", 451], ["site", 462], ["(", 467], ["threonine", 468], ["171", 478], [")", 481], ["in", 483], ["CPEB", 486], ["in", 491], ["vitro", 494], [".", 499], ["In", 501], ["postsynaptic", 504], ["density", 517], ["fractions", 525], ["or", 535], ["hippocampal", 538], ["neurons", 550], [",", 557], ["CPEB", 559], ["phosphorylation", 564], ["increased", 580], ["when", 590], ["CaMKII", 595], ["was", 602], ["activated", 606], [".", 615], ["These", 617], ["increases", 623], ["in", 633], ["CPEB", 636], ["phosphorylation", 641], ["were", 657], ["attenuated", 662], ["by", 673], ["a", 676], ["specific", 678], ["peptide", 687], ["inhibitor", 695], ["of", 705], ["CaMKII", 708], ["and", 715], ["by", 719], ["the", 722], ["general", 726], ["CaM", 734], ["-", 737], ["kinase", 738], ["inhibitor", 745], ["KN-93", 755], [".", 760], ["Inhibitors", 762], ["of", 773], ["protein", 776], ["phosphatase", 784], ["1", 796], ["increased", 798], ["basal", 808], ["CPEB", 814], ["phosphorylation", 819], ["in", 835], ["neurons", 838], [";", 845], ["this", 847], ["was", 852], ["also", 856], ["attenuated", 861], ["by", 872], ["a", 875], ["CaM", 877], ["-", 880], ["kinase", 881], ["inhibitor", 888], [".", 897], ["To", 899], ["determine", 902], ["whether", 912], ["CaM", 920], ["-", 923], ["kinase", 924], ["activity", 931], ["regulates", 940], ["CPEB", 950], ["-", 954], ["dependent", 955], ["mRNA", 965], ["translation", 970], [",", 981], ["hippocampal", 983], ["neurons", 995], ["were", 1003], ["transfected", 1008], ["with", 1020], ["luciferase", 1025], ["fused", 1036], ["to", 1042], ["a", 1045], ["3", 1047], ["'", 1048], ["UTR", 1050], ["containing", 1054], ["CPE", 1065], ["-", 1068], ["binding", 1069], ["elements", 1077], [".", 1085], ["Depolarization", 1087], ["of", 1102], ["neurons", 1105], ["stimulated", 1113], ["synthesis", 1124], ["of", 1134], ["luciferase", 1137], [";", 1147], ["this", 1149], ["was", 1154], ["abrogated", 1158], ["by", 1168], ["inhibitors", 1171], ["of", 1182], ["protein", 1185], ["synthesis", 1193], [",", 1202], ["mRNA", 1204], ["polyadenylation", 1209], [",", 1224], ["and", 1226], ["CaMKII", 1230], [".", 1236], ["These", 1238], ["results", 1244], ["demonstrate", 1252], ["that", 1264], ["CPEB", 1269], ["phosphorylation", 1274], ["and", 1290], ["translation", 1294], ["are", 1306], ["regulated", 1310], ["by", 1320], ["CaMKII", 1323], ["activity", 1330], ["and", 1339], ["provide", 1343], ["a", 1351], ["possible", 1353], ["mechanism", 1362], ["for", 1372], ["how", 1376], ["dendritic", 1380], ["protein", 1390], ["synthesis", 1398], ["in", 1408], ["the", 1411], ["hippocampus", 1415], ["may", 1427], ["be", 1431], ["stimulated", 1434], ["during", 1445], ["synaptic", 1452], ["plasticity", 1461], [".", 1471]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce the complications associated with type 2 diabetes mellitus (T2DM). The renal sodium-glucose co-transporter 2 (SGLT2) is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors of SGLT2 lower blood glucose independent of the secretion and action of insulin by inhibiting renal reabsorption of glucose, thereby promoting the increased urinary excretion of excess glucose. Canagliflozin, dapagliflozin, and empagliflozin are SGLT2 inhibitors approved as treatments for T2DM in the United States, Europe, and other countries. Canagliflozin, dapagliflozin, and empagliflozin increase renal excretion of glucose and improve glycemic parameters in patients with T2DM when used as monotherapy or in combination with other antihyperglycemic agents. Treatment with SGLT2 inhibitors is associated with weight reduction, lowered blood pressure, and a low intrinsic propensity to cause hypoglycemia. Overall, canagliflozin, dapagliflozin, and empagliflozin are well tolerated. Cases of genital infections and, in some studies, urinary tract infections have been more frequent in canagliflozin-, dapagliflozin-, and empagliflozin-treated patients compared with those receiving placebo. Evidence from clinical trials suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "9c1cec01e81040259bbab2a5f1f03f84", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[90, 90], [249, 249], [72, 72], [126, 126], [177, 177]], "char_spans": [[549, 553], [1586, 1590], [449, 453], [792, 796], [1125, 1129]]}]}], "context_tokens": [["Although", 0], ["several", 9], ["treatment", 17], ["options", 27], ["are", 35], ["available", 39], ["to", 49], ["reduce", 52], ["hyperglycemia", 59], [",", 72], ["only", 74], ["about", 79], ["half", 85], ["of", 90], ["individuals", 93], ["with", 105], ["diagnosed", 110], ["diabetes", 120], ["mellitus", 129], ["(", 138], ["DM", 139], [")", 141], ["achieve", 143], ["recommended", 151], ["glycemic", 163], ["targets", 172], [".", 179], ["New", 181], ["agents", 185], ["that", 192], ["reduce", 197], ["blood", 204], ["glucose", 210], ["concentrations", 218], ["by", 233], ["novel", 236], ["mechanisms", 242], ["and", 253], ["have", 257], ["acceptable", 262], ["safety", 273], ["profiles", 280], ["are", 289], ["needed", 293], ["to", 300], ["improve", 303], ["glycemic", 311], ["control", 320], ["and", 328], ["reduce", 332], ["the", 339], ["complications", 343], ["associated", 357], ["with", 368], ["type", 373], ["2", 378], ["diabetes", 380], ["mellitus", 389], ["(", 398], ["T2DM", 399], [")", 403], [".", 404], ["The", 406], ["renal", 410], ["sodium", 416], ["-", 422], ["glucose", 423], ["co", 431], ["-", 433], ["transporter", 434], ["2", 446], ["(", 448], ["SGLT2", 449], [")", 454], ["is", 456], ["responsible", 459], ["for", 471], ["reabsorption", 475], ["of", 488], ["most", 491], ["of", 496], ["the", 499], ["glucose", 503], ["filtered", 511], ["by", 520], ["the", 523], ["kidney", 527], [".", 533], ["Inhibitors", 535], ["of", 546], ["SGLT2", 549], ["lower", 555], ["blood", 561], ["glucose", 567], ["independent", 575], ["of", 587], ["the", 590], ["secretion", 594], ["and", 604], ["action", 608], ["of", 615], ["insulin", 618], ["by", 626], ["inhibiting", 629], ["renal", 640], ["reabsorption", 646], ["of", 659], ["glucose", 662], [",", 669], ["thereby", 671], ["promoting", 679], ["the", 689], ["increased", 693], ["urinary", 703], ["excretion", 711], ["of", 721], ["excess", 724], ["glucose", 731], [".", 738], ["Canagliflozin", 740], [",", 753], ["dapagliflozin", 755], [",", 768], ["and", 770], ["empagliflozin", 774], ["are", 788], ["SGLT2", 792], ["inhibitors", 798], ["approved", 809], ["as", 818], ["treatments", 821], ["for", 832], ["T2DM", 836], ["in", 841], ["the", 844], ["United", 848], ["States", 855], [",", 861], ["Europe", 863], [",", 869], ["and", 871], ["other", 875], ["countries", 881], [".", 890], ["Canagliflozin", 892], [",", 905], ["dapagliflozin", 907], [",", 920], ["and", 922], ["empagliflozin", 926], ["increase", 940], ["renal", 949], ["excretion", 955], ["of", 965], ["glucose", 968], ["and", 976], ["improve", 980], ["glycemic", 988], ["parameters", 997], ["in", 1008], ["patients", 1011], ["with", 1020], ["T2DM", 1025], ["when", 1030], ["used", 1035], ["as", 1040], ["monotherapy", 1043], ["or", 1055], ["in", 1058], ["combination", 1061], ["with", 1073], ["other", 1078], ["antihyperglycemic", 1084], ["agents", 1102], [".", 1108], ["Treatment", 1110], ["with", 1120], ["SGLT2", 1125], ["inhibitors", 1131], ["is", 1142], ["associated", 1145], ["with", 1156], ["weight", 1161], ["reduction", 1168], [",", 1177], ["lowered", 1179], ["blood", 1187], ["pressure", 1193], [",", 1201], ["and", 1203], ["a", 1207], ["low", 1209], ["intrinsic", 1213], ["propensity", 1223], ["to", 1234], ["cause", 1237], ["hypoglycemia", 1243], [".", 1255], ["Overall", 1257], [",", 1264], ["canagliflozin", 1266], [",", 1279], ["dapagliflozin", 1281], [",", 1294], ["and", 1296], ["empagliflozin", 1300], ["are", 1314], ["well", 1318], ["tolerated", 1323], [".", 1332], ["Cases", 1334], ["of", 1340], ["genital", 1343], ["infections", 1351], ["and", 1362], [",", 1365], ["in", 1367], ["some", 1370], ["studies", 1375], [",", 1382], ["urinary", 1384], ["tract", 1392], ["infections", 1398], ["have", 1409], ["been", 1414], ["more", 1419], ["frequent", 1424], ["in", 1433], ["canagliflozin-", 1436], [",", 1450], ["dapagliflozin-", 1452], [",", 1466], ["and", 1468], ["empagliflozin", 1472], ["-", 1485], ["treated", 1486], ["patients", 1494], ["compared", 1503], ["with", 1512], ["those", 1517], ["receiving", 1523], ["placebo", 1533], [".", 1540], ["Evidence", 1542], ["from", 1551], ["clinical", 1556], ["trials", 1565], ["suggests", 1572], ["that", 1581], ["SGLT2", 1586], ["inhibitors", 1592], ["are", 1603], ["a", 1607], ["promising", 1609], ["new", 1619], ["treatment", 1623], ["option", 1633], ["for", 1640], ["T2DM", 1644], [".", 1648]]}
{"context": "To demonstrate the importance of preventive measures when a case of tuberculosis is detected, identify the causes that favored a tuberculosis outbreak in a school and determine the efficiency of obtaining induced sputum samples. Descriptive, study. The Santa Maria de la Providencia school, located in the municipality of Alcala de Henares in Spain. On April 11, 2005, a case of bacilliform pulmonary tuberculosis was notified in a teacher. Study of contacts in the collective was performed as a programmed intervention. Mantoux skin test and, if positive, chest radiograph were performed in contacts. Treatment of latent or active tuberculosis was recommended according to the result. School exposures were identified and underwent the Mantoux skin test (142 students in years 1, 2, 3, and 4 of compulsory secondary education and 22 teachers). The Mantoux test was positive in 68 students (48 %) and seven teachers (32 %). In seven students with results compatible with active tuberculosis disease, sputum induction was performed and treatment was started. A further two students, identified as contacts, were studied in another center and also started treatment for active tuberculosis disease. Due to the high risk of contagion, study of contacts was extended to the remaining students in compulsory secondary education. In this second phase, 134 students received the Mantoux skin test and seven were Mantoux positive (5.2 %). In all these students, active tuberculosis disease was ruled out. Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "432d404973ba41318c6fe93752543d01", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[11, 11], [21, 21], [70, 70], [210, 210], [263, 263], [270, 270], [178, 178], [110, 110]], "char_spans": [[68, 79], [129, 140], [401, 412], [1175, 1186], [1461, 1472], [1504, 1515], [978, 989], [632, 643]]}]}], "context_tokens": [["To", 0], ["demonstrate", 3], ["the", 15], ["importance", 19], ["of", 30], ["preventive", 33], ["measures", 44], ["when", 53], ["a", 58], ["case", 60], ["of", 65], ["tuberculosis", 68], ["is", 81], ["detected", 84], [",", 92], ["identify", 94], ["the", 103], ["causes", 107], ["that", 114], ["favored", 119], ["a", 127], ["tuberculosis", 129], ["outbreak", 142], ["in", 151], ["a", 154], ["school", 156], ["and", 163], ["determine", 167], ["the", 177], ["efficiency", 181], ["of", 192], ["obtaining", 195], ["induced", 205], ["sputum", 213], ["samples", 220], [".", 227], ["Descriptive", 229], [",", 240], ["study", 242], [".", 247], ["The", 249], ["Santa", 253], ["Maria", 259], ["de", 265], ["la", 268], ["Providencia", 271], ["school", 283], [",", 289], ["located", 291], ["in", 299], ["the", 302], ["municipality", 306], ["of", 319], ["Alcala", 322], ["de", 329], ["Henares", 332], ["in", 340], ["Spain", 343], [".", 348], ["On", 350], ["April", 353], ["11", 359], [",", 361], ["2005", 363], [",", 367], ["a", 369], ["case", 371], ["of", 376], ["bacilliform", 379], ["pulmonary", 391], ["tuberculosis", 401], ["was", 414], ["notified", 418], ["in", 427], ["a", 430], ["teacher", 432], [".", 439], ["Study", 441], ["of", 447], ["contacts", 450], ["in", 459], ["the", 462], ["collective", 466], ["was", 477], ["performed", 481], ["as", 491], ["a", 494], ["programmed", 496], ["intervention", 507], [".", 519], ["Mantoux", 521], ["skin", 529], ["test", 534], ["and", 539], [",", 542], ["if", 544], ["positive", 547], [",", 555], ["chest", 557], ["radiograph", 563], ["were", 574], ["performed", 579], ["in", 589], ["contacts", 592], [".", 600], ["Treatment", 602], ["of", 612], ["latent", 615], ["or", 622], ["active", 625], ["tuberculosis", 632], ["was", 645], ["recommended", 649], ["according", 661], ["to", 671], ["the", 674], ["result", 678], [".", 684], ["School", 686], ["exposures", 693], ["were", 703], ["identified", 708], ["and", 719], ["underwent", 723], ["the", 733], ["Mantoux", 737], ["skin", 745], ["test", 750], ["(", 755], ["142", 756], ["students", 760], ["in", 769], ["years", 772], ["1", 778], [",", 779], ["2", 781], [",", 782], ["3", 784], [",", 785], ["and", 787], ["4", 791], ["of", 793], ["compulsory", 796], ["secondary", 807], ["education", 817], ["and", 827], ["22", 831], ["teachers", 834], [")", 842], [".", 843], ["The", 845], ["Mantoux", 849], ["test", 857], ["was", 862], ["positive", 866], ["in", 875], ["68", 878], ["students", 881], ["(", 890], ["48", 891], ["%", 894], [")", 895], ["and", 897], ["seven", 901], ["teachers", 907], ["(", 916], ["32", 917], ["%", 920], [")", 921], [".", 922], ["In", 924], ["seven", 927], ["students", 933], ["with", 942], ["results", 947], ["compatible", 955], ["with", 966], ["active", 971], ["tuberculosis", 978], ["disease", 991], [",", 998], ["sputum", 1000], ["induction", 1007], ["was", 1017], ["performed", 1021], ["and", 1031], ["treatment", 1035], ["was", 1045], ["started", 1049], [".", 1056], ["A", 1058], ["further", 1060], ["two", 1068], ["students", 1072], [",", 1080], ["identified", 1082], ["as", 1093], ["contacts", 1096], [",", 1104], ["were", 1106], ["studied", 1111], ["in", 1119], ["another", 1122], ["center", 1130], ["and", 1137], ["also", 1141], ["started", 1146], ["treatment", 1154], ["for", 1164], ["active", 1168], ["tuberculosis", 1175], ["disease", 1188], [".", 1195], ["Due", 1197], ["to", 1201], ["the", 1204], ["high", 1208], ["risk", 1213], ["of", 1218], ["contagion", 1221], [",", 1230], ["study", 1232], ["of", 1238], ["contacts", 1241], ["was", 1250], ["extended", 1254], ["to", 1263], ["the", 1266], ["remaining", 1270], ["students", 1280], ["in", 1289], ["compulsory", 1292], ["secondary", 1303], ["education", 1313], [".", 1322], ["In", 1324], ["this", 1327], ["second", 1332], ["phase", 1339], [",", 1344], ["134", 1346], ["students", 1350], ["received", 1359], ["the", 1368], ["Mantoux", 1372], ["skin", 1380], ["test", 1385], ["and", 1390], ["seven", 1394], ["were", 1400], ["Mantoux", 1405], ["positive", 1413], ["(", 1422], ["5.2", 1423], ["%", 1427], [")", 1428], [".", 1429], ["In", 1431], ["all", 1434], ["these", 1438], ["students", 1444], [",", 1452], ["active", 1454], ["tuberculosis", 1461], ["disease", 1474], ["was", 1482], ["ruled", 1486], ["out", 1492], [".", 1495], ["Latent", 1497], ["tuberculosis", 1504], ["treatment", 1517], ["was", 1527], ["recommended", 1531], ["in", 1543], ["all", 1546], ["Mantoux", 1550], ["-", 1557], ["positive", 1558], ["contacts", 1567], [".", 1575]]}
{"context": "Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 \u03bcg were used. Bioequivalence between 8 x 200 \u03bcg and a new 1,600 \u03bcg tablet was evaluated at steady state in healthy male subjects. This was an open-label, 2-treatment, 2-period, crossover, up-titration, phase 1 study. The treatments were selexipag at 1,600 \u03bcg b.i.d. for 4.5 days either as 8 x 200 \u03bcg tablets (reference: A) or 1 x 1,600 \u03bcg tablet (test: B), both preceded by an up-titration phase starting from 400 \u03bcg b.i.d. doses, in 200-\u03bcg steps every 4th day. Subjects were randomized 1 : 1 to the A-B or B-A sequence. The pharmacokinetics and tolerability of selexipag and its active metabolite, ACT-333679, were investigated. 80 subjects were enrolled in the study: 65 subjects completed the study according to protocol, and 15 subjects withdrew from the study. The most frequent adverse events (AEs) were headache (86%), myalgia (73%), and jaw pain (73%). There was no difference in nature and overall frequency of AEs between the two treatments. Steady state was attained within 3 days of the selexipag 1,600 \u00ce\u00bcg b.i.d. The 90% confidence intervals (CIs) of the geometric mean ratio (B/A) at steady state for AUC\u00cf\u0084 and Cmax,ss were within (0.80, 1.25) bioequivalence interval: (0.92, 1.06) and (0.95, 1.14), respectively, for selexipag and (0.95, 1.06) and (0.94, 1.07), respectively, for the active metabolite, ACT-333679. Bioequivalence was demonstrated between 8 x 200 \u03bcg and 1 x 1,600 \u03bcg selexipag at steady state.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "990c3fbed6b34ba08dd9a7685e257613", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[21, 23]], "char_spans": [[120, 150]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["novel", 15], [",", 20], ["oral", 22], [",", 26], ["selective", 28], ["prostacyclin", 38], ["(", 51], ["PGI2", 52], [")", 56], ["receptor", 58], ["agonist", 67], ["in", 75], ["clinical", 78], ["development", 87], ["for", 99], ["the", 103], ["treatment", 107], ["of", 117], ["pulmonary", 120], ["arterial", 130], ["hypertension", 139], [".", 151], ["Film", 153], ["-", 157], ["coated", 158], ["tablets", 165], ["with", 173], ["strength", 178], ["between", 187], ["200", 195], ["and", 199], ["1,600", 203], ["\u03bcg", 209], ["were", 212], ["used", 217], [".", 221], ["Bioequivalence", 223], ["between", 238], ["8", 246], ["x", 248], ["200", 250], ["\u03bcg", 254], ["and", 257], ["a", 261], ["new", 263], ["1,600", 267], ["\u03bcg", 273], ["tablet", 276], ["was", 283], ["evaluated", 287], ["at", 297], ["steady", 300], ["state", 307], ["in", 313], ["healthy", 316], ["male", 324], ["subjects", 329], [".", 337], ["This", 339], ["was", 344], ["an", 348], ["open", 351], ["-", 355], ["label", 356], [",", 361], ["2-treatment", 363], [",", 374], ["2-period", 376], [",", 384], ["crossover", 386], [",", 395], ["up", 397], ["-", 399], ["titration", 400], [",", 409], ["phase", 411], ["1", 417], ["study", 419], [".", 424], ["The", 426], ["treatments", 430], ["were", 441], ["selexipag", 446], ["at", 456], ["1,600", 459], ["\u03bcg", 465], ["b.i.d", 468], [".", 473], ["for", 475], ["4.5", 479], ["days", 483], ["either", 488], ["as", 495], ["8", 498], ["x", 500], ["200", 502], ["\u03bcg", 506], ["tablets", 509], ["(", 517], ["reference", 518], [":", 527], ["A", 529], [")", 530], ["or", 532], ["1", 535], ["x", 537], ["1,600", 539], ["\u03bcg", 545], ["tablet", 548], ["(", 555], ["test", 556], [":", 560], ["B", 562], [")", 563], [",", 564], ["both", 566], ["preceded", 571], ["by", 580], ["an", 583], ["up", 586], ["-", 588], ["titration", 589], ["phase", 599], ["starting", 605], ["from", 614], ["400", 619], ["\u03bcg", 623], ["b.i.d", 626], [".", 631], ["doses", 633], [",", 638], ["in", 640], ["200-\u03bcg", 643], ["steps", 650], ["every", 656], ["4th", 662], ["day", 666], [".", 669], ["Subjects", 671], ["were", 680], ["randomized", 685], ["1", 696], [":", 698], ["1", 700], ["to", 702], ["the", 705], ["A", 709], ["-", 710], ["B", 711], ["or", 713], ["B", 716], ["-", 717], ["A", 718], ["sequence", 720], [".", 728], ["The", 730], ["pharmacokinetics", 734], ["and", 751], ["tolerability", 755], ["of", 768], ["selexipag", 771], ["and", 781], ["its", 785], ["active", 789], ["metabolite", 796], [",", 806], ["ACT-333679", 808], [",", 818], ["were", 820], ["investigated", 825], [".", 837], ["80", 839], ["subjects", 842], ["were", 851], ["enrolled", 856], ["in", 865], ["the", 868], ["study", 872], [":", 877], ["65", 879], ["subjects", 882], ["completed", 891], ["the", 901], ["study", 905], ["according", 911], ["to", 921], ["protocol", 924], [",", 932], ["and", 934], ["15", 938], ["subjects", 941], ["withdrew", 950], ["from", 959], ["the", 964], ["study", 968], [".", 973], ["The", 975], ["most", 979], ["frequent", 984], ["adverse", 993], ["events", 1001], ["(", 1008], ["AEs", 1009], [")", 1012], ["were", 1014], ["headache", 1019], ["(", 1028], ["86", 1029], ["%", 1031], [")", 1032], [",", 1033], ["myalgia", 1035], ["(", 1043], ["73", 1044], ["%", 1046], [")", 1047], [",", 1048], ["and", 1050], ["jaw", 1054], ["pain", 1058], ["(", 1063], ["73", 1064], ["%", 1066], [")", 1067], [".", 1068], ["There", 1070], ["was", 1076], ["no", 1080], ["difference", 1083], ["in", 1094], ["nature", 1097], ["and", 1104], ["overall", 1108], ["frequency", 1116], ["of", 1126], ["AEs", 1129], ["between", 1133], ["the", 1141], ["two", 1145], ["treatments", 1149], [".", 1159], ["Steady", 1161], ["state", 1168], ["was", 1174], ["attained", 1178], ["within", 1187], ["3", 1194], ["days", 1196], ["of", 1201], ["the", 1204], ["selexipag", 1208], ["1,600", 1218], ["\u00ce\u00bcg", 1224], ["b.i.d", 1228], [".", 1233], ["The", 1235], ["90", 1239], ["%", 1241], ["confidence", 1243], ["intervals", 1254], ["(", 1264], ["CIs", 1265], [")", 1268], ["of", 1270], ["the", 1273], ["geometric", 1277], ["mean", 1287], ["ratio", 1292], ["(", 1298], ["B", 1299], ["/", 1300], ["A", 1301], [")", 1302], ["at", 1304], ["steady", 1307], ["state", 1314], ["for", 1320], ["AUC\u00cf\u0084", 1324], ["and", 1330], ["Cmax", 1334], [",", 1338], ["ss", 1339], ["were", 1342], ["within", 1347], ["(", 1354], ["0.80", 1355], [",", 1359], ["1.25", 1361], [")", 1365], ["bioequivalence", 1367], ["interval", 1382], [":", 1390], ["(", 1392], ["0.92", 1393], [",", 1397], ["1.06", 1399], [")", 1403], ["and", 1405], ["(", 1409], ["0.95", 1410], [",", 1414], ["1.14", 1416], [")", 1420], [",", 1421], ["respectively", 1423], [",", 1435], ["for", 1437], ["selexipag", 1441], ["and", 1451], ["(", 1455], ["0.95", 1456], [",", 1460], ["1.06", 1462], [")", 1466], ["and", 1468], ["(", 1472], ["0.94", 1473], [",", 1477], ["1.07", 1479], [")", 1483], [",", 1484], ["respectively", 1486], [",", 1498], ["for", 1500], ["the", 1504], ["active", 1508], ["metabolite", 1515], [",", 1525], ["ACT-333679", 1527], [".", 1537], ["Bioequivalence", 1539], ["was", 1554], ["demonstrated", 1558], ["between", 1571], ["8", 1579], ["x", 1581], ["200", 1583], ["\u03bcg", 1587], ["and", 1590], ["1", 1594], ["x", 1596], ["1,600", 1598], ["\u03bcg", 1604], ["selexipag", 1607], ["at", 1617], ["steady", 1620], ["state", 1627], [".", 1632]]}
{"context": "Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world. Immune dysregulation during acute lung infection plays a role in lung injury and the systemic inflammatory response. Cytokines seem to be major players in severe lung infection cases. Here, we present a review of published papers in the last 3\u00a0years regarding this topic. The cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as CURB65 or SOFA. Treatment focused in the cytokine environment is an interesting area that could impact the prognosis of CAP. Some of the agents that have been studied as co-adjuvant therapy are corticosteroids, macrolides, and linezolid, but anyone of those have shown a clear or proven efficacy or have been recommended as a part of the standard of care for CAP. More studies designed to define the role of immunomodulatory agents, such as co-adjuvant therapy in pneumonia, are needed.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "77c8c610c2b44cfdadd28ce51c2e8c6b", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[177, 177], [3, 3], [70, 70]], "char_spans": [[984, 992], [19, 27], [391, 399]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["pneumonia", 19], ["(", 29], ["CAP", 30], [")", 33], ["is", 35], ["the", 38], ["leading", 42], ["cause", 50], ["of", 56], ["infectious", 59], ["death", 70], ["in", 76], ["the", 79], ["world", 83], [".", 88], ["Immune", 90], ["dysregulation", 97], ["during", 111], ["acute", 118], ["lung", 124], ["infection", 129], ["plays", 139], ["a", 145], ["role", 147], ["in", 152], ["lung", 155], ["injury", 160], ["and", 167], ["the", 171], ["systemic", 175], ["inflammatory", 184], ["response", 197], [".", 205], ["Cytokines", 207], ["seem", 217], ["to", 222], ["be", 225], ["major", 228], ["players", 234], ["in", 242], ["severe", 245], ["lung", 252], ["infection", 257], ["cases", 267], [".", 272], ["Here", 274], [",", 278], ["we", 280], ["present", 283], ["a", 291], ["review", 293], ["of", 300], ["published", 303], ["papers", 313], ["in", 320], ["the", 323], ["last", 327], ["3", 332], ["years", 334], ["regarding", 340], ["this", 350], ["topic", 355], [".", 360], ["The", 362], ["cytokine", 366], ["response", 375], ["during", 384], ["pneumonia", 391], ["is", 401], ["different", 404], ["in", 414], ["bacterial", 417], ["vs", 427], ["viral", 430], ["infections", 436], [";", 446], ["some", 448], ["of", 453], ["these", 456], ["cytokines", 462], ["correlate", 472], ["with", 482], ["clinical", 487], ["severity", 496], ["scales", 505], ["such", 512], ["as", 517], ["CURB65", 520], ["or", 527], ["SOFA", 530], [".", 534], ["Treatment", 536], ["focused", 546], ["in", 554], ["the", 557], ["cytokine", 561], ["environment", 570], ["is", 582], ["an", 585], ["interesting", 588], ["area", 600], ["that", 605], ["could", 610], ["impact", 616], ["the", 623], ["prognosis", 627], ["of", 637], ["CAP", 640], [".", 643], ["Some", 645], ["of", 650], ["the", 653], ["agents", 657], ["that", 664], ["have", 669], ["been", 674], ["studied", 679], ["as", 687], ["co", 690], ["-", 692], ["adjuvant", 693], ["therapy", 702], ["are", 710], ["corticosteroids", 714], [",", 729], ["macrolides", 731], [",", 741], ["and", 743], ["linezolid", 747], [",", 756], ["but", 758], ["anyone", 762], ["of", 769], ["those", 772], ["have", 778], ["shown", 783], ["a", 789], ["clear", 791], ["or", 797], ["proven", 800], ["efficacy", 807], ["or", 816], ["have", 819], ["been", 824], ["recommended", 829], ["as", 841], ["a", 844], ["part", 846], ["of", 851], ["the", 854], ["standard", 858], ["of", 867], ["care", 870], ["for", 875], ["CAP", 879], [".", 882], ["More", 884], ["studies", 889], ["designed", 897], ["to", 906], ["define", 909], ["the", 916], ["role", 920], ["of", 925], ["immunomodulatory", 928], ["agents", 945], [",", 951], ["such", 953], ["as", 958], ["co", 961], ["-", 963], ["adjuvant", 964], ["therapy", 973], ["in", 981], ["pneumonia", 984], [",", 993], ["are", 995], ["needed", 999], [".", 1005]]}
{"context": "Two different subpathways play a role in removal of UV-induced cyclobutane pyrimidine dimers (CPDs) by nucleotide excision repair (NER). The relatively slow global genome repair subpathway operates on all CPDs irrespective of their position in the DNA, whereas the transcription-coupled repair subpathway is responsible for the rapid removal of CPDs from transcribed strands. In Saccharomyces cerevisiae, the RAD26 gene is implicated in transcription-coupled repair. However, transcription-coupled repair is not completely absent in rad26 mutants, and therefore other gene products are possibly involved in this subpathway. Based on in vitro experiments with purified components, the transcription elongation factor S-II appeared to be a candidate for a function in transcription-coupled repair. To investigate a possible role of S-II in transcription-coupled repair in vivo in yeast, S-II null mutations were introduced into various genetic backgrounds differing in NER capacity. UV sensitivity was not altered by disruption of the S-II gene in a RAD+ (NER proficient) strain, or in rad26 (impaired in efficient transcription-coupled repair), rad7 (lacking global genome repair), or rad7 rad26 (lacking global genome repair, but having residual transcription-coupled repair capacity) mutants. Moreover, S-II did not influence the repair rate on the transcribed strand of the RPB2 gene, either in repair-proficient or in rad7 rad26 backgrounds. Hence, transcription-coupled repair is fully functional in yeast cells lacking the gene encoding S-II. Furthermore, S-II is not required for the Rad26-independent residual transcription-coupled repair in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "fdcb8dcef6764b62b68b68ff7284f24c", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[246, 247]], "char_spans": [[1350, 1367]]}]}], "context_tokens": [["Two", 0], ["different", 4], ["subpathways", 14], ["play", 26], ["a", 31], ["role", 33], ["in", 38], ["removal", 41], ["of", 49], ["UV", 52], ["-", 54], ["induced", 55], ["cyclobutane", 63], ["pyrimidine", 75], ["dimers", 86], ["(", 93], ["CPDs", 94], [")", 98], ["by", 100], ["nucleotide", 103], ["excision", 114], ["repair", 123], ["(", 130], ["NER", 131], [")", 134], [".", 135], ["The", 137], ["relatively", 141], ["slow", 152], ["global", 157], ["genome", 164], ["repair", 171], ["subpathway", 178], ["operates", 189], ["on", 198], ["all", 201], ["CPDs", 205], ["irrespective", 210], ["of", 223], ["their", 226], ["position", 232], ["in", 241], ["the", 244], ["DNA", 248], [",", 251], ["whereas", 253], ["the", 261], ["transcription", 265], ["-", 278], ["coupled", 279], ["repair", 287], ["subpathway", 294], ["is", 305], ["responsible", 308], ["for", 320], ["the", 324], ["rapid", 328], ["removal", 334], ["of", 342], ["CPDs", 345], ["from", 350], ["transcribed", 355], ["strands", 367], [".", 374], ["In", 376], ["Saccharomyces", 379], ["cerevisiae", 393], [",", 403], ["the", 405], ["RAD26", 409], ["gene", 415], ["is", 420], ["implicated", 423], ["in", 434], ["transcription", 437], ["-", 450], ["coupled", 451], ["repair", 459], [".", 465], ["However", 467], [",", 474], ["transcription", 476], ["-", 489], ["coupled", 490], ["repair", 498], ["is", 505], ["not", 508], ["completely", 512], ["absent", 523], ["in", 530], ["rad26", 533], ["mutants", 539], [",", 546], ["and", 548], ["therefore", 552], ["other", 562], ["gene", 568], ["products", 573], ["are", 582], ["possibly", 586], ["involved", 595], ["in", 604], ["this", 607], ["subpathway", 612], [".", 622], ["Based", 624], ["on", 630], ["in", 633], ["vitro", 636], ["experiments", 642], ["with", 654], ["purified", 659], ["components", 668], [",", 678], ["the", 680], ["transcription", 684], ["elongation", 698], ["factor", 709], ["S", 716], ["-", 717], ["II", 718], ["appeared", 721], ["to", 730], ["be", 733], ["a", 736], ["candidate", 738], ["for", 748], ["a", 752], ["function", 754], ["in", 763], ["transcription", 766], ["-", 779], ["coupled", 780], ["repair", 788], [".", 794], ["To", 796], ["investigate", 799], ["a", 811], ["possible", 813], ["role", 822], ["of", 827], ["S", 830], ["-", 831], ["II", 832], ["in", 835], ["transcription", 838], ["-", 851], ["coupled", 852], ["repair", 860], ["in", 867], ["vivo", 870], ["in", 875], ["yeast", 878], [",", 883], ["S", 885], ["-", 886], ["II", 887], ["null", 890], ["mutations", 895], ["were", 905], ["introduced", 910], ["into", 921], ["various", 926], ["genetic", 934], ["backgrounds", 942], ["differing", 954], ["in", 964], ["NER", 967], ["capacity", 971], [".", 979], ["UV", 981], ["sensitivity", 984], ["was", 996], ["not", 1000], ["altered", 1004], ["by", 1012], ["disruption", 1015], ["of", 1026], ["the", 1029], ["S", 1033], ["-", 1034], ["II", 1035], ["gene", 1038], ["in", 1043], ["a", 1046], ["RAD+", 1048], ["(", 1053], ["NER", 1054], ["proficient", 1058], [")", 1068], ["strain", 1070], [",", 1076], ["or", 1078], ["in", 1081], ["rad26", 1084], ["(", 1090], ["impaired", 1091], ["in", 1100], ["efficient", 1103], ["transcription", 1113], ["-", 1126], ["coupled", 1127], ["repair", 1135], [")", 1141], [",", 1142], ["rad7", 1144], ["(", 1149], ["lacking", 1150], ["global", 1158], ["genome", 1165], ["repair", 1172], [")", 1178], [",", 1179], ["or", 1181], ["rad7", 1184], ["rad26", 1189], ["(", 1195], ["lacking", 1196], ["global", 1204], ["genome", 1211], ["repair", 1218], [",", 1224], ["but", 1226], ["having", 1230], ["residual", 1237], ["transcription", 1246], ["-", 1259], ["coupled", 1260], ["repair", 1268], ["capacity", 1275], [")", 1283], ["mutants", 1285], [".", 1292], ["Moreover", 1294], [",", 1302], ["S", 1304], ["-", 1305], ["II", 1306], ["did", 1309], ["not", 1313], ["influence", 1317], ["the", 1327], ["repair", 1331], ["rate", 1338], ["on", 1343], ["the", 1346], ["transcribed", 1350], ["strand", 1362], ["of", 1369], ["the", 1372], ["RPB2", 1376], ["gene", 1381], [",", 1385], ["either", 1387], ["in", 1394], ["repair", 1397], ["-", 1403], ["proficient", 1404], ["or", 1415], ["in", 1418], ["rad7", 1421], ["rad26", 1426], ["backgrounds", 1432], [".", 1443], ["Hence", 1445], [",", 1450], ["transcription", 1452], ["-", 1465], ["coupled", 1466], ["repair", 1474], ["is", 1481], ["fully", 1484], ["functional", 1490], ["in", 1501], ["yeast", 1504], ["cells", 1510], ["lacking", 1516], ["the", 1524], ["gene", 1528], ["encoding", 1533], ["S", 1542], ["-", 1543], ["II", 1544], [".", 1546], ["Furthermore", 1548], [",", 1559], ["S", 1561], ["-", 1562], ["II", 1563], ["is", 1566], ["not", 1569], ["required", 1573], ["for", 1582], ["the", 1586], ["Rad26-independent", 1590], ["residual", 1608], ["transcription", 1617], ["-", 1630], ["coupled", 1631], ["repair", 1639], ["in", 1646], ["vivo", 1649], [".", 1653]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome (t 9.22). Our main objective was to assess the efficacy of imatinib in CML patients, measured by their survival. Over a six-year period (June 2003 through May 2009), 25 patients were seen regularly for CML at the Lom\u00e9 Campus teaching hospital. Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio by RT-PCR). Patients' survival and treatment response were evaluated. Patients' mean age at diagnosis was 40 years (range: 9 to 72 years). Men predominated (17 compared with 7 women). Splenomegaly was found in 80% of cases. The mean leukocyte level was 188.71 g/L (24.4-350). Six patients (24%) had thrombocytosis with a mean platelet count of 491.15 g/L (108-2000). Six patients (24%) died after developing accelerated-phase CML or blast crisis. Estimated overall survival of patients at 6 years was 60%. Molecular biology monitoring detected a secondary G250E mutation with resistance to imatinib in one patient. Standard hematological side effects led to reduction in imatinib doses. The principal nonhematological side effects were weight gain and transient digestible disorders. At six years after diagnosis, imatinib was effective in treating patients with CML, even in sub-Saharan Africa. Mutation-induced resistance required regular molecular biological monitoring to determine the need to switch to later-generation tyrosine kinase inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5d0e918abb8649f49a8cdb096d471c53", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[88, 90]], "char_spans": [[522, 528]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["malignant", 43], ["myeloproliferative", 53], ["disorder", 72], ["characterized", 81], ["by", 95], ["the", 98], ["expansion", 102], ["of", 112], ["hematopoietic", 115], ["cells", 129], ["carrying", 135], ["the", 144], ["Philadelphia", 148], ["chromosome", 161], ["(", 172], ["t", 173], ["9.22", 175], [")", 179], [".", 180], ["Our", 182], ["main", 186], ["objective", 191], ["was", 201], ["to", 205], ["assess", 208], ["the", 215], ["efficacy", 219], ["of", 228], ["imatinib", 231], ["in", 240], ["CML", 243], ["patients", 247], [",", 255], ["measured", 257], ["by", 266], ["their", 269], ["survival", 275], [".", 283], ["Over", 285], ["a", 290], ["six", 292], ["-", 295], ["year", 296], ["period", 301], ["(", 308], ["June", 309], ["2003", 314], ["through", 319], ["May", 327], ["2009", 331], [")", 335], [",", 336], ["25", 338], ["patients", 341], ["were", 350], ["seen", 355], ["regularly", 360], ["for", 370], ["CML", 374], ["at", 378], ["the", 381], ["Lom\u00e9", 385], ["Campus", 390], ["teaching", 397], ["hospital", 406], [".", 414], ["Patients", 416], ["received", 425], ["imatinib", 434], ["after", 443], ["diagnosis", 449], ["and", 459], ["underwent", 463], ["regular", 473], ["laboratory", 481], ["monitoring", 492], ["(", 503], ["quantification", 504], ["of", 519], ["BCR", 522], ["-", 525], ["ABL", 526], ["ratio", 530], ["by", 536], ["RT", 539], ["-", 541], ["PCR", 542], [")", 545], [".", 546], ["Patients", 548], ["'", 556], ["survival", 558], ["and", 567], ["treatment", 571], ["response", 581], ["were", 590], ["evaluated", 595], [".", 604], ["Patients", 606], ["'", 614], ["mean", 616], ["age", 621], ["at", 625], ["diagnosis", 628], ["was", 638], ["40", 642], ["years", 645], ["(", 651], ["range", 652], [":", 657], ["9", 659], ["to", 661], ["72", 664], ["years", 667], [")", 672], [".", 673], ["Men", 675], ["predominated", 679], ["(", 692], ["17", 693], ["compared", 696], ["with", 705], ["7", 710], ["women", 712], [")", 717], [".", 718], ["Splenomegaly", 720], ["was", 733], ["found", 737], ["in", 743], ["80", 746], ["%", 748], ["of", 750], ["cases", 753], [".", 758], ["The", 760], ["mean", 764], ["leukocyte", 769], ["level", 779], ["was", 785], ["188.71", 789], ["g", 796], ["/", 797], ["L", 798], ["(", 800], ["24.4", 801], ["-", 805], ["350", 806], [")", 809], [".", 810], ["Six", 812], ["patients", 816], ["(", 825], ["24", 826], ["%", 828], [")", 829], ["had", 831], ["thrombocytosis", 835], ["with", 850], ["a", 855], ["mean", 857], ["platelet", 862], ["count", 871], ["of", 877], ["491.15", 880], ["g", 887], ["/", 888], ["L", 889], ["(", 891], ["108", 892], ["-", 895], ["2000", 896], [")", 900], [".", 901], ["Six", 903], ["patients", 907], ["(", 916], ["24", 917], ["%", 919], [")", 920], ["died", 922], ["after", 927], ["developing", 933], ["accelerated", 944], ["-", 955], ["phase", 956], ["CML", 962], ["or", 966], ["blast", 969], ["crisis", 975], [".", 981], ["Estimated", 983], ["overall", 993], ["survival", 1001], ["of", 1010], ["patients", 1013], ["at", 1022], ["6", 1025], ["years", 1027], ["was", 1033], ["60", 1037], ["%", 1039], [".", 1040], ["Molecular", 1042], ["biology", 1052], ["monitoring", 1060], ["detected", 1071], ["a", 1080], ["secondary", 1082], ["G250E", 1092], ["mutation", 1098], ["with", 1107], ["resistance", 1112], ["to", 1123], ["imatinib", 1126], ["in", 1135], ["one", 1138], ["patient", 1142], [".", 1149], ["Standard", 1151], ["hematological", 1160], ["side", 1174], ["effects", 1179], ["led", 1187], ["to", 1191], ["reduction", 1194], ["in", 1204], ["imatinib", 1207], ["doses", 1216], [".", 1221], ["The", 1223], ["principal", 1227], ["nonhematological", 1237], ["side", 1254], ["effects", 1259], ["were", 1267], ["weight", 1272], ["gain", 1279], ["and", 1284], ["transient", 1288], ["digestible", 1298], ["disorders", 1309], [".", 1318], ["At", 1320], ["six", 1323], ["years", 1327], ["after", 1333], ["diagnosis", 1339], [",", 1348], ["imatinib", 1350], ["was", 1359], ["effective", 1363], ["in", 1373], ["treating", 1376], ["patients", 1385], ["with", 1394], ["CML", 1399], [",", 1402], ["even", 1404], ["in", 1409], ["sub", 1412], ["-", 1415], ["Saharan", 1416], ["Africa", 1424], [".", 1430], ["Mutation", 1432], ["-", 1440], ["induced", 1441], ["resistance", 1449], ["required", 1460], ["regular", 1469], ["molecular", 1477], ["biological", 1487], ["monitoring", 1498], ["to", 1509], ["determine", 1512], ["the", 1522], ["need", 1526], ["to", 1531], ["switch", 1534], ["to", 1541], ["later", 1544], ["-", 1549], ["generation", 1550], ["tyrosine", 1561], ["kinase", 1570], ["inhibitors", 1577], [".", 1587]]}
{"context": "A dedicated excision repair pathway, termed transcription-coupled repair (TCR), targets the removal of DNA lesions from transcribed strands of expressed genes. Transcription arrest at the site of the lesion has been proposed as the first step for initiation of TCR. In support of this model, a strong correlation between arrest of transcription by a lesion in vitro and TCR of that lesion in vivo has been found in most cases analyzed. TCR has been reported for oxidative DNA damage; however, very little is known about how frequently occurring and spontaneous DNA damage, such as depurination and base deamination, affects progression of the transcription complex. We have previously determined that the oxidative lesion, thymine glycol, is a significant block to transcription by T7 RNA polymerase (T7 RNAP) but has no detectable effect on transcription by RNA polymerase II (RNAP II) in a reconstituted system with all of the required factors. Another oxidative lesion, 8-oxoguanine, only slightly blocked T7 RNAP and caused RNAP II to briefly pause at the lesion before bypassing it. Because an abasic site is an intermediate in the repair of oxidative damage, it was of interest to learn whether it arrested transcription. Using in vitro transcription assays and substrates containing a specifically positioned lesion, we found that an abasic site in the transcribed strand is a 60% block to transcription by T7 RNAP but nearly a complete block to transcription by mammalian RNAP II. An abasic site in the nontranscribed strand did not block either polymerase. Our results clearly indicate that an abasic site is a much stronger block to transcription than either a thymine glycol or an 8-oxoguanine. Because the predominant model for TCR postulates that only lesions that block RNAP will be subject to TCR, our findings suggest that the abasic site may be sufficient to initiate TCR in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6960bdbb74c3432a83bd3a3c0a6c30f1", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[242, 243]], "char_spans": [[1360, 1377]]}]}], "context_tokens": [["A", 0], ["dedicated", 2], ["excision", 12], ["repair", 21], ["pathway", 28], [",", 35], ["termed", 37], ["transcription", 44], ["-", 57], ["coupled", 58], ["repair", 66], ["(", 73], ["TCR", 74], [")", 77], [",", 78], ["targets", 80], ["the", 88], ["removal", 92], ["of", 100], ["DNA", 103], ["lesions", 107], ["from", 115], ["transcribed", 120], ["strands", 132], ["of", 140], ["expressed", 143], ["genes", 153], [".", 158], ["Transcription", 160], ["arrest", 174], ["at", 181], ["the", 184], ["site", 188], ["of", 193], ["the", 196], ["lesion", 200], ["has", 207], ["been", 211], ["proposed", 216], ["as", 225], ["the", 228], ["first", 232], ["step", 238], ["for", 243], ["initiation", 247], ["of", 258], ["TCR", 261], [".", 264], ["In", 266], ["support", 269], ["of", 277], ["this", 280], ["model", 285], [",", 290], ["a", 292], ["strong", 294], ["correlation", 301], ["between", 313], ["arrest", 321], ["of", 328], ["transcription", 331], ["by", 345], ["a", 348], ["lesion", 350], ["in", 357], ["vitro", 360], ["and", 366], ["TCR", 370], ["of", 374], ["that", 377], ["lesion", 382], ["in", 389], ["vivo", 392], ["has", 397], ["been", 401], ["found", 406], ["in", 412], ["most", 415], ["cases", 420], ["analyzed", 426], [".", 434], ["TCR", 436], ["has", 440], ["been", 444], ["reported", 449], ["for", 458], ["oxidative", 462], ["DNA", 472], ["damage", 476], [";", 482], ["however", 484], [",", 491], ["very", 493], ["little", 498], ["is", 505], ["known", 508], ["about", 514], ["how", 520], ["frequently", 524], ["occurring", 535], ["and", 545], ["spontaneous", 549], ["DNA", 561], ["damage", 565], [",", 571], ["such", 573], ["as", 578], ["depurination", 581], ["and", 594], ["base", 598], ["deamination", 603], [",", 614], ["affects", 616], ["progression", 624], ["of", 636], ["the", 639], ["transcription", 643], ["complex", 657], [".", 664], ["We", 666], ["have", 669], ["previously", 674], ["determined", 685], ["that", 696], ["the", 701], ["oxidative", 705], ["lesion", 715], [",", 721], ["thymine", 723], ["glycol", 731], [",", 737], ["is", 739], ["a", 742], ["significant", 744], ["block", 756], ["to", 762], ["transcription", 765], ["by", 779], ["T7", 782], ["RNA", 785], ["polymerase", 789], ["(", 800], ["T7", 801], ["RNAP", 804], [")", 808], ["but", 810], ["has", 814], ["no", 818], ["detectable", 821], ["effect", 832], ["on", 839], ["transcription", 842], ["by", 856], ["RNA", 859], ["polymerase", 863], ["II", 874], ["(", 877], ["RNAP", 878], ["II", 883], [")", 885], ["in", 887], ["a", 890], ["reconstituted", 892], ["system", 906], ["with", 913], ["all", 918], ["of", 922], ["the", 925], ["required", 929], ["factors", 938], [".", 945], ["Another", 947], ["oxidative", 955], ["lesion", 965], [",", 971], ["8-oxoguanine", 973], [",", 985], ["only", 987], ["slightly", 992], ["blocked", 1001], ["T7", 1009], ["RNAP", 1012], ["and", 1017], ["caused", 1021], ["RNAP", 1028], ["II", 1033], ["to", 1036], ["briefly", 1039], ["pause", 1047], ["at", 1053], ["the", 1056], ["lesion", 1060], ["before", 1067], ["bypassing", 1074], ["it", 1084], [".", 1086], ["Because", 1088], ["an", 1096], ["abasic", 1099], ["site", 1106], ["is", 1111], ["an", 1114], ["intermediate", 1117], ["in", 1130], ["the", 1133], ["repair", 1137], ["of", 1144], ["oxidative", 1147], ["damage", 1157], [",", 1163], ["it", 1165], ["was", 1168], ["of", 1172], ["interest", 1175], ["to", 1184], ["learn", 1187], ["whether", 1193], ["it", 1201], ["arrested", 1204], ["transcription", 1213], [".", 1226], ["Using", 1228], ["in", 1234], ["vitro", 1237], ["transcription", 1243], ["assays", 1257], ["and", 1264], ["substrates", 1268], ["containing", 1279], ["a", 1290], ["specifically", 1292], ["positioned", 1305], ["lesion", 1316], [",", 1322], ["we", 1324], ["found", 1327], ["that", 1333], ["an", 1338], ["abasic", 1341], ["site", 1348], ["in", 1353], ["the", 1356], ["transcribed", 1360], ["strand", 1372], ["is", 1379], ["a", 1382], ["60", 1384], ["%", 1386], ["block", 1388], ["to", 1394], ["transcription", 1397], ["by", 1411], ["T7", 1414], ["RNAP", 1417], ["but", 1422], ["nearly", 1426], ["a", 1433], ["complete", 1435], ["block", 1444], ["to", 1450], ["transcription", 1453], ["by", 1467], ["mammalian", 1470], ["RNAP", 1480], ["II", 1485], [".", 1487], ["An", 1489], ["abasic", 1492], ["site", 1499], ["in", 1504], ["the", 1507], ["nontranscribed", 1511], ["strand", 1526], ["did", 1533], ["not", 1537], ["block", 1541], ["either", 1547], ["polymerase", 1554], [".", 1564], ["Our", 1566], ["results", 1570], ["clearly", 1578], ["indicate", 1586], ["that", 1595], ["an", 1600], ["abasic", 1603], ["site", 1610], ["is", 1615], ["a", 1618], ["much", 1620], ["stronger", 1625], ["block", 1634], ["to", 1640], ["transcription", 1643], ["than", 1657], ["either", 1662], ["a", 1669], ["thymine", 1671], ["glycol", 1679], ["or", 1686], ["an", 1689], ["8-oxoguanine", 1692], [".", 1704], ["Because", 1706], ["the", 1714], ["predominant", 1718], ["model", 1730], ["for", 1736], ["TCR", 1740], ["postulates", 1744], ["that", 1755], ["only", 1760], ["lesions", 1765], ["that", 1773], ["block", 1778], ["RNAP", 1784], ["will", 1789], ["be", 1794], ["subject", 1797], ["to", 1805], ["TCR", 1808], [",", 1811], ["our", 1813], ["findings", 1817], ["suggest", 1826], ["that", 1834], ["the", 1839], ["abasic", 1843], ["site", 1850], ["may", 1855], ["be", 1859], ["sufficient", 1862], ["to", 1873], ["initiate", 1876], ["TCR", 1885], ["in", 1889], ["vivo", 1892], [".", 1896]]}
{"context": "Hallervorden-Spatz syndrome (HSS) is a rare autosomal recessive disorder clinically characterized by extrapyramidal signs and progressive dementia. In a typical case, the clinical symptoms become apparent during late childhood, and usually the course is protracted over a decade or more. We recently had an opportunity to study the brains of two cases of HSS with a clinical course of over 30 years. Case 1 was a 44-year-old female and case 2 was a 37-year-old male. Grossly, the brains showed severe fronto-temporal lobar atrophy with abundant spheroids and mild iron deposits in the globus pallidus, associated with features of motor neuron disease. In addition, there was diffuse sponginess in the atrophic cortex as well as widespread Alzheimer's neurofibrillary tangles (NFTs) and Lewy bodies (LBs) in the cortical and subcortical regions, including the spinal cord. Ultrastructurally, NFTs were composed of paired helical filaments, and LBs of central dense cores with radiating fibrils. Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein. In addition, diffuse, overlapping immunoreactivity of alpha-synuclein and phosphorylated tau was seen within the cytoplasm of many neurons. However, when LBs and NFTs coexisted within the same neurons, they were clearly segregated. The findings of our present cases as well as those reported in the literature may indicate that simultaneous and extensive occurrence of abnormal phosphorylation of tau and accumulation of alpha-synuclein may constitute cardinal pathological features of HSS with protracted clinical course.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "4a2d924caf4d464aa5a7837b4e6e320d", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[214, 216], [202, 204], [275, 277]], "char_spans": [[1220, 1234], [1149, 1163], [1587, 1601]]}]}], "context_tokens": [["Hallervorden", 0], ["-", 12], ["Spatz", 13], ["syndrome", 19], ["(", 28], ["HSS", 29], [")", 32], ["is", 34], ["a", 37], ["rare", 39], ["autosomal", 44], ["recessive", 54], ["disorder", 64], ["clinically", 73], ["characterized", 84], ["by", 98], ["extrapyramidal", 101], ["signs", 116], ["and", 122], ["progressive", 126], ["dementia", 138], [".", 146], ["In", 148], ["a", 151], ["typical", 153], ["case", 161], [",", 165], ["the", 167], ["clinical", 171], ["symptoms", 180], ["become", 189], ["apparent", 196], ["during", 205], ["late", 212], ["childhood", 217], [",", 226], ["and", 228], ["usually", 232], ["the", 240], ["course", 244], ["is", 251], ["protracted", 254], ["over", 265], ["a", 270], ["decade", 272], ["or", 279], ["more", 282], [".", 286], ["We", 288], ["recently", 291], ["had", 300], ["an", 304], ["opportunity", 307], ["to", 319], ["study", 322], ["the", 328], ["brains", 332], ["of", 339], ["two", 342], ["cases", 346], ["of", 352], ["HSS", 355], ["with", 359], ["a", 364], ["clinical", 366], ["course", 375], ["of", 382], ["over", 385], ["30", 390], ["years", 393], [".", 398], ["Case", 400], ["1", 405], ["was", 407], ["a", 411], ["44-year", 413], ["-", 420], ["old", 421], ["female", 425], ["and", 432], ["case", 436], ["2", 441], ["was", 443], ["a", 447], ["37-year", 449], ["-", 456], ["old", 457], ["male", 461], [".", 465], ["Grossly", 467], [",", 474], ["the", 476], ["brains", 480], ["showed", 487], ["severe", 494], ["fronto", 501], ["-", 507], ["temporal", 508], ["lobar", 517], ["atrophy", 523], ["with", 531], ["abundant", 536], ["spheroids", 545], ["and", 555], ["mild", 559], ["iron", 564], ["deposits", 569], ["in", 578], ["the", 581], ["globus", 585], ["pallidus", 592], [",", 600], ["associated", 602], ["with", 613], ["features", 618], ["of", 627], ["motor", 630], ["neuron", 636], ["disease", 643], [".", 650], ["In", 652], ["addition", 655], [",", 663], ["there", 665], ["was", 671], ["diffuse", 675], ["sponginess", 683], ["in", 694], ["the", 697], ["atrophic", 701], ["cortex", 710], ["as", 717], ["well", 720], ["as", 725], ["widespread", 728], ["Alzheimer", 739], ["'s", 748], ["neurofibrillary", 751], ["tangles", 767], ["(", 775], ["NFTs", 776], [")", 780], ["and", 782], ["Lewy", 786], ["bodies", 791], ["(", 798], ["LBs", 799], [")", 802], ["in", 804], ["the", 807], ["cortical", 811], ["and", 820], ["subcortical", 824], ["regions", 836], [",", 843], ["including", 845], ["the", 855], ["spinal", 859], ["cord", 866], [".", 870], ["Ultrastructurally", 872], [",", 889], ["NFTs", 891], ["were", 896], ["composed", 901], ["of", 910], ["paired", 913], ["helical", 920], ["filaments", 928], [",", 937], ["and", 939], ["LBs", 943], ["of", 947], ["central", 950], ["dense", 958], ["cores", 964], ["with", 970], ["radiating", 975], ["fibrils", 985], [".", 992], ["Discrete", 994], ["immunostaining", 1003], ["was", 1018], ["demonstrated", 1022], ["in", 1035], ["NFTs", 1038], ["and", 1043], ["neuropil", 1047], ["threads", 1056], ["with", 1064], ["various", 1069], ["antibodies", 1077], ["against", 1088], ["phosphorylated", 1096], ["tau", 1111], [",", 1114], ["and", 1116], ["in", 1120], ["LBs", 1123], ["with", 1127], ["antibody", 1132], ["against", 1141], ["alpha", 1149], ["-", 1154], ["synuclein", 1155], [".", 1164], ["In", 1166], ["addition", 1169], [",", 1177], ["diffuse", 1179], [",", 1186], ["overlapping", 1188], ["immunoreactivity", 1200], ["of", 1217], ["alpha", 1220], ["-", 1225], ["synuclein", 1226], ["and", 1236], ["phosphorylated", 1240], ["tau", 1255], ["was", 1259], ["seen", 1263], ["within", 1268], ["the", 1275], ["cytoplasm", 1279], ["of", 1289], ["many", 1292], ["neurons", 1297], [".", 1304], ["However", 1306], [",", 1313], ["when", 1315], ["LBs", 1320], ["and", 1324], ["NFTs", 1328], ["coexisted", 1333], ["within", 1343], ["the", 1350], ["same", 1354], ["neurons", 1359], [",", 1366], ["they", 1368], ["were", 1373], ["clearly", 1378], ["segregated", 1386], [".", 1396], ["The", 1398], ["findings", 1402], ["of", 1411], ["our", 1414], ["present", 1418], ["cases", 1426], ["as", 1432], ["well", 1435], ["as", 1440], ["those", 1443], ["reported", 1449], ["in", 1458], ["the", 1461], ["literature", 1465], ["may", 1476], ["indicate", 1480], ["that", 1489], ["simultaneous", 1494], ["and", 1507], ["extensive", 1511], ["occurrence", 1521], ["of", 1532], ["abnormal", 1535], ["phosphorylation", 1544], ["of", 1560], ["tau", 1563], ["and", 1567], ["accumulation", 1571], ["of", 1584], ["alpha", 1587], ["-", 1592], ["synuclein", 1593], ["may", 1603], ["constitute", 1607], ["cardinal", 1618], ["pathological", 1627], ["features", 1640], ["of", 1649], ["HSS", 1652], ["with", 1656], ["protracted", 1661], ["clinical", 1672], ["course", 1681], [".", 1687]]}
{"context": "Histone methyltransferase (HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is histone methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf7e56357754453da53cec3c83cb7ef2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[22, 23], [134, 135]], "char_spans": [[150, 159], [799, 808]]}]}], "context_tokens": [["Histone", 0], ["methyltransferase", 8], ["(", 26], ["HMT)(1", 27], [")", 33], ["class", 35], ["enzymes", 41], ["that", 49], ["methylate", 54], ["lysine", 64], ["residues", 71], ["of", 80], ["histones", 83], ["or", 92], ["proteins", 95], ["contain", 104], ["a", 112], ["conserved", 114], ["catalytic", 124], ["core", 134], ["termed", 139], ["the", 146], ["SET", 150], ["domain", 154], [",", 160], ["which", 162], ["shares", 168], ["sequence", 175], ["homology", 184], ["with", 193], ["an", 198], ["independently", 201], ["described", 215], ["sequence", 225], ["motif", 234], [",", 239], ["the", 241], ["PR", 245], ["domain", 248], [".", 254], ["Intact", 256], ["PR", 263], ["or", 266], ["SET", 269], ["sequence", 273], ["is", 282], ["required", 285], ["for", 294], ["tumor", 298], ["suppression", 304], ["functions", 316], [",", 325], ["but", 327], ["it", 331], ["remains", 334], ["unclear", 342], ["whether", 350], ["it", 358], ["is", 361], ["histone", 364], ["methyltransferase", 372], ["activity", 390], ["that", 399], ["underlies", 404], ["tumor", 414], ["suppression", 420], [".", 431], ["We", 433], ["now", 436], ["show", 440], ["that", 445], ["tumor", 450], ["suppressor", 456], ["RIZ1", 467], ["(", 472], ["PRDM2", 473], [")", 478], ["methylates", 480], ["histone", 491], ["H3", 499], ["on", 502], ["lysine", 505], ["9", 512], [",", 513], ["and", 515], ["this", 519], ["activity", 524], ["is", 533], ["reduced", 536], ["by", 544], ["mutations", 547], ["in", 557], ["the", 560], ["PR", 564], ["domain", 567], ["found", 574], ["in", 580], ["human", 583], ["cancers", 589], [".", 596], ["Also", 598], [",", 602], ["S", 604], ["-", 605], ["adenosylhomocysteine", 606], ["or", 627], ["methyl", 630], ["donor", 637], ["deficiency", 643], ["inhibits", 654], ["RIZ1", 663], ["and", 668], ["other", 672], ["H3", 678], ["lysine", 681], ["9", 688], ["methylation", 690], ["activities", 702], [".", 712], ["These", 714], ["results", 720], ["support", 728], ["the", 736], ["hypothesis", 740], ["that", 751], ["H3", 756], ["lysine", 759], ["9", 766], ["methylation", 768], ["activities", 780], ["of", 791], ["a", 794], ["PR", 796], ["/", 798], ["SET", 799], ["domain", 803], ["have", 810], ["tumor", 815], ["suppression", 821], ["functions", 833], ["and", 843], ["may", 847], ["underlie", 851], ["carcinogenesis", 860], ["associated", 875], ["with", 886], ["dietary", 891], ["methyl", 899], ["donor", 906], ["deficiency", 912], [".", 922]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been implicated in several physiological and pathophysiological processes. To date seven members of this family have been reported, including Nox1-5 and Duox1 and 2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity. Recently, we identified the c-Src substrate proteins Tks4 and Tks5 as functional members of a p47(phox)-related organizer superfamily. As a functional consequence of this interaction, Nox1 localizes to invadopodia, actin-rich membrane protrusions of cancer cells which facilitate pericellular proteolysis and invasive behavior. Here, we report that Tks4 and Tks5 directly bind to NoxA1. Moreover, the integrity of the N-terminal PRR of NoxA1 is essential for this direct interaction with the Tks proteins. When the PRR in NoxA1 is disrupted, Tks proteins cannot bind NoxA1 and lose their ability to support Nox1-dependent ROS generation. Consistent with this, Tks4 and Tks5 are unable to act as organizers for Nox2 because of their inability to interact with p67(phox), which lacks the N-terminal PRR, thus conferring a unique specificity to Tks4 and 5. Taken together, these results clarify the molecular basis for the interaction between NoxA1 and the Tks proteins and may provide new insights into the pharmacological design of a more effective anti-metastatic strategy.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "809980294d6346f88b44bf8f45d50ed7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[137, 137], [45, 45], [70, 70]], "char_spans": [[753, 756], [259, 262], [373, 376]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["implicated", 122], ["in", 133], ["several", 136], ["physiological", 144], ["and", 158], ["pathophysiological", 162], ["processes", 181], [".", 190], ["To", 192], ["date", 195], ["seven", 200], ["members", 206], ["of", 214], ["this", 217], ["family", 222], ["have", 229], ["been", 234], ["reported", 239], [",", 247], ["including", 249], ["Nox1", 259], ["-", 263], ["5", 264], ["and", 266], ["Duox1", 270], ["and", 276], ["2", 280], [".", 281], ["With", 283], ["the", 288], ["exception", 292], ["of", 302], ["Nox2", 305], [",", 309], ["the", 311], ["regulation", 315], ["of", 326], ["the", 329], ["Nox", 333], ["enzymes", 337], ["is", 345], ["still", 348], ["poorly", 354], ["understood", 361], [".", 371], ["Nox1", 373], ["is", 378], ["highly", 381], ["expressed", 388], ["in", 398], ["the", 401], ["colon", 405], [",", 410], ["and", 412], ["requires", 416], ["two", 425], ["cytosolic", 429], ["regulators", 439], [",", 449], ["the", 451], ["organizer", 455], ["subunit", 465], ["NoxO1", 473], ["and", 479], ["the", 483], ["activator", 487], ["subunit", 497], ["NoxA1", 505], [",", 510], ["as", 512], ["well", 515], ["as", 520], ["the", 523], ["binding", 527], ["of", 535], ["Rac1", 538], ["GTPase", 543], [",", 549], ["for", 551], ["its", 555], ["activity", 559], [".", 567], ["Recently", 569], [",", 577], ["we", 579], ["identified", 582], ["the", 593], ["c", 597], ["-", 598], ["Src", 599], ["substrate", 603], ["proteins", 613], ["Tks4", 622], ["and", 627], ["Tks5", 631], ["as", 636], ["functional", 639], ["members", 650], ["of", 658], ["a", 661], ["p47(phox)-related", 663], ["organizer", 681], ["superfamily", 691], [".", 702], ["As", 704], ["a", 707], ["functional", 709], ["consequence", 720], ["of", 732], ["this", 735], ["interaction", 740], [",", 751], ["Nox1", 753], ["localizes", 758], ["to", 768], ["invadopodia", 771], [",", 782], ["actin", 784], ["-", 789], ["rich", 790], ["membrane", 795], ["protrusions", 804], ["of", 816], ["cancer", 819], ["cells", 826], ["which", 832], ["facilitate", 838], ["pericellular", 849], ["proteolysis", 862], ["and", 874], ["invasive", 878], ["behavior", 887], [".", 895], ["Here", 897], [",", 901], ["we", 903], ["report", 906], ["that", 913], ["Tks4", 918], ["and", 923], ["Tks5", 927], ["directly", 932], ["bind", 941], ["to", 946], ["NoxA1", 949], [".", 954], ["Moreover", 956], [",", 964], ["the", 966], ["integrity", 970], ["of", 980], ["the", 983], ["N", 987], ["-", 988], ["terminal", 989], ["PRR", 998], ["of", 1002], ["NoxA1", 1005], ["is", 1011], ["essential", 1014], ["for", 1024], ["this", 1028], ["direct", 1033], ["interaction", 1040], ["with", 1052], ["the", 1057], ["Tks", 1061], ["proteins", 1065], [".", 1073], ["When", 1075], ["the", 1080], ["PRR", 1084], ["in", 1088], ["NoxA1", 1091], ["is", 1097], ["disrupted", 1100], [",", 1109], ["Tks", 1111], ["proteins", 1115], ["can", 1124], ["not", 1127], ["bind", 1131], ["NoxA1", 1136], ["and", 1142], ["lose", 1146], ["their", 1151], ["ability", 1157], ["to", 1165], ["support", 1168], ["Nox1-dependent", 1176], ["ROS", 1191], ["generation", 1195], [".", 1205], ["Consistent", 1207], ["with", 1218], ["this", 1223], [",", 1227], ["Tks4", 1229], ["and", 1234], ["Tks5", 1238], ["are", 1243], ["unable", 1247], ["to", 1254], ["act", 1257], ["as", 1261], ["organizers", 1264], ["for", 1275], ["Nox2", 1279], ["because", 1284], ["of", 1292], ["their", 1295], ["inability", 1301], ["to", 1311], ["interact", 1314], ["with", 1323], ["p67(phox", 1328], [")", 1336], [",", 1337], ["which", 1339], ["lacks", 1345], ["the", 1351], ["N", 1355], ["-", 1356], ["terminal", 1357], ["PRR", 1366], [",", 1369], ["thus", 1371], ["conferring", 1376], ["a", 1387], ["unique", 1389], ["specificity", 1396], ["to", 1408], ["Tks4", 1411], ["and", 1416], ["5", 1420], [".", 1421], ["Taken", 1423], ["together", 1429], [",", 1437], ["these", 1439], ["results", 1445], ["clarify", 1453], ["the", 1461], ["molecular", 1465], ["basis", 1475], ["for", 1481], ["the", 1485], ["interaction", 1489], ["between", 1501], ["NoxA1", 1509], ["and", 1515], ["the", 1519], ["Tks", 1523], ["proteins", 1527], ["and", 1536], ["may", 1540], ["provide", 1544], ["new", 1552], ["insights", 1556], ["into", 1565], ["the", 1570], ["pharmacological", 1574], ["design", 1590], ["of", 1597], ["a", 1600], ["more", 1602], ["effective", 1607], ["anti", 1617], ["-", 1621], ["metastatic", 1622], ["strategy", 1633], [".", 1641]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "56f2ae49145640039f519cc53fd849b2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Purpose To determine the frequency of, and yield after, provider overrides of evidence-based clinical decision support (CDS) for ordering computed tomographic (CT) pulmonary angiography in the emergency department (ED). Materials and Methods This HIPAA-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011, and August 31, 2013. The requirement to obtain informed consent was waived. Each CT order for pulmonary angiography was exposed to CDS on the basis of the Wells criteria. For patients with a Wells score of 4 or less, CDS alerts suggested d-dimer testing because acute PE is highly unlikely in these patients if d-dimer levels are normal. The yield of CT pulmonary angiography (number of positive PE diagnoses/total number of CT pulmonary angiographic examinations) was compared in patients in whom providers overrode CDS alerts (by performing CT pulmonary angiography in patients with a Wells score \u22644 and a normal d-dimer level or no d-dimer testing) (override group) and those in whom providers followed Wells criteria (CT pulmonary angiography only in patients with Wells score >4 or \u22644 with elevated d-dimer level) (adherent group). A validated natural language processing tool identified positive PE diagnoses, with subsegmental and/or indeterminate diagnoses removed by means of chart review. Statistical analysis was performed with the \u03c7", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "0e98ec9fa2fc434f89b5688800607a86", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[80, 81]], "char_spans": [[462, 479]]}]}], "context_tokens": [["Purpose", 0], ["To", 8], ["determine", 11], ["the", 21], ["frequency", 25], ["of", 35], [",", 37], ["and", 39], ["yield", 43], ["after", 49], [",", 54], ["provider", 56], ["overrides", 65], ["of", 75], ["evidence", 78], ["-", 86], ["based", 87], ["clinical", 93], ["decision", 102], ["support", 111], ["(", 119], ["CDS", 120], [")", 123], ["for", 125], ["ordering", 129], ["computed", 138], ["tomographic", 147], ["(", 159], ["CT", 160], [")", 162], ["pulmonary", 164], ["angiography", 174], ["in", 186], ["the", 189], ["emergency", 193], ["department", 203], ["(", 214], ["ED", 215], [")", 217], [".", 218], ["Materials", 220], ["and", 230], ["Methods", 234], ["This", 242], ["HIPAA", 247], ["-", 252], ["compliant", 253], [",", 262], ["institutional", 264], ["review", 278], ["board", 285], ["-", 290], ["approved", 291], ["study", 300], ["was", 306], ["performed", 310], ["at", 320], ["a", 323], ["tertiary", 325], ["care", 334], [",", 338], ["academic", 340], ["medical", 349], ["center", 357], ["ED", 364], ["with", 367], ["approximately", 372], ["60", 386], ["000", 389], ["annual", 393], ["visits", 400], ["and", 407], ["included", 411], ["all", 420], ["patients", 424], ["who", 433], ["were", 437], ["suspected", 442], ["of", 452], ["having", 455], ["pulmonary", 462], ["embolism", 472], ["(", 481], ["PE", 482], [")", 484], ["and", 486], ["who", 490], ["underwent", 494], ["CT", 504], ["pulmonary", 507], ["angiography", 517], ["between", 529], ["January", 537], ["1", 545], [",", 546], ["2011", 548], [",", 552], ["and", 554], ["August", 558], ["31", 565], [",", 567], ["2013", 569], [".", 573], ["The", 575], ["requirement", 579], ["to", 591], ["obtain", 594], ["informed", 601], ["consent", 610], ["was", 618], ["waived", 622], [".", 628], ["Each", 630], ["CT", 635], ["order", 638], ["for", 644], ["pulmonary", 648], ["angiography", 658], ["was", 670], ["exposed", 674], ["to", 682], ["CDS", 685], ["on", 689], ["the", 692], ["basis", 696], ["of", 702], ["the", 705], ["Wells", 709], ["criteria", 715], [".", 723], ["For", 725], ["patients", 729], ["with", 738], ["a", 743], ["Wells", 745], ["score", 751], ["of", 757], ["4", 760], ["or", 762], ["less", 765], [",", 769], ["CDS", 771], ["alerts", 775], ["suggested", 782], ["d", 792], ["-", 793], ["dimer", 794], ["testing", 800], ["because", 808], ["acute", 816], ["PE", 822], ["is", 825], ["highly", 828], ["unlikely", 835], ["in", 844], ["these", 847], ["patients", 853], ["if", 862], ["d", 865], ["-", 866], ["dimer", 867], ["levels", 873], ["are", 880], ["normal", 884], [".", 890], ["The", 892], ["yield", 896], ["of", 902], ["CT", 905], ["pulmonary", 908], ["angiography", 918], ["(", 930], ["number", 931], ["of", 938], ["positive", 941], ["PE", 950], ["diagnoses", 953], ["/", 962], ["total", 963], ["number", 969], ["of", 976], ["CT", 979], ["pulmonary", 982], ["angiographic", 992], ["examinations", 1005], [")", 1017], ["was", 1019], ["compared", 1023], ["in", 1032], ["patients", 1035], ["in", 1044], ["whom", 1047], ["providers", 1052], ["overrode", 1062], ["CDS", 1071], ["alerts", 1075], ["(", 1082], ["by", 1083], ["performing", 1086], ["CT", 1097], ["pulmonary", 1100], ["angiography", 1110], ["in", 1122], ["patients", 1125], ["with", 1134], ["a", 1139], ["Wells", 1141], ["score", 1147], ["\u22644", 1153], ["and", 1156], ["a", 1160], ["normal", 1162], ["d", 1169], ["-", 1170], ["dimer", 1171], ["level", 1177], ["or", 1183], ["no", 1186], ["d", 1189], ["-", 1190], ["dimer", 1191], ["testing", 1197], [")", 1204], ["(", 1206], ["override", 1207], ["group", 1216], [")", 1221], ["and", 1223], ["those", 1227], ["in", 1233], ["whom", 1236], ["providers", 1241], ["followed", 1251], ["Wells", 1260], ["criteria", 1266], ["(", 1275], ["CT", 1276], ["pulmonary", 1279], ["angiography", 1289], ["only", 1301], ["in", 1306], ["patients", 1309], ["with", 1318], ["Wells", 1323], ["score", 1329], [">", 1335], ["4", 1336], ["or", 1338], ["\u22644", 1341], ["with", 1344], ["elevated", 1349], ["d", 1358], ["-", 1359], ["dimer", 1360], ["level", 1366], [")", 1371], ["(", 1373], ["adherent", 1374], ["group", 1383], [")", 1388], [".", 1389], ["A", 1391], ["validated", 1393], ["natural", 1403], ["language", 1411], ["processing", 1420], ["tool", 1431], ["identified", 1436], ["positive", 1447], ["PE", 1456], ["diagnoses", 1459], [",", 1468], ["with", 1470], ["subsegmental", 1475], ["and/or", 1488], ["indeterminate", 1495], ["diagnoses", 1509], ["removed", 1519], ["by", 1527], ["means", 1530], ["of", 1536], ["chart", 1539], ["review", 1545], [".", 1551], ["Statistical", 1553], ["analysis", 1565], ["was", 1574], ["performed", 1578], ["with", 1588], ["the", 1593], ["\u03c7", 1597]]}
{"context": "The aim of the study was to determine the frequency and type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital, Isfahan, Iran. In an analytic descriptive survey in 2005 and early 2006, patients admitted to the hospital who contracted S. aureus nosocomial infections were enrolled in the study. All isolates were identified by the conventional laboratory tests. Minimal Inhibitory Concentration (MIC) of oxacillin on isolated bacteria was determined by E-Test method. According to Clinical and Laboratory Standard Institute (CLSI) criteria all strains with MIC of > or = 4 microg for oxacillin were identified as MRSA. Intrinsic high level resistance (mecA positive) and borderline oxacillin resistant Staphylococcus aureus (BORSA) were detected by amoxicillin-clavulanate E-test strips. Strains with MIC of > or = 4 microg for oxacillin and > or = 8 microg for amoxicillin-clavulanate were identified as mecA positive MRSA. Other staphylococcus with MIC > or = 4 microg for oxacillin and < or = 4 for amoxicillin-clavulanate were identified as mecA negative MRSA (BORSA). MIC of vancomycin also was determined on isolated bacteria. Data were analyzed by SPSS version 13 and Who net version 5. Out of 134 Staphylococcus aureus samples which were isolated from nosocomial infections 90 (67.2%) were MRSA. Sixty seven out of 90 (74.5%) MRSA were mecA positive and 23 out of 90 (25.5%) were mecA negative (BORSA). Although most of the MRSA strains were isolated from surgical site infections, there were no statistically significant differences between types of Staphylococcus aureus growing from variant sites of infections. Only one (1.49) of the mecA positive MRSA had reduced susceptibility to vancomycin but all of the mecA-negative MRSA (BORSA) were sensitive to it. Because one fourth of our staphylococcus strains are mecA negative BORSA and there is no alternative for vancomycin against mecA positive MRSA and Enterococcus spp. in our hospital, vancomycin should be reserved only for life threatening infections due to these organisms. Thus MRSA typing should be done to choose appropriate antibiotic for optimal treatment of MRSA infections.", "qas": [{"question": "What is BORSA?", "answers": ["borderline oxacillin resistant Staphylococcus aureus", "Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "d3cb2ae20ed644fa9da62fd47344b395", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[122, 126]], "char_spans": [[687, 738]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["determine", 28], ["the", 38], ["frequency", 42], ["and", 52], ["type", 56], ["of", 61], ["MRSA", 64], ["strains", 69], ["and", 77], ["antibiotic", 81], ["susceptibility", 92], ["in", 107], ["Al", 110], ["-", 112], ["Zahra", 113], ["Hospital", 119], [",", 127], ["Isfahan", 129], [",", 136], ["Iran", 138], [".", 142], ["In", 144], ["an", 147], ["analytic", 150], ["descriptive", 159], ["survey", 171], ["in", 178], ["2005", 181], ["and", 186], ["early", 190], ["2006", 196], [",", 200], ["patients", 202], ["admitted", 211], ["to", 220], ["the", 223], ["hospital", 227], ["who", 236], ["contracted", 240], ["S.", 251], ["aureus", 254], ["nosocomial", 261], ["infections", 272], ["were", 283], ["enrolled", 288], ["in", 297], ["the", 300], ["study", 304], [".", 309], ["All", 311], ["isolates", 315], ["were", 324], ["identified", 329], ["by", 340], ["the", 343], ["conventional", 347], ["laboratory", 360], ["tests", 371], [".", 376], ["Minimal", 378], ["Inhibitory", 386], ["Concentration", 397], ["(", 411], ["MIC", 412], [")", 415], ["of", 417], ["oxacillin", 420], ["on", 430], ["isolated", 433], ["bacteria", 442], ["was", 451], ["determined", 455], ["by", 466], ["E", 469], ["-", 470], ["Test", 471], ["method", 476], [".", 482], ["According", 484], ["to", 494], ["Clinical", 497], ["and", 506], ["Laboratory", 510], ["Standard", 521], ["Institute", 530], ["(", 540], ["CLSI", 541], [")", 545], ["criteria", 547], ["all", 556], ["strains", 560], ["with", 568], ["MIC", 573], ["of", 577], [">", 580], ["or", 582], ["=", 585], ["4", 587], ["microg", 589], ["for", 596], ["oxacillin", 600], ["were", 610], ["identified", 615], ["as", 626], ["MRSA", 629], [".", 633], ["Intrinsic", 635], ["high", 645], ["level", 650], ["resistance", 656], ["(", 667], ["mecA", 668], ["positive", 673], [")", 681], ["and", 683], ["borderline", 687], ["oxacillin", 698], ["resistant", 708], ["Staphylococcus", 718], ["aureus", 733], ["(", 740], ["BORSA", 741], [")", 746], ["were", 748], ["detected", 753], ["by", 762], ["amoxicillin", 765], ["-", 776], ["clavulanate", 777], ["E", 789], ["-", 790], ["test", 791], ["strips", 796], [".", 802], ["Strains", 804], ["with", 812], ["MIC", 817], ["of", 821], [">", 824], ["or", 826], ["=", 829], ["4", 831], ["microg", 833], ["for", 840], ["oxacillin", 844], ["and", 854], [">", 858], ["or", 860], ["=", 863], ["8", 865], ["microg", 867], ["for", 874], ["amoxicillin", 878], ["-", 889], ["clavulanate", 890], ["were", 902], ["identified", 907], ["as", 918], ["mecA", 921], ["positive", 926], ["MRSA", 935], [".", 939], ["Other", 941], ["staphylococcus", 947], ["with", 962], ["MIC", 967], [">", 971], ["or", 973], ["=", 976], ["4", 978], ["microg", 980], ["for", 987], ["oxacillin", 991], ["and", 1001], ["<", 1005], ["or", 1007], ["=", 1010], ["4", 1012], ["for", 1014], ["amoxicillin", 1018], ["-", 1029], ["clavulanate", 1030], ["were", 1042], ["identified", 1047], ["as", 1058], ["mecA", 1061], ["negative", 1066], ["MRSA", 1075], ["(", 1080], ["BORSA", 1081], [")", 1086], [".", 1087], ["MIC", 1089], ["of", 1093], ["vancomycin", 1096], ["also", 1107], ["was", 1112], ["determined", 1116], ["on", 1127], ["isolated", 1130], ["bacteria", 1139], [".", 1147], ["Data", 1149], ["were", 1154], ["analyzed", 1159], ["by", 1168], ["SPSS", 1171], ["version", 1176], ["13", 1184], ["and", 1187], ["Who", 1191], ["net", 1195], ["version", 1199], ["5", 1207], [".", 1208], ["Out", 1210], ["of", 1214], ["134", 1217], ["Staphylococcus", 1221], ["aureus", 1236], ["samples", 1243], ["which", 1251], ["were", 1257], ["isolated", 1262], ["from", 1271], ["nosocomial", 1276], ["infections", 1287], ["90", 1298], ["(", 1301], ["67.2", 1302], ["%", 1306], [")", 1307], ["were", 1309], ["MRSA", 1314], [".", 1318], ["Sixty", 1320], ["seven", 1326], ["out", 1332], ["of", 1336], ["90", 1339], ["(", 1342], ["74.5", 1343], ["%", 1347], [")", 1348], ["MRSA", 1350], ["were", 1355], ["mecA", 1360], ["positive", 1365], ["and", 1374], ["23", 1378], ["out", 1381], ["of", 1385], ["90", 1388], ["(", 1391], ["25.5", 1392], ["%", 1396], [")", 1397], ["were", 1399], ["mecA", 1404], ["negative", 1409], ["(", 1418], ["BORSA", 1419], [")", 1424], [".", 1425], ["Although", 1427], ["most", 1436], ["of", 1441], ["the", 1444], ["MRSA", 1448], ["strains", 1453], ["were", 1461], ["isolated", 1466], ["from", 1475], ["surgical", 1480], ["site", 1489], ["infections", 1494], [",", 1504], ["there", 1506], ["were", 1512], ["no", 1517], ["statistically", 1520], ["significant", 1534], ["differences", 1546], ["between", 1558], ["types", 1566], ["of", 1572], ["Staphylococcus", 1575], ["aureus", 1590], ["growing", 1597], ["from", 1605], ["variant", 1610], ["sites", 1618], ["of", 1624], ["infections", 1627], [".", 1637], ["Only", 1639], ["one", 1644], ["(", 1648], ["1.49", 1649], [")", 1653], ["of", 1655], ["the", 1658], ["mecA", 1662], ["positive", 1667], ["MRSA", 1676], ["had", 1681], ["reduced", 1685], ["susceptibility", 1693], ["to", 1708], ["vancomycin", 1711], ["but", 1722], ["all", 1726], ["of", 1730], ["the", 1733], ["mecA", 1737], ["-", 1741], ["negative", 1742], ["MRSA", 1751], ["(", 1756], ["BORSA", 1757], [")", 1762], ["were", 1764], ["sensitive", 1769], ["to", 1779], ["it", 1782], [".", 1784], ["Because", 1786], ["one", 1794], ["fourth", 1798], ["of", 1805], ["our", 1808], ["staphylococcus", 1812], ["strains", 1827], ["are", 1835], ["mecA", 1839], ["negative", 1844], ["BORSA", 1853], ["and", 1859], ["there", 1863], ["is", 1869], ["no", 1872], ["alternative", 1875], ["for", 1887], ["vancomycin", 1891], ["against", 1902], ["mecA", 1910], ["positive", 1915], ["MRSA", 1924], ["and", 1929], ["Enterococcus", 1933], ["spp", 1946], [".", 1949], ["in", 1951], ["our", 1954], ["hospital", 1958], [",", 1966], ["vancomycin", 1968], ["should", 1979], ["be", 1986], ["reserved", 1989], ["only", 1998], ["for", 2003], ["life", 2007], ["threatening", 2012], ["infections", 2024], ["due", 2035], ["to", 2039], ["these", 2042], ["organisms", 2048], [".", 2057], ["Thus", 2059], ["MRSA", 2064], ["typing", 2069], ["should", 2076], ["be", 2083], ["done", 2086], ["to", 2091], ["choose", 2094], ["appropriate", 2101], ["antibiotic", 2113], ["for", 2124], ["optimal", 2128], ["treatment", 2136], ["of", 2146], ["MRSA", 2149], ["infections", 2154], [".", 2164]]}
{"context": "The rash in infectious mononucleosis is usually diffusely macular. A 15-year-old boy presented to us with high grade fever, sore throat, malaise, body aches, and polyarthralgia. He developed annular, erythematous, and non-scaly eruptions on chest and right arm. Blanching erythema was noted on his trunk. He had bilateral tender cervical lymph nodes, severe pharyngeal congestion, petechiae on soft palate, uvular edema, infraorbital edema, and marginal tender hepatomegaly. Investigations revealed lymphocytosis and activated atypical lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient. To our knowledge, this atypical case is the third reported case of annular lesions in infectious mononucleosis. Dermatologists and other clinicians should be alerted to this special presentation of primary EBV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "2fa6c155febe4bc2bb8a93675adab78c", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[118, 121]], "char_spans": [[682, 699]]}]}], "context_tokens": [["The", 0], ["rash", 4], ["in", 9], ["infectious", 12], ["mononucleosis", 23], ["is", 37], ["usually", 40], ["diffusely", 48], ["macular", 58], [".", 65], ["A", 67], ["15-year", 69], ["-", 76], ["old", 77], ["boy", 81], ["presented", 85], ["to", 95], ["us", 98], ["with", 101], ["high", 106], ["grade", 111], ["fever", 117], [",", 122], ["sore", 124], ["throat", 129], [",", 135], ["malaise", 137], [",", 144], ["body", 146], ["aches", 151], [",", 156], ["and", 158], ["polyarthralgia", 162], [".", 176], ["He", 178], ["developed", 181], ["annular", 191], [",", 198], ["erythematous", 200], [",", 212], ["and", 214], ["non", 218], ["-", 221], ["scaly", 222], ["eruptions", 228], ["on", 238], ["chest", 241], ["and", 247], ["right", 251], ["arm", 257], [".", 260], ["Blanching", 262], ["erythema", 272], ["was", 281], ["noted", 285], ["on", 291], ["his", 294], ["trunk", 298], [".", 303], ["He", 305], ["had", 308], ["bilateral", 312], ["tender", 322], ["cervical", 329], ["lymph", 338], ["nodes", 344], [",", 349], ["severe", 351], ["pharyngeal", 358], ["congestion", 369], [",", 379], ["petechiae", 381], ["on", 391], ["soft", 394], ["palate", 399], [",", 405], ["uvular", 407], ["edema", 414], [",", 419], ["infraorbital", 421], ["edema", 434], [",", 439], ["and", 441], ["marginal", 445], ["tender", 454], ["hepatomegaly", 461], [".", 473], ["Investigations", 475], ["revealed", 490], ["lymphocytosis", 499], ["and", 513], ["activated", 517], ["atypical", 527], ["lymphocytes", 536], ["in", 548], ["the", 551], ["peripheral", 555], ["smear", 566], [",", 571], ["and", 573], ["positive", 577], ["monospot", 586], ["test", 595], [".", 599], ["The", 601], ["boy", 605], ["subsequently", 609], ["recovered", 622], ["in", 632], ["one", 635], ["week", 639], ["with", 644], ["total", 649], ["disappearance", 655], ["of", 669], ["his", 672], ["rash", 676], [".", 680], ["Epstein", 682], ["-", 689], ["Barr", 690], ["virus", 695], ["-", 700], ["related", 701], ["infectious", 709], ["mononucleosis", 720], ["was", 734], ["considered", 738], ["the", 749], ["most", 753], ["likely", 758], ["diagnosis", 765], ["for", 775], ["our", 779], ["patient", 783], [".", 790], ["To", 792], ["our", 795], ["knowledge", 799], [",", 808], ["this", 810], ["atypical", 815], ["case", 824], ["is", 829], ["the", 832], ["third", 836], ["reported", 842], ["case", 851], ["of", 856], ["annular", 859], ["lesions", 867], ["in", 875], ["infectious", 878], ["mononucleosis", 889], [".", 902], ["Dermatologists", 904], ["and", 919], ["other", 923], ["clinicians", 929], ["should", 940], ["be", 947], ["alerted", 950], ["to", 958], ["this", 961], ["special", 966], ["presentation", 974], ["of", 987], ["primary", 990], ["EBV", 998], ["infection", 1002], [".", 1011]]}
{"context": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. Fostamatinib has shown significantly superior efficacy (when compared with placebo) in the control of patients with rheumatoid arthritis not responding to methotrexate in Phase II clinical trials. Treatment emergent adverse events with a higher frequency than in those on placebo included diarrhea, hypertension, urinary tract infections, neutropenia and elevated transaminases. The studied doses have shown a linear pharmacokinetic pattern and the administration of methotrexate does not affect it. Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. If these results are confirmed once Phase III studies are completed, it may find a place in the evolving treatment algorithm for rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7c88f7862dc74ae8bded750a958b2e65", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[28, 30]], "char_spans": [[146, 167]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["a", 23], ["prodrug", 25], ["rapidly", 33], ["converted", 41], ["to", 51], ["its", 54], ["active", 58], ["metabolite", 65], ["on", 76], ["oral", 79], ["administration", 84], [".", 98], ["This", 100], ["(", 105], ["known", 106], ["as", 112], ["R406", 115], [")", 119], ["is", 121], ["a", 124], ["potent", 126], ["inhibitor", 133], ["of", 143], ["spleen", 146], ["tyrosine", 153], ["kinase", 162], [",", 168], ["required", 170], ["for", 179], ["the", 183], ["expression", 187], ["of", 198], ["a", 201], ["number", 203], ["of", 210], ["proinflammatory", 213], ["cytokines", 229], [".", 238], ["Fostamatinib", 240], ["has", 253], ["shown", 257], ["significantly", 263], ["superior", 277], ["efficacy", 286], ["(", 295], ["when", 296], ["compared", 301], ["with", 310], ["placebo", 315], [")", 322], ["in", 324], ["the", 327], ["control", 331], ["of", 339], ["patients", 342], ["with", 351], ["rheumatoid", 356], ["arthritis", 367], ["not", 377], ["responding", 381], ["to", 392], ["methotrexate", 395], ["in", 408], ["Phase", 411], ["II", 417], ["clinical", 420], ["trials", 429], [".", 435], ["Treatment", 437], ["emergent", 447], ["adverse", 456], ["events", 464], ["with", 471], ["a", 476], ["higher", 478], ["frequency", 485], ["than", 495], ["in", 500], ["those", 503], ["on", 509], ["placebo", 512], ["included", 520], ["diarrhea", 529], [",", 537], ["hypertension", 539], [",", 551], ["urinary", 553], ["tract", 561], ["infections", 567], [",", 577], ["neutropenia", 579], ["and", 591], ["elevated", 595], ["transaminases", 604], [".", 617], ["The", 619], ["studied", 623], ["doses", 631], ["have", 637], ["shown", 642], ["a", 648], ["linear", 650], ["pharmacokinetic", 657], ["pattern", 673], ["and", 681], ["the", 685], ["administration", 689], ["of", 704], ["methotrexate", 707], ["does", 720], ["not", 725], ["affect", 729], ["it", 736], [".", 738], ["Fostamatinib", 740], ["may", 753], ["have", 757], ["a", 762], ["role", 764], ["in", 769], ["the", 772], ["therapy", 776], ["of", 784], ["patients", 787], ["with", 796], ["rheumatoid", 801], ["arthritis", 812], ["with", 822], ["poor", 827], ["response", 832], ["to", 841], ["conventional", 844], ["therapy", 857], [".", 864], ["If", 866], ["these", 869], ["results", 875], ["are", 883], ["confirmed", 887], ["once", 897], ["Phase", 902], ["III", 908], ["studies", 912], ["are", 920], ["completed", 924], [",", 933], ["it", 935], ["may", 938], ["find", 942], ["a", 947], ["place", 949], ["in", 955], ["the", 958], ["evolving", 962], ["treatment", 971], ["algorithm", 981], ["for", 991], ["rheumatoid", 995], ["arthritis", 1006], [".", 1015]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem. Rapid detection of MRSA-colonized patients has the potential to limit spread of the organism. We evaluated the sensitivities and specificities of MRSA detection by two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) and three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA), using 205 (101 nasal, 52 groin, and 52 axillary samples) samples from consecutive known MRSA-infected and/or -colonized patients. All detection methods had higher MRSA detection rates for nasal swabs than for axillary and groin swabs. Detection of MRSA by IDI-MRSA was the most sensitive method, independent of the site (94% for nasal samples, 80% for nonnasal samples, and 90% overall). The sensitivities of the GenoType MRSA Direct assay and the MRSA ID, MRSASelect, and CHROMagar MRSA agars with nasal swabs were 70%, 72%, 68%, and 75%, respectively. All detection methods had high specificities (95 to 99%), independent of the swab site. Extended incubation for a further 24 h with selective MRSA agars increased the detection of MRSA, with a corresponding decline in specificity secondary to a significant increase in false-positive results. There was a noticeable difference in test performance of the GenoType MRSA Direct assay in detection of MRSA (28/38 samples [74%]) compared with detection of nonmultiresistant MRSA (17/31 samples [55%]) (susceptible to two or more non-beta-lactam antibiotics). This was not observed with selective MRSA agar plates or IDI-MRSA. Although it is more expensive, in addition to rapid turnaround times of 2 to 4 h, IDI-MRSA offers greater detection of MRSA colonization, independent of the swab site, than do conventional selective agars and GenoType MRSA Direct.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b942fc23c0bf4ebe9bf8e76ac4b3a998", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[161, 161], [351, 351], [16, 16], [51, 51], [117, 117], [6, 6], [308, 308], [121, 121], [259, 259], [59, 59], [69, 69], [253, 253], [302, 302], [62, 62], [335, 335], [90, 90], [102, 102], [217, 217], [273, 273], [37, 37], [330, 330], [156, 156], [168, 168], [46, 46], [223, 223]], "char_spans": [[841, 844], [1786, 1789], [96, 99], [296, 299], [641, 644], [45, 48], [1562, 1565], [653, 656], [1344, 1347], [339, 342], [386, 389], [1310, 1313], [1538, 1541], [351, 354], [1687, 1690], [481, 484], [556, 559], [1089, 1092], [1416, 1419], [223, 226], [1654, 1657], [815, 818], [876, 879], [268, 271], [1127, 1130]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["increasing", 57], ["problem", 68], [".", 75], ["Rapid", 77], ["detection", 83], ["of", 93], ["MRSA", 96], ["-", 100], ["colonized", 101], ["patients", 111], ["has", 120], ["the", 124], ["potential", 128], ["to", 138], ["limit", 141], ["spread", 147], ["of", 154], ["the", 157], ["organism", 161], [".", 169], ["We", 171], ["evaluated", 174], ["the", 184], ["sensitivities", 188], ["and", 202], ["specificities", 206], ["of", 220], ["MRSA", 223], ["detection", 228], ["by", 238], ["two", 241], ["molecular", 245], ["methods", 255], ["(", 263], ["IDI", 264], ["-", 267], ["MRSA", 268], ["PCR", 273], ["assay", 277], ["and", 283], ["GenoType", 287], ["MRSA", 296], ["Direct", 301], ["PCR", 308], ["assay", 312], [")", 317], ["and", 319], ["three", 323], ["selective", 329], ["MRSA", 339], ["agars", 344], ["(", 350], ["MRSA", 351], ["ID", 356], [",", 358], ["MRSASelect", 360], [",", 370], ["and", 372], ["CHROMagar", 376], ["MRSA", 386], [")", 390], [",", 391], ["using", 393], ["205", 399], ["(", 403], ["101", 404], ["nasal", 408], [",", 413], ["52", 415], ["groin", 418], [",", 423], ["and", 425], ["52", 429], ["axillary", 432], ["samples", 441], [")", 448], ["samples", 450], ["from", 458], ["consecutive", 463], ["known", 475], ["MRSA", 481], ["-", 485], ["infected", 486], ["and/or", 495], ["-colonized", 502], ["patients", 513], [".", 521], ["All", 523], ["detection", 527], ["methods", 537], ["had", 545], ["higher", 549], ["MRSA", 556], ["detection", 561], ["rates", 571], ["for", 577], ["nasal", 581], ["swabs", 587], ["than", 593], ["for", 598], ["axillary", 602], ["and", 611], ["groin", 615], ["swabs", 621], [".", 626], ["Detection", 628], ["of", 638], ["MRSA", 641], ["by", 646], ["IDI", 649], ["-", 652], ["MRSA", 653], ["was", 658], ["the", 662], ["most", 666], ["sensitive", 671], ["method", 681], [",", 687], ["independent", 689], ["of", 701], ["the", 704], ["site", 708], ["(", 713], ["94", 714], ["%", 716], ["for", 718], ["nasal", 722], ["samples", 728], [",", 735], ["80", 737], ["%", 739], ["for", 741], ["nonnasal", 745], ["samples", 754], [",", 761], ["and", 763], ["90", 767], ["%", 769], ["overall", 771], [")", 778], [".", 779], ["The", 781], ["sensitivities", 785], ["of", 799], ["the", 802], ["GenoType", 806], ["MRSA", 815], ["Direct", 820], ["assay", 827], ["and", 833], ["the", 837], ["MRSA", 841], ["ID", 846], [",", 848], ["MRSASelect", 850], [",", 860], ["and", 862], ["CHROMagar", 866], ["MRSA", 876], ["agars", 881], ["with", 887], ["nasal", 892], ["swabs", 898], ["were", 904], ["70", 909], ["%", 911], [",", 912], ["72", 914], ["%", 916], [",", 917], ["68", 919], ["%", 921], [",", 922], ["and", 924], ["75", 928], ["%", 930], [",", 931], ["respectively", 933], [".", 945], ["All", 947], ["detection", 951], ["methods", 961], ["had", 969], ["high", 973], ["specificities", 978], ["(", 992], ["95", 993], ["to", 996], ["99", 999], ["%", 1001], [")", 1002], [",", 1003], ["independent", 1005], ["of", 1017], ["the", 1020], ["swab", 1024], ["site", 1029], [".", 1033], ["Extended", 1035], ["incubation", 1044], ["for", 1055], ["a", 1059], ["further", 1061], ["24", 1069], ["h", 1072], ["with", 1074], ["selective", 1079], ["MRSA", 1089], ["agars", 1094], ["increased", 1100], ["the", 1110], ["detection", 1114], ["of", 1124], ["MRSA", 1127], [",", 1131], ["with", 1133], ["a", 1138], ["corresponding", 1140], ["decline", 1154], ["in", 1162], ["specificity", 1165], ["secondary", 1177], ["to", 1187], ["a", 1190], ["significant", 1192], ["increase", 1204], ["in", 1213], ["false", 1216], ["-", 1221], ["positive", 1222], ["results", 1231], [".", 1238], ["There", 1240], ["was", 1246], ["a", 1250], ["noticeable", 1252], ["difference", 1263], ["in", 1274], ["test", 1277], ["performance", 1282], ["of", 1294], ["the", 1297], ["GenoType", 1301], ["MRSA", 1310], ["Direct", 1315], ["assay", 1322], ["in", 1328], ["detection", 1331], ["of", 1341], ["MRSA", 1344], ["(", 1349], ["28/38", 1350], ["samples", 1356], ["[", 1364], ["74", 1365], ["%", 1367], ["]", 1368], [")", 1369], ["compared", 1371], ["with", 1380], ["detection", 1385], ["of", 1395], ["nonmultiresistant", 1398], ["MRSA", 1416], ["(", 1421], ["17/31", 1422], ["samples", 1428], ["[", 1436], ["55", 1437], ["%", 1439], ["]", 1440], [")", 1441], ["(", 1443], ["susceptible", 1444], ["to", 1456], ["two", 1459], ["or", 1463], ["more", 1466], ["non", 1471], ["-", 1474], ["beta", 1475], ["-", 1479], ["lactam", 1480], ["antibiotics", 1487], [")", 1498], [".", 1499], ["This", 1501], ["was", 1506], ["not", 1510], ["observed", 1514], ["with", 1523], ["selective", 1528], ["MRSA", 1538], ["agar", 1543], ["plates", 1548], ["or", 1555], ["IDI", 1558], ["-", 1561], ["MRSA", 1562], [".", 1566], ["Although", 1568], ["it", 1577], ["is", 1580], ["more", 1583], ["expensive", 1588], [",", 1597], ["in", 1599], ["addition", 1602], ["to", 1611], ["rapid", 1614], ["turnaround", 1620], ["times", 1631], ["of", 1637], ["2", 1640], ["to", 1642], ["4", 1645], ["h", 1647], [",", 1648], ["IDI", 1650], ["-", 1653], ["MRSA", 1654], ["offers", 1659], ["greater", 1666], ["detection", 1674], ["of", 1684], ["MRSA", 1687], ["colonization", 1692], [",", 1704], ["independent", 1706], ["of", 1718], ["the", 1721], ["swab", 1725], ["site", 1730], [",", 1734], ["than", 1736], ["do", 1741], ["conventional", 1744], ["selective", 1757], ["agars", 1767], ["and", 1773], ["GenoType", 1777], ["MRSA", 1786], ["Direct", 1791], [".", 1797]]}
{"context": "To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides. A solvent casting method was used to manufacture the films. Solid phase solubility was used to identify potential polymers for use in the film formulation. Physical and chemical properties (such as water content, puncture strength and in vitro release) and product stability were determined. The bioactivity of the film products against HIV was assessed using the TZM-bl assay and a cervical explant model. Polymers identified from the solid phase solubility study maintained tenofovir and maraviroc in an amorphous state and prevented drug crystallization. Three combination film products were developed using cellulose polymers and polyvinyl alcohol. The residual water content in all films was <10% (w/w). All films delivered the active agents with release of >50% of film drug content within 30 min. Stability testing confirmed that the combination film products were stable for 12 months at ambient temperature and 6 months under stressed conditions. Antiviral activity was confirmed in TZM-bl and cervical explant models. Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "387330c38e704509996ffc03774c1391", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[82, 82], [10, 10]], "char_spans": [[505, 507], [64, 66]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["polymeric", 11], ["films", 21], ["containing", 27], ["dual", 38], ["combinations", 43], ["of", 56], ["anti", 59], ["-", 63], ["HIV", 64], ["drug", 68], ["candidate", 73], ["tenofovir", 83], [",", 92], ["maraviroc", 94], ["and", 104], ["dapivirine", 108], ["for", 119], ["vaginal", 123], ["application", 131], ["as", 143], ["topical", 146], ["microbicides", 154], [".", 166], ["A", 168], ["solvent", 170], ["casting", 178], ["method", 186], ["was", 193], ["used", 197], ["to", 202], ["manufacture", 205], ["the", 217], ["films", 221], [".", 226], ["Solid", 228], ["phase", 234], ["solubility", 240], ["was", 251], ["used", 255], ["to", 260], ["identify", 263], ["potential", 272], ["polymers", 282], ["for", 291], ["use", 295], ["in", 299], ["the", 302], ["film", 306], ["formulation", 311], [".", 322], ["Physical", 324], ["and", 333], ["chemical", 337], ["properties", 346], ["(", 357], ["such", 358], ["as", 363], ["water", 366], ["content", 372], [",", 379], ["puncture", 381], ["strength", 390], ["and", 399], ["in", 403], ["vitro", 406], ["release", 412], [")", 419], ["and", 421], ["product", 425], ["stability", 433], ["were", 443], ["determined", 448], [".", 458], ["The", 460], ["bioactivity", 464], ["of", 476], ["the", 479], ["film", 483], ["products", 488], ["against", 497], ["HIV", 505], ["was", 509], ["assessed", 513], ["using", 522], ["the", 528], ["TZM", 532], ["-", 535], ["bl", 536], ["assay", 539], ["and", 545], ["a", 549], ["cervical", 551], ["explant", 560], ["model", 568], [".", 573], ["Polymers", 575], ["identified", 584], ["from", 595], ["the", 600], ["solid", 604], ["phase", 610], ["solubility", 616], ["study", 627], ["maintained", 633], ["tenofovir", 644], ["and", 654], ["maraviroc", 658], ["in", 668], ["an", 671], ["amorphous", 674], ["state", 684], ["and", 690], ["prevented", 694], ["drug", 704], ["crystallization", 709], [".", 724], ["Three", 726], ["combination", 732], ["film", 744], ["products", 749], ["were", 758], ["developed", 763], ["using", 773], ["cellulose", 779], ["polymers", 789], ["and", 798], ["polyvinyl", 802], ["alcohol", 812], [".", 819], ["The", 821], ["residual", 825], ["water", 834], ["content", 840], ["in", 848], ["all", 851], ["films", 855], ["was", 861], ["<", 865], ["10", 866], ["%", 868], ["(", 870], ["w", 871], ["/", 872], ["w", 873], [")", 874], [".", 875], ["All", 877], ["films", 881], ["delivered", 887], ["the", 897], ["active", 901], ["agents", 908], ["with", 915], ["release", 920], ["of", 928], [">", 931], ["50", 932], ["%", 934], ["of", 936], ["film", 939], ["drug", 944], ["content", 949], ["within", 957], ["30", 964], ["min", 967], [".", 970], ["Stability", 972], ["testing", 982], ["confirmed", 990], ["that", 1000], ["the", 1005], ["combination", 1009], ["film", 1021], ["products", 1026], ["were", 1035], ["stable", 1040], ["for", 1047], ["12", 1051], ["months", 1054], ["at", 1061], ["ambient", 1064], ["temperature", 1072], ["and", 1084], ["6", 1088], ["months", 1090], ["under", 1097], ["stressed", 1103], ["conditions", 1112], [".", 1122], ["Antiviral", 1124], ["activity", 1134], ["was", 1143], ["confirmed", 1147], ["in", 1157], ["TZM", 1160], ["-", 1163], ["bl", 1164], ["and", 1167], ["cervical", 1171], ["explant", 1180], ["models", 1188], [".", 1194], ["Polymeric", 1196], ["films", 1206], ["can", 1212], ["be", 1216], ["used", 1219], ["as", 1224], ["a", 1227], ["stable", 1229], ["dosage", 1236], ["form", 1243], ["for", 1248], ["the", 1252], ["delivery", 1256], ["of", 1265], ["antiretroviral", 1268], ["combinations", 1283], ["as", 1296], ["microbicides", 1299], [".", 1311]]}
{"context": "N6-methyladenosine (m6A) is a common modification of mRNA with potential roles in fine-tuning the RNA life cycle. Here, we identify a dense network of proteins interacting with METTL3, a component of the methyltransferase complex, and show that three of them (WTAP, METTL14, and KIAA1429) are required for methylation. Monitoring m6A levels upon WTAP depletion allowed the definition of accurate and near single-nucleotide resolution methylation maps and their classification into WTAP-dependent and -independent sites. WTAP-dependent sites are located at internal positions in transcripts, topologically static across a variety of systems we surveyed, and inversely correlated with mRNA stability, consistent with a role in establishing \"basal\" degradation rates. WTAP-independent sites form at the first transcribed base as part of the cap structure and are present at thousands of sites, forming a previously unappreciated layer of transcriptome complexity. Our data shed light on the proteomic and transcriptional underpinnings of this RNA modification.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "c3596cdec1b2483b889a950b0ae18039", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[117, 118]], "char_spans": [[683, 696]]}]}], "context_tokens": [["N6-methyladenosine", 0], ["(", 19], ["m6A", 20], [")", 23], ["is", 25], ["a", 28], ["common", 30], ["modification", 37], ["of", 50], ["mRNA", 53], ["with", 58], ["potential", 63], ["roles", 73], ["in", 79], ["fine", 82], ["-", 86], ["tuning", 87], ["the", 94], ["RNA", 98], ["life", 102], ["cycle", 107], [".", 112], ["Here", 114], [",", 118], ["we", 120], ["identify", 123], ["a", 132], ["dense", 134], ["network", 140], ["of", 148], ["proteins", 151], ["interacting", 160], ["with", 172], ["METTL3", 177], [",", 183], ["a", 185], ["component", 187], ["of", 197], ["the", 200], ["methyltransferase", 204], ["complex", 222], [",", 229], ["and", 231], ["show", 235], ["that", 240], ["three", 245], ["of", 251], ["them", 254], ["(", 259], ["WTAP", 260], [",", 264], ["METTL14", 266], [",", 273], ["and", 275], ["KIAA1429", 279], [")", 287], ["are", 289], ["required", 293], ["for", 302], ["methylation", 306], [".", 317], ["Monitoring", 319], ["m6A", 330], ["levels", 334], ["upon", 341], ["WTAP", 346], ["depletion", 351], ["allowed", 361], ["the", 369], ["definition", 373], ["of", 384], ["accurate", 387], ["and", 396], ["near", 400], ["single", 405], ["-", 411], ["nucleotide", 412], ["resolution", 423], ["methylation", 434], ["maps", 446], ["and", 451], ["their", 455], ["classification", 461], ["into", 476], ["WTAP", 481], ["-", 485], ["dependent", 486], ["and", 496], ["-independent", 500], ["sites", 513], [".", 518], ["WTAP", 520], ["-", 524], ["dependent", 525], ["sites", 535], ["are", 541], ["located", 545], ["at", 553], ["internal", 556], ["positions", 565], ["in", 575], ["transcripts", 578], [",", 589], ["topologically", 591], ["static", 605], ["across", 612], ["a", 619], ["variety", 621], ["of", 629], ["systems", 632], ["we", 640], ["surveyed", 643], [",", 651], ["and", 653], ["inversely", 657], ["correlated", 667], ["with", 678], ["mRNA", 683], ["stability", 688], [",", 697], ["consistent", 699], ["with", 710], ["a", 715], ["role", 717], ["in", 722], ["establishing", 725], ["\"", 738], ["basal", 739], ["\"", 744], ["degradation", 746], ["rates", 758], [".", 763], ["WTAP", 765], ["-", 769], ["independent", 770], ["sites", 782], ["form", 788], ["at", 793], ["the", 796], ["first", 800], ["transcribed", 806], ["base", 818], ["as", 823], ["part", 826], ["of", 831], ["the", 834], ["cap", 838], ["structure", 842], ["and", 852], ["are", 856], ["present", 860], ["at", 868], ["thousands", 871], ["of", 881], ["sites", 884], [",", 889], ["forming", 891], ["a", 899], ["previously", 901], ["unappreciated", 912], ["layer", 926], ["of", 932], ["transcriptome", 935], ["complexity", 949], [".", 959], ["Our", 961], ["data", 965], ["shed", 970], ["light", 975], ["on", 981], ["the", 984], ["proteomic", 988], ["and", 998], ["transcriptional", 1002], ["underpinnings", 1018], ["of", 1032], ["this", 1035], ["RNA", 1040], ["modification", 1044], [".", 1056]]}
{"context": "We evaluated the predictive value of serum biomarkers and various clinical risk scales for the 28-day mortality of community-acquired pneumonia (CAP). Serum biomarkers including procalcitonin (PCT) and C-reactive protein (CRP) were evaluated in the emergency department. Scores for the pneumonia severity index (PSI); CURB65 (confusion, urea, respiration, blood pressure; age >65\u2009years); Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) guidelines for severe CAP; Acute Physiology, Chronic Health Evaluation (APACHE) II; Sequential Organ Failure Assessment (SOFA); and quick SOFA (qSOFA) were calculated. Receiver-operating characteristic curves for 28-day mortality were calculated for each predictor using cut-off values, and we applied logistic regression models and area under the curve (AUC) analysis to compare the performance of predictors. Of the 125 enrolled patients, 13 died within 28\u2009days. The AUCs of the PCT and CRP were 0.83 and 0.77, respectively. Using a PCT level >5.6\u2009\u03bcg/L as the cut-off, the sensitivity and specificity for mortality were 76.9% and 90.2%, respectively. The three pneumonia severity scales showed an AUC of 0.86 (PSI), 0.87 (IDSA/ATS) and 0.77 (CURB65). The AUCs of the APACHE II, SOFA and qSOFA scores were 0.85, 0.83 and 0.81, respectively. The models combining CRP and/or PCT with PSI or the IDSA/ATS guidelines demonstrated superior performance to those of either PSI or the IDAS/ATS guidelines alone. In conclusion, serum PCT is a reliable single predictor for short-term mortality. Inclusion of CRP and/or PCT could significantly improve the performance of the PSI and IDAS/ATS guidelines.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "7c707712084d4ceda79cb8580017408e", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[21, 21], [51, 51], [222, 222]], "char_spans": [[134, 142], [286, 294], [1132, 1140]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["predictive", 17], ["value", 28], ["of", 34], ["serum", 37], ["biomarkers", 43], ["and", 54], ["various", 58], ["clinical", 66], ["risk", 75], ["scales", 80], ["for", 87], ["the", 91], ["28-day", 95], ["mortality", 102], ["of", 112], ["community", 115], ["-", 124], ["acquired", 125], ["pneumonia", 134], ["(", 144], ["CAP", 145], [")", 148], [".", 149], ["Serum", 151], ["biomarkers", 157], ["including", 168], ["procalcitonin", 178], ["(", 192], ["PCT", 193], [")", 196], ["and", 198], ["C", 202], ["-", 203], ["reactive", 204], ["protein", 213], ["(", 221], ["CRP", 222], [")", 225], ["were", 227], ["evaluated", 232], ["in", 242], ["the", 245], ["emergency", 249], ["department", 259], [".", 269], ["Scores", 271], ["for", 278], ["the", 282], ["pneumonia", 286], ["severity", 296], ["index", 305], ["(", 311], ["PSI", 312], [")", 315], [";", 316], ["CURB65", 318], ["(", 325], ["confusion", 326], [",", 335], ["urea", 337], [",", 341], ["respiration", 343], [",", 354], ["blood", 356], ["pressure", 362], [";", 370], ["age", 372], [">", 376], ["65", 377], ["years", 380], [")", 385], [";", 386], ["Infectious", 388], ["Disease", 399], ["Society", 407], ["of", 415], ["America", 418], ["(", 426], ["IDSA", 427], [")", 431], ["and", 433], ["American", 437], ["Thoracic", 446], ["Society", 455], ["(", 463], ["ATS", 464], [")", 467], ["guidelines", 469], ["for", 480], ["severe", 484], ["CAP", 491], [";", 494], ["Acute", 496], ["Physiology", 502], [",", 512], ["Chronic", 514], ["Health", 522], ["Evaluation", 529], ["(", 540], ["APACHE", 541], [")", 547], ["II", 549], [";", 551], ["Sequential", 553], ["Organ", 564], ["Failure", 570], ["Assessment", 578], ["(", 589], ["SOFA", 590], [")", 594], [";", 595], ["and", 597], ["quick", 601], ["SOFA", 607], ["(", 612], ["qSOFA", 613], [")", 618], ["were", 620], ["calculated", 625], [".", 635], ["Receiver", 637], ["-", 645], ["operating", 646], ["characteristic", 656], ["curves", 671], ["for", 678], ["28-day", 682], ["mortality", 689], ["were", 699], ["calculated", 704], ["for", 715], ["each", 719], ["predictor", 724], ["using", 734], ["cut", 740], ["-", 743], ["off", 744], ["values", 748], [",", 754], ["and", 756], ["we", 760], ["applied", 763], ["logistic", 771], ["regression", 780], ["models", 791], ["and", 798], ["area", 802], ["under", 807], ["the", 813], ["curve", 817], ["(", 823], ["AUC", 824], [")", 827], ["analysis", 829], ["to", 838], ["compare", 841], ["the", 849], ["performance", 853], ["of", 865], ["predictors", 868], [".", 878], ["Of", 880], ["the", 883], ["125", 887], ["enrolled", 891], ["patients", 900], [",", 908], ["13", 910], ["died", 913], ["within", 918], ["28", 925], ["days", 928], [".", 932], ["The", 934], ["AUCs", 938], ["of", 943], ["the", 946], ["PCT", 950], ["and", 954], ["CRP", 958], ["were", 962], ["0.83", 967], ["and", 972], ["0.77", 976], [",", 980], ["respectively", 982], [".", 994], ["Using", 996], ["a", 1002], ["PCT", 1004], ["level", 1008], [">", 1014], ["5.6", 1015], ["\u03bcg", 1019], ["/", 1021], ["L", 1022], ["as", 1024], ["the", 1027], ["cut", 1031], ["-", 1034], ["off", 1035], [",", 1038], ["the", 1040], ["sensitivity", 1044], ["and", 1056], ["specificity", 1060], ["for", 1072], ["mortality", 1076], ["were", 1086], ["76.9", 1091], ["%", 1095], ["and", 1097], ["90.2", 1101], ["%", 1105], [",", 1106], ["respectively", 1108], [".", 1120], ["The", 1122], ["three", 1126], ["pneumonia", 1132], ["severity", 1142], ["scales", 1151], ["showed", 1158], ["an", 1165], ["AUC", 1168], ["of", 1172], ["0.86", 1175], ["(", 1180], ["PSI", 1181], [")", 1184], [",", 1185], ["0.87", 1187], ["(", 1192], ["IDSA", 1193], ["/", 1197], ["ATS", 1198], [")", 1201], ["and", 1203], ["0.77", 1207], ["(", 1212], ["CURB65", 1213], [")", 1219], [".", 1220], ["The", 1222], ["AUCs", 1226], ["of", 1231], ["the", 1234], ["APACHE", 1238], ["II", 1245], [",", 1247], ["SOFA", 1249], ["and", 1254], ["qSOFA", 1258], ["scores", 1264], ["were", 1271], ["0.85", 1276], [",", 1280], ["0.83", 1282], ["and", 1287], ["0.81", 1291], [",", 1295], ["respectively", 1297], [".", 1309], ["The", 1311], ["models", 1315], ["combining", 1322], ["CRP", 1332], ["and/or", 1336], ["PCT", 1343], ["with", 1347], ["PSI", 1352], ["or", 1356], ["the", 1359], ["IDSA", 1363], ["/", 1367], ["ATS", 1368], ["guidelines", 1372], ["demonstrated", 1383], ["superior", 1396], ["performance", 1405], ["to", 1417], ["those", 1420], ["of", 1426], ["either", 1429], ["PSI", 1436], ["or", 1440], ["the", 1443], ["IDAS", 1447], ["/", 1451], ["ATS", 1452], ["guidelines", 1456], ["alone", 1467], [".", 1472], ["In", 1474], ["conclusion", 1477], [",", 1487], ["serum", 1489], ["PCT", 1495], ["is", 1499], ["a", 1502], ["reliable", 1504], ["single", 1513], ["predictor", 1520], ["for", 1530], ["short", 1534], ["-", 1539], ["term", 1540], ["mortality", 1545], [".", 1554], ["Inclusion", 1556], ["of", 1566], ["CRP", 1569], ["and/or", 1573], ["PCT", 1580], ["could", 1584], ["significantly", 1590], ["improve", 1604], ["the", 1612], ["performance", 1616], ["of", 1628], ["the", 1631], ["PSI", 1635], ["and", 1639], ["IDAS", 1643], ["/", 1647], ["ATS", 1648], ["guidelines", 1652], [".", 1662]]}
{"context": "Rates of remission were examined in two controlled 12-week studies of sertraline and placebo for post-traumatic stress disorder (PTSD). The performance of three scales was evaluated: the self-rated Davidson Trauma Scale (DTS), and two interviewer scales: the Clinician Administered PTSD Scale (CAPS) and Clinical Global Impressions (CGI). Sertraline proved significantly superior to placebo with respect to remission on all three ratings. Rates of remission were very similar for all scales, ranging from 23.1-26.3% for sertraline and 13.9-14.9% for placebo. Traditional thresholds for the CAPS and DTS were tested relative to the CGI and to each other. The CAPS and DTS thresholds of < 20 and < 18 were found to be valid.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b086ca841a4040e58142b56004268573", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[15, 19]], "char_spans": [[97, 126]]}, {"text": "PTSD", "token_spans": [[21, 21], [51, 51]], "char_spans": [[129, 132], [282, 285]]}]}], "context_tokens": [["Rates", 0], ["of", 6], ["remission", 9], ["were", 19], ["examined", 24], ["in", 33], ["two", 36], ["controlled", 40], ["12-week", 51], ["studies", 59], ["of", 67], ["sertraline", 70], ["and", 81], ["placebo", 85], ["for", 93], ["post", 97], ["-", 101], ["traumatic", 102], ["stress", 112], ["disorder", 119], ["(", 128], ["PTSD", 129], [")", 133], [".", 134], ["The", 136], ["performance", 140], ["of", 152], ["three", 155], ["scales", 161], ["was", 168], ["evaluated", 172], [":", 181], ["the", 183], ["self", 187], ["-", 191], ["rated", 192], ["Davidson", 198], ["Trauma", 207], ["Scale", 214], ["(", 220], ["DTS", 221], [")", 224], [",", 225], ["and", 227], ["two", 231], ["interviewer", 235], ["scales", 247], [":", 253], ["the", 255], ["Clinician", 259], ["Administered", 269], ["PTSD", 282], ["Scale", 287], ["(", 293], ["CAPS", 294], [")", 298], ["and", 300], ["Clinical", 304], ["Global", 313], ["Impressions", 320], ["(", 332], ["CGI", 333], [")", 336], [".", 337], ["Sertraline", 339], ["proved", 350], ["significantly", 357], ["superior", 371], ["to", 380], ["placebo", 383], ["with", 391], ["respect", 396], ["to", 404], ["remission", 407], ["on", 417], ["all", 420], ["three", 424], ["ratings", 430], [".", 437], ["Rates", 439], ["of", 445], ["remission", 448], ["were", 458], ["very", 463], ["similar", 468], ["for", 476], ["all", 480], ["scales", 484], [",", 490], ["ranging", 492], ["from", 500], ["23.1", 505], ["-", 509], ["26.3", 510], ["%", 514], ["for", 516], ["sertraline", 520], ["and", 531], ["13.9", 535], ["-", 539], ["14.9", 540], ["%", 544], ["for", 546], ["placebo", 550], [".", 557], ["Traditional", 559], ["thresholds", 571], ["for", 582], ["the", 586], ["CAPS", 590], ["and", 595], ["DTS", 599], ["were", 603], ["tested", 608], ["relative", 615], ["to", 624], ["the", 627], ["CGI", 631], ["and", 635], ["to", 639], ["each", 642], ["other", 647], [".", 652], ["The", 654], ["CAPS", 658], ["and", 663], ["DTS", 667], ["thresholds", 671], ["of", 682], ["<", 685], ["20", 687], ["and", 690], ["<", 694], ["18", 696], ["were", 699], ["found", 704], ["to", 710], ["be", 713], ["valid", 716], [".", 721]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "Nestin is a unique intermediate filament protein. While it is robustly expressed in developing brain, postnatal expression is limited to the brain's subventricular zone (SVZ) and endothelial cells. Reexpression occurs, however, under several pathological conditions, including injury and neoplasia. We hypothesized that nestin would be a sensitive marker of early neoplasia after transplacental exposure of rats to ethylnitrosourea (ENU). Rats of various ages were administered bromodeoxyuridine (BudR) before sacrifice, and brain sections were examined for proliferative cells and several immunohistochemical markers, including nestin. Additional rats were examined after a stab wound injury to assess the expression of two of these markers, GFAP and nestin, in reactive astrocytes. All ENU-induced brain tumors (n = 9) were classified as gliomas (astrocytomas or oligoastrocytomas) based on their histology and immunophenotype. Nestin expression was noted in all tumors examined and was present in tumor cells as well as endothelial cells. During tumor development, we consistently noted nestin-expressing cells bearing multiple processes distributed throughout brain parenchyma. Both single cells and multiple cell clusters were observed as early as postnatal day 30 in all ENU-exposed brains examined (n = 11). Such distinctive nestin-expressing cells were not seen in nestin-stained control brains or ENU-exposed brains stained for GFAP or vimentin, nor was such a cell seen in a stab wound model used to assess reactive astrocytosis. While the number of these clusters was highly variable among rats, their size increased between 30 and 90 days. The data suggest that these nestin-expressing cells represent an early stage of the neoplastic process. It remains to be determined whether these cells become apparent at 30 days of age due to \"dedifferentiation\" of a local resident astrocyte or astrocyte precursor cell or migration of a relatively undifferentiated precursor/stem cell from the SVZ.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "36dc5cbeedc44c65ab77495e3f481e0d", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[0, 0], [224, 224], [99, 99], [155, 155], [122, 122], [182, 182], [291, 291], [52, 52], [232, 232]], "char_spans": [[0, 5], [1332, 1337], [629, 634], [930, 935], [752, 757], [1090, 1095], [1680, 1685], [320, 325], [1373, 1378]]}]}], "context_tokens": [["Nestin", 0], ["is", 7], ["a", 10], ["unique", 12], ["intermediate", 19], ["filament", 32], ["protein", 41], [".", 48], ["While", 50], ["it", 56], ["is", 59], ["robustly", 62], ["expressed", 71], ["in", 81], ["developing", 84], ["brain", 95], [",", 100], ["postnatal", 102], ["expression", 112], ["is", 123], ["limited", 126], ["to", 134], ["the", 137], ["brain", 141], ["'s", 146], ["subventricular", 149], ["zone", 164], ["(", 169], ["SVZ", 170], [")", 173], ["and", 175], ["endothelial", 179], ["cells", 191], [".", 196], ["Reexpression", 198], ["occurs", 211], [",", 217], ["however", 219], [",", 226], ["under", 228], ["several", 234], ["pathological", 242], ["conditions", 255], [",", 265], ["including", 267], ["injury", 277], ["and", 284], ["neoplasia", 288], [".", 297], ["We", 299], ["hypothesized", 302], ["that", 315], ["nestin", 320], ["would", 327], ["be", 333], ["a", 336], ["sensitive", 338], ["marker", 348], ["of", 355], ["early", 358], ["neoplasia", 364], ["after", 374], ["transplacental", 380], ["exposure", 395], ["of", 404], ["rats", 407], ["to", 412], ["ethylnitrosourea", 415], ["(", 432], ["ENU", 433], [")", 436], [".", 437], ["Rats", 439], ["of", 444], ["various", 447], ["ages", 455], ["were", 460], ["administered", 465], ["bromodeoxyuridine", 478], ["(", 496], ["BudR", 497], [")", 501], ["before", 503], ["sacrifice", 510], [",", 519], ["and", 521], ["brain", 525], ["sections", 531], ["were", 540], ["examined", 545], ["for", 554], ["proliferative", 558], ["cells", 572], ["and", 578], ["several", 582], ["immunohistochemical", 590], ["markers", 610], [",", 617], ["including", 619], ["nestin", 629], [".", 635], ["Additional", 637], ["rats", 648], ["were", 653], ["examined", 658], ["after", 667], ["a", 673], ["stab", 675], ["wound", 680], ["injury", 686], ["to", 693], ["assess", 696], ["the", 703], ["expression", 707], ["of", 718], ["two", 721], ["of", 725], ["these", 728], ["markers", 734], [",", 741], ["GFAP", 743], ["and", 748], ["nestin", 752], [",", 758], ["in", 760], ["reactive", 763], ["astrocytes", 772], [".", 782], ["All", 784], ["ENU", 788], ["-", 791], ["induced", 792], ["brain", 800], ["tumors", 806], ["(", 813], ["n", 814], ["=", 816], ["9", 818], [")", 819], ["were", 821], ["classified", 826], ["as", 837], ["gliomas", 840], ["(", 848], ["astrocytomas", 849], ["or", 862], ["oligoastrocytomas", 865], [")", 882], ["based", 884], ["on", 890], ["their", 893], ["histology", 899], ["and", 909], ["immunophenotype", 913], [".", 928], ["Nestin", 930], ["expression", 937], ["was", 948], ["noted", 952], ["in", 958], ["all", 961], ["tumors", 965], ["examined", 972], ["and", 981], ["was", 985], ["present", 989], ["in", 997], ["tumor", 1000], ["cells", 1006], ["as", 1012], ["well", 1015], ["as", 1020], ["endothelial", 1023], ["cells", 1035], [".", 1040], ["During", 1042], ["tumor", 1049], ["development", 1055], [",", 1066], ["we", 1068], ["consistently", 1071], ["noted", 1084], ["nestin", 1090], ["-", 1096], ["expressing", 1097], ["cells", 1108], ["bearing", 1114], ["multiple", 1122], ["processes", 1131], ["distributed", 1141], ["throughout", 1153], ["brain", 1164], ["parenchyma", 1170], [".", 1180], ["Both", 1182], ["single", 1187], ["cells", 1194], ["and", 1200], ["multiple", 1204], ["cell", 1213], ["clusters", 1218], ["were", 1227], ["observed", 1232], ["as", 1241], ["early", 1244], ["as", 1250], ["postnatal", 1253], ["day", 1263], ["30", 1267], ["in", 1270], ["all", 1273], ["ENU", 1277], ["-", 1280], ["exposed", 1281], ["brains", 1289], ["examined", 1296], ["(", 1305], ["n", 1306], ["=", 1308], ["11", 1310], [")", 1312], [".", 1313], ["Such", 1315], ["distinctive", 1320], ["nestin", 1332], ["-", 1338], ["expressing", 1339], ["cells", 1350], ["were", 1356], ["not", 1361], ["seen", 1365], ["in", 1370], ["nestin", 1373], ["-", 1379], ["stained", 1380], ["control", 1388], ["brains", 1396], ["or", 1403], ["ENU", 1406], ["-", 1409], ["exposed", 1410], ["brains", 1418], ["stained", 1425], ["for", 1433], ["GFAP", 1437], ["or", 1442], ["vimentin", 1445], [",", 1453], ["nor", 1455], ["was", 1459], ["such", 1463], ["a", 1468], ["cell", 1470], ["seen", 1475], ["in", 1480], ["a", 1483], ["stab", 1485], ["wound", 1490], ["model", 1496], ["used", 1502], ["to", 1507], ["assess", 1510], ["reactive", 1517], ["astrocytosis", 1526], [".", 1538], ["While", 1540], ["the", 1546], ["number", 1550], ["of", 1557], ["these", 1560], ["clusters", 1566], ["was", 1575], ["highly", 1579], ["variable", 1586], ["among", 1595], ["rats", 1601], [",", 1605], ["their", 1607], ["size", 1613], ["increased", 1618], ["between", 1628], ["30", 1636], ["and", 1639], ["90", 1643], ["days", 1646], [".", 1650], ["The", 1652], ["data", 1656], ["suggest", 1661], ["that", 1669], ["these", 1674], ["nestin", 1680], ["-", 1686], ["expressing", 1687], ["cells", 1698], ["represent", 1704], ["an", 1714], ["early", 1717], ["stage", 1723], ["of", 1729], ["the", 1732], ["neoplastic", 1736], ["process", 1747], [".", 1754], ["It", 1756], ["remains", 1759], ["to", 1767], ["be", 1770], ["determined", 1773], ["whether", 1784], ["these", 1792], ["cells", 1798], ["become", 1804], ["apparent", 1811], ["at", 1820], ["30", 1823], ["days", 1826], ["of", 1831], ["age", 1834], ["due", 1838], ["to", 1842], ["\"", 1845], ["dedifferentiation", 1846], ["\"", 1863], ["of", 1865], ["a", 1868], ["local", 1870], ["resident", 1876], ["astrocyte", 1885], ["or", 1895], ["astrocyte", 1898], ["precursor", 1908], ["cell", 1918], ["or", 1923], ["migration", 1926], ["of", 1936], ["a", 1939], ["relatively", 1941], ["undifferentiated", 1952], ["precursor", 1969], ["/", 1978], ["stem", 1979], ["cell", 1984], ["from", 1989], ["the", 1994], ["SVZ", 1998], [".", 2001]]}
{"context": "Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "7084fb7065f745f3870b1046a517cc3a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[231, 233], [199, 201], [93, 95], [186, 188], [153, 155], [112, 114], [75, 77]], "char_spans": [[1279, 1284], [1087, 1092], [628, 633], [1028, 1033], [869, 874], [704, 709], [550, 555]]}]}], "context_tokens": [["Clozapine", 0], ["reduces", 10], ["L-3,4-dihydroxyphenylalanine", 18], ["(", 47], ["L", 48], ["-", 49], ["Dopa)-induced", 50], ["dyskinesias", 64], ["in", 76], ["parkinsonian", 79], ["patients", 92], [".", 100], ["To", 102], ["test", 105], ["if", 110], ["the", 113], ["antidyskinetic", 117], ["effect", 132], ["of", 139], ["clozapine", 142], ["is", 152], ["related", 155], ["to", 163], ["antagonism", 166], ["at", 177], ["the", 180], ["dopamine", 184], ["D(4", 193], [")", 196], ["receptor", 198], [",", 206], ["we", 208], ["investigated", 211], ["the", 224], ["effect", 228], ["of", 235], ["8-methyl-6-(4-methyl-1-piperazinyl)-11H", 238], ["-", 277], ["pyrido[2,3-b][1", 278], [",", 293], ["4]benzodiazepine", 295], ["(", 312], ["JL-18", 313], [")", 318], [",", 319], ["a", 321], ["structural", 323], ["analog", 334], ["of", 341], ["clozapine", 344], ["which", 354], ["is", 360], ["more", 363], ["selective", 368], ["for", 378], ["this", 382], ["receptor", 387], [".", 395], ["Four", 397], ["1-methyl-4-phenyl-1,2,3", 402], [",", 425], ["6-tetrahydropyridine", 427], ["(", 448], ["MPTP)-treated", 449], ["cynomolgus", 463], ["monkeys", 474], ["with", 482], ["a", 487], ["stable", 489], ["parkinsonian", 496], ["syndrome", 509], ["and", 518], ["reproducible", 522], ["dyskinesias", 535], ["to", 547], ["L", 550], ["-", 551], ["Dopa", 552], ["were", 557], ["used", 562], ["in", 567], ["this", 570], ["study", 575], [".", 580], ["They", 582], ["were", 587], ["injected", 592], ["subcutaneously", 601], ["(", 616], ["s.c", 617], [".", 620], [")", 621], ["with", 623], ["L", 628], ["-", 629], ["Dopa", 630], ["methyl", 635], ["ester", 642], ["(", 648], ["125", 649], ["mg", 653], ["per", 656], ["animal", 660], [")", 666], ["plus", 668], ["benserazide", 673], ["(", 685], ["50", 686], ["mg", 689], ["per", 692], ["animal", 696], [";", 702], ["L", 704], ["-", 705], ["Dopa", 706], ["/", 710], ["benserazide", 711], [")", 722], ["alone", 724], ["or", 730], ["in", 733], ["combination", 736], ["with", 748], ["JL-18", 753], ["(", 759], ["at", 760], ["the", 763], ["doses", 767], ["of", 773], ["0.1", 776], [",", 779], ["0.3", 781], [",", 784], ["or", 786], ["0.9", 789], ["mg", 793], ["/", 795], ["kg", 796], [",", 798], ["s.c", 800], [".", 803], [")", 804], [".", 805], ["Subcutaneous", 807], ["injection", 820], ["of", 830], ["sterile", 833], ["saline", 841], ["was", 848], ["used", 852], ["as", 857], ["control", 860], [".", 867], ["L", 869], ["-", 870], ["Dopa", 871], ["/", 875], ["benserazide", 876], ["increased", 888], ["locomotion", 898], ["and", 909], ["improved", 913], ["parkinsonism", 922], ["but", 935], ["also", 939], ["induced", 944], ["dyskinesias", 952], [".", 963], ["Co", 965], ["-", 967], ["administration", 968], ["of", 983], ["JL-18", 986], [",", 991], ["at", 993], ["low", 996], ["doses", 1000], ["(", 1006], ["0.1", 1007], [",", 1010], ["0.3", 1012], ["mg", 1016], ["/", 1018], ["kg", 1019], [")", 1021], ["with", 1023], ["L", 1028], ["-", 1029], ["Dopa", 1030], ["/", 1034], ["benserazide", 1035], [",", 1046], ["produced", 1048], ["a", 1057], ["dose", 1059], ["-", 1063], ["dependent", 1064], ["reduction", 1074], ["in", 1084], ["L", 1087], ["-", 1088], ["Dopa", 1089], ["-", 1093], ["induced", 1094], ["dyskinesias", 1102], ["without", 1114], ["a", 1122], ["parallel", 1124], ["return", 1133], ["to", 1140], ["parkinsonism", 1143], [".", 1155], ["The", 1157], ["present", 1161], ["results", 1169], ["suggest", 1177], ["that", 1185], ["novel", 1190], ["selective", 1196], ["dopamine", 1206], ["D(4", 1215], [")", 1218], ["receptor", 1220], ["antagonists", 1229], ["may", 1241], ["represent", 1245], ["a", 1255], ["useful", 1257], ["tool", 1264], ["to", 1269], ["reduce", 1272], ["L", 1279], ["-", 1280], ["Dopa", 1281], ["-", 1285], ["induced", 1286], ["dyskinesias", 1294], [".", 1305]]}
{"context": "Nucleotide excision repair (NER) is a multistep process capable to remove a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires more than 30 proteins to perform the different steps, i.e. recognition of DNA damage, single strand incisions and excision of the lesion-containing DNA fragment and DNA repair synthesis/ligation. NER can operate via two subpathways: global genome repair (GGR) and a specialized pathway coupled to active transcription (transcription-coupled repair, TCR) and directed to DNA lesions in the transcribed strand of active genes. Both in vivo as well as in cultured cells the fast removal of transcription blocking lesions by TCR is crucial to escape from lethal effects of inhibited transcription inhibition The most delicate step in NER is the recognition of the DNA lesions in their different chromatin context and the mechanism of damage recognition in GGR and TCR is principally different and requires specific proteins. In GGR, the XPC-HR23B is essential for the formation of the incision complex. In TCR the Cockayne syndrome (CS) gene products are key players in the recognition of a stalled RNA polymerase the presumed signaling structure for repair of transcribed strands. In this study, we show that the extent of recovery of UV-inhibited transcription and TCR strictly depends on the amount of CSB protein as well as the amount of DNA damage present in the cell. This indicates that the ratio between DNA damage frequency and CSB protein concentration in the cell is rather critical for acute cellular response, i.e. recovery of inhibited transcription upon DNA damage infliction, and hence cellular survival.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "dfc374abfd1246c8bd30686662c51d05", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[582, 599]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["multistep", 38], ["process", 48], ["capable", 56], ["to", 64], ["remove", 67], ["a", 74], ["variety", 76], ["of", 84], ["DNA", 87], ["distorting", 91], ["lesions", 102], ["from", 110], ["prokaryotic", 115], ["and", 127], ["eukaryotic", 131], ["genomes", 142], [".", 149], ["In", 151], ["eukaryotic", 154], ["cells", 165], [",", 170], ["the", 172], ["process", 176], ["requires", 184], ["more", 193], ["than", 198], ["30", 203], ["proteins", 206], ["to", 215], ["perform", 218], ["the", 226], ["different", 230], ["steps", 240], [",", 245], ["i.e.", 247], ["recognition", 252], ["of", 264], ["DNA", 267], ["damage", 271], [",", 277], ["single", 279], ["strand", 286], ["incisions", 293], ["and", 303], ["excision", 307], ["of", 316], ["the", 319], ["lesion", 323], ["-", 329], ["containing", 330], ["DNA", 341], ["fragment", 345], ["and", 354], ["DNA", 358], ["repair", 362], ["synthesis", 369], ["/", 378], ["ligation", 379], [".", 387], ["NER", 389], ["can", 393], ["operate", 397], ["via", 405], ["two", 409], ["subpathways", 413], [":", 424], ["global", 426], ["genome", 433], ["repair", 440], ["(", 447], ["GGR", 448], [")", 451], ["and", 453], ["a", 457], ["specialized", 459], ["pathway", 471], ["coupled", 479], ["to", 487], ["active", 490], ["transcription", 497], ["(", 511], ["transcription", 512], ["-", 525], ["coupled", 526], ["repair", 534], [",", 540], ["TCR", 542], [")", 545], ["and", 547], ["directed", 551], ["to", 560], ["DNA", 563], ["lesions", 567], ["in", 575], ["the", 578], ["transcribed", 582], ["strand", 594], ["of", 601], ["active", 604], ["genes", 611], [".", 616], ["Both", 618], ["in", 623], ["vivo", 626], ["as", 631], ["well", 634], ["as", 639], ["in", 642], ["cultured", 645], ["cells", 654], ["the", 660], ["fast", 664], ["removal", 669], ["of", 677], ["transcription", 680], ["blocking", 694], ["lesions", 703], ["by", 711], ["TCR", 714], ["is", 718], ["crucial", 721], ["to", 729], ["escape", 732], ["from", 739], ["lethal", 744], ["effects", 751], ["of", 759], ["inhibited", 762], ["transcription", 772], ["inhibition", 786], ["The", 797], ["most", 801], ["delicate", 806], ["step", 815], ["in", 820], ["NER", 823], ["is", 827], ["the", 830], ["recognition", 834], ["of", 846], ["the", 849], ["DNA", 853], ["lesions", 857], ["in", 865], ["their", 868], ["different", 874], ["chromatin", 884], ["context", 894], ["and", 902], ["the", 906], ["mechanism", 910], ["of", 920], ["damage", 923], ["recognition", 930], ["in", 942], ["GGR", 945], ["and", 949], ["TCR", 953], ["is", 957], ["principally", 960], ["different", 972], ["and", 982], ["requires", 986], ["specific", 995], ["proteins", 1004], [".", 1012], ["In", 1014], ["GGR", 1017], [",", 1020], ["the", 1022], ["XPC", 1026], ["-", 1029], ["HR23B", 1030], ["is", 1036], ["essential", 1039], ["for", 1049], ["the", 1053], ["formation", 1057], ["of", 1067], ["the", 1070], ["incision", 1074], ["complex", 1083], [".", 1090], ["In", 1092], ["TCR", 1095], ["the", 1099], ["Cockayne", 1103], ["syndrome", 1112], ["(", 1121], ["CS", 1122], [")", 1124], ["gene", 1126], ["products", 1131], ["are", 1140], ["key", 1144], ["players", 1148], ["in", 1156], ["the", 1159], ["recognition", 1163], ["of", 1175], ["a", 1178], ["stalled", 1180], ["RNA", 1188], ["polymerase", 1192], ["the", 1203], ["presumed", 1207], ["signaling", 1216], ["structure", 1226], ["for", 1236], ["repair", 1240], ["of", 1247], ["transcribed", 1250], ["strands", 1262], [".", 1269], ["In", 1271], ["this", 1274], ["study", 1279], [",", 1284], ["we", 1286], ["show", 1289], ["that", 1294], ["the", 1299], ["extent", 1303], ["of", 1310], ["recovery", 1313], ["of", 1322], ["UV", 1325], ["-", 1327], ["inhibited", 1328], ["transcription", 1338], ["and", 1352], ["TCR", 1356], ["strictly", 1360], ["depends", 1369], ["on", 1377], ["the", 1380], ["amount", 1384], ["of", 1391], ["CSB", 1394], ["protein", 1398], ["as", 1406], ["well", 1409], ["as", 1414], ["the", 1417], ["amount", 1421], ["of", 1428], ["DNA", 1431], ["damage", 1435], ["present", 1442], ["in", 1450], ["the", 1453], ["cell", 1457], [".", 1461], ["This", 1463], ["indicates", 1468], ["that", 1478], ["the", 1483], ["ratio", 1487], ["between", 1493], ["DNA", 1501], ["damage", 1505], ["frequency", 1512], ["and", 1522], ["CSB", 1526], ["protein", 1530], ["concentration", 1538], ["in", 1552], ["the", 1555], ["cell", 1559], ["is", 1564], ["rather", 1567], ["critical", 1574], ["for", 1583], ["acute", 1587], ["cellular", 1593], ["response", 1602], [",", 1610], ["i.e.", 1612], ["recovery", 1617], ["of", 1626], ["inhibited", 1629], ["transcription", 1639], ["upon", 1653], ["DNA", 1658], ["damage", 1662], ["infliction", 1669], [",", 1679], ["and", 1681], ["hence", 1685], ["cellular", 1691], ["survival", 1700], [".", 1708]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical areas. The disease is responsible for migraine with aura and ischemic strokes, and is associated with various degrees of cognitive impairment and with mood disturbances. CADASIL is considered as a unique model to investigate what is known as \"subcortical ischemic vascular dementia.\" Recent data suggest that the number of lacunar infarctions and severity of cerebral atrophy are the main magnetic resonance imaging markers associated with cognitive and motor disabilities in this disorder. Mood disturbances are reported in 10% to 20% of patients, most often in association with cognitive alterations. Their exact origin remains unknown; the presence of ischemic lesions within the basal ganglia or the frontal white matter may promote the occurrence of these symptoms. Further studies are needed to better understand the relationships between cerebral lesions and both cognitive and psychiatric symptoms in this small-vessel disease of the brain.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "b2f73e6827624d46a50622245bc0bc8c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[182, 192]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["small", 117], ["-", 122], ["artery", 123], ["disease", 130], ["of", 138], ["mid", 141], ["-", 144], ["adulthood", 145], ["caused", 155], ["by", 162], ["mutations", 165], ["of", 175], ["the", 178], ["NOTCH3", 182], ["gene", 189], [".", 193], ["The", 195], ["disease", 199], ["is", 207], ["responsible", 210], ["for", 222], ["widespread", 226], ["white", 237], ["-", 242], ["matter", 243], ["lesions", 250], ["associated", 258], ["with", 269], ["lacunar", 274], ["infarctions", 282], ["in", 294], ["various", 297], ["subcortical", 305], ["areas", 317], [".", 322], ["The", 324], ["disease", 328], ["is", 336], ["responsible", 339], ["for", 351], ["migraine", 355], ["with", 364], ["aura", 369], ["and", 374], ["ischemic", 378], ["strokes", 387], [",", 394], ["and", 396], ["is", 400], ["associated", 403], ["with", 414], ["various", 419], ["degrees", 427], ["of", 435], ["cognitive", 438], ["impairment", 448], ["and", 459], ["with", 463], ["mood", 468], ["disturbances", 473], [".", 485], ["CADASIL", 487], ["is", 495], ["considered", 498], ["as", 509], ["a", 512], ["unique", 514], ["model", 521], ["to", 527], ["investigate", 530], ["what", 542], ["is", 547], ["known", 550], ["as", 556], ["\"", 559], ["subcortical", 560], ["ischemic", 572], ["vascular", 581], ["dementia", 590], [".", 598], ["\"", 599], ["Recent", 601], ["data", 608], ["suggest", 613], ["that", 621], ["the", 626], ["number", 630], ["of", 637], ["lacunar", 640], ["infarctions", 648], ["and", 660], ["severity", 664], ["of", 673], ["cerebral", 676], ["atrophy", 685], ["are", 693], ["the", 697], ["main", 701], ["magnetic", 706], ["resonance", 715], ["imaging", 725], ["markers", 733], ["associated", 741], ["with", 752], ["cognitive", 757], ["and", 767], ["motor", 771], ["disabilities", 777], ["in", 790], ["this", 793], ["disorder", 798], [".", 806], ["Mood", 808], ["disturbances", 813], ["are", 826], ["reported", 830], ["in", 839], ["10", 842], ["%", 844], ["to", 846], ["20", 849], ["%", 851], ["of", 853], ["patients", 856], [",", 864], ["most", 866], ["often", 871], ["in", 877], ["association", 880], ["with", 892], ["cognitive", 897], ["alterations", 907], [".", 918], ["Their", 920], ["exact", 926], ["origin", 932], ["remains", 939], ["unknown", 947], [";", 954], ["the", 956], ["presence", 960], ["of", 969], ["ischemic", 972], ["lesions", 981], ["within", 989], ["the", 996], ["basal", 1000], ["ganglia", 1006], ["or", 1014], ["the", 1017], ["frontal", 1021], ["white", 1029], ["matter", 1035], ["may", 1042], ["promote", 1046], ["the", 1054], ["occurrence", 1058], ["of", 1069], ["these", 1072], ["symptoms", 1078], [".", 1086], ["Further", 1088], ["studies", 1096], ["are", 1104], ["needed", 1108], ["to", 1115], ["better", 1118], ["understand", 1125], ["the", 1136], ["relationships", 1140], ["between", 1154], ["cerebral", 1162], ["lesions", 1171], ["and", 1179], ["both", 1183], ["cognitive", 1188], ["and", 1198], ["psychiatric", 1202], ["symptoms", 1214], ["in", 1223], ["this", 1226], ["small", 1231], ["-", 1236], ["vessel", 1237], ["disease", 1244], ["of", 1252], ["the", 1255], ["brain", 1259], [".", 1264]]}
{"context": "To investigate the migraine locus around the C19p13 region through analysis of the NOTCH3 gene (C19p13.2-p13.1), previously shown to be a gene involved in CADASIL and the TNFSF7 gene (C19p13), homologous to the ligands of TNF-alpha and TNF-beta, genes that have previously been associated with migraine. The NOTCH3 gene was analysed by sequencing all exons with known CADASIL mutations in a typical (non-familial hemiplegic) migraine family (MF1) that has previously been shown to be linked to C19p13. The TNFSF7 gene was investigated through SNP association analysis using a matched case-control migraine population. NOTCH3 gene sequencing results for affected members of MF1 proved to be negative for all known sequence variants giving rise to mutations for CADASIL. TNFSF7 gene chi-square results showed non-significant P values across all populations tested against controls, except for the MO subgroup which displayed a possible association with the TNFSF7 SNP (genotype, allele analysis P = 0.036, P = 0.017 respectively). Our results suggest that common migraine is not caused by any known CADASIL mutations in the NOTCH3 gene of interest. However, the TNFSF7 gene displayed signs of involvement in a MO affected population and indicates that further independent studies of this marker are warranted.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "fc24f2392a694a878abd703ed179be42", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[13, 14], [203, 204], [59, 60], [114, 115]], "char_spans": [[83, 93], [1122, 1132], [308, 318], [618, 628]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["migraine", 19], ["locus", 28], ["around", 34], ["the", 41], ["C19p13", 45], ["region", 52], ["through", 59], ["analysis", 67], ["of", 76], ["the", 79], ["NOTCH3", 83], ["gene", 90], ["(", 95], ["C19p13.2-p13.1", 96], [")", 110], [",", 111], ["previously", 113], ["shown", 124], ["to", 130], ["be", 133], ["a", 136], ["gene", 138], ["involved", 143], ["in", 152], ["CADASIL", 155], ["and", 163], ["the", 167], ["TNFSF7", 171], ["gene", 178], ["(", 183], ["C19p13", 184], [")", 190], [",", 191], ["homologous", 193], ["to", 204], ["the", 207], ["ligands", 211], ["of", 219], ["TNF", 222], ["-", 225], ["alpha", 226], ["and", 232], ["TNF", 236], ["-", 239], ["beta", 240], [",", 244], ["genes", 246], ["that", 252], ["have", 257], ["previously", 262], ["been", 273], ["associated", 278], ["with", 289], ["migraine", 294], [".", 302], ["The", 304], ["NOTCH3", 308], ["gene", 315], ["was", 320], ["analysed", 324], ["by", 333], ["sequencing", 336], ["all", 347], ["exons", 351], ["with", 357], ["known", 362], ["CADASIL", 368], ["mutations", 376], ["in", 386], ["a", 389], ["typical", 391], ["(", 399], ["non", 400], ["-", 403], ["familial", 404], ["hemiplegic", 413], [")", 423], ["migraine", 425], ["family", 434], ["(", 441], ["MF1", 442], [")", 445], ["that", 447], ["has", 452], ["previously", 456], ["been", 467], ["shown", 472], ["to", 478], ["be", 481], ["linked", 484], ["to", 491], ["C19p13", 494], [".", 500], ["The", 502], ["TNFSF7", 506], ["gene", 513], ["was", 518], ["investigated", 522], ["through", 535], ["SNP", 543], ["association", 547], ["analysis", 559], ["using", 568], ["a", 574], ["matched", 576], ["case", 584], ["-", 588], ["control", 589], ["migraine", 597], ["population", 606], [".", 616], ["NOTCH3", 618], ["gene", 625], ["sequencing", 630], ["results", 641], ["for", 649], ["affected", 653], ["members", 662], ["of", 670], ["MF1", 673], ["proved", 677], ["to", 684], ["be", 687], ["negative", 690], ["for", 699], ["all", 703], ["known", 707], ["sequence", 713], ["variants", 722], ["giving", 731], ["rise", 738], ["to", 743], ["mutations", 746], ["for", 756], ["CADASIL", 760], [".", 767], ["TNFSF7", 769], ["gene", 776], ["chi", 781], ["-", 784], ["square", 785], ["results", 792], ["showed", 800], ["non", 807], ["-", 810], ["significant", 811], ["P", 823], ["values", 825], ["across", 832], ["all", 839], ["populations", 843], ["tested", 855], ["against", 862], ["controls", 870], [",", 878], ["except", 880], ["for", 887], ["the", 891], ["MO", 895], ["subgroup", 898], ["which", 907], ["displayed", 913], ["a", 923], ["possible", 925], ["association", 934], ["with", 946], ["the", 951], ["TNFSF7", 955], ["SNP", 962], ["(", 966], ["genotype", 967], [",", 975], ["allele", 977], ["analysis", 984], ["P", 993], ["=", 995], ["0.036", 997], [",", 1002], ["P", 1004], ["=", 1006], ["0.017", 1008], ["respectively", 1014], [")", 1026], [".", 1027], ["Our", 1029], ["results", 1033], ["suggest", 1041], ["that", 1049], ["common", 1054], ["migraine", 1061], ["is", 1070], ["not", 1073], ["caused", 1077], ["by", 1084], ["any", 1087], ["known", 1091], ["CADASIL", 1097], ["mutations", 1105], ["in", 1115], ["the", 1118], ["NOTCH3", 1122], ["gene", 1129], ["of", 1134], ["interest", 1137], [".", 1145], ["However", 1147], [",", 1154], ["the", 1156], ["TNFSF7", 1160], ["gene", 1167], ["displayed", 1172], ["signs", 1182], ["of", 1188], ["involvement", 1191], ["in", 1203], ["a", 1206], ["MO", 1208], ["affected", 1211], ["population", 1220], ["and", 1231], ["indicates", 1235], ["that", 1245], ["further", 1250], ["independent", 1258], ["studies", 1270], ["of", 1278], ["this", 1281], ["marker", 1286], ["are", 1293], ["warranted", 1297], [".", 1306]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular\ndystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "938e72116a3b4c978813f177d96b52ba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["\n", 63], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. Drugs inhibiting this transporter have recently been approved for clinical use and have been suggested to have potential renoprotective benefits by limiting glycotoxicity in the proximal tubule. We aimed to determine the renoprotective benefits of empagliflozin, an SGLT2 inhibitor, independent of its glucose lowering effect. We induced diabetes using a low dose streptozotocin protocol in 7-8 week old endothelial nitric oxide (eNOS) synthase knockout mice. We measured fasting blood glucose on a monthly basis, terminal urinary albumin/creatinine ratio. Renal histology was assessed for inflammatory and fibrotic changes. Renal cortical mRNA transcription of inflammatory and profibrotic cytokines, glucose transporters and protein expression of SGLT2 and GLUT1 were determined. Outcomes were compared to diabetic animals receiving the angiotensin receptor blocker telmisartan (current best practice). Diabetic mice had high matched blood glucose levels. Empagliflozin did not attenuate diabetes-induced albuminuria, unlike telmisartan. Empagliflozin did not improve glomerulosclerosis, tubular atrophy, tubulointerstitial inflammation or fibrosis, while telmisartan attenuated these. Empagliflozin did not modify tubular toll-like receptor-2 expression in diabetic mice. Empagliflozin did not reduce the upregulation of macrophage chemoattractant protein-1 (MCP-1), transforming growth factor \u03b21 and fibronectin mRNA observed in the diabetic animals, while telmisartan decreased transcription of MCP-1 and fibronectin. Empagliflozin increased GLUT1 mRNA expression and telmisartan increased SGLT2 mRNA expression in comparison to untreated diabetic mice. However no significant difference was found in protein expression of GLUT1 or SGLT2 among the different groups. Hence SGLT2 inhibition does not have renoprotective benefits independent of glucose lowering.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "7319749c99d7437480b077f9c67163c7", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[144, 144], [288, 288], [5, 5], [266, 266], [295, 295], [66, 66], [17, 17]], "char_spans": [[914, 918], [1902, 1906], [32, 36], [1760, 1764], [1942, 1946], [431, 435], [94, 98]]}]}], "context_tokens": [["Sodium", 0], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["is", 39], ["the", 42], ["main", 46], ["luminal", 51], ["glucose", 59], ["transporter", 67], ["in", 79], ["the", 82], ["kidney", 86], [".", 92], ["SGLT2", 94], ["inhibition", 100], ["results", 111], ["in", 119], ["glycosuria", 122], ["and", 133], ["improved", 137], ["glycaemic", 146], ["control", 156], [".", 163], ["Drugs", 165], ["inhibiting", 171], ["this", 182], ["transporter", 187], ["have", 199], ["recently", 204], ["been", 213], ["approved", 218], ["for", 227], ["clinical", 231], ["use", 240], ["and", 244], ["have", 248], ["been", 253], ["suggested", 258], ["to", 268], ["have", 271], ["potential", 276], ["renoprotective", 286], ["benefits", 301], ["by", 310], ["limiting", 313], ["glycotoxicity", 322], ["in", 336], ["the", 339], ["proximal", 343], ["tubule", 352], [".", 358], ["We", 360], ["aimed", 363], ["to", 369], ["determine", 372], ["the", 382], ["renoprotective", 386], ["benefits", 401], ["of", 410], ["empagliflozin", 413], [",", 426], ["an", 428], ["SGLT2", 431], ["inhibitor", 437], [",", 446], ["independent", 448], ["of", 460], ["its", 463], ["glucose", 467], ["lowering", 475], ["effect", 484], [".", 490], ["We", 492], ["induced", 495], ["diabetes", 503], ["using", 512], ["a", 518], ["low", 520], ["dose", 524], ["streptozotocin", 529], ["protocol", 544], ["in", 553], ["7", 556], ["-", 557], ["8", 558], ["week", 560], ["old", 565], ["endothelial", 569], ["nitric", 581], ["oxide", 588], ["(", 594], ["eNOS", 595], [")", 599], ["synthase", 601], ["knockout", 610], ["mice", 619], [".", 623], ["We", 625], ["measured", 628], ["fasting", 637], ["blood", 645], ["glucose", 651], ["on", 659], ["a", 662], ["monthly", 664], ["basis", 672], [",", 677], ["terminal", 679], ["urinary", 688], ["albumin", 696], ["/", 703], ["creatinine", 704], ["ratio", 715], [".", 720], ["Renal", 722], ["histology", 728], ["was", 738], ["assessed", 742], ["for", 751], ["inflammatory", 755], ["and", 768], ["fibrotic", 772], ["changes", 781], [".", 788], ["Renal", 790], ["cortical", 796], ["mRNA", 805], ["transcription", 810], ["of", 824], ["inflammatory", 827], ["and", 840], ["profibrotic", 844], ["cytokines", 856], [",", 865], ["glucose", 867], ["transporters", 875], ["and", 888], ["protein", 892], ["expression", 900], ["of", 911], ["SGLT2", 914], ["and", 920], ["GLUT1", 924], ["were", 930], ["determined", 935], [".", 945], ["Outcomes", 947], ["were", 956], ["compared", 961], ["to", 970], ["diabetic", 973], ["animals", 982], ["receiving", 990], ["the", 1000], ["angiotensin", 1004], ["receptor", 1016], ["blocker", 1025], ["telmisartan", 1033], ["(", 1045], ["current", 1046], ["best", 1054], ["practice", 1059], [")", 1067], [".", 1068], ["Diabetic", 1070], ["mice", 1079], ["had", 1084], ["high", 1088], ["matched", 1093], ["blood", 1101], ["glucose", 1107], ["levels", 1115], [".", 1121], ["Empagliflozin", 1123], ["did", 1137], ["not", 1141], ["attenuate", 1145], ["diabetes", 1155], ["-", 1163], ["induced", 1164], ["albuminuria", 1172], [",", 1183], ["unlike", 1185], ["telmisartan", 1192], [".", 1203], ["Empagliflozin", 1205], ["did", 1219], ["not", 1223], ["improve", 1227], ["glomerulosclerosis", 1235], [",", 1253], ["tubular", 1255], ["atrophy", 1263], [",", 1270], ["tubulointerstitial", 1272], ["inflammation", 1291], ["or", 1304], ["fibrosis", 1307], [",", 1315], ["while", 1317], ["telmisartan", 1323], ["attenuated", 1335], ["these", 1346], [".", 1351], ["Empagliflozin", 1353], ["did", 1367], ["not", 1371], ["modify", 1375], ["tubular", 1382], ["toll", 1390], ["-", 1394], ["like", 1395], ["receptor-2", 1400], ["expression", 1411], ["in", 1422], ["diabetic", 1425], ["mice", 1434], [".", 1438], ["Empagliflozin", 1440], ["did", 1454], ["not", 1458], ["reduce", 1462], ["the", 1469], ["upregulation", 1473], ["of", 1486], ["macrophage", 1489], ["chemoattractant", 1500], ["protein-1", 1516], ["(", 1526], ["MCP-1", 1527], [")", 1532], [",", 1533], ["transforming", 1535], ["growth", 1548], ["factor", 1555], ["\u03b21", 1562], ["and", 1565], ["fibronectin", 1569], ["mRNA", 1581], ["observed", 1586], ["in", 1595], ["the", 1598], ["diabetic", 1602], ["animals", 1611], [",", 1618], ["while", 1620], ["telmisartan", 1626], ["decreased", 1638], ["transcription", 1648], ["of", 1662], ["MCP-1", 1665], ["and", 1671], ["fibronectin", 1675], [".", 1686], ["Empagliflozin", 1688], ["increased", 1702], ["GLUT1", 1712], ["mRNA", 1718], ["expression", 1723], ["and", 1734], ["telmisartan", 1738], ["increased", 1750], ["SGLT2", 1760], ["mRNA", 1766], ["expression", 1771], ["in", 1782], ["comparison", 1785], ["to", 1796], ["untreated", 1799], ["diabetic", 1809], ["mice", 1818], [".", 1822], ["However", 1824], ["no", 1832], ["significant", 1835], ["difference", 1847], ["was", 1858], ["found", 1862], ["in", 1868], ["protein", 1871], ["expression", 1879], ["of", 1890], ["GLUT1", 1893], ["or", 1899], ["SGLT2", 1902], ["among", 1908], ["the", 1914], ["different", 1918], ["groups", 1928], [".", 1934], ["Hence", 1936], ["SGLT2", 1942], ["inhibition", 1948], ["does", 1959], ["not", 1964], ["have", 1968], ["renoprotective", 1973], ["benefits", 1988], ["independent", 1997], ["of", 2009], ["glucose", 2012], ["lowering", 2020], [".", 2028]]}
{"context": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "d33ad3bcc29749269c3aa087a59610af", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[38, 55]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["(", 26], ["DM1", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], ["disorder", 57], [",", 65], ["caused", 67], ["by", 74], ["an", 77], ["expansion", 80], ["of", 90], ["a", 93], ["CTG", 95], ["triplet", 99], ["repeat", 107], ["in", 114], ["the", 117], ["DMPK", 121], ["gene", 126], [".", 130], ["The", 132], ["aims", 136], ["of", 141], ["the", 144], ["present", 148], ["study", 156], ["were", 162], ["to", 167], ["classify", 170], ["a", 179], ["cohort", 181], ["of", 188], ["children", 191], ["with", 200], ["DM1", 205], [",", 208], ["to", 210], ["describe", 213], ["their", 222], ["neuropsychiatric", 228], ["problems", 245], ["and", 254], ["cognitive", 258], ["level", 268], [",", 273], ["to", 275], ["estimate", 278], ["the", 287], ["size", 291], ["of", 296], ["the", 299], ["CTG", 303], ["expansion", 307], [",", 316], ["and", 318], ["to", 322], ["correlate", 325], ["the", 335], ["molecular", 339], ["findings", 349], ["with", 358], ["the", 363], ["neuropsychiatric", 367], ["problems", 384], [".", 392], ["Fifty", 394], ["-", 399], ["seven", 400], ["children", 406], ["and", 415], ["adolescents", 419], ["(", 431], ["26", 432], ["females", 435], [";", 442], ["31", 444], ["males", 447], [")", 452], ["with", 454], ["DM1", 459], ["(", 463], ["CTG", 464], ["repeats", 468], [">", 476], ["40", 478], [")", 480], ["were", 482], ["included", 487], ["in", 496], ["the", 499], ["study", 503], [".", 508], ["The", 510], ["following", 514], ["instruments", 524], ["were", 536], ["used", 541], [":", 545], ["Autism", 547], ["Diagnostic", 554], ["Interview", 565], ["-", 574], ["Revised", 575], ["(", 583], ["ADI", 584], ["-", 587], ["R", 588], [")", 589], [",", 590], ["5", 592], ["-", 593], ["15", 594], [",", 596], ["Griffiths", 598], ["Mental", 608], ["Development", 615], ["Scales", 627], [",", 633], ["and", 635], ["the", 639], ["Wechsler", 643], ["Scales", 652], [".", 658], ["Based", 660], ["on", 666], ["age", 669], ["at", 673], ["onset", 676], ["and", 682], ["presenting", 686], ["symptoms", 697], [",", 705], ["the", 707], ["children", 711], ["were", 720], ["divided", 725], ["into", 733], ["four", 738], ["DM1", 743], ["groups", 747], [";", 753], ["severe", 755], ["congenital", 762], ["(", 773], ["n", 774], ["=", 776], ["19", 778], [")", 780], [",", 781], ["mild", 783], ["congenital", 788], ["(", 799], ["n", 800], ["=", 802], ["18", 804], [")", 806], [",", 807], ["childhood", 809], ["(", 819], ["n", 820], ["=", 822], ["18", 824], [")", 826], [",", 827], ["and", 829], ["classical", 833], ["DM1", 843], ["(", 847], ["n", 848], ["=", 850], ["2", 852], [")", 853], [".", 854], ["Forty", 856], ["-", 861], ["nine", 862], ["percent", 867], ["had", 875], ["an", 879], ["autism", 882], ["spectrum", 889], ["disorder", 898], ["(", 907], ["ASD", 908], [")", 911], ["and", 913], ["autistic", 917], ["disorder", 926], ["was", 935], ["the", 939], ["most", 943], ["common", 948], ["diagnosis", 955], ["present", 965], ["in", 973], ["35", 976], ["%", 978], ["of", 980], ["the", 983], ["subjects", 987], [".", 995], ["Eighty", 997], ["-", 1003], ["six", 1004], ["percent", 1008], ["of", 1016], ["the", 1019], ["individuals", 1023], ["with", 1035], ["DM1", 1040], ["had", 1044], ["mental", 1048], ["retardation", 1055], ["(", 1067], ["MR", 1068], [")", 1070], [",", 1071], ["most", 1073], ["of", 1078], ["them", 1081], ["moderate", 1086], ["or", 1095], ["severe", 1098], ["MR", 1105], [".", 1107], ["ASD", 1109], ["was", 1113], ["significantly", 1117], ["correlated", 1131], ["with", 1142], ["the", 1147], ["DM1", 1151], ["form", 1155], [";", 1159], ["the", 1161], ["more", 1165], ["severe", 1170], ["the", 1177], ["form", 1181], ["of", 1186], ["DM1", 1189], [",", 1192], ["the", 1194], ["higher", 1198], ["the", 1205], ["frequency", 1209], ["of", 1219], ["ASD", 1222], [".", 1225], ["The", 1227], ["frequency", 1231], ["of", 1241], ["ASD", 1244], ["increased", 1248], ["with", 1258], ["increasing", 1263], ["CTG", 1274], ["repeat", 1278], ["expansions", 1285], [".", 1295], ["ASD", 1297], ["and/or", 1301], ["other", 1308], ["neuropsychiatric", 1314], ["disorders", 1331], ["such", 1341], ["as", 1346], ["attention", 1349], ["deficit", 1359], ["hyperactivity", 1367], ["disorder", 1381], [",", 1389], ["and", 1391], ["Tourette", 1395], ["'s", 1403], ["disorder", 1406], ["were", 1415], ["found", 1420], ["in", 1426], ["54", 1429], ["%", 1431], ["of", 1433], ["the", 1436], ["total", 1440], ["DM1", 1446], ["group", 1450], [".", 1455], ["In", 1457], ["conclusion", 1460], [",", 1470], ["awareness", 1472], ["of", 1482], ["ASD", 1485], ["comorbidity", 1489], ["in", 1501], ["DM1", 1504], ["is", 1508], ["essential", 1511], [".", 1520], ["Further", 1522], ["studies", 1530], ["are", 1538], ["warranted", 1542], ["to", 1552], ["elucidate", 1555], ["the", 1565], ["molecular", 1569], ["etiology", 1579], ["causing", 1588], ["neurodevelopmental", 1596], ["symptoms", 1615], ["such", 1624], ["as", 1629], ["ASD", 1632], ["and", 1636], ["MR", 1640], ["in", 1643], ["DM1", 1646], [".", 1649]]}
{"context": "L-DOPA-induced dyskinesia is a common side effect developed after chronic treatment with 3,4-dihydroxyphenyl-l-alanine (l-DOPA) in Parkinson's disease. The biological mechanisms behind this side effect are not fully comprehended although involvement of dopaminergic, serotonergic, and glutamatergic systems has been suggested. The present study utilizes in vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and l-DOPA (4 mg/kg, including benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats. Recordings were performed before and after local L-DOPA application in the striatum. In addition, effects from the 5-HT(1A) receptor agonist (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OHDPAT; 1 mg/kg) was assessed on glutamate release and on dyskinetic behavior. The results revealed a bilateral \u2248 30% reduction of basal extracellular glutamate concentration and attenuated potassium-evoked glutamate release after a unilateral dopamine-depletion in L-DOPA na\u00efve animals. In dyskinetic subjects, basal glutamate concentration was comparable to normal controls, although potassium-evoked glutamate release was reduced to similar levels as in drug na\u00efve dopamine-lesioned animals. Furthermore, acute striatal L-DOPA administration attenuated glutamate release in all groups, except in the dopamine-lesioned striatum of dyskinetic animals. Co-administration of 8-OHDPAT and L-DOPA decreased dyskinesia in dopamine-lesioned animals, but did not affect potassium-evoked glutamate release, which was seen in normal animals. These findings indicate altered glutamate transmission upon dopamine-depletion and dyskinesia.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "51cc9b8c720b4a8da80558914feaa7f7", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[258, 260], [22, 24], [116, 118], [230, 232], [72, 74], [0, 2], [187, 189]], "char_spans": [[1542, 1547], [120, 125], [699, 704], [1378, 1383], [446, 451], [0, 5], [1121, 1126]]}]}], "context_tokens": [["L", 0], ["-", 1], ["DOPA", 2], ["-", 6], ["induced", 7], ["dyskinesia", 15], ["is", 26], ["a", 29], ["common", 31], ["side", 38], ["effect", 43], ["developed", 50], ["after", 60], ["chronic", 66], ["treatment", 74], ["with", 84], ["3,4-dihydroxyphenyl", 89], ["-", 108], ["l", 109], ["-", 110], ["alanine", 111], ["(", 119], ["l", 120], ["-", 121], ["DOPA", 122], [")", 126], ["in", 128], ["Parkinson", 131], ["'s", 140], ["disease", 143], [".", 150], ["The", 152], ["biological", 156], ["mechanisms", 167], ["behind", 178], ["this", 185], ["side", 190], ["effect", 195], ["are", 202], ["not", 206], ["fully", 210], ["comprehended", 216], ["although", 229], ["involvement", 238], ["of", 250], ["dopaminergic", 253], [",", 265], ["serotonergic", 267], [",", 279], ["and", 281], ["glutamatergic", 285], ["systems", 299], ["has", 307], ["been", 311], ["suggested", 316], [".", 325], ["The", 327], ["present", 331], ["study", 339], ["utilizes", 345], ["in", 354], ["vivo", 357], ["amperometry", 362], ["to", 374], ["investigate", 377], ["the", 389], ["impact", 393], ["from", 400], ["unilateral", 405], ["6-hydroxydopamine", 416], ["lesions", 434], ["and", 442], ["l", 446], ["-", 447], ["DOPA", 448], ["(", 453], ["4", 454], ["mg", 456], ["/", 458], ["kg", 459], [",", 461], ["including", 463], ["benserazide", 473], ["15", 485], ["mg", 488], ["/", 490], ["kg", 491], [")", 493], ["-induced", 495], ["dyskinetic", 504], ["behavior", 515], ["on", 524], ["striatal", 527], ["basal", 536], ["extracellular", 542], ["glutamate", 556], ["concentration", 566], ["and", 580], ["potassium", 584], ["-", 593], ["evoked", 594], ["glutamate", 601], ["release", 611], ["in", 619], ["urethane", 622], ["-", 630], ["anesthetized", 631], ["rats", 644], [".", 648], ["Recordings", 650], ["were", 661], ["performed", 666], ["before", 676], ["and", 683], ["after", 687], ["local", 693], ["L", 699], ["-", 700], ["DOPA", 701], ["application", 706], ["in", 718], ["the", 721], ["striatum", 725], [".", 733], ["In", 735], ["addition", 738], [",", 746], ["effects", 748], ["from", 756], ["the", 761], ["5-HT(1A", 765], [")", 772], ["receptor", 774], ["agonist", 783], ["(", 791], ["2R)-(+)-8-hydroxy-2-(di", 792], ["-", 815], ["n", 816], ["-", 817], ["propylamino)tetralin", 818], ["hydrobromide", 839], ["(", 852], ["8-OHDPAT", 853], [";", 861], ["1", 863], ["mg", 865], ["/", 867], ["kg", 868], [")", 870], ["was", 872], ["assessed", 876], ["on", 885], ["glutamate", 888], ["release", 898], ["and", 906], ["on", 910], ["dyskinetic", 913], ["behavior", 924], [".", 932], ["The", 934], ["results", 938], ["revealed", 946], ["a", 955], ["bilateral", 957], ["\u2248", 967], ["30", 969], ["%", 971], ["reduction", 973], ["of", 983], ["basal", 986], ["extracellular", 992], ["glutamate", 1006], ["concentration", 1016], ["and", 1030], ["attenuated", 1034], ["potassium", 1045], ["-", 1054], ["evoked", 1055], ["glutamate", 1062], ["release", 1072], ["after", 1080], ["a", 1086], ["unilateral", 1088], ["dopamine", 1099], ["-", 1107], ["depletion", 1108], ["in", 1118], ["L", 1121], ["-", 1122], ["DOPA", 1123], ["na\u00efve", 1128], ["animals", 1134], [".", 1141], ["In", 1143], ["dyskinetic", 1146], ["subjects", 1157], [",", 1165], ["basal", 1167], ["glutamate", 1173], ["concentration", 1183], ["was", 1197], ["comparable", 1201], ["to", 1212], ["normal", 1215], ["controls", 1222], [",", 1230], ["although", 1232], ["potassium", 1241], ["-", 1250], ["evoked", 1251], ["glutamate", 1258], ["release", 1268], ["was", 1276], ["reduced", 1280], ["to", 1288], ["similar", 1291], ["levels", 1299], ["as", 1306], ["in", 1309], ["drug", 1312], ["na\u00efve", 1317], ["dopamine", 1323], ["-", 1331], ["lesioned", 1332], ["animals", 1341], [".", 1348], ["Furthermore", 1350], [",", 1361], ["acute", 1363], ["striatal", 1369], ["L", 1378], ["-", 1379], ["DOPA", 1380], ["administration", 1385], ["attenuated", 1400], ["glutamate", 1411], ["release", 1421], ["in", 1429], ["all", 1432], ["groups", 1436], [",", 1442], ["except", 1444], ["in", 1451], ["the", 1454], ["dopamine", 1458], ["-", 1466], ["lesioned", 1467], ["striatum", 1476], ["of", 1485], ["dyskinetic", 1488], ["animals", 1499], [".", 1506], ["Co", 1508], ["-", 1510], ["administration", 1511], ["of", 1526], ["8-OHDPAT", 1529], ["and", 1538], ["L", 1542], ["-", 1543], ["DOPA", 1544], ["decreased", 1549], ["dyskinesia", 1559], ["in", 1570], ["dopamine", 1573], ["-", 1581], ["lesioned", 1582], ["animals", 1591], [",", 1598], ["but", 1600], ["did", 1604], ["not", 1608], ["affect", 1612], ["potassium", 1619], ["-", 1628], ["evoked", 1629], ["glutamate", 1636], ["release", 1646], [",", 1653], ["which", 1655], ["was", 1661], ["seen", 1665], ["in", 1670], ["normal", 1673], ["animals", 1680], [".", 1687], ["These", 1689], ["findings", 1695], ["indicate", 1704], ["altered", 1713], ["glutamate", 1721], ["transmission", 1731], ["upon", 1744], ["dopamine", 1749], ["-", 1757], ["depletion", 1758], ["and", 1768], ["dyskinesia", 1772], [".", 1782]]}
{"context": "p73 is a p53 family transcription factor. Due to the presence in the 5' flanking region of two promoters, there are two N-terminal variants, TAp73, which retains a fully active transactivation domain (TA), and \u0394Np73, in which the N terminus is truncated. In addition, extensive 3' splicing gives rise to at least seven distinctive isoforms; TAp73-selective knockout highlights its role as a regulator of cell death, senescence and tumor suppressor. \u0394Np73-selective knockout, on the other hand, highlights anti-apoptotic function of \u0394Np73 and its involvement in DNA damage response. In this work, we investigated the expression pattern of murine p73 C-terminal isoforms. By using a RT-PCR approach, we were able to detect mRNAs of all the C-terminal isoforms described in humans. We characterized their in vivo expression profile in mouse organs and in different mouse developmental stages. Finally, we investigated p73 C-terminal expression profile following DNA damage, ex vivo after primary cultures treatment and in vivo after systemic administration of cytotoxic compounds. Overall, our study first elucidates spatio-temporal expression of mouse p73 isoforms and provides novel insights on their expression-switch under triggered conditions.", "qas": [{"question": "How many TAp73 isoforms have been identified in humans?", "answers": ["seven", "7"], "qid": "4d0d8f548cf94dc489db689b3aa53512", "question_tokens": [["How", 0], ["many", 4], ["TAp73", 9], ["isoforms", 15], ["have", 24], ["been", 29], ["identified", 34], ["in", 45], ["humans", 48], ["?", 54]], "detected_answers": [{"text": "seven", "token_spans": [[66, 66]], "char_spans": [[313, 317]]}]}], "context_tokens": [["p73", 0], ["is", 4], ["a", 7], ["p53", 9], ["family", 13], ["transcription", 20], ["factor", 34], [".", 40], ["Due", 42], ["to", 46], ["the", 49], ["presence", 53], ["in", 62], ["the", 65], ["5", 69], ["'", 70], ["flanking", 72], ["region", 81], ["of", 88], ["two", 91], ["promoters", 95], [",", 104], ["there", 106], ["are", 112], ["two", 116], ["N", 120], ["-", 121], ["terminal", 122], ["variants", 131], [",", 139], ["TAp73", 141], [",", 146], ["which", 148], ["retains", 154], ["a", 162], ["fully", 164], ["active", 170], ["transactivation", 177], ["domain", 193], ["(", 200], ["TA", 201], [")", 203], [",", 204], ["and", 206], ["\u0394Np73", 210], [",", 215], ["in", 217], ["which", 220], ["the", 226], ["N", 230], ["terminus", 232], ["is", 241], ["truncated", 244], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["extensive", 268], ["3", 278], ["'", 279], ["splicing", 281], ["gives", 290], ["rise", 296], ["to", 301], ["at", 304], ["least", 307], ["seven", 313], ["distinctive", 319], ["isoforms", 331], [";", 339], ["TAp73-selective", 341], ["knockout", 357], ["highlights", 366], ["its", 377], ["role", 381], ["as", 386], ["a", 389], ["regulator", 391], ["of", 401], ["cell", 404], ["death", 409], [",", 414], ["senescence", 416], ["and", 427], ["tumor", 431], ["suppressor", 437], [".", 447], ["\u0394Np73-selective", 449], ["knockout", 465], [",", 473], ["on", 475], ["the", 478], ["other", 482], ["hand", 488], [",", 492], ["highlights", 494], ["anti", 505], ["-", 509], ["apoptotic", 510], ["function", 520], ["of", 529], ["\u0394Np73", 532], ["and", 538], ["its", 542], ["involvement", 546], ["in", 558], ["DNA", 561], ["damage", 565], ["response", 572], [".", 580], ["In", 582], ["this", 585], ["work", 590], [",", 594], ["we", 596], ["investigated", 599], ["the", 612], ["expression", 616], ["pattern", 627], ["of", 635], ["murine", 638], ["p73", 645], ["C", 649], ["-", 650], ["terminal", 651], ["isoforms", 660], [".", 668], ["By", 670], ["using", 673], ["a", 679], ["RT", 681], ["-", 683], ["PCR", 684], ["approach", 688], [",", 696], ["we", 698], ["were", 701], ["able", 706], ["to", 711], ["detect", 714], ["mRNAs", 721], ["of", 727], ["all", 730], ["the", 734], ["C", 738], ["-", 739], ["terminal", 740], ["isoforms", 749], ["described", 758], ["in", 768], ["humans", 771], [".", 777], ["We", 779], ["characterized", 782], ["their", 796], ["in", 802], ["vivo", 805], ["expression", 810], ["profile", 821], ["in", 829], ["mouse", 832], ["organs", 838], ["and", 845], ["in", 849], ["different", 852], ["mouse", 862], ["developmental", 868], ["stages", 882], [".", 888], ["Finally", 890], [",", 897], ["we", 899], ["investigated", 902], ["p73", 915], ["C", 919], ["-", 920], ["terminal", 921], ["expression", 930], ["profile", 941], ["following", 949], ["DNA", 959], ["damage", 963], [",", 969], ["ex", 971], ["vivo", 974], ["after", 979], ["primary", 985], ["cultures", 993], ["treatment", 1002], ["and", 1012], ["in", 1016], ["vivo", 1019], ["after", 1024], ["systemic", 1030], ["administration", 1039], ["of", 1054], ["cytotoxic", 1057], ["compounds", 1067], [".", 1076], ["Overall", 1078], [",", 1085], ["our", 1087], ["study", 1091], ["first", 1097], ["elucidates", 1103], ["spatio", 1114], ["-", 1120], ["temporal", 1121], ["expression", 1130], ["of", 1141], ["mouse", 1144], ["p73", 1150], ["isoforms", 1154], ["and", 1163], ["provides", 1167], ["novel", 1176], ["insights", 1182], ["on", 1191], ["their", 1194], ["expression", 1200], ["-", 1210], ["switch", 1211], ["under", 1218], ["triggered", 1224], ["conditions", 1234], [".", 1244]]}
{"context": "Stem cells, one of the progenitors of cancer, exist predominately in a quiescent state. Thus, understanding the mechanisms of DNA repair and mutagenesis in such arrested cells may help unravel the complex process of tumorigenesis. Two major nucleotide excision repair (NER) pathways are known to remove bulky physical or chemical lesions from DNA. Transcription-coupled repair (TCR) acts solely on the transcribed strand of expressed genes, while global genomic repair (GGR) is responsible for the ubiquitous repair of the genome. Indirectly, it has been shown that while TCR functions in quiescent cells GGR does not. To explicitly elucidate this phenomenon, we adapted a quantitative PCR (QPCR) assay to study UV-damage repair via TCR and GGR in quiescent and proliferating cells. We present evidence that repair of untranscribed silent regions of the genome and repair of the non-transcribed strand of active genes proceeds by two discrete mechanisms in quiescent cells; rather than by GGR, which was believed to encompass both. Thus, our findings suggest the existence of an alternate NER pathway in quiescent cells. The proposed subcategories of NER are as follows: (i) TCR, responsible for maintenance of transcribed strands; (ii) GGR, responsible for ubiquitous genome repair; and (iii) non-transcribed strand repair (NTSR), predominantly responsible for the repair of the NTS in arrested cells. In quiescent cells, it is evident that TCR and NTSR function and GGR are arrested. As a consequence, mutation accumulation at temporally silent genes and incomplete or imperfect repair of transcribed genes, in quiescent stem cells, may provide a source of cancer causing mutations.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d4a589e25b7e41539ef282bbbf96e4a6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[72, 73], [241, 242], [161, 162]], "char_spans": [[402, 419], [1298, 1315], [883, 900]]}]}], "context_tokens": [["Stem", 0], ["cells", 5], [",", 10], ["one", 12], ["of", 16], ["the", 19], ["progenitors", 23], ["of", 35], ["cancer", 38], [",", 44], ["exist", 46], ["predominately", 52], ["in", 66], ["a", 69], ["quiescent", 71], ["state", 81], [".", 86], ["Thus", 88], [",", 92], ["understanding", 94], ["the", 108], ["mechanisms", 112], ["of", 123], ["DNA", 126], ["repair", 130], ["and", 137], ["mutagenesis", 141], ["in", 153], ["such", 156], ["arrested", 161], ["cells", 170], ["may", 176], ["help", 180], ["unravel", 185], ["the", 193], ["complex", 197], ["process", 205], ["of", 213], ["tumorigenesis", 216], [".", 229], ["Two", 231], ["major", 235], ["nucleotide", 241], ["excision", 252], ["repair", 261], ["(", 268], ["NER", 269], [")", 272], ["pathways", 274], ["are", 283], ["known", 287], ["to", 293], ["remove", 296], ["bulky", 303], ["physical", 309], ["or", 318], ["chemical", 321], ["lesions", 330], ["from", 338], ["DNA", 343], [".", 346], ["Transcription", 348], ["-", 361], ["coupled", 362], ["repair", 370], ["(", 377], ["TCR", 378], [")", 381], ["acts", 383], ["solely", 388], ["on", 395], ["the", 398], ["transcribed", 402], ["strand", 414], ["of", 421], ["expressed", 424], ["genes", 434], [",", 439], ["while", 441], ["global", 447], ["genomic", 454], ["repair", 462], ["(", 469], ["GGR", 470], [")", 473], ["is", 475], ["responsible", 478], ["for", 490], ["the", 494], ["ubiquitous", 498], ["repair", 509], ["of", 516], ["the", 519], ["genome", 523], [".", 529], ["Indirectly", 531], [",", 541], ["it", 543], ["has", 546], ["been", 550], ["shown", 555], ["that", 561], ["while", 566], ["TCR", 572], ["functions", 576], ["in", 586], ["quiescent", 589], ["cells", 599], ["GGR", 605], ["does", 609], ["not", 614], [".", 617], ["To", 619], ["explicitly", 622], ["elucidate", 633], ["this", 643], ["phenomenon", 648], [",", 658], ["we", 660], ["adapted", 663], ["a", 671], ["quantitative", 673], ["PCR", 686], ["(", 690], ["QPCR", 691], [")", 695], ["assay", 697], ["to", 703], ["study", 706], ["UV", 712], ["-", 714], ["damage", 715], ["repair", 722], ["via", 729], ["TCR", 733], ["and", 737], ["GGR", 741], ["in", 745], ["quiescent", 748], ["and", 758], ["proliferating", 762], ["cells", 776], [".", 781], ["We", 783], ["present", 786], ["evidence", 794], ["that", 803], ["repair", 808], ["of", 815], ["untranscribed", 818], ["silent", 832], ["regions", 839], ["of", 847], ["the", 850], ["genome", 854], ["and", 861], ["repair", 865], ["of", 872], ["the", 875], ["non", 879], ["-", 882], ["transcribed", 883], ["strand", 895], ["of", 902], ["active", 905], ["genes", 912], ["proceeds", 918], ["by", 927], ["two", 930], ["discrete", 934], ["mechanisms", 943], ["in", 954], ["quiescent", 957], ["cells", 967], [";", 972], ["rather", 974], ["than", 981], ["by", 986], ["GGR", 989], [",", 992], ["which", 994], ["was", 1000], ["believed", 1004], ["to", 1013], ["encompass", 1016], ["both", 1026], [".", 1030], ["Thus", 1032], [",", 1036], ["our", 1038], ["findings", 1042], ["suggest", 1051], ["the", 1059], ["existence", 1063], ["of", 1073], ["an", 1076], ["alternate", 1079], ["NER", 1089], ["pathway", 1093], ["in", 1101], ["quiescent", 1104], ["cells", 1114], [".", 1119], ["The", 1121], ["proposed", 1125], ["subcategories", 1134], ["of", 1148], ["NER", 1151], ["are", 1155], ["as", 1159], ["follows", 1162], [":", 1169], ["(", 1171], ["i", 1172], [")", 1173], ["TCR", 1175], [",", 1178], ["responsible", 1180], ["for", 1192], ["maintenance", 1196], ["of", 1208], ["transcribed", 1211], ["strands", 1223], [";", 1230], ["(", 1232], ["ii", 1233], [")", 1235], ["GGR", 1237], [",", 1240], ["responsible", 1242], ["for", 1254], ["ubiquitous", 1258], ["genome", 1269], ["repair", 1276], [";", 1282], ["and", 1284], ["(", 1288], ["iii", 1289], [")", 1292], ["non", 1294], ["-", 1297], ["transcribed", 1298], ["strand", 1310], ["repair", 1317], ["(", 1324], ["NTSR", 1325], [")", 1329], [",", 1330], ["predominantly", 1332], ["responsible", 1346], ["for", 1358], ["the", 1362], ["repair", 1366], ["of", 1373], ["the", 1376], ["NTS", 1380], ["in", 1384], ["arrested", 1387], ["cells", 1396], [".", 1401], ["In", 1403], ["quiescent", 1406], ["cells", 1416], [",", 1421], ["it", 1423], ["is", 1426], ["evident", 1429], ["that", 1437], ["TCR", 1442], ["and", 1446], ["NTSR", 1450], ["function", 1455], ["and", 1464], ["GGR", 1468], ["are", 1472], ["arrested", 1476], [".", 1484], ["As", 1486], ["a", 1489], ["consequence", 1491], [",", 1502], ["mutation", 1504], ["accumulation", 1513], ["at", 1526], ["temporally", 1529], ["silent", 1540], ["genes", 1547], ["and", 1553], ["incomplete", 1557], ["or", 1568], ["imperfect", 1571], ["repair", 1581], ["of", 1588], ["transcribed", 1591], ["genes", 1603], [",", 1608], ["in", 1610], ["quiescent", 1613], ["stem", 1623], ["cells", 1628], [",", 1633], ["may", 1635], ["provide", 1639], ["a", 1647], ["source", 1649], ["of", 1656], ["cancer", 1659], ["causing", 1666], ["mutations", 1674], [".", 1683]]}
{"context": "To assess the pharmacokinetics of dapivirine in plasma and dapivirine concentrations in cervicovaginal fluids (CVF) and cervicovaginal tissues following vaginal administration of dapivirine microbicide gel in healthy, HIV-negative women for 10 days. A randomized, double-blind, phase I study was conducted at a single research center in South Africa. A total of 18 women used dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9. Pharmacokinetics of dapivirine were assessed in plasma on Days 1 and 10. Dapivirine concentrations were measured in CVF on Days 1 and 10 and in cervicovaginal tissues on Day 10. Safety was evaluated through laboratory tests (hematology, clinical chemistry, and urinalysis), physical examinations, and assessment of adverse events. Plasma concentrations of dapivirine increased over time with gel dose and were greater on Day 10 (C(max) 31 to 471\u2009pg/ml) than Day 1 (C(max) 23 to 80\u2009pg/ml). T(max) was 10-12\u2009h on Day 1, and 9\u2009h on Day 10. Concentrations in CVF generally increased with dose but were highly variable among participants. Mean peak values ranged from 4.6-8.3\u2009\u00d7\u200910(6) pg/ml on Day 1 and from 2.3-20.7\u2009\u00d7\u200910(6) pg/ml on Day 10 across dose groups. Dapivirine was detectable in all tissue biopsies on Day 10 at concentrations of 1.0-356\u2009\u00d7\u200910(3) pg/mg. Dapivirine was widely distributed throughout the lower genital tract with low systemic absorption when administered in a vaginal gel formulation for 10 consecutive days. The gel was safe and well tolerated.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "8e635a9039f64438813f3959150c7590", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[30, 30]], "char_spans": [[218, 220]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["pharmacokinetics", 14], ["of", 31], ["dapivirine", 34], ["in", 45], ["plasma", 48], ["and", 55], ["dapivirine", 59], ["concentrations", 70], ["in", 85], ["cervicovaginal", 88], ["fluids", 103], ["(", 110], ["CVF", 111], [")", 114], ["and", 116], ["cervicovaginal", 120], ["tissues", 135], ["following", 143], ["vaginal", 153], ["administration", 161], ["of", 176], ["dapivirine", 179], ["microbicide", 190], ["gel", 202], ["in", 206], ["healthy", 209], [",", 216], ["HIV", 218], ["-", 221], ["negative", 222], ["women", 231], ["for", 237], ["10", 241], ["days", 244], [".", 248], ["A", 250], ["randomized", 252], [",", 262], ["double", 264], ["-", 270], ["blind", 271], [",", 276], ["phase", 278], ["I", 284], ["study", 286], ["was", 292], ["conducted", 296], ["at", 306], ["a", 309], ["single", 311], ["research", 318], ["center", 327], ["in", 334], ["South", 337], ["Africa", 343], [".", 349], ["A", 351], ["total", 353], ["of", 359], ["18", 362], ["women", 365], ["used", 371], ["dapivirine", 376], ["gel", 387], ["(", 391], ["0.001", 392], ["%", 397], [",", 398], ["0.005", 400], ["%", 405], [",", 406], ["or", 408], ["0.02", 411], ["%", 415], [")", 416], ["once", 418], ["daily", 423], ["on", 429], ["Days", 432], ["1", 437], ["and", 439], ["10", 443], ["and", 446], ["twice", 450], ["daily", 456], ["on", 462], ["Days", 465], ["2", 470], ["-", 471], ["9", 472], [".", 473], ["Pharmacokinetics", 475], ["of", 492], ["dapivirine", 495], ["were", 506], ["assessed", 511], ["in", 520], ["plasma", 523], ["on", 530], ["Days", 533], ["1", 538], ["and", 540], ["10", 544], [".", 546], ["Dapivirine", 548], ["concentrations", 559], ["were", 574], ["measured", 579], ["in", 588], ["CVF", 591], ["on", 595], ["Days", 598], ["1", 603], ["and", 605], ["10", 609], ["and", 612], ["in", 616], ["cervicovaginal", 619], ["tissues", 634], ["on", 642], ["Day", 645], ["10", 649], [".", 651], ["Safety", 653], ["was", 660], ["evaluated", 664], ["through", 674], ["laboratory", 682], ["tests", 693], ["(", 699], ["hematology", 700], [",", 710], ["clinical", 712], ["chemistry", 721], [",", 730], ["and", 732], ["urinalysis", 736], [")", 746], [",", 747], ["physical", 749], ["examinations", 758], [",", 770], ["and", 772], ["assessment", 776], ["of", 787], ["adverse", 790], ["events", 798], [".", 804], ["Plasma", 806], ["concentrations", 813], ["of", 828], ["dapivirine", 831], ["increased", 842], ["over", 852], ["time", 857], ["with", 862], ["gel", 867], ["dose", 871], ["and", 876], ["were", 880], ["greater", 885], ["on", 893], ["Day", 896], ["10", 900], ["(", 903], ["C(max", 904], [")", 909], ["31", 911], ["to", 914], ["471", 917], ["pg", 921], ["/", 923], ["ml", 924], [")", 926], ["than", 928], ["Day", 933], ["1", 937], ["(", 939], ["C(max", 940], [")", 945], ["23", 947], ["to", 950], ["80", 953], ["pg", 956], ["/", 958], ["ml", 959], [")", 961], [".", 962], ["T(max", 964], [")", 969], ["was", 971], ["10", 975], ["-", 977], ["12", 978], ["h", 981], ["on", 983], ["Day", 986], ["1", 990], [",", 991], ["and", 993], ["9", 997], ["h", 999], ["on", 1001], ["Day", 1004], ["10", 1008], [".", 1010], ["Concentrations", 1012], ["in", 1027], ["CVF", 1030], ["generally", 1034], ["increased", 1044], ["with", 1054], ["dose", 1059], ["but", 1064], ["were", 1068], ["highly", 1073], ["variable", 1080], ["among", 1089], ["participants", 1095], [".", 1107], ["Mean", 1109], ["peak", 1114], ["values", 1119], ["ranged", 1126], ["from", 1133], ["4.6", 1138], ["-", 1141], ["8.3", 1142], ["\u00d7", 1146], ["10(6", 1148], [")", 1152], ["pg", 1154], ["/", 1156], ["ml", 1157], ["on", 1160], ["Day", 1163], ["1", 1167], ["and", 1169], ["from", 1173], ["2.3", 1178], ["-", 1181], ["20.7", 1182], ["\u00d7", 1187], ["10(6", 1189], [")", 1193], ["pg", 1195], ["/", 1197], ["ml", 1198], ["on", 1201], ["Day", 1204], ["10", 1208], ["across", 1211], ["dose", 1218], ["groups", 1223], [".", 1229], ["Dapivirine", 1231], ["was", 1242], ["detectable", 1246], ["in", 1257], ["all", 1260], ["tissue", 1264], ["biopsies", 1271], ["on", 1280], ["Day", 1283], ["10", 1287], ["at", 1290], ["concentrations", 1293], ["of", 1308], ["1.0", 1311], ["-", 1314], ["356", 1315], ["\u00d7", 1319], ["10(3", 1321], [")", 1325], ["pg", 1327], ["/", 1329], ["mg", 1330], [".", 1332], ["Dapivirine", 1334], ["was", 1345], ["widely", 1349], ["distributed", 1356], ["throughout", 1368], ["the", 1379], ["lower", 1383], ["genital", 1389], ["tract", 1397], ["with", 1403], ["low", 1408], ["systemic", 1412], ["absorption", 1421], ["when", 1432], ["administered", 1437], ["in", 1450], ["a", 1453], ["vaginal", 1455], ["gel", 1463], ["formulation", 1467], ["for", 1479], ["10", 1483], ["consecutive", 1486], ["days", 1498], [".", 1502], ["The", 1504], ["gel", 1508], ["was", 1512], ["safe", 1516], ["and", 1521], ["well", 1525], ["tolerated", 1530], [".", 1539]]}
{"context": "Metastasis is the major factor affecting patient survival in ovarian cancer. However, its molecular mechanisms remain unclear. Our study used isogenic pairs of low- and high-invasive ovarian cancer cell lines to demonstrate the downregulation of miRNA-138 in the highly invasive cells, and its functioning as an inhibitor of cell migration and invasion. An orthotopic xenograft mouse model further demonstrated that the expression of miRNA-138 inhibited ovarian cancer metastasis to other organs. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u03b1 by way of proteasome-mediated degradation. Analysis of human ovarian tumors further revealed downregulation of miR-138 and upregulation of SOX4 in late-stage tumors. Patients with miR-138(low)/SOX(high) signature are predominant in late stage and tend to have malignant phenotypes including lymph nodes metastasis, larger ascites volume and higher tumor grade. Our study demonstrates the role and clinical relevance of miR-138 in ovarian cancer cell invasion and metastasis, providing a potential therapeutic strategy for suppression of ovarian cancer metastasis by targeting SOX4 and HIF-1\u03b1 pathways.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "8975f12eced24dab8b0c41383c7ba4d8", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[212, 212], [163, 163], [82, 82]], "char_spans": [[1329, 1335], [1021, 1027], [520, 526]]}]}], "context_tokens": [["Metastasis", 0], ["is", 11], ["the", 14], ["major", 18], ["factor", 24], ["affecting", 31], ["patient", 41], ["survival", 49], ["in", 58], ["ovarian", 61], ["cancer", 69], [".", 75], ["However", 77], [",", 84], ["its", 86], ["molecular", 90], ["mechanisms", 100], ["remain", 111], ["unclear", 118], [".", 125], ["Our", 127], ["study", 131], ["used", 137], ["isogenic", 142], ["pairs", 151], ["of", 157], ["low-", 160], ["and", 165], ["high", 169], ["-", 173], ["invasive", 174], ["ovarian", 183], ["cancer", 191], ["cell", 198], ["lines", 203], ["to", 209], ["demonstrate", 212], ["the", 224], ["downregulation", 228], ["of", 243], ["miRNA-138", 246], ["in", 256], ["the", 259], ["highly", 263], ["invasive", 270], ["cells", 279], [",", 284], ["and", 286], ["its", 290], ["functioning", 294], ["as", 306], ["an", 309], ["inhibitor", 312], ["of", 322], ["cell", 325], ["migration", 330], ["and", 340], ["invasion", 344], [".", 352], ["An", 354], ["orthotopic", 357], ["xenograft", 368], ["mouse", 378], ["model", 384], ["further", 390], ["demonstrated", 398], ["that", 411], ["the", 416], ["expression", 420], ["of", 431], ["miRNA-138", 434], ["inhibited", 444], ["ovarian", 454], ["cancer", 462], ["metastasis", 469], ["to", 480], ["other", 483], ["organs", 489], [".", 495], ["Results", 497], ["indicated", 505], ["that", 515], ["miR-138", 520], ["directly", 528], ["targeted", 537], ["SRY", 546], ["-", 549], ["related", 550], ["high", 558], ["mobility", 563], ["group", 572], ["box", 578], ["4", 582], ["(", 584], ["SOX4", 585], [")", 589], ["and", 591], ["hypoxia", 595], ["-", 602], ["inducible", 603], ["factor-1\u03b1", 613], ["(", 623], ["HIF-1\u03b1", 624], [")", 630], [",", 631], ["and", 633], ["overexpression", 637], ["of", 652], ["SOX4", 655], ["and", 660], ["HIF-1\u03b1", 664], ["effectively", 671], ["reversed", 683], ["the", 692], ["miR-138-mediated", 696], ["suppression", 713], ["of", 725], ["cell", 728], ["invasion", 733], [".", 741], ["Epidermal", 743], ["growth", 753], ["factor", 760], ["receptor", 767], ["acted", 776], ["as", 782], ["the", 785], ["downstream", 789], ["molecule", 800], ["of", 809], ["SOX4", 812], ["by", 817], ["way", 820], ["of", 824], ["direct", 827], ["transcriptional", 834], ["control", 850], [",", 857], ["whereas", 859], ["Slug", 867], ["was", 872], ["the", 876], ["downstream", 880], ["molecule", 891], ["of", 900], ["HIF-1\u03b1", 903], ["by", 910], ["way", 913], ["of", 917], ["proteasome", 920], ["-", 930], ["mediated", 931], ["degradation", 940], [".", 951], ["Analysis", 953], ["of", 962], ["human", 965], ["ovarian", 971], ["tumors", 979], ["further", 986], ["revealed", 994], ["downregulation", 1003], ["of", 1018], ["miR-138", 1021], ["and", 1029], ["upregulation", 1033], ["of", 1046], ["SOX4", 1049], ["in", 1054], ["late", 1057], ["-", 1061], ["stage", 1062], ["tumors", 1068], [".", 1074], ["Patients", 1076], ["with", 1085], ["miR-138(low)/SOX(high", 1090], [")", 1111], ["signature", 1113], ["are", 1123], ["predominant", 1127], ["in", 1139], ["late", 1142], ["stage", 1147], ["and", 1153], ["tend", 1157], ["to", 1162], ["have", 1165], ["malignant", 1170], ["phenotypes", 1180], ["including", 1191], ["lymph", 1201], ["nodes", 1207], ["metastasis", 1213], [",", 1223], ["larger", 1225], ["ascites", 1232], ["volume", 1240], ["and", 1247], ["higher", 1251], ["tumor", 1258], ["grade", 1264], [".", 1269], ["Our", 1271], ["study", 1275], ["demonstrates", 1281], ["the", 1294], ["role", 1298], ["and", 1303], ["clinical", 1307], ["relevance", 1316], ["of", 1326], ["miR-138", 1329], ["in", 1337], ["ovarian", 1340], ["cancer", 1348], ["cell", 1355], ["invasion", 1360], ["and", 1369], ["metastasis", 1373], [",", 1383], ["providing", 1385], ["a", 1395], ["potential", 1397], ["therapeutic", 1407], ["strategy", 1419], ["for", 1428], ["suppression", 1432], ["of", 1444], ["ovarian", 1447], ["cancer", 1455], ["metastasis", 1462], ["by", 1473], ["targeting", 1476], ["SOX4", 1486], ["and", 1491], ["HIF-1\u03b1", 1495], ["pathways", 1502], [".", 1510]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "The article briefly summarizes the milestones leading to current knowledge and the possibility of treating one of the most widespread and perhaps least known diseases, restless legs syndrome (RLS). Until the mid-twentieth century, the syndrome first described by Willis (1685), was sporadically reported in medical literature and in most cases deemed a bizzare condition. It was only with Ekbom's detailed clinical description of the syndrome (1944) and the polygraphic recordings of Coccagna et al. (1962) that RLS became well-recognised clinical entity. Since then, almost all sleep laboratories have devoted much of their research to discovering the pathogenetic mechanisms underlying the disease and devise increasingly specific treatment. Major advances have been made in recent years, but a full understanding of RLS is still a long way off.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "4f93de9591b34369ba45f43f3f6efb52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[26, 28]], "char_spans": [[168, 189]]}]}], "context_tokens": [["The", 0], ["article", 4], ["briefly", 12], ["summarizes", 20], ["the", 31], ["milestones", 35], ["leading", 46], ["to", 54], ["current", 57], ["knowledge", 65], ["and", 75], ["the", 79], ["possibility", 83], ["of", 95], ["treating", 98], ["one", 107], ["of", 111], ["the", 114], ["most", 118], ["widespread", 123], ["and", 134], ["perhaps", 138], ["least", 146], ["known", 152], ["diseases", 158], [",", 166], ["restless", 168], ["legs", 177], ["syndrome", 182], ["(", 191], ["RLS", 192], [")", 195], [".", 196], ["Until", 198], ["the", 204], ["mid", 208], ["-", 211], ["twentieth", 212], ["century", 222], [",", 229], ["the", 231], ["syndrome", 235], ["first", 244], ["described", 250], ["by", 260], ["Willis", 263], ["(", 270], ["1685", 271], [")", 275], [",", 276], ["was", 278], ["sporadically", 282], ["reported", 295], ["in", 304], ["medical", 307], ["literature", 315], ["and", 326], ["in", 330], ["most", 333], ["cases", 338], ["deemed", 344], ["a", 351], ["bizzare", 353], ["condition", 361], [".", 370], ["It", 372], ["was", 375], ["only", 379], ["with", 384], ["Ekbom", 389], ["'s", 394], ["detailed", 397], ["clinical", 406], ["description", 415], ["of", 427], ["the", 430], ["syndrome", 434], ["(", 443], ["1944", 444], [")", 448], ["and", 450], ["the", 454], ["polygraphic", 458], ["recordings", 470], ["of", 481], ["Coccagna", 484], ["et", 493], ["al", 496], [".", 498], ["(", 500], ["1962", 501], [")", 505], ["that", 507], ["RLS", 512], ["became", 516], ["well", 523], ["-", 527], ["recognised", 528], ["clinical", 539], ["entity", 548], [".", 554], ["Since", 556], ["then", 562], [",", 566], ["almost", 568], ["all", 575], ["sleep", 579], ["laboratories", 585], ["have", 598], ["devoted", 603], ["much", 611], ["of", 616], ["their", 619], ["research", 625], ["to", 634], ["discovering", 637], ["the", 649], ["pathogenetic", 653], ["mechanisms", 666], ["underlying", 677], ["the", 688], ["disease", 692], ["and", 700], ["devise", 704], ["increasingly", 711], ["specific", 724], ["treatment", 733], [".", 742], ["Major", 744], ["advances", 750], ["have", 759], ["been", 764], ["made", 769], ["in", 774], ["recent", 777], ["years", 784], [",", 789], ["but", 791], ["a", 795], ["full", 797], ["understanding", 802], ["of", 816], ["RLS", 819], ["is", 823], ["still", 826], ["a", 832], ["long", 834], ["way", 839], ["off", 843], [".", 846]]}
{"context": "Since the early 2000s, the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections among the community of people lacking known healthcare risk factors has increased. This MRSA infection is referred to as community-associated MRSA (CA-MRSA) infection and is distinct from hospital-associated MRSA (HA-MRSA) infection, which occurs among people with known healthcare risk factors. Understanding the epidemiology of CA-MRSA infections is critical; however, this has not been investigated in detail in Japan. Our objective was to investigate the incidence of CA-MRSA infections in a regional hospital. We investigated CA-MRSA isolates and infections in a rural regional hospital by reviewing medical records of one year. Infections were classified as CA-MRSA if no established risk factors were identified. During 2008, 31 Staphylococcus aureus (S. aureus) isolates were detected in 29 unique patients, with 1 methicillin-sensitive S. aureus (MSSA) isolates obtained from 19 patients (66%) and MRSA obtained from 10 patients (34%). In the 10 patients with MRSA, the number of HA-MRSA and CA-MRSA cases were nine (32% of patients with S. aureus isolates) and one (3%), respectively. The patient with CA-MRSA was diagnosed with cellulitis due to CA-MRSA. All nine patients with HA-MRSA exhibited colonization. We observed a CA-MRSA case in a regional hospital in Japan, suggesting that incidence trends of CA-MRSA should be considered in future research and treatment.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "0d5291094d50485392d99b2aa3d5c380", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [139, 139], [58, 58], [186, 186], [44, 44], [116, 116], [212, 212], [249, 249], [78, 78], [14, 14], [257, 257], [240, 240], [282, 282], [54, 54], [266, 266], [105, 105], [201, 201], [40, 40], [31, 31]], "char_spans": [[1094, 1097], [769, 772], [319, 322], [1009, 1012], [253, 256], [636, 639], [1106, 1109], [1262, 1265], [435, 438], [85, 88], [1294, 1297], [1217, 1220], [1422, 1425], [310, 313], [1340, 1343], [577, 580], [1071, 1074], [244, 247], [190, 193]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["early", 10], ["2000s", 16], [",", 21], ["the", 23], ["incidence", 27], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["infections", 91], ["among", 102], ["the", 108], ["community", 112], ["of", 122], ["people", 125], ["lacking", 132], ["known", 140], ["healthcare", 146], ["risk", 157], ["factors", 162], ["has", 170], ["increased", 174], [".", 183], ["This", 185], ["MRSA", 190], ["infection", 195], ["is", 205], ["referred", 208], ["to", 217], ["as", 220], ["community", 223], ["-", 232], ["associated", 233], ["MRSA", 244], ["(", 249], ["CA", 250], ["-", 252], ["MRSA", 253], [")", 257], ["infection", 259], ["and", 269], ["is", 273], ["distinct", 276], ["from", 285], ["hospital", 290], ["-", 298], ["associated", 299], ["MRSA", 310], ["(", 315], ["HA", 316], ["-", 318], ["MRSA", 319], [")", 323], ["infection", 325], [",", 334], ["which", 336], ["occurs", 342], ["among", 349], ["people", 355], ["with", 362], ["known", 367], ["healthcare", 373], ["risk", 384], ["factors", 389], [".", 396], ["Understanding", 398], ["the", 412], ["epidemiology", 416], ["of", 429], ["CA", 432], ["-", 434], ["MRSA", 435], ["infections", 440], ["is", 451], ["critical", 454], [";", 462], ["however", 464], [",", 471], ["this", 473], ["has", 478], ["not", 482], ["been", 486], ["investigated", 491], ["in", 504], ["detail", 507], ["in", 514], ["Japan", 517], [".", 522], ["Our", 524], ["objective", 528], ["was", 538], ["to", 542], ["investigate", 545], ["the", 557], ["incidence", 561], ["of", 571], ["CA", 574], ["-", 576], ["MRSA", 577], ["infections", 582], ["in", 593], ["a", 596], ["regional", 598], ["hospital", 607], [".", 615], ["We", 617], ["investigated", 620], ["CA", 633], ["-", 635], ["MRSA", 636], ["isolates", 641], ["and", 650], ["infections", 654], ["in", 665], ["a", 668], ["rural", 670], ["regional", 676], ["hospital", 685], ["by", 694], ["reviewing", 697], ["medical", 707], ["records", 715], ["of", 723], ["one", 726], ["year", 730], [".", 734], ["Infections", 736], ["were", 747], ["classified", 752], ["as", 763], ["CA", 766], ["-", 768], ["MRSA", 769], ["if", 774], ["no", 777], ["established", 780], ["risk", 792], ["factors", 797], ["were", 805], ["identified", 810], [".", 820], ["During", 822], ["2008", 829], [",", 833], ["31", 835], ["Staphylococcus", 838], ["aureus", 853], ["(", 860], ["S.", 861], ["aureus", 864], [")", 870], ["isolates", 872], ["were", 881], ["detected", 886], ["in", 895], ["29", 898], ["unique", 901], ["patients", 908], [",", 916], ["with", 918], ["1", 923], ["methicillin", 925], ["-", 936], ["sensitive", 937], ["S.", 947], ["aureus", 950], ["(", 957], ["MSSA", 958], [")", 962], ["isolates", 964], ["obtained", 973], ["from", 982], ["19", 987], ["patients", 990], ["(", 999], ["66", 1000], ["%", 1002], [")", 1003], ["and", 1005], ["MRSA", 1009], ["obtained", 1014], ["from", 1023], ["10", 1028], ["patients", 1031], ["(", 1040], ["34", 1041], ["%", 1043], [")", 1044], [".", 1045], ["In", 1047], ["the", 1050], ["10", 1054], ["patients", 1057], ["with", 1066], ["MRSA", 1071], [",", 1075], ["the", 1077], ["number", 1081], ["of", 1088], ["HA", 1091], ["-", 1093], ["MRSA", 1094], ["and", 1099], ["CA", 1103], ["-", 1105], ["MRSA", 1106], ["cases", 1111], ["were", 1117], ["nine", 1122], ["(", 1127], ["32", 1128], ["%", 1130], ["of", 1132], ["patients", 1135], ["with", 1144], ["S.", 1149], ["aureus", 1152], ["isolates", 1159], [")", 1167], ["and", 1169], ["one", 1173], ["(", 1177], ["3", 1178], ["%", 1179], [")", 1180], [",", 1181], ["respectively", 1183], [".", 1195], ["The", 1197], ["patient", 1201], ["with", 1209], ["CA", 1214], ["-", 1216], ["MRSA", 1217], ["was", 1222], ["diagnosed", 1226], ["with", 1236], ["cellulitis", 1241], ["due", 1252], ["to", 1256], ["CA", 1259], ["-", 1261], ["MRSA", 1262], [".", 1266], ["All", 1268], ["nine", 1272], ["patients", 1277], ["with", 1286], ["HA", 1291], ["-", 1293], ["MRSA", 1294], ["exhibited", 1299], ["colonization", 1309], [".", 1321], ["We", 1323], ["observed", 1326], ["a", 1335], ["CA", 1337], ["-", 1339], ["MRSA", 1340], ["case", 1345], ["in", 1350], ["a", 1353], ["regional", 1355], ["hospital", 1364], ["in", 1373], ["Japan", 1376], [",", 1381], ["suggesting", 1383], ["that", 1394], ["incidence", 1399], ["trends", 1409], ["of", 1416], ["CA", 1419], ["-", 1421], ["MRSA", 1422], ["should", 1427], ["be", 1434], ["considered", 1437], ["in", 1448], ["future", 1451], ["research", 1458], ["and", 1467], ["treatment", 1471], [".", 1480]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "9a096b481413444ea01bcdaa55383924", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [55, 55], [78, 78]], "char_spans": [[0, 3], [360, 363], [489, 492]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["anemia", 16], ["is", 23], ["common", 26], ["in", 33], ["people", 36], ["with", 43], ["chronic", 48], ["kidney", 56], ["disease", 63], ["(", 71], ["CKD", 72], [")", 75], ["and", 77], ["its", 81], ["importance", 85], ["in", 96], ["supporting", 99], ["erythropoiesis", 110], ["is", 125], ["unquestioned", 128], ["especially", 141], ["in", 152], ["those", 155], ["patients", 161], ["treated", 170], ["with", 178], ["erythropoietin", 183], [".", 197], ["Clinical", 199], ["symptomatology", 208], ["such", 223], ["as", 228], ["fatigability", 231], [",", 243], ["cold", 245], ["intolerance", 250], [",", 261], ["failure", 263], ["to", 271], ["concentrate", 274], ["and", 286], ["poor", 290], ["effort", 295], ["intolerance", 302], ["is", 314], ["often", 317], ["attributed", 323], ["to", 334], ["anemia", 337], ["or", 344], ["uremia", 347], [".", 353], ["That", 355], ["iron", 360], ["deficiency", 365], [",", 375], ["per", 377], ["se", 381], [",", 383], ["can", 385], ["cause", 389], ["these", 395], ["symptoms", 401], ["is", 410], ["poorly", 413], ["recognized", 420], [".", 430], ["Clinical", 432], ["and", 441], ["animal", 445], ["studies", 452], ["that", 460], ["support", 465], ["the", 473], ["benefits", 477], ["of", 486], ["iron", 489], ["supplementation", 494], [",", 509], ["independent", 511], ["of", 523], ["increasing", 526], ["hemoglobin", 537], [",", 547], ["such", 549], ["as", 554], ["those", 557], ["on", 563], ["immune", 566], ["function", 573], [",", 581], ["physical", 583], ["performance", 592], [",", 603], ["thermoregulation", 605], [",", 621], ["cognition", 623], [",", 632], ["and", 634], ["restless", 638], ["leg", 647], ["syndrome", 651], ["and", 660], ["aluminum", 664], ["absorption", 673], ["is", 684], ["the", 687], ["subject", 691], ["of", 699], ["this", 702], ["narrative", 707], ["review", 717], [".", 723]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "Centrioles are essential for the formation of cilia and flagella. They also form the core of the centrosome, which organizes microtubule arrays important for cell shape, polarity, motility and division. Here, we have used super-resolution 3D-structured illumination microscopy to analyse the spatial relationship of 18 centriole and pericentriolar matrix (PCM) components of human centrosomes at different cell cycle stages. During mitosis, PCM proteins formed extended networks with interspersed \u03b3-Tubulin. During interphase, most proteins were arranged at specific distances from the walls of centrioles, resulting in ring staining, often with discernible density masses. Through use of site-specific antibodies, we found the C-terminus of Cep152 to be closer to centrioles than the N-terminus, illustrating the power of 3D-SIM to study protein disposition. Appendage proteins showed rings with multiple density masses, and the number of these masses was strongly reduced during mitosis. At the proximal end of centrioles, Sas-6 formed a dot at the site of daughter centriole assembly, consistent with its role in cartwheel formation. Plk4 and STIL co-localized with Sas-6, but Cep135 was associated mostly with mother centrioles. Remarkably, Plk4 formed a dot on the surface of the mother centriole before Sas-6 staining became detectable, indicating that Plk4 constitutes an early marker for the site of nascent centriole formation. Our study provides novel insights into the architecture of human centrosomes and illustrates the power of super-resolution microscopy in revealing the relative localization of centriole and PCM proteins in unprecedented detail.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "9ac493dfeaa446d1b53b353bcedbf4eb", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[18, 18]], "char_spans": [[97, 106]]}]}], "context_tokens": [["Centrioles", 0], ["are", 11], ["essential", 15], ["for", 25], ["the", 29], ["formation", 33], ["of", 43], ["cilia", 46], ["and", 52], ["flagella", 56], [".", 64], ["They", 66], ["also", 71], ["form", 76], ["the", 81], ["core", 85], ["of", 90], ["the", 93], ["centrosome", 97], [",", 107], ["which", 109], ["organizes", 115], ["microtubule", 125], ["arrays", 137], ["important", 144], ["for", 154], ["cell", 158], ["shape", 163], [",", 168], ["polarity", 170], [",", 178], ["motility", 180], ["and", 189], ["division", 193], [".", 201], ["Here", 203], [",", 207], ["we", 209], ["have", 212], ["used", 217], ["super", 222], ["-", 227], ["resolution", 228], ["3D", 239], ["-", 241], ["structured", 242], ["illumination", 253], ["microscopy", 266], ["to", 277], ["analyse", 280], ["the", 288], ["spatial", 292], ["relationship", 300], ["of", 313], ["18", 316], ["centriole", 319], ["and", 329], ["pericentriolar", 333], ["matrix", 348], ["(", 355], ["PCM", 356], [")", 359], ["components", 361], ["of", 372], ["human", 375], ["centrosomes", 381], ["at", 393], ["different", 396], ["cell", 406], ["cycle", 411], ["stages", 417], [".", 423], ["During", 425], ["mitosis", 432], [",", 439], ["PCM", 441], ["proteins", 445], ["formed", 454], ["extended", 461], ["networks", 470], ["with", 479], ["interspersed", 484], ["\u03b3", 497], ["-", 498], ["Tubulin", 499], [".", 506], ["During", 508], ["interphase", 515], [",", 525], ["most", 527], ["proteins", 532], ["were", 541], ["arranged", 546], ["at", 555], ["specific", 558], ["distances", 567], ["from", 577], ["the", 582], ["walls", 586], ["of", 592], ["centrioles", 595], [",", 605], ["resulting", 607], ["in", 617], ["ring", 620], ["staining", 625], [",", 633], ["often", 635], ["with", 641], ["discernible", 646], ["density", 658], ["masses", 666], [".", 672], ["Through", 674], ["use", 682], ["of", 686], ["site", 689], ["-", 693], ["specific", 694], ["antibodies", 703], [",", 713], ["we", 715], ["found", 718], ["the", 724], ["C", 728], ["-", 729], ["terminus", 730], ["of", 739], ["Cep152", 742], ["to", 749], ["be", 752], ["closer", 755], ["to", 762], ["centrioles", 765], ["than", 776], ["the", 781], ["N", 785], ["-", 786], ["terminus", 787], [",", 795], ["illustrating", 797], ["the", 810], ["power", 814], ["of", 820], ["3D", 823], ["-", 825], ["SIM", 826], ["to", 830], ["study", 833], ["protein", 839], ["disposition", 847], [".", 858], ["Appendage", 860], ["proteins", 870], ["showed", 879], ["rings", 886], ["with", 892], ["multiple", 897], ["density", 906], ["masses", 914], [",", 920], ["and", 922], ["the", 926], ["number", 930], ["of", 937], ["these", 940], ["masses", 946], ["was", 953], ["strongly", 957], ["reduced", 966], ["during", 974], ["mitosis", 981], [".", 988], ["At", 990], ["the", 993], ["proximal", 997], ["end", 1006], ["of", 1010], ["centrioles", 1013], [",", 1023], ["Sas-6", 1025], ["formed", 1031], ["a", 1038], ["dot", 1040], ["at", 1044], ["the", 1047], ["site", 1051], ["of", 1056], ["daughter", 1059], ["centriole", 1068], ["assembly", 1078], [",", 1086], ["consistent", 1088], ["with", 1099], ["its", 1104], ["role", 1108], ["in", 1113], ["cartwheel", 1116], ["formation", 1126], [".", 1135], ["Plk4", 1137], ["and", 1142], ["STIL", 1146], ["co", 1151], ["-", 1153], ["localized", 1154], ["with", 1164], ["Sas-6", 1169], [",", 1174], ["but", 1176], ["Cep135", 1180], ["was", 1187], ["associated", 1191], ["mostly", 1202], ["with", 1209], ["mother", 1214], ["centrioles", 1221], [".", 1231], ["Remarkably", 1233], [",", 1243], ["Plk4", 1245], ["formed", 1250], ["a", 1257], ["dot", 1259], ["on", 1263], ["the", 1266], ["surface", 1270], ["of", 1278], ["the", 1281], ["mother", 1285], ["centriole", 1292], ["before", 1302], ["Sas-6", 1309], ["staining", 1315], ["became", 1324], ["detectable", 1331], [",", 1341], ["indicating", 1343], ["that", 1354], ["Plk4", 1359], ["constitutes", 1364], ["an", 1376], ["early", 1379], ["marker", 1385], ["for", 1392], ["the", 1396], ["site", 1400], ["of", 1405], ["nascent", 1408], ["centriole", 1416], ["formation", 1426], [".", 1435], ["Our", 1437], ["study", 1441], ["provides", 1447], ["novel", 1456], ["insights", 1462], ["into", 1471], ["the", 1476], ["architecture", 1480], ["of", 1493], ["human", 1496], ["centrosomes", 1502], ["and", 1514], ["illustrates", 1518], ["the", 1530], ["power", 1534], ["of", 1540], ["super", 1543], ["-", 1548], ["resolution", 1549], ["microscopy", 1560], ["in", 1571], ["revealing", 1574], ["the", 1584], ["relative", 1588], ["localization", 1597], ["of", 1610], ["centriole", 1613], ["and", 1623], ["PCM", 1627], ["proteins", 1631], ["in", 1640], ["unprecedented", 1643], ["detail", 1657], [".", 1663]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids. Three distinct stages in the mechanism can be recognized. Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus. Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence. Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation. In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "3b60bd7ce68145749fb65cfe5ee7d2cf", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3]], "char_spans": [[4, 13]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["/", 10], ["Cas", 11], ["system", 15], ["in", 22], ["prokaryotes", 25], ["provides", 37], ["resistance", 46], ["against", 57], ["invading", 65], ["viruses", 74], ["and", 82], ["plasmids", 86], [".", 94], ["Three", 96], ["distinct", 102], ["stages", 111], ["in", 118], ["the", 121], ["mechanism", 125], ["can", 135], ["be", 139], ["recognized", 142], [".", 152], ["Initially", 154], [",", 163], ["fragments", 165], ["of", 175], ["invader", 178], ["DNA", 186], ["are", 190], ["integrated", 194], ["as", 205], ["new", 208], ["spacers", 212], ["into", 220], ["the", 225], ["repetitive", 229], ["CRISPR", 240], ["locus", 247], [".", 252], ["Subsequently", 254], [",", 266], ["the", 268], ["CRISPR", 272], ["is", 279], ["transcribed", 282], ["and", 294], ["the", 298], ["transcript", 302], ["is", 313], ["cleaved", 316], ["by", 324], ["a", 327], ["Cas", 329], ["protein", 333], ["within", 341], ["the", 348], ["repeats", 352], [",", 359], ["generating", 361], ["short", 372], ["RNAs", 378], ["(", 383], ["crRNAs", 384], [")", 390], ["that", 392], ["contain", 397], ["the", 405], ["spacer", 409], ["sequence", 416], [".", 424], ["Finally", 426], [",", 433], ["crRNAs", 435], ["guide", 442], ["the", 448], ["Cas", 452], ["protein", 456], ["machinery", 464], ["to", 474], ["a", 477], ["complementary", 479], ["invader", 493], ["target", 501], [",", 507], ["either", 509], ["DNA", 516], ["or", 520], ["RNA", 523], [",", 526], ["resulting", 528], ["in", 538], ["inhibition", 541], ["of", 552], ["virus", 555], ["or", 561], ["plasmid", 564], ["proliferation", 572], [".", 585], ["In", 587], ["this", 590], ["article", 595], [",", 602], ["we", 604], ["discuss", 607], ["our", 615], ["current", 619], ["understanding", 627], ["of", 641], ["this", 644], ["fascinating", 649], ["adaptive", 661], ["and", 670], ["heritable", 674], ["defense", 684], ["system", 692], [",", 698], ["and", 700], ["describe", 704], ["functional", 713], ["similarities", 724], ["and", 737], ["differences", 741], ["with", 753], ["RNAi", 758], ["in", 763], ["eukaryotes", 766], [".", 776]]}
{"context": "Carpal tunnel syndrome (CTS) is the most common median nerve neuropathy, accounting for 90% of all neuropathies. Carpal tunnel syndrome presents in 3.8% of the general population, with a higher prevalence among women. There are several risk factors associated with CTS, including both medical and non medical factors. The pathophysiologic mechanisms involved in the median nerve compression and traction are thought to be complex, and as yet are not fully understood. The present review aimed to provide an overview of the pathophysiology of median nerve neuropathy in the carpal tunnel, and subsequent development of CTS.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "7d31ab9e001e4207a7f6499a2b13dd0e", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[64, 64], [95, 95], [10, 10]], "char_spans": [[366, 371], [542, 547], [48, 53]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["(", 23], ["CTS", 24], [")", 27], ["is", 29], ["the", 32], ["most", 36], ["common", 41], ["median", 48], ["nerve", 55], ["neuropathy", 61], [",", 71], ["accounting", 73], ["for", 84], ["90", 88], ["%", 90], ["of", 92], ["all", 95], ["neuropathies", 99], [".", 111], ["Carpal", 113], ["tunnel", 120], ["syndrome", 127], ["presents", 136], ["in", 145], ["3.8", 148], ["%", 151], ["of", 153], ["the", 156], ["general", 160], ["population", 168], [",", 178], ["with", 180], ["a", 185], ["higher", 187], ["prevalence", 194], ["among", 205], ["women", 211], [".", 216], ["There", 218], ["are", 224], ["several", 228], ["risk", 236], ["factors", 241], ["associated", 249], ["with", 260], ["CTS", 265], [",", 268], ["including", 270], ["both", 280], ["medical", 285], ["and", 293], ["non", 297], ["medical", 301], ["factors", 309], [".", 316], ["The", 318], ["pathophysiologic", 322], ["mechanisms", 339], ["involved", 350], ["in", 359], ["the", 362], ["median", 366], ["nerve", 373], ["compression", 379], ["and", 391], ["traction", 395], ["are", 404], ["thought", 408], ["to", 416], ["be", 419], ["complex", 422], [",", 429], ["and", 431], ["as", 435], ["yet", 438], ["are", 442], ["not", 446], ["fully", 450], ["understood", 456], [".", 466], ["The", 468], ["present", 472], ["review", 480], ["aimed", 487], ["to", 493], ["provide", 496], ["an", 504], ["overview", 507], ["of", 516], ["the", 519], ["pathophysiology", 523], ["of", 539], ["median", 542], ["nerve", 549], ["neuropathy", 555], ["in", 566], ["the", 569], ["carpal", 573], ["tunnel", 580], [",", 586], ["and", 588], ["subsequent", 592], ["development", 603], ["of", 615], ["CTS", 618], [".", 621]]}
{"context": "\u03b1-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that \u03b1-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions of \u03b1-synuclein remains to be elucidated. To address this issue, we investigated the subcellular localization of \u03b1-synuclein in normal and pathological conditions using primary mouse hippocampal neuronal cultures. While some neurons expressed high levels of \u03b1-synuclein in presynaptic boutons and cell bodies, other neurons either did not or only very weakly expressed the protein. These \u03b1-synuclein-negative cells were identified as inhibitory neurons by immunostaining with specific antibodies against glutamic acid decarboxylase (GAD), parvalbumin, and somatostatin. In contrast, \u03b1-synuclein-positive synapses were colocalized with the excitatory synapse marker vesicular glutamate transporter-1. This expression profile of \u03b1-synuclein was conserved in the hippocampus in vivo. In addition, we found that while presynaptic \u03b1-synuclein colocalizes with synapsin, a marker of presynaptic vesicles, it is not essential for activity-dependent membrane recycling induced by high potassium treatment. Exogenous supply of preformed fibrils generated by recombinant \u03b1-synuclein was shown to promote the formation of Lewy body (LB) -like intracellular aggregates involving endogenous \u03b1-synuclein. GAD-positive neurons did not form LB-like aggregates following treatment with preformed fibrils, however, exogenous expression of human \u03b1-synuclein allowed intracellular aggregate formation in these cells. These results suggest the presence of a different mechanism for regulation of the expression of \u03b1-synuclein between excitatory and inhibitory neurons. Furthermore, \u03b1-synuclein expression levels may determine the efficiency of intracellular aggregate formation in different neuronal subtypes.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "02aedd384e0844e18fd9364151f02926", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[195, 197], [305, 307], [176, 178], [252, 254], [316, 318], [155, 157], [77, 79], [58, 60], [232, 234], [279, 281], [25, 27], [123, 125], [0, 2], [99, 101]], "char_spans": [[1208, 1218], [1875, 1885], [1109, 1119], [1560, 1570], [1943, 1953], [965, 975], [495, 505], [386, 396], [1443, 1453], [1709, 1719], [168, 178], [770, 780], [0, 10], [640, 650]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["pathological", 25], ["component", 38], ["of", 48], ["synucleinopathies", 51], ["including", 69], ["Parkinson", 79], ["'s", 88], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [".", 128], ["Recent", 130], ["studies", 137], ["have", 145], ["demonstrated", 150], ["that", 163], ["\u03b1", 168], ["-", 169], ["synuclein", 170], ["also", 180], ["plays", 185], ["important", 191], ["roles", 201], ["in", 207], ["the", 210], ["release", 214], ["of", 222], ["synaptic", 225], ["vesicles", 234], ["and", 243], ["synaptic", 247], ["membrane", 256], ["recycling", 265], ["in", 275], ["healthy", 278], ["neurons", 286], [".", 293], ["However", 295], [",", 302], ["the", 304], ["precise", 308], ["relationship", 316], ["between", 329], ["the", 337], ["pathogenicity", 341], ["and", 355], ["physiological", 359], ["functions", 373], ["of", 383], ["\u03b1", 386], ["-", 387], ["synuclein", 388], ["remains", 398], ["to", 406], ["be", 409], ["elucidated", 412], [".", 422], ["To", 424], ["address", 427], ["this", 435], ["issue", 440], [",", 445], ["we", 447], ["investigated", 450], ["the", 463], ["subcellular", 467], ["localization", 479], ["of", 492], ["\u03b1", 495], ["-", 496], ["synuclein", 497], ["in", 507], ["normal", 510], ["and", 517], ["pathological", 521], ["conditions", 534], ["using", 545], ["primary", 551], ["mouse", 559], ["hippocampal", 565], ["neuronal", 577], ["cultures", 586], [".", 594], ["While", 596], ["some", 602], ["neurons", 607], ["expressed", 615], ["high", 625], ["levels", 630], ["of", 637], ["\u03b1", 640], ["-", 641], ["synuclein", 642], ["in", 652], ["presynaptic", 655], ["boutons", 667], ["and", 675], ["cell", 679], ["bodies", 684], [",", 690], ["other", 692], ["neurons", 698], ["either", 706], ["did", 713], ["not", 717], ["or", 721], ["only", 724], ["very", 729], ["weakly", 734], ["expressed", 741], ["the", 751], ["protein", 755], [".", 762], ["These", 764], ["\u03b1", 770], ["-", 771], ["synuclein", 772], ["-", 781], ["negative", 782], ["cells", 791], ["were", 797], ["identified", 802], ["as", 813], ["inhibitory", 816], ["neurons", 827], ["by", 835], ["immunostaining", 838], ["with", 853], ["specific", 858], ["antibodies", 867], ["against", 878], ["glutamic", 886], ["acid", 895], ["decarboxylase", 900], ["(", 914], ["GAD", 915], [")", 918], [",", 919], ["parvalbumin", 921], [",", 932], ["and", 934], ["somatostatin", 938], [".", 950], ["In", 952], ["contrast", 955], [",", 963], ["\u03b1", 965], ["-", 966], ["synuclein", 967], ["-", 976], ["positive", 977], ["synapses", 986], ["were", 995], ["colocalized", 1000], ["with", 1012], ["the", 1017], ["excitatory", 1021], ["synapse", 1032], ["marker", 1040], ["vesicular", 1047], ["glutamate", 1057], ["transporter-1", 1067], [".", 1080], ["This", 1082], ["expression", 1087], ["profile", 1098], ["of", 1106], ["\u03b1", 1109], ["-", 1110], ["synuclein", 1111], ["was", 1121], ["conserved", 1125], ["in", 1135], ["the", 1138], ["hippocampus", 1142], ["in", 1154], ["vivo", 1157], [".", 1161], ["In", 1163], ["addition", 1166], [",", 1174], ["we", 1176], ["found", 1179], ["that", 1185], ["while", 1190], ["presynaptic", 1196], ["\u03b1", 1208], ["-", 1209], ["synuclein", 1210], ["colocalizes", 1220], ["with", 1232], ["synapsin", 1237], [",", 1245], ["a", 1247], ["marker", 1249], ["of", 1256], ["presynaptic", 1259], ["vesicles", 1271], [",", 1279], ["it", 1281], ["is", 1284], ["not", 1287], ["essential", 1291], ["for", 1301], ["activity", 1305], ["-", 1313], ["dependent", 1314], ["membrane", 1324], ["recycling", 1333], ["induced", 1343], ["by", 1351], ["high", 1354], ["potassium", 1359], ["treatment", 1369], [".", 1378], ["Exogenous", 1380], ["supply", 1390], ["of", 1397], ["preformed", 1400], ["fibrils", 1410], ["generated", 1418], ["by", 1428], ["recombinant", 1431], ["\u03b1", 1443], ["-", 1444], ["synuclein", 1445], ["was", 1455], ["shown", 1459], ["to", 1465], ["promote", 1468], ["the", 1476], ["formation", 1480], ["of", 1490], ["Lewy", 1493], ["body", 1498], ["(", 1503], ["LB", 1504], [")", 1506], ["-like", 1508], ["intracellular", 1514], ["aggregates", 1528], ["involving", 1539], ["endogenous", 1549], ["\u03b1", 1560], ["-", 1561], ["synuclein", 1562], [".", 1571], ["GAD", 1573], ["-", 1576], ["positive", 1577], ["neurons", 1586], ["did", 1594], ["not", 1598], ["form", 1602], ["LB", 1607], ["-", 1609], ["like", 1610], ["aggregates", 1615], ["following", 1626], ["treatment", 1636], ["with", 1646], ["preformed", 1651], ["fibrils", 1661], [",", 1668], ["however", 1670], [",", 1677], ["exogenous", 1679], ["expression", 1689], ["of", 1700], ["human", 1703], ["\u03b1", 1709], ["-", 1710], ["synuclein", 1711], ["allowed", 1721], ["intracellular", 1729], ["aggregate", 1743], ["formation", 1753], ["in", 1763], ["these", 1766], ["cells", 1772], [".", 1777], ["These", 1779], ["results", 1785], ["suggest", 1793], ["the", 1801], ["presence", 1805], ["of", 1814], ["a", 1817], ["different", 1819], ["mechanism", 1829], ["for", 1839], ["regulation", 1843], ["of", 1854], ["the", 1857], ["expression", 1861], ["of", 1872], ["\u03b1", 1875], ["-", 1876], ["synuclein", 1877], ["between", 1887], ["excitatory", 1895], ["and", 1906], ["inhibitory", 1910], ["neurons", 1921], [".", 1928], ["Furthermore", 1930], [",", 1941], ["\u03b1", 1943], ["-", 1944], ["synuclein", 1945], ["expression", 1955], ["levels", 1966], ["may", 1973], ["determine", 1977], ["the", 1987], ["efficiency", 1991], ["of", 2002], ["intracellular", 2005], ["aggregate", 2019], ["formation", 2029], ["in", 2039], ["different", 2042], ["neuronal", 2052], ["subtypes", 2061], [".", 2069]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "This report describes the reliability, validity, treatment sensitivity, diagnostic performance and normative values for the Short Post-Traumatic Stress Disorder (PTSD) Rating Interview (SPRINT), a brief, global assessment for PTSD. The SPRINT was administered to subjects participating in a clinical trial of PTSD and in a population survey assessing PTSD prevalence. The 8-item SPRINT includes questions assessing the core symptoms of PTSD, as well as related aspects of somatic malaise, stress vulnerability and functional impairment. Validity was assessed against the MINI structured interview, the Davidson Trauma Scale, Treatment Outcome for PTSD Scale, Connor-Davidson Resilience Scale, Sheehan Stress Vulnerability Scale, Sheehan Disability Scale and Clinical Global Impressions of Severity and Improvement Scales. Good test-retest reliability, internal consistency, convergent and divergent validity were obtained. The SPRINT was responsive to symptom change over time and correlated with comparable PTSD symptom measures. In victims of trauma, a score of 14-17 was associated with 96% diagnostic accuracy, whereas in those with PTSD, highest efficiency corresponded to a range of 11-13. The SPRINT demonstrates solid psychometric properties and can serve as a reliable, valid and homogeneous measure of PTSD illness severity and of global improvement.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "4426d2042a6d4887bdddfa6bb9150c20", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[19, 23]], "char_spans": [[130, 159]]}, {"text": "PTSD", "token_spans": [[53, 53], [107, 107], [163, 163], [221, 221], [60, 60], [39, 39], [25, 25], [73, 73], [190, 190]], "char_spans": [[309, 312], [647, 650], [1008, 1011], [1312, 1315], [351, 354], [226, 229], [162, 165], [436, 439], [1137, 1140]]}]}], "context_tokens": [["This", 0], ["report", 5], ["describes", 12], ["the", 22], ["reliability", 26], [",", 37], ["validity", 39], [",", 47], ["treatment", 49], ["sensitivity", 59], [",", 70], ["diagnostic", 72], ["performance", 83], ["and", 95], ["normative", 99], ["values", 109], ["for", 116], ["the", 120], ["Short", 124], ["Post", 130], ["-", 134], ["Traumatic", 135], ["Stress", 145], ["Disorder", 152], ["(", 161], ["PTSD", 162], [")", 166], ["Rating", 168], ["Interview", 175], ["(", 185], ["SPRINT", 186], [")", 192], [",", 193], ["a", 195], ["brief", 197], [",", 202], ["global", 204], ["assessment", 211], ["for", 222], ["PTSD", 226], [".", 230], ["The", 232], ["SPRINT", 236], ["was", 243], ["administered", 247], ["to", 260], ["subjects", 263], ["participating", 272], ["in", 286], ["a", 289], ["clinical", 291], ["trial", 300], ["of", 306], ["PTSD", 309], ["and", 314], ["in", 318], ["a", 321], ["population", 323], ["survey", 334], ["assessing", 341], ["PTSD", 351], ["prevalence", 356], [".", 366], ["The", 368], ["8-item", 372], ["SPRINT", 379], ["includes", 386], ["questions", 395], ["assessing", 405], ["the", 415], ["core", 419], ["symptoms", 424], ["of", 433], ["PTSD", 436], [",", 440], ["as", 442], ["well", 445], ["as", 450], ["related", 453], ["aspects", 461], ["of", 469], ["somatic", 472], ["malaise", 480], [",", 487], ["stress", 489], ["vulnerability", 496], ["and", 510], ["functional", 514], ["impairment", 525], [".", 535], ["Validity", 537], ["was", 546], ["assessed", 550], ["against", 559], ["the", 567], ["MINI", 571], ["structured", 576], ["interview", 587], [",", 596], ["the", 598], ["Davidson", 602], ["Trauma", 611], ["Scale", 618], [",", 623], ["Treatment", 625], ["Outcome", 635], ["for", 643], ["PTSD", 647], ["Scale", 652], [",", 657], ["Connor", 659], ["-", 665], ["Davidson", 666], ["Resilience", 675], ["Scale", 686], [",", 691], ["Sheehan", 693], ["Stress", 701], ["Vulnerability", 708], ["Scale", 722], [",", 727], ["Sheehan", 729], ["Disability", 737], ["Scale", 748], ["and", 754], ["Clinical", 758], ["Global", 767], ["Impressions", 774], ["of", 786], ["Severity", 789], ["and", 798], ["Improvement", 802], ["Scales", 814], [".", 820], ["Good", 822], ["test", 827], ["-", 831], ["retest", 832], ["reliability", 839], [",", 850], ["internal", 852], ["consistency", 861], [",", 872], ["convergent", 874], ["and", 885], ["divergent", 889], ["validity", 899], ["were", 908], ["obtained", 913], [".", 921], ["The", 923], ["SPRINT", 927], ["was", 934], ["responsive", 938], ["to", 949], ["symptom", 952], ["change", 960], ["over", 967], ["time", 972], ["and", 977], ["correlated", 981], ["with", 992], ["comparable", 997], ["PTSD", 1008], ["symptom", 1013], ["measures", 1021], [".", 1029], ["In", 1031], ["victims", 1034], ["of", 1042], ["trauma", 1045], [",", 1051], ["a", 1053], ["score", 1055], ["of", 1061], ["14", 1064], ["-", 1066], ["17", 1067], ["was", 1070], ["associated", 1074], ["with", 1085], ["96", 1090], ["%", 1092], ["diagnostic", 1094], ["accuracy", 1105], [",", 1113], ["whereas", 1115], ["in", 1123], ["those", 1126], ["with", 1132], ["PTSD", 1137], [",", 1141], ["highest", 1143], ["efficiency", 1151], ["corresponded", 1162], ["to", 1175], ["a", 1178], ["range", 1180], ["of", 1186], ["11", 1189], ["-", 1191], ["13", 1192], [".", 1194], ["The", 1196], ["SPRINT", 1200], ["demonstrates", 1207], ["solid", 1220], ["psychometric", 1226], ["properties", 1239], ["and", 1250], ["can", 1254], ["serve", 1258], ["as", 1264], ["a", 1267], ["reliable", 1269], [",", 1277], ["valid", 1279], ["and", 1285], ["homogeneous", 1289], ["measure", 1301], ["of", 1309], ["PTSD", 1312], ["illness", 1317], ["severity", 1325], ["and", 1334], ["of", 1338], ["global", 1341], ["improvement", 1348], [".", 1359]]}
{"context": "Loss of consciousness in childhood may be due to cardiovascular causes, and the Long Q-T syndromes can present with seizures. The Romano-Ward syndrome is of autosomal dominant inheritance, and the Jervell and Lange-Nielson syndrome, with associated deafness, of autosomal recessive inheritance. The diagnosis is often delayed, but a careful history can avoid this. The syndromes can appear to be due to an imbalance in the sympathetic nerve to the ventricular myocardium, and precipitating causes such as stress suggest a CNS influence on this. The electrocardiogram can confirm the prolonged Q-T interval, but this is not always present, at least without an exercise test. Treatment with beta-blockers is often successful. If a wrong diagnosis of epilepsy is made a chance may be missed of avoiding sudden death, quite apart from all the medical, and social consequences that can result from such a diagnosis.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "8f255d79fc124b75bbeb22b7b675d5cd", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[31, 32]], "char_spans": [[157, 174]]}]}], "context_tokens": [["Loss", 0], ["of", 5], ["consciousness", 8], ["in", 22], ["childhood", 25], ["may", 35], ["be", 39], ["due", 42], ["to", 46], ["cardiovascular", 49], ["causes", 64], [",", 70], ["and", 72], ["the", 76], ["Long", 80], ["Q", 85], ["-", 86], ["T", 87], ["syndromes", 89], ["can", 99], ["present", 103], ["with", 111], ["seizures", 116], [".", 124], ["The", 126], ["Romano", 130], ["-", 136], ["Ward", 137], ["syndrome", 142], ["is", 151], ["of", 154], ["autosomal", 157], ["dominant", 167], ["inheritance", 176], [",", 187], ["and", 189], ["the", 193], ["Jervell", 197], ["and", 205], ["Lange", 209], ["-", 214], ["Nielson", 215], ["syndrome", 223], [",", 231], ["with", 233], ["associated", 238], ["deafness", 249], [",", 257], ["of", 259], ["autosomal", 262], ["recessive", 272], ["inheritance", 282], [".", 293], ["The", 295], ["diagnosis", 299], ["is", 309], ["often", 312], ["delayed", 318], [",", 325], ["but", 327], ["a", 331], ["careful", 333], ["history", 341], ["can", 349], ["avoid", 353], ["this", 359], [".", 363], ["The", 365], ["syndromes", 369], ["can", 379], ["appear", 383], ["to", 390], ["be", 393], ["due", 396], ["to", 400], ["an", 403], ["imbalance", 406], ["in", 416], ["the", 419], ["sympathetic", 423], ["nerve", 435], ["to", 441], ["the", 444], ["ventricular", 448], ["myocardium", 460], [",", 470], ["and", 472], ["precipitating", 476], ["causes", 490], ["such", 497], ["as", 502], ["stress", 505], ["suggest", 512], ["a", 520], ["CNS", 522], ["influence", 526], ["on", 536], ["this", 539], [".", 543], ["The", 545], ["electrocardiogram", 549], ["can", 567], ["confirm", 571], ["the", 579], ["prolonged", 583], ["Q", 593], ["-", 594], ["T", 595], ["interval", 597], [",", 605], ["but", 607], ["this", 611], ["is", 616], ["not", 619], ["always", 623], ["present", 630], [",", 637], ["at", 639], ["least", 642], ["without", 648], ["an", 656], ["exercise", 659], ["test", 668], [".", 672], ["Treatment", 674], ["with", 684], ["beta", 689], ["-", 693], ["blockers", 694], ["is", 703], ["often", 706], ["successful", 712], [".", 722], ["If", 724], ["a", 727], ["wrong", 729], ["diagnosis", 735], ["of", 745], ["epilepsy", 748], ["is", 757], ["made", 760], ["a", 765], ["chance", 767], ["may", 774], ["be", 778], ["missed", 781], ["of", 788], ["avoiding", 791], ["sudden", 800], ["death", 807], [",", 812], ["quite", 814], ["apart", 820], ["from", 826], ["all", 831], ["the", 835], ["medical", 839], [",", 846], ["and", 848], ["social", 852], ["consequences", 859], ["that", 872], ["can", 877], ["result", 881], ["from", 888], ["such", 893], ["a", 898], ["diagnosis", 900], [".", 909]]}
{"context": "The literature suggests that the d -dimer is useful in patients suspected of having pulmonary embolism and who have a low pretest probability of disease. A previously defined clinical decision rule, the Wells Criteria, may provide a reliable and reproducible means of determining this pretest probability. We evaluate the interrater agreement and external validity of Wells Criteria in determining pretest probability in patients suspected of having pulmonary embolism. This was a prospective observational study. Trained research assistants enrolled patients during 120 random 8-hour shifts. Patients who underwent imaging for pulmonary embolism after a medical history, physical examination, and chest radiograph were enrolled. Treating providers and research assistants determined pretest probability according to Wells Criteria in a blinded fashion. Two d -dimer assays were run. Three-month follow-up for the diagnosis of pulmonary embolism was performed. Interrater agreement tables were created. kappa Values, sensitivities, and specificities were determined. Of the 153 eligible patients, 3 patients were missed, 16 patients declined, and 134 (88%) patients were enrolled. Sixteen (12%) patients were diagnosed with pulmonary embolism. The kappa values for Wells Criteria were 0.54 and 0.72 for the trichotomized and dichotomized scorings, respectively. When Wells Criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively. When Wells Criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively. The immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%). Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "28e8fe6709904ff19ee941b716a6183e", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[96, 97], [70, 71], [294, 295], [261, 262], [364, 365], [201, 202], [14, 15], [146, 147], [283, 284]], "char_spans": [[628, 645], [450, 467], [1682, 1699], [1530, 1547], [2059, 2076], [1224, 1241], [84, 101], [927, 944], [1639, 1656]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["suggests", 15], ["that", 24], ["the", 29], ["d", 33], ["-dimer", 35], ["is", 42], ["useful", 45], ["in", 52], ["patients", 55], ["suspected", 64], ["of", 74], ["having", 77], ["pulmonary", 84], ["embolism", 94], ["and", 103], ["who", 107], ["have", 111], ["a", 116], ["low", 118], ["pretest", 122], ["probability", 130], ["of", 142], ["disease", 145], [".", 152], ["A", 154], ["previously", 156], ["defined", 167], ["clinical", 175], ["decision", 184], ["rule", 193], [",", 197], ["the", 199], ["Wells", 203], ["Criteria", 209], [",", 217], ["may", 219], ["provide", 223], ["a", 231], ["reliable", 233], ["and", 242], ["reproducible", 246], ["means", 259], ["of", 265], ["determining", 268], ["this", 280], ["pretest", 285], ["probability", 293], [".", 304], ["We", 306], ["evaluate", 309], ["the", 318], ["interrater", 322], ["agreement", 333], ["and", 343], ["external", 347], ["validity", 356], ["of", 365], ["Wells", 368], ["Criteria", 374], ["in", 383], ["determining", 386], ["pretest", 398], ["probability", 406], ["in", 418], ["patients", 421], ["suspected", 430], ["of", 440], ["having", 443], ["pulmonary", 450], ["embolism", 460], [".", 468], ["This", 470], ["was", 475], ["a", 479], ["prospective", 481], ["observational", 493], ["study", 507], [".", 512], ["Trained", 514], ["research", 522], ["assistants", 531], ["enrolled", 542], ["patients", 551], ["during", 560], ["120", 567], ["random", 571], ["8-hour", 578], ["shifts", 585], [".", 591], ["Patients", 593], ["who", 602], ["underwent", 606], ["imaging", 616], ["for", 624], ["pulmonary", 628], ["embolism", 638], ["after", 647], ["a", 653], ["medical", 655], ["history", 663], [",", 670], ["physical", 672], ["examination", 681], [",", 692], ["and", 694], ["chest", 698], ["radiograph", 704], ["were", 715], ["enrolled", 720], [".", 728], ["Treating", 730], ["providers", 739], ["and", 749], ["research", 753], ["assistants", 762], ["determined", 773], ["pretest", 784], ["probability", 792], ["according", 804], ["to", 814], ["Wells", 817], ["Criteria", 823], ["in", 832], ["a", 835], ["blinded", 837], ["fashion", 845], [".", 852], ["Two", 854], ["d", 858], ["-dimer", 860], ["assays", 867], ["were", 874], ["run", 879], [".", 882], ["Three", 884], ["-", 889], ["month", 890], ["follow", 896], ["-", 902], ["up", 903], ["for", 906], ["the", 910], ["diagnosis", 914], ["of", 924], ["pulmonary", 927], ["embolism", 937], ["was", 946], ["performed", 950], [".", 959], ["Interrater", 961], ["agreement", 972], ["tables", 982], ["were", 989], ["created", 994], [".", 1001], ["kappa", 1003], ["Values", 1009], [",", 1015], ["sensitivities", 1017], [",", 1030], ["and", 1032], ["specificities", 1036], ["were", 1050], ["determined", 1055], [".", 1065], ["Of", 1067], ["the", 1070], ["153", 1074], ["eligible", 1078], ["patients", 1087], [",", 1095], ["3", 1097], ["patients", 1099], ["were", 1108], ["missed", 1113], [",", 1119], ["16", 1121], ["patients", 1124], ["declined", 1133], [",", 1141], ["and", 1143], ["134", 1147], ["(", 1151], ["88", 1152], ["%", 1154], [")", 1155], ["patients", 1157], ["were", 1166], ["enrolled", 1171], [".", 1179], ["Sixteen", 1181], ["(", 1189], ["12", 1190], ["%", 1192], [")", 1193], ["patients", 1195], ["were", 1204], ["diagnosed", 1209], ["with", 1219], ["pulmonary", 1224], ["embolism", 1234], [".", 1242], ["The", 1244], ["kappa", 1248], ["values", 1254], ["for", 1261], ["Wells", 1265], ["Criteria", 1271], ["were", 1280], ["0.54", 1285], ["and", 1290], ["0.72", 1294], ["for", 1299], ["the", 1303], ["trichotomized", 1307], ["and", 1321], ["dichotomized", 1325], ["scorings", 1338], [",", 1346], ["respectively", 1348], [".", 1360], ["When", 1362], ["Wells", 1367], ["Criteria", 1373], ["were", 1382], ["trichotomized", 1387], ["into", 1401], ["low", 1406], ["pretest", 1410], ["probability", 1418], ["(", 1430], ["n=59", 1431], [",", 1435], ["44", 1437], ["%", 1439], [")", 1440], [",", 1441], ["moderate", 1443], ["pretest", 1452], ["probability", 1460], ["(", 1472], ["n=61", 1473], [",", 1477], ["46", 1479], ["%", 1481], [")", 1482], [",", 1483], ["or", 1485], ["high", 1488], ["pretest", 1493], ["probability", 1501], ["(", 1513], ["n=14", 1514], [",", 1518], ["10", 1520], ["%", 1522], [")", 1523], [",", 1524], ["the", 1526], ["pulmonary", 1530], ["embolism", 1540], ["prevalence", 1549], ["was", 1560], ["2", 1564], ["%", 1565], [",", 1566], ["15", 1568], ["%", 1570], [",", 1571], ["and", 1573], ["43", 1577], ["%", 1579], [",", 1580], ["respectively", 1582], [".", 1594], ["When", 1596], ["Wells", 1601], ["Criteria", 1607], ["were", 1616], ["dichotomized", 1621], ["into", 1634], ["pulmonary", 1639], ["embolism", 1649], ["-", 1657], ["unlikely", 1658], ["(", 1667], ["n=88", 1668], [",", 1672], ["66", 1674], ["%", 1676], [")", 1677], ["or", 1679], ["pulmonary", 1682], ["embolism", 1692], ["-", 1700], ["likely", 1701], ["(", 1708], ["n=46", 1709], [",", 1713], ["34", 1715], ["%", 1717], [")", 1718], [",", 1719], ["the", 1721], ["prevalence", 1725], ["was", 1736], ["3", 1740], ["%", 1741], ["and", 1743], ["28", 1747], ["%", 1749], [",", 1750], ["respectively", 1752], [".", 1764], ["The", 1766], ["immunoturbidimetric", 1770], ["and", 1790], ["rapid", 1794], ["enzyme", 1800], ["-", 1806], ["linked", 1807], ["immunosorbent", 1814], ["assay", 1828], ["d", 1834], ["-dimer", 1836], ["assays", 1843], ["had", 1850], ["similar", 1854], ["sensitivities", 1862], ["(", 1876], ["94", 1877], ["%", 1879], [")", 1880], ["and", 1882], ["specificities", 1886], ["(", 1900], ["45", 1901], ["%", 1903], ["versus", 1905], ["46", 1912], ["%", 1914], [")", 1915], [".", 1916], ["Wells", 1918], ["Criteria", 1924], ["have", 1933], ["a", 1938], ["moderate", 1940], ["to", 1949], ["substantial", 1952], ["interrater", 1964], ["agreement", 1975], ["and", 1985], ["reliably", 1989], ["risk", 1998], ["stratify", 2003], ["pretest", 2012], ["probability", 2020], ["in", 2032], ["patients", 2035], ["with", 2044], ["suspected", 2049], ["pulmonary", 2059], ["embolism", 2069], [".", 2077]]}
{"context": "The large size of spectrin, the flexible protein promoting reversible deformation of red cells, has been an obstacle to elucidating the molecular mechanism of its function. By studying cloned fragments of the repeating unit domain, we have found a correspondence between positions of selected spectrin repeats in a tetramer with their stabilities of folding. Six fragments consisting of two spectrin repeats were selected for study primarily on the basis of the predicted secondary structures of their linker regions. Fragments with a putatively helical linker were more stable to urea- and heat-induced unfolding than those with a putatively nonhelical linker. Two of the less stably folded fragments, human erythroid alpha-spectrin repeats 13 and 14 (HEalpha13,14) and human erythroid beta-spectrin repeats 8 and 9 (HEbeta8,9), are located opposite each other on antiparallel spectrin dimers. At least partial unfolding of these repeats under physiological conditions indicates that they may serve as a hinge. Also less stably folded, the fragment of human erythroid alpha-spectrin repeats 4 and 5 (HEalpha4,5) lies opposite the site of interaction between the partial repeats at the C- and N-terminal ends of beta- and alpha-spectrin, respectively, on the opposing dimer. More stably folded fragments, human erythroid alpha-spectrin repeats 1 and 2 (HEalpha1,2) and human erythroid alpha-spectrin repeats 2 and 3 (HEalpha2,3), lie nearly opposite each other on antiparallel spectrin dimers of a tetramer. These clusterings along the spectrin tetramer of repeats with similar stabilities of folding may have relevance for spectrin function, particularly for its well known flexibility.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "47e09473d3cd4d209e14ce17285a816e", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[148, 148], [260, 260]], "char_spans": [[865, 876], [1464, 1475]]}]}], "context_tokens": [["The", 0], ["large", 4], ["size", 10], ["of", 15], ["spectrin", 18], [",", 26], ["the", 28], ["flexible", 32], ["protein", 41], ["promoting", 49], ["reversible", 59], ["deformation", 70], ["of", 82], ["red", 85], ["cells", 89], [",", 94], ["has", 96], ["been", 100], ["an", 105], ["obstacle", 108], ["to", 117], ["elucidating", 120], ["the", 132], ["molecular", 136], ["mechanism", 146], ["of", 156], ["its", 159], ["function", 163], [".", 171], ["By", 173], ["studying", 176], ["cloned", 185], ["fragments", 192], ["of", 202], ["the", 205], ["repeating", 209], ["unit", 219], ["domain", 224], [",", 230], ["we", 232], ["have", 235], ["found", 240], ["a", 246], ["correspondence", 248], ["between", 263], ["positions", 271], ["of", 281], ["selected", 284], ["spectrin", 293], ["repeats", 302], ["in", 310], ["a", 313], ["tetramer", 315], ["with", 324], ["their", 329], ["stabilities", 335], ["of", 347], ["folding", 350], [".", 357], ["Six", 359], ["fragments", 363], ["consisting", 373], ["of", 384], ["two", 387], ["spectrin", 391], ["repeats", 400], ["were", 408], ["selected", 413], ["for", 422], ["study", 426], ["primarily", 432], ["on", 442], ["the", 445], ["basis", 449], ["of", 455], ["the", 458], ["predicted", 462], ["secondary", 472], ["structures", 482], ["of", 493], ["their", 496], ["linker", 502], ["regions", 509], [".", 516], ["Fragments", 518], ["with", 528], ["a", 533], ["putatively", 535], ["helical", 546], ["linker", 554], ["were", 561], ["more", 566], ["stable", 571], ["to", 578], ["urea-", 581], ["and", 587], ["heat", 591], ["-", 595], ["induced", 596], ["unfolding", 604], ["than", 614], ["those", 619], ["with", 625], ["a", 630], ["putatively", 632], ["nonhelical", 643], ["linker", 654], [".", 660], ["Two", 662], ["of", 666], ["the", 669], ["less", 673], ["stably", 678], ["folded", 685], ["fragments", 692], [",", 701], ["human", 703], ["erythroid", 709], ["alpha", 719], ["-", 724], ["spectrin", 725], ["repeats", 734], ["13", 742], ["and", 745], ["14", 749], ["(", 752], ["HEalpha13,14", 753], [")", 765], ["and", 767], ["human", 771], ["erythroid", 777], ["beta", 787], ["-", 791], ["spectrin", 792], ["repeats", 801], ["8", 809], ["and", 811], ["9", 815], ["(", 817], ["HEbeta8,9", 818], [")", 827], [",", 828], ["are", 830], ["located", 834], ["opposite", 842], ["each", 851], ["other", 856], ["on", 862], ["antiparallel", 865], ["spectrin", 878], ["dimers", 887], [".", 893], ["At", 895], ["least", 898], ["partial", 904], ["unfolding", 912], ["of", 922], ["these", 925], ["repeats", 931], ["under", 939], ["physiological", 945], ["conditions", 959], ["indicates", 970], ["that", 980], ["they", 985], ["may", 990], ["serve", 994], ["as", 1000], ["a", 1003], ["hinge", 1005], [".", 1010], ["Also", 1012], ["less", 1017], ["stably", 1022], ["folded", 1029], [",", 1035], ["the", 1037], ["fragment", 1041], ["of", 1050], ["human", 1053], ["erythroid", 1059], ["alpha", 1069], ["-", 1074], ["spectrin", 1075], ["repeats", 1084], ["4", 1092], ["and", 1094], ["5", 1098], ["(", 1100], ["HEalpha4,5", 1101], [")", 1111], ["lies", 1113], ["opposite", 1118], ["the", 1127], ["site", 1131], ["of", 1136], ["interaction", 1139], ["between", 1151], ["the", 1159], ["partial", 1163], ["repeats", 1171], ["at", 1179], ["the", 1182], ["C-", 1186], ["and", 1189], ["N", 1193], ["-", 1194], ["terminal", 1195], ["ends", 1204], ["of", 1209], ["beta-", 1212], ["and", 1218], ["alpha", 1222], ["-", 1227], ["spectrin", 1228], [",", 1236], ["respectively", 1238], [",", 1250], ["on", 1252], ["the", 1255], ["opposing", 1259], ["dimer", 1268], [".", 1273], ["More", 1275], ["stably", 1280], ["folded", 1287], ["fragments", 1294], [",", 1303], ["human", 1305], ["erythroid", 1311], ["alpha", 1321], ["-", 1326], ["spectrin", 1327], ["repeats", 1336], ["1", 1344], ["and", 1346], ["2", 1350], ["(", 1352], ["HEalpha1,2", 1353], [")", 1363], ["and", 1365], ["human", 1369], ["erythroid", 1375], ["alpha", 1385], ["-", 1390], ["spectrin", 1391], ["repeats", 1400], ["2", 1408], ["and", 1410], ["3", 1414], ["(", 1416], ["HEalpha2,3", 1417], [")", 1427], [",", 1428], ["lie", 1430], ["nearly", 1434], ["opposite", 1441], ["each", 1450], ["other", 1455], ["on", 1461], ["antiparallel", 1464], ["spectrin", 1477], ["dimers", 1486], ["of", 1493], ["a", 1496], ["tetramer", 1498], [".", 1506], ["These", 1508], ["clusterings", 1514], ["along", 1526], ["the", 1532], ["spectrin", 1536], ["tetramer", 1545], ["of", 1554], ["repeats", 1557], ["with", 1565], ["similar", 1570], ["stabilities", 1578], ["of", 1590], ["folding", 1593], ["may", 1601], ["have", 1605], ["relevance", 1610], ["for", 1620], ["spectrin", 1624], ["function", 1633], [",", 1641], ["particularly", 1643], ["for", 1656], ["its", 1660], ["well", 1664], ["known", 1669], ["flexibility", 1675], [".", 1686]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "The performance of two proteomic sample preparation methods, \"pseudoshotgun\" (PSG) and filter-aided sample preparation (FASP) were compared in terms of the number of identified proteins, representation of cellular component GO (gene ontology) categories in the obtained list of proteins, and the efficiency of both methods in the proteomic analysis of a very low number of cells. Both methods were combined to obtain a proteomic profile of a short-term culture (passage 3) of melanoma cells, established in our laboratory from a human metastatic melanoma lesion. The data revealed that with FASP, usually more proteins are identified than with PSG when analyzing a higher number of cells (\u2265 5000/injection), whereas PSG is favorable when analyzing only a very small amount of cells (250-500/injection). PSG and FASP, however, are complementary techniques, as combining both methods further increases the number of identified proteins. Moreover, we show that it is feasible to identify a substantial number of proteins from only 250 cells/injection that is equivalent to 60 ng of protein.", "qas": [{"question": "What is the method FASP used for?", "answers": ["proteomic sample preparation"], "qid": "302b827bb3634be7b8c958d4d56fa6da", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["method", 12], ["FASP", 19], ["used", 24], ["for", 29], ["?", 32]], "detected_answers": [{"text": "proteomic sample preparation", "token_spans": [[4, 6]], "char_spans": [[23, 50]]}]}], "context_tokens": [["The", 0], ["performance", 4], ["of", 16], ["two", 19], ["proteomic", 23], ["sample", 33], ["preparation", 40], ["methods", 52], [",", 59], ["\"", 61], ["pseudoshotgun", 62], ["\"", 75], ["(", 77], ["PSG", 78], [")", 81], ["and", 83], ["filter", 87], ["-", 93], ["aided", 94], ["sample", 100], ["preparation", 107], ["(", 119], ["FASP", 120], [")", 124], ["were", 126], ["compared", 131], ["in", 140], ["terms", 143], ["of", 149], ["the", 152], ["number", 156], ["of", 163], ["identified", 166], ["proteins", 177], [",", 185], ["representation", 187], ["of", 202], ["cellular", 205], ["component", 214], ["GO", 224], ["(", 227], ["gene", 228], ["ontology", 233], [")", 241], ["categories", 243], ["in", 254], ["the", 257], ["obtained", 261], ["list", 270], ["of", 275], ["proteins", 278], [",", 286], ["and", 288], ["the", 292], ["efficiency", 296], ["of", 307], ["both", 310], ["methods", 315], ["in", 323], ["the", 326], ["proteomic", 330], ["analysis", 340], ["of", 349], ["a", 352], ["very", 354], ["low", 359], ["number", 363], ["of", 370], ["cells", 373], [".", 378], ["Both", 380], ["methods", 385], ["were", 393], ["combined", 398], ["to", 407], ["obtain", 410], ["a", 417], ["proteomic", 419], ["profile", 429], ["of", 437], ["a", 440], ["short", 442], ["-", 447], ["term", 448], ["culture", 453], ["(", 461], ["passage", 462], ["3", 470], [")", 471], ["of", 473], ["melanoma", 476], ["cells", 485], [",", 490], ["established", 492], ["in", 504], ["our", 507], ["laboratory", 511], ["from", 522], ["a", 527], ["human", 529], ["metastatic", 535], ["melanoma", 546], ["lesion", 555], [".", 561], ["The", 563], ["data", 567], ["revealed", 572], ["that", 581], ["with", 586], ["FASP", 591], [",", 595], ["usually", 597], ["more", 605], ["proteins", 610], ["are", 619], ["identified", 623], ["than", 634], ["with", 639], ["PSG", 644], ["when", 648], ["analyzing", 653], ["a", 663], ["higher", 665], ["number", 672], ["of", 679], ["cells", 682], ["(", 688], ["\u2265", 689], ["5000/injection", 691], [")", 705], [",", 706], ["whereas", 708], ["PSG", 716], ["is", 720], ["favorable", 723], ["when", 733], ["analyzing", 738], ["only", 748], ["a", 753], ["very", 755], ["small", 760], ["amount", 766], ["of", 773], ["cells", 776], ["(", 782], ["250", 783], ["-", 786], ["500/injection", 787], [")", 800], [".", 801], ["PSG", 803], ["and", 807], ["FASP", 811], [",", 815], ["however", 817], [",", 824], ["are", 826], ["complementary", 830], ["techniques", 844], [",", 854], ["as", 856], ["combining", 859], ["both", 869], ["methods", 874], ["further", 882], ["increases", 890], ["the", 900], ["number", 904], ["of", 911], ["identified", 914], ["proteins", 925], [".", 933], ["Moreover", 935], [",", 943], ["we", 945], ["show", 948], ["that", 953], ["it", 958], ["is", 961], ["feasible", 964], ["to", 973], ["identify", 976], ["a", 985], ["substantial", 987], ["number", 999], ["of", 1006], ["proteins", 1009], ["from", 1018], ["only", 1023], ["250", 1028], ["cells", 1032], ["/", 1037], ["injection", 1038], ["that", 1048], ["is", 1053], ["equivalent", 1056], ["to", 1067], ["60", 1070], ["ng", 1073], ["of", 1076], ["protein", 1079], [".", 1086]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "51a1889816af46d0bc6c17f5001e75f4", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[65, 67]], "char_spans": [[374, 380]]}]}], "context_tokens": [["The", 0], ["translocation", 4], ["(", 18], ["9;22", 19], [")", 23], ["gives", 25], ["rise", 31], ["to", 36], ["the", 39], ["p190(Bcr", 43], ["-", 51], ["Abl", 52], [")", 55], ["and", 57], ["p210(Bcr", 61], ["-", 69], ["Abl", 70], [")", 73], ["tyrosine", 75], ["kinase", 84], ["proteins", 91], [",", 99], ["considered", 101], ["sufficient", 112], ["for", 123], ["leukemic", 127], ["transformation", 136], [".", 150], ["Philadelphia", 152], ["-", 164], ["positive", 165], ["(", 174], ["Ph(+", 175], [")", 179], [")", 180], ["acute", 182], ["leukemia", 188], ["patients", 197], ["failing", 206], ["to", 214], ["respond", 217], ["to", 225], ["initial", 228], ["induction", 236], ["therapy", 246], ["have", 254], ["a", 259], ["poor", 261], ["prognosis", 266], ["with", 276], ["few", 281], ["effective", 285], ["treatment", 295], ["options", 305], [".", 312], ["Imatinib", 314], ["is", 323], ["an", 326], ["orally", 329], ["administered", 336], [",", 348], ["potent", 350], ["inhibitor", 357], ["of", 367], ["the", 370], ["Bcr", 374], ["-", 377], ["Abl", 378], ["tyrosine", 382], ["kinase", 391], [".", 397], ["We", 399], ["conducted", 402], ["a", 412], ["clinical", 414], ["trial", 423], ["in", 429], ["56", 432], ["patients", 435], ["with", 444], ["relapsed", 449], ["or", 458], ["refractory", 461], ["Ph(+", 472], [")", 476], ["acute", 478], ["lymphoblastic", 484], ["leukemia", 498], ["(", 507], ["ALL", 508], [";", 511], ["48", 513], ["patients", 516], [")", 524], ["or", 526], ["chronic", 529], ["myelogenous", 537], ["leukemia", 549], ["in", 558], ["lymphoid", 561], ["blast", 570], ["crisis", 576], ["(", 583], ["LyBC", 584], [";", 588], ["8", 590], ["patients", 592], [")", 600], [".", 601], ["Imatinib", 603], ["was", 612], ["given", 616], ["once", 622], ["daily", 627], ["at", 633], ["400", 636], ["mg", 640], ["or", 643], ["600", 646], ["mg", 650], [".", 652], ["Imatinib", 654], ["induced", 663], ["complete", 671], ["hematologic", 680], ["responses", 692], ["(", 702], ["CHRs", 703], [")", 707], ["and", 709], ["complete", 713], ["marrow", 722], ["responses", 729], ["(", 739], ["marrow", 740], ["-", 746], ["CRs", 747], [")", 750], ["in", 752], ["29", 755], ["%", 757], ["of", 759], ["ALL", 762], ["patients", 766], ["(", 775], ["CHR", 776], [",", 779], ["19", 781], ["%", 783], [";", 784], ["marrow", 786], ["-", 792], ["CR", 793], [",", 795], ["10", 797], ["%", 799], [")", 800], [",", 801], ["which", 803], ["were", 809], ["sustained", 814], ["for", 824], ["at", 828], ["least", 831], ["4", 837], ["weeks", 839], ["in", 845], ["6", 848], ["%", 849], ["of", 851], ["patients", 854], [".", 862], ["Median", 864], ["estimated", 871], ["time", 881], ["to", 886], ["progression", 889], ["and", 901], ["overall", 905], ["survival", 913], ["for", 922], ["ALL", 926], ["patients", 930], ["were", 939], ["2.2", 944], ["and", 948], ["4.9", 952], ["months", 956], [",", 962], ["respectively", 964], [".", 976], ["CHRs", 978], ["were", 983], ["reported", 988], ["for", 997], ["3", 1001], ["(", 1003], ["38", 1004], ["%", 1006], [")", 1007], ["of", 1009], ["the", 1012], ["patients", 1016], ["with", 1025], ["LyBC", 1030], ["(", 1035], ["one", 1036], ["sustained", 1040], ["CHR", 1050], [")", 1053], [".", 1054], ["Grade", 1056], ["3", 1062], ["or", 1064], ["4", 1067], ["treatment", 1069], ["-", 1078], ["related", 1079], ["nonhematologic", 1087], ["toxicity", 1102], ["was", 1111], ["reported", 1115], ["for", 1124], ["9", 1128], ["%", 1129], ["of", 1131], ["patients", 1134], [";", 1142], ["none", 1144], ["of", 1149], ["the", 1152], ["patients", 1156], ["discontinued", 1165], ["therapy", 1178], ["because", 1186], ["of", 1194], ["nonhematologic", 1197], ["adverse", 1212], ["reactions", 1220], [".", 1229], ["Grade", 1231], ["4", 1237], ["neutropenia", 1239], ["and", 1251], ["thrombocytopenia", 1255], ["occurred", 1272], ["in", 1281], ["54", 1284], ["%", 1286], ["and", 1288], ["27", 1292], ["%", 1294], ["of", 1296], ["patients", 1299], [",", 1307], ["respectively", 1309], [".", 1321], ["Imatinib", 1323], ["therapy", 1332], ["resulted", 1340], ["in", 1349], ["a", 1352], ["clinically", 1354], ["relevant", 1365], ["hematologic", 1374], ["response", 1386], ["rate", 1395], ["in", 1400], ["relapsed", 1403], ["or", 1412], ["refractory", 1415], ["Ph(+", 1426], [")", 1430], ["acute", 1432], ["lymphoid", 1438], ["leukemia", 1447], ["patients", 1456], [",", 1464], ["but", 1466], ["development", 1470], ["of", 1482], ["resistance", 1485], ["and", 1496], ["subsequent", 1500], ["disease", 1511], ["progression", 1519], ["were", 1531], ["rapid", 1536], [".", 1541], ["Further", 1543], ["studies", 1551], ["are", 1559], ["warranted", 1563], ["to", 1573], ["test", 1576], ["the", 1581], ["effects", 1585], ["of", 1593], ["imatinib", 1596], ["in", 1605], ["combination", 1608], ["with", 1620], ["other", 1625], ["agents", 1631], ["and", 1638], ["to", 1642], ["define", 1645], ["the", 1652], ["mechanisms", 1656], ["of", 1667], ["resistance", 1670], ["to", 1681], ["imatinib", 1684], [".", 1692]]}
{"context": "Untreated sleep disorders may contribute to secondary causes of uncontrolled hypertension, cardiovascular disease (CVD), and stroke. Restless legs syndrome, or Willis-Ekbom Disease (RLS/WED), is a common sensorimotor disorder with a circadian rhythmicity defined by an uncontrollable urge to move the legs that worsens during periods of inactivity or at rest in the evening, often resulting in sleep disruptions. Sleep disorders such as insomnia and obstructive sleep apnea (OSA) are established risk factors for increased risk of hypertension and vascular diseases. This literature review outlines the lessons learned from studies demonstrating insomnia and OSA as risk factors for hypertension and vascular diseases to support the epidemiologic and physiologic evidence suggesting a similar increase in hypertension and vascular disease risk due to RLS. Understanding the relationships between RLS and hypertension, CVD, and stroke has important implications for reducing the risks associated with these diseases.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3117044f9a5c499699d0b54e0b238a5a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[133, 154]]}]}], "context_tokens": [["Untreated", 0], ["sleep", 10], ["disorders", 16], ["may", 26], ["contribute", 30], ["to", 41], ["secondary", 44], ["causes", 54], ["of", 61], ["uncontrolled", 64], ["hypertension", 77], [",", 89], ["cardiovascular", 91], ["disease", 106], ["(", 114], ["CVD", 115], [")", 118], [",", 119], ["and", 121], ["stroke", 125], [".", 131], ["Restless", 133], ["legs", 142], ["syndrome", 147], [",", 155], ["or", 157], ["Willis", 160], ["-", 166], ["Ekbom", 167], ["Disease", 173], ["(", 181], ["RLS", 182], ["/", 185], ["WED", 186], [")", 189], [",", 190], ["is", 192], ["a", 195], ["common", 197], ["sensorimotor", 204], ["disorder", 217], ["with", 226], ["a", 231], ["circadian", 233], ["rhythmicity", 243], ["defined", 255], ["by", 263], ["an", 266], ["uncontrollable", 269], ["urge", 284], ["to", 289], ["move", 292], ["the", 297], ["legs", 301], ["that", 306], ["worsens", 311], ["during", 319], ["periods", 326], ["of", 334], ["inactivity", 337], ["or", 348], ["at", 351], ["rest", 354], ["in", 359], ["the", 362], ["evening", 366], [",", 373], ["often", 375], ["resulting", 381], ["in", 391], ["sleep", 394], ["disruptions", 400], [".", 411], ["Sleep", 413], ["disorders", 419], ["such", 429], ["as", 434], ["insomnia", 437], ["and", 446], ["obstructive", 450], ["sleep", 462], ["apnea", 468], ["(", 474], ["OSA", 475], [")", 478], ["are", 480], ["established", 484], ["risk", 496], ["factors", 501], ["for", 509], ["increased", 513], ["risk", 523], ["of", 528], ["hypertension", 531], ["and", 544], ["vascular", 548], ["diseases", 557], [".", 565], ["This", 567], ["literature", 572], ["review", 583], ["outlines", 590], ["the", 599], ["lessons", 603], ["learned", 611], ["from", 619], ["studies", 624], ["demonstrating", 632], ["insomnia", 646], ["and", 655], ["OSA", 659], ["as", 663], ["risk", 666], ["factors", 671], ["for", 679], ["hypertension", 683], ["and", 696], ["vascular", 700], ["diseases", 709], ["to", 718], ["support", 721], ["the", 729], ["epidemiologic", 733], ["and", 747], ["physiologic", 751], ["evidence", 763], ["suggesting", 772], ["a", 783], ["similar", 785], ["increase", 793], ["in", 802], ["hypertension", 805], ["and", 818], ["vascular", 822], ["disease", 831], ["risk", 839], ["due", 844], ["to", 848], ["RLS", 851], [".", 854], ["Understanding", 856], ["the", 870], ["relationships", 874], ["between", 888], ["RLS", 896], ["and", 900], ["hypertension", 904], [",", 916], ["CVD", 918], [",", 921], ["and", 923], ["stroke", 927], ["has", 934], ["important", 938], ["implications", 948], ["for", 961], ["reducing", 965], ["the", 974], ["risks", 978], ["associated", 984], ["with", 995], ["these", 1000], ["diseases", 1006], [".", 1014]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01(E) coadministration groups. RTS,S/AS01(E) generated high anti-circumsporozoite protein and anti-hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01(E) at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation. Trial registration. ClinicalTrials.gov identifier: NCT00436007 . GlaxoSmithKline study ID number: 106369 (Malaria-050).", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "a83fcafc8fb6472ba0ed2aea6e7a78a3", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[7, 7]], "char_spans": [[18, 24]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["malaria", 18], ["candidate", 26], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunization", 67], ["of", 80], ["African", 83], ["infants", 91], ["through", 99], ["the", 107], ["Expanded", 111], ["Program", 120], ["of", 128], ["Immunization", 131], ["(", 144], ["EPI", 145], [")", 148], [".", 149], ["This", 151], ["phase", 156], ["2", 162], [",", 163], ["randomized", 165], [",", 175], ["open", 177], [",", 181], ["controlled", 183], ["trial", 194], ["conducted", 200], ["in", 210], ["Ghana", 213], [",", 218], ["Tanzania", 220], [",", 228], ["and", 230], ["Gabon", 234], ["evaluated", 240], ["the", 250], ["safety", 254], ["and", 261], ["immunogenicity", 265], ["of", 280], ["RTS", 283], [",", 286], ["S", 287], ["/", 288], ["AS01(E", 289], [")", 295], ["when", 297], ["coadministered", 302], ["with", 317], ["EPI", 322], ["vaccines", 326], [".", 334], ["Five", 336], ["hundred", 341], ["eleven", 349], ["infants", 356], ["were", 364], ["randomized", 369], ["to", 380], ["receive", 383], ["RTS", 391], [",", 394], ["S", 395], ["/", 396], ["AS01(E", 397], [")", 403], ["at", 405], ["0", 408], [",", 409], ["1", 411], [",", 412], ["and", 414], ["2", 418], ["months", 420], ["(", 427], ["in", 428], ["3", 431], ["doses", 433], ["with", 439], ["diphtheria", 444], [",", 454], ["tetanus", 456], [",", 463], ["and", 465], ["whole", 469], ["-", 474], ["cell", 475], ["pertussis", 480], ["conjugate", 490], ["[", 500], ["DTPw", 501], ["]", 505], [";", 506], ["hepatitis", 508], ["B", 518], ["[", 520], ["HepB", 521], ["]", 525], [";", 526], ["Haemophilus", 528], ["influenzae", 540], ["type", 551], ["b", 556], ["[", 558], ["Hib", 559], ["]", 562], [";", 563], ["and", 565], ["oral", 569], ["polio", 574], ["vaccine", 580], ["[", 588], ["OPV", 589], ["]", 592], [")", 593], [",", 594], ["RTS", 596], [",", 599], ["S", 600], ["/", 601], ["AS01(E", 602], [")", 608], ["at", 610], ["0", 613], [",", 614], ["1", 616], [",", 617], ["and", 619], ["7", 623], ["months", 625], ["(", 632], ["2", 633], ["doses", 635], ["with", 641], ["DTPwHepB", 646], ["/", 654], ["Hib+OPV", 655], ["and", 663], ["1", 667], ["dose", 669], ["with", 674], ["measles", 679], ["and", 687], ["yellow", 691], ["fever", 698], [")", 703], [",", 704], ["or", 706], ["EPI", 709], ["vaccines", 713], ["only", 722], [".", 726], ["The", 728], ["occurrences", 732], ["of", 744], ["serious", 747], ["adverse", 755], ["events", 763], ["were", 770], ["balanced", 775], ["across", 784], ["groups", 791], [";", 797], ["none", 799], ["were", 804], ["vaccine", 809], ["-", 816], ["related", 817], [".", 824], ["One", 826], ["child", 830], ["from", 836], ["the", 841], ["control", 845], ["group", 853], ["died", 859], [".", 863], ["Mild", 865], ["to", 870], ["moderate", 873], ["fever", 882], ["and", 888], ["diaper", 892], ["dermatitis", 899], ["occurred", 910], ["more", 919], ["frequently", 924], ["in", 935], ["the", 938], ["RTS", 942], [",", 945], ["S", 946], ["/", 947], ["AS01(E", 948], [")", 954], ["coadministration", 956], ["groups", 973], [".", 979], ["RTS", 981], [",", 984], ["S", 985], ["/", 986], ["AS01(E", 987], [")", 993], ["generated", 995], ["high", 1005], ["anti", 1010], ["-", 1014], ["circumsporozoite", 1015], ["protein", 1032], ["and", 1040], ["anti", 1044], ["-", 1048], ["hepatitis", 1049], ["B", 1059], ["surface", 1061], ["antigen", 1069], ["antibody", 1077], ["levels", 1086], [".", 1092], ["Regarding", 1094], ["EPI", 1104], ["vaccine", 1108], ["responses", 1116], ["upon", 1126], ["coadministration", 1131], ["when", 1148], ["considering", 1153], ["both", 1165], ["immunization", 1170], ["schedules", 1183], [",", 1192], ["despite", 1194], ["a", 1202], ["tendency", 1204], ["toward", 1213], ["lower", 1220], ["geometric", 1226], ["mean", 1236], ["titers", 1241], ["to", 1248], ["some", 1251], ["EPI", 1256], ["antigens", 1260], [",", 1268], ["predefined", 1270], ["noninferiority", 1281], ["criteria", 1296], ["were", 1305], ["met", 1310], ["for", 1314], ["all", 1318], ["EPI", 1322], ["antigens", 1326], ["except", 1335], ["for", 1342], ["polio", 1346], ["3", 1352], ["when", 1354], ["EPI", 1359], ["vaccines", 1363], ["were", 1372], ["given", 1377], ["with", 1383], ["RTS", 1388], [",", 1391], ["S", 1392], ["/", 1393], ["AS01(E", 1394], [")", 1400], ["at", 1402], ["0", 1405], [",", 1406], ["1", 1408], [",", 1409], ["and", 1411], ["2", 1415], ["months", 1417], [".", 1423], ["However", 1425], [",", 1432], ["when", 1434], ["antibody", 1439], ["levels", 1448], ["at", 1455], ["screening", 1458], ["were", 1468], ["taken", 1473], ["into", 1479], ["account", 1484], [",", 1491], ["the", 1493], ["rates", 1497], ["of", 1503], ["response", 1506], ["to", 1515], ["polio", 1518], ["3", 1524], ["antigens", 1526], ["were", 1535], ["comparable", 1540], ["between", 1551], ["groups", 1559], [".", 1565], ["RTS", 1567], [",", 1570], ["S", 1571], ["/", 1572], ["AS01(E", 1573], [")", 1579], ["integrated", 1581], ["in", 1592], ["the", 1595], ["EPI", 1599], ["showed", 1603], ["a", 1610], ["favorable", 1612], ["safety", 1622], ["and", 1629], ["immunogenicity", 1633], ["evaluation", 1648], [".", 1658], ["Trial", 1660], ["registration", 1666], [".", 1678], ["ClinicalTrials.gov", 1680], ["identifier", 1699], [":", 1709], ["NCT00436007", 1711], [".", 1723], ["GlaxoSmithKline", 1725], ["study", 1741], ["ID", 1747], ["number", 1750], [":", 1756], ["106369", 1758], ["(", 1765], ["Malaria-050", 1766], [")", 1777], [".", 1778]]}
{"context": "In plant, primary transcripts (pri-miRNAs) transcribed from miRNA genes by RNA polymerase II are first processed into stem-loop pre-miRNAs and further chopped into \u223c21\u2009nt long miRNAs by RNase III-like enzyme DCL1. SERRATE (SE) protein is an essential component for miRNA processing by assisting DCL1 for accurate cleavage. Here we report the crystal structure of Arabidopsis SE core (residues 194-543) at 2.7\u2009\u00c5. SE core adopts the 'walking man-like' topology with N-terminal \u03b1 helices, C-terminal non-canonical zinc-finger domain and novel Middle domain resembling the leading leg, the lagging leg and the body, respectively. Pull-down assay shows that SE core provides the platform for HYL1 and DCL1 binding, whereas in vitro RNA binding and in vivo mutant rescue experiments suggest that the non-canonical zinc-finger domain coupled with C-terminal tail binds miRNA precursors. SE presumably works as a scaffold-like protein capable of binding both protein and RNA to guide the positioning of miRNA precursor toward DCL1 catalytic site within miRNA processing machinery in plant.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "1d7bdd75c990481ca677c46e2eb7a4db", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[15, 17]], "char_spans": [[75, 91]]}]}], "context_tokens": [["In", 0], ["plant", 3], [",", 8], ["primary", 10], ["transcripts", 18], ["(", 30], ["pri", 31], ["-", 34], ["miRNAs", 35], [")", 41], ["transcribed", 43], ["from", 55], ["miRNA", 60], ["genes", 66], ["by", 72], ["RNA", 75], ["polymerase", 79], ["II", 90], ["are", 93], ["first", 97], ["processed", 103], ["into", 113], ["stem", 118], ["-", 122], ["loop", 123], ["pre", 128], ["-", 131], ["miRNAs", 132], ["and", 139], ["further", 143], ["chopped", 151], ["into", 159], ["\u223c21", 164], ["nt", 168], ["long", 171], ["miRNAs", 176], ["by", 183], ["RNase", 186], ["III", 192], ["-", 195], ["like", 196], ["enzyme", 201], ["DCL1", 208], [".", 212], ["SERRATE", 214], ["(", 222], ["SE", 223], [")", 225], ["protein", 227], ["is", 235], ["an", 238], ["essential", 241], ["component", 251], ["for", 261], ["miRNA", 265], ["processing", 271], ["by", 282], ["assisting", 285], ["DCL1", 295], ["for", 300], ["accurate", 304], ["cleavage", 313], [".", 321], ["Here", 323], ["we", 328], ["report", 331], ["the", 338], ["crystal", 342], ["structure", 350], ["of", 360], ["Arabidopsis", 363], ["SE", 375], ["core", 378], ["(", 383], ["residues", 384], ["194", 393], ["-", 396], ["543", 397], [")", 400], ["at", 402], ["2.7", 405], ["\u00c5.", 409], ["SE", 412], ["core", 415], ["adopts", 420], ["the", 427], ["'", 431], ["walking", 432], ["man", 440], ["-", 443], ["like", 444], ["'", 448], ["topology", 450], ["with", 459], ["N", 464], ["-", 465], ["terminal", 466], ["\u03b1", 475], ["helices", 477], [",", 484], ["C", 486], ["-", 487], ["terminal", 488], ["non", 497], ["-", 500], ["canonical", 501], ["zinc", 511], ["-", 515], ["finger", 516], ["domain", 523], ["and", 530], ["novel", 534], ["Middle", 540], ["domain", 547], ["resembling", 554], ["the", 565], ["leading", 569], ["leg", 577], [",", 580], ["the", 582], ["lagging", 586], ["leg", 594], ["and", 598], ["the", 602], ["body", 606], [",", 610], ["respectively", 612], [".", 624], ["Pull", 626], ["-", 630], ["down", 631], ["assay", 636], ["shows", 642], ["that", 648], ["SE", 653], ["core", 656], ["provides", 661], ["the", 670], ["platform", 674], ["for", 683], ["HYL1", 687], ["and", 692], ["DCL1", 696], ["binding", 701], [",", 708], ["whereas", 710], ["in", 718], ["vitro", 721], ["RNA", 727], ["binding", 731], ["and", 739], ["in", 743], ["vivo", 746], ["mutant", 751], ["rescue", 758], ["experiments", 765], ["suggest", 777], ["that", 785], ["the", 790], ["non", 794], ["-", 797], ["canonical", 798], ["zinc", 808], ["-", 812], ["finger", 813], ["domain", 820], ["coupled", 827], ["with", 835], ["C", 840], ["-", 841], ["terminal", 842], ["tail", 851], ["binds", 856], ["miRNA", 862], ["precursors", 868], [".", 878], ["SE", 880], ["presumably", 883], ["works", 894], ["as", 900], ["a", 903], ["scaffold", 905], ["-", 913], ["like", 914], ["protein", 919], ["capable", 927], ["of", 935], ["binding", 938], ["both", 946], ["protein", 951], ["and", 959], ["RNA", 963], ["to", 967], ["guide", 970], ["the", 976], ["positioning", 980], ["of", 992], ["miRNA", 995], ["precursor", 1001], ["toward", 1011], ["DCL1", 1018], ["catalytic", 1023], ["site", 1033], ["within", 1038], ["miRNA", 1045], ["processing", 1051], ["machinery", 1062], ["in", 1072], ["plant", 1075], [".", 1080]]}
{"context": "Mutations within the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL mutations appear to be restricted to the first twenty-four exons, resulting in the gain or loss of a cysteine amino acid. The role of other exonic NOTCH3 variation not involving cysteine residues and mutations in exons 25-33 in ischemic stroke remains unresolved. All 33 exons of NOTCH3 were sequenced in 269 Caucasian probands from the Siblings With Ischemic Stroke Study (SWISS), a 70-center North American affected sibling pair study and 95 healthy Caucasian control subjects. Variants identified by sequencing in the SWISS probands were then tested for association with ischemic stroke using US Caucasian controls collected at the Mayo Clinic (n=654), and further assessed in a Caucasian (n=802) and African American (n=298) patient-control series collected through the Ischemic Stroke Genetics Study (ISGS). Sequencing of the 269 SWISS probands identified one (0.4%) with small vessel type stroke carrying a known CADASIL mutation (p.R558C; Exon 11). Of the 19 common NOTCH3 variants identified, the only variant significantly associated with ischemic stroke after multiple testing adjustment was p.R1560P (rs78501403; Exon 25) in the combined SWISS and ISGS Caucasian series (Odds Ratio [OR] 0.50, P=0.0022) where presence of the minor allele was protective against ischemic stroke. Although only significant prior to adjustment for multiple testing, p.T101T (rs3815188; Exon 3) was associated with an increased risk of small-vessel stroke (OR: 1.56, P=0.008) and p.P380P (rs61749020; Exon 7) was associated with decreased risk of large-vessel stroke (OR: 0.35, P=0.047) in Caucasians. No significant associations were observed in the small African American series. Cysteine-affecting NOTCH3 mutations are rare in patients with typical ischemic stroke, however our observation that common NOTCH3 variants may be associated with risk of ischemic stroke warrants further study.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "5d67f3f3e8fc4a01a62f519db556744e", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[336, 336], [41, 41], [54, 54]], "char_spans": [[1821, 1828], [250, 257], [327, 334]]}]}], "context_tokens": [["Mutations", 0], ["within", 10], ["the", 17], ["NOTCH3", 21], ["gene", 28], ["cause", 33], ["cerebral", 39], ["autosomal", 48], ["dominant", 58], ["arteriopathy", 67], ["with", 80], ["subcortical", 85], ["infarcts", 97], ["and", 106], ["leukoencephalopathy", 110], ["(", 130], ["CADASIL", 131], [")", 138], [".", 139], ["CADASIL", 141], ["mutations", 149], ["appear", 159], ["to", 166], ["be", 169], ["restricted", 172], ["to", 183], ["the", 186], ["first", 190], ["twenty", 196], ["-", 202], ["four", 203], ["exons", 208], [",", 213], ["resulting", 215], ["in", 225], ["the", 228], ["gain", 232], ["or", 237], ["loss", 240], ["of", 245], ["a", 248], ["cysteine", 250], ["amino", 259], ["acid", 265], [".", 269], ["The", 271], ["role", 275], ["of", 280], ["other", 283], ["exonic", 289], ["NOTCH3", 296], ["variation", 303], ["not", 313], ["involving", 317], ["cysteine", 327], ["residues", 336], ["and", 345], ["mutations", 349], ["in", 359], ["exons", 362], ["25", 368], ["-", 370], ["33", 371], ["in", 374], ["ischemic", 377], ["stroke", 386], ["remains", 393], ["unresolved", 401], [".", 411], ["All", 413], ["33", 417], ["exons", 420], ["of", 426], ["NOTCH3", 429], ["were", 436], ["sequenced", 441], ["in", 451], ["269", 454], ["Caucasian", 458], ["probands", 468], ["from", 477], ["the", 482], ["Siblings", 486], ["With", 495], ["Ischemic", 500], ["Stroke", 509], ["Study", 516], ["(", 522], ["SWISS", 523], [")", 528], [",", 529], ["a", 531], ["70-center", 533], ["North", 543], ["American", 549], ["affected", 558], ["sibling", 567], ["pair", 575], ["study", 580], ["and", 586], ["95", 590], ["healthy", 593], ["Caucasian", 601], ["control", 611], ["subjects", 619], [".", 627], ["Variants", 629], ["identified", 638], ["by", 649], ["sequencing", 652], ["in", 663], ["the", 666], ["SWISS", 670], ["probands", 676], ["were", 685], ["then", 690], ["tested", 695], ["for", 702], ["association", 706], ["with", 718], ["ischemic", 723], ["stroke", 732], ["using", 739], ["US", 745], ["Caucasian", 748], ["controls", 758], ["collected", 767], ["at", 777], ["the", 780], ["Mayo", 784], ["Clinic", 789], ["(", 796], ["n=654", 797], [")", 802], [",", 803], ["and", 805], ["further", 809], ["assessed", 817], ["in", 826], ["a", 829], ["Caucasian", 831], ["(", 841], ["n=802", 842], [")", 847], ["and", 849], ["African", 853], ["American", 861], ["(", 870], ["n=298", 871], [")", 876], ["patient", 878], ["-", 885], ["control", 886], ["series", 894], ["collected", 901], ["through", 911], ["the", 919], ["Ischemic", 923], ["Stroke", 932], ["Genetics", 939], ["Study", 948], ["(", 954], ["ISGS", 955], [")", 959], [".", 960], ["Sequencing", 962], ["of", 973], ["the", 976], ["269", 980], ["SWISS", 984], ["probands", 990], ["identified", 999], ["one", 1010], ["(", 1014], ["0.4", 1015], ["%", 1018], [")", 1019], ["with", 1021], ["small", 1026], ["vessel", 1032], ["type", 1039], ["stroke", 1044], ["carrying", 1051], ["a", 1060], ["known", 1062], ["CADASIL", 1068], ["mutation", 1076], ["(", 1085], ["p", 1086], [".", 1087], ["R558C", 1088], [";", 1093], ["Exon", 1095], ["11", 1100], [")", 1102], [".", 1103], ["Of", 1105], ["the", 1108], ["19", 1112], ["common", 1115], ["NOTCH3", 1122], ["variants", 1129], ["identified", 1138], [",", 1148], ["the", 1150], ["only", 1154], ["variant", 1159], ["significantly", 1167], ["associated", 1181], ["with", 1192], ["ischemic", 1197], ["stroke", 1206], ["after", 1213], ["multiple", 1219], ["testing", 1228], ["adjustment", 1236], ["was", 1247], ["p", 1251], [".", 1252], ["R1560P", 1253], ["(", 1260], ["rs78501403", 1261], [";", 1271], ["Exon", 1273], ["25", 1278], [")", 1280], ["in", 1282], ["the", 1285], ["combined", 1289], ["SWISS", 1298], ["and", 1304], ["ISGS", 1308], ["Caucasian", 1313], ["series", 1323], ["(", 1330], ["Odds", 1331], ["Ratio", 1336], ["[", 1342], ["OR", 1343], ["]", 1345], ["0.50", 1347], [",", 1351], ["P=0.0022", 1353], [")", 1361], ["where", 1363], ["presence", 1369], ["of", 1378], ["the", 1381], ["minor", 1385], ["allele", 1391], ["was", 1398], ["protective", 1402], ["against", 1413], ["ischemic", 1421], ["stroke", 1430], [".", 1436], ["Although", 1438], ["only", 1447], ["significant", 1452], ["prior", 1464], ["to", 1470], ["adjustment", 1473], ["for", 1484], ["multiple", 1488], ["testing", 1497], [",", 1504], ["p", 1506], [".", 1507], ["T101", 1508], ["T", 1512], ["(", 1514], ["rs3815188", 1515], [";", 1524], ["Exon", 1526], ["3", 1531], [")", 1532], ["was", 1534], ["associated", 1538], ["with", 1549], ["an", 1554], ["increased", 1557], ["risk", 1567], ["of", 1572], ["small", 1575], ["-", 1580], ["vessel", 1581], ["stroke", 1588], ["(", 1595], ["OR", 1596], [":", 1598], ["1.56", 1600], [",", 1604], ["P=0.008", 1606], [")", 1613], ["and", 1615], ["p", 1619], [".", 1620], ["P380P", 1621], ["(", 1627], ["rs61749020", 1628], [";", 1638], ["Exon", 1640], ["7", 1645], [")", 1646], ["was", 1648], ["associated", 1652], ["with", 1663], ["decreased", 1668], ["risk", 1678], ["of", 1683], ["large", 1686], ["-", 1691], ["vessel", 1692], ["stroke", 1699], ["(", 1706], ["OR", 1707], [":", 1709], ["0.35", 1711], [",", 1715], ["P=0.047", 1717], [")", 1724], ["in", 1726], ["Caucasians", 1729], [".", 1739], ["No", 1741], ["significant", 1744], ["associations", 1756], ["were", 1769], ["observed", 1774], ["in", 1783], ["the", 1786], ["small", 1790], ["African", 1796], ["American", 1804], ["series", 1813], [".", 1819], ["Cysteine", 1821], ["-", 1829], ["affecting", 1830], ["NOTCH3", 1840], ["mutations", 1847], ["are", 1857], ["rare", 1861], ["in", 1866], ["patients", 1869], ["with", 1878], ["typical", 1883], ["ischemic", 1891], ["stroke", 1900], [",", 1906], ["however", 1908], ["our", 1916], ["observation", 1920], ["that", 1932], ["common", 1937], ["NOTCH3", 1944], ["variants", 1951], ["may", 1960], ["be", 1964], ["associated", 1967], ["with", 1978], ["risk", 1983], ["of", 1988], ["ischemic", 1991], ["stroke", 2000], ["warrants", 2007], ["further", 2016], ["study", 2024], [".", 2029]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7a4fa67d3e7042d388d3a34034a61556", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[11, 13]], "char_spans": [[71, 92]]}]}], "context_tokens": [["Rigel", 0], ["Pharmaceuticals", 6], ["Inc", 22], ["is", 26], ["developing", 29], ["fostamatinib", 40], [",", 52], ["a", 54], ["prodrug", 56], ["of", 64], ["the", 67], ["spleen", 71], ["tyrosine", 78], ["kinase", 87], ["(", 94], ["Syk", 95], [")", 98], ["inhibitor", 100], ["R-406", 110], [",", 115], ["for", 117], ["the", 121], ["potential", 125], ["treatment", 135], ["of", 145], ["autoimmune", 148], ["diseases", 159], ["such", 168], ["as", 173], ["rheumatoid", 176], ["arthritis", 187], ["(", 197], ["RA", 198], [")", 200], [",", 201], ["idiopathic", 203], ["thrombocytopenic", 214], ["purpura", 231], ["(", 239], ["ITP", 240], [")", 243], ["and", 245], ["B", 249], ["-", 250], ["cell", 251], ["lymphomas", 256], [".", 265], ["Syk", 267], ["is", 271], ["a", 274], ["key", 276], ["mediator", 280], ["of", 289], ["Fc", 292], ["and", 295], ["B", 299], ["-", 300], ["cell", 301], ["receptor", 306], ["signaling", 315], ["in", 325], ["inflammatory", 328], ["cells", 341], [",", 346], ["such", 348], ["as", 353], ["B", 356], ["-", 357], ["cells", 358], [",", 363], ["mast", 365], ["cells", 370], [",", 375], ["macrophages", 377], ["and", 389], ["neutrophils", 393], [".", 404], ["Preclinical", 406], ["studies", 418], ["of", 426], ["R-406", 429], ["or", 435], ["fostamatinib", 438], ["demonstrated", 451], ["a", 464], ["significant", 466], ["reduction", 478], ["in", 488], ["major", 491], ["inflammatory", 497], ["mediators", 510], ["such", 520], ["as", 525], ["TNFalpha", 528], [",", 536], ["IL-1", 538], [",", 542], ["IL-6", 544], ["and", 549], ["IL-18", 553], [",", 558], ["leading", 560], ["to", 568], ["reduced", 571], ["inflammation", 579], ["and", 592], ["bone", 596], ["degradation", 601], ["in", 613], ["models", 616], ["of", 623], ["RA", 626], [".", 628], ["In", 630], ["a", 633], ["phase", 635], ["II", 641], ["clinical", 644], ["trial", 653], [",", 658], ["fostamatinib", 660], ["treatment", 673], ["effectively", 683], ["improved", 695], ["American", 704], ["College", 713], ["of", 721], ["Rheumatology", 724], ["response", 737], ["rates", 746], ["in", 752], ["patients", 755], ["with", 764], ["RA", 769], [".", 771], ["Preclinical", 773], ["studies", 785], ["and", 793], ["phase", 797], ["II", 803], ["trials", 806], ["also", 813], ["suggested", 818], ["the", 828], ["potential", 832], ["of", 842], ["using", 845], ["fostamatinib", 851], ["for", 864], ["the", 868], ["treatment", 872], ["of", 882], ["ITP", 885], ["and", 889], ["B", 893], ["-", 894], ["cell", 895], ["lymphomas", 900], [",", 909], ["by", 911], ["increasing", 914], ["platelet", 925], ["counts", 934], ["and", 941], ["inducing", 945], ["response", 954], ["rates", 963], [",", 968], ["respectively", 970], [".", 982], ["Fostamatinib", 984], ["is", 997], ["orally", 1000], ["bioavailable", 1007], ["and", 1020], ["was", 1024], ["well", 1028], ["tolerated", 1033], ["in", 1043], ["phase", 1046], ["I", 1052], ["and", 1054], ["II", 1058], ["trials", 1061], [",", 1067], ["with", 1069], ["the", 1074], ["most", 1078], ["common", 1083], ["side", 1090], ["effect", 1095], ["being", 1102], ["gastrointestinal", 1108], ["symptoms", 1125], [".", 1133], ["At", 1135], ["the", 1138], ["time", 1142], ["of", 1147], ["publication", 1150], [",", 1161], ["phase", 1163], ["II", 1169], ["trials", 1172], ["for", 1179], ["fostamatinib", 1183], ["were", 1196], ["ongoing", 1201], ["in", 1209], ["patients", 1212], ["with", 1221], ["RA", 1226], [",", 1228], ["ITP", 1230], ["and", 1234], ["B", 1238], ["-", 1239], ["cell", 1240], ["lymphomas", 1245], [".", 1254], ["The", 1256], ["Syk", 1260], ["inhibitor", 1264], ["appears", 1274], ["to", 1282], ["be", 1285], ["a", 1288], ["promising", 1290], ["therapeutic", 1300], ["for", 1312], ["immunological", 1316], ["diseases", 1330], [",", 1338], ["but", 1340], ["further", 1344], ["data", 1352], ["are", 1357], ["required", 1361], ["to", 1370], ["establish", 1373], ["the", 1383], ["efficacy", 1387], ["and", 1396], ["long", 1400], ["-", 1404], ["term", 1405], ["safety", 1410], ["of", 1417], ["the", 1420], ["drug", 1424], ["in", 1429], ["humans", 1432], [".", 1438]]}
{"context": "We investigated high- or low-dose irradiation-responsive proteins using proteomics on two-dimensional (2D) PAGE, and the effects of ageing on cell responses to radiation in variously aged rat astrocytes. After 5 Gy irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased. The induction of these proteins was suppressed by ageing, suggesting that the response to high-dose radiation decreased with ageing. The relative abundance of elongation factor 2 (EF-2) fragment increased 3 h and reduced 24 h after 0.1 Gy irradiation. Temporal enhancement of the EF-2 fragment due to low-dose irradiation was suppressed by ageing. Since radiation adaptive response in cultured astrocytes was observed 3 h but not 24 h after 0.1 Gy irradiation and suppressed by ageing as previously reported, alteration of the EF-2 fragment corresponded to the radiation adaptive response. We also examined phospho-protein profiles, resulting in the relative abundance of phospho-EF-1beta and phospho-beta-actin being altered by 0.1 Gy irradiation; however, ageing did not affect the alteration of phospho-EF-1beta and phospho-beta-actin, unlike the EF-2 fragment. The results suggested that the EF-2 fragment was a possible candidate for the protein responsible for the radiation adaptive response in cultured astrocytes.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "b7cd2f0a380d4d14b488e20ddf88b204", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[51, 51]], "char_spans": [[274, 284]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["high-", 16], ["or", 22], ["low", 25], ["-", 28], ["dose", 29], ["irradiation", 34], ["-", 45], ["responsive", 46], ["proteins", 57], ["using", 66], ["proteomics", 72], ["on", 83], ["two", 86], ["-", 89], ["dimensional", 90], ["(", 102], ["2D", 103], [")", 105], ["PAGE", 107], [",", 111], ["and", 113], ["the", 117], ["effects", 121], ["of", 129], ["ageing", 132], ["on", 139], ["cell", 142], ["responses", 147], ["to", 157], ["radiation", 160], ["in", 170], ["variously", 173], ["aged", 183], ["rat", 188], ["astrocytes", 192], [".", 202], ["After", 204], ["5", 210], ["Gy", 212], ["irradiation", 215], [",", 226], ["the", 228], ["relative", 232], ["abundance", 241], ["of", 251], ["peroxiredoxin", 254], ["2", 268], [",", 269], ["an", 271], ["antioxidant", 274], ["enzyme", 286], [",", 292], ["and", 294], ["latexin", 298], [",", 305], ["an", 307], ["inhibitor", 310], ["of", 320], ["carboxypeptidase", 323], [",", 339], ["increased", 341], [".", 350], ["The", 352], ["induction", 356], ["of", 366], ["these", 369], ["proteins", 375], ["was", 384], ["suppressed", 388], ["by", 399], ["ageing", 402], [",", 408], ["suggesting", 410], ["that", 421], ["the", 426], ["response", 430], ["to", 439], ["high", 442], ["-", 446], ["dose", 447], ["radiation", 452], ["decreased", 462], ["with", 472], ["ageing", 477], [".", 483], ["The", 485], ["relative", 489], ["abundance", 498], ["of", 508], ["elongation", 511], ["factor", 522], ["2", 529], ["(", 531], ["EF-2", 532], [")", 536], ["fragment", 538], ["increased", 547], ["3", 557], ["h", 559], ["and", 561], ["reduced", 565], ["24", 573], ["h", 576], ["after", 578], ["0.1", 584], ["Gy", 588], ["irradiation", 591], [".", 602], ["Temporal", 604], ["enhancement", 613], ["of", 625], ["the", 628], ["EF-2", 632], ["fragment", 637], ["due", 646], ["to", 650], ["low", 653], ["-", 656], ["dose", 657], ["irradiation", 662], ["was", 674], ["suppressed", 678], ["by", 689], ["ageing", 692], [".", 698], ["Since", 700], ["radiation", 706], ["adaptive", 716], ["response", 725], ["in", 734], ["cultured", 737], ["astrocytes", 746], ["was", 757], ["observed", 761], ["3", 770], ["h", 772], ["but", 774], ["not", 778], ["24", 782], ["h", 785], ["after", 787], ["0.1", 793], ["Gy", 797], ["irradiation", 800], ["and", 812], ["suppressed", 816], ["by", 827], ["ageing", 830], ["as", 837], ["previously", 840], ["reported", 851], [",", 859], ["alteration", 861], ["of", 872], ["the", 875], ["EF-2", 879], ["fragment", 884], ["corresponded", 893], ["to", 906], ["the", 909], ["radiation", 913], ["adaptive", 923], ["response", 932], [".", 940], ["We", 942], ["also", 945], ["examined", 950], ["phospho", 959], ["-", 966], ["protein", 967], ["profiles", 975], [",", 983], ["resulting", 985], ["in", 995], ["the", 998], ["relative", 1002], ["abundance", 1011], ["of", 1021], ["phospho", 1024], ["-", 1031], ["EF-1beta", 1032], ["and", 1041], ["phospho", 1045], ["-", 1052], ["beta", 1053], ["-", 1057], ["actin", 1058], ["being", 1064], ["altered", 1070], ["by", 1078], ["0.1", 1081], ["Gy", 1085], ["irradiation", 1088], [";", 1099], ["however", 1101], [",", 1108], ["ageing", 1110], ["did", 1117], ["not", 1121], ["affect", 1125], ["the", 1132], ["alteration", 1136], ["of", 1147], ["phospho", 1150], ["-", 1157], ["EF-1beta", 1158], ["and", 1167], ["phospho", 1171], ["-", 1178], ["beta", 1179], ["-", 1183], ["actin", 1184], [",", 1189], ["unlike", 1191], ["the", 1198], ["EF-2", 1202], ["fragment", 1207], [".", 1215], ["The", 1217], ["results", 1221], ["suggested", 1229], ["that", 1239], ["the", 1244], ["EF-2", 1248], ["fragment", 1253], ["was", 1262], ["a", 1266], ["possible", 1268], ["candidate", 1277], ["for", 1287], ["the", 1291], ["protein", 1295], ["responsible", 1303], ["for", 1315], ["the", 1319], ["radiation", 1323], ["adaptive", 1333], ["response", 1342], ["in", 1351], ["cultured", 1354], ["astrocytes", 1363], [".", 1373]]}
{"context": "Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal immune disorder characterized by uncontrolled lymphocyte- and macrophage-activation. The resulting hypercytokinemia and cell infiltration of organs lead to the clinical and laboratory features of HLH. Viral infections and other triggers can induce both, inherited and acquired forms of HLH. Disease-causing mutations in the genes encoding perforin (PRF1, FHL2), munc13-4 (UNC13D, FHL3), syntaxin 11 (STX11, FHL4), and munc18-2 (UNC18-2/STXBP2, FHL5) have been previously identified in Familial Hemophagocyic Lymphohistiocytosis (FHL), whereas mutation in RAB27A and LYST account for Griscelli syndome type 2 and Chediak-Higashi syndrome, respectively. These genes all encode proteins which are involved in the cytotoxic activity of lymphocytes. The inability of activated cytotoxic cells to clear antigen-presenting targets results in sustained immune stimulation, likely accounting for the unremitting polyclonal CD8 T-cell activation and hyperimmune reaction which characterizes FHL. Treatment of HLH consists of elimination of the trigger and immunosuppressive treatment in order to induce remission from the uncontrolled inflammation. Allogeneic hematopoietic stem cell transplantation can be indicated in the inherited forms of HLH.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "ec77a7e4587a4882bcd45d55cf28a629", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[122, 125]], "char_spans": [[676, 699]]}]}], "context_tokens": [["Hemophagocytic", 0], ["lymphohistiocytosis", 15], ["(", 35], ["HLH", 36], [")", 39], ["is", 41], ["a", 44], ["potentially", 46], ["fatal", 58], ["immune", 64], ["disorder", 71], ["characterized", 80], ["by", 94], ["uncontrolled", 97], ["lymphocyte-", 110], ["and", 122], ["macrophage", 126], ["-", 136], ["activation", 137], [".", 147], ["The", 149], ["resulting", 153], ["hypercytokinemia", 163], ["and", 180], ["cell", 184], ["infiltration", 189], ["of", 202], ["organs", 205], ["lead", 212], ["to", 217], ["the", 220], ["clinical", 224], ["and", 233], ["laboratory", 237], ["features", 248], ["of", 257], ["HLH", 260], [".", 263], ["Viral", 265], ["infections", 271], ["and", 282], ["other", 286], ["triggers", 292], ["can", 301], ["induce", 305], ["both", 312], [",", 316], ["inherited", 318], ["and", 328], ["acquired", 332], ["forms", 341], ["of", 347], ["HLH", 350], [".", 353], ["Disease", 355], ["-", 362], ["causing", 363], ["mutations", 371], ["in", 381], ["the", 384], ["genes", 388], ["encoding", 394], ["perforin", 403], ["(", 412], ["PRF1", 413], [",", 417], ["FHL2", 419], [")", 423], [",", 424], ["munc13", 426], ["-", 432], ["4", 433], ["(", 435], ["UNC13D", 436], [",", 442], ["FHL3", 444], [")", 448], [",", 449], ["syntaxin", 451], ["11", 460], ["(", 463], ["STX11", 464], [",", 469], ["FHL4", 471], [")", 475], [",", 476], ["and", 478], ["munc18", 482], ["-", 488], ["2", 489], ["(", 491], ["UNC18", 492], ["-", 497], ["2/STXBP2", 498], [",", 506], ["FHL5", 508], [")", 512], ["have", 514], ["been", 519], ["previously", 524], ["identified", 535], ["in", 546], ["Familial", 549], ["Hemophagocyic", 558], ["Lymphohistiocytosis", 572], ["(", 592], ["FHL", 593], [")", 596], [",", 597], ["whereas", 599], ["mutation", 607], ["in", 616], ["RAB27A", 619], ["and", 626], ["LYST", 630], ["account", 635], ["for", 643], ["Griscelli", 647], ["syndome", 657], ["type", 665], ["2", 670], ["and", 672], ["Chediak", 676], ["-", 683], ["Higashi", 684], ["syndrome", 692], [",", 700], ["respectively", 702], [".", 714], ["These", 716], ["genes", 722], ["all", 728], ["encode", 732], ["proteins", 739], ["which", 748], ["are", 754], ["involved", 758], ["in", 767], ["the", 770], ["cytotoxic", 774], ["activity", 784], ["of", 793], ["lymphocytes", 796], [".", 807], ["The", 809], ["inability", 813], ["of", 823], ["activated", 826], ["cytotoxic", 836], ["cells", 846], ["to", 852], ["clear", 855], ["antigen", 861], ["-", 868], ["presenting", 869], ["targets", 880], ["results", 888], ["in", 896], ["sustained", 899], ["immune", 909], ["stimulation", 916], [",", 927], ["likely", 929], ["accounting", 936], ["for", 947], ["the", 951], ["unremitting", 955], ["polyclonal", 967], ["CD8", 978], ["T", 982], ["-", 983], ["cell", 984], ["activation", 989], ["and", 1000], ["hyperimmune", 1004], ["reaction", 1016], ["which", 1025], ["characterizes", 1031], ["FHL", 1045], [".", 1048], ["Treatment", 1050], ["of", 1060], ["HLH", 1063], ["consists", 1067], ["of", 1076], ["elimination", 1079], ["of", 1091], ["the", 1094], ["trigger", 1098], ["and", 1106], ["immunosuppressive", 1110], ["treatment", 1128], ["in", 1138], ["order", 1141], ["to", 1147], ["induce", 1150], ["remission", 1157], ["from", 1167], ["the", 1172], ["uncontrolled", 1176], ["inflammation", 1189], [".", 1201], ["Allogeneic", 1203], ["hematopoietic", 1214], ["stem", 1228], ["cell", 1233], ["transplantation", 1238], ["can", 1254], ["be", 1258], ["indicated", 1261], ["in", 1271], ["the", 1274], ["inherited", 1278], ["forms", 1288], ["of", 1294], ["HLH", 1297], [".", 1300]]}
{"context": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women. Individuals with TS show characteristic difficulties with executive functions, visual-spatial and mathematical cognition, with relatively intact verbal skills, and congruent abnormalities in structural development of the posterior parietal cortex (PPC). The functionally heterogeneous PPC has recently been investigated using connectivity-based clustering methods, which sub-divide a given region into clusters of voxels showing similar structural or functional connectivity to other brain regions. In the present study, we extended this method to compare connectivity-based clustering between groups and investigate whether functional networks differentially recruit the PPC in TS. To this end, we parcellated the PPC into sub-regions based on temporal correlations with other regions of the brain. fMRI data were collected from 15 girls with TS and 14 typically developing (TD) girls, aged 7-14, while they performed a visual-spatial task. Temporal correlations between voxels in the PPC and a set of seed regions were calculated, and the PPC divided into clusters of voxels showing similar connectivity. It was found that in general the PPC parcellates similarly in TS and TD girls, but that regions in bilateral inferior parietal lobules, and posterior right superior parietal lobule, were reliably recruited by different networks in TS relative to TD participants. These regions showed weaker correlation in TS with a set of regions involved in visual processing. These results suggest that abnormal development of visuospatial functional networks in TS may relate to the well documented cognitive difficulties in this disorder.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "9aae75f96acc4b5ba4f5bc32a39f1e8f", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[15, 15]], "char_spans": [[86, 86]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["genetic", 21], ["disorder", 29], ["caused", 38], ["by", 45], ["the", 48], ["complete", 52], ["or", 61], ["partial", 64], ["absence", 72], ["of", 80], ["an", 83], ["X", 86], ["chromosome", 88], ["in", 99], ["affected", 102], ["women", 111], [".", 116], ["Individuals", 118], ["with", 130], ["TS", 135], ["show", 138], ["characteristic", 143], ["difficulties", 158], ["with", 171], ["executive", 176], ["functions", 186], [",", 195], ["visual", 197], ["-", 203], ["spatial", 204], ["and", 212], ["mathematical", 216], ["cognition", 229], [",", 238], ["with", 240], ["relatively", 245], ["intact", 256], ["verbal", 263], ["skills", 270], [",", 276], ["and", 278], ["congruent", 282], ["abnormalities", 292], ["in", 306], ["structural", 309], ["development", 320], ["of", 332], ["the", 335], ["posterior", 339], ["parietal", 349], ["cortex", 358], ["(", 365], ["PPC", 366], [")", 369], [".", 370], ["The", 372], ["functionally", 376], ["heterogeneous", 389], ["PPC", 403], ["has", 407], ["recently", 411], ["been", 420], ["investigated", 425], ["using", 438], ["connectivity", 444], ["-", 456], ["based", 457], ["clustering", 463], ["methods", 474], [",", 481], ["which", 483], ["sub", 489], ["-", 492], ["divide", 493], ["a", 500], ["given", 502], ["region", 508], ["into", 515], ["clusters", 520], ["of", 529], ["voxels", 532], ["showing", 539], ["similar", 547], ["structural", 555], ["or", 566], ["functional", 569], ["connectivity", 580], ["to", 593], ["other", 596], ["brain", 602], ["regions", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], [",", 637], ["we", 639], ["extended", 642], ["this", 651], ["method", 656], ["to", 663], ["compare", 666], ["connectivity", 674], ["-", 686], ["based", 687], ["clustering", 693], ["between", 704], ["groups", 712], ["and", 719], ["investigate", 723], ["whether", 735], ["functional", 743], ["networks", 754], ["differentially", 763], ["recruit", 778], ["the", 786], ["PPC", 790], ["in", 794], ["TS", 797], [".", 799], ["To", 801], ["this", 804], ["end", 809], [",", 812], ["we", 814], ["parcellated", 817], ["the", 829], ["PPC", 833], ["into", 837], ["sub", 842], ["-", 845], ["regions", 846], ["based", 854], ["on", 860], ["temporal", 863], ["correlations", 872], ["with", 885], ["other", 890], ["regions", 896], ["of", 904], ["the", 907], ["brain", 911], [".", 916], ["fMRI", 918], ["data", 923], ["were", 928], ["collected", 933], ["from", 943], ["15", 948], ["girls", 951], ["with", 957], ["TS", 962], ["and", 965], ["14", 969], ["typically", 972], ["developing", 982], ["(", 993], ["TD", 994], [")", 996], ["girls", 998], [",", 1003], ["aged", 1005], ["7", 1010], ["-", 1011], ["14", 1012], [",", 1014], ["while", 1016], ["they", 1022], ["performed", 1027], ["a", 1037], ["visual", 1039], ["-", 1045], ["spatial", 1046], ["task", 1054], [".", 1058], ["Temporal", 1060], ["correlations", 1069], ["between", 1082], ["voxels", 1090], ["in", 1097], ["the", 1100], ["PPC", 1104], ["and", 1108], ["a", 1112], ["set", 1114], ["of", 1118], ["seed", 1121], ["regions", 1126], ["were", 1134], ["calculated", 1139], [",", 1149], ["and", 1151], ["the", 1155], ["PPC", 1159], ["divided", 1163], ["into", 1171], ["clusters", 1176], ["of", 1185], ["voxels", 1188], ["showing", 1195], ["similar", 1203], ["connectivity", 1211], [".", 1223], ["It", 1225], ["was", 1228], ["found", 1232], ["that", 1238], ["in", 1243], ["general", 1246], ["the", 1254], ["PPC", 1258], ["parcellates", 1262], ["similarly", 1274], ["in", 1284], ["TS", 1287], ["and", 1290], ["TD", 1294], ["girls", 1297], [",", 1302], ["but", 1304], ["that", 1308], ["regions", 1313], ["in", 1321], ["bilateral", 1324], ["inferior", 1334], ["parietal", 1343], ["lobules", 1352], [",", 1359], ["and", 1361], ["posterior", 1365], ["right", 1375], ["superior", 1381], ["parietal", 1390], ["lobule", 1399], [",", 1405], ["were", 1407], ["reliably", 1412], ["recruited", 1421], ["by", 1431], ["different", 1434], ["networks", 1444], ["in", 1453], ["TS", 1456], ["relative", 1459], ["to", 1468], ["TD", 1471], ["participants", 1474], [".", 1486], ["These", 1488], ["regions", 1494], ["showed", 1502], ["weaker", 1509], ["correlation", 1516], ["in", 1528], ["TS", 1531], ["with", 1534], ["a", 1539], ["set", 1541], ["of", 1545], ["regions", 1548], ["involved", 1556], ["in", 1565], ["visual", 1568], ["processing", 1575], [".", 1585], ["These", 1587], ["results", 1593], ["suggest", 1601], ["that", 1609], ["abnormal", 1614], ["development", 1623], ["of", 1635], ["visuospatial", 1638], ["functional", 1651], ["networks", 1662], ["in", 1671], ["TS", 1674], ["may", 1677], ["relate", 1681], ["to", 1688], ["the", 1691], ["well", 1695], ["documented", 1700], ["cognitive", 1711], ["difficulties", 1721], ["in", 1734], ["this", 1737], ["disorder", 1742], [".", 1750]]}
{"context": "The SWR1 complex (SWR1C) in yeast catalyzes the replacement of nucleosomal H2A with the H2AZ variant, which ensures full activation of underlying genes. We compared the phenotype of mutants in the homologs of SWR1C components in Arabidopsis thaliana. Mutations in Arabidopsis SWC6 (AtSWC6), SUPPRESSOR OF FRIGIDA 3 (SUF3) and PHOTOPERIOD-INDEPENDENT EARLY FLOWERING 1 (PIE1), homologs of SWC6, ARP6 and SWR1, respectively, caused similar developmental defects, including leaf serration, weak apical dominance, flowers with extra petals and early flowering by reduction in expression of FLOWERING LOCUS C (FLC), a strong floral repressor. Chromatin immunoprecipitation assays showed that AtSWC6 and SUF3 bind to the proximal region of the FLC promoter, and protoplast transfection assays showed that AtSWC6 colocalizes with SUF3. Protein interaction analyses suggested the formation of a complex between PIE1, SUF3, AtSWC6 and AtSWC2. In addition, H2AZ, a substrate of SWR1C, interacts with both PIE1 and AtSWC2. Finally, knockdown of the H2AZ genes by RNA interference or artificial microRNA caused a phenotype similar to that of atswc6 or suf3. Our results strongly support the presence of an SWR1C-like complex in Arabidopsis that ensures proper development, including floral repression through full activation of FLC.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "40d8ce56de49432180bd5735b35937f1", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[75, 75], [1, 1]], "char_spans": [[403, 406], [4, 7]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["(", 17], ["SWR1C", 18], [")", 23], ["in", 25], ["yeast", 28], ["catalyzes", 34], ["the", 44], ["replacement", 48], ["of", 60], ["nucleosomal", 63], ["H2A", 75], ["with", 79], ["the", 84], ["H2AZ", 88], ["variant", 93], [",", 100], ["which", 102], ["ensures", 108], ["full", 116], ["activation", 121], ["of", 132], ["underlying", 135], ["genes", 146], [".", 151], ["We", 153], ["compared", 156], ["the", 165], ["phenotype", 169], ["of", 179], ["mutants", 182], ["in", 190], ["the", 193], ["homologs", 197], ["of", 206], ["SWR1C", 209], ["components", 215], ["in", 226], ["Arabidopsis", 229], ["thaliana", 241], [".", 249], ["Mutations", 251], ["in", 261], ["Arabidopsis", 264], ["SWC6", 276], ["(", 281], ["AtSWC6", 282], [")", 288], [",", 289], ["SUPPRESSOR", 291], ["OF", 302], ["FRIGIDA", 305], ["3", 313], ["(", 315], ["SUF3", 316], [")", 320], ["and", 322], ["PHOTOPERIOD", 326], ["-", 337], ["INDEPENDENT", 338], ["EARLY", 350], ["FLOWERING", 356], ["1", 366], ["(", 368], ["PIE1", 369], [")", 373], [",", 374], ["homologs", 376], ["of", 385], ["SWC6", 388], [",", 392], ["ARP6", 394], ["and", 399], ["SWR1", 403], [",", 407], ["respectively", 409], [",", 421], ["caused", 423], ["similar", 430], ["developmental", 438], ["defects", 452], [",", 459], ["including", 461], ["leaf", 471], ["serration", 476], [",", 485], ["weak", 487], ["apical", 492], ["dominance", 499], [",", 508], ["flowers", 510], ["with", 518], ["extra", 523], ["petals", 529], ["and", 536], ["early", 540], ["flowering", 546], ["by", 556], ["reduction", 559], ["in", 569], ["expression", 572], ["of", 583], ["FLOWERING", 586], ["LOCUS", 596], ["C", 602], ["(", 604], ["FLC", 605], [")", 608], [",", 609], ["a", 611], ["strong", 613], ["floral", 620], ["repressor", 627], [".", 636], ["Chromatin", 638], ["immunoprecipitation", 648], ["assays", 668], ["showed", 675], ["that", 682], ["AtSWC6", 687], ["and", 694], ["SUF3", 698], ["bind", 703], ["to", 708], ["the", 711], ["proximal", 715], ["region", 724], ["of", 731], ["the", 734], ["FLC", 738], ["promoter", 742], [",", 750], ["and", 752], ["protoplast", 756], ["transfection", 767], ["assays", 780], ["showed", 787], ["that", 794], ["AtSWC6", 799], ["colocalizes", 806], ["with", 818], ["SUF3", 823], [".", 827], ["Protein", 829], ["interaction", 837], ["analyses", 849], ["suggested", 858], ["the", 868], ["formation", 872], ["of", 882], ["a", 885], ["complex", 887], ["between", 895], ["PIE1", 903], [",", 907], ["SUF3", 909], [",", 913], ["AtSWC6", 915], ["and", 922], ["AtSWC2", 926], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["H2AZ", 947], [",", 951], ["a", 953], ["substrate", 955], ["of", 965], ["SWR1C", 968], [",", 973], ["interacts", 975], ["with", 985], ["both", 990], ["PIE1", 995], ["and", 1000], ["AtSWC2", 1004], [".", 1010], ["Finally", 1012], [",", 1019], ["knockdown", 1021], ["of", 1031], ["the", 1034], ["H2AZ", 1038], ["genes", 1043], ["by", 1049], ["RNA", 1052], ["interference", 1056], ["or", 1069], ["artificial", 1072], ["microRNA", 1083], ["caused", 1092], ["a", 1099], ["phenotype", 1101], ["similar", 1111], ["to", 1119], ["that", 1122], ["of", 1127], ["atswc6", 1130], ["or", 1137], ["suf3", 1140], [".", 1144], ["Our", 1146], ["results", 1150], ["strongly", 1158], ["support", 1167], ["the", 1175], ["presence", 1179], ["of", 1188], ["an", 1191], ["SWR1C", 1194], ["-", 1199], ["like", 1200], ["complex", 1205], ["in", 1213], ["Arabidopsis", 1216], ["that", 1228], ["ensures", 1233], ["proper", 1241], ["development", 1248], [",", 1259], ["including", 1261], ["floral", 1271], ["repression", 1278], ["through", 1289], ["full", 1297], ["activation", 1302], ["of", 1313], ["FLC", 1316], [".", 1319]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. We offer guidelines for a more thoughtful approach to the management of patients with cancer who present with encephalopathy.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bbac40c6eb3c41cd806dbc42ad8f54dc", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[52, 52], [72, 72], [22, 22]], "char_spans": [[332, 339], [458, 465], [150, 157]]}]}], "context_tokens": [["Opioid", 0], ["overdose", 7], ["is", 16], ["rarely", 19], ["the", 26], ["primary", 30], ["cause", 38], ["of", 44], ["altered", 47], ["mental", 55], ["status", 62], ["in", 69], ["cancer", 72], ["patients", 79], ["receiving", 88], ["opioid", 98], ["therapy", 105], [".", 112], ["The", 114], ["inappropriate", 118], ["administration", 132], ["of", 147], ["naloxone", 150], ["to", 159], ["reverse", 162], ["an", 170], ["abnormal", 173], ["mental", 182], ["status", 189], ["can", 196], ["cause", 200], ["severe", 206], ["withdrawal", 213], ["symptoms", 224], ["and", 233], ["pain", 237], [".", 241], ["To", 243], ["illustrate", 246], ["this", 257], ["problem", 262], [",", 269], ["we", 271], ["report", 274], ["the", 281], ["case", 285], ["of", 290], ["a", 293], ["patient", 295], ["inappropriately", 303], ["treated", 319], ["with", 327], ["naloxone", 332], ["and", 341], ["the", 345], ["results", 349], ["of", 357], ["a", 360], ["retrospective", 362], ["review", 376], ["of", 383], ["the", 386], ["medical", 390], ["records", 398], ["of", 406], ["15", 409], ["consecutive", 412], ["patients", 424], ["with", 433], ["cancer", 438], ["treated", 445], ["with", 453], ["naloxone", 458], ["in", 467], ["the", 470], ["emergency", 474], ["department", 484], ["over", 495], ["a", 500], ["5-month", 502], ["period", 510], [".", 516], ["We", 518], ["offer", 521], ["guidelines", 527], ["for", 538], ["a", 542], ["more", 544], ["thoughtful", 549], ["approach", 560], ["to", 569], ["the", 572], ["management", 576], ["of", 587], ["patients", 590], ["with", 599], ["cancer", 604], ["who", 611], ["present", 615], ["with", 623], ["encephalopathy", 628], [".", 642]]}
{"context": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information. First, it includes a genome browser which interrogates 1260 genomic sequence scaffolds and features gene, transcript and CDS annotation tracks. Second, we annotated gene models with gene ontology (GO) terms and InterPro domains which are directly accessible in the browser with links to their entries in the GO (http://www.geneontology.org/) and InterPro (http://www.ebi.ac.uk/interpro/) databases, and we provide transcript and peptide links for sequence downloads. Third, we introduce the transcriptomics of a comprehensive set of developmental stages of O. dioica at high resolution and provide downloadable gene expression data for all developmental stages. Fourth, we incorporate a BLAST tool to identify homologs of genes and proteins. Finally, we include a tutorial that describes how to use OikoBase as well as a link to detailed methods, explaining the data generation and analysis pipeline. OikoBase will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism.", "qas": [{"question": "Mention the only available genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "answers": ["OikoBase"], "qid": "6fc08188d45a419184053b7f1897cddc", "question_tokens": [["Mention", 0], ["the", 8], ["only", 12], ["available", 17], ["genomics", 27], ["and", 36], ["developmental", 40], ["transcriptomics", 54], ["resource", 70], ["for", 79], ["the", 83], ["urochordate", 87], ["Oikopleura", 99], ["dioica", 110]], "detected_answers": [{"text": "OikoBase", "token_spans": [[36, 36], [180, 180], [5, 5], [198, 198]], "char_spans": [[234, 241], [1120, 1127], [29, 36], [1222, 1229]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["development", 14], ["of", 26], ["OikoBase", 29], ["(", 38], ["http://oikoarrays.biology.uiowa.edu/Oiko/", 39], [")", 80], [",", 81], ["a", 83], ["tiling", 85], ["array", 92], ["-", 97], ["based", 98], ["genome", 104], ["browser", 111], ["resource", 119], ["for", 128], ["Oikopleura", 132], ["dioica", 143], [",", 149], ["a", 151], ["metazoan", 153], ["belonging", 162], ["to", 172], ["the", 175], ["urochordates", 179], [",", 191], ["the", 193], ["closest", 197], ["extant", 205], ["group", 212], ["to", 218], ["vertebrates", 221], [".", 232], ["OikoBase", 234], ["facilitates", 243], ["retrieval", 255], ["and", 265], ["mining", 269], ["of", 276], ["a", 279], ["variety", 281], ["of", 289], ["useful", 292], ["genomics", 299], ["information", 308], [".", 319], ["First", 321], [",", 326], ["it", 328], ["includes", 331], ["a", 340], ["genome", 342], ["browser", 349], ["which", 357], ["interrogates", 363], ["1260", 376], ["genomic", 381], ["sequence", 389], ["scaffolds", 398], ["and", 408], ["features", 412], ["gene", 421], [",", 425], ["transcript", 427], ["and", 438], ["CDS", 442], ["annotation", 446], ["tracks", 457], [".", 463], ["Second", 465], [",", 471], ["we", 473], ["annotated", 476], ["gene", 486], ["models", 491], ["with", 498], ["gene", 503], ["ontology", 508], ["(", 517], ["GO", 518], [")", 520], ["terms", 522], ["and", 528], ["InterPro", 532], ["domains", 541], ["which", 549], ["are", 555], ["directly", 559], ["accessible", 568], ["in", 579], ["the", 582], ["browser", 586], ["with", 594], ["links", 599], ["to", 605], ["their", 608], ["entries", 614], ["in", 622], ["the", 625], ["GO", 629], ["(", 632], ["http://www.geneontology.org/", 633], [")", 661], ["and", 663], ["InterPro", 667], ["(", 676], ["http://www.ebi.ac.uk/interpro/", 677], [")", 707], ["databases", 709], [",", 718], ["and", 720], ["we", 724], ["provide", 727], ["transcript", 735], ["and", 746], ["peptide", 750], ["links", 758], ["for", 764], ["sequence", 768], ["downloads", 777], [".", 786], ["Third", 788], [",", 793], ["we", 795], ["introduce", 798], ["the", 808], ["transcriptomics", 812], ["of", 828], ["a", 831], ["comprehensive", 833], ["set", 847], ["of", 851], ["developmental", 854], ["stages", 868], ["of", 875], ["O.", 878], ["dioica", 881], ["at", 888], ["high", 891], ["resolution", 896], ["and", 907], ["provide", 911], ["downloadable", 919], ["gene", 932], ["expression", 937], ["data", 948], ["for", 953], ["all", 957], ["developmental", 961], ["stages", 975], [".", 981], ["Fourth", 983], [",", 989], ["we", 991], ["incorporate", 994], ["a", 1006], ["BLAST", 1008], ["tool", 1014], ["to", 1019], ["identify", 1022], ["homologs", 1031], ["of", 1040], ["genes", 1043], ["and", 1049], ["proteins", 1053], [".", 1061], ["Finally", 1063], [",", 1070], ["we", 1072], ["include", 1075], ["a", 1083], ["tutorial", 1085], ["that", 1094], ["describes", 1099], ["how", 1109], ["to", 1113], ["use", 1116], ["OikoBase", 1120], ["as", 1129], ["well", 1132], ["as", 1137], ["a", 1140], ["link", 1142], ["to", 1147], ["detailed", 1150], ["methods", 1159], [",", 1166], ["explaining", 1168], ["the", 1179], ["data", 1183], ["generation", 1188], ["and", 1199], ["analysis", 1203], ["pipeline", 1212], [".", 1220], ["OikoBase", 1222], ["will", 1231], ["provide", 1236], ["a", 1244], ["valuable", 1246], ["resource", 1255], ["for", 1264], ["research", 1268], ["in", 1277], ["chordate", 1280], ["development", 1289], [",", 1300], ["genome", 1302], ["evolution", 1309], ["and", 1319], ["plasticity", 1323], ["and", 1334], ["the", 1338], ["molecular", 1342], ["ecology", 1352], ["of", 1360], ["this", 1363], ["important", 1368], ["marine", 1378], ["planktonic", 1385], ["organism", 1396], [".", 1404]]}
{"context": "Approximately 2-4% of genetic material in human populations outside Africa is derived from Neanderthals who interbred with anatomically modern humans. Recent studies have shown that this Neanderthal DNA is depleted around functional genomic regions; this has been suggested to be a consequence of harmful epistatic interactions between human and Neanderthal alleles. However, using published estimates of Neanderthal inbreeding and the distribution of mutational fitness effects, we infer that Neanderthals had at least 40% lower fitness than humans on average; this increased load predicts the reduction in Neanderthal introgression around genes without the need to invoke epistasis. We also predict a residual Neanderthal mutational load in non-Africans, leading to a fitness reduction of at least 0.5%. This effect of Neanderthal admixture has been left out of previous debate on mutation load differences between Africans and non-Africans. We also show that if many deleterious mutations are recessive, the Neanderthal admixture fraction could increase over time due to the protective effect of Neanderthal haplotypes against deleterious alleles that arose recently in the human population. This might partially explain why so many organisms retain gene flow from other species and appear to derive adaptive benefits from introgression.", "qas": [{"question": "What percentage of Homo sapiens DNA is of Neanderthal origin?", "answers": ["2-4%"], "qid": "483a3885738d4b65a527e3fd3445ef78", "question_tokens": [["What", 0], ["percentage", 5], ["of", 16], ["Homo", 19], ["sapiens", 24], ["DNA", 32], ["is", 36], ["of", 39], ["Neanderthal", 42], ["origin", 54], ["?", 60]], "detected_answers": [{"text": "2-4%", "token_spans": [[1, 3]], "char_spans": [[14, 16]]}]}], "context_tokens": [["Approximately", 0], ["2", 14], ["-", 15], ["4", 16], ["%", 17], ["of", 19], ["genetic", 22], ["material", 30], ["in", 39], ["human", 42], ["populations", 48], ["outside", 60], ["Africa", 68], ["is", 75], ["derived", 78], ["from", 86], ["Neanderthals", 91], ["who", 104], ["interbred", 108], ["with", 118], ["anatomically", 123], ["modern", 136], ["humans", 143], [".", 149], ["Recent", 151], ["studies", 158], ["have", 166], ["shown", 171], ["that", 177], ["this", 182], ["Neanderthal", 187], ["DNA", 199], ["is", 203], ["depleted", 206], ["around", 215], ["functional", 222], ["genomic", 233], ["regions", 241], [";", 248], ["this", 250], ["has", 255], ["been", 259], ["suggested", 264], ["to", 274], ["be", 277], ["a", 280], ["consequence", 282], ["of", 294], ["harmful", 297], ["epistatic", 305], ["interactions", 315], ["between", 328], ["human", 336], ["and", 342], ["Neanderthal", 346], ["alleles", 358], [".", 365], ["However", 367], [",", 374], ["using", 376], ["published", 382], ["estimates", 392], ["of", 402], ["Neanderthal", 405], ["inbreeding", 417], ["and", 428], ["the", 432], ["distribution", 436], ["of", 449], ["mutational", 452], ["fitness", 463], ["effects", 471], [",", 478], ["we", 480], ["infer", 483], ["that", 489], ["Neanderthals", 494], ["had", 507], ["at", 511], ["least", 514], ["40", 520], ["%", 522], ["lower", 524], ["fitness", 530], ["than", 538], ["humans", 543], ["on", 550], ["average", 553], [";", 560], ["this", 562], ["increased", 567], ["load", 577], ["predicts", 582], ["the", 591], ["reduction", 595], ["in", 605], ["Neanderthal", 608], ["introgression", 620], ["around", 634], ["genes", 641], ["without", 647], ["the", 655], ["need", 659], ["to", 664], ["invoke", 667], ["epistasis", 674], [".", 683], ["We", 685], ["also", 688], ["predict", 693], ["a", 701], ["residual", 703], ["Neanderthal", 712], ["mutational", 724], ["load", 735], ["in", 740], ["non", 743], ["-", 746], ["Africans", 747], [",", 755], ["leading", 757], ["to", 765], ["a", 768], ["fitness", 770], ["reduction", 778], ["of", 788], ["at", 791], ["least", 794], ["0.5", 800], ["%", 803], [".", 804], ["This", 806], ["effect", 811], ["of", 818], ["Neanderthal", 821], ["admixture", 833], ["has", 843], ["been", 847], ["left", 852], ["out", 857], ["of", 861], ["previous", 864], ["debate", 873], ["on", 880], ["mutation", 883], ["load", 892], ["differences", 897], ["between", 909], ["Africans", 917], ["and", 926], ["non", 930], ["-", 933], ["Africans", 934], [".", 942], ["We", 944], ["also", 947], ["show", 952], ["that", 957], ["if", 962], ["many", 965], ["deleterious", 970], ["mutations", 982], ["are", 992], ["recessive", 996], [",", 1005], ["the", 1007], ["Neanderthal", 1011], ["admixture", 1023], ["fraction", 1033], ["could", 1042], ["increase", 1048], ["over", 1057], ["time", 1062], ["due", 1067], ["to", 1071], ["the", 1074], ["protective", 1078], ["effect", 1089], ["of", 1096], ["Neanderthal", 1099], ["haplotypes", 1111], ["against", 1122], ["deleterious", 1130], ["alleles", 1142], ["that", 1150], ["arose", 1155], ["recently", 1161], ["in", 1170], ["the", 1173], ["human", 1177], ["population", 1183], [".", 1193], ["This", 1195], ["might", 1200], ["partially", 1206], ["explain", 1216], ["why", 1224], ["so", 1228], ["many", 1231], ["organisms", 1236], ["retain", 1246], ["gene", 1253], ["flow", 1258], ["from", 1263], ["other", 1268], ["species", 1274], ["and", 1282], ["appear", 1286], ["to", 1293], ["derive", 1296], ["adaptive", 1303], ["benefits", 1312], ["from", 1321], ["introgression", 1326], [".", 1339]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery. They are essential for the elongation and closure of the phagophore into a proper autophagosome. Moreover, Atg8-family proteins are associated with the phagophore from the initiation of the autophagic process to, or just prior to, the fusion between autophagosomes with lysosomes. In addition to their implication in autophagosome biogenesis, they are crucial for selective autophagy through their ability to interact with selective autophagy receptor proteins necessary for the specific targeting of substrates for autophagic degradation. In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy. Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins. These proteins are referred to as LIR-containing proteins (LIRCPs). So far, many experimental efforts have been carried out to identify new LIRCPs, leading to the characterization of some of them in the past 10\u00a0years. Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis. Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.", "qas": [{"question": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "answers": ["The iLIR database"], "qid": "16c89e69edec4f89b7e12d57432d4b48", "question_tokens": [["Which", 0], ["web", 6], ["resource", 10], ["for", 19], ["LIR", 23], ["motif", 27], ["-", 32], ["containing", 33], ["proteins", 44], ["in", 53], ["eukaryotes", 56], ["has", 67], ["been", 71], ["developed", 76], ["?", 85]], "detected_answers": [{"text": "The iLIR database", "token_spans": [[230, 231]], "char_spans": [[1416, 1428]]}]}], "context_tokens": [["Atg8-family", 0], ["proteins", 12], ["are", 21], ["the", 25], ["best", 29], ["-", 33], ["studied", 34], ["proteins", 42], ["of", 51], ["the", 54], ["core", 58], ["autophagic", 63], ["machinery", 74], [".", 83], ["They", 85], ["are", 90], ["essential", 94], ["for", 104], ["the", 108], ["elongation", 112], ["and", 123], ["closure", 127], ["of", 135], ["the", 138], ["phagophore", 142], ["into", 153], ["a", 158], ["proper", 160], ["autophagosome", 167], [".", 180], ["Moreover", 182], [",", 190], ["Atg8-family", 192], ["proteins", 204], ["are", 213], ["associated", 217], ["with", 228], ["the", 233], ["phagophore", 237], ["from", 248], ["the", 253], ["initiation", 257], ["of", 268], ["the", 271], ["autophagic", 275], ["process", 286], ["to", 294], [",", 296], ["or", 298], ["just", 301], ["prior", 306], ["to", 312], [",", 314], ["the", 316], ["fusion", 320], ["between", 327], ["autophagosomes", 335], ["with", 350], ["lysosomes", 355], [".", 364], ["In", 366], ["addition", 369], ["to", 378], ["their", 381], ["implication", 387], ["in", 399], ["autophagosome", 402], ["biogenesis", 416], [",", 426], ["they", 428], ["are", 433], ["crucial", 437], ["for", 445], ["selective", 449], ["autophagy", 459], ["through", 469], ["their", 477], ["ability", 483], ["to", 491], ["interact", 494], ["with", 503], ["selective", 508], ["autophagy", 518], ["receptor", 528], ["proteins", 537], ["necessary", 546], ["for", 556], ["the", 560], ["specific", 564], ["targeting", 573], ["of", 583], ["substrates", 586], ["for", 597], ["autophagic", 601], ["degradation", 612], [".", 623], ["In", 625], ["the", 628], ["past", 632], ["few", 637], ["years", 641], ["it", 647], ["has", 650], ["been", 654], ["revealed", 659], ["that", 668], ["Atg8-interacting", 673], ["proteins", 690], ["include", 699], ["not", 707], ["only", 711], ["receptors", 716], ["but", 726], ["also", 730], ["components", 735], ["of", 746], ["the", 749], ["core", 753], ["autophagic", 758], ["machinery", 769], [",", 778], ["proteins", 780], ["associated", 789], ["with", 800], ["vesicles", 805], ["and", 814], ["their", 818], ["transport", 824], [",", 833], ["and", 835], ["specific", 839], ["proteins", 848], ["that", 857], ["are", 862], ["selectively", 866], ["degraded", 878], ["by", 887], ["autophagy", 890], [".", 899], ["Atg8-interacting", 901], ["proteins", 918], ["contain", 927], ["a", 935], ["short", 937], ["linear", 943], ["LC3-interacting", 950], ["region", 966], ["/", 972], ["LC3", 973], ["recognition", 977], ["sequence", 989], ["/", 997], ["Atg8-interacting", 998], ["motif", 1015], ["(", 1021], ["LIR", 1022], ["/", 1025], ["LRS", 1026], ["/", 1029], ["AIM", 1030], [")", 1033], ["motif", 1035], ["which", 1041], ["is", 1047], ["responsible", 1050], ["for", 1062], ["their", 1066], ["interaction", 1072], ["with", 1084], ["Atg8-family", 1089], ["proteins", 1101], [".", 1109], ["These", 1111], ["proteins", 1117], ["are", 1126], ["referred", 1130], ["to", 1139], ["as", 1142], ["LIR", 1145], ["-", 1148], ["containing", 1149], ["proteins", 1160], ["(", 1169], ["LIRCPs", 1170], [")", 1176], [".", 1177], ["So", 1179], ["far", 1182], [",", 1185], ["many", 1187], ["experimental", 1192], ["efforts", 1205], ["have", 1213], ["been", 1218], ["carried", 1223], ["out", 1231], ["to", 1235], ["identify", 1238], ["new", 1247], ["LIRCPs", 1251], [",", 1257], ["leading", 1259], ["to", 1267], ["the", 1270], ["characterization", 1274], ["of", 1291], ["some", 1294], ["of", 1299], ["them", 1302], ["in", 1307], ["the", 1310], ["past", 1314], ["10", 1319], ["years", 1322], [".", 1327], ["Given", 1329], ["the", 1335], ["need", 1339], ["for", 1344], ["the", 1348], ["identification", 1352], ["of", 1367], ["LIRCPs", 1370], ["in", 1377], ["various", 1380], ["organisms", 1388], [",", 1397], ["we", 1399], ["developed", 1402], ["the", 1412], ["iLIR", 1416], ["database", 1421], ["(", 1430], ["https://ilir.warwick.ac.uk", 1432], [")", 1459], ["as", 1461], ["a", 1464], ["freely", 1466], ["available", 1473], ["web", 1483], ["resource", 1487], [",", 1495], ["listing", 1497], ["all", 1505], ["the", 1509], ["putative", 1513], ["canonical", 1522], ["LIRCPs", 1532], ["identified", 1539], ["in", 1550], ["silico", 1553], ["in", 1560], ["the", 1563], ["proteomes", 1567], ["of", 1577], ["8", 1580], ["model", 1582], ["organisms", 1588], ["using", 1598], ["the", 1604], ["iLIR", 1608], ["server", 1613], [",", 1619], ["combined", 1621], ["with", 1630], ["a", 1635], ["Gene", 1637], ["Ontology", 1642], ["(", 1651], ["GO", 1652], [")", 1654], ["term", 1656], ["analysis", 1661], [".", 1669], ["Additionally", 1671], [",", 1683], ["a", 1685], ["curated", 1687], ["text", 1695], ["-", 1699], ["mining", 1700], ["analysis", 1707], ["of", 1716], ["the", 1719], ["literature", 1723], ["permitted", 1734], ["us", 1744], ["to", 1747], ["identify", 1750], ["novel", 1759], ["putative", 1765], ["LICRPs", 1774], ["in", 1781], ["mammals", 1784], ["that", 1792], ["have", 1797], ["not", 1802], ["previously", 1806], ["been", 1817], ["associated", 1822], ["with", 1833], ["autophagy", 1838], [".", 1847]]}
{"context": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1. However, the role of the small GTPase Rac remained to be clarified. Here we show that Rac directly participates in Nox1 activation via interacting with Noxa1. Electropermeabilized HeLa cells, ectopically expressing Nox1, Noxo1, and Noxa1, produce superoxide in a GTP-dependent manner, which is abrogated by expression of a mutant Noxa1(R103E), defective in Rac binding. Superoxide production in Nox1-expressing HeLa and Caco-2 cells is decreased by depletion or sequestration of Rac; on the other hand, it is enhanced by expression of the constitutively active Rac1(Q61L), but not by that of a mutant Rac1 with the A27K substitution, deficient in binding to Noxa1. We also demonstrate that Nox1 activation requires membrane recruitment of Noxa1, which is normally mediated via Noxa1 binding to Noxo1, a protein tethered to the Nox1 partner p22(phox): the Noxa1-Noxo1 and Noxo1-p22(phox) interactions are both essential for Nox1 activity. Rac likely facilitates the membrane localization of Noxa1: although Noxa1(W436R), defective in Noxo1 binding, neither associates with the membrane nor activates Nox1, the effects of the W436R substitution are restored by expression of Rac1(Q61L). The Rac-Noxa1 interaction also serves at a step different from the Noxa1 localization, because the binding-defective Noxa1(R103E), albeit targeted to the membrane, does not support superoxide production by Nox1. Furthermore, a mutant Noxa1 carrying the substitution of Ala for Val-205 in the activation domain, which is expected to undergo a conformational change upon Rac binding, fully localizes to the membrane but fails to activate Nox1.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "7b72b7fbe25641d2afc299fbcc7284d8", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[11, 11], [155, 155], [221, 221], [52, 52], [313, 313], [178, 178], [273, 273], [193, 193], [65, 65]], "char_spans": [[68, 71], [864, 867], [1273, 1276], [289, 292], [1795, 1798], [1001, 1004], [1565, 1568], [1097, 1100], [389, 392]]}]}], "context_tokens": [["Activation", 0], ["of", 11], ["the", 14], ["non", 18], ["-", 21], ["phagocytic", 22], ["superoxide", 33], ["-", 43], ["producing", 44], ["NADPH", 54], ["oxidase", 60], ["Nox1", 68], [",", 72], ["complexed", 74], ["with", 84], ["p22(phox", 89], [")", 97], ["at", 99], ["the", 102], ["membrane", 106], [",", 114], ["requires", 116], ["its", 125], ["regulatory", 129], ["soluble", 140], ["proteins", 148], ["Noxo1", 157], ["and", 163], ["Noxa1", 167], [".", 172], ["However", 174], [",", 181], ["the", 183], ["role", 187], ["of", 192], ["the", 195], ["small", 199], ["GTPase", 205], ["Rac", 212], ["remained", 216], ["to", 225], ["be", 228], ["clarified", 231], [".", 240], ["Here", 242], ["we", 247], ["show", 250], ["that", 255], ["Rac", 260], ["directly", 264], ["participates", 273], ["in", 286], ["Nox1", 289], ["activation", 294], ["via", 305], ["interacting", 309], ["with", 321], ["Noxa1", 326], [".", 331], ["Electropermeabilized", 333], ["HeLa", 354], ["cells", 359], [",", 364], ["ectopically", 366], ["expressing", 378], ["Nox1", 389], [",", 393], ["Noxo1", 395], [",", 400], ["and", 402], ["Noxa1", 406], [",", 411], ["produce", 413], ["superoxide", 421], ["in", 432], ["a", 435], ["GTP", 437], ["-", 440], ["dependent", 441], ["manner", 451], [",", 457], ["which", 459], ["is", 465], ["abrogated", 468], ["by", 478], ["expression", 481], ["of", 492], ["a", 495], ["mutant", 497], ["Noxa1(R103E", 504], [")", 515], [",", 516], ["defective", 518], ["in", 528], ["Rac", 531], ["binding", 535], [".", 542], ["Superoxide", 544], ["production", 555], ["in", 566], ["Nox1-expressing", 569], ["HeLa", 585], ["and", 590], ["Caco-2", 594], ["cells", 601], ["is", 607], ["decreased", 610], ["by", 620], ["depletion", 623], ["or", 633], ["sequestration", 636], ["of", 650], ["Rac", 653], [";", 656], ["on", 658], ["the", 661], ["other", 665], ["hand", 671], [",", 675], ["it", 677], ["is", 680], ["enhanced", 683], ["by", 692], ["expression", 695], ["of", 706], ["the", 709], ["constitutively", 713], ["active", 728], ["Rac1(Q61L", 735], [")", 744], [",", 745], ["but", 747], ["not", 751], ["by", 755], ["that", 758], ["of", 763], ["a", 766], ["mutant", 768], ["Rac1", 775], ["with", 780], ["the", 785], ["A27", 789], ["K", 792], ["substitution", 794], [",", 806], ["deficient", 808], ["in", 818], ["binding", 821], ["to", 829], ["Noxa1", 832], [".", 837], ["We", 839], ["also", 842], ["demonstrate", 847], ["that", 859], ["Nox1", 864], ["activation", 869], ["requires", 880], ["membrane", 889], ["recruitment", 898], ["of", 910], ["Noxa1", 913], [",", 918], ["which", 920], ["is", 926], ["normally", 929], ["mediated", 938], ["via", 947], ["Noxa1", 951], ["binding", 957], ["to", 965], ["Noxo1", 968], [",", 973], ["a", 975], ["protein", 977], ["tethered", 985], ["to", 994], ["the", 997], ["Nox1", 1001], ["partner", 1006], ["p22(phox", 1014], [")", 1022], [":", 1023], ["the", 1025], ["Noxa1-Noxo1", 1029], ["and", 1041], ["Noxo1-p22(phox", 1045], [")", 1059], ["interactions", 1061], ["are", 1074], ["both", 1078], ["essential", 1083], ["for", 1093], ["Nox1", 1097], ["activity", 1102], [".", 1110], ["Rac", 1112], ["likely", 1116], ["facilitates", 1123], ["the", 1135], ["membrane", 1139], ["localization", 1148], ["of", 1161], ["Noxa1", 1164], [":", 1169], ["although", 1171], ["Noxa1(W436R", 1180], [")", 1191], [",", 1192], ["defective", 1194], ["in", 1204], ["Noxo1", 1207], ["binding", 1213], [",", 1220], ["neither", 1222], ["associates", 1230], ["with", 1241], ["the", 1246], ["membrane", 1250], ["nor", 1259], ["activates", 1263], ["Nox1", 1273], [",", 1277], ["the", 1279], ["effects", 1283], ["of", 1291], ["the", 1294], ["W436R", 1298], ["substitution", 1304], ["are", 1317], ["restored", 1321], ["by", 1330], ["expression", 1333], ["of", 1344], ["Rac1(Q61L", 1347], [")", 1356], [".", 1357], ["The", 1359], ["Rac", 1363], ["-", 1366], ["Noxa1", 1367], ["interaction", 1373], ["also", 1385], ["serves", 1390], ["at", 1397], ["a", 1400], ["step", 1402], ["different", 1407], ["from", 1417], ["the", 1422], ["Noxa1", 1426], ["localization", 1432], [",", 1444], ["because", 1446], ["the", 1454], ["binding", 1458], ["-", 1465], ["defective", 1466], ["Noxa1(R103E", 1476], [")", 1487], [",", 1488], ["albeit", 1490], ["targeted", 1497], ["to", 1506], ["the", 1509], ["membrane", 1513], [",", 1521], ["does", 1523], ["not", 1528], ["support", 1532], ["superoxide", 1540], ["production", 1551], ["by", 1562], ["Nox1", 1565], [".", 1569], ["Furthermore", 1571], [",", 1582], ["a", 1584], ["mutant", 1586], ["Noxa1", 1593], ["carrying", 1599], ["the", 1608], ["substitution", 1612], ["of", 1625], ["Ala", 1628], ["for", 1632], ["Val-205", 1636], ["in", 1644], ["the", 1647], ["activation", 1651], ["domain", 1662], [",", 1668], ["which", 1670], ["is", 1676], ["expected", 1679], ["to", 1688], ["undergo", 1691], ["a", 1699], ["conformational", 1701], ["change", 1716], ["upon", 1723], ["Rac", 1728], ["binding", 1732], [",", 1739], ["fully", 1741], ["localizes", 1747], ["to", 1757], ["the", 1760], ["membrane", 1764], ["but", 1773], ["fails", 1777], ["to", 1783], ["activate", 1786], ["Nox1", 1795], [".", 1799]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "The effect of levodopa (L-dopa), alone or in combination with a peripheral decarboxylase inhibitor (PDI), on plasma levels of aromatic-L-amino acid decarboxylase (ALAAD, = dopa decarboxylase), L-dopa, 3-O-methyl-dopa (3-OMD), dopamine (DA), noradrenaline, adrenaline and dopamine beta-hydroxylase has been studied. In healthy subjects and in patients with parkinsonism plasma ALAAD level fell after administration of L-dopa + benserazide, but returned to previous levels within 90 min. In a cross-sectional study blood was obtained, 2 h after dosing, from 104 patients with idiopathic parkinsonism, divided into four groups: no L-dopa treatment (group 1), L-dopa alone (group 2), L-dopa + benserazide (Madopar) (group 3) and L-dopa + carbidopa (Sinemet) (group 4). Plasma ALAAD, which was normal in groups 1 and 2, was increased 3-fold in groups 3 and 4, indicating that there was induction of ALAAD by the co-administration of PDI. Despite this induction of ALAAD, in groups 3 and 4, with half the daily L-dopa dose compared with group 2, plasma L-dopa and 3-OMD levels were 5 times higher, while plasma DA levels were not different. The DA/L-dopa ratio was decreased 5-fold in group 2 and 16-fold in groups 3 and 4 as compared with group 1. Neither 3-OMD levels nor 3-OMD/L-dopa ratios correlated with the occurrence of on-off fluctuations. In a longitudinal study of three patients started on Madopar treatment the induction of plasma ALAAD was found to occur gradually over 3-4 weeks. Further detailed pharmacokinetic studies in plasma and cerebrospinal fluid are required in order to elucidate whether the ALAAD induction by PDI may be related to the loss of clinical efficacy of combination therapy in some patients and how it is related to end-of-dose deterioration and on-off phenomena.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "5aad124ed6b3449e87579c5571aa6c64", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[161, 163], [258, 260], [87, 89], [148, 150], [236, 238], [5, 7], [226, 228], [42, 44], [287, 289], [130, 132], [139, 141]], "char_spans": [[725, 730], [1142, 1147], [417, 422], [680, 685], [1047, 1052], [24, 29], [1005, 1010], [193, 198], [1274, 1279], [628, 633], [656, 661]]}]}], "context_tokens": [["The", 0], ["effect", 4], ["of", 11], ["levodopa", 14], ["(", 23], ["L", 24], ["-", 25], ["dopa", 26], [")", 30], [",", 31], ["alone", 33], ["or", 39], ["in", 42], ["combination", 45], ["with", 57], ["a", 62], ["peripheral", 64], ["decarboxylase", 75], ["inhibitor", 89], ["(", 99], ["PDI", 100], [")", 103], [",", 104], ["on", 106], ["plasma", 109], ["levels", 116], ["of", 123], ["aromatic", 126], ["-", 134], ["L", 135], ["-", 136], ["amino", 137], ["acid", 143], ["decarboxylase", 148], ["(", 162], ["ALAAD", 163], [",", 168], ["=", 170], ["dopa", 172], ["decarboxylase", 177], [")", 190], [",", 191], ["L", 193], ["-", 194], ["dopa", 195], [",", 199], ["3-O", 201], ["-", 204], ["methyl", 205], ["-", 211], ["dopa", 212], ["(", 217], ["3-OMD", 218], [")", 223], [",", 224], ["dopamine", 226], ["(", 235], ["DA", 236], [")", 238], [",", 239], ["noradrenaline", 241], [",", 254], ["adrenaline", 256], ["and", 267], ["dopamine", 271], ["beta", 280], ["-", 284], ["hydroxylase", 285], ["has", 297], ["been", 301], ["studied", 306], [".", 313], ["In", 315], ["healthy", 318], ["subjects", 326], ["and", 335], ["in", 339], ["patients", 342], ["with", 351], ["parkinsonism", 356], ["plasma", 369], ["ALAAD", 376], ["level", 382], ["fell", 388], ["after", 393], ["administration", 399], ["of", 414], ["L", 417], ["-", 418], ["dopa", 419], ["+", 424], ["benserazide", 426], [",", 437], ["but", 439], ["returned", 443], ["to", 452], ["previous", 455], ["levels", 464], ["within", 471], ["90", 478], ["min", 481], [".", 484], ["In", 486], ["a", 489], ["cross", 491], ["-", 496], ["sectional", 497], ["study", 507], ["blood", 513], ["was", 519], ["obtained", 523], [",", 531], ["2", 533], ["h", 535], ["after", 537], ["dosing", 543], [",", 549], ["from", 551], ["104", 556], ["patients", 560], ["with", 569], ["idiopathic", 574], ["parkinsonism", 585], [",", 597], ["divided", 599], ["into", 607], ["four", 612], ["groups", 617], [":", 623], ["no", 625], ["L", 628], ["-", 629], ["dopa", 630], ["treatment", 635], ["(", 645], ["group", 646], ["1", 652], [")", 653], [",", 654], ["L", 656], ["-", 657], ["dopa", 658], ["alone", 663], ["(", 669], ["group", 670], ["2", 676], [")", 677], [",", 678], ["L", 680], ["-", 681], ["dopa", 682], ["+", 687], ["benserazide", 689], ["(", 701], ["Madopar", 702], [")", 709], ["(", 711], ["group", 712], ["3", 718], [")", 719], ["and", 721], ["L", 725], ["-", 726], ["dopa", 727], ["+", 732], ["carbidopa", 734], ["(", 744], ["Sinemet", 745], [")", 752], ["(", 754], ["group", 755], ["4", 761], [")", 762], [".", 763], ["Plasma", 765], ["ALAAD", 772], [",", 777], ["which", 779], ["was", 785], ["normal", 789], ["in", 796], ["groups", 799], ["1", 806], ["and", 808], ["2", 812], [",", 813], ["was", 815], ["increased", 819], ["3-fold", 829], ["in", 836], ["groups", 839], ["3", 846], ["and", 848], ["4", 852], [",", 853], ["indicating", 855], ["that", 866], ["there", 871], ["was", 877], ["induction", 881], ["of", 891], ["ALAAD", 894], ["by", 900], ["the", 903], ["co", 907], ["-", 909], ["administration", 910], ["of", 925], ["PDI", 928], [".", 931], ["Despite", 933], ["this", 941], ["induction", 946], ["of", 956], ["ALAAD", 959], [",", 964], ["in", 966], ["groups", 969], ["3", 976], ["and", 978], ["4", 982], [",", 983], ["with", 985], ["half", 990], ["the", 995], ["daily", 999], ["L", 1005], ["-", 1006], ["dopa", 1007], ["dose", 1012], ["compared", 1017], ["with", 1026], ["group", 1031], ["2", 1037], [",", 1038], ["plasma", 1040], ["L", 1047], ["-", 1048], ["dopa", 1049], ["and", 1054], ["3-OMD", 1058], ["levels", 1064], ["were", 1071], ["5", 1076], ["times", 1078], ["higher", 1084], [",", 1090], ["while", 1092], ["plasma", 1098], ["DA", 1105], ["levels", 1108], ["were", 1115], ["not", 1120], ["different", 1124], [".", 1133], ["The", 1135], ["DA", 1139], ["/", 1141], ["L", 1142], ["-", 1143], ["dopa", 1144], ["ratio", 1149], ["was", 1155], ["decreased", 1159], ["5-fold", 1169], ["in", 1176], ["group", 1179], ["2", 1185], ["and", 1187], ["16-fold", 1191], ["in", 1199], ["groups", 1202], ["3", 1209], ["and", 1211], ["4", 1215], ["as", 1217], ["compared", 1220], ["with", 1229], ["group", 1234], ["1", 1240], [".", 1241], ["Neither", 1243], ["3-OMD", 1251], ["levels", 1257], ["nor", 1264], ["3-OMD", 1268], ["/", 1273], ["L", 1274], ["-", 1275], ["dopa", 1276], ["ratios", 1281], ["correlated", 1288], ["with", 1299], ["the", 1304], ["occurrence", 1308], ["of", 1319], ["on", 1322], ["-", 1324], ["off", 1325], ["fluctuations", 1329], [".", 1341], ["In", 1343], ["a", 1346], ["longitudinal", 1348], ["study", 1361], ["of", 1367], ["three", 1370], ["patients", 1376], ["started", 1385], ["on", 1393], ["Madopar", 1396], ["treatment", 1404], ["the", 1414], ["induction", 1418], ["of", 1428], ["plasma", 1431], ["ALAAD", 1438], ["was", 1444], ["found", 1448], ["to", 1454], ["occur", 1457], ["gradually", 1463], ["over", 1473], ["3", 1478], ["-", 1479], ["4", 1480], ["weeks", 1482], [".", 1487], ["Further", 1489], ["detailed", 1497], ["pharmacokinetic", 1506], ["studies", 1522], ["in", 1530], ["plasma", 1533], ["and", 1540], ["cerebrospinal", 1544], ["fluid", 1558], ["are", 1564], ["required", 1568], ["in", 1577], ["order", 1580], ["to", 1586], ["elucidate", 1589], ["whether", 1599], ["the", 1607], ["ALAAD", 1611], ["induction", 1617], ["by", 1627], ["PDI", 1630], ["may", 1634], ["be", 1638], ["related", 1641], ["to", 1649], ["the", 1652], ["loss", 1656], ["of", 1661], ["clinical", 1664], ["efficacy", 1673], ["of", 1682], ["combination", 1685], ["therapy", 1697], ["in", 1705], ["some", 1708], ["patients", 1713], ["and", 1722], ["how", 1726], ["it", 1730], ["is", 1733], ["related", 1736], ["to", 1744], ["end", 1747], ["-", 1750], ["of", 1751], ["-", 1753], ["dose", 1754], ["deterioration", 1759], ["and", 1773], ["on", 1777], ["-", 1779], ["off", 1780], ["phenomena", 1784], [".", 1793]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or in combination with other therapies to improve glycemic control in patients with T2DM. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion. This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin. Empagliflozin offers good glycemic efficacy, weight loss, blood pressure reduction, and a low risk of hypoglycemia. These attributes, coupled with the ability to be used in virtually any combination with other anti-diabetes agents and at any stage in the disease process, provide a welcome new agent to our armamentarium of drugs to help manage T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "48dc9bc52067412fa103828ee4ac558d", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[109, 109], [73, 73]], "char_spans": [[673, 677], [425, 429]]}]}], "context_tokens": [["Despite", 0], ["the", 8], ["availability", 12], ["of", 25], ["numerous", 28], ["anti", 37], ["-", 41], ["diabetes", 42], ["drugs", 51], ["and", 57], ["treatment", 61], ["guidelines", 71], [",", 81], ["many", 83], ["patients", 88], ["with", 97], ["type", 102], ["2", 107], ["diabetes", 109], ["mellitus", 118], ["(", 127], ["T2DM", 128], [")", 132], ["do", 134], ["not", 137], ["reach", 141], ["recommended", 147], ["targets", 159], ["for", 167], ["glycemic", 171], ["control", 180], [".", 187], ["There", 189], ["remains", 195], ["an", 203], ["unmet", 206], ["need", 212], ["for", 217], ["effective", 221], ["and", 231], ["well", 235], ["-", 239], ["tolerated", 240], ["anti", 250], ["-", 254], ["diabetes", 255], ["agents", 264], ["that", 271], ["can", 276], ["be", 280], ["used", 283], ["as", 288], ["monotherapy", 291], ["or", 303], ["in", 306], ["combination", 309], ["with", 321], ["other", 326], ["therapies", 332], ["to", 342], ["improve", 345], ["glycemic", 353], ["control", 362], ["in", 370], ["patients", 373], ["with", 382], ["T2DM", 387], [".", 391], ["Sodium", 393], ["glucose", 400], ["cotransporter", 408], ["2", 422], ["(", 424], ["SGLT2", 425], [")", 430], ["inhibitors", 432], ["are", 443], ["a", 447], ["new", 449], ["class", 453], ["of", 459], ["treatment", 462], ["for", 472], ["T2DM", 476], ["that", 481], ["reduce", 486], ["hyperglycemia", 493], ["by", 507], ["reducing", 510], ["renal", 519], ["glucose", 525], ["reabsorption", 533], ["and", 546], ["thereby", 550], ["increasing", 558], ["urinary", 569], ["glucose", 577], ["excretion", 585], [".", 594], ["This", 596], ["paper", 601], ["reviews", 607], ["the", 615], ["pharmacokinetic", 619], ["and", 635], ["pharmacodynamic", 639], ["properties", 655], ["of", 666], ["the", 669], ["SGLT2", 673], ["inhibitor", 679], ["empagliflozin", 689], [",", 703], ["the", 705], ["results", 709], ["of", 717], ["clinical", 720], ["trials", 729], ["investigating", 736], ["the", 750], ["efficacy", 754], ["of", 763], ["empagliflozin", 766], ["given", 780], ["as", 786], ["monotherapy", 789], ["or", 801], ["as", 804], ["add", 807], ["-", 810], ["on", 811], ["therapy", 814], ["on", 822], ["glycemic", 825], ["control", 834], [",", 841], ["body", 843], ["weight", 848], [",", 854], ["and", 856], ["blood", 860], ["pressure", 866], ["in", 875], ["patients", 878], ["with", 887], ["T2DM", 892], [",", 896], ["and", 898], ["the", 902], ["safety", 906], ["and", 913], ["tolerability", 917], ["profile", 930], ["of", 938], ["empagliflozin", 941], [".", 954], ["Empagliflozin", 956], ["offers", 970], ["good", 977], ["glycemic", 982], ["efficacy", 991], [",", 999], ["weight", 1001], ["loss", 1008], [",", 1012], ["blood", 1014], ["pressure", 1020], ["reduction", 1029], [",", 1038], ["and", 1040], ["a", 1044], ["low", 1046], ["risk", 1050], ["of", 1055], ["hypoglycemia", 1058], [".", 1070], ["These", 1072], ["attributes", 1078], [",", 1088], ["coupled", 1090], ["with", 1098], ["the", 1103], ["ability", 1107], ["to", 1115], ["be", 1118], ["used", 1121], ["in", 1126], ["virtually", 1129], ["any", 1139], ["combination", 1143], ["with", 1155], ["other", 1160], ["anti", 1166], ["-", 1170], ["diabetes", 1171], ["agents", 1180], ["and", 1187], ["at", 1191], ["any", 1194], ["stage", 1198], ["in", 1204], ["the", 1207], ["disease", 1211], ["process", 1219], [",", 1226], ["provide", 1228], ["a", 1236], ["welcome", 1238], ["new", 1246], ["agent", 1250], ["to", 1256], ["our", 1259], ["armamentarium", 1263], ["of", 1277], ["drugs", 1280], ["to", 1286], ["help", 1289], ["manage", 1294], ["T2DM", 1301], [".", 1305]]}
{"context": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells. The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs. Mouse embryomic fibroblasts (MEFs) lacking TIA-1 exhibit impaired ability to form SGs, although they exhibit normal phosphorylation of eukaryotic initiation factor (eIF)2alpha in response to arsenite. Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress.", "qas": [{"question": "Which domain of TIA-1 is necessary for stress granule assembly?", "answers": ["The glutamine-rich prion-related domain (PRD)"], "qid": "b0c5cb7e458c48f9a369b023a6f154ef", "question_tokens": [["Which", 0], ["domain", 6], ["of", 13], ["TIA-1", 16], ["is", 22], ["necessary", 25], ["for", 35], ["stress", 39], ["granule", 46], ["assembly", 54], ["?", 62]], "detected_answers": [{"text": "The glutamine-rich prion-related domain (PRD)", "token_spans": [[46, 54]], "char_spans": [[291, 330]]}]}], "context_tokens": [["TIA-1", 0], ["is", 6], ["an", 9], ["RNA", 12], ["binding", 16], ["protein", 24], ["that", 32], ["promotes", 37], ["the", 46], ["assembly", 50], ["of", 59], ["stress", 62], ["granules", 69], ["(", 78], ["SGs", 79], [")", 82], [",", 83], ["discrete", 85], ["cytoplasmic", 94], ["inclusions", 106], ["into", 117], ["which", 122], ["stalled", 128], ["translation", 136], ["initiation", 148], ["complexes", 159], ["are", 169], ["dynamically", 173], ["recruited", 185], ["in", 195], ["cells", 198], ["subjected", 204], ["to", 214], ["environmental", 217], ["stress", 231], [".", 237], ["The", 239], ["RNA", 243], ["recognition", 247], ["motifs", 259], ["of", 266], ["TIA-1", 269], ["are", 275], ["linked", 279], ["to", 286], ["a", 289], ["glutamine", 291], ["-", 300], ["rich", 301], ["prion", 306], ["-", 311], ["related", 312], ["domain", 320], ["(", 327], ["PRD", 328], [")", 331], [".", 332], ["Truncation", 334], ["mutants", 345], ["lacking", 353], ["the", 361], ["PRD", 365], ["domain", 369], ["do", 376], ["not", 379], ["induce", 383], ["spontaneous", 390], ["SGs", 402], ["and", 406], ["are", 410], ["not", 414], ["recruited", 418], ["to", 428], ["arsenite", 431], ["-", 439], ["induced", 440], ["SGs", 448], [",", 451], ["whereas", 453], ["the", 461], ["PRD", 465], ["forms", 469], ["aggregates", 475], ["that", 486], ["are", 491], ["recruited", 495], ["to", 505], ["SGs", 508], ["in", 512], ["low", 515], ["-", 518], ["level", 519], ["-", 524], ["expressing", 525], ["cells", 536], ["but", 542], ["prevent", 546], ["SG", 554], ["assembly", 557], ["in", 566], ["high", 569], ["-", 573], ["level", 574], ["-", 579], ["expressing", 580], ["cells", 591], [".", 596], ["The", 598], ["PRD", 602], ["of", 606], ["TIA-1", 609], ["exhibits", 615], ["many", 624], ["characteristics", 629], ["of", 645], ["prions", 648], [":", 654], ["concentration", 656], ["-", 669], ["dependent", 670], ["aggregation", 680], ["that", 692], ["is", 697], ["inhibited", 700], ["by", 710], ["the", 713], ["molecular", 717], ["chaperone", 727], ["heat", 737], ["shock", 742], ["protein", 748], ["(", 756], ["HSP)70", 757], [";", 763], ["resistance", 765], ["to", 776], ["protease", 779], ["digestion", 788], [";", 797], ["sequestration", 799], ["of", 813], ["HSP27", 816], [",", 821], ["HSP40", 823], [",", 828], ["and", 830], ["HSP70", 834], [";", 839], ["and", 841], ["induction", 845], ["of", 855], ["HSP70", 858], [",", 863], ["a", 865], ["feedback", 867], ["regulator", 876], ["of", 886], ["PRD", 889], ["disaggregation", 893], [".", 907], ["Substitution", 909], ["of", 922], ["the", 925], ["PRD", 929], ["with", 933], ["the", 938], ["aggregation", 942], ["domain", 954], ["of", 961], ["a", 964], ["yeast", 966], ["prion", 972], [",", 977], ["SUP35-NM", 979], [",", 987], ["reconstitutes", 989], ["SG", 1003], ["assembly", 1006], [",", 1014], ["confirming", 1016], ["that", 1027], ["a", 1032], ["prion", 1034], ["domain", 1040], ["can", 1047], ["mediate", 1051], ["the", 1059], ["assembly", 1063], ["of", 1072], ["SGs", 1075], [".", 1078], ["Mouse", 1080], ["embryomic", 1086], ["fibroblasts", 1096], ["(", 1108], ["MEFs", 1109], [")", 1113], ["lacking", 1115], ["TIA-1", 1123], ["exhibit", 1129], ["impaired", 1137], ["ability", 1146], ["to", 1154], ["form", 1157], ["SGs", 1162], [",", 1165], ["although", 1167], ["they", 1176], ["exhibit", 1181], ["normal", 1189], ["phosphorylation", 1196], ["of", 1212], ["eukaryotic", 1215], ["initiation", 1226], ["factor", 1237], ["(", 1244], ["eIF)2alpha", 1245], ["in", 1256], ["response", 1259], ["to", 1268], ["arsenite", 1271], [".", 1279], ["Our", 1281], ["results", 1285], ["reveal", 1293], ["that", 1300], ["prion", 1305], ["-", 1310], ["like", 1311], ["aggregation", 1316], ["of", 1328], ["TIA-1", 1331], ["regulates", 1337], ["SG", 1347], ["formation", 1350], ["downstream", 1360], ["of", 1371], ["eIF2alpha", 1374], ["phosphorylation", 1384], ["in", 1400], ["response", 1403], ["to", 1412], ["stress", 1415], [".", 1421]]}
{"context": "More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278 bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179 or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper, or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar: 47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to exon 47. Of all sequence variants determined in our study, <20% represent C-->T or G-->A transitions within a CpG dinucleotide, and only six different mutations also occur in NF1 pseudogenes, with five being typical C-->T transitions in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%) missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, the GAP-related domain (GRD) and an upstream gene segment comprising exons 11-17. The latter forms a so-called cysteine/serine-rich domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those conserved between human and Drosophila strongly suggest significant functional relevance of this region, with major roles played by exons 12a and 15 and part of exon 16.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "beeb58f583fa4c9192e2fdb72f727d1a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[224, 224], [18, 18], [256, 256], [10, 10]], "char_spans": [[1174, 1176], [104, 106], [1382, 1384], [64, 66]]}]}], "context_tokens": [["More", 0], ["than", 5], ["500", 10], ["unrelated", 14], ["patients", 24], ["with", 33], ["neurofibromatosis", 38], ["type", 56], ["1", 61], ["(", 63], ["NF1", 64], [")", 67], ["were", 69], ["screened", 74], ["for", 83], ["mutations", 87], ["in", 97], ["the", 100], ["NF1", 104], ["gene", 108], [".", 112], ["For", 114], ["each", 118], ["patient", 123], [",", 130], ["the", 132], ["whole", 136], ["coding", 142], ["sequence", 149], ["and", 158], ["all", 162], ["splice", 166], ["sites", 173], ["were", 179], ["studied", 184], ["for", 192], ["aberrations", 196], [",", 207], ["either", 209], ["by", 216], ["the", 219], ["protein", 223], ["truncation", 231], ["test", 242], ["(", 247], ["PTT", 248], [")", 251], [",", 252], ["temperature", 254], ["-", 265], ["gradient", 266], ["gel", 275], ["electrophoresis", 279], ["(", 295], ["TGGE", 296], [")", 300], ["of", 302], ["genomic", 305], ["PCR", 313], ["products", 317], [",", 325], ["or", 327], [",", 329], ["most", 331], ["often", 336], [",", 341], ["by", 343], ["direct", 346], ["genomic", 353], ["sequencing", 361], ["(", 372], ["DGS", 373], [")", 376], ["of", 378], ["all", 381], ["individual", 385], ["exons", 396], [".", 401], ["A", 403], ["total", 405], ["of", 411], ["301", 414], ["sequence", 418], ["variants", 427], [",", 435], ["including", 437], ["278", 447], ["bona", 451], ["fide", 456], ["pathogenic", 461], ["mutations", 472], [",", 481], ["were", 483], ["identified", 488], [".", 498], ["As", 500], ["many", 503], ["as", 508], ["216", 511], ["or", 515], ["183", 518], ["of", 522], ["the", 525], ["genuine", 529], ["mutations", 537], [",", 546], ["comprising", 548], ["179", 559], ["or", 563], ["161", 566], ["different", 570], ["ones", 580], [",", 584], ["can", 586], ["be", 590], ["considered", 593], ["novel", 604], ["when", 610], ["compared", 615], ["to", 624], ["the", 627], ["recent", 631], ["findings", 638], ["of", 647], ["Upadhyaya", 650], ["and", 660], ["Cooper", 664], [",", 670], ["or", 672], ["to", 675], ["the", 678], ["NNFF", 682], ["mutation", 687], ["database", 696], [".", 704], ["Mutation", 706], ["-", 714], ["detection", 715], ["efficiencies", 725], ["of", 738], ["the", 741], ["various", 745], ["screening", 753], ["methods", 763], ["were", 771], ["similar", 776], [":", 783], ["47.1", 785], ["%", 789], ["for", 791], ["PTT", 795], [",", 798], ["53.7", 800], ["%", 804], ["for", 806], ["TGGE", 810], [",", 814], ["and", 816], ["54.9", 820], ["%", 824], ["for", 826], ["DGS", 830], [".", 833], ["Some", 835], ["224", 840], ["mutations", 844], ["(", 854], ["80.2", 855], ["%", 859], [")", 860], ["yielded", 862], ["directly", 870], ["or", 879], ["indirectly", 882], ["premature", 893], ["termination", 903], ["codons", 915], [".", 921], ["These", 923], ["mutations", 929], ["showed", 939], ["even", 946], ["distribution", 951], ["over", 964], ["the", 969], ["whole", 973], ["gene", 979], ["from", 984], ["exon", 989], ["1", 994], ["to", 996], ["exon", 999], ["47", 1004], [".", 1006], ["Of", 1008], ["all", 1011], ["sequence", 1015], ["variants", 1024], ["determined", 1033], ["in", 1044], ["our", 1047], ["study", 1051], [",", 1056], ["<", 1058], ["20", 1059], ["%", 1061], ["represent", 1063], ["C-->T", 1073], ["or", 1079], ["G-->A", 1082], ["transitions", 1088], ["within", 1100], ["a", 1107], ["CpG", 1109], ["dinucleotide", 1113], [",", 1125], ["and", 1127], ["only", 1131], ["six", 1136], ["different", 1140], ["mutations", 1150], ["also", 1160], ["occur", 1165], ["in", 1171], ["NF1", 1174], ["pseudogenes", 1178], [",", 1189], ["with", 1191], ["five", 1196], ["being", 1201], ["typical", 1207], ["C-->T", 1215], ["transitions", 1221], ["in", 1233], ["a", 1236], ["CpG.", 1238], ["Thus", 1243], [",", 1247], ["neither", 1249], ["frequent", 1257], ["deamination", 1266], ["of", 1278], ["5-methylcytosines", 1281], ["nor", 1299], ["interchromosomal", 1303], ["gene", 1320], ["conversion", 1325], ["may", 1336], ["account", 1340], ["for", 1348], ["the", 1352], ["high", 1356], ["mutation", 1361], ["rate", 1370], ["of", 1375], ["the", 1378], ["NF1", 1382], ["gene", 1386], [".", 1390], ["As", 1392], ["opposed", 1395], ["to", 1403], ["the", 1406], ["truncating", 1410], ["mutations", 1421], [",", 1430], ["the", 1432], ["28", 1436], ["(", 1439], ["10.1", 1440], ["%", 1444], [")", 1445], ["missense", 1447], ["or", 1456], ["single", 1459], ["-", 1465], ["amino", 1466], ["-", 1471], ["acid", 1472], ["-", 1476], ["deletion", 1477], ["mutations", 1486], ["identified", 1496], ["clustered", 1507], ["in", 1517], ["two", 1520], ["distinct", 1524], ["regions", 1533], [",", 1540], ["the", 1542], ["GAP", 1546], ["-", 1549], ["related", 1550], ["domain", 1558], ["(", 1565], ["GRD", 1566], [")", 1569], ["and", 1571], ["an", 1575], ["upstream", 1578], ["gene", 1587], ["segment", 1592], ["comprising", 1600], ["exons", 1611], ["11", 1617], ["-", 1619], ["17", 1620], [".", 1622], ["The", 1624], ["latter", 1628], ["forms", 1635], ["a", 1641], ["so", 1643], ["-", 1645], ["called", 1646], ["cysteine", 1653], ["/", 1661], ["serine", 1662], ["-", 1668], ["rich", 1669], ["domain", 1674], ["with", 1681], ["three", 1686], ["cysteine", 1692], ["pairs", 1701], ["suggestive", 1707], ["of", 1718], ["ATP", 1721], ["binding", 1725], [",", 1732], ["as", 1734], ["well", 1737], ["as", 1742], ["three", 1745], ["potential", 1751], ["cAMP", 1761], ["-", 1765], ["dependent", 1766], ["protein", 1776], ["kinase", 1784], ["(", 1791], ["PKA", 1792], [")", 1795], ["recognition", 1797], ["sites", 1809], ["obviously", 1815], ["phosphorylated", 1825], ["by", 1840], ["PKA", 1843], [".", 1846], ["Coincidence", 1848], ["of", 1860], ["mutated", 1863], ["amino", 1871], ["acids", 1877], ["and", 1883], ["those", 1887], ["conserved", 1893], ["between", 1903], ["human", 1911], ["and", 1917], ["Drosophila", 1921], ["strongly", 1932], ["suggest", 1941], ["significant", 1949], ["functional", 1961], ["relevance", 1972], ["of", 1982], ["this", 1985], ["region", 1990], [",", 1996], ["with", 1998], ["major", 2003], ["roles", 2009], ["played", 2015], ["by", 2022], ["exons", 2025], ["12a", 2031], ["and", 2035], ["15", 2039], ["and", 2042], ["part", 2046], ["of", 2051], ["exon", 2054], ["16", 2059], [".", 2061]]}
{"context": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "8031bea26fff4e0ca71ad6c3b3448396", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [140, 140], [23, 23], [9, 9], [50, 50], [193, 193], [81, 81]], "char_spans": [[405, 414], [903, 912], [164, 173], [72, 81], [338, 347], [1219, 1228], [550, 559]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["specifically", 47], ["targeted", 60], ["to", 69], ["dabigatran", 72], [".", 82], ["It", 84], ["has", 87], ["demonstrated", 91], ["prompt", 104], ["and", 111], ["durable", 115], ["reversal", 123], ["of", 132], ["the", 135], ["anticoagulant", 139], ["effects", 153], ["of", 161], ["dabigatran", 164], ["in", 175], ["animal", 178], ["studies", 185], ["and", 193], ["phase", 197], ["1", 203], ["studies", 205], ["of", 213], ["young", 216], [",", 221], ["elderly", 223], [",", 230], ["and", 232], ["renally", 236], ["impaired", 244], ["volunteers", 253], [".", 263], ["Although", 265], ["elective", 274], ["invasive", 283], ["procedures", 292], ["and", 303], ["most", 307], ["bleeding", 312], ["complications", 321], ["in", 335], ["dabigatran", 338], ["-", 348], ["treated", 349], ["patients", 357], ["can", 366], ["be", 370], ["managed", 373], ["by", 381], ["temporarily", 384], ["stopping", 396], ["dabigatran", 405], ["therapy", 416], ["and", 424], ["using", 428], ["supportive", 434], ["measures", 445], [",", 453], ["there", 455], ["are", 461], ["rare", 465], ["clinical", 470], ["situations", 479], ["that", 490], ["require", 495], ["urgent", 503], ["reversal", 510], ["of", 519], ["the", 522], ["anticoagulant", 526], ["effect", 540], ["of", 547], ["dabigatran", 550], [".", 560], ["The", 562], ["effectiveness", 566], ["and", 580], ["safety", 584], ["of", 591], ["5", 594], ["g", 596], ["of", 598], ["intravenous", 601], ["idarucizumab", 613], ["is", 626], ["being", 629], ["investigated", 635], ["in", 648], ["a", 651], ["prospective", 653], [",", 664], ["open", 666], ["-", 670], ["label", 671], [",", 676], ["single", 678], ["-", 684], ["cohort", 685], ["study", 692], ["in", 698], ["patients", 701], ["with", 710], ["serious", 715], ["bleeding", 723], ["or", 732], ["in", 735], ["those", 738], ["requiring", 744], ["an", 754], ["urgent", 757], ["procedure", 764], [".", 773], ["In", 775], ["an", 778], ["interim", 781], ["analysis", 789], ["of", 798], ["the", 801], ["first", 805], ["90", 811], ["participants", 814], [",", 826], ["idarucizumab", 828], ["rapidly", 841], ["and", 849], ["completely", 853], ["reversed", 864], ["the", 873], ["anticoagulant", 877], ["activity", 891], ["of", 900], ["dabigatran", 903], ["in", 914], ["88%-98", 917], ["%", 923], ["of", 925], ["participants", 928], [",", 940], ["and", 942], ["there", 946], ["were", 952], ["no", 957], ["safety", 960], ["concerns", 967], [",", 975], ["with", 977], ["no", 982], ["deaths", 985], ["or", 992], ["serious", 995], ["adverse", 1003], ["events", 1011], ["being", 1018], ["attributable", 1024], ["to", 1037], ["idarucizumab", 1040], [".", 1052], ["Supported", 1054], ["by", 1064], ["these", 1067], ["interim", 1073], ["results", 1081], [",", 1088], ["idarucizumab", 1090], ["has", 1103], ["been", 1107], ["approved", 1112], ["in", 1121], ["the", 1124], ["United", 1128], ["States", 1135], ["and", 1142], ["the", 1146], ["European", 1150], ["Union", 1159], ["for", 1165], ["use", 1169], ["when", 1173], ["reversal", 1178], ["of", 1187], ["the", 1190], ["anticoagulant", 1194], ["effects", 1208], ["of", 1216], ["dabigatran", 1219], ["is", 1230], ["needed", 1233], ["for", 1240], ["emergency", 1244], ["surgery", 1254], ["/", 1261], ["urgent", 1262], ["procedures", 1269], ["or", 1280], ["in", 1283], ["patients", 1286], ["with", 1295], ["life", 1300], ["-", 1304], ["threatening", 1305], ["or", 1317], ["uncontrolled", 1320], ["bleeding", 1333], [".", 1341], ["Clinical", 1343], ["use", 1352], ["of", 1356], ["idarucizumab", 1359], ["should", 1372], ["follow", 1379], ["the", 1386], ["same", 1390], ["processes", 1395], ["as", 1405], ["patient", 1408], ["enrollment", 1416], ["in", 1427], ["this", 1430], ["study", 1435], [",", 1440], ["which", 1442], ["is", 1448], ["projected", 1451], ["to", 1461], ["be", 1464], ["completed", 1467], ["in", 1477], ["2016", 1480], [".", 1484], ["The", 1486], ["outcomes", 1490], ["achieved", 1499], ["with", 1508], ["this", 1513], ["specific", 1518], ["reversal", 1527], ["agent", 1536], ["are", 1542], ["likely", 1546], ["to", 1553], ["be", 1556], ["of", 1559], ["continued", 1562], ["interest", 1572], ["to", 1581], ["treating", 1584], ["physicians", 1593], [".", 1603]]}
{"context": "Spleen tyrosine kinase (SYK) has come into focus as a potential therapeutic target in chronic inflammatory diseases, such as rheumatoid arthritis and asthma, as well as in B-cell lymphomas. SYK has also been involved in the signaling of immunoreceptors, cytokine receptors, and integrins. We therefore hypothesized that inhibition of SYK attenuates the inflammatory process underlying atherosclerosis and reduces plaque development. Low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with 2 doses of the orally available SYK inhibitor fostamatinib for 16 weeks showed a dose-dependent reduction in atherosclerotic lesion size by up to 59\u00b16% compared with the respective controls. Lesions of fostamatinib-treated animals contained fewer macrophages but more smooth muscle cells and collagen-characteristics associated with more stable plaques in humans. Mechanistically, fostamatinib attenuated adhesion and migration of inflammatory cells and limited macrophage survival. Furthermore, fostamatinib normalized high-cholesterol diet -induced monocytosis and inflammatory gene expression. We present the novel finding that the SYK inhibitor fostamatinib attenuates atherogenesis in mice. Our data identify SYK inhibition as a potentially fruitful antiinflammatory therapeutic strategy in atherosclerosis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "89a7ef2839a844569cd9d4d936eba6c3", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["SYK", 24], [")", 27], ["has", 29], ["come", 33], ["into", 38], ["focus", 43], ["as", 49], ["a", 52], ["potential", 54], ["therapeutic", 64], ["target", 76], ["in", 83], ["chronic", 86], ["inflammatory", 94], ["diseases", 107], [",", 115], ["such", 117], ["as", 122], ["rheumatoid", 125], ["arthritis", 136], ["and", 146], ["asthma", 150], [",", 156], ["as", 158], ["well", 161], ["as", 166], ["in", 169], ["B", 172], ["-", 173], ["cell", 174], ["lymphomas", 179], [".", 188], ["SYK", 190], ["has", 194], ["also", 198], ["been", 203], ["involved", 208], ["in", 217], ["the", 220], ["signaling", 224], ["of", 234], ["immunoreceptors", 237], [",", 252], ["cytokine", 254], ["receptors", 263], [",", 272], ["and", 274], ["integrins", 278], [".", 287], ["We", 289], ["therefore", 292], ["hypothesized", 302], ["that", 315], ["inhibition", 320], ["of", 331], ["SYK", 334], ["attenuates", 338], ["the", 349], ["inflammatory", 353], ["process", 366], ["underlying", 374], ["atherosclerosis", 385], ["and", 401], ["reduces", 405], ["plaque", 413], ["development", 420], [".", 431], ["Low", 433], ["-", 436], ["density", 437], ["lipoprotein", 445], ["receptor", 457], ["-", 465], ["deficient", 466], ["mice", 476], ["consuming", 481], ["a", 491], ["high", 493], ["-", 497], ["cholesterol", 498], ["diet", 510], ["supplemented", 515], ["with", 528], ["2", 533], ["doses", 535], ["of", 541], ["the", 544], ["orally", 548], ["available", 555], ["SYK", 565], ["inhibitor", 569], ["fostamatinib", 579], ["for", 592], ["16", 596], ["weeks", 599], ["showed", 605], ["a", 612], ["dose", 614], ["-", 618], ["dependent", 619], ["reduction", 629], ["in", 639], ["atherosclerotic", 642], ["lesion", 658], ["size", 665], ["by", 670], ["up", 673], ["to", 676], ["59\u00b16", 679], ["%", 683], ["compared", 685], ["with", 694], ["the", 699], ["respective", 703], ["controls", 714], [".", 722], ["Lesions", 724], ["of", 732], ["fostamatinib", 735], ["-", 747], ["treated", 748], ["animals", 756], ["contained", 764], ["fewer", 774], ["macrophages", 780], ["but", 792], ["more", 796], ["smooth", 801], ["muscle", 808], ["cells", 815], ["and", 821], ["collagen", 825], ["-", 833], ["characteristics", 834], ["associated", 850], ["with", 861], ["more", 866], ["stable", 871], ["plaques", 878], ["in", 886], ["humans", 889], [".", 895], ["Mechanistically", 897], [",", 912], ["fostamatinib", 914], ["attenuated", 927], ["adhesion", 938], ["and", 947], ["migration", 951], ["of", 961], ["inflammatory", 964], ["cells", 977], ["and", 983], ["limited", 987], ["macrophage", 995], ["survival", 1006], [".", 1014], ["Furthermore", 1016], [",", 1027], ["fostamatinib", 1029], ["normalized", 1042], ["high", 1053], ["-", 1057], ["cholesterol", 1058], ["diet", 1070], ["-induced", 1075], ["monocytosis", 1084], ["and", 1096], ["inflammatory", 1100], ["gene", 1113], ["expression", 1118], [".", 1128], ["We", 1130], ["present", 1133], ["the", 1141], ["novel", 1145], ["finding", 1151], ["that", 1159], ["the", 1164], ["SYK", 1168], ["inhibitor", 1172], ["fostamatinib", 1182], ["attenuates", 1195], ["atherogenesis", 1206], ["in", 1220], ["mice", 1223], [".", 1227], ["Our", 1229], ["data", 1233], ["identify", 1238], ["SYK", 1247], ["inhibition", 1251], ["as", 1262], ["a", 1265], ["potentially", 1267], ["fruitful", 1279], ["antiinflammatory", 1288], ["therapeutic", 1305], ["strategy", 1317], ["in", 1326], ["atherosclerosis", 1329], [".", 1344]]}
{"context": "Fibrillar \u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. Mouse AS (mAS) aggregates much faster than human AS (hAS), although mAS differs from hAS at only seven positions in its primary sequence. Currently, little is known about the site-specific structural differences between mAS and hAS fibrils. Here, we applied state-of-the-art solid-state nuclear magnetic resonance (ssNMR) methods to structurally characterize mAS fibrils. The assignment strategy employed a set of high-resolution 2D and 3D ssNMR spectra recorded on uniformly [(13)C, (15)N], [1-(13)C]glucose, and [2-(13)C]glucose labeled mAS fibrils. An almost complete resonance assignment (96% of backbone amide (15)N and 93% of all (13)C nuclei) was obtained for residues from Gly41 to Val95, which form the core of mAS fibrils. Six \u03b2-strands were identified to be within the fibril core of mAS based on a secondary chemical shift and NHHC analysis. Intermolecular (13)C:(15)N labeled restraints obtained from mixed 1:1 (13)C/(15)N-labeled mAS fibrils reveal a parallel, in-register supramolecular \u03b2-sheet arrangement. The results were compared in detail to recent structural studies on hAS fibrils and indicate the presence of a structurally conserved motif comprising residues Glu61-Lys80.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "0a1c02809201488c903f97ee1cd9280f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["AS", 23], [")", 25], ["is", 27], ["the", 30], ["major", 34], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["disease", 107], [".", 114], ["Mouse", 116], ["AS", 122], ["(", 125], ["mAS", 126], [")", 129], ["aggregates", 131], ["much", 142], ["faster", 147], ["than", 154], ["human", 159], ["AS", 165], ["(", 168], ["hAS", 169], [")", 172], [",", 173], ["although", 175], ["mAS", 184], ["differs", 188], ["from", 196], ["hAS", 201], ["at", 205], ["only", 208], ["seven", 213], ["positions", 219], ["in", 229], ["its", 232], ["primary", 236], ["sequence", 244], [".", 252], ["Currently", 254], [",", 263], ["little", 265], ["is", 272], ["known", 275], ["about", 281], ["the", 287], ["site", 291], ["-", 295], ["specific", 296], ["structural", 305], ["differences", 316], ["between", 328], ["mAS", 336], ["and", 340], ["hAS", 344], ["fibrils", 348], [".", 355], ["Here", 357], [",", 361], ["we", 363], ["applied", 366], ["state", 374], ["-", 379], ["of", 380], ["-", 382], ["the", 383], ["-", 386], ["art", 387], ["solid", 391], ["-", 396], ["state", 397], ["nuclear", 403], ["magnetic", 411], ["resonance", 420], ["(", 430], ["ssNMR", 431], [")", 436], ["methods", 438], ["to", 446], ["structurally", 449], ["characterize", 462], ["mAS", 475], ["fibrils", 479], [".", 486], ["The", 488], ["assignment", 492], ["strategy", 503], ["employed", 512], ["a", 521], ["set", 523], ["of", 527], ["high", 530], ["-", 534], ["resolution", 535], ["2D", 546], ["and", 549], ["3D", 553], ["ssNMR", 556], ["spectra", 562], ["recorded", 570], ["on", 579], ["uniformly", 582], ["[", 592], ["(", 593], ["13)C", 594], [",", 598], ["(", 600], ["15)N", 601], ["]", 605], [",", 606], ["[", 608], ["1-(13)C]glucose", 609], [",", 624], ["and", 626], ["[", 630], ["2-(13)C]glucose", 631], ["labeled", 647], ["mAS", 655], ["fibrils", 659], [".", 666], ["An", 668], ["almost", 671], ["complete", 678], ["resonance", 687], ["assignment", 697], ["(", 708], ["96", 709], ["%", 711], ["of", 713], ["backbone", 716], ["amide", 725], ["(", 731], ["15)N", 732], ["and", 737], ["93", 741], ["%", 743], ["of", 745], ["all", 748], ["(", 752], ["13)C", 753], ["nuclei", 758], [")", 764], ["was", 766], ["obtained", 770], ["for", 779], ["residues", 783], ["from", 792], ["Gly41", 797], ["to", 803], ["Val95", 806], [",", 811], ["which", 813], ["form", 819], ["the", 824], ["core", 828], ["of", 833], ["mAS", 836], ["fibrils", 840], [".", 847], ["Six", 849], ["\u03b2", 853], ["-", 854], ["strands", 855], ["were", 863], ["identified", 868], ["to", 879], ["be", 882], ["within", 885], ["the", 892], ["fibril", 896], ["core", 903], ["of", 908], ["mAS", 911], ["based", 915], ["on", 921], ["a", 924], ["secondary", 926], ["chemical", 936], ["shift", 945], ["and", 951], ["NHHC", 955], ["analysis", 960], [".", 968], ["Intermolecular", 970], ["(", 985], ["13)C:(15)N", 986], ["labeled", 997], ["restraints", 1005], ["obtained", 1016], ["from", 1025], ["mixed", 1030], ["1:1", 1036], ["(", 1040], ["13)C/(15)N", 1041], ["-", 1051], ["labeled", 1052], ["mAS", 1060], ["fibrils", 1064], ["reveal", 1072], ["a", 1079], ["parallel", 1081], [",", 1089], ["in", 1091], ["-", 1093], ["register", 1094], ["supramolecular", 1103], ["\u03b2", 1118], ["-", 1119], ["sheet", 1120], ["arrangement", 1126], [".", 1137], ["The", 1139], ["results", 1143], ["were", 1151], ["compared", 1156], ["in", 1165], ["detail", 1168], ["to", 1175], ["recent", 1178], ["structural", 1185], ["studies", 1196], ["on", 1204], ["hAS", 1207], ["fibrils", 1211], ["and", 1219], ["indicate", 1223], ["the", 1232], ["presence", 1236], ["of", 1245], ["a", 1248], ["structurally", 1250], ["conserved", 1263], ["motif", 1273], ["comprising", 1279], ["residues", 1290], ["Glu61-Lys80", 1299], [".", 1310]]}
{"context": "Nucleotide excision repair (NER) is a remarkably versatile DNA repair system, essential for maintenance of genomic stability. Hereditary alterations in NER enzymes can result in increased cancer propensity, but also in developmental, neurodegenerative, and progeroid syndromes. NER can be operationally divided in three subtypes, which share many common steps: global genomic repair (GGR) operates on the whole genome level, transcription domain-associated repair (DAR) is a concentration of NER activity within transcription factories, and transcription-coupled repair (TCR) provides faster repair of the transcribed strand of active genes. Interestingly, ubiquitination plays an important role in all three classes of NER, as well as in associated phenomena, such as damage signalling by histone ubiquitination, and degradation of stalled RNA polymerase II when repair does not occur in a timely manner.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eac37c9c5ffd4618bcc7270e473097f6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[606, 623]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["remarkably", 38], ["versatile", 49], ["DNA", 59], ["repair", 63], ["system", 70], [",", 76], ["essential", 78], ["for", 88], ["maintenance", 92], ["of", 104], ["genomic", 107], ["stability", 115], [".", 124], ["Hereditary", 126], ["alterations", 137], ["in", 149], ["NER", 152], ["enzymes", 156], ["can", 164], ["result", 168], ["in", 175], ["increased", 178], ["cancer", 188], ["propensity", 195], [",", 205], ["but", 207], ["also", 211], ["in", 216], ["developmental", 219], [",", 232], ["neurodegenerative", 234], [",", 251], ["and", 253], ["progeroid", 257], ["syndromes", 267], [".", 276], ["NER", 278], ["can", 282], ["be", 286], ["operationally", 289], ["divided", 303], ["in", 311], ["three", 314], ["subtypes", 320], [",", 328], ["which", 330], ["share", 336], ["many", 342], ["common", 347], ["steps", 354], [":", 359], ["global", 361], ["genomic", 368], ["repair", 376], ["(", 383], ["GGR", 384], [")", 387], ["operates", 389], ["on", 398], ["the", 401], ["whole", 405], ["genome", 411], ["level", 418], [",", 423], ["transcription", 425], ["domain", 439], ["-", 445], ["associated", 446], ["repair", 457], ["(", 464], ["DAR", 465], [")", 468], ["is", 470], ["a", 473], ["concentration", 475], ["of", 489], ["NER", 492], ["activity", 496], ["within", 505], ["transcription", 512], ["factories", 526], [",", 535], ["and", 537], ["transcription", 541], ["-", 554], ["coupled", 555], ["repair", 563], ["(", 570], ["TCR", 571], [")", 574], ["provides", 576], ["faster", 585], ["repair", 592], ["of", 599], ["the", 602], ["transcribed", 606], ["strand", 618], ["of", 625], ["active", 628], ["genes", 635], [".", 640], ["Interestingly", 642], [",", 655], ["ubiquitination", 657], ["plays", 672], ["an", 678], ["important", 681], ["role", 691], ["in", 696], ["all", 699], ["three", 703], ["classes", 709], ["of", 717], ["NER", 720], [",", 723], ["as", 725], ["well", 728], ["as", 733], ["in", 736], ["associated", 739], ["phenomena", 750], [",", 759], ["such", 761], ["as", 766], ["damage", 769], ["signalling", 776], ["by", 787], ["histone", 790], ["ubiquitination", 798], [",", 812], ["and", 814], ["degradation", 818], ["of", 830], ["stalled", 833], ["RNA", 841], ["polymerase", 845], ["II", 856], ["when", 859], ["repair", 864], ["does", 871], ["not", 876], ["occur", 880], ["in", 886], ["a", 889], ["timely", 891], ["manner", 898], [".", 904]]}
{"context": "Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to use this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy, we interrogated CLL membrane-specific autologous immunoglobulin G reactivity. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "692ffa1dbcd344f7b86b7f0d61e5403f", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[188, 188]], "char_spans": [[1168, 1176]]}]}], "context_tokens": [["Membrane", 0], ["antigens", 9], ["are", 18], ["critical", 22], ["to", 31], ["the", 34], ["pathogenesis", 38], ["of", 51], ["chronic", 54], ["lymphocytic", 62], ["leukemia", 74], ["(", 83], ["CLL", 84], [")", 87], ["as", 89], ["they", 92], ["facilitate", 97], ["microenvironment", 108], ["homing", 125], [",", 131], ["proliferation", 133], [",", 146], ["and", 148], ["survival", 152], [".", 160], ["Targeting", 162], ["the", 172], ["CLL", 176], ["membrane", 180], ["and", 189], ["associated", 193], ["signaling", 204], ["patterns", 214], ["is", 223], ["a", 226], ["current", 228], ["focus", 236], ["of", 242], ["therapeutic", 245], ["development", 257], [".", 268], ["Many", 270], ["tumor", 275], ["membrane", 281], ["targets", 290], ["are", 298], ["simultaneously", 302], ["targeted", 317], ["by", 326], ["humoral", 329], ["immunity", 337], [",", 345], ["thus", 347], ["forming", 352], ["recognizable", 360], ["immunoglobulin", 373], ["responses", 388], [".", 397], ["We", 399], ["sought", 402], ["to", 409], ["use", 412], ["this", 416], ["immune", 421], ["response", 428], ["to", 437], ["identify", 440], ["novel", 449], ["membrane", 455], ["-", 463], ["associated", 464], ["targets", 475], ["for", 483], ["CLL", 487], [".", 490], ["Using", 492], ["a", 498], ["novel", 500], ["strategy", 506], [",", 514], ["we", 516], ["interrogated", 519], ["CLL", 532], ["membrane", 536], ["-", 544], ["specific", 545], ["autologous", 554], ["immunoglobulin", 565], ["G", 580], ["reactivity", 582], [".", 592], ["Our", 594], ["analysis", 598], ["unveiled", 607], ["lymphocyte", 616], ["cytosolic", 627], ["protein", 637], ["1", 645], ["(", 647], ["LCP1", 648], [")", 652], [",", 653], ["a", 655], ["lymphocyte", 657], ["-", 667], ["specific", 668], ["target", 677], ["that", 684], ["is", 689], ["highly", 692], ["expressed", 699], ["in", 709], ["CLL", 712], [".", 715], ["LCP1", 717], ["plays", 722], ["a", 728], ["critical", 730], ["role", 739], ["in", 744], ["B", 747], ["-", 748], ["cell", 749], ["biology", 754], ["by", 762], ["crosslinking", 765], ["F", 778], ["-", 779], ["actin", 780], ["filaments", 786], [",", 795], ["thereby", 797], ["solidifying", 805], ["cytoskeletal", 817], ["structures", 830], ["and", 841], ["providing", 845], ["a", 855], ["scaffold", 857], ["for", 866], ["critical", 870], ["signaling", 879], ["pathways", 889], [".", 897], ["Small", 899], ["interfering", 905], ["RNA", 917], ["knockdown", 921], ["of", 931], ["LCP1", 934], ["blocked", 939], ["migration", 947], ["toward", 957], ["CXCL12", 964], ["in", 971], ["transwell", 974], ["assays", 984], ["and", 991], ["to", 995], ["bone", 998], ["marrow", 1003], ["in", 1010], ["an", 1013], ["in", 1016], ["vivo", 1019], ["xenotransplant", 1024], ["model", 1039], [",", 1044], ["confirming", 1046], ["a", 1057], ["role", 1059], ["for", 1064], ["LCP1", 1068], ["in", 1073], ["leukemia", 1076], ["migration", 1085], [".", 1094], ["Furthermore", 1096], [",", 1107], ["we", 1109], ["demonstrate", 1112], ["that", 1124], ["the", 1129], ["Bruton", 1133], ["'s", 1139], ["tyrosine", 1142], ["kinase", 1151], ["inhibitor", 1158], ["ibrutinib", 1168], ["or", 1178], ["the", 1181], ["PI3", 1185], ["K", 1188], ["inhibitor", 1190], ["idelalisib", 1200], ["block", 1211], ["B", 1217], ["-", 1218], ["cell", 1219], ["receptor", 1224], ["induced", 1233], ["activation", 1241], ["of", 1252], ["LCP1", 1255], [".", 1259], ["Our", 1261], ["data", 1265], ["demonstrate", 1270], ["a", 1282], ["novel", 1284], ["strategy", 1290], ["to", 1299], ["identify", 1302], ["cancer", 1311], ["membrane", 1318], ["target", 1327], ["antigens", 1334], ["using", 1343], ["humoral", 1349], ["anti", 1357], ["-", 1361], ["tumor", 1362], ["immunity", 1368], [".", 1376], ["In", 1378], ["addition", 1381], [",", 1389], ["we", 1391], ["identify", 1394], ["LCP1", 1403], ["as", 1408], ["a", 1411], ["membrane", 1413], ["-", 1421], ["associated", 1422], ["target", 1433], ["in", 1440], ["CLL", 1443], ["with", 1447], ["confirmed", 1452], ["pathogenic", 1462], ["significance", 1473], [".", 1485], ["This", 1487], ["clinical", 1492], ["trial", 1501], ["was", 1507], ["registered", 1511], ["at", 1522], ["clinicaltrials.gov", 1525], [";", 1543], ["study", 1545], ["ID", 1551], ["number", 1554], [":", 1560], ["OSU-0025", 1562], ["OSU-0156", 1571], [".", 1579]]}
{"context": "The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K antagonists is the lack of the need for monitoring and dose adjustment. Their main disadvantage is currently the absence of a specific reversal agent. Dabigatran's, unlike the anti-Xa agents, absorption can be reduced by activated charcoal if administered shortly after ingestion and it can be removed from the blood with hemodialysis. Prothrombin complex concentrate, activated prothrombin complex concentrate, and recombinant factor VIIa all show some activity in reversing the anticoagulant effect of these drugs but this is based on ex vivo, animal, and volunteer studies. It is unclear, which, if any, of these drugs is the most suitable for emergency reversal. Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal. These agents are currently in premarketing studies.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "8dfe7776209f42c6b08aeb043f1ac872", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[4, 4], [57, 57]], "char_spans": [[30, 39], [331, 340]]}]}], "context_tokens": [["The", 0], ["direct", 4], ["thrombin", 11], ["inhibitor", 20], ["dabigatran", 30], ["and", 41], ["the", 45], ["anti", 49], ["-", 53], ["Xa", 54], ["agents", 57], ["rivaroxaban", 64], [",", 75], ["edoxaban", 77], [",", 85], ["and", 87], ["apixaban", 91], ["are", 100], ["a", 104], ["new", 106], ["generation", 110], ["of", 121], ["oral", 124], ["anticoagulants", 129], [".", 143], ["Their", 145], ["advantage", 151], ["over", 161], ["the", 166], ["vitamin", 170], ["K", 178], ["antagonists", 180], ["is", 192], ["the", 195], ["lack", 199], ["of", 204], ["the", 207], ["need", 211], ["for", 216], ["monitoring", 220], ["and", 231], ["dose", 235], ["adjustment", 240], [".", 250], ["Their", 252], ["main", 258], ["disadvantage", 263], ["is", 276], ["currently", 279], ["the", 289], ["absence", 293], ["of", 301], ["a", 304], ["specific", 306], ["reversal", 315], ["agent", 324], [".", 329], ["Dabigatran", 331], ["'s", 341], [",", 343], ["unlike", 345], ["the", 352], ["anti", 356], ["-", 360], ["Xa", 361], ["agents", 364], [",", 370], ["absorption", 372], ["can", 383], ["be", 387], ["reduced", 390], ["by", 398], ["activated", 401], ["charcoal", 411], ["if", 420], ["administered", 423], ["shortly", 436], ["after", 444], ["ingestion", 450], ["and", 460], ["it", 464], ["can", 467], ["be", 471], ["removed", 474], ["from", 482], ["the", 487], ["blood", 491], ["with", 497], ["hemodialysis", 502], [".", 514], ["Prothrombin", 516], ["complex", 528], ["concentrate", 536], [",", 547], ["activated", 549], ["prothrombin", 559], ["complex", 571], ["concentrate", 579], [",", 590], ["and", 592], ["recombinant", 596], ["factor", 608], ["VIIa", 615], ["all", 620], ["show", 624], ["some", 629], ["activity", 634], ["in", 643], ["reversing", 646], ["the", 656], ["anticoagulant", 660], ["effect", 674], ["of", 681], ["these", 684], ["drugs", 690], ["but", 696], ["this", 700], ["is", 705], ["based", 708], ["on", 714], ["ex", 717], ["vivo", 720], [",", 724], ["animal", 726], [",", 732], ["and", 734], ["volunteer", 738], ["studies", 748], [".", 755], ["It", 757], ["is", 760], ["unclear", 763], [",", 770], ["which", 772], [",", 777], ["if", 779], ["any", 782], [",", 785], ["of", 787], ["these", 790], ["drugs", 796], ["is", 802], ["the", 805], ["most", 809], ["suitable", 814], ["for", 823], ["emergency", 827], ["reversal", 837], [".", 845], ["Three", 847], ["novel", 853], ["molecules", 859], ["(", 869], ["idarucizumab", 870], [",", 882], ["andexanet", 884], [",", 893], ["and", 895], ["PER977", 899], [")", 905], ["may", 907], ["provide", 911], ["the", 919], ["most", 923], ["effective", 928], ["and", 938], ["safest", 942], ["way", 949], ["of", 953], ["reversal", 956], [".", 964], ["These", 966], ["agents", 972], ["are", 979], ["currently", 983], ["in", 993], ["premarketing", 996], ["studies", 1009], [".", 1016]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is a common multidrug-resistant (MDR) pathogen. We herein discussed MRSA and its infections in Krasnoyarsk, Siberian Russia between 2007 and 2011. The incidence of MRSA in 3,662 subjects was 22.0% and 2.9% for healthcare- and community-associated MRSA (HA- and CA-MRSA), respectively. The 15-day mortality rates for MRSA hospital- and community-acquired pneumonia (HAP and CAP) were 6.5% and 50%, respectively. MRSA CAP cases included pediatric deaths; of the MRSA pneumonia episodes available, \u226527.3% were associated with bacteremia. Most cases of HA-MRSA examined exhibited ST239/spa3(t037)/SCCmecIII.1.1.2 (designated as ST239Kras), while all CA-MRSA cases examined were ST8/spa1(t008)/SCCmecIV.3.1.1(IVc) (designated as ST8Kras). ST239Kras and ST8Kras strongly expressed cytolytic peptide (phenol-soluble modulin \u03b1, PSM\u03b1; and \u03b4-hemolysin, Hld) genes, similar to CA-MRSA. ST239Kras pneumonia may have been attributed to a unique set of multiple virulence factors (MVFs): toxic shock syndrome toxin-1 (TSST-1), elevated PSM\u03b1/Hld expression, \u03b1-hemolysin, the staphylococcal enterotoxin SEK/SEQ, the immune evasion factor SCIN/SAK, and collagen adhesin. Regarding ST8Kras, SEA was included in MVFs, some of which were common to ST239Kras. The ST239Kras (strain OC3) genome contained: a completely unique phage, \u03c6Sa7-like (W), with no att repetition; S. aureus pathogenicity island SaPI2R, the first TSST-1 gene-positive (tst+) SaPI in the ST239 lineage; and a super copy of IS256 (\u226522 copies/genome). ST239Kras carried the Brazilian SCCmecIII.1.1.2 and United Kingdom-type tst. ST239Kras and ST8Kras were MDR, with the same levofloxacin resistance mutations; small, but transmissible chloramphenicol resistance plasmids spread widely enough to not be ignored. These results suggest that novel MDR and MVF+ HA- and CA-MRSA (ST239Kras and ST8Kras) emerged in Siberian Russia (Krasnoyarsk) associated with fatal pneumonia, and also with ST239Kras, a new (Siberian Russian) clade of the ST239 lineage, which was created through stepwise evolution during its potential transmission route of Brazil-Europe-Russia/Krasnoyarsk, thereby selective advantages from unique MVFs and the MDR.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b720f34ec0e14433b46b51f2661ed750", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[61, 61], [101, 101], [22, 22], [6, 6], [118, 118], [173, 173], [92, 92], [132, 132], [55, 55], [39, 39], [71, 71], [357, 357]], "char_spans": [[315, 318], [511, 514], [119, 122], [45, 48], [603, 606], [920, 923], [462, 465], [700, 703], [298, 301], [215, 218], [367, 370], [1868, 1871]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["a", 54], ["common", 56], ["multidrug", 63], ["-", 72], ["resistant", 73], ["(", 83], ["MDR", 84], [")", 87], ["pathogen", 89], [".", 97], ["We", 99], ["herein", 102], ["discussed", 109], ["MRSA", 119], ["and", 124], ["its", 128], ["infections", 132], ["in", 143], ["Krasnoyarsk", 146], [",", 157], ["Siberian", 159], ["Russia", 168], ["between", 175], ["2007", 183], ["and", 188], ["2011", 192], [".", 196], ["The", 198], ["incidence", 202], ["of", 212], ["MRSA", 215], ["in", 220], ["3,662", 223], ["subjects", 229], ["was", 238], ["22.0", 242], ["%", 246], ["and", 248], ["2.9", 252], ["%", 255], ["for", 257], ["healthcare-", 261], ["and", 273], ["community", 277], ["-", 286], ["associated", 287], ["MRSA", 298], ["(", 303], ["HA-", 304], ["and", 308], ["CA", 312], ["-", 314], ["MRSA", 315], [")", 319], [",", 320], ["respectively", 322], [".", 334], ["The", 336], ["15-day", 340], ["mortality", 347], ["rates", 357], ["for", 363], ["MRSA", 367], ["hospital-", 372], ["and", 382], ["community", 386], ["-", 395], ["acquired", 396], ["pneumonia", 405], ["(", 415], ["HAP", 416], ["and", 420], ["CAP", 424], [")", 427], ["were", 429], ["6.5", 434], ["%", 437], ["and", 439], ["50", 443], ["%", 445], [",", 446], ["respectively", 448], [".", 460], ["MRSA", 462], ["CAP", 467], ["cases", 471], ["included", 477], ["pediatric", 486], ["deaths", 496], [";", 502], ["of", 504], ["the", 507], ["MRSA", 511], ["pneumonia", 516], ["episodes", 526], ["available", 535], [",", 544], ["\u226527.3", 546], ["%", 551], ["were", 553], ["associated", 558], ["with", 569], ["bacteremia", 574], [".", 584], ["Most", 586], ["cases", 591], ["of", 597], ["HA", 600], ["-", 602], ["MRSA", 603], ["examined", 608], ["exhibited", 617], ["ST239/spa3(t037)/SCCmecIII.1.1.2", 627], ["(", 660], ["designated", 661], ["as", 672], ["ST239Kras", 675], [")", 684], [",", 685], ["while", 687], ["all", 693], ["CA", 697], ["-", 699], ["MRSA", 700], ["cases", 705], ["examined", 711], ["were", 720], ["ST8/spa1(t008)/SCCmecIV.3.1.1(IVc", 725], [")", 758], ["(", 760], ["designated", 761], ["as", 772], ["ST8Kras", 775], [")", 782], [".", 783], ["ST239Kras", 785], ["and", 795], ["ST8Kras", 799], ["strongly", 807], ["expressed", 816], ["cytolytic", 826], ["peptide", 836], ["(", 844], ["phenol", 845], ["-", 851], ["soluble", 852], ["modulin", 860], ["\u03b1", 868], [",", 869], ["PSM\u03b1", 871], [";", 875], ["and", 877], ["\u03b4", 881], ["-", 882], ["hemolysin", 883], [",", 892], ["Hld", 894], [")", 897], ["genes", 899], [",", 904], ["similar", 906], ["to", 914], ["CA", 917], ["-", 919], ["MRSA", 920], [".", 924], ["ST239Kras", 926], ["pneumonia", 936], ["may", 946], ["have", 950], ["been", 955], ["attributed", 960], ["to", 971], ["a", 974], ["unique", 976], ["set", 983], ["of", 987], ["multiple", 990], ["virulence", 999], ["factors", 1009], ["(", 1017], ["MVFs", 1018], [")", 1022], [":", 1023], ["toxic", 1025], ["shock", 1031], ["syndrome", 1037], ["toxin-1", 1046], ["(", 1054], ["TSST-1", 1055], [")", 1061], [",", 1062], ["elevated", 1064], ["PSM\u03b1", 1073], ["/", 1077], ["Hld", 1078], ["expression", 1082], [",", 1092], ["\u03b1", 1094], ["-", 1095], ["hemolysin", 1096], [",", 1105], ["the", 1107], ["staphylococcal", 1111], ["enterotoxin", 1126], ["SEK", 1138], ["/", 1141], ["SEQ", 1142], [",", 1145], ["the", 1147], ["immune", 1151], ["evasion", 1158], ["factor", 1166], ["SCIN", 1173], ["/", 1177], ["SAK", 1178], [",", 1181], ["and", 1183], ["collagen", 1187], ["adhesin", 1196], [".", 1203], ["Regarding", 1205], ["ST8Kras", 1215], [",", 1222], ["SEA", 1224], ["was", 1228], ["included", 1232], ["in", 1241], ["MVFs", 1244], [",", 1248], ["some", 1250], ["of", 1255], ["which", 1258], ["were", 1264], ["common", 1269], ["to", 1276], ["ST239Kras", 1279], [".", 1288], ["The", 1290], ["ST239Kras", 1294], ["(", 1304], ["strain", 1305], ["OC3", 1312], [")", 1315], ["genome", 1317], ["contained", 1324], [":", 1333], ["a", 1335], ["completely", 1337], ["unique", 1348], ["phage", 1355], [",", 1360], ["\u03c6Sa7-like", 1362], ["(", 1372], ["W", 1373], [")", 1374], [",", 1375], ["with", 1377], ["no", 1382], ["att", 1385], ["repetition", 1389], [";", 1399], ["S.", 1401], ["aureus", 1404], ["pathogenicity", 1411], ["island", 1425], ["SaPI2R", 1432], [",", 1438], ["the", 1440], ["first", 1444], ["TSST-1", 1450], ["gene", 1457], ["-", 1461], ["positive", 1462], ["(", 1471], ["tst+", 1472], [")", 1476], ["SaPI", 1478], ["in", 1483], ["the", 1486], ["ST239", 1490], ["lineage", 1496], [";", 1503], ["and", 1505], ["a", 1509], ["super", 1511], ["copy", 1517], ["of", 1522], ["IS256", 1525], ["(", 1531], ["\u226522", 1532], ["copies", 1536], ["/", 1542], ["genome", 1543], [")", 1549], [".", 1550], ["ST239Kras", 1552], ["carried", 1562], ["the", 1570], ["Brazilian", 1574], ["SCCmecIII.1.1.2", 1584], ["and", 1600], ["United", 1604], ["Kingdom", 1611], ["-", 1618], ["type", 1619], ["tst", 1624], [".", 1627], ["ST239Kras", 1629], ["and", 1639], ["ST8Kras", 1643], ["were", 1651], ["MDR", 1656], [",", 1659], ["with", 1661], ["the", 1666], ["same", 1670], ["levofloxacin", 1675], ["resistance", 1688], ["mutations", 1699], [";", 1708], ["small", 1710], [",", 1715], ["but", 1717], ["transmissible", 1721], ["chloramphenicol", 1735], ["resistance", 1751], ["plasmids", 1762], ["spread", 1771], ["widely", 1778], ["enough", 1785], ["to", 1792], ["not", 1795], ["be", 1799], ["ignored", 1802], [".", 1809], ["These", 1811], ["results", 1817], ["suggest", 1825], ["that", 1833], ["novel", 1838], ["MDR", 1844], ["and", 1848], ["MVF+", 1852], ["HA-", 1857], ["and", 1861], ["CA", 1865], ["-", 1867], ["MRSA", 1868], ["(", 1873], ["ST239Kras", 1874], ["and", 1884], ["ST8Kras", 1888], [")", 1895], ["emerged", 1897], ["in", 1905], ["Siberian", 1908], ["Russia", 1917], ["(", 1924], ["Krasnoyarsk", 1925], [")", 1936], ["associated", 1938], ["with", 1949], ["fatal", 1954], ["pneumonia", 1960], [",", 1969], ["and", 1971], ["also", 1975], ["with", 1980], ["ST239Kras", 1985], [",", 1994], ["a", 1996], ["new", 1998], ["(", 2002], ["Siberian", 2003], ["Russian", 2012], [")", 2019], ["clade", 2021], ["of", 2027], ["the", 2030], ["ST239", 2034], ["lineage", 2040], [",", 2047], ["which", 2049], ["was", 2055], ["created", 2059], ["through", 2067], ["stepwise", 2075], ["evolution", 2084], ["during", 2094], ["its", 2101], ["potential", 2105], ["transmission", 2115], ["route", 2128], ["of", 2134], ["Brazil", 2137], ["-", 2143], ["Europe", 2144], ["-", 2150], ["Russia", 2151], ["/", 2157], ["Krasnoyarsk", 2158], [",", 2169], ["thereby", 2171], ["selective", 2179], ["advantages", 2189], ["from", 2200], ["unique", 2205], ["MVFs", 2212], ["and", 2217], ["the", 2221], ["MDR", 2225], [".", 2228]]}
{"context": "In cancer research, background models for mutation rates have been extensively calibrated in coding regions, leading to the identification of many driver genes, recurrently mutated more than expected. Noncoding regions are also associated with disease; however, background models for them have not been investigated in as much detail. This is partially due to limited noncoding functional annotation. Also, great mutation heterogeneity and potential correlations between neighboring sites give rise to substantial overdispersion in mutation count, resulting in problematic background rate estimation. Here, we address these issues with a new computational framework called LARVA. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. We demonstrate LARVA's effectiveness on 760 whole-genome tumor sequences, showing that it identifies well-known noncoding drivers, such as mutations in the TERT promoter. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers. We make LARVA available as a software tool and release our highly mutated annotations as an online resource (larva.gersteinlab.org).", "qas": [{"question": "Which tool is used for the identification of recurrent variants in noncoding regions?", "answers": ["LARVA"], "qid": "b64f61ec5c4c4a3383e26a39db26cd14", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["the", 23], ["identification", 27], ["of", 42], ["recurrent", 45], ["variants", 55], ["in", 64], ["noncoding", 67], ["regions", 77], ["?", 84]], "detected_answers": [{"text": "LARVA", "token_spans": [[135, 135], [104, 104], [159, 159], [190, 190], [207, 207]], "char_spans": [[864, 868], [673, 677], [1019, 1023], [1188, 1192], [1304, 1308]]}]}], "context_tokens": [["In", 0], ["cancer", 3], ["research", 10], [",", 18], ["background", 20], ["models", 31], ["for", 38], ["mutation", 42], ["rates", 51], ["have", 57], ["been", 62], ["extensively", 67], ["calibrated", 79], ["in", 90], ["coding", 93], ["regions", 100], [",", 107], ["leading", 109], ["to", 117], ["the", 120], ["identification", 124], ["of", 139], ["many", 142], ["driver", 147], ["genes", 154], [",", 159], ["recurrently", 161], ["mutated", 173], ["more", 181], ["than", 186], ["expected", 191], [".", 199], ["Noncoding", 201], ["regions", 211], ["are", 219], ["also", 223], ["associated", 228], ["with", 239], ["disease", 244], [";", 251], ["however", 253], [",", 260], ["background", 262], ["models", 273], ["for", 280], ["them", 284], ["have", 289], ["not", 294], ["been", 298], ["investigated", 303], ["in", 316], ["as", 319], ["much", 322], ["detail", 327], [".", 333], ["This", 335], ["is", 340], ["partially", 343], ["due", 353], ["to", 357], ["limited", 360], ["noncoding", 368], ["functional", 378], ["annotation", 389], [".", 399], ["Also", 401], [",", 405], ["great", 407], ["mutation", 413], ["heterogeneity", 422], ["and", 436], ["potential", 440], ["correlations", 450], ["between", 463], ["neighboring", 471], ["sites", 483], ["give", 489], ["rise", 494], ["to", 499], ["substantial", 502], ["overdispersion", 514], ["in", 529], ["mutation", 532], ["count", 541], [",", 546], ["resulting", 548], ["in", 558], ["problematic", 561], ["background", 573], ["rate", 584], ["estimation", 589], [".", 599], ["Here", 601], [",", 605], ["we", 607], ["address", 610], ["these", 618], ["issues", 624], ["with", 631], ["a", 636], ["new", 638], ["computational", 642], ["framework", 656], ["called", 666], ["LARVA", 673], [".", 678], ["It", 680], ["integrates", 683], ["variants", 694], ["with", 703], ["a", 708], ["comprehensive", 710], ["set", 724], ["of", 728], ["noncoding", 731], ["functional", 741], ["elements", 752], [",", 760], ["modeling", 762], ["the", 771], ["mutation", 775], ["counts", 784], ["of", 791], ["the", 794], ["elements", 798], ["with", 807], ["a", 812], ["\u03b2", 814], ["-", 815], ["binomial", 816], ["distribution", 825], ["to", 838], ["handle", 841], ["overdispersion", 848], [".", 862], ["LARVA", 864], [",", 869], ["moreover", 871], [",", 879], ["uses", 881], ["regional", 886], ["genomic", 895], ["features", 903], ["such", 912], ["as", 917], ["replication", 920], ["timing", 932], ["to", 939], ["better", 942], ["estimate", 949], ["local", 958], ["mutation", 964], ["rates", 973], ["and", 979], ["mutational", 983], ["hotspots", 994], [".", 1002], ["We", 1004], ["demonstrate", 1007], ["LARVA", 1019], ["'s", 1024], ["effectiveness", 1027], ["on", 1041], ["760", 1044], ["whole", 1048], ["-", 1053], ["genome", 1054], ["tumor", 1061], ["sequences", 1067], [",", 1076], ["showing", 1078], ["that", 1086], ["it", 1091], ["identifies", 1094], ["well", 1105], ["-", 1109], ["known", 1110], ["noncoding", 1116], ["drivers", 1126], [",", 1133], ["such", 1135], ["as", 1140], ["mutations", 1143], ["in", 1153], ["the", 1156], ["TERT", 1160], ["promoter", 1165], [".", 1173], ["Furthermore", 1175], [",", 1186], ["LARVA", 1188], ["highlights", 1194], ["several", 1205], ["novel", 1213], ["highly", 1219], ["mutated", 1226], ["regulatory", 1234], ["sites", 1245], ["that", 1251], ["could", 1256], ["potentially", 1262], ["be", 1274], ["noncoding", 1277], ["drivers", 1287], [".", 1294], ["We", 1296], ["make", 1299], ["LARVA", 1304], ["available", 1310], ["as", 1320], ["a", 1323], ["software", 1325], ["tool", 1334], ["and", 1339], ["release", 1343], ["our", 1351], ["highly", 1355], ["mutated", 1362], ["annotations", 1370], ["as", 1382], ["an", 1385], ["online", 1388], ["resource", 1395], ["(", 1404], ["larva.gersteinlab.org", 1405], [")", 1426], [".", 1427]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital red-cell aplasia characterized by anemia, bone-marrow erythroblastopenia, and congenital anomalies and is associated with heterozygous mutations in the ribosomal protein (RP) S19 gene (RPS19) in approximately 25% of probands. We report identification of de novo nonsense and splice-site mutations in another RP, RPS24 (encoded by RPS24 [10q22-q23]) in approximately 2% of RPS19 mutation-negative probands. This finding strongly suggests that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted ribosomal biogenesis and/or function may also cause DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f987a6c739454ffa9a27e24c4e5235c2", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[93, 93], [120, 120], [5, 5]], "char_spans": [[493, 495], [659, 661], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["red", 51], ["-", 54], ["cell", 55], ["aplasia", 60], ["characterized", 68], ["by", 82], ["anemia", 85], [",", 91], ["bone", 93], ["-", 97], ["marrow", 98], ["erythroblastopenia", 105], [",", 123], ["and", 125], ["congenital", 129], ["anomalies", 140], ["and", 150], ["is", 154], ["associated", 157], ["with", 168], ["heterozygous", 173], ["mutations", 186], ["in", 196], ["the", 199], ["ribosomal", 203], ["protein", 213], ["(", 221], ["RP", 222], [")", 224], ["S19", 226], ["gene", 230], ["(", 235], ["RPS19", 236], [")", 241], ["in", 243], ["approximately", 246], ["25", 260], ["%", 262], ["of", 264], ["probands", 267], [".", 275], ["We", 277], ["report", 280], ["identification", 287], ["of", 302], ["de", 305], ["novo", 308], ["nonsense", 313], ["and", 322], ["splice", 326], ["-", 332], ["site", 333], ["mutations", 338], ["in", 348], ["another", 351], ["RP", 359], [",", 361], ["RPS24", 363], ["(", 369], ["encoded", 370], ["by", 378], ["RPS24", 381], ["[", 387], ["10q22-q23", 388], ["]", 397], [")", 398], ["in", 400], ["approximately", 403], ["2", 417], ["%", 418], ["of", 420], ["RPS19", 423], ["mutation", 429], ["-", 437], ["negative", 438], ["probands", 447], [".", 455], ["This", 457], ["finding", 462], ["strongly", 470], ["suggests", 479], ["that", 488], ["DBA", 493], ["is", 497], ["a", 500], ["disorder", 502], ["of", 511], ["ribosome", 514], ["synthesis", 523], ["and", 533], ["that", 537], ["mutations", 542], ["in", 552], ["other", 555], ["RP", 561], ["or", 564], ["associated", 567], ["genes", 578], ["that", 584], ["lead", 589], ["to", 594], ["disrupted", 597], ["ribosomal", 607], ["biogenesis", 617], ["and/or", 628], ["function", 635], ["may", 644], ["also", 648], ["cause", 653], ["DBA", 659], [".", 662]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disease with characteristics and symptoms that are well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies inside neurons. \u03b1-Synuclein (\u03b1-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence suggests that \u03b1-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy bodies localized in the dopaminergic neurons of PD patients. In the present study, we investigated the influence of wild type (WT) and A30P \u03b1-syn overexpression on neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged with lipopolysaccharide (LPS) from Escherichia coli. We observed that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show evidence of cell death, which is not reverted by NF-\u03baB inhibition by sodium salicylate or by blockage of P50 (NF-\u03baB subunit). Furthermore, the expression of A30P \u03b1-syn in neuroblastoma SH-SY5Y decreases the cell death triggered by the CM of activated glia versus WT \u03b1-syn or control group. This effect of A30P \u03b1-syn may be due to the low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release by CM in SH-SY5Y cells. Our results suggest that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show cell death, which is not reverted by NF-\u03baB blockage. Additionally, the expression of A30P \u03b1-syn on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT \u03b1-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present data suggest that MAPK42/44 phosphorylation plays an important role in this process. CRD42015020829.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "770cdf4bff11453d9e85c2d6c5857367", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[38, 40]], "char_spans": [[225, 235]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disease", 48], ["with", 56], ["characteristics", 61], ["and", 77], ["symptoms", 81], ["that", 90], ["are", 95], ["well", 99], ["defined", 104], [".", 111], ["Nevertheless", 113], [",", 125], ["its", 127], ["aetiology", 131], ["remains", 141], ["unknown", 149], [".", 156], ["PD", 158], ["is", 161], ["characterized", 164], ["by", 178], ["the", 181], ["presence", 185], ["of", 194], ["Lewy", 197], ["bodies", 202], ["inside", 209], ["neurons", 216], [".", 223], ["\u03b1", 225], ["-", 226], ["Synuclein", 227], ["(", 237], ["\u03b1", 238], ["-", 239], ["syn", 240], [")", 243], ["is", 245], ["a", 248], ["soluble", 250], ["protein", 258], ["present", 266], ["in", 274], ["the", 277], ["pre", 281], ["-", 284], ["synaptic", 285], ["terminal", 294], ["of", 303], ["neurons", 306], [".", 313], ["Evidence", 315], ["suggests", 324], ["that", 333], ["\u03b1", 338], ["-", 339], ["syn", 340], ["has", 344], ["a", 348], ["fundamental", 350], ["role", 362], ["in", 367], ["PD", 370], ["pathogenesis", 373], [",", 385], ["given", 387], ["that", 393], ["it", 398], ["is", 401], ["an", 404], ["important", 407], ["component", 417], ["of", 427], ["Lewy", 430], ["bodies", 435], ["localized", 442], ["in", 452], ["the", 455], ["dopaminergic", 459], ["neurons", 472], ["of", 480], ["PD", 483], ["patients", 486], [".", 494], ["In", 496], ["the", 499], ["present", 503], ["study", 511], [",", 516], ["we", 518], ["investigated", 521], ["the", 534], ["influence", 538], ["of", 548], ["wild", 551], ["type", 556], ["(", 561], ["WT", 562], [")", 564], ["and", 566], ["A30P", 570], ["\u03b1", 575], ["-", 576], ["syn", 577], ["overexpression", 581], ["on", 596], ["neuroblastoma", 599], ["SH", 613], ["-", 615], ["SY5Y", 616], ["toxicity", 621], ["induced", 630], ["by", 638], ["the", 641], ["conditioned", 645], ["medium", 657], ["(", 664], ["CM", 665], [")", 667], ["from", 669], ["primary", 674], ["cultures", 682], ["of", 691], ["glia", 694], ["challenged", 699], ["with", 710], ["lipopolysaccharide", 715], ["(", 734], ["LPS", 735], [")", 738], ["from", 740], ["Escherichia", 745], ["coli", 757], [".", 761], ["We", 763], ["observed", 766], ["that", 775], ["SH", 780], ["-", 782], ["SY5Y", 783], ["cells", 788], ["transduced", 794], ["with", 805], ["\u03b1", 810], ["-", 811], ["syn", 812], ["(", 816], ["WT", 817], ["or", 820], ["A30P", 823], [")", 827], ["and", 829], ["treated", 833], ["with", 841], ["CM", 846], ["from", 849], ["LPS", 854], ["-", 857], ["activated", 858], ["glia", 868], ["cells", 873], ["show", 879], ["evidence", 884], ["of", 893], ["cell", 896], ["death", 901], [",", 906], ["which", 908], ["is", 914], ["not", 917], ["reverted", 921], ["by", 930], ["NF", 933], ["-", 935], ["\u03baB", 936], ["inhibition", 939], ["by", 950], ["sodium", 953], ["salicylate", 960], ["or", 971], ["by", 974], ["blockage", 977], ["of", 986], ["P50", 989], ["(", 993], ["NF", 994], ["-", 996], ["\u03baB", 997], ["subunit", 1000], [")", 1007], [".", 1008], ["Furthermore", 1010], [",", 1021], ["the", 1023], ["expression", 1027], ["of", 1038], ["A30P", 1041], ["\u03b1", 1046], ["-", 1047], ["syn", 1048], ["in", 1052], ["neuroblastoma", 1055], ["SH", 1069], ["-", 1071], ["SY5Y", 1072], ["decreases", 1077], ["the", 1087], ["cell", 1091], ["death", 1096], ["triggered", 1102], ["by", 1112], ["the", 1115], ["CM", 1119], ["of", 1122], ["activated", 1125], ["glia", 1135], ["versus", 1140], ["WT", 1147], ["\u03b1", 1150], ["-", 1151], ["syn", 1152], ["or", 1156], ["control", 1159], ["group", 1167], [".", 1172], ["This", 1174], ["effect", 1179], ["of", 1186], ["A30P", 1189], ["\u03b1", 1194], ["-", 1195], ["syn", 1196], ["may", 1200], ["be", 1204], ["due", 1207], ["to", 1211], ["the", 1214], ["low", 1218], ["MAPK42/44", 1222], ["phosphorylation", 1232], [".", 1247], ["This", 1249], ["finding", 1254], ["is", 1262], ["substantiated", 1265], ["by", 1279], ["MEK1", 1282], ["inhibition", 1287], ["by", 1298], ["PD98059", 1301], [",", 1308], ["decreasing", 1310], ["LDH", 1321], ["release", 1325], ["by", 1333], ["CM", 1336], ["in", 1339], ["SH", 1342], ["-", 1344], ["SY5Y", 1345], ["cells", 1350], [".", 1355], ["Our", 1357], ["results", 1361], ["suggest", 1369], ["that", 1377], ["SH", 1382], ["-", 1384], ["SY5Y", 1385], ["cells", 1390], ["transduced", 1396], ["with", 1407], ["\u03b1", 1412], ["-", 1413], ["syn", 1414], ["(", 1418], ["WT", 1419], ["or", 1422], ["A30P", 1425], [")", 1429], ["and", 1431], ["treated", 1435], ["with", 1443], ["CM", 1448], ["from", 1451], ["LPS", 1456], ["-", 1459], ["activated", 1460], ["glia", 1470], ["cells", 1475], ["show", 1481], ["cell", 1486], ["death", 1491], [",", 1496], ["which", 1498], ["is", 1504], ["not", 1507], ["reverted", 1511], ["by", 1520], ["NF", 1523], ["-", 1525], ["\u03baB", 1526], ["blockage", 1529], [".", 1537], ["Additionally", 1539], [",", 1551], ["the", 1553], ["expression", 1557], ["of", 1568], ["A30P", 1571], ["\u03b1", 1576], ["-", 1577], ["syn", 1578], ["on", 1582], ["neuroblastoma", 1585], ["SH", 1599], ["-", 1601], ["SY5Y", 1602], ["leads", 1607], ["to", 1613], ["decreased", 1616], ["cell", 1626], ["death", 1631], ["triggered", 1637], ["by", 1647], ["the", 1650], ["CM", 1654], ["of", 1657], ["activated", 1660], ["glia", 1670], [",", 1674], ["when", 1676], ["compared", 1681], ["to", 1690], ["WT", 1693], ["\u03b1", 1696], ["-", 1697], ["syn", 1698], ["or", 1702], ["control", 1705], ["group", 1713], [".", 1718], ["The", 1720], ["mechanism", 1724], ["underlying", 1734], ["this", 1745], ["process", 1750], ["remains", 1758], ["to", 1766], ["be", 1769], ["completely", 1772], ["elucidated", 1783], [",", 1793], ["but", 1795], ["the", 1799], ["present", 1803], ["data", 1811], ["suggest", 1816], ["that", 1824], ["MAPK42/44", 1829], ["phosphorylation", 1839], ["plays", 1855], ["an", 1861], ["important", 1864], ["role", 1874], ["in", 1879], ["this", 1882], ["process", 1887], [".", 1894], ["CRD42015020829", 1896], [".", 1910]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Turner's syndrome is defined as a congenital disease determining by quantitative and/or structural aberrations of one from two X chromosomes with frequent presence of mosaicism. Clinically it is characterized by growth and body proportion abnormalities, gonadal dysgenesis resulting in sexual infantilism, primary amenorrhoea, infertility, characteristic stigmata, anomalies of heart, renal and bones and the presence of some diseases like Hashimoto thyroiditis with hypothyroidism, diabetes mellitus type 2, osteoporosis, hypertension. Turner's syndrome occurs in 1:2000 to 1:2500 female livebirth. The most frequent X chromosome aberrations in patients with phenotype of Turner syndrome are as follows: X monosomy - 45,X; mosaicism (50-75%), including 45,X/46,XX (10-15%), 45,X/46,XY (2-6%), 45,X/46,X,i(Xq), 45,X/46,X,del(Xp), 45,X/46,XX/47,XXX; aberration of X structure: total or partial deletion of short arm of X chromosome (46,X,del(Xp)) isochromosom of long arm of X chromosome (46,X,(i(Xq)), ring chromosome (46, X,r(X)), marker chromosome (46,X+m). Searching of X chromosome and mapping and sequencing of genes located at this chromosome (such as SHOX, ODG2, VSPA, SOX 3) have made possible to look for linkage between phenotypes and adequate genes or regions of X chromosome. In this paper current data concerning correlation between phenotype and karyotype in patients with TS have been presented.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f06f14b35c864f9093f9fae1b78fcd15", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[109, 109], [19, 19], [177, 177], [189, 189], [203, 203], [164, 164], [153, 153], [242, 242], [95, 95]], "char_spans": [[705, 705], [127, 127], [974, 974], [1023, 1023], [1073, 1073], [918, 918], [863, 863], [1274, 1274], [618, 618]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["is", 18], ["defined", 21], ["as", 29], ["a", 32], ["congenital", 34], ["disease", 45], ["determining", 53], ["by", 65], ["quantitative", 68], ["and/or", 81], ["structural", 88], ["aberrations", 99], ["of", 111], ["one", 114], ["from", 118], ["two", 123], ["X", 127], ["chromosomes", 129], ["with", 141], ["frequent", 146], ["presence", 155], ["of", 164], ["mosaicism", 167], [".", 176], ["Clinically", 178], ["it", 189], ["is", 192], ["characterized", 195], ["by", 209], ["growth", 212], ["and", 219], ["body", 223], ["proportion", 228], ["abnormalities", 239], [",", 252], ["gonadal", 254], ["dysgenesis", 262], ["resulting", 273], ["in", 283], ["sexual", 286], ["infantilism", 293], [",", 304], ["primary", 306], ["amenorrhoea", 314], [",", 325], ["infertility", 327], [",", 338], ["characteristic", 340], ["stigmata", 355], [",", 363], ["anomalies", 365], ["of", 375], ["heart", 378], [",", 383], ["renal", 385], ["and", 391], ["bones", 395], ["and", 401], ["the", 405], ["presence", 409], ["of", 418], ["some", 421], ["diseases", 426], ["like", 435], ["Hashimoto", 440], ["thyroiditis", 450], ["with", 462], ["hypothyroidism", 467], [",", 481], ["diabetes", 483], ["mellitus", 492], ["type", 501], ["2", 506], [",", 507], ["osteoporosis", 509], [",", 521], ["hypertension", 523], [".", 535], ["Turner", 537], ["'s", 543], ["syndrome", 546], ["occurs", 555], ["in", 562], ["1:2000", 565], ["to", 572], ["1:2500", 575], ["female", 582], ["livebirth", 589], [".", 598], ["The", 600], ["most", 604], ["frequent", 609], ["X", 618], ["chromosome", 620], ["aberrations", 631], ["in", 643], ["patients", 646], ["with", 655], ["phenotype", 660], ["of", 670], ["Turner", 673], ["syndrome", 680], ["are", 689], ["as", 693], ["follows", 696], [":", 703], ["X", 705], ["monosomy", 707], ["-", 716], ["45,X", 718], [";", 722], ["mosaicism", 724], ["(", 734], ["50", 735], ["-", 737], ["75", 738], ["%", 740], [")", 741], [",", 742], ["including", 744], ["45,X/46,XX", 754], ["(", 765], ["10", 766], ["-", 768], ["15", 769], ["%", 771], [")", 772], [",", 773], ["45,X/46,XY", 775], ["(", 786], ["2", 787], ["-", 788], ["6", 789], ["%", 790], [")", 791], [",", 792], ["45,X/46,X", 794], [",", 803], ["i(Xq", 804], [")", 808], [",", 809], ["45,X/46,X", 811], [",", 820], ["del(Xp", 821], [")", 827], [",", 828], ["45,X/46,XX/47,XXX", 830], [";", 847], ["aberration", 849], ["of", 860], ["X", 863], ["structure", 865], [":", 874], ["total", 876], ["or", 882], ["partial", 885], ["deletion", 893], ["of", 902], ["short", 905], ["arm", 911], ["of", 915], ["X", 918], ["chromosome", 920], ["(", 931], ["46,X", 932], [",", 936], ["del(Xp", 937], [")", 943], [")", 944], ["isochromosom", 946], ["of", 959], ["long", 962], ["arm", 967], ["of", 971], ["X", 974], ["chromosome", 976], ["(", 987], ["46,X,(i(Xq", 988], [")", 998], [")", 999], [",", 1000], ["ring", 1002], ["chromosome", 1007], ["(", 1018], ["46", 1019], [",", 1021], ["X", 1023], [",", 1024], ["r(X", 1025], [")", 1028], [")", 1029], [",", 1030], ["marker", 1032], ["chromosome", 1039], ["(", 1050], ["46,X+m", 1051], [")", 1057], [".", 1058], ["Searching", 1060], ["of", 1070], ["X", 1073], ["chromosome", 1075], ["and", 1086], ["mapping", 1090], ["and", 1098], ["sequencing", 1102], ["of", 1113], ["genes", 1116], ["located", 1122], ["at", 1130], ["this", 1133], ["chromosome", 1138], ["(", 1149], ["such", 1150], ["as", 1155], ["SHOX", 1158], [",", 1162], ["ODG2", 1164], [",", 1168], ["VSPA", 1170], [",", 1174], ["SOX", 1176], ["3", 1180], [")", 1181], ["have", 1183], ["made", 1188], ["possible", 1193], ["to", 1202], ["look", 1205], ["for", 1210], ["linkage", 1214], ["between", 1222], ["phenotypes", 1230], ["and", 1241], ["adequate", 1245], ["genes", 1254], ["or", 1260], ["regions", 1263], ["of", 1271], ["X", 1274], ["chromosome", 1276], [".", 1286], ["In", 1288], ["this", 1291], ["paper", 1296], ["current", 1302], ["data", 1310], ["concerning", 1315], ["correlation", 1326], ["between", 1338], ["phenotype", 1346], ["and", 1356], ["karyotype", 1360], ["in", 1370], ["patients", 1373], ["with", 1382], ["TS", 1387], ["have", 1390], ["been", 1395], ["presented", 1400], [".", 1409]]}
{"context": "Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch receptors with ligands leads to cleavage of the Notch intracellular domain (NICD) which then translocates to the nucleus and activates the transcription factor CBF1/JBP-Jkappa, regulating downstream gene expression. To date four Notch receptors have been found in mammals. Of these, Notch3 is predominantly expressed in adult arterial smooth muscle cells in human. NOTCH3 gene mutations cause the autosomal dominant condition, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), an inherited early stroke syndrome leading to dementia due to systemic vascular degeneration. This suggests that Notch3 plays a critical role in maintaining the phenotypic stability of vascular smooth muscle cells (VSMCs). Recent publications indicate that Notch3 is involved in vascular injury and is a determinant of VSMC survival, but its exact function is unknown. The molecular mechanisms underlying CADASIL pathology are therefore intriguing. Investigation of CADASIL mutant Notch3 shows that the majority of mutations do not change CBF1/JBP-Jkappa mediated classic Notch activation, so the pathological consequences of NOTCH3 mutations in CADASIL patients can not be simply explained by loss- or gain-of-function in the classic Notch signalling pathway. This suggests that a novel Notch3-mediated signalling pathway may be present in VSMCs, or cross-regulation of Notch3 to other signalling pathway(s) may play a critical role on VSMCs survival. Alternatively, the mutant Notch3 may gain a novel or toxic function in VSMCs. This review will focus on recent findings of Notch3 in vascular development and in regulating the VSMC behaviour and phenotype, and will use findings on investigating the molecular pathology of the single gene disorder CADASIL to understand the function of Notch3 in VSMCs.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "2c9f414f7a3a499893e29b02c1e7994e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[106, 107]], "char_spans": [[680, 690]]}]}], "context_tokens": [["Proteins", 0], ["of", 9], ["the", 12], ["Notch", 16], ["family", 22], ["are", 29], ["cell", 33], ["surface", 38], ["receptors", 46], ["that", 56], ["transduce", 61], ["signals", 71], ["between", 79], ["neighbouring", 87], ["cells", 100], [".", 105], ["The", 107], ["Notch", 111], ["signalling", 117], ["pathway", 128], ["is", 136], ["highly", 139], ["evolutionarily", 146], ["conserved", 161], ["and", 171], ["critical", 175], ["for", 184], ["cell", 188], ["fate", 193], ["determination", 198], ["during", 212], ["embryonic", 219], ["development", 229], [",", 240], ["including", 242], ["many", 252], ["aspects", 257], ["of", 265], ["vascular", 268], ["development", 277], [".", 288], ["The", 290], ["interaction", 294], ["of", 306], ["Notch", 309], ["receptors", 315], ["with", 325], ["ligands", 330], ["leads", 338], ["to", 344], ["cleavage", 347], ["of", 356], ["the", 359], ["Notch", 363], ["intracellular", 369], ["domain", 383], ["(", 390], ["NICD", 391], [")", 395], ["which", 397], ["then", 403], ["translocates", 408], ["to", 421], ["the", 424], ["nucleus", 428], ["and", 436], ["activates", 440], ["the", 450], ["transcription", 454], ["factor", 468], ["CBF1/JBP", 475], ["-", 483], ["Jkappa", 484], [",", 490], ["regulating", 492], ["downstream", 503], ["gene", 514], ["expression", 519], [".", 529], ["To", 531], ["date", 534], ["four", 539], ["Notch", 544], ["receptors", 550], ["have", 560], ["been", 565], ["found", 570], ["in", 576], ["mammals", 579], [".", 586], ["Of", 588], ["these", 591], [",", 596], ["Notch3", 598], ["is", 605], ["predominantly", 608], ["expressed", 622], ["in", 632], ["adult", 635], ["arterial", 641], ["smooth", 650], ["muscle", 657], ["cells", 664], ["in", 670], ["human", 673], [".", 678], ["NOTCH3", 680], ["gene", 687], ["mutations", 692], ["cause", 702], ["the", 708], ["autosomal", 712], ["dominant", 722], ["condition", 731], [",", 740], ["cerebral", 742], ["autosomal", 751], ["dominant", 761], ["arteriopathy", 770], ["with", 783], ["subcortical", 788], ["infarcts", 800], ["and", 809], ["leukoecephelopathy", 813], ["(", 832], ["CADASIL", 833], [")", 840], [",", 841], ["an", 843], ["inherited", 846], ["early", 856], ["stroke", 862], ["syndrome", 869], ["leading", 878], ["to", 886], ["dementia", 889], ["due", 898], ["to", 902], ["systemic", 905], ["vascular", 914], ["degeneration", 923], [".", 935], ["This", 937], ["suggests", 942], ["that", 951], ["Notch3", 956], ["plays", 963], ["a", 969], ["critical", 971], ["role", 980], ["in", 985], ["maintaining", 988], ["the", 1000], ["phenotypic", 1004], ["stability", 1015], ["of", 1025], ["vascular", 1028], ["smooth", 1037], ["muscle", 1044], ["cells", 1051], ["(", 1057], ["VSMCs", 1058], [")", 1063], [".", 1064], ["Recent", 1066], ["publications", 1073], ["indicate", 1086], ["that", 1095], ["Notch3", 1100], ["is", 1107], ["involved", 1110], ["in", 1119], ["vascular", 1122], ["injury", 1131], ["and", 1138], ["is", 1142], ["a", 1145], ["determinant", 1147], ["of", 1159], ["VSMC", 1162], ["survival", 1167], [",", 1175], ["but", 1177], ["its", 1181], ["exact", 1185], ["function", 1191], ["is", 1200], ["unknown", 1203], [".", 1210], ["The", 1212], ["molecular", 1216], ["mechanisms", 1226], ["underlying", 1237], ["CADASIL", 1248], ["pathology", 1256], ["are", 1266], ["therefore", 1270], ["intriguing", 1280], [".", 1290], ["Investigation", 1292], ["of", 1306], ["CADASIL", 1309], ["mutant", 1317], ["Notch3", 1324], ["shows", 1331], ["that", 1337], ["the", 1342], ["majority", 1346], ["of", 1355], ["mutations", 1358], ["do", 1368], ["not", 1371], ["change", 1375], ["CBF1/JBP", 1382], ["-", 1390], ["Jkappa", 1391], ["mediated", 1398], ["classic", 1407], ["Notch", 1415], ["activation", 1421], [",", 1431], ["so", 1433], ["the", 1436], ["pathological", 1440], ["consequences", 1453], ["of", 1466], ["NOTCH3", 1469], ["mutations", 1476], ["in", 1486], ["CADASIL", 1489], ["patients", 1497], ["can", 1506], ["not", 1510], ["be", 1514], ["simply", 1517], ["explained", 1524], ["by", 1534], ["loss-", 1537], ["or", 1543], ["gain", 1546], ["-", 1550], ["of", 1551], ["-", 1553], ["function", 1554], ["in", 1563], ["the", 1566], ["classic", 1570], ["Notch", 1578], ["signalling", 1584], ["pathway", 1595], [".", 1602], ["This", 1604], ["suggests", 1609], ["that", 1618], ["a", 1623], ["novel", 1625], ["Notch3-mediated", 1631], ["signalling", 1647], ["pathway", 1658], ["may", 1666], ["be", 1670], ["present", 1673], ["in", 1681], ["VSMCs", 1684], [",", 1689], ["or", 1691], ["cross", 1694], ["-", 1699], ["regulation", 1700], ["of", 1711], ["Notch3", 1714], ["to", 1721], ["other", 1724], ["signalling", 1730], ["pathway(s", 1741], [")", 1750], ["may", 1752], ["play", 1756], ["a", 1761], ["critical", 1763], ["role", 1772], ["on", 1777], ["VSMCs", 1780], ["survival", 1786], [".", 1794], ["Alternatively", 1796], [",", 1809], ["the", 1811], ["mutant", 1815], ["Notch3", 1822], ["may", 1829], ["gain", 1833], ["a", 1838], ["novel", 1840], ["or", 1846], ["toxic", 1849], ["function", 1855], ["in", 1864], ["VSMCs", 1867], [".", 1872], ["This", 1874], ["review", 1879], ["will", 1886], ["focus", 1891], ["on", 1897], ["recent", 1900], ["findings", 1907], ["of", 1916], ["Notch3", 1919], ["in", 1926], ["vascular", 1929], ["development", 1938], ["and", 1950], ["in", 1954], ["regulating", 1957], ["the", 1968], ["VSMC", 1972], ["behaviour", 1977], ["and", 1987], ["phenotype", 1991], [",", 2000], ["and", 2002], ["will", 2006], ["use", 2011], ["findings", 2015], ["on", 2024], ["investigating", 2027], ["the", 2041], ["molecular", 2045], ["pathology", 2055], ["of", 2065], ["the", 2068], ["single", 2072], ["gene", 2079], ["disorder", 2084], ["CADASIL", 2093], ["to", 2101], ["understand", 2104], ["the", 2115], ["function", 2119], ["of", 2128], ["Notch3", 2131], ["in", 2138], ["VSMCs", 2141], [".", 2146]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "This was a 12-week randomized, placebo-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic stress disorder (PTSD). Eighty patients were randomly assigned to treatment with either quetiapine or placebo. The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of Illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A). Safety measurements included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizona Sexual Experiences Scale. After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg (range, 50-800 mg). Reductions in CAPS total, re-experiencing, and hyperarousal scores were significantly greater for the quetiapine group than for the placebo group. Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales, HAM-A, and HAM-D than for placebo. Adverse events were generally mild and expected based on prior studies of quetiapine in this and other patient population. There were no differences in safety measures between groups. Quetiapine monotherapy was efficacious in the treatment of PTSD. These findings suggest quetiapine as a single agent is effective in treating military PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "9dafa681f75c4bb190fa51f4757a6056", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[295, 295], [25, 25], [310, 310], [50, 50]], "char_spans": [[1617, 1620], [156, 159], [1709, 1712], [309, 312]]}]}], "context_tokens": [["This", 0], ["was", 5], ["a", 9], ["12-week", 11], ["randomized", 19], [",", 29], ["placebo", 31], ["-", 38], ["controlled", 39], ["trial", 50], ["to", 56], ["assess", 59], ["the", 66], ["efficacy", 70], ["of", 79], ["quetiapine", 82], ["monotherapy", 93], ["in", 105], ["the", 108], ["treatment", 112], ["of", 122], ["posttraumatic", 125], ["stress", 139], ["disorder", 146], ["(", 155], ["PTSD", 156], [")", 160], [".", 161], ["Eighty", 163], ["patients", 170], ["were", 179], ["randomly", 184], ["assigned", 193], ["to", 202], ["treatment", 205], ["with", 215], ["either", 220], ["quetiapine", 227], ["or", 238], ["placebo", 241], [".", 248], ["The", 250], ["primary", 254], ["outcome", 262], ["measure", 270], ["was", 278], ["the", 282], ["Clinician", 286], ["-", 295], ["Administered", 296], ["PTSD", 309], ["Scale", 314], ["(", 320], ["CAPS", 321], [")", 325], [".", 326], ["Secondary", 328], ["efficacy", 338], ["measures", 347], ["included", 356], ["the", 365], ["CAPS", 369], ["subscales", 374], [",", 383], ["the", 385], ["Davidson", 389], ["Trauma", 398], ["Scale", 405], [",", 410], ["the", 412], ["Positive", 416], ["and", 425], ["Negative", 429], ["Syndrome", 438], ["Scale", 447], ["(", 453], ["PANSS", 454], [")", 459], [",", 460], ["the", 462], ["Clinical", 466], ["Global", 475], ["Impressions", 482], ["(", 494], ["CGI", 495], [")", 498], ["scales", 500], ["for", 507], ["severity", 511], ["of", 520], ["Illness", 523], ["and", 531], ["improvement", 535], [",", 546], ["the", 548], ["Hamilton", 552], ["Depression", 561], ["Rating", 572], ["Scale", 579], ["(", 585], ["HAM", 586], ["-", 589], ["D", 590], [")", 591], [",", 592], ["and", 594], ["the", 598], ["Hamilton", 602], ["Anxiety", 611], ["Rating", 619], ["Scale", 626], ["(", 632], ["HAM", 633], ["-", 636], ["A", 637], [")", 638], [".", 639], ["Safety", 641], ["measurements", 648], ["included", 661], ["adverse", 670], ["events", 678], [",", 684], ["vital", 686], ["signs", 692], [",", 697], ["the", 699], ["Abnormal", 703], ["Involuntary", 712], ["Movement", 724], ["Scale", 733], [",", 738], ["the", 740], ["Barnes", 744], ["Akathisia", 751], ["Scale", 761], [",", 766], ["the", 768], ["Simpson", 772], ["-", 779], ["Angus", 780], ["Scale", 786], [",", 791], ["and", 793], ["the", 797], ["Arizona", 801], ["Sexual", 809], ["Experiences", 816], ["Scale", 828], [".", 833], ["After", 835], ["a", 841], ["1-week", 843], ["placebo", 850], ["run", 858], ["-", 861], ["in", 862], [",", 864], ["quetiapine", 866], ["was", 877], ["started", 881], ["at", 889], ["a", 892], ["daily", 894], ["dosage", 900], ["of", 907], ["25", 910], ["mg", 913], ["and", 916], ["increased", 920], ["to", 930], ["a", 933], ["maximum", 935], ["of", 943], ["800", 946], ["mg", 950], [";", 952], ["the", 954], ["average", 958], ["was", 966], ["258", 970], ["mg", 974], ["(", 977], ["range", 978], [",", 983], ["50", 985], ["-", 987], ["800", 988], ["mg", 992], [")", 994], [".", 995], ["Reductions", 997], ["in", 1008], ["CAPS", 1011], ["total", 1016], [",", 1021], ["re", 1023], ["-", 1025], ["experiencing", 1026], [",", 1038], ["and", 1040], ["hyperarousal", 1044], ["scores", 1057], ["were", 1064], ["significantly", 1069], ["greater", 1083], ["for", 1091], ["the", 1095], ["quetiapine", 1099], ["group", 1110], ["than", 1116], ["for", 1121], ["the", 1125], ["placebo", 1129], ["group", 1137], [".", 1142], ["Greater", 1144], ["improvements", 1152], ["were", 1165], ["also", 1170], ["observed", 1175], ["for", 1184], ["quetiapine", 1188], ["in", 1199], ["scores", 1202], ["on", 1209], ["the", 1212], ["Davidson", 1216], ["Trauma", 1225], ["Scale", 1232], [",", 1237], ["CGI", 1239], ["severity", 1243], ["and", 1252], ["improvement", 1256], ["ratings", 1268], [",", 1275], ["PANSS", 1277], ["positive", 1283], ["symptom", 1292], ["and", 1300], ["general", 1304], ["psychopathology", 1312], ["subscales", 1328], [",", 1337], ["HAM", 1339], ["-", 1342], ["A", 1343], [",", 1344], ["and", 1346], ["HAM", 1350], ["-", 1353], ["D", 1354], ["than", 1356], ["for", 1361], ["placebo", 1365], [".", 1372], ["Adverse", 1374], ["events", 1382], ["were", 1389], ["generally", 1394], ["mild", 1404], ["and", 1409], ["expected", 1413], ["based", 1422], ["on", 1428], ["prior", 1431], ["studies", 1437], ["of", 1445], ["quetiapine", 1448], ["in", 1459], ["this", 1462], ["and", 1467], ["other", 1471], ["patient", 1477], ["population", 1485], [".", 1495], ["There", 1497], ["were", 1503], ["no", 1508], ["differences", 1511], ["in", 1523], ["safety", 1526], ["measures", 1533], ["between", 1542], ["groups", 1550], [".", 1556], ["Quetiapine", 1558], ["monotherapy", 1569], ["was", 1581], ["efficacious", 1585], ["in", 1597], ["the", 1600], ["treatment", 1604], ["of", 1614], ["PTSD", 1617], [".", 1621], ["These", 1623], ["findings", 1629], ["suggest", 1638], ["quetiapine", 1646], ["as", 1657], ["a", 1660], ["single", 1662], ["agent", 1669], ["is", 1675], ["effective", 1678], ["in", 1688], ["treating", 1691], ["military", 1700], ["PTSD", 1709], [".", 1713]]}
{"context": "Quantitative real-time PCR (QPCR) has emerged as an accurate and valuable tool in profiling gene expression levels. One of its many advantages is a lower detection limit compared to other methods of gene expression profiling while using smaller amounts of input for each assay. Automated qPCR setup has improved this field by allowing for greater reproducibility. Its convenient and rapid setup allows for high-throughput experiments, enabling the profiling of many different genes simultaneously in each experiment. This method along with internal plate controls also reduces experimental variables common to other techniques. We recently developed a qPCR assay for profiling of pre-microRNAs (pre-miRNAs) using a set of 186 primer pairs. MicroRNAs have emerged as a novel class of small, non-coding RNAs with the ability to regulate many mRNA targets at the post-transcriptional level. These small RNAs are first transcribed by RNA polymerase II as a primary miRNA (pri-miRNA) transcript, which is then cleaved into the precursor miRNA (pre-miRNA). Pre-miRNAs are exported to the cytoplasm where Dicer cleaves the hairpin loop to yield mature miRNAs. Increases in miRNA levels can be observed at both the precursor and mature miRNA levels and profiling of both of these forms can be useful. There are several commercially available assays for mature miRNAs; however, their high cost may deter researchers from this profiling technique. Here, we discuss a cost-effective, reliable, SYBR-based qPCR method of profiling pre-miRNAs. Changes in pre-miRNA levels often reflect mature miRNA changes and can be a useful indicator of mature miRNA expression. However, simultaneous profiling of both pre-miRNAs and mature miRNAs may be optimal as they can contribute nonredundant information and provide insight into microRNA processing. Furthermore, the technique described here can be expanded to encompass the profiling of other library sets for specific pathways or pathogens.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "d5012159612c4b0b9722b00581b7cf34", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[164, 166]], "char_spans": [[930, 946]]}]}], "context_tokens": [["Quantitative", 0], ["real", 13], ["-", 17], ["time", 18], ["PCR", 23], ["(", 27], ["QPCR", 28], [")", 32], ["has", 34], ["emerged", 38], ["as", 46], ["an", 49], ["accurate", 52], ["and", 61], ["valuable", 65], ["tool", 74], ["in", 79], ["profiling", 82], ["gene", 92], ["expression", 97], ["levels", 108], [".", 114], ["One", 116], ["of", 120], ["its", 123], ["many", 127], ["advantages", 132], ["is", 143], ["a", 146], ["lower", 148], ["detection", 154], ["limit", 164], ["compared", 170], ["to", 179], ["other", 182], ["methods", 188], ["of", 196], ["gene", 199], ["expression", 204], ["profiling", 215], ["while", 225], ["using", 231], ["smaller", 237], ["amounts", 245], ["of", 253], ["input", 256], ["for", 262], ["each", 266], ["assay", 271], [".", 276], ["Automated", 278], ["qPCR", 288], ["setup", 293], ["has", 299], ["improved", 303], ["this", 312], ["field", 317], ["by", 323], ["allowing", 326], ["for", 335], ["greater", 339], ["reproducibility", 347], [".", 362], ["Its", 364], ["convenient", 368], ["and", 379], ["rapid", 383], ["setup", 389], ["allows", 395], ["for", 402], ["high", 406], ["-", 410], ["throughput", 411], ["experiments", 422], [",", 433], ["enabling", 435], ["the", 444], ["profiling", 448], ["of", 458], ["many", 461], ["different", 466], ["genes", 476], ["simultaneously", 482], ["in", 497], ["each", 500], ["experiment", 505], [".", 515], ["This", 517], ["method", 522], ["along", 529], ["with", 535], ["internal", 540], ["plate", 549], ["controls", 555], ["also", 564], ["reduces", 569], ["experimental", 577], ["variables", 590], ["common", 600], ["to", 607], ["other", 610], ["techniques", 616], [".", 626], ["We", 628], ["recently", 631], ["developed", 640], ["a", 650], ["qPCR", 652], ["assay", 657], ["for", 663], ["profiling", 667], ["of", 677], ["pre", 680], ["-", 683], ["microRNAs", 684], ["(", 694], ["pre", 695], ["-", 698], ["miRNAs", 699], [")", 705], ["using", 707], ["a", 713], ["set", 715], ["of", 719], ["186", 722], ["primer", 726], ["pairs", 733], [".", 738], ["MicroRNAs", 740], ["have", 750], ["emerged", 755], ["as", 763], ["a", 766], ["novel", 768], ["class", 774], ["of", 780], ["small", 783], [",", 788], ["non", 790], ["-", 793], ["coding", 794], ["RNAs", 801], ["with", 806], ["the", 811], ["ability", 815], ["to", 823], ["regulate", 826], ["many", 835], ["mRNA", 840], ["targets", 845], ["at", 853], ["the", 856], ["post", 860], ["-", 864], ["transcriptional", 865], ["level", 881], [".", 886], ["These", 888], ["small", 894], ["RNAs", 900], ["are", 905], ["first", 909], ["transcribed", 915], ["by", 927], ["RNA", 930], ["polymerase", 934], ["II", 945], ["as", 948], ["a", 951], ["primary", 953], ["miRNA", 961], ["(", 967], ["pri", 968], ["-", 971], ["miRNA", 972], [")", 977], ["transcript", 979], [",", 989], ["which", 991], ["is", 997], ["then", 1000], ["cleaved", 1005], ["into", 1013], ["the", 1018], ["precursor", 1022], ["miRNA", 1032], ["(", 1038], ["pre", 1039], ["-", 1042], ["miRNA", 1043], [")", 1048], [".", 1049], ["Pre", 1051], ["-", 1054], ["miRNAs", 1055], ["are", 1062], ["exported", 1066], ["to", 1075], ["the", 1078], ["cytoplasm", 1082], ["where", 1092], ["Dicer", 1098], ["cleaves", 1104], ["the", 1112], ["hairpin", 1116], ["loop", 1124], ["to", 1129], ["yield", 1132], ["mature", 1138], ["miRNAs", 1145], [".", 1151], ["Increases", 1153], ["in", 1163], ["miRNA", 1166], ["levels", 1172], ["can", 1179], ["be", 1183], ["observed", 1186], ["at", 1195], ["both", 1198], ["the", 1203], ["precursor", 1207], ["and", 1217], ["mature", 1221], ["miRNA", 1228], ["levels", 1234], ["and", 1241], ["profiling", 1245], ["of", 1255], ["both", 1258], ["of", 1263], ["these", 1266], ["forms", 1272], ["can", 1278], ["be", 1282], ["useful", 1285], [".", 1291], ["There", 1293], ["are", 1299], ["several", 1303], ["commercially", 1311], ["available", 1324], ["assays", 1334], ["for", 1341], ["mature", 1345], ["miRNAs", 1352], [";", 1358], ["however", 1360], [",", 1367], ["their", 1369], ["high", 1375], ["cost", 1380], ["may", 1385], ["deter", 1389], ["researchers", 1395], ["from", 1407], ["this", 1412], ["profiling", 1417], ["technique", 1427], [".", 1436], ["Here", 1438], [",", 1442], ["we", 1444], ["discuss", 1447], ["a", 1455], ["cost", 1457], ["-", 1461], ["effective", 1462], [",", 1471], ["reliable", 1473], [",", 1481], ["SYBR", 1483], ["-", 1487], ["based", 1488], ["qPCR", 1494], ["method", 1499], ["of", 1506], ["profiling", 1509], ["pre", 1519], ["-", 1522], ["miRNAs", 1523], [".", 1529], ["Changes", 1531], ["in", 1539], ["pre", 1542], ["-", 1545], ["miRNA", 1546], ["levels", 1552], ["often", 1559], ["reflect", 1565], ["mature", 1573], ["miRNA", 1580], ["changes", 1586], ["and", 1594], ["can", 1598], ["be", 1602], ["a", 1605], ["useful", 1607], ["indicator", 1614], ["of", 1624], ["mature", 1627], ["miRNA", 1634], ["expression", 1640], [".", 1650], ["However", 1652], [",", 1659], ["simultaneous", 1661], ["profiling", 1674], ["of", 1684], ["both", 1687], ["pre", 1692], ["-", 1695], ["miRNAs", 1696], ["and", 1703], ["mature", 1707], ["miRNAs", 1714], ["may", 1721], ["be", 1725], ["optimal", 1728], ["as", 1736], ["they", 1739], ["can", 1744], ["contribute", 1748], ["nonredundant", 1759], ["information", 1772], ["and", 1784], ["provide", 1788], ["insight", 1796], ["into", 1804], ["microRNA", 1809], ["processing", 1818], [".", 1828], ["Furthermore", 1830], [",", 1841], ["the", 1843], ["technique", 1847], ["described", 1857], ["here", 1867], ["can", 1872], ["be", 1876], ["expanded", 1879], ["to", 1888], ["encompass", 1891], ["the", 1901], ["profiling", 1905], ["of", 1915], ["other", 1918], ["library", 1924], ["sets", 1932], ["for", 1937], ["specific", 1941], ["pathways", 1950], ["or", 1959], ["pathogens", 1962], [".", 1971]]}
{"context": "A 2-month-old female infant, born to consanguineous parents, presented with infections in skin and upper respiratory tract. She was notable for delayed umbilical cord detachment, partial albinism, and neurological irritability. Giant granules were present in white blood cells. The intracellular perforin content in CD8 T cells seems to correlate to the immune activation state of the patient with 82% and 8% perforin-containing CD8 T cells at active and nonactive hemophagocytic lymphohistiocytosis (HLH) disease, respectively. HLH was confirmed by hemophagocytosis in bone marrow and absent natural killer cell activity. The patient carried a homozygous G>A mutation in the 3' splice site of intron 24 of the LYST/CHS1 gene, leading to the use of an alternative YAG splice site located in exon 25, introducing a premature STOP codon (L2355fsX2370; NP_000072.2). The early-onset accelerated phase in this severe phenotype of Chediak-Higashi syndrome was probably induced by rotaviral infection. Interestingly, the intracellular perforin content in CD8 T cells seems to correlate to the immune activation state of the patient. Late separation of the umbilical cord in concordance with clinical symptoms should lead to evaluation of a possible neutrophil dysfunction including Chediak-Higashi syndrome before onset of HLH.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "502fe409d7d94564b083ec1308dc8740", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[168, 171], [222, 225]], "char_spans": [[926, 949], [1276, 1299]]}]}], "context_tokens": [["A", 0], ["2-month", 2], ["-", 9], ["old", 10], ["female", 14], ["infant", 21], [",", 27], ["born", 29], ["to", 34], ["consanguineous", 37], ["parents", 52], [",", 59], ["presented", 61], ["with", 71], ["infections", 76], ["in", 87], ["skin", 90], ["and", 95], ["upper", 99], ["respiratory", 105], ["tract", 117], [".", 122], ["She", 124], ["was", 128], ["notable", 132], ["for", 140], ["delayed", 144], ["umbilical", 152], ["cord", 162], ["detachment", 167], [",", 177], ["partial", 179], ["albinism", 187], [",", 195], ["and", 197], ["neurological", 201], ["irritability", 214], [".", 226], ["Giant", 228], ["granules", 234], ["were", 243], ["present", 248], ["in", 256], ["white", 259], ["blood", 265], ["cells", 271], [".", 276], ["The", 278], ["intracellular", 282], ["perforin", 296], ["content", 305], ["in", 313], ["CD8", 316], ["T", 320], ["cells", 322], ["seems", 328], ["to", 334], ["correlate", 337], ["to", 347], ["the", 350], ["immune", 354], ["activation", 361], ["state", 372], ["of", 378], ["the", 381], ["patient", 385], ["with", 393], ["82", 398], ["%", 400], ["and", 402], ["8", 406], ["%", 407], ["perforin", 409], ["-", 417], ["containing", 418], ["CD8", 429], ["T", 433], ["cells", 435], ["at", 441], ["active", 444], ["and", 451], ["nonactive", 455], ["hemophagocytic", 465], ["lymphohistiocytosis", 480], ["(", 500], ["HLH", 501], [")", 504], ["disease", 506], [",", 513], ["respectively", 515], [".", 527], ["HLH", 529], ["was", 533], ["confirmed", 537], ["by", 547], ["hemophagocytosis", 550], ["in", 567], ["bone", 570], ["marrow", 575], ["and", 582], ["absent", 586], ["natural", 593], ["killer", 601], ["cell", 608], ["activity", 613], [".", 621], ["The", 623], ["patient", 627], ["carried", 635], ["a", 643], ["homozygous", 645], ["G", 656], [">", 657], ["A", 658], ["mutation", 660], ["in", 669], ["the", 672], ["3", 676], ["'", 677], ["splice", 679], ["site", 686], ["of", 691], ["intron", 694], ["24", 701], ["of", 704], ["the", 707], ["LYST", 711], ["/", 715], ["CHS1", 716], ["gene", 721], [",", 725], ["leading", 727], ["to", 735], ["the", 738], ["use", 742], ["of", 746], ["an", 749], ["alternative", 752], ["YAG", 764], ["splice", 768], ["site", 775], ["located", 780], ["in", 788], ["exon", 791], ["25", 796], [",", 798], ["introducing", 800], ["a", 812], ["premature", 814], ["STOP", 824], ["codon", 829], ["(", 835], ["L2355fsX2370", 836], [";", 848], ["NP_000072.2", 850], [")", 861], [".", 862], ["The", 864], ["early", 868], ["-", 873], ["onset", 874], ["accelerated", 880], ["phase", 892], ["in", 898], ["this", 901], ["severe", 906], ["phenotype", 913], ["of", 923], ["Chediak", 926], ["-", 933], ["Higashi", 934], ["syndrome", 942], ["was", 951], ["probably", 955], ["induced", 964], ["by", 972], ["rotaviral", 975], ["infection", 985], [".", 994], ["Interestingly", 996], [",", 1009], ["the", 1011], ["intracellular", 1015], ["perforin", 1029], ["content", 1038], ["in", 1046], ["CD8", 1049], ["T", 1053], ["cells", 1055], ["seems", 1061], ["to", 1067], ["correlate", 1070], ["to", 1080], ["the", 1083], ["immune", 1087], ["activation", 1094], ["state", 1105], ["of", 1111], ["the", 1114], ["patient", 1118], [".", 1125], ["Late", 1127], ["separation", 1132], ["of", 1143], ["the", 1146], ["umbilical", 1150], ["cord", 1160], ["in", 1165], ["concordance", 1168], ["with", 1180], ["clinical", 1185], ["symptoms", 1194], ["should", 1203], ["lead", 1210], ["to", 1215], ["evaluation", 1218], ["of", 1229], ["a", 1232], ["possible", 1234], ["neutrophil", 1243], ["dysfunction", 1254], ["including", 1266], ["Chediak", 1276], ["-", 1283], ["Higashi", 1284], ["syndrome", 1292], ["before", 1301], ["onset", 1308], ["of", 1314], ["HLH", 1317], [".", 1320]]}
{"context": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "aac69dde3c754b6ab56366207d37f1f7", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[214, 214]], "char_spans": [[1199, 1205]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["important", 23], ["post", 33], ["-", 37], ["transcriptional", 38], ["regulators", 54], ["of", 65], ["gene", 68], ["expression", 73], ["that", 84], ["act", 89], ["by", 93], ["direct", 96], ["base", 103], ["pairing", 108], ["to", 116], ["target", 119], ["sites", 126], ["within", 132], ["untranslated", 139], ["regions", 152], ["of", 160], ["messenger", 163], ["RNAs", 173], [".", 177], ["Recently", 179], [",", 187], ["miRNA", 189], ["activity", 195], ["has", 204], ["been", 208], ["shown", 213], ["to", 219], ["be", 222], ["affected", 225], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["miRNA", 253], ["sponge", 259], ["transcripts", 266], [",", 277], ["the", 279], ["so", 283], ["-", 285], ["called", 286], ["competing", 293], ["endogenous", 303], ["RNA", 314], ["in", 318], ["humans", 321], ["and", 328], ["target", 332], ["mimicry", 339], ["in", 347], ["plants", 350], [".", 356], ["We", 358], ["previously", 361], ["identified", 372], ["a", 383], ["highly", 385], ["expressed", 392], ["circular", 402], ["RNA", 411], ["(", 415], ["circRNA", 416], [")", 423], ["in", 425], ["human", 428], ["and", 434], ["mouse", 438], ["brain", 444], [".", 449], ["Here", 451], ["we", 456], ["show", 459], ["that", 464], ["this", 469], ["circRNA", 474], ["acts", 482], ["as", 487], ["a", 490], ["miR-7", 492], ["sponge", 498], [";", 504], ["we", 506], ["term", 509], ["this", 514], ["circular", 519], ["transcript", 528], ["ciRS-7", 539], ["(", 546], ["circular", 547], ["RNA", 556], ["sponge", 560], ["for", 567], ["miR-7", 571], [")", 576], [".", 577], ["ciRS-7", 579], ["contains", 586], ["more", 595], ["than", 600], ["70", 605], ["selectively", 608], ["conserved", 620], ["miRNA", 630], ["target", 636], ["sites", 643], [",", 648], ["and", 650], ["it", 654], ["is", 657], ["highly", 660], ["and", 667], ["widely", 671], ["associated", 678], ["with", 689], ["Argonaute", 694], ["(", 704], ["AGO", 705], [")", 708], ["proteins", 710], ["in", 719], ["a", 722], ["miR-7-dependent", 724], ["manner", 740], [".", 746], ["Although", 748], ["the", 757], ["circRNA", 761], ["is", 769], ["completely", 772], ["resistant", 783], ["to", 793], ["miRNA", 796], ["-", 801], ["mediated", 802], ["target", 811], ["destabilization", 818], [",", 833], ["it", 835], ["strongly", 838], ["suppresses", 847], ["miR-7", 858], ["activity", 864], [",", 872], ["resulting", 874], ["in", 884], ["increased", 887], ["levels", 897], ["of", 904], ["miR-7", 907], ["targets", 913], [".", 920], ["In", 922], ["the", 925], ["mouse", 929], ["brain", 935], [",", 940], ["we", 942], ["observe", 945], ["overlapping", 953], ["co", 965], ["-", 967], ["expression", 968], ["of", 979], ["ciRS-7", 982], ["and", 989], ["miR-7", 993], [",", 998], ["particularly", 1000], ["in", 1013], ["neocortical", 1016], ["and", 1028], ["hippocampal", 1032], ["neurons", 1044], [",", 1051], ["suggesting", 1053], ["a", 1064], ["high", 1066], ["degree", 1071], ["of", 1078], ["endogenous", 1081], ["interaction", 1092], [".", 1103], ["We", 1105], ["further", 1108], ["show", 1116], ["that", 1121], ["the", 1126], ["testis", 1130], ["-", 1136], ["specific", 1137], ["circRNA", 1146], [",", 1153], ["sex", 1155], ["-", 1158], ["determining", 1159], ["region", 1171], ["Y", 1178], ["(", 1180], ["Sry", 1181], [")", 1184], [",", 1185], ["serves", 1187], ["as", 1194], ["a", 1197], ["miR-138", 1199], ["sponge", 1207], [",", 1213], ["suggesting", 1215], ["that", 1226], ["miRNA", 1231], ["sponge", 1237], ["effects", 1244], ["achieved", 1252], ["by", 1261], ["circRNA", 1264], ["formation", 1272], ["are", 1282], ["a", 1286], ["general", 1288], ["phenomenon", 1296], [".", 1306], ["This", 1308], ["study", 1313], ["serves", 1319], ["as", 1326], ["the", 1329], ["first", 1333], [",", 1338], ["to", 1340], ["our", 1343], ["knowledge", 1347], [",", 1356], ["functional", 1358], ["analysis", 1369], ["of", 1378], ["a", 1381], ["naturally", 1383], ["expressed", 1393], ["circRNA", 1403], [".", 1410]]}
{"context": "Mutations in the CLN3 gene, which encodes a lysosomal membrane protein, are responsible for the neurodegenerative disorder juvenile Batten disease. A previous study on the yeast homolog to CLN3, designated Btn1p, revealed a potential role for CLN3 in the transport of arginine into the yeast vacuole, the equivalent organelle to the mammalian lysosome. Lysosomes isolated from lymphoblast cell lines, established from individuals with juvenile Batten disease-bearing mutations in CLN3, but not age-matched controls, demonstrate defective transport of arginine. Furthermore, we show that there is a depletion of arginine in cells derived from individuals with juvenile Batten disease. We have, therefore, characterized lysosomal arginine transport in normal lysosomes and show that it is ATP-, v-ATPase- and cationic-dependent. This and previous studies have shown that both arginine and lysine are transported by the same transport system, designated system c. However, we report that lysosomes isolated from juvenile Batten disease lymphoblasts are only defective for arginine transport. These results suggest that the CLN3 defect in juvenile Batten disease may affect how intracellular levels of arginine are regulated or distributed throughout the cell. This assertion is supported by two other experimental approaches. First, an antibody to CLN3 can block lysosomal arginine transport and second, expression of CLN3 in JNCL cells using a lentiviral vector can restore lysosomal arginine transport. CLN3 may have a role in regulating intracellular levels of arginine possibly through control of the transport of this amino acid into lysosomes.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "3dc4e3f9a1154fac800afd66066ee701", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[20, 21], [172, 173], [191, 192], [72, 73], [111, 112]], "char_spans": [[132, 145], [1018, 1031], [1144, 1157], [444, 457], [668, 681]]}, {"text": "JNCL", "token_spans": [[236, 236]], "char_spans": [[1423, 1426]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["CLN3", 17], ["gene", 22], [",", 26], ["which", 28], ["encodes", 34], ["a", 42], ["lysosomal", 44], ["membrane", 54], ["protein", 63], [",", 70], ["are", 72], ["responsible", 76], ["for", 88], ["the", 92], ["neurodegenerative", 96], ["disorder", 114], ["juvenile", 123], ["Batten", 132], ["disease", 139], [".", 146], ["A", 148], ["previous", 150], ["study", 159], ["on", 165], ["the", 168], ["yeast", 172], ["homolog", 178], ["to", 186], ["CLN3", 189], [",", 193], ["designated", 195], ["Btn1p", 206], [",", 211], ["revealed", 213], ["a", 222], ["potential", 224], ["role", 234], ["for", 239], ["CLN3", 243], ["in", 248], ["the", 251], ["transport", 255], ["of", 265], ["arginine", 268], ["into", 277], ["the", 282], ["yeast", 286], ["vacuole", 292], [",", 299], ["the", 301], ["equivalent", 305], ["organelle", 316], ["to", 326], ["the", 329], ["mammalian", 333], ["lysosome", 343], [".", 351], ["Lysosomes", 353], ["isolated", 363], ["from", 372], ["lymphoblast", 377], ["cell", 389], ["lines", 394], [",", 399], ["established", 401], ["from", 413], ["individuals", 418], ["with", 430], ["juvenile", 435], ["Batten", 444], ["disease", 451], ["-", 458], ["bearing", 459], ["mutations", 467], ["in", 477], ["CLN3", 480], [",", 484], ["but", 486], ["not", 490], ["age", 494], ["-", 497], ["matched", 498], ["controls", 506], [",", 514], ["demonstrate", 516], ["defective", 528], ["transport", 538], ["of", 548], ["arginine", 551], [".", 559], ["Furthermore", 561], [",", 572], ["we", 574], ["show", 577], ["that", 582], ["there", 587], ["is", 593], ["a", 596], ["depletion", 598], ["of", 608], ["arginine", 611], ["in", 620], ["cells", 623], ["derived", 629], ["from", 637], ["individuals", 642], ["with", 654], ["juvenile", 659], ["Batten", 668], ["disease", 675], [".", 682], ["We", 684], ["have", 687], [",", 691], ["therefore", 693], [",", 702], ["characterized", 704], ["lysosomal", 718], ["arginine", 728], ["transport", 737], ["in", 747], ["normal", 750], ["lysosomes", 757], ["and", 767], ["show", 771], ["that", 776], ["it", 781], ["is", 784], ["ATP-", 787], [",", 791], ["v", 793], ["-", 794], ["ATPase-", 795], ["and", 803], ["cationic", 807], ["-", 815], ["dependent", 816], [".", 825], ["This", 827], ["and", 832], ["previous", 836], ["studies", 845], ["have", 853], ["shown", 858], ["that", 864], ["both", 869], ["arginine", 874], ["and", 883], ["lysine", 887], ["are", 894], ["transported", 898], ["by", 910], ["the", 913], ["same", 917], ["transport", 922], ["system", 932], [",", 938], ["designated", 940], ["system", 951], ["c.", 958], ["However", 961], [",", 968], ["we", 970], ["report", 973], ["that", 980], ["lysosomes", 985], ["isolated", 995], ["from", 1004], ["juvenile", 1009], ["Batten", 1018], ["disease", 1025], ["lymphoblasts", 1033], ["are", 1046], ["only", 1050], ["defective", 1055], ["for", 1065], ["arginine", 1069], ["transport", 1078], [".", 1087], ["These", 1089], ["results", 1095], ["suggest", 1103], ["that", 1111], ["the", 1116], ["CLN3", 1120], ["defect", 1125], ["in", 1132], ["juvenile", 1135], ["Batten", 1144], ["disease", 1151], ["may", 1159], ["affect", 1163], ["how", 1170], ["intracellular", 1174], ["levels", 1188], ["of", 1195], ["arginine", 1198], ["are", 1207], ["regulated", 1211], ["or", 1221], ["distributed", 1224], ["throughout", 1236], ["the", 1247], ["cell", 1251], [".", 1255], ["This", 1257], ["assertion", 1262], ["is", 1272], ["supported", 1275], ["by", 1285], ["two", 1288], ["other", 1292], ["experimental", 1298], ["approaches", 1311], [".", 1321], ["First", 1323], [",", 1328], ["an", 1330], ["antibody", 1333], ["to", 1342], ["CLN3", 1345], ["can", 1350], ["block", 1354], ["lysosomal", 1360], ["arginine", 1370], ["transport", 1379], ["and", 1389], ["second", 1393], [",", 1399], ["expression", 1401], ["of", 1412], ["CLN3", 1415], ["in", 1420], ["JNCL", 1423], ["cells", 1428], ["using", 1434], ["a", 1440], ["lentiviral", 1442], ["vector", 1453], ["can", 1460], ["restore", 1464], ["lysosomal", 1472], ["arginine", 1482], ["transport", 1491], [".", 1500], ["CLN3", 1502], ["may", 1507], ["have", 1511], ["a", 1516], ["role", 1518], ["in", 1523], ["regulating", 1526], ["intracellular", 1537], ["levels", 1551], ["of", 1558], ["arginine", 1561], ["possibly", 1570], ["through", 1579], ["control", 1587], ["of", 1595], ["the", 1598], ["transport", 1602], ["of", 1612], ["this", 1615], ["amino", 1620], ["acid", 1626], ["into", 1631], ["lysosomes", 1636], [".", 1645]]}
{"context": "A monoclonal antibody (mAb) has been produced which reacts with human mitofilin, a mitochondrial inner membrane protein. This mAb immunocaptures its target protein in association with six other proteins, metaxins 1 and 2, SAM50, CHCHD3, CHCHD6 and DnaJC11, respectively. The first three are outer membrane proteins, CHCHD3 has been assigned to the matrix space, and the other two proteins have not been described in mitochondria previously. The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", "qas": [{"question": "What is the localization of the protein encoded by the gene DNAJC11?", "answers": ["mitochondrial inner membrane"], "qid": "8c2a0605602f461d93cb146b331734aa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["localization", 12], ["of", 25], ["the", 28], ["protein", 32], ["encoded", 40], ["by", 48], ["the", 51], ["gene", 55], ["DNAJC11", 60], ["?", 67]], "detected_answers": [{"text": "mitochondrial inner membrane", "token_spans": [[16, 18]], "char_spans": [[83, 110]]}]}], "context_tokens": [["A", 0], ["monoclonal", 2], ["antibody", 13], ["(", 22], ["mAb", 23], [")", 26], ["has", 28], ["been", 32], ["produced", 37], ["which", 46], ["reacts", 52], ["with", 59], ["human", 64], ["mitofilin", 70], [",", 79], ["a", 81], ["mitochondrial", 83], ["inner", 97], ["membrane", 103], ["protein", 112], [".", 119], ["This", 121], ["mAb", 126], ["immunocaptures", 130], ["its", 145], ["target", 149], ["protein", 156], ["in", 164], ["association", 167], ["with", 179], ["six", 184], ["other", 188], ["proteins", 194], [",", 202], ["metaxins", 204], ["1", 213], ["and", 215], ["2", 219], [",", 220], ["SAM50", 222], [",", 227], ["CHCHD3", 229], [",", 235], ["CHCHD6", 237], ["and", 244], ["DnaJC11", 248], [",", 255], ["respectively", 257], [".", 269], ["The", 271], ["first", 275], ["three", 281], ["are", 287], ["outer", 291], ["membrane", 297], ["proteins", 306], [",", 314], ["CHCHD3", 316], ["has", 323], ["been", 327], ["assigned", 332], ["to", 341], ["the", 344], ["matrix", 348], ["space", 355], [",", 360], ["and", 362], ["the", 366], ["other", 370], ["two", 376], ["proteins", 380], ["have", 389], ["not", 394], ["been", 398], ["described", 403], ["in", 413], ["mitochondria", 416], ["previously", 429], [".", 439], ["The", 441], ["functional", 445], ["role", 456], ["of", 461], ["this", 464], ["new", 469], ["complex", 473], ["is", 481], ["uncertain", 484], [".", 493], ["However", 495], [",", 502], ["a", 504], ["role", 506], ["in", 511], ["protein", 514], ["import", 522], ["related", 529], ["to", 537], ["maintenance", 540], ["of", 552], ["mitochondrial", 555], ["structure", 569], ["is", 579], ["suggested", 582], ["as", 592], ["mitofilin", 595], ["helps", 605], ["regulate", 611], ["mitochondrial", 620], ["morphology", 634], ["and", 645], ["at", 649], ["least", 652], ["four", 658], ["of", 663], ["the", 666], ["associated", 670], ["proteins", 681], ["(", 690], ["metaxins", 691], ["1", 700], ["and", 702], ["2", 706], [",", 707], ["SAM50", 709], ["and", 715], ["CHCHD3", 719], [")", 725], ["have", 727], ["been", 732], ["implicated", 737], ["in", 748], ["protein", 751], ["import", 759], [",", 765], ["while", 767], ["DnaJC11", 773], ["is", 781], ["a", 784], ["chaperone", 786], ["-", 795], ["like", 796], ["protein", 801], ["that", 809], ["may", 814], ["have", 818], ["a", 823], ["similar", 825], ["role", 833], [".", 837]]}
{"context": "SECIS elements form stem-loop structures in the 3' untranslated regions (UTR) of eukaryotic mRNAs that encode selenoproteins. These elements direct incorporation of selenocysteine at UGA codons, provided the SECIS element lies a sufficient distance from the UGA. The cDNAs encoding skeletal muscle selenoprotein W from human, rhesus monkey, sheep, rat, and mouse contained highly similar SECIS elements that retained important features common to all known SECIS elements. Comparative analysis of these SECIS elements showed that in some regions both predicted secondary structure and nucleotide sequences were conserved, in other areas secondary structure was maintained using different primary sequence, and in still other portions, base pairing was not conserved. The rodent and sheep selenoprotein W mRNAs used UGA as a stop codon and as a selenocysteine codon. Thus, UGA specified both selenocysteine incorporation and termination in a single mRNA. The selenoprotein W SECIS elements contained an additional highly conserved base-paired stem that may prevent inappropriate selenocysteine incorporation at the UGA stop codons.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22a6d5d4fcc740a0998d3d943187fa60", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [35, 35], [77, 77], [67, 67], [84, 84], [161, 161]], "char_spans": [[0, 4], [208, 212], [456, 460], [388, 392], [502, 506], [973, 977]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["form", 15], ["stem", 20], ["-", 24], ["loop", 25], ["structures", 30], ["in", 41], ["the", 44], ["3", 48], ["'", 49], ["untranslated", 51], ["regions", 64], ["(", 72], ["UTR", 73], [")", 76], ["of", 78], ["eukaryotic", 81], ["mRNAs", 92], ["that", 98], ["encode", 103], ["selenoproteins", 110], [".", 124], ["These", 126], ["elements", 132], ["direct", 141], ["incorporation", 148], ["of", 162], ["selenocysteine", 165], ["at", 180], ["UGA", 183], ["codons", 187], [",", 193], ["provided", 195], ["the", 204], ["SECIS", 208], ["element", 214], ["lies", 222], ["a", 227], ["sufficient", 229], ["distance", 240], ["from", 249], ["the", 254], ["UGA", 258], [".", 261], ["The", 263], ["cDNAs", 267], ["encoding", 273], ["skeletal", 282], ["muscle", 291], ["selenoprotein", 298], ["W", 312], ["from", 314], ["human", 319], [",", 324], ["rhesus", 326], ["monkey", 333], [",", 339], ["sheep", 341], [",", 346], ["rat", 348], [",", 351], ["and", 353], ["mouse", 357], ["contained", 363], ["highly", 373], ["similar", 380], ["SECIS", 388], ["elements", 394], ["that", 403], ["retained", 408], ["important", 417], ["features", 427], ["common", 436], ["to", 443], ["all", 446], ["known", 450], ["SECIS", 456], ["elements", 462], [".", 470], ["Comparative", 472], ["analysis", 484], ["of", 493], ["these", 496], ["SECIS", 502], ["elements", 508], ["showed", 517], ["that", 524], ["in", 529], ["some", 532], ["regions", 537], ["both", 545], ["predicted", 550], ["secondary", 560], ["structure", 570], ["and", 580], ["nucleotide", 584], ["sequences", 595], ["were", 605], ["conserved", 610], [",", 619], ["in", 621], ["other", 624], ["areas", 630], ["secondary", 636], ["structure", 646], ["was", 656], ["maintained", 660], ["using", 671], ["different", 677], ["primary", 687], ["sequence", 695], [",", 703], ["and", 705], ["in", 709], ["still", 712], ["other", 718], ["portions", 724], [",", 732], ["base", 734], ["pairing", 739], ["was", 747], ["not", 751], ["conserved", 755], [".", 764], ["The", 766], ["rodent", 770], ["and", 777], ["sheep", 781], ["selenoprotein", 787], ["W", 801], ["mRNAs", 803], ["used", 809], ["UGA", 814], ["as", 818], ["a", 821], ["stop", 823], ["codon", 828], ["and", 834], ["as", 838], ["a", 841], ["selenocysteine", 843], ["codon", 858], [".", 863], ["Thus", 865], [",", 869], ["UGA", 871], ["specified", 875], ["both", 885], ["selenocysteine", 890], ["incorporation", 905], ["and", 919], ["termination", 923], ["in", 935], ["a", 938], ["single", 940], ["mRNA", 947], [".", 951], ["The", 953], ["selenoprotein", 957], ["W", 971], ["SECIS", 973], ["elements", 979], ["contained", 988], ["an", 998], ["additional", 1001], ["highly", 1012], ["conserved", 1019], ["base", 1029], ["-", 1033], ["paired", 1034], ["stem", 1041], ["that", 1046], ["may", 1051], ["prevent", 1055], ["inappropriate", 1063], ["selenocysteine", 1077], ["incorporation", 1092], ["at", 1106], ["the", 1109], ["UGA", 1113], ["stop", 1117], ["codons", 1122], [".", 1128]]}
{"context": "Iron is the most important transitional metal in the body, as it is implicated in many metabolic processes, mostly related to its capacity as an electron donor/acceptor. Iron deficiency has been long been known to cause anaemia, iron excess to cause haemochromatosis. As excess free iron can cause oxidative damage, it is important that the levels of iron in the body are tightly regulated which appears to be done only by digestive absorption, as there is no known regulating mechanism for elimination of iron. The amount of free iron is also kept to a minimum thanks to binding to transferrin for transport, and to ferritin for storage. Recent research has put emphasis on the possible role of excess iron in the brain in several degenerative diseases. Iron deficiency in the central nervous system is known to cause motor impairment and cognitive deficits; more recently, it has been suggested that it may play a role in the pathophysiology of the restless leg syndrome. 2001 Harcourt Publishers Ltd", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "a60d3d614fee41baa0ba11c2f3e0061f", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [32, 32], [43, 43], [139, 139], [52, 52], [92, 92], [98, 98], [130, 130], [65, 65]], "char_spans": [[0, 3], [170, 173], [229, 232], [755, 758], [283, 286], [506, 509], [531, 534], [703, 706], [351, 354]]}]}], "context_tokens": [["Iron", 0], ["is", 5], ["the", 8], ["most", 12], ["important", 17], ["transitional", 27], ["metal", 40], ["in", 46], ["the", 49], ["body", 53], [",", 57], ["as", 59], ["it", 62], ["is", 65], ["implicated", 68], ["in", 79], ["many", 82], ["metabolic", 87], ["processes", 97], [",", 106], ["mostly", 108], ["related", 115], ["to", 123], ["its", 126], ["capacity", 130], ["as", 139], ["an", 142], ["electron", 145], ["donor", 154], ["/", 159], ["acceptor", 160], [".", 168], ["Iron", 170], ["deficiency", 175], ["has", 186], ["been", 190], ["long", 195], ["been", 200], ["known", 205], ["to", 211], ["cause", 214], ["anaemia", 220], [",", 227], ["iron", 229], ["excess", 234], ["to", 241], ["cause", 244], ["haemochromatosis", 250], [".", 266], ["As", 268], ["excess", 271], ["free", 278], ["iron", 283], ["can", 288], ["cause", 292], ["oxidative", 298], ["damage", 308], [",", 314], ["it", 316], ["is", 319], ["important", 322], ["that", 332], ["the", 337], ["levels", 341], ["of", 348], ["iron", 351], ["in", 356], ["the", 359], ["body", 363], ["are", 368], ["tightly", 372], ["regulated", 380], ["which", 390], ["appears", 396], ["to", 404], ["be", 407], ["done", 410], ["only", 415], ["by", 420], ["digestive", 423], ["absorption", 433], [",", 443], ["as", 445], ["there", 448], ["is", 454], ["no", 457], ["known", 460], ["regulating", 466], ["mechanism", 477], ["for", 487], ["elimination", 491], ["of", 503], ["iron", 506], [".", 510], ["The", 512], ["amount", 516], ["of", 523], ["free", 526], ["iron", 531], ["is", 536], ["also", 539], ["kept", 544], ["to", 549], ["a", 552], ["minimum", 554], ["thanks", 562], ["to", 569], ["binding", 572], ["to", 580], ["transferrin", 583], ["for", 595], ["transport", 599], [",", 608], ["and", 610], ["to", 614], ["ferritin", 617], ["for", 626], ["storage", 630], [".", 637], ["Recent", 639], ["research", 646], ["has", 655], ["put", 659], ["emphasis", 663], ["on", 672], ["the", 675], ["possible", 679], ["role", 688], ["of", 693], ["excess", 696], ["iron", 703], ["in", 708], ["the", 711], ["brain", 715], ["in", 721], ["several", 724], ["degenerative", 732], ["diseases", 745], [".", 753], ["Iron", 755], ["deficiency", 760], ["in", 771], ["the", 774], ["central", 778], ["nervous", 786], ["system", 794], ["is", 801], ["known", 804], ["to", 810], ["cause", 813], ["motor", 819], ["impairment", 825], ["and", 836], ["cognitive", 840], ["deficits", 850], [";", 858], ["more", 860], ["recently", 865], [",", 873], ["it", 875], ["has", 878], ["been", 882], ["suggested", 887], ["that", 897], ["it", 902], ["may", 905], ["play", 909], ["a", 914], ["role", 916], ["in", 921], ["the", 924], ["pathophysiology", 928], ["of", 944], ["the", 947], ["restless", 951], ["leg", 960], ["syndrome", 964], [".", 972], ["2001", 974], ["Harcourt", 979], ["Publishers", 988], ["Ltd", 999]]}
{"context": "Neurofibromatosis type 1 (NF1) is characterized primarily by tumor formation in the nervous system, but patients report other neurological complications including pain and itch. Individuals with NF1 harbor 1 mutated NF1 allele causing heterozygous expression in all of their cells. In mice, Nf1 heterozygosity leads to hyperexcitability of sensory neurons and hyperproliferation of mast cells, both of which could lead to increased hypersensitivity and scratching in response to noxious and pruritic stimuli. To determine whether Nf1 heterozygosity may increase pain and itch behaviors independent of secondary effects of tumor formation, we used mice with a targeted, heterozygous Nf1 gene deletion (Nf1\u00b1) that lack tumors. Nf1\u00b1 mice exhibited normal baseline responses to thermal and mechanical stimuli. Moreover, similar to wild-type littermates, Nf1\u00b1 mice developed inflammation-induced heat\u00a0and mechanical hypersensitivity, capsaicin-induced nocifensive behavior, histamine-dependent or -independent scratching, and chronic constriction injury-induced cold allodynia. However, Nf1\u00b1\u00a0mice exhibited an attenuated first phase of formalin-induced spontaneous behavior and expedited resolution of formalin-induced heat hypersensitivity. These results are not consistent with the hypothesis that Nf1 heterozygosity alone is sufficient to increase pain and itch sensation in mice, and they suggest that additional mechanisms may underlie reports of increased pain and itch in NF1 patients. This study assessed whether Nf1 heterozygosity in mice increased hypersensitivity and scratching following noxious and pruritic stimuli. Using Nf1\u00b1 mice lacking tumors, this study finds no increases in pain or itch behavior, suggesting that there is no predisposition for either clinical symptom solely due to Nf1 heterozygosity.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "40227f76b00344a78411177630545e7b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[48, 48], [83, 83], [107, 107], [30, 30], [205, 205], [234, 234], [285, 285], [4, 4], [34, 34], [241, 241]], "char_spans": [[291, 293], [530, 532], [682, 684], [195, 197], [1295, 1297], [1474, 1476], [1798, 1800], [26, 28], [216, 218], [1516, 1518]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["characterized", 34], ["primarily", 48], ["by", 58], ["tumor", 61], ["formation", 67], ["in", 77], ["the", 80], ["nervous", 84], ["system", 92], [",", 98], ["but", 100], ["patients", 104], ["report", 113], ["other", 120], ["neurological", 126], ["complications", 139], ["including", 153], ["pain", 163], ["and", 168], ["itch", 172], [".", 176], ["Individuals", 178], ["with", 190], ["NF1", 195], ["harbor", 199], ["1", 206], ["mutated", 208], ["NF1", 216], ["allele", 220], ["causing", 227], ["heterozygous", 235], ["expression", 248], ["in", 259], ["all", 262], ["of", 266], ["their", 269], ["cells", 275], [".", 280], ["In", 282], ["mice", 285], [",", 289], ["Nf1", 291], ["heterozygosity", 295], ["leads", 310], ["to", 316], ["hyperexcitability", 319], ["of", 337], ["sensory", 340], ["neurons", 348], ["and", 356], ["hyperproliferation", 360], ["of", 379], ["mast", 382], ["cells", 387], [",", 392], ["both", 394], ["of", 399], ["which", 402], ["could", 408], ["lead", 414], ["to", 419], ["increased", 422], ["hypersensitivity", 432], ["and", 449], ["scratching", 453], ["in", 464], ["response", 467], ["to", 476], ["noxious", 479], ["and", 487], ["pruritic", 491], ["stimuli", 500], [".", 507], ["To", 509], ["determine", 512], ["whether", 522], ["Nf1", 530], ["heterozygosity", 534], ["may", 549], ["increase", 553], ["pain", 562], ["and", 567], ["itch", 571], ["behaviors", 576], ["independent", 586], ["of", 598], ["secondary", 601], ["effects", 611], ["of", 619], ["tumor", 622], ["formation", 628], [",", 637], ["we", 639], ["used", 642], ["mice", 647], ["with", 652], ["a", 657], ["targeted", 659], [",", 667], ["heterozygous", 669], ["Nf1", 682], ["gene", 686], ["deletion", 691], ["(", 700], ["Nf1\u00b1", 701], [")", 705], ["that", 707], ["lack", 712], ["tumors", 717], [".", 723], ["Nf1\u00b1", 725], ["mice", 730], ["exhibited", 735], ["normal", 745], ["baseline", 752], ["responses", 761], ["to", 771], ["thermal", 774], ["and", 782], ["mechanical", 786], ["stimuli", 797], [".", 804], ["Moreover", 806], [",", 814], ["similar", 816], ["to", 824], ["wild", 827], ["-", 831], ["type", 832], ["littermates", 837], [",", 848], ["Nf1\u00b1", 850], ["mice", 855], ["developed", 860], ["inflammation", 870], ["-", 882], ["induced", 883], ["heat", 891], ["and", 896], ["mechanical", 900], ["hypersensitivity", 911], [",", 927], ["capsaicin", 929], ["-", 938], ["induced", 939], ["nocifensive", 947], ["behavior", 959], [",", 967], ["histamine", 969], ["-", 978], ["dependent", 979], ["or", 989], ["-independent", 992], ["scratching", 1005], [",", 1015], ["and", 1017], ["chronic", 1021], ["constriction", 1029], ["injury", 1042], ["-", 1048], ["induced", 1049], ["cold", 1057], ["allodynia", 1062], [".", 1071], ["However", 1073], [",", 1080], ["Nf1\u00b1", 1082], ["mice", 1087], ["exhibited", 1092], ["an", 1102], ["attenuated", 1105], ["first", 1116], ["phase", 1122], ["of", 1128], ["formalin", 1131], ["-", 1139], ["induced", 1140], ["spontaneous", 1148], ["behavior", 1160], ["and", 1169], ["expedited", 1173], ["resolution", 1183], ["of", 1194], ["formalin", 1197], ["-", 1205], ["induced", 1206], ["heat", 1214], ["hypersensitivity", 1219], [".", 1235], ["These", 1237], ["results", 1243], ["are", 1251], ["not", 1255], ["consistent", 1259], ["with", 1270], ["the", 1275], ["hypothesis", 1279], ["that", 1290], ["Nf1", 1295], ["heterozygosity", 1299], ["alone", 1314], ["is", 1320], ["sufficient", 1323], ["to", 1334], ["increase", 1337], ["pain", 1346], ["and", 1351], ["itch", 1355], ["sensation", 1360], ["in", 1370], ["mice", 1373], [",", 1377], ["and", 1379], ["they", 1383], ["suggest", 1388], ["that", 1396], ["additional", 1401], ["mechanisms", 1412], ["may", 1423], ["underlie", 1427], ["reports", 1436], ["of", 1444], ["increased", 1447], ["pain", 1457], ["and", 1462], ["itch", 1466], ["in", 1471], ["NF1", 1474], ["patients", 1478], [".", 1486], ["This", 1488], ["study", 1493], ["assessed", 1499], ["whether", 1508], ["Nf1", 1516], ["heterozygosity", 1520], ["in", 1535], ["mice", 1538], ["increased", 1543], ["hypersensitivity", 1553], ["and", 1570], ["scratching", 1574], ["following", 1585], ["noxious", 1595], ["and", 1603], ["pruritic", 1607], ["stimuli", 1616], [".", 1623], ["Using", 1625], ["Nf1\u00b1", 1631], ["mice", 1636], ["lacking", 1641], ["tumors", 1649], [",", 1655], ["this", 1657], ["study", 1662], ["finds", 1668], ["no", 1674], ["increases", 1677], ["in", 1687], ["pain", 1690], ["or", 1695], ["itch", 1698], ["behavior", 1703], [",", 1711], ["suggesting", 1713], ["that", 1724], ["there", 1729], ["is", 1735], ["no", 1738], ["predisposition", 1741], ["for", 1756], ["either", 1760], ["clinical", 1767], ["symptom", 1776], ["solely", 1784], ["due", 1791], ["to", 1795], ["Nf1", 1798], ["heterozygosity", 1802], [".", 1816]]}
{"context": "Anterograde amnesia, possibly accompanied by acute brain syndrome, is a potential side-effect of certain benzodiazepines, particularly triazolam. Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose. We report a case of triazolam overdose resulting in anterograde amnesia after flumazenil administration had restored clear consciousness. The defect in memory may have been due to too little flumazenil being given or failure of memory consolidation affected by the character of triazolam during the induced lucent period. We feel that physicians should be aware of the potential occurrence of acute brain syndrome in patients with benzodiazepine overdose despite treatment with flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6d6de0afbd534ae696a092a6416d4001", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[116, 116], [55, 55], [23, 23], [73, 73]], "char_spans": [[767, 776], [367, 376], [146, 155], [480, 489]]}]}], "context_tokens": [["Anterograde", 0], ["amnesia", 12], [",", 19], ["possibly", 21], ["accompanied", 30], ["by", 42], ["acute", 45], ["brain", 51], ["syndrome", 57], [",", 65], ["is", 67], ["a", 70], ["potential", 72], ["side", 82], ["-", 86], ["effect", 87], ["of", 94], ["certain", 97], ["benzodiazepines", 105], [",", 120], ["particularly", 122], ["triazolam", 135], [".", 144], ["Flumazenil", 146], ["is", 157], ["a", 160], ["benzodiazepine", 162], ["antagonist", 177], ["that", 188], ["is", 193], ["highly", 196], ["effective", 203], ["in", 213], ["reversing", 216], ["the", 226], ["central", 230], ["nervous", 238], ["system", 246], ["effects", 253], ["of", 261], ["benzodiazepine", 264], ["overdose", 279], [".", 287], ["We", 289], ["report", 292], ["a", 299], ["case", 301], ["of", 306], ["triazolam", 309], ["overdose", 319], ["resulting", 328], ["in", 338], ["anterograde", 341], ["amnesia", 353], ["after", 361], ["flumazenil", 367], ["administration", 378], ["had", 393], ["restored", 397], ["clear", 406], ["consciousness", 412], [".", 425], ["The", 427], ["defect", 431], ["in", 438], ["memory", 441], ["may", 448], ["have", 452], ["been", 457], ["due", 462], ["to", 466], ["too", 469], ["little", 473], ["flumazenil", 480], ["being", 491], ["given", 497], ["or", 503], ["failure", 506], ["of", 514], ["memory", 517], ["consolidation", 524], ["affected", 538], ["by", 547], ["the", 550], ["character", 554], ["of", 564], ["triazolam", 567], ["during", 577], ["the", 584], ["induced", 588], ["lucent", 596], ["period", 603], [".", 609], ["We", 611], ["feel", 614], ["that", 619], ["physicians", 624], ["should", 635], ["be", 642], ["aware", 645], ["of", 651], ["the", 654], ["potential", 658], ["occurrence", 668], ["of", 679], ["acute", 682], ["brain", 688], ["syndrome", 694], ["in", 703], ["patients", 706], ["with", 715], ["benzodiazepine", 720], ["overdose", 735], ["despite", 744], ["treatment", 752], ["with", 762], ["flumazenil", 767], [".", 777]]}
{"context": "To identify the origin and study the morphology of small supernumerary marker chromosome (sSMC) in Turner syndrome with 45, X/46, X, + mar karyotype. Using the conventional chromosome G-banding technique, 10 cases of Turner syndrome with 45, X/46, X, + mar chromosome karyotype were obtained, dual-color fluorescence in situ hybridization was applied to study the origin and morphology of the sSMC. In the 10 cases of Turner syndrome with 45, X/46, X, + mar karyotype, the sSMC of 7 cases was derived from X chromosome [sSMC(X)], the sSMC of 2 cases was derived from Y chromosome [sSMC(Y)] and the remaining 1 case was derived from the autosome. There were 4 cases of ring(r) chromosomes and 3 of centric minutes (min) in the 7 sSMC (X) cases. In the 2 sSMC(Y), one case was dicentric (dic) and the other was centric minute (min). The sSMC originated from the autosome was a centric minute (min). The origin of sSMC of Turner syndrome with 45, X/46, X, + mar karyotype was almost all from sex chromosomes, and rarely from autosomes. sSMC can exist as isodicentric, ring, or centric minute. The molecular cytogenetic features of the sSMC can provide useful information for genetic counseling, prenatal diagnosis and treatment of the Turner syndrome patients with a 45, X/46, X, + mar karyotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "00f4c5c0e5df41acb2f90c62057cceb8", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[156, 156], [268, 268], [103, 103], [89, 89], [24, 24], [209, 209], [49, 49]], "char_spans": [[734, 734], [1274, 1274], [506, 506], [449, 449], [130, 130], [950, 950], [248, 248]]}]}], "context_tokens": [["To", 0], ["identify", 3], ["the", 12], ["origin", 16], ["and", 23], ["study", 27], ["the", 33], ["morphology", 37], ["of", 48], ["small", 51], ["supernumerary", 57], ["marker", 71], ["chromosome", 78], ["(", 89], ["sSMC", 90], [")", 94], ["in", 96], ["Turner", 99], ["syndrome", 106], ["with", 115], ["45", 120], [",", 122], ["X/46", 124], [",", 128], ["X", 130], [",", 131], ["+", 133], ["mar", 135], ["karyotype", 139], [".", 148], ["Using", 150], ["the", 156], ["conventional", 160], ["chromosome", 173], ["G", 184], ["-", 185], ["banding", 186], ["technique", 194], [",", 203], ["10", 205], ["cases", 208], ["of", 214], ["Turner", 217], ["syndrome", 224], ["with", 233], ["45", 238], [",", 240], ["X/46", 242], [",", 246], ["X", 248], [",", 249], ["+", 251], ["mar", 253], ["chromosome", 257], ["karyotype", 268], ["were", 278], ["obtained", 283], [",", 291], ["dual", 293], ["-", 297], ["color", 298], ["fluorescence", 304], ["in", 317], ["situ", 320], ["hybridization", 325], ["was", 339], ["applied", 343], ["to", 351], ["study", 354], ["the", 360], ["origin", 364], ["and", 371], ["morphology", 375], ["of", 386], ["the", 389], ["sSMC", 393], [".", 397], ["In", 399], ["the", 402], ["10", 406], ["cases", 409], ["of", 415], ["Turner", 418], ["syndrome", 425], ["with", 434], ["45", 439], [",", 441], ["X/46", 443], [",", 447], ["X", 449], [",", 450], ["+", 452], ["mar", 454], ["karyotype", 458], [",", 467], ["the", 469], ["sSMC", 473], ["of", 478], ["7", 481], ["cases", 483], ["was", 489], ["derived", 493], ["from", 501], ["X", 506], ["chromosome", 508], ["[", 519], ["sSMC(X", 520], [")", 526], ["]", 527], [",", 528], ["the", 530], ["sSMC", 534], ["of", 539], ["2", 542], ["cases", 544], ["was", 550], ["derived", 554], ["from", 562], ["Y", 567], ["chromosome", 569], ["[", 580], ["sSMC(Y", 581], [")", 587], ["]", 588], ["and", 590], ["the", 594], ["remaining", 598], ["1", 608], ["case", 610], ["was", 615], ["derived", 619], ["from", 627], ["the", 632], ["autosome", 636], [".", 644], ["There", 646], ["were", 652], ["4", 657], ["cases", 659], ["of", 665], ["ring(r", 668], [")", 674], ["chromosomes", 676], ["and", 688], ["3", 692], ["of", 694], ["centric", 697], ["minutes", 705], ["(", 713], ["min", 714], [")", 717], ["in", 719], ["the", 722], ["7", 726], ["sSMC", 728], ["(", 733], ["X", 734], [")", 735], ["cases", 737], [".", 742], ["In", 744], ["the", 747], ["2", 751], ["sSMC(Y", 753], [")", 759], [",", 760], ["one", 762], ["case", 766], ["was", 771], ["dicentric", 775], ["(", 785], ["dic", 786], [")", 789], ["and", 791], ["the", 795], ["other", 799], ["was", 805], ["centric", 809], ["minute", 817], ["(", 824], ["min", 825], [")", 828], [".", 829], ["The", 831], ["sSMC", 835], ["originated", 840], ["from", 851], ["the", 856], ["autosome", 860], ["was", 869], ["a", 873], ["centric", 875], ["minute", 883], ["(", 890], ["min", 891], [")", 894], [".", 895], ["The", 897], ["origin", 901], ["of", 908], ["sSMC", 911], ["of", 916], ["Turner", 919], ["syndrome", 926], ["with", 935], ["45", 940], [",", 942], ["X/46", 944], [",", 948], ["X", 950], [",", 951], ["+", 953], ["mar", 955], ["karyotype", 959], ["was", 969], ["almost", 973], ["all", 980], ["from", 984], ["sex", 989], ["chromosomes", 993], [",", 1004], ["and", 1006], ["rarely", 1010], ["from", 1017], ["autosomes", 1022], [".", 1031], ["sSMC", 1033], ["can", 1038], ["exist", 1042], ["as", 1048], ["isodicentric", 1051], [",", 1063], ["ring", 1065], [",", 1069], ["or", 1071], ["centric", 1074], ["minute", 1082], [".", 1088], ["The", 1090], ["molecular", 1094], ["cytogenetic", 1104], ["features", 1116], ["of", 1125], ["the", 1128], ["sSMC", 1132], ["can", 1137], ["provide", 1141], ["useful", 1149], ["information", 1156], ["for", 1168], ["genetic", 1172], ["counseling", 1180], [",", 1190], ["prenatal", 1192], ["diagnosis", 1201], ["and", 1211], ["treatment", 1215], ["of", 1225], ["the", 1228], ["Turner", 1232], ["syndrome", 1239], ["patients", 1248], ["with", 1257], ["a", 1262], ["45", 1264], [",", 1266], ["X/46", 1268], [",", 1272], ["X", 1274], [",", 1275], ["+", 1277], ["mar", 1279], ["karyotype", 1283], [".", 1292]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy. Using antibodies specific for the cytosolic tail of lamp2a and others recognizing all lamp2 isoforms, we found that in rat liver lamp2a represents 25% of lamp2s in the lysosome. We show that lamp2a levels in the lysosomal membrane in rat liver and fibroblasts in culture directly correlate with rates of chaperone-mediated autophagy in a variety of physiological and pathological conditions. The concentration of other lamp2s in the lysosomal membrane show no correlation under the same conditions. Furthermore, substrate proteins bind to lamp2a but not to other lamp2s. Four positively-charged amino acids uniquely present in the cytosolic tail of lamp2a are required for the binding of substrate proteins. Lamp2a also distributes to an unique subpopulation of perinuclear lysosomes in cultured fibroblasts in response to serum withdrawal, and lamp2a, more than other lamp2s, tends to multimerize. These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "4688b81a249a4edd87b46d5ce300cfcf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[0, 0], [107, 107], [53, 53], [26, 26], [157, 157], [137, 137], [40, 40], [174, 174], [127, 127]], "char_spans": [[0, 5], [647, 652], [299, 304], [160, 165], [953, 958], [816, 821], [237, 242], [1050, 1055], [757, 762]]}]}], "context_tokens": [["Lamp2a", 0], ["acts", 7], ["as", 12], ["a", 15], ["receptor", 17], ["in", 26], ["the", 29], ["lysosomal", 33], ["membrane", 43], ["for", 52], ["substrate", 56], ["proteins", 66], ["of", 75], ["chaperone", 78], ["-", 87], ["mediated", 88], ["autophagy", 97], [".", 106], ["Using", 108], ["antibodies", 114], ["specific", 125], ["for", 134], ["the", 138], ["cytosolic", 142], ["tail", 152], ["of", 157], ["lamp2a", 160], ["and", 167], ["others", 171], ["recognizing", 178], ["all", 190], ["lamp2", 194], ["isoforms", 200], [",", 208], ["we", 210], ["found", 213], ["that", 219], ["in", 224], ["rat", 227], ["liver", 231], ["lamp2a", 237], ["represents", 244], ["25", 255], ["%", 257], ["of", 259], ["lamp2s", 262], ["in", 269], ["the", 272], ["lysosome", 276], [".", 284], ["We", 286], ["show", 289], ["that", 294], ["lamp2a", 299], ["levels", 306], ["in", 313], ["the", 316], ["lysosomal", 320], ["membrane", 330], ["in", 339], ["rat", 342], ["liver", 346], ["and", 352], ["fibroblasts", 356], ["in", 368], ["culture", 371], ["directly", 379], ["correlate", 388], ["with", 398], ["rates", 403], ["of", 409], ["chaperone", 412], ["-", 421], ["mediated", 422], ["autophagy", 431], ["in", 441], ["a", 444], ["variety", 446], ["of", 454], ["physiological", 457], ["and", 471], ["pathological", 475], ["conditions", 488], [".", 498], ["The", 500], ["concentration", 504], ["of", 518], ["other", 521], ["lamp2s", 527], ["in", 534], ["the", 537], ["lysosomal", 541], ["membrane", 551], ["show", 560], ["no", 565], ["correlation", 568], ["under", 580], ["the", 586], ["same", 590], ["conditions", 595], [".", 605], ["Furthermore", 607], [",", 618], ["substrate", 620], ["proteins", 630], ["bind", 639], ["to", 644], ["lamp2a", 647], ["but", 654], ["not", 658], ["to", 662], ["other", 665], ["lamp2s", 671], [".", 677], ["Four", 679], ["positively", 684], ["-", 694], ["charged", 695], ["amino", 703], ["acids", 709], ["uniquely", 715], ["present", 724], ["in", 732], ["the", 735], ["cytosolic", 739], ["tail", 749], ["of", 754], ["lamp2a", 757], ["are", 764], ["required", 768], ["for", 777], ["the", 781], ["binding", 785], ["of", 793], ["substrate", 796], ["proteins", 806], [".", 814], ["Lamp2a", 816], ["also", 823], ["distributes", 828], ["to", 840], ["an", 843], ["unique", 846], ["subpopulation", 853], ["of", 867], ["perinuclear", 870], ["lysosomes", 882], ["in", 892], ["cultured", 895], ["fibroblasts", 904], ["in", 916], ["response", 919], ["to", 928], ["serum", 931], ["withdrawal", 937], [",", 947], ["and", 949], ["lamp2a", 953], [",", 959], ["more", 961], ["than", 966], ["other", 971], ["lamp2s", 977], [",", 983], ["tends", 985], ["to", 991], ["multimerize", 994], [".", 1005], ["These", 1007], ["characteristics", 1013], ["may", 1029], ["be", 1033], ["important", 1036], ["for", 1046], ["lamp2a", 1050], ["to", 1057], ["act", 1060], ["as", 1064], ["a", 1067], ["receptor", 1069], ["for", 1078], ["chaperone", 1082], ["-", 1091], ["mediated", 1092], ["autophagy", 1101], [".", 1110]]}
{"context": "Restless legs syndrome (RLS)/Willis-Ekbom disease (WED) is a common disorder, occurring at least twice a week and causing at least moderate distress in 1.5% to 2.7% of the population. It is important for primary care physicians to be familiar with this disorder and its management. Much has changed in its management since our previous algorithm was published in 2004, including the availability of several new drugs. This revised algorithm was written by members of the Medical Advisory Board of the Willis-Ekbom Disease Syndrome Foundation based on scientific evidence and expert opinion. It considers the management of RLS/WED under intermittent RLS/WED, chronic persistent RLS/WED, and refractory RLS/WED. Nonpharmacological approaches, including mental alerting activities, avoiding substances or medications that may exacerbate RLS, and the role of iron supplementation, are outlined. Chronic persistent RLS/WED should be treated with either a nonergot dopamine agonist or a calcium channel \u03b1-2-\u03b4 ligand. We discuss the available drugs, the factors determining which to use, and their adverse effects. We define refractory RLS/WED and describe management approaches, including combination therapy and the use of high-potency opioids.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "aaaca8061b664f71a0d95197ca5ed5a3", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS)/Willis", 24], ["-", 35], ["Ekbom", 36], ["disease", 42], ["(", 50], ["WED", 51], [")", 54], ["is", 56], ["a", 59], ["common", 61], ["disorder", 68], [",", 76], ["occurring", 78], ["at", 88], ["least", 91], ["twice", 97], ["a", 103], ["week", 105], ["and", 110], ["causing", 114], ["at", 122], ["least", 125], ["moderate", 131], ["distress", 140], ["in", 149], ["1.5", 152], ["%", 155], ["to", 157], ["2.7", 160], ["%", 163], ["of", 165], ["the", 168], ["population", 172], [".", 182], ["It", 184], ["is", 187], ["important", 190], ["for", 200], ["primary", 204], ["care", 212], ["physicians", 217], ["to", 228], ["be", 231], ["familiar", 234], ["with", 243], ["this", 248], ["disorder", 253], ["and", 262], ["its", 266], ["management", 270], [".", 280], ["Much", 282], ["has", 287], ["changed", 291], ["in", 299], ["its", 302], ["management", 306], ["since", 317], ["our", 323], ["previous", 327], ["algorithm", 336], ["was", 346], ["published", 350], ["in", 360], ["2004", 363], [",", 367], ["including", 369], ["the", 379], ["availability", 383], ["of", 396], ["several", 399], ["new", 407], ["drugs", 411], [".", 416], ["This", 418], ["revised", 423], ["algorithm", 431], ["was", 441], ["written", 445], ["by", 453], ["members", 456], ["of", 464], ["the", 467], ["Medical", 471], ["Advisory", 479], ["Board", 488], ["of", 494], ["the", 497], ["Willis", 501], ["-", 507], ["Ekbom", 508], ["Disease", 514], ["Syndrome", 522], ["Foundation", 531], ["based", 542], ["on", 548], ["scientific", 551], ["evidence", 562], ["and", 571], ["expert", 575], ["opinion", 582], [".", 589], ["It", 591], ["considers", 594], ["the", 604], ["management", 608], ["of", 619], ["RLS", 622], ["/", 625], ["WED", 626], ["under", 630], ["intermittent", 636], ["RLS", 649], ["/", 652], ["WED", 653], [",", 656], ["chronic", 658], ["persistent", 666], ["RLS", 677], ["/", 680], ["WED", 681], [",", 684], ["and", 686], ["refractory", 690], ["RLS", 701], ["/", 704], ["WED", 705], [".", 708], ["Nonpharmacological", 710], ["approaches", 729], [",", 739], ["including", 741], ["mental", 751], ["alerting", 758], ["activities", 767], [",", 777], ["avoiding", 779], ["substances", 788], ["or", 799], ["medications", 802], ["that", 814], ["may", 819], ["exacerbate", 823], ["RLS", 834], [",", 837], ["and", 839], ["the", 843], ["role", 847], ["of", 852], ["iron", 855], ["supplementation", 860], [",", 875], ["are", 877], ["outlined", 881], [".", 889], ["Chronic", 891], ["persistent", 899], ["RLS", 910], ["/", 913], ["WED", 914], ["should", 918], ["be", 925], ["treated", 928], ["with", 936], ["either", 941], ["a", 948], ["nonergot", 950], ["dopamine", 959], ["agonist", 968], ["or", 976], ["a", 979], ["calcium", 981], ["channel", 989], ["\u03b1-2-\u03b4", 997], ["ligand", 1003], [".", 1009], ["We", 1011], ["discuss", 1014], ["the", 1022], ["available", 1026], ["drugs", 1036], [",", 1041], ["the", 1043], ["factors", 1047], ["determining", 1055], ["which", 1067], ["to", 1073], ["use", 1076], [",", 1079], ["and", 1081], ["their", 1085], ["adverse", 1091], ["effects", 1099], [".", 1106], ["We", 1108], ["define", 1111], ["refractory", 1118], ["RLS", 1129], ["/", 1132], ["WED", 1133], ["and", 1137], ["describe", 1141], ["management", 1150], ["approaches", 1161], [",", 1171], ["including", 1173], ["combination", 1183], ["therapy", 1195], ["and", 1203], ["the", 1207], ["use", 1211], ["of", 1215], ["high", 1218], ["-", 1222], ["potency", 1223], ["opioids", 1231], [".", 1238]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose. Thirteen emergency departments enrolled 326 patients in this double-blind, placebo-controlled trial; 162 patients were randomly allocated to receive flumazenil (maximum dose, 30 ml, providing 3 mg of flumazenil), and 164 were allocated to receive placebo (maximum dose, 30 ml). A successful response was the attainment of a score of 1 or 2 on the Clinical Global Impression Scale (CGIS), denoting a very much improved or much improved status, 10 minutes after the start of intravenous administration of the test drug. Among those patients whose drug screen revealed the presence of benzodiazepines, 75 (77%) of 97 patients given flumazenil and 13 (16%) of 83 given placebo attained such a response. The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo. As determined by the Neurobehavioral Assessment Scale, 61% of patients who initially responded became resedated; in these patients, the effect of flumazenil lasted a median of 90 minutes. At the investigator's discretion, patients who did not achieve a criterion response in the double-blind trial could receive open-label flumazenil, titrated as in the double-blind phase. Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded. Safety was assessed in all 326 patients given the test drug. The most frequent adverse experiences after the administration of flumazenil were agitation (7%), vomiting (7%), abnormal crying (4%), and nausea (4%); these effects were observed with a lower frequency in the placebo group. Serious adverse experiences were reported in 4 patients; these included seizures and cardiac arrhythmias. Of the 3 patients with seizures, 2 had ingested large doses of cyclic antidepressants in addition to the benzodiazepine. The toxicology screen for 1 of the 2 showed 1900 ng/ml of amoxapine and 900 ng/ml of nortriptyline; the toxicology screen for the other, who also had ventricular tachycardia, showed 1928 ng/ml of loxapine and 301 ng/ml of amoxapine. The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose. This was accomplished irrespective of the presence of coingested drugs. Flumazenil is not recommended for patients with serious cyclic antidepressant poisoning or those who use benzodiazepines therapeutically to control seizure disorders. When used as recommended, however, flumazenil has been shown to have an acceptable safety level.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c0676b791a034e7e90ddf7a04c68ddd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [272, 272], [43, 43], [205, 205], [170, 170], [266, 266], [502, 502], [140, 140], [308, 308], [55, 55], [473, 473], [238, 238], [449, 449]], "char_spans": [[0, 9], [1467, 1476], [281, 290], [1118, 1127], [915, 924], [1422, 1431], [2729, 2738], [761, 770], [1667, 1676], [332, 341], [2527, 2536], [1295, 1304], [2357, 2366]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["was", 50], ["evaluated", 54], ["as", 64], ["adjunctive", 67], ["therapy", 78], ["in", 86], ["the", 89], ["management", 93], ["of", 104], ["benzodiazepine", 107], ["overdose", 122], [".", 130], ["Thirteen", 132], ["emergency", 141], ["departments", 151], ["enrolled", 163], ["326", 172], ["patients", 176], ["in", 185], ["this", 188], ["double", 193], ["-", 199], ["blind", 200], [",", 205], ["placebo", 207], ["-", 214], ["controlled", 215], ["trial", 226], [";", 231], ["162", 233], ["patients", 237], ["were", 246], ["randomly", 251], ["allocated", 260], ["to", 270], ["receive", 273], ["flumazenil", 281], ["(", 292], ["maximum", 293], ["dose", 301], [",", 305], ["30", 307], ["ml", 310], [",", 312], ["providing", 314], ["3", 324], ["mg", 326], ["of", 329], ["flumazenil", 332], [")", 342], [",", 343], ["and", 345], ["164", 349], ["were", 353], ["allocated", 358], ["to", 368], ["receive", 371], ["placebo", 379], ["(", 387], ["maximum", 388], ["dose", 396], [",", 400], ["30", 402], ["ml", 405], [")", 407], [".", 408], ["A", 410], ["successful", 412], ["response", 423], ["was", 432], ["the", 436], ["attainment", 440], ["of", 451], ["a", 454], ["score", 456], ["of", 462], ["1", 465], ["or", 467], ["2", 470], ["on", 472], ["the", 475], ["Clinical", 479], ["Global", 488], ["Impression", 495], ["Scale", 506], ["(", 512], ["CGIS", 513], [")", 517], [",", 518], ["denoting", 520], ["a", 529], ["very", 531], ["much", 536], ["improved", 541], ["or", 550], ["much", 553], ["improved", 558], ["status", 567], [",", 573], ["10", 575], ["minutes", 578], ["after", 586], ["the", 592], ["start", 596], ["of", 602], ["intravenous", 605], ["administration", 617], ["of", 632], ["the", 635], ["test", 639], ["drug", 644], [".", 648], ["Among", 650], ["those", 656], ["patients", 662], ["whose", 671], ["drug", 677], ["screen", 682], ["revealed", 689], ["the", 698], ["presence", 702], ["of", 711], ["benzodiazepines", 714], [",", 729], ["75", 731], ["(", 734], ["77", 735], ["%", 737], [")", 738], ["of", 740], ["97", 743], ["patients", 746], ["given", 755], ["flumazenil", 761], ["and", 772], ["13", 776], ["(", 779], ["16", 780], ["%", 782], [")", 783], ["of", 785], ["83", 788], ["given", 791], ["placebo", 797], ["attained", 805], ["such", 814], ["a", 819], ["response", 821], [".", 829], ["The", 831], ["mean", 835], ["CGIS", 840], ["score", 845], ["at", 851], ["10", 854], ["minutes", 857], ["for", 865], ["benzodiazepine", 869], ["-", 883], ["positive", 884], ["patients", 893], ["treated", 902], ["with", 910], ["flumazenil", 915], ["was", 926], ["1.95", 930], ["versus", 935], ["3.58", 942], ["for", 947], ["those", 951], ["given", 957], ["placebo", 963], [".", 970], ["As", 972], ["determined", 975], ["by", 986], ["the", 989], ["Neurobehavioral", 993], ["Assessment", 1009], ["Scale", 1020], [",", 1025], ["61", 1027], ["%", 1029], ["of", 1031], ["patients", 1034], ["who", 1043], ["initially", 1047], ["responded", 1057], ["became", 1067], ["resedated", 1074], [";", 1083], ["in", 1085], ["these", 1088], ["patients", 1094], [",", 1102], ["the", 1104], ["effect", 1108], ["of", 1115], ["flumazenil", 1118], ["lasted", 1129], ["a", 1136], ["median", 1138], ["of", 1145], ["90", 1148], ["minutes", 1151], [".", 1158], ["At", 1160], ["the", 1163], ["investigator", 1167], ["'s", 1179], ["discretion", 1182], [",", 1192], ["patients", 1194], ["who", 1203], ["did", 1207], ["not", 1211], ["achieve", 1215], ["a", 1223], ["criterion", 1225], ["response", 1235], ["in", 1244], ["the", 1247], ["double", 1251], ["-", 1257], ["blind", 1258], ["trial", 1264], ["could", 1270], ["receive", 1276], ["open", 1284], ["-", 1288], ["label", 1289], ["flumazenil", 1295], [",", 1305], ["titrated", 1307], ["as", 1316], ["in", 1319], ["the", 1322], ["double", 1326], ["-", 1332], ["blind", 1333], ["phase", 1339], [".", 1344], ["Among", 1346], ["the", 1352], ["benzodiazepine", 1356], ["-", 1370], ["positive", 1371], ["patients", 1380], [",", 1388], ["9", 1390], ["(", 1392], ["53", 1393], ["%", 1395], [")", 1396], ["of", 1398], ["17", 1401], ["patients", 1404], ["from", 1413], ["the", 1418], ["flumazenil", 1422], ["group", 1433], ["responded", 1439], ["to", 1449], ["the", 1452], ["additional", 1456], ["flumazenil", 1467], [",", 1477], ["and", 1479], ["58", 1483], ["(", 1486], ["81", 1487], ["%", 1489], [")", 1490], ["of", 1492], ["patients", 1495], ["previously", 1504], ["given", 1515], ["placebo", 1521], ["responded", 1529], [".", 1538], ["Safety", 1540], ["was", 1547], ["assessed", 1551], ["in", 1560], ["all", 1563], ["326", 1567], ["patients", 1571], ["given", 1580], ["the", 1586], ["test", 1590], ["drug", 1595], [".", 1599], ["The", 1601], ["most", 1605], ["frequent", 1610], ["adverse", 1619], ["experiences", 1627], ["after", 1639], ["the", 1645], ["administration", 1649], ["of", 1664], ["flumazenil", 1667], ["were", 1678], ["agitation", 1683], ["(", 1693], ["7", 1694], ["%", 1695], [")", 1696], [",", 1697], ["vomiting", 1699], ["(", 1708], ["7", 1709], ["%", 1710], [")", 1711], [",", 1712], ["abnormal", 1714], ["crying", 1723], ["(", 1730], ["4", 1731], ["%", 1732], [")", 1733], [",", 1734], ["and", 1736], ["nausea", 1740], ["(", 1747], ["4", 1748], ["%", 1749], [")", 1750], [";", 1751], ["these", 1753], ["effects", 1759], ["were", 1767], ["observed", 1772], ["with", 1781], ["a", 1786], ["lower", 1788], ["frequency", 1794], ["in", 1804], ["the", 1807], ["placebo", 1811], ["group", 1819], [".", 1824], ["Serious", 1826], ["adverse", 1834], ["experiences", 1842], ["were", 1854], ["reported", 1859], ["in", 1868], ["4", 1871], ["patients", 1873], [";", 1881], ["these", 1883], ["included", 1889], ["seizures", 1898], ["and", 1907], ["cardiac", 1911], ["arrhythmias", 1919], [".", 1930], ["Of", 1932], ["the", 1935], ["3", 1939], ["patients", 1941], ["with", 1950], ["seizures", 1955], [",", 1963], ["2", 1965], ["had", 1967], ["ingested", 1971], ["large", 1980], ["doses", 1986], ["of", 1992], ["cyclic", 1995], ["antidepressants", 2002], ["in", 2018], ["addition", 2021], ["to", 2030], ["the", 2033], ["benzodiazepine", 2037], [".", 2051], ["The", 2053], ["toxicology", 2057], ["screen", 2068], ["for", 2075], ["1", 2079], ["of", 2081], ["the", 2084], ["2", 2088], ["showed", 2090], ["1900", 2097], ["ng", 2102], ["/", 2104], ["ml", 2105], ["of", 2108], ["amoxapine", 2111], ["and", 2121], ["900", 2125], ["ng", 2129], ["/", 2131], ["ml", 2132], ["of", 2135], ["nortriptyline", 2138], [";", 2151], ["the", 2153], ["toxicology", 2157], ["screen", 2168], ["for", 2175], ["the", 2179], ["other", 2183], [",", 2188], ["who", 2190], ["also", 2194], ["had", 2199], ["ventricular", 2203], ["tachycardia", 2215], [",", 2226], ["showed", 2228], ["1928", 2235], ["ng", 2240], ["/", 2242], ["ml", 2243], ["of", 2246], ["loxapine", 2249], ["and", 2258], ["301", 2262], ["ng", 2266], ["/", 2268], ["ml", 2269], ["of", 2272], ["amoxapine", 2275], [".", 2284], ["The", 2286], ["results", 2290], ["of", 2298], ["this", 2301], ["study", 2306], ["confirm", 2312], ["published", 2320], ["reports", 2330], ["of", 2338], ["the", 2341], ["efficacy", 2345], ["of", 2354], ["flumazenil", 2357], ["in", 2368], ["reversing", 2371], ["benzodiazepine", 2381], ["-", 2395], ["induced", 2396], ["sedation", 2404], ["in", 2413], ["patients", 2416], ["with", 2425], ["benzodiazepine", 2430], ["overdose", 2445], [".", 2453], ["This", 2455], ["was", 2460], ["accomplished", 2464], ["irrespective", 2477], ["of", 2490], ["the", 2493], ["presence", 2497], ["of", 2506], ["coingested", 2509], ["drugs", 2520], [".", 2525], ["Flumazenil", 2527], ["is", 2538], ["not", 2541], ["recommended", 2545], ["for", 2557], ["patients", 2561], ["with", 2570], ["serious", 2575], ["cyclic", 2583], ["antidepressant", 2590], ["poisoning", 2605], ["or", 2615], ["those", 2618], ["who", 2624], ["use", 2628], ["benzodiazepines", 2632], ["therapeutically", 2648], ["to", 2664], ["control", 2667], ["seizure", 2675], ["disorders", 2683], [".", 2692], ["When", 2694], ["used", 2699], ["as", 2704], ["recommended", 2707], [",", 2718], ["however", 2720], [",", 2727], ["flumazenil", 2729], ["has", 2740], ["been", 2744], ["shown", 2749], ["to", 2755], ["have", 2758], ["an", 2763], ["acceptable", 2766], ["safety", 2777], ["level", 2784], [".", 2789]]}
{"context": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "c1fed25571dd435caf919c7770d931d8", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[70, 113]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["exons", 21], ["encoding", 27], ["the", 36], ["tyrosine", 40], ["kinase", 49], ["domain", 56], ["of", 63], ["the", 66], ["epidermal", 70], ["growth", 80], ["factor", 87], ["receptor", 94], ["(", 103], ["EGFR", 104], [")", 108], ["gene", 110], ["are", 115], ["found", 119], ["in", 125], ["human", 128], ["lung", 134], ["adenocarcinomas", 139], ["and", 155], ["are", 159], ["associated", 163], ["with", 174], ["sensitivity", 179], ["to", 191], ["the", 194], ["tyrosine", 198], ["kinase", 207], ["inhibitors", 214], ["gefitinib", 225], ["and", 235], ["erlotinib", 239], [".", 248], ["Nearly", 250], ["90", 257], ["%", 259], ["of", 261], ["the", 264], ["EGFR", 268], ["mutations", 273], ["are", 283], ["either", 287], ["short", 294], [",", 299], ["in", 301], ["-", 303], ["frame", 304], ["deletions", 310], ["in", 320], ["exon", 323], ["19", 328], ["or", 331], ["point", 334], ["mutations", 340], ["that", 350], ["result", 355], ["in", 362], ["substitution", 365], ["of", 378], ["arginine", 381], ["for", 390], ["leucine", 394], ["at", 402], ["amino", 405], ["acid", 411], ["858", 416], ["(", 420], ["L858R", 421], [")", 426], [".", 427], ["To", 429], ["study", 432], ["further", 438], ["the", 446], ["role", 450], ["of", 455], ["these", 458], ["mutations", 464], ["in", 474], ["the", 477], ["initiation", 481], ["and", 492], ["maintenance", 496], ["of", 508], ["lung", 511], ["cancer", 516], [",", 522], ["we", 524], ["have", 527], ["developed", 532], ["transgenic", 542], ["mice", 553], ["that", 558], ["express", 563], ["an", 571], ["exon", 574], ["19", 579], ["deletion", 582], ["mutant", 591], ["(", 598], ["EGFR(DeltaL747-S752", 599], [")", 618], [")", 619], ["or", 621], ["the", 624], ["L858R", 628], ["mutant", 634], ["(", 641], ["EGFR(L858R", 642], [")", 652], [")", 653], ["in", 655], ["type", 658], ["II", 663], ["pneumocytes", 666], ["under", 678], ["the", 684], ["control", 688], ["of", 696], ["doxycycline", 699], [".", 710], ["Expression", 712], ["of", 723], ["either", 726], ["EGFR", 733], ["mutant", 738], ["leads", 745], ["to", 751], ["the", 754], ["development", 758], ["of", 770], ["lung", 773], ["adenocarcinomas", 778], [".", 793], ["Two", 795], ["weeks", 799], ["after", 805], ["induction", 811], ["with", 821], ["doxycycline", 826], [",", 837], ["mice", 839], ["that", 844], ["express", 849], ["the", 857], ["EGFR(L858R", 861], [")", 871], ["allele", 873], ["show", 880], ["diffuse", 885], ["lung", 893], ["cancer", 898], ["highly", 905], ["reminiscent", 912], ["of", 924], ["human", 927], ["bronchioloalveolar", 933], ["carcinoma", 952], ["and", 962], ["later", 966], ["develop", 972], ["interspersed", 980], ["multifocal", 993], ["adenocarcinomas", 1004], [".", 1019], ["In", 1021], ["contrast", 1024], [",", 1032], ["mice", 1034], ["expressing", 1039], ["EGFR(DeltaL747-S752", 1050], [")", 1069], ["develop", 1071], ["multifocal", 1079], ["tumors", 1090], ["embedded", 1097], ["in", 1106], ["normal", 1109], ["lung", 1116], ["parenchyma", 1121], ["with", 1132], ["a", 1137], ["longer", 1139], ["latency", 1146], [".", 1153], ["With", 1155], ["mice", 1160], ["carrying", 1165], ["either", 1174], ["EGFR", 1181], ["allele", 1186], [",", 1192], ["withdrawal", 1194], ["of", 1205], ["doxycycline", 1208], ["(", 1220], ["to", 1221], ["reduce", 1224], ["expression", 1231], ["of", 1242], ["the", 1245], ["transgene", 1249], [")", 1258], ["or", 1260], ["treatment", 1263], ["with", 1273], ["erlotinib", 1278], ["(", 1288], ["to", 1289], ["inhibit", 1292], ["kinase", 1300], ["activity", 1307], [")", 1315], ["causes", 1317], ["rapid", 1324], ["tumor", 1330], ["regression", 1336], [",", 1346], ["as", 1348], ["assessed", 1351], ["by", 1360], ["magnetic", 1363], ["resonance", 1372], ["imaging", 1382], ["and", 1390], ["histopathology", 1394], [",", 1408], ["demonstrating", 1410], ["that", 1424], ["mutant", 1429], ["EGFR", 1436], ["is", 1441], ["required", 1444], ["for", 1453], ["tumor", 1457], ["maintenance", 1463], [".", 1474], ["These", 1476], ["models", 1482], ["may", 1489], ["be", 1493], ["useful", 1496], ["for", 1503], ["developing", 1507], ["improved", 1518], ["therapies", 1527], ["for", 1537], ["patients", 1541], ["with", 1550], ["lung", 1555], ["cancers", 1560], ["bearing", 1568], ["EGFR", 1576], ["mutations", 1581], [".", 1590]]}
{"context": "Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder affecting one in 3,500 individuals. The mutation rate in the NF1 gene is one of the highest known for human genes. Compared to other methods, the protein truncation test (PTT) provides improved efficiency in detecting NF1 mutations which are dispersed throughout the gene which spans 350 kilobases of genomic DNA. We have applied the PTT and subsequent sequence analysis of cloned cDNA to identify mutations in NF1 patients. We report here the identification of two novel (W336X and Q315X), and one recurrent (R304X) mutation located in exon 7 and show that all three premature termination codons lead to skipping of exon 7 in a proportion of the transcripts derived from the mutated allele. Possible mutation-induced alterations of the RNA secondary structure and their impact on skipping of exon 7 of the NF1 gene are explored and discussed.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "b4e786bd8b8a4087859d3959d3641b2a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[84, 84], [4, 4], [52, 52], [23, 23], [158, 158]], "char_spans": [[484, 486], [26, 28], [291, 293], [134, 136], [880, 882]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["an", 34], ["autosomal", 37], ["dominant", 47], ["genetic", 56], ["disorder", 64], ["affecting", 73], ["one", 83], ["in", 87], ["3,500", 90], ["individuals", 96], [".", 107], ["The", 109], ["mutation", 113], ["rate", 122], ["in", 127], ["the", 130], ["NF1", 134], ["gene", 138], ["is", 143], ["one", 146], ["of", 150], ["the", 153], ["highest", 157], ["known", 165], ["for", 171], ["human", 175], ["genes", 181], [".", 186], ["Compared", 188], ["to", 197], ["other", 200], ["methods", 206], [",", 213], ["the", 215], ["protein", 219], ["truncation", 227], ["test", 238], ["(", 243], ["PTT", 244], [")", 247], ["provides", 249], ["improved", 258], ["efficiency", 267], ["in", 278], ["detecting", 281], ["NF1", 291], ["mutations", 295], ["which", 305], ["are", 311], ["dispersed", 315], ["throughout", 325], ["the", 336], ["gene", 340], ["which", 345], ["spans", 351], ["350", 357], ["kilobases", 361], ["of", 371], ["genomic", 374], ["DNA", 382], [".", 385], ["We", 387], ["have", 390], ["applied", 395], ["the", 403], ["PTT", 407], ["and", 411], ["subsequent", 415], ["sequence", 426], ["analysis", 435], ["of", 444], ["cloned", 447], ["cDNA", 454], ["to", 459], ["identify", 462], ["mutations", 471], ["in", 481], ["NF1", 484], ["patients", 488], [".", 496], ["We", 498], ["report", 501], ["here", 508], ["the", 513], ["identification", 517], ["of", 532], ["two", 535], ["novel", 539], ["(", 545], ["W336X", 546], ["and", 552], ["Q315X", 556], [")", 561], [",", 562], ["and", 564], ["one", 568], ["recurrent", 572], ["(", 582], ["R304X", 583], [")", 588], ["mutation", 590], ["located", 599], ["in", 607], ["exon", 610], ["7", 615], ["and", 617], ["show", 621], ["that", 626], ["all", 631], ["three", 635], ["premature", 641], ["termination", 651], ["codons", 663], ["lead", 670], ["to", 675], ["skipping", 678], ["of", 687], ["exon", 690], ["7", 695], ["in", 697], ["a", 700], ["proportion", 702], ["of", 713], ["the", 716], ["transcripts", 720], ["derived", 732], ["from", 740], ["the", 745], ["mutated", 749], ["allele", 757], [".", 763], ["Possible", 765], ["mutation", 774], ["-", 782], ["induced", 783], ["alterations", 791], ["of", 803], ["the", 806], ["RNA", 810], ["secondary", 814], ["structure", 824], ["and", 834], ["their", 838], ["impact", 844], ["on", 851], ["skipping", 854], ["of", 863], ["exon", 866], ["7", 871], ["of", 873], ["the", 876], ["NF1", 880], ["gene", 884], ["are", 889], ["explored", 893], ["and", 902], ["discussed", 906], [".", 915]]}
{"context": "Mutations in the alpha-synuclein gene have been linked to rare cases of familial Parkinson's disease (PD). Alpha-synuclein is a major component of Lewy bodies (LB), a pathological hallmark of PD. Transgenic mice and Drosophila expressing either wild-type or mutant human alpha-synuclein develop motor deficits, LB-like inclusions in some neurons, and neuronal degeneration. However, the relationship between abnormal aggregates of alpha-synuclein and human dopamine (DA) neuron degeneration remains unclear. In this report, we have investigated the influence of alpha-synuclein expression on DA neurons in primary culture of embryonic human mesencephalon. Two days after culture, human DA cells were transduced with wild-type or mutant human (Ala(53)Thr) alpha-synuclein adenoviruses and maintained for 5 days. Overexpression of mutant and wild-type human alpha-synuclein resulted in 49% (P<0.01) and 27% (P<0.05) loss of DA neurons, respectively, while not affecting viability of other cells in the culture. Overexpression of rat alpha-synuclein or GFP (green fluorescent protein) had no effect on DA neuron survival. Cytoplasmic inclusions of alpha-synuclein were detected immunohistochemically in DA cells transduced with mutant human alpha-synuclein, but not wild-type alpha-synuclein. These results show that overexpression of human alpha-synuclein, particularly the mutant form, can cause human DA neuron death, suggesting that alpha-synuclein may have a primary role in the pathogenesis of PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "5d3ed014bc4046eda811724747a7aa23", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[195, 197], [81, 83], [54, 56], [22, 24], [140, 142], [158, 160], [238, 240], [267, 269], [229, 231], [216, 218], [105, 107], [249, 251], [3, 5]], "char_spans": [[1031, 1045], [431, 445], [271, 285], [107, 121], [755, 769], [856, 870], [1273, 1287], [1434, 1448], [1238, 1252], [1145, 1159], [562, 576], [1338, 1352], [17, 31]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["alpha", 17], ["-", 22], ["synuclein", 23], ["gene", 33], ["have", 38], ["been", 43], ["linked", 48], ["to", 55], ["rare", 58], ["cases", 63], ["of", 69], ["familial", 72], ["Parkinson", 81], ["'s", 90], ["disease", 93], ["(", 101], ["PD", 102], [")", 104], [".", 105], ["Alpha", 107], ["-", 112], ["synuclein", 113], ["is", 123], ["a", 126], ["major", 128], ["component", 134], ["of", 144], ["Lewy", 147], ["bodies", 152], ["(", 159], ["LB", 160], [")", 162], [",", 163], ["a", 165], ["pathological", 167], ["hallmark", 180], ["of", 189], ["PD", 192], [".", 194], ["Transgenic", 196], ["mice", 207], ["and", 212], ["Drosophila", 216], ["expressing", 227], ["either", 238], ["wild", 245], ["-", 249], ["type", 250], ["or", 255], ["mutant", 258], ["human", 265], ["alpha", 271], ["-", 276], ["synuclein", 277], ["develop", 287], ["motor", 295], ["deficits", 301], [",", 309], ["LB", 311], ["-", 313], ["like", 314], ["inclusions", 319], ["in", 330], ["some", 333], ["neurons", 338], [",", 345], ["and", 347], ["neuronal", 351], ["degeneration", 360], [".", 372], ["However", 374], [",", 381], ["the", 383], ["relationship", 387], ["between", 400], ["abnormal", 408], ["aggregates", 417], ["of", 428], ["alpha", 431], ["-", 436], ["synuclein", 437], ["and", 447], ["human", 451], ["dopamine", 457], ["(", 466], ["DA", 467], [")", 469], ["neuron", 471], ["degeneration", 478], ["remains", 491], ["unclear", 499], [".", 506], ["In", 508], ["this", 511], ["report", 516], [",", 522], ["we", 524], ["have", 527], ["investigated", 532], ["the", 545], ["influence", 549], ["of", 559], ["alpha", 562], ["-", 567], ["synuclein", 568], ["expression", 578], ["on", 589], ["DA", 592], ["neurons", 595], ["in", 603], ["primary", 606], ["culture", 614], ["of", 622], ["embryonic", 625], ["human", 635], ["mesencephalon", 641], [".", 654], ["Two", 656], ["days", 660], ["after", 665], ["culture", 671], [",", 678], ["human", 680], ["DA", 686], ["cells", 689], ["were", 695], ["transduced", 700], ["with", 711], ["wild", 716], ["-", 720], ["type", 721], ["or", 726], ["mutant", 729], ["human", 736], ["(", 742], ["Ala(53)Thr", 743], [")", 753], ["alpha", 755], ["-", 760], ["synuclein", 761], ["adenoviruses", 771], ["and", 784], ["maintained", 788], ["for", 799], ["5", 803], ["days", 805], [".", 809], ["Overexpression", 811], ["of", 826], ["mutant", 829], ["and", 836], ["wild", 840], ["-", 844], ["type", 845], ["human", 850], ["alpha", 856], ["-", 861], ["synuclein", 862], ["resulted", 872], ["in", 881], ["49", 884], ["%", 886], ["(", 888], ["P<0.01", 889], [")", 895], ["and", 897], ["27", 901], ["%", 903], ["(", 905], ["P<0.05", 906], [")", 912], ["loss", 914], ["of", 919], ["DA", 922], ["neurons", 925], [",", 932], ["respectively", 934], [",", 946], ["while", 948], ["not", 954], ["affecting", 958], ["viability", 968], ["of", 978], ["other", 981], ["cells", 987], ["in", 993], ["the", 996], ["culture", 1000], [".", 1007], ["Overexpression", 1009], ["of", 1024], ["rat", 1027], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["or", 1047], ["GFP", 1050], ["(", 1054], ["green", 1055], ["fluorescent", 1061], ["protein", 1073], [")", 1080], ["had", 1082], ["no", 1086], ["effect", 1089], ["on", 1096], ["DA", 1099], ["neuron", 1102], ["survival", 1109], [".", 1117], ["Cytoplasmic", 1119], ["inclusions", 1131], ["of", 1142], ["alpha", 1145], ["-", 1150], ["synuclein", 1151], ["were", 1161], ["detected", 1166], ["immunohistochemically", 1175], ["in", 1197], ["DA", 1200], ["cells", 1203], ["transduced", 1209], ["with", 1220], ["mutant", 1225], ["human", 1232], ["alpha", 1238], ["-", 1243], ["synuclein", 1244], [",", 1253], ["but", 1255], ["not", 1259], ["wild", 1263], ["-", 1267], ["type", 1268], ["alpha", 1273], ["-", 1278], ["synuclein", 1279], [".", 1288], ["These", 1290], ["results", 1296], ["show", 1304], ["that", 1309], ["overexpression", 1314], ["of", 1329], ["human", 1332], ["alpha", 1338], ["-", 1343], ["synuclein", 1344], [",", 1353], ["particularly", 1355], ["the", 1368], ["mutant", 1372], ["form", 1379], [",", 1383], ["can", 1385], ["cause", 1389], ["human", 1395], ["DA", 1401], ["neuron", 1404], ["death", 1411], [",", 1416], ["suggesting", 1418], ["that", 1429], ["alpha", 1434], ["-", 1439], ["synuclein", 1440], ["may", 1450], ["have", 1454], ["a", 1459], ["primary", 1461], ["role", 1469], ["in", 1474], ["the", 1477], ["pathogenesis", 1481], ["of", 1494], ["PD", 1497], [".", 1499]]}
{"context": "To elucidate the phenotype, genotype, and MRI findings of Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mutation carriers. The authors studied 40 members of nine unrelated Korean CADASIL families. After genetic analysis of Notch3, clinical and MRI findings were correlated in 27 mutation carriers. Notch3 mutation sites were C174R (one family, n = 3), R133C (one family, n = 3), R587C (one family, n = 1), R544C (two families, n = 5), and R75P (four families, n = 15). The clinical features were typical of CADASIL, but the frequency of migraine in the Korean population appears low. MRI abnormalities were found in 54% of the mutant carriers, the most common being white matter hyperintensities. The prevalence of lacunes and microbleeds increased with patient age. Anterior temporal areas were less often involved in subjects with R75P mutations than in those where mutations occurred in other sites (p = 0.02). Gradient echo imaging identified microbleedings in 33% of mutation carriers (64% of those with abnormal MRI), whereas diffusion-weighted MRI showed abnormal findings in only one patient. Neurologic disability was related to the number of lacunar infarcts and the lesion volume of white matter hyperintensities (p < 0.001) whereas MMSE score was related to the number of lacunar infarcts (p < 0.005). Although Korean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutation carriers show similar clinical and MRI findings, these abnormalities appear less frequently than in other populations. Relatively frequent microbleedings on gradient echo imaging suggest that treatment should be individualized according to MRI findings. The novel mutation of R75P, not involving a cysteine residue, is related to less frequent involvement of the anterior temporal area, thus broadening the spectrum of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "ea472668bef643f08d9793d914e6370d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[326, 326]], "char_spans": [[1818, 1825]]}]}], "context_tokens": [["To", 0], ["elucidate", 3], ["the", 13], ["phenotype", 17], [",", 26], ["genotype", 28], [",", 36], ["and", 38], ["MRI", 42], ["findings", 46], ["of", 55], ["Korean", 58], ["patients", 65], ["with", 74], ["cerebral", 79], ["autosomal", 88], ["dominant", 98], ["arteriopathy", 107], ["with", 120], ["subcortical", 125], ["infarcts", 137], ["and", 146], ["leukoencephalopathy", 150], ["(", 170], ["CADASIL", 171], [")", 178], ["and", 180], ["mutation", 184], ["carriers", 193], [".", 201], ["The", 203], ["authors", 207], ["studied", 215], ["40", 223], ["members", 226], ["of", 234], ["nine", 237], ["unrelated", 242], ["Korean", 252], ["CADASIL", 259], ["families", 267], [".", 275], ["After", 277], ["genetic", 283], ["analysis", 291], ["of", 300], ["Notch3", 303], [",", 309], ["clinical", 311], ["and", 320], ["MRI", 324], ["findings", 328], ["were", 337], ["correlated", 342], ["in", 353], ["27", 356], ["mutation", 359], ["carriers", 368], [".", 376], ["Notch3", 378], ["mutation", 385], ["sites", 394], ["were", 400], ["C174R", 405], ["(", 411], ["one", 412], ["family", 416], [",", 422], ["n", 424], ["=", 426], ["3", 428], [")", 429], [",", 430], ["R133C", 432], ["(", 438], ["one", 439], ["family", 443], [",", 449], ["n", 451], ["=", 453], ["3", 455], [")", 456], [",", 457], ["R587C", 459], ["(", 465], ["one", 466], ["family", 470], [",", 476], ["n", 478], ["=", 480], ["1", 482], [")", 483], [",", 484], ["R544C", 486], ["(", 492], ["two", 493], ["families", 497], [",", 505], ["n", 507], ["=", 509], ["5", 511], [")", 512], [",", 513], ["and", 515], ["R75P", 519], ["(", 524], ["four", 525], ["families", 530], [",", 538], ["n", 540], ["=", 542], ["15", 544], [")", 546], [".", 547], ["The", 549], ["clinical", 553], ["features", 562], ["were", 571], ["typical", 576], ["of", 584], ["CADASIL", 587], [",", 594], ["but", 596], ["the", 600], ["frequency", 604], ["of", 614], ["migraine", 617], ["in", 626], ["the", 629], ["Korean", 633], ["population", 640], ["appears", 651], ["low", 659], [".", 662], ["MRI", 664], ["abnormalities", 668], ["were", 682], ["found", 687], ["in", 693], ["54", 696], ["%", 698], ["of", 700], ["the", 703], ["mutant", 707], ["carriers", 714], [",", 722], ["the", 724], ["most", 728], ["common", 733], ["being", 740], ["white", 746], ["matter", 752], ["hyperintensities", 759], [".", 775], ["The", 777], ["prevalence", 781], ["of", 792], ["lacunes", 795], ["and", 803], ["microbleeds", 807], ["increased", 819], ["with", 829], ["patient", 834], ["age", 842], [".", 845], ["Anterior", 847], ["temporal", 856], ["areas", 865], ["were", 871], ["less", 876], ["often", 881], ["involved", 887], ["in", 896], ["subjects", 899], ["with", 908], ["R75P", 913], ["mutations", 918], ["than", 928], ["in", 933], ["those", 936], ["where", 942], ["mutations", 948], ["occurred", 958], ["in", 967], ["other", 970], ["sites", 976], ["(", 982], ["p", 983], ["=", 985], ["0.02", 987], [")", 991], [".", 992], ["Gradient", 994], ["echo", 1003], ["imaging", 1008], ["identified", 1016], ["microbleedings", 1027], ["in", 1042], ["33", 1045], ["%", 1047], ["of", 1049], ["mutation", 1052], ["carriers", 1061], ["(", 1070], ["64", 1071], ["%", 1073], ["of", 1075], ["those", 1078], ["with", 1084], ["abnormal", 1089], ["MRI", 1098], [")", 1101], [",", 1102], ["whereas", 1104], ["diffusion", 1112], ["-", 1121], ["weighted", 1122], ["MRI", 1131], ["showed", 1135], ["abnormal", 1142], ["findings", 1151], ["in", 1160], ["only", 1163], ["one", 1168], ["patient", 1172], [".", 1179], ["Neurologic", 1181], ["disability", 1192], ["was", 1203], ["related", 1207], ["to", 1215], ["the", 1218], ["number", 1222], ["of", 1229], ["lacunar", 1232], ["infarcts", 1240], ["and", 1249], ["the", 1253], ["lesion", 1257], ["volume", 1264], ["of", 1271], ["white", 1274], ["matter", 1280], ["hyperintensities", 1287], ["(", 1304], ["p", 1305], ["<", 1307], ["0.001", 1309], [")", 1314], ["whereas", 1316], ["MMSE", 1324], ["score", 1329], ["was", 1335], ["related", 1339], ["to", 1347], ["the", 1350], ["number", 1354], ["of", 1361], ["lacunar", 1364], ["infarcts", 1372], ["(", 1381], ["p", 1382], ["<", 1384], ["0.005", 1386], [")", 1391], [".", 1392], ["Although", 1394], ["Korean", 1403], ["cerebral", 1410], ["autosomal", 1419], ["dominant", 1429], ["arteriopathy", 1438], ["with", 1451], ["subcortical", 1456], ["infarcts", 1468], ["and", 1477], ["leukoencephalopathy", 1481], ["(", 1501], ["CADASIL", 1502], [")", 1509], ["mutation", 1511], ["carriers", 1520], ["show", 1529], ["similar", 1534], ["clinical", 1542], ["and", 1551], ["MRI", 1555], ["findings", 1559], [",", 1567], ["these", 1569], ["abnormalities", 1575], ["appear", 1589], ["less", 1596], ["frequently", 1601], ["than", 1612], ["in", 1617], ["other", 1620], ["populations", 1626], [".", 1637], ["Relatively", 1639], ["frequent", 1650], ["microbleedings", 1659], ["on", 1674], ["gradient", 1677], ["echo", 1686], ["imaging", 1691], ["suggest", 1699], ["that", 1707], ["treatment", 1712], ["should", 1722], ["be", 1729], ["individualized", 1732], ["according", 1747], ["to", 1757], ["MRI", 1760], ["findings", 1764], [".", 1772], ["The", 1774], ["novel", 1778], ["mutation", 1784], ["of", 1793], ["R75P", 1796], [",", 1800], ["not", 1802], ["involving", 1806], ["a", 1816], ["cysteine", 1818], ["residue", 1827], [",", 1834], ["is", 1836], ["related", 1839], ["to", 1847], ["less", 1850], ["frequent", 1855], ["involvement", 1864], ["of", 1876], ["the", 1879], ["anterior", 1883], ["temporal", 1892], ["area", 1901], [",", 1905], ["thus", 1907], ["broadening", 1912], ["the", 1923], ["spectrum", 1927], ["of", 1936], ["CADASIL", 1939], [".", 1946]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear. Brain iron insufficiency and altered dopaminergic function appear to play important roles in the etiology of the disorder. This concept is based partly on extensive research studies using cerebrospinal fluid (CSF), autopsy material, and brain imaging indicating reduced regional brain iron and on the clinical efficacy of dopamine receptor agonists for alleviating RLS symptoms. Finding causal relations, linking low brain iron to altered dopaminergic function in RLS, has required however the use of animal models. These models have provided insights into how alterations in brain iron homeostasis and dopaminergic system may be involved in RLS. The results of animal models of RLS and biochemical, postmortem, and imaging studies in patients with the disease suggest that disruptions in brain iron trafficking lead to disturbances in striatal dopamine neurotransmission for at least some patients with RLS. This review examines the data supporting an iron deficiency-dopamine metabolic theory of RLS by relating the results from animal model investigations of the influence of brain iron deficiency on dopaminergic systems to data from clinical studies in patients with RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "363dd991aef248d6b70acffea567a64a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["Disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["sensorimotor", 77], ["disorder", 90], ["for", 99], ["which", 103], ["the", 109], ["exact", 113], ["pathophysiology", 119], ["remains", 135], ["unclear", 143], [".", 150], ["Brain", 152], ["iron", 158], ["insufficiency", 163], ["and", 177], ["altered", 181], ["dopaminergic", 189], ["function", 202], ["appear", 211], ["to", 218], ["play", 221], ["important", 226], ["roles", 236], ["in", 242], ["the", 245], ["etiology", 249], ["of", 258], ["the", 261], ["disorder", 265], [".", 273], ["This", 275], ["concept", 280], ["is", 288], ["based", 291], ["partly", 297], ["on", 304], ["extensive", 307], ["research", 317], ["studies", 326], ["using", 334], ["cerebrospinal", 340], ["fluid", 354], ["(", 360], ["CSF", 361], [")", 364], [",", 365], ["autopsy", 367], ["material", 375], [",", 383], ["and", 385], ["brain", 389], ["imaging", 395], ["indicating", 403], ["reduced", 414], ["regional", 422], ["brain", 431], ["iron", 437], ["and", 442], ["on", 446], ["the", 449], ["clinical", 453], ["efficacy", 462], ["of", 471], ["dopamine", 474], ["receptor", 483], ["agonists", 492], ["for", 501], ["alleviating", 505], ["RLS", 517], ["symptoms", 521], [".", 529], ["Finding", 531], ["causal", 539], ["relations", 546], [",", 555], ["linking", 557], ["low", 565], ["brain", 569], ["iron", 575], ["to", 580], ["altered", 583], ["dopaminergic", 591], ["function", 604], ["in", 613], ["RLS", 616], [",", 619], ["has", 621], ["required", 625], ["however", 634], ["the", 642], ["use", 646], ["of", 650], ["animal", 653], ["models", 660], [".", 666], ["These", 668], ["models", 674], ["have", 681], ["provided", 686], ["insights", 695], ["into", 704], ["how", 709], ["alterations", 713], ["in", 725], ["brain", 728], ["iron", 734], ["homeostasis", 739], ["and", 751], ["dopaminergic", 755], ["system", 768], ["may", 775], ["be", 779], ["involved", 782], ["in", 791], ["RLS", 794], [".", 797], ["The", 799], ["results", 803], ["of", 811], ["animal", 814], ["models", 821], ["of", 828], ["RLS", 831], ["and", 835], ["biochemical", 839], [",", 850], ["postmortem", 852], [",", 862], ["and", 864], ["imaging", 868], ["studies", 876], ["in", 884], ["patients", 887], ["with", 896], ["the", 901], ["disease", 905], ["suggest", 913], ["that", 921], ["disruptions", 926], ["in", 938], ["brain", 941], ["iron", 947], ["trafficking", 952], ["lead", 964], ["to", 969], ["disturbances", 972], ["in", 985], ["striatal", 988], ["dopamine", 997], ["neurotransmission", 1006], ["for", 1024], ["at", 1028], ["least", 1031], ["some", 1037], ["patients", 1042], ["with", 1051], ["RLS", 1056], [".", 1059], ["This", 1061], ["review", 1066], ["examines", 1073], ["the", 1082], ["data", 1086], ["supporting", 1091], ["an", 1102], ["iron", 1105], ["deficiency", 1110], ["-", 1120], ["dopamine", 1121], ["metabolic", 1130], ["theory", 1140], ["of", 1147], ["RLS", 1150], ["by", 1154], ["relating", 1157], ["the", 1166], ["results", 1170], ["from", 1178], ["animal", 1183], ["model", 1190], ["investigations", 1196], ["of", 1211], ["the", 1214], ["influence", 1218], ["of", 1228], ["brain", 1231], ["iron", 1237], ["deficiency", 1242], ["on", 1253], ["dopaminergic", 1256], ["systems", 1269], ["to", 1277], ["data", 1280], ["from", 1285], ["clinical", 1290], ["studies", 1299], ["in", 1307], ["patients", 1310], ["with", 1319], ["RLS", 1324], [".", 1327]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. Multivariable logistic regression models were used to evaluate prognostic indicators of complete hematological response (CHR), complete cytogenetic response (CCyR), and complete or major molecular response (C/MMR). Among patients treated with first-line imatinib, CHR at three months, CCyR at 12 months, and C/MMR at 18 months were observed in 53, 53.1, and 57.8 % of patients, respectively. Among patients treated with second-line dasatinib or nilotinib, CHR was achieved at three months in 49 and 42 %, CCyR at 12 months in 32 and 23 %, and MMR at 18 months in 30.5 and 26.1 % of patients, respectively. Prognostic indicators of first-line response included age, race, and Sokal score. For second-line treatment, duration of first-line hematological response and choice of drug used were also significant.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7f2a7d1273d0421f802f06a3bb2fdbbe", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[67, 69]], "char_spans": [[394, 400]]}]}], "context_tokens": [["We", 0], ["conducted", 3], ["a", 13], ["review", 15], ["of", 22], ["patient", 25], ["medical", 33], ["records", 41], ["to", 49], ["assess", 52], ["treatment", 59], ["response", 69], ["patterns", 78], ["and", 87], ["prognostic", 91], ["indicators", 102], ["of", 113], ["response", 116], ["among", 125], ["chronic", 131], ["myeloid", 139], ["leukemia", 147], ["(", 156], ["CML", 157], [")", 160], ["patients", 162], ["in", 171], ["the", 174], ["United", 178], ["States", 185], [",", 191], ["the", 193], ["United", 197], ["Kingdom", 204], [",", 211], ["Germany", 213], [",", 220], ["and", 222], ["Japan", 226], [".", 231], ["All", 233], ["1,063", 237], ["patients", 243], ["selected", 252], ["met", 261], ["the", 265], ["following", 269], ["inclusion", 279], ["criteria", 289], [":", 297], ["aged", 299], ["18", 304], ["or", 307], ["older", 310], ["and", 316], ["in", 320], ["chronic", 323], ["phase", 331], ["at", 337], ["the", 340], ["time", 344], ["of", 349], ["diagnosis", 352], [",", 361], ["Philadelphia", 363], ["chromosome", 376], ["and/or", 387], ["BCR", 394], ["-", 397], ["ABL", 398], ["positive", 402], [",", 410], ["received", 412], ["first", 421], ["-", 426], ["line", 427], ["treatment", 432], ["with", 442], ["imatinib", 447], [",", 455], ["and", 457], ["not", 461], ["enrolled", 465], ["in", 474], ["a", 477], ["randomized", 479], ["clinical", 490], ["trial", 499], ["during", 505], ["the", 512], ["period", 516], ["of", 523], ["retrospective", 526], ["review", 540], [".", 546], ["Multivariable", 548], ["logistic", 562], ["regression", 571], ["models", 582], ["were", 589], ["used", 594], ["to", 599], ["evaluate", 602], ["prognostic", 611], ["indicators", 622], ["of", 633], ["complete", 636], ["hematological", 645], ["response", 659], ["(", 668], ["CHR", 669], [")", 672], [",", 673], ["complete", 675], ["cytogenetic", 684], ["response", 696], ["(", 705], ["CCyR", 706], [")", 710], [",", 711], ["and", 713], ["complete", 717], ["or", 726], ["major", 729], ["molecular", 735], ["response", 745], ["(", 754], ["C", 755], ["/", 756], ["MMR", 757], [")", 760], [".", 761], ["Among", 763], ["patients", 769], ["treated", 778], ["with", 786], ["first", 791], ["-", 796], ["line", 797], ["imatinib", 802], [",", 810], ["CHR", 812], ["at", 816], ["three", 819], ["months", 825], [",", 831], ["CCyR", 833], ["at", 838], ["12", 841], ["months", 844], [",", 850], ["and", 852], ["C", 856], ["/", 857], ["MMR", 858], ["at", 862], ["18", 865], ["months", 868], ["were", 875], ["observed", 880], ["in", 889], ["53", 892], [",", 894], ["53.1", 896], [",", 900], ["and", 902], ["57.8", 906], ["%", 911], ["of", 913], ["patients", 916], [",", 924], ["respectively", 926], [".", 938], ["Among", 940], ["patients", 946], ["treated", 955], ["with", 963], ["second", 968], ["-", 974], ["line", 975], ["dasatinib", 980], ["or", 990], ["nilotinib", 993], [",", 1002], ["CHR", 1004], ["was", 1008], ["achieved", 1012], ["at", 1021], ["three", 1024], ["months", 1030], ["in", 1037], ["49", 1040], ["and", 1043], ["42", 1047], ["%", 1050], [",", 1051], ["CCyR", 1053], ["at", 1058], ["12", 1061], ["months", 1064], ["in", 1071], ["32", 1074], ["and", 1077], ["23", 1081], ["%", 1084], [",", 1085], ["and", 1087], ["MMR", 1091], ["at", 1095], ["18", 1098], ["months", 1101], ["in", 1108], ["30.5", 1111], ["and", 1116], ["26.1", 1120], ["%", 1125], ["of", 1127], ["patients", 1130], [",", 1138], ["respectively", 1140], [".", 1152], ["Prognostic", 1154], ["indicators", 1165], ["of", 1176], ["first", 1179], ["-", 1184], ["line", 1185], ["response", 1190], ["included", 1199], ["age", 1208], [",", 1211], ["race", 1213], [",", 1217], ["and", 1219], ["Sokal", 1223], ["score", 1229], [".", 1234], ["For", 1236], ["second", 1240], ["-", 1246], ["line", 1247], ["treatment", 1252], [",", 1261], ["duration", 1263], ["of", 1272], ["first", 1275], ["-", 1280], ["line", 1281], ["hematological", 1286], ["response", 1300], ["and", 1309], ["choice", 1313], ["of", 1320], ["drug", 1323], ["used", 1328], ["were", 1333], ["also", 1338], ["significant", 1343], [".", 1354]]}
{"context": "Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with over 1400 mutations identified in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Mutations in the CFTR gene may be also causative for CBAVD (Congenital Bilateral Absence of the Vas Deferens). The type and distribution of mutations varies widely between different countries and/or ethnic groups, and is relatively unknown in Iran. We therefore performed a comprehensive analysis of the CFTR gene in Iranian CF patients. 69 Iranian CF patients, and 1 CBAVD patient, were analysed for mutations in the complete coding region, and its exon/intron junctions, of their CFTR genes, using different methods, such as ARMS (amplification refractory mutation system)-PCR, SSCP (single stranded conformation polymorphism) analysis, restriction enzyme digestion analysis, direct sequencing, and MLPA (Multiplex Ligation-mediated Probe Amplification). CFTR mutation analysis revealed the identification of 37 mutations in 69 Iranian CF patients. Overall, 81.9% (113/138) CFTR genes derived from Iranian CF patients could be characterized for a disease-causing mutation. The CBAVD patient was found to be homozygous for the p.W1145R mutation. The most common mutations were p.F508del (DeltaF508) (18.1%), c.2183_2184delAAinsG (2183AA>G) (6.5%), p.S466X (5.8%), p.N1303K (4.3%), c.2789+5G>A (4.3%), p.G542X (3.6%), c.3120+1G>A (3.6%), p.R334W (2.9%) and c.3130delA (2.9%). These 9 types of mutant CFTR genes totaled for 52% of all CFTR genes derived from the 69 Iranian CF patients. Eight mutations, c.406-8T>C, p.A566D, c.2576delA, c.2752-1_2756delGGTGGCinsTTG, p.T1036I, p.W1145R, c.3850-24G>A, c.1342-?_1524+?del, were found for the first time in this study. We identified 37 CFTR mutations in 69 well characterized Iranian CF patients, obtaining a CFTR mutation detection rate of 81.9%, the highest detection rate obtained in the Iranian population so far. These findings will assist in genetic counseling, prenatal diagnosis and future screening of CF in Iran.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "721f570c564a469791dc784b8d46492b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[226, 226]], "char_spans": [[1282, 1290]]}]}], "context_tokens": [["Cystic", 0], ["fibrosis", 7], ["(", 16], ["CF", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["inherited", 40], ["disorder", 50], ["in", 59], ["Caucasian", 62], ["populations", 72], [",", 83], ["with", 85], ["over", 90], ["1400", 95], ["mutations", 100], ["identified", 110], ["in", 121], ["the", 124], ["Cystic", 128], ["Fibrosis", 135], ["Transmembrane", 144], ["conductance", 158], ["Regulator", 170], ["(", 180], ["CFTR", 181], [")", 185], ["gene", 187], [".", 191], ["Mutations", 193], ["in", 203], ["the", 206], ["CFTR", 210], ["gene", 215], ["may", 220], ["be", 224], ["also", 227], ["causative", 232], ["for", 242], ["CBAVD", 246], ["(", 252], ["Congenital", 253], ["Bilateral", 264], ["Absence", 274], ["of", 282], ["the", 285], ["Vas", 289], ["Deferens", 293], [")", 301], [".", 302], ["The", 304], ["type", 308], ["and", 313], ["distribution", 317], ["of", 330], ["mutations", 333], ["varies", 343], ["widely", 350], ["between", 357], ["different", 365], ["countries", 375], ["and/or", 385], ["ethnic", 392], ["groups", 399], [",", 405], ["and", 407], ["is", 411], ["relatively", 414], ["unknown", 425], ["in", 433], ["Iran", 436], [".", 440], ["We", 442], ["therefore", 445], ["performed", 455], ["a", 465], ["comprehensive", 467], ["analysis", 481], ["of", 490], ["the", 493], ["CFTR", 497], ["gene", 502], ["in", 507], ["Iranian", 510], ["CF", 518], ["patients", 521], [".", 529], ["69", 531], ["Iranian", 534], ["CF", 542], ["patients", 545], [",", 553], ["and", 555], ["1", 559], ["CBAVD", 561], ["patient", 567], [",", 574], ["were", 576], ["analysed", 581], ["for", 590], ["mutations", 594], ["in", 604], ["the", 607], ["complete", 611], ["coding", 620], ["region", 627], [",", 633], ["and", 635], ["its", 639], ["exon", 643], ["/", 647], ["intron", 648], ["junctions", 655], [",", 664], ["of", 666], ["their", 669], ["CFTR", 675], ["genes", 680], [",", 685], ["using", 687], ["different", 693], ["methods", 703], [",", 710], ["such", 712], ["as", 717], ["ARMS", 720], ["(", 725], ["amplification", 726], ["refractory", 740], ["mutation", 751], ["system)-PCR", 760], [",", 771], ["SSCP", 773], ["(", 778], ["single", 779], ["stranded", 786], ["conformation", 795], ["polymorphism", 808], [")", 820], ["analysis", 822], [",", 830], ["restriction", 832], ["enzyme", 844], ["digestion", 851], ["analysis", 861], [",", 869], ["direct", 871], ["sequencing", 878], [",", 888], ["and", 890], ["MLPA", 894], ["(", 899], ["Multiplex", 900], ["Ligation", 910], ["-", 918], ["mediated", 919], ["Probe", 928], ["Amplification", 934], [")", 947], [".", 948], ["CFTR", 950], ["mutation", 955], ["analysis", 964], ["revealed", 973], ["the", 982], ["identification", 986], ["of", 1001], ["37", 1004], ["mutations", 1007], ["in", 1017], ["69", 1020], ["Iranian", 1023], ["CF", 1031], ["patients", 1034], [".", 1042], ["Overall", 1044], [",", 1051], ["81.9", 1053], ["%", 1057], ["(", 1059], ["113/138", 1060], [")", 1067], ["CFTR", 1069], ["genes", 1074], ["derived", 1080], ["from", 1088], ["Iranian", 1093], ["CF", 1101], ["patients", 1104], ["could", 1113], ["be", 1119], ["characterized", 1122], ["for", 1136], ["a", 1140], ["disease", 1142], ["-", 1149], ["causing", 1150], ["mutation", 1158], [".", 1166], ["The", 1168], ["CBAVD", 1172], ["patient", 1178], ["was", 1186], ["found", 1190], ["to", 1196], ["be", 1199], ["homozygous", 1202], ["for", 1213], ["the", 1217], ["p", 1221], [".", 1222], ["W1145R", 1223], ["mutation", 1230], [".", 1238], ["The", 1240], ["most", 1244], ["common", 1249], ["mutations", 1256], ["were", 1266], ["p", 1271], [".", 1272], ["F508del", 1273], ["(", 1281], ["DeltaF508", 1282], [")", 1291], ["(", 1293], ["18.1", 1294], ["%", 1298], [")", 1299], [",", 1300], ["c.2183_2184delAAinsG", 1302], ["(", 1323], ["2183AA", 1324], [">", 1330], ["G", 1331], [")", 1332], ["(", 1334], ["6.5", 1335], ["%", 1338], [")", 1339], [",", 1340], ["p", 1342], [".", 1343], ["S466X", 1344], ["(", 1350], ["5.8", 1351], ["%", 1354], [")", 1355], [",", 1356], ["p", 1358], [".", 1359], ["N1303", 1360], ["K", 1365], ["(", 1367], ["4.3", 1368], ["%", 1371], [")", 1372], [",", 1373], ["c.2789", 1375], ["+", 1381], ["5G", 1382], [">", 1384], ["A", 1385], ["(", 1387], ["4.3", 1388], ["%", 1391], [")", 1392], [",", 1393], ["p", 1395], [".", 1396], ["G542X", 1397], ["(", 1403], ["3.6", 1404], ["%", 1407], [")", 1408], [",", 1409], ["c.3120", 1411], ["+", 1417], ["1G", 1418], [">", 1420], ["A", 1421], ["(", 1423], ["3.6", 1424], ["%", 1427], [")", 1428], [",", 1429], ["p", 1431], [".", 1432], ["R334W", 1433], ["(", 1439], ["2.9", 1440], ["%", 1443], [")", 1444], ["and", 1446], ["c.3130delA", 1450], ["(", 1461], ["2.9", 1462], ["%", 1465], [")", 1466], [".", 1467], ["These", 1469], ["9", 1475], ["types", 1477], ["of", 1483], ["mutant", 1486], ["CFTR", 1493], ["genes", 1498], ["totaled", 1504], ["for", 1512], ["52", 1516], ["%", 1518], ["of", 1520], ["all", 1523], ["CFTR", 1527], ["genes", 1532], ["derived", 1538], ["from", 1546], ["the", 1551], ["69", 1555], ["Iranian", 1558], ["CF", 1566], ["patients", 1569], [".", 1577], ["Eight", 1579], ["mutations", 1585], [",", 1594], ["c.406", 1596], ["-", 1601], ["8T", 1602], [">", 1604], ["C", 1605], [",", 1606], ["p", 1608], [".", 1609], ["A566D", 1610], [",", 1615], ["c.2576delA", 1617], [",", 1627], ["c.2752", 1629], ["-", 1635], ["1_2756delGGTGGCinsTTG", 1636], [",", 1657], ["p", 1659], [".", 1660], ["T1036I", 1661], [",", 1667], ["p", 1669], [".", 1670], ["W1145R", 1671], [",", 1677], ["c.3850", 1679], ["-", 1685], ["24G", 1686], [">", 1689], ["A", 1690], [",", 1691], ["c.1342-?_1524+?del", 1693], [",", 1711], ["were", 1713], ["found", 1718], ["for", 1724], ["the", 1728], ["first", 1732], ["time", 1738], ["in", 1743], ["this", 1746], ["study", 1751], [".", 1756], ["We", 1758], ["identified", 1761], ["37", 1772], ["CFTR", 1775], ["mutations", 1780], ["in", 1790], ["69", 1793], ["well", 1796], ["characterized", 1801], ["Iranian", 1815], ["CF", 1823], ["patients", 1826], [",", 1834], ["obtaining", 1836], ["a", 1846], ["CFTR", 1848], ["mutation", 1853], ["detection", 1862], ["rate", 1872], ["of", 1877], ["81.9", 1880], ["%", 1884], [",", 1885], ["the", 1887], ["highest", 1891], ["detection", 1899], ["rate", 1909], ["obtained", 1914], ["in", 1923], ["the", 1926], ["Iranian", 1930], ["population", 1938], ["so", 1949], ["far", 1952], [".", 1955], ["These", 1957], ["findings", 1963], ["will", 1972], ["assist", 1977], ["in", 1984], ["genetic", 1987], ["counseling", 1995], [",", 2005], ["prenatal", 2007], ["diagnosis", 2016], ["and", 2026], ["future", 2030], ["screening", 2037], ["of", 2047], ["CF", 2050], ["in", 2053], ["Iran", 2056], [".", 2060]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder linked to contractions of the D4Z4 repeat array in the subtelomeric region of chromosome 4q. By comparing genome-wide gene expression data from muscle biopsies of patients with FSHD to those of 11 other neuromuscular disorders, paired-like homeodomain transcription factor 1 (PITX1) was found specifically up-regulated in patients with FSHD. In addition, we showed that the double homeobox 4 gene (DUX4) that maps within the D4Z4 repeat unit was up-regulated in patient myoblasts at both mRNA and protein level. We further showed that the DUX4 protein could activate transient expression of a luciferase reporter gene fused to the Pitx1 promoter as well as the endogenous Pitx1 gene in transfected C2C12 cells. In EMSAs, DUX4 specifically interacted with a 30-bp sequence 5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3' in the Pitx1 promoter. Mutations of the TAAT core affected Pitx1-LUC activation in C2C12 cells and DUX4 binding in vitro. Our results suggest that up-regulation of both DUX4 and PITX1 in FSHD muscles may play critical roles in the molecular mechanisms of the disease.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "5d0d556d41284947986e2a22525e867b", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[4, 4], [69, 69], [41, 41], [186, 186]], "char_spans": [[40, 43], [416, 419], [257, 260], [1076, 1079]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["an", 49], ["autosomal", 52], ["dominant", 62], ["disorder", 71], ["linked", 80], ["to", 87], ["contractions", 90], ["of", 103], ["the", 106], ["D4Z4", 110], ["repeat", 115], ["array", 122], ["in", 128], ["the", 131], ["subtelomeric", 135], ["region", 148], ["of", 155], ["chromosome", 158], ["4q", 169], [".", 171], ["By", 173], ["comparing", 176], ["genome", 186], ["-", 192], ["wide", 193], ["gene", 198], ["expression", 203], ["data", 214], ["from", 219], ["muscle", 224], ["biopsies", 231], ["of", 240], ["patients", 243], ["with", 252], ["FSHD", 257], ["to", 262], ["those", 265], ["of", 271], ["11", 274], ["other", 277], ["neuromuscular", 283], ["disorders", 297], [",", 306], ["paired", 308], ["-", 314], ["like", 315], ["homeodomain", 320], ["transcription", 332], ["factor", 346], ["1", 353], ["(", 355], ["PITX1", 356], [")", 361], ["was", 363], ["found", 367], ["specifically", 373], ["up", 386], ["-", 388], ["regulated", 389], ["in", 399], ["patients", 402], ["with", 411], ["FSHD", 416], [".", 420], ["In", 422], ["addition", 425], [",", 433], ["we", 435], ["showed", 438], ["that", 445], ["the", 450], ["double", 454], ["homeobox", 461], ["4", 470], ["gene", 472], ["(", 477], ["DUX4", 478], [")", 482], ["that", 484], ["maps", 489], ["within", 494], ["the", 501], ["D4Z4", 505], ["repeat", 510], ["unit", 517], ["was", 522], ["up", 526], ["-", 528], ["regulated", 529], ["in", 539], ["patient", 542], ["myoblasts", 550], ["at", 560], ["both", 563], ["mRNA", 568], ["and", 573], ["protein", 577], ["level", 585], [".", 590], ["We", 592], ["further", 595], ["showed", 603], ["that", 610], ["the", 615], ["DUX4", 619], ["protein", 624], ["could", 632], ["activate", 638], ["transient", 647], ["expression", 657], ["of", 668], ["a", 671], ["luciferase", 673], ["reporter", 684], ["gene", 693], ["fused", 698], ["to", 704], ["the", 707], ["Pitx1", 711], ["promoter", 717], ["as", 726], ["well", 729], ["as", 734], ["the", 737], ["endogenous", 741], ["Pitx1", 752], ["gene", 758], ["in", 763], ["transfected", 766], ["C2C12", 778], ["cells", 784], [".", 789], ["In", 791], ["EMSAs", 794], [",", 799], ["DUX4", 801], ["specifically", 806], ["interacted", 819], ["with", 830], ["a", 835], ["30-bp", 837], ["sequence", 843], ["5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3", 852], ["'", 887], ["in", 889], ["the", 892], ["Pitx1", 896], ["promoter", 902], [".", 910], ["Mutations", 912], ["of", 922], ["the", 925], ["TAAT", 929], ["core", 934], ["affected", 939], ["Pitx1-LUC", 948], ["activation", 958], ["in", 969], ["C2C12", 972], ["cells", 978], ["and", 984], ["DUX4", 988], ["binding", 993], ["in", 1001], ["vitro", 1004], [".", 1009], ["Our", 1011], ["results", 1015], ["suggest", 1023], ["that", 1031], ["up", 1036], ["-", 1038], ["regulation", 1039], ["of", 1050], ["both", 1053], ["DUX4", 1058], ["and", 1063], ["PITX1", 1067], ["in", 1073], ["FSHD", 1076], ["muscles", 1081], ["may", 1089], ["play", 1093], ["critical", 1098], ["roles", 1107], ["in", 1113], ["the", 1116], ["molecular", 1120], ["mechanisms", 1130], ["of", 1141], ["the", 1144], ["disease", 1148], [".", 1155]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "88499aa29e45416bba7bf6cc24031571", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals. Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation. We report that rapid evolution of enhancers is a universal feature of mammalian genomes. Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements. In contrast, almost all liver promoters are partially or fully conserved across these species. Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences. These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "ce06b70fdbb149389828f705b0d6faaf", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[119, 119], [36, 36], [65, 65], [79, 79]], "char_spans": [[742, 750], [220, 228], [410, 418], [494, 502]]}]}], "context_tokens": [["The", 0], ["mammalian", 4], ["radiation", 14], ["has", 24], ["corresponded", 28], ["with", 41], ["rapid", 46], ["changes", 52], ["in", 60], ["noncoding", 63], ["regions", 73], ["of", 81], ["the", 84], ["genome", 88], [",", 94], ["but", 96], ["we", 100], ["lack", 103], ["a", 108], ["comprehensive", 110], ["understanding", 124], ["of", 138], ["regulatory", 141], ["evolution", 152], ["in", 162], ["mammals", 165], [".", 172], ["Here", 174], [",", 178], ["we", 180], ["track", 183], ["the", 189], ["evolution", 193], ["of", 203], ["promoters", 206], ["and", 216], ["enhancers", 220], ["active", 230], ["in", 237], ["liver", 240], ["across", 246], ["20", 253], ["mammalian", 256], ["species", 266], ["from", 274], ["six", 279], ["diverse", 283], ["orders", 291], ["by", 298], ["profiling", 301], ["genomic", 311], ["enrichment", 319], ["of", 330], ["H3K27", 333], ["acetylation", 339], ["and", 351], ["H3K4", 355], ["trimethylation", 360], [".", 374], ["We", 376], ["report", 379], ["that", 386], ["rapid", 391], ["evolution", 397], ["of", 407], ["enhancers", 410], ["is", 420], ["a", 423], ["universal", 425], ["feature", 435], ["of", 443], ["mammalian", 446], ["genomes", 456], [".", 463], ["Most", 465], ["of", 470], ["the", 473], ["recently", 477], ["evolved", 486], ["enhancers", 494], ["arise", 504], ["from", 510], ["ancestral", 515], ["DNA", 525], ["exaptation", 529], [",", 539], ["rather", 541], ["than", 548], ["lineage", 553], ["-", 560], ["specific", 561], ["expansions", 570], ["of", 581], ["repeat", 584], ["elements", 591], [".", 599], ["In", 601], ["contrast", 604], [",", 612], ["almost", 614], ["all", 621], ["liver", 625], ["promoters", 631], ["are", 641], ["partially", 645], ["or", 655], ["fully", 658], ["conserved", 664], ["across", 674], ["these", 681], ["species", 687], [".", 694], ["Our", 696], ["data", 700], ["further", 705], ["reveal", 713], ["that", 720], ["recently", 725], ["evolved", 734], ["enhancers", 742], ["can", 752], ["be", 756], ["associated", 759], ["with", 770], ["genes", 775], ["under", 781], ["positive", 787], ["selection", 796], [",", 805], ["demonstrating", 807], ["the", 821], ["power", 825], ["of", 831], ["this", 834], ["approach", 839], ["for", 848], ["annotating", 852], ["regulatory", 863], ["adaptations", 874], ["in", 886], ["genomic", 889], ["sequences", 897], [".", 906], ["These", 908], ["results", 914], ["provide", 922], ["important", 930], ["insight", 940], ["into", 948], ["the", 953], ["functional", 957], ["genetics", 968], ["underpinning", 977], ["mammalian", 990], ["regulatory", 1000], ["evolution", 1011], [".", 1020]]}
{"context": "Clinical evidence for failure with beta-lactam therapy has been lacking for patients with borderline oxacillin-resistant Staphylococcus aureus (BORSA) infections. We describe a failure of cloxacillin for a patient with endocarditis due to BORSA. The isolate also had false-negative thermonuclease and coagulase test results.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6b5bba7ac78e49bf91eca71131576311", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[15, 20]], "char_spans": [[90, 141]]}]}], "context_tokens": [["Clinical", 0], ["evidence", 9], ["for", 18], ["failure", 22], ["with", 30], ["beta", 35], ["-", 39], ["lactam", 40], ["therapy", 47], ["has", 55], ["been", 59], ["lacking", 64], ["for", 72], ["patients", 76], ["with", 85], ["borderline", 90], ["oxacillin", 101], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["BORSA", 144], [")", 149], ["infections", 151], [".", 161], ["We", 163], ["describe", 166], ["a", 175], ["failure", 177], ["of", 185], ["cloxacillin", 188], ["for", 200], ["a", 204], ["patient", 206], ["with", 214], ["endocarditis", 219], ["due", 232], ["to", 236], ["BORSA", 239], [".", 244], ["The", 246], ["isolate", 250], ["also", 258], ["had", 263], ["false", 267], ["-", 272], ["negative", 273], ["thermonuclease", 282], ["and", 297], ["coagulase", 301], ["test", 311], ["results", 316], [".", 323]]}
{"context": "The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results. We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon. Eligible children were 6-10 weeks of age at first vaccination, without serious acute or chronic illness. All children received the EPI diphtheria, tetanus, pertussis (inactivated whole-cell), and hepatitis-B vaccines, Haemophilus influenzae type b vaccine, and oral polio vaccine at study months 0, 1, and 2, and measles vaccine and yellow fever vaccines at study month 7. Participants were randomly assigned (1:1:1) to receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo. Randomisation was according to a predefined block list with a computer-generated randomisation code. Detection of serious adverse events and malaria was by passive case detection. Antibodies against Plasmodium falciparum circumsporozoite protein and HBsAg were monitored for 19 months. This study is registered with ClinicalTrials.gov, number NCT00436007. 511 children were enrolled. Serious adverse events occurred in 57 participants in the RTS,S/AS01(E) 0, 1, 2 month group (34%, 95% CI 27-41), 47 in the 0, 1, 7 month group (28%, 21-35), and 49 (29%, 22-36) in the control group; none were judged to be related to study vaccination. At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. Vaccine efficacy for the 0, 1, 2 month schedule (2 weeks after dose three to month 19, site-adjusted according-to-protocol analysis) was 53% (95% CI 26-70; p=0\u00b70012) against first malaria episodes and 59% (36-74; p=0\u00b70001) against all malaria episodes. For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=0\u00b70002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=0\u00b70003). 1 year after dose three, vaccine efficacy against first malaria episodes was similar for both schedules (0, 1, 2 month group, 61\u00b76% [95% CI 35\u00b76-77\u00b71], p<0\u00b7001; 0, 1, 7 month group, 63\u00b78% [40\u00b74-78\u00b70], p<0\u00b7001, according-to-protocol cohort). Vaccine efficacy was consistent with the target put forward by the WHO-sponsored malaria vaccine technology roadmap for a first-generation malaria vaccine. The 0, 1, 2 month vaccine schedule has been selected for phase 3 candidate vaccine assessment. Program for Appropriate Technology in Health Malaria Vaccine Initiative; GlaxoSmithKline Biologicals.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e902e6f0d961453ba6bc3e8ea9ab9588", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[275, 275], [549, 549], [474, 474], [618, 618], [627, 627], [460, 460], [492, 492], [8, 8], [94, 94], [655, 655]], "char_spans": [[1279, 1285], [2452, 2458], [2141, 2147], [2718, 2724], [2776, 2782], [2086, 2092], [2243, 2249], [28, 34], [446, 452], [2933, 2939]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["candidate", 18], ["malaria", 28], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunisation", 67], ["of", 80], ["infants", 83], ["in", 91], ["Africa", 94], ["through", 101], ["the", 109], ["expanded", 113], ["programme", 122], ["on", 132], ["immunisation", 135], ["(", 148], ["EPI", 149], [")", 152], [".", 153], ["8", 155], ["month", 157], ["follow", 163], ["-", 169], ["up", 170], ["data", 173], ["have", 178], ["been", 183], ["reported", 188], ["for", 197], ["safety", 201], ["and", 208], ["immunogenicity", 212], ["of", 227], ["RTS", 230], [",", 233], ["S", 234], ["/", 235], ["AS01(E", 236], [")", 242], ["when", 244], ["integrated", 249], ["into", 260], ["the", 265], ["EPI", 269], [".", 272], ["We", 274], ["report", 277], ["extended", 284], ["follow", 293], ["-", 299], ["up", 300], ["to", 303], ["19", 306], ["months", 309], [",", 315], ["including", 317], ["efficacy", 327], ["results", 336], [".", 343], ["We", 345], ["did", 348], ["a", 352], ["randomised", 354], [",", 364], ["open", 366], ["-", 370], ["label", 371], [",", 376], ["phase", 378], ["2", 384], ["trial", 386], ["of", 392], ["safety", 395], ["and", 402], ["efficacy", 406], ["of", 415], ["the", 418], ["RTS", 422], [",", 425], ["S", 426], ["/", 427], ["AS01(E", 428], [")", 434], ["candidate", 436], ["malaria", 446], ["vaccine", 454], ["given", 462], ["with", 468], ["EPI", 473], ["vaccines", 477], ["between", 486], ["April", 494], ["30", 500], [",", 502], ["2007", 504], [",", 508], ["and", 510], ["Oct", 514], ["7", 518], [",", 519], ["2009", 521], [",", 525], ["in", 527], ["Ghana", 530], [",", 535], ["Tanzania", 537], [",", 545], ["and", 547], ["Gabon", 551], [".", 556], ["Eligible", 558], ["children", 567], ["were", 576], ["6", 581], ["-", 582], ["10", 583], ["weeks", 586], ["of", 592], ["age", 595], ["at", 599], ["first", 602], ["vaccination", 608], [",", 619], ["without", 621], ["serious", 629], ["acute", 637], ["or", 643], ["chronic", 646], ["illness", 654], [".", 661], ["All", 663], ["children", 667], ["received", 676], ["the", 685], ["EPI", 689], ["diphtheria", 693], [",", 703], ["tetanus", 705], [",", 712], ["pertussis", 714], ["(", 724], ["inactivated", 725], ["whole", 737], ["-", 742], ["cell", 743], [")", 747], [",", 748], ["and", 750], ["hepatitis", 754], ["-", 763], ["B", 764], ["vaccines", 766], [",", 774], ["Haemophilus", 776], ["influenzae", 788], ["type", 799], ["b", 804], ["vaccine", 806], [",", 813], ["and", 815], ["oral", 819], ["polio", 824], ["vaccine", 830], ["at", 838], ["study", 841], ["months", 847], ["0", 854], [",", 855], ["1", 857], [",", 858], ["and", 860], ["2", 864], [",", 865], ["and", 867], ["measles", 871], ["vaccine", 879], ["and", 887], ["yellow", 891], ["fever", 898], ["vaccines", 904], ["at", 913], ["study", 916], ["month", 922], ["7", 928], [".", 929], ["Participants", 931], ["were", 944], ["randomly", 949], ["assigned", 958], ["(", 967], ["1:1:1", 968], [")", 973], ["to", 975], ["receive", 978], ["three", 986], ["doses", 992], ["of", 998], ["RTS", 1001], [",", 1004], ["S", 1005], ["/", 1006], ["AS01(E", 1007], [")", 1013], ["at", 1015], ["6", 1018], [",", 1019], ["10", 1021], [",", 1023], ["and", 1025], ["14", 1029], ["weeks", 1032], ["(", 1038], ["0", 1039], [",", 1040], ["1", 1042], [",", 1043], ["2", 1045], ["month", 1047], ["schedule", 1053], [")", 1061], ["or", 1063], ["at", 1066], ["6", 1069], ["weeks", 1071], [",", 1076], ["10", 1078], ["weeks", 1081], [",", 1086], ["and", 1088], ["9", 1092], ["months", 1094], ["(", 1101], ["0", 1102], [",", 1103], ["2", 1105], [",", 1106], ["7", 1108], ["month", 1110], ["schedule", 1116], [")", 1124], ["or", 1126], ["placebo", 1129], [".", 1136], ["Randomisation", 1138], ["was", 1152], ["according", 1156], ["to", 1166], ["a", 1169], ["predefined", 1171], ["block", 1182], ["list", 1188], ["with", 1193], ["a", 1198], ["computer", 1200], ["-", 1208], ["generated", 1209], ["randomisation", 1219], ["code", 1233], [".", 1237], ["Detection", 1239], ["of", 1249], ["serious", 1252], ["adverse", 1260], ["events", 1268], ["and", 1275], ["malaria", 1279], ["was", 1287], ["by", 1291], ["passive", 1294], ["case", 1302], ["detection", 1307], [".", 1316], ["Antibodies", 1318], ["against", 1329], ["Plasmodium", 1337], ["falciparum", 1348], ["circumsporozoite", 1359], ["protein", 1376], ["and", 1384], ["HBsAg", 1388], ["were", 1394], ["monitored", 1399], ["for", 1409], ["19", 1413], ["months", 1416], [".", 1422], ["This", 1424], ["study", 1429], ["is", 1435], ["registered", 1438], ["with", 1449], ["ClinicalTrials.gov", 1454], [",", 1472], ["number", 1474], ["NCT00436007", 1481], [".", 1492], ["511", 1494], ["children", 1498], ["were", 1507], ["enrolled", 1512], [".", 1520], ["Serious", 1522], ["adverse", 1530], ["events", 1538], ["occurred", 1545], ["in", 1554], ["57", 1557], ["participants", 1560], ["in", 1573], ["the", 1576], ["RTS", 1580], [",", 1583], ["S", 1584], ["/", 1585], ["AS01(E", 1586], [")", 1592], ["0", 1594], [",", 1595], ["1", 1597], [",", 1598], ["2", 1600], ["month", 1602], ["group", 1608], ["(", 1614], ["34", 1615], ["%", 1617], [",", 1618], ["95", 1620], ["%", 1622], ["CI", 1624], ["27", 1627], ["-", 1629], ["41", 1630], [")", 1632], [",", 1633], ["47", 1635], ["in", 1638], ["the", 1641], ["0", 1645], [",", 1646], ["1", 1648], [",", 1649], ["7", 1651], ["month", 1653], ["group", 1659], ["(", 1665], ["28", 1666], ["%", 1668], [",", 1669], ["21", 1671], ["-", 1673], ["35", 1674], [")", 1676], [",", 1677], ["and", 1679], ["49", 1683], ["(", 1686], ["29", 1687], ["%", 1689], [",", 1690], ["22", 1692], ["-", 1694], ["36", 1695], [")", 1697], ["in", 1699], ["the", 1702], ["control", 1706], ["group", 1714], [";", 1719], ["none", 1721], ["were", 1726], ["judged", 1731], ["to", 1738], ["be", 1741], ["related", 1744], ["to", 1752], ["study", 1755], ["vaccination", 1761], [".", 1772], ["At", 1774], ["month", 1777], ["19", 1783], [",", 1785], ["anticircumsporozoite", 1787], ["immune", 1808], ["responses", 1815], ["were", 1825], ["significantly", 1830], ["higher", 1844], ["in", 1851], ["the", 1854], ["RTS", 1858], [",", 1861], ["S", 1862], ["/", 1863], ["AS01(E", 1864], [")", 1870], ["groups", 1872], ["than", 1879], ["in", 1884], ["the", 1887], ["control", 1891], ["group", 1899], [".", 1904], ["Vaccine", 1906], ["efficacy", 1914], ["for", 1923], ["the", 1927], ["0", 1931], [",", 1932], ["1", 1934], [",", 1935], ["2", 1937], ["month", 1939], ["schedule", 1945], ["(", 1954], ["2", 1955], ["weeks", 1957], ["after", 1963], ["dose", 1969], ["three", 1974], ["to", 1980], ["month", 1983], ["19", 1989], [",", 1991], ["site", 1993], ["-", 1997], ["adjusted", 1998], ["according", 2007], ["-", 2016], ["to", 2017], ["-", 2019], ["protocol", 2020], ["analysis", 2029], [")", 2037], ["was", 2039], ["53", 2043], ["%", 2045], ["(", 2047], ["95", 2048], ["%", 2050], ["CI", 2052], ["26", 2055], ["-", 2057], ["70", 2058], [";", 2060], ["p=0\u00b70012", 2062], [")", 2070], ["against", 2072], ["first", 2080], ["malaria", 2086], ["episodes", 2094], ["and", 2103], ["59", 2107], ["%", 2109], ["(", 2111], ["36", 2112], ["-", 2114], ["74", 2115], [";", 2117], ["p=0\u00b70001", 2119], [")", 2127], ["against", 2129], ["all", 2137], ["malaria", 2141], ["episodes", 2149], [".", 2157], ["For", 2159], ["the", 2163], ["entire", 2167], ["study", 2174], ["period", 2180], [",", 2186], ["(", 2188], ["total", 2189], ["vaccinated", 2195], ["cohort", 2206], [")", 2212], ["vaccine", 2214], ["efficacy", 2222], ["against", 2231], ["all", 2239], ["malaria", 2243], ["episodes", 2251], ["was", 2260], ["higher", 2264], ["with", 2271], ["the", 2276], ["0", 2280], [",", 2281], ["1", 2283], [",", 2284], ["2", 2286], ["month", 2288], ["schedule", 2294], ["(", 2303], ["57", 2304], ["%", 2306], [",", 2307], ["95", 2309], ["%", 2311], ["CI", 2313], ["33", 2316], ["-", 2318], ["73", 2319], [";", 2321], ["p=0\u00b70002", 2323], [")", 2331], ["than", 2333], ["with", 2338], ["the", 2343], ["0", 2347], [",", 2348], ["1", 2350], [",", 2351], ["7", 2353], ["month", 2355], ["schedule", 2361], ["(", 2370], ["32", 2371], ["%", 2373], ["CI", 2375], ["16", 2378], ["-", 2380], ["45", 2381], [";", 2383], ["p=0\u00b70003", 2385], [")", 2393], [".", 2394], ["1", 2396], ["year", 2398], ["after", 2403], ["dose", 2409], ["three", 2414], [",", 2419], ["vaccine", 2421], ["efficacy", 2429], ["against", 2438], ["first", 2446], ["malaria", 2452], ["episodes", 2460], ["was", 2469], ["similar", 2473], ["for", 2481], ["both", 2485], ["schedules", 2490], ["(", 2500], ["0", 2501], [",", 2502], ["1", 2504], [",", 2505], ["2", 2507], ["month", 2509], ["group", 2515], [",", 2520], ["61\u00b76", 2522], ["%", 2526], ["[", 2528], ["95", 2529], ["%", 2531], ["CI", 2533], ["35\u00b76", 2536], ["-", 2540], ["77\u00b71", 2541], ["]", 2545], [",", 2546], ["p<0\u00b7001", 2548], [";", 2555], ["0", 2557], [",", 2558], ["1", 2560], [",", 2561], ["7", 2563], ["month", 2565], ["group", 2571], [",", 2576], ["63\u00b78", 2578], ["%", 2582], ["[", 2584], ["40\u00b74", 2585], ["-", 2589], ["78\u00b70", 2590], ["]", 2594], [",", 2595], ["p<0\u00b7001", 2597], [",", 2604], ["according", 2606], ["-", 2615], ["to", 2616], ["-", 2618], ["protocol", 2619], ["cohort", 2628], [")", 2634], [".", 2635], ["Vaccine", 2637], ["efficacy", 2645], ["was", 2654], ["consistent", 2658], ["with", 2669], ["the", 2674], ["target", 2678], ["put", 2685], ["forward", 2689], ["by", 2697], ["the", 2700], ["WHO", 2704], ["-", 2707], ["sponsored", 2708], ["malaria", 2718], ["vaccine", 2726], ["technology", 2734], ["roadmap", 2745], ["for", 2753], ["a", 2757], ["first", 2759], ["-", 2764], ["generation", 2765], ["malaria", 2776], ["vaccine", 2784], [".", 2791], ["The", 2793], ["0", 2797], [",", 2798], ["1", 2800], [",", 2801], ["2", 2803], ["month", 2805], ["vaccine", 2811], ["schedule", 2819], ["has", 2828], ["been", 2832], ["selected", 2837], ["for", 2846], ["phase", 2850], ["3", 2856], ["candidate", 2858], ["vaccine", 2868], ["assessment", 2876], [".", 2886], ["Program", 2888], ["for", 2896], ["Appropriate", 2900], ["Technology", 2912], ["in", 2923], ["Health", 2926], ["Malaria", 2933], ["Vaccine", 2941], ["Initiative", 2949], [";", 2959], ["GlaxoSmithKline", 2961], ["Biologicals", 2977], [".", 2988]]}
{"context": "The natural phytoalexin resveratrol, found in grapes and red wine, recently rose to public fame for its positive effects on longevity in yeasts, worms and flies. Resveratrol anti-cancer and anti-inflammatory in vitro action on mammalian cell cultures also suggest a possible positive effect on human health and life-expectancy. To study the effects of resveratrol on vertebrate aging is obviously a particularly relevant question. We have studied resveratrol effects in a very short-lived vertebrate: the annual fish Nothobranchius furzeri. Resveratrol treatment prolonged lifespan and delayed the onset of age-related dysfunctions in this fish. This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. Moreover, being related to stickleback (Gasterosteus aculeatus) the \"pufferfishes\" Takifugu and Tetraodon, and even more closely related to medaka (Oryzias latipes), it can greatly beneficiate from the recent development of genomic resources for these fish models and in the future become a complete model system for the aging research community.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "28273676388a4bd8b10c28cc78703649", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[212, 213]], "char_spans": [[1219, 1232]]}]}], "context_tokens": [["The", 0], ["natural", 4], ["phytoalexin", 12], ["resveratrol", 24], [",", 35], ["found", 37], ["in", 43], ["grapes", 46], ["and", 53], ["red", 57], ["wine", 61], [",", 65], ["recently", 67], ["rose", 76], ["to", 81], ["public", 84], ["fame", 91], ["for", 96], ["its", 100], ["positive", 104], ["effects", 113], ["on", 121], ["longevity", 124], ["in", 134], ["yeasts", 137], [",", 143], ["worms", 145], ["and", 151], ["flies", 155], [".", 160], ["Resveratrol", 162], ["anti", 174], ["-", 178], ["cancer", 179], ["and", 186], ["anti", 190], ["-", 194], ["inflammatory", 195], ["in", 208], ["vitro", 211], ["action", 217], ["on", 224], ["mammalian", 227], ["cell", 237], ["cultures", 242], ["also", 251], ["suggest", 256], ["a", 264], ["possible", 266], ["positive", 275], ["effect", 284], ["on", 291], ["human", 294], ["health", 300], ["and", 307], ["life", 311], ["-", 315], ["expectancy", 316], [".", 326], ["To", 328], ["study", 331], ["the", 337], ["effects", 341], ["of", 349], ["resveratrol", 352], ["on", 364], ["vertebrate", 367], ["aging", 378], ["is", 384], ["obviously", 387], ["a", 397], ["particularly", 399], ["relevant", 412], ["question", 421], [".", 429], ["We", 431], ["have", 434], ["studied", 439], ["resveratrol", 447], ["effects", 459], ["in", 467], ["a", 470], ["very", 472], ["short", 477], ["-", 482], ["lived", 483], ["vertebrate", 489], [":", 499], ["the", 501], ["annual", 505], ["fish", 512], ["Nothobranchius", 517], ["furzeri", 532], [".", 539], ["Resveratrol", 541], ["treatment", 553], ["prolonged", 563], ["lifespan", 573], ["and", 582], ["delayed", 586], ["the", 594], ["onset", 598], ["of", 604], ["age", 607], ["-", 610], ["related", 611], ["dysfunctions", 619], ["in", 632], ["this", 635], ["fish", 640], [".", 644], ["This", 646], ["result", 651], ["identifies", 658], ["resveratrol", 669], ["as", 681], ["the", 684], ["first", 688], ["molecule", 694], ["which", 703], ["consistently", 709], ["retards", 722], ["aging", 730], ["in", 736], ["organisms", 739], ["as", 749], ["diverse", 752], ["as", 760], ["yeast", 763], [",", 768], ["worm", 770], [",", 774], ["fly", 776], ["and", 780], ["fish", 784], [",", 788], ["but", 790], ["it", 794], ["also", 797], ["reveals", 802], ["the", 810], ["potential", 814], ["of", 824], ["this", 827], ["short", 832], ["-", 837], ["lived", 838], ["fish", 844], ["as", 849], ["an", 852], ["animal", 855], ["model", 862], ["for", 868], ["pharmacological", 872], ["research", 888], [".", 896], ["Moreover", 898], [",", 906], ["being", 908], ["related", 914], ["to", 922], ["stickleback", 925], ["(", 937], ["Gasterosteus", 938], ["aculeatus", 951], [")", 960], ["the", 962], ["\"", 966], ["pufferfishes", 967], ["\"", 979], ["Takifugu", 981], ["and", 990], ["Tetraodon", 994], [",", 1003], ["and", 1005], ["even", 1009], ["more", 1014], ["closely", 1019], ["related", 1027], ["to", 1035], ["medaka", 1038], ["(", 1045], ["Oryzias", 1046], ["latipes", 1054], [")", 1061], [",", 1062], ["it", 1064], ["can", 1067], ["greatly", 1071], ["beneficiate", 1079], ["from", 1091], ["the", 1096], ["recent", 1100], ["development", 1107], ["of", 1119], ["genomic", 1122], ["resources", 1130], ["for", 1140], ["these", 1144], ["fish", 1150], ["models", 1155], ["and", 1162], ["in", 1166], ["the", 1169], ["future", 1173], ["become", 1180], ["a", 1187], ["complete", 1189], ["model", 1198], ["system", 1204], ["for", 1211], ["the", 1215], ["aging", 1219], ["research", 1225], ["community", 1234], [".", 1243]]}
{"context": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrythmogenic disease characterized by exercise--or stress--induced ventricular tachyarrythmias, syncope, or sudden death, usually in the pediatric age group. Familial occurrence has been noted in about 30% of cases. Inheritance may be autosomal dominant or recessive, usually with high penetrance. The causative genes have been mapped to chromosome 1. Mutations of the cardiac ryanodine receptor gene (RyR2) have been identified in autosomal dominant pedigrees, while calsequestrin gene (CASQ2) mutations are seen in recessive cases. Due to its potential lethal outcome, exclusion or confirmation of catecholaminergic polymorphic ventricular tachycardia in children with physical and emotional syncope is mandatory. We report a case of catecholaminergic polymorphic ventricular tachycardia in a three-year-old child only diagnosed by genetic mapping.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "023fcc86e5c846d2b6220e8e9e90de4c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[85, 86], [51, 52]], "char_spans": [[504, 521], [307, 324]]}]}], "context_tokens": [["Catecholaminergic", 0], ["polymorphic", 18], ["ventricular", 30], ["tachycardia", 42], ["(", 54], ["CPVT", 55], [")", 59], ["is", 61], ["a", 64], ["rare", 66], ["arrythmogenic", 71], ["disease", 85], ["characterized", 93], ["by", 107], ["exercise", 110], ["--", 118], ["or", 120], ["stress", 123], ["--", 129], ["induced", 131], ["ventricular", 139], ["tachyarrythmias", 151], [",", 166], ["syncope", 168], [",", 175], ["or", 177], ["sudden", 180], ["death", 187], [",", 192], ["usually", 194], ["in", 202], ["the", 205], ["pediatric", 209], ["age", 219], ["group", 223], [".", 228], ["Familial", 230], ["occurrence", 239], ["has", 250], ["been", 254], ["noted", 259], ["in", 265], ["about", 268], ["30", 274], ["%", 276], ["of", 278], ["cases", 281], [".", 286], ["Inheritance", 288], ["may", 300], ["be", 304], ["autosomal", 307], ["dominant", 317], ["or", 326], ["recessive", 329], [",", 338], ["usually", 340], ["with", 348], ["high", 353], ["penetrance", 358], [".", 368], ["The", 370], ["causative", 374], ["genes", 384], ["have", 390], ["been", 395], ["mapped", 400], ["to", 407], ["chromosome", 410], ["1", 421], [".", 422], ["Mutations", 424], ["of", 434], ["the", 437], ["cardiac", 441], ["ryanodine", 449], ["receptor", 459], ["gene", 468], ["(", 473], ["RyR2", 474], [")", 478], ["have", 480], ["been", 485], ["identified", 490], ["in", 501], ["autosomal", 504], ["dominant", 514], ["pedigrees", 523], [",", 532], ["while", 534], ["calsequestrin", 540], ["gene", 554], ["(", 559], ["CASQ2", 560], [")", 565], ["mutations", 567], ["are", 577], ["seen", 581], ["in", 586], ["recessive", 589], ["cases", 599], [".", 604], ["Due", 606], ["to", 610], ["its", 613], ["potential", 617], ["lethal", 627], ["outcome", 634], [",", 641], ["exclusion", 643], ["or", 653], ["confirmation", 656], ["of", 669], ["catecholaminergic", 672], ["polymorphic", 690], ["ventricular", 702], ["tachycardia", 714], ["in", 726], ["children", 729], ["with", 738], ["physical", 743], ["and", 752], ["emotional", 756], ["syncope", 766], ["is", 774], ["mandatory", 777], [".", 786], ["We", 788], ["report", 791], ["a", 798], ["case", 800], ["of", 805], ["catecholaminergic", 808], ["polymorphic", 826], ["ventricular", 838], ["tachycardia", 850], ["in", 862], ["a", 865], ["three", 867], ["-", 872], ["year", 873], ["-", 877], ["old", 878], ["child", 882], ["only", 888], ["diagnosed", 893], ["by", 903], ["genetic", 906], ["mapping", 914], [".", 921]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). The drug shows great efficacy in chronic phase, but is less effective in maintaining hematologic remissions in blast crisis patients. Our group has previously described several cell lines made resistant to imatinib. We now examine the question of cross-resistance to other chemotherapeutic drugs used in CML. Four paired imatinib-sensitive/resistant CML cell lines were assessed by caspase-3 and MTS assays for their proliferative response to cytosine arabinoside (Ara-C), daunorubicin (DNR), homoharringtonine (HHT) and hydroxyurea (HU), either alone or in combination with imatinib. Primary blasts from advanced-stage CML patients refractory to imatinib therapy were studied by semi-solid media clonogenic assays. We found that these drugs are generally capable of major inhibition of proliferation of the CML cell lines, although differential responses to DNR and HHT were noted between some sensitive and resistant cell line pairs, implying that resistance to imatinib may confer a growth advantage under such conditions. The four drugs were also effective in preventing the formation of progenitor cell colonies from CML patients both before treatment with imatinib, and after relapse on the drug. Isobolographic analysis implied that these drugs will generally combine well with imatinib, and in some cases will be synergistic. We conclude that Ara-C, DNR or HHT, either alone or in combination with imatinib, are likely to be the best therapeutic alternatives in the management of patients who become resistant to imatinib monotherapy.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "29e2e1a616a44ac1921297ac7f7c34c6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[19, 21]], "char_spans": [[103, 109]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI571", 19], [",", 25], ["Glivec", 27], [",", 33], ["Gleevec", 35], [")", 42], ["is", 44], ["a", 47], ["powerful", 49], ["inhibitor", 58], ["of", 68], ["the", 71], ["tyrosine", 75], ["kinase", 84], ["activity", 91], ["of", 100], ["Bcr", 103], ["-", 106], ["Abl", 107], [",", 110], ["the", 112], ["oncoprotein", 116], ["responsible", 128], ["for", 140], ["chronic", 144], ["myeloid", 152], ["leukemia", 160], ["(", 169], ["CML", 170], [")", 173], [".", 174], ["The", 176], ["drug", 180], ["shows", 185], ["great", 191], ["efficacy", 197], ["in", 206], ["chronic", 209], ["phase", 217], [",", 222], ["but", 224], ["is", 228], ["less", 231], ["effective", 236], ["in", 246], ["maintaining", 249], ["hematologic", 261], ["remissions", 273], ["in", 284], ["blast", 287], ["crisis", 293], ["patients", 300], [".", 308], ["Our", 310], ["group", 314], ["has", 320], ["previously", 324], ["described", 335], ["several", 345], ["cell", 353], ["lines", 358], ["made", 364], ["resistant", 369], ["to", 379], ["imatinib", 382], [".", 390], ["We", 392], ["now", 395], ["examine", 399], ["the", 407], ["question", 411], ["of", 420], ["cross", 423], ["-", 428], ["resistance", 429], ["to", 440], ["other", 443], ["chemotherapeutic", 449], ["drugs", 466], ["used", 472], ["in", 477], ["CML", 480], [".", 483], ["Four", 485], ["paired", 490], ["imatinib", 497], ["-", 505], ["sensitive", 506], ["/", 515], ["resistant", 516], ["CML", 526], ["cell", 530], ["lines", 535], ["were", 541], ["assessed", 546], ["by", 555], ["caspase-3", 558], ["and", 568], ["MTS", 572], ["assays", 576], ["for", 583], ["their", 587], ["proliferative", 593], ["response", 607], ["to", 616], ["cytosine", 619], ["arabinoside", 628], ["(", 640], ["Ara", 641], ["-", 644], ["C", 645], [")", 646], [",", 647], ["daunorubicin", 649], ["(", 662], ["DNR", 663], [")", 666], [",", 667], ["homoharringtonine", 669], ["(", 687], ["HHT", 688], [")", 691], ["and", 693], ["hydroxyurea", 697], ["(", 709], ["HU", 710], [")", 712], [",", 713], ["either", 715], ["alone", 722], ["or", 728], ["in", 731], ["combination", 734], ["with", 746], ["imatinib", 751], [".", 759], ["Primary", 761], ["blasts", 769], ["from", 776], ["advanced", 781], ["-", 789], ["stage", 790], ["CML", 796], ["patients", 800], ["refractory", 809], ["to", 820], ["imatinib", 823], ["therapy", 832], ["were", 840], ["studied", 845], ["by", 853], ["semi", 856], ["-", 860], ["solid", 861], ["media", 867], ["clonogenic", 873], ["assays", 884], [".", 890], ["We", 892], ["found", 895], ["that", 901], ["these", 906], ["drugs", 912], ["are", 918], ["generally", 922], ["capable", 932], ["of", 940], ["major", 943], ["inhibition", 949], ["of", 960], ["proliferation", 963], ["of", 977], ["the", 980], ["CML", 984], ["cell", 988], ["lines", 993], [",", 998], ["although", 1000], ["differential", 1009], ["responses", 1022], ["to", 1032], ["DNR", 1035], ["and", 1039], ["HHT", 1043], ["were", 1047], ["noted", 1052], ["between", 1058], ["some", 1066], ["sensitive", 1071], ["and", 1081], ["resistant", 1085], ["cell", 1095], ["line", 1100], ["pairs", 1105], [",", 1110], ["implying", 1112], ["that", 1121], ["resistance", 1126], ["to", 1137], ["imatinib", 1140], ["may", 1149], ["confer", 1153], ["a", 1160], ["growth", 1162], ["advantage", 1169], ["under", 1179], ["such", 1185], ["conditions", 1190], [".", 1200], ["The", 1202], ["four", 1206], ["drugs", 1211], ["were", 1217], ["also", 1222], ["effective", 1227], ["in", 1237], ["preventing", 1240], ["the", 1251], ["formation", 1255], ["of", 1265], ["progenitor", 1268], ["cell", 1279], ["colonies", 1284], ["from", 1293], ["CML", 1298], ["patients", 1302], ["both", 1311], ["before", 1316], ["treatment", 1323], ["with", 1333], ["imatinib", 1338], [",", 1346], ["and", 1348], ["after", 1352], ["relapse", 1358], ["on", 1366], ["the", 1369], ["drug", 1373], [".", 1377], ["Isobolographic", 1379], ["analysis", 1394], ["implied", 1403], ["that", 1411], ["these", 1416], ["drugs", 1422], ["will", 1428], ["generally", 1433], ["combine", 1443], ["well", 1451], ["with", 1456], ["imatinib", 1461], [",", 1469], ["and", 1471], ["in", 1475], ["some", 1478], ["cases", 1483], ["will", 1489], ["be", 1494], ["synergistic", 1497], [".", 1508], ["We", 1510], ["conclude", 1513], ["that", 1522], ["Ara", 1527], ["-", 1530], ["C", 1531], [",", 1532], ["DNR", 1534], ["or", 1538], ["HHT", 1541], [",", 1544], ["either", 1546], ["alone", 1553], ["or", 1559], ["in", 1562], ["combination", 1565], ["with", 1577], ["imatinib", 1582], [",", 1590], ["are", 1592], ["likely", 1596], ["to", 1603], ["be", 1606], ["the", 1609], ["best", 1613], ["therapeutic", 1618], ["alternatives", 1630], ["in", 1643], ["the", 1646], ["management", 1650], ["of", 1661], ["patients", 1664], ["who", 1673], ["become", 1677], ["resistant", 1684], ["to", 1694], ["imatinib", 1697], ["monotherapy", 1706], [".", 1717]]}
{"context": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenopausal women with osteoporosis [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial]. Denosumab causes somewhat greater increases in bone mineral density (BMD) than the class of bisphosphonate antiresorptives. Denosumab also causes an increase in bone mass and bone strength in the spine, ultradistal and diaphysis of the radius, proximal tibia and the hip. Recently long-term treatment with denosumab has been shown to cause a continued almost linear increase in total hip and femoral neck BMD beyond 3 years up to 8 years. In this respect, denosumab seems to differ from the bisphosphonate group in which the rate of improvement of BMD diminishes and for some drugs becomes negative after 3-4 years when the process of secondary mineralization flattens out. This unique property of an antiresorptive drug points towards mechanisms of action which differ from the bisphosphonate group. Both types of antiresorptives decrease cortical porosity but contrary to bisphosphonates the reduction in cortical porosity continues with denosumab which, in addition, also seems to cause a slight continuous modeling-based formation of new bone despite suppression of bone remodeling. The net effect is an increase in cortical thickening and bone mass, and increased strength of cortical bone. This may contribute substantially to the significant further reduction of the nonvertebral fracture risk which was found in the long-term denosumab arm of the FREEDOM extension trial during years 4-7.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor \u03baB ligand", "RANKL", "receptor activator of nuclear factor-\u03baB ligand"], "qid": "d38d490c5d9f45a0818bec552463879b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[9, 15]], "char_spans": [[67, 112]]}]}], "context_tokens": [["Denosumab", 0], ["is", 10], ["a", 13], ["human", 15], ["monoclonal", 21], ["antibody", 32], ["which", 41], ["specifically", 47], ["blocks", 60], ["receptor", 67], ["activator", 76], ["of", 86], ["nuclear", 89], ["factor", 97], ["\u03baB", 104], ["ligand", 107], ["and", 114], ["is", 118], ["a", 121], ["very", 123], ["potent", 128], ["antiresorptive", 135], ["drug", 150], [".", 154], ["Its", 156], ["efficacy", 160], ["in", 169], ["reducing", 172], ["the", 181], ["risk", 185], ["of", 190], ["vertebral", 193], [",", 202], ["hip", 204], ["and", 208], ["nonskeletal", 212], ["fracture", 224], ["has", 233], ["been", 237], ["proven", 242], ["in", 249], ["a", 252], ["large", 254], ["prospective", 260], [",", 271], ["randomized", 273], ["multicenter", 284], ["study", 296], ["of", 302], ["7808", 305], ["postmenopausal", 310], ["women", 325], ["with", 331], ["osteoporosis", 336], ["[", 349], ["Fracture", 350], ["Reduction", 359], ["Evaluation", 369], ["of", 380], ["Denosumab", 383], ["in", 393], ["Osteoporosis", 396], ["Every", 409], ["6", 415], ["Months", 417], ["(", 424], ["FREEDOM", 425], [")", 432], ["trial].", 434], ["Denosumab", 442], ["causes", 452], ["somewhat", 459], ["greater", 468], ["increases", 476], ["in", 486], ["bone", 489], ["mineral", 494], ["density", 502], ["(", 510], ["BMD", 511], [")", 514], ["than", 516], ["the", 521], ["class", 525], ["of", 531], ["bisphosphonate", 534], ["antiresorptives", 549], [".", 564], ["Denosumab", 566], ["also", 576], ["causes", 581], ["an", 588], ["increase", 591], ["in", 600], ["bone", 603], ["mass", 608], ["and", 613], ["bone", 617], ["strength", 622], ["in", 631], ["the", 634], ["spine", 638], [",", 643], ["ultradistal", 645], ["and", 657], ["diaphysis", 661], ["of", 671], ["the", 674], ["radius", 678], [",", 684], ["proximal", 686], ["tibia", 695], ["and", 701], ["the", 705], ["hip", 709], [".", 712], ["Recently", 714], ["long", 723], ["-", 727], ["term", 728], ["treatment", 733], ["with", 743], ["denosumab", 748], ["has", 758], ["been", 762], ["shown", 767], ["to", 773], ["cause", 776], ["a", 782], ["continued", 784], ["almost", 794], ["linear", 801], ["increase", 808], ["in", 817], ["total", 820], ["hip", 826], ["and", 830], ["femoral", 834], ["neck", 842], ["BMD", 847], ["beyond", 851], ["3", 858], ["years", 860], ["up", 866], ["to", 869], ["8", 872], ["years", 874], [".", 879], ["In", 881], ["this", 884], ["respect", 889], [",", 896], ["denosumab", 898], ["seems", 908], ["to", 914], ["differ", 917], ["from", 924], ["the", 929], ["bisphosphonate", 933], ["group", 948], ["in", 954], ["which", 957], ["the", 963], ["rate", 967], ["of", 972], ["improvement", 975], ["of", 987], ["BMD", 990], ["diminishes", 994], ["and", 1005], ["for", 1009], ["some", 1013], ["drugs", 1018], ["becomes", 1024], ["negative", 1032], ["after", 1041], ["3", 1047], ["-", 1048], ["4", 1049], ["years", 1051], ["when", 1057], ["the", 1062], ["process", 1066], ["of", 1074], ["secondary", 1077], ["mineralization", 1087], ["flattens", 1102], ["out", 1111], [".", 1114], ["This", 1116], ["unique", 1121], ["property", 1128], ["of", 1137], ["an", 1140], ["antiresorptive", 1143], ["drug", 1158], ["points", 1163], ["towards", 1170], ["mechanisms", 1178], ["of", 1189], ["action", 1192], ["which", 1199], ["differ", 1205], ["from", 1212], ["the", 1217], ["bisphosphonate", 1221], ["group", 1236], [".", 1241], ["Both", 1243], ["types", 1248], ["of", 1254], ["antiresorptives", 1257], ["decrease", 1273], ["cortical", 1282], ["porosity", 1291], ["but", 1300], ["contrary", 1304], ["to", 1313], ["bisphosphonates", 1316], ["the", 1332], ["reduction", 1336], ["in", 1346], ["cortical", 1349], ["porosity", 1358], ["continues", 1367], ["with", 1377], ["denosumab", 1382], ["which", 1392], [",", 1397], ["in", 1399], ["addition", 1402], [",", 1410], ["also", 1412], ["seems", 1417], ["to", 1423], ["cause", 1426], ["a", 1432], ["slight", 1434], ["continuous", 1441], ["modeling", 1452], ["-", 1460], ["based", 1461], ["formation", 1467], ["of", 1477], ["new", 1480], ["bone", 1484], ["despite", 1489], ["suppression", 1497], ["of", 1509], ["bone", 1512], ["remodeling", 1517], [".", 1527], ["The", 1529], ["net", 1533], ["effect", 1537], ["is", 1544], ["an", 1547], ["increase", 1550], ["in", 1559], ["cortical", 1562], ["thickening", 1571], ["and", 1582], ["bone", 1586], ["mass", 1591], [",", 1595], ["and", 1597], ["increased", 1601], ["strength", 1611], ["of", 1620], ["cortical", 1623], ["bone", 1632], [".", 1636], ["This", 1638], ["may", 1643], ["contribute", 1647], ["substantially", 1658], ["to", 1672], ["the", 1675], ["significant", 1679], ["further", 1691], ["reduction", 1699], ["of", 1709], ["the", 1712], ["nonvertebral", 1716], ["fracture", 1729], ["risk", 1738], ["which", 1743], ["was", 1749], ["found", 1753], ["in", 1759], ["the", 1762], ["long", 1766], ["-", 1770], ["term", 1771], ["denosumab", 1776], ["arm", 1786], ["of", 1790], ["the", 1793], ["FREEDOM", 1797], ["extension", 1805], ["trial", 1815], ["during", 1821], ["years", 1828], ["4", 1834], ["-", 1835], ["7", 1836], [".", 1837]]}
{"context": "Interstitial deletions of chromosome band Xq26.3 are rare. We report on a 2-year-old boy in whom array comparative genomic hybridization analysis revealed an interstitial 314 kb deletion in Xq26.3 affecting SLC9A6 and FHL1. Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718). The clinical problems of the patient reported here comprised severe intellectual disability, absent speech, ataxia, epilepsy, and gastroesophageal reflux, and could mostly be attributed to SLC9A6 insufficiency. In contrast to the majority of reported Christianson syndrome patients who were microcephalic, this patient was normocephalic, but his head circumference had decelerated from the 50th centile at birth to the 25th centile at the age of 2 \u00b2/\u00b9\u00b2 years. Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy. This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. This is also the first patient with a deletion affecting both SLC9A6 and the complete FHL1 gene.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "66ed19703ab9429588260046aacc2ac1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[235, 235], [151, 151], [39, 39], [258, 258], [33, 33]], "char_spans": [[1346, 1351], [860, 865], [237, 242], [1495, 1500], [207, 212]]}]}], "context_tokens": [["Interstitial", 0], ["deletions", 13], ["of", 23], ["chromosome", 26], ["band", 37], ["Xq26.3", 42], ["are", 49], ["rare", 53], [".", 57], ["We", 59], ["report", 62], ["on", 69], ["a", 72], ["2-year", 74], ["-", 80], ["old", 81], ["boy", 85], ["in", 89], ["whom", 92], ["array", 97], ["comparative", 103], ["genomic", 115], ["hybridization", 123], ["analysis", 137], ["revealed", 146], ["an", 155], ["interstitial", 158], ["314", 171], ["kb", 175], ["deletion", 178], ["in", 187], ["Xq26.3", 190], ["affecting", 197], ["SLC9A6", 207], ["and", 214], ["FHL1", 218], [".", 222], ["Mutations", 224], ["in", 234], ["SLC9A6", 237], ["are", 244], ["associated", 248], ["with", 259], ["Christianson", 264], ["syndrome", 277], ["(", 286], ["OMIM", 287], ["300243", 292], [")", 298], [",", 299], ["a", 301], ["syndromic", 303], ["form", 313], ["of", 318], ["X", 321], ["-", 322], ["linked", 323], ["mental", 330], ["retardation", 337], ["(", 349], ["XLMR", 350], [")", 354], ["characterized", 356], ["by", 370], ["microcephaly", 373], [",", 385], ["severe", 387], ["global", 394], ["developmental", 401], ["delay", 415], [",", 420], ["ataxia", 422], ["and", 429], ["seizures", 433], [".", 441], ["FHL1", 443], ["mutations", 448], ["cause", 458], ["Emery", 464], ["-", 469], ["Dreifuss", 470], ["muscular", 479], ["dystrophy", 488], ["(", 498], ["OMIM", 499], ["310300", 504], [")", 510], [",", 511], ["X", 513], ["-", 514], ["linked", 515], ["myopathy", 522], ["with", 531], ["postural", 536], ["muscle", 545], ["atrophy", 552], ["(", 560], ["XMPMA", 561], [",", 566], ["OMIM", 568], ["300696", 573], [")", 579], [",", 580], ["scapuloperoneal", 582], ["myopathy", 598], ["(", 607], ["OMIM", 608], ["300695", 613], [")", 619], [",", 620], ["or", 622], ["reducing", 625], ["body", 634], ["myopathy", 639], ["(", 648], ["OMIM", 649], ["300717", 654], [",", 660], ["300718", 662], [")", 668], [".", 669], ["The", 671], ["clinical", 675], ["problems", 684], ["of", 693], ["the", 696], ["patient", 700], ["reported", 708], ["here", 717], ["comprised", 722], ["severe", 732], ["intellectual", 739], ["disability", 752], [",", 762], ["absent", 764], ["speech", 771], [",", 777], ["ataxia", 779], [",", 785], ["epilepsy", 787], [",", 795], ["and", 797], ["gastroesophageal", 801], ["reflux", 818], [",", 824], ["and", 826], ["could", 830], ["mostly", 836], ["be", 843], ["attributed", 846], ["to", 857], ["SLC9A6", 860], ["insufficiency", 867], [".", 880], ["In", 882], ["contrast", 885], ["to", 894], ["the", 897], ["majority", 901], ["of", 910], ["reported", 913], ["Christianson", 922], ["syndrome", 935], ["patients", 944], ["who", 953], ["were", 957], ["microcephalic", 962], [",", 975], ["this", 977], ["patient", 982], ["was", 990], ["normocephalic", 994], [",", 1007], ["but", 1009], ["his", 1013], ["head", 1017], ["circumference", 1022], ["had", 1036], ["decelerated", 1040], ["from", 1052], ["the", 1057], ["50th", 1061], ["centile", 1066], ["at", 1074], ["birth", 1077], ["to", 1083], ["the", 1086], ["25th", 1090], ["centile", 1095], ["at", 1103], ["the", 1106], ["age", 1110], ["of", 1114], ["2", 1117], ["\u00b2/\u00b9\u00b2", 1119], ["years", 1124], [".", 1129], ["Muscle", 1131], ["problems", 1138], ["due", 1147], ["to", 1151], ["the", 1154], ["FHL1", 1158], ["deletion", 1163], ["are", 1172], ["not", 1176], ["to", 1180], ["be", 1183], ["expected", 1186], ["before", 1195], ["late", 1202], ["childhood", 1207], [",", 1216], ["which", 1218], ["is", 1224], ["the", 1227], ["earliest", 1231], ["age", 1240], ["of", 1244], ["onset", 1247], ["for", 1253], ["FHL1", 1257], ["associated", 1262], ["Emery", 1273], ["-", 1278], ["Dreifuss", 1279], ["muscular", 1288], ["dystrophy", 1297], [".", 1306], ["This", 1308], ["patient", 1313], ["broadens", 1321], ["the", 1330], ["spectrum", 1334], ["of", 1343], ["SLC9A6", 1346], ["mutations", 1353], ["and", 1363], ["contributes", 1367], ["to", 1379], ["the", 1382], ["clinical", 1386], ["delineation", 1395], ["of", 1407], ["Christianson", 1410], ["syndrome", 1423], [".", 1431], ["This", 1433], ["is", 1438], ["also", 1441], ["the", 1446], ["first", 1450], ["patient", 1456], ["with", 1464], ["a", 1469], ["deletion", 1471], ["affecting", 1480], ["both", 1490], ["SLC9A6", 1495], ["and", 1502], ["the", 1506], ["complete", 1510], ["FHL1", 1519], ["gene", 1524], [".", 1528]]}
{"context": "The superoxide-producing phagocyte NADPH oxidase gp91(phox)/Nox2 and the non-phagocytic oxidases Nox1 and Nox3 each form a complex in the membrane with p22(phox), which provides both stabilization and a docking site for organizer proteins. The p22(phox)-complexed Nox2 and Nox1 are dormant on their own, and their activation requires soluble supportive proteins such as a Nox organizer (p47(phox) or Noxo1) and a Nox activator (p67(phox) or Noxa1). The small GTPase Rac directly binds to the activators, and thus plays an essential role in the Nox2-based oxidase containing p47(phox) and p67(phox) or a positive role in Nox1 activity supported by Noxo1 and Noxa1. Although Nox3 complexed with p22(phox) constitutively produce superoxide, the production can be enhanced by supportive proteins. Here we compare the roles of Rac in these p22(phox)-dependent oxidases using the organizer and activator in different combinations. Expression of constitutively active Rac1(Q61L) is essential for activation of the Nox2- or Nox1-based oxidase containing the organizer p47(phox) and either p67(phox) or Noxa1. When these oxidases use Noxo1 as an organizer instead of p47(phox), they produce a small but significant amount of superoxide without expression of Rac1(Q61L), although the production is enhanced by Rac1(Q61L). Thus p47(phox) is likely related to strict dependence on Rac. The Nox3-based oxidase has a similar tendency in the change of the dependence: Rac plays a positive role in Nox3 activation in the presence of p47(phox) and either p67(phox) or Noxa1, whereas Rac fails to upregulate Nox3 activity when p47(phox) is replaced with Noxo1. We also demonstrate that, in the Nox3-based oxidase containing solely p67(phox) as supportive protein, expression of Rac1(Q61L) enhances not only superoxide production but also membrane translocation of p67(phox). Since the enhancements are not observed with a mutant p67(phox) defective in binding to Rac, this GTPase appear to directly recruit p67(phox) to the membrane.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "3e6978c75bef49edbd8b728bbe7b06de", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[44, 44], [111, 111], [14, 14]], "char_spans": [[273, 276], [620, 623], [97, 100]]}]}], "context_tokens": [["The", 0], ["superoxide", 4], ["-", 14], ["producing", 15], ["phagocyte", 25], ["NADPH", 35], ["oxidase", 41], ["gp91(phox)/Nox2", 49], ["and", 65], ["the", 69], ["non", 73], ["-", 76], ["phagocytic", 77], ["oxidases", 88], ["Nox1", 97], ["and", 102], ["Nox3", 106], ["each", 111], ["form", 116], ["a", 121], ["complex", 123], ["in", 131], ["the", 134], ["membrane", 138], ["with", 147], ["p22(phox", 152], [")", 160], [",", 161], ["which", 163], ["provides", 169], ["both", 178], ["stabilization", 183], ["and", 197], ["a", 201], ["docking", 203], ["site", 211], ["for", 216], ["organizer", 220], ["proteins", 230], [".", 238], ["The", 240], ["p22(phox)-complexed", 244], ["Nox2", 264], ["and", 269], ["Nox1", 273], ["are", 278], ["dormant", 282], ["on", 290], ["their", 293], ["own", 299], [",", 302], ["and", 304], ["their", 308], ["activation", 314], ["requires", 325], ["soluble", 334], ["supportive", 342], ["proteins", 353], ["such", 362], ["as", 367], ["a", 370], ["Nox", 372], ["organizer", 376], ["(", 386], ["p47(phox", 387], [")", 395], ["or", 397], ["Noxo1", 400], [")", 405], ["and", 407], ["a", 411], ["Nox", 413], ["activator", 417], ["(", 427], ["p67(phox", 428], [")", 436], ["or", 438], ["Noxa1", 441], [")", 446], [".", 447], ["The", 449], ["small", 453], ["GTPase", 459], ["Rac", 466], ["directly", 470], ["binds", 479], ["to", 485], ["the", 488], ["activators", 492], [",", 502], ["and", 504], ["thus", 508], ["plays", 513], ["an", 519], ["essential", 522], ["role", 532], ["in", 537], ["the", 540], ["Nox2-based", 544], ["oxidase", 555], ["containing", 563], ["p47(phox", 574], [")", 582], ["and", 584], ["p67(phox", 588], [")", 596], ["or", 598], ["a", 601], ["positive", 603], ["role", 612], ["in", 617], ["Nox1", 620], ["activity", 625], ["supported", 634], ["by", 644], ["Noxo1", 647], ["and", 653], ["Noxa1", 657], [".", 662], ["Although", 664], ["Nox3", 673], ["complexed", 678], ["with", 688], ["p22(phox", 693], [")", 701], ["constitutively", 703], ["produce", 718], ["superoxide", 726], [",", 736], ["the", 738], ["production", 742], ["can", 753], ["be", 757], ["enhanced", 760], ["by", 769], ["supportive", 772], ["proteins", 783], [".", 791], ["Here", 793], ["we", 798], ["compare", 801], ["the", 809], ["roles", 813], ["of", 819], ["Rac", 822], ["in", 826], ["these", 829], ["p22(phox)-dependent", 835], ["oxidases", 855], ["using", 864], ["the", 870], ["organizer", 874], ["and", 884], ["activator", 888], ["in", 898], ["different", 901], ["combinations", 911], [".", 923], ["Expression", 925], ["of", 936], ["constitutively", 939], ["active", 954], ["Rac1(Q61L", 961], [")", 970], ["is", 972], ["essential", 975], ["for", 985], ["activation", 989], ["of", 1000], ["the", 1003], ["Nox2-", 1007], ["or", 1013], ["Nox1-based", 1016], ["oxidase", 1027], ["containing", 1035], ["the", 1046], ["organizer", 1050], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["either", 1074], ["p67(phox", 1081], [")", 1089], ["or", 1091], ["Noxa1", 1094], [".", 1099], ["When", 1101], ["these", 1106], ["oxidases", 1112], ["use", 1121], ["Noxo1", 1125], ["as", 1131], ["an", 1134], ["organizer", 1137], ["instead", 1147], ["of", 1155], ["p47(phox", 1158], [")", 1166], [",", 1167], ["they", 1169], ["produce", 1174], ["a", 1182], ["small", 1184], ["but", 1190], ["significant", 1194], ["amount", 1206], ["of", 1213], ["superoxide", 1216], ["without", 1227], ["expression", 1235], ["of", 1246], ["Rac1(Q61L", 1249], [")", 1258], [",", 1259], ["although", 1261], ["the", 1270], ["production", 1274], ["is", 1285], ["enhanced", 1288], ["by", 1297], ["Rac1(Q61L", 1300], [")", 1309], [".", 1310], ["Thus", 1312], ["p47(phox", 1317], [")", 1325], ["is", 1327], ["likely", 1330], ["related", 1337], ["to", 1345], ["strict", 1348], ["dependence", 1355], ["on", 1366], ["Rac", 1369], [".", 1372], ["The", 1374], ["Nox3-based", 1378], ["oxidase", 1389], ["has", 1397], ["a", 1401], ["similar", 1403], ["tendency", 1411], ["in", 1420], ["the", 1423], ["change", 1427], ["of", 1434], ["the", 1437], ["dependence", 1441], [":", 1451], ["Rac", 1453], ["plays", 1457], ["a", 1463], ["positive", 1465], ["role", 1474], ["in", 1479], ["Nox3", 1482], ["activation", 1487], ["in", 1498], ["the", 1501], ["presence", 1505], ["of", 1514], ["p47(phox", 1517], [")", 1525], ["and", 1527], ["either", 1531], ["p67(phox", 1538], [")", 1546], ["or", 1548], ["Noxa1", 1551], [",", 1556], ["whereas", 1558], ["Rac", 1566], ["fails", 1570], ["to", 1576], ["upregulate", 1579], ["Nox3", 1590], ["activity", 1595], ["when", 1604], ["p47(phox", 1609], [")", 1617], ["is", 1619], ["replaced", 1622], ["with", 1631], ["Noxo1", 1636], [".", 1641], ["We", 1643], ["also", 1646], ["demonstrate", 1651], ["that", 1663], [",", 1667], ["in", 1669], ["the", 1672], ["Nox3-based", 1676], ["oxidase", 1687], ["containing", 1695], ["solely", 1706], ["p67(phox", 1713], [")", 1721], ["as", 1723], ["supportive", 1726], ["protein", 1737], [",", 1744], ["expression", 1746], ["of", 1757], ["Rac1(Q61L", 1760], [")", 1769], ["enhances", 1771], ["not", 1780], ["only", 1784], ["superoxide", 1789], ["production", 1800], ["but", 1811], ["also", 1815], ["membrane", 1820], ["translocation", 1829], ["of", 1843], ["p67(phox", 1846], [")", 1854], [".", 1855], ["Since", 1857], ["the", 1863], ["enhancements", 1867], ["are", 1880], ["not", 1884], ["observed", 1888], ["with", 1897], ["a", 1902], ["mutant", 1904], ["p67(phox", 1911], [")", 1919], ["defective", 1921], ["in", 1931], ["binding", 1934], ["to", 1942], ["Rac", 1945], [",", 1948], ["this", 1950], ["GTPase", 1955], ["appear", 1962], ["to", 1969], ["directly", 1972], ["recruit", 1981], ["p67(phox", 1989], [")", 1997], ["to", 1999], ["the", 2002], ["membrane", 2006], [".", 2014]]}
{"context": "Transcription-coupled repair (TCR) is the major pathway involved in the removal of UV-induced photolesions from the transcribed strand of active genes. Two Cockayne syndrome (CS) complementation group proteins, CSA and CSB, are important for TCR repair. The molecular mechanisms by which CS proteins regulate TCR remain elusive. Here, we report the characterization of KIAA1530, an evolutionarily conserved protein that participates in this pathway through its interaction with CSA and the TFIIH complex. We found that UV irradiation led to the recruitment of KIAA1530 onto chromatin in a CSA-dependent manner. Cells lacking KIAA1530 were highly sensitive to UV irradiation and displayed deficiency in TCR. In addition, KIAA1530 depletion abrogated stability of the CSB protein following UV irradiation. More excitingly, we found that a unique CSA mutant (W361C), which was previously identified in a patient with UV(s)S syndrome, showed defective KIAA1530 binding and resulted in a failure of recruiting KIAA1530 and stabilizing CSB after UV treatment. Together, our data not only reveal that KIAA1530 is an important player in TCR but also lead to a better understanding of the molecular mechanism underlying UV(s)S syndrome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "0ee48960a85e4cb08d71437204c23131", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[22, 23]], "char_spans": [[116, 133]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["the", 38], ["major", 42], ["pathway", 48], ["involved", 56], ["in", 65], ["the", 68], ["removal", 72], ["of", 80], ["UV", 83], ["-", 85], ["induced", 86], ["photolesions", 94], ["from", 107], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["active", 138], ["genes", 145], [".", 150], ["Two", 152], ["Cockayne", 156], ["syndrome", 165], ["(", 174], ["CS", 175], [")", 177], ["complementation", 179], ["group", 195], ["proteins", 201], [",", 209], ["CSA", 211], ["and", 215], ["CSB", 219], [",", 222], ["are", 224], ["important", 228], ["for", 238], ["TCR", 242], ["repair", 246], [".", 252], ["The", 254], ["molecular", 258], ["mechanisms", 268], ["by", 279], ["which", 282], ["CS", 288], ["proteins", 291], ["regulate", 300], ["TCR", 309], ["remain", 313], ["elusive", 320], [".", 327], ["Here", 329], [",", 333], ["we", 335], ["report", 338], ["the", 345], ["characterization", 349], ["of", 366], ["KIAA1530", 369], [",", 377], ["an", 379], ["evolutionarily", 382], ["conserved", 397], ["protein", 407], ["that", 415], ["participates", 420], ["in", 433], ["this", 436], ["pathway", 441], ["through", 449], ["its", 457], ["interaction", 461], ["with", 473], ["CSA", 478], ["and", 482], ["the", 486], ["TFIIH", 490], ["complex", 496], [".", 503], ["We", 505], ["found", 508], ["that", 514], ["UV", 519], ["irradiation", 522], ["led", 534], ["to", 538], ["the", 541], ["recruitment", 545], ["of", 557], ["KIAA1530", 560], ["onto", 569], ["chromatin", 574], ["in", 584], ["a", 587], ["CSA", 589], ["-", 592], ["dependent", 593], ["manner", 603], [".", 609], ["Cells", 611], ["lacking", 617], ["KIAA1530", 625], ["were", 634], ["highly", 639], ["sensitive", 646], ["to", 656], ["UV", 659], ["irradiation", 662], ["and", 674], ["displayed", 678], ["deficiency", 688], ["in", 699], ["TCR", 702], [".", 705], ["In", 707], ["addition", 710], [",", 718], ["KIAA1530", 720], ["depletion", 729], ["abrogated", 739], ["stability", 749], ["of", 759], ["the", 762], ["CSB", 766], ["protein", 770], ["following", 778], ["UV", 788], ["irradiation", 791], [".", 802], ["More", 804], ["excitingly", 809], [",", 819], ["we", 821], ["found", 824], ["that", 830], ["a", 835], ["unique", 837], ["CSA", 844], ["mutant", 848], ["(", 855], ["W361C", 856], [")", 861], [",", 862], ["which", 864], ["was", 870], ["previously", 874], ["identified", 885], ["in", 896], ["a", 899], ["patient", 901], ["with", 909], ["UV(s)S", 914], ["syndrome", 921], [",", 929], ["showed", 931], ["defective", 938], ["KIAA1530", 948], ["binding", 957], ["and", 965], ["resulted", 969], ["in", 978], ["a", 981], ["failure", 983], ["of", 991], ["recruiting", 994], ["KIAA1530", 1005], ["and", 1014], ["stabilizing", 1018], ["CSB", 1030], ["after", 1034], ["UV", 1040], ["treatment", 1043], [".", 1052], ["Together", 1054], [",", 1062], ["our", 1064], ["data", 1068], ["not", 1073], ["only", 1077], ["reveal", 1082], ["that", 1089], ["KIAA1530", 1094], ["is", 1103], ["an", 1106], ["important", 1109], ["player", 1119], ["in", 1126], ["TCR", 1129], ["but", 1133], ["also", 1137], ["lead", 1142], ["to", 1147], ["a", 1150], ["better", 1152], ["understanding", 1159], ["of", 1173], ["the", 1176], ["molecular", 1180], ["mechanism", 1190], ["underlying", 1200], ["UV(s)S", 1211], ["syndrome", 1218], [".", 1226]]}
{"context": "mDia proteins are members of the formin family of actin nucleating proteins that polymerize linear actin filaments. Such filaments form the core of thin, tubular, membrane-bound cell surface protrusions known as filopodia, which are a major feature of mammalian cell morphology. Filopodia are dynamic structures that help cells sense environmental cues, and play a role in cell migration, axon guidance, angiogenesis and other processes. RhoGTPases bind to and control the activity of mDia proteins, and several other binding partners of the three mDia1 isoforms-mDia1, mDia2 and mDia3-have been documented. Two independent pathways controlling mammalian filopodium formation have emerged, with one driven by the RhoGTPase Cdc42, and the other by Rif. While mDia2 has been the main formin implicated in forming filopodia, mDia1 has recently surfaced as the key formin utilized by both the Cdc42 and Rif pathways to drive filopodial protrusion.", "qas": [{"question": "What family do mDia proteins belong in?", "answers": ["mDia proteins are members of the formin family"], "qid": "df45d243d5b846c9b8dd26f62bbe479e", "question_tokens": [["What", 0], ["family", 5], ["do", 12], ["mDia", 15], ["proteins", 20], ["belong", 29], ["in", 36], ["?", 38]], "detected_answers": [{"text": "mDia proteins are members of the formin family", "token_spans": [[0, 7]], "char_spans": [[0, 45]]}]}], "context_tokens": [["mDia", 0], ["proteins", 5], ["are", 14], ["members", 18], ["of", 26], ["the", 29], ["formin", 33], ["family", 40], ["of", 47], ["actin", 50], ["nucleating", 56], ["proteins", 67], ["that", 76], ["polymerize", 81], ["linear", 92], ["actin", 99], ["filaments", 105], [".", 114], ["Such", 116], ["filaments", 121], ["form", 131], ["the", 136], ["core", 140], ["of", 145], ["thin", 148], [",", 152], ["tubular", 154], [",", 161], ["membrane", 163], ["-", 171], ["bound", 172], ["cell", 178], ["surface", 183], ["protrusions", 191], ["known", 203], ["as", 209], ["filopodia", 212], [",", 221], ["which", 223], ["are", 229], ["a", 233], ["major", 235], ["feature", 241], ["of", 249], ["mammalian", 252], ["cell", 262], ["morphology", 267], [".", 277], ["Filopodia", 279], ["are", 289], ["dynamic", 293], ["structures", 301], ["that", 312], ["help", 317], ["cells", 322], ["sense", 328], ["environmental", 334], ["cues", 348], [",", 352], ["and", 354], ["play", 358], ["a", 363], ["role", 365], ["in", 370], ["cell", 373], ["migration", 378], [",", 387], ["axon", 389], ["guidance", 394], [",", 402], ["angiogenesis", 404], ["and", 417], ["other", 421], ["processes", 427], [".", 436], ["RhoGTPases", 438], ["bind", 449], ["to", 454], ["and", 457], ["control", 461], ["the", 469], ["activity", 473], ["of", 482], ["mDia", 485], ["proteins", 490], [",", 498], ["and", 500], ["several", 504], ["other", 512], ["binding", 518], ["partners", 526], ["of", 535], ["the", 538], ["three", 542], ["mDia1", 548], ["isoforms", 554], ["-", 562], ["mDia1", 563], [",", 568], ["mDia2", 570], ["and", 576], ["mDia3-have", 580], ["been", 591], ["documented", 596], [".", 606], ["Two", 608], ["independent", 612], ["pathways", 624], ["controlling", 633], ["mammalian", 645], ["filopodium", 655], ["formation", 666], ["have", 676], ["emerged", 681], [",", 688], ["with", 690], ["one", 695], ["driven", 699], ["by", 706], ["the", 709], ["RhoGTPase", 713], ["Cdc42", 723], [",", 728], ["and", 730], ["the", 734], ["other", 738], ["by", 744], ["Rif", 747], [".", 750], ["While", 752], ["mDia2", 758], ["has", 764], ["been", 768], ["the", 773], ["main", 777], ["formin", 782], ["implicated", 789], ["in", 800], ["forming", 803], ["filopodia", 811], [",", 820], ["mDia1", 822], ["has", 828], ["recently", 832], ["surfaced", 841], ["as", 850], ["the", 853], ["key", 857], ["formin", 861], ["utilized", 868], ["by", 877], ["both", 880], ["the", 885], ["Cdc42", 889], ["and", 895], ["Rif", 899], ["pathways", 903], ["to", 912], ["drive", 915], ["filopodial", 921], ["protrusion", 932], [".", 942]]}
{"context": "To determine if flumazenil, when used in doses higher than those currently recommended, could reverse the effects of a benzodiazepine (BDZ) overdose in patients who might not otherwise respond and whether the higher dose was associated with increased adverse effects. Multicenter, randomized, double-blind, placebo-controlled, balanced, with parallel groups. Open-label flumazenil administration was available if a patient failed to respond or became resedated. Sixteen emergency departments in the United States. Patients presenting to the ED with clinically significant signs and symptoms of a known or suspected BDZ overdose. Patients were randomized to receive 10 mL/min of placebo or flumazenil (1 mg/10 mL) each minute for ten minutes. If there was no response, up to 3 mg of open-label flumazenil could be administered. Of 170 patients enrolled, 87 received flumazenil and 83 received placebo. The demographic characteristics of both groups were comparable. Ten minutes after the beginning of study drug infusion, patients were evaluated using the Clinical Global Impression Scale (CGIS), Glasgow Coma Scale (GSC), and Neurobehavioral Assessment Scale (NAS). The mean +/- SD CGIS score at ten minutes for BDZ-positive patients was 1.41 +/- 0.72 for patients who received flumazenil and 3.41 +/- 0.91 for the placebo group (P < .01). There was no difference in the mean CGIS score between the flumazenil (3.25 +/- 1.15) and placebo (3.75 +/- 0.69) groups in BDZ-negative patients. The GCS and NAS were also significantly better in patients who were BDZ-positive and received flumazenil. The mean +/- SD dose of flumazenil administered during the double-blind phase was 71.3 +/- 34.2 mL (7.13 mg) compared with 95.06 +/- 16.03 mL of placebo. Of the 39 patients who had BDZ-positive drug screens and received flumazenil, 29 (74%) responded to 3 mg or less. Six additional patients responded to 4 or 5 mg, and one patient responded to 8 mg. The most common adverse effects in patients who received flumazenil were injection site pain (10.3%), agitation (8%), vomiting (3.4%), dizziness (3.4%), headache (3.4%), tachycardia (3.4%), and crying (3.4%). Three patients developed seizures. Two were associated with significant tricyclic antidepressant overdoses and one with propoxyphene ingestion. Two patients had positive drug screens for BDZ. Flumazenil rapidly and effectively reverses the clinical signs and symptoms of a BDZ overdose. Most patients will respond to 3 mg or less, but a small number may require a higher dose for reversal of clinical symptoms. Patients with concomitant tricyclic antidepressant overdose may be at risk for developing seizures.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "bdaa9885c8734f2a9a3843206e721bc1", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[157, 157], [3, 3], [234, 234], [261, 261], [309, 309], [466, 466], [300, 300], [119, 119], [391, 391], [66, 66], [145, 145], [350, 350]], "char_spans": [[865, 874], [16, 25], [1278, 1287], [1399, 1408], [1617, 1626], [2345, 2354], [1581, 1590], [689, 698], [2001, 2010], [370, 379], [793, 802], [1813, 1822]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["if", 13], ["flumazenil", 16], [",", 26], ["when", 28], ["used", 33], ["in", 38], ["doses", 41], ["higher", 47], ["than", 54], ["those", 59], ["currently", 65], ["recommended", 75], [",", 86], ["could", 88], ["reverse", 94], ["the", 102], ["effects", 106], ["of", 114], ["a", 117], ["benzodiazepine", 119], ["(", 134], ["BDZ", 135], [")", 138], ["overdose", 140], ["in", 149], ["patients", 152], ["who", 161], ["might", 165], ["not", 171], ["otherwise", 175], ["respond", 185], ["and", 193], ["whether", 197], ["the", 205], ["higher", 209], ["dose", 216], ["was", 221], ["associated", 225], ["with", 236], ["increased", 241], ["adverse", 251], ["effects", 259], [".", 266], ["Multicenter", 268], [",", 279], ["randomized", 281], [",", 291], ["double", 293], ["-", 299], ["blind", 300], [",", 305], ["placebo", 307], ["-", 314], ["controlled", 315], [",", 325], ["balanced", 327], [",", 335], ["with", 337], ["parallel", 342], ["groups", 351], [".", 357], ["Open", 359], ["-", 363], ["label", 364], ["flumazenil", 370], ["administration", 381], ["was", 396], ["available", 400], ["if", 410], ["a", 413], ["patient", 415], ["failed", 423], ["to", 430], ["respond", 433], ["or", 441], ["became", 444], ["resedated", 451], [".", 460], ["Sixteen", 462], ["emergency", 470], ["departments", 480], ["in", 492], ["the", 495], ["United", 499], ["States", 506], [".", 512], ["Patients", 514], ["presenting", 523], ["to", 534], ["the", 537], ["ED", 541], ["with", 544], ["clinically", 549], ["significant", 560], ["signs", 572], ["and", 578], ["symptoms", 582], ["of", 591], ["a", 594], ["known", 596], ["or", 602], ["suspected", 605], ["BDZ", 615], ["overdose", 619], [".", 627], ["Patients", 629], ["were", 638], ["randomized", 643], ["to", 654], ["receive", 657], ["10", 665], ["mL", 668], ["/", 670], ["min", 671], ["of", 675], ["placebo", 678], ["or", 686], ["flumazenil", 689], ["(", 700], ["1", 701], ["mg/10", 703], ["mL", 709], [")", 711], ["each", 713], ["minute", 718], ["for", 725], ["ten", 729], ["minutes", 733], [".", 740], ["If", 742], ["there", 745], ["was", 751], ["no", 755], ["response", 758], [",", 766], ["up", 768], ["to", 771], ["3", 774], ["mg", 776], ["of", 779], ["open", 782], ["-", 786], ["label", 787], ["flumazenil", 793], ["could", 804], ["be", 810], ["administered", 813], [".", 825], ["Of", 827], ["170", 830], ["patients", 834], ["enrolled", 843], [",", 851], ["87", 853], ["received", 856], ["flumazenil", 865], ["and", 876], ["83", 880], ["received", 883], ["placebo", 892], [".", 899], ["The", 901], ["demographic", 905], ["characteristics", 917], ["of", 933], ["both", 936], ["groups", 941], ["were", 948], ["comparable", 953], [".", 963], ["Ten", 965], ["minutes", 969], ["after", 977], ["the", 983], ["beginning", 987], ["of", 997], ["study", 1000], ["drug", 1006], ["infusion", 1011], [",", 1019], ["patients", 1021], ["were", 1030], ["evaluated", 1035], ["using", 1045], ["the", 1051], ["Clinical", 1055], ["Global", 1064], ["Impression", 1071], ["Scale", 1082], ["(", 1088], ["CGIS", 1089], [")", 1093], [",", 1094], ["Glasgow", 1096], ["Coma", 1104], ["Scale", 1109], ["(", 1115], ["GSC", 1116], [")", 1119], [",", 1120], ["and", 1122], ["Neurobehavioral", 1126], ["Assessment", 1142], ["Scale", 1153], ["(", 1159], ["NAS", 1160], [")", 1163], [".", 1164], ["The", 1166], ["mean", 1170], ["+", 1175], ["/-", 1176], ["SD", 1179], ["CGIS", 1182], ["score", 1187], ["at", 1193], ["ten", 1196], ["minutes", 1200], ["for", 1208], ["BDZ", 1212], ["-", 1215], ["positive", 1216], ["patients", 1225], ["was", 1234], ["1.41", 1238], ["+", 1243], ["/-", 1244], ["0.72", 1247], ["for", 1252], ["patients", 1256], ["who", 1265], ["received", 1269], ["flumazenil", 1278], ["and", 1289], ["3.41", 1293], ["+", 1298], ["/-", 1299], ["0.91", 1302], ["for", 1307], ["the", 1311], ["placebo", 1315], ["group", 1323], ["(", 1329], ["P", 1330], ["<", 1332], [".01", 1334], [")", 1337], [".", 1338], ["There", 1340], ["was", 1346], ["no", 1350], ["difference", 1353], ["in", 1364], ["the", 1367], ["mean", 1371], ["CGIS", 1376], ["score", 1381], ["between", 1387], ["the", 1395], ["flumazenil", 1399], ["(", 1410], ["3.25", 1411], ["+", 1416], ["/-", 1417], ["1.15", 1420], [")", 1424], ["and", 1426], ["placebo", 1430], ["(", 1438], ["3.75", 1439], ["+", 1444], ["/-", 1445], ["0.69", 1448], [")", 1452], ["groups", 1454], ["in", 1461], ["BDZ", 1464], ["-", 1467], ["negative", 1468], ["patients", 1477], [".", 1485], ["The", 1487], ["GCS", 1491], ["and", 1495], ["NAS", 1499], ["were", 1503], ["also", 1508], ["significantly", 1513], ["better", 1527], ["in", 1534], ["patients", 1537], ["who", 1546], ["were", 1550], ["BDZ", 1555], ["-", 1558], ["positive", 1559], ["and", 1568], ["received", 1572], ["flumazenil", 1581], [".", 1591], ["The", 1593], ["mean", 1597], ["+", 1602], ["/-", 1603], ["SD", 1606], ["dose", 1609], ["of", 1614], ["flumazenil", 1617], ["administered", 1628], ["during", 1641], ["the", 1648], ["double", 1652], ["-", 1658], ["blind", 1659], ["phase", 1665], ["was", 1671], ["71.3", 1675], ["+", 1680], ["/-", 1681], ["34.2", 1684], ["mL", 1689], ["(", 1692], ["7.13", 1693], ["mg", 1698], [")", 1700], ["compared", 1702], ["with", 1711], ["95.06", 1716], ["+", 1722], ["/-", 1723], ["16.03", 1726], ["mL", 1732], ["of", 1735], ["placebo", 1738], [".", 1745], ["Of", 1747], ["the", 1750], ["39", 1754], ["patients", 1757], ["who", 1766], ["had", 1770], ["BDZ", 1774], ["-", 1777], ["positive", 1778], ["drug", 1787], ["screens", 1792], ["and", 1800], ["received", 1804], ["flumazenil", 1813], [",", 1823], ["29", 1825], ["(", 1828], ["74", 1829], ["%", 1831], [")", 1832], ["responded", 1834], ["to", 1844], ["3", 1847], ["mg", 1849], ["or", 1852], ["less", 1855], [".", 1859], ["Six", 1861], ["additional", 1865], ["patients", 1876], ["responded", 1885], ["to", 1895], ["4", 1898], ["or", 1900], ["5", 1903], ["mg", 1905], [",", 1907], ["and", 1909], ["one", 1913], ["patient", 1917], ["responded", 1925], ["to", 1935], ["8", 1938], ["mg", 1940], [".", 1942], ["The", 1944], ["most", 1948], ["common", 1953], ["adverse", 1960], ["effects", 1968], ["in", 1976], ["patients", 1979], ["who", 1988], ["received", 1992], ["flumazenil", 2001], ["were", 2012], ["injection", 2017], ["site", 2027], ["pain", 2032], ["(", 2037], ["10.3", 2038], ["%", 2042], [")", 2043], [",", 2044], ["agitation", 2046], ["(", 2056], ["8", 2057], ["%", 2058], [")", 2059], [",", 2060], ["vomiting", 2062], ["(", 2071], ["3.4", 2072], ["%", 2075], [")", 2076], [",", 2077], ["dizziness", 2079], ["(", 2089], ["3.4", 2090], ["%", 2093], [")", 2094], [",", 2095], ["headache", 2097], ["(", 2106], ["3.4", 2107], ["%", 2110], [")", 2111], [",", 2112], ["tachycardia", 2114], ["(", 2126], ["3.4", 2127], ["%", 2130], [")", 2131], [",", 2132], ["and", 2134], ["crying", 2138], ["(", 2145], ["3.4", 2146], ["%", 2149], [")", 2150], [".", 2151], ["Three", 2153], ["patients", 2159], ["developed", 2168], ["seizures", 2178], [".", 2186], ["Two", 2188], ["were", 2192], ["associated", 2197], ["with", 2208], ["significant", 2213], ["tricyclic", 2225], ["antidepressant", 2235], ["overdoses", 2250], ["and", 2260], ["one", 2264], ["with", 2268], ["propoxyphene", 2273], ["ingestion", 2286], [".", 2295], ["Two", 2297], ["patients", 2301], ["had", 2310], ["positive", 2314], ["drug", 2323], ["screens", 2328], ["for", 2336], ["BDZ", 2340], [".", 2343], ["Flumazenil", 2345], ["rapidly", 2356], ["and", 2364], ["effectively", 2368], ["reverses", 2380], ["the", 2389], ["clinical", 2393], ["signs", 2402], ["and", 2408], ["symptoms", 2412], ["of", 2421], ["a", 2424], ["BDZ", 2426], ["overdose", 2430], [".", 2438], ["Most", 2440], ["patients", 2445], ["will", 2454], ["respond", 2459], ["to", 2467], ["3", 2470], ["mg", 2472], ["or", 2475], ["less", 2478], [",", 2482], ["but", 2484], ["a", 2488], ["small", 2490], ["number", 2496], ["may", 2503], ["require", 2507], ["a", 2515], ["higher", 2517], ["dose", 2524], ["for", 2529], ["reversal", 2533], ["of", 2542], ["clinical", 2545], ["symptoms", 2554], [".", 2562], ["Patients", 2564], ["with", 2573], ["concomitant", 2578], ["tricyclic", 2590], ["antidepressant", 2600], ["overdose", 2615], ["may", 2624], ["be", 2628], ["at", 2631], ["risk", 2634], ["for", 2639], ["developing", 2643], ["seizures", 2654], [".", 2662]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "Self-report questionnaires are frequently used to identify PTSD among U.S. military personnel and Veterans. Two common scoring methods used to classify PTSD include: (1) a cut score threshold and (2) endorsement of PTSD symptoms meeting DSM-IV-TR symptom cluster criteria (SCM). A third method requiring a cut score in addition to SCM has been proposed, but has received little study. The current study examined the diagnostic accuracy of three scoring methods for the Davidson Trauma Scale (DTS) among 804 Afghanistan and Iraq war-era military Service Members and Veterans. Data were weighted to approximate the prevalence of PTSD and other Axis I disorders in VA primary care. As expected, adding a cut score criterion to SCM improved specificity and positive predictive power. However, a cut score of 68-72 provided optimal diagnostic accuracy. The utility of the DTS, the role of baseline prevalence, and recommendations for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "30101ccbda904d208ed2525e9f6e992c", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[117, 117], [24, 24], [9, 9], [40, 40]], "char_spans": [[627, 630], [152, 155], [59, 62], [215, 218]]}]}], "context_tokens": [["Self", 0], ["-", 4], ["report", 5], ["questionnaires", 12], ["are", 27], ["frequently", 31], ["used", 42], ["to", 47], ["identify", 50], ["PTSD", 59], ["among", 64], ["U.S.", 70], ["military", 75], ["personnel", 84], ["and", 94], ["Veterans", 98], [".", 106], ["Two", 108], ["common", 112], ["scoring", 119], ["methods", 127], ["used", 135], ["to", 140], ["classify", 143], ["PTSD", 152], ["include", 157], [":", 164], ["(", 166], ["1", 167], [")", 168], ["a", 170], ["cut", 172], ["score", 176], ["threshold", 182], ["and", 192], ["(", 196], ["2", 197], [")", 198], ["endorsement", 200], ["of", 212], ["PTSD", 215], ["symptoms", 220], ["meeting", 229], ["DSM", 237], ["-", 240], ["IV", 241], ["-", 243], ["TR", 244], ["symptom", 247], ["cluster", 255], ["criteria", 263], ["(", 272], ["SCM", 273], [")", 276], [".", 277], ["A", 279], ["third", 281], ["method", 287], ["requiring", 294], ["a", 304], ["cut", 306], ["score", 310], ["in", 316], ["addition", 319], ["to", 328], ["SCM", 331], ["has", 335], ["been", 339], ["proposed", 344], [",", 352], ["but", 354], ["has", 358], ["received", 362], ["little", 371], ["study", 378], [".", 383], ["The", 385], ["current", 389], ["study", 397], ["examined", 403], ["the", 412], ["diagnostic", 416], ["accuracy", 427], ["of", 436], ["three", 439], ["scoring", 445], ["methods", 453], ["for", 461], ["the", 465], ["Davidson", 469], ["Trauma", 478], ["Scale", 485], ["(", 491], ["DTS", 492], [")", 495], ["among", 497], ["804", 503], ["Afghanistan", 507], ["and", 519], ["Iraq", 523], ["war", 528], ["-", 531], ["era", 532], ["military", 536], ["Service", 545], ["Members", 553], ["and", 561], ["Veterans", 565], [".", 573], ["Data", 575], ["were", 580], ["weighted", 585], ["to", 594], ["approximate", 597], ["the", 609], ["prevalence", 613], ["of", 624], ["PTSD", 627], ["and", 632], ["other", 636], ["Axis", 642], ["I", 647], ["disorders", 649], ["in", 659], ["VA", 662], ["primary", 665], ["care", 673], [".", 677], ["As", 679], ["expected", 682], [",", 690], ["adding", 692], ["a", 699], ["cut", 701], ["score", 705], ["criterion", 711], ["to", 721], ["SCM", 724], ["improved", 728], ["specificity", 737], ["and", 749], ["positive", 753], ["predictive", 762], ["power", 773], [".", 778], ["However", 780], [",", 787], ["a", 789], ["cut", 791], ["score", 795], ["of", 801], ["68", 804], ["-", 806], ["72", 807], ["provided", 810], ["optimal", 819], ["diagnostic", 827], ["accuracy", 838], [".", 846], ["The", 848], ["utility", 852], ["of", 860], ["the", 863], ["DTS", 867], [",", 870], ["the", 872], ["role", 876], ["of", 881], ["baseline", 884], ["prevalence", 893], [",", 903], ["and", 905], ["recommendations", 909], ["for", 925], ["future", 929], ["research", 936], ["are", 945], ["discussed", 949], [".", 958]]}
{"context": "Common cellular and molecular mechanisms including protein aggregation and inclusion body formation are involved in many neurodegenerative diseases. \u03b1-Synuclein is a major component of Lewy bodies in Parkinson's disease (PD) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA). Tau is a principal component of neurofibrillary and glial tangles in tauopathies. Recently, TDP-43 was identified as a component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PD is traditionally considered a movement disorder with hallmark lesions in the brainstem pigmented nuclei. However, pathological changes occur in widespread regions of the central and peripheral nervous systems in this disease. Furthermore, primary glial involvement (\"gliodegeneration\") can be observed in PD and MSA as well as in tauopathy. The present article reviews abnormal protein accumulation and inclusion body formation inside and outside the central nervous system.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "1943cdaa336f472f827be07ba6e57bb5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[19, 21]], "char_spans": [[149, 159]]}]}], "context_tokens": [["Common", 0], ["cellular", 7], ["and", 16], ["molecular", 20], ["mechanisms", 30], ["including", 41], ["protein", 51], ["aggregation", 59], ["and", 71], ["inclusion", 75], ["body", 85], ["formation", 90], ["are", 100], ["involved", 104], ["in", 113], ["many", 116], ["neurodegenerative", 121], ["diseases", 139], [".", 147], ["\u03b1", 149], ["-", 150], ["Synuclein", 151], ["is", 161], ["a", 164], ["major", 166], ["component", 172], ["of", 182], ["Lewy", 185], ["bodies", 190], ["in", 197], ["Parkinson", 200], ["'s", 209], ["disease", 212], ["(", 220], ["PD", 221], [")", 223], ["as", 225], ["well", 228], ["as", 233], ["in", 236], ["glial", 239], ["cytoplasmic", 245], ["inclusions", 257], ["in", 268], ["multiple", 271], ["system", 280], ["atrophy", 287], ["(", 295], ["MSA", 296], [")", 299], [".", 300], ["Tau", 302], ["is", 306], ["a", 309], ["principal", 311], ["component", 321], ["of", 331], ["neurofibrillary", 334], ["and", 350], ["glial", 354], ["tangles", 360], ["in", 368], ["tauopathies", 371], [".", 382], ["Recently", 384], [",", 392], ["TDP-43", 394], ["was", 401], ["identified", 405], ["as", 416], ["a", 419], ["component", 421], ["of", 431], ["ubiquitinated", 434], ["inclusions", 448], ["in", 459], ["amyotrophic", 462], ["lateral", 474], ["sclerosis", 482], ["and", 492], ["frontotemporal", 496], ["lobar", 511], ["degeneration", 517], [".", 529], ["PD", 531], ["is", 534], ["traditionally", 537], ["considered", 551], ["a", 562], ["movement", 564], ["disorder", 573], ["with", 582], ["hallmark", 587], ["lesions", 596], ["in", 604], ["the", 607], ["brainstem", 611], ["pigmented", 621], ["nuclei", 631], [".", 637], ["However", 639], [",", 646], ["pathological", 648], ["changes", 661], ["occur", 669], ["in", 675], ["widespread", 678], ["regions", 689], ["of", 697], ["the", 700], ["central", 704], ["and", 712], ["peripheral", 716], ["nervous", 727], ["systems", 735], ["in", 743], ["this", 746], ["disease", 751], [".", 758], ["Furthermore", 760], [",", 771], ["primary", 773], ["glial", 781], ["involvement", 787], ["(", 799], ["\"", 800], ["gliodegeneration", 801], ["\"", 817], [")", 818], ["can", 820], ["be", 824], ["observed", 827], ["in", 836], ["PD", 839], ["and", 842], ["MSA", 846], ["as", 850], ["well", 853], ["as", 858], ["in", 861], ["tauopathy", 864], [".", 873], ["The", 875], ["present", 879], ["article", 887], ["reviews", 895], ["abnormal", 903], ["protein", 912], ["accumulation", 920], ["and", 933], ["inclusion", 937], ["body", 947], ["formation", 952], ["inside", 962], ["and", 969], ["outside", 973], ["the", 981], ["central", 985], ["nervous", 993], ["system", 1001], [".", 1007]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective form of autophagy whose distinctive feature is the fact that substrate proteins are translocated directly from the cytosol across the lysosomal membrane for degradation inside lysosomes. CMA substrates are cytosolic proteins bearing a pentapeptide motif in their sequence that, when recognized by the cytosolic chaperone HSPA8/HSC70, targets them to the surface of the lysosomes. Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. CMA is constitutively active in most cells but it is maximally activated under conditions of stress.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "00514408a6c643d68ffbd2cf86d20e0e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[86, 86]], "char_spans": [[528, 533]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["form", 50], ["of", 55], ["autophagy", 58], ["whose", 68], ["distinctive", 74], ["feature", 86], ["is", 94], ["the", 97], ["fact", 101], ["that", 106], ["substrate", 111], ["proteins", 121], ["are", 130], ["translocated", 134], ["directly", 147], ["from", 156], ["the", 161], ["cytosol", 165], ["across", 173], ["the", 180], ["lysosomal", 184], ["membrane", 194], ["for", 203], ["degradation", 207], ["inside", 219], ["lysosomes", 226], [".", 235], ["CMA", 237], ["substrates", 241], ["are", 252], ["cytosolic", 256], ["proteins", 266], ["bearing", 275], ["a", 283], ["pentapeptide", 285], ["motif", 298], ["in", 304], ["their", 307], ["sequence", 313], ["that", 322], [",", 326], ["when", 328], ["recognized", 333], ["by", 344], ["the", 347], ["cytosolic", 351], ["chaperone", 361], ["HSPA8/HSC70", 371], [",", 382], ["targets", 384], ["them", 392], ["to", 397], ["the", 400], ["surface", 404], ["of", 412], ["the", 415], ["lysosomes", 419], [".", 428], ["Once", 430], ["there", 435], [",", 440], ["substrate", 442], ["proteins", 452], ["bind", 461], ["to", 466], ["the", 469], ["lysosome", 473], ["-", 481], ["associated", 482], ["membrane", 493], ["protein", 502], ["type", 510], ["2", 515], ["isoform", 517], ["A", 525], ["(", 527], ["LAMP2A", 528], [")", 534], [",", 535], ["inducing", 537], ["assembly", 546], ["of", 555], ["this", 558], ["receptor", 563], ["protein", 572], ["into", 580], ["a", 585], ["higher", 587], ["molecular", 594], ["weight", 604], ["protein", 611], ["complex", 619], ["that", 627], ["is", 632], ["used", 635], ["by", 640], ["the", 643], ["substrate", 647], ["proteins", 657], ["to", 666], ["reach", 669], ["the", 675], ["lysosomal", 679], ["lumen", 689], [".", 694], ["CMA", 696], ["is", 700], ["constitutively", 703], ["active", 718], ["in", 725], ["most", 728], ["cells", 733], ["but", 739], ["it", 743], ["is", 746], ["maximally", 749], ["activated", 759], ["under", 769], ["conditions", 775], ["of", 786], ["stress", 789], [".", 795]]}
{"context": "Attempts to prevent HIV infection through pre-exposure prophylaxis (PrEP) include topical application of anti-HIV drugs to the mucosal sites of infection; however, a potential role for local drug metabolizing enzymes in modulating the exposure of the mucosal tissues to these drugs has yet to be explored. Here we present the first report that enzymes belonging to the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) families of drug metabolizing enzymes are expressed and active in vaginal and colorectal tissue using biopsies collected from healthy volunteers. In doing so, we discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor and an entry inhibitor currently in development as microbicides for HIV PrEP, are differentially metabolized in colorectal tissue and vaginal tissue. Taken together, these data should help to guide the optimization of small molecules being developed for HIV PrEP.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "a245513a68e54764b2b701bf8135c90a", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[157, 157], [19, 19], [127, 127], [3, 3]], "char_spans": [[936, 938], [110, 112], [750, 752], [20, 22]]}]}], "context_tokens": [["Attempts", 0], ["to", 9], ["prevent", 12], ["HIV", 20], ["infection", 24], ["through", 34], ["pre", 42], ["-", 45], ["exposure", 46], ["prophylaxis", 55], ["(", 67], ["PrEP", 68], [")", 72], ["include", 74], ["topical", 82], ["application", 90], ["of", 102], ["anti", 105], ["-", 109], ["HIV", 110], ["drugs", 114], ["to", 120], ["the", 123], ["mucosal", 127], ["sites", 135], ["of", 141], ["infection", 144], [";", 153], ["however", 155], [",", 162], ["a", 164], ["potential", 166], ["role", 176], ["for", 181], ["local", 185], ["drug", 191], ["metabolizing", 196], ["enzymes", 209], ["in", 217], ["modulating", 220], ["the", 231], ["exposure", 235], ["of", 244], ["the", 247], ["mucosal", 251], ["tissues", 259], ["to", 267], ["these", 270], ["drugs", 276], ["has", 282], ["yet", 286], ["to", 290], ["be", 293], ["explored", 296], [".", 304], ["Here", 306], ["we", 311], ["present", 314], ["the", 322], ["first", 326], ["report", 332], ["that", 339], ["enzymes", 344], ["belonging", 352], ["to", 362], ["the", 365], ["cytochrome", 369], ["P450", 380], ["(", 385], ["CYP", 386], [")", 389], ["and", 391], ["UDP", 395], ["-", 398], ["glucuronosyltransferase", 399], ["(", 423], ["UGT", 424], [")", 427], ["families", 429], ["of", 438], ["drug", 441], ["metabolizing", 446], ["enzymes", 459], ["are", 467], ["expressed", 471], ["and", 481], ["active", 485], ["in", 492], ["vaginal", 495], ["and", 503], ["colorectal", 507], ["tissue", 518], ["using", 525], ["biopsies", 531], ["collected", 540], ["from", 550], ["healthy", 555], ["volunteers", 563], [".", 573], ["In", 575], ["doing", 578], ["so", 584], [",", 586], ["we", 588], ["discovered", 591], ["that", 602], ["dapivirine", 607], ["and", 618], ["maraviroc", 622], [",", 631], ["a", 633], ["non", 635], ["-", 638], ["nucleoside", 639], ["reverse", 650], ["transcriptase", 658], ["inhibitor", 672], ["and", 682], ["an", 686], ["entry", 689], ["inhibitor", 695], ["currently", 705], ["in", 715], ["development", 718], ["as", 730], ["microbicides", 733], ["for", 746], ["HIV", 750], ["PrEP", 754], [",", 758], ["are", 760], ["differentially", 764], ["metabolized", 779], ["in", 791], ["colorectal", 794], ["tissue", 805], ["and", 812], ["vaginal", 816], ["tissue", 824], [".", 830], ["Taken", 832], ["together", 838], [",", 846], ["these", 848], ["data", 854], ["should", 859], ["help", 866], ["to", 871], ["guide", 874], ["the", 880], ["optimization", 884], ["of", 897], ["small", 900], ["molecules", 906], ["being", 916], ["developed", 922], ["for", 932], ["HIV", 936], ["PrEP", 940], [".", 944]]}
{"context": "Neurofibromatosis type 1 is one of the most common autosomal dominant disorders, affecting about 1:3,500 individuals. NF1 exon 7 displays weakly defined exon-intron boundaries, and is particularly prone to missplicing. In this study we investigated the expression of exon 7 transcripts using bioinformatic identification of splicing regulatory sequences, and functional minigene analysis of four sequence changes [c.910C>T (R304X), c.945G>A/c.946C>A (Q315Q/L316M), c.1005T>C (N335N)] identified in exon 7 of three different NF1 patients. Our results detected the presence of three exonic splicing enhancers (ESEs) and one putative exonic splicing silencer (ESS) element. The wild type minigene assay resulted in three alternative isoforms, including a transcript lacking NF1 exon 7 (NF1DeltaE7). Both the wild type and the mutated constructs shared NF1DeltaE7 in addition to the complete messenger, but displayed a different ratio between the two transcripts. In the presence of R304X and Q315Q/L316M mutations, the relative proportion between the different isoforms is shifted toward the expression of NF1DeltaE7, while in the presence of N335N variant, the NF1DeltaE7 expression is abolished. In conclusion, it appears mandatory to investigate the role of each nucleotide change within the NF1 coding sequence, since a significant proportion of NF1 exon 7 mutations affects pre-mRNA splicing, by disrupting exonic splicing motifs and modifying the delicate balance between aberrantly and correctly spliced transcripts.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "8264477aefe0438e81189bea1f1be19d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[99, 99], [141, 141], [232, 232], [18, 18], [241, 241]], "char_spans": [[524, 526], [771, 773], [1292, 1294], [118, 120], [1347, 1349]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["is", 25], ["one", 28], ["of", 32], ["the", 35], ["most", 39], ["common", 44], ["autosomal", 51], ["dominant", 61], ["disorders", 70], [",", 79], ["affecting", 81], ["about", 91], ["1:3,500", 97], ["individuals", 105], [".", 116], ["NF1", 118], ["exon", 122], ["7", 127], ["displays", 129], ["weakly", 138], ["defined", 145], ["exon", 153], ["-", 157], ["intron", 158], ["boundaries", 165], [",", 175], ["and", 177], ["is", 181], ["particularly", 184], ["prone", 197], ["to", 203], ["missplicing", 206], [".", 217], ["In", 219], ["this", 222], ["study", 227], ["we", 233], ["investigated", 236], ["the", 249], ["expression", 253], ["of", 264], ["exon", 267], ["7", 272], ["transcripts", 274], ["using", 286], ["bioinformatic", 292], ["identification", 306], ["of", 321], ["splicing", 324], ["regulatory", 333], ["sequences", 344], [",", 353], ["and", 355], ["functional", 359], ["minigene", 370], ["analysis", 379], ["of", 388], ["four", 391], ["sequence", 396], ["changes", 405], ["[", 413], ["c.910C", 414], [">", 420], ["T", 421], ["(", 423], ["R304X", 424], [")", 429], [",", 430], ["c.945G", 432], [">", 438], ["A", 439], ["/", 440], ["c.946C", 441], [">", 447], ["A", 448], ["(", 450], ["Q315Q", 451], ["/", 456], ["L316", 457], ["M", 461], [")", 462], [",", 463], ["c.1005T", 465], [">", 472], ["C", 473], ["(", 475], ["N335N", 476], [")", 481], ["]", 482], ["identified", 484], ["in", 495], ["exon", 498], ["7", 503], ["of", 505], ["three", 508], ["different", 514], ["NF1", 524], ["patients", 528], [".", 536], ["Our", 538], ["results", 542], ["detected", 550], ["the", 559], ["presence", 563], ["of", 572], ["three", 575], ["exonic", 581], ["splicing", 588], ["enhancers", 597], ["(", 607], ["ESEs", 608], [")", 612], ["and", 614], ["one", 618], ["putative", 622], ["exonic", 631], ["splicing", 638], ["silencer", 647], ["(", 656], ["ESS", 657], [")", 660], ["element", 662], [".", 669], ["The", 671], ["wild", 675], ["type", 680], ["minigene", 685], ["assay", 694], ["resulted", 700], ["in", 709], ["three", 712], ["alternative", 718], ["isoforms", 730], [",", 738], ["including", 740], ["a", 750], ["transcript", 752], ["lacking", 763], ["NF1", 771], ["exon", 775], ["7", 780], ["(", 782], ["NF1DeltaE7", 783], [")", 793], [".", 794], ["Both", 796], ["the", 801], ["wild", 805], ["type", 810], ["and", 815], ["the", 819], ["mutated", 823], ["constructs", 831], ["shared", 842], ["NF1DeltaE7", 849], ["in", 860], ["addition", 863], ["to", 872], ["the", 875], ["complete", 879], ["messenger", 888], [",", 897], ["but", 899], ["displayed", 903], ["a", 913], ["different", 915], ["ratio", 925], ["between", 931], ["the", 939], ["two", 943], ["transcripts", 947], [".", 958], ["In", 960], ["the", 963], ["presence", 967], ["of", 976], ["R304X", 979], ["and", 985], ["Q315Q", 989], ["/", 994], ["L316", 995], ["M", 999], ["mutations", 1001], [",", 1010], ["the", 1012], ["relative", 1016], ["proportion", 1025], ["between", 1036], ["the", 1044], ["different", 1048], ["isoforms", 1058], ["is", 1067], ["shifted", 1070], ["toward", 1078], ["the", 1085], ["expression", 1089], ["of", 1100], ["NF1DeltaE7", 1103], [",", 1113], ["while", 1115], ["in", 1121], ["the", 1124], ["presence", 1128], ["of", 1137], ["N335N", 1140], ["variant", 1146], [",", 1153], ["the", 1155], ["NF1DeltaE7", 1159], ["expression", 1170], ["is", 1181], ["abolished", 1184], [".", 1193], ["In", 1195], ["conclusion", 1198], [",", 1208], ["it", 1210], ["appears", 1213], ["mandatory", 1221], ["to", 1231], ["investigate", 1234], ["the", 1246], ["role", 1250], ["of", 1255], ["each", 1258], ["nucleotide", 1263], ["change", 1274], ["within", 1281], ["the", 1288], ["NF1", 1292], ["coding", 1296], ["sequence", 1303], [",", 1311], ["since", 1313], ["a", 1319], ["significant", 1321], ["proportion", 1333], ["of", 1344], ["NF1", 1347], ["exon", 1351], ["7", 1356], ["mutations", 1358], ["affects", 1368], ["pre", 1376], ["-", 1379], ["mRNA", 1380], ["splicing", 1385], [",", 1393], ["by", 1395], ["disrupting", 1398], ["exonic", 1409], ["splicing", 1416], ["motifs", 1425], ["and", 1432], ["modifying", 1436], ["the", 1446], ["delicate", 1450], ["balance", 1459], ["between", 1467], ["aberrantly", 1475], ["and", 1486], ["correctly", 1490], ["spliced", 1500], ["transcripts", 1508], [".", 1519]]}
{"context": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. Our objective is to report our experience in Greece with patients suffering from TS and trying to conceive; therefore, we present four patients with TS, who underwent In vitro fertilization (ICSI) with donor oocytes in order to get pregnant. Three out of four patients managed to conceive and bring pregnancy to completion. It was shown that patients diagnosed in childhood or adolescence with TS have the possibility to undergo hormone replacement therapy (HRT) and thus, secondary sexual characteristics as well as uterus of almost normal size can develop. Assisted reproduction techniques (ART), predominantly with donated oocytes, could give these patients the possibility to have children.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "80b1b799ab8b4a54ad19e73ff5640506", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[17, 17]], "char_spans": [[84, 84]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["defect", 40], ["with", 47], ["partial", 52], ["or", 60], ["total", 63], ["absence", 69], ["of", 77], ["the", 80], ["X", 84], ["chromosome", 86], [".", 96], ["Our", 98], ["objective", 102], ["is", 112], ["to", 115], ["report", 118], ["our", 125], ["experience", 129], ["in", 140], ["Greece", 143], ["with", 150], ["patients", 155], ["suffering", 164], ["from", 174], ["TS", 179], ["and", 182], ["trying", 186], ["to", 193], ["conceive", 196], [";", 204], ["therefore", 206], [",", 215], ["we", 217], ["present", 220], ["four", 228], ["patients", 233], ["with", 242], ["TS", 247], [",", 249], ["who", 251], ["underwent", 255], ["In", 265], ["vitro", 268], ["fertilization", 274], ["(", 288], ["ICSI", 289], [")", 293], ["with", 295], ["donor", 300], ["oocytes", 306], ["in", 314], ["order", 317], ["to", 323], ["get", 326], ["pregnant", 330], [".", 338], ["Three", 340], ["out", 346], ["of", 350], ["four", 353], ["patients", 358], ["managed", 367], ["to", 375], ["conceive", 378], ["and", 387], ["bring", 391], ["pregnancy", 397], ["to", 407], ["completion", 410], [".", 420], ["It", 422], ["was", 425], ["shown", 429], ["that", 435], ["patients", 440], ["diagnosed", 449], ["in", 459], ["childhood", 462], ["or", 472], ["adolescence", 475], ["with", 487], ["TS", 492], ["have", 495], ["the", 500], ["possibility", 504], ["to", 516], ["undergo", 519], ["hormone", 527], ["replacement", 535], ["therapy", 547], ["(", 555], ["HRT", 556], [")", 559], ["and", 561], ["thus", 565], [",", 569], ["secondary", 571], ["sexual", 581], ["characteristics", 588], ["as", 604], ["well", 607], ["as", 612], ["uterus", 615], ["of", 622], ["almost", 625], ["normal", 632], ["size", 639], ["can", 644], ["develop", 648], [".", 655], ["Assisted", 657], ["reproduction", 666], ["techniques", 679], ["(", 690], ["ART", 691], [")", 694], [",", 695], ["predominantly", 697], ["with", 711], ["donated", 716], ["oocytes", 724], [",", 731], ["could", 733], ["give", 739], ["these", 744], ["patients", 750], ["the", 759], ["possibility", 763], ["to", 775], ["have", 778], ["children", 783], [".", 791]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "0b4eb5fc8d864052918d6cffa3730c7d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[118, 147]]}, {"text": "PTSD", "token_spans": [[48, 48], [226, 226], [93, 93], [205, 205], [138, 138], [36, 36], [68, 68], [153, 153], [215, 215], [233, 233], [24, 24], [146, 146]], "char_spans": [[267, 270], [1271, 1274], [507, 510], [1160, 1163], [752, 755], [212, 215], [383, 386], [848, 851], [1217, 1220], [1316, 1319], [150, 153], [803, 806]]}]}], "context_tokens": [["Emerging", 0], ["data", 9], ["suggest", 14], ["that", 22], ["second", 27], ["-", 33], ["generation", 34], ["antipsychotics", 45], ["such", 60], ["as", 65], ["aripiprazole", 68], ["may", 81], ["be", 85], ["effective", 88], ["in", 98], ["the", 101], ["treatment", 105], ["of", 115], ["post", 118], ["-", 122], ["traumatic", 123], ["stress", 133], ["disorder", 140], ["(", 149], ["PTSD", 150], [")", 154], [".", 155], ["However", 157], [",", 164], ["few", 166], ["clinical", 170], ["trials", 179], ["have", 186], ["used", 191], ["aripiprazole", 196], ["in", 209], ["PTSD", 212], [",", 216], ["and", 218], ["data", 222], ["are", 227], ["limited", 231], ["on", 239], ["its", 242], ["use", 246], ["in", 250], ["Veterans", 253], ["with", 262], ["PTSD", 267], [".", 271], ["The", 273], ["objective", 277], ["of", 287], ["this", 290], ["pilot", 295], ["trial", 301], ["was", 307], ["to", 311], ["investigate", 314], ["the", 326], ["safety", 330], ["and", 337], ["efficacy", 341], ["of", 350], ["aripiprazole", 353], ["in", 366], ["Veterans", 369], ["with", 378], ["PTSD", 383], [".", 387], ["Ten", 389], ["individuals", 393], ["(", 405], ["five", 406], ["men", 411], ["and", 415], ["five", 419], ["women", 424], [")", 429], ["meeting", 431], ["the", 439], ["Diagnostic", 443], ["and", 454], ["statistical", 458], ["manual", 470], ["of", 477], ["mental", 480], ["disorders", 487], [",", 496], ["4th", 498], ["ed", 502], [".", 504], [",", 505], ["PTSD", 507], ["criteria", 512], ["participated", 521], ["in", 534], ["this", 537], ["12-week", 542], [",", 549], ["open", 551], ["-", 555], ["label", 556], [",", 561], ["flexibly", 563], ["dosed", 572], ["monotherapy", 578], ["trial", 590], [".", 595], ["The", 597], ["dose", 601], ["range", 606], ["of", 612], ["aripiprazole", 615], ["was", 628], ["5", 632], ["-", 633], ["30", 634], ["mg", 637], ["/", 639], ["day", 640], [",", 643], ["titrated", 645], ["to", 654], ["tolerability", 657], ["and", 670], ["clinical", 674], ["response", 683], [".", 691], ["The", 693], ["primary", 697], ["outcome", 705], ["measure", 713], ["was", 721], ["the", 725], ["Clinician", 729], ["-", 738], ["Administered", 739], ["PTSD", 752], ["Scale", 757], [".", 762], ["Additional", 764], ["outcomes", 775], ["included", 784], ["the", 793], ["Short", 797], ["PTSD", 803], ["Rating", 808], ["Interview", 815], [",", 824], ["the", 826], ["Treatment", 830], ["Outcome", 840], ["PTSD", 848], ["Scale", 853], ["(", 859], ["Top-8", 860], [")", 865], [",", 866], ["the", 868], ["Davidson", 872], ["Trauma", 881], ["Scale", 888], [",", 893], ["the", 895], ["Positive", 899], ["and", 908], ["Negative", 912], ["Syndrome", 921], ["Scale", 930], [",", 935], ["the", 937], ["Beck", 941], ["Depression", 946], ["Inventory", 957], ["-", 966], ["Fast", 967], ["Screen", 972], [",", 978], ["and", 980], ["Clinical", 984], ["Global", 993], ["Impressions", 1000], ["-", 1011], ["Improvement", 1012], [".", 1023], ["Eight", 1025], ["participants", 1031], ["completed", 1044], ["the", 1054], ["study", 1058], [",", 1063], ["and", 1065], ["aripiprazole", 1069], ["was", 1082], ["generally", 1086], ["well", 1096], ["tolerated", 1101], ["and", 1111], ["associated", 1115], ["with", 1126], ["a", 1131], ["significant", 1133], ["improvement", 1145], ["in", 1157], ["PTSD", 1160], ["symptoms", 1165], [",", 1173], ["as", 1175], ["measured", 1178], ["by", 1187], ["the", 1190], ["Clinician", 1194], ["-", 1203], ["Administered", 1204], ["PTSD", 1217], ["Scale", 1222], ["(", 1228], ["primary", 1229], ["outcome", 1237], ["measure", 1245], [")", 1252], ["and", 1254], ["by", 1258], ["the", 1261], ["Short", 1265], ["PTSD", 1271], ["Rating", 1276], ["Interview", 1283], [",", 1292], ["the", 1294], ["Treatment", 1298], ["Outcome", 1308], ["PTSD", 1316], ["Scale", 1321], [",", 1326], ["and", 1328], ["the", 1332], ["Davidson", 1336], ["Trauma", 1345], ["Scale", 1352], [".", 1357], ["An", 1359], ["improvement", 1362], ["was", 1374], ["also", 1378], ["observed", 1383], ["on", 1392], ["all", 1395], ["three", 1399], ["Positive", 1405], ["and", 1414], ["Negative", 1418], ["Syndrome", 1427], ["Scale", 1436], ["subscales", 1442], ["and", 1452], ["the", 1456], ["Beck", 1460], ["Depression", 1465], ["Inventory", 1476], ["-", 1485], ["Fast", 1486], ["Screen", 1491], [",", 1497], ["and", 1499], ["the", 1503], ["average", 1507], ["Clinical", 1515], ["Global", 1524], ["Impressions", 1531], ["-", 1542], ["Improvement", 1543], ["ratings", 1555], ["indicated", 1563], ["that", 1573], ["patients", 1578], ["were", 1587], ["'", 1592], ["much", 1593], ["improved", 1598], ["'", 1606], [".", 1607], ["These", 1609], ["promising", 1615], ["initial", 1625], ["results", 1633], ["merit", 1641], ["further", 1647], ["investigation", 1655], ["in", 1669], ["a", 1672], ["larger", 1674], [",", 1680], ["randomized", 1682], ["-", 1692], ["controlled", 1693], ["trial", 1704], [".", 1709]]}
{"context": "The origin of brain tumors has attracted much controversy. Recent advances in neural stem cell biology coupled with the new concepts of central nervous system development have raised interesting possibilities regarding the oncogenic properties of neural stem/progenitor cells. To elucidate these putative properties further, the clinical materials from an infant brain tumor were analyzed, focusing on the relation with the neural stem/progenitor cells. The expression of neural stem/progenitor cell markers in the tumor cells and the cellular components of the infant brain tumor were examined using immunohistochemistry. The tumor cell biology was analyzed both in culture and in the grafted brain environment. Three main bodies of evidence were demonstrated indicating that the tumor was of possible subventricular zone postnatal or adult normal neural stem cell origin. First, in the tumor specimen we demonstrated the strong positive expression of the neural stem/progenitor cell markers, nestin and Musashi-1. Second, immunohistochemistry revealed the presence of neuronal, astrocytic, and immature precursor cells in the tumor tissue, similar to the cellular components of the subventricular zone, thereby pointing to the subventricular zone as the possible origin of the tumor. The subventricular zone also is one of the strong candidates for the location of postnatal/adult neural stem cells. This cellular evidence was strengthened further by the clinicoradiological findings that demonstrated the involvement of the subventricular zone of the lateral ventricle by the tumor. Third, in the in vitro and in vivo experiments, a dynamic shift in expression patterns between neural stem cells (nestin, Musashi-1) and differentiated cells (glial fibrillary acidic protein, neuron-specific Class III beta-tubulin) markers was seen, similar to the proposed behavior of postnatal/adult neural stem cells in situ. These findings suggest that this brain tumor originated from neural stem cells located in the subventricular zone, and the further possibility of the general oncogenic potential of neural stem cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "71a8f4bdfee54f928c7a8b69ef3ca448", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[161, 161], [278, 278]], "char_spans": [[994, 999], [1700, 1705]]}]}], "context_tokens": [["The", 0], ["origin", 4], ["of", 11], ["brain", 14], ["tumors", 20], ["has", 27], ["attracted", 31], ["much", 41], ["controversy", 46], [".", 57], ["Recent", 59], ["advances", 66], ["in", 75], ["neural", 78], ["stem", 85], ["cell", 90], ["biology", 95], ["coupled", 103], ["with", 111], ["the", 116], ["new", 120], ["concepts", 124], ["of", 133], ["central", 136], ["nervous", 144], ["system", 152], ["development", 159], ["have", 171], ["raised", 176], ["interesting", 183], ["possibilities", 195], ["regarding", 209], ["the", 219], ["oncogenic", 223], ["properties", 233], ["of", 244], ["neural", 247], ["stem", 254], ["/", 258], ["progenitor", 259], ["cells", 270], [".", 275], ["To", 277], ["elucidate", 280], ["these", 290], ["putative", 296], ["properties", 305], ["further", 316], [",", 323], ["the", 325], ["clinical", 329], ["materials", 338], ["from", 348], ["an", 353], ["infant", 356], ["brain", 363], ["tumor", 369], ["were", 375], ["analyzed", 380], [",", 388], ["focusing", 390], ["on", 399], ["the", 402], ["relation", 406], ["with", 415], ["the", 420], ["neural", 424], ["stem", 431], ["/", 435], ["progenitor", 436], ["cells", 447], [".", 452], ["The", 454], ["expression", 458], ["of", 469], ["neural", 472], ["stem", 479], ["/", 483], ["progenitor", 484], ["cell", 495], ["markers", 500], ["in", 508], ["the", 511], ["tumor", 515], ["cells", 521], ["and", 527], ["the", 531], ["cellular", 535], ["components", 544], ["of", 555], ["the", 558], ["infant", 562], ["brain", 569], ["tumor", 575], ["were", 581], ["examined", 586], ["using", 595], ["immunohistochemistry", 601], [".", 621], ["The", 623], ["tumor", 627], ["cell", 633], ["biology", 638], ["was", 646], ["analyzed", 650], ["both", 659], ["in", 664], ["culture", 667], ["and", 675], ["in", 679], ["the", 682], ["grafted", 686], ["brain", 694], ["environment", 700], [".", 711], ["Three", 713], ["main", 719], ["bodies", 724], ["of", 731], ["evidence", 734], ["were", 743], ["demonstrated", 748], ["indicating", 761], ["that", 772], ["the", 777], ["tumor", 781], ["was", 787], ["of", 791], ["possible", 794], ["subventricular", 803], ["zone", 818], ["postnatal", 823], ["or", 833], ["adult", 836], ["normal", 842], ["neural", 849], ["stem", 856], ["cell", 861], ["origin", 866], [".", 872], ["First", 874], [",", 879], ["in", 881], ["the", 884], ["tumor", 888], ["specimen", 894], ["we", 903], ["demonstrated", 906], ["the", 919], ["strong", 923], ["positive", 930], ["expression", 939], ["of", 950], ["the", 953], ["neural", 957], ["stem", 964], ["/", 968], ["progenitor", 969], ["cell", 980], ["markers", 985], [",", 992], ["nestin", 994], ["and", 1001], ["Musashi-1", 1005], [".", 1014], ["Second", 1016], [",", 1022], ["immunohistochemistry", 1024], ["revealed", 1045], ["the", 1054], ["presence", 1058], ["of", 1067], ["neuronal", 1070], [",", 1078], ["astrocytic", 1080], [",", 1090], ["and", 1092], ["immature", 1096], ["precursor", 1105], ["cells", 1115], ["in", 1121], ["the", 1124], ["tumor", 1128], ["tissue", 1134], [",", 1140], ["similar", 1142], ["to", 1150], ["the", 1153], ["cellular", 1157], ["components", 1166], ["of", 1177], ["the", 1180], ["subventricular", 1184], ["zone", 1199], [",", 1203], ["thereby", 1205], ["pointing", 1213], ["to", 1222], ["the", 1225], ["subventricular", 1229], ["zone", 1244], ["as", 1249], ["the", 1252], ["possible", 1256], ["origin", 1265], ["of", 1272], ["the", 1275], ["tumor", 1279], [".", 1284], ["The", 1286], ["subventricular", 1290], ["zone", 1305], ["also", 1310], ["is", 1315], ["one", 1318], ["of", 1322], ["the", 1325], ["strong", 1329], ["candidates", 1336], ["for", 1347], ["the", 1351], ["location", 1355], ["of", 1364], ["postnatal", 1367], ["/", 1376], ["adult", 1377], ["neural", 1383], ["stem", 1390], ["cells", 1395], [".", 1400], ["This", 1402], ["cellular", 1407], ["evidence", 1416], ["was", 1425], ["strengthened", 1429], ["further", 1442], ["by", 1450], ["the", 1453], ["clinicoradiological", 1457], ["findings", 1477], ["that", 1486], ["demonstrated", 1491], ["the", 1504], ["involvement", 1508], ["of", 1520], ["the", 1523], ["subventricular", 1527], ["zone", 1542], ["of", 1547], ["the", 1550], ["lateral", 1554], ["ventricle", 1562], ["by", 1572], ["the", 1575], ["tumor", 1579], [".", 1584], ["Third", 1586], [",", 1591], ["in", 1593], ["the", 1596], ["in", 1600], ["vitro", 1603], ["and", 1609], ["in", 1613], ["vivo", 1616], ["experiments", 1621], [",", 1632], ["a", 1634], ["dynamic", 1636], ["shift", 1644], ["in", 1650], ["expression", 1653], ["patterns", 1664], ["between", 1673], ["neural", 1681], ["stem", 1688], ["cells", 1693], ["(", 1699], ["nestin", 1700], [",", 1706], ["Musashi-1", 1708], [")", 1717], ["and", 1719], ["differentiated", 1723], ["cells", 1738], ["(", 1744], ["glial", 1745], ["fibrillary", 1751], ["acidic", 1762], ["protein", 1769], [",", 1776], ["neuron", 1778], ["-", 1784], ["specific", 1785], ["Class", 1794], ["III", 1800], ["beta", 1804], ["-", 1808], ["tubulin", 1809], [")", 1816], ["markers", 1818], ["was", 1826], ["seen", 1830], [",", 1834], ["similar", 1836], ["to", 1844], ["the", 1847], ["proposed", 1851], ["behavior", 1860], ["of", 1869], ["postnatal", 1872], ["/", 1881], ["adult", 1882], ["neural", 1888], ["stem", 1895], ["cells", 1900], ["in", 1906], ["situ", 1909], [".", 1913], ["These", 1915], ["findings", 1921], ["suggest", 1930], ["that", 1938], ["this", 1943], ["brain", 1948], ["tumor", 1954], ["originated", 1960], ["from", 1971], ["neural", 1976], ["stem", 1983], ["cells", 1988], ["located", 1994], ["in", 2002], ["the", 2005], ["subventricular", 2009], ["zone", 2024], [",", 2028], ["and", 2030], ["the", 2034], ["further", 2038], ["possibility", 2046], ["of", 2058], ["the", 2061], ["general", 2065], ["oncogenic", 2073], ["potential", 2083], ["of", 2093], ["neural", 2096], ["stem", 2103], ["cells", 2108], [".", 2113]]}
{"context": "Henoch-Sch\u00f6nlein purpura (HSP) is the most common form of childhood vasculitis. Various viral and bacterial infections, drugs, vaccines, food allergy and even insect bites have been considered as triggering factors in pathogenesis of HSP. Epstein-Barr virus (EBV) infection, which is associated with HSP, have been rarely reported. Herein we present HSP patient possibly caused by EBV infection. A 8-year old boy was admitted to our department with fever, rashes on legs and arms and intermittent mild abdominal pain. Multiple purpuric rashes were on his extremities, abdomen and buttock. Laboratory investigations revealed that monospot test was positive, EBV serology tests; Anti-EA-D Ig G: 3+, Anti-VCA gp125 Ig G: 3+, Anti-VCA p19 Ig M: 2+, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig G: negative. The patient was interpreted as the primary active acute EBV infection. A skin biopsy showed leucocytoclastic vasculitis. The other viral and bacterial investigations were negative. The patient was diagnosed as HSP vasculitis according to EULAR criteria and treated with intravenous hydration and ibuprofen. He was discharged after 15 days with normal laboratory findings and physical examination. We think that EBV infection may be stimulant factor for autoimmune reactions and may cause HSP vasculitis. Hence, it may be useful to investigate the EBV infection in etiology of HSP cases.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0e6c87f5f0c94291853b04cbabd336bd", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[43, 46]], "char_spans": [[239, 256]]}]}], "context_tokens": [["Henoch", 0], ["-", 6], ["Sch\u00f6nlein", 7], ["purpura", 17], ["(", 25], ["HSP", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["form", 50], ["of", 55], ["childhood", 58], ["vasculitis", 68], [".", 78], ["Various", 80], ["viral", 88], ["and", 94], ["bacterial", 98], ["infections", 108], [",", 118], ["drugs", 120], [",", 125], ["vaccines", 127], [",", 135], ["food", 137], ["allergy", 142], ["and", 150], ["even", 154], ["insect", 159], ["bites", 166], ["have", 172], ["been", 177], ["considered", 182], ["as", 193], ["triggering", 196], ["factors", 207], ["in", 215], ["pathogenesis", 218], ["of", 231], ["HSP", 234], [".", 237], ["Epstein", 239], ["-", 246], ["Barr", 247], ["virus", 252], ["(", 258], ["EBV", 259], [")", 262], ["infection", 264], [",", 273], ["which", 275], ["is", 281], ["associated", 284], ["with", 295], ["HSP", 300], [",", 303], ["have", 305], ["been", 310], ["rarely", 315], ["reported", 322], [".", 330], ["Herein", 332], ["we", 339], ["present", 342], ["HSP", 350], ["patient", 354], ["possibly", 362], ["caused", 371], ["by", 378], ["EBV", 381], ["infection", 385], [".", 394], ["A", 396], ["8-year", 398], ["old", 405], ["boy", 409], ["was", 413], ["admitted", 417], ["to", 426], ["our", 429], ["department", 433], ["with", 444], ["fever", 449], [",", 454], ["rashes", 456], ["on", 463], ["legs", 466], ["and", 471], ["arms", 475], ["and", 480], ["intermittent", 484], ["mild", 497], ["abdominal", 502], ["pain", 512], [".", 516], ["Multiple", 518], ["purpuric", 527], ["rashes", 536], ["were", 543], ["on", 548], ["his", 551], ["extremities", 555], [",", 566], ["abdomen", 568], ["and", 576], ["buttock", 580], [".", 587], ["Laboratory", 589], ["investigations", 600], ["revealed", 615], ["that", 624], ["monospot", 629], ["test", 638], ["was", 643], ["positive", 647], [",", 655], ["EBV", 657], ["serology", 661], ["tests", 670], [";", 675], ["Anti", 677], ["-", 681], ["EA", 682], ["-", 684], ["D", 685], ["Ig", 687], ["G", 690], [":", 691], ["3", 693], ["+", 694], [",", 695], ["Anti", 697], ["-", 701], ["VCA", 702], ["gp125", 706], ["Ig", 712], ["G", 715], [":", 716], ["3", 718], ["+", 719], [",", 720], ["Anti", 722], ["-", 726], ["VCA", 727], ["p19", 731], ["Ig", 735], ["M", 738], [":", 739], ["2", 741], ["+", 742], [",", 743], ["Anti", 745], ["EBNA-1", 750], ["Ig", 757], ["M", 760], [":", 761], ["negative", 763], [",", 771], ["Anti", 773], ["EBNA-1", 778], ["Ig", 785], ["M", 788], [":", 789], ["negative", 791], [",", 799], ["Anti", 801], ["EBNA-1", 806], ["Ig", 813], ["G", 816], [":", 817], ["negative", 819], [".", 827], ["The", 829], ["patient", 833], ["was", 841], ["interpreted", 845], ["as", 857], ["the", 860], ["primary", 864], ["active", 872], ["acute", 879], ["EBV", 885], ["infection", 889], [".", 898], ["A", 900], ["skin", 902], ["biopsy", 907], ["showed", 914], ["leucocytoclastic", 921], ["vasculitis", 938], [".", 948], ["The", 950], ["other", 954], ["viral", 960], ["and", 966], ["bacterial", 970], ["investigations", 980], ["were", 995], ["negative", 1000], [".", 1008], ["The", 1010], ["patient", 1014], ["was", 1022], ["diagnosed", 1026], ["as", 1036], ["HSP", 1039], ["vasculitis", 1043], ["according", 1054], ["to", 1064], ["EULAR", 1067], ["criteria", 1073], ["and", 1082], ["treated", 1086], ["with", 1094], ["intravenous", 1099], ["hydration", 1111], ["and", 1121], ["ibuprofen", 1125], [".", 1134], ["He", 1136], ["was", 1139], ["discharged", 1143], ["after", 1154], ["15", 1160], ["days", 1163], ["with", 1168], ["normal", 1173], ["laboratory", 1180], ["findings", 1191], ["and", 1200], ["physical", 1204], ["examination", 1213], [".", 1224], ["We", 1226], ["think", 1229], ["that", 1235], ["EBV", 1240], ["infection", 1244], ["may", 1254], ["be", 1258], ["stimulant", 1261], ["factor", 1271], ["for", 1278], ["autoimmune", 1282], ["reactions", 1293], ["and", 1303], ["may", 1307], ["cause", 1311], ["HSP", 1317], ["vasculitis", 1321], [".", 1331], ["Hence", 1333], [",", 1338], ["it", 1340], ["may", 1343], ["be", 1347], ["useful", 1350], ["to", 1357], ["investigate", 1360], ["the", 1372], ["EBV", 1376], ["infection", 1380], ["in", 1390], ["etiology", 1393], ["of", 1402], ["HSP", 1405], ["cases", 1409], [".", 1414]]}
{"context": "Chediak-Higashi syndrome (CHS) is an autosomal recessive hereditary disorder in Japanese Black cattle, caused by a mutation of the Lyst gene. So far, the mutation has been detected by PCR-restriction fragment length polymorphism (PCR-RFLP) analysis. However, this method is disadvantaged by its low-throughput performance. Here, we report an alternative method involving real-time PCR with TaqMan minor groove binder probes, which shortens the total assay time by more than 120 min, analyzing 10 samples in a duplicated manner. Using this method, we examined 102 Japanese Black cattle and found that 8.8% of the cattle were CHS-carriers. These data indicate that our technique is useful for routine diagnostic testing for CHS in Japanese Black cattle.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "6de488eb1d614d6d9605a4bf3e86a220", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[24, 25]], "char_spans": [[131, 139]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["autosomal", 37], ["recessive", 47], ["hereditary", 57], ["disorder", 68], ["in", 77], ["Japanese", 80], ["Black", 89], ["cattle", 95], [",", 101], ["caused", 103], ["by", 110], ["a", 113], ["mutation", 115], ["of", 124], ["the", 127], ["Lyst", 131], ["gene", 136], [".", 140], ["So", 142], ["far", 145], [",", 148], ["the", 150], ["mutation", 154], ["has", 163], ["been", 167], ["detected", 172], ["by", 181], ["PCR", 184], ["-", 187], ["restriction", 188], ["fragment", 200], ["length", 209], ["polymorphism", 216], ["(", 229], ["PCR", 230], ["-", 233], ["RFLP", 234], [")", 238], ["analysis", 240], [".", 248], ["However", 250], [",", 257], ["this", 259], ["method", 264], ["is", 271], ["disadvantaged", 274], ["by", 288], ["its", 291], ["low", 295], ["-", 298], ["throughput", 299], ["performance", 310], [".", 321], ["Here", 323], [",", 327], ["we", 329], ["report", 332], ["an", 339], ["alternative", 342], ["method", 354], ["involving", 361], ["real", 371], ["-", 375], ["time", 376], ["PCR", 381], ["with", 385], ["TaqMan", 390], ["minor", 397], ["groove", 403], ["binder", 410], ["probes", 417], [",", 423], ["which", 425], ["shortens", 431], ["the", 440], ["total", 444], ["assay", 450], ["time", 456], ["by", 461], ["more", 464], ["than", 469], ["120", 474], ["min", 478], [",", 481], ["analyzing", 483], ["10", 493], ["samples", 496], ["in", 504], ["a", 507], ["duplicated", 509], ["manner", 520], [".", 526], ["Using", 528], ["this", 534], ["method", 539], [",", 545], ["we", 547], ["examined", 550], ["102", 559], ["Japanese", 563], ["Black", 572], ["cattle", 578], ["and", 585], ["found", 589], ["that", 595], ["8.8", 600], ["%", 603], ["of", 605], ["the", 608], ["cattle", 612], ["were", 619], ["CHS", 624], ["-", 627], ["carriers", 628], [".", 636], ["These", 638], ["data", 644], ["indicate", 649], ["that", 658], ["our", 663], ["technique", 667], ["is", 677], ["useful", 680], ["for", 687], ["routine", 691], ["diagnostic", 699], ["testing", 710], ["for", 718], ["CHS", 722], ["in", 726], ["Japanese", 729], ["Black", 738], ["cattle", 744], [".", 750]]}
{"context": "We evaluated the new, fully automated molecular BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay for detection of methicillin-resistant S. aureus in a low-prevalence (4.1%) setting. Sensitivity, specificity, and positive and negative predictive values were 93.9%, 99.2%, 83.8%, and 99.7%, respectively. The assay reported fewer unresolved results than the BD GeneOhm MRSA ACP assay.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "66854406960a4a4ba4cff23625202de8", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[22, 26]], "char_spans": [[129, 159]]}, {"text": "MRSA", "token_spans": [[16, 16], [74, 74]], "char_spans": [[100, 103], [382, 385]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["new", 17], [",", 20], ["fully", 22], ["automated", 28], ["molecular", 38], ["BD", 48], ["Max", 51], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["assay", 106], ["for", 112], ["detection", 116], ["of", 126], ["methicillin", 129], ["-", 140], ["resistant", 141], ["S.", 151], ["aureus", 154], ["in", 161], ["a", 164], ["low", 166], ["-", 169], ["prevalence", 170], ["(", 181], ["4.1", 182], ["%", 185], [")", 186], ["setting", 188], [".", 195], ["Sensitivity", 197], [",", 208], ["specificity", 210], [",", 221], ["and", 223], ["positive", 227], ["and", 236], ["negative", 240], ["predictive", 249], ["values", 260], ["were", 267], ["93.9", 272], ["%", 276], [",", 277], ["99.2", 279], ["%", 283], [",", 284], ["83.8", 286], ["%", 290], [",", 291], ["and", 293], ["99.7", 297], ["%", 301], [",", 302], ["respectively", 304], [".", 316], ["The", 318], ["assay", 322], ["reported", 328], ["fewer", 337], ["unresolved", 343], ["results", 354], ["than", 362], ["the", 367], ["BD", 371], ["GeneOhm", 374], ["MRSA", 382], ["ACP", 387], ["assay", 391], [".", 396]]}
{"context": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy. This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. Eligible participants were of either gender aged between 3 weeks and 7 months old with onset of spinal muscular atrophy symptoms between 3 weeks and 6 months, who had SMN1 homozygous gene deletion or mutation. Safety assessments included adverse events, physical and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laboratory tests, and electrocardiographs. Clinical efficacy assessments included event free survival, and change from baseline of two assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2 (HINE-2) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test, and compound motor action potentials. Autopsy tissue was analysed for target engagement, drug concentrations, and pharmacological activity. HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test. Age at death or permanent ventilation was compared with natural history using the log-rank test. The study is registered at ClinicalTrials.gov, number NCT01839656. 20 participants were enrolled between May 3, 2013, and July 9, 2014, and assessed through to an interim analysis done on Jan 26, 2016. All participants experienced adverse events, with 77 serious adverse events reported in 16 participants, all considered by study investigators not related or unlikely related to the study drug. In the 12 mg dose group, incremental achievements of motor milestones (p<0\u00b70001), improvements in CHOP-INTEND motor function scores (p=0\u00b70013), and increased compound muscle action potential amplitude of the ulnar nerve (p=0\u00b70103) and peroneal nerve (p<0\u00b70001), compared with baseline, were observed. Median age at death or permanent ventilation was not reached and the Kaplan-Meier survival curve diverged from a published natural history case series (p=0\u00b70014). Analysis of autopsy tissue from patients exposed to nusinersen showed drug uptake into motor neurons throughout the spinal cord and neurons and other cell types in the brainstem and other brain regions, exposure at therapeutic concentrations, and increased SMN2 mRNA exon 7 inclusion and SMN protein concentrations in the spinal cord. Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy. Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy. Ionis Pharmaceuticals, Inc and Biogen.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "0ddc50b6e2eb4c54b88303df7172ac37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[120, 122], [99, 101], [15, 17], [546, 548], [51, 53]], "char_spans": [[702, 724], [581, 603], [100, 122], [3221, 3243], [310, 332]]}]}], "context_tokens": [["Nusinersen", 0], ["is", 11], ["a", 14], ["2'-O", 16], ["-", 20], ["methoxyethyl", 21], ["phosphorothioate", 34], ["-", 50], ["modified", 51], ["antisense", 60], ["drug", 70], ["being", 75], ["developed", 81], ["to", 91], ["treat", 94], ["spinal", 100], ["muscular", 107], ["atrophy", 116], [".", 123], ["Nusinersen", 125], ["is", 136], ["specifically", 139], ["designed", 152], ["to", 161], ["alter", 164], ["splicing", 170], ["of", 179], ["SMN2", 182], ["pre", 187], ["-", 190], ["mRNA", 191], ["and", 196], ["thus", 200], ["increase", 205], ["the", 214], ["amount", 218], ["of", 225], ["functional", 228], ["survival", 239], ["motor", 248], ["neuron", 254], ["(", 261], ["SMN", 262], [")", 265], ["protein", 267], ["that", 275], ["is", 280], ["deficient", 283], ["in", 293], ["patients", 296], ["with", 305], ["spinal", 310], ["muscular", 317], ["atrophy", 326], [".", 333], ["This", 335], ["open", 340], ["-", 344], ["label", 345], [",", 350], ["phase", 352], ["2", 358], [",", 359], ["escalating", 361], ["dose", 372], ["clinical", 377], ["study", 386], ["assessed", 392], ["the", 401], ["safety", 405], ["and", 412], ["tolerability", 416], [",", 428], ["pharmacokinetics", 430], [",", 446], ["and", 448], ["clinical", 452], ["efficacy", 461], ["of", 470], ["multiple", 473], ["intrathecal", 482], ["doses", 494], ["of", 500], ["nusinersen", 503], ["(", 514], ["6", 515], ["mg", 517], ["and", 520], ["12", 524], ["mg", 527], ["dose", 530], ["equivalents", 535], [")", 546], ["in", 548], ["patients", 551], ["with", 560], ["infantile", 565], ["-", 574], ["onset", 575], ["spinal", 581], ["muscular", 588], ["atrophy", 597], [".", 604], ["Eligible", 606], ["participants", 615], ["were", 628], ["of", 633], ["either", 636], ["gender", 643], ["aged", 650], ["between", 655], ["3", 663], ["weeks", 665], ["and", 671], ["7", 675], ["months", 677], ["old", 684], ["with", 688], ["onset", 693], ["of", 699], ["spinal", 702], ["muscular", 709], ["atrophy", 718], ["symptoms", 726], ["between", 735], ["3", 743], ["weeks", 745], ["and", 751], ["6", 755], ["months", 757], [",", 763], ["who", 765], ["had", 769], ["SMN1", 773], ["homozygous", 778], ["gene", 789], ["deletion", 794], ["or", 803], ["mutation", 806], [".", 814], ["Safety", 816], ["assessments", 823], ["included", 835], ["adverse", 844], ["events", 852], [",", 858], ["physical", 860], ["and", 869], ["neurological", 873], ["examinations", 886], [",", 898], ["vital", 900], ["signs", 906], [",", 911], ["clinical", 913], ["laboratory", 922], ["tests", 933], [",", 938], ["cerebrospinal", 940], ["fluid", 954], ["laboratory", 960], ["tests", 971], [",", 976], ["and", 978], ["electrocardiographs", 982], [".", 1001], ["Clinical", 1003], ["efficacy", 1012], ["assessments", 1021], ["included", 1033], ["event", 1042], ["free", 1048], ["survival", 1053], [",", 1061], ["and", 1063], ["change", 1067], ["from", 1074], ["baseline", 1079], ["of", 1088], ["two", 1091], ["assessments", 1095], ["of", 1107], ["motor", 1110], ["function", 1116], [":", 1124], ["the", 1126], ["motor", 1130], ["milestones", 1136], ["portion", 1147], ["of", 1155], ["the", 1158], ["Hammersmith", 1162], ["Infant", 1174], ["Neurological", 1181], ["Exam", 1194], ["-", 1198], ["Part", 1199], ["2", 1204], ["(", 1206], ["HINE-2", 1207], [")", 1213], ["and", 1215], ["the", 1219], ["Children", 1223], ["'s", 1231], ["Hospital", 1234], ["of", 1243], ["Philadelphia", 1246], ["Infant", 1259], ["Test", 1266], ["of", 1271], ["Neuromuscular", 1274], ["Disorders", 1288], ["(", 1298], ["CHOP", 1299], ["-", 1303], ["INTEND", 1304], [")", 1310], ["motor", 1312], ["function", 1318], ["test", 1327], [",", 1331], ["and", 1333], ["compound", 1337], ["motor", 1346], ["action", 1352], ["potentials", 1359], [".", 1369], ["Autopsy", 1371], ["tissue", 1379], ["was", 1386], ["analysed", 1390], ["for", 1399], ["target", 1403], ["engagement", 1410], [",", 1420], ["drug", 1422], ["concentrations", 1427], [",", 1441], ["and", 1443], ["pharmacological", 1447], ["activity", 1463], [".", 1471], ["HINE-2", 1473], [",", 1479], ["CHOP", 1481], ["-", 1485], ["INTEND", 1486], [",", 1492], ["and", 1494], ["compound", 1498], ["motor", 1507], ["action", 1513], ["potential", 1520], ["were", 1530], ["compared", 1535], ["between", 1544], ["baseline", 1552], ["and", 1561], ["last", 1565], ["visit", 1570], ["using", 1576], ["the", 1582], ["Wilcoxon", 1586], ["signed", 1595], ["-", 1601], ["rank", 1602], ["test", 1607], [".", 1611], ["Age", 1613], ["at", 1617], ["death", 1620], ["or", 1626], ["permanent", 1629], ["ventilation", 1639], ["was", 1651], ["compared", 1655], ["with", 1664], ["natural", 1669], ["history", 1677], ["using", 1685], ["the", 1691], ["log", 1695], ["-", 1698], ["rank", 1699], ["test", 1704], [".", 1708], ["The", 1710], ["study", 1714], ["is", 1720], ["registered", 1723], ["at", 1734], ["ClinicalTrials.gov", 1737], [",", 1755], ["number", 1757], ["NCT01839656", 1764], [".", 1775], ["20", 1777], ["participants", 1780], ["were", 1793], ["enrolled", 1798], ["between", 1807], ["May", 1815], ["3", 1819], [",", 1820], ["2013", 1822], [",", 1826], ["and", 1828], ["July", 1832], ["9", 1837], [",", 1838], ["2014", 1840], [",", 1844], ["and", 1846], ["assessed", 1850], ["through", 1859], ["to", 1867], ["an", 1870], ["interim", 1873], ["analysis", 1881], ["done", 1890], ["on", 1895], ["Jan", 1898], ["26", 1902], [",", 1904], ["2016", 1906], [".", 1910], ["All", 1912], ["participants", 1916], ["experienced", 1929], ["adverse", 1941], ["events", 1949], [",", 1955], ["with", 1957], ["77", 1962], ["serious", 1965], ["adverse", 1973], ["events", 1981], ["reported", 1988], ["in", 1997], ["16", 2000], ["participants", 2003], [",", 2015], ["all", 2017], ["considered", 2021], ["by", 2032], ["study", 2035], ["investigators", 2041], ["not", 2055], ["related", 2059], ["or", 2067], ["unlikely", 2070], ["related", 2079], ["to", 2087], ["the", 2090], ["study", 2094], ["drug", 2100], [".", 2104], ["In", 2106], ["the", 2109], ["12", 2113], ["mg", 2116], ["dose", 2119], ["group", 2124], [",", 2129], ["incremental", 2131], ["achievements", 2143], ["of", 2156], ["motor", 2159], ["milestones", 2165], ["(", 2176], ["p<0\u00b70001", 2177], [")", 2185], [",", 2186], ["improvements", 2188], ["in", 2201], ["CHOP", 2204], ["-", 2208], ["INTEND", 2209], ["motor", 2216], ["function", 2222], ["scores", 2231], ["(", 2238], ["p=0\u00b70013", 2239], [")", 2247], [",", 2248], ["and", 2250], ["increased", 2254], ["compound", 2264], ["muscle", 2273], ["action", 2280], ["potential", 2287], ["amplitude", 2297], ["of", 2307], ["the", 2310], ["ulnar", 2314], ["nerve", 2320], ["(", 2326], ["p=0\u00b70103", 2327], [")", 2335], ["and", 2337], ["peroneal", 2341], ["nerve", 2350], ["(", 2356], ["p<0\u00b70001", 2357], [")", 2365], [",", 2366], ["compared", 2368], ["with", 2377], ["baseline", 2382], [",", 2390], ["were", 2392], ["observed", 2397], [".", 2405], ["Median", 2407], ["age", 2414], ["at", 2418], ["death", 2421], ["or", 2427], ["permanent", 2430], ["ventilation", 2440], ["was", 2452], ["not", 2456], ["reached", 2460], ["and", 2468], ["the", 2472], ["Kaplan", 2476], ["-", 2482], ["Meier", 2483], ["survival", 2489], ["curve", 2498], ["diverged", 2504], ["from", 2513], ["a", 2518], ["published", 2520], ["natural", 2530], ["history", 2538], ["case", 2546], ["series", 2551], ["(", 2558], ["p=0\u00b70014", 2559], [")", 2567], [".", 2568], ["Analysis", 2570], ["of", 2579], ["autopsy", 2582], ["tissue", 2590], ["from", 2597], ["patients", 2602], ["exposed", 2611], ["to", 2619], ["nusinersen", 2622], ["showed", 2633], ["drug", 2640], ["uptake", 2645], ["into", 2652], ["motor", 2657], ["neurons", 2663], ["throughout", 2671], ["the", 2682], ["spinal", 2686], ["cord", 2693], ["and", 2698], ["neurons", 2702], ["and", 2710], ["other", 2714], ["cell", 2720], ["types", 2725], ["in", 2731], ["the", 2734], ["brainstem", 2738], ["and", 2748], ["other", 2752], ["brain", 2758], ["regions", 2764], [",", 2771], ["exposure", 2773], ["at", 2782], ["therapeutic", 2785], ["concentrations", 2797], [",", 2811], ["and", 2813], ["increased", 2817], ["SMN2", 2827], ["mRNA", 2832], ["exon", 2837], ["7", 2842], ["inclusion", 2844], ["and", 2854], ["SMN", 2858], ["protein", 2862], ["concentrations", 2870], ["in", 2885], ["the", 2888], ["spinal", 2892], ["cord", 2899], [".", 2903], ["Administration", 2905], ["of", 2920], ["multiple", 2923], ["intrathecal", 2932], ["doses", 2944], ["of", 2950], ["nusinersen", 2953], ["showed", 2964], ["acceptable", 2971], ["safety", 2982], ["and", 2989], ["tolerability", 2993], [",", 3005], ["pharmacology", 3007], ["consistent", 3020], ["with", 3031], ["its", 3036], ["intended", 3040], ["mechanism", 3049], ["of", 3059], ["action", 3062], [",", 3068], ["and", 3070], ["encouraging", 3074], ["clinical", 3086], ["efficacy", 3095], [".", 3103], ["Results", 3105], ["informed", 3113], ["the", 3122], ["design", 3126], ["of", 3133], ["an", 3136], ["ongoing", 3139], [",", 3146], ["sham", 3148], ["-", 3152], ["controlled", 3153], [",", 3163], ["phase", 3165], ["3", 3171], ["clinical", 3173], ["study", 3182], ["of", 3188], ["nusinersen", 3191], ["in", 3202], ["infantile", 3205], ["-", 3214], ["onset", 3215], ["spinal", 3221], ["muscular", 3228], ["atrophy", 3237], [".", 3244], ["Ionis", 3246], ["Pharmaceuticals", 3252], [",", 3267], ["Inc", 3269], ["and", 3273], ["Biogen", 3277], [".", 3283]]}
{"context": "To evaluate gender differences in score on 28-joint Disease Activity Score (DAS28), Health Assessment Questionnaire (HAQ) and Signals Of Functional Impairment (SOFI) and to relate these scores to radiographic joint destruction. In all, 549 patients with early RA (62% women) from the BARFOT (for \"Better Anti-Rheumatic FarmacOTherapy\") study were included. At baseline, 1, 2 and 5 years DAS28, HAQ and SOFI scoring, and radiographs of hands and feet were performed. The radiographs were scored using the van der Heijde-Sharp score. In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women. The SOFI score was worse in men during the first 2 years, depending on higher upper limb scores. Total Sharp score (TotSharp), erosion score and joint space narrowing score did not differ between the sexes at any time point. The DAS28 area under the curve (AUC) correlated significantly with TotSharp at 5 years in both genders (r = 0.316, r = 0.313) mainly owing to swollen joints and erythrocyte sedimentation rate (ESR). The SOFI AUC correlated significantly with TotSharp in women (r = 0.135 to 0.220) but not in men. Despite a similar degree of radiographic joint destruction women had, compared with men, worse scores for DAS28 and HAQ, possibly due to higher pain perception and less muscular strength and perhaps because men overestimate their functional capacity.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "3a09c991f94d49ac9f85560e9ef63b8f", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[256, 256], [139, 139], [235, 235], [108, 108], [50, 50]], "char_spans": [[1297, 1301], [709, 713], [1195, 1199], [535, 539], [268, 272]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["gender", 12], ["differences", 19], ["in", 31], ["score", 34], ["on", 40], ["28-joint", 43], ["Disease", 52], ["Activity", 60], ["Score", 69], ["(", 75], ["DAS28", 76], [")", 81], [",", 82], ["Health", 84], ["Assessment", 91], ["Questionnaire", 102], ["(", 116], ["HAQ", 117], [")", 120], ["and", 122], ["Signals", 126], ["Of", 134], ["Functional", 137], ["Impairment", 148], ["(", 159], ["SOFI", 160], [")", 164], ["and", 166], ["to", 170], ["relate", 173], ["these", 180], ["scores", 186], ["to", 193], ["radiographic", 196], ["joint", 209], ["destruction", 215], [".", 226], ["In", 228], ["all", 231], [",", 234], ["549", 236], ["patients", 240], ["with", 249], ["early", 254], ["RA", 260], ["(", 263], ["62", 264], ["%", 266], ["women", 268], [")", 273], ["from", 275], ["the", 280], ["BARFOT", 284], ["(", 291], ["for", 292], ["\"", 296], ["Better", 297], ["Anti", 304], ["-", 308], ["Rheumatic", 309], ["FarmacOTherapy", 319], ["\"", 333], [")", 334], ["study", 336], ["were", 342], ["included", 347], [".", 355], ["At", 357], ["baseline", 360], [",", 368], ["1", 370], [",", 371], ["2", 373], ["and", 375], ["5", 379], ["years", 381], ["DAS28", 387], [",", 392], ["HAQ", 394], ["and", 398], ["SOFI", 402], ["scoring", 407], [",", 414], ["and", 416], ["radiographs", 420], ["of", 432], ["hands", 435], ["and", 441], ["feet", 445], ["were", 450], ["performed", 455], [".", 464], ["The", 466], ["radiographs", 470], ["were", 482], ["scored", 487], ["using", 494], ["the", 500], ["van", 504], ["der", 508], ["Heijde", 512], ["-", 518], ["Sharp", 519], ["score", 525], [".", 530], ["In", 532], ["women", 535], ["the", 541], ["DAS28", 545], ["was", 551], ["significantly", 555], ["higher", 569], ["than", 576], ["in", 581], ["men", 584], ["due", 588], ["to", 592], ["higher", 595], ["scores", 602], ["for", 609], ["general", 613], ["health", 621], ["and", 628], ["tender", 632], ["joints", 639], [".", 645], ["Likewise", 647], [",", 655], ["HAQ", 657], ["and", 661], ["VAS", 665], ["pain", 669], ["were", 674], ["rated", 679], ["significantly", 685], ["higher", 699], ["in", 706], ["women", 709], [".", 714], ["The", 716], ["SOFI", 720], ["score", 725], ["was", 731], ["worse", 735], ["in", 741], ["men", 744], ["during", 748], ["the", 755], ["first", 759], ["2", 765], ["years", 767], [",", 772], ["depending", 774], ["on", 784], ["higher", 787], ["upper", 794], ["limb", 800], ["scores", 805], [".", 811], ["Total", 813], ["Sharp", 819], ["score", 825], ["(", 831], ["TotSharp", 832], [")", 840], [",", 841], ["erosion", 843], ["score", 851], ["and", 857], ["joint", 861], ["space", 867], ["narrowing", 873], ["score", 883], ["did", 889], ["not", 893], ["differ", 897], ["between", 904], ["the", 912], ["sexes", 916], ["at", 922], ["any", 925], ["time", 929], ["point", 934], [".", 939], ["The", 941], ["DAS28", 945], ["area", 951], ["under", 956], ["the", 962], ["curve", 966], ["(", 972], ["AUC", 973], [")", 976], ["correlated", 978], ["significantly", 989], ["with", 1003], ["TotSharp", 1008], ["at", 1017], ["5", 1020], ["years", 1022], ["in", 1028], ["both", 1031], ["genders", 1036], ["(", 1044], ["r", 1045], ["=", 1047], ["0.316", 1049], [",", 1054], ["r", 1056], ["=", 1058], ["0.313", 1060], [")", 1065], ["mainly", 1067], ["owing", 1074], ["to", 1080], ["swollen", 1083], ["joints", 1091], ["and", 1098], ["erythrocyte", 1102], ["sedimentation", 1114], ["rate", 1128], ["(", 1133], ["ESR", 1134], [")", 1137], [".", 1138], ["The", 1140], ["SOFI", 1144], ["AUC", 1149], ["correlated", 1153], ["significantly", 1164], ["with", 1178], ["TotSharp", 1183], ["in", 1192], ["women", 1195], ["(", 1201], ["r", 1202], ["=", 1204], ["0.135", 1206], ["to", 1212], ["0.220", 1215], [")", 1220], ["but", 1222], ["not", 1226], ["in", 1230], ["men", 1233], [".", 1236], ["Despite", 1238], ["a", 1246], ["similar", 1248], ["degree", 1256], ["of", 1263], ["radiographic", 1266], ["joint", 1279], ["destruction", 1285], ["women", 1297], ["had", 1303], [",", 1306], ["compared", 1308], ["with", 1317], ["men", 1322], [",", 1325], ["worse", 1327], ["scores", 1333], ["for", 1340], ["DAS28", 1344], ["and", 1350], ["HAQ", 1354], [",", 1357], ["possibly", 1359], ["due", 1368], ["to", 1372], ["higher", 1375], ["pain", 1382], ["perception", 1387], ["and", 1398], ["less", 1402], ["muscular", 1407], ["strength", 1416], ["and", 1425], ["perhaps", 1429], ["because", 1437], ["men", 1445], ["overestimate", 1449], ["their", 1462], ["functional", 1468], ["capacity", 1479], [".", 1487]]}
{"context": "To study the effects of siltuximab on the interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (Stat3) signaling pathway in ovarian epithelial carcinoma. (1) Expressions of IL-6 in ovarian cancer patient specimens were assessed by immunohistochemistry. (2) Expression of phosphorylation Stat3 (pStat3) protein in siltuximab and IL-6 treated SKOV3 cell lines was determined by western blot, and expression levels of Stat3-induced bcl-XL, MCL-1, survivin, in siltuximab treated SKOV3/TR and CAOV3/TR cells lines were also determined by western blot. (3) Real-time image analysis was used to study the nuclear translocation of pEGFP-Stat3 fusion protein in ovarian cancer cell line SKOV3-pEGFP-Stat3 treated with siltuximab and IL-6. (4) Paclitaxel sensitivity in siltuximab treated SKOV3/TR and CAOV3/TR cell lines were assessed using the methyl thiazolyl tetrazolium (MTT). The 50% inhibiting concentration (IC(50)) was defined as the paclitaxel concentration required to decrease the A(490) value to 50%. (1) There were significantly difference in IL-6 staining density and the positive rate of IL-6 protein stained among the metastatic, and drug-resistant recurrent tumors, and matched primary tumors [69% (18/26)] vs. 77% (20/26) vs. 23% (6/26), P < 0.05]. (2)A clear increase in Stat3 phosphorylation levels was observed in the IL-6-treated SKOV3 cell lines as compared to the SKOV3 cell lines. When the IL-6-treated SKOV3 cells were incubated with siltuximab with a range of concentrations of 0.001, 0.01, 0.1, 1.0 and 10 \u00b5g/ml, there were trends toward reduced pStat3 expression in the treated cell lines. Compared without treatment with siltuximab, the expression of the anti-apoptotic proteins MCL-1, bcl-XL and survivin in SKOV3/TR and CAOV3/TR cell lines were significantly decreased after treated with siltuximab. (3) In resting cells, the majority of pEGFP-Stat3 was cytoplasmic until the addition of human IL-6, which promptly induced the translocation of fluorescent Stat3 molecules to the nucleus. Exposure of cells to siltuximab with a range of concentrations of 0.001, 0.01, 0.1, 1.0 and 10 \u00b5g/ml, followed by an incubation in IL-6 significantly reduced pEGFP-Stat3 nucleocytoplasmic translocation. (4) MTT cytotoxicity assay demonstrated that siltuximab increased paclitaxel-induced cell death and partially overcame paclitaxel resistance. Treated with siltuximab (1 and 10 \u00b5g/ml), the paclitaxel IC(50) value of siltuximab in SKOV3/TR (0.49, 0.19 \u00b5g/ml) and CAOV3/TR (0.0010, 0.0008 \u00b5g/ml) cells were significantly lower than those in untreated cells (0.71, 0.0021 \u00b5g/ml; all P < 0.05). These results demonstrated that siltuximab effectively block the IL-6 signaling pathways, which. Blockage of IL-6 signaling may provide benefits for the treatment of ovarian cancer.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "0913b9c795bf4b8b9f202745a57d8d03", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[8, 8]], "char_spans": [[42, 54]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["effects", 13], ["of", 21], ["siltuximab", 24], ["on", 35], ["the", 38], ["interleukin-6", 42], ["(", 56], ["IL-6)/signal", 57], ["transducer", 70], ["and", 81], ["activator", 85], ["of", 95], ["transcription", 98], ["3", 112], ["(", 114], ["Stat3", 115], [")", 120], ["signaling", 122], ["pathway", 132], ["in", 140], ["ovarian", 143], ["epithelial", 151], ["carcinoma", 162], [".", 171], ["(", 173], ["1", 174], [")", 175], ["Expressions", 177], ["of", 189], ["IL-6", 192], ["in", 197], ["ovarian", 200], ["cancer", 208], ["patient", 215], ["specimens", 223], ["were", 233], ["assessed", 238], ["by", 247], ["immunohistochemistry", 250], [".", 270], ["(", 272], ["2", 273], [")", 274], ["Expression", 276], ["of", 287], ["phosphorylation", 290], ["Stat3", 306], ["(", 312], ["pStat3", 313], [")", 319], ["protein", 321], ["in", 329], ["siltuximab", 332], ["and", 343], ["IL-6", 347], ["treated", 352], ["SKOV3", 360], ["cell", 366], ["lines", 371], ["was", 377], ["determined", 381], ["by", 392], ["western", 395], ["blot", 403], [",", 407], ["and", 409], ["expression", 413], ["levels", 424], ["of", 431], ["Stat3-induced", 434], ["bcl", 448], ["-", 451], ["XL", 452], [",", 454], ["MCL-1", 456], [",", 461], ["survivin", 463], [",", 471], ["in", 473], ["siltuximab", 476], ["treated", 487], ["SKOV3/TR", 495], ["and", 504], ["CAOV3/TR", 508], ["cells", 517], ["lines", 523], ["were", 529], ["also", 534], ["determined", 539], ["by", 550], ["western", 553], ["blot", 561], [".", 565], ["(", 567], ["3", 568], [")", 569], ["Real", 571], ["-", 575], ["time", 576], ["image", 581], ["analysis", 587], ["was", 596], ["used", 600], ["to", 605], ["study", 608], ["the", 614], ["nuclear", 618], ["translocation", 626], ["of", 640], ["pEGFP", 643], ["-", 648], ["Stat3", 649], ["fusion", 655], ["protein", 662], ["in", 670], ["ovarian", 673], ["cancer", 681], ["cell", 688], ["line", 693], ["SKOV3-pEGFP", 698], ["-", 709], ["Stat3", 710], ["treated", 716], ["with", 724], ["siltuximab", 729], ["and", 740], ["IL-6", 744], [".", 748], ["(", 750], ["4", 751], [")", 752], ["Paclitaxel", 754], ["sensitivity", 765], ["in", 777], ["siltuximab", 780], ["treated", 791], ["SKOV3/TR", 799], ["and", 808], ["CAOV3/TR", 812], ["cell", 821], ["lines", 826], ["were", 832], ["assessed", 837], ["using", 846], ["the", 852], ["methyl", 856], ["thiazolyl", 863], ["tetrazolium", 873], ["(", 885], ["MTT", 886], [")", 889], [".", 890], ["The", 892], ["50", 896], ["%", 898], ["inhibiting", 900], ["concentration", 911], ["(", 925], ["IC(50", 926], [")", 931], [")", 932], ["was", 934], ["defined", 938], ["as", 946], ["the", 949], ["paclitaxel", 953], ["concentration", 964], ["required", 978], ["to", 987], ["decrease", 990], ["the", 999], ["A(490", 1003], [")", 1008], ["value", 1010], ["to", 1016], ["50", 1019], ["%", 1021], [".", 1022], ["(", 1024], ["1", 1025], [")", 1026], ["There", 1028], ["were", 1034], ["significantly", 1039], ["difference", 1053], ["in", 1064], ["IL-6", 1067], ["staining", 1072], ["density", 1081], ["and", 1089], ["the", 1093], ["positive", 1097], ["rate", 1106], ["of", 1111], ["IL-6", 1114], ["protein", 1119], ["stained", 1127], ["among", 1135], ["the", 1141], ["metastatic", 1145], [",", 1155], ["and", 1157], ["drug", 1161], ["-", 1165], ["resistant", 1166], ["recurrent", 1176], ["tumors", 1186], [",", 1192], ["and", 1194], ["matched", 1198], ["primary", 1206], ["tumors", 1214], ["[", 1221], ["69", 1222], ["%", 1224], ["(", 1226], ["18/26", 1227], [")", 1232], ["]", 1233], ["vs.", 1235], ["77", 1239], ["%", 1241], ["(", 1243], ["20/26", 1244], [")", 1249], ["vs.", 1251], ["23", 1255], ["%", 1257], ["(", 1259], ["6/26", 1260], [")", 1264], [",", 1265], ["P", 1267], ["<", 1269], ["0.05].", 1271], ["(", 1278], ["2)A", 1279], ["clear", 1283], ["increase", 1289], ["in", 1298], ["Stat3", 1301], ["phosphorylation", 1307], ["levels", 1323], ["was", 1330], ["observed", 1334], ["in", 1343], ["the", 1346], ["IL-6-treated", 1350], ["SKOV3", 1363], ["cell", 1369], ["lines", 1374], ["as", 1380], ["compared", 1383], ["to", 1392], ["the", 1395], ["SKOV3", 1399], ["cell", 1405], ["lines", 1410], [".", 1415], ["When", 1417], ["the", 1422], ["IL-6-treated", 1426], ["SKOV3", 1439], ["cells", 1445], ["were", 1451], ["incubated", 1456], ["with", 1466], ["siltuximab", 1471], ["with", 1482], ["a", 1487], ["range", 1489], ["of", 1495], ["concentrations", 1498], ["of", 1513], ["0.001", 1516], [",", 1521], ["0.01", 1523], [",", 1527], ["0.1", 1529], [",", 1532], ["1.0", 1534], ["and", 1538], ["10", 1542], ["\u00b5g", 1545], ["/", 1547], ["ml", 1548], [",", 1550], ["there", 1552], ["were", 1558], ["trends", 1563], ["toward", 1570], ["reduced", 1577], ["pStat3", 1585], ["expression", 1592], ["in", 1603], ["the", 1606], ["treated", 1610], ["cell", 1618], ["lines", 1623], [".", 1628], ["Compared", 1630], ["without", 1639], ["treatment", 1647], ["with", 1657], ["siltuximab", 1662], [",", 1672], ["the", 1674], ["expression", 1678], ["of", 1689], ["the", 1692], ["anti", 1696], ["-", 1700], ["apoptotic", 1701], ["proteins", 1711], ["MCL-1", 1720], [",", 1725], ["bcl", 1727], ["-", 1730], ["XL", 1731], ["and", 1734], ["survivin", 1738], ["in", 1747], ["SKOV3/TR", 1750], ["and", 1759], ["CAOV3/TR", 1763], ["cell", 1772], ["lines", 1777], ["were", 1783], ["significantly", 1788], ["decreased", 1802], ["after", 1812], ["treated", 1818], ["with", 1826], ["siltuximab", 1831], [".", 1841], ["(", 1843], ["3", 1844], [")", 1845], ["In", 1847], ["resting", 1850], ["cells", 1858], [",", 1863], ["the", 1865], ["majority", 1869], ["of", 1878], ["pEGFP", 1881], ["-", 1886], ["Stat3", 1887], ["was", 1893], ["cytoplasmic", 1897], ["until", 1909], ["the", 1915], ["addition", 1919], ["of", 1928], ["human", 1931], ["IL-6", 1937], [",", 1941], ["which", 1943], ["promptly", 1949], ["induced", 1958], ["the", 1966], ["translocation", 1970], ["of", 1984], ["fluorescent", 1987], ["Stat3", 1999], ["molecules", 2005], ["to", 2015], ["the", 2018], ["nucleus", 2022], [".", 2029], ["Exposure", 2031], ["of", 2040], ["cells", 2043], ["to", 2049], ["siltuximab", 2052], ["with", 2063], ["a", 2068], ["range", 2070], ["of", 2076], ["concentrations", 2079], ["of", 2094], ["0.001", 2097], [",", 2102], ["0.01", 2104], [",", 2108], ["0.1", 2110], [",", 2113], ["1.0", 2115], ["and", 2119], ["10", 2123], ["\u00b5g", 2126], ["/", 2128], ["ml", 2129], [",", 2131], ["followed", 2133], ["by", 2142], ["an", 2145], ["incubation", 2148], ["in", 2159], ["IL-6", 2162], ["significantly", 2167], ["reduced", 2181], ["pEGFP", 2189], ["-", 2194], ["Stat3", 2195], ["nucleocytoplasmic", 2201], ["translocation", 2219], [".", 2232], ["(", 2234], ["4", 2235], [")", 2236], ["MTT", 2238], ["cytotoxicity", 2242], ["assay", 2255], ["demonstrated", 2261], ["that", 2274], ["siltuximab", 2279], ["increased", 2290], ["paclitaxel", 2300], ["-", 2310], ["induced", 2311], ["cell", 2319], ["death", 2324], ["and", 2330], ["partially", 2334], ["overcame", 2344], ["paclitaxel", 2353], ["resistance", 2364], [".", 2374], ["Treated", 2376], ["with", 2384], ["siltuximab", 2389], ["(", 2400], ["1", 2401], ["and", 2403], ["10", 2407], ["\u00b5g", 2410], ["/", 2412], ["ml", 2413], [")", 2415], [",", 2416], ["the", 2418], ["paclitaxel", 2422], ["IC(50", 2433], [")", 2438], ["value", 2440], ["of", 2446], ["siltuximab", 2449], ["in", 2460], ["SKOV3/TR", 2463], ["(", 2472], ["0.49", 2473], [",", 2477], ["0.19", 2479], ["\u00b5g", 2484], ["/", 2486], ["ml", 2487], [")", 2489], ["and", 2491], ["CAOV3/TR", 2495], ["(", 2504], ["0.0010", 2505], [",", 2511], ["0.0008", 2513], ["\u00b5g", 2520], ["/", 2522], ["ml", 2523], [")", 2525], ["cells", 2527], ["were", 2533], ["significantly", 2538], ["lower", 2552], ["than", 2558], ["those", 2563], ["in", 2569], ["untreated", 2572], ["cells", 2582], ["(", 2588], ["0.71", 2589], [",", 2593], ["0.0021", 2595], ["\u00b5g", 2602], ["/", 2604], ["ml", 2605], [";", 2607], ["all", 2609], ["P", 2613], ["<", 2615], ["0.05", 2617], [")", 2621], [".", 2622], ["These", 2624], ["results", 2630], ["demonstrated", 2638], ["that", 2651], ["siltuximab", 2656], ["effectively", 2667], ["block", 2679], ["the", 2685], ["IL-6", 2689], ["signaling", 2694], ["pathways", 2704], [",", 2712], ["which", 2714], [".", 2719], ["Blockage", 2721], ["of", 2730], ["IL-6", 2733], ["signaling", 2738], ["may", 2748], ["provide", 2752], ["benefits", 2760], ["for", 2769], ["the", 2773], ["treatment", 2777], ["of", 2787], ["ovarian", 2790], ["cancer", 2798], [".", 2804]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "The evolutionarily conserved histone variant H2A.Z has an important role in the regulation of gene expression and the establishment of a buffer to the spread of silent heterochromatin. Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z. Swr1 is required for the deposition of histone H2A.Z at stereotypical promoter locations in vivo, and Swr1 and H2A.Z commonly regulate a subset of yeast genes. Here, we describe an integrated nucleosome assembly-histone replacement system whereby histone exchange by chromatin remodeling activities may be analyzed in vitro. The system demonstrates ATP- and SWR1-complex-dependent replacement of histone H2A for histone H2A.Z on a preassembled nucleosome array. This system may also be adapted to analyze dynamic interactions between chromatin remodeling and modifying enzymes, histone chaperones, and nucleosome substrates containing canonical, variant, or covalently modified histones.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "068cbc54100446149c56fc5412d2fb84", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[81, 81], [64, 64], [31, 31], [50, 50]], "char_spans": [[526, 529], [424, 427], [210, 213], [324, 327]]}]}], "context_tokens": [["The", 0], ["evolutionarily", 4], ["conserved", 19], ["histone", 29], ["variant", 37], ["H2A.Z", 45], ["has", 51], ["an", 55], ["important", 58], ["role", 68], ["in", 73], ["the", 76], ["regulation", 80], ["of", 91], ["gene", 94], ["expression", 99], ["and", 110], ["the", 114], ["establishment", 118], ["of", 132], ["a", 135], ["buffer", 137], ["to", 144], ["the", 147], ["spread", 151], ["of", 158], ["silent", 161], ["heterochromatin", 168], [".", 183], ["Saccharomyces", 185], ["cerevisiae", 199], ["Swr1", 210], [",", 214], ["a", 216], ["Swi2/Snf2-related", 218], ["ATPase", 236], [",", 242], ["is", 244], ["the", 247], ["catalytic", 251], ["core", 261], ["of", 266], ["a", 269], ["multisubunit", 271], ["chromatin", 284], ["remodeling", 294], ["enzyme", 305], [",", 311], ["called", 313], ["the", 320], ["SWR1", 324], ["complex", 329], [",", 336], ["that", 338], ["efficiently", 343], ["replaces", 355], ["conventional", 364], ["histone", 377], ["H2A", 385], ["in", 389], ["nucleosomes", 392], ["with", 404], ["histone", 409], ["H2A.Z.", 417], ["Swr1", 424], ["is", 429], ["required", 432], ["for", 441], ["the", 445], ["deposition", 449], ["of", 460], ["histone", 463], ["H2A.Z", 471], ["at", 477], ["stereotypical", 480], ["promoter", 494], ["locations", 503], ["in", 513], ["vivo", 516], [",", 520], ["and", 522], ["Swr1", 526], ["and", 531], ["H2A.Z", 535], ["commonly", 541], ["regulate", 550], ["a", 559], ["subset", 561], ["of", 568], ["yeast", 571], ["genes", 577], [".", 582], ["Here", 584], [",", 588], ["we", 590], ["describe", 593], ["an", 602], ["integrated", 605], ["nucleosome", 616], ["assembly", 627], ["-", 635], ["histone", 636], ["replacement", 644], ["system", 656], ["whereby", 663], ["histone", 671], ["exchange", 679], ["by", 688], ["chromatin", 691], ["remodeling", 701], ["activities", 712], ["may", 723], ["be", 727], ["analyzed", 730], ["in", 739], ["vitro", 742], [".", 747], ["The", 749], ["system", 753], ["demonstrates", 760], ["ATP-", 773], ["and", 778], ["SWR1-complex", 782], ["-", 794], ["dependent", 795], ["replacement", 805], ["of", 817], ["histone", 820], ["H2A", 828], ["for", 832], ["histone", 836], ["H2A.Z", 844], ["on", 850], ["a", 853], ["preassembled", 855], ["nucleosome", 868], ["array", 879], [".", 884], ["This", 886], ["system", 891], ["may", 898], ["also", 902], ["be", 907], ["adapted", 910], ["to", 918], ["analyze", 921], ["dynamic", 929], ["interactions", 937], ["between", 950], ["chromatin", 958], ["remodeling", 968], ["and", 979], ["modifying", 983], ["enzymes", 993], [",", 1000], ["histone", 1002], ["chaperones", 1010], [",", 1020], ["and", 1022], ["nucleosome", 1026], ["substrates", 1037], ["containing", 1048], ["canonical", 1059], [",", 1068], ["variant", 1070], [",", 1077], ["or", 1079], ["covalently", 1082], ["modified", 1093], ["histones", 1102], [".", 1110]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "9bb5d9f90f804b34971f0a239f63343b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[18, 19], [115, 116]], "char_spans": [[95, 108], [628, 641]]}]}], "context_tokens": [["1", 0], [".", 1], ["In", 3], ["order", 6], ["to", 12], ["investigate", 15], ["the", 27], ["biological", 31], ["function", 42], ["of", 51], ["the", 54], ["human", 58], ["CLN3", 64], ["gene", 69], ["that", 74], ["is", 79], ["defective", 82], ["in", 92], ["Batten", 95], ["disease", 102], [",", 109], ["we", 111], ["created", 114], ["a", 122], ["yeast", 124], ["strain", 130], ["by", 137], ["PCR", 140], ["-", 143], ["targeted", 144], ["disruption", 153], ["of", 164], ["the", 167], ["yeast", 171], ["gene", 177], ["(", 182], ["YHC3", 183], [")", 187], [",", 188], ["which", 190], ["is", 196], ["a", 199], ["homologue", 201], ["of", 211], ["the", 214], ["human", 218], ["CLN3", 224], ["gene", 229], [".", 233], ["2", 235], [".", 236], ["The", 238], ["phenotypic", 242], ["characterization", 253], ["revealed", 270], ["that", 279], ["the", 284], ["yhc3", 288], ["delta", 293], ["mutants", 299], ["are", 307], ["more", 311], ["sensitive", 316], ["to", 326], ["combined", 329], ["heat", 338], ["and", 343], ["alkaline", 347], ["stress", 356], ["than", 363], ["the", 368], ["wild", 372], ["-", 376], ["type", 377], ["strains", 382], ["as", 390], ["determined", 393], ["by", 404], ["inhibition", 407], ["of", 418], ["cell", 421], ["proliferation", 426], [".", 439], ["3", 441], [".", 442], ["This", 444], ["suggests", 449], ["that", 458], ["the", 463], ["yhc3", 467], ["delta", 472], ["mutant", 478], ["is", 485], ["a", 488], ["good", 490], ["model", 495], ["to", 501], ["investigate", 504], ["the", 516], ["biological", 520], ["function", 531], ["of", 540], ["human", 543], ["CLN3", 549], ["gene", 554], ["in", 559], ["mammalian", 562], ["cells", 572], ["and", 578], ["to", 582], ["understand", 585], ["the", 596], ["pathophysiology", 600], ["of", 616], ["juvenile", 619], ["Batten", 628], ["disease", 635], [".", 642]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ed0c4a0629ff46d1b8993188f8a0e5c4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[326, 326], [90, 90], [28, 28], [217, 217], [55, 55]], "char_spans": [[1870, 1879], [538, 547], [177, 186], [1232, 1241], [348, 357]]}]}], "context_tokens": [["Specific", 0], ["reversal", 9], ["agents", 18], ["for", 25], ["non", 29], ["-", 32], ["vitamin", 33], ["K", 41], ["antagonist", 43], ["oral", 54], ["anticoagulants", 59], ["are", 74], ["lacking", 78], [".", 85], ["Idarucizumab", 87], [",", 99], ["an", 101], ["antibody", 104], ["fragment", 113], [",", 121], ["was", 123], ["developed", 127], ["to", 137], ["reverse", 140], ["the", 148], ["anticoagulant", 152], ["effects", 166], ["of", 174], ["dabigatran", 177], [".", 187], ["We", 189], ["undertook", 192], ["this", 202], ["prospective", 207], ["cohort", 219], ["study", 226], ["to", 232], ["determine", 235], ["the", 245], ["safety", 249], ["of", 256], ["5", 259], ["g", 261], ["of", 263], ["intravenous", 266], ["idarucizumab", 278], ["and", 291], ["its", 295], ["capacity", 299], ["to", 308], ["reverse", 311], ["the", 319], ["anticoagulant", 323], ["effects", 337], ["of", 345], ["dabigatran", 348], ["in", 359], ["patients", 362], ["who", 371], ["had", 375], ["serious", 379], ["bleeding", 387], ["(", 396], ["group", 397], ["A", 403], [")", 404], ["or", 406], ["required", 409], ["an", 418], ["urgent", 421], ["procedure", 428], ["(", 438], ["group", 439], ["B", 445], [")", 446], [".", 447], ["The", 449], ["primary", 453], ["end", 461], ["point", 465], ["was", 471], ["the", 475], ["maximum", 479], ["percentage", 487], ["reversal", 498], ["of", 507], ["the", 510], ["anticoagulant", 514], ["effect", 528], ["of", 535], ["dabigatran", 538], ["within", 549], ["4", 556], ["hours", 558], ["after", 564], ["the", 570], ["administration", 574], ["of", 589], ["idarucizumab", 592], [",", 604], ["on", 606], ["the", 609], ["basis", 613], ["of", 619], ["the", 622], ["determination", 626], ["at", 640], ["a", 643], ["central", 645], ["laboratory", 653], ["of", 664], ["the", 667], ["dilute", 671], ["thrombin", 678], ["time", 687], ["or", 692], ["ecarin", 695], ["clotting", 702], ["time", 711], [".", 715], ["A", 717], ["key", 719], ["secondary", 723], ["end", 733], ["point", 737], ["was", 743], ["the", 747], ["restoration", 751], ["of", 763], ["hemostasis", 766], [".", 776], ["This", 778], ["interim", 783], ["analysis", 791], ["included", 800], ["90", 809], ["patients", 812], ["who", 821], ["received", 825], ["idarucizumab", 834], ["(", 847], ["51", 848], ["patients", 851], ["in", 860], ["group", 863], ["A", 869], ["and", 871], ["39", 875], ["in", 878], ["group", 881], ["B", 887], [")", 888], [".", 889], ["Among", 891], ["68", 897], ["patients", 900], ["with", 909], ["an", 914], ["elevated", 917], ["dilute", 926], ["thrombin", 933], ["time", 942], ["and", 947], ["81", 951], ["with", 954], ["an", 959], ["elevated", 962], ["ecarin", 971], ["clotting", 978], ["time", 987], ["at", 992], ["baseline", 995], [",", 1003], ["the", 1005], ["median", 1009], ["maximum", 1016], ["percentage", 1024], ["reversal", 1035], ["was", 1044], ["100", 1048], ["%", 1051], ["(", 1053], ["95", 1054], ["%", 1056], ["confidence", 1058], ["interval", 1069], [",", 1077], ["100", 1079], ["to", 1083], ["100", 1086], [")", 1089], [".", 1090], ["Idarucizumab", 1092], ["normalized", 1105], ["the", 1116], ["test", 1120], ["results", 1125], ["in", 1133], ["88", 1136], ["to", 1139], ["98", 1142], ["%", 1144], ["of", 1146], ["the", 1149], ["patients", 1153], [",", 1161], ["an", 1163], ["effect", 1166], ["that", 1173], ["was", 1178], ["evident", 1182], ["within", 1190], ["minutes", 1197], [".", 1204], ["Concentrations", 1206], ["of", 1221], ["unbound", 1224], ["dabigatran", 1232], ["remained", 1243], ["below", 1252], ["20", 1258], ["ng", 1261], ["per", 1264], ["milliliter", 1268], ["at", 1279], ["24", 1282], ["hours", 1285], ["in", 1291], ["79", 1294], ["%", 1296], ["of", 1298], ["the", 1301], ["patients", 1305], [".", 1313], ["Among", 1315], ["35", 1321], ["patients", 1324], ["in", 1333], ["group", 1336], ["A", 1342], ["who", 1344], ["could", 1348], ["be", 1354], ["assessed", 1357], [",", 1365], ["hemostasis", 1367], [",", 1377], ["as", 1379], ["determined", 1382], ["by", 1393], ["local", 1396], ["investigators", 1402], [",", 1415], ["was", 1417], ["restored", 1421], ["at", 1430], ["a", 1433], ["median", 1435], ["of", 1442], ["11.4", 1445], ["hours", 1450], [".", 1455], ["Among", 1457], ["36", 1463], ["patients", 1466], ["in", 1475], ["group", 1478], ["B", 1484], ["who", 1486], ["underwent", 1490], ["a", 1500], ["procedure", 1502], [",", 1511], ["normal", 1513], ["intraoperative", 1520], ["hemostasis", 1535], ["was", 1546], ["reported", 1550], ["in", 1559], ["33", 1562], [",", 1564], ["and", 1566], ["mildly", 1570], ["or", 1577], ["moderately", 1580], ["abnormal", 1591], ["hemostasis", 1600], ["was", 1611], ["reported", 1615], ["in", 1624], ["2", 1627], ["patients", 1629], ["and", 1638], ["1", 1642], ["patient", 1644], [",", 1651], ["respectively", 1653], [".", 1665], ["One", 1667], ["thrombotic", 1671], ["event", 1682], ["occurred", 1688], ["within", 1697], ["72", 1704], ["hours", 1707], ["after", 1713], ["idarucizumab", 1719], ["administration", 1732], ["in", 1747], ["a", 1750], ["patient", 1752], ["in", 1760], ["whom", 1763], ["anticoagulants", 1768], ["had", 1783], ["not", 1787], ["been", 1791], ["reinitiated", 1796], [".", 1807], ["Idarucizumab", 1809], ["completely", 1822], ["reversed", 1833], ["the", 1842], ["anticoagulant", 1846], ["effect", 1860], ["of", 1867], ["dabigatran", 1870], ["within", 1881], ["minutes", 1888], [".", 1895], ["(", 1897], ["Funded", 1898], ["by", 1905], ["Boehringer", 1908], ["Ingelheim", 1919], [";", 1928], ["RE", 1930], ["-", 1932], ["VERSE", 1933], ["AD", 1939], ["ClinicalTrials.gov", 1942], ["number", 1961], [",", 1967], ["NCT02104947", 1969], [".", 1980], [")", 1981], [".", 1982]]}
{"context": "Dementia with Lewy bodies is an \u03b1-synucleinopathy characterized by neocortical Lewy-related pathology (LRP). We carried out a genome-wide association study (GWAS) on neocortical LRP in a population-based sample of subjects aged 85 or over. LRP was analyzed in 304 subjects in the Vantaa 85+ sample from Southern Finland. The GWAS included 41 cases with midbrain, hippocampal, and neocortical LRP and 177 controls without midbrain and hippocampal LRP. The Medical Research Council Cognitive Function and Ageing Study (CFAS) material was used for replication (51 cases and 131 controls). By analyzing 327,010 markers the top signal was obtained at the HLA-DPA1/DPB1 locus (P\u00a0=\u00a01.29\u00a0\u00d7\u00a010(-7)); five other loci on chromosomes 15q14, 2p21, 2q31, 18p11, and 5q23 were associated with neocortical LRP at P\u00a0<\u00a010(-5). Two loci were marked by multiple markers, 2p21 (P\u00a0=\u00a03.9\u00a0\u00d7\u00a010(-6), upstream of the SPTBN1 gene), and HLA-DPA1/DPB1; these were tested in the CFAS material. Single marker (P\u00a0=\u00a00.0035) and haplotype (P\u00a0=\u00a00.04) associations on 2p21 were replicated in CFAS, whereas HLA-DPA1/DPB1 association was not. Bioinformatic analyses suggest functional effects for the HLA-DPA1/DPB1 markers as well as the 15q14 marker rs8037309. We identified suggestive novel risk factors for neocortical LRP. SPTBN1 is the candidate on 2p21, it encodes beta-spectrin, an \u03b1-synuclein binding protein and a component of Lewy bodies. The HLA-DPA1/DPB1 association suggests a role for antigen presentation or alternatively, cis-regulatory effects, one of the regulated neighboring genes identified here (vacuolar protein sorting 52) plays a role in vesicular trafficking and has been shown to interact with \u03b1-synuclein in a yeast model.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a9b0e00be51344dca4d96c64bd53c6e7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[329, 331], [271, 273]], "char_spans": [[1683, 1693], [1351, 1361]]}]}], "context_tokens": [["Dementia", 0], ["with", 9], ["Lewy", 14], ["bodies", 19], ["is", 26], ["an", 29], ["\u03b1", 32], ["-", 33], ["synucleinopathy", 34], ["characterized", 50], ["by", 64], ["neocortical", 67], ["Lewy", 79], ["-", 83], ["related", 84], ["pathology", 92], ["(", 102], ["LRP", 103], [")", 106], [".", 107], ["We", 109], ["carried", 112], ["out", 120], ["a", 124], ["genome", 126], ["-", 132], ["wide", 133], ["association", 138], ["study", 150], ["(", 156], ["GWAS", 157], [")", 161], ["on", 163], ["neocortical", 166], ["LRP", 178], ["in", 182], ["a", 185], ["population", 187], ["-", 197], ["based", 198], ["sample", 204], ["of", 211], ["subjects", 214], ["aged", 223], ["85", 228], ["or", 231], ["over", 234], [".", 238], ["LRP", 240], ["was", 244], ["analyzed", 248], ["in", 257], ["304", 260], ["subjects", 264], ["in", 273], ["the", 276], ["Vantaa", 280], ["85", 287], ["+", 289], ["sample", 291], ["from", 298], ["Southern", 303], ["Finland", 312], [".", 319], ["The", 321], ["GWAS", 325], ["included", 330], ["41", 339], ["cases", 342], ["with", 348], ["midbrain", 353], [",", 361], ["hippocampal", 363], [",", 374], ["and", 376], ["neocortical", 380], ["LRP", 392], ["and", 396], ["177", 400], ["controls", 404], ["without", 413], ["midbrain", 421], ["and", 430], ["hippocampal", 434], ["LRP", 446], [".", 449], ["The", 451], ["Medical", 455], ["Research", 463], ["Council", 472], ["Cognitive", 480], ["Function", 490], ["and", 499], ["Ageing", 503], ["Study", 510], ["(", 516], ["CFAS", 517], [")", 521], ["material", 523], ["was", 532], ["used", 536], ["for", 541], ["replication", 545], ["(", 557], ["51", 558], ["cases", 561], ["and", 567], ["131", 571], ["controls", 575], [")", 583], [".", 584], ["By", 586], ["analyzing", 589], ["327,010", 599], ["markers", 607], ["the", 615], ["top", 619], ["signal", 623], ["was", 630], ["obtained", 634], ["at", 643], ["the", 646], ["HLA", 650], ["-", 653], ["DPA1/DPB1", 654], ["locus", 664], ["(", 670], ["P", 671], ["=", 673], ["1.29", 675], ["\u00d7", 680], ["10(-7", 682], [")", 687], [")", 688], [";", 689], ["five", 691], ["other", 696], ["loci", 702], ["on", 707], ["chromosomes", 710], ["15q14", 722], [",", 727], ["2p21", 729], [",", 733], ["2q31", 735], [",", 739], ["18p11", 741], [",", 746], ["and", 748], ["5q23", 752], ["were", 757], ["associated", 762], ["with", 773], ["neocortical", 778], ["LRP", 790], ["at", 794], ["P", 797], ["<", 799], ["10(-5", 801], [")", 806], [".", 807], ["Two", 809], ["loci", 813], ["were", 818], ["marked", 823], ["by", 830], ["multiple", 833], ["markers", 842], [",", 849], ["2p21", 851], ["(", 856], ["P", 857], ["=", 859], ["3.9", 861], ["\u00d7", 865], ["10(-6", 867], [")", 872], [",", 873], ["upstream", 875], ["of", 884], ["the", 887], ["SPTBN1", 891], ["gene", 898], [")", 902], [",", 903], ["and", 905], ["HLA", 909], ["-", 912], ["DPA1/DPB1", 913], [";", 922], ["these", 924], ["were", 930], ["tested", 935], ["in", 942], ["the", 945], ["CFAS", 949], ["material", 954], [".", 962], ["Single", 964], ["marker", 971], ["(", 978], ["P", 979], ["=", 981], ["0.0035", 983], [")", 989], ["and", 991], ["haplotype", 995], ["(", 1005], ["P", 1006], ["=", 1008], ["0.04", 1010], [")", 1014], ["associations", 1016], ["on", 1029], ["2p21", 1032], ["were", 1037], ["replicated", 1042], ["in", 1053], ["CFAS", 1056], [",", 1060], ["whereas", 1062], ["HLA", 1070], ["-", 1073], ["DPA1/DPB1", 1074], ["association", 1084], ["was", 1096], ["not", 1100], [".", 1103], ["Bioinformatic", 1105], ["analyses", 1119], ["suggest", 1128], ["functional", 1136], ["effects", 1147], ["for", 1155], ["the", 1159], ["HLA", 1163], ["-", 1166], ["DPA1/DPB1", 1167], ["markers", 1177], ["as", 1185], ["well", 1188], ["as", 1193], ["the", 1196], ["15q14", 1200], ["marker", 1206], ["rs8037309", 1213], [".", 1222], ["We", 1224], ["identified", 1227], ["suggestive", 1238], ["novel", 1249], ["risk", 1255], ["factors", 1260], ["for", 1268], ["neocortical", 1272], ["LRP", 1284], [".", 1287], ["SPTBN1", 1289], ["is", 1296], ["the", 1299], ["candidate", 1303], ["on", 1313], ["2p21", 1316], [",", 1320], ["it", 1322], ["encodes", 1325], ["beta", 1333], ["-", 1337], ["spectrin", 1338], [",", 1346], ["an", 1348], ["\u03b1", 1351], ["-", 1352], ["synuclein", 1353], ["binding", 1363], ["protein", 1371], ["and", 1379], ["a", 1383], ["component", 1385], ["of", 1395], ["Lewy", 1398], ["bodies", 1403], [".", 1409], ["The", 1411], ["HLA", 1415], ["-", 1418], ["DPA1/DPB1", 1419], ["association", 1429], ["suggests", 1441], ["a", 1450], ["role", 1452], ["for", 1457], ["antigen", 1461], ["presentation", 1469], ["or", 1482], ["alternatively", 1485], [",", 1498], ["cis", 1500], ["-", 1503], ["regulatory", 1504], ["effects", 1515], [",", 1522], ["one", 1524], ["of", 1528], ["the", 1531], ["regulated", 1535], ["neighboring", 1545], ["genes", 1557], ["identified", 1563], ["here", 1574], ["(", 1579], ["vacuolar", 1580], ["protein", 1589], ["sorting", 1597], ["52", 1605], [")", 1607], ["plays", 1609], ["a", 1615], ["role", 1617], ["in", 1622], ["vesicular", 1625], ["trafficking", 1635], ["and", 1647], ["has", 1651], ["been", 1655], ["shown", 1660], ["to", 1666], ["interact", 1669], ["with", 1678], ["\u03b1", 1683], ["-", 1684], ["synuclein", 1685], ["in", 1695], ["a", 1698], ["yeast", 1700], ["model", 1706], [".", 1711]]}
{"context": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection. We now show that this dystrophin expression was accompanied by an elevated expression of \u03b1-sarcoglycan, \u03b2-dystroglycan (BDG) and--in relevant cases--neuronal nitric oxide synthase (nNOS) at the sarcolemma, each of which is a component of a different subcomplex of the dystrophin-associated glycoprotein complex (DAPC). As expected, nNOS expression was relocalized to the sarcolemma in Duchenne patients in whom the dystrophin deletion left the nNOS-binding domain (exons 42-45) intact, whereas this did not occur in patients with deletions that involved this domain. Our results indicate that the novel internally deleted and shorter dystrophin induced by skipping exon 51 in patients with amenable deletions, can also restore the dystrophin-associated complex, further suggesting preserved functionality of the newly translated dystrophin.", "qas": [{"question": "What is the role of eteplirsen in DMD patients?", "answers": ["skipping of dystrophin exon 51"], "qid": "3d5eec0702a04e5a95da8cdd5d1454d8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["role", 12], ["of", 17], ["eteplirsen", 20], ["in", 31], ["DMD", 34], ["patients", 38], ["?", 46]], "detected_answers": [{"text": "skipping of dystrophin exon 51", "token_spans": [[32, 36]], "char_spans": [[203, 232]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["conducted", 14], ["a", 24], ["proof", 26], ["of", 32], ["principle", 35], [";", 44], ["dose", 46], ["escalation", 51], ["study", 62], ["in", 68], ["Duchenne", 71], ["muscular", 80], ["dystrophy", 89], ["(", 99], ["DMD", 100], [")", 103], ["patients", 105], ["using", 114], ["the", 120], ["morpholino", 124], ["splice", 135], ["-", 141], ["switching", 142], ["oligonucleotide", 152], ["AVI-4658", 168], ["(", 177], ["eteplirsen", 178], [")", 188], ["that", 190], ["induces", 195], ["skipping", 203], ["of", 212], ["dystrophin", 215], ["exon", 226], ["51", 231], ["in", 234], ["patients", 237], ["with", 246], ["relevant", 251], ["deletions", 260], [",", 269], ["restores", 271], ["the", 280], ["open", 284], ["reading", 289], ["frame", 297], ["and", 303], ["induces", 307], ["dystrophin", 315], ["protein", 326], ["expression", 334], ["after", 345], ["intramuscular", 351], ["(", 365], ["i.m", 366], [".", 369], [")", 370], ["injection", 372], [".", 381], ["We", 383], ["now", 386], ["show", 390], ["that", 395], ["this", 400], ["dystrophin", 405], ["expression", 416], ["was", 427], ["accompanied", 431], ["by", 443], ["an", 446], ["elevated", 449], ["expression", 458], ["of", 469], ["\u03b1", 472], ["-", 473], ["sarcoglycan", 474], [",", 485], ["\u03b2", 487], ["-", 488], ["dystroglycan", 489], ["(", 502], ["BDG", 503], [")", 506], ["and", 508], ["--", 511], ["in", 513], ["relevant", 516], ["cases", 525], ["--", 530], ["neuronal", 532], ["nitric", 541], ["oxide", 548], ["synthase", 554], ["(", 563], ["nNOS", 564], [")", 568], ["at", 570], ["the", 573], ["sarcolemma", 577], [",", 587], ["each", 589], ["of", 594], ["which", 597], ["is", 603], ["a", 606], ["component", 608], ["of", 618], ["a", 621], ["different", 623], ["subcomplex", 633], ["of", 644], ["the", 647], ["dystrophin", 651], ["-", 661], ["associated", 662], ["glycoprotein", 673], ["complex", 686], ["(", 694], ["DAPC", 695], [")", 699], [".", 700], ["As", 702], ["expected", 705], [",", 713], ["nNOS", 715], ["expression", 720], ["was", 731], ["relocalized", 735], ["to", 747], ["the", 750], ["sarcolemma", 754], ["in", 765], ["Duchenne", 768], ["patients", 777], ["in", 786], ["whom", 789], ["the", 794], ["dystrophin", 798], ["deletion", 809], ["left", 818], ["the", 823], ["nNOS", 827], ["-", 831], ["binding", 832], ["domain", 840], ["(", 847], ["exons", 848], ["42", 854], ["-", 856], ["45", 857], [")", 859], ["intact", 861], [",", 867], ["whereas", 869], ["this", 877], ["did", 882], ["not", 886], ["occur", 890], ["in", 896], ["patients", 899], ["with", 908], ["deletions", 913], ["that", 923], ["involved", 928], ["this", 937], ["domain", 942], [".", 948], ["Our", 950], ["results", 954], ["indicate", 962], ["that", 971], ["the", 976], ["novel", 980], ["internally", 986], ["deleted", 997], ["and", 1005], ["shorter", 1009], ["dystrophin", 1017], ["induced", 1028], ["by", 1036], ["skipping", 1039], ["exon", 1048], ["51", 1053], ["in", 1056], ["patients", 1059], ["with", 1068], ["amenable", 1073], ["deletions", 1082], [",", 1091], ["can", 1093], ["also", 1097], ["restore", 1102], ["the", 1110], ["dystrophin", 1114], ["-", 1124], ["associated", 1125], ["complex", 1136], [",", 1143], ["further", 1145], ["suggesting", 1153], ["preserved", 1164], ["functionality", 1174], ["of", 1188], ["the", 1191], ["newly", 1195], ["translated", 1201], ["dystrophin", 1212], [".", 1222]]}
{"context": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. Two known mutations were found in the Thanatophoric Dysplasia referred cases. No mutations were identified in the LADD syndrome patient. In Achondroplasia and Hypochondroplasia, genetic heterogeneity was present amongst the 70 clinically diagnosed patients with 5 different mutations identified. As in other studies, complex phenotypic heterogeneity amongst patients carrying the same gene defect was observed. In several cases, the new amino acids encoded, as a consequence of mutations, were related to the severity of patients' phenotype. The presence of 10 misdiagnosed cases emphasizes the importance of performing mutation analysis of the hotspot regions responsible for both dysplasias (Ach and Hch). For patients with an unquestionable clinical diagnosis, lacking the most common mutations, a complete screening of FGFR3 is necessary.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "761f9e814759455eb96445c42ae4b986", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[6, 12]], "char_spans": [[35, 76]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["gene", 17], ["that", 22], ["encodes", 27], ["Fibroblast", 35], ["Growth", 46], ["Factor", 53], ["Receptor", 60], ["3", 69], ["(", 71], ["FGFR3", 72], [")", 77], ["are", 79], ["associated", 83], ["with", 94], ["Achondroplasia", 99], ["(", 114], ["MIM", 115], ["100800", 119], [")", 125], [",", 126], ["Hypochondroplasia", 128], ["(", 146], ["MIM", 147], ["146000", 151], [")", 157], [",", 158], ["Muenke", 160], ["Syndrome", 167], ["(", 176], ["MIM", 177], ["602849", 181], [")", 187], [",", 188], ["Thanatophoric", 190], ["Dysplasia", 204], ["(", 214], ["MIM", 215], ["187600", 219], [",", 225], ["MIM", 227], ["187601", 231], [")", 237], ["and", 239], ["Lacrimo", 243], ["-", 250], ["Auriculo", 251], ["-", 259], ["Dento", 260], ["-", 265], ["Digital", 266], ["Syndrome", 274], ["(", 283], ["MIM", 284], ["149730).Here", 288], ["we", 301], ["report", 304], ["a", 311], ["clinical", 313], ["and", 322], ["molecular", 326], ["study", 336], ["in", 342], ["a", 345], ["large", 347], ["cohort", 353], ["of", 360], ["125", 363], ["Portuguese", 367], ["patients", 378], ["with", 387], ["these", 392], ["skeletal", 398], ["disorders", 407], [".", 416], ["The", 418], ["identification", 422], ["of", 437], ["the", 440], ["P250R", 444], ["mutation", 450], ["allowed", 459], ["the", 467], ["confirmation", 471], ["of", 484], ["the", 487], ["Muenke", 491], ["Syndrome", 498], ["in", 507], ["9", 510], ["out", 512], ["of", 516], ["the", 519], ["52", 523], ["cases", 526], ["referred", 532], [".", 540], ["Two", 542], ["known", 546], ["mutations", 552], ["were", 562], ["found", 567], ["in", 573], ["the", 576], ["Thanatophoric", 580], ["Dysplasia", 594], ["referred", 604], ["cases", 613], [".", 618], ["No", 620], ["mutations", 623], ["were", 633], ["identified", 638], ["in", 649], ["the", 652], ["LADD", 656], ["syndrome", 661], ["patient", 670], [".", 677], ["In", 679], ["Achondroplasia", 682], ["and", 697], ["Hypochondroplasia", 701], [",", 718], ["genetic", 720], ["heterogeneity", 728], ["was", 742], ["present", 746], ["amongst", 754], ["the", 762], ["70", 766], ["clinically", 769], ["diagnosed", 780], ["patients", 790], ["with", 799], ["5", 804], ["different", 806], ["mutations", 816], ["identified", 826], [".", 836], ["As", 838], ["in", 841], ["other", 844], ["studies", 850], [",", 857], ["complex", 859], ["phenotypic", 867], ["heterogeneity", 878], ["amongst", 892], ["patients", 900], ["carrying", 909], ["the", 918], ["same", 922], ["gene", 927], ["defect", 932], ["was", 939], ["observed", 943], [".", 951], ["In", 953], ["several", 956], ["cases", 964], [",", 969], ["the", 971], ["new", 975], ["amino", 979], ["acids", 985], ["encoded", 991], [",", 998], ["as", 1000], ["a", 1003], ["consequence", 1005], ["of", 1017], ["mutations", 1020], [",", 1029], ["were", 1031], ["related", 1036], ["to", 1044], ["the", 1047], ["severity", 1051], ["of", 1060], ["patients", 1063], ["'", 1071], ["phenotype", 1073], [".", 1082], ["The", 1084], ["presence", 1088], ["of", 1097], ["10", 1100], ["misdiagnosed", 1103], ["cases", 1116], ["emphasizes", 1122], ["the", 1133], ["importance", 1137], ["of", 1148], ["performing", 1151], ["mutation", 1162], ["analysis", 1171], ["of", 1180], ["the", 1183], ["hotspot", 1187], ["regions", 1195], ["responsible", 1203], ["for", 1215], ["both", 1219], ["dysplasias", 1224], ["(", 1235], ["Ach", 1236], ["and", 1240], ["Hch", 1244], [")", 1247], [".", 1248], ["For", 1250], ["patients", 1254], ["with", 1263], ["an", 1268], ["unquestionable", 1271], ["clinical", 1286], ["diagnosis", 1295], [",", 1304], ["lacking", 1306], ["the", 1314], ["most", 1318], ["common", 1323], ["mutations", 1330], [",", 1339], ["a", 1341], ["complete", 1343], ["screening", 1352], ["of", 1362], ["FGFR3", 1365], ["is", 1371], ["necessary", 1374], [".", 1383]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental disorder caused by deleterious mutations in SLC9A6. Affected families organized the inaugural Christianson Syndrome Association conference to advance CS knowledge and develop questions that may be prioritized in future research.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "7bc7d50257d34f87ab4fb5cf15488ef8", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[17, 17]], "char_spans": [[105, 110]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["disorder", 61], ["caused", 70], ["by", 77], ["deleterious", 80], ["mutations", 92], ["in", 102], ["SLC9A6", 105], [".", 111], ["Affected", 113], ["families", 122], ["organized", 131], ["the", 141], ["inaugural", 145], ["Christianson", 155], ["Syndrome", 168], ["Association", 177], ["conference", 189], ["to", 200], ["advance", 203], ["CS", 211], ["knowledge", 214], ["and", 224], ["develop", 228], ["questions", 236], ["that", 246], ["may", 251], ["be", 255], ["prioritized", 258], ["in", 270], ["future", 273], ["research", 280], [".", 288]]}
{"context": "Prior studies, all using SPECT techniques, failed to find any differences for dopamine transporter (DAT) in restless legs syndrome (RLS) subjects. The distinct pharmacokinetic properties associated with SPECT-determined DAT along with rapid biodynamic changes in DAT may, however, have missed membrane-bound DAT differences. The current studies assessed real-time DAT binding potentials (BP) in striatum of RLS patients using (11)C-methylphenidate and PET techniques. RLS medications were stopped at least 11 days prior to the PET study. Clinical severity of RLS was also assessed. PET scans were performed at 2 different times of day (starting at 08:30 and 19:30) in separate groups of subjects. The primary outcome measure was total striatal DAT BP. Thirty-six patients with primary RLS and 34 age- and gender-matched controls. RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans. DAT was decreased in putamen and caudate but not the ventral striatum of RLS subjects. There were no diurnal differences in DAT for the total group or for control and RLS separately. DAT BP did not correlate with any clinical measures of RLS. The current study found a significant decrease in DAT BP in two independent studies. These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b2a12b8918344a65a2cc5f9b028e8d2b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[258, 258]], "char_spans": [[1392, 1395]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], [",", 13], ["all", 15], ["using", 19], ["SPECT", 25], ["techniques", 31], [",", 41], ["failed", 43], ["to", 50], ["find", 53], ["any", 58], ["differences", 62], ["for", 74], ["dopamine", 78], ["transporter", 87], ["(", 99], ["DAT", 100], [")", 103], ["in", 105], ["restless", 108], ["legs", 117], ["syndrome", 122], ["(", 131], ["RLS", 132], [")", 135], ["subjects", 137], [".", 145], ["The", 147], ["distinct", 151], ["pharmacokinetic", 160], ["properties", 176], ["associated", 187], ["with", 198], ["SPECT", 203], ["-", 208], ["determined", 209], ["DAT", 220], ["along", 224], ["with", 230], ["rapid", 235], ["biodynamic", 241], ["changes", 252], ["in", 260], ["DAT", 263], ["may", 267], [",", 270], ["however", 272], [",", 279], ["have", 281], ["missed", 286], ["membrane", 293], ["-", 301], ["bound", 302], ["DAT", 308], ["differences", 312], [".", 323], ["The", 325], ["current", 329], ["studies", 337], ["assessed", 345], ["real", 354], ["-", 358], ["time", 359], ["DAT", 364], ["binding", 368], ["potentials", 376], ["(", 387], ["BP", 388], [")", 390], ["in", 392], ["striatum", 395], ["of", 404], ["RLS", 407], ["patients", 411], ["using", 420], ["(", 426], ["11)C", 427], ["-", 431], ["methylphenidate", 432], ["and", 448], ["PET", 452], ["techniques", 456], [".", 466], ["RLS", 468], ["medications", 472], ["were", 484], ["stopped", 489], ["at", 497], ["least", 500], ["11", 506], ["days", 509], ["prior", 514], ["to", 520], ["the", 523], ["PET", 527], ["study", 531], [".", 536], ["Clinical", 538], ["severity", 547], ["of", 556], ["RLS", 559], ["was", 563], ["also", 567], ["assessed", 572], [".", 580], ["PET", 582], ["scans", 586], ["were", 592], ["performed", 597], ["at", 607], ["2", 610], ["different", 612], ["times", 622], ["of", 628], ["day", 631], ["(", 635], ["starting", 636], ["at", 645], ["08:30", 648], ["and", 654], ["19:30", 658], [")", 663], ["in", 665], ["separate", 668], ["groups", 677], ["of", 684], ["subjects", 687], [".", 695], ["The", 697], ["primary", 701], ["outcome", 709], ["measure", 717], ["was", 725], ["total", 729], ["striatal", 735], ["DAT", 744], ["BP", 748], [".", 750], ["Thirty", 752], ["-", 758], ["six", 759], ["patients", 763], ["with", 772], ["primary", 777], ["RLS", 785], ["and", 789], ["34", 793], ["age-", 796], ["and", 801], ["gender", 805], ["-", 811], ["matched", 812], ["controls", 820], [".", 828], ["RLS", 830], ["subjects", 834], ["had", 843], ["significantly", 847], ["lower", 861], ["DAT", 867], ["binding", 871], ["in", 879], ["the", 882], ["striatum", 886], ["compared", 895], ["to", 904], ["controls", 907], ["on", 916], ["both", 919], ["the", 924], ["Day", 928], ["and", 932], ["the", 936], ["Night", 940], ["scans", 946], [".", 951], ["DAT", 953], ["was", 957], ["decreased", 961], ["in", 971], ["putamen", 974], ["and", 982], ["caudate", 986], ["but", 994], ["not", 998], ["the", 1002], ["ventral", 1006], ["striatum", 1014], ["of", 1023], ["RLS", 1026], ["subjects", 1030], [".", 1038], ["There", 1040], ["were", 1046], ["no", 1051], ["diurnal", 1054], ["differences", 1062], ["in", 1074], ["DAT", 1077], ["for", 1081], ["the", 1085], ["total", 1089], ["group", 1095], ["or", 1101], ["for", 1104], ["control", 1108], ["and", 1116], ["RLS", 1120], ["separately", 1124], [".", 1134], ["DAT", 1136], ["BP", 1140], ["did", 1143], ["not", 1147], ["correlate", 1151], ["with", 1161], ["any", 1166], ["clinical", 1170], ["measures", 1179], ["of", 1188], ["RLS", 1191], [".", 1194], ["The", 1196], ["current", 1200], ["study", 1208], ["found", 1214], ["a", 1220], ["significant", 1222], ["decrease", 1234], ["in", 1243], ["DAT", 1246], ["BP", 1250], ["in", 1253], ["two", 1256], ["independent", 1260], ["studies", 1272], [".", 1279], ["These", 1281], ["results", 1287], ["when", 1295], ["viewed", 1300], ["along", 1307], ["with", 1313], ["prior", 1318], ["RLS", 1324], ["SPECT", 1328], ["and", 1334], ["autopsy", 1338], ["studies", 1346], ["of", 1354], ["DAT", 1357], [",", 1360], ["and", 1362], ["cell", 1366], ["culture", 1371], ["studies", 1379], ["with", 1387], ["iron", 1392], ["deficiency", 1397], ["and", 1408], ["DAT", 1412], [",", 1415], ["suggest", 1417], ["that", 1425], ["membrane", 1430], ["-", 1438], ["bound", 1439], ["striatal", 1445], ["DAT", 1454], [",", 1457], ["but", 1459], ["not", 1463], ["total", 1467], ["cellular", 1473], ["DAT", 1482], [",", 1485], ["may", 1487], ["be", 1491], ["decreased", 1494], ["in", 1504], ["RLS", 1507], [".", 1510]]}
{"context": "Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH). Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized. In addition, the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily. Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014). The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure. Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "d69c9463ec08444a919447d7f33855f7", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[38, 40]], "char_spans": [[201, 231]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["first", 15], ["-", 20], ["in", 21], ["-", 23], ["class", 24], ["orally", 30], ["available", 37], ["selective", 47], ["non", 57], ["-", 60], ["prostanoid", 61], ["IP", 72], ["receptor", 75], ["agonist", 84], [".", 91], ["This", 93], ["review", 98], ["was", 105], ["based", 109], ["on", 115], ["a", 118], ["PubMed", 120], ["search", 127], ["and", 134], ["focuses", 138], ["on", 146], ["the", 149], ["potential", 153], ["role", 163], ["of", 168], ["selexipag", 171], ["in", 181], ["the", 184], ["treatment", 188], ["of", 198], ["pulmonary", 201], ["arterial", 211], ["hypertension", 220], ["(", 233], ["PAH", 234], [")", 237], [".", 238], ["Selexipag", 240], ["is", 250], ["rapidly", 253], ["hydrolyzed", 261], ["to", 272], ["an", 275], ["active", 278], ["metabolite", 285], [",", 295], ["ACT-333679", 297], [".", 307], ["Both", 309], ["selexipag", 314], ["and", 324], ["its", 328], ["metabolite", 332], ["are", 343], ["highly", 347], ["selective", 354], ["for", 364], ["the", 368], ["IP", 372], ["receptor", 375], ["compared", 384], ["with", 393], ["other", 398], ["prostanoid", 404], ["receptors", 415], [".", 424], ["This", 426], ["selectivity", 431], ["for", 443], ["the", 447], ["IP", 451], ["receptor", 454], ["offers", 463], ["the", 470], ["potential", 474], ["for", 484], ["improved", 488], ["tolerability", 497], ["with", 510], ["selexipag", 515], [",", 524], ["as", 526], ["side", 529], ["effects", 534], ["(", 542], ["e.g.", 543], [",", 547], ["nausea", 549], ["and", 556], ["vomiting", 560], [")", 568], ["that", 570], ["might", 575], ["result", 581], ["from", 588], ["activation", 593], ["of", 604], ["the", 607], ["other", 611], ["prostanoid", 617], ["receptors", 628], ["may", 638], ["be", 642], ["minimized", 645], [".", 654], ["In", 656], ["addition", 659], [",", 667], ["the", 669], ["selexipag", 673], ["metabolite", 683], ["has", 694], ["a", 698], ["half", 700], ["-", 704], ["life", 705], ["of", 710], ["7.9", 713], ["h", 717], [",", 718], ["thus", 720], ["permitting", 725], ["oral", 736], ["dosing", 741], ["twice", 748], ["daily", 754], [".", 759], ["Selexipag", 761], ["showed", 771], ["effects", 778], ["on", 786], ["pharmacodynamic", 789], ["end", 805], ["points", 809], ["obtained", 816], ["with", 825], ["right", 830], ["heart", 836], ["catheterization", 842], ["in", 858], ["a", 861], ["Phase", 863], ["II", 869], ["trial", 872], ["in", 878], ["patients", 881], ["with", 890], ["PAH", 895], [",", 898], ["and", 900], ["is", 904], ["being", 907], ["evaluated", 913], ["in", 923], ["the", 926], ["ongoing", 930], ["Phase", 938], ["III", 944], ["trial", 948], ["(", 954], ["GRIPHON", 955], ["trial", 963], [",", 968], ["Clinicaltrials.gov", 970], ["NCT01106014", 989], [")", 1000], [".", 1001], ["The", 1003], ["signal", 1007], ["of", 1014], ["a", 1017], ["beneficial", 1019], ["effect", 1030], ["of", 1037], ["selexipag", 1040], ["on", 1050], ["disease", 1053], ["progression", 1061], ["may", 1073], ["become", 1077], ["more", 1084], ["robust", 1089], ["for", 1096], ["long", 1100], ["term", 1105], ["under", 1110], ["prolonged", 1116], ["exposure", 1126], [".", 1134], ["Pending", 1136], ["the", 1144], ["GRIPHON", 1148], ["trial", 1156], ["results", 1162], [",", 1169], ["selexipag", 1171], ["could", 1181], ["provide", 1187], ["a", 1195], ["convenient", 1197], ["first", 1208], ["-", 1213], ["line", 1214], ["prostacyclin", 1219], ["treatment", 1232], ["option", 1242], ["for", 1249], ["patients", 1253], ["with", 1262], ["PAH", 1267], [".", 1270]]}
{"context": "The Ehlers-Danlos syndrome (EDS) comprises a group of hereditary connective tissue disorders. Periventricular nodular heterotopia (PNH) is a human neuronal migration disorder characterised by seizures and conglomerates of neural cells around the lateral ventricles of the brain, caused by FLNA mutations. FLNA encodes filamin A, an actin binding protein involved in cytoskeletal organisation. The amino-terminal actin binding domain (ABD) of filamins contains two tandem calponin homology domains, CHD1 and CHD2. To report clinical and genetic analyses in a Spanish family affected by a connective tissue disorder suggestive of EDS type III and PNH. A clinical and molecular study was undertaken in the three affected women. Clinical histories, physical and neurological examinations, brain magnetic resonance imaging studies, and skin biopsies were done. Genetic analysis of the FLNA gene was undertaken by direct sequencing and restriction fragment length polymorphism analysis. Mutation analysis of the FLNA gene resulted in the identification of a novel mutation in exon 3 (c.383C-->T) segregating with the combination of both syndromes. This mutation results in a substitution of an alanine residue (A128V) in CHD1. The findings suggest that the Ala128Val mutation causes the dual EDS-PNH phenotype. This association constitutes a new variant within the EDS spectrum. This is the first description of a familial EDS-PNH association with a mutation in FLNA.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "684689885e4249239d6a8040baf14481", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [100, 101]], "char_spans": [[65, 81], [587, 603]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["comprises", 33], ["a", 43], ["group", 45], ["of", 51], ["hereditary", 54], ["connective", 65], ["tissue", 76], ["disorders", 83], [".", 92], ["Periventricular", 94], ["nodular", 110], ["heterotopia", 118], ["(", 130], ["PNH", 131], [")", 134], ["is", 136], ["a", 139], ["human", 141], ["neuronal", 147], ["migration", 156], ["disorder", 166], ["characterised", 175], ["by", 189], ["seizures", 192], ["and", 201], ["conglomerates", 205], ["of", 219], ["neural", 222], ["cells", 229], ["around", 235], ["the", 242], ["lateral", 246], ["ventricles", 254], ["of", 265], ["the", 268], ["brain", 272], [",", 277], ["caused", 279], ["by", 286], ["FLNA", 289], ["mutations", 294], [".", 303], ["FLNA", 305], ["encodes", 310], ["filamin", 318], ["A", 326], [",", 327], ["an", 329], ["actin", 332], ["binding", 338], ["protein", 346], ["involved", 354], ["in", 363], ["cytoskeletal", 366], ["organisation", 379], [".", 391], ["The", 393], ["amino", 397], ["-", 402], ["terminal", 403], ["actin", 412], ["binding", 418], ["domain", 426], ["(", 433], ["ABD", 434], [")", 437], ["of", 439], ["filamins", 442], ["contains", 451], ["two", 460], ["tandem", 464], ["calponin", 471], ["homology", 480], ["domains", 489], [",", 496], ["CHD1", 498], ["and", 503], ["CHD2", 507], [".", 511], ["To", 513], ["report", 516], ["clinical", 523], ["and", 532], ["genetic", 536], ["analyses", 544], ["in", 553], ["a", 556], ["Spanish", 558], ["family", 566], ["affected", 573], ["by", 582], ["a", 585], ["connective", 587], ["tissue", 598], ["disorder", 605], ["suggestive", 614], ["of", 625], ["EDS", 628], ["type", 632], ["III", 637], ["and", 641], ["PNH", 645], [".", 648], ["A", 650], ["clinical", 652], ["and", 661], ["molecular", 665], ["study", 675], ["was", 681], ["undertaken", 685], ["in", 696], ["the", 699], ["three", 703], ["affected", 709], ["women", 718], [".", 723], ["Clinical", 725], ["histories", 734], [",", 743], ["physical", 745], ["and", 754], ["neurological", 758], ["examinations", 771], [",", 783], ["brain", 785], ["magnetic", 791], ["resonance", 800], ["imaging", 810], ["studies", 818], [",", 825], ["and", 827], ["skin", 831], ["biopsies", 836], ["were", 845], ["done", 850], [".", 854], ["Genetic", 856], ["analysis", 864], ["of", 873], ["the", 876], ["FLNA", 880], ["gene", 885], ["was", 890], ["undertaken", 894], ["by", 905], ["direct", 908], ["sequencing", 915], ["and", 926], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], [".", 979], ["Mutation", 981], ["analysis", 990], ["of", 999], ["the", 1002], ["FLNA", 1006], ["gene", 1011], ["resulted", 1016], ["in", 1025], ["the", 1028], ["identification", 1032], ["of", 1047], ["a", 1050], ["novel", 1052], ["mutation", 1058], ["in", 1067], ["exon", 1070], ["3", 1075], ["(", 1077], ["c.383C-->T", 1078], [")", 1088], ["segregating", 1090], ["with", 1102], ["the", 1107], ["combination", 1111], ["of", 1123], ["both", 1126], ["syndromes", 1131], [".", 1140], ["This", 1142], ["mutation", 1147], ["results", 1156], ["in", 1164], ["a", 1167], ["substitution", 1169], ["of", 1182], ["an", 1185], ["alanine", 1188], ["residue", 1196], ["(", 1204], ["A128V", 1205], [")", 1210], ["in", 1212], ["CHD1", 1215], [".", 1219], ["The", 1221], ["findings", 1225], ["suggest", 1234], ["that", 1242], ["the", 1247], ["Ala128Val", 1251], ["mutation", 1261], ["causes", 1270], ["the", 1277], ["dual", 1281], ["EDS", 1286], ["-", 1289], ["PNH", 1290], ["phenotype", 1294], [".", 1303], ["This", 1305], ["association", 1310], ["constitutes", 1322], ["a", 1334], ["new", 1336], ["variant", 1340], ["within", 1348], ["the", 1355], ["EDS", 1359], ["spectrum", 1363], [".", 1371], ["This", 1373], ["is", 1378], ["the", 1381], ["first", 1385], ["description", 1391], ["of", 1403], ["a", 1406], ["familial", 1408], ["EDS", 1417], ["-", 1420], ["PNH", 1421], ["association", 1425], ["with", 1437], ["a", 1442], ["mutation", 1444], ["in", 1453], ["FLNA", 1456], [".", 1460]]}
{"context": "Emotion regulation has been associated with perceived health in rheumatoid arthritis, which is diagnosed three times more often in women than men. Our aim was to examine gender differences in styles of emotion regulation (ambiguity, control, orientation, and expression) and gender-specificity of the associations between emotion regulation and perceived health (psychological well-being, social functioning, physical functioning, and disease activity) in 244 female and 91 male patients with rheumatoid arthritis. Women reported more emotional orientation than men, but did not differ from men with regard to ambiguity, control, and expression. Structural equation modelling showed that relationships between emotion regulation and perceived health were more frequent and stronger for women than men. This held especially for the affective dimension of health, while associations were similar for both women and men with regard to social and physical functioning. Only for women, the association between ambiguity and disease activity was significant, which appeared to be mediated by affective functioning. The observations that women are more emotionally oriented than men and that emotion regulation is more interwoven with psychological health in women than men, support the usefulness of a gender-sensitive approach in research and health care of patients with rheumatoid arthritis.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "33ce31f2b31e434a8646df96cc8b9daa", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[128, 128], [203, 203], [86, 86], [148, 148], [20, 20], [185, 185], [161, 161]], "char_spans": [[786, 790], [1252, 1256], [515, 519], [903, 907], [131, 135], [1131, 1135], [974, 978]]}]}], "context_tokens": [["Emotion", 0], ["regulation", 8], ["has", 19], ["been", 23], ["associated", 28], ["with", 39], ["perceived", 44], ["health", 54], ["in", 61], ["rheumatoid", 64], ["arthritis", 75], [",", 84], ["which", 86], ["is", 92], ["diagnosed", 95], ["three", 105], ["times", 111], ["more", 117], ["often", 122], ["in", 128], ["women", 131], ["than", 137], ["men", 142], [".", 145], ["Our", 147], ["aim", 151], ["was", 155], ["to", 159], ["examine", 162], ["gender", 170], ["differences", 177], ["in", 189], ["styles", 192], ["of", 199], ["emotion", 202], ["regulation", 210], ["(", 221], ["ambiguity", 222], [",", 231], ["control", 233], [",", 240], ["orientation", 242], [",", 253], ["and", 255], ["expression", 259], [")", 269], ["and", 271], ["gender", 275], ["-", 281], ["specificity", 282], ["of", 294], ["the", 297], ["associations", 301], ["between", 314], ["emotion", 322], ["regulation", 330], ["and", 341], ["perceived", 345], ["health", 355], ["(", 362], ["psychological", 363], ["well", 377], ["-", 381], ["being", 382], [",", 387], ["social", 389], ["functioning", 396], [",", 407], ["physical", 409], ["functioning", 418], [",", 429], ["and", 431], ["disease", 435], ["activity", 443], [")", 451], ["in", 453], ["244", 456], ["female", 460], ["and", 467], ["91", 471], ["male", 474], ["patients", 479], ["with", 488], ["rheumatoid", 493], ["arthritis", 504], [".", 513], ["Women", 515], ["reported", 521], ["more", 530], ["emotional", 535], ["orientation", 545], ["than", 557], ["men", 562], [",", 565], ["but", 567], ["did", 571], ["not", 575], ["differ", 579], ["from", 586], ["men", 591], ["with", 595], ["regard", 600], ["to", 607], ["ambiguity", 610], [",", 619], ["control", 621], [",", 628], ["and", 630], ["expression", 634], [".", 644], ["Structural", 646], ["equation", 657], ["modelling", 666], ["showed", 676], ["that", 683], ["relationships", 688], ["between", 702], ["emotion", 710], ["regulation", 718], ["and", 729], ["perceived", 733], ["health", 743], ["were", 750], ["more", 755], ["frequent", 760], ["and", 769], ["stronger", 773], ["for", 782], ["women", 786], ["than", 792], ["men", 797], [".", 800], ["This", 802], ["held", 807], ["especially", 812], ["for", 823], ["the", 827], ["affective", 831], ["dimension", 841], ["of", 851], ["health", 854], [",", 860], ["while", 862], ["associations", 868], ["were", 881], ["similar", 886], ["for", 894], ["both", 898], ["women", 903], ["and", 909], ["men", 913], ["with", 917], ["regard", 922], ["to", 929], ["social", 932], ["and", 939], ["physical", 943], ["functioning", 952], [".", 963], ["Only", 965], ["for", 970], ["women", 974], [",", 979], ["the", 981], ["association", 985], ["between", 997], ["ambiguity", 1005], ["and", 1015], ["disease", 1019], ["activity", 1027], ["was", 1036], ["significant", 1040], [",", 1051], ["which", 1053], ["appeared", 1059], ["to", 1068], ["be", 1071], ["mediated", 1074], ["by", 1083], ["affective", 1086], ["functioning", 1096], [".", 1107], ["The", 1109], ["observations", 1113], ["that", 1126], ["women", 1131], ["are", 1137], ["more", 1141], ["emotionally", 1146], ["oriented", 1158], ["than", 1167], ["men", 1172], ["and", 1176], ["that", 1180], ["emotion", 1185], ["regulation", 1193], ["is", 1204], ["more", 1207], ["interwoven", 1212], ["with", 1223], ["psychological", 1228], ["health", 1242], ["in", 1249], ["women", 1252], ["than", 1258], ["men", 1263], [",", 1266], ["support", 1268], ["the", 1276], ["usefulness", 1280], ["of", 1291], ["a", 1294], ["gender", 1296], ["-", 1302], ["sensitive", 1303], ["approach", 1313], ["in", 1322], ["research", 1325], ["and", 1334], ["health", 1338], ["care", 1345], ["of", 1350], ["patients", 1353], ["with", 1362], ["rheumatoid", 1367], ["arthritis", 1378], [".", 1387]]}
{"context": "In neurodegenerative diseases, it remains unclear why certain brain regions are selectively vulnerable to protein aggregation. In transgenic mice expressing human A53T \u03b1-synuclein, the brainstem and spinal cord develop the most prominent \u03b1-synuclein inclusions which correlate with age-dependent motor dysfunction. Herein we present the novel finding that this selective aggregation is in part dependent on the inability of chaperone-mediated autophagy (CMA) to effectively degrade \u03b1-synuclein in these brain regions. Lysosomal assays revealed that CMA activity was significantly decreased in aggregation-prone regions compared to the remainder of the brain. Previously, CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a. Using antibodies, brain tissue from Lamp-2a null mice, enzymatic deglycosylation, and mass spectrometry, we identified Lamp2a as a novel 72kDa glycoprotein in the mouse brain. Examination of Lamp-2a levels revealed differences in expression across brain regions. The brainstem and the spinal cord had a more than three-fold greater levels of Lamp-2a as compared to regions less vulnerable to aggregation and exhibited a selective upregulation of Lamp-2a during development of \u03b1-synuclein inclusions. Despite this dynamic response of Lamp-2a, the levels of substrates bound to the brain lysosomes as well as the rates of substrate uptake and degradation were not proportional to the levels of Lamp-2a. These regional differences in CMA activity and Lamp-2a expression were found in both non-transgenic mice as well as A53T \u03b1-syn mice. Therefore, these are inherent variations and not a transgene-specific effect. However, differences in CMA activity may render select brain regions vulnerable to homeostatic dysfunction in the presence of stressors such as overexpression of human A53T \u03b1-syn. Collectively, the data provide a potential mechanism to explain the dichotomy of vulnerability or resistance that underlies brain regions during aggregate formation in neurodegenerative disease.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "fdc608c223704b0ca4a61d478dc8dbe2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[146, 146]], "char_spans": [[876, 881]]}]}], "context_tokens": [["In", 0], ["neurodegenerative", 3], ["diseases", 21], [",", 29], ["it", 31], ["remains", 34], ["unclear", 42], ["why", 50], ["certain", 54], ["brain", 62], ["regions", 68], ["are", 76], ["selectively", 80], ["vulnerable", 92], ["to", 103], ["protein", 106], ["aggregation", 114], [".", 125], ["In", 127], ["transgenic", 130], ["mice", 141], ["expressing", 146], ["human", 157], ["A53", 163], ["T", 166], ["\u03b1", 168], ["-", 169], ["synuclein", 170], [",", 179], ["the", 181], ["brainstem", 185], ["and", 195], ["spinal", 199], ["cord", 206], ["develop", 211], ["the", 219], ["most", 223], ["prominent", 228], ["\u03b1", 238], ["-", 239], ["synuclein", 240], ["inclusions", 250], ["which", 261], ["correlate", 267], ["with", 277], ["age", 282], ["-", 285], ["dependent", 286], ["motor", 296], ["dysfunction", 302], [".", 313], ["Herein", 315], ["we", 322], ["present", 325], ["the", 333], ["novel", 337], ["finding", 343], ["that", 351], ["this", 356], ["selective", 361], ["aggregation", 371], ["is", 383], ["in", 386], ["part", 389], ["dependent", 394], ["on", 404], ["the", 407], ["inability", 411], ["of", 421], ["chaperone", 424], ["-", 433], ["mediated", 434], ["autophagy", 443], ["(", 453], ["CMA", 454], [")", 457], ["to", 459], ["effectively", 462], ["degrade", 474], ["\u03b1", 482], ["-", 483], ["synuclein", 484], ["in", 494], ["these", 497], ["brain", 503], ["regions", 509], [".", 516], ["Lysosomal", 518], ["assays", 528], ["revealed", 535], ["that", 544], ["CMA", 549], ["activity", 553], ["was", 562], ["significantly", 566], ["decreased", 580], ["in", 590], ["aggregation", 593], ["-", 604], ["prone", 605], ["regions", 611], ["compared", 619], ["to", 628], ["the", 631], ["remainder", 635], ["of", 645], ["the", 648], ["brain", 652], [".", 657], ["Previously", 659], [",", 669], ["CMA", 671], ["activity", 675], ["has", 684], ["been", 688], ["shown", 693], ["to", 699], ["be", 702], ["proportional", 705], ["to", 718], ["levels", 721], ["of", 728], ["the", 731], ["CMA", 735], ["receptor", 739], ["Lamp-2a", 748], [".", 755], ["Using", 757], ["antibodies", 763], [",", 773], ["brain", 775], ["tissue", 781], ["from", 788], ["Lamp-2a", 793], ["null", 801], ["mice", 806], [",", 810], ["enzymatic", 812], ["deglycosylation", 822], [",", 837], ["and", 839], ["mass", 843], ["spectrometry", 848], [",", 860], ["we", 862], ["identified", 865], ["Lamp2a", 876], ["as", 883], ["a", 886], ["novel", 888], ["72kDa", 894], ["glycoprotein", 900], ["in", 913], ["the", 916], ["mouse", 920], ["brain", 926], [".", 931], ["Examination", 933], ["of", 945], ["Lamp-2a", 948], ["levels", 956], ["revealed", 963], ["differences", 972], ["in", 984], ["expression", 987], ["across", 998], ["brain", 1005], ["regions", 1011], [".", 1018], ["The", 1020], ["brainstem", 1024], ["and", 1034], ["the", 1038], ["spinal", 1042], ["cord", 1049], ["had", 1054], ["a", 1058], ["more", 1060], ["than", 1065], ["three", 1070], ["-", 1075], ["fold", 1076], ["greater", 1081], ["levels", 1089], ["of", 1096], ["Lamp-2a", 1099], ["as", 1107], ["compared", 1110], ["to", 1119], ["regions", 1122], ["less", 1130], ["vulnerable", 1135], ["to", 1146], ["aggregation", 1149], ["and", 1161], ["exhibited", 1165], ["a", 1175], ["selective", 1177], ["upregulation", 1187], ["of", 1200], ["Lamp-2a", 1203], ["during", 1211], ["development", 1218], ["of", 1230], ["\u03b1", 1233], ["-", 1234], ["synuclein", 1235], ["inclusions", 1245], [".", 1255], ["Despite", 1257], ["this", 1265], ["dynamic", 1270], ["response", 1278], ["of", 1287], ["Lamp-2a", 1290], [",", 1297], ["the", 1299], ["levels", 1303], ["of", 1310], ["substrates", 1313], ["bound", 1324], ["to", 1330], ["the", 1333], ["brain", 1337], ["lysosomes", 1343], ["as", 1353], ["well", 1356], ["as", 1361], ["the", 1364], ["rates", 1368], ["of", 1374], ["substrate", 1377], ["uptake", 1387], ["and", 1394], ["degradation", 1398], ["were", 1410], ["not", 1415], ["proportional", 1419], ["to", 1432], ["the", 1435], ["levels", 1439], ["of", 1446], ["Lamp-2a", 1449], [".", 1456], ["These", 1458], ["regional", 1464], ["differences", 1473], ["in", 1485], ["CMA", 1488], ["activity", 1492], ["and", 1501], ["Lamp-2a", 1505], ["expression", 1513], ["were", 1524], ["found", 1529], ["in", 1535], ["both", 1538], ["non", 1543], ["-", 1546], ["transgenic", 1547], ["mice", 1558], ["as", 1563], ["well", 1566], ["as", 1571], ["A53", 1574], ["T", 1577], ["\u03b1", 1579], ["-", 1580], ["syn", 1581], ["mice", 1585], [".", 1589], ["Therefore", 1591], [",", 1600], ["these", 1602], ["are", 1608], ["inherent", 1612], ["variations", 1621], ["and", 1632], ["not", 1636], ["a", 1640], ["transgene", 1642], ["-", 1651], ["specific", 1652], ["effect", 1661], [".", 1667], ["However", 1669], [",", 1676], ["differences", 1678], ["in", 1690], ["CMA", 1693], ["activity", 1697], ["may", 1706], ["render", 1710], ["select", 1717], ["brain", 1724], ["regions", 1730], ["vulnerable", 1738], ["to", 1749], ["homeostatic", 1752], ["dysfunction", 1764], ["in", 1776], ["the", 1779], ["presence", 1783], ["of", 1792], ["stressors", 1795], ["such", 1805], ["as", 1810], ["overexpression", 1813], ["of", 1828], ["human", 1831], ["A53", 1837], ["T", 1840], ["\u03b1", 1842], ["-", 1843], ["syn", 1844], [".", 1847], ["Collectively", 1849], [",", 1861], ["the", 1863], ["data", 1867], ["provide", 1872], ["a", 1880], ["potential", 1882], ["mechanism", 1892], ["to", 1902], ["explain", 1905], ["the", 1913], ["dichotomy", 1917], ["of", 1927], ["vulnerability", 1930], ["or", 1944], ["resistance", 1947], ["that", 1958], ["underlies", 1963], ["brain", 1973], ["regions", 1979], ["during", 1987], ["aggregate", 1994], ["formation", 2004], ["in", 2014], ["neurodegenerative", 2017], ["disease", 2035], [".", 2042]]}
{"context": "The genetic disorders xeroderma pigmentosum (XP) and Cockayne syndrome (CS) exhibit deficiencies in the repair of UV-induced DNA damage. CS fibroblasts retain proficient nucleotide excision repair (NER) of inactive (or bulk) DNA, but are deficient in the transcription-coupled repair (TCR) of active genes. In contrast, XP complementation group C (XP-C) fibroblasts retain proficient TCR, but are deficient in bulk DNA repair. The remaining NER-deficient XP groups exhibit deficiencies in both repair pathways. Ad5HCMVsp1lacZ is a recombinant adenovirus vector that is unable to replicate in human fibroblasts, but can efficiently infect and express the beta-galactosidase reporter gene in these cells. We have examined the host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ in non-irradiated and UV-irradiated normal, XP-B, XP-C, XP-D, XP-F, XP-G, CS-A and CS-B fibroblasts. HCR of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ was reduced in non-irradiated cells from each of the repair-deficient groups examined (including XP-C) relative to that in non-irradiated normal cells. Prior irradiation of cells with low UV fluences resulted in an enhancement of HCR for normal and XP-C strains, but not for the remaining XP and CS strains. HCR of the UV-damaged reporter gene in UV-irradiated XP and CS strains was similar to measurements of TCR reported previously for these cells. These results suggest that UV treatment results in an induced repair of UV-damaged DNA in the transcribed strand of an active gene in XP-C and normal cells through an enhancement of TCR or a mechanism which involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "9ee2e86c5d1a4a1a9251990f2f2d84c6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[310, 311]], "char_spans": [[1531, 1548]]}]}], "context_tokens": [["The", 0], ["genetic", 4], ["disorders", 12], ["xeroderma", 22], ["pigmentosum", 32], ["(", 44], ["XP", 45], [")", 47], ["and", 49], ["Cockayne", 53], ["syndrome", 62], ["(", 71], ["CS", 72], [")", 74], ["exhibit", 76], ["deficiencies", 84], ["in", 97], ["the", 100], ["repair", 104], ["of", 111], ["UV", 114], ["-", 116], ["induced", 117], ["DNA", 125], ["damage", 129], [".", 135], ["CS", 137], ["fibroblasts", 140], ["retain", 152], ["proficient", 159], ["nucleotide", 170], ["excision", 181], ["repair", 190], ["(", 197], ["NER", 198], [")", 201], ["of", 203], ["inactive", 206], ["(", 215], ["or", 216], ["bulk", 219], [")", 223], ["DNA", 225], [",", 228], ["but", 230], ["are", 234], ["deficient", 238], ["in", 248], ["the", 251], ["transcription", 255], ["-", 268], ["coupled", 269], ["repair", 277], ["(", 284], ["TCR", 285], [")", 288], ["of", 290], ["active", 293], ["genes", 300], [".", 305], ["In", 307], ["contrast", 310], [",", 318], ["XP", 320], ["complementation", 323], ["group", 339], ["C", 345], ["(", 347], ["XP", 348], ["-", 350], ["C", 351], [")", 352], ["fibroblasts", 354], ["retain", 366], ["proficient", 373], ["TCR", 384], [",", 387], ["but", 389], ["are", 393], ["deficient", 397], ["in", 407], ["bulk", 410], ["DNA", 415], ["repair", 419], [".", 425], ["The", 427], ["remaining", 431], ["NER", 441], ["-", 444], ["deficient", 445], ["XP", 455], ["groups", 458], ["exhibit", 465], ["deficiencies", 473], ["in", 486], ["both", 489], ["repair", 494], ["pathways", 501], [".", 509], ["Ad5HCMVsp1lacZ", 511], ["is", 526], ["a", 529], ["recombinant", 531], ["adenovirus", 543], ["vector", 554], ["that", 561], ["is", 566], ["unable", 569], ["to", 576], ["replicate", 579], ["in", 589], ["human", 592], ["fibroblasts", 598], [",", 609], ["but", 611], ["can", 615], ["efficiently", 619], ["infect", 631], ["and", 638], ["express", 642], ["the", 650], ["beta", 654], ["-", 658], ["galactosidase", 659], ["reporter", 673], ["gene", 682], ["in", 687], ["these", 690], ["cells", 696], [".", 701], ["We", 703], ["have", 706], ["examined", 711], ["the", 720], ["host", 724], ["cell", 729], ["reactivation", 734], ["(", 747], ["HCR", 748], [")", 751], ["of", 753], ["beta", 756], ["-", 760], ["galactosidase", 761], ["activity", 775], ["for", 784], ["UV", 788], ["-", 790], ["irradiated", 791], ["Ad5HCMVsp1lacZ", 802], ["in", 817], ["non", 820], ["-", 823], ["irradiated", 824], ["and", 835], ["UV", 839], ["-", 841], ["irradiated", 842], ["normal", 853], [",", 859], ["XP", 861], ["-", 863], ["B", 864], [",", 865], ["XP", 867], ["-", 869], ["C", 870], [",", 871], ["XP", 873], ["-", 875], ["D", 876], [",", 877], ["XP", 879], ["-", 881], ["F", 882], [",", 883], ["XP", 885], ["-", 887], ["G", 888], [",", 889], ["CS", 891], ["-", 893], ["A", 894], ["and", 896], ["CS", 900], ["-", 902], ["B", 903], ["fibroblasts", 905], [".", 916], ["HCR", 918], ["of", 922], ["beta", 925], ["-", 929], ["galactosidase", 930], ["activity", 944], ["for", 953], ["UV", 957], ["-", 959], ["irradiated", 960], ["Ad5HCMVsp1lacZ", 971], ["was", 986], ["reduced", 990], ["in", 998], ["non", 1001], ["-", 1004], ["irradiated", 1005], ["cells", 1016], ["from", 1022], ["each", 1027], ["of", 1032], ["the", 1035], ["repair", 1039], ["-", 1045], ["deficient", 1046], ["groups", 1056], ["examined", 1063], ["(", 1072], ["including", 1073], ["XP", 1083], ["-", 1085], ["C", 1086], [")", 1087], ["relative", 1089], ["to", 1098], ["that", 1101], ["in", 1106], ["non", 1109], ["-", 1112], ["irradiated", 1113], ["normal", 1124], ["cells", 1131], [".", 1136], ["Prior", 1138], ["irradiation", 1144], ["of", 1156], ["cells", 1159], ["with", 1165], ["low", 1170], ["UV", 1174], ["fluences", 1177], ["resulted", 1186], ["in", 1195], ["an", 1198], ["enhancement", 1201], ["of", 1213], ["HCR", 1216], ["for", 1220], ["normal", 1224], ["and", 1231], ["XP", 1235], ["-", 1237], ["C", 1238], ["strains", 1240], [",", 1247], ["but", 1249], ["not", 1253], ["for", 1257], ["the", 1261], ["remaining", 1265], ["XP", 1275], ["and", 1278], ["CS", 1282], ["strains", 1285], [".", 1292], ["HCR", 1294], ["of", 1298], ["the", 1301], ["UV", 1305], ["-", 1307], ["damaged", 1308], ["reporter", 1316], ["gene", 1325], ["in", 1330], ["UV", 1333], ["-", 1335], ["irradiated", 1336], ["XP", 1347], ["and", 1350], ["CS", 1354], ["strains", 1357], ["was", 1365], ["similar", 1369], ["to", 1377], ["measurements", 1380], ["of", 1393], ["TCR", 1396], ["reported", 1400], ["previously", 1409], ["for", 1420], ["these", 1424], ["cells", 1430], [".", 1435], ["These", 1437], ["results", 1443], ["suggest", 1451], ["that", 1459], ["UV", 1464], ["treatment", 1467], ["results", 1477], ["in", 1485], ["an", 1488], ["induced", 1491], ["repair", 1499], ["of", 1506], ["UV", 1509], ["-", 1511], ["damaged", 1512], ["DNA", 1520], ["in", 1524], ["the", 1527], ["transcribed", 1531], ["strand", 1543], ["of", 1550], ["an", 1553], ["active", 1556], ["gene", 1563], ["in", 1568], ["XP", 1571], ["-", 1573], ["C", 1574], ["and", 1576], ["normal", 1580], ["cells", 1587], ["through", 1593], ["an", 1601], ["enhancement", 1604], ["of", 1616], ["TCR", 1619], ["or", 1623], ["a", 1626], ["mechanism", 1628], ["which", 1638], ["involves", 1644], ["the", 1653], ["TCR", 1657], ["pathway", 1661], [".", 1668]]}
{"context": "GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "301b11ff9a5742d3b24508da29ebffcd", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[229, 229], [5, 5], [74, 74], [124, 124], [281, 281], [158, 158], [255, 255]], "char_spans": [[1325, 1328], [26, 29], [459, 462], [712, 715], [1670, 1673], [930, 933], [1485, 1488]]}]}], "context_tokens": [["GATA-1", 0], ["and", 7], ["the", 11], ["ets", 15], ["factor", 19], ["PU.1", 26], ["have", 31], ["been", 36], ["reported", 41], ["to", 50], ["functionally", 53], ["antagonize", 66], ["one", 77], ["another", 81], ["in", 89], ["the", 92], ["regulation", 96], ["of", 107], ["erythroid", 110], ["versus", 120], ["myeloid", 127], ["gene", 135], ["transcription", 140], ["and", 154], ["development", 158], [".", 169], ["The", 171], ["CCAAT", 175], ["enhancer", 181], ["binding", 190], ["protein", 198], ["epsilon", 206], ["(", 214], ["C", 215], ["/", 216], ["EBPepsilon", 217], [")", 227], ["is", 229], ["expressed", 232], ["as", 242], ["multiple", 245], ["isoforms", 254], ["and", 263], ["has", 267], ["been", 271], ["shown", 276], ["to", 282], ["be", 285], ["essential", 288], ["to", 298], ["myeloid", 301], ["(", 309], ["granulocyte", 310], [")", 321], ["terminal", 323], ["differentiation", 332], [".", 347], ["We", 349], ["have", 352], ["defined", 357], ["a", 365], ["novel", 367], ["synergistic", 373], [",", 384], ["as", 386], ["opposed", 389], ["to", 397], ["antagonistic", 400], [",", 412], ["combinatorial", 414], ["interaction", 428], ["between", 440], ["GATA-1", 448], ["and", 455], ["PU.1", 459], [",", 463], ["and", 465], ["a", 469], ["unique", 471], ["repressor", 478], ["role", 488], ["for", 493], ["certain", 497], ["C", 505], ["/", 506], ["EBPepsilon", 507], ["isoforms", 518], ["in", 527], ["the", 530], ["transcriptional", 534], ["regulation", 550], ["of", 561], ["a", 564], ["model", 566], ["eosinophil", 572], ["granulocyte", 583], ["gene", 595], [",", 599], ["the", 601], ["major", 605], ["basic", 611], ["protein", 617], ["(", 625], ["MBP", 626], [")", 629], [".", 630], ["The", 632], ["eosinophil", 636], ["-", 646], ["specific", 647], ["P2", 656], ["promoter", 659], ["of", 668], ["the", 671], ["MBP", 675], ["gene", 679], ["contains", 684], ["GATA-1", 693], [",", 699], ["C", 701], ["/", 702], ["EBP", 703], [",", 706], ["and", 708], ["PU.1", 712], ["consensus", 717], ["sites", 727], ["that", 733], ["bind", 738], ["these", 743], ["factors", 749], ["in", 757], ["nuclear", 760], ["extracts", 768], ["of", 777], ["the", 780], ["eosinophil", 784], ["myelocyte", 795], ["cell", 805], ["line", 810], [",", 814], ["AML14.3D10", 816], [".", 826], ["The", 828], ["promoter", 832], ["is", 841], ["transactivated", 844], ["by", 859], ["GATA-1", 862], ["alone", 869], ["but", 875], ["is", 879], ["synergistically", 882], ["transactivated", 898], ["by", 913], ["low", 916], ["levels", 920], ["of", 927], ["PU.1", 930], ["in", 935], ["the", 938], ["context", 942], ["of", 950], ["optimal", 953], ["levels", 961], ["of", 968], ["GATA-1", 971], [".", 977], ["The", 979], ["C", 983], ["/", 984], ["EBPepsilon(27", 985], [")", 998], ["isoform", 1000], ["strongly", 1008], ["represses", 1017], ["GATA-1", 1027], ["activity", 1034], ["and", 1043], ["completely", 1047], ["blocks", 1058], ["GATA-1/PU.1", 1065], ["synergy", 1077], [".", 1084], ["In", 1086], ["vitro", 1089], ["mutational", 1095], ["analyses", 1106], ["of", 1115], ["the", 1118], ["MBP", 1122], ["-", 1125], ["P2", 1126], ["promoter", 1129], ["showed", 1138], ["that", 1145], ["both", 1150], ["the", 1155], ["GATA-1/PU.1", 1159], ["synergy", 1171], [",", 1178], ["and", 1180], ["repressor", 1184], ["activity", 1194], ["of", 1203], ["C", 1206], ["/", 1207], ["EBPepsilon(27", 1208], [")", 1221], ["are", 1223], ["mediated", 1227], ["via", 1236], ["protein", 1240], ["-", 1247], ["protein", 1248], ["interactions", 1256], ["through", 1269], ["the", 1277], ["C", 1281], ["/", 1282], ["EBP", 1283], ["and/or", 1287], ["GATA", 1294], ["-", 1298], ["binding", 1299], ["sites", 1307], ["but", 1313], ["not", 1317], ["the", 1321], ["PU.1", 1325], ["sites", 1330], [".", 1335], ["Co", 1337], ["-", 1339], ["immunoprecipitations", 1340], ["using", 1361], ["lysates", 1367], ["of", 1375], ["AML14.3D10", 1378], ["eosinophils", 1389], ["show", 1401], ["that", 1406], ["both", 1411], ["C", 1416], ["/", 1417], ["EBPepsilon(32/30", 1418], [")", 1434], ["and", 1436], ["epsilon(27", 1440], [")", 1450], ["physically", 1452], ["interact", 1463], ["in", 1472], ["vivo", 1475], ["with", 1480], ["PU.1", 1485], ["and", 1490], ["GATA-1", 1494], [",", 1500], ["demonstrating", 1502], ["functional", 1516], ["interactions", 1527], ["among", 1540], ["these", 1546], ["factors", 1552], ["in", 1560], ["eosinophil", 1563], ["progenitors", 1574], [".", 1585], ["Our", 1587], ["findings", 1591], ["identify", 1600], ["novel", 1609], ["combinatorial", 1615], ["protein", 1629], ["-", 1636], ["protein", 1637], ["interactions", 1645], ["for", 1658], ["GATA-1", 1662], [",", 1668], ["PU.1", 1670], [",", 1674], ["and", 1676], ["C", 1680], ["/", 1681], ["EBPepsilon", 1682], ["isoforms", 1693], ["in", 1702], ["eosinophil", 1705], ["gene", 1716], ["transcription", 1721], ["that", 1735], ["include", 1740], ["GATA-1/PU.1", 1748], ["synergy", 1760], ["and", 1768], ["repressor", 1772], ["activity", 1782], ["for", 1791], ["C", 1795], ["/", 1796], ["EBPepsilon(27", 1797], [")", 1810], [".", 1811]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "The approval of the oral direct thrombin inhibitor, dabigatran etexilate, gave patients an alternative to oral anticoagulation with warfarin. Like all anticoagulants, the primary adverse event (AE) associated with dabigatran is bleeding. Until the FDA approval of idarucizumab, there had been no reversal agent for dabigatran-induced anticoagulation in patients with life-threatening or uncontrollable bleeding, or those requiring emergent procedures. The primary purpose of this review is to summarize the safety and efficacy of idarucizumab, a monoclonal antibody fragment, and its use as a reversal agent for dabigatran. A literature search was conducted through MEDLINE (1946 to November week 1 2015) and Embase (1980-2015 week 46) using the search term idarucizumab. Clinicaltrials.gov was consulted for a comprehensive list of ongoing and completed studies. Additional studies were identified through bibliographical citations. Clinical trials in animals and humans published in English evaluating the safety and efficacy of idarucizumab for reversal of anticoagulant treatment with dabigatran were included for review. Idarucizumab has been shown to significantly reverse the anticoagulant effects of dabigatran in both healthy volunteers and patients requiring a reversal agent because of either overt bleeding or an emergency surgery or invasive procedure. The most common AEs were headache, nasopharyngitis, back pain, skin irritation, hypokalemia, delirium, constipation, pyrexia, and pneumonia. Deaths reported in idarucizumab studies were attributed to either the index event or a preexisting comorbidity. Most adverse effects were minor, but 21 serious AEs have been reported in the published data including thrombotic events. Given the increased use of direct oral anticoagulants, such as dabigatran, a need for specific reversal agents exists. Idarucizumab has been shown to be safe and effective in the reversal of dabigatran-induced anticoagulation in patients requiring emergent or urgent surgery or in patients with severe bleeding.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2e849ad8ec784301ae7f31f0261ab00e", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[35, 35], [53, 53], [102, 102], [293, 293], [316, 316], [9, 9], [194, 194], [177, 177]], "char_spans": [[214, 223], [315, 324], [612, 621], [1804, 1813], [1932, 1941], [52, 61], [1208, 1217], [1089, 1098]]}]}], "context_tokens": [["The", 0], ["approval", 4], ["of", 13], ["the", 16], ["oral", 20], ["direct", 25], ["thrombin", 32], ["inhibitor", 41], [",", 50], ["dabigatran", 52], ["etexilate", 63], [",", 72], ["gave", 74], ["patients", 79], ["an", 88], ["alternative", 91], ["to", 103], ["oral", 106], ["anticoagulation", 111], ["with", 127], ["warfarin", 132], [".", 140], ["Like", 142], ["all", 147], ["anticoagulants", 151], [",", 165], ["the", 167], ["primary", 171], ["adverse", 179], ["event", 187], ["(", 193], ["AE", 194], [")", 196], ["associated", 198], ["with", 209], ["dabigatran", 214], ["is", 225], ["bleeding", 228], [".", 236], ["Until", 238], ["the", 244], ["FDA", 248], ["approval", 252], ["of", 261], ["idarucizumab", 264], [",", 276], ["there", 278], ["had", 284], ["been", 288], ["no", 293], ["reversal", 296], ["agent", 305], ["for", 311], ["dabigatran", 315], ["-", 325], ["induced", 326], ["anticoagulation", 334], ["in", 350], ["patients", 353], ["with", 362], ["life", 367], ["-", 371], ["threatening", 372], ["or", 384], ["uncontrollable", 387], ["bleeding", 402], [",", 410], ["or", 412], ["those", 415], ["requiring", 421], ["emergent", 431], ["procedures", 440], [".", 450], ["The", 452], ["primary", 456], ["purpose", 464], ["of", 472], ["this", 475], ["review", 480], ["is", 487], ["to", 490], ["summarize", 493], ["the", 503], ["safety", 507], ["and", 514], ["efficacy", 518], ["of", 527], ["idarucizumab", 530], [",", 542], ["a", 544], ["monoclonal", 546], ["antibody", 557], ["fragment", 566], [",", 574], ["and", 576], ["its", 580], ["use", 584], ["as", 588], ["a", 591], ["reversal", 593], ["agent", 602], ["for", 608], ["dabigatran", 612], [".", 622], ["A", 624], ["literature", 626], ["search", 637], ["was", 644], ["conducted", 648], ["through", 658], ["MEDLINE", 666], ["(", 674], ["1946", 675], ["to", 680], ["November", 683], ["week", 692], ["1", 697], ["2015", 699], [")", 703], ["and", 705], ["Embase", 709], ["(", 716], ["1980", 717], ["-", 721], ["2015", 722], ["week", 727], ["46", 732], [")", 734], ["using", 736], ["the", 742], ["search", 746], ["term", 753], ["idarucizumab", 758], [".", 770], ["Clinicaltrials.gov", 772], ["was", 791], ["consulted", 795], ["for", 805], ["a", 809], ["comprehensive", 811], ["list", 825], ["of", 830], ["ongoing", 833], ["and", 841], ["completed", 845], ["studies", 855], [".", 862], ["Additional", 864], ["studies", 875], ["were", 883], ["identified", 888], ["through", 899], ["bibliographical", 907], ["citations", 923], [".", 932], ["Clinical", 934], ["trials", 943], ["in", 950], ["animals", 953], ["and", 961], ["humans", 965], ["published", 972], ["in", 982], ["English", 985], ["evaluating", 993], ["the", 1004], ["safety", 1008], ["and", 1015], ["efficacy", 1019], ["of", 1028], ["idarucizumab", 1031], ["for", 1044], ["reversal", 1048], ["of", 1057], ["anticoagulant", 1060], ["treatment", 1074], ["with", 1084], ["dabigatran", 1089], ["were", 1100], ["included", 1105], ["for", 1114], ["review", 1118], [".", 1124], ["Idarucizumab", 1126], ["has", 1139], ["been", 1143], ["shown", 1148], ["to", 1154], ["significantly", 1157], ["reverse", 1171], ["the", 1179], ["anticoagulant", 1183], ["effects", 1197], ["of", 1205], ["dabigatran", 1208], ["in", 1219], ["both", 1222], ["healthy", 1227], ["volunteers", 1235], ["and", 1246], ["patients", 1250], ["requiring", 1259], ["a", 1269], ["reversal", 1271], ["agent", 1280], ["because", 1286], ["of", 1294], ["either", 1297], ["overt", 1304], ["bleeding", 1310], ["or", 1319], ["an", 1322], ["emergency", 1325], ["surgery", 1335], ["or", 1343], ["invasive", 1346], ["procedure", 1355], [".", 1364], ["The", 1366], ["most", 1370], ["common", 1375], ["AEs", 1382], ["were", 1386], ["headache", 1391], [",", 1399], ["nasopharyngitis", 1401], [",", 1416], ["back", 1418], ["pain", 1423], [",", 1427], ["skin", 1429], ["irritation", 1434], [",", 1444], ["hypokalemia", 1446], [",", 1457], ["delirium", 1459], [",", 1467], ["constipation", 1469], [",", 1481], ["pyrexia", 1483], [",", 1490], ["and", 1492], ["pneumonia", 1496], [".", 1505], ["Deaths", 1507], ["reported", 1514], ["in", 1523], ["idarucizumab", 1526], ["studies", 1539], ["were", 1547], ["attributed", 1552], ["to", 1563], ["either", 1566], ["the", 1573], ["index", 1577], ["event", 1583], ["or", 1589], ["a", 1592], ["preexisting", 1594], ["comorbidity", 1606], [".", 1617], ["Most", 1619], ["adverse", 1624], ["effects", 1632], ["were", 1640], ["minor", 1645], [",", 1650], ["but", 1652], ["21", 1656], ["serious", 1659], ["AEs", 1667], ["have", 1671], ["been", 1676], ["reported", 1681], ["in", 1690], ["the", 1693], ["published", 1697], ["data", 1707], ["including", 1712], ["thrombotic", 1722], ["events", 1733], [".", 1739], ["Given", 1741], ["the", 1747], ["increased", 1751], ["use", 1761], ["of", 1765], ["direct", 1768], ["oral", 1775], ["anticoagulants", 1780], [",", 1794], ["such", 1796], ["as", 1801], ["dabigatran", 1804], [",", 1814], ["a", 1816], ["need", 1818], ["for", 1823], ["specific", 1827], ["reversal", 1836], ["agents", 1845], ["exists", 1852], [".", 1858], ["Idarucizumab", 1860], ["has", 1873], ["been", 1877], ["shown", 1882], ["to", 1888], ["be", 1891], ["safe", 1894], ["and", 1899], ["effective", 1903], ["in", 1913], ["the", 1916], ["reversal", 1920], ["of", 1929], ["dabigatran", 1932], ["-", 1942], ["induced", 1943], ["anticoagulation", 1951], ["in", 1967], ["patients", 1970], ["requiring", 1979], ["emergent", 1989], ["or", 1998], ["urgent", 2001], ["surgery", 2008], ["or", 2016], ["in", 2019], ["patients", 2022], ["with", 2031], ["severe", 2036], ["bleeding", 2043], [".", 2051]]}
{"context": "Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models. The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. Bronchoalveolar lavage fluid was obtained from 40 neonates affected by hyaline membrane disease, infections, or meconium aspiration and divided in 4 aliquots added with increasing varespladib or saline. sPLA2 activity, proteins, and albumin were measured. Dilution was corrected with the urea ratio. Varespladib was also tested in vitro against pancreatic sPLA2 mixed with different albumin concentration. Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P < .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M. An inverse relationship existed between protein level and activity reduction (r = 0.5; P = .029). The activity reduction/protein ratio tended to be higher in hyaline membrane disease. Varespladib efficacy was higher in vitro than in lavage fluids obtained from neonates (P < .001).", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "1aedf35d15b449439a4efb13c4c5ebd0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], [",", 34], ["which", 36], ["links", 42], ["surfactant", 48], ["catabolism", 59], ["and", 70], ["lung", 74], ["inflammation", 79], [",", 91], ["is", 93], ["associated", 96], ["with", 107], ["lung", 112], ["stiffness", 117], [",", 126], ["surfactant", 128], ["dysfunction", 139], [",", 150], ["and", 152], ["degree", 156], ["of", 163], ["respiratory", 166], ["support", 178], ["in", 186], ["acute", 189], ["respiratory", 195], ["distress", 207], ["syndrome", 216], ["and", 225], ["in", 229], ["some", 232], ["forms", 237], ["of", 243], ["neonatal", 246], ["lung", 255], ["injury", 260], [".", 266], ["Varespladib", 268], ["potently", 280], ["inhibits", 289], ["sPLA2", 298], ["in", 304], ["animal", 307], ["models", 314], [".", 320], ["The", 322], ["authors", 326], ["investigate", 334], ["varespladib", 346], ["ex", 358], ["vivo", 361], ["efficacy", 366], ["in", 375], ["different", 378], ["forms", 388], ["of", 394], ["neonatal", 397], ["lung", 406], ["injury", 411], [".", 417], ["Bronchoalveolar", 419], ["lavage", 435], ["fluid", 442], ["was", 448], ["obtained", 452], ["from", 461], ["40", 466], ["neonates", 469], ["affected", 478], ["by", 487], ["hyaline", 490], ["membrane", 498], ["disease", 507], [",", 514], ["infections", 516], [",", 526], ["or", 528], ["meconium", 531], ["aspiration", 540], ["and", 551], ["divided", 555], ["in", 563], ["4", 566], ["aliquots", 568], ["added", 577], ["with", 583], ["increasing", 588], ["varespladib", 599], ["or", 611], ["saline", 614], [".", 620], ["sPLA2", 622], ["activity", 628], [",", 636], ["proteins", 638], [",", 646], ["and", 648], ["albumin", 652], ["were", 660], ["measured", 665], [".", 673], ["Dilution", 675], ["was", 684], ["corrected", 688], ["with", 698], ["the", 703], ["urea", 707], ["ratio", 712], [".", 717], ["Varespladib", 719], ["was", 731], ["also", 735], ["tested", 740], ["in", 747], ["vitro", 750], ["against", 756], ["pancreatic", 764], ["sPLA2", 775], ["mixed", 781], ["with", 787], ["different", 792], ["albumin", 802], ["concentration", 810], [".", 823], ["Varespladib", 825], ["was", 837], ["able", 841], ["to", 846], ["inhibit", 849], ["sPLA2", 857], ["in", 863], ["the", 866], ["types", 870], ["of", 876], ["neonatal", 879], ["lung", 888], ["injury", 893], ["investigated", 900], [".", 912], ["sPLA2", 914], ["activity", 920], ["was", 929], ["reduced", 933], ["in", 941], ["hyaline", 944], ["membrane", 952], ["disease", 961], ["(", 969], ["P", 970], ["<", 972], [".0001", 974], [")", 979], [",", 980], ["infections", 982], ["(", 993], ["P", 994], ["=", 996], [".003", 998], [")", 1002], [",", 1003], ["and", 1005], ["meconium", 1009], ["aspiration", 1018], ["(", 1029], ["P", 1030], ["=", 1032], [".04", 1034], [")", 1037], ["using", 1039], ["40", 1045], ["\u00b5M", 1048], ["varespladib", 1051], [";", 1062], ["10", 1064], ["\u00b5M", 1067], ["was", 1070], ["able", 1074], ["to", 1079], ["lower", 1082], ["enzyme", 1088], ["activity", 1095], ["(", 1104], ["P", 1105], ["=", 1107], [".001", 1109], [")", 1113], [",", 1114], ["with", 1116], ["an", 1121], ["IC(50", 1124], [")", 1129], ["of", 1131], ["87", 1134], ["\u00b5M.", 1137], ["An", 1141], ["inverse", 1144], ["relationship", 1152], ["existed", 1165], ["between", 1173], ["protein", 1181], ["level", 1189], ["and", 1195], ["activity", 1199], ["reduction", 1208], ["(", 1218], ["r", 1219], ["=", 1221], ["0.5", 1223], [";", 1226], ["P", 1228], ["=", 1230], [".029", 1232], [")", 1236], [".", 1237], ["The", 1239], ["activity", 1243], ["reduction", 1252], ["/", 1261], ["protein", 1262], ["ratio", 1270], ["tended", 1276], ["to", 1283], ["be", 1286], ["higher", 1289], ["in", 1296], ["hyaline", 1299], ["membrane", 1307], ["disease", 1316], [".", 1323], ["Varespladib", 1325], ["efficacy", 1337], ["was", 1346], ["higher", 1350], ["in", 1357], ["vitro", 1360], ["than", 1366], ["in", 1371], ["lavage", 1374], ["fluids", 1381], ["obtained", 1388], ["from", 1397], ["neonates", 1402], ["(", 1411], ["P", 1412], ["<", 1414], [".001", 1416], [")", 1420], [".", 1421]]}
{"context": "Neurofibromatosis type 1 (NF1) is one of the most common human genetic disorders and is associated with significant morbidity and mortality. The gene responsible for this disorder, NF1, encodes neurofibromin, which can function to down-regulate ras activity. Mutations that inactivate NF7 result in elevated levels of ras signaling and increased cell proliferation in some tissues. NF7 functions as a tumor suppressor gene; patients inherit one mutated copy and are believed to acquire a \"second hit\" in tissues that go on to form benign or malignant tumors. NF7 is expressed widely, yet certain tissues are more susceptible to growth dysregulation in NF1 patients. Cardiovascular defects also contribute to NF1, though the cause remains unclear. In a recent study, we used tissue-specific gene inactivation in mice to study the role of neurofibromin in heart development. A further understanding of neurofibromin function will help to elucidate the pathophysiology of NF1 and will also lead to a better understanding of cell cycle regulation and ras pathways in specific cell types. Finally, we comment on how similar genetic strategies can be used in mice to study the role of additional signaling pathways involved in heart development.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "85c02eb57c7c40d099713e942323c658", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[123, 123], [115, 115], [4, 4], [168, 168], [31, 31]], "char_spans": [[708, 710], [652, 654], [26, 28], [969, 971], [181, 183]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["one", 34], ["of", 38], ["the", 41], ["most", 45], ["common", 50], ["human", 57], ["genetic", 63], ["disorders", 71], ["and", 81], ["is", 85], ["associated", 88], ["with", 99], ["significant", 104], ["morbidity", 116], ["and", 126], ["mortality", 130], [".", 139], ["The", 141], ["gene", 145], ["responsible", 150], ["for", 162], ["this", 166], ["disorder", 171], [",", 179], ["NF1", 181], [",", 184], ["encodes", 186], ["neurofibromin", 194], [",", 207], ["which", 209], ["can", 215], ["function", 219], ["to", 228], ["down", 231], ["-", 235], ["regulate", 236], ["ras", 245], ["activity", 249], [".", 257], ["Mutations", 259], ["that", 269], ["inactivate", 274], ["NF7", 285], ["result", 289], ["in", 296], ["elevated", 299], ["levels", 308], ["of", 315], ["ras", 318], ["signaling", 322], ["and", 332], ["increased", 336], ["cell", 346], ["proliferation", 351], ["in", 365], ["some", 368], ["tissues", 373], [".", 380], ["NF7", 382], ["functions", 386], ["as", 396], ["a", 399], ["tumor", 401], ["suppressor", 407], ["gene", 418], [";", 422], ["patients", 424], ["inherit", 433], ["one", 441], ["mutated", 445], ["copy", 453], ["and", 458], ["are", 462], ["believed", 466], ["to", 475], ["acquire", 478], ["a", 486], ["\"", 488], ["second", 489], ["hit", 496], ["\"", 499], ["in", 501], ["tissues", 504], ["that", 512], ["go", 517], ["on", 520], ["to", 523], ["form", 526], ["benign", 531], ["or", 538], ["malignant", 541], ["tumors", 551], [".", 557], ["NF7", 559], ["is", 563], ["expressed", 566], ["widely", 576], [",", 582], ["yet", 584], ["certain", 588], ["tissues", 596], ["are", 604], ["more", 608], ["susceptible", 613], ["to", 625], ["growth", 628], ["dysregulation", 635], ["in", 649], ["NF1", 652], ["patients", 656], [".", 664], ["Cardiovascular", 666], ["defects", 681], ["also", 689], ["contribute", 694], ["to", 705], ["NF1", 708], [",", 711], ["though", 713], ["the", 720], ["cause", 724], ["remains", 730], ["unclear", 738], [".", 745], ["In", 747], ["a", 750], ["recent", 752], ["study", 759], [",", 764], ["we", 766], ["used", 769], ["tissue", 774], ["-", 780], ["specific", 781], ["gene", 790], ["inactivation", 795], ["in", 808], ["mice", 811], ["to", 816], ["study", 819], ["the", 825], ["role", 829], ["of", 834], ["neurofibromin", 837], ["in", 851], ["heart", 854], ["development", 860], [".", 871], ["A", 873], ["further", 875], ["understanding", 883], ["of", 897], ["neurofibromin", 900], ["function", 914], ["will", 923], ["help", 928], ["to", 933], ["elucidate", 936], ["the", 946], ["pathophysiology", 950], ["of", 966], ["NF1", 969], ["and", 973], ["will", 977], ["also", 982], ["lead", 987], ["to", 992], ["a", 995], ["better", 997], ["understanding", 1004], ["of", 1018], ["cell", 1021], ["cycle", 1026], ["regulation", 1032], ["and", 1043], ["ras", 1047], ["pathways", 1051], ["in", 1060], ["specific", 1063], ["cell", 1072], ["types", 1077], [".", 1082], ["Finally", 1084], [",", 1091], ["we", 1093], ["comment", 1096], ["on", 1104], ["how", 1107], ["similar", 1111], ["genetic", 1119], ["strategies", 1127], ["can", 1138], ["be", 1142], ["used", 1145], ["in", 1150], ["mice", 1153], ["to", 1158], ["study", 1161], ["the", 1167], ["role", 1171], ["of", 1176], ["additional", 1179], ["signaling", 1190], ["pathways", 1200], ["involved", 1209], ["in", 1218], ["heart", 1221], ["development", 1227], [".", 1238]]}
{"context": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites. The aim of this study was to assess the morphology and distribution of alpha-synuclein immunoreactivity in cases of dementia with LB (DLB), and to compare alpha-synuclein with ubiquitin immunostaining. We examined substantia nigra, paralimbic regions (entorhinal cortex, cingulate gyrus, insula and hippocampus), and neocortex (frontal and occipital association cortices) with double alpha-synuclein and ubiquitin immunostaining in 25 cases meeting neuropathological criteria for DLB. alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles. It was also slightly more sensitive, staining 4-5% more intracytoplasmic structures, especially diffuse alpha-synuclein deposits that were ubiquitin negative. In addition to LB, alpha-synuclein staining showed filiform and globose neurites in the substantia nigra, CA2-3 regions of the hippocampus, and entorhinal cortex. A spectrum of alpha-synuclein staining was seen in substantia nigra: from diffuse \"cloud-like\" inclusions to aggregated intracytoplasmic inclusions with variable ubiquitin staining to classic LB. We hypothesize that these represent different stages in LB formation.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "657d5d7eecf249cb96e36f5b3a818fcf", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[36, 38], [142, 144], [156, 158], [53, 55], [90, 92], [105, 107], [185, 187], [0, 2]], "char_spans": [[195, 209], [843, 857], [917, 931], [279, 293], [508, 522], [609, 623], [1075, 1089], [0, 14]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["is", 16], ["a", 19], ["presynaptic", 21], ["protein", 33], ["recently", 41], ["identified", 50], ["as", 61], ["a", 64], ["specific", 66], ["component", 75], ["of", 85], ["Lewy", 88], ["bodies", 93], ["(", 100], ["LB", 101], [")", 103], ["and", 105], ["Lewy", 109], ["neurites", 114], [".", 122], ["The", 124], ["aim", 128], ["of", 132], ["this", 135], ["study", 140], ["was", 146], ["to", 150], ["assess", 153], ["the", 160], ["morphology", 164], ["and", 175], ["distribution", 179], ["of", 192], ["alpha", 195], ["-", 200], ["synuclein", 201], ["immunoreactivity", 211], ["in", 228], ["cases", 231], ["of", 237], ["dementia", 240], ["with", 249], ["LB", 254], ["(", 257], ["DLB", 258], [")", 261], [",", 262], ["and", 264], ["to", 268], ["compare", 271], ["alpha", 279], ["-", 284], ["synuclein", 285], ["with", 295], ["ubiquitin", 300], ["immunostaining", 310], [".", 324], ["We", 326], ["examined", 329], ["substantia", 338], ["nigra", 349], [",", 354], ["paralimbic", 356], ["regions", 367], ["(", 375], ["entorhinal", 376], ["cortex", 387], [",", 393], ["cingulate", 395], ["gyrus", 405], [",", 410], ["insula", 412], ["and", 419], ["hippocampus", 423], [")", 434], [",", 435], ["and", 437], ["neocortex", 441], ["(", 451], ["frontal", 452], ["and", 460], ["occipital", 464], ["association", 474], ["cortices", 486], [")", 494], ["with", 496], ["double", 501], ["alpha", 508], ["-", 513], ["synuclein", 514], ["and", 524], ["ubiquitin", 528], ["immunostaining", 538], ["in", 553], ["25", 556], ["cases", 559], ["meeting", 565], ["neuropathological", 573], ["criteria", 591], ["for", 600], ["DLB", 604], [".", 607], ["alpha", 609], ["-", 614], ["Synuclein", 615], ["immunostaining", 625], ["was", 640], ["more", 644], ["specific", 649], ["than", 658], ["ubiquitin", 663], ["immunostaining", 673], ["in", 688], ["that", 691], ["it", 696], ["differentiated", 699], ["LB", 714], ["from", 717], ["globose", 722], ["tangles", 730], [".", 737], ["It", 739], ["was", 742], ["also", 746], ["slightly", 751], ["more", 760], ["sensitive", 765], [",", 774], ["staining", 776], ["4", 785], ["-", 786], ["5", 787], ["%", 788], ["more", 790], ["intracytoplasmic", 795], ["structures", 812], [",", 822], ["especially", 824], ["diffuse", 835], ["alpha", 843], ["-", 848], ["synuclein", 849], ["deposits", 859], ["that", 868], ["were", 873], ["ubiquitin", 878], ["negative", 888], [".", 896], ["In", 898], ["addition", 901], ["to", 910], ["LB", 913], [",", 915], ["alpha", 917], ["-", 922], ["synuclein", 923], ["staining", 933], ["showed", 942], ["filiform", 949], ["and", 958], ["globose", 962], ["neurites", 970], ["in", 979], ["the", 982], ["substantia", 986], ["nigra", 997], [",", 1002], ["CA2", 1004], ["-", 1007], ["3", 1008], ["regions", 1010], ["of", 1018], ["the", 1021], ["hippocampus", 1025], [",", 1036], ["and", 1038], ["entorhinal", 1042], ["cortex", 1053], [".", 1059], ["A", 1061], ["spectrum", 1063], ["of", 1072], ["alpha", 1075], ["-", 1080], ["synuclein", 1081], ["staining", 1091], ["was", 1100], ["seen", 1104], ["in", 1109], ["substantia", 1112], ["nigra", 1123], [":", 1128], ["from", 1130], ["diffuse", 1135], ["\"", 1143], ["cloud", 1144], ["-", 1149], ["like", 1150], ["\"", 1154], ["inclusions", 1156], ["to", 1167], ["aggregated", 1170], ["intracytoplasmic", 1181], ["inclusions", 1198], ["with", 1209], ["variable", 1214], ["ubiquitin", 1223], ["staining", 1233], ["to", 1242], ["classic", 1245], ["LB", 1253], [".", 1255], ["We", 1257], ["hypothesize", 1260], ["that", 1272], ["these", 1277], ["represent", 1283], ["different", 1293], ["stages", 1303], ["in", 1310], ["LB", 1313], ["formation", 1316], [".", 1325]]}
{"context": "Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. It comprises Ehlers-Danlos syndrome type I and Ehlers-Danlos syndrome type II, but it is now apparent that these form a continuum of clinical findings and differ only in phenotypic severity. It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene, encoding the \u03b11 and the \u03b12-chain of type V collagen, respectively. However, because no prospective molecular studies of COL5A1 and COL5A2 have been performed in a clinically well-defined patient group, this number may underestimate the real proportion of patients with classic Ehlers-Danlos syndrome harboring a mutation in one of these genes. In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen. A smaller proportion of patients harbor a structural mutation in COL5A1 or COL5A2, causing the production of a functionally defective type V collagen protein. Most mutations identified so far result in a reduced amount of type V collagen in the connective tissues available for collagen fibrillogenesis. Inter- and intrafamilial phenotypic variability is observed, but no genotype-phenotype correlations have been observed. No treatment for the underlying defect is presently available for Ehlers-Danlos syndrome. However, a series of preventive guidelines are applicable.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "90435bdf04fb46fd88c52fcb14d2c478", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[46, 62]]}]}], "context_tokens": [["Classic", 0], ["Ehlers", 8], ["-", 14], ["Danlos", 15], ["syndrome", 22], ["is", 31], ["a", 34], ["heritable", 36], ["connective", 46], ["tissue", 57], ["disorder", 64], ["characterized", 73], ["by", 87], ["skin", 90], ["hyperextensibility", 95], [",", 113], ["fragile", 115], ["and", 123], ["soft", 127], ["skin", 132], [",", 136], ["delayed", 138], ["wound", 146], ["healing", 152], ["with", 160], ["formation", 165], ["of", 175], ["atrophic", 178], ["scars", 187], [",", 192], ["easy", 194], ["bruising", 199], [",", 207], ["and", 209], ["generalized", 213], ["joint", 225], ["hypermobility", 231], [".", 244], ["It", 246], ["comprises", 249], ["Ehlers", 259], ["-", 265], ["Danlos", 266], ["syndrome", 273], ["type", 282], ["I", 287], ["and", 289], ["Ehlers", 293], ["-", 299], ["Danlos", 300], ["syndrome", 307], ["type", 316], ["II", 321], [",", 323], ["but", 325], ["it", 329], ["is", 332], ["now", 335], ["apparent", 339], ["that", 348], ["these", 353], ["form", 359], ["a", 364], ["continuum", 366], ["of", 376], ["clinical", 379], ["findings", 388], ["and", 397], ["differ", 401], ["only", 408], ["in", 413], ["phenotypic", 416], ["severity", 427], [".", 435], ["It", 437], ["is", 440], ["currently", 443], ["estimated", 453], ["that", 463], ["approximately", 468], ["50", 482], ["%", 484], ["of", 486], ["patients", 489], ["with", 498], ["a", 503], ["clinical", 505], ["diagnosis", 514], ["of", 524], ["classic", 527], ["Ehlers", 535], ["-", 541], ["Danlos", 542], ["syndrome", 549], ["harbor", 558], ["mutations", 565], ["in", 575], ["the", 578], ["COL5A1", 582], ["and", 589], ["the", 593], ["COL5A2", 597], ["gene", 604], [",", 608], ["encoding", 610], ["the", 619], ["\u03b11", 623], ["and", 626], ["the", 630], ["\u03b12-chain", 634], ["of", 643], ["type", 646], ["V", 651], ["collagen", 653], [",", 661], ["respectively", 663], [".", 675], ["However", 677], [",", 684], ["because", 686], ["no", 694], ["prospective", 697], ["molecular", 709], ["studies", 719], ["of", 727], ["COL5A1", 730], ["and", 737], ["COL5A2", 741], ["have", 748], ["been", 753], ["performed", 758], ["in", 768], ["a", 771], ["clinically", 773], ["well", 784], ["-", 788], ["defined", 789], ["patient", 797], ["group", 805], [",", 810], ["this", 812], ["number", 817], ["may", 824], ["underestimate", 828], ["the", 842], ["real", 846], ["proportion", 851], ["of", 862], ["patients", 865], ["with", 874], ["classic", 879], ["Ehlers", 887], ["-", 893], ["Danlos", 894], ["syndrome", 901], ["harboring", 910], ["a", 920], ["mutation", 922], ["in", 931], ["one", 934], ["of", 938], ["these", 941], ["genes", 947], [".", 952], ["In", 954], ["the", 957], ["majority", 961], ["of", 970], ["patients", 973], ["with", 982], ["molecularly", 987], ["characterized", 999], ["classic", 1013], ["Ehlers", 1021], ["-", 1027], ["Danlos", 1028], ["syndrome", 1035], [",", 1043], ["the", 1045], ["disease", 1049], ["is", 1057], ["caused", 1060], ["by", 1067], ["a", 1070], ["mutation", 1072], ["leading", 1081], ["to", 1089], ["a", 1092], ["nonfunctional", 1094], ["COL5A1", 1108], ["allele", 1115], ["and", 1122], ["resulting", 1126], ["in", 1136], ["haploinsufficiency", 1139], ["of", 1158], ["type", 1161], ["V", 1166], ["collagen", 1168], [".", 1176], ["A", 1178], ["smaller", 1180], ["proportion", 1188], ["of", 1199], ["patients", 1202], ["harbor", 1211], ["a", 1218], ["structural", 1220], ["mutation", 1231], ["in", 1240], ["COL5A1", 1243], ["or", 1250], ["COL5A2", 1253], [",", 1259], ["causing", 1261], ["the", 1269], ["production", 1273], ["of", 1284], ["a", 1287], ["functionally", 1289], ["defective", 1302], ["type", 1312], ["V", 1317], ["collagen", 1319], ["protein", 1328], [".", 1335], ["Most", 1337], ["mutations", 1342], ["identified", 1352], ["so", 1363], ["far", 1366], ["result", 1370], ["in", 1377], ["a", 1380], ["reduced", 1382], ["amount", 1390], ["of", 1397], ["type", 1400], ["V", 1405], ["collagen", 1407], ["in", 1416], ["the", 1419], ["connective", 1423], ["tissues", 1434], ["available", 1442], ["for", 1452], ["collagen", 1456], ["fibrillogenesis", 1465], [".", 1480], ["Inter-", 1482], ["and", 1489], ["intrafamilial", 1493], ["phenotypic", 1507], ["variability", 1518], ["is", 1530], ["observed", 1533], [",", 1541], ["but", 1543], ["no", 1547], ["genotype", 1550], ["-", 1558], ["phenotype", 1559], ["correlations", 1569], ["have", 1582], ["been", 1587], ["observed", 1592], [".", 1600], ["No", 1602], ["treatment", 1605], ["for", 1615], ["the", 1619], ["underlying", 1623], ["defect", 1634], ["is", 1641], ["presently", 1644], ["available", 1654], ["for", 1664], ["Ehlers", 1668], ["-", 1674], ["Danlos", 1675], ["syndrome", 1682], [".", 1690], ["However", 1692], [",", 1699], ["a", 1701], ["series", 1703], ["of", 1710], ["preventive", 1713], ["guidelines", 1724], ["are", 1735], ["applicable", 1739], [".", 1749]]}
{"context": "Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f60b00cd2c9944dc95889093639a4381", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[102, 104], [142, 144], [211, 213], [93, 95], [13, 15], [226, 228], [82, 84], [127, 129]], "char_spans": [[609, 615], [847, 853], [1224, 1230], [569, 575], [93, 99], [1290, 1296], [506, 512], [766, 772]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["developed", 13], ["as", 23], ["the", 26], ["first", 30], ["molecularly", 36], ["targeted", 48], ["therapy", 57], ["to", 65], ["specifically", 68], ["inhibit", 81], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["kinase", 101], ["in", 108], ["Philadelphia", 111], ["chromosome", 124], ["(", 135], ["Ph)-positive", 136], ["chronic", 149], ["myeloid", 157], ["leukemia", 165], ["(", 174], ["CML", 175], [")", 178], [".", 179], ["Because", 181], ["of", 189], ["the", 192], ["excellent", 196], ["hematologic", 206], ["and", 218], ["cytogenetic", 222], ["responses", 234], [",", 243], ["imatinib", 245], ["has", 254], ["moved", 258], ["toward", 264], ["first", 271], ["-", 276], ["line", 277], ["treatment", 282], ["for", 292], ["newly", 296], ["diagnosed", 302], ["CML", 312], [".", 315], ["However", 317], [",", 324], ["the", 326], ["emergence", 330], ["of", 340], ["resistance", 343], ["to", 354], ["imatinib", 357], ["remains", 366], ["a", 374], ["major", 376], ["problem", 382], ["in", 390], ["the", 393], ["treatment", 397], ["of", 407], ["Ph", 410], ["-", 412], ["positive", 413], ["leukemia", 422], [".", 430], ["Several", 432], ["mechanisms", 440], ["of", 451], ["imatinib", 454], ["resistance", 463], ["have", 474], ["been", 479], ["identified", 484], [",", 494], ["including", 496], ["BCR", 506], ["-", 509], ["ABL", 510], ["gene", 514], ["amplification", 519], ["that", 533], ["leads", 538], ["to", 544], ["overexpression", 547], ["of", 562], ["the", 565], ["BCR", 569], ["-", 572], ["ABL", 573], ["protein", 577], [",", 584], ["point", 586], ["mutations", 592], ["in", 602], ["the", 605], ["BCR", 609], ["-", 612], ["ABL", 613], ["kinase", 617], ["domain", 624], ["that", 631], ["interfere", 636], ["with", 646], ["imatinib", 651], ["binding", 660], [",", 667], ["and", 669], ["point", 673], ["mutations", 679], ["outside", 689], ["of", 697], ["the", 700], ["kinase", 704], ["domain", 711], ["that", 718], ["allosterically", 723], ["inhibit", 738], ["imatinib", 746], ["binding", 755], ["to", 763], ["BCR", 766], ["-", 769], ["ABL", 770], [".", 773], ["The", 775], ["need", 779], ["for", 784], ["alternative", 788], ["or", 800], ["additional", 803], ["treatment", 814], ["for", 824], ["imatinib", 828], ["-", 836], ["resistant", 837], ["BCR", 847], ["-", 850], ["ABL", 851], ["-", 854], ["positive", 855], ["leukemia", 864], ["has", 873], ["guided", 877], ["the", 884], ["way", 888], ["to", 892], ["the", 895], ["design", 899], ["of", 906], ["a", 909], ["second", 911], ["generation", 918], ["of", 929], ["targeted", 932], ["therapies", 941], [",", 950], ["which", 952], ["has", 958], ["resulted", 962], ["mainly", 971], ["in", 978], ["the", 981], ["development", 985], ["of", 997], ["novel", 1000], ["small", 1006], ["-", 1011], ["molecule", 1012], ["inhibitors", 1021], ["such", 1032], ["as", 1037], ["AMN107", 1040], [",", 1046], ["dasatinib", 1048], [",", 1057], ["NS-187", 1059], [",", 1065], ["and", 1067], ["ON012380", 1071], [".", 1079], ["The", 1081], ["major", 1085], ["goal", 1091], ["of", 1096], ["these", 1099], ["efforts", 1105], ["is", 1113], ["to", 1116], ["create", 1119], ["new", 1126], ["compounds", 1130], ["that", 1140], ["are", 1145], ["more", 1149], ["potent", 1154], ["than", 1161], ["imatinib", 1166], ["and/or", 1175], ["more", 1182], ["effective", 1187], ["against", 1197], ["imatinib", 1205], ["-", 1213], ["resistant", 1214], ["BCR", 1224], ["-", 1227], ["ABL", 1228], ["clones", 1232], [".", 1238], ["In", 1240], ["this", 1243], ["review", 1248], [",", 1254], ["we", 1256], ["discuss", 1259], ["the", 1267], ["next", 1271], ["generation", 1276], ["of", 1287], ["BCR", 1290], ["-", 1293], ["ABL", 1294], ["kinase", 1298], ["inhibitors", 1305], ["for", 1316], ["overcoming", 1320], ["imatinib", 1331], ["resistance", 1340], [".", 1350]]}
{"context": "A central goal of evolutionary biology is to understand the genetic origin of morphological novelties-i.e. anatomical structures unique to a taxonomic group. Elaboration of morphology during development depends on networks of regulatory genes that activate patterned gene expression through transcriptional enhancer regions. We summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise. We also discuss how these enhancer-originating mechanisms have clarified the history of genetic networks underlying diversification of genital structures in flies, limbs and neural crest in chordates, and plant leaves. These studies have identified enhancers that were pivotal for morphological divergence and highlighted how novel genetic networks shaping form emerged from pre-existing ones.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "444e58e7c396480e8fcad64fbbced173", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[65, 65], [107, 107]], "char_spans": [[445, 453], [711, 719]]}]}], "context_tokens": [["A", 0], ["central", 2], ["goal", 10], ["of", 15], ["evolutionary", 18], ["biology", 31], ["is", 39], ["to", 42], ["understand", 45], ["the", 56], ["genetic", 60], ["origin", 68], ["of", 75], ["morphological", 78], ["novelties", 92], ["-", 101], ["i.e", 102], [".", 105], ["anatomical", 107], ["structures", 118], ["unique", 129], ["to", 136], ["a", 139], ["taxonomic", 141], ["group", 151], [".", 156], ["Elaboration", 158], ["of", 170], ["morphology", 173], ["during", 184], ["development", 191], ["depends", 203], ["on", 211], ["networks", 214], ["of", 223], ["regulatory", 226], ["genes", 237], ["that", 243], ["activate", 248], ["patterned", 257], ["gene", 267], ["expression", 272], ["through", 283], ["transcriptional", 291], ["enhancer", 307], ["regions", 316], [".", 323], ["We", 325], ["summarize", 328], ["recent", 338], ["case", 345], ["studies", 350], ["and", 358], ["genome", 362], ["-", 368], ["wide", 369], ["investigations", 374], ["that", 389], ["have", 394], ["uncovered", 399], ["diverse", 409], ["mechanisms", 417], ["though", 428], ["which", 435], ["new", 441], ["enhancers", 445], ["arise", 455], [".", 460], ["We", 462], ["also", 465], ["discuss", 470], ["how", 478], ["these", 482], ["enhancer", 488], ["-", 496], ["originating", 497], ["mechanisms", 509], ["have", 520], ["clarified", 525], ["the", 535], ["history", 539], ["of", 547], ["genetic", 550], ["networks", 558], ["underlying", 567], ["diversification", 578], ["of", 594], ["genital", 597], ["structures", 605], ["in", 616], ["flies", 619], [",", 624], ["limbs", 626], ["and", 632], ["neural", 636], ["crest", 643], ["in", 649], ["chordates", 652], [",", 661], ["and", 663], ["plant", 667], ["leaves", 673], [".", 679], ["These", 681], ["studies", 687], ["have", 695], ["identified", 700], ["enhancers", 711], ["that", 721], ["were", 726], ["pivotal", 731], ["for", 739], ["morphological", 743], ["divergence", 757], ["and", 768], ["highlighted", 772], ["how", 784], ["novel", 788], ["genetic", 794], ["networks", 802], ["shaping", 811], ["form", 819], ["emerged", 824], ["from", 832], ["pre", 837], ["-", 840], ["existing", 841], ["ones", 850], [".", 854]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS is thought to proceed from a primarily disordered state with nascent secondary structure through intermediate conformations to oligomeric forms and finally to mature amyloid fibrils. Low pH conditions lead to conformational changes associated with increased alphaS fibril formation. Here we characterize these structural and dynamic changes using solution state NMR measurements of secondary chemical shifts, relaxation parameters, residual dipolar couplings, and paramagnetic relaxation enhancement. We find that the neutralization of negatively charged side-chains eliminates electrostatic repulsion in the C-terminal tail of alphaS and leads to a collapse of this region at low pH. Hydrophobic contacts between the compact C-terminal tail and the NAC (non-amyloid-beta component) region are maintained and may lead to the formation of a globular domain. Transient long-range contacts between the C-terminus of the protein and regions N-terminal to the NAC region are also preserved. Thus, the release of long-range contacts does not play a role in the increased aggregation of alphaS at low pH, which we instead attribute to the increased hydrophobicity of the protein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "49df234dddfb4af6b70443ee0df3e00d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["alphaS", 17], [")", 23], ["is", 25], ["the", 28], ["primary", 32], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["Disease", 107], [".", 114], ["Aggregation", 116], ["of", 128], ["alphaS", 131], ["is", 138], ["thought", 141], ["to", 149], ["proceed", 152], ["from", 160], ["a", 165], ["primarily", 167], ["disordered", 177], ["state", 188], ["with", 194], ["nascent", 199], ["secondary", 207], ["structure", 217], ["through", 227], ["intermediate", 235], ["conformations", 248], ["to", 262], ["oligomeric", 265], ["forms", 276], ["and", 282], ["finally", 286], ["to", 294], ["mature", 297], ["amyloid", 304], ["fibrils", 312], [".", 319], ["Low", 321], ["pH", 325], ["conditions", 328], ["lead", 339], ["to", 344], ["conformational", 347], ["changes", 362], ["associated", 370], ["with", 381], ["increased", 386], ["alphaS", 396], ["fibril", 403], ["formation", 410], [".", 419], ["Here", 421], ["we", 426], ["characterize", 429], ["these", 442], ["structural", 448], ["and", 459], ["dynamic", 463], ["changes", 471], ["using", 479], ["solution", 485], ["state", 494], ["NMR", 500], ["measurements", 504], ["of", 517], ["secondary", 520], ["chemical", 530], ["shifts", 539], [",", 545], ["relaxation", 547], ["parameters", 558], [",", 568], ["residual", 570], ["dipolar", 579], ["couplings", 587], [",", 596], ["and", 598], ["paramagnetic", 602], ["relaxation", 615], ["enhancement", 626], [".", 637], ["We", 639], ["find", 642], ["that", 647], ["the", 652], ["neutralization", 656], ["of", 671], ["negatively", 674], ["charged", 685], ["side", 693], ["-", 697], ["chains", 698], ["eliminates", 705], ["electrostatic", 716], ["repulsion", 730], ["in", 740], ["the", 743], ["C", 747], ["-", 748], ["terminal", 749], ["tail", 758], ["of", 763], ["alphaS", 766], ["and", 773], ["leads", 777], ["to", 783], ["a", 786], ["collapse", 788], ["of", 797], ["this", 800], ["region", 805], ["at", 812], ["low", 815], ["pH.", 819], ["Hydrophobic", 823], ["contacts", 835], ["between", 844], ["the", 852], ["compact", 856], ["C", 864], ["-", 865], ["terminal", 866], ["tail", 875], ["and", 880], ["the", 884], ["NAC", 888], ["(", 892], ["non", 893], ["-", 896], ["amyloid", 897], ["-", 904], ["beta", 905], ["component", 910], [")", 919], ["region", 921], ["are", 928], ["maintained", 932], ["and", 943], ["may", 947], ["lead", 951], ["to", 956], ["the", 959], ["formation", 963], ["of", 973], ["a", 976], ["globular", 978], ["domain", 987], [".", 993], ["Transient", 995], ["long", 1005], ["-", 1009], ["range", 1010], ["contacts", 1016], ["between", 1025], ["the", 1033], ["C", 1037], ["-", 1038], ["terminus", 1039], ["of", 1048], ["the", 1051], ["protein", 1055], ["and", 1063], ["regions", 1067], ["N", 1075], ["-", 1076], ["terminal", 1077], ["to", 1086], ["the", 1089], ["NAC", 1093], ["region", 1097], ["are", 1104], ["also", 1108], ["preserved", 1113], [".", 1122], ["Thus", 1124], [",", 1128], ["the", 1130], ["release", 1134], ["of", 1142], ["long", 1145], ["-", 1149], ["range", 1150], ["contacts", 1156], ["does", 1165], ["not", 1170], ["play", 1174], ["a", 1179], ["role", 1181], ["in", 1186], ["the", 1189], ["increased", 1193], ["aggregation", 1203], ["of", 1215], ["alphaS", 1218], ["at", 1225], ["low", 1228], ["pH", 1232], [",", 1234], ["which", 1236], ["we", 1242], ["instead", 1245], ["attribute", 1253], ["to", 1263], ["the", 1266], ["increased", 1270], ["hydrophobicity", 1280], ["of", 1295], ["the", 1298], ["protein", 1302], [".", 1309]]}
{"context": "Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The hallmark of CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene, which, in turn, is translated into a chimeric Bcr-Abl protein with deregulated tyrosine kinase activity. Constitutive Bcr-Abl expression has been shown to be necessary and sufficient for the transformed phenotype of CML cells. CML is unique among human cancers in that a single genetic defect, the Ph chromosome, is responsible for the transformed phenotype. Since this discovery more than 40 years ago, our understanding of the clinical course, therapy, and prognosis of patients with CML has changed significantly. These changes have culminated in the emergence of imatinib, the first rationally designed, molecularly targeted therapy for human malignancy. In this review, the authors describe the molecular biology of CML and the development of imatinib as a therapeutic agent for the treatment of CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d4a15945d8304a3898c6f391152041af", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[85, 87], [69, 71], [96, 98]], "char_spans": [[476, 482], [409, 415], [548, 554]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["results", 35], ["from", 43], ["the", 48], ["neoplastic", 52], ["transformation", 63], ["of", 78], ["primitive", 81], ["hematopoietic", 91], ["stem", 105], ["cells", 110], [",", 115], ["and", 117], ["has", 121], ["been", 125], ["classified", 130], ["as", 141], ["a", 144], ["myeloproliferative", 146], ["disorder", 165], [".", 173], ["The", 175], ["hallmark", 179], ["of", 188], ["CML", 191], ["is", 195], ["the", 198], ["presence", 202], ["of", 211], ["a", 214], ["balanced", 216], ["translocation", 225], ["between", 239], ["the", 247], ["long", 251], ["arms", 256], ["of", 261], ["chromosomes", 264], ["9", 276], ["and", 278], ["22", 282], [",", 284], ["t(9;22)(q34;q11.2", 286], [")", 303], [",", 304], ["which", 306], ["is", 312], ["known", 315], ["as", 321], ["the", 324], ["Philadelphia", 328], ["(", 341], ["Ph", 342], [")", 344], ["chromosome", 346], [".", 356], ["This", 358], ["translocation", 363], ["results", 377], ["in", 385], ["the", 388], ["formation", 392], ["of", 402], ["the", 405], ["bcr", 409], ["-", 412], ["abl", 413], ["fusion", 417], ["gene", 424], [",", 428], ["which", 430], [",", 435], ["in", 437], ["turn", 440], [",", 444], ["is", 446], ["translated", 449], ["into", 460], ["a", 465], ["chimeric", 467], ["Bcr", 476], ["-", 479], ["Abl", 480], ["protein", 484], ["with", 492], ["deregulated", 497], ["tyrosine", 509], ["kinase", 518], ["activity", 525], [".", 533], ["Constitutive", 535], ["Bcr", 548], ["-", 551], ["Abl", 552], ["expression", 556], ["has", 567], ["been", 571], ["shown", 576], ["to", 582], ["be", 585], ["necessary", 588], ["and", 598], ["sufficient", 602], ["for", 613], ["the", 617], ["transformed", 621], ["phenotype", 633], ["of", 643], ["CML", 646], ["cells", 650], [".", 655], ["CML", 657], ["is", 661], ["unique", 664], ["among", 671], ["human", 677], ["cancers", 683], ["in", 691], ["that", 694], ["a", 699], ["single", 701], ["genetic", 708], ["defect", 716], [",", 722], ["the", 724], ["Ph", 728], ["chromosome", 731], [",", 741], ["is", 743], ["responsible", 746], ["for", 758], ["the", 762], ["transformed", 766], ["phenotype", 778], [".", 787], ["Since", 789], ["this", 795], ["discovery", 800], ["more", 810], ["than", 815], ["40", 820], ["years", 823], ["ago", 829], [",", 832], ["our", 834], ["understanding", 838], ["of", 852], ["the", 855], ["clinical", 859], ["course", 868], [",", 874], ["therapy", 876], [",", 883], ["and", 885], ["prognosis", 889], ["of", 899], ["patients", 902], ["with", 911], ["CML", 916], ["has", 920], ["changed", 924], ["significantly", 932], [".", 945], ["These", 947], ["changes", 953], ["have", 961], ["culminated", 966], ["in", 977], ["the", 980], ["emergence", 984], ["of", 994], ["imatinib", 997], [",", 1005], ["the", 1007], ["first", 1011], ["rationally", 1017], ["designed", 1028], [",", 1036], ["molecularly", 1038], ["targeted", 1050], ["therapy", 1059], ["for", 1067], ["human", 1071], ["malignancy", 1077], [".", 1087], ["In", 1089], ["this", 1092], ["review", 1097], [",", 1103], ["the", 1105], ["authors", 1109], ["describe", 1117], ["the", 1126], ["molecular", 1130], ["biology", 1140], ["of", 1148], ["CML", 1151], ["and", 1155], ["the", 1159], ["development", 1163], ["of", 1175], ["imatinib", 1178], ["as", 1187], ["a", 1190], ["therapeutic", 1192], ["agent", 1204], ["for", 1210], ["the", 1214], ["treatment", 1218], ["of", 1228], ["CML", 1231], [".", 1234]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "The transcriptional networks that regulate embryonic stem (ES) cell pluripotency and lineage specification are the subject of considerable attention. To date such studies have focused almost exclusively on protein-coding transcripts. However, recent transcriptome analyses show that the mammalian genome contains thousands of long noncoding RNAs (ncRNAs), many of which appear to be expressed in a developmentally regulated manner. The functions of these remain untested. To identify ncRNAs involved in ES cell biology, we used a custom-designed microarray to examine the expression profiles of mouse ES cells differentiating as embryoid bodies (EBs) over a 16-d time course. We identified 945 ncRNAs expressed during EB differentiation, of which 174 were differentially expressed, many correlating with pluripotency or specific differentiation events. Candidate ncRNAs were identified for further characterization by an integrated examination of expression profiles, genomic context, chromatin state, and promoter analysis. Many ncRNAs showed coordinated expression with genomically associated developmental genes, such as Dlx1, Dlx4, Gata6, and Ecsit. We examined two novel developmentally regulated ncRNAs, Evx1as and Hoxb5/6as, which are derived from homeotic loci and share similar expression patterns and localization in mouse embryos with their associated protein-coding genes. Using chromatin immunoprecipitation, we provide evidence that both ncRNAs are associated with trimethylated H3K4 histones and histone methyltransferase MLL1, suggesting a role in epigenetic regulation of homeotic loci during ES cell differentiation. Taken together, our data indicate that long ncRNAs are likely to be important in processes directing pluripotency and alternative differentiation programs, in some cases through engagement of the epigenetic machinery.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "7f852a929e6a4b24adcfac462afb1477", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[236, 236]], "char_spans": [[1493, 1496]]}]}], "context_tokens": [["The", 0], ["transcriptional", 4], ["networks", 20], ["that", 29], ["regulate", 34], ["embryonic", 43], ["stem", 53], ["(", 58], ["ES", 59], [")", 61], ["cell", 63], ["pluripotency", 68], ["and", 81], ["lineage", 85], ["specification", 93], ["are", 107], ["the", 111], ["subject", 115], ["of", 123], ["considerable", 126], ["attention", 139], [".", 148], ["To", 150], ["date", 153], ["such", 158], ["studies", 163], ["have", 171], ["focused", 176], ["almost", 184], ["exclusively", 191], ["on", 203], ["protein", 206], ["-", 213], ["coding", 214], ["transcripts", 221], [".", 232], ["However", 234], [",", 241], ["recent", 243], ["transcriptome", 250], ["analyses", 264], ["show", 273], ["that", 278], ["the", 283], ["mammalian", 287], ["genome", 297], ["contains", 304], ["thousands", 313], ["of", 323], ["long", 326], ["noncoding", 331], ["RNAs", 341], ["(", 346], ["ncRNAs", 347], [")", 353], [",", 354], ["many", 356], ["of", 361], ["which", 364], ["appear", 370], ["to", 377], ["be", 380], ["expressed", 383], ["in", 393], ["a", 396], ["developmentally", 398], ["regulated", 414], ["manner", 424], [".", 430], ["The", 432], ["functions", 436], ["of", 446], ["these", 449], ["remain", 455], ["untested", 462], [".", 470], ["To", 472], ["identify", 475], ["ncRNAs", 484], ["involved", 491], ["in", 500], ["ES", 503], ["cell", 506], ["biology", 511], [",", 518], ["we", 520], ["used", 523], ["a", 528], ["custom", 530], ["-", 536], ["designed", 537], ["microarray", 546], ["to", 557], ["examine", 560], ["the", 568], ["expression", 572], ["profiles", 583], ["of", 592], ["mouse", 595], ["ES", 601], ["cells", 604], ["differentiating", 610], ["as", 626], ["embryoid", 629], ["bodies", 638], ["(", 645], ["EBs", 646], [")", 649], ["over", 651], ["a", 656], ["16-d", 658], ["time", 663], ["course", 668], [".", 674], ["We", 676], ["identified", 679], ["945", 690], ["ncRNAs", 694], ["expressed", 701], ["during", 711], ["EB", 718], ["differentiation", 721], [",", 736], ["of", 738], ["which", 741], ["174", 747], ["were", 751], ["differentially", 756], ["expressed", 771], [",", 780], ["many", 782], ["correlating", 787], ["with", 799], ["pluripotency", 804], ["or", 817], ["specific", 820], ["differentiation", 829], ["events", 845], [".", 851], ["Candidate", 853], ["ncRNAs", 863], ["were", 870], ["identified", 875], ["for", 886], ["further", 890], ["characterization", 898], ["by", 915], ["an", 918], ["integrated", 921], ["examination", 932], ["of", 944], ["expression", 947], ["profiles", 958], [",", 966], ["genomic", 968], ["context", 976], [",", 983], ["chromatin", 985], ["state", 995], [",", 1000], ["and", 1002], ["promoter", 1006], ["analysis", 1015], [".", 1023], ["Many", 1025], ["ncRNAs", 1030], ["showed", 1037], ["coordinated", 1044], ["expression", 1056], ["with", 1067], ["genomically", 1072], ["associated", 1084], ["developmental", 1095], ["genes", 1109], [",", 1114], ["such", 1116], ["as", 1121], ["Dlx1", 1124], [",", 1128], ["Dlx4", 1130], [",", 1134], ["Gata6", 1136], [",", 1141], ["and", 1143], ["Ecsit", 1147], [".", 1152], ["We", 1154], ["examined", 1157], ["two", 1166], ["novel", 1170], ["developmentally", 1176], ["regulated", 1192], ["ncRNAs", 1202], [",", 1208], ["Evx1as", 1210], ["and", 1217], ["Hoxb5/6as", 1221], [",", 1230], ["which", 1232], ["are", 1238], ["derived", 1242], ["from", 1250], ["homeotic", 1255], ["loci", 1264], ["and", 1269], ["share", 1273], ["similar", 1279], ["expression", 1287], ["patterns", 1298], ["and", 1307], ["localization", 1311], ["in", 1324], ["mouse", 1327], ["embryos", 1333], ["with", 1341], ["their", 1346], ["associated", 1352], ["protein", 1363], ["-", 1370], ["coding", 1371], ["genes", 1378], [".", 1383], ["Using", 1385], ["chromatin", 1391], ["immunoprecipitation", 1401], [",", 1420], ["we", 1422], ["provide", 1425], ["evidence", 1433], ["that", 1442], ["both", 1447], ["ncRNAs", 1452], ["are", 1459], ["associated", 1463], ["with", 1474], ["trimethylated", 1479], ["H3K4", 1493], ["histones", 1498], ["and", 1507], ["histone", 1511], ["methyltransferase", 1519], ["MLL1", 1537], [",", 1541], ["suggesting", 1543], ["a", 1554], ["role", 1556], ["in", 1561], ["epigenetic", 1564], ["regulation", 1575], ["of", 1586], ["homeotic", 1589], ["loci", 1598], ["during", 1603], ["ES", 1610], ["cell", 1613], ["differentiation", 1618], [".", 1633], ["Taken", 1635], ["together", 1641], [",", 1649], ["our", 1651], ["data", 1655], ["indicate", 1660], ["that", 1669], ["long", 1674], ["ncRNAs", 1679], ["are", 1686], ["likely", 1690], ["to", 1697], ["be", 1700], ["important", 1703], ["in", 1713], ["processes", 1716], ["directing", 1726], ["pluripotency", 1736], ["and", 1749], ["alternative", 1753], ["differentiation", 1765], ["programs", 1781], [",", 1789], ["in", 1791], ["some", 1794], ["cases", 1799], ["through", 1805], ["engagement", 1813], ["of", 1824], ["the", 1827], ["epigenetic", 1831], ["machinery", 1842], [".", 1851]]}
{"context": "Ataxin-3, the disease protein in the neurodegenerative disorder Spinocerebellar Ataxia Type 3 or Machado Joseph disease, is a cysteine protease implicated in the ubiquitin proteasome pathway. It contains multiple ubiquitin binding sites through which it anchors polyubiquitin chains of different linkages that are then cleaved by the N-terminal catalytic (Josephin) domain. The properties of the ubiquitin interacting motifs (UIMs) in the C-terminus of ataxin-3 are well established. Very little is known, however, about how two recently identified ubiquitin-binding sites in the Josephin domain contribute to ubiquitin chain binding and cleavage. In the current study, we sought to define the specific contribution of the Josephin domain to the catalytic properties of ataxin-3 and assess how the topology and affinity of these binding sites modulate ataxin-3 activity. Using NMR we modeled the structure of diUb/Josephin complexes and showed that linkage preferences are imposed by the topology of the two binding sites. Enzymatic studies further helped us to determine a precise hierarchy between the sites. We establish that the structure of Josephin dictates specificity for K48-linked chains. Site 1, which is close to the active site, is indispensable for cleavage. Our studies open the way to understand better the cellular function of ataxin-3 and its link to pathology.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5e25c3d45f5646e79edcd84d6308a178", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [227, 227], [75, 75], [142, 142], [129, 129]], "char_spans": [[0, 7], [1344, 1351], [453, 460], [852, 859], [770, 777]]}]}], "context_tokens": [["Ataxin-3", 0], [",", 8], ["the", 10], ["disease", 14], ["protein", 22], ["in", 30], ["the", 33], ["neurodegenerative", 37], ["disorder", 55], ["Spinocerebellar", 64], ["Ataxia", 80], ["Type", 87], ["3", 92], ["or", 94], ["Machado", 97], ["Joseph", 105], ["disease", 112], [",", 119], ["is", 121], ["a", 124], ["cysteine", 126], ["protease", 135], ["implicated", 144], ["in", 155], ["the", 158], ["ubiquitin", 162], ["proteasome", 172], ["pathway", 183], [".", 190], ["It", 192], ["contains", 195], ["multiple", 204], ["ubiquitin", 213], ["binding", 223], ["sites", 231], ["through", 237], ["which", 245], ["it", 251], ["anchors", 254], ["polyubiquitin", 262], ["chains", 276], ["of", 283], ["different", 286], ["linkages", 296], ["that", 305], ["are", 310], ["then", 314], ["cleaved", 319], ["by", 327], ["the", 330], ["N", 334], ["-", 335], ["terminal", 336], ["catalytic", 345], ["(", 355], ["Josephin", 356], [")", 364], ["domain", 366], [".", 372], ["The", 374], ["properties", 378], ["of", 389], ["the", 392], ["ubiquitin", 396], ["interacting", 406], ["motifs", 418], ["(", 425], ["UIMs", 426], [")", 430], ["in", 432], ["the", 435], ["C", 439], ["-", 440], ["terminus", 441], ["of", 450], ["ataxin-3", 453], ["are", 462], ["well", 466], ["established", 471], [".", 482], ["Very", 484], ["little", 489], ["is", 496], ["known", 499], [",", 504], ["however", 506], [",", 513], ["about", 515], ["how", 521], ["two", 525], ["recently", 529], ["identified", 538], ["ubiquitin", 549], ["-", 558], ["binding", 559], ["sites", 567], ["in", 573], ["the", 576], ["Josephin", 580], ["domain", 589], ["contribute", 596], ["to", 607], ["ubiquitin", 610], ["chain", 620], ["binding", 626], ["and", 634], ["cleavage", 638], [".", 646], ["In", 648], ["the", 651], ["current", 655], ["study", 663], [",", 668], ["we", 670], ["sought", 673], ["to", 680], ["define", 683], ["the", 690], ["specific", 694], ["contribution", 703], ["of", 716], ["the", 719], ["Josephin", 723], ["domain", 732], ["to", 739], ["the", 742], ["catalytic", 746], ["properties", 756], ["of", 767], ["ataxin-3", 770], ["and", 779], ["assess", 783], ["how", 790], ["the", 794], ["topology", 798], ["and", 807], ["affinity", 811], ["of", 820], ["these", 823], ["binding", 829], ["sites", 837], ["modulate", 843], ["ataxin-3", 852], ["activity", 861], [".", 869], ["Using", 871], ["NMR", 877], ["we", 881], ["modeled", 884], ["the", 892], ["structure", 896], ["of", 906], ["diUb", 909], ["/", 913], ["Josephin", 914], ["complexes", 923], ["and", 933], ["showed", 937], ["that", 944], ["linkage", 949], ["preferences", 957], ["are", 969], ["imposed", 973], ["by", 981], ["the", 984], ["topology", 988], ["of", 997], ["the", 1000], ["two", 1004], ["binding", 1008], ["sites", 1016], [".", 1021], ["Enzymatic", 1023], ["studies", 1033], ["further", 1041], ["helped", 1049], ["us", 1056], ["to", 1059], ["determine", 1062], ["a", 1072], ["precise", 1074], ["hierarchy", 1082], ["between", 1092], ["the", 1100], ["sites", 1104], [".", 1109], ["We", 1111], ["establish", 1114], ["that", 1124], ["the", 1129], ["structure", 1133], ["of", 1143], ["Josephin", 1146], ["dictates", 1155], ["specificity", 1164], ["for", 1176], ["K48-linked", 1180], ["chains", 1191], [".", 1197], ["Site", 1199], ["1", 1204], [",", 1205], ["which", 1207], ["is", 1213], ["close", 1216], ["to", 1222], ["the", 1225], ["active", 1229], ["site", 1236], [",", 1240], ["is", 1242], ["indispensable", 1245], ["for", 1259], ["cleavage", 1263], [".", 1271], ["Our", 1273], ["studies", 1277], ["open", 1285], ["the", 1290], ["way", 1294], ["to", 1298], ["understand", 1301], ["better", 1312], ["the", 1319], ["cellular", 1323], ["function", 1332], ["of", 1341], ["ataxin-3", 1344], ["and", 1353], ["its", 1357], ["link", 1361], ["to", 1366], ["pathology", 1369], [".", 1378]]}
{"context": "Dot1 is an evolutionarily conserved histone methyltransferase that methylates lysine-79 of histone H3 in the core domain. Unlike other histone methyltransferases, Dot1 does not contain a SET domain, and it specifically methylates nucleosomal histone H3. We have solved a 2.5 A resolution structure of the catalytic domain of human Dot1, hDOT1L, in complex with S-adenosyl-L-methionine (SAM). The structure reveals a unique organization of a mainly alpha-helical N-terminal domain and a central open alpha/beta structure, an active site consisting of a SAM binding pocket, and a potential lysine binding channel. We also show that a flexible, positively charged region at the C terminus of the catalytic domain is critical for nucleosome binding and enzymatic activity. These structural and biochemical analyses, combined with molecular modeling, provide mechanistic insights into the catalytic mechanism and nucleosomal specificity of Dot1 proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "aa7139e1cfe6425786610c4bf1781099", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[28, 29]], "char_spans": [[187, 196]]}]}], "context_tokens": [["Dot1", 0], ["is", 5], ["an", 8], ["evolutionarily", 11], ["conserved", 26], ["histone", 36], ["methyltransferase", 44], ["that", 62], ["methylates", 67], ["lysine-79", 78], ["of", 88], ["histone", 91], ["H3", 99], ["in", 102], ["the", 105], ["core", 109], ["domain", 114], [".", 120], ["Unlike", 122], ["other", 129], ["histone", 135], ["methyltransferases", 143], [",", 161], ["Dot1", 163], ["does", 168], ["not", 173], ["contain", 177], ["a", 185], ["SET", 187], ["domain", 191], [",", 197], ["and", 199], ["it", 203], ["specifically", 206], ["methylates", 219], ["nucleosomal", 230], ["histone", 242], ["H3", 250], [".", 252], ["We", 254], ["have", 257], ["solved", 262], ["a", 269], ["2.5", 271], ["A", 275], ["resolution", 277], ["structure", 288], ["of", 298], ["the", 301], ["catalytic", 305], ["domain", 315], ["of", 322], ["human", 325], ["Dot1", 331], [",", 335], ["hDOT1L", 337], [",", 343], ["in", 345], ["complex", 348], ["with", 356], ["S", 361], ["-", 362], ["adenosyl", 363], ["-", 371], ["L", 372], ["-", 373], ["methionine", 374], ["(", 385], ["SAM", 386], [")", 389], [".", 390], ["The", 392], ["structure", 396], ["reveals", 406], ["a", 414], ["unique", 416], ["organization", 423], ["of", 436], ["a", 439], ["mainly", 441], ["alpha", 448], ["-", 453], ["helical", 454], ["N", 462], ["-", 463], ["terminal", 464], ["domain", 473], ["and", 480], ["a", 484], ["central", 486], ["open", 494], ["alpha", 499], ["/", 504], ["beta", 505], ["structure", 510], [",", 519], ["an", 521], ["active", 524], ["site", 531], ["consisting", 536], ["of", 547], ["a", 550], ["SAM", 552], ["binding", 556], ["pocket", 564], [",", 570], ["and", 572], ["a", 576], ["potential", 578], ["lysine", 588], ["binding", 595], ["channel", 603], [".", 610], ["We", 612], ["also", 615], ["show", 620], ["that", 625], ["a", 630], ["flexible", 632], [",", 640], ["positively", 642], ["charged", 653], ["region", 661], ["at", 668], ["the", 671], ["C", 675], ["terminus", 677], ["of", 686], ["the", 689], ["catalytic", 693], ["domain", 703], ["is", 710], ["critical", 713], ["for", 722], ["nucleosome", 726], ["binding", 737], ["and", 745], ["enzymatic", 749], ["activity", 759], [".", 767], ["These", 769], ["structural", 775], ["and", 786], ["biochemical", 790], ["analyses", 802], [",", 810], ["combined", 812], ["with", 821], ["molecular", 826], ["modeling", 836], [",", 844], ["provide", 846], ["mechanistic", 854], ["insights", 866], ["into", 875], ["the", 880], ["catalytic", 884], ["mechanism", 894], ["and", 904], ["nucleosomal", 908], ["specificity", 920], ["of", 932], ["Dot1", 935], ["proteins", 940], [".", 948]]}
{"context": "Dapivirine, formerly known as TMC 120, is a poorly-water soluble anti-HIV drug, currently being developed as a vaginal microbicide. The clinical use of this drug has been limited due to its poor solubility. The aim of this study was to design solid dispersion systems of Dapivirine to improve its solubility. Solid dispersions were prepared by solvent and fusion methods. Dapivirine release from the solid dispersion system was determined by conducting in-vitro dissolution studies. The physicochemical characteristics of the drug and its formulation were studied using Differential Scanning Calorimetry (DSC), powder X-ray Diffraction (XRD), Fourier-transform Infrared Spectroscopy (FTIR) and Scanning Electron Microscopy (SEM). A significant improvement in drug dissolution rate was observed with the solid dispersion systems. XRD, SEM and DSC results indicated the transformation of pure Dapivirine which exists in crystalline form into an amorphous form in selected solid dispersion formulations. FTIR and HPLC analysis confirmed the absence of drug-excipient interactions. Solid dispersion systems can be used to improve the dissolution rate of Dapivirine. This improvement could be attributed to the reduction or absence of drug crystallinity, existence of drug particles in an amorphous form and improved wettability of the drug.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "ac9d766d13164566b8388415dae6d5db", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[16, 16]], "char_spans": [[70, 72]]}]}], "context_tokens": [["Dapivirine", 0], [",", 10], ["formerly", 12], ["known", 21], ["as", 27], ["TMC", 30], ["120", 34], [",", 37], ["is", 39], ["a", 42], ["poorly", 44], ["-", 50], ["water", 51], ["soluble", 57], ["anti", 65], ["-", 69], ["HIV", 70], ["drug", 74], [",", 78], ["currently", 80], ["being", 90], ["developed", 96], ["as", 106], ["a", 109], ["vaginal", 111], ["microbicide", 119], [".", 130], ["The", 132], ["clinical", 136], ["use", 145], ["of", 149], ["this", 152], ["drug", 157], ["has", 162], ["been", 166], ["limited", 171], ["due", 179], ["to", 183], ["its", 186], ["poor", 190], ["solubility", 195], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["this", 218], ["study", 223], ["was", 229], ["to", 233], ["design", 236], ["solid", 243], ["dispersion", 249], ["systems", 260], ["of", 268], ["Dapivirine", 271], ["to", 282], ["improve", 285], ["its", 293], ["solubility", 297], [".", 307], ["Solid", 309], ["dispersions", 315], ["were", 327], ["prepared", 332], ["by", 341], ["solvent", 344], ["and", 352], ["fusion", 356], ["methods", 363], [".", 370], ["Dapivirine", 372], ["release", 383], ["from", 391], ["the", 396], ["solid", 400], ["dispersion", 406], ["system", 417], ["was", 424], ["determined", 428], ["by", 439], ["conducting", 442], ["in", 453], ["-", 455], ["vitro", 456], ["dissolution", 462], ["studies", 474], [".", 481], ["The", 483], ["physicochemical", 487], ["characteristics", 503], ["of", 519], ["the", 522], ["drug", 526], ["and", 531], ["its", 535], ["formulation", 539], ["were", 551], ["studied", 556], ["using", 564], ["Differential", 570], ["Scanning", 583], ["Calorimetry", 592], ["(", 604], ["DSC", 605], [")", 608], [",", 609], ["powder", 611], ["X", 618], ["-", 619], ["ray", 620], ["Diffraction", 624], ["(", 636], ["XRD", 637], [")", 640], [",", 641], ["Fourier", 643], ["-", 650], ["transform", 651], ["Infrared", 661], ["Spectroscopy", 670], ["(", 683], ["FTIR", 684], [")", 688], ["and", 690], ["Scanning", 694], ["Electron", 703], ["Microscopy", 712], ["(", 723], ["SEM", 724], [")", 727], [".", 728], ["A", 730], ["significant", 732], ["improvement", 744], ["in", 756], ["drug", 759], ["dissolution", 764], ["rate", 776], ["was", 781], ["observed", 785], ["with", 794], ["the", 799], ["solid", 803], ["dispersion", 809], ["systems", 820], [".", 827], ["XRD", 829], [",", 832], ["SEM", 834], ["and", 838], ["DSC", 842], ["results", 846], ["indicated", 854], ["the", 864], ["transformation", 868], ["of", 883], ["pure", 886], ["Dapivirine", 891], ["which", 902], ["exists", 908], ["in", 915], ["crystalline", 918], ["form", 930], ["into", 935], ["an", 940], ["amorphous", 943], ["form", 953], ["in", 958], ["selected", 961], ["solid", 970], ["dispersion", 976], ["formulations", 987], [".", 999], ["FTIR", 1001], ["and", 1006], ["HPLC", 1010], ["analysis", 1015], ["confirmed", 1024], ["the", 1034], ["absence", 1038], ["of", 1046], ["drug", 1049], ["-", 1053], ["excipient", 1054], ["interactions", 1064], [".", 1076], ["Solid", 1078], ["dispersion", 1084], ["systems", 1095], ["can", 1103], ["be", 1107], ["used", 1110], ["to", 1115], ["improve", 1118], ["the", 1126], ["dissolution", 1130], ["rate", 1142], ["of", 1147], ["Dapivirine", 1150], [".", 1160], ["This", 1162], ["improvement", 1167], ["could", 1179], ["be", 1185], ["attributed", 1188], ["to", 1199], ["the", 1202], ["reduction", 1206], ["or", 1216], ["absence", 1219], ["of", 1227], ["drug", 1230], ["crystallinity", 1235], [",", 1248], ["existence", 1250], ["of", 1260], ["drug", 1263], ["particles", 1268], ["in", 1278], ["an", 1281], ["amorphous", 1284], ["form", 1294], ["and", 1299], ["improved", 1303], ["wettability", 1312], ["of", 1324], ["the", 1327], ["drug", 1331], [".", 1335]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo. However, reliance on single chromatin marks leads to high rates of false-positive predictions. More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability. Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface. We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements. By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance. Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance. We demonstrate the utility of our approach through in vivo validation of newly predicted elements. Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "qas": [{"question": "Which resource contains accurate enhancer predictions in the developing limb?", "answers": ["Limb-Enhancer Genie (LEG)"], "qid": "a1f4e0c1a4c84385836fb9879b463d73", "question_tokens": [["Which", 0], ["resource", 6], ["contains", 15], ["accurate", 24], ["enhancer", 33], ["predictions", 42], ["in", 54], ["the", 57], ["developing", 61], ["limb", 72], ["?", 76]], "detected_answers": [{"text": "Limb-Enhancer Genie (LEG)", "token_spans": [[67, 72]], "char_spans": [[435, 458]]}]}], "context_tokens": [["Epigenomic", 0], ["mapping", 11], ["of", 19], ["enhancer", 22], ["-", 30], ["associated", 31], ["chromatin", 42], ["modifications", 52], ["facilitates", 66], ["the", 78], ["genome", 82], ["-", 88], ["wide", 89], ["discovery", 94], ["of", 104], ["tissue", 107], ["-", 113], ["specific", 114], ["enhancers", 123], ["in", 133], ["vivo", 136], [".", 140], ["However", 142], [",", 149], ["reliance", 151], ["on", 160], ["single", 163], ["chromatin", 170], ["marks", 180], ["leads", 186], ["to", 192], ["high", 195], ["rates", 200], ["of", 206], ["false", 209], ["-", 214], ["positive", 215], ["predictions", 224], [".", 235], ["More", 237], ["sophisticated", 242], [",", 255], ["integrative", 257], ["methods", 269], ["have", 277], ["been", 282], ["described", 287], [",", 296], ["but", 298], ["commonly", 302], ["suffer", 311], ["from", 318], ["limited", 323], ["accessibility", 331], ["to", 345], ["the", 348], ["resulting", 352], ["predictions", 362], ["and", 374], ["reduced", 378], ["biological", 386], ["interpretability", 397], [".", 413], ["Here", 415], ["we", 420], ["present", 423], ["the", 431], ["Limb", 435], ["-", 439], ["Enhancer", 440], ["Genie", 449], ["(", 455], ["LEG", 456], [")", 459], [",", 460], ["a", 462], ["collection", 464], ["of", 475], ["highly", 478], ["accurate", 485], [",", 493], ["genome", 495], ["-", 501], ["wide", 502], ["predictions", 507], ["of", 519], ["enhancers", 522], ["in", 532], ["the", 535], ["developing", 539], ["limb", 550], [",", 554], ["available", 556], ["through", 566], ["a", 574], ["user", 576], ["-", 580], ["friendly", 581], ["online", 590], ["interface", 597], [".", 606], ["We", 608], ["predict", 611], ["limb", 619], ["enhancers", 624], ["using", 634], ["a", 640], ["combination", 642], ["of", 654], [">", 657], ["50", 658], ["published", 661], ["limb", 671], ["-", 675], ["specific", 676], ["datasets", 685], ["and", 694], ["clusters", 698], ["of", 707], ["evolutionarily", 710], ["conserved", 725], ["transcription", 735], ["factor", 749], ["binding", 756], ["sites", 764], [",", 769], ["taking", 771], ["advantage", 778], ["of", 788], ["the", 791], ["patterns", 795], ["observed", 804], ["at", 813], ["previously", 816], ["in", 827], ["vivo", 830], ["validated", 835], ["elements", 845], [".", 853], ["By", 855], ["combining", 858], ["different", 868], ["statistical", 878], ["models", 890], [",", 896], ["our", 898], ["approach", 902], ["outperforms", 911], ["current", 923], ["state", 931], ["-", 936], ["of", 937], ["-", 939], ["the", 940], ["-", 943], ["art", 944], ["methods", 948], ["and", 956], ["provides", 960], ["interpretable", 969], ["measures", 983], ["of", 992], ["feature", 995], ["importance", 1003], [".", 1013], ["Our", 1015], ["results", 1019], ["indicate", 1027], ["that", 1036], ["including", 1041], ["a", 1051], ["previously", 1053], ["unappreciated", 1064], ["score", 1078], ["that", 1084], ["quantifies", 1089], ["tissue", 1100], ["-", 1106], ["specific", 1107], ["nuclease", 1116], ["accessibility", 1125], ["significantly", 1139], ["improves", 1153], ["prediction", 1162], ["performance", 1173], [".", 1184], ["We", 1186], ["demonstrate", 1189], ["the", 1201], ["utility", 1205], ["of", 1213], ["our", 1216], ["approach", 1220], ["through", 1229], ["in", 1237], ["vivo", 1240], ["validation", 1245], ["of", 1256], ["newly", 1259], ["predicted", 1265], ["elements", 1275], [".", 1283], ["Moreover", 1285], [",", 1293], ["we", 1295], ["describe", 1298], ["general", 1307], ["features", 1315], ["that", 1324], ["can", 1329], ["guide", 1333], ["the", 1339], ["type", 1343], ["of", 1348], ["datasets", 1351], ["to", 1360], ["include", 1363], ["when", 1371], ["predicting", 1376], ["tissue", 1387], ["-", 1393], ["specific", 1394], ["enhancers", 1403], ["genome", 1413], ["-", 1419], ["wide", 1420], [",", 1424], ["while", 1426], ["providing", 1432], ["an", 1442], ["accessible", 1445], ["resource", 1456], ["to", 1465], ["the", 1468], ["general", 1472], ["biological", 1480], ["community", 1491], ["and", 1501], ["facilitating", 1505], ["the", 1518], ["functional", 1522], ["interpretation", 1533], ["of", 1548], ["genetic", 1551], ["studies", 1559], ["of", 1567], ["limb", 1570], ["malformations", 1575], [".", 1588]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disorder that is characterized by two major neuropathological hallmarks: the degeneration of dopaminergic neurons in the substantia nigra (SN) and the presence of Lewy bodies in the surviving SN neurons, as well as other regions of the central and peripheral nervous system. Animal models have been invaluable tools for investigating the underlying mechanisms of the pathogenesis of PD and testing new potential symptomatic, neuroprotective and neurorestorative therapies. However, the usefulness of these models is dependent on how precisely they replicate the features of clinical PD with some studies now employing combined gene-environment models to replicate more of the affected pathways. The rotenone model of PD has become of great interest following the seminal paper by the Greenamyre group in 2000 (Betarbet et al., 2000). This paper reported for the first time that systemic rotenone was able to reproduce the two pathological hallmarks of PD as well as certain parkinsonian motor deficits. Since 2000, many research groups have actively used the rotenone model worldwide. This paper will review rotenone models, focusing upon their ability to reproduce the two pathological hallmarks of PD, motor deficits, extranigral pathology and non-motor symptoms. We will also summarize the recent advances in neuroprotective therapies, focusing on those that investigated non-motor symptoms and review rotenone models used in combination with PD genetic models to investigate gene-environment interactions.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "93e3e9fa03db483194b1dc67af0aa5af", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disorder", 69], ["that", 78], ["is", 83], ["characterized", 86], ["by", 100], ["two", 103], ["major", 107], ["neuropathological", 113], ["hallmarks", 131], [":", 140], ["the", 142], ["degeneration", 146], ["of", 159], ["dopaminergic", 162], ["neurons", 175], ["in", 183], ["the", 186], ["substantia", 190], ["nigra", 201], ["(", 207], ["SN", 208], [")", 210], ["and", 212], ["the", 216], ["presence", 220], ["of", 229], ["Lewy", 232], ["bodies", 237], ["in", 244], ["the", 247], ["surviving", 251], ["SN", 261], ["neurons", 264], [",", 271], ["as", 273], ["well", 276], ["as", 281], ["other", 284], ["regions", 290], ["of", 298], ["the", 301], ["central", 305], ["and", 313], ["peripheral", 317], ["nervous", 328], ["system", 336], [".", 342], ["Animal", 344], ["models", 351], ["have", 358], ["been", 363], ["invaluable", 368], ["tools", 379], ["for", 385], ["investigating", 389], ["the", 403], ["underlying", 407], ["mechanisms", 418], ["of", 429], ["the", 432], ["pathogenesis", 436], ["of", 449], ["PD", 452], ["and", 455], ["testing", 459], ["new", 467], ["potential", 471], ["symptomatic", 481], [",", 492], ["neuroprotective", 494], ["and", 510], ["neurorestorative", 514], ["therapies", 531], [".", 540], ["However", 542], [",", 549], ["the", 551], ["usefulness", 555], ["of", 566], ["these", 569], ["models", 575], ["is", 582], ["dependent", 585], ["on", 595], ["how", 598], ["precisely", 602], ["they", 612], ["replicate", 617], ["the", 627], ["features", 631], ["of", 640], ["clinical", 643], ["PD", 652], ["with", 655], ["some", 660], ["studies", 665], ["now", 673], ["employing", 677], ["combined", 687], ["gene", 696], ["-", 700], ["environment", 701], ["models", 713], ["to", 720], ["replicate", 723], ["more", 733], ["of", 738], ["the", 741], ["affected", 745], ["pathways", 754], [".", 762], ["The", 764], ["rotenone", 768], ["model", 777], ["of", 783], ["PD", 786], ["has", 789], ["become", 793], ["of", 800], ["great", 803], ["interest", 809], ["following", 818], ["the", 828], ["seminal", 832], ["paper", 840], ["by", 846], ["the", 849], ["Greenamyre", 853], ["group", 864], ["in", 870], ["2000", 873], ["(", 878], ["Betarbet", 879], ["et", 888], ["al", 891], [".", 893], [",", 894], ["2000", 896], [")", 900], [".", 901], ["This", 903], ["paper", 908], ["reported", 914], ["for", 923], ["the", 927], ["first", 931], ["time", 937], ["that", 942], ["systemic", 947], ["rotenone", 956], ["was", 965], ["able", 969], ["to", 974], ["reproduce", 977], ["the", 987], ["two", 991], ["pathological", 995], ["hallmarks", 1008], ["of", 1018], ["PD", 1021], ["as", 1024], ["well", 1027], ["as", 1032], ["certain", 1035], ["parkinsonian", 1043], ["motor", 1056], ["deficits", 1062], [".", 1070], ["Since", 1072], ["2000", 1078], [",", 1082], ["many", 1084], ["research", 1089], ["groups", 1098], ["have", 1105], ["actively", 1110], ["used", 1119], ["the", 1124], ["rotenone", 1128], ["model", 1137], ["worldwide", 1143], [".", 1152], ["This", 1154], ["paper", 1159], ["will", 1165], ["review", 1170], ["rotenone", 1177], ["models", 1186], [",", 1192], ["focusing", 1194], ["upon", 1203], ["their", 1208], ["ability", 1214], ["to", 1222], ["reproduce", 1225], ["the", 1235], ["two", 1239], ["pathological", 1243], ["hallmarks", 1256], ["of", 1266], ["PD", 1269], [",", 1271], ["motor", 1273], ["deficits", 1279], [",", 1287], ["extranigral", 1289], ["pathology", 1301], ["and", 1311], ["non", 1315], ["-", 1318], ["motor", 1319], ["symptoms", 1325], [".", 1333], ["We", 1335], ["will", 1338], ["also", 1343], ["summarize", 1348], ["the", 1358], ["recent", 1362], ["advances", 1369], ["in", 1378], ["neuroprotective", 1381], ["therapies", 1397], [",", 1406], ["focusing", 1408], ["on", 1417], ["those", 1420], ["that", 1426], ["investigated", 1431], ["non", 1444], ["-", 1447], ["motor", 1448], ["symptoms", 1454], ["and", 1463], ["review", 1467], ["rotenone", 1474], ["models", 1483], ["used", 1490], ["in", 1495], ["combination", 1498], ["with", 1510], ["PD", 1515], ["genetic", 1518], ["models", 1526], ["to", 1533], ["investigate", 1536], ["gene", 1548], ["-", 1552], ["environment", 1553], ["interactions", 1565], [".", 1577]]}
{"context": "The selective serotonin reuptake inhibitors have become a first line treatment for post-traumatic stress disorder (PTSD). In a recent double-blind study in civilians, fluoxetine produced clinically and statistically significant effects on all general measures of PTSD. We examined the specific effects of fluoxetine versus placebo in the above mentioned study of PTSD clusters and individual symptoms. Individuals were included if they met criteria for PTSD according to the Structured Clinical Interview for DSM-III-R (SCID). Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). A total of 53 patients were included in the analysis. On the SIP and DTS, fluoxetine was found to produce statistically significant changes on all clusters. Significant effects for fluoxetine were noted on 10 items of the DTS, and 8 items of the SIP. The SIP and DTS had 6 items in common that were significant. Fluoxetine exerts a broad spectrum effect in reducing all the symptom clusters of PTSD in this sample. The symptoms of being physically upset at reminders of the trauma, avoiding thoughts of the trauma, having difficulty enjoying things, feeling distant/estranged, having a sense of foreshortened future, and impaired concentration, were the symptoms most responsive to the effects of treatment with fluoxetine on both scales.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "8358e9aead9e4d0e8e8aa54a33b9eff9", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[12, 16]], "char_spans": [[83, 112]]}, {"text": "PTSD", "token_spans": [[43, 43], [74, 74], [60, 60], [204, 204], [103, 103], [18, 18]], "char_spans": [[263, 266], [453, 456], [363, 366], [1112, 1115], [608, 611], [115, 118]]}]}], "context_tokens": [["The", 0], ["selective", 4], ["serotonin", 14], ["reuptake", 24], ["inhibitors", 33], ["have", 44], ["become", 49], ["a", 56], ["first", 58], ["line", 64], ["treatment", 69], ["for", 79], ["post", 83], ["-", 87], ["traumatic", 88], ["stress", 98], ["disorder", 105], ["(", 114], ["PTSD", 115], [")", 119], [".", 120], ["In", 122], ["a", 125], ["recent", 127], ["double", 134], ["-", 140], ["blind", 141], ["study", 147], ["in", 153], ["civilians", 156], [",", 165], ["fluoxetine", 167], ["produced", 178], ["clinically", 187], ["and", 198], ["statistically", 202], ["significant", 216], ["effects", 228], ["on", 236], ["all", 239], ["general", 243], ["measures", 251], ["of", 260], ["PTSD", 263], [".", 267], ["We", 269], ["examined", 272], ["the", 281], ["specific", 285], ["effects", 294], ["of", 302], ["fluoxetine", 305], ["versus", 316], ["placebo", 323], ["in", 331], ["the", 334], ["above", 338], ["mentioned", 344], ["study", 354], ["of", 360], ["PTSD", 363], ["clusters", 368], ["and", 377], ["individual", 381], ["symptoms", 392], [".", 400], ["Individuals", 402], ["were", 414], ["included", 419], ["if", 428], ["they", 431], ["met", 436], ["criteria", 440], ["for", 449], ["PTSD", 453], ["according", 458], ["to", 468], ["the", 471], ["Structured", 475], ["Clinical", 486], ["Interview", 495], ["for", 505], ["DSM", 509], ["-", 512], ["III", 513], ["-", 516], ["R", 517], ["(", 519], ["SCID", 520], [")", 524], [".", 525], ["Symptoms", 527], ["were", 536], ["assessed", 541], ["at", 550], ["sequential", 553], ["time", 564], ["points", 569], ["by", 576], ["the", 579], ["Structured", 583], ["Interview", 594], ["for", 604], ["PTSD", 608], ["(", 613], ["SIP", 614], [")", 617], [",", 618], ["a", 620], ["clinician", 622], ["interview", 632], ["based", 642], ["assessment", 648], [",", 658], ["and", 660], ["a", 664], ["self", 666], ["-", 670], ["report", 671], ["scale", 678], [",", 683], ["the", 685], ["Davidson", 689], ["Trauma", 698], ["Scale", 705], ["(", 711], ["DTS", 712], [")", 715], [".", 716], ["A", 718], ["total", 720], ["of", 726], ["53", 729], ["patients", 732], ["were", 741], ["included", 746], ["in", 755], ["the", 758], ["analysis", 762], [".", 770], ["On", 772], ["the", 775], ["SIP", 779], ["and", 783], ["DTS", 787], [",", 790], ["fluoxetine", 792], ["was", 803], ["found", 807], ["to", 813], ["produce", 816], ["statistically", 824], ["significant", 838], ["changes", 850], ["on", 858], ["all", 861], ["clusters", 865], [".", 873], ["Significant", 875], ["effects", 887], ["for", 895], ["fluoxetine", 899], ["were", 910], ["noted", 915], ["on", 921], ["10", 924], ["items", 927], ["of", 933], ["the", 936], ["DTS", 940], [",", 943], ["and", 945], ["8", 949], ["items", 951], ["of", 957], ["the", 960], ["SIP", 964], [".", 967], ["The", 969], ["SIP", 973], ["and", 977], ["DTS", 981], ["had", 985], ["6", 989], ["items", 991], ["in", 997], ["common", 1000], ["that", 1007], ["were", 1012], ["significant", 1017], [".", 1028], ["Fluoxetine", 1030], ["exerts", 1041], ["a", 1048], ["broad", 1050], ["spectrum", 1056], ["effect", 1065], ["in", 1072], ["reducing", 1075], ["all", 1084], ["the", 1088], ["symptom", 1092], ["clusters", 1100], ["of", 1109], ["PTSD", 1112], ["in", 1117], ["this", 1120], ["sample", 1125], [".", 1131], ["The", 1133], ["symptoms", 1137], ["of", 1146], ["being", 1149], ["physically", 1155], ["upset", 1166], ["at", 1172], ["reminders", 1175], ["of", 1185], ["the", 1188], ["trauma", 1192], [",", 1198], ["avoiding", 1200], ["thoughts", 1209], ["of", 1218], ["the", 1221], ["trauma", 1225], [",", 1231], ["having", 1233], ["difficulty", 1240], ["enjoying", 1251], ["things", 1260], [",", 1266], ["feeling", 1268], ["distant", 1276], ["/", 1283], ["estranged", 1284], [",", 1293], ["having", 1295], ["a", 1302], ["sense", 1304], ["of", 1310], ["foreshortened", 1313], ["future", 1327], [",", 1333], ["and", 1335], ["impaired", 1339], ["concentration", 1348], [",", 1361], ["were", 1363], ["the", 1368], ["symptoms", 1372], ["most", 1381], ["responsive", 1386], ["to", 1397], ["the", 1400], ["effects", 1404], ["of", 1412], ["treatment", 1415], ["with", 1425], ["fluoxetine", 1430], ["on", 1441], ["both", 1444], ["scales", 1449], [".", 1455]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "Malaria is one of the most devastating infectious diseases in the developing world. Until now, only one candidate malaria vaccine RTS,S/AS01 has shown modest protection in phase 3 trial in African infants. Hence the treatment of malaria still depends on the current chemotherapeutic drugs. Considering the resistance of malaria parasites to almost all used antimalarial drugs, aiming at multi-targets rather than a single target will be a more promising strategy. Previous studies have shown that myricetin and fisetin exhibited in vitro antimalarial activity against Plasmodium falciparum, but very little research focused on the molecular mechanism for their parasiticidal activity. The cysteine protease falcipain-2 and aspartic protease plasmepsin II have long been considered as important antimalarial drug targets, especially combined inhibition of these two proteases. In this study, we determined that myricetin and fisetin are dual inhibitors of falcipain-2 and plasmepsin II, which might account for their antimalarial properties. Overall, the dual inhibition of falcipain-2 and plasmepsin II by myricetin and fisetin has shed light on a possible mechanism for their antimalarial activity and provided a rationale for further development as antimalarial drugs.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "7d74ba9e281e40f4942cf692644eec7b", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[20, 20], [56, 56], [0, 0], [43, 43]], "char_spans": [[114, 120], [320, 326], [0, 6], [229, 235]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["one", 11], ["of", 15], ["the", 18], ["most", 22], ["devastating", 27], ["infectious", 39], ["diseases", 50], ["in", 59], ["the", 62], ["developing", 66], ["world", 77], [".", 82], ["Until", 84], ["now", 90], [",", 93], ["only", 95], ["one", 100], ["candidate", 104], ["malaria", 114], ["vaccine", 122], ["RTS", 130], [",", 133], ["S", 134], ["/", 135], ["AS01", 136], ["has", 141], ["shown", 145], ["modest", 151], ["protection", 158], ["in", 169], ["phase", 172], ["3", 178], ["trial", 180], ["in", 186], ["African", 189], ["infants", 197], [".", 204], ["Hence", 206], ["the", 212], ["treatment", 216], ["of", 226], ["malaria", 229], ["still", 237], ["depends", 243], ["on", 251], ["the", 254], ["current", 258], ["chemotherapeutic", 266], ["drugs", 283], [".", 288], ["Considering", 290], ["the", 302], ["resistance", 306], ["of", 317], ["malaria", 320], ["parasites", 328], ["to", 338], ["almost", 341], ["all", 348], ["used", 352], ["antimalarial", 357], ["drugs", 370], [",", 375], ["aiming", 377], ["at", 384], ["multi", 387], ["-", 392], ["targets", 393], ["rather", 401], ["than", 408], ["a", 413], ["single", 415], ["target", 422], ["will", 429], ["be", 434], ["a", 437], ["more", 439], ["promising", 444], ["strategy", 454], [".", 462], ["Previous", 464], ["studies", 473], ["have", 481], ["shown", 486], ["that", 492], ["myricetin", 497], ["and", 507], ["fisetin", 511], ["exhibited", 519], ["in", 529], ["vitro", 532], ["antimalarial", 538], ["activity", 551], ["against", 560], ["Plasmodium", 568], ["falciparum", 579], [",", 589], ["but", 591], ["very", 595], ["little", 600], ["research", 607], ["focused", 616], ["on", 624], ["the", 627], ["molecular", 631], ["mechanism", 641], ["for", 651], ["their", 655], ["parasiticidal", 661], ["activity", 675], [".", 683], ["The", 685], ["cysteine", 689], ["protease", 698], ["falcipain-2", 707], ["and", 719], ["aspartic", 723], ["protease", 732], ["plasmepsin", 741], ["II", 752], ["have", 755], ["long", 760], ["been", 765], ["considered", 770], ["as", 781], ["important", 784], ["antimalarial", 794], ["drug", 807], ["targets", 812], [",", 819], ["especially", 821], ["combined", 832], ["inhibition", 841], ["of", 852], ["these", 855], ["two", 861], ["proteases", 865], [".", 874], ["In", 876], ["this", 879], ["study", 884], [",", 889], ["we", 891], ["determined", 894], ["that", 905], ["myricetin", 910], ["and", 920], ["fisetin", 924], ["are", 932], ["dual", 936], ["inhibitors", 941], ["of", 952], ["falcipain-2", 955], ["and", 967], ["plasmepsin", 971], ["II", 982], [",", 984], ["which", 986], ["might", 992], ["account", 998], ["for", 1006], ["their", 1010], ["antimalarial", 1016], ["properties", 1029], [".", 1039], ["Overall", 1041], [",", 1048], ["the", 1050], ["dual", 1054], ["inhibition", 1059], ["of", 1070], ["falcipain-2", 1073], ["and", 1085], ["plasmepsin", 1089], ["II", 1100], ["by", 1103], ["myricetin", 1106], ["and", 1116], ["fisetin", 1120], ["has", 1128], ["shed", 1132], ["light", 1137], ["on", 1143], ["a", 1146], ["possible", 1148], ["mechanism", 1157], ["for", 1167], ["their", 1171], ["antimalarial", 1177], ["activity", 1190], ["and", 1199], ["provided", 1203], ["a", 1212], ["rationale", 1214], ["for", 1224], ["further", 1228], ["development", 1236], ["as", 1248], ["antimalarial", 1251], ["drugs", 1264], [".", 1269]]}
{"context": "The objective was to determine the composition of the Cystic Fibrosis (CF) Population attending specialist UK CF centres in terms of age, gender, age at diagnosis, genotype and ethnicity. With the planned introduction of the national CF screening programme in the UK, cystic fibrosis transmembrane regulator (CFTR) mutations were compared between different ethnic groups enabling a UK-specific frequency of mutations to be defined. Data were analysed from the patient biographies held in the UK CF Database (see www.cystic-fibrosis.org.uk). The currently registered population of 5,274 CF patients is 96.3% Caucasian with a male preponderance that significantly increases with age. The majority of the 196 non-Caucasian CF patients are from the Indian Subcontinent (ISC), of which one in 84 UK CF patients are of Pakistani origin. The commonest CFTR mutation, deltaF508, is found in 74.1% of all CF chromosomes. In the Caucasian CF population, 57.5% are deltaF508 homozygotes but the UK ISC CF population with only 24.7%, has significantly fewer deltaF508 homozygotes patients (95% confidence interval (CI) 0.2-0.4). The distribution of Caucasian patients with deltaF508/deltaF508, deltaF508/Other and Other/Other does not fit the expected distribution with a Hardy-Weinberg model unless those patients without a detected mutation are excluded (P<0.001). The UK CF Database has shown the UK CF population to have distinct characteristics separate from the North American and European CF Registries. The ISC group contains many mutations not recognised by current genetic analysis, and one in four ISC patients have no CFTR mutations identified. The CFTR analysis proposed for the screening programme would detect 96% of patients registered in the database, but is unlikely to achieve the desired >80% detection rates in the ethnic minority groups. Screen-positive, non-Caucasian infants without an identifiable CFTR mutation should be referred for a sweat test and genetic counselling when serum trypsinogen concentrations remain elevated after birth.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "7d3f2b1fca4442a8ae60dafaeaa4cb04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[152, 152], [173, 173], [189, 189]], "char_spans": [[860, 868], [954, 962], [1046, 1054]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["was", 14], ["to", 18], ["determine", 21], ["the", 31], ["composition", 35], ["of", 47], ["the", 50], ["Cystic", 54], ["Fibrosis", 61], ["(", 70], ["CF", 71], [")", 73], ["Population", 75], ["attending", 86], ["specialist", 96], ["UK", 107], ["CF", 110], ["centres", 113], ["in", 121], ["terms", 124], ["of", 130], ["age", 133], [",", 136], ["gender", 138], [",", 144], ["age", 146], ["at", 150], ["diagnosis", 153], [",", 162], ["genotype", 164], ["and", 173], ["ethnicity", 177], [".", 186], ["With", 188], ["the", 193], ["planned", 197], ["introduction", 205], ["of", 218], ["the", 221], ["national", 225], ["CF", 234], ["screening", 237], ["programme", 247], ["in", 257], ["the", 260], ["UK", 264], [",", 266], ["cystic", 268], ["fibrosis", 275], ["transmembrane", 284], ["regulator", 298], ["(", 308], ["CFTR", 309], [")", 313], ["mutations", 315], ["were", 325], ["compared", 330], ["between", 339], ["different", 347], ["ethnic", 357], ["groups", 364], ["enabling", 371], ["a", 380], ["UK", 382], ["-", 384], ["specific", 385], ["frequency", 394], ["of", 404], ["mutations", 407], ["to", 417], ["be", 420], ["defined", 423], [".", 430], ["Data", 432], ["were", 437], ["analysed", 442], ["from", 451], ["the", 456], ["patient", 460], ["biographies", 468], ["held", 480], ["in", 485], ["the", 488], ["UK", 492], ["CF", 495], ["Database", 498], ["(", 507], ["see", 508], ["www.cystic-fibrosis.org.uk", 512], [")", 538], [".", 539], ["The", 541], ["currently", 545], ["registered", 555], ["population", 566], ["of", 577], ["5,274", 580], ["CF", 586], ["patients", 589], ["is", 598], ["96.3", 601], ["%", 605], ["Caucasian", 607], ["with", 617], ["a", 622], ["male", 624], ["preponderance", 629], ["that", 643], ["significantly", 648], ["increases", 662], ["with", 672], ["age", 677], [".", 680], ["The", 682], ["majority", 686], ["of", 695], ["the", 698], ["196", 702], ["non", 706], ["-", 709], ["Caucasian", 710], ["CF", 720], ["patients", 723], ["are", 732], ["from", 736], ["the", 741], ["Indian", 745], ["Subcontinent", 752], ["(", 765], ["ISC", 766], [")", 769], [",", 770], ["of", 772], ["which", 775], ["one", 781], ["in", 785], ["84", 788], ["UK", 791], ["CF", 794], ["patients", 797], ["are", 806], ["of", 810], ["Pakistani", 813], ["origin", 823], [".", 829], ["The", 831], ["commonest", 835], ["CFTR", 845], ["mutation", 850], [",", 858], ["deltaF508", 860], [",", 869], ["is", 871], ["found", 874], ["in", 880], ["74.1", 883], ["%", 887], ["of", 889], ["all", 892], ["CF", 896], ["chromosomes", 899], [".", 910], ["In", 912], ["the", 915], ["Caucasian", 919], ["CF", 929], ["population", 932], [",", 942], ["57.5", 944], ["%", 948], ["are", 950], ["deltaF508", 954], ["homozygotes", 964], ["but", 976], ["the", 980], ["UK", 984], ["ISC", 987], ["CF", 991], ["population", 994], ["with", 1005], ["only", 1010], ["24.7", 1015], ["%", 1019], [",", 1020], ["has", 1022], ["significantly", 1026], ["fewer", 1040], ["deltaF508", 1046], ["homozygotes", 1056], ["patients", 1068], ["(", 1077], ["95", 1078], ["%", 1080], ["confidence", 1082], ["interval", 1093], ["(", 1102], ["CI", 1103], [")", 1105], ["0.2", 1107], ["-", 1110], ["0.4", 1111], [")", 1114], [".", 1115], ["The", 1117], ["distribution", 1121], ["of", 1134], ["Caucasian", 1137], ["patients", 1147], ["with", 1156], ["deltaF508/deltaF508", 1161], [",", 1180], ["deltaF508/Other", 1182], ["and", 1198], ["Other", 1202], ["/", 1207], ["Other", 1208], ["does", 1214], ["not", 1219], ["fit", 1223], ["the", 1227], ["expected", 1231], ["distribution", 1240], ["with", 1253], ["a", 1258], ["Hardy", 1260], ["-", 1265], ["Weinberg", 1266], ["model", 1275], ["unless", 1281], ["those", 1288], ["patients", 1294], ["without", 1303], ["a", 1311], ["detected", 1313], ["mutation", 1322], ["are", 1331], ["excluded", 1335], ["(", 1344], ["P<0.001", 1345], [")", 1352], [".", 1353], ["The", 1355], ["UK", 1359], ["CF", 1362], ["Database", 1365], ["has", 1374], ["shown", 1378], ["the", 1384], ["UK", 1388], ["CF", 1391], ["population", 1394], ["to", 1405], ["have", 1408], ["distinct", 1413], ["characteristics", 1422], ["separate", 1438], ["from", 1447], ["the", 1452], ["North", 1456], ["American", 1462], ["and", 1471], ["European", 1475], ["CF", 1484], ["Registries", 1487], [".", 1497], ["The", 1499], ["ISC", 1503], ["group", 1507], ["contains", 1513], ["many", 1522], ["mutations", 1527], ["not", 1537], ["recognised", 1541], ["by", 1552], ["current", 1555], ["genetic", 1563], ["analysis", 1571], [",", 1579], ["and", 1581], ["one", 1585], ["in", 1589], ["four", 1592], ["ISC", 1597], ["patients", 1601], ["have", 1610], ["no", 1615], ["CFTR", 1618], ["mutations", 1623], ["identified", 1633], [".", 1643], ["The", 1645], ["CFTR", 1649], ["analysis", 1654], ["proposed", 1663], ["for", 1672], ["the", 1676], ["screening", 1680], ["programme", 1690], ["would", 1700], ["detect", 1706], ["96", 1713], ["%", 1715], ["of", 1717], ["patients", 1720], ["registered", 1729], ["in", 1740], ["the", 1743], ["database", 1747], [",", 1755], ["but", 1757], ["is", 1761], ["unlikely", 1764], ["to", 1773], ["achieve", 1776], ["the", 1784], ["desired", 1788], [">", 1796], ["80", 1797], ["%", 1799], ["detection", 1801], ["rates", 1811], ["in", 1817], ["the", 1820], ["ethnic", 1824], ["minority", 1831], ["groups", 1840], [".", 1846], ["Screen", 1848], ["-", 1854], ["positive", 1855], [",", 1863], ["non", 1865], ["-", 1868], ["Caucasian", 1869], ["infants", 1879], ["without", 1887], ["an", 1895], ["identifiable", 1898], ["CFTR", 1911], ["mutation", 1916], ["should", 1925], ["be", 1932], ["referred", 1935], ["for", 1944], ["a", 1948], ["sweat", 1950], ["test", 1956], ["and", 1961], ["genetic", 1965], ["counselling", 1973], ["when", 1985], ["serum", 1990], ["trypsinogen", 1996], ["concentrations", 2008], ["remain", 2023], ["elevated", 2030], ["after", 2039], ["birth", 2045], [".", 2050]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Focusing on three Anglo-American outbreaks of industrial anthrax, this essay engages the question of how local circumstances influenced the transmission of scientific knowledge in the late nineteenth century. Walpole (Massachusetts), Glasgow, and Bradford (Yorkshire) served as important nodes of transnational investigation into anthrax. Knowledge about the morphology and behavior of Bacillus anthracis changed little while in transit between these nodes, even during complex debates about the nature of bacterial morphology, disease causation, and spontaneous generation. Working independently of their more famous counterparts (Robert Koch and Louis Pasteur), Anglo-American anthrax investigators used visual representations of anthrax bacilli to persuade their peers that a specific, identifiable cause produced all forms of anthrax-malignant pustule (cutaneous anthrax), intestinal anthrax, and woolsorter's disease (pneumonic anthrax). By the late 1870s, this point of view also supported what we would today call an ecological notion of the disease's origins in the interactions of people, animals, and microorganisms in the context of global commerce.", "qas": [{"question": "What organism causes woolsorter's disease", "answers": ["Bacillus Anthracis"], "qid": "7cb5e988b4514ab3944739cfd8b67239", "question_tokens": [["What", 0], ["organism", 5], ["causes", 14], ["woolsorter", 21], ["'s", 31], ["disease", 34]], "detected_answers": [{"text": "Bacillus Anthracis", "token_spans": [[61, 62]], "char_spans": [[386, 403]]}]}], "context_tokens": [["Focusing", 0], ["on", 9], ["three", 12], ["Anglo", 18], ["-", 23], ["American", 24], ["outbreaks", 33], ["of", 43], ["industrial", 46], ["anthrax", 57], [",", 64], ["this", 66], ["essay", 71], ["engages", 77], ["the", 85], ["question", 89], ["of", 98], ["how", 101], ["local", 105], ["circumstances", 111], ["influenced", 125], ["the", 136], ["transmission", 140], ["of", 153], ["scientific", 156], ["knowledge", 167], ["in", 177], ["the", 180], ["late", 184], ["nineteenth", 189], ["century", 200], [".", 207], ["Walpole", 209], ["(", 217], ["Massachusetts", 218], [")", 231], [",", 232], ["Glasgow", 234], [",", 241], ["and", 243], ["Bradford", 247], ["(", 256], ["Yorkshire", 257], [")", 266], ["served", 268], ["as", 275], ["important", 278], ["nodes", 288], ["of", 294], ["transnational", 297], ["investigation", 311], ["into", 325], ["anthrax", 330], [".", 337], ["Knowledge", 339], ["about", 349], ["the", 355], ["morphology", 359], ["and", 370], ["behavior", 374], ["of", 383], ["Bacillus", 386], ["anthracis", 395], ["changed", 405], ["little", 413], ["while", 420], ["in", 426], ["transit", 429], ["between", 437], ["these", 445], ["nodes", 451], [",", 456], ["even", 458], ["during", 463], ["complex", 470], ["debates", 478], ["about", 486], ["the", 492], ["nature", 496], ["of", 503], ["bacterial", 506], ["morphology", 516], [",", 526], ["disease", 528], ["causation", 536], [",", 545], ["and", 547], ["spontaneous", 551], ["generation", 563], [".", 573], ["Working", 575], ["independently", 583], ["of", 597], ["their", 600], ["more", 606], ["famous", 611], ["counterparts", 618], ["(", 631], ["Robert", 632], ["Koch", 639], ["and", 644], ["Louis", 648], ["Pasteur", 654], [")", 661], [",", 662], ["Anglo", 664], ["-", 669], ["American", 670], ["anthrax", 679], ["investigators", 687], ["used", 701], ["visual", 706], ["representations", 713], ["of", 729], ["anthrax", 732], ["bacilli", 740], ["to", 748], ["persuade", 751], ["their", 760], ["peers", 766], ["that", 772], ["a", 777], ["specific", 779], [",", 787], ["identifiable", 789], ["cause", 802], ["produced", 808], ["all", 817], ["forms", 821], ["of", 827], ["anthrax", 830], ["-", 837], ["malignant", 838], ["pustule", 848], ["(", 856], ["cutaneous", 857], ["anthrax", 867], [")", 874], [",", 875], ["intestinal", 877], ["anthrax", 888], [",", 895], ["and", 897], ["woolsorter", 901], ["'s", 911], ["disease", 914], ["(", 922], ["pneumonic", 923], ["anthrax", 933], [")", 940], [".", 941], ["By", 943], ["the", 946], ["late", 950], ["1870s", 955], [",", 960], ["this", 962], ["point", 967], ["of", 973], ["view", 976], ["also", 981], ["supported", 986], ["what", 996], ["we", 1001], ["would", 1004], ["today", 1010], ["call", 1016], ["an", 1021], ["ecological", 1024], ["notion", 1035], ["of", 1042], ["the", 1045], ["disease", 1049], ["'s", 1056], ["origins", 1059], ["in", 1067], ["the", 1070], ["interactions", 1074], ["of", 1087], ["people", 1090], [",", 1096], ["animals", 1098], [",", 1105], ["and", 1107], ["microorganisms", 1111], ["in", 1126], ["the", 1129], ["context", 1133], ["of", 1141], ["global", 1144], ["commerce", 1151], [".", 1159]]}
{"context": "The RNA editing enzyme ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a guanosine. Here we assess cotranscriptional A-to-I editing in Drosophila by isolating nascent RNA from adult fly heads and subjecting samples to high throughput sequencing. There are a large number of edited sites within nascent exons. Nascent RNA from an ADAR-null strain was also sequenced, indicating that almost all A-to-I events require ADAR. Moreover, mRNA editing levels correlate with editing levels within the cognate nascent RNA sequence, indicating that the extent of editing is set cotranscriptionally. Surprisingly, the nascent data also identify an excess of intronic over exonic editing sites. These intronic sites occur preferentially within introns that are poorly spliced cotranscriptionally, suggesting a link between editing and splicing. We conclude that ADAR-mediated editing is more widespread than previously indicated and largely occurs cotranscriptionally.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "3b3c2659bbbc4cff90c610175d5dae05", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[158, 158], [4, 4], [71, 71], [90, 90]], "char_spans": [[896, 899], [23, 26], [376, 379], [462, 465]]}]}], "context_tokens": [["The", 0], ["RNA", 4], ["editing", 8], ["enzyme", 16], ["ADAR", 23], ["chemically", 28], ["modifies", 39], ["adenosine", 48], ["(", 58], ["A", 59], [")", 60], ["to", 62], ["inosine", 65], ["(", 73], ["I", 74], [")", 75], [",", 76], ["which", 78], ["is", 84], ["interpreted", 87], ["by", 99], ["the", 102], ["ribosome", 106], ["as", 115], ["a", 118], ["guanosine", 120], [".", 129], ["Here", 131], ["we", 136], ["assess", 139], ["cotranscriptional", 146], ["A", 164], ["-", 165], ["to", 166], ["-", 168], ["I", 169], ["editing", 171], ["in", 179], ["Drosophila", 182], ["by", 193], ["isolating", 196], ["nascent", 206], ["RNA", 214], ["from", 218], ["adult", 223], ["fly", 229], ["heads", 233], ["and", 239], ["subjecting", 243], ["samples", 254], ["to", 262], ["high", 265], ["throughput", 270], ["sequencing", 281], [".", 291], ["There", 293], ["are", 299], ["a", 303], ["large", 305], ["number", 311], ["of", 318], ["edited", 321], ["sites", 328], ["within", 334], ["nascent", 341], ["exons", 349], [".", 354], ["Nascent", 356], ["RNA", 364], ["from", 368], ["an", 373], ["ADAR", 376], ["-", 380], ["null", 381], ["strain", 386], ["was", 393], ["also", 397], ["sequenced", 402], [",", 411], ["indicating", 413], ["that", 424], ["almost", 429], ["all", 436], ["A", 440], ["-", 441], ["to", 442], ["-", 444], ["I", 445], ["events", 447], ["require", 454], ["ADAR", 462], [".", 466], ["Moreover", 468], [",", 476], ["mRNA", 478], ["editing", 483], ["levels", 491], ["correlate", 498], ["with", 508], ["editing", 513], ["levels", 521], ["within", 528], ["the", 535], ["cognate", 539], ["nascent", 547], ["RNA", 555], ["sequence", 559], [",", 567], ["indicating", 569], ["that", 580], ["the", 585], ["extent", 589], ["of", 596], ["editing", 599], ["is", 607], ["set", 610], ["cotranscriptionally", 614], [".", 633], ["Surprisingly", 635], [",", 647], ["the", 649], ["nascent", 653], ["data", 661], ["also", 666], ["identify", 671], ["an", 680], ["excess", 683], ["of", 690], ["intronic", 693], ["over", 702], ["exonic", 707], ["editing", 714], ["sites", 722], [".", 727], ["These", 729], ["intronic", 735], ["sites", 744], ["occur", 750], ["preferentially", 756], ["within", 771], ["introns", 778], ["that", 786], ["are", 791], ["poorly", 795], ["spliced", 802], ["cotranscriptionally", 810], [",", 829], ["suggesting", 831], ["a", 842], ["link", 844], ["between", 849], ["editing", 857], ["and", 865], ["splicing", 869], [".", 877], ["We", 879], ["conclude", 882], ["that", 891], ["ADAR", 896], ["-", 900], ["mediated", 901], ["editing", 910], ["is", 918], ["more", 921], ["widespread", 926], ["than", 937], ["previously", 942], ["indicated", 953], ["and", 963], ["largely", 967], ["occurs", 975], ["cotranscriptionally", 982], [".", 1001]]}
{"context": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA, which typically function as stop codon. The function of HSelP remains unclear, in part due to the inability to express it by gene recombinant technique. This study is to investigate expression and purification of recombinant HSelP in prokaryotic expression system, and its activity to induce apoptosis in vitro. The shorter HSelP isoform was cloned. After the selenocysteine (SeCys) at 40th position from N terminus of the HSelP shorter isoform was mutated into cysteine by PCR, it was expressed in E. coli. The expressed product was purified with DEAE column and identified by Western blot. Subsequently, its function on induction of mitochondrial apoptotic activity was studied. The mutant HSelP shorter isoform expressed in prokaryotic system was purified by DEAE column to 90% homogeneity. The purified product, HSelP280m, induced the opening of mitochondrial permeability transition pore (PTP) and decreased the transmembrane potential in a dose-dependent manner. These events could be abolished by PTP specific inhibitors. HSelP280m can induce the opening of mitochondrial PTP, which provides a basis for investigating the structure and function of recombinant HSelP.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "c67a56187ba94d478fbc8c8608cabb52", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[1, 2]], "char_spans": [[6, 20]]}]}], "context_tokens": [["Human", 0], ["selenoprotein", 6], ["P", 20], ["(", 22], ["HSelP", 23], [")", 28], ["is", 30], ["unique", 33], ["protein", 40], ["that", 48], ["contains", 53], ["10", 62], ["selenocysteines", 65], ["encoded", 81], ["by", 89], ["10", 92], ["inframe", 95], ["UGA", 103], [",", 106], ["which", 108], ["typically", 114], ["function", 124], ["as", 133], ["stop", 136], ["codon", 141], [".", 146], ["The", 148], ["function", 152], ["of", 161], ["HSelP", 164], ["remains", 170], ["unclear", 178], [",", 185], ["in", 187], ["part", 190], ["due", 195], ["to", 199], ["the", 202], ["inability", 206], ["to", 216], ["express", 219], ["it", 227], ["by", 230], ["gene", 233], ["recombinant", 238], ["technique", 250], [".", 259], ["This", 261], ["study", 266], ["is", 272], ["to", 275], ["investigate", 278], ["expression", 290], ["and", 301], ["purification", 305], ["of", 318], ["recombinant", 321], ["HSelP", 333], ["in", 339], ["prokaryotic", 342], ["expression", 354], ["system", 365], [",", 371], ["and", 373], ["its", 377], ["activity", 381], ["to", 390], ["induce", 393], ["apoptosis", 400], ["in", 410], ["vitro", 413], [".", 418], ["The", 420], ["shorter", 424], ["HSelP", 432], ["isoform", 438], ["was", 446], ["cloned", 450], [".", 456], ["After", 458], ["the", 464], ["selenocysteine", 468], ["(", 483], ["SeCys", 484], [")", 489], ["at", 491], ["40th", 494], ["position", 499], ["from", 508], ["N", 513], ["terminus", 515], ["of", 524], ["the", 527], ["HSelP", 531], ["shorter", 537], ["isoform", 545], ["was", 553], ["mutated", 557], ["into", 565], ["cysteine", 570], ["by", 579], ["PCR", 582], [",", 585], ["it", 587], ["was", 590], ["expressed", 594], ["in", 604], ["E.", 607], ["coli", 610], [".", 614], ["The", 616], ["expressed", 620], ["product", 630], ["was", 638], ["purified", 642], ["with", 651], ["DEAE", 656], ["column", 661], ["and", 668], ["identified", 672], ["by", 683], ["Western", 686], ["blot", 694], [".", 698], ["Subsequently", 700], [",", 712], ["its", 714], ["function", 718], ["on", 727], ["induction", 730], ["of", 740], ["mitochondrial", 743], ["apoptotic", 757], ["activity", 767], ["was", 776], ["studied", 780], [".", 787], ["The", 789], ["mutant", 793], ["HSelP", 800], ["shorter", 806], ["isoform", 814], ["expressed", 822], ["in", 832], ["prokaryotic", 835], ["system", 847], ["was", 854], ["purified", 858], ["by", 867], ["DEAE", 870], ["column", 875], ["to", 882], ["90", 885], ["%", 887], ["homogeneity", 889], [".", 900], ["The", 902], ["purified", 906], ["product", 915], [",", 922], ["HSelP280", 924], ["m", 932], [",", 933], ["induced", 935], ["the", 943], ["opening", 947], ["of", 955], ["mitochondrial", 958], ["permeability", 972], ["transition", 985], ["pore", 996], ["(", 1001], ["PTP", 1002], [")", 1005], ["and", 1007], ["decreased", 1011], ["the", 1021], ["transmembrane", 1025], ["potential", 1039], ["in", 1049], ["a", 1052], ["dose", 1054], ["-", 1058], ["dependent", 1059], ["manner", 1069], [".", 1075], ["These", 1077], ["events", 1083], ["could", 1090], ["be", 1096], ["abolished", 1099], ["by", 1109], ["PTP", 1112], ["specific", 1116], ["inhibitors", 1125], [".", 1135], ["HSelP280", 1137], ["m", 1145], ["can", 1147], ["induce", 1151], ["the", 1158], ["opening", 1162], ["of", 1170], ["mitochondrial", 1173], ["PTP", 1187], [",", 1190], ["which", 1192], ["provides", 1198], ["a", 1207], ["basis", 1209], ["for", 1215], ["investigating", 1219], ["the", 1233], ["structure", 1237], ["and", 1247], ["function", 1251], ["of", 1260], ["recombinant", 1263], ["HSelP.", 1275]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Defects in DNA mismatch repair have been shown to lead to increased genomic instability and mutability. We recently found that human cells defective in the DNA mismatch repair gene, hMSH2, were deficient in the transcription-coupled repair (TCR) of both oxidative DNA damage, including thymine glycols, and UV-induced DNA damage. However, in a hMLH1 mutant, only a reduction in the TCR of UV damage was observed. In this study, we examined whether TCR of thymine glycols in Saccharomyces cerecisiae also requires the genes involved in DNA mismatch repair. We found that yeast cells containing mutations in MSH2 were deficient in the removal of thymine glycols from the transcribed strand of the RPB2 gene, while cells with mutations in either MLH1 or PMS1 alone showed near normal levels of TCR of thymine glycols. Interestingly, double mutants in the MLH1 and PMS1 genes were deficient in TCR of thymine glycols. Taken together, these results suggest that these two MutL homologues can act independently of each other, but that they have overlapping roles in TCR. Overall levels of thymine glycol removal were not reduced in the mismatch repair mutants. In contrast to the results with thymine glycols, no defects in TCR of pyrimidine dimers were found in cells with mutations in MSH2, MLH1, PMS1, and MLH1/PMS1.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e3dbeab284f84daeb820a11a28cd701d", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[123, 124]], "char_spans": [[669, 686]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["shown", 41], ["to", 47], ["lead", 50], ["to", 55], ["increased", 58], ["genomic", 68], ["instability", 76], ["and", 88], ["mutability", 92], [".", 102], ["We", 104], ["recently", 107], ["found", 116], ["that", 122], ["human", 127], ["cells", 133], ["defective", 139], ["in", 149], ["the", 152], ["DNA", 156], ["mismatch", 160], ["repair", 169], ["gene", 176], [",", 180], ["hMSH2", 182], [",", 187], ["were", 189], ["deficient", 194], ["in", 204], ["the", 207], ["transcription", 211], ["-", 224], ["coupled", 225], ["repair", 233], ["(", 240], ["TCR", 241], [")", 244], ["of", 246], ["both", 249], ["oxidative", 254], ["DNA", 264], ["damage", 268], [",", 274], ["including", 276], ["thymine", 286], ["glycols", 294], [",", 301], ["and", 303], ["UV", 307], ["-", 309], ["induced", 310], ["DNA", 318], ["damage", 322], [".", 328], ["However", 330], [",", 337], ["in", 339], ["a", 342], ["hMLH1", 344], ["mutant", 350], [",", 356], ["only", 358], ["a", 363], ["reduction", 365], ["in", 375], ["the", 378], ["TCR", 382], ["of", 386], ["UV", 389], ["damage", 392], ["was", 399], ["observed", 403], [".", 411], ["In", 413], ["this", 416], ["study", 421], [",", 426], ["we", 428], ["examined", 431], ["whether", 440], ["TCR", 448], ["of", 452], ["thymine", 455], ["glycols", 463], ["in", 471], ["Saccharomyces", 474], ["cerecisiae", 488], ["also", 499], ["requires", 504], ["the", 513], ["genes", 517], ["involved", 523], ["in", 532], ["DNA", 535], ["mismatch", 539], ["repair", 548], [".", 554], ["We", 556], ["found", 559], ["that", 565], ["yeast", 570], ["cells", 576], ["containing", 582], ["mutations", 593], ["in", 603], ["MSH2", 606], ["were", 611], ["deficient", 616], ["in", 626], ["the", 629], ["removal", 633], ["of", 641], ["thymine", 644], ["glycols", 652], ["from", 660], ["the", 665], ["transcribed", 669], ["strand", 681], ["of", 688], ["the", 691], ["RPB2", 695], ["gene", 700], [",", 704], ["while", 706], ["cells", 712], ["with", 718], ["mutations", 723], ["in", 733], ["either", 736], ["MLH1", 743], ["or", 748], ["PMS1", 751], ["alone", 756], ["showed", 762], ["near", 769], ["normal", 774], ["levels", 781], ["of", 788], ["TCR", 791], ["of", 795], ["thymine", 798], ["glycols", 806], [".", 813], ["Interestingly", 815], [",", 828], ["double", 830], ["mutants", 837], ["in", 845], ["the", 848], ["MLH1", 852], ["and", 857], ["PMS1", 861], ["genes", 866], ["were", 872], ["deficient", 877], ["in", 887], ["TCR", 890], ["of", 894], ["thymine", 897], ["glycols", 905], [".", 912], ["Taken", 914], ["together", 920], [",", 928], ["these", 930], ["results", 936], ["suggest", 944], ["that", 952], ["these", 957], ["two", 963], ["MutL", 967], ["homologues", 972], ["can", 983], ["act", 987], ["independently", 991], ["of", 1005], ["each", 1008], ["other", 1013], [",", 1018], ["but", 1020], ["that", 1024], ["they", 1029], ["have", 1034], ["overlapping", 1039], ["roles", 1051], ["in", 1057], ["TCR", 1060], [".", 1063], ["Overall", 1065], ["levels", 1073], ["of", 1080], ["thymine", 1083], ["glycol", 1091], ["removal", 1098], ["were", 1106], ["not", 1111], ["reduced", 1115], ["in", 1123], ["the", 1126], ["mismatch", 1130], ["repair", 1139], ["mutants", 1146], [".", 1153], ["In", 1155], ["contrast", 1158], ["to", 1167], ["the", 1170], ["results", 1174], ["with", 1182], ["thymine", 1187], ["glycols", 1195], [",", 1202], ["no", 1204], ["defects", 1207], ["in", 1215], ["TCR", 1218], ["of", 1222], ["pyrimidine", 1225], ["dimers", 1236], ["were", 1243], ["found", 1248], ["in", 1254], ["cells", 1257], ["with", 1263], ["mutations", 1268], ["in", 1278], ["MSH2", 1281], [",", 1285], ["MLH1", 1287], [",", 1291], ["PMS1", 1293], [",", 1297], ["and", 1299], ["MLH1/PMS1", 1303], [".", 1312]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "MicroRNAs (miRNAs) play a major part in the post-transcriptional regulation of gene expression. Mammalian miRNA biogenesis begins with cotranscriptional cleavage of RNA polymerase II (Pol II) transcripts by the Microprocessor complex. Although most miRNAs are located within introns of protein-coding transcripts, a substantial minority of miRNAs originate from long noncoding (lnc) RNAs, for which transcript processing is largely uncharacterized. We show, by detailed characterization of liver-specific lnc-pri-miR-122 and genome-wide analysis in human cell lines, that most lncRNA transcripts containing miRNAs (lnc-pri-miRNAs) do not use the canonical cleavage-and-polyadenylation pathway but instead use Microprocessor cleavage to terminate transcription. Microprocessor inactivation leads to extensive transcriptional readthrough of lnc-pri-miRNA and transcriptional interference with downstream genes. Consequently we define a new RNase III-mediated, polyadenylation-independent mechanism of Pol II transcription termination in mammalian cells.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cc8c050eacbc476399b7a6d1ccc9c404", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[26, 28]], "char_spans": [[165, 181]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["play", 19], ["a", 24], ["major", 26], ["part", 32], ["in", 37], ["the", 40], ["post", 44], ["-", 48], ["transcriptional", 49], ["regulation", 65], ["of", 76], ["gene", 79], ["expression", 84], [".", 94], ["Mammalian", 96], ["miRNA", 106], ["biogenesis", 112], ["begins", 123], ["with", 130], ["cotranscriptional", 135], ["cleavage", 153], ["of", 162], ["RNA", 165], ["polymerase", 169], ["II", 180], ["(", 183], ["Pol", 184], ["II", 188], [")", 190], ["transcripts", 192], ["by", 204], ["the", 207], ["Microprocessor", 211], ["complex", 226], [".", 233], ["Although", 235], ["most", 244], ["miRNAs", 249], ["are", 256], ["located", 260], ["within", 268], ["introns", 275], ["of", 283], ["protein", 286], ["-", 293], ["coding", 294], ["transcripts", 301], [",", 312], ["a", 314], ["substantial", 316], ["minority", 328], ["of", 337], ["miRNAs", 340], ["originate", 347], ["from", 357], ["long", 362], ["noncoding", 367], ["(", 377], ["lnc", 378], [")", 381], ["RNAs", 383], [",", 387], ["for", 389], ["which", 393], ["transcript", 399], ["processing", 410], ["is", 421], ["largely", 424], ["uncharacterized", 432], [".", 447], ["We", 449], ["show", 452], [",", 456], ["by", 458], ["detailed", 461], ["characterization", 470], ["of", 487], ["liver", 490], ["-", 495], ["specific", 496], ["lnc", 505], ["-", 508], ["pri", 509], ["-", 512], ["miR-122", 513], ["and", 521], ["genome", 525], ["-", 531], ["wide", 532], ["analysis", 537], ["in", 546], ["human", 549], ["cell", 555], ["lines", 560], [",", 565], ["that", 567], ["most", 572], ["lncRNA", 577], ["transcripts", 584], ["containing", 596], ["miRNAs", 607], ["(", 614], ["lnc", 615], ["-", 618], ["pri", 619], ["-", 622], ["miRNAs", 623], [")", 629], ["do", 631], ["not", 634], ["use", 638], ["the", 642], ["canonical", 646], ["cleavage", 656], ["-", 664], ["and", 665], ["-", 668], ["polyadenylation", 669], ["pathway", 685], ["but", 693], ["instead", 697], ["use", 705], ["Microprocessor", 709], ["cleavage", 724], ["to", 733], ["terminate", 736], ["transcription", 746], [".", 759], ["Microprocessor", 761], ["inactivation", 776], ["leads", 789], ["to", 795], ["extensive", 798], ["transcriptional", 808], ["readthrough", 824], ["of", 836], ["lnc", 839], ["-", 842], ["pri", 843], ["-", 846], ["miRNA", 847], ["and", 853], ["transcriptional", 857], ["interference", 873], ["with", 886], ["downstream", 891], ["genes", 902], [".", 907], ["Consequently", 909], ["we", 922], ["define", 925], ["a", 932], ["new", 934], ["RNase", 938], ["III", 944], ["-", 947], ["mediated", 948], [",", 956], ["polyadenylation", 958], ["-", 973], ["independent", 974], ["mechanism", 986], ["of", 996], ["Pol", 999], ["II", 1003], ["transcription", 1006], ["termination", 1020], ["in", 1032], ["mammalian", 1035], ["cells", 1045], [".", 1050]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, and competes effectively with catalase and glutathione peroxidase to scavenge low levels of hydrogen peroxide, including that derived from hemoglobin autoxidation. Low thioredoxin reductase activity in the erythrocyte is able to keep up with this basal oxidation and maintain the Prx2 in its reduced form, but exposure to exogenous hydrogen peroxide causes accumulation of the disulfide-linked dimer. The high cellular concentration means that although turnover is slow, erythrocyte Prx2 can act as a noncatalytic scavenger of hydrogen peroxide and a sink for hydrogen peroxide before turnover becomes limiting. The consequences of Prx2 oxidation for the erythrocyte are not well characterized, but mice deficient in this protein develop severe hemolytic anemia associated with Heinz body formation. Prx2, also known as calpromotin, regulates ion transport by associating with the membrane and activating the G\u00e1rdos channel. How Prx2 redox transformations are linked to membrane association and channel activation is yet to be established. In this review, we discuss the functional properties of Prx2 and its role as a major component of the erythrocyte antioxidant system.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "26a83e722adc4516a5e0f6a8f7c8caaa", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[212, 212], [7, 7]], "char_spans": [[1311, 1321], [29, 39]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["Prx2", 17], [")", 21], ["is", 23], ["an", 26], ["antioxidant", 29], ["enzyme", 41], ["that", 48], ["uses", 53], ["cysteine", 58], ["residues", 67], ["to", 76], ["decompose", 79], ["peroxides", 89], [".", 98], ["Prx2", 100], ["is", 105], ["the", 108], ["third", 112], ["most", 118], ["abundant", 123], ["protein", 132], ["in", 140], ["erythrocytes", 143], [",", 155], ["and", 157], ["competes", 161], ["effectively", 170], ["with", 182], ["catalase", 187], ["and", 196], ["glutathione", 200], ["peroxidase", 212], ["to", 223], ["scavenge", 226], ["low", 235], ["levels", 239], ["of", 246], ["hydrogen", 249], ["peroxide", 258], [",", 266], ["including", 268], ["that", 278], ["derived", 283], ["from", 291], ["hemoglobin", 296], ["autoxidation", 307], [".", 319], ["Low", 321], ["thioredoxin", 325], ["reductase", 337], ["activity", 347], ["in", 356], ["the", 359], ["erythrocyte", 363], ["is", 375], ["able", 378], ["to", 383], ["keep", 386], ["up", 391], ["with", 394], ["this", 399], ["basal", 404], ["oxidation", 410], ["and", 420], ["maintain", 424], ["the", 433], ["Prx2", 437], ["in", 442], ["its", 445], ["reduced", 449], ["form", 457], [",", 461], ["but", 463], ["exposure", 467], ["to", 476], ["exogenous", 479], ["hydrogen", 489], ["peroxide", 498], ["causes", 507], ["accumulation", 514], ["of", 527], ["the", 530], ["disulfide", 534], ["-", 543], ["linked", 544], ["dimer", 551], [".", 556], ["The", 558], ["high", 562], ["cellular", 567], ["concentration", 576], ["means", 590], ["that", 596], ["although", 601], ["turnover", 610], ["is", 619], ["slow", 622], [",", 626], ["erythrocyte", 628], ["Prx2", 640], ["can", 645], ["act", 649], ["as", 653], ["a", 656], ["noncatalytic", 658], ["scavenger", 671], ["of", 681], ["hydrogen", 684], ["peroxide", 693], ["and", 702], ["a", 706], ["sink", 708], ["for", 713], ["hydrogen", 717], ["peroxide", 726], ["before", 735], ["turnover", 742], ["becomes", 751], ["limiting", 759], [".", 767], ["The", 769], ["consequences", 773], ["of", 786], ["Prx2", 789], ["oxidation", 794], ["for", 804], ["the", 808], ["erythrocyte", 812], ["are", 824], ["not", 828], ["well", 832], ["characterized", 837], [",", 850], ["but", 852], ["mice", 856], ["deficient", 861], ["in", 871], ["this", 874], ["protein", 879], ["develop", 887], ["severe", 895], ["hemolytic", 902], ["anemia", 912], ["associated", 919], ["with", 930], ["Heinz", 935], ["body", 941], ["formation", 946], [".", 955], ["Prx2", 957], [",", 961], ["also", 963], ["known", 968], ["as", 974], ["calpromotin", 977], [",", 988], ["regulates", 990], ["ion", 1000], ["transport", 1004], ["by", 1014], ["associating", 1017], ["with", 1029], ["the", 1034], ["membrane", 1038], ["and", 1047], ["activating", 1051], ["the", 1062], ["G\u00e1rdos", 1066], ["channel", 1073], [".", 1080], ["How", 1082], ["Prx2", 1086], ["redox", 1091], ["transformations", 1097], ["are", 1113], ["linked", 1117], ["to", 1124], ["membrane", 1127], ["association", 1136], ["and", 1148], ["channel", 1152], ["activation", 1160], ["is", 1171], ["yet", 1174], ["to", 1178], ["be", 1181], ["established", 1184], [".", 1195], ["In", 1197], ["this", 1200], ["review", 1205], [",", 1211], ["we", 1213], ["discuss", 1216], ["the", 1224], ["functional", 1228], ["properties", 1239], ["of", 1250], ["Prx2", 1253], ["and", 1258], ["its", 1262], ["role", 1266], ["as", 1271], ["a", 1274], ["major", 1276], ["component", 1282], ["of", 1292], ["the", 1295], ["erythrocyte", 1299], ["antioxidant", 1311], ["system", 1323], [".", 1329]]}
{"context": "We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66%), grade \u22653 neutropenia (49 versus 29%), thrombocytopenia (48 versus 34%), and all-grade infections (62 versus 49%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "a40400d3b6ae46289bee04c76ca63f0d", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[15, 15], [194, 194]], "char_spans": [[63, 75], [894, 906]]}]}], "context_tokens": [["We", 0], ["compared", 3], ["the", 12], ["safety", 16], ["and", 23], ["efficacy", 27], ["of", 36], ["siltuximab", 39], ["(", 50], ["S", 51], [")", 52], [",", 53], ["an", 55], ["anti", 58], ["-", 62], ["interleukin-6", 63], ["chimeric", 77], ["monoclonal", 86], ["antibody", 97], [",", 105], ["plus", 107], ["bortezomib", 112], ["(", 123], ["B", 124], [")", 125], ["with", 127], ["placebo", 132], ["(", 140], ["plc", 141], [")", 144], ["+", 146], ["B", 148], ["in", 150], ["patients", 153], ["with", 162], ["relapsed", 167], ["/", 175], ["refractory", 176], ["multiple", 187], ["myeloma", 196], ["in", 204], ["a", 207], ["randomized", 209], ["phase", 220], ["2", 226], ["study", 228], [".", 233], ["Siltuximab", 235], ["was", 246], ["given", 250], ["by", 256], ["6", 259], ["mg", 261], ["/", 263], ["kg", 264], ["IV", 267], ["every", 270], ["2", 276], ["weeks", 278], [".", 283], ["On", 285], ["progression", 288], [",", 299], ["B", 301], ["was", 303], ["discontinued", 307], ["and", 320], ["high", 324], ["-", 328], ["dose", 329], ["dexamethasone", 334], ["could", 348], ["be", 354], ["added", 357], ["to", 363], ["S", 366], ["/", 367], ["plc", 368], [".", 371], ["Response", 373], ["and", 382], ["progression", 386], ["-", 397], ["free", 398], ["survival", 403], ["(", 412], ["PFS", 413], [")", 416], ["were", 418], ["analyzed", 423], ["pre", 432], ["-", 435], ["dexamethasone", 436], ["by", 450], ["European", 453], ["Group", 462], ["for", 468], ["Blood", 472], ["and", 478], ["Marrow", 482], ["Transplantation", 489], ["(", 505], ["EBMT", 506], [")", 510], ["criteria", 512], [".", 520], ["For", 522], ["the", 526], ["281", 530], ["randomized", 534], ["patients", 545], [",", 553], ["median", 555], ["PFS", 562], ["for", 566], ["S", 570], ["+", 572], ["B", 574], ["and", 576], ["plc", 580], ["+", 584], ["B", 586], ["was", 588], ["8.0", 592], ["and", 596], ["7.6", 600], ["months", 604], ["(", 611], ["HR", 612], ["0.869", 615], [",", 620], ["P", 622], ["=", 624], ["0.345", 626], [")", 631], [",", 632], ["overall", 634], ["response", 642], ["rate", 651], ["was", 656], ["55", 660], ["versus", 663], ["47", 670], ["%", 672], ["(", 674], ["P", 675], ["=", 677], ["0.213", 679], [")", 684], [",", 685], ["complete", 687], ["response", 696], ["rate", 705], ["was", 710], ["11", 714], ["versus", 717], ["7", 724], ["%", 725], [",", 726], ["and", 728], ["median", 732], ["overall", 739], ["survival", 747], ["(", 756], ["OS", 757], [")", 759], ["was", 761], ["30.8", 765], ["versus", 770], ["36.8", 777], ["months", 782], ["(", 789], ["HR", 790], ["1.353", 793], [",", 798], ["P", 800], ["=", 802], ["0.103", 804], [")", 809], [".", 810], ["Sustained", 812], ["suppression", 822], ["of", 834], ["C", 837], ["-", 838], ["reactive", 839], ["protein", 848], [",", 855], ["a", 857], ["marker", 859], ["reflective", 866], ["of", 877], ["inhibition", 880], ["of", 891], ["interleukin-6", 894], ["activity", 908], [",", 916], ["was", 918], ["seen", 922], ["with", 927], ["S", 932], ["+", 934], ["B.", 936], ["Siltuximab", 939], ["did", 950], ["not", 954], ["affect", 958], ["B", 965], ["pharmacokinetics", 967], [".", 983], ["Siltuximab", 985], ["/", 995], ["placebo", 996], ["discontinuation", 1004], ["(", 1020], ["75", 1021], ["versus", 1024], ["66", 1031], ["%", 1033], [")", 1034], [",", 1035], ["grade", 1037], ["\u22653", 1043], ["neutropenia", 1046], ["(", 1058], ["49", 1059], ["versus", 1062], ["29", 1069], ["%", 1071], [")", 1072], [",", 1073], ["thrombocytopenia", 1075], ["(", 1092], ["48", 1093], ["versus", 1096], ["34", 1103], ["%", 1105], [")", 1106], [",", 1107], ["and", 1109], ["all", 1113], ["-", 1116], ["grade", 1117], ["infections", 1123], ["(", 1134], ["62", 1135], ["versus", 1138], ["49", 1145], ["%", 1147], [")", 1148], ["occurred", 1150], ["more", 1159], ["frequently", 1164], ["with", 1175], ["S", 1180], ["+", 1182], ["B.", 1184], ["The", 1187], ["addition", 1191], ["of", 1200], ["siltuximab", 1203], ["to", 1214], ["bortezomib", 1217], ["did", 1228], ["not", 1232], ["appear", 1236], ["to", 1243], ["improve", 1246], ["PFS", 1254], ["or", 1258], ["OS", 1261], ["despite", 1264], ["a", 1272], ["numerical", 1274], ["increase", 1284], ["in", 1293], ["response", 1296], ["rate", 1305], ["in", 1310], ["patients", 1313], ["with", 1322], ["relapsed", 1327], ["or", 1336], ["refractory", 1339], ["multiple", 1350], ["myeloma", 1359], [".", 1366]]}
{"context": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose. Flumazenil is known to induce cardiac arythmias and seizures, in part because of drug interactions. We present a 75-year-old woman, who was brought to the Emergency Department with a drug overdose following a suicide attempt. She developed generalized seizures shortly after the administration of flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b31d0f65b3754a4091a4d59b39e2a6a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[24, 24], [0, 0], [74, 74]], "char_spans": [[153, 162], [0, 9], [450, 459]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["benzodiazepine", 16], ["antagonist", 31], [".", 41], ["It", 43], ["is", 46], ["widely", 49], ["used", 56], ["as", 61], ["an", 64], ["antidote", 67], ["in", 76], ["comatose", 79], ["patients", 88], ["suspected", 97], ["of", 107], ["having", 110], ["ingested", 117], ["a", 126], ["benzodiazepine", 128], ["overdose", 143], [".", 151], ["Flumazenil", 153], ["is", 164], ["known", 167], ["to", 173], ["induce", 176], ["cardiac", 183], ["arythmias", 191], ["and", 201], ["seizures", 205], [",", 213], ["in", 215], ["part", 218], ["because", 223], ["of", 231], ["drug", 234], ["interactions", 239], [".", 251], ["We", 253], ["present", 256], ["a", 264], ["75-year", 266], ["-", 273], ["old", 274], ["woman", 278], [",", 283], ["who", 285], ["was", 289], ["brought", 293], ["to", 301], ["the", 304], ["Emergency", 308], ["Department", 318], ["with", 329], ["a", 334], ["drug", 336], ["overdose", 341], ["following", 350], ["a", 360], ["suicide", 362], ["attempt", 370], [".", 377], ["She", 379], ["developed", 383], ["generalized", 393], ["seizures", 405], ["shortly", 414], ["after", 422], ["the", 428], ["administration", 432], ["of", 447], ["flumazenil", 450], [".", 460]]}
{"context": "Protein-protein interactions are essential for many cellular processes. We have developed a technology called light-activated dimerization (LAD) to artificially induce protein hetero- and homodimerization in live cells using light. Using the FKF1 and GIGANTEA (GI) proteins of Arabidopsis thaliana, we have generated protein tags whose interaction is controlled by blue light. We demonstrated the utility of this system with LAD constructs that can recruit the small G-protein Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination. We also generated a light-activated transcription factor by fusing domains of GI and FKF1 to the DNA binding domain of Gal4 and the transactivation domain of VP16, respectively, showing that this technology is easily adapted to other systems. These studies set the stage for the development of light-regulated signaling molecules for controlling receptor activation, synapse formation and other signaling events in organisms.", "qas": [{"question": "Which G protein is essential in the formation and function of lamellipodia?", "answers": ["Rac1"], "qid": "9bf503906c3b425bb54cf156d27e9101", "question_tokens": [["Which", 0], ["G", 6], ["protein", 8], ["is", 16], ["essential", 19], ["in", 29], ["the", 32], ["formation", 36], ["and", 46], ["function", 50], ["of", 59], ["lamellipodia", 62], ["?", 74]], "detected_answers": [{"text": "Rac1", "token_spans": [[81, 81]], "char_spans": [[477, 480]]}]}], "context_tokens": [["Protein", 0], ["-", 7], ["protein", 8], ["interactions", 16], ["are", 29], ["essential", 33], ["for", 43], ["many", 47], ["cellular", 52], ["processes", 61], [".", 70], ["We", 72], ["have", 75], ["developed", 80], ["a", 90], ["technology", 92], ["called", 103], ["light", 110], ["-", 115], ["activated", 116], ["dimerization", 126], ["(", 139], ["LAD", 140], [")", 143], ["to", 145], ["artificially", 148], ["induce", 161], ["protein", 168], ["hetero-", 176], ["and", 184], ["homodimerization", 188], ["in", 205], ["live", 208], ["cells", 213], ["using", 219], ["light", 225], [".", 230], ["Using", 232], ["the", 238], ["FKF1", 242], ["and", 247], ["GIGANTEA", 251], ["(", 260], ["GI", 261], [")", 263], ["proteins", 265], ["of", 274], ["Arabidopsis", 277], ["thaliana", 289], [",", 297], ["we", 299], ["have", 302], ["generated", 307], ["protein", 317], ["tags", 325], ["whose", 330], ["interaction", 336], ["is", 348], ["controlled", 351], ["by", 362], ["blue", 365], ["light", 370], [".", 375], ["We", 377], ["demonstrated", 380], ["the", 393], ["utility", 397], ["of", 405], ["this", 408], ["system", 413], ["with", 420], ["LAD", 425], ["constructs", 429], ["that", 440], ["can", 445], ["recruit", 449], ["the", 457], ["small", 461], ["G", 467], ["-", 468], ["protein", 469], ["Rac1", 477], ["to", 482], ["the", 485], ["plasma", 489], ["membrane", 496], ["and", 505], ["induce", 509], ["the", 516], ["local", 520], ["formation", 526], ["of", 536], ["lamellipodia", 539], ["in", 552], ["response", 555], ["to", 564], ["focal", 567], ["illumination", 573], [".", 585], ["We", 587], ["also", 590], ["generated", 595], ["a", 605], ["light", 607], ["-", 612], ["activated", 613], ["transcription", 623], ["factor", 637], ["by", 644], ["fusing", 647], ["domains", 654], ["of", 662], ["GI", 665], ["and", 668], ["FKF1", 672], ["to", 677], ["the", 680], ["DNA", 684], ["binding", 688], ["domain", 696], ["of", 703], ["Gal4", 706], ["and", 711], ["the", 715], ["transactivation", 719], ["domain", 735], ["of", 742], ["VP16", 745], [",", 749], ["respectively", 751], [",", 763], ["showing", 765], ["that", 773], ["this", 778], ["technology", 783], ["is", 794], ["easily", 797], ["adapted", 804], ["to", 812], ["other", 815], ["systems", 821], [".", 828], ["These", 830], ["studies", 836], ["set", 844], ["the", 848], ["stage", 852], ["for", 858], ["the", 862], ["development", 866], ["of", 878], ["light", 881], ["-", 886], ["regulated", 887], ["signaling", 897], ["molecules", 907], ["for", 917], ["controlling", 921], ["receptor", 933], ["activation", 942], [",", 952], ["synapse", 954], ["formation", 962], ["and", 972], ["other", 976], ["signaling", 982], ["events", 992], ["in", 999], ["organisms", 1002], [".", 1011]]}
{"context": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that is characterized by splenomegaly and marked elevation of the blood leukocyte count with granulocyte in maturity. Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22. Abnormal ABL-related protein with increased tyrosine kinase activity suggested a molecular mechanism of CML. The BCR/ABL fusion gene can be found not only in the chromosome but in interphase nuclei by fluorescence in situ hybridization (FISH). We employed both fluorescence activated cell sorter (FACS) and FISH to study the lineage involvement of individual stem cells and progenitor cells in patients with CML. Evidence of BCR/ABL fusion was found in pluripotent stem cells (CD34+, Thy1+), myeloid cells, B progenitor cells (CD34+, CD19+) and T/NK progenitor cells (CD34+, CD7+, CD5+) but not mature T cells (CD3+) or natural killer cells (CD3-, CD56+). These data suggested that BCR/ABL gene fusion occurs in pluripotent stem cells and that Ph+ T cells and natural killer cells are eliminated during differentiation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "6d9bef92c6174aa29bde5d03ae2f5809", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[281, 285]], "char_spans": [[1444, 1462]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["hematopoietic", 36], ["stem", 50], ["cell", 55], ["disorder", 60], ["that", 69], ["is", 74], ["characterized", 77], ["by", 91], ["splenomegaly", 94], ["and", 107], ["marked", 111], ["elevation", 118], ["of", 128], ["the", 131], ["blood", 135], ["leukocyte", 141], ["count", 151], ["with", 157], ["granulocyte", 162], ["in", 174], ["maturity", 177], [".", 185], ["Ph", 187], ["chromosome", 190], ["was", 201], ["identified", 205], ["in", 216], ["CML", 219], ["in", 223], ["1960", 226], ["and", 231], ["was", 235], ["found", 239], ["to", 245], ["clearly", 248], ["result", 256], ["from", 263], ["reciprocal", 268], ["translocation", 279], ["between", 293], ["chromosome", 301], ["9", 312], ["and", 314], ["chromosome", 318], ["22", 329], ["(", 332], ["t(q;22", 333], [")", 339], [")", 340], ["(", 342], ["q34;q11", 343], [")", 350], [".", 351], ["CML", 353], ["arises", 357], ["from", 364], ["a", 369], ["single", 371], ["pluripotent", 378], ["hematopoietic", 390], ["stem", 404], ["cell", 409], ["with", 414], ["the", 419], ["Ph", 423], ["chromosome", 426], ["and", 437], ["demonstration", 441], ["of", 455], ["the", 458], ["Ph", 462], ["chromosome", 465], ["in", 476], ["blood", 479], ["or", 485], ["marrow", 488], ["cells", 495], ["establishes", 501], ["and", 513], ["unequivocal", 517], ["diagnosis", 529], ["of", 539], ["CML", 542], [".", 545], ["The", 547], ["Ph", 551], ["chromosome", 554], ["is", 565], ["recognized", 568], ["as", 579], ["the", 582], ["cytogenetic", 586], ["result", 598], ["of", 605], ["a", 608], ["rearrangement", 610], ["of", 624], ["the", 627], ["ABL", 631], ["gene", 635], ["on", 640], ["chromosome", 643], ["9", 654], ["and", 656], ["the", 660], ["BCL", 664], ["gene", 668], ["on", 673], ["chromosome", 676], ["22", 687], [",", 689], ["which", 691], ["leads", 697], ["to", 703], ["the", 706], ["creation", 710], ["of", 719], ["a", 722], ["BCR", 724], ["/", 727], ["ABL", 728], ["fusion", 732], ["gene", 739], ["on", 744], ["chromosome", 747], ["22", 758], [".", 760], ["Abnormal", 762], ["ABL", 771], ["-", 774], ["related", 775], ["protein", 783], ["with", 791], ["increased", 796], ["tyrosine", 806], ["kinase", 815], ["activity", 822], ["suggested", 831], ["a", 841], ["molecular", 843], ["mechanism", 853], ["of", 863], ["CML", 866], [".", 869], ["The", 871], ["BCR", 875], ["/", 878], ["ABL", 879], ["fusion", 883], ["gene", 890], ["can", 895], ["be", 899], ["found", 902], ["not", 908], ["only", 912], ["in", 917], ["the", 920], ["chromosome", 924], ["but", 935], ["in", 939], ["interphase", 942], ["nuclei", 953], ["by", 960], ["fluorescence", 963], ["in", 976], ["situ", 979], ["hybridization", 984], ["(", 998], ["FISH", 999], [")", 1003], [".", 1004], ["We", 1006], ["employed", 1009], ["both", 1018], ["fluorescence", 1023], ["activated", 1036], ["cell", 1046], ["sorter", 1051], ["(", 1058], ["FACS", 1059], [")", 1063], ["and", 1065], ["FISH", 1069], ["to", 1074], ["study", 1077], ["the", 1083], ["lineage", 1087], ["involvement", 1095], ["of", 1107], ["individual", 1110], ["stem", 1121], ["cells", 1126], ["and", 1132], ["progenitor", 1136], ["cells", 1147], ["in", 1153], ["patients", 1156], ["with", 1165], ["CML", 1170], [".", 1173], ["Evidence", 1175], ["of", 1184], ["BCR", 1187], ["/", 1190], ["ABL", 1191], ["fusion", 1195], ["was", 1202], ["found", 1206], ["in", 1212], ["pluripotent", 1215], ["stem", 1227], ["cells", 1232], ["(", 1238], ["CD34", 1239], ["+", 1243], [",", 1244], ["Thy1", 1246], ["+", 1250], [")", 1251], [",", 1252], ["myeloid", 1254], ["cells", 1262], [",", 1267], ["B", 1269], ["progenitor", 1271], ["cells", 1282], ["(", 1288], ["CD34", 1289], ["+", 1293], [",", 1294], ["CD19", 1296], ["+", 1300], [")", 1301], ["and", 1303], ["T", 1307], ["/", 1308], ["NK", 1309], ["progenitor", 1312], ["cells", 1323], ["(", 1329], ["CD34", 1330], ["+", 1334], [",", 1335], ["CD7", 1337], ["+", 1340], [",", 1341], ["CD5", 1343], ["+", 1346], [")", 1347], ["but", 1349], ["not", 1353], ["mature", 1357], ["T", 1364], ["cells", 1366], ["(", 1372], ["CD3", 1373], ["+", 1376], [")", 1377], ["or", 1379], ["natural", 1382], ["killer", 1390], ["cells", 1397], ["(", 1403], ["CD3-", 1404], [",", 1408], ["CD56", 1410], ["+", 1414], [")", 1415], [".", 1416], ["These", 1418], ["data", 1424], ["suggested", 1429], ["that", 1439], ["BCR", 1444], ["/", 1447], ["ABL", 1448], ["gene", 1452], ["fusion", 1457], ["occurs", 1464], ["in", 1471], ["pluripotent", 1474], ["stem", 1486], ["cells", 1491], ["and", 1497], ["that", 1501], ["Ph+", 1506], ["T", 1510], ["cells", 1512], ["and", 1518], ["natural", 1522], ["killer", 1530], ["cells", 1537], ["are", 1543], ["eliminated", 1547], ["during", 1558], ["differentiation", 1565], [".", 1580]]}
{"context": "Oral empagliflozin (Jardiance(\u00ae)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (\u2264104\u00a0weeks' duration; typically 24\u00a0weeks' duration) and extension studies (typically\u00a0\u226576\u00a0weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes. In a large phase III trial, as add-on therapy to metformin, empagliflozin was shown to be noninferior to glimepiride at 52 and 104\u00a0weeks and superior to glimepiride at 104\u00a0weeks, in terms of reductions in glycated haemoglobin level (primary endpoint). Empagliflozin was well tolerated by participants in these clinical trials, with most adverse events being mild or moderate in intensity. Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea. With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "95f5fe67a6334781a72627254072209a", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[49, 49], [14, 14]], "char_spans": [[270, 274], [69, 73]]}]}], "context_tokens": [["Oral", 0], ["empagliflozin", 5], ["(", 19], ["Jardiance", 20], ["(", 29], ["\u00ae", 30], [")", 31], [")", 32], [",", 33], ["a", 35], ["sodium", 37], ["glucose", 44], ["cotransporter-2", 52], ["(", 68], ["SGLT2", 69], [")", 74], ["inhibitor", 76], [",", 85], ["is", 87], ["a", 90], ["convenient", 92], ["once", 103], ["-", 107], ["daily", 108], ["treatment", 114], ["for", 124], ["adult", 128], ["patients", 134], ["with", 143], ["type", 148], ["2", 153], ["diabetes", 155], ["mellitus", 164], [".", 172], ["By", 174], ["inhibiting", 177], ["reabsorption", 188], ["of", 201], ["glucose", 204], ["from", 212], ["the", 217], ["proximal", 221], ["tubules", 230], ["in", 238], ["the", 241], ["kidney", 245], ["via", 252], ["inhibition", 256], ["of", 267], ["SGLT2", 270], [",", 275], ["empagliflozin", 277], ["provides", 291], ["a", 300], ["novel", 302], ["insulin", 308], ["-", 315], ["independent", 316], ["mechanism", 328], ["of", 338], ["lowering", 341], ["blood", 350], ["glucose", 356], [".", 363], ["In", 365], ["several", 368], ["phase", 376], ["III", 382], ["trials", 386], ["(", 393], ["\u2264104", 394], ["weeks", 399], ["'", 404], ["duration", 406], [";", 414], ["typically", 416], ["24", 426], ["weeks", 429], ["'", 434], ["duration", 436], [")", 444], ["and", 446], ["extension", 450], ["studies", 460], ["(", 468], ["typically", 469], ["\u226576", 479], ["weeks", 483], ["'", 488], ["treatment", 490], [")", 499], [",", 500], ["empagliflozin", 502], ["monotherapy", 516], ["or", 528], ["add", 531], ["-", 534], ["on", 535], ["therapy", 538], ["to", 546], ["other", 549], ["antihyperglycaemics", 555], [",", 574], ["including", 576], ["insulin", 586], [",", 593], ["improved", 595], ["glycaemic", 604], ["control", 614], ["and", 622], ["reduced", 626], ["bodyweight", 634], ["and", 645], ["systolic", 649], ["blood", 658], ["pressure", 664], ["in", 673], ["adult", 676], ["patients", 682], ["with", 691], ["type", 696], ["2", 701], ["diabetes", 703], [".", 711], ["In", 713], ["a", 716], ["large", 718], ["phase", 724], ["III", 730], ["trial", 734], [",", 739], ["as", 741], ["add", 744], ["-", 747], ["on", 748], ["therapy", 751], ["to", 759], ["metformin", 762], [",", 771], ["empagliflozin", 773], ["was", 787], ["shown", 791], ["to", 797], ["be", 800], ["noninferior", 803], ["to", 815], ["glimepiride", 818], ["at", 830], ["52", 833], ["and", 836], ["104", 840], ["weeks", 844], ["and", 850], ["superior", 854], ["to", 863], ["glimepiride", 866], ["at", 878], ["104", 881], ["weeks", 885], [",", 890], ["in", 892], ["terms", 895], ["of", 901], ["reductions", 904], ["in", 915], ["glycated", 918], ["haemoglobin", 927], ["level", 939], ["(", 945], ["primary", 946], ["endpoint", 954], [")", 962], [".", 963], ["Empagliflozin", 965], ["was", 979], ["well", 983], ["tolerated", 988], ["by", 998], ["participants", 1001], ["in", 1014], ["these", 1017], ["clinical", 1023], ["trials", 1032], [",", 1038], ["with", 1040], ["most", 1045], ["adverse", 1050], ["events", 1058], ["being", 1065], ["mild", 1071], ["or", 1076], ["moderate", 1079], ["in", 1088], ["intensity", 1091], [".", 1100], ["Empagliflozin", 1102], ["treatment", 1116], ["appeared", 1126], ["to", 1135], ["have", 1138], ["no", 1143], ["intrinsic", 1146], ["risk", 1156], ["of", 1161], ["hypoglycaemia", 1164], [",", 1177], ["although", 1179], ["hypoglycaemia", 1188], ["occurred", 1202], ["more", 1211], ["frequently", 1216], ["when", 1227], ["empagliflozin", 1232], ["was", 1246], ["coadministered", 1250], ["with", 1265], ["insulin", 1270], ["and/or", 1278], ["a", 1285], ["sulfonylurea", 1287], [".", 1299], ["With", 1301], ["its", 1306], ["insulin", 1310], ["-", 1317], ["independent", 1318], ["mechanism", 1330], ["of", 1340], ["action", 1343], [",", 1349], ["empagliflozin", 1351], ["monotherapy", 1365], ["or", 1377], ["combination", 1380], ["therapy", 1392], ["with", 1400], ["other", 1405], ["antidiabetic", 1411], ["drugs", 1424], [",", 1429], ["including", 1431], ["insulin", 1441], [",", 1448], ["provides", 1450], ["a", 1459], ["useful", 1461], ["addition", 1468], ["to", 1477], ["the", 1480], ["therapeutic", 1484], ["options", 1496], ["for", 1504], ["the", 1508], ["management", 1512], ["of", 1523], ["type", 1526], ["2", 1531], ["diabetes", 1533], [".", 1541], ["This", 1543], ["article", 1548], ["reviews", 1556], ["the", 1564], ["pharmacological", 1568], ["properties", 1584], ["and", 1595], ["clinical", 1599], ["use", 1608], ["of", 1612], ["empagliflozin", 1615], ["in", 1629], ["patients", 1632], ["with", 1641], ["type", 1646], ["2", 1651], ["diabetes", 1653], [".", 1661]]}
{"context": "Recently, bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia. A male infant developed severe hyperglycemia (446\u2009mg/dL) within 24\u2009h of birth. Acute abdominal concerns by day five necessitated exploratory surgery that revealed duodenal atresia, gallbladder agenesis, annular pancreas and intestinal malrotation. He also exhibited chronic diarrhea and feeding intolerance, cholestatic jaundice, and subsequent liver failure. He died of sepsis at four months old while awaiting liver transplantation. The phenotype of neonatal diabetes with intestinal atresia and biliary agenesis clearly pointed to RFX6 as the causative gene; indeed, whole exome sequencing revealed a novel homozygous RFX6 mutation c.779A>C; p.Lys260Thr (K260T). This missense mutation also changes the consensus 5' splice donor site before intron 7 and is thus predicted to cause disruption in splicing. Both parents, who were not known to be related, were heterozygous carriers. Targeted genetic testing based on consideration of phenotypic features may reveal a cause among the many genes now associated with heterogeneous forms of monogenic neonatal diabetes. Our study demonstrates the feasibility of using modern sequencing technology to identify one such rare cause. Continued research is needed to determine the possible cost-effectiveness of this approach, especially when clear phenotypic clues are absent. Further study of patients with RFX6 mutations should clarify its role in pancreatic, intestinal and enteroendocrine cellular development and explain features such as the diarrhea exhibited in our case.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "2e07fab624c345f486c1445ba1811034", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[120, 120], [135, 135], [261, 261], [10, 10]], "char_spans": [[750, 753], [837, 840], [1567, 1570], [59, 62]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["bi", 10], ["-", 12], ["allelic", 13], ["mutations", 21], ["in", 31], ["the", 34], ["transcription", 38], ["factor", 52], ["RFX6", 59], ["were", 64], ["described", 69], ["as", 79], ["the", 82], ["cause", 86], ["of", 92], ["a", 95], ["rare", 97], ["condition", 102], ["characterized", 112], ["by", 126], ["neonatal", 129], ["diabetes", 138], ["with", 147], ["pancreatic", 152], ["and", 163], ["biliary", 167], ["hypoplasia", 175], ["and", 186], ["duodenal", 190], ["/", 198], ["jejunal", 199], ["atresia", 207], [".", 214], ["A", 216], ["male", 218], ["infant", 223], ["developed", 230], ["severe", 240], ["hyperglycemia", 247], ["(", 261], ["446", 262], ["mg", 266], ["/", 268], ["dL", 269], [")", 271], ["within", 273], ["24", 280], ["h", 283], ["of", 285], ["birth", 288], [".", 293], ["Acute", 295], ["abdominal", 301], ["concerns", 311], ["by", 320], ["day", 323], ["five", 327], ["necessitated", 332], ["exploratory", 345], ["surgery", 357], ["that", 365], ["revealed", 370], ["duodenal", 379], ["atresia", 388], [",", 395], ["gallbladder", 397], ["agenesis", 409], [",", 417], ["annular", 419], ["pancreas", 427], ["and", 436], ["intestinal", 440], ["malrotation", 451], [".", 462], ["He", 464], ["also", 467], ["exhibited", 472], ["chronic", 482], ["diarrhea", 490], ["and", 499], ["feeding", 503], ["intolerance", 511], [",", 522], ["cholestatic", 524], ["jaundice", 536], [",", 544], ["and", 546], ["subsequent", 550], ["liver", 561], ["failure", 567], [".", 574], ["He", 576], ["died", 579], ["of", 584], ["sepsis", 587], ["at", 594], ["four", 597], ["months", 602], ["old", 609], ["while", 613], ["awaiting", 619], ["liver", 628], ["transplantation", 634], [".", 649], ["The", 651], ["phenotype", 655], ["of", 665], ["neonatal", 668], ["diabetes", 677], ["with", 686], ["intestinal", 691], ["atresia", 702], ["and", 710], ["biliary", 714], ["agenesis", 722], ["clearly", 731], ["pointed", 739], ["to", 747], ["RFX6", 750], ["as", 755], ["the", 758], ["causative", 762], ["gene", 772], [";", 776], ["indeed", 778], [",", 784], ["whole", 786], ["exome", 792], ["sequencing", 798], ["revealed", 809], ["a", 818], ["novel", 820], ["homozygous", 826], ["RFX6", 837], ["mutation", 842], ["c.779A", 851], [">", 857], ["C", 858], [";", 859], ["p", 861], [".", 862], ["Lys260Thr", 863], ["(", 873], ["K260", 874], ["T", 878], [")", 879], [".", 880], ["This", 882], ["missense", 887], ["mutation", 896], ["also", 905], ["changes", 910], ["the", 918], ["consensus", 922], ["5", 932], ["'", 933], ["splice", 935], ["donor", 942], ["site", 948], ["before", 953], ["intron", 960], ["7", 967], ["and", 969], ["is", 973], ["thus", 976], ["predicted", 981], ["to", 991], ["cause", 994], ["disruption", 1000], ["in", 1011], ["splicing", 1014], [".", 1022], ["Both", 1024], ["parents", 1029], [",", 1036], ["who", 1038], ["were", 1042], ["not", 1047], ["known", 1051], ["to", 1057], ["be", 1060], ["related", 1063], [",", 1070], ["were", 1072], ["heterozygous", 1077], ["carriers", 1090], [".", 1098], ["Targeted", 1100], ["genetic", 1109], ["testing", 1117], ["based", 1125], ["on", 1131], ["consideration", 1134], ["of", 1148], ["phenotypic", 1151], ["features", 1162], ["may", 1171], ["reveal", 1175], ["a", 1182], ["cause", 1184], ["among", 1190], ["the", 1196], ["many", 1200], ["genes", 1205], ["now", 1211], ["associated", 1215], ["with", 1226], ["heterogeneous", 1231], ["forms", 1245], ["of", 1251], ["monogenic", 1254], ["neonatal", 1264], ["diabetes", 1273], [".", 1281], ["Our", 1283], ["study", 1287], ["demonstrates", 1293], ["the", 1306], ["feasibility", 1310], ["of", 1322], ["using", 1325], ["modern", 1331], ["sequencing", 1338], ["technology", 1349], ["to", 1360], ["identify", 1363], ["one", 1372], ["such", 1376], ["rare", 1381], ["cause", 1386], [".", 1391], ["Continued", 1393], ["research", 1403], ["is", 1412], ["needed", 1415], ["to", 1422], ["determine", 1425], ["the", 1435], ["possible", 1439], ["cost", 1448], ["-", 1452], ["effectiveness", 1453], ["of", 1467], ["this", 1470], ["approach", 1475], [",", 1483], ["especially", 1485], ["when", 1496], ["clear", 1501], ["phenotypic", 1507], ["clues", 1518], ["are", 1524], ["absent", 1528], [".", 1534], ["Further", 1536], ["study", 1544], ["of", 1550], ["patients", 1553], ["with", 1562], ["RFX6", 1567], ["mutations", 1572], ["should", 1582], ["clarify", 1589], ["its", 1597], ["role", 1601], ["in", 1606], ["pancreatic", 1609], [",", 1619], ["intestinal", 1621], ["and", 1632], ["enteroendocrine", 1636], ["cellular", 1652], ["development", 1661], ["and", 1673], ["explain", 1677], ["features", 1685], ["such", 1694], ["as", 1699], ["the", 1702], ["diarrhea", 1706], ["exhibited", 1715], ["in", 1725], ["our", 1728], ["case", 1732], [".", 1736]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "Parkinson's disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8cb2d5ed371845bdbc1aef1bc23e2418", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[116, 118], [165, 167], [53, 55], [90, 92], [146, 148]], "char_spans": [[697, 711], [959, 973], [327, 341], [562, 576], [841, 855]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["characterized", 28], ["as", 42], ["a", 45], ["neurodegenerative", 47], ["movement", 65], ["disorder", 74], ["presenting", 83], ["with", 94], ["rigidity", 99], [",", 107], ["resting", 109], ["tremor", 117], [",", 123], ["disturbances", 125], ["in", 138], ["balance", 141], ["and", 149], ["slowness", 153], ["in", 162], ["movement", 165], [".", 173], ["An", 175], ["important", 178], ["pathologic", 188], ["feature", 199], ["of", 207], ["PD", 210], ["is", 213], ["the", 216], ["presence", 220], ["of", 229], ["Lewy", 232], ["bodies", 237], [".", 243], ["The", 245], ["primary", 249], ["structural", 257], ["component", 268], ["of", 278], ["Lewy", 281], ["bodies", 286], ["are", 293], ["fibrils", 297], ["composed", 305], ["primarily", 314], ["of", 324], ["alpha", 327], ["-", 332], ["synuclein", 333], [",", 342], ["a", 344], ["highly", 346], ["conserved", 353], ["140", 363], ["amino", 367], ["acid", 373], ["protein", 378], ["that", 386], ["is", 391], ["predominantly", 394], ["expressed", 408], ["in", 418], ["neurons", 421], ["and", 429], ["which", 433], ["may", 439], ["play", 443], ["a", 448], ["role", 450], ["in", 455], ["synaptic", 458], ["plasticity", 467], ["and", 478], ["neurotransmission", 482], [".", 499], ["Numerous", 501], ["studies", 510], ["suggest", 518], ["the", 526], ["aggregation", 530], ["and", 542], ["modification", 546], ["of", 559], ["alpha", 562], ["-", 567], ["synuclein", 568], ["as", 578], ["a", 581], ["key", 583], ["step", 587], ["leading", 592], ["to", 600], ["Lewy", 603], ["body", 608], ["formation", 613], ["and", 623], ["neuronal", 627], ["cell", 636], ["loss", 641], ["associated", 646], ["with", 657], ["PD", 662], [".", 664], ["Because", 666], ["of", 674], ["the", 677], ["central", 681], ["role", 689], ["of", 694], ["alpha", 697], ["-", 702], ["synuclein", 703], ["in", 713], ["PD", 716], [",", 718], ["it", 720], ["represents", 723], ["a", 734], ["novel", 736], ["drug", 742], ["target", 747], ["for", 754], ["the", 758], ["possible", 762], ["treatment", 771], ["of", 781], ["this", 784], ["disease", 789], [".", 796], ["In", 798], ["this", 801], ["review", 806], [",", 812], ["an", 814], ["overview", 817], ["of", 826], ["the", 829], ["role", 833], ["of", 838], ["alpha", 841], ["-", 846], ["synuclein", 847], ["in", 857], ["PD", 860], ["will", 863], ["be", 868], ["discussed", 871], ["with", 881], ["an", 886], ["emphasis", 889], ["on", 898], ["recent", 901], ["studies", 908], ["utilizing", 916], ["an", 926], ["immunization", 929], ["approach", 942], ["against", 951], ["alpha", 959], ["-", 964], ["synuclein", 965], ["as", 975], ["a", 978], ["possible", 980], ["treatment", 989], ["option", 999], ["for", 1006], ["this", 1010], ["debilitating", 1015], ["disease", 1028], [".", 1035]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of AS do not have an identifiable molecular defect. It is likely that most of those individuals have an AS-like syndrome that is clinically and molecularly distinct from AS. These AS-like syndromes can be broadly classified into chromosomal microdeletion and microduplication syndromes, and single-gene disorders. The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan\u2013McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion). The single-gene disorders include Pitt\u2013Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat\u2013Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome. They also include disorders due to mutations in HERC2, adenylosuccinase lyase (ADSL), CDKL5, FOXG1, MECP2 (duplications), MEF2C, and ATRX. Although many of these single-gene disorders can be caused by chromosomal microdeletions resulting in haploinsufficiency of the critical gene, the individual disorders are often caused by intragenic mutations that cannot be detected by chromosomal microarray analysis. We provide an overview of the clinical features of these syndromes, comparing and contrasting them with AS, in the hope that it will help guide clinicians in the diagnostic work-up of individuals with AS-like syndromes.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "ddf1ff17a2ea4e5088dd93222e4a7289", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[149, 149]], "char_spans": [[879, 884]]}]}], "context_tokens": [["Angelman", 0], ["syndrome", 9], ["(", 18], ["AS", 19], [")", 21], ["is", 23], ["caused", 26], ["by", 33], ["a", 36], ["lack", 38], ["of", 43], ["expression", 46], ["of", 57], ["the", 60], ["maternally", 64], ["inherited", 75], ["UBE3A", 85], ["gene", 91], ["in", 96], ["the", 99], ["brain", 103], [".", 108], ["However", 110], [",", 117], ["about", 119], ["10", 125], ["%", 127], ["of", 129], ["individuals", 132], ["with", 144], ["a", 149], ["clinical", 151], ["diagnosis", 160], ["of", 170], ["AS", 173], ["do", 176], ["not", 179], ["have", 183], ["an", 188], ["identifiable", 191], ["molecular", 204], ["defect", 214], [".", 220], ["It", 222], ["is", 225], ["likely", 228], ["that", 235], ["most", 240], ["of", 245], ["those", 248], ["individuals", 254], ["have", 266], ["an", 271], ["AS", 274], ["-", 276], ["like", 277], ["syndrome", 282], ["that", 291], ["is", 296], ["clinically", 299], ["and", 310], ["molecularly", 314], ["distinct", 326], ["from", 335], ["AS", 340], [".", 342], ["These", 344], ["AS", 350], ["-", 352], ["like", 353], ["syndromes", 358], ["can", 368], ["be", 372], ["broadly", 375], ["classified", 383], ["into", 394], ["chromosomal", 399], ["microdeletion", 411], ["and", 425], ["microduplication", 429], ["syndromes", 446], [",", 455], ["and", 457], ["single", 461], ["-", 467], ["gene", 468], ["disorders", 473], [".", 482], ["The", 484], ["microdeletion", 488], ["/", 501], ["microduplication", 502], ["syndromes", 519], ["are", 529], ["now", 533], ["easily", 537], ["identified", 544], ["by", 555], ["chromosomal", 558], ["microarray", 570], ["analysis", 581], ["and", 590], ["include", 594], ["Phelan", 602], ["\u2013", 608], ["McDermid", 609], ["syndrome", 618], ["(", 627], ["chromosome", 628], ["22q13.3", 639], ["deletion", 647], [")", 655], [",", 656], ["MBD5", 658], ["haploinsufficiency", 663], ["syndrome", 682], ["(", 691], ["chromosome", 692], ["2q23.1", 703], ["deletion", 710], [")", 718], [",", 719], ["and", 721], ["KANSL1", 725], ["haploinsufficiency", 732], ["syndrome", 751], ["(", 760], ["chromosome", 761], ["17q21.31", 772], ["deletion", 781], [")", 789], [".", 790], ["The", 792], ["single", 796], ["-", 802], ["gene", 803], ["disorders", 808], ["include", 818], ["Pitt", 826], ["\u2013", 830], ["Hopkins", 831], ["syndrome", 839], ["(", 848], ["TCF4", 849], [")", 853], [",", 854], ["Christianson", 856], ["syndrome", 869], ["(", 878], ["SLC9A6", 879], [")", 885], [",", 886], ["Mowat", 888], ["\u2013", 893], ["Wilson", 894], ["syndrome", 901], ["(", 910], ["ZEB2", 911], [")", 915], [",", 916], ["Kleefstra", 918], ["syndrome", 928], ["(", 937], ["EHMT1", 938], [")", 943], [",", 944], ["and", 946], ["Rett", 950], ["(", 955], ["MECP2", 956], [")", 961], ["syndrome", 963], [".", 971], ["They", 973], ["also", 978], ["include", 983], ["disorders", 991], ["due", 1001], ["to", 1005], ["mutations", 1008], ["in", 1018], ["HERC2", 1021], [",", 1026], ["adenylosuccinase", 1028], ["lyase", 1045], ["(", 1051], ["ADSL", 1052], [")", 1056], [",", 1057], ["CDKL5", 1059], [",", 1064], ["FOXG1", 1066], [",", 1071], ["MECP2", 1073], ["(", 1079], ["duplications", 1080], [")", 1092], [",", 1093], ["MEF2C", 1095], [",", 1100], ["and", 1102], ["ATRX", 1106], [".", 1110], ["Although", 1112], ["many", 1121], ["of", 1126], ["these", 1129], ["single", 1135], ["-", 1141], ["gene", 1142], ["disorders", 1147], ["can", 1157], ["be", 1161], ["caused", 1164], ["by", 1171], ["chromosomal", 1174], ["microdeletions", 1186], ["resulting", 1201], ["in", 1211], ["haploinsufficiency", 1214], ["of", 1233], ["the", 1236], ["critical", 1240], ["gene", 1249], [",", 1253], ["the", 1255], ["individual", 1259], ["disorders", 1270], ["are", 1280], ["often", 1284], ["caused", 1290], ["by", 1297], ["intragenic", 1300], ["mutations", 1311], ["that", 1321], ["can", 1326], ["not", 1329], ["be", 1333], ["detected", 1336], ["by", 1345], ["chromosomal", 1348], ["microarray", 1360], ["analysis", 1371], [".", 1379], ["We", 1381], ["provide", 1384], ["an", 1392], ["overview", 1395], ["of", 1404], ["the", 1407], ["clinical", 1411], ["features", 1420], ["of", 1429], ["these", 1432], ["syndromes", 1438], [",", 1447], ["comparing", 1449], ["and", 1459], ["contrasting", 1463], ["them", 1475], ["with", 1480], ["AS", 1485], [",", 1487], ["in", 1489], ["the", 1492], ["hope", 1496], ["that", 1501], ["it", 1506], ["will", 1509], ["help", 1514], ["guide", 1519], ["clinicians", 1525], ["in", 1536], ["the", 1539], ["diagnostic", 1543], ["work", 1554], ["-", 1558], ["up", 1559], ["of", 1562], ["individuals", 1565], ["with", 1577], ["AS", 1582], ["-", 1584], ["like", 1585], ["syndromes", 1590], [".", 1599]]}
{"context": "An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis. Idarucizumab is an antibody fragment that binds dabigatran with high affinity. It reverses the anticoagulant effect of dabigatran within minutes and is approved for the reversal of dabigatran during emergency situations. We describe the use of idarucizumab in the management of a 68-year-old woman who was taking dabigatran 150\u2009mg twice daily and ingested 125 capsules. Despite gastric lavage and administration of activated charcoal within two hours of drug intake, the activated partial thromboplastin time (aPTT) and prothrombin time (PT) remained prolonged. The administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26\u2009s, PT from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s). The initially planned emergency hemodialysis was canceled. This case highlights the potential use of idarucizumab for the management of massive dabigatran overdoses.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2b3f550f6fc74ff89e6391af6883b958", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[13, 13], [61, 61], [42, 42], [163, 163], [219, 219], [105, 105], [72, 72], [82, 82]], "char_spans": [[95, 104], [368, 377], [250, 259], [999, 1008], [1298, 1307], [633, 642], [439, 448], [501, 510]]}]}], "context_tokens": [["An", 0], ["overdose", 3], ["of", 12], ["oral", 15], ["anticoagulants", 20], ["represents", 35], ["a", 46], ["challenging", 48], ["scenario", 60], ["for", 69], ["emergency", 73], ["physicians", 83], [".", 93], ["Dabigatran", 95], [",", 105], ["an", 107], ["oral", 110], ["direct", 115], ["thrombin", 122], ["inhibitor", 131], [",", 140], ["is", 142], ["increasingly", 145], ["used", 158], ["in", 163], ["place", 166], ["of", 172], ["warfarin", 175], [".", 183], ["The", 185], ["lack", 189], ["of", 194], ["an", 197], ["antidote", 200], ["is", 209], ["a", 212], ["concern", 214], ["in", 222], ["patients", 225], ["who", 234], ["overdose", 238], ["on", 247], ["dabigatran", 250], [",", 260], ["even", 262], ["though", 267], ["the", 274], ["drug", 278], ["can", 283], ["be", 287], ["eliminated", 290], ["with", 301], ["hemodialysis", 306], [".", 318], ["Idarucizumab", 320], ["is", 333], ["an", 336], ["antibody", 339], ["fragment", 348], ["that", 357], ["binds", 362], ["dabigatran", 368], ["with", 379], ["high", 384], ["affinity", 389], [".", 397], ["It", 399], ["reverses", 402], ["the", 411], ["anticoagulant", 415], ["effect", 429], ["of", 436], ["dabigatran", 439], ["within", 450], ["minutes", 457], ["and", 465], ["is", 469], ["approved", 472], ["for", 481], ["the", 485], ["reversal", 489], ["of", 498], ["dabigatran", 501], ["during", 512], ["emergency", 519], ["situations", 529], [".", 539], ["We", 541], ["describe", 544], ["the", 553], ["use", 557], ["of", 561], ["idarucizumab", 564], ["in", 577], ["the", 580], ["management", 584], ["of", 595], ["a", 598], ["68-year", 600], ["-", 607], ["old", 608], ["woman", 612], ["who", 618], ["was", 622], ["taking", 626], ["dabigatran", 633], ["150", 644], ["mg", 648], ["twice", 651], ["daily", 657], ["and", 663], ["ingested", 667], ["125", 676], ["capsules", 680], [".", 688], ["Despite", 690], ["gastric", 698], ["lavage", 706], ["and", 713], ["administration", 717], ["of", 732], ["activated", 735], ["charcoal", 745], ["within", 754], ["two", 761], ["hours", 765], ["of", 771], ["drug", 774], ["intake", 779], [",", 785], ["the", 787], ["activated", 791], ["partial", 801], ["thromboplastin", 809], ["time", 824], ["(", 829], ["aPTT", 830], [")", 834], ["and", 836], ["prothrombin", 840], ["time", 852], ["(", 857], ["PT", 858], [")", 860], ["remained", 862], ["prolonged", 871], [".", 880], ["The", 882], ["administration", 886], ["of", 901], ["5", 904], ["g", 906], ["of", 908], ["intravenous", 911], ["idarucizumab", 923], ["promptly", 936], ["and", 945], ["completely", 949], ["reversed", 960], ["the", 969], ["anticoagulant", 973], ["activity", 987], ["of", 996], ["dabigatran", 999], ["as", 1010], ["assessed", 1013], ["by", 1022], ["routine", 1025], ["and", 1033], ["specific", 1037], ["coagulation", 1046], ["assays", 1058], ["(", 1065], ["aPTT", 1066], ["from", 1071], ["to", 1076], ["75", 1079], ["to", 1082], ["26", 1085], ["s", 1088], [",", 1089], ["PT", 1091], ["from", 1094], ["26", 1099], ["to", 1102], ["11", 1105], ["s", 1108], ["and", 1110], ["diluted", 1114], ["thrombin", 1122], ["time", 1131], ["from", 1136], ["92", 1141], ["to", 1144], ["27", 1147], ["s", 1150], [")", 1151], [".", 1152], ["The", 1154], ["initially", 1158], ["planned", 1168], ["emergency", 1176], ["hemodialysis", 1186], ["was", 1199], ["canceled", 1203], [".", 1211], ["This", 1213], ["case", 1218], ["highlights", 1223], ["the", 1234], ["potential", 1238], ["use", 1248], ["of", 1252], ["idarucizumab", 1255], ["for", 1268], ["the", 1272], ["management", 1276], ["of", 1287], ["massive", 1290], ["dabigatran", 1298], ["overdoses", 1309], [".", 1318]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "1d0edfd264d5465fadb7c6268c608128", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[229, 232]], "char_spans": [[1388, 1401]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["formation", 51], ["of", 61], ["a", 64], ["BCR", 66], ["-", 69], ["ABL", 70], ["fusion", 74], ["gene", 81], [",", 85], ["usually", 87], ["as", 95], ["a", 98], ["consequence", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["(", 132], ["Ph", 133], [")", 135], ["translocation", 137], ["between", 151], ["chromosomes", 159], ["9", 171], ["and", 173], ["22", 177], [".", 179], ["Recently", 181], ["the", 190], ["development", 194], ["of", 206], ["new", 209], ["fluorescence", 213], ["in", 226], ["-", 228], ["situ", 229], ["hybridization", 234], ["(", 248], ["FISH", 249], [")", 253], ["techniques", 255], ["has", 266], ["allowed", 270], ["identification", 278], ["of", 293], ["unexpected", 296], ["deletions", 307], ["of", 317], ["the", 320], ["reciprocal", 324], ["translocation", 335], ["product", 349], [",", 356], ["the", 358], ["derivative", 362], ["chromosome", 373], ["9", 384], [",", 385], ["in", 387], ["10", 390], ["%", 392], ["to", 394], ["15", 397], ["%", 399], ["of", 401], ["patients", 404], ["with", 413], ["CML", 418], [".", 421], ["These", 423], ["deletions", 429], ["are", 439], ["large", 443], [",", 448], ["span", 450], ["the", 455], ["translocation", 459], ["breakpoint", 473], [",", 483], ["and", 485], ["occur", 489], ["at", 495], ["the", 498], ["same", 502], ["time", 507], ["as", 512], ["the", 515], ["Ph", 519], ["translocation", 522], [".", 535], ["Such", 537], ["deletions", 542], ["therefore", 552], ["give", 562], ["rise", 567], ["to", 572], ["previously", 575], ["unsuspected", 586], ["molecular", 598], ["heterogeneity", 608], ["from", 622], ["the", 627], ["very", 631], ["beginning", 636], ["of", 646], ["this", 649], ["disease", 654], [",", 661], ["and", 663], ["there", 667], ["is", 673], ["mounting", 676], ["evidence", 685], ["for", 694], ["similar", 698], ["deletions", 706], ["associated", 716], ["with", 727], ["other", 732], ["translocations", 738], [".", 752], ["Several", 754], ["studies", 762], ["have", 770], ["demonstrated", 775], ["that", 788], ["CML", 793], ["patients", 797], ["who", 806], ["carry", 810], ["derivative", 816], ["chromosome", 827], ["9", 838], ["deletions", 840], ["exhibit", 850], ["a", 858], ["more", 860], ["rapid", 865], ["progression", 871], ["to", 883], ["blast", 886], ["crisis", 892], ["and", 899], ["a", 903], ["shorter", 905], ["survival", 913], [".", 921], ["Deletion", 923], ["status", 932], ["is", 939], ["independent", 942], ["of", 954], [",", 956], ["and", 958], ["more", 962], ["powerful", 967], ["than", 976], [",", 980], ["the", 982], ["Sokal", 986], ["and", 992], ["Hasford", 996], ["/", 1003], ["European", 1004], ["prognostic", 1013], ["scoring", 1024], ["systems", 1032], [".", 1039], ["The", 1041], ["poor", 1045], ["prognosis", 1050], ["associated", 1060], ["with", 1071], ["deletions", 1076], ["is", 1086], ["seen", 1089], ["in", 1094], ["patients", 1097], ["treated", 1106], ["with", 1114], ["hydroxyurea", 1119], ["or", 1131], ["interferon", 1134], [",", 1144], ["and", 1146], ["preliminary", 1150], ["evidence", 1162], ["suggests", 1171], ["that", 1180], ["patients", 1185], ["with", 1194], ["deletions", 1199], ["may", 1209], ["also", 1213], ["have", 1218], ["a", 1223], ["worse", 1225], ["outcome", 1231], ["than", 1239], ["nondeleted", 1244], ["patients", 1255], ["following", 1264], ["stem", 1274], ["cell", 1279], ["transplantation", 1284], ["or", 1300], ["treatment", 1303], ["with", 1313], ["imatinib", 1318], [".", 1326], ["Poor", 1328], ["outcome", 1333], ["can", 1341], ["not", 1344], ["be", 1348], ["attributed", 1351], ["to", 1362], ["loss", 1365], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["fusion", 1396], ["gene", 1403], ["expression", 1408], ["alone", 1419], [",", 1424], ["and", 1426], ["is", 1430], ["likely", 1433], ["to", 1440], ["reflect", 1443], ["loss", 1451], ["of", 1456], ["one", 1459], ["or", 1463], ["more", 1466], ["critical", 1471], ["genes", 1480], ["within", 1486], ["the", 1493], ["deleted", 1497], ["region", 1505], [".", 1511], ["The", 1513], ["molecular", 1517], ["heterogeneity", 1527], ["associated", 1541], ["with", 1552], ["the", 1557], ["Philadelphia", 1561], ["translocation", 1574], ["provides", 1588], ["a", 1597], ["new", 1599], ["paradigm", 1603], ["with", 1612], ["potential", 1617], ["relevance", 1627], ["to", 1637], ["all", 1640], ["malignancies", 1644], ["associated", 1657], ["with", 1668], ["reciprocal", 1673], ["chromosomal", 1684], ["translocations", 1696], ["and/or", 1711], ["fusion", 1718], ["gene", 1725], ["formation", 1730], [".", 1739]]}
{"context": "The McLeod syndrome is an X-linked disorder caused by mutations of the XK gene encoding the XK protein. The syndrome is characterized by absent Kx erythrocyte antigen, weak expression of Kell blood group system antigens, and acanthocytosis. In some allelic variants, elevated creatine kinase, myopathy, neurogenic muscle atrophy, and progressive chorea are found. We describe a family with a novel point mutation in the XK gene consisting of a C to T base transition at nucleotide position 977, introducing a stop codon. Among seven affected males, five manifested with psychiatric disorders such as depression, bipolar disorder, or personality disorder, but only two presented with chorea Positron emission tomography and magnetic resonance volumetry revealed reduced striatal 2-fluoro-2-deoxy-glucose (FDG) uptake and diminished volumes of the caudate nucleus and putamen that correlated with disease duration. In contrast, none of 12 female mutation carriers showed psychiatric or movement disorders. However, a semidominant effect of the mutation was suggested by erythrocyte and blood group mosaicism and reduced striatal FDG uptake without structural abnormalities. Therefore, patients with psychiatric signs or symptoms segregating in an X-linked trait should be examined for acanthocytosis and Kell/Kx blood group serology.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2f7b7e71153e42089cfb1ba8aff9bd9e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[18, 18], [75, 75], [14, 14]], "char_spans": [[92, 93], [420, 421], [71, 72]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["disorder", 35], ["caused", 44], ["by", 51], ["mutations", 54], ["of", 64], ["the", 67], ["XK", 71], ["gene", 74], ["encoding", 79], ["the", 88], ["XK", 92], ["protein", 95], [".", 102], ["The", 104], ["syndrome", 108], ["is", 117], ["characterized", 120], ["by", 134], ["absent", 137], ["Kx", 144], ["erythrocyte", 147], ["antigen", 159], [",", 166], ["weak", 168], ["expression", 173], ["of", 184], ["Kell", 187], ["blood", 192], ["group", 198], ["system", 204], ["antigens", 211], [",", 219], ["and", 221], ["acanthocytosis", 225], [".", 239], ["In", 241], ["some", 244], ["allelic", 249], ["variants", 257], [",", 265], ["elevated", 267], ["creatine", 276], ["kinase", 285], [",", 291], ["myopathy", 293], [",", 301], ["neurogenic", 303], ["muscle", 314], ["atrophy", 321], [",", 328], ["and", 330], ["progressive", 334], ["chorea", 346], ["are", 353], ["found", 357], [".", 362], ["We", 364], ["describe", 367], ["a", 376], ["family", 378], ["with", 385], ["a", 390], ["novel", 392], ["point", 398], ["mutation", 404], ["in", 413], ["the", 416], ["XK", 420], ["gene", 423], ["consisting", 428], ["of", 439], ["a", 442], ["C", 444], ["to", 446], ["T", 449], ["base", 451], ["transition", 456], ["at", 467], ["nucleotide", 470], ["position", 481], ["977", 490], [",", 493], ["introducing", 495], ["a", 507], ["stop", 509], ["codon", 514], [".", 519], ["Among", 521], ["seven", 527], ["affected", 533], ["males", 542], [",", 547], ["five", 549], ["manifested", 554], ["with", 565], ["psychiatric", 570], ["disorders", 582], ["such", 592], ["as", 597], ["depression", 600], [",", 610], ["bipolar", 612], ["disorder", 620], [",", 628], ["or", 630], ["personality", 633], ["disorder", 645], [",", 653], ["but", 655], ["only", 659], ["two", 664], ["presented", 668], ["with", 678], ["chorea", 683], ["Positron", 690], ["emission", 699], ["tomography", 708], ["and", 719], ["magnetic", 723], ["resonance", 732], ["volumetry", 742], ["revealed", 752], ["reduced", 761], ["striatal", 769], ["2-fluoro-2-deoxy", 778], ["-", 794], ["glucose", 795], ["(", 803], ["FDG", 804], [")", 807], ["uptake", 809], ["and", 816], ["diminished", 820], ["volumes", 831], ["of", 839], ["the", 842], ["caudate", 846], ["nucleus", 854], ["and", 862], ["putamen", 866], ["that", 874], ["correlated", 879], ["with", 890], ["disease", 895], ["duration", 903], [".", 911], ["In", 913], ["contrast", 916], [",", 924], ["none", 926], ["of", 931], ["12", 934], ["female", 937], ["mutation", 944], ["carriers", 953], ["showed", 962], ["psychiatric", 969], ["or", 981], ["movement", 984], ["disorders", 993], [".", 1002], ["However", 1004], [",", 1011], ["a", 1013], ["semidominant", 1015], ["effect", 1028], ["of", 1035], ["the", 1038], ["mutation", 1042], ["was", 1051], ["suggested", 1055], ["by", 1065], ["erythrocyte", 1068], ["and", 1080], ["blood", 1084], ["group", 1090], ["mosaicism", 1096], ["and", 1106], ["reduced", 1110], ["striatal", 1118], ["FDG", 1127], ["uptake", 1131], ["without", 1138], ["structural", 1146], ["abnormalities", 1157], [".", 1170], ["Therefore", 1172], [",", 1181], ["patients", 1183], ["with", 1192], ["psychiatric", 1197], ["signs", 1209], ["or", 1215], ["symptoms", 1218], ["segregating", 1227], ["in", 1239], ["an", 1242], ["X", 1245], ["-", 1246], ["linked", 1247], ["trait", 1254], ["should", 1260], ["be", 1267], ["examined", 1270], ["for", 1279], ["acanthocytosis", 1283], ["and", 1298], ["Kell", 1302], ["/", 1306], ["Kx", 1307], ["blood", 1310], ["group", 1316], ["serology", 1322], [".", 1330]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "Transactivation response DNA-binding protein 43 (TDP-43) proteinopathies are classified based upon the extent of modified TDP-43 and include a growing number of neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration with ubiquitin-immunoreactive, tau-negative inclusions and frontotemporal lobar degeneration with motor neuron disease. The purpose of the study was to examine whether proteolytic modifications of TDP-43 are a relevant finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A novel site-directed caspase cleavage antibody, termed TDP caspase cleavage product antibody (TDPccp), was utilized based upon a known caspase 3 cleavage consensus site within TDP-43 at position 219. Application of this antibody to postmortem brain sections from PD and DLB patients revealed the presence of caspase-cleaved TDP-43 in Lewy bodies and Hirano bodies in all cases examined. Colocalization of TDPccp with an antibody to alpha-synuclein (alpha-Syn), which served as a general marker for Lewy bodies, was evident within the substantia nigra in both alpha-synucleinopathies. Interestingly, the TDPccp antibody detected a greater number of Lewy bodies in PD and DLB compared to the alpha-Syn antibody. In addition, a semiquantitative analysis in both diseases confirmed this finding by indicating that the percentage of caspase-cleaved TDP-43 single-labeled Lewy bodies was approximately twice that of alpha-Syn labeling (in DLB 13.4 vs. 5.5%, while in PD 34.6 vs. 17.6%). Collectively, these data have identified caspase-cleaved TDP-43 as a primary component of Lewy and Hirano bodies in PD and DLB, and suggest that the TDPccp antibody is an effective marker for the detection of Lewy bodies in these neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4a93e831ea4b4c5fb6f059f0b2cca5be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[163, 165]], "char_spans": [[986, 1000]]}]}], "context_tokens": [["Transactivation", 0], ["response", 16], ["DNA", 25], ["-", 28], ["binding", 29], ["protein", 37], ["43", 45], ["(", 48], ["TDP-43", 49], [")", 55], ["proteinopathies", 57], ["are", 73], ["classified", 77], ["based", 88], ["upon", 94], ["the", 99], ["extent", 103], ["of", 110], ["modified", 113], ["TDP-43", 122], ["and", 129], ["include", 133], ["a", 141], ["growing", 143], ["number", 151], ["of", 158], ["neurodegenerative", 161], ["diseases", 179], ["such", 188], ["as", 193], ["amyotrophic", 196], ["lateral", 208], ["sclerosis", 216], [",", 225], ["frontotemporal", 227], ["lobar", 242], ["degeneration", 248], ["with", 261], ["ubiquitin", 266], ["-", 275], ["immunoreactive", 276], [",", 290], ["tau", 292], ["-", 295], ["negative", 296], ["inclusions", 305], ["and", 316], ["frontotemporal", 320], ["lobar", 335], ["degeneration", 341], ["with", 354], ["motor", 359], ["neuron", 365], ["disease", 372], [".", 379], ["The", 381], ["purpose", 385], ["of", 393], ["the", 396], ["study", 400], ["was", 406], ["to", 410], ["examine", 413], ["whether", 421], ["proteolytic", 429], ["modifications", 441], ["of", 455], ["TDP-43", 458], ["are", 465], ["a", 469], ["relevant", 471], ["finding", 480], ["in", 488], ["Parkinson", 491], ["'s", 500], ["disease", 503], ["(", 511], ["PD", 512], [")", 514], ["and", 516], ["dementia", 520], ["with", 529], ["Lewy", 534], ["bodies", 539], ["(", 546], ["DLB", 547], [")", 550], [".", 551], ["A", 553], ["novel", 555], ["site", 561], ["-", 565], ["directed", 566], ["caspase", 575], ["cleavage", 583], ["antibody", 592], [",", 600], ["termed", 602], ["TDP", 609], ["caspase", 613], ["cleavage", 621], ["product", 630], ["antibody", 638], ["(", 647], ["TDPccp", 648], [")", 654], [",", 655], ["was", 657], ["utilized", 661], ["based", 670], ["upon", 676], ["a", 681], ["known", 683], ["caspase", 689], ["3", 697], ["cleavage", 699], ["consensus", 708], ["site", 718], ["within", 723], ["TDP-43", 730], ["at", 737], ["position", 740], ["219", 749], [".", 752], ["Application", 754], ["of", 766], ["this", 769], ["antibody", 774], ["to", 783], ["postmortem", 786], ["brain", 797], ["sections", 803], ["from", 812], ["PD", 817], ["and", 820], ["DLB", 824], ["patients", 828], ["revealed", 837], ["the", 846], ["presence", 850], ["of", 859], ["caspase", 862], ["-", 869], ["cleaved", 870], ["TDP-43", 878], ["in", 885], ["Lewy", 888], ["bodies", 893], ["and", 900], ["Hirano", 904], ["bodies", 911], ["in", 918], ["all", 921], ["cases", 925], ["examined", 931], [".", 939], ["Colocalization", 941], ["of", 956], ["TDPccp", 959], ["with", 966], ["an", 971], ["antibody", 974], ["to", 983], ["alpha", 986], ["-", 991], ["synuclein", 992], ["(", 1002], ["alpha", 1003], ["-", 1008], ["Syn", 1009], [")", 1012], [",", 1013], ["which", 1015], ["served", 1021], ["as", 1028], ["a", 1031], ["general", 1033], ["marker", 1041], ["for", 1048], ["Lewy", 1052], ["bodies", 1057], [",", 1063], ["was", 1065], ["evident", 1069], ["within", 1077], ["the", 1084], ["substantia", 1088], ["nigra", 1099], ["in", 1105], ["both", 1108], ["alpha", 1113], ["-", 1118], ["synucleinopathies", 1119], [".", 1136], ["Interestingly", 1138], [",", 1151], ["the", 1153], ["TDPccp", 1157], ["antibody", 1164], ["detected", 1173], ["a", 1182], ["greater", 1184], ["number", 1192], ["of", 1199], ["Lewy", 1202], ["bodies", 1207], ["in", 1214], ["PD", 1217], ["and", 1220], ["DLB", 1224], ["compared", 1228], ["to", 1237], ["the", 1240], ["alpha", 1244], ["-", 1249], ["Syn", 1250], ["antibody", 1254], [".", 1262], ["In", 1264], ["addition", 1267], [",", 1275], ["a", 1277], ["semiquantitative", 1279], ["analysis", 1296], ["in", 1305], ["both", 1308], ["diseases", 1313], ["confirmed", 1322], ["this", 1332], ["finding", 1337], ["by", 1345], ["indicating", 1348], ["that", 1359], ["the", 1364], ["percentage", 1368], ["of", 1379], ["caspase", 1382], ["-", 1389], ["cleaved", 1390], ["TDP-43", 1398], ["single", 1405], ["-", 1411], ["labeled", 1412], ["Lewy", 1420], ["bodies", 1425], ["was", 1432], ["approximately", 1436], ["twice", 1450], ["that", 1456], ["of", 1461], ["alpha", 1464], ["-", 1469], ["Syn", 1470], ["labeling", 1474], ["(", 1483], ["in", 1484], ["DLB", 1487], ["13.4", 1491], ["vs.", 1496], ["5.5", 1500], ["%", 1503], [",", 1504], ["while", 1506], ["in", 1512], ["PD", 1515], ["34.6", 1518], ["vs.", 1523], ["17.6", 1527], ["%", 1531], [")", 1532], [".", 1533], ["Collectively", 1535], [",", 1547], ["these", 1549], ["data", 1555], ["have", 1560], ["identified", 1565], ["caspase", 1576], ["-", 1583], ["cleaved", 1584], ["TDP-43", 1592], ["as", 1599], ["a", 1602], ["primary", 1604], ["component", 1612], ["of", 1622], ["Lewy", 1625], ["and", 1630], ["Hirano", 1634], ["bodies", 1641], ["in", 1648], ["PD", 1651], ["and", 1654], ["DLB", 1658], [",", 1661], ["and", 1663], ["suggest", 1667], ["that", 1675], ["the", 1680], ["TDPccp", 1684], ["antibody", 1691], ["is", 1700], ["an", 1703], ["effective", 1706], ["marker", 1716], ["for", 1723], ["the", 1727], ["detection", 1731], ["of", 1741], ["Lewy", 1744], ["bodies", 1749], ["in", 1756], ["these", 1759], ["neurodegenerative", 1765], ["diseases", 1783], [".", 1791]]}
{"context": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6. These findings expand the clinical spectrum of the syndrome and indicate NHE6 dysfunction as a new cause of electrical status epilepticus during slow-wave sleep (ESES).", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9051b478ee6f41f98b58e2be06353573", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[100, 100], [13, 13]], "char_spans": [[576, 581], [64, 69]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["solute", 17], ["carrier", 24], ["family", 32], ["9", 39], [",", 40], ["subfamily", 42], ["A", 52], ["member", 54], ["6", 61], ["(", 63], ["SLC9A6", 64], [")", 70], ["gene", 72], [",", 76], ["encoding", 78], ["the", 87], ["endosomal", 91], ["Na+/H+", 101], ["exchanger", 108], ["6", 118], ["(", 120], ["NHE6", 121], [")", 125], ["are", 127], ["associated", 131], ["with", 142], ["Christianson", 147], ["syndrome", 160], [",", 168], ["a", 170], ["syndromic", 172], ["form", 182], ["of", 187], ["X", 190], ["-", 191], ["linked", 192], ["intellectual", 199], ["disability", 212], ["characterized", 223], ["by", 237], ["microcephaly", 240], [",", 252], ["severe", 254], ["global", 261], ["developmental", 268], ["delay", 282], [",", 287], ["autistic", 289], ["behavior", 298], [",", 306], ["early", 308], ["onset", 314], ["seizures", 320], ["and", 329], ["ataxia", 333], [".", 339], ["In", 341], ["a", 344], ["7-year", 346], ["-", 352], ["old", 353], ["boy", 357], ["with", 361], ["characteristic", 366], ["clinical", 381], ["and", 390], ["neuroimaging", 394], ["features", 407], ["of", 416], ["Christianson", 419], ["syndrome", 432], ["and", 441], ["epileptic", 445], ["encephalopathy", 455], ["with", 470], ["continuous", 475], ["spikes", 486], ["and", 493], ["waves", 497], ["during", 503], ["sleep", 510], [",", 515], ["we", 517], ["identified", 520], ["a", 531], ["novel", 533], ["splice", 539], ["site", 546], ["mutation", 551], ["(", 560], ["IVS10", 561], ["-", 566], ["1G", 567], [">", 569], ["A", 570], [")", 571], ["in", 573], ["SLC9A6", 576], [".", 582], ["These", 584], ["findings", 590], ["expand", 599], ["the", 606], ["clinical", 610], ["spectrum", 619], ["of", 628], ["the", 631], ["syndrome", 635], ["and", 644], ["indicate", 648], ["NHE6", 657], ["dysfunction", 662], ["as", 674], ["a", 677], ["new", 679], ["cause", 683], ["of", 689], ["electrical", 692], ["status", 703], ["epilepticus", 710], ["during", 722], ["slow", 729], ["-", 733], ["wave", 734], ["sleep", 739], ["(", 745], ["ESES", 746], [")", 750], [".", 751]]}
{"context": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1\u00a0h intravenous infusion weekly for 3\u00a0weeks every 4\u00a0weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30\u00a0months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee5c985a3d3b4cd89647bbe76b8def7b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[66, 68], [244, 246], [184, 186], [6, 8]], "char_spans": [[376, 384], [1416, 1422], [1081, 1087], [32, 38]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["an", 12], ["inhibitor", 15], ["of", 25], ["the", 28], ["Bcr", 32], ["-", 35], ["Abl", 36], ["tyrosine", 40], ["kinase", 49], [";", 55], ["however", 57], [",", 64], ["resistance", 66], ["is", 77], ["common", 80], [".", 86], ["Flavopiridol", 88], [",", 100], ["a", 102], ["cyclin", 104], ["-", 110], ["dependent", 111], ["kinase", 121], ["(", 128], ["CDK", 129], [")", 132], ["inhibitor", 134], [",", 143], ["down", 145], ["-", 149], ["regulates", 150], ["short", 160], ["-", 165], ["lived", 166], ["anti", 172], ["-", 176], ["apoptotic", 177], ["proteins", 187], ["via", 196], ["inhibition", 200], ["of", 211], ["transcription", 214], [".", 227], ["In", 229], ["preclinical", 232], ["studies", 244], [",", 251], ["flavopiridol", 253], ["synergizes", 266], ["with", 277], ["imatinib", 282], ["to", 291], ["induce", 294], ["apoptosis", 301], [".", 310], ["We", 312], ["investigated", 315], ["this", 328], ["novel", 333], ["combination", 339], ["regimen", 351], ["in", 359], ["patients", 362], ["with", 371], ["Bcr", 376], ["-", 379], ["Abl(+", 380], [")", 385], ["malignancies", 387], [".", 399], ["In", 401], ["a", 404], ["phase", 406], ["I", 412], ["dose", 414], ["-", 418], ["escalation", 419], ["study", 430], [",", 435], ["imatinib", 437], ["was", 446], ["administered", 450], ["orally", 463], ["daily", 470], [",", 475], ["and", 477], ["flavopiridol", 481], ["by", 494], ["1", 497], ["h", 499], ["intravenous", 501], ["infusion", 513], ["weekly", 522], ["for", 529], ["3", 533], ["weeks", 535], ["every", 541], ["4", 547], ["weeks", 549], [".", 554], ["Adults", 556], ["with", 563], ["chronic", 568], ["myelogenous", 576], ["leukemia", 588], ["or", 597], ["Philadelphia", 600], ["chromosome", 613], ["-", 623], ["positive", 624], ["acute", 633], ["leukemia", 639], ["were", 648], ["eligible", 653], [".", 661], ["Patients", 663], ["were", 672], ["divided", 677], ["into", 685], ["two", 690], ["strata", 694], ["based", 701], ["on", 707], ["peripheral", 710], ["blood", 721], ["and", 727], ["bone", 731], ["marrow", 736], ["blast", 743], ["counts", 749], [".", 755], ["The", 757], ["primary", 761], ["objective", 769], ["was", 779], ["to", 783], ["identify", 786], ["the", 795], ["recommended", 799], ["phase", 811], ["II", 817], ["doses", 820], ["for", 826], ["the", 830], ["combination", 834], [".", 845], ["Correlative", 847], ["pharmacokinetic", 859], ["and", 875], ["pharmacodynamic", 879], ["studies", 895], ["were", 903], ["also", 908], ["performed", 913], [".", 922], ["A", 924], ["total", 926], ["of", 932], ["21", 935], ["patients", 938], ["received", 947], ["study", 956], ["treatment", 962], [".", 971], ["Four", 973], ["dose", 978], ["levels", 983], ["were", 990], ["evaluated", 995], ["before", 1005], ["the", 1012], ["study", 1016], ["was", 1022], ["closed", 1026], ["following", 1033], ["the", 1043], ["approval", 1047], ["of", 1056], ["the", 1059], ["second", 1063], ["-", 1069], ["generation", 1070], ["Bcr", 1081], ["-", 1084], ["Abl", 1085], ["tyrosine", 1089], ["kinase", 1098], ["inhibitors", 1105], ["(", 1116], ["TKIs", 1117], [")", 1121], [".", 1122], ["Five", 1124], ["patients", 1129], ["responded", 1138], [",", 1147], ["including", 1149], ["four", 1159], ["sustained", 1164], ["responses", 1174], [".", 1183], ["Four", 1185], ["patients", 1190], ["had", 1199], ["stable", 1203], ["disease", 1210], [".", 1217], ["All", 1219], ["but", 1223], ["one", 1227], ["responder", 1231], [",", 1240], ["and", 1242], ["all", 1246], ["patients", 1250], ["with", 1259], ["stable", 1264], ["disease", 1271], ["had", 1279], ["previously", 1283], ["been", 1294], ["treated", 1299], ["with", 1307], ["imatinib", 1312], [".", 1320], ["One", 1322], ["patient", 1326], ["had", 1334], ["a", 1338], ["complete", 1340], ["response", 1349], ["sustained", 1358], ["for", 1368], ["30", 1372], ["months", 1375], [".", 1381], ["Changes", 1383], ["in", 1391], ["expression", 1394], ["of", 1405], ["phospho", 1408], ["-", 1415], ["Bcr", 1416], ["/", 1419], ["Abl", 1420], [",", 1423], ["-Stat5", 1425], [",", 1431], ["and", 1433], ["Mcl-1", 1437], ["were", 1443], ["monitored", 1448], [".", 1457], ["No", 1459], ["major", 1462], ["pharmacokinetic", 1468], ["interaction", 1484], ["was", 1496], ["observed", 1500], [".", 1508], ["This", 1510], ["is", 1515], ["the", 1518], ["first", 1522], ["study", 1528], ["to", 1534], ["evaluate", 1537], ["the", 1546], ["combination", 1550], ["of", 1562], ["a", 1565], ["CDK", 1567], ["inhibitor", 1571], ["and", 1581], ["a", 1585], ["TKI", 1587], ["in", 1591], ["humans", 1594], [".", 1600], ["The", 1602], ["combination", 1606], ["of", 1618], ["flavopiridol", 1621], ["and", 1634], ["imatinib", 1638], ["is", 1647], ["tolerable", 1650], ["and", 1660], ["produces", 1664], ["encouraging", 1673], ["responses", 1685], [",", 1694], ["including", 1696], ["in", 1706], ["some", 1709], ["patients", 1714], ["with", 1723], ["imatinib", 1728], ["-", 1736], ["resistant", 1737], ["disease", 1747], [".", 1754]]}
{"context": "Focal cortical dysplasia is a malformation of cortical development, which is the most common cause of medically refractory epilepsy in the pediatric population and the second/third most common etiology of medically intractable seizures in adults.Both genetic and acquired factors are involved in the pathogenesis of cortical dysplasia. Numerous classifications of the complex structural abnormalities of focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia are recognized.Type I focal cortical dysplasia with mild symptomatic expression and late onset, is more often seen in adults, with changes present in the temporal lobe.Clinical symptoms are more severe in type II of cortical dysplasia usually seen in children. In this type, more extensive changes occur outside the temporal lobe with predilection for the frontal lobes.New type III is one of the above dysplasias with associated another principal lesion as hippocampal sclerosis, tumor, vascular malformation or acquired pathology during early life.Brain MRI imaging shows abnormalities in the majority of type II dysplasias and in only some of type I cortical dysplasias.THE MOST COMMON FINDINGS ON MRI IMAGING INCLUDE: focal cortical thickening or thinning, areas of focal brain atrophy, blurring of the gray-white junction, increased signal on T2- and FLAIR-weighted images in the gray and subcortical white matter often tapering toward the ventricle. On the basis of the MRI findings, it is possible to differentiate between type I and type II cortical dysplasia. A complete resection of the epileptogenic zone is required for seizure-free life. MRI imaging is very helpful to identify those patients who are likely to benefit from surgical treatment in a group of patients with drug-resistant epilepsy.However, in type I cortical dysplasia, MR imaging is often normal, and also in both types the lesion seen on MRI may be smaller than the seizure-generating region seen in the EEG. The abnormalities may also involve vital for life brain parts, where curative surgery will not be an option. Therefore, other diagnostic imaging techniques such as FDG PET, MEG, DTI and intra-cranial EEG are widely used to establish the diagnosis and to decide on management.With advances in both genetics and neuroimaging, we may develop a better understanding of patients with drug-resistant epilepsy, which will help us to provide more successful pharmacological and/or surgical treatment in the future.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "6016428d0f8e493c8cbd0a4863c7c102", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[101, 103], [61, 63], [0, 2]], "char_spans": [[621, 644], [404, 427], [0, 23]]}]}], "context_tokens": [["Focal", 0], ["cortical", 6], ["dysplasia", 15], ["is", 25], ["a", 28], ["malformation", 30], ["of", 43], ["cortical", 46], ["development", 55], [",", 66], ["which", 68], ["is", 74], ["the", 77], ["most", 81], ["common", 86], ["cause", 93], ["of", 99], ["medically", 102], ["refractory", 112], ["epilepsy", 123], ["in", 132], ["the", 135], ["pediatric", 139], ["population", 149], ["and", 160], ["the", 164], ["second", 168], ["/", 174], ["third", 175], ["most", 181], ["common", 186], ["etiology", 193], ["of", 202], ["medically", 205], ["intractable", 215], ["seizures", 227], ["in", 236], ["adults", 239], [".", 245], ["Both", 246], ["genetic", 251], ["and", 259], ["acquired", 263], ["factors", 272], ["are", 280], ["involved", 284], ["in", 293], ["the", 296], ["pathogenesis", 300], ["of", 313], ["cortical", 316], ["dysplasia", 325], [".", 334], ["Numerous", 336], ["classifications", 345], ["of", 361], ["the", 364], ["complex", 368], ["structural", 376], ["abnormalities", 387], ["of", 401], ["focal", 404], ["cortical", 410], ["dysplasia", 419], ["have", 429], ["been", 434], ["proposed", 439], ["-", 448], ["from", 450], ["Taylor", 455], ["et", 462], ["al", 465], [".", 467], ["in", 469], ["1971", 472], ["to", 477], ["the", 480], ["last", 484], ["modification", 489], ["of", 502], ["Palmini", 505], ["classification", 513], ["made", 528], ["by", 533], ["Blumcke", 536], ["in", 544], ["2011", 547], [".", 551], ["In", 553], ["general", 556], [",", 563], ["three", 565], ["types", 571], ["of", 577], ["cortical", 580], ["dysplasia", 589], ["are", 599], ["recognized", 603], [".", 613], ["Type", 614], ["I", 619], ["focal", 621], ["cortical", 627], ["dysplasia", 636], ["with", 646], ["mild", 651], ["symptomatic", 656], ["expression", 668], ["and", 679], ["late", 683], ["onset", 688], [",", 693], ["is", 695], ["more", 698], ["often", 703], ["seen", 709], ["in", 714], ["adults", 717], [",", 723], ["with", 725], ["changes", 730], ["present", 738], ["in", 746], ["the", 749], ["temporal", 753], ["lobe", 762], [".", 766], ["Clinical", 767], ["symptoms", 776], ["are", 785], ["more", 789], ["severe", 794], ["in", 801], ["type", 804], ["II", 809], ["of", 812], ["cortical", 815], ["dysplasia", 824], ["usually", 834], ["seen", 842], ["in", 847], ["children", 850], [".", 858], ["In", 860], ["this", 863], ["type", 868], [",", 872], ["more", 874], ["extensive", 879], ["changes", 889], ["occur", 897], ["outside", 903], ["the", 911], ["temporal", 915], ["lobe", 924], ["with", 929], ["predilection", 934], ["for", 947], ["the", 951], ["frontal", 955], ["lobes", 963], [".", 968], ["New", 969], ["type", 973], ["III", 978], ["is", 982], ["one", 985], ["of", 989], ["the", 992], ["above", 996], ["dysplasias", 1002], ["with", 1013], ["associated", 1018], ["another", 1029], ["principal", 1037], ["lesion", 1047], ["as", 1054], ["hippocampal", 1057], ["sclerosis", 1069], [",", 1078], ["tumor", 1080], [",", 1085], ["vascular", 1087], ["malformation", 1096], ["or", 1109], ["acquired", 1112], ["pathology", 1121], ["during", 1131], ["early", 1138], ["life", 1144], [".", 1148], ["Brain", 1149], ["MRI", 1155], ["imaging", 1159], ["shows", 1167], ["abnormalities", 1173], ["in", 1187], ["the", 1190], ["majority", 1194], ["of", 1203], ["type", 1206], ["II", 1211], ["dysplasias", 1214], ["and", 1225], ["in", 1229], ["only", 1232], ["some", 1237], ["of", 1242], ["type", 1245], ["I", 1250], ["cortical", 1252], ["dysplasias", 1261], [".", 1271], ["THE", 1272], ["MOST", 1276], ["COMMON", 1281], ["FINDINGS", 1288], ["ON", 1297], ["MRI", 1300], ["IMAGING", 1304], ["INCLUDE", 1312], [":", 1319], ["focal", 1321], ["cortical", 1327], ["thickening", 1336], ["or", 1347], ["thinning", 1350], [",", 1358], ["areas", 1360], ["of", 1366], ["focal", 1369], ["brain", 1375], ["atrophy", 1381], [",", 1388], ["blurring", 1390], ["of", 1399], ["the", 1402], ["gray", 1406], ["-", 1410], ["white", 1411], ["junction", 1417], [",", 1425], ["increased", 1427], ["signal", 1437], ["on", 1444], ["T2-", 1447], ["and", 1451], ["FLAIR", 1455], ["-", 1460], ["weighted", 1461], ["images", 1470], ["in", 1477], ["the", 1480], ["gray", 1484], ["and", 1489], ["subcortical", 1493], ["white", 1505], ["matter", 1511], ["often", 1518], ["tapering", 1524], ["toward", 1533], ["the", 1540], ["ventricle", 1544], [".", 1553], ["On", 1555], ["the", 1558], ["basis", 1562], ["of", 1568], ["the", 1571], ["MRI", 1575], ["findings", 1579], [",", 1587], ["it", 1589], ["is", 1592], ["possible", 1595], ["to", 1604], ["differentiate", 1607], ["between", 1621], ["type", 1629], ["I", 1634], ["and", 1636], ["type", 1640], ["II", 1645], ["cortical", 1648], ["dysplasia", 1657], [".", 1666], ["A", 1668], ["complete", 1670], ["resection", 1679], ["of", 1689], ["the", 1692], ["epileptogenic", 1696], ["zone", 1710], ["is", 1715], ["required", 1718], ["for", 1727], ["seizure", 1731], ["-", 1738], ["free", 1739], ["life", 1744], [".", 1748], ["MRI", 1750], ["imaging", 1754], ["is", 1762], ["very", 1765], ["helpful", 1770], ["to", 1778], ["identify", 1781], ["those", 1790], ["patients", 1796], ["who", 1805], ["are", 1809], ["likely", 1813], ["to", 1820], ["benefit", 1823], ["from", 1831], ["surgical", 1836], ["treatment", 1845], ["in", 1855], ["a", 1858], ["group", 1860], ["of", 1866], ["patients", 1869], ["with", 1878], ["drug", 1883], ["-", 1887], ["resistant", 1888], ["epilepsy", 1898], [".", 1906], ["However", 1907], [",", 1914], ["in", 1916], ["type", 1919], ["I", 1924], ["cortical", 1926], ["dysplasia", 1935], [",", 1944], ["MR", 1946], ["imaging", 1949], ["is", 1957], ["often", 1960], ["normal", 1966], [",", 1972], ["and", 1974], ["also", 1978], ["in", 1983], ["both", 1986], ["types", 1991], ["the", 1997], ["lesion", 2001], ["seen", 2008], ["on", 2013], ["MRI", 2016], ["may", 2020], ["be", 2024], ["smaller", 2027], ["than", 2035], ["the", 2040], ["seizure", 2044], ["-", 2051], ["generating", 2052], ["region", 2063], ["seen", 2070], ["in", 2075], ["the", 2078], ["EEG", 2082], [".", 2085], ["The", 2087], ["abnormalities", 2091], ["may", 2105], ["also", 2109], ["involve", 2114], ["vital", 2122], ["for", 2128], ["life", 2132], ["brain", 2137], ["parts", 2143], [",", 2148], ["where", 2150], ["curative", 2156], ["surgery", 2165], ["will", 2173], ["not", 2178], ["be", 2182], ["an", 2185], ["option", 2188], [".", 2194], ["Therefore", 2196], [",", 2205], ["other", 2207], ["diagnostic", 2213], ["imaging", 2224], ["techniques", 2232], ["such", 2243], ["as", 2248], ["FDG", 2251], ["PET", 2255], [",", 2258], ["MEG", 2260], [",", 2263], ["DTI", 2265], ["and", 2269], ["intra", 2273], ["-", 2278], ["cranial", 2279], ["EEG", 2287], ["are", 2291], ["widely", 2295], ["used", 2302], ["to", 2307], ["establish", 2310], ["the", 2320], ["diagnosis", 2324], ["and", 2334], ["to", 2338], ["decide", 2341], ["on", 2348], ["management", 2351], [".", 2361], ["With", 2362], ["advances", 2367], ["in", 2376], ["both", 2379], ["genetics", 2384], ["and", 2393], ["neuroimaging", 2397], [",", 2409], ["we", 2411], ["may", 2414], ["develop", 2418], ["a", 2426], ["better", 2428], ["understanding", 2435], ["of", 2449], ["patients", 2452], ["with", 2461], ["drug", 2466], ["-", 2470], ["resistant", 2471], ["epilepsy", 2481], [",", 2489], ["which", 2491], ["will", 2497], ["help", 2502], ["us", 2507], ["to", 2510], ["provide", 2513], ["more", 2521], ["successful", 2526], ["pharmacological", 2537], ["and/or", 2553], ["surgical", 2560], ["treatment", 2569], ["in", 2579], ["the", 2582], ["future", 2586], [".", 2592]]}
{"context": "Recently mutations in the gene ZFHX1B (SIP1) were shown in patients with \"syndromic Hirschsprung disease\" with mental retardation (MR) and multiple congenital anomalies (MCA), but it was unclear if Hirschsprung disease is an obligate symptom of these mutations and if the distinct facial phenotype delineated by Mowat et al. [1998: J Med Genet 35: 617-623] is specific for ZFHX1B mutations. In order to address these open questions we analyzed the ZFHX1B gene in five patients, three of whom had \"syndromic Hirschsprung disease\" two with and one without the facial phenotype described by Mowat et al. [1998], and two of whom had the distinct facial gestalt without Hirschsprung disease. Analyses of microsatellite markers and newly identified SNPs, and/or FISH with BACs from the ZFHX1B region excluded large deletions in all five patients. Direct sequencing demonstrated truncating ZFHX1B mutations in all four patients with the characteristic facial phenotype, but not in the patient with syndromic Hirschsprung disease without the distinct facial appearance. We demonstrate that there is a specific clinical entity with a recognizable facial gestalt, mental retardation and variable MCAs which we propose be called the \"Mowat-Wilson syndrome.\"", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "49821b4f42eb402d87d1e96b5eaef2d8", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[5, 5], [74, 74], [148, 148], [87, 87], [162, 162]], "char_spans": [[31, 36], [373, 378], [780, 785], [448, 453], [883, 888]]}]}], "context_tokens": [["Recently", 0], ["mutations", 9], ["in", 19], ["the", 22], ["gene", 26], ["ZFHX1B", 31], ["(", 38], ["SIP1", 39], [")", 43], ["were", 45], ["shown", 50], ["in", 56], ["patients", 59], ["with", 68], ["\"", 73], ["syndromic", 74], ["Hirschsprung", 84], ["disease", 97], ["\"", 104], ["with", 106], ["mental", 111], ["retardation", 118], ["(", 130], ["MR", 131], [")", 133], ["and", 135], ["multiple", 139], ["congenital", 148], ["anomalies", 159], ["(", 169], ["MCA", 170], [")", 173], [",", 174], ["but", 176], ["it", 180], ["was", 183], ["unclear", 187], ["if", 195], ["Hirschsprung", 198], ["disease", 211], ["is", 219], ["an", 222], ["obligate", 225], ["symptom", 234], ["of", 242], ["these", 245], ["mutations", 251], ["and", 261], ["if", 265], ["the", 268], ["distinct", 272], ["facial", 281], ["phenotype", 288], ["delineated", 298], ["by", 309], ["Mowat", 312], ["et", 318], ["al", 321], [".", 323], ["[", 325], ["1998", 326], [":", 330], ["J", 332], ["Med", 334], ["Genet", 338], ["35", 344], [":", 346], ["617", 348], ["-", 351], ["623", 352], ["]", 355], ["is", 357], ["specific", 360], ["for", 369], ["ZFHX1B", 373], ["mutations", 380], [".", 389], ["In", 391], ["order", 394], ["to", 400], ["address", 403], ["these", 411], ["open", 417], ["questions", 422], ["we", 432], ["analyzed", 435], ["the", 444], ["ZFHX1B", 448], ["gene", 455], ["in", 460], ["five", 463], ["patients", 468], [",", 476], ["three", 478], ["of", 484], ["whom", 487], ["had", 492], ["\"", 496], ["syndromic", 497], ["Hirschsprung", 507], ["disease", 520], ["\"", 527], ["two", 529], ["with", 533], ["and", 538], ["one", 542], ["without", 546], ["the", 554], ["facial", 558], ["phenotype", 565], ["described", 575], ["by", 585], ["Mowat", 588], ["et", 594], ["al", 597], [".", 599], ["[", 601], ["1998", 602], ["]", 606], [",", 607], ["and", 609], ["two", 613], ["of", 617], ["whom", 620], ["had", 625], ["the", 629], ["distinct", 633], ["facial", 642], ["gestalt", 649], ["without", 657], ["Hirschsprung", 665], ["disease", 678], [".", 685], ["Analyses", 687], ["of", 696], ["microsatellite", 699], ["markers", 714], ["and", 722], ["newly", 726], ["identified", 732], ["SNPs", 743], [",", 747], ["and/or", 749], ["FISH", 756], ["with", 761], ["BACs", 766], ["from", 771], ["the", 776], ["ZFHX1B", 780], ["region", 787], ["excluded", 794], ["large", 803], ["deletions", 809], ["in", 819], ["all", 822], ["five", 826], ["patients", 831], [".", 839], ["Direct", 841], ["sequencing", 848], ["demonstrated", 859], ["truncating", 872], ["ZFHX1B", 883], ["mutations", 890], ["in", 900], ["all", 903], ["four", 907], ["patients", 912], ["with", 921], ["the", 926], ["characteristic", 930], ["facial", 945], ["phenotype", 952], [",", 961], ["but", 963], ["not", 967], ["in", 971], ["the", 974], ["patient", 978], ["with", 986], ["syndromic", 991], ["Hirschsprung", 1001], ["disease", 1014], ["without", 1022], ["the", 1030], ["distinct", 1034], ["facial", 1043], ["appearance", 1050], [".", 1060], ["We", 1062], ["demonstrate", 1065], ["that", 1077], ["there", 1082], ["is", 1088], ["a", 1091], ["specific", 1093], ["clinical", 1102], ["entity", 1111], ["with", 1118], ["a", 1123], ["recognizable", 1125], ["facial", 1138], ["gestalt", 1145], [",", 1152], ["mental", 1154], ["retardation", 1161], ["and", 1173], ["variable", 1177], ["MCAs", 1186], ["which", 1191], ["we", 1197], ["propose", 1200], ["be", 1208], ["called", 1211], ["the", 1218], ["\"", 1222], ["Mowat", 1223], ["-", 1228], ["Wilson", 1229], ["syndrome", 1236], [".", 1244], ["\"", 1245]]}
{"context": "Mutations in rfx6 were recently associated with Mitchell-Riley syndrome, which involves neonatal diabetes, and other digestive system defects. To better define the function of Rfx6 in early endoderm development we cloned the Xenopus homologue. Expression of rfx6 begins early, showing broad expression throughout the anterior endoderm; at later stages rfx6 expression becomes restricted to the endocrine cells of the gut and pancreas. Morpholino knockdown of rfx6 caused a loss of pancreas marker expression, as well as other abnormalities. Co-injection of exogenous wild-type rfx6 rescued the morpholino phenotype in Xenopus tadpoles, whereas attempts to rescue the loss-of-function phenotype using mutant rfx6 based on Mitchell-Riley patients were unsuccessful. To better define the pleiotropic effects, we performed microarray analyses of gene expression in knockdown foregut tissue. In addition to pancreatic defects, the microarray analyses revealed downregulation of lung, stomach and heart markers and an upregulation of kidney markers. We verified these results using RT-PCR and in situ hybridization. Based on the different rfx6 expression patterns and our functional analyses, we propose that rfx6 has both early and late functions. In early development Rfx6 plays a broad role, being essential for development of most anterior endodermal organs. At later stages however, Rfx6 function is restricted to endocrine cells.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "23231ba1735c46b7b4dbacd35b95a111", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[29, 29], [42, 42], [74, 74], [212, 212], [57, 57], [119, 119], [201, 201], [233, 233], [190, 190], [2, 2], [97, 97]], "char_spans": [[176, 179], [258, 261], [459, 462], [1264, 1267], [352, 355], [707, 710], [1203, 1206], [1382, 1385], [1133, 1136], [13, 16], [577, 580]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["rfx6", 13], ["were", 18], ["recently", 23], ["associated", 32], ["with", 43], ["Mitchell", 48], ["-", 56], ["Riley", 57], ["syndrome", 63], [",", 71], ["which", 73], ["involves", 79], ["neonatal", 88], ["diabetes", 97], [",", 105], ["and", 107], ["other", 111], ["digestive", 117], ["system", 127], ["defects", 134], [".", 141], ["To", 143], ["better", 146], ["define", 153], ["the", 160], ["function", 164], ["of", 173], ["Rfx6", 176], ["in", 181], ["early", 184], ["endoderm", 190], ["development", 199], ["we", 211], ["cloned", 214], ["the", 221], ["Xenopus", 225], ["homologue", 233], [".", 242], ["Expression", 244], ["of", 255], ["rfx6", 258], ["begins", 263], ["early", 270], [",", 275], ["showing", 277], ["broad", 285], ["expression", 291], ["throughout", 302], ["the", 313], ["anterior", 317], ["endoderm", 326], [";", 334], ["at", 336], ["later", 339], ["stages", 345], ["rfx6", 352], ["expression", 357], ["becomes", 368], ["restricted", 376], ["to", 387], ["the", 390], ["endocrine", 394], ["cells", 404], ["of", 410], ["the", 413], ["gut", 417], ["and", 421], ["pancreas", 425], [".", 433], ["Morpholino", 435], ["knockdown", 446], ["of", 456], ["rfx6", 459], ["caused", 464], ["a", 471], ["loss", 473], ["of", 478], ["pancreas", 481], ["marker", 490], ["expression", 497], [",", 507], ["as", 509], ["well", 512], ["as", 517], ["other", 520], ["abnormalities", 526], [".", 539], ["Co", 541], ["-", 543], ["injection", 544], ["of", 554], ["exogenous", 557], ["wild", 567], ["-", 571], ["type", 572], ["rfx6", 577], ["rescued", 582], ["the", 590], ["morpholino", 594], ["phenotype", 605], ["in", 615], ["Xenopus", 618], ["tadpoles", 626], [",", 634], ["whereas", 636], ["attempts", 644], ["to", 653], ["rescue", 656], ["the", 663], ["loss", 667], ["-", 671], ["of", 672], ["-", 674], ["function", 675], ["phenotype", 684], ["using", 694], ["mutant", 700], ["rfx6", 707], ["based", 712], ["on", 718], ["Mitchell", 721], ["-", 729], ["Riley", 730], ["patients", 736], ["were", 745], ["unsuccessful", 750], [".", 762], ["To", 764], ["better", 767], ["define", 774], ["the", 781], ["pleiotropic", 785], ["effects", 797], [",", 804], ["we", 806], ["performed", 809], ["microarray", 819], ["analyses", 830], ["of", 839], ["gene", 842], ["expression", 847], ["in", 858], ["knockdown", 861], ["foregut", 871], ["tissue", 879], [".", 885], ["In", 887], ["addition", 890], ["to", 899], ["pancreatic", 902], ["defects", 913], [",", 920], ["the", 922], ["microarray", 926], ["analyses", 937], ["revealed", 946], ["downregulation", 955], ["of", 970], ["lung", 973], [",", 977], ["stomach", 979], ["and", 987], ["heart", 991], ["markers", 997], ["and", 1005], ["an", 1009], ["upregulation", 1012], ["of", 1025], ["kidney", 1028], ["markers", 1035], [".", 1042], ["We", 1044], ["verified", 1047], ["these", 1056], ["results", 1062], ["using", 1070], ["RT", 1076], ["-", 1078], ["PCR", 1079], ["and", 1083], ["in", 1087], ["situ", 1090], ["hybridization", 1095], [".", 1108], ["Based", 1110], ["on", 1116], ["the", 1119], ["different", 1123], ["rfx6", 1133], ["expression", 1138], ["patterns", 1149], ["and", 1158], ["our", 1162], ["functional", 1166], ["analyses", 1177], [",", 1185], ["we", 1187], ["propose", 1190], ["that", 1198], ["rfx6", 1203], ["has", 1208], ["both", 1212], ["early", 1217], ["and", 1223], ["late", 1227], ["functions", 1232], [".", 1241], ["In", 1243], ["early", 1246], ["development", 1252], ["Rfx6", 1264], ["plays", 1269], ["a", 1275], ["broad", 1277], ["role", 1283], [",", 1287], ["being", 1289], ["essential", 1295], ["for", 1305], ["development", 1309], ["of", 1321], ["most", 1324], ["anterior", 1329], ["endodermal", 1338], ["organs", 1349], [".", 1355], ["At", 1357], ["later", 1360], ["stages", 1366], ["however", 1373], [",", 1380], ["Rfx6", 1382], ["function", 1387], ["is", 1396], ["restricted", 1399], ["to", 1410], ["endocrine", 1413], ["cells", 1423], [".", 1428]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "1. Using SEA0400, a potent and selective inhibitor of the Na+-Ca2+ exchanger (NCX), we examined whether NCX is involved in nitric oxide (NO)-induced disturbance of endoplasmic reticulum (ER) Ca2+ homeostasis followed by apoptosis in cultured rat microglia. 2. Sodium nitroprusside (SNP), an NO donor, decreased cell viability in a dose- and time-dependent manner with apoptotic cell death in cultured microglia. 3. Treatment with SNP decreased the ER Ca2+ levels as evaluated by measuring the increase in cytosolic Ca2+ level induced by exposing cells to thapsigargin, an irreversible inhibitor of ER Ca2+-ATPase. 4. The treatment with SNP also increased mRNA expression of CHOP and GPR78, makers of ER stress. 5. SEA0400 at 0.3-1.0 microM protected microglia against SNP-induced apoptosis. 6. SEA0400 blocked not only the SNP-induced decrease in ER Ca2+ levels but also SNP-induced increase in CHOP and GRP78 mRNAs. 7. SEA0400 did not affect capacitative Ca2+ entry in the presence and absence of SNP. 8. SNP increased Na+-dependent 45Ca2+ uptake and this increase was blocked by SEA0400. 9. These results suggest that SNP induces apoptosis via the ER stress pathway and SEA0400 attenuates SNP-induced apoptosis via suppression of the ER stress in cultured microglia. Our findings imply that NCX plays a role in ER Ca2+ depletion under pathological conditions.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "0e4286e02a654fdcade9b809d5a16301", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[250, 250], [16, 16], [22, 22]], "char_spans": [[1293, 1295], [78, 80], [104, 106]]}]}], "context_tokens": [["1", 0], [".", 1], ["Using", 3], ["SEA0400", 9], [",", 16], ["a", 18], ["potent", 20], ["and", 27], ["selective", 31], ["inhibitor", 41], ["of", 51], ["the", 54], ["Na+-Ca2", 58], ["+", 65], ["exchanger", 67], ["(", 77], ["NCX", 78], [")", 81], [",", 82], ["we", 84], ["examined", 87], ["whether", 96], ["NCX", 104], ["is", 108], ["involved", 111], ["in", 120], ["nitric", 123], ["oxide", 130], ["(", 136], ["NO)-induced", 137], ["disturbance", 149], ["of", 161], ["endoplasmic", 164], ["reticulum", 176], ["(", 186], ["ER", 187], [")", 189], ["Ca2", 191], ["+", 194], ["homeostasis", 196], ["followed", 208], ["by", 217], ["apoptosis", 220], ["in", 230], ["cultured", 233], ["rat", 242], ["microglia", 246], [".", 255], ["2", 257], [".", 258], ["Sodium", 260], ["nitroprusside", 267], ["(", 281], ["SNP", 282], [")", 285], [",", 286], ["an", 288], ["NO", 291], ["donor", 294], [",", 299], ["decreased", 301], ["cell", 311], ["viability", 316], ["in", 326], ["a", 329], ["dose-", 331], ["and", 337], ["time", 341], ["-", 345], ["dependent", 346], ["manner", 356], ["with", 363], ["apoptotic", 368], ["cell", 378], ["death", 383], ["in", 389], ["cultured", 392], ["microglia", 401], [".", 410], ["3", 412], [".", 413], ["Treatment", 415], ["with", 425], ["SNP", 430], ["decreased", 434], ["the", 444], ["ER", 448], ["Ca2", 451], ["+", 454], ["levels", 456], ["as", 463], ["evaluated", 466], ["by", 476], ["measuring", 479], ["the", 489], ["increase", 493], ["in", 502], ["cytosolic", 505], ["Ca2", 515], ["+", 518], ["level", 520], ["induced", 526], ["by", 534], ["exposing", 537], ["cells", 546], ["to", 552], ["thapsigargin", 555], [",", 567], ["an", 569], ["irreversible", 572], ["inhibitor", 585], ["of", 595], ["ER", 598], ["Ca2", 601], ["+", 604], ["-ATPase", 605], [".", 612], ["4", 614], [".", 615], ["The", 617], ["treatment", 621], ["with", 631], ["SNP", 636], ["also", 640], ["increased", 645], ["mRNA", 655], ["expression", 660], ["of", 671], ["CHOP", 674], ["and", 679], ["GPR78", 683], [",", 688], ["makers", 690], ["of", 697], ["ER", 700], ["stress", 703], [".", 709], ["5", 711], [".", 712], ["SEA0400", 714], ["at", 722], ["0.3", 725], ["-", 728], ["1.0", 729], ["microM", 733], ["protected", 740], ["microglia", 750], ["against", 760], ["SNP", 768], ["-", 771], ["induced", 772], ["apoptosis", 780], [".", 789], ["6", 791], [".", 792], ["SEA0400", 794], ["blocked", 802], ["not", 810], ["only", 814], ["the", 819], ["SNP", 823], ["-", 826], ["induced", 827], ["decrease", 835], ["in", 844], ["ER", 847], ["Ca2", 850], ["+", 853], ["levels", 855], ["but", 862], ["also", 866], ["SNP", 871], ["-", 874], ["induced", 875], ["increase", 883], ["in", 892], ["CHOP", 895], ["and", 900], ["GRP78", 904], ["mRNAs", 910], [".", 915], ["7", 917], [".", 918], ["SEA0400", 920], ["did", 928], ["not", 932], ["affect", 936], ["capacitative", 943], ["Ca2", 956], ["+", 959], ["entry", 961], ["in", 967], ["the", 970], ["presence", 974], ["and", 983], ["absence", 987], ["of", 995], ["SNP", 998], [".", 1001], ["8", 1003], [".", 1004], ["SNP", 1006], ["increased", 1010], ["Na+-dependent", 1020], ["45Ca2", 1034], ["+", 1039], ["uptake", 1041], ["and", 1048], ["this", 1052], ["increase", 1057], ["was", 1066], ["blocked", 1070], ["by", 1078], ["SEA0400", 1081], [".", 1088], ["9", 1090], [".", 1091], ["These", 1093], ["results", 1099], ["suggest", 1107], ["that", 1115], ["SNP", 1120], ["induces", 1124], ["apoptosis", 1132], ["via", 1142], ["the", 1146], ["ER", 1150], ["stress", 1153], ["pathway", 1160], ["and", 1168], ["SEA0400", 1172], ["attenuates", 1180], ["SNP", 1191], ["-", 1194], ["induced", 1195], ["apoptosis", 1203], ["via", 1213], ["suppression", 1217], ["of", 1229], ["the", 1232], ["ER", 1236], ["stress", 1239], ["in", 1246], ["cultured", 1249], ["microglia", 1258], [".", 1267], ["Our", 1269], ["findings", 1273], ["imply", 1282], ["that", 1288], ["NCX", 1293], ["plays", 1297], ["a", 1303], ["role", 1305], ["in", 1310], ["ER", 1313], ["Ca2", 1316], ["+", 1319], ["depletion", 1321], ["under", 1331], ["pathological", 1337], ["conditions", 1350], [".", 1360]]}
{"context": "Carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel. As nerve entrapment induces impairment of somatic fibres followed by clinical symptoms and signs of the syndrome, one can assume that sympathetic fibres are involved too. Results of studies focused on this problem show presence of sympathetic symptoms in about half of patients, including Raynaud phenomenon, blanching of hands, painful swelling of fingers, dry or excessive sweating of palms. Activity of sympathetic system can be investigated by means of sympathetic skin response and vasomotor response. Eight papers presenting the results of sympathetic skin response from median nerve in carpal tunnel syndrome were analysed. Results of 4 studies showed decreased sympathetic activity, in 2 findings were equivocal and 2 studies failed to reveal any abnormalities. The following variables were considered in the interpretation of sympathetic skin response curve: amplitude, latency and area under the chart, each of them having limited diagnostic value due to inter-and intrasubject variation of these parameters. Vasomotor response was investigated in 2 studies by means of Doppler ultrasound flow examination in digital arteries. Results of both studies showed decreased vasomotor response in carpal tunnel syndrome. The review of current knowledge on sympathetic impairment in carpal tunnel syndrome fails to provide a definitive determination of its range and clinical consequences. It confirms, however, that routine examination of sympathetic disturbances is unnecessary due to their minor clinical significance.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "3da4e2bccf984afb8212d78a6eab3d6f", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[15, 15], [115, 115]], "char_spans": [[82, 87], [694, 699]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["of", 36], ["symptoms", 39], ["as", 48], ["a", 51], ["result", 53], ["of", 60], ["compression", 63], ["of", 75], ["the", 78], ["median", 82], ["nerve", 89], ["in", 95], ["the", 98], ["carpal", 102], ["tunnel", 109], [".", 115], ["As", 117], ["nerve", 120], ["entrapment", 126], ["induces", 137], ["impairment", 145], ["of", 156], ["somatic", 159], ["fibres", 167], ["followed", 174], ["by", 183], ["clinical", 186], ["symptoms", 195], ["and", 204], ["signs", 208], ["of", 214], ["the", 217], ["syndrome", 221], [",", 229], ["one", 231], ["can", 235], ["assume", 239], ["that", 246], ["sympathetic", 251], ["fibres", 263], ["are", 270], ["involved", 274], ["too", 283], [".", 286], ["Results", 288], ["of", 296], ["studies", 299], ["focused", 307], ["on", 315], ["this", 318], ["problem", 323], ["show", 331], ["presence", 336], ["of", 345], ["sympathetic", 348], ["symptoms", 360], ["in", 369], ["about", 372], ["half", 378], ["of", 383], ["patients", 386], [",", 394], ["including", 396], ["Raynaud", 406], ["phenomenon", 414], [",", 424], ["blanching", 426], ["of", 436], ["hands", 439], [",", 444], ["painful", 446], ["swelling", 454], ["of", 463], ["fingers", 466], [",", 473], ["dry", 475], ["or", 479], ["excessive", 482], ["sweating", 492], ["of", 501], ["palms", 504], [".", 509], ["Activity", 511], ["of", 520], ["sympathetic", 523], ["system", 535], ["can", 542], ["be", 546], ["investigated", 549], ["by", 562], ["means", 565], ["of", 571], ["sympathetic", 574], ["skin", 586], ["response", 591], ["and", 600], ["vasomotor", 604], ["response", 614], [".", 622], ["Eight", 624], ["papers", 630], ["presenting", 637], ["the", 648], ["results", 652], ["of", 660], ["sympathetic", 663], ["skin", 675], ["response", 680], ["from", 689], ["median", 694], ["nerve", 701], ["in", 707], ["carpal", 710], ["tunnel", 717], ["syndrome", 724], ["were", 733], ["analysed", 738], [".", 746], ["Results", 748], ["of", 756], ["4", 759], ["studies", 761], ["showed", 769], ["decreased", 776], ["sympathetic", 786], ["activity", 798], [",", 806], ["in", 808], ["2", 811], ["findings", 813], ["were", 822], ["equivocal", 827], ["and", 837], ["2", 841], ["studies", 843], ["failed", 851], ["to", 858], ["reveal", 861], ["any", 868], ["abnormalities", 872], [".", 885], ["The", 887], ["following", 891], ["variables", 901], ["were", 911], ["considered", 916], ["in", 927], ["the", 930], ["interpretation", 934], ["of", 949], ["sympathetic", 952], ["skin", 964], ["response", 969], ["curve", 978], [":", 983], ["amplitude", 985], [",", 994], ["latency", 996], ["and", 1004], ["area", 1008], ["under", 1013], ["the", 1019], ["chart", 1023], [",", 1028], ["each", 1030], ["of", 1035], ["them", 1038], ["having", 1043], ["limited", 1050], ["diagnostic", 1058], ["value", 1069], ["due", 1075], ["to", 1079], ["inter", 1082], ["-", 1087], ["and", 1088], ["intrasubject", 1092], ["variation", 1105], ["of", 1115], ["these", 1118], ["parameters", 1124], [".", 1134], ["Vasomotor", 1136], ["response", 1146], ["was", 1155], ["investigated", 1159], ["in", 1172], ["2", 1175], ["studies", 1177], ["by", 1185], ["means", 1188], ["of", 1194], ["Doppler", 1197], ["ultrasound", 1205], ["flow", 1216], ["examination", 1221], ["in", 1233], ["digital", 1236], ["arteries", 1244], [".", 1252], ["Results", 1254], ["of", 1262], ["both", 1265], ["studies", 1270], ["showed", 1278], ["decreased", 1285], ["vasomotor", 1295], ["response", 1305], ["in", 1314], ["carpal", 1317], ["tunnel", 1324], ["syndrome", 1331], [".", 1339], ["The", 1341], ["review", 1345], ["of", 1352], ["current", 1355], ["knowledge", 1363], ["on", 1373], ["sympathetic", 1376], ["impairment", 1388], ["in", 1399], ["carpal", 1402], ["tunnel", 1409], ["syndrome", 1416], ["fails", 1425], ["to", 1431], ["provide", 1434], ["a", 1442], ["definitive", 1444], ["determination", 1455], ["of", 1469], ["its", 1472], ["range", 1476], ["and", 1482], ["clinical", 1486], ["consequences", 1495], [".", 1507], ["It", 1509], ["confirms", 1512], [",", 1520], ["however", 1522], [",", 1529], ["that", 1531], ["routine", 1536], ["examination", 1544], ["of", 1556], ["sympathetic", 1559], ["disturbances", 1571], ["is", 1584], ["unnecessary", 1587], ["due", 1599], ["to", 1603], ["their", 1606], ["minor", 1612], ["clinical", 1618], ["significance", 1627], [".", 1639]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "Once acquired, Epstein-Barr virus (EBV), a latent virus, remains in the body for what appears to be the lifetime of the human host. Circumstantial data suggest EBV is involved in clinical disease including malignancies far more often than previously recognized. A serologic test for early antigen (EA) is more specific for diagnosing active EBV disease than the monospot or heterophile test. A case study of active Epstein-Barr infection is reported showing persistently elevated early antigen titers prior to and following malignant transformation.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "f210d60705384548a979b62bca881946", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[3, 6]], "char_spans": [[15, 32]]}]}], "context_tokens": [["Once", 0], ["acquired", 5], [",", 13], ["Epstein", 15], ["-", 22], ["Barr", 23], ["virus", 28], ["(", 34], ["EBV", 35], [")", 38], [",", 39], ["a", 41], ["latent", 43], ["virus", 50], [",", 55], ["remains", 57], ["in", 65], ["the", 68], ["body", 72], ["for", 77], ["what", 81], ["appears", 86], ["to", 94], ["be", 97], ["the", 100], ["lifetime", 104], ["of", 113], ["the", 116], ["human", 120], ["host", 126], [".", 130], ["Circumstantial", 132], ["data", 147], ["suggest", 152], ["EBV", 160], ["is", 164], ["involved", 167], ["in", 176], ["clinical", 179], ["disease", 188], ["including", 196], ["malignancies", 206], ["far", 219], ["more", 223], ["often", 228], ["than", 234], ["previously", 239], ["recognized", 250], [".", 260], ["A", 262], ["serologic", 264], ["test", 274], ["for", 279], ["early", 283], ["antigen", 289], ["(", 297], ["EA", 298], [")", 300], ["is", 302], ["more", 305], ["specific", 310], ["for", 319], ["diagnosing", 323], ["active", 334], ["EBV", 341], ["disease", 345], ["than", 353], ["the", 358], ["monospot", 362], ["or", 371], ["heterophile", 374], ["test", 386], [".", 390], ["A", 392], ["case", 394], ["study", 399], ["of", 405], ["active", 408], ["Epstein", 415], ["-", 422], ["Barr", 423], ["infection", 428], ["is", 438], ["reported", 441], ["showing", 450], ["persistently", 458], ["elevated", 471], ["early", 480], ["antigen", 486], ["titers", 494], ["prior", 501], ["to", 507], ["and", 510], ["following", 514], ["malignant", 524], ["transformation", 534], [".", 548]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Calcineurin signaling has been implicated in a broad spectrum of developmental processes in a variety of organ systems. Calcineurin is a calmodulin-dependent, calcium-activated protein phosphatase composed of catalytic and regulatory subunits. The serine/threonine-specific phosphatase functions within a signal transduction pathway that regulates gene expression and biological responses in many developmentally important cell types. Calcineurin signaling was first defined in T lymphocytes as a regulator of nuclear factor of activated T cells (NFAT) transcription factor nuclear translocation and activation. Recent studies have demonstrated the vital nature of calcium/calcineurin/NFAT signaling in cardiovascular and skeletal muscle development in vertebrates. Inhibition, mutation, or forced expression of calcineurin pathway genes result in defects or alterations in cardiomyocyte maturation, heart valve formation, vascular development, skeletal muscle differentiation and fiber-type switching, and cardiac and skeletal muscle hypertrophy. Conserved calcineurin genes are found in invertebrates such as Drosophila and Caenorhabditis elegans, and genetic studies have demonstrated specific myogenic functions for the phosphatase in their development. The ability to investigate calcineurin signaling pathways in vertebrates and model genetic organisms provides a great potential to more fully comprehend the functions of calcineurin and its interacting genes in heart, blood vessel, and muscle development.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "f5da104a83c341a2b668ac142d827213", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [160, 160], [19, 19], [192, 192], [124, 124], [212, 212], [103, 103], [65, 65]], "char_spans": [[0, 10], [1058, 1068], [120, 130], [1285, 1295], [812, 822], [1428, 1438], [673, 683], [435, 445]]}]}], "context_tokens": [["Calcineurin", 0], ["signaling", 12], ["has", 22], ["been", 26], ["implicated", 31], ["in", 42], ["a", 45], ["broad", 47], ["spectrum", 53], ["of", 62], ["developmental", 65], ["processes", 79], ["in", 89], ["a", 92], ["variety", 94], ["of", 102], ["organ", 105], ["systems", 111], [".", 118], ["Calcineurin", 120], ["is", 132], ["a", 135], ["calmodulin", 137], ["-", 147], ["dependent", 148], [",", 157], ["calcium", 159], ["-", 166], ["activated", 167], ["protein", 177], ["phosphatase", 185], ["composed", 197], ["of", 206], ["catalytic", 209], ["and", 219], ["regulatory", 223], ["subunits", 234], [".", 242], ["The", 244], ["serine", 248], ["/", 254], ["threonine", 255], ["-", 264], ["specific", 265], ["phosphatase", 274], ["functions", 286], ["within", 296], ["a", 303], ["signal", 305], ["transduction", 312], ["pathway", 325], ["that", 333], ["regulates", 338], ["gene", 348], ["expression", 353], ["and", 364], ["biological", 368], ["responses", 379], ["in", 389], ["many", 392], ["developmentally", 397], ["important", 413], ["cell", 423], ["types", 428], [".", 433], ["Calcineurin", 435], ["signaling", 447], ["was", 457], ["first", 461], ["defined", 467], ["in", 475], ["T", 478], ["lymphocytes", 480], ["as", 492], ["a", 495], ["regulator", 497], ["of", 507], ["nuclear", 510], ["factor", 518], ["of", 525], ["activated", 528], ["T", 538], ["cells", 540], ["(", 546], ["NFAT", 547], [")", 551], ["transcription", 553], ["factor", 567], ["nuclear", 574], ["translocation", 582], ["and", 596], ["activation", 600], [".", 610], ["Recent", 612], ["studies", 619], ["have", 627], ["demonstrated", 632], ["the", 645], ["vital", 649], ["nature", 655], ["of", 662], ["calcium", 665], ["/", 672], ["calcineurin", 673], ["/", 684], ["NFAT", 685], ["signaling", 690], ["in", 700], ["cardiovascular", 703], ["and", 718], ["skeletal", 722], ["muscle", 731], ["development", 738], ["in", 750], ["vertebrates", 753], [".", 764], ["Inhibition", 766], [",", 776], ["mutation", 778], [",", 786], ["or", 788], ["forced", 791], ["expression", 798], ["of", 809], ["calcineurin", 812], ["pathway", 824], ["genes", 832], ["result", 838], ["in", 845], ["defects", 848], ["or", 856], ["alterations", 859], ["in", 871], ["cardiomyocyte", 874], ["maturation", 888], [",", 898], ["heart", 900], ["valve", 906], ["formation", 912], [",", 921], ["vascular", 923], ["development", 932], [",", 943], ["skeletal", 945], ["muscle", 954], ["differentiation", 961], ["and", 977], ["fiber", 981], ["-", 986], ["type", 987], ["switching", 992], [",", 1001], ["and", 1003], ["cardiac", 1007], ["and", 1015], ["skeletal", 1019], ["muscle", 1028], ["hypertrophy", 1035], [".", 1046], ["Conserved", 1048], ["calcineurin", 1058], ["genes", 1070], ["are", 1076], ["found", 1080], ["in", 1086], ["invertebrates", 1089], ["such", 1103], ["as", 1108], ["Drosophila", 1111], ["and", 1122], ["Caenorhabditis", 1126], ["elegans", 1141], [",", 1148], ["and", 1150], ["genetic", 1154], ["studies", 1162], ["have", 1170], ["demonstrated", 1175], ["specific", 1188], ["myogenic", 1197], ["functions", 1206], ["for", 1216], ["the", 1220], ["phosphatase", 1224], ["in", 1236], ["their", 1239], ["development", 1245], [".", 1256], ["The", 1258], ["ability", 1262], ["to", 1270], ["investigate", 1273], ["calcineurin", 1285], ["signaling", 1297], ["pathways", 1307], ["in", 1316], ["vertebrates", 1319], ["and", 1331], ["model", 1335], ["genetic", 1341], ["organisms", 1349], ["provides", 1359], ["a", 1368], ["great", 1370], ["potential", 1376], ["to", 1386], ["more", 1389], ["fully", 1394], ["comprehend", 1400], ["the", 1411], ["functions", 1415], ["of", 1425], ["calcineurin", 1428], ["and", 1440], ["its", 1444], ["interacting", 1448], ["genes", 1460], ["in", 1466], ["heart", 1469], [",", 1474], ["blood", 1476], ["vessel", 1482], [",", 1488], ["and", 1490], ["muscle", 1494], ["development", 1501], [".", 1512]]}
{"context": "Double homeobox 4 (DUX4) is a candidate disease gene for facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophies characterized by progressive skeletal muscle degeneration. Despite great strides in understanding precise genetics of FSHD, the molecular pathophysiology of the disease remains unclear. One of the major limitations has been the availability of appropriate molecular tools to study DUX4 protein. In the present study, we report the development of five new monoclonal antibodies targeted against the N- and C-termini of human DUX4, and characterize their reactivity using Western blot and immunofluorescence staining. Additionally, we show that expression of the canonical full coding DUX4 induces cell death in human primary muscle cells, whereas the expression of a shorter splice form of DUX4 results in no such toxicity. Immunostaining with these new antibodies reveals a differential effect of two DUX4 isoforms on human muscle cells. These antibodies will provide an excellent tool for investigating the role of DUX4 in FSHD pathogenesis.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7247ffe169f140339020744b6f54923c", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[12, 13]], "char_spans": [[57, 85]]}, {"text": "FSHD", "token_spans": [[175, 175], [40, 40], [15, 15]], "char_spans": [[1063, 1066], [257, 260], [88, 91]]}]}], "context_tokens": [["Double", 0], ["homeobox", 7], ["4", 16], ["(", 18], ["DUX4", 19], [")", 23], ["is", 25], ["a", 28], ["candidate", 30], ["disease", 40], ["gene", 48], ["for", 53], ["facioscapulohumeral", 57], ["dystrophy", 77], ["(", 87], ["FSHD", 88], [")", 92], [",", 93], ["one", 95], ["of", 99], ["the", 102], ["most", 106], ["common", 111], ["muscular", 118], ["dystrophies", 127], ["characterized", 139], ["by", 153], ["progressive", 156], ["skeletal", 168], ["muscle", 177], ["degeneration", 184], [".", 196], ["Despite", 198], ["great", 206], ["strides", 212], ["in", 220], ["understanding", 223], ["precise", 237], ["genetics", 245], ["of", 254], ["FSHD", 257], [",", 261], ["the", 263], ["molecular", 267], ["pathophysiology", 277], ["of", 293], ["the", 296], ["disease", 300], ["remains", 308], ["unclear", 316], [".", 323], ["One", 325], ["of", 329], ["the", 332], ["major", 336], ["limitations", 342], ["has", 354], ["been", 358], ["the", 363], ["availability", 367], ["of", 380], ["appropriate", 383], ["molecular", 395], ["tools", 405], ["to", 411], ["study", 414], ["DUX4", 420], ["protein", 425], [".", 432], ["In", 434], ["the", 437], ["present", 441], ["study", 449], [",", 454], ["we", 456], ["report", 459], ["the", 466], ["development", 470], ["of", 482], ["five", 485], ["new", 490], ["monoclonal", 494], ["antibodies", 505], ["targeted", 516], ["against", 525], ["the", 533], ["N-", 537], ["and", 540], ["C", 544], ["-", 545], ["termini", 546], ["of", 554], ["human", 557], ["DUX4", 563], [",", 567], ["and", 569], ["characterize", 573], ["their", 586], ["reactivity", 592], ["using", 603], ["Western", 609], ["blot", 617], ["and", 622], ["immunofluorescence", 626], ["staining", 645], [".", 653], ["Additionally", 655], [",", 667], ["we", 669], ["show", 672], ["that", 677], ["expression", 682], ["of", 693], ["the", 696], ["canonical", 700], ["full", 710], ["coding", 715], ["DUX4", 722], ["induces", 727], ["cell", 735], ["death", 740], ["in", 746], ["human", 749], ["primary", 755], ["muscle", 763], ["cells", 770], [",", 775], ["whereas", 777], ["the", 785], ["expression", 789], ["of", 800], ["a", 803], ["shorter", 805], ["splice", 813], ["form", 820], ["of", 825], ["DUX4", 828], ["results", 833], ["in", 841], ["no", 844], ["such", 847], ["toxicity", 852], [".", 860], ["Immunostaining", 862], ["with", 877], ["these", 882], ["new", 888], ["antibodies", 892], ["reveals", 903], ["a", 911], ["differential", 913], ["effect", 926], ["of", 933], ["two", 936], ["DUX4", 940], ["isoforms", 945], ["on", 954], ["human", 957], ["muscle", 963], ["cells", 970], [".", 975], ["These", 977], ["antibodies", 983], ["will", 994], ["provide", 999], ["an", 1007], ["excellent", 1010], ["tool", 1020], ["for", 1025], ["investigating", 1029], ["the", 1043], ["role", 1047], ["of", 1052], ["DUX4", 1055], ["in", 1060], ["FSHD", 1063], ["pathogenesis", 1068], [".", 1080]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "Bone destruction is a prominent feature of multiple myeloma, but conflicting data exist on the expression and pathophysiologic involvement of the bone remodeling ligand RANKL in this disease and the potential therapeutic benefits of its targeted inhibition. Here, we show that RANKL is expressed by primary multiple myeloma and chronic lymphocytic leukemia (CLL) cells, whereas release of soluble RANKL was observed exclusively with multiple myeloma cells and was strongly influenced by posttranscriptional/posttranslational regulation. Signaling via RANKL into multiple myeloma and CLL cells induced release of cytokines involved in disease pathophysiology. Both the effects of RANKL on osteoclastogenesis and cytokine production by malignant cells could be blocked by disruption of RANK-RANKL interaction with denosumab. As we aimed to combine neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural killer (NK) cells against RANKL-expressing malignant cells and as denosumab does not stimulate NK reactivity, we generated RANK-Fc fusion proteins with modified Fc moieties. The latter displayed similar capacity compared with denosumab to neutralize the effects of RANKL on osteoclastogenesis in vitro, but also potently stimulated NK cell reactivity against primary RANKL-expressing malignant B cells, which was dependent on their engineered affinity to CD16. Our findings introduce Fc-optimized RANK-Ig fusion proteins as attractive tools to neutralize the detrimental function of RANKL while at the same time potently stimulating NK cell antitumor immunity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "513ee6b7112740b7afa36d176c0f833f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[64, 64], [133, 133], [189, 189], [150, 150], [44, 44], [84, 84], [25, 25], [121, 121], [204, 204], [104, 104], [241, 241]], "char_spans": [[397, 401], [864, 868], [1205, 1209], [966, 970], [277, 281], [551, 555], [169, 173], [789, 793], [1307, 1311], [679, 683], [1523, 1527]]}]}], "context_tokens": [["Bone", 0], ["destruction", 5], ["is", 17], ["a", 20], ["prominent", 22], ["feature", 32], ["of", 40], ["multiple", 43], ["myeloma", 52], [",", 59], ["but", 61], ["conflicting", 65], ["data", 77], ["exist", 82], ["on", 88], ["the", 91], ["expression", 95], ["and", 106], ["pathophysiologic", 110], ["involvement", 127], ["of", 139], ["the", 142], ["bone", 146], ["remodeling", 151], ["ligand", 162], ["RANKL", 169], ["in", 175], ["this", 178], ["disease", 183], ["and", 191], ["the", 195], ["potential", 199], ["therapeutic", 209], ["benefits", 221], ["of", 230], ["its", 233], ["targeted", 237], ["inhibition", 246], [".", 256], ["Here", 258], [",", 262], ["we", 264], ["show", 267], ["that", 272], ["RANKL", 277], ["is", 283], ["expressed", 286], ["by", 296], ["primary", 299], ["multiple", 307], ["myeloma", 316], ["and", 324], ["chronic", 328], ["lymphocytic", 336], ["leukemia", 348], ["(", 357], ["CLL", 358], [")", 361], ["cells", 363], [",", 368], ["whereas", 370], ["release", 378], ["of", 386], ["soluble", 389], ["RANKL", 397], ["was", 403], ["observed", 407], ["exclusively", 416], ["with", 428], ["multiple", 433], ["myeloma", 442], ["cells", 450], ["and", 456], ["was", 460], ["strongly", 464], ["influenced", 473], ["by", 484], ["posttranscriptional", 487], ["/", 506], ["posttranslational", 507], ["regulation", 525], [".", 535], ["Signaling", 537], ["via", 547], ["RANKL", 551], ["into", 557], ["multiple", 562], ["myeloma", 571], ["and", 579], ["CLL", 583], ["cells", 587], ["induced", 593], ["release", 601], ["of", 609], ["cytokines", 612], ["involved", 622], ["in", 631], ["disease", 634], ["pathophysiology", 642], [".", 657], ["Both", 659], ["the", 664], ["effects", 668], ["of", 676], ["RANKL", 679], ["on", 685], ["osteoclastogenesis", 688], ["and", 707], ["cytokine", 711], ["production", 720], ["by", 731], ["malignant", 734], ["cells", 744], ["could", 750], ["be", 756], ["blocked", 759], ["by", 767], ["disruption", 770], ["of", 781], ["RANK", 784], ["-", 788], ["RANKL", 789], ["interaction", 795], ["with", 807], ["denosumab", 812], [".", 821], ["As", 823], ["we", 826], ["aimed", 829], ["to", 835], ["combine", 838], ["neutralization", 846], ["of", 861], ["RANKL", 864], ["with", 870], ["induction", 875], ["of", 885], ["antibody", 888], ["-", 896], ["dependent", 897], ["cellular", 907], ["cytotoxicity", 916], ["of", 929], ["natural", 932], ["killer", 940], ["(", 947], ["NK", 948], [")", 950], ["cells", 952], ["against", 958], ["RANKL", 966], ["-", 971], ["expressing", 972], ["malignant", 983], ["cells", 993], ["and", 999], ["as", 1003], ["denosumab", 1006], ["does", 1016], ["not", 1021], ["stimulate", 1025], ["NK", 1035], ["reactivity", 1038], [",", 1048], ["we", 1050], ["generated", 1053], ["RANK", 1063], ["-", 1067], ["Fc", 1068], ["fusion", 1071], ["proteins", 1078], ["with", 1087], ["modified", 1092], ["Fc", 1101], ["moieties", 1104], [".", 1112], ["The", 1114], ["latter", 1118], ["displayed", 1125], ["similar", 1135], ["capacity", 1143], ["compared", 1152], ["with", 1161], ["denosumab", 1166], ["to", 1176], ["neutralize", 1179], ["the", 1190], ["effects", 1194], ["of", 1202], ["RANKL", 1205], ["on", 1211], ["osteoclastogenesis", 1214], ["in", 1233], ["vitro", 1236], [",", 1241], ["but", 1243], ["also", 1247], ["potently", 1252], ["stimulated", 1261], ["NK", 1272], ["cell", 1275], ["reactivity", 1280], ["against", 1291], ["primary", 1299], ["RANKL", 1307], ["-", 1312], ["expressing", 1313], ["malignant", 1324], ["B", 1334], ["cells", 1336], [",", 1341], ["which", 1343], ["was", 1349], ["dependent", 1353], ["on", 1363], ["their", 1366], ["engineered", 1372], ["affinity", 1383], ["to", 1392], ["CD16", 1395], [".", 1399], ["Our", 1401], ["findings", 1405], ["introduce", 1414], ["Fc", 1424], ["-", 1426], ["optimized", 1427], ["RANK", 1437], ["-", 1441], ["Ig", 1442], ["fusion", 1445], ["proteins", 1452], ["as", 1461], ["attractive", 1464], ["tools", 1475], ["to", 1481], ["neutralize", 1484], ["the", 1495], ["detrimental", 1499], ["function", 1511], ["of", 1520], ["RANKL", 1523], ["while", 1529], ["at", 1535], ["the", 1538], ["same", 1542], ["time", 1547], ["potently", 1552], ["stimulating", 1561], ["NK", 1573], ["cell", 1576], ["antitumor", 1581], ["immunity", 1591], [".", 1599]]}
{"context": "To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Beh\u00e7et's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Beh\u00e7et's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Beh\u00e7et's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "a40b195dc80a430a92a47b3b524bd7c3", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[19, 19]], "char_spans": [[119, 133]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["efficacy", 17], ["and", 26], ["safety", 30], ["of", 37], ["different", 40], ["doses", 50], ["of", 56], ["secukinumab", 59], [",", 70], ["a", 72], ["fully", 74], ["human", 80], ["monoclonal", 86], ["antibody", 97], ["for", 106], ["targeted", 110], ["interleukin-17A", 119], ["blockade", 135], [",", 143], ["in", 145], ["patients", 148], ["with", 157], ["noninfectious", 162], ["uveitis", 176], [".", 183], ["Three", 185], ["multicenter", 191], [",", 202], ["randomized", 204], [",", 214], ["double", 216], ["-", 222], ["masked", 223], [",", 229], ["placebo", 231], ["-", 238], ["controlled", 239], [",", 249], ["dose", 251], ["-", 255], ["ranging", 256], ["phase", 264], ["III", 270], ["studies", 274], [":", 281], ["SHIELD", 283], [",", 289], ["INSURE", 291], [",", 297], ["and", 299], ["ENDURE", 303], [".", 309], ["A", 311], ["total", 313], ["of", 319], ["118", 322], ["patients", 326], ["with", 335], ["Beh\u00e7et", 340], ["'s", 346], ["uveitis", 349], ["(", 357], ["SHIELD", 358], ["study", 365], [")", 370], [";", 371], ["31", 373], ["patients", 376], ["with", 385], ["active", 390], [",", 396], ["noninfectious", 398], [",", 411], ["non", 413], ["-", 416], ["Beh\u00e7et", 417], ["'s", 423], ["uveitis", 426], ["(", 434], ["INSURE", 435], ["study", 442], [")", 447], [";", 448], ["and", 450], ["125", 454], ["patients", 458], ["with", 467], ["quiescent", 472], [",", 481], ["noninfectious", 483], [",", 496], ["non", 498], ["-", 501], ["Beh\u00e7et", 502], ["'s", 508], ["uveitis", 511], ["(", 519], ["ENDURE", 520], ["study", 527], [")", 532], ["were", 534], ["enrolled", 539], [".", 547], ["After", 549], ["an", 555], ["initial", 558], ["subcutaneous", 566], ["(", 579], ["s.c", 580], [".", 583], [")", 584], ["loading", 586], ["phase", 594], ["in", 600], ["each", 603], ["treatment", 608], ["arm", 618], [",", 621], ["patients", 623], ["received", 632], ["s.c", 641], [".", 644], ["maintenance", 646], ["therapy", 658], ["with", 666], ["secukinumab", 671], ["300", 683], ["mg", 687], ["every", 690], ["2", 696], ["weeks", 698], ["(", 704], ["q2w", 705], [")", 708], [",", 709], ["secukinumab", 711], ["300", 723], ["mg", 727], ["monthly", 730], ["(", 738], ["q4w", 739], [")", 742], [",", 743], ["or", 745], ["placebo", 748], ["in", 756], ["the", 759], ["SHIELD", 763], ["study", 770], [";", 775], ["secukinumab", 777], ["300", 789], ["mg", 793], ["q2w", 796], [",", 799], ["secukinumab", 801], ["300", 813], ["mg", 817], ["q4w", 820], [",", 823], ["secukinumab", 825], ["150", 837], ["mg", 841], ["q4w", 844], [",", 847], ["or", 849], ["placebo", 852], ["in", 860], ["the", 863], ["INSURE", 867], ["study", 874], [";", 879], ["or", 881], ["secukinumab", 884], ["300", 896], ["mg", 900], ["q2w", 903], [",", 906], ["secukinumab", 908], ["300", 920], ["mg", 924], ["q4w", 927], [",", 930], ["secukinumab", 932], ["150", 944], ["mg", 948], ["q4w", 951], [",", 954], ["or", 956], ["placebo", 959], ["in", 967], ["the", 970], ["ENDURE", 974], ["study", 981], [".", 986], ["Reduction", 988], ["of", 998], ["uveitis", 1001], ["recurrence", 1009], ["or", 1020], ["vitreous", 1023], ["haze", 1032], ["score", 1037], ["during", 1043], ["withdrawal", 1050], ["of", 1061], ["concomitant", 1064], ["immunosuppressive", 1076], ["medication", 1094], ["(", 1105], ["ISM", 1106], [")", 1109], [".", 1110], ["Other", 1112], ["end", 1118], ["points", 1122], ["included", 1129], ["best", 1138], ["-", 1142], ["corrected", 1143], ["visual", 1153], ["acuity", 1160], [",", 1166], ["ISM", 1168], ["use", 1172], ["(", 1176], ["expressed", 1177], ["as", 1187], ["a", 1190], ["standardized", 1192], ["ISM", 1205], ["score", 1209], [")", 1214], [",", 1215], ["and", 1217], ["safety", 1221], ["outcomes", 1228], [".", 1236], ["After", 1238], ["completion", 1244], ["or", 1255], ["early", 1258], ["termination", 1264], ["of", 1276], ["each", 1279], ["trial", 1284], [",", 1289], ["there", 1291], ["were", 1297], ["no", 1302], ["statistically", 1305], ["significant", 1319], ["differences", 1331], ["in", 1343], ["uveitis", 1346], ["recurrence", 1354], ["between", 1365], ["the", 1373], ["secukinumab", 1377], ["treatment", 1389], ["groups", 1399], ["and", 1406], ["placebo", 1410], ["groups", 1418], ["in", 1425], ["any", 1428], ["study", 1432], [".", 1437], ["Secukinumab", 1439], ["was", 1451], ["associated", 1455], ["with", 1466], ["a", 1471], ["significant", 1473], ["reduction", 1485], ["in", 1495], ["mean", 1498], ["total", 1503], ["post", 1509], ["-", 1513], ["baseline", 1514], ["ISM", 1523], ["score", 1527], ["(", 1533], ["P", 1534], ["=", 1536], ["0.019", 1538], [";", 1543], ["300", 1545], ["mg", 1549], ["q4w", 1552], ["vs.", 1556], ["placebo", 1560], [")", 1567], ["in", 1569], ["the", 1572], ["SHIELD", 1576], ["study", 1583], [".", 1588], ["Likewise", 1590], [",", 1598], ["secukinumab", 1600], ["was", 1612], ["associated", 1616], ["with", 1627], ["a", 1632], ["greater", 1634], ["median", 1642], ["reduction", 1649], ["in", 1659], ["ISM", 1662], ["score", 1666], ["versus", 1672], ["placebo", 1679], ["in", 1687], ["the", 1690], ["INSURE", 1694], ["study", 1701], [",", 1706], ["although", 1708], ["no", 1717], ["statistical", 1720], ["analysis", 1732], ["of", 1741], ["the", 1744], ["difference", 1748], ["was", 1759], ["conducted", 1763], ["because", 1773], ["of", 1781], ["the", 1784], ["small", 1788], ["sample", 1794], ["size", 1801], [".", 1805], ["Overall", 1807], [",", 1814], ["there", 1816], ["was", 1822], ["no", 1826], ["loss", 1829], ["in", 1834], ["visual", 1837], ["acuity", 1844], ["reported", 1851], ["in", 1860], ["any", 1863], ["treatment", 1867], ["group", 1877], ["during", 1883], ["follow", 1890], ["-", 1896], ["up", 1897], ["in", 1900], ["all", 1903], ["3", 1907], ["studies", 1909], [".", 1916], ["According", 1918], ["to", 1928], ["descriptive", 1931], ["safety", 1943], ["statistics", 1950], [",", 1960], ["the", 1962], ["frequencies", 1966], ["of", 1978], ["ocular", 1981], ["and", 1988], ["nonocular", 1992], ["adverse", 2002], ["events", 2010], ["seemed", 2017], ["to", 2024], ["be", 2027], ["slightly", 2030], ["higher", 2039], ["among", 2046], ["secukinumab", 2052], ["groups", 2064], ["versus", 2071], ["placebo", 2078], ["across", 2086], ["the", 2093], ["3", 2097], ["studies", 2099], [".", 2106], ["The", 2108], ["primary", 2112], ["efficacy", 2120], ["end", 2129], ["points", 2133], ["of", 2140], ["the", 2143], ["3", 2147], ["studies", 2149], ["were", 2157], ["not", 2162], ["met", 2166], [".", 2169], ["The", 2171], ["secondary", 2175], ["efficacy", 2185], ["data", 2194], ["from", 2199], ["these", 2204], ["studies", 2210], ["suggest", 2218], ["a", 2226], ["beneficial", 2228], ["effect", 2239], ["of", 2246], ["secukinumab", 2249], ["in", 2261], ["reducing", 2264], ["the", 2273], ["use", 2277], ["of", 2281], ["concomitant", 2284], ["ISM", 2296], [".", 2299]]}
{"context": "Methylation of lysine residues of histones is an important epigenetic mark that correlates with functionally distinct regions of chromatin. We present here the crystal structure of a ternary complex of the enzyme Pr-Set7 (also known as Set8) that methylates Lys 20 of histone H4 (H4-K20). We show that the enzyme is exclusively a mono-methylase and is therefore responsible for a signaling role quite distinct from that established by other enzymes that target this histone residue. We provide evidence from NMR for the C-flanking domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes. The crystal structure reveals the basis of the specificity of the enzyme for H4-K20 because a histidine residue within the substrate, close to the target lysine, is required for completion of the active site. We also show how a highly variable component of the SET domain is responsible for many of the enzymes' interactions with its target histone peptide and probably also how this part of the structure ensures that Pr-Set7 is nucleosome specific.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f424eb5bb7c24c5185b12545eb402821", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[166, 167]], "char_spans": [[928, 937]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["of", 31], ["histones", 34], ["is", 43], ["an", 46], ["important", 49], ["epigenetic", 59], ["mark", 70], ["that", 75], ["correlates", 80], ["with", 91], ["functionally", 96], ["distinct", 109], ["regions", 118], ["of", 126], ["chromatin", 129], [".", 138], ["We", 140], ["present", 143], ["here", 151], ["the", 156], ["crystal", 160], ["structure", 168], ["of", 178], ["a", 181], ["ternary", 183], ["complex", 191], ["of", 199], ["the", 202], ["enzyme", 206], ["Pr", 213], ["-", 215], ["Set7", 216], ["(", 221], ["also", 222], ["known", 227], ["as", 233], ["Set8", 236], [")", 240], ["that", 242], ["methylates", 247], ["Lys", 258], ["20", 262], ["of", 265], ["histone", 268], ["H4", 276], ["(", 279], ["H4-K20", 280], [")", 286], [".", 287], ["We", 289], ["show", 292], ["that", 297], ["the", 302], ["enzyme", 306], ["is", 313], ["exclusively", 316], ["a", 328], ["mono", 330], ["-", 334], ["methylase", 335], ["and", 345], ["is", 349], ["therefore", 352], ["responsible", 362], ["for", 374], ["a", 378], ["signaling", 380], ["role", 390], ["quite", 395], ["distinct", 401], ["from", 410], ["that", 415], ["established", 420], ["by", 432], ["other", 435], ["enzymes", 441], ["that", 449], ["target", 454], ["this", 461], ["histone", 466], ["residue", 474], [".", 481], ["We", 483], ["provide", 486], ["evidence", 494], ["from", 503], ["NMR", 508], ["for", 512], ["the", 516], ["C", 520], ["-", 521], ["flanking", 522], ["domains", 531], ["of", 539], ["SET", 542], ["proteins", 546], ["becoming", 555], ["ordered", 564], ["upon", 572], ["addition", 577], ["of", 586], ["AdoMet", 589], ["cofactor", 596], ["and", 605], ["develop", 609], ["a", 617], ["model", 619], ["for", 625], ["the", 629], ["catalytic", 633], ["cycle", 643], ["of", 649], ["these", 652], ["enzymes", 658], [".", 665], ["The", 667], ["crystal", 671], ["structure", 679], ["reveals", 689], ["the", 697], ["basis", 701], ["of", 707], ["the", 710], ["specificity", 714], ["of", 726], ["the", 729], ["enzyme", 733], ["for", 740], ["H4-K20", 744], ["because", 751], ["a", 759], ["histidine", 761], ["residue", 771], ["within", 779], ["the", 786], ["substrate", 790], [",", 799], ["close", 801], ["to", 807], ["the", 810], ["target", 814], ["lysine", 821], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["completion", 845], ["of", 856], ["the", 859], ["active", 863], ["site", 870], [".", 874], ["We", 876], ["also", 879], ["show", 884], ["how", 889], ["a", 893], ["highly", 895], ["variable", 902], ["component", 911], ["of", 921], ["the", 924], ["SET", 928], ["domain", 932], ["is", 939], ["responsible", 942], ["for", 954], ["many", 958], ["of", 963], ["the", 966], ["enzymes", 970], ["'", 977], ["interactions", 979], ["with", 992], ["its", 997], ["target", 1001], ["histone", 1008], ["peptide", 1016], ["and", 1024], ["probably", 1028], ["also", 1037], ["how", 1042], ["this", 1046], ["part", 1051], ["of", 1056], ["the", 1059], ["structure", 1063], ["ensures", 1073], ["that", 1081], ["Pr", 1086], ["-", 1088], ["Set7", 1089], ["is", 1094], ["nucleosome", 1097], ["specific", 1108], [".", 1116]]}
{"context": "Susceptibility to autoimmune disorders results from the interaction of multiple genetic factors that regulate the threshold of autoreactivity. Genome-wide microsatellite screens and large-scale single nucleotide polymorphism (SNP) association studies have identified chromosomal loci that are associated with specific disorders including systemic lupus erythematosus, rheumatoid arthritis, juvenile arthritis, multiple sclerosis, and diabetes. Numerous candidate gene association studies have in turn investigated the association of specific genes within these chromosomal regions, with susceptibility to autoimmune diseases (e.g. FcgammaReceptors, TYK2 and systemic lupus). More recently, large-scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature in lupus). In the future, integrated analyses of gene (and protein) expression together with SNP data will allow us to sketch an intelligible picture of the genesis of autoimmunity in humans. This review sets out to illustrate how the most recent advances in the field of systemic lupus erythematosus, rheumatoid arthritis and juvenile arthritis have led to a better understanding of these disorders.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "b57e6d932c6f403896f80cdbf5c54bf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[137, 138]], "char_spans": [[936, 955]]}]}], "context_tokens": [["Susceptibility", 0], ["to", 15], ["autoimmune", 18], ["disorders", 29], ["results", 39], ["from", 47], ["the", 52], ["interaction", 56], ["of", 68], ["multiple", 71], ["genetic", 80], ["factors", 88], ["that", 96], ["regulate", 101], ["the", 110], ["threshold", 114], ["of", 124], ["autoreactivity", 127], [".", 141], ["Genome", 143], ["-", 149], ["wide", 150], ["microsatellite", 155], ["screens", 170], ["and", 178], ["large", 182], ["-", 187], ["scale", 188], ["single", 194], ["nucleotide", 201], ["polymorphism", 212], ["(", 225], ["SNP", 226], [")", 229], ["association", 231], ["studies", 243], ["have", 251], ["identified", 256], ["chromosomal", 267], ["loci", 279], ["that", 284], ["are", 289], ["associated", 293], ["with", 304], ["specific", 309], ["disorders", 318], ["including", 328], ["systemic", 338], ["lupus", 347], ["erythematosus", 353], [",", 366], ["rheumatoid", 368], ["arthritis", 379], [",", 388], ["juvenile", 390], ["arthritis", 399], [",", 408], ["multiple", 410], ["sclerosis", 419], [",", 428], ["and", 430], ["diabetes", 434], [".", 442], ["Numerous", 444], ["candidate", 453], ["gene", 463], ["association", 468], ["studies", 480], ["have", 488], ["in", 493], ["turn", 496], ["investigated", 501], ["the", 514], ["association", 518], ["of", 530], ["specific", 533], ["genes", 542], ["within", 548], ["these", 555], ["chromosomal", 561], ["regions", 573], [",", 580], ["with", 582], ["susceptibility", 587], ["to", 602], ["autoimmune", 605], ["diseases", 616], ["(", 625], ["e.g.", 626], ["FcgammaReceptors", 631], [",", 647], ["TYK2", 649], ["and", 654], ["systemic", 658], ["lupus", 667], [")", 672], [".", 673], ["More", 675], ["recently", 680], [",", 688], ["large", 690], ["-", 695], ["scale", 696], ["differential", 702], ["gene", 715], ["expression", 720], ["studies", 731], ["performed", 739], ["on", 749], ["selected", 752], ["tissues", 761], ["from", 769], ["patients", 774], ["with", 783], ["autoimmune", 788], ["disorders", 799], [",", 808], ["have", 810], ["led", 815], ["to", 819], ["the", 822], ["identification", 826], ["of", 841], ["gene", 844], ["signatures", 849], ["associated", 860], ["with", 871], ["the", 876], ["activation", 880], ["of", 891], ["specific", 894], ["pathways", 903], ["in", 912], ["these", 915], ["diseases", 921], ["(", 930], ["e.g.", 931], ["interferon", 936], ["signature", 947], ["in", 957], ["lupus", 960], [")", 965], [".", 966], ["In", 968], ["the", 971], ["future", 975], [",", 981], ["integrated", 983], ["analyses", 994], ["of", 1003], ["gene", 1006], ["(", 1011], ["and", 1012], ["protein", 1016], [")", 1023], ["expression", 1025], ["together", 1036], ["with", 1045], ["SNP", 1050], ["data", 1054], ["will", 1059], ["allow", 1064], ["us", 1070], ["to", 1073], ["sketch", 1076], ["an", 1083], ["intelligible", 1086], ["picture", 1099], ["of", 1107], ["the", 1110], ["genesis", 1114], ["of", 1122], ["autoimmunity", 1125], ["in", 1138], ["humans", 1141], [".", 1147], ["This", 1149], ["review", 1154], ["sets", 1161], ["out", 1166], ["to", 1170], ["illustrate", 1173], ["how", 1184], ["the", 1188], ["most", 1192], ["recent", 1197], ["advances", 1204], ["in", 1213], ["the", 1216], ["field", 1220], ["of", 1226], ["systemic", 1229], ["lupus", 1238], ["erythematosus", 1244], [",", 1257], ["rheumatoid", 1259], ["arthritis", 1270], ["and", 1280], ["juvenile", 1284], ["arthritis", 1293], ["have", 1303], ["led", 1308], ["to", 1312], ["a", 1315], ["better", 1317], ["understanding", 1324], ["of", 1338], ["these", 1341], ["disorders", 1347], [".", 1356]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "To assess whether vancomycin minimum inhibitory concentration (MIC) creeps among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in a regional hospital in China. Furthermore, to analyze the causes of vancomycin MIC creeps and the relationship between vancomycin MICs and the outcome among patients with MRSA infection. All clinical isolates of MRSA from 2006-2010 were retrieved and tested by the broth microdilution procedure to determine their vancomycin MIC. Meanwhile, related patient records were analyzed. While all isolates were susceptive to vancomycin, the percentage of isolates with a vancomycin MIC = 1 mg/L increased significantly from 2006 (37.0%) to 2010 (75.7%). Meanwhile, vancomycin usage density (DDDs/1000 bed-days) had increased significantly from 2006-2010. Mean linear correlation analysis showed a statistically significant positive correlation (r = 0.905, P < 0.05) between the consumption of vancomycin and the percentage of MRSA isolates with a vancomycin MIC = 1 mg/L. Clinical records revealed high vancomycin MIC was associated with a higher microbiologic failure rate in MRSA bloodstream infections. The data demonstrated vancomycin MIC creep among clinical isolates in our hospital, and the MIC creep may be caused by the increasing usage of vancomycin. Furthermore, the analysis strongly suggested this shift of vancomycin MIC within the susceptible range may be associated with an increasing probability of treatment failure.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d121248484f240caaf83cd0a81473232", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[59, 59], [21, 21], [170, 170], [52, 52], [196, 196]], "char_spans": [[368, 371], [147, 150], [975, 978], [327, 330], [1126, 1129]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["whether", 10], ["vancomycin", 18], ["minimum", 29], ["inhibitory", 37], ["concentration", 48], ["(", 62], ["MIC", 63], [")", 66], ["creeps", 68], ["among", 75], ["clinical", 81], ["isolates", 90], ["of", 99], ["methicillin", 102], ["-", 113], ["resistant", 114], ["Staphylococcus", 124], ["aureus", 139], ["(", 146], ["MRSA", 147], [")", 151], ["in", 153], ["a", 156], ["regional", 158], ["hospital", 167], ["in", 176], ["China", 179], [".", 184], ["Furthermore", 186], [",", 197], ["to", 199], ["analyze", 202], ["the", 210], ["causes", 214], ["of", 221], ["vancomycin", 224], ["MIC", 235], ["creeps", 239], ["and", 246], ["the", 250], ["relationship", 254], ["between", 267], ["vancomycin", 275], ["MICs", 286], ["and", 291], ["the", 295], ["outcome", 299], ["among", 307], ["patients", 313], ["with", 322], ["MRSA", 327], ["infection", 332], [".", 341], ["All", 343], ["clinical", 347], ["isolates", 356], ["of", 365], ["MRSA", 368], ["from", 373], ["2006", 378], ["-", 382], ["2010", 383], ["were", 388], ["retrieved", 393], ["and", 403], ["tested", 407], ["by", 414], ["the", 417], ["broth", 421], ["microdilution", 427], ["procedure", 441], ["to", 451], ["determine", 454], ["their", 464], ["vancomycin", 470], ["MIC", 481], [".", 484], ["Meanwhile", 486], [",", 495], ["related", 497], ["patient", 505], ["records", 513], ["were", 521], ["analyzed", 526], [".", 534], ["While", 536], ["all", 542], ["isolates", 546], ["were", 555], ["susceptive", 560], ["to", 571], ["vancomycin", 574], [",", 584], ["the", 586], ["percentage", 590], ["of", 601], ["isolates", 604], ["with", 613], ["a", 618], ["vancomycin", 620], ["MIC", 631], ["=", 635], ["1", 637], ["mg", 639], ["/", 641], ["L", 642], ["increased", 644], ["significantly", 654], ["from", 668], ["2006", 673], ["(", 678], ["37.0", 679], ["%", 683], [")", 684], ["to", 686], ["2010", 689], ["(", 694], ["75.7", 695], ["%", 699], [")", 700], [".", 701], ["Meanwhile", 703], [",", 712], ["vancomycin", 714], ["usage", 725], ["density", 731], ["(", 739], ["DDDs/1000", 740], ["bed", 750], ["-", 753], ["days", 754], [")", 758], ["had", 760], ["increased", 764], ["significantly", 774], ["from", 788], ["2006", 793], ["-", 797], ["2010", 798], [".", 802], ["Mean", 804], ["linear", 809], ["correlation", 816], ["analysis", 828], ["showed", 837], ["a", 844], ["statistically", 846], ["significant", 860], ["positive", 872], ["correlation", 881], ["(", 893], ["r", 894], ["=", 896], ["0.905", 898], [",", 903], ["P", 905], ["<", 907], ["0.05", 909], [")", 913], ["between", 915], ["the", 923], ["consumption", 927], ["of", 939], ["vancomycin", 942], ["and", 953], ["the", 957], ["percentage", 961], ["of", 972], ["MRSA", 975], ["isolates", 980], ["with", 989], ["a", 994], ["vancomycin", 996], ["MIC", 1007], ["=", 1011], ["1", 1013], ["mg", 1015], ["/", 1017], ["L.", 1018], ["Clinical", 1021], ["records", 1030], ["revealed", 1038], ["high", 1047], ["vancomycin", 1052], ["MIC", 1063], ["was", 1067], ["associated", 1071], ["with", 1082], ["a", 1087], ["higher", 1089], ["microbiologic", 1096], ["failure", 1110], ["rate", 1118], ["in", 1123], ["MRSA", 1126], ["bloodstream", 1131], ["infections", 1143], [".", 1153], ["The", 1155], ["data", 1159], ["demonstrated", 1164], ["vancomycin", 1177], ["MIC", 1188], ["creep", 1192], ["among", 1198], ["clinical", 1204], ["isolates", 1213], ["in", 1222], ["our", 1225], ["hospital", 1229], [",", 1237], ["and", 1239], ["the", 1243], ["MIC", 1247], ["creep", 1251], ["may", 1257], ["be", 1261], ["caused", 1264], ["by", 1271], ["the", 1274], ["increasing", 1278], ["usage", 1289], ["of", 1295], ["vancomycin", 1298], [".", 1308], ["Furthermore", 1310], [",", 1321], ["the", 1323], ["analysis", 1327], ["strongly", 1336], ["suggested", 1345], ["this", 1355], ["shift", 1360], ["of", 1366], ["vancomycin", 1369], ["MIC", 1380], ["within", 1384], ["the", 1391], ["susceptible", 1395], ["range", 1407], ["may", 1413], ["be", 1417], ["associated", 1420], ["with", 1431], ["an", 1436], ["increasing", 1439], ["probability", 1450], ["of", 1462], ["treatment", 1465], ["failure", 1475], [".", 1482]]}
{"context": "The first step in the management of restless legs syndrome (RLS) is to identify, and if possible to treat any condition which might cause or worsen RLS, such as iron deficiency or some drug treatments. The patients suffering from RLS should be prompted to keep a healthy sleep schedule. Drug treatment should be restricted to patients with a clear clinical diagnosis, decided on an individual basis, when the clinical impact is serious. Four drug classes are central to the treatment of RLS: dopaminergic agents, some antiepileptics, opioids, and benzodiazepines. Dopaminergic agonists are the treatment of choice, especially when daily treatment is indicated, or if the symptoms are severe. Two dopaminergic agonists are licensed in France for the treatment of RLS: ropinirole (Adartrel) and pramipexole (Sifrol). After initiation of treatment, the patients should benefit from a regular follow-up in order to evaluate the efficacy of treatment and to identify possible side-effects. Special care should be given to the detection of augmentation, a phenomenon characterized by a paradoxical worsening of the symptoms with treatment. Some particular conditions, such as RLS comorbid with renal insufficiency, during pregnancy, and in the child are discussed.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "aea77da44e294600b63d4260d7490d59", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[33, 33]], "char_spans": [[161, 164]]}]}], "context_tokens": [["The", 0], ["first", 4], ["step", 10], ["in", 15], ["the", 18], ["management", 22], ["of", 33], ["restless", 36], ["legs", 45], ["syndrome", 50], ["(", 59], ["RLS", 60], [")", 63], ["is", 65], ["to", 68], ["identify", 71], [",", 79], ["and", 81], ["if", 85], ["possible", 88], ["to", 97], ["treat", 100], ["any", 106], ["condition", 110], ["which", 120], ["might", 126], ["cause", 132], ["or", 138], ["worsen", 141], ["RLS", 148], [",", 151], ["such", 153], ["as", 158], ["iron", 161], ["deficiency", 166], ["or", 177], ["some", 180], ["drug", 185], ["treatments", 190], [".", 200], ["The", 202], ["patients", 206], ["suffering", 215], ["from", 225], ["RLS", 230], ["should", 234], ["be", 241], ["prompted", 244], ["to", 253], ["keep", 256], ["a", 261], ["healthy", 263], ["sleep", 271], ["schedule", 277], [".", 285], ["Drug", 287], ["treatment", 292], ["should", 302], ["be", 309], ["restricted", 312], ["to", 323], ["patients", 326], ["with", 335], ["a", 340], ["clear", 342], ["clinical", 348], ["diagnosis", 357], [",", 366], ["decided", 368], ["on", 376], ["an", 379], ["individual", 382], ["basis", 393], [",", 398], ["when", 400], ["the", 405], ["clinical", 409], ["impact", 418], ["is", 425], ["serious", 428], [".", 435], ["Four", 437], ["drug", 442], ["classes", 447], ["are", 455], ["central", 459], ["to", 467], ["the", 470], ["treatment", 474], ["of", 484], ["RLS", 487], [":", 490], ["dopaminergic", 492], ["agents", 505], [",", 511], ["some", 513], ["antiepileptics", 518], [",", 532], ["opioids", 534], [",", 541], ["and", 543], ["benzodiazepines", 547], [".", 562], ["Dopaminergic", 564], ["agonists", 577], ["are", 586], ["the", 590], ["treatment", 594], ["of", 604], ["choice", 607], [",", 613], ["especially", 615], ["when", 626], ["daily", 631], ["treatment", 637], ["is", 647], ["indicated", 650], [",", 659], ["or", 661], ["if", 664], ["the", 667], ["symptoms", 671], ["are", 680], ["severe", 684], [".", 690], ["Two", 692], ["dopaminergic", 696], ["agonists", 709], ["are", 718], ["licensed", 722], ["in", 731], ["France", 734], ["for", 741], ["the", 745], ["treatment", 749], ["of", 759], ["RLS", 762], [":", 765], ["ropinirole", 767], ["(", 778], ["Adartrel", 779], [")", 787], ["and", 789], ["pramipexole", 793], ["(", 805], ["Sifrol", 806], [")", 812], [".", 813], ["After", 815], ["initiation", 821], ["of", 832], ["treatment", 835], [",", 844], ["the", 846], ["patients", 850], ["should", 859], ["benefit", 866], ["from", 874], ["a", 879], ["regular", 881], ["follow", 889], ["-", 895], ["up", 896], ["in", 899], ["order", 902], ["to", 908], ["evaluate", 911], ["the", 920], ["efficacy", 924], ["of", 933], ["treatment", 936], ["and", 946], ["to", 950], ["identify", 953], ["possible", 962], ["side", 971], ["-", 975], ["effects", 976], [".", 983], ["Special", 985], ["care", 993], ["should", 998], ["be", 1005], ["given", 1008], ["to", 1014], ["the", 1017], ["detection", 1021], ["of", 1031], ["augmentation", 1034], [",", 1046], ["a", 1048], ["phenomenon", 1050], ["characterized", 1061], ["by", 1075], ["a", 1078], ["paradoxical", 1080], ["worsening", 1092], ["of", 1102], ["the", 1105], ["symptoms", 1109], ["with", 1118], ["treatment", 1123], [".", 1132], ["Some", 1134], ["particular", 1139], ["conditions", 1150], [",", 1160], ["such", 1162], ["as", 1167], ["RLS", 1170], ["comorbid", 1174], ["with", 1183], ["renal", 1188], ["insufficiency", 1194], [",", 1207], ["during", 1209], ["pregnancy", 1216], [",", 1225], ["and", 1227], ["in", 1231], ["the", 1234], ["child", 1238], ["are", 1244], ["discussed", 1248], [".", 1257]]}
{"context": "An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments. To determine what hospital-associated factors drove the outbreak of this particular strain we performed a case-control study. Cases (n = 79), diagnosed with CDI due to C. difficile ribotype 027 were matched for age and treating medical specialty to four control patients (n = 316). Patients diagnosed with CDI due to other ribotypes were included as a second control group. A random selection of C. difficile ribotype 027 strains (n = 10) was genotyped by Whole Genome Sequencing (WGS). WGS showed the outbreak was likely caused by a single strain of C. difficile (two or less single-nucleotide variants between isolates). Ninety-five percent of cases had used antibiotics, compared to 56% of controls. Previous admission to the intensive care unit (ICU) (OR: 2.4, 95% CI 1.0-5.6), longer length of stay (LOS), and recent hospital admission were associated with CDI ribotype 027. Cases were less likely to have been admitted to a ward with a known isolated CDI patient (OR: 0.2, 95% CI 0.1-0.6). Analysis of patients who stayed at the ICU (35 cases; 51 controls), indicated that the use of selective decontamination of the digestive tract (SDD) and a longer LOS in the ICU were associated with CDI risk. In this large outbreak, any antibiotic use, including SDD use, appeared as a prerequisite for acquisition of the outbreak strain. The role of use of SDD and prolonged stay on the ICU could not be disentangled, but both factors can play a biologically plausible role in C. difficile acquisition and infection.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "3624fe9b9dca47c98be7dc8c2d2db870", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[5, 6], [57, 58], [199, 200], [99, 100]], "char_spans": [[37, 48], [309, 320], [994, 1005], [537, 548]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["ribotype", 37], ["027", 46], ["infection", 50], ["(", 60], ["CDI", 61], [")", 64], ["occurred", 66], ["at", 75], ["an", 78], ["university", 81], ["hospital", 92], [",", 100], ["involving", 102], ["19", 112], ["departments", 115], [".", 126], ["To", 128], ["determine", 131], ["what", 141], ["hospital", 146], ["-", 154], ["associated", 155], ["factors", 166], ["drove", 174], ["the", 180], ["outbreak", 184], ["of", 193], ["this", 196], ["particular", 201], ["strain", 212], ["we", 219], ["performed", 222], ["a", 232], ["case", 234], ["-", 238], ["control", 239], ["study", 247], [".", 252], ["Cases", 254], ["(", 260], ["n", 261], ["=", 263], ["79", 265], [")", 267], [",", 268], ["diagnosed", 270], ["with", 280], ["CDI", 285], ["due", 289], ["to", 293], ["C.", 296], ["difficile", 299], ["ribotype", 309], ["027", 318], ["were", 322], ["matched", 327], ["for", 335], ["age", 339], ["and", 343], ["treating", 347], ["medical", 356], ["specialty", 364], ["to", 374], ["four", 377], ["control", 382], ["patients", 390], ["(", 399], ["n", 400], ["=", 402], ["316", 404], [")", 407], [".", 408], ["Patients", 410], ["diagnosed", 419], ["with", 429], ["CDI", 434], ["due", 438], ["to", 442], ["other", 445], ["ribotypes", 451], ["were", 461], ["included", 466], ["as", 475], ["a", 478], ["second", 480], ["control", 487], ["group", 495], [".", 500], ["A", 502], ["random", 504], ["selection", 511], ["of", 521], ["C.", 524], ["difficile", 527], ["ribotype", 537], ["027", 546], ["strains", 550], ["(", 558], ["n", 559], ["=", 561], ["10", 563], [")", 565], ["was", 567], ["genotyped", 571], ["by", 581], ["Whole", 584], ["Genome", 590], ["Sequencing", 597], ["(", 608], ["WGS", 609], [")", 612], [".", 613], ["WGS", 615], ["showed", 619], ["the", 626], ["outbreak", 630], ["was", 639], ["likely", 643], ["caused", 650], ["by", 657], ["a", 660], ["single", 662], ["strain", 669], ["of", 676], ["C.", 679], ["difficile", 682], ["(", 692], ["two", 693], ["or", 697], ["less", 700], ["single", 705], ["-", 711], ["nucleotide", 712], ["variants", 723], ["between", 732], ["isolates", 740], [")", 748], [".", 749], ["Ninety", 751], ["-", 757], ["five", 758], ["percent", 763], ["of", 771], ["cases", 774], ["had", 780], ["used", 784], ["antibiotics", 789], [",", 800], ["compared", 802], ["to", 811], ["56", 814], ["%", 816], ["of", 818], ["controls", 821], [".", 829], ["Previous", 831], ["admission", 840], ["to", 850], ["the", 853], ["intensive", 857], ["care", 867], ["unit", 872], ["(", 877], ["ICU", 878], [")", 881], ["(", 883], ["OR", 884], [":", 886], ["2.4", 888], [",", 891], ["95", 893], ["%", 895], ["CI", 897], ["1.0", 900], ["-", 903], ["5.6", 904], [")", 907], [",", 908], ["longer", 910], ["length", 917], ["of", 924], ["stay", 927], ["(", 932], ["LOS", 933], [")", 936], [",", 937], ["and", 939], ["recent", 943], ["hospital", 950], ["admission", 959], ["were", 969], ["associated", 974], ["with", 985], ["CDI", 990], ["ribotype", 994], ["027", 1003], [".", 1006], ["Cases", 1008], ["were", 1014], ["less", 1019], ["likely", 1024], ["to", 1031], ["have", 1034], ["been", 1039], ["admitted", 1044], ["to", 1053], ["a", 1056], ["ward", 1058], ["with", 1063], ["a", 1068], ["known", 1070], ["isolated", 1076], ["CDI", 1085], ["patient", 1089], ["(", 1097], ["OR", 1098], [":", 1100], ["0.2", 1102], [",", 1105], ["95", 1107], ["%", 1109], ["CI", 1111], ["0.1", 1114], ["-", 1117], ["0.6", 1118], [")", 1121], [".", 1122], ["Analysis", 1124], ["of", 1133], ["patients", 1136], ["who", 1145], ["stayed", 1149], ["at", 1156], ["the", 1159], ["ICU", 1163], ["(", 1167], ["35", 1168], ["cases", 1171], [";", 1176], ["51", 1178], ["controls", 1181], [")", 1189], [",", 1190], ["indicated", 1192], ["that", 1202], ["the", 1207], ["use", 1211], ["of", 1215], ["selective", 1218], ["decontamination", 1228], ["of", 1244], ["the", 1247], ["digestive", 1251], ["tract", 1261], ["(", 1267], ["SDD", 1268], [")", 1271], ["and", 1273], ["a", 1277], ["longer", 1279], ["LOS", 1286], ["in", 1290], ["the", 1293], ["ICU", 1297], ["were", 1301], ["associated", 1306], ["with", 1317], ["CDI", 1322], ["risk", 1326], [".", 1330], ["In", 1332], ["this", 1335], ["large", 1340], ["outbreak", 1346], [",", 1354], ["any", 1356], ["antibiotic", 1360], ["use", 1371], [",", 1374], ["including", 1376], ["SDD", 1386], ["use", 1390], [",", 1393], ["appeared", 1395], ["as", 1404], ["a", 1407], ["prerequisite", 1409], ["for", 1422], ["acquisition", 1426], ["of", 1438], ["the", 1441], ["outbreak", 1445], ["strain", 1454], [".", 1460], ["The", 1462], ["role", 1466], ["of", 1471], ["use", 1474], ["of", 1478], ["SDD", 1481], ["and", 1485], ["prolonged", 1489], ["stay", 1499], ["on", 1504], ["the", 1507], ["ICU", 1511], ["could", 1515], ["not", 1521], ["be", 1525], ["disentangled", 1528], [",", 1540], ["but", 1542], ["both", 1546], ["factors", 1551], ["can", 1559], ["play", 1563], ["a", 1568], ["biologically", 1570], ["plausible", 1583], ["role", 1593], ["in", 1598], ["C.", 1601], ["difficile", 1604], ["acquisition", 1614], ["and", 1626], ["infection", 1630], [".", 1639]]}
{"context": "Eukaryotic centromeres are maintained at specific chromosomal sites over many generations. In the budding yeast Saccharomyces cerevisiae, centromeres are genetic elements defined by a DNA sequence that is both necessary and sufficient for function; whereas, in most other eukaryotes, centromeres are maintained by poorly characterized epigenetic mechanisms in which DNA has a less definitive role. Here we use the pathogenic yeast Candida albicans as a model organism to study the DNA replication properties of centromeric DNA. By determining the genome-wide replication timing program of the C. albicans genome, we discovered that each centromere is associated with a replication origin that is the first to fire on its respective chromosome. Importantly, epigenetic formation of new ectopic centromeres (neocentromeres) was accompanied by shifts in replication timing, such that a neocentromere became the first to replicate and became associated with origin recognition complex (ORC) components. Furthermore, changing the level of the centromere-specific histone H3 isoform led to a concomitant change in levels of ORC association with centromere regions, further supporting the idea that centromere proteins determine origin activity. Finally, analysis of centromere-associated DNA revealed a replication-dependent sequence pattern characteristic of constitutively active replication origins. This strand-biased pattern is conserved, together with centromere position, among related strains and species, in a manner independent of primary DNA sequence. Thus, inheritance of centromere position is correlated with a constitutively active origin of replication that fires at a distinct early time. We suggest a model in which the distinct timing of DNA replication serves as an epigenetic mechanism for the inheritance of centromere position.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "f86ba8d933b746bc9dcc170bdad24a09", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[268, 268]], "char_spans": [[1688, 1692]]}]}], "context_tokens": [["Eukaryotic", 0], ["centromeres", 11], ["are", 23], ["maintained", 27], ["at", 38], ["specific", 41], ["chromosomal", 50], ["sites", 62], ["over", 68], ["many", 73], ["generations", 78], [".", 89], ["In", 91], ["the", 94], ["budding", 98], ["yeast", 106], ["Saccharomyces", 112], ["cerevisiae", 126], [",", 136], ["centromeres", 138], ["are", 150], ["genetic", 154], ["elements", 162], ["defined", 171], ["by", 179], ["a", 182], ["DNA", 184], ["sequence", 188], ["that", 197], ["is", 202], ["both", 205], ["necessary", 210], ["and", 220], ["sufficient", 224], ["for", 235], ["function", 239], [";", 247], ["whereas", 249], [",", 256], ["in", 258], ["most", 261], ["other", 266], ["eukaryotes", 272], [",", 282], ["centromeres", 284], ["are", 296], ["maintained", 300], ["by", 311], ["poorly", 314], ["characterized", 321], ["epigenetic", 335], ["mechanisms", 346], ["in", 357], ["which", 360], ["DNA", 366], ["has", 370], ["a", 374], ["less", 376], ["definitive", 381], ["role", 392], [".", 396], ["Here", 398], ["we", 403], ["use", 406], ["the", 410], ["pathogenic", 414], ["yeast", 425], ["Candida", 431], ["albicans", 439], ["as", 448], ["a", 451], ["model", 453], ["organism", 459], ["to", 468], ["study", 471], ["the", 477], ["DNA", 481], ["replication", 485], ["properties", 497], ["of", 508], ["centromeric", 511], ["DNA", 523], [".", 526], ["By", 528], ["determining", 531], ["the", 543], ["genome", 547], ["-", 553], ["wide", 554], ["replication", 559], ["timing", 571], ["program", 578], ["of", 586], ["the", 589], ["C.", 593], ["albicans", 596], ["genome", 605], [",", 611], ["we", 613], ["discovered", 616], ["that", 627], ["each", 632], ["centromere", 637], ["is", 648], ["associated", 651], ["with", 662], ["a", 667], ["replication", 669], ["origin", 681], ["that", 688], ["is", 693], ["the", 696], ["first", 700], ["to", 706], ["fire", 709], ["on", 714], ["its", 717], ["respective", 721], ["chromosome", 732], [".", 742], ["Importantly", 744], [",", 755], ["epigenetic", 757], ["formation", 768], ["of", 778], ["new", 781], ["ectopic", 785], ["centromeres", 793], ["(", 805], ["neocentromeres", 806], [")", 820], ["was", 822], ["accompanied", 826], ["by", 838], ["shifts", 841], ["in", 848], ["replication", 851], ["timing", 863], [",", 869], ["such", 871], ["that", 876], ["a", 881], ["neocentromere", 883], ["became", 897], ["the", 904], ["first", 908], ["to", 914], ["replicate", 917], ["and", 927], ["became", 931], ["associated", 938], ["with", 949], ["origin", 954], ["recognition", 961], ["complex", 973], ["(", 981], ["ORC", 982], [")", 985], ["components", 987], [".", 997], ["Furthermore", 999], [",", 1010], ["changing", 1012], ["the", 1021], ["level", 1025], ["of", 1031], ["the", 1034], ["centromere", 1038], ["-", 1048], ["specific", 1049], ["histone", 1058], ["H3", 1066], ["isoform", 1069], ["led", 1077], ["to", 1081], ["a", 1084], ["concomitant", 1086], ["change", 1098], ["in", 1105], ["levels", 1108], ["of", 1115], ["ORC", 1118], ["association", 1122], ["with", 1134], ["centromere", 1139], ["regions", 1150], [",", 1157], ["further", 1159], ["supporting", 1167], ["the", 1178], ["idea", 1182], ["that", 1187], ["centromere", 1192], ["proteins", 1203], ["determine", 1212], ["origin", 1222], ["activity", 1229], [".", 1237], ["Finally", 1239], [",", 1246], ["analysis", 1248], ["of", 1257], ["centromere", 1260], ["-", 1270], ["associated", 1271], ["DNA", 1282], ["revealed", 1286], ["a", 1295], ["replication", 1297], ["-", 1308], ["dependent", 1309], ["sequence", 1319], ["pattern", 1328], ["characteristic", 1336], ["of", 1351], ["constitutively", 1354], ["active", 1369], ["replication", 1376], ["origins", 1388], [".", 1395], ["This", 1397], ["strand", 1402], ["-", 1408], ["biased", 1409], ["pattern", 1416], ["is", 1424], ["conserved", 1427], [",", 1436], ["together", 1438], ["with", 1447], ["centromere", 1452], ["position", 1463], [",", 1471], ["among", 1473], ["related", 1479], ["strains", 1487], ["and", 1495], ["species", 1499], [",", 1506], ["in", 1508], ["a", 1511], ["manner", 1513], ["independent", 1520], ["of", 1532], ["primary", 1535], ["DNA", 1543], ["sequence", 1547], [".", 1555], ["Thus", 1557], [",", 1561], ["inheritance", 1563], ["of", 1575], ["centromere", 1578], ["position", 1589], ["is", 1598], ["correlated", 1601], ["with", 1612], ["a", 1617], ["constitutively", 1619], ["active", 1634], ["origin", 1641], ["of", 1648], ["replication", 1651], ["that", 1663], ["fires", 1668], ["at", 1674], ["a", 1677], ["distinct", 1679], ["early", 1688], ["time", 1694], [".", 1698], ["We", 1700], ["suggest", 1703], ["a", 1711], ["model", 1713], ["in", 1719], ["which", 1722], ["the", 1728], ["distinct", 1732], ["timing", 1741], ["of", 1748], ["DNA", 1751], ["replication", 1755], ["serves", 1767], ["as", 1774], ["an", 1777], ["epigenetic", 1780], ["mechanism", 1791], ["for", 1801], ["the", 1805], ["inheritance", 1809], ["of", 1821], ["centromere", 1824], ["position", 1835], [".", 1843]]}
{"context": "Chediak-Higashi syndrome, a rare autosomal recessive disorder, was described over 50 years ago. Patients show hypopigmentation, recurrent infections, mild coagulation defects and varying neurologic problems. Treatment is bone marrow transplant, which is effective in treating the hematologic and immune defects, however the neurologic problems persist. The CHS1/LYST gene was identified over 10 years ago and homologous CHS1/LYST genes are present in all eukaryotes. This review will discuss the advances made in understanding the clinical aspects of the syndrome and the function of CHS1/LYST/Beige. Clinical reports of Chediak-Higashi syndrome have identified mutations throughout the CHS1/LYST gene. The nature of the mutation can be a predictor of the severity of the disease. Over the past decade the CHS1/LYST family of proteins has been analyzed using model organisms, two-hybrid analysis, overexpression phenotypes and dominant negatives. These studies suggest that the CHS1/LYST protein is involved in either vesicle fusion or fission. Although CHS is a rare disease, the Chediak-like family of proteins is providing insight into the regulation of vesicle trafficking. Understanding the basic mechanisms that govern vesicle trafficking will provide essential information regarding how loss of CHS1/LYST affects hematologic, immunologic and neurologic processes.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "8283a8628bfe440b908b5fe0ef0625ea", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3], [101, 104]], "char_spans": [[0, 23], [621, 644]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], [",", 24], ["a", 26], ["rare", 28], ["autosomal", 33], ["recessive", 43], ["disorder", 53], [",", 61], ["was", 63], ["described", 67], ["over", 77], ["50", 82], ["years", 85], ["ago", 91], [".", 94], ["Patients", 96], ["show", 105], ["hypopigmentation", 110], [",", 126], ["recurrent", 128], ["infections", 138], [",", 148], ["mild", 150], ["coagulation", 155], ["defects", 167], ["and", 175], ["varying", 179], ["neurologic", 187], ["problems", 198], [".", 206], ["Treatment", 208], ["is", 218], ["bone", 221], ["marrow", 226], ["transplant", 233], [",", 243], ["which", 245], ["is", 251], ["effective", 254], ["in", 264], ["treating", 267], ["the", 276], ["hematologic", 280], ["and", 292], ["immune", 296], ["defects", 303], [",", 310], ["however", 312], ["the", 320], ["neurologic", 324], ["problems", 335], ["persist", 344], [".", 351], ["The", 353], ["CHS1/LYST", 357], ["gene", 367], ["was", 372], ["identified", 376], ["over", 387], ["10", 392], ["years", 395], ["ago", 401], ["and", 405], ["homologous", 409], ["CHS1/LYST", 420], ["genes", 430], ["are", 436], ["present", 440], ["in", 448], ["all", 451], ["eukaryotes", 455], [".", 465], ["This", 467], ["review", 472], ["will", 479], ["discuss", 484], ["the", 492], ["advances", 496], ["made", 505], ["in", 510], ["understanding", 513], ["the", 527], ["clinical", 531], ["aspects", 540], ["of", 548], ["the", 551], ["syndrome", 555], ["and", 564], ["the", 568], ["function", 572], ["of", 581], ["CHS1/LYST", 584], ["/", 593], ["Beige", 594], [".", 599], ["Clinical", 601], ["reports", 610], ["of", 618], ["Chediak", 621], ["-", 628], ["Higashi", 629], ["syndrome", 637], ["have", 646], ["identified", 651], ["mutations", 662], ["throughout", 672], ["the", 683], ["CHS1/LYST", 687], ["gene", 697], [".", 701], ["The", 703], ["nature", 707], ["of", 714], ["the", 717], ["mutation", 721], ["can", 730], ["be", 734], ["a", 737], ["predictor", 739], ["of", 749], ["the", 752], ["severity", 756], ["of", 765], ["the", 768], ["disease", 772], [".", 779], ["Over", 781], ["the", 786], ["past", 790], ["decade", 795], ["the", 802], ["CHS1/LYST", 806], ["family", 816], ["of", 823], ["proteins", 826], ["has", 835], ["been", 839], ["analyzed", 844], ["using", 853], ["model", 859], ["organisms", 865], [",", 874], ["two", 876], ["-", 879], ["hybrid", 880], ["analysis", 887], [",", 895], ["overexpression", 897], ["phenotypes", 912], ["and", 923], ["dominant", 927], ["negatives", 936], [".", 945], ["These", 947], ["studies", 953], ["suggest", 961], ["that", 969], ["the", 974], ["CHS1/LYST", 978], ["protein", 988], ["is", 996], ["involved", 999], ["in", 1008], ["either", 1011], ["vesicle", 1018], ["fusion", 1026], ["or", 1033], ["fission", 1036], [".", 1043], ["Although", 1045], ["CHS", 1054], ["is", 1058], ["a", 1061], ["rare", 1063], ["disease", 1068], [",", 1075], ["the", 1077], ["Chediak", 1081], ["-", 1088], ["like", 1089], ["family", 1094], ["of", 1101], ["proteins", 1104], ["is", 1113], ["providing", 1116], ["insight", 1126], ["into", 1134], ["the", 1139], ["regulation", 1143], ["of", 1154], ["vesicle", 1157], ["trafficking", 1165], [".", 1176], ["Understanding", 1178], ["the", 1192], ["basic", 1196], ["mechanisms", 1202], ["that", 1213], ["govern", 1218], ["vesicle", 1225], ["trafficking", 1233], ["will", 1245], ["provide", 1250], ["essential", 1258], ["information", 1268], ["regarding", 1280], ["how", 1290], ["loss", 1294], ["of", 1299], ["CHS1/LYST", 1302], ["affects", 1312], ["hematologic", 1320], [",", 1331], ["immunologic", 1333], ["and", 1345], ["neurologic", 1349], ["processes", 1360], [".", 1369]]}
{"context": "BACKGROUND Fractionated plasma separation and absorption (FPSA) is an extracorporeal liver support method that detoxifies accumulated toxins. There are limited data of its use in the treatment of Amanita phalloides intoxication. The objective of this study was to investigate whether FPSA before liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides poisoning. MATERIAL AND METHODS The study population consisted of ten patients who had liver transplantation (LT) due to acute liver failure (ALF) caused by Amanita phalloides poisoning. Six patients were treated with FPSA before liver transplantation. All the patients who were started on FPSA were also placed on the liver transplantation list according to emergent liver transplantation criteria. RESULTS Patients treated with FPSA were in a more severe clinical condition presenting in higher mean MELD, total bilirubin, INR and ammonia along with more frequent hypoglycemia and hepatic encephalopathy grade 3/4. FPSA group had longer mean waiting time on the recipient list (3.5 vs. 1.25 days) but inferior thirty-day survival rate (16.5% vs. 100%). CONCLUSIONS When conservative medical modalities are ineffective, the only treatment for Amanita phalloides poisoning is a liver transplant. Although FPSA treated patients had inferior post-LT survival, FPSA was found to prolong the pre surgical waiting time for critically ill patients, consequently giving a chance of life-saving procedure.", "qas": [{"question": "Which mushroom is poisonous, Amanita phalloides or Agaricus Bisporus", "answers": ["Amanita phalloides"], "qid": "b5dbf261c2ac47798a218fa9f7495791", "question_tokens": [["Which", 0], ["mushroom", 6], ["is", 15], ["poisonous", 18], [",", 27], ["Amanita", 29], ["phalloides", 37], ["or", 48], ["Agaricus", 51], ["Bisporus", 60]], "detected_answers": [{"text": "Amanita phalloides", "token_spans": [[59, 60], [90, 91], [31, 32], [206, 207]], "char_spans": [[387, 404], [563, 580], [196, 213], [1250, 1267]]}]}], "context_tokens": [["BACKGROUND", 0], ["Fractionated", 11], ["plasma", 24], ["separation", 31], ["and", 42], ["absorption", 46], ["(", 57], ["FPSA", 58], [")", 62], ["is", 64], ["an", 67], ["extracorporeal", 70], ["liver", 85], ["support", 91], ["method", 99], ["that", 106], ["detoxifies", 111], ["accumulated", 122], ["toxins", 134], [".", 140], ["There", 142], ["are", 148], ["limited", 152], ["data", 160], ["of", 165], ["its", 168], ["use", 172], ["in", 176], ["the", 179], ["treatment", 183], ["of", 193], ["Amanita", 196], ["phalloides", 204], ["intoxication", 215], [".", 227], ["The", 229], ["objective", 233], ["of", 243], ["this", 246], ["study", 251], ["was", 257], ["to", 261], ["investigate", 264], ["whether", 276], ["FPSA", 284], ["before", 289], ["liver", 296], ["transplantation", 302], ["improves", 318], ["patients", 327], ["'", 335], ["short", 337], ["-", 342], ["term", 343], ["post", 348], ["liver", 353], ["transplantation", 359], ["survival", 375], ["in", 384], ["Amanita", 387], ["phalloides", 395], ["poisoning", 406], [".", 415], ["MATERIAL", 417], ["AND", 426], ["METHODS", 430], ["The", 438], ["study", 442], ["population", 448], ["consisted", 459], ["of", 469], ["ten", 472], ["patients", 476], ["who", 485], ["had", 489], ["liver", 493], ["transplantation", 499], ["(", 515], ["LT", 516], [")", 518], ["due", 520], ["to", 524], ["acute", 527], ["liver", 533], ["failure", 539], ["(", 547], ["ALF", 548], [")", 551], ["caused", 553], ["by", 560], ["Amanita", 563], ["phalloides", 571], ["poisoning", 582], [".", 591], ["Six", 593], ["patients", 597], ["were", 606], ["treated", 611], ["with", 619], ["FPSA", 624], ["before", 629], ["liver", 636], ["transplantation", 642], [".", 657], ["All", 659], ["the", 663], ["patients", 667], ["who", 676], ["were", 680], ["started", 685], ["on", 693], ["FPSA", 696], ["were", 701], ["also", 706], ["placed", 711], ["on", 718], ["the", 721], ["liver", 725], ["transplantation", 731], ["list", 747], ["according", 752], ["to", 762], ["emergent", 765], ["liver", 774], ["transplantation", 780], ["criteria", 796], [".", 804], ["RESULTS", 806], ["Patients", 814], ["treated", 823], ["with", 831], ["FPSA", 836], ["were", 841], ["in", 846], ["a", 849], ["more", 851], ["severe", 856], ["clinical", 863], ["condition", 872], ["presenting", 882], ["in", 893], ["higher", 896], ["mean", 903], ["MELD", 908], [",", 912], ["total", 914], ["bilirubin", 920], [",", 929], ["INR", 931], ["and", 935], ["ammonia", 939], ["along", 947], ["with", 953], ["more", 958], ["frequent", 963], ["hypoglycemia", 972], ["and", 985], ["hepatic", 989], ["encephalopathy", 997], ["grade", 1012], ["3/4", 1018], [".", 1021], ["FPSA", 1023], ["group", 1028], ["had", 1034], ["longer", 1038], ["mean", 1045], ["waiting", 1050], ["time", 1058], ["on", 1063], ["the", 1066], ["recipient", 1070], ["list", 1080], ["(", 1085], ["3.5", 1086], ["vs.", 1090], ["1.25", 1094], ["days", 1099], [")", 1103], ["but", 1105], ["inferior", 1109], ["thirty", 1118], ["-", 1124], ["day", 1125], ["survival", 1129], ["rate", 1138], ["(", 1143], ["16.5", 1144], ["%", 1148], ["vs.", 1150], ["100", 1154], ["%", 1157], [")", 1158], [".", 1159], ["CONCLUSIONS", 1161], ["When", 1173], ["conservative", 1178], ["medical", 1191], ["modalities", 1199], ["are", 1210], ["ineffective", 1214], [",", 1225], ["the", 1227], ["only", 1231], ["treatment", 1236], ["for", 1246], ["Amanita", 1250], ["phalloides", 1258], ["poisoning", 1269], ["is", 1279], ["a", 1282], ["liver", 1284], ["transplant", 1290], [".", 1300], ["Although", 1302], ["FPSA", 1311], ["treated", 1316], ["patients", 1324], ["had", 1333], ["inferior", 1337], ["post", 1346], ["-", 1350], ["LT", 1351], ["survival", 1354], [",", 1362], ["FPSA", 1364], ["was", 1369], ["found", 1373], ["to", 1379], ["prolong", 1382], ["the", 1390], ["pre", 1394], ["surgical", 1398], ["waiting", 1407], ["time", 1415], ["for", 1420], ["critically", 1424], ["ill", 1435], ["patients", 1439], [",", 1447], ["consequently", 1449], ["giving", 1462], ["a", 1469], ["chance", 1471], ["of", 1478], ["life", 1481], ["-", 1485], ["saving", 1486], ["procedure", 1493], [".", 1502]]}
{"context": "Species-specific sets of chromosomes-karyotypes-are traditionally depicted as linear ideograms with individual chromosomes represented by vertical bars. However, linear visualization has its limitations when the shared collinearity and/or chromosomal rearrangements differentiating two or more karyotypes need to be demonstrated. In these instances, circular visualization might provide easier comprehension and interpretation of inter-species chromosomal collinearity. The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", "qas": [{"question": "Which R package is used for visualization of linear and circular karyotypes?", "answers": ["chromDraw"], "qid": "9c678887061c48e688347d3c09889e6c", "question_tokens": [["Which", 0], ["R", 6], ["package", 8], ["is", 16], ["used", 19], ["for", 24], ["visualization", 28], ["of", 42], ["linear", 45], ["and", 52], ["circular", 56], ["karyotypes", 65], ["?", 75]], "detected_answers": [{"text": "chromDraw", "token_spans": [[147, 147], [67, 67]], "char_spans": [[916, 924], [474, 482]]}]}], "context_tokens": [["Species", 0], ["-", 7], ["specific", 8], ["sets", 17], ["of", 22], ["chromosomes", 25], ["-", 36], ["karyotypes", 37], ["-", 47], ["are", 48], ["traditionally", 52], ["depicted", 66], ["as", 75], ["linear", 78], ["ideograms", 85], ["with", 95], ["individual", 100], ["chromosomes", 111], ["represented", 123], ["by", 135], ["vertical", 138], ["bars", 147], [".", 151], ["However", 153], [",", 160], ["linear", 162], ["visualization", 169], ["has", 183], ["its", 187], ["limitations", 191], ["when", 203], ["the", 208], ["shared", 212], ["collinearity", 219], ["and/or", 232], ["chromosomal", 239], ["rearrangements", 251], ["differentiating", 266], ["two", 282], ["or", 286], ["more", 289], ["karyotypes", 294], ["need", 305], ["to", 310], ["be", 313], ["demonstrated", 316], [".", 328], ["In", 330], ["these", 333], ["instances", 339], [",", 348], ["circular", 350], ["visualization", 359], ["might", 373], ["provide", 379], ["easier", 387], ["comprehension", 394], ["and", 408], ["interpretation", 412], ["of", 427], ["inter", 430], ["-", 435], ["species", 436], ["chromosomal", 444], ["collinearity", 456], [".", 468], ["The", 470], ["chromDraw", 474], ["graphical", 484], ["tool", 494], ["was", 499], ["developed", 503], ["as", 513], ["a", 516], ["user", 518], ["-", 522], ["friendly", 523], ["graphical", 532], ["tool", 542], ["for", 547], ["visualizing", 551], ["both", 563], ["linear", 568], ["and", 575], ["circular", 579], ["karyotypes", 588], ["based", 599], ["on", 605], ["the", 608], ["same", 612], ["input", 617], ["data", 623], ["matrix", 628], [".", 634], ["The", 636], ["output", 640], ["graphics", 647], [",", 655], ["saved", 657], ["in", 663], ["two", 666], ["different", 670], ["formats", 680], ["(", 688], ["EPS", 689], ["and", 693], ["SVG", 697], [")", 700], [",", 701], ["can", 703], ["be", 707], ["easily", 710], ["imported", 717], ["to", 726], ["and", 729], ["modified", 733], ["in", 742], ["presentation", 745], ["and", 758], ["image", 762], ["-", 767], ["editing", 768], ["computer", 776], ["programs", 785], [".", 793], ["The", 795], ["tool", 799], ["is", 804], ["freely", 807], ["distributed", 814], ["under", 826], ["GNU", 832], ["General", 836], ["Public", 844], ["License", 851], ["(", 859], ["GPL", 860], [")", 863], ["and", 865], ["can", 869], ["be", 873], ["installed", 876], ["from", 886], ["Bioconductor", 891], ["or", 904], ["from", 907], ["the", 912], ["chromDraw", 916], ["home", 926], ["page", 931], [".", 935]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (CTS). There is some evidence to suggest that immediate changes may occur in the median nerve before and after hand activity. The evidence for the validity and reliability of ultrasound for testing acute changes in the median nerve has not been systematically reviewed to date. To evaluate the evidence for visible change in ultrasound appearance of the median nerve after hand activity. A literature search was designed, and three reviewers independently selected published research for inclusion. Two reviewers independently appraised papers using the Evidence Based Library and Information Practice (EBLIP) appraisal checklist, while the third reviewer resolved discrepancies between appraisals. Ten studies were appraised and the results showed an increase in median nerve cross-sectional area following activity, with a return to normal size within 1 h following activity. Both healthy individuals and those diagnosed with CTS participated, all were small convenience samples. Ultrasonographic measurements of the median nerve were reliable in the four studies reporting this, and the studies demonstrated high quality. Good-quality evidence as identified by the EBLIP appraisal checklist suggests that following hand activity, the median nerve changes in size in the carpal tunnel. The results may not be generalizable to all people and activities due to the use of small convenience sampling and narrow range of activities studied, in all of the studies appraised.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "189f48ba6a4e4b66bd3f554956186a5b", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[32, 32], [77, 77], [179, 179], [138, 138], [55, 55], [215, 215], [8, 8]], "char_spans": [[175, 180], [448, 453], [1113, 1118], [858, 863], [313, 318], [1331, 1336], [51, 56]]}]}], "context_tokens": [["Ultrasound", 0], ["is", 11], ["an", 14], ["established", 17], ["method", 29], ["of", 36], ["viewing", 39], ["the", 47], ["median", 51], ["nerve", 58], ["in", 64], ["the", 67], ["carpal", 71], ["tunnel", 78], ["syndrome", 85], ["(", 94], ["CTS", 95], [")", 98], [".", 99], ["There", 101], ["is", 107], ["some", 110], ["evidence", 115], ["to", 124], ["suggest", 127], ["that", 135], ["immediate", 140], ["changes", 150], ["may", 158], ["occur", 162], ["in", 168], ["the", 171], ["median", 175], ["nerve", 182], ["before", 188], ["and", 195], ["after", 199], ["hand", 205], ["activity", 210], [".", 218], ["The", 220], ["evidence", 224], ["for", 233], ["the", 237], ["validity", 241], ["and", 250], ["reliability", 254], ["of", 266], ["ultrasound", 269], ["for", 280], ["testing", 284], ["acute", 292], ["changes", 298], ["in", 306], ["the", 309], ["median", 313], ["nerve", 320], ["has", 326], ["not", 330], ["been", 334], ["systematically", 339], ["reviewed", 354], ["to", 363], ["date", 366], [".", 370], ["To", 372], ["evaluate", 375], ["the", 384], ["evidence", 388], ["for", 397], ["visible", 401], ["change", 409], ["in", 416], ["ultrasound", 419], ["appearance", 430], ["of", 441], ["the", 444], ["median", 448], ["nerve", 455], ["after", 461], ["hand", 467], ["activity", 472], [".", 480], ["A", 482], ["literature", 484], ["search", 495], ["was", 502], ["designed", 506], [",", 514], ["and", 516], ["three", 520], ["reviewers", 526], ["independently", 536], ["selected", 550], ["published", 559], ["research", 569], ["for", 578], ["inclusion", 582], [".", 591], ["Two", 593], ["reviewers", 597], ["independently", 607], ["appraised", 621], ["papers", 631], ["using", 638], ["the", 644], ["Evidence", 648], ["Based", 657], ["Library", 663], ["and", 671], ["Information", 675], ["Practice", 687], ["(", 696], ["EBLIP", 697], [")", 702], ["appraisal", 704], ["checklist", 714], [",", 723], ["while", 725], ["the", 731], ["third", 735], ["reviewer", 741], ["resolved", 750], ["discrepancies", 759], ["between", 773], ["appraisals", 781], [".", 791], ["Ten", 793], ["studies", 797], ["were", 805], ["appraised", 810], ["and", 820], ["the", 824], ["results", 828], ["showed", 836], ["an", 843], ["increase", 846], ["in", 855], ["median", 858], ["nerve", 865], ["cross", 871], ["-", 876], ["sectional", 877], ["area", 887], ["following", 892], ["activity", 902], [",", 910], ["with", 912], ["a", 917], ["return", 919], ["to", 926], ["normal", 929], ["size", 936], ["within", 941], ["1", 948], ["h", 950], ["following", 952], ["activity", 962], [".", 970], ["Both", 972], ["healthy", 977], ["individuals", 985], ["and", 997], ["those", 1001], ["diagnosed", 1007], ["with", 1017], ["CTS", 1022], ["participated", 1026], [",", 1038], ["all", 1040], ["were", 1044], ["small", 1049], ["convenience", 1055], ["samples", 1067], [".", 1074], ["Ultrasonographic", 1076], ["measurements", 1093], ["of", 1106], ["the", 1109], ["median", 1113], ["nerve", 1120], ["were", 1126], ["reliable", 1131], ["in", 1140], ["the", 1143], ["four", 1147], ["studies", 1152], ["reporting", 1160], ["this", 1170], [",", 1174], ["and", 1176], ["the", 1180], ["studies", 1184], ["demonstrated", 1192], ["high", 1205], ["quality", 1210], [".", 1217], ["Good", 1219], ["-", 1223], ["quality", 1224], ["evidence", 1232], ["as", 1241], ["identified", 1244], ["by", 1255], ["the", 1258], ["EBLIP", 1262], ["appraisal", 1268], ["checklist", 1278], ["suggests", 1288], ["that", 1297], ["following", 1302], ["hand", 1312], ["activity", 1317], [",", 1325], ["the", 1327], ["median", 1331], ["nerve", 1338], ["changes", 1344], ["in", 1352], ["size", 1355], ["in", 1360], ["the", 1363], ["carpal", 1367], ["tunnel", 1374], [".", 1380], ["The", 1382], ["results", 1386], ["may", 1394], ["not", 1398], ["be", 1402], ["generalizable", 1405], ["to", 1419], ["all", 1422], ["people", 1426], ["and", 1433], ["activities", 1437], ["due", 1448], ["to", 1452], ["the", 1455], ["use", 1459], ["of", 1463], ["small", 1466], ["convenience", 1472], ["sampling", 1484], ["and", 1493], ["narrow", 1497], ["range", 1504], ["of", 1510], ["activities", 1513], ["studied", 1524], [",", 1531], ["in", 1533], ["all", 1536], ["of", 1540], ["the", 1543], ["studies", 1547], ["appraised", 1555], [".", 1564]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "The pathogenesis of restless legs syndrome (RLS) is unknown. Although iron deficiency anemia (IDA) is related with RLS, the mechanism of this relationship is still unknown. Therefore, we decided to examine some neurophysiological parameters that reflect the function of brainstem, spinal cord and peripheral nervous system. 34 patients diagnosed with IDA at the hematology department were questioned with a structured battery for RLS and additional symptoms. Of those, 14 patients had symptoms of RLS, while remaining 20 had no signs of this disorder. In both groups, electrophysiological examination including motor and sensory nerve conduction, F-responses, H-reflex, blink-reflex, and mixed nerve silent periods was performed. Neurological examination of all patients was normal. The two groups were identical for age and sex, and the difference between both groups concerning motor and sensory nerve conduction, F-wave, H-reflex, blink-reflex, and mixed nerve silent periods was insignificant. Results suggest that IDA does not cause electrophysiological changes in the peripheral nerves, spinal cord and brainstem, and therefore, measurement of these parameters in IDA patients does not seem effective for the confirmation of RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "c11e38b5379143f9895440d3ed5f0ff2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[13, 13]], "char_spans": [[70, 73]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["restless", 20], ["legs", 29], ["syndrome", 34], ["(", 43], ["RLS", 44], [")", 47], ["is", 49], ["unknown", 52], [".", 59], ["Although", 61], ["iron", 70], ["deficiency", 75], ["anemia", 86], ["(", 93], ["IDA", 94], [")", 97], ["is", 99], ["related", 102], ["with", 110], ["RLS", 115], [",", 118], ["the", 120], ["mechanism", 124], ["of", 134], ["this", 137], ["relationship", 142], ["is", 155], ["still", 158], ["unknown", 164], [".", 171], ["Therefore", 173], [",", 182], ["we", 184], ["decided", 187], ["to", 195], ["examine", 198], ["some", 206], ["neurophysiological", 211], ["parameters", 230], ["that", 241], ["reflect", 246], ["the", 254], ["function", 258], ["of", 267], ["brainstem", 270], [",", 279], ["spinal", 281], ["cord", 288], ["and", 293], ["peripheral", 297], ["nervous", 308], ["system", 316], [".", 322], ["34", 324], ["patients", 327], ["diagnosed", 336], ["with", 346], ["IDA", 351], ["at", 355], ["the", 358], ["hematology", 362], ["department", 373], ["were", 384], ["questioned", 389], ["with", 400], ["a", 405], ["structured", 407], ["battery", 418], ["for", 426], ["RLS", 430], ["and", 434], ["additional", 438], ["symptoms", 449], [".", 457], ["Of", 459], ["those", 462], [",", 467], ["14", 469], ["patients", 472], ["had", 481], ["symptoms", 485], ["of", 494], ["RLS", 497], [",", 500], ["while", 502], ["remaining", 508], ["20", 518], ["had", 521], ["no", 525], ["signs", 528], ["of", 534], ["this", 537], ["disorder", 542], [".", 550], ["In", 552], ["both", 555], ["groups", 560], [",", 566], ["electrophysiological", 568], ["examination", 589], ["including", 601], ["motor", 611], ["and", 617], ["sensory", 621], ["nerve", 629], ["conduction", 635], [",", 645], ["F", 647], ["-", 648], ["responses", 649], [",", 658], ["H", 660], ["-", 661], ["reflex", 662], [",", 668], ["blink", 670], ["-", 675], ["reflex", 676], [",", 682], ["and", 684], ["mixed", 688], ["nerve", 694], ["silent", 700], ["periods", 707], ["was", 715], ["performed", 719], [".", 728], ["Neurological", 730], ["examination", 743], ["of", 755], ["all", 758], ["patients", 762], ["was", 771], ["normal", 775], [".", 781], ["The", 783], ["two", 787], ["groups", 791], ["were", 798], ["identical", 803], ["for", 813], ["age", 817], ["and", 821], ["sex", 825], [",", 828], ["and", 830], ["the", 834], ["difference", 838], ["between", 849], ["both", 857], ["groups", 862], ["concerning", 869], ["motor", 880], ["and", 886], ["sensory", 890], ["nerve", 898], ["conduction", 904], [",", 914], ["F", 916], ["-", 917], ["wave", 918], [",", 922], ["H", 924], ["-", 925], ["reflex", 926], [",", 932], ["blink", 934], ["-", 939], ["reflex", 940], [",", 946], ["and", 948], ["mixed", 952], ["nerve", 958], ["silent", 964], ["periods", 971], ["was", 979], ["insignificant", 983], [".", 996], ["Results", 998], ["suggest", 1006], ["that", 1014], ["IDA", 1019], ["does", 1023], ["not", 1028], ["cause", 1032], ["electrophysiological", 1038], ["changes", 1059], ["in", 1067], ["the", 1070], ["peripheral", 1074], ["nerves", 1085], [",", 1091], ["spinal", 1093], ["cord", 1100], ["and", 1105], ["brainstem", 1109], [",", 1118], ["and", 1120], ["therefore", 1124], [",", 1133], ["measurement", 1135], ["of", 1147], ["these", 1150], ["parameters", 1156], ["in", 1167], ["IDA", 1170], ["patients", 1174], ["does", 1183], ["not", 1188], ["seem", 1192], ["effective", 1197], ["for", 1207], ["the", 1211], ["confirmation", 1215], ["of", 1228], ["RLS", 1231], [".", 1234]]}
{"context": "Calcium activated gene transcription through Nuclear Factor of Activated T-cells, (NFAT) proteins, is emerging as a ubiquitous mechanism for the control of important physiological processes. Of the five mammalian NFAT isoforms, transcriptional activities of NFATs 1-4 are stimulated by a calcium driven association between the ubiquitous phosphatase calcineurin and the calcium-sensing protein calmodulin. Published in vitro evidence has suggested that other members of the calmodulin super-family, in particular the neuronal calcium sensor (NCS) proteins, can similarly modulate calcineurin activity. In this study we have assessed the ability of NCS proteins to interact directly with calcineurin in vitro and report a specific if weak association between various NCS proteins and the phosphatase. In an extension to these analyses we have also examined the effects of over-expression of NCS-1 or NCS-1 mutants on calcineurin signalling in HeLa cells in experiments examining the dephosphorylation of an NFAT-GFP reporter construct as a readout of calcineurin activity. Results from these experiments indicate that NCS-1 was not able to detectably modulate calcineurin/NFAT signalling in a live mammalian cell system, findings that are consistent with the idea that calmodulin and not NCS-1 or other NCS family proteins is the physiologically relevant modulator of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "8c7b90d3f4324749a409830dd407b9ea", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[96, 96], [154, 154], [57, 57], [225, 225], [114, 114], [191, 191], [175, 175]], "char_spans": [[580, 590], [916, 926], [350, 360], [1367, 1377], [687, 697], [1159, 1169], [1050, 1060]]}, {"text": "CaN", "token_spans": [[93, 93]], "char_spans": [[557, 559]]}]}], "context_tokens": [["Calcium", 0], ["activated", 8], ["gene", 18], ["transcription", 23], ["through", 37], ["Nuclear", 45], ["Factor", 53], ["of", 60], ["Activated", 63], ["T", 73], ["-", 74], ["cells", 75], [",", 80], ["(", 82], ["NFAT", 83], [")", 87], ["proteins", 89], [",", 97], ["is", 99], ["emerging", 102], ["as", 111], ["a", 114], ["ubiquitous", 116], ["mechanism", 127], ["for", 137], ["the", 141], ["control", 145], ["of", 153], ["important", 156], ["physiological", 166], ["processes", 180], [".", 189], ["Of", 191], ["the", 194], ["five", 198], ["mammalian", 203], ["NFAT", 213], ["isoforms", 218], [",", 226], ["transcriptional", 228], ["activities", 244], ["of", 255], ["NFATs", 258], ["1", 264], ["-", 265], ["4", 266], ["are", 268], ["stimulated", 272], ["by", 283], ["a", 286], ["calcium", 288], ["driven", 296], ["association", 303], ["between", 315], ["the", 323], ["ubiquitous", 327], ["phosphatase", 338], ["calcineurin", 350], ["and", 362], ["the", 366], ["calcium", 370], ["-", 377], ["sensing", 378], ["protein", 386], ["calmodulin", 394], [".", 404], ["Published", 406], ["in", 416], ["vitro", 419], ["evidence", 425], ["has", 434], ["suggested", 438], ["that", 448], ["other", 453], ["members", 459], ["of", 467], ["the", 470], ["calmodulin", 474], ["super", 485], ["-", 490], ["family", 491], [",", 497], ["in", 499], ["particular", 502], ["the", 513], ["neuronal", 517], ["calcium", 526], ["sensor", 534], ["(", 541], ["NCS", 542], [")", 545], ["proteins", 547], [",", 555], ["can", 557], ["similarly", 561], ["modulate", 571], ["calcineurin", 580], ["activity", 592], [".", 600], ["In", 602], ["this", 605], ["study", 610], ["we", 616], ["have", 619], ["assessed", 624], ["the", 633], ["ability", 637], ["of", 645], ["NCS", 648], ["proteins", 652], ["to", 661], ["interact", 664], ["directly", 673], ["with", 682], ["calcineurin", 687], ["in", 699], ["vitro", 702], ["and", 708], ["report", 712], ["a", 719], ["specific", 721], ["if", 730], ["weak", 733], ["association", 738], ["between", 750], ["various", 758], ["NCS", 766], ["proteins", 770], ["and", 779], ["the", 783], ["phosphatase", 787], [".", 798], ["In", 800], ["an", 803], ["extension", 806], ["to", 816], ["these", 819], ["analyses", 825], ["we", 834], ["have", 837], ["also", 842], ["examined", 847], ["the", 856], ["effects", 860], ["of", 868], ["over", 871], ["-", 875], ["expression", 876], ["of", 887], ["NCS-1", 890], ["or", 896], ["NCS-1", 899], ["mutants", 905], ["on", 913], ["calcineurin", 916], ["signalling", 928], ["in", 939], ["HeLa", 942], ["cells", 947], ["in", 953], ["experiments", 956], ["examining", 968], ["the", 978], ["dephosphorylation", 982], ["of", 1000], ["an", 1003], ["NFAT", 1006], ["-", 1010], ["GFP", 1011], ["reporter", 1015], ["construct", 1024], ["as", 1034], ["a", 1037], ["readout", 1039], ["of", 1047], ["calcineurin", 1050], ["activity", 1062], [".", 1070], ["Results", 1072], ["from", 1080], ["these", 1085], ["experiments", 1091], ["indicate", 1103], ["that", 1112], ["NCS-1", 1117], ["was", 1123], ["not", 1127], ["able", 1131], ["to", 1136], ["detectably", 1139], ["modulate", 1150], ["calcineurin", 1159], ["/", 1170], ["NFAT", 1171], ["signalling", 1176], ["in", 1187], ["a", 1190], ["live", 1192], ["mammalian", 1197], ["cell", 1207], ["system", 1212], [",", 1218], ["findings", 1220], ["that", 1229], ["are", 1234], ["consistent", 1238], ["with", 1249], ["the", 1254], ["idea", 1258], ["that", 1263], ["calmodulin", 1268], ["and", 1279], ["not", 1283], ["NCS-1", 1287], ["or", 1293], ["other", 1296], ["NCS", 1302], ["family", 1306], ["proteins", 1313], ["is", 1322], ["the", 1325], ["physiologically", 1329], ["relevant", 1345], ["modulator", 1354], ["of", 1364], ["calcineurin", 1367], ["activity", 1379], [".", 1387]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "An 11-day embryonic Swiss Webster/NIH mouse cDNA library was screened with a partial murine selenoprotein P cDNA probe and a murine selenoprotein-P-type cDNA clone of 2075 bp length was obtained. The clone contained a 5'-leader sequence of 132 bp length, the selenoprotein P coding frame, and 803 base pairs in the 3' untranslated region. Alignment and RNA folding studies revealed the presence of two well conserved selenocysteine inserting motifs in the 3' flanking region. The deduced polypeptide sequence comprises 380 residues including ten selenocysteines. Identical amino acid residues in homologous positions are 86%, 71%, and 64% when compared to the previously reported selenoprotein P sequences of rat, man, and cattle, respectively. The comparatively low similarity between the selenoprotein P sequences reported so far leaves open the question whether they belong to the same molecular clade.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["selenoprotein P", "selenoprotein-P", "Selenoprotein P"], "qid": "acb923e812724d94bc4863897a19ef39", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[16, 17], [49, 50], [140, 141], [121, 122], [23, 25]], "char_spans": [[92, 106], [259, 273], [790, 804], [680, 694], [132, 146]]}]}], "context_tokens": [["An", 0], ["11-day", 3], ["embryonic", 10], ["Swiss", 20], ["Webster", 26], ["/", 33], ["NIH", 34], ["mouse", 38], ["cDNA", 44], ["library", 49], ["was", 57], ["screened", 61], ["with", 70], ["a", 75], ["partial", 77], ["murine", 85], ["selenoprotein", 92], ["P", 106], ["cDNA", 108], ["probe", 113], ["and", 119], ["a", 123], ["murine", 125], ["selenoprotein", 132], ["-", 145], ["P", 146], ["-", 147], ["type", 148], ["cDNA", 153], ["clone", 158], ["of", 164], ["2075", 167], ["bp", 172], ["length", 175], ["was", 182], ["obtained", 186], [".", 194], ["The", 196], ["clone", 200], ["contained", 206], ["a", 216], ["5'-leader", 218], ["sequence", 228], ["of", 237], ["132", 240], ["bp", 244], ["length", 247], [",", 253], ["the", 255], ["selenoprotein", 259], ["P", 273], ["coding", 275], ["frame", 282], [",", 287], ["and", 289], ["803", 293], ["base", 297], ["pairs", 302], ["in", 308], ["the", 311], ["3", 315], ["'", 316], ["untranslated", 318], ["region", 331], [".", 337], ["Alignment", 339], ["and", 349], ["RNA", 353], ["folding", 357], ["studies", 365], ["revealed", 373], ["the", 382], ["presence", 386], ["of", 395], ["two", 398], ["well", 402], ["conserved", 407], ["selenocysteine", 417], ["inserting", 432], ["motifs", 442], ["in", 449], ["the", 452], ["3", 456], ["'", 457], ["flanking", 459], ["region", 468], [".", 474], ["The", 476], ["deduced", 480], ["polypeptide", 488], ["sequence", 500], ["comprises", 509], ["380", 519], ["residues", 523], ["including", 532], ["ten", 542], ["selenocysteines", 546], [".", 561], ["Identical", 563], ["amino", 573], ["acid", 579], ["residues", 584], ["in", 593], ["homologous", 596], ["positions", 607], ["are", 617], ["86", 621], ["%", 623], [",", 624], ["71", 626], ["%", 628], [",", 629], ["and", 631], ["64", 635], ["%", 637], ["when", 639], ["compared", 644], ["to", 653], ["the", 656], ["previously", 660], ["reported", 671], ["selenoprotein", 680], ["P", 694], ["sequences", 696], ["of", 706], ["rat", 709], [",", 712], ["man", 714], [",", 717], ["and", 719], ["cattle", 723], [",", 729], ["respectively", 731], [".", 743], ["The", 745], ["comparatively", 749], ["low", 763], ["similarity", 767], ["between", 778], ["the", 786], ["selenoprotein", 790], ["P", 804], ["sequences", 806], ["reported", 816], ["so", 825], ["far", 828], ["leaves", 832], ["open", 839], ["the", 844], ["question", 848], ["whether", 857], ["they", 865], ["belong", 870], ["to", 877], ["the", 880], ["same", 884], ["molecular", 889], ["clade", 899], [".", 904]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent adult muscular dystrophies. The common clinical signs usually appear during the second decade of life but when the first molecular dysregulations occur is still unknown. Our aim was to determine whether molecular dysregulations can be identified during FSHD fetal muscle development. We compared muscle biopsies derived from FSHD1 fetuses and the cells derived from some of these biopsies with biopsies and cells derived from control fetuses. We mainly focus on DUX4 isoform expression because the expression of DUX4 has been confirmed in both FSHD cells and biopsies by several laboratories. We measured DUX4 isoform expression by using qRT-PCR in fetal FSHD1 myotubes treated or not with an shRNA directed against DUX4 mRNA. We also analyzed DUX4 downstream target gene expression in myotubes and fetal or adult FSHD1 and control quadriceps biopsies. We show that both DUX4-FL isoforms are already expressed in FSHD1 myotubes. Interestingly, DUX4-FL expression level is much lower in trapezius than in quadriceps myotubes, which is confirmed by the level of expression of DUX4 downstream genes. We observed that TRIM43 and MBD3L2 are already overexpressed in FSHD1 fetal quadriceps biopsies, at similar levels to those observed in adult FSHD1 quadriceps biopsies. These results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "ecab61b49d944c2daff330eafcf4f174", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[99, 99], [4, 4], [51, 51], [247, 247]], "char_spans": [[619, 622], [40, 43], [328, 331], [1511, 1514]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["one", 49], ["of", 53], ["the", 56], ["most", 60], ["prevalent", 65], ["adult", 75], ["muscular", 81], ["dystrophies", 90], [".", 101], ["The", 103], ["common", 107], ["clinical", 114], ["signs", 123], ["usually", 129], ["appear", 137], ["during", 144], ["the", 151], ["second", 155], ["decade", 162], ["of", 169], ["life", 172], ["but", 177], ["when", 181], ["the", 186], ["first", 190], ["molecular", 196], ["dysregulations", 206], ["occur", 221], ["is", 227], ["still", 230], ["unknown", 236], [".", 243], ["Our", 245], ["aim", 249], ["was", 253], ["to", 257], ["determine", 260], ["whether", 270], ["molecular", 278], ["dysregulations", 288], ["can", 303], ["be", 307], ["identified", 310], ["during", 321], ["FSHD", 328], ["fetal", 333], ["muscle", 339], ["development", 346], [".", 357], ["We", 359], ["compared", 362], ["muscle", 371], ["biopsies", 378], ["derived", 387], ["from", 395], ["FSHD1", 400], ["fetuses", 406], ["and", 414], ["the", 418], ["cells", 422], ["derived", 428], ["from", 436], ["some", 441], ["of", 446], ["these", 449], ["biopsies", 455], ["with", 464], ["biopsies", 469], ["and", 478], ["cells", 482], ["derived", 488], ["from", 496], ["control", 501], ["fetuses", 509], [".", 516], ["We", 518], ["mainly", 521], ["focus", 528], ["on", 534], ["DUX4", 537], ["isoform", 542], ["expression", 550], ["because", 561], ["the", 569], ["expression", 573], ["of", 584], ["DUX4", 587], ["has", 592], ["been", 596], ["confirmed", 601], ["in", 611], ["both", 614], ["FSHD", 619], ["cells", 624], ["and", 630], ["biopsies", 634], ["by", 643], ["several", 646], ["laboratories", 654], [".", 666], ["We", 668], ["measured", 671], ["DUX4", 680], ["isoform", 685], ["expression", 693], ["by", 704], ["using", 707], ["qRT", 713], ["-", 716], ["PCR", 717], ["in", 721], ["fetal", 724], ["FSHD1", 730], ["myotubes", 736], ["treated", 745], ["or", 753], ["not", 756], ["with", 760], ["an", 765], ["shRNA", 768], ["directed", 774], ["against", 783], ["DUX4", 791], ["mRNA", 796], [".", 800], ["We", 802], ["also", 805], ["analyzed", 810], ["DUX4", 819], ["downstream", 824], ["target", 835], ["gene", 842], ["expression", 847], ["in", 858], ["myotubes", 861], ["and", 870], ["fetal", 874], ["or", 880], ["adult", 883], ["FSHD1", 889], ["and", 895], ["control", 899], ["quadriceps", 907], ["biopsies", 918], [".", 926], ["We", 928], ["show", 931], ["that", 936], ["both", 941], ["DUX4-FL", 946], ["isoforms", 954], ["are", 963], ["already", 967], ["expressed", 975], ["in", 985], ["FSHD1", 988], ["myotubes", 994], [".", 1002], ["Interestingly", 1004], [",", 1017], ["DUX4-FL", 1019], ["expression", 1027], ["level", 1038], ["is", 1044], ["much", 1047], ["lower", 1052], ["in", 1058], ["trapezius", 1061], ["than", 1071], ["in", 1076], ["quadriceps", 1079], ["myotubes", 1090], [",", 1098], ["which", 1100], ["is", 1106], ["confirmed", 1109], ["by", 1119], ["the", 1122], ["level", 1126], ["of", 1132], ["expression", 1135], ["of", 1146], ["DUX4", 1149], ["downstream", 1154], ["genes", 1165], [".", 1170], ["We", 1172], ["observed", 1175], ["that", 1184], ["TRIM43", 1189], ["and", 1196], ["MBD3L2", 1200], ["are", 1207], ["already", 1211], ["overexpressed", 1219], ["in", 1233], ["FSHD1", 1236], ["fetal", 1242], ["quadriceps", 1248], ["biopsies", 1259], [",", 1267], ["at", 1269], ["similar", 1272], ["levels", 1280], ["to", 1287], ["those", 1290], ["observed", 1296], ["in", 1305], ["adult", 1308], ["FSHD1", 1314], ["quadriceps", 1320], ["biopsies", 1331], [".", 1339], ["These", 1341], ["results", 1347], ["indicate", 1355], ["that", 1364], ["molecular", 1369], ["markers", 1379], ["of", 1387], ["the", 1390], ["disease", 1394], ["are", 1402], ["already", 1406], ["expressed", 1414], ["during", 1424], ["fetal", 1431], ["life", 1437], [",", 1441], ["thus", 1443], ["opening", 1448], ["a", 1456], ["new", 1458], ["field", 1462], ["of", 1468], ["investigation", 1471], ["for", 1485], ["mechanisms", 1489], ["leading", 1500], ["to", 1508], ["FSHD", 1511], [".", 1515]]}
{"context": "\u03b1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Its accumulation into intracellular aggregates is implicated in the process of Lewy body formation. However, its roles in both normal function, and disease, remain controversial. Using a novel model of chronic oxidative stress in cultured dopaminergic and cortical neurons, we report that endogenous \u03b1-synuclein is upregulated in response to low dose toxicity. This response is conserved between subpopulations of cortical and dopaminergic neurons, and confers relative resistance to apoptosis following secondary insult. Additional acute oxidative stress leads to intracellular accumulation of \u03b1-synuclein. These punctate deposits colocalize with ubiquitin, which is central to proteosome-mediated protein degeneration, and is the second major component of Lewy bodies. The current results imply that differential levels of \u03b1-synuclein expression may influence neuronal vulnerability in chronic neurodegenerative diseases. They further support a 'two hit' hypothesis for Lewy body formation, whereby mild stress causes a protective upregulation of \u03b1-synuclein. However, such increased levels of \u03b1-synuclein may drive its accumulation, following additional toxic insult. Finally, these results support a common mechanism for degeneration of dopaminergic and cortical neurons, affected in PD, and DLB, respectively.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4504ae5e0d41435984b259c276b8cf7f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[80, 82], [0, 2], [197, 199], [207, 209], [162, 164], [123, 125]], "char_spans": [[450, 460], [0, 10], [1199, 1209], [1246, 1256], [975, 985], [745, 755]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["protein", 25], ["component", 33], ["of", 43], ["Lewy", 46], ["bodies", 51], ["--", 57], ["the", 59], ["pathological", 63], ["hallmark", 76], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], ["(", 108], ["PD", 109], [")", 111], ["and", 113], ["Dementia", 117], ["with", 126], ["Lewy", 131], ["bodies", 136], ["(", 143], ["DLB", 144], [")", 147], [".", 148], ["Its", 150], ["accumulation", 154], ["into", 167], ["intracellular", 172], ["aggregates", 186], ["is", 197], ["implicated", 200], ["in", 211], ["the", 214], ["process", 218], ["of", 226], ["Lewy", 229], ["body", 234], ["formation", 239], [".", 248], ["However", 250], [",", 257], ["its", 259], ["roles", 263], ["in", 269], ["both", 272], ["normal", 277], ["function", 284], [",", 292], ["and", 294], ["disease", 298], [",", 305], ["remain", 307], ["controversial", 314], [".", 327], ["Using", 329], ["a", 335], ["novel", 337], ["model", 343], ["of", 349], ["chronic", 352], ["oxidative", 360], ["stress", 370], ["in", 377], ["cultured", 380], ["dopaminergic", 389], ["and", 402], ["cortical", 406], ["neurons", 415], [",", 422], ["we", 424], ["report", 427], ["that", 434], ["endogenous", 439], ["\u03b1", 450], ["-", 451], ["synuclein", 452], ["is", 462], ["upregulated", 465], ["in", 477], ["response", 480], ["to", 489], ["low", 492], ["dose", 496], ["toxicity", 501], [".", 509], ["This", 511], ["response", 516], ["is", 525], ["conserved", 528], ["between", 538], ["subpopulations", 546], ["of", 561], ["cortical", 564], ["and", 573], ["dopaminergic", 577], ["neurons", 590], [",", 597], ["and", 599], ["confers", 603], ["relative", 611], ["resistance", 620], ["to", 631], ["apoptosis", 634], ["following", 644], ["secondary", 654], ["insult", 664], [".", 670], ["Additional", 672], ["acute", 683], ["oxidative", 689], ["stress", 699], ["leads", 706], ["to", 712], ["intracellular", 715], ["accumulation", 729], ["of", 742], ["\u03b1", 745], ["-", 746], ["synuclein", 747], [".", 756], ["These", 758], ["punctate", 764], ["deposits", 773], ["colocalize", 782], ["with", 793], ["ubiquitin", 798], [",", 807], ["which", 809], ["is", 815], ["central", 818], ["to", 826], ["proteosome", 829], ["-", 839], ["mediated", 840], ["protein", 849], ["degeneration", 857], [",", 869], ["and", 871], ["is", 875], ["the", 878], ["second", 882], ["major", 889], ["component", 895], ["of", 905], ["Lewy", 908], ["bodies", 913], [".", 919], ["The", 921], ["current", 925], ["results", 933], ["imply", 941], ["that", 947], ["differential", 952], ["levels", 965], ["of", 972], ["\u03b1", 975], ["-", 976], ["synuclein", 977], ["expression", 987], ["may", 998], ["influence", 1002], ["neuronal", 1012], ["vulnerability", 1021], ["in", 1035], ["chronic", 1038], ["neurodegenerative", 1046], ["diseases", 1064], [".", 1072], ["They", 1074], ["further", 1079], ["support", 1087], ["a", 1095], ["'", 1097], ["two", 1098], ["hit", 1102], ["'", 1105], ["hypothesis", 1107], ["for", 1118], ["Lewy", 1122], ["body", 1127], ["formation", 1132], [",", 1141], ["whereby", 1143], ["mild", 1151], ["stress", 1156], ["causes", 1163], ["a", 1170], ["protective", 1172], ["upregulation", 1183], ["of", 1196], ["\u03b1", 1199], ["-", 1200], ["synuclein", 1201], [".", 1210], ["However", 1212], [",", 1219], ["such", 1221], ["increased", 1226], ["levels", 1236], ["of", 1243], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["may", 1258], ["drive", 1262], ["its", 1268], ["accumulation", 1272], [",", 1284], ["following", 1286], ["additional", 1296], ["toxic", 1307], ["insult", 1313], [".", 1319], ["Finally", 1321], [",", 1328], ["these", 1330], ["results", 1336], ["support", 1344], ["a", 1352], ["common", 1354], ["mechanism", 1361], ["for", 1371], ["degeneration", 1375], ["of", 1388], ["dopaminergic", 1391], ["and", 1404], ["cortical", 1408], ["neurons", 1417], [",", 1424], ["affected", 1426], ["in", 1435], ["PD", 1438], [",", 1440], ["and", 1442], ["DLB", 1446], [",", 1449], ["respectively", 1451], [".", 1463]]}
{"context": "MicroRNAs (miRNAs) are 21 nt RNAs that regulate many biological processes in plants by mediating translational inhibition or cleavage of target transcripts. Arabidopsis mutants defective in miRNA biogenesis have overlapping and highly pleiotropic phenotypes including serrated leaves and ABA hypersensitivity. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II). Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels. Co-immunoprecipitation experiments revealed that pri-miRNAs 159, 166, 168 and 172 could be associated with CBP20 and CBP80. We found that CBP20 and CBP80 are stabilized by ABA by a post-translational mechanism, and these proteins are needed for ABA induction of miR159 during seed germination. The lack of miR159 accumulation in ABA-treated seeds of cbp20/80 mutants leads to increased MYB33 and MYB101 transcript levels, and presumably higher levels of these positive regulators result in ABA hypersensitivity. Genetic and molecular analyses show that CBP20 and 80 have overlapping function in the same developmental pathway as SE and HYL1. Our results identify new components in miRNA biogenesis.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "f8691bdd04254433a162cdef7998689e", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[53, 55]], "char_spans": [[372, 388]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["21", 23], ["nt", 26], ["RNAs", 29], ["that", 34], ["regulate", 39], ["many", 48], ["biological", 53], ["processes", 64], ["in", 74], ["plants", 77], ["by", 84], ["mediating", 87], ["translational", 97], ["inhibition", 111], ["or", 122], ["cleavage", 125], ["of", 134], ["target", 137], ["transcripts", 144], [".", 155], ["Arabidopsis", 157], ["mutants", 169], ["defective", 177], ["in", 187], ["miRNA", 190], ["biogenesis", 196], ["have", 207], ["overlapping", 212], ["and", 224], ["highly", 228], ["pleiotropic", 235], ["phenotypes", 247], ["including", 258], ["serrated", 268], ["leaves", 277], ["and", 284], ["ABA", 288], ["hypersensitivity", 292], [".", 308], ["Recent", 310], ["evidence", 317], ["indicates", 326], ["that", 336], ["miRNA", 341], ["genes", 347], ["are", 353], ["transcribed", 357], ["by", 369], ["RNA", 372], ["polymerase", 376], ["II", 387], ["(", 390], ["Pol", 391], ["II", 395], [")", 397], [".", 398], ["Since", 400], ["Pol", 406], ["II", 410], ["transcripts", 413], ["are", 425], ["capped", 429], [",", 435], ["we", 437], ["hypothesized", 440], ["that", 453], ["CBP", 458], ["(", 462], ["cap", 463], ["-", 466], ["binding", 467], ["protein", 475], [")", 482], ["20", 484], ["and", 487], ["80", 491], ["may", 494], ["bind", 498], ["to", 503], ["capped", 506], ["primary", 513], ["miRNA", 521], ["(", 527], ["pri", 528], ["-", 531], ["miRNA", 532], [")", 537], ["transcripts", 539], ["and", 551], ["play", 555], ["a", 560], ["role", 562], ["in", 567], ["their", 570], ["processing", 576], [".", 586], ["Here", 588], [",", 592], ["we", 594], ["show", 597], ["that", 602], ["cbp20", 607], ["and", 613], ["cbp80", 617], ["mutants", 623], ["have", 631], ["reduced", 636], ["miRNA", 644], ["levels", 650], ["and", 657], ["increased", 661], ["pri", 671], ["-", 674], ["miRNA", 675], ["levels", 681], [".", 687], ["Co", 689], ["-", 691], ["immunoprecipitation", 692], ["experiments", 712], ["revealed", 724], ["that", 733], ["pri", 738], ["-", 741], ["miRNAs", 742], ["159", 749], [",", 752], ["166", 754], [",", 757], ["168", 759], ["and", 763], ["172", 767], ["could", 771], ["be", 777], ["associated", 780], ["with", 791], ["CBP20", 796], ["and", 802], ["CBP80", 806], [".", 811], ["We", 813], ["found", 816], ["that", 822], ["CBP20", 827], ["and", 833], ["CBP80", 837], ["are", 843], ["stabilized", 847], ["by", 858], ["ABA", 861], ["by", 865], ["a", 868], ["post", 870], ["-", 874], ["translational", 875], ["mechanism", 889], [",", 898], ["and", 900], ["these", 904], ["proteins", 910], ["are", 919], ["needed", 923], ["for", 930], ["ABA", 934], ["induction", 938], ["of", 948], ["miR159", 951], ["during", 958], ["seed", 965], ["germination", 970], [".", 981], ["The", 983], ["lack", 987], ["of", 992], ["miR159", 995], ["accumulation", 1002], ["in", 1015], ["ABA", 1018], ["-", 1021], ["treated", 1022], ["seeds", 1030], ["of", 1036], ["cbp20/80", 1039], ["mutants", 1048], ["leads", 1056], ["to", 1062], ["increased", 1065], ["MYB33", 1075], ["and", 1081], ["MYB101", 1085], ["transcript", 1092], ["levels", 1103], [",", 1109], ["and", 1111], ["presumably", 1115], ["higher", 1126], ["levels", 1133], ["of", 1140], ["these", 1143], ["positive", 1149], ["regulators", 1158], ["result", 1169], ["in", 1176], ["ABA", 1179], ["hypersensitivity", 1183], [".", 1199], ["Genetic", 1201], ["and", 1209], ["molecular", 1213], ["analyses", 1223], ["show", 1232], ["that", 1237], ["CBP20", 1242], ["and", 1248], ["80", 1252], ["have", 1255], ["overlapping", 1260], ["function", 1272], ["in", 1281], ["the", 1284], ["same", 1288], ["developmental", 1293], ["pathway", 1307], ["as", 1315], ["SE", 1318], ["and", 1321], ["HYL1", 1325], [".", 1329], ["Our", 1331], ["results", 1335], ["identify", 1343], ["new", 1352], ["components", 1356], ["in", 1367], ["miRNA", 1370], ["biogenesis", 1376], [".", 1386]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Although Gaucher disease is a rare disorder, recent developments in novel means for therapeutic intervention have invigorated both academic research and pharmaceutical industry discovery programmes. The common mutations found in the lysosomal enzyme deficient in Gaucher disease, beta-glucocerebrosidase, earmark these proteins for destruction by the endoplasmic reticulum-localised protein folding machinery, resulting in enzyme insufficiency, lysosomal glycolipid storage and subsequent pathology. However, many of these mutants can be rescued from global misfolding to preserve glycolipid substrate binding and eventual catalysis in the lysosome, by the addition of subinhibitory concentrations of pharmacologically active small molecules. This novel, chaperon-mediated approach has benefited from insights into the molecular understanding of beta-glucocerebrosidase structure, drug design and development in cellular models for disease.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["beta-glucocerebrosidase", "Beta glucocerebrosidase"], "qid": "60b2647e211743f5a7666d2124d1686a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[40, 42], [123, 125]], "char_spans": [[280, 302], [846, 868]]}]}], "context_tokens": [["Although", 0], ["Gaucher", 9], ["disease", 17], ["is", 25], ["a", 28], ["rare", 30], ["disorder", 35], [",", 43], ["recent", 45], ["developments", 52], ["in", 65], ["novel", 68], ["means", 74], ["for", 80], ["therapeutic", 84], ["intervention", 96], ["have", 109], ["invigorated", 114], ["both", 126], ["academic", 131], ["research", 140], ["and", 149], ["pharmaceutical", 153], ["industry", 168], ["discovery", 177], ["programmes", 187], [".", 197], ["The", 199], ["common", 203], ["mutations", 210], ["found", 220], ["in", 226], ["the", 229], ["lysosomal", 233], ["enzyme", 243], ["deficient", 250], ["in", 260], ["Gaucher", 263], ["disease", 271], [",", 278], ["beta", 280], ["-", 284], ["glucocerebrosidase", 285], [",", 303], ["earmark", 305], ["these", 313], ["proteins", 319], ["for", 328], ["destruction", 332], ["by", 344], ["the", 347], ["endoplasmic", 351], ["reticulum", 363], ["-", 372], ["localised", 373], ["protein", 383], ["folding", 391], ["machinery", 399], [",", 408], ["resulting", 410], ["in", 420], ["enzyme", 423], ["insufficiency", 430], [",", 443], ["lysosomal", 445], ["glycolipid", 455], ["storage", 466], ["and", 474], ["subsequent", 478], ["pathology", 489], [".", 498], ["However", 500], [",", 507], ["many", 509], ["of", 514], ["these", 517], ["mutants", 523], ["can", 531], ["be", 535], ["rescued", 538], ["from", 546], ["global", 551], ["misfolding", 558], ["to", 569], ["preserve", 572], ["glycolipid", 581], ["substrate", 592], ["binding", 602], ["and", 610], ["eventual", 614], ["catalysis", 623], ["in", 633], ["the", 636], ["lysosome", 640], [",", 648], ["by", 650], ["the", 653], ["addition", 657], ["of", 666], ["subinhibitory", 669], ["concentrations", 683], ["of", 698], ["pharmacologically", 701], ["active", 719], ["small", 726], ["molecules", 732], [".", 741], ["This", 743], ["novel", 748], [",", 753], ["chaperon", 755], ["-", 763], ["mediated", 764], ["approach", 773], ["has", 782], ["benefited", 786], ["from", 796], ["insights", 801], ["into", 810], ["the", 815], ["molecular", 819], ["understanding", 829], ["of", 843], ["beta", 846], ["-", 850], ["glucocerebrosidase", 851], ["structure", 870], [",", 879], ["drug", 881], ["design", 886], ["and", 893], ["development", 897], ["in", 909], ["cellular", 912], ["models", 921], ["for", 928], ["disease", 932], [".", 939]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300\u00a0mg per day) due to intolerance, in comparison to optimal-dose imatinib (\u2265300\u00a0mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420\u00a0days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720\u00a0days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "169d1ca25e78425dbd60b6192286d3dd", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[4, 6]], "char_spans": [[23, 29]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["the", 13], ["first", 17], ["BCR", 23], ["-", 26], ["ABL", 27], ["tyrosine", 31], ["kinase", 40], ["inhibitor", 47], ["to", 57], ["become", 60], ["clinically", 67], ["available", 78], [".", 87], ["In", 89], ["this", 92], ["study", 97], [",", 102], ["we", 104], ["retrospectively", 107], ["evaluated", 123], ["the", 133], ["long", 137], ["-", 141], ["term", 142], ["efficacy", 147], ["of", 156], ["low", 159], ["-", 162], ["dose", 163], ["imatinib", 168], ["(", 177], ["final", 178], ["maintenance", 184], ["dose", 196], ["<", 201], ["300", 202], ["mg", 206], ["per", 209], ["day", 213], [")", 216], ["due", 218], ["to", 222], ["intolerance", 225], [",", 236], ["in", 238], ["comparison", 241], ["to", 252], ["optimal", 255], ["-", 262], ["dose", 263], ["imatinib", 268], ["(", 277], ["\u2265300", 278], ["mg", 283], ["per", 286], ["day", 290], [")", 293], ["in", 295], ["patients", 298], ["with", 307], ["Philadelphia", 312], ["chromosome", 325], ["-", 335], ["positive", 336], ["chronic", 345], ["myeloid", 353], ["leukemia", 361], ["in", 370], ["the", 373], ["chronic", 377], ["phase", 385], [".", 390], ["The", 392], ["Kaplan", 396], ["-", 402], ["Meier", 403], ["estimates", 409], ["of", 419], ["the", 422], ["median", 426], ["time", 433], ["to", 438], ["complete", 441], ["cytogenetic", 450], ["response", 462], [",", 470], ["major", 472], ["molecular", 478], ["response", 488], [",", 496], ["and", 498], ["complete", 502], ["molecular", 511], ["response", 521], ["were", 530], ["longer", 535], ["for", 542], ["31", 546], ["patients", 549], ["receiving", 558], ["low", 568], ["-", 571], ["dose", 572], ["imatinib", 577], ["(", 586], ["360", 587], [",", 590], ["1360", 592], [",", 596], ["and", 598], ["1420", 602], ["days", 607], [",", 611], ["respectively", 613], [")", 625], ["than", 627], ["74", 632], ["patients", 635], ["receiving", 644], ["optimal", 654], ["-", 661], ["dose", 662], ["imatinib", 667], ["(", 676], ["170", 677], [",", 680], ["420", 682], [",", 685], ["and", 687], ["720", 691], ["days", 695], [",", 699], ["respectively", 701], [")", 713], [".", 714], ["However", 716], [",", 723], ["the", 725], ["differences", 729], ["in", 741], ["response", 744], ["shrank", 753], ["over", 760], ["time", 765], ["and", 770], ["progression", 774], ["-", 785], ["free", 786], ["survival", 791], ["were", 800], ["comparable", 805], ["between", 816], ["the", 824], ["two", 828], ["groups", 832], [".", 838], ["These", 840], ["findings", 846], ["suggest", 855], ["that", 863], ["long", 868], ["-", 872], ["term", 873], ["treatment", 878], ["with", 888], ["low", 893], ["-", 896], ["dose", 897], ["imatinib", 902], ["is", 911], ["an", 914], ["acceptable", 917], ["alternative", 928], ["for", 940], ["patients", 944], ["with", 953], ["intolerance", 958], ["to", 970], ["the", 973], ["optimal", 977], ["dose", 985], [".", 989]]}
{"context": "The expression of selenoproteins requires the translational recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS), and SECIS-binding protein 2 (SBP2). This study implicates SBP2 in dictating the hierarchy of selenoprotein expression, because it is the first to show that SBP2 distinguishes between SECIS elements in vitro. Using RNA electrophoretic mobility shift assays, we demonstrate that a naturally occurring mutation in SBP2, which correlates with abnormal thyroid hormone function in humans, lies within a novel, bipartite RNA-binding domain. This mutation alters the RNA binding affinity of SBP2 such that it no longer stably interacts with a subset of SECIS elements. Assays performed under competitive conditions to mimic intracellular conditions suggest that the differential affinity of SBP2 for various SECIS elements will determine the expression pattern of the selenoproteome. We hypothesize that the selective loss of a subset of selenoproteins, including some involved in thyroid hormone homeostasis, is responsible for the abnormal thyroid hormone metabolism previously observed in the affected individuals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "4a2ea59ce04b469fb5deddf4edb5b587", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[157, 157], [37, 37], [41, 41], [73, 73], [136, 136]], "char_spans": [[950, 954], [241, 245], [253, 257], [432, 436], [795, 799]]}]}], "context_tokens": [["The", 0], ["expression", 4], ["of", 15], ["selenoproteins", 18], ["requires", 33], ["the", 42], ["translational", 46], ["recoding", 60], ["of", 69], ["the", 72], ["UGA", 76], ["stop", 80], ["codon", 85], ["to", 91], ["selenocysteine", 94], [".", 108], ["In", 110], ["eukaryotes", 113], [",", 123], ["this", 125], ["requires", 130], ["an", 139], ["RNA", 142], ["stem", 146], ["loop", 151], ["structure", 156], ["in", 166], ["the", 169], ["3'-untranslated", 173], ["region", 189], [",", 195], ["termed", 197], ["a", 204], ["selenocysteine", 206], ["insertion", 221], ["sequence", 231], ["(", 240], ["SECIS", 241], [")", 246], [",", 247], ["and", 249], ["SECIS", 253], ["-", 258], ["binding", 259], ["protein", 267], ["2", 275], ["(", 277], ["SBP2", 278], [")", 282], [".", 283], ["This", 285], ["study", 290], ["implicates", 296], ["SBP2", 307], ["in", 312], ["dictating", 315], ["the", 325], ["hierarchy", 329], ["of", 339], ["selenoprotein", 342], ["expression", 356], [",", 366], ["because", 368], ["it", 376], ["is", 379], ["the", 382], ["first", 386], ["to", 392], ["show", 395], ["that", 400], ["SBP2", 405], ["distinguishes", 410], ["between", 424], ["SECIS", 432], ["elements", 438], ["in", 447], ["vitro", 450], [".", 455], ["Using", 457], ["RNA", 463], ["electrophoretic", 467], ["mobility", 483], ["shift", 492], ["assays", 498], [",", 504], ["we", 506], ["demonstrate", 509], ["that", 521], ["a", 526], ["naturally", 528], ["occurring", 538], ["mutation", 548], ["in", 557], ["SBP2", 560], [",", 564], ["which", 566], ["correlates", 572], ["with", 583], ["abnormal", 588], ["thyroid", 597], ["hormone", 605], ["function", 613], ["in", 622], ["humans", 625], [",", 631], ["lies", 633], ["within", 638], ["a", 645], ["novel", 647], [",", 652], ["bipartite", 654], ["RNA", 664], ["-", 667], ["binding", 668], ["domain", 676], [".", 682], ["This", 684], ["mutation", 689], ["alters", 698], ["the", 705], ["RNA", 709], ["binding", 713], ["affinity", 721], ["of", 730], ["SBP2", 733], ["such", 738], ["that", 743], ["it", 748], ["no", 751], ["longer", 754], ["stably", 761], ["interacts", 768], ["with", 778], ["a", 783], ["subset", 785], ["of", 792], ["SECIS", 795], ["elements", 801], [".", 809], ["Assays", 811], ["performed", 818], ["under", 828], ["competitive", 834], ["conditions", 846], ["to", 857], ["mimic", 860], ["intracellular", 866], ["conditions", 880], ["suggest", 891], ["that", 899], ["the", 904], ["differential", 908], ["affinity", 921], ["of", 930], ["SBP2", 933], ["for", 938], ["various", 942], ["SECIS", 950], ["elements", 956], ["will", 965], ["determine", 970], ["the", 980], ["expression", 984], ["pattern", 995], ["of", 1003], ["the", 1006], ["selenoproteome", 1010], [".", 1024], ["We", 1026], ["hypothesize", 1029], ["that", 1041], ["the", 1046], ["selective", 1050], ["loss", 1060], ["of", 1065], ["a", 1068], ["subset", 1070], ["of", 1077], ["selenoproteins", 1080], [",", 1094], ["including", 1096], ["some", 1106], ["involved", 1111], ["in", 1120], ["thyroid", 1123], ["hormone", 1131], ["homeostasis", 1139], [",", 1150], ["is", 1152], ["responsible", 1155], ["for", 1167], ["the", 1171], ["abnormal", 1175], ["thyroid", 1184], ["hormone", 1192], ["metabolism", 1200], ["previously", 1211], ["observed", 1222], ["in", 1231], ["the", 1234], ["affected", 1238], ["individuals", 1247], [".", 1258]]}
{"context": "Mowat-Wilson syndrome is a genetic condition characterized by a recognizable facial phenotype in addition to moderate to severe cognitive disability with severe speech impairment and variable multiple congenital anomalies. The anomalies may include Hirschsprung disease, heart defects, structural eye anomalies including microphthalmia, agenesis of the corpus callosum, and urogenital anomalies. Microcephaly, seizure disorder and constipation are common. All typical cases result from haploinsufficiency of the ZEB2 (also known as ZFHX1B or SIP-1) gene, with over 100 distinct mutations now described. Approximately 80% of patients have a nonsense or frameshift mutation detectable by sequencing, with the rest having gross deletions necessitating a dosage sensitive assay. Here we report on the results of comprehensive molecular testing for 27 patients testing positive for MWS. Twenty-one patients had a nonsense, frameshift, or splice site mutation identified by sequencing; 14 of which localized to exon 8 and 17 of which are novel. Six patients had deletions in the ZEB2 gene, including two novel partial gene deletions. This report, the first such analysis in North American patients, adds to the growing list of both novel pathogenic mutations associated with MWS, as well as other variants in the ZEB2 gene. In addition, we suggest an economical testing strategy.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "6aab95b5bc40449b812caabddc308265", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[80, 80]], "char_spans": [[532, 537]]}, {"text": "ZEB2", "token_spans": [[220, 220], [75, 75], [177, 177]], "char_spans": [[1307, 1310], [512, 515], [1073, 1076]]}, {"text": "SIP-1", "token_spans": [[82, 82]], "char_spans": [[542, 546]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["condition", 35], ["characterized", 45], ["by", 59], ["a", 62], ["recognizable", 64], ["facial", 77], ["phenotype", 84], ["in", 94], ["addition", 97], ["to", 106], ["moderate", 109], ["to", 118], ["severe", 121], ["cognitive", 128], ["disability", 138], ["with", 149], ["severe", 154], ["speech", 161], ["impairment", 168], ["and", 179], ["variable", 183], ["multiple", 192], ["congenital", 201], ["anomalies", 212], [".", 221], ["The", 223], ["anomalies", 227], ["may", 237], ["include", 241], ["Hirschsprung", 249], ["disease", 262], [",", 269], ["heart", 271], ["defects", 277], [",", 284], ["structural", 286], ["eye", 297], ["anomalies", 301], ["including", 311], ["microphthalmia", 321], [",", 335], ["agenesis", 337], ["of", 346], ["the", 349], ["corpus", 353], ["callosum", 360], [",", 368], ["and", 370], ["urogenital", 374], ["anomalies", 385], [".", 394], ["Microcephaly", 396], [",", 408], ["seizure", 410], ["disorder", 418], ["and", 427], ["constipation", 431], ["are", 444], ["common", 448], [".", 454], ["All", 456], ["typical", 460], ["cases", 468], ["result", 474], ["from", 481], ["haploinsufficiency", 486], ["of", 505], ["the", 508], ["ZEB2", 512], ["(", 517], ["also", 518], ["known", 523], ["as", 529], ["ZFHX1B", 532], ["or", 539], ["SIP-1", 542], [")", 547], ["gene", 549], [",", 553], ["with", 555], ["over", 560], ["100", 565], ["distinct", 569], ["mutations", 578], ["now", 588], ["described", 592], [".", 601], ["Approximately", 603], ["80", 617], ["%", 619], ["of", 621], ["patients", 624], ["have", 633], ["a", 638], ["nonsense", 640], ["or", 649], ["frameshift", 652], ["mutation", 663], ["detectable", 672], ["by", 683], ["sequencing", 686], [",", 696], ["with", 698], ["the", 703], ["rest", 707], ["having", 712], ["gross", 719], ["deletions", 725], ["necessitating", 735], ["a", 749], ["dosage", 751], ["sensitive", 758], ["assay", 768], [".", 773], ["Here", 775], ["we", 780], ["report", 783], ["on", 790], ["the", 793], ["results", 797], ["of", 805], ["comprehensive", 808], ["molecular", 822], ["testing", 832], ["for", 840], ["27", 844], ["patients", 847], ["testing", 856], ["positive", 864], ["for", 873], ["MWS", 877], [".", 880], ["Twenty", 882], ["-", 888], ["one", 889], ["patients", 893], ["had", 902], ["a", 906], ["nonsense", 908], [",", 916], ["frameshift", 918], [",", 928], ["or", 930], ["splice", 933], ["site", 940], ["mutation", 945], ["identified", 954], ["by", 965], ["sequencing", 968], [";", 978], ["14", 980], ["of", 983], ["which", 986], ["localized", 992], ["to", 1002], ["exon", 1005], ["8", 1010], ["and", 1012], ["17", 1016], ["of", 1019], ["which", 1022], ["are", 1028], ["novel", 1032], [".", 1037], ["Six", 1039], ["patients", 1043], ["had", 1052], ["deletions", 1056], ["in", 1066], ["the", 1069], ["ZEB2", 1073], ["gene", 1078], [",", 1082], ["including", 1084], ["two", 1094], ["novel", 1098], ["partial", 1104], ["gene", 1112], ["deletions", 1117], [".", 1126], ["This", 1128], ["report", 1133], [",", 1139], ["the", 1141], ["first", 1145], ["such", 1151], ["analysis", 1156], ["in", 1165], ["North", 1168], ["American", 1174], ["patients", 1183], [",", 1191], ["adds", 1193], ["to", 1198], ["the", 1201], ["growing", 1205], ["list", 1213], ["of", 1218], ["both", 1221], ["novel", 1226], ["pathogenic", 1232], ["mutations", 1243], ["associated", 1253], ["with", 1264], ["MWS", 1269], [",", 1272], ["as", 1274], ["well", 1277], ["as", 1282], ["other", 1285], ["variants", 1291], ["in", 1300], ["the", 1303], ["ZEB2", 1307], ["gene", 1312], [".", 1316], ["In", 1318], ["addition", 1321], [",", 1329], ["we", 1331], ["suggest", 1334], ["an", 1342], ["economical", 1345], ["testing", 1356], ["strategy", 1364], [".", 1372]]}
{"context": "Plague is still an endemic disease in different regions of the world. Increasing reports of incidence, the discovery of antibiotic resistance strains, and concern about a potential use of the causative bacteria Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine. The use of F1 and V antigens and the derived protein fusion F1-V has shown great potential as a protective vaccine in animal studies. Plants have been extensively studied for the production of pharmaceutical proteins as an inexpensive and scalable alternative to common expression systems. In the current study the recombinant plague antigens F1, V, and fusion protein F1-V were produced by transient expression in Nicotiana benthamiana by using a deconstructed tobacco mosaic virus-based system that allowed very rapid and extremely high levels of expression. All of the plant-derived purified antigens, administered s.c. to guinea pigs, generated systemic immune responses and provided protection against an aerosol challenge of virulent Y. pestis.", "qas": [{"question": "Which bacteria caused plague?", "answers": ["Yersinia pestis"], "qid": "4ce4a14391204eb893a5d9a49f0652af", "question_tokens": [["Which", 0], ["bacteria", 6], ["caused", 15], ["plague", 22], ["?", 28]], "detected_answers": [{"text": "Yersinia pestis", "token_spans": [[35, 36]], "char_spans": [[211, 225]]}]}], "context_tokens": [["Plague", 0], ["is", 7], ["still", 10], ["an", 16], ["endemic", 19], ["disease", 27], ["in", 35], ["different", 38], ["regions", 48], ["of", 56], ["the", 59], ["world", 63], [".", 68], ["Increasing", 70], ["reports", 81], ["of", 89], ["incidence", 92], [",", 101], ["the", 103], ["discovery", 107], ["of", 117], ["antibiotic", 120], ["resistance", 131], ["strains", 142], [",", 149], ["and", 151], ["concern", 155], ["about", 163], ["a", 169], ["potential", 171], ["use", 181], ["of", 185], ["the", 188], ["causative", 192], ["bacteria", 202], ["Yersinia", 211], ["pestis", 220], ["as", 227], ["an", 230], ["agent", 233], ["of", 239], ["biological", 242], ["warfare", 253], ["have", 261], ["highlighted", 266], ["the", 278], ["need", 282], ["for", 287], ["a", 291], ["safe", 293], [",", 297], ["efficacious", 299], [",", 310], ["and", 312], ["rapidly", 316], ["producible", 324], ["vaccine", 335], [".", 342], ["The", 344], ["use", 348], ["of", 352], ["F1", 355], ["and", 358], ["V", 362], ["antigens", 364], ["and", 373], ["the", 377], ["derived", 381], ["protein", 389], ["fusion", 397], ["F1-V", 404], ["has", 409], ["shown", 413], ["great", 419], ["potential", 425], ["as", 435], ["a", 438], ["protective", 440], ["vaccine", 451], ["in", 459], ["animal", 462], ["studies", 469], [".", 476], ["Plants", 478], ["have", 485], ["been", 490], ["extensively", 495], ["studied", 507], ["for", 515], ["the", 519], ["production", 523], ["of", 534], ["pharmaceutical", 537], ["proteins", 552], ["as", 561], ["an", 564], ["inexpensive", 567], ["and", 579], ["scalable", 583], ["alternative", 592], ["to", 604], ["common", 607], ["expression", 614], ["systems", 625], [".", 632], ["In", 634], ["the", 637], ["current", 641], ["study", 649], ["the", 655], ["recombinant", 659], ["plague", 671], ["antigens", 678], ["F1", 687], [",", 689], ["V", 691], [",", 692], ["and", 694], ["fusion", 698], ["protein", 705], ["F1-V", 713], ["were", 718], ["produced", 723], ["by", 732], ["transient", 735], ["expression", 745], ["in", 756], ["Nicotiana", 759], ["benthamiana", 769], ["by", 781], ["using", 784], ["a", 790], ["deconstructed", 792], ["tobacco", 806], ["mosaic", 814], ["virus", 821], ["-", 826], ["based", 827], ["system", 833], ["that", 840], ["allowed", 845], ["very", 853], ["rapid", 858], ["and", 864], ["extremely", 868], ["high", 878], ["levels", 883], ["of", 890], ["expression", 893], [".", 903], ["All", 905], ["of", 909], ["the", 912], ["plant", 916], ["-", 921], ["derived", 922], ["purified", 930], ["antigens", 939], [",", 947], ["administered", 949], ["s.c", 962], [".", 965], ["to", 967], ["guinea", 970], ["pigs", 977], [",", 981], ["generated", 983], ["systemic", 993], ["immune", 1002], ["responses", 1009], ["and", 1019], ["provided", 1023], ["protection", 1032], ["against", 1043], ["an", 1051], ["aerosol", 1054], ["challenge", 1062], ["of", 1072], ["virulent", 1075], ["Y.", 1084], ["pestis", 1087], [".", 1093]]}
{"context": "To evaluate and compare outcomes for patients with vestibular schwannoma (VS) treated in a single institution with linac-based stereotactic radiosurgery (SRS) or by fractionated stereotactic radiotherapy (SRT). One hundred and nineteen patients (SRS = 78, SRT = 41) were treated. For both SRS and SRT, beam shaping is performed by a mini-multileaf collimator. For SRS, a median single dose of 12.5 Gy (range, 11-14 Gy), prescribed to the 80% isodose line encompassing the target, was applied. Of the 42 SRT treatments, 32 treatments consisted of 10 fractions of 3-4 Gy, and 10 patients received 25 sessions of 2 Gy, prescribed to the 100% with the 95% isodose line encompassing the planning target volume. Mean largest tumor diameter was 16.6 mm in the SRS and 24.6 mm in the SRT group. Local tumor control, cranial nerve toxicity, and preservation of useful hearing were recorded. Any new treatment-induced cranial nerve neuropathy was scored as a complication. Median follow-up was 62 months (range, 6-136 months), 5 patients progressed, resulting in an overall 5-year local tumor control of 95%. The overall 5-year facial nerve preservation probability was 88% and facial nerve neuropathy was statistically significantly higher after SRS, after prior surgery, for larger tumors, and in Koos Grade \u22653. The overall 5-year trigeminal nerve preservation probability was 96%, not significantly influenced by any of the risk factors. The overall 4-year probability of preservation of useful hearing (Gardner-Robertson score 1 or 2) was 68%, not significantly different between SRS or SRT (59% vs. 82%, p = 0.089, log rank). Linac-based RT results in good local control and acceptable clinical outcome in small to medium-sized vestibular schwannomas (VSs). Radiosurgery for large VSs (Koos Grade \u22653) remains a challenge because of increased facial nerve neuropathy.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "212829ec9421495797a732770b08731b", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[8, 9]], "char_spans": [[51, 71]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["and", 12], ["compare", 16], ["outcomes", 24], ["for", 33], ["patients", 37], ["with", 46], ["vestibular", 51], ["schwannoma", 62], ["(", 73], ["VS", 74], [")", 76], ["treated", 78], ["in", 86], ["a", 89], ["single", 91], ["institution", 98], ["with", 110], ["linac", 115], ["-", 120], ["based", 121], ["stereotactic", 127], ["radiosurgery", 140], ["(", 153], ["SRS", 154], [")", 157], ["or", 159], ["by", 162], ["fractionated", 165], ["stereotactic", 178], ["radiotherapy", 191], ["(", 204], ["SRT", 205], [")", 208], [".", 209], ["One", 211], ["hundred", 215], ["and", 223], ["nineteen", 227], ["patients", 236], ["(", 245], ["SRS", 246], ["=", 250], ["78", 252], [",", 254], ["SRT", 256], ["=", 260], ["41", 262], [")", 264], ["were", 266], ["treated", 271], [".", 278], ["For", 280], ["both", 284], ["SRS", 289], ["and", 293], ["SRT", 297], [",", 300], ["beam", 302], ["shaping", 307], ["is", 315], ["performed", 318], ["by", 328], ["a", 331], ["mini", 333], ["-", 337], ["multileaf", 338], ["collimator", 348], [".", 358], ["For", 360], ["SRS", 364], [",", 367], ["a", 369], ["median", 371], ["single", 378], ["dose", 385], ["of", 390], ["12.5", 393], ["Gy", 398], ["(", 401], ["range", 402], [",", 407], ["11", 409], ["-", 411], ["14", 412], ["Gy", 415], [")", 417], [",", 418], ["prescribed", 420], ["to", 431], ["the", 434], ["80", 438], ["%", 440], ["isodose", 442], ["line", 450], ["encompassing", 455], ["the", 468], ["target", 472], [",", 478], ["was", 480], ["applied", 484], [".", 491], ["Of", 493], ["the", 496], ["42", 500], ["SRT", 503], ["treatments", 507], [",", 517], ["32", 519], ["treatments", 522], ["consisted", 533], ["of", 543], ["10", 546], ["fractions", 549], ["of", 559], ["3", 562], ["-", 563], ["4", 564], ["Gy", 566], [",", 568], ["and", 570], ["10", 574], ["patients", 577], ["received", 586], ["25", 595], ["sessions", 598], ["of", 607], ["2", 610], ["Gy", 612], [",", 614], ["prescribed", 616], ["to", 627], ["the", 630], ["100", 634], ["%", 637], ["with", 639], ["the", 644], ["95", 648], ["%", 650], ["isodose", 652], ["line", 660], ["encompassing", 665], ["the", 678], ["planning", 682], ["target", 691], ["volume", 698], [".", 704], ["Mean", 706], ["largest", 711], ["tumor", 719], ["diameter", 725], ["was", 734], ["16.6", 738], ["mm", 743], ["in", 746], ["the", 749], ["SRS", 753], ["and", 757], ["24.6", 761], ["mm", 766], ["in", 769], ["the", 772], ["SRT", 776], ["group", 780], [".", 785], ["Local", 787], ["tumor", 793], ["control", 799], [",", 806], ["cranial", 808], ["nerve", 816], ["toxicity", 822], [",", 830], ["and", 832], ["preservation", 836], ["of", 849], ["useful", 852], ["hearing", 859], ["were", 867], ["recorded", 872], [".", 880], ["Any", 882], ["new", 886], ["treatment", 890], ["-", 899], ["induced", 900], ["cranial", 908], ["nerve", 916], ["neuropathy", 922], ["was", 933], ["scored", 937], ["as", 944], ["a", 947], ["complication", 949], [".", 961], ["Median", 963], ["follow", 970], ["-", 976], ["up", 977], ["was", 980], ["62", 984], ["months", 987], ["(", 994], ["range", 995], [",", 1000], ["6", 1002], ["-", 1003], ["136", 1004], ["months", 1008], [")", 1014], [",", 1015], ["5", 1017], ["patients", 1019], ["progressed", 1028], [",", 1038], ["resulting", 1040], ["in", 1050], ["an", 1053], ["overall", 1056], ["5-year", 1064], ["local", 1071], ["tumor", 1077], ["control", 1083], ["of", 1091], ["95", 1094], ["%", 1096], [".", 1097], ["The", 1099], ["overall", 1103], ["5-year", 1111], ["facial", 1118], ["nerve", 1125], ["preservation", 1131], ["probability", 1144], ["was", 1156], ["88", 1160], ["%", 1162], ["and", 1164], ["facial", 1168], ["nerve", 1175], ["neuropathy", 1181], ["was", 1192], ["statistically", 1196], ["significantly", 1210], ["higher", 1224], ["after", 1231], ["SRS", 1237], [",", 1240], ["after", 1242], ["prior", 1248], ["surgery", 1254], [",", 1261], ["for", 1263], ["larger", 1267], ["tumors", 1274], [",", 1280], ["and", 1282], ["in", 1286], ["Koos", 1289], ["Grade", 1294], ["\u22653", 1300], [".", 1302], ["The", 1304], ["overall", 1308], ["5-year", 1316], ["trigeminal", 1323], ["nerve", 1334], ["preservation", 1340], ["probability", 1353], ["was", 1365], ["96", 1369], ["%", 1371], [",", 1372], ["not", 1374], ["significantly", 1378], ["influenced", 1392], ["by", 1403], ["any", 1406], ["of", 1410], ["the", 1413], ["risk", 1417], ["factors", 1422], [".", 1429], ["The", 1431], ["overall", 1435], ["4-year", 1443], ["probability", 1450], ["of", 1462], ["preservation", 1465], ["of", 1478], ["useful", 1481], ["hearing", 1488], ["(", 1496], ["Gardner", 1497], ["-", 1504], ["Robertson", 1505], ["score", 1515], ["1", 1521], ["or", 1523], ["2", 1526], [")", 1527], ["was", 1529], ["68", 1533], ["%", 1535], [",", 1536], ["not", 1538], ["significantly", 1542], ["different", 1556], ["between", 1566], ["SRS", 1574], ["or", 1578], ["SRT", 1581], ["(", 1585], ["59", 1586], ["%", 1588], ["vs.", 1590], ["82", 1594], ["%", 1596], [",", 1597], ["p", 1599], ["=", 1601], ["0.089", 1603], [",", 1608], ["log", 1610], ["rank", 1614], [")", 1618], [".", 1619], ["Linac", 1621], ["-", 1626], ["based", 1627], ["RT", 1633], ["results", 1636], ["in", 1644], ["good", 1647], ["local", 1652], ["control", 1658], ["and", 1666], ["acceptable", 1670], ["clinical", 1681], ["outcome", 1690], ["in", 1698], ["small", 1701], ["to", 1707], ["medium", 1710], ["-", 1716], ["sized", 1717], ["vestibular", 1723], ["schwannomas", 1734], ["(", 1746], ["VSs", 1747], [")", 1750], [".", 1751], ["Radiosurgery", 1753], ["for", 1766], ["large", 1770], ["VSs", 1776], ["(", 1780], ["Koos", 1781], ["Grade", 1786], ["\u22653", 1792], [")", 1794], ["remains", 1796], ["a", 1804], ["challenge", 1806], ["because", 1816], ["of", 1824], ["increased", 1827], ["facial", 1837], ["nerve", 1844], ["neuropathy", 1850], [".", 1860]]}
{"context": "Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). This study was undertaken to investigate the effect of food on the pharmacokinetics of 25 mg empagliflozin and to assess dose proportionality between 10 mg and 25 mg empagliflozin under fasted conditions. In this open-label, 3-way, cross-over study, 18 healthy volunteers received 3 single doses of empagliflozin in a randomized sequence (25 mg empagliflozin under fasted conditions, 25 mg empagliflozin after a high-fat, high-calorie breakfast and 10 mg empagliflozin under fasted conditions), each separated by a washout period of at least 7 days. Serial plasma samples were collected at selected time points over a period of 72 hours. Administration with food had no clinically relevant effect on the area under the plasma concentration-time curve (AUC0-\u221e) of empagliflozin (geometric mean ratio (GMR): 84.04, 90% confidence interval (CI): 80.86 - 87.34). The decrease observed in the maximum plasma concentrations (Cmax) of empagliflozin (GMR: 63.22, 90% CI: 56.74 - 70.44) when administered with food was not considered clinically meaningful. The increases in AUC0-\u221e and Cmax for 10 mg vs. 25 mg empagliflozin administered under fasting conditions were roughly dose-proportional, as demonstrated by the slope \u03b2 of the regression lines being slightly less than 1 (slope \u03b2 for AUC0-\u221e: 0.94, 95% CI: 0.90 - 0.97; slope \u03b2 for Cmax: 0.91, 95% CI: 0.80 - 1.01). Empagliflozin was well tolerated under fed and fasting conditions. The results support administration of empagliflozin tablets independently of food. Increases in empagliflozin exposure under fasting conditions were roughly dose-proportional between 10 mg and 25 mg empagliflozin.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "1ac6a774b34748d0b2f90a6dd51379eb", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[18, 18]], "char_spans": [[115, 119]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["an", 17], ["orally", 20], ["available", 27], [",", 36], ["potent", 38], ["and", 45], ["highly", 49], ["selective", 56], ["inhibitor", 66], ["of", 76], ["the", 79], ["sodium", 83], ["glucose", 90], ["cotransporter", 98], ["2", 112], ["(", 114], ["SGLT2", 115], [")", 120], [".", 121], ["This", 123], ["study", 128], ["was", 134], ["undertaken", 138], ["to", 149], ["investigate", 152], ["the", 164], ["effect", 168], ["of", 175], ["food", 178], ["on", 183], ["the", 186], ["pharmacokinetics", 190], ["of", 207], ["25", 210], ["mg", 213], ["empagliflozin", 216], ["and", 230], ["to", 234], ["assess", 237], ["dose", 244], ["proportionality", 249], ["between", 265], ["10", 273], ["mg", 276], ["and", 279], ["25", 283], ["mg", 286], ["empagliflozin", 289], ["under", 303], ["fasted", 309], ["conditions", 316], [".", 326], ["In", 328], ["this", 331], ["open", 336], ["-", 340], ["label", 341], [",", 346], ["3-way", 348], [",", 353], ["cross", 355], ["-", 360], ["over", 361], ["study", 366], [",", 371], ["18", 373], ["healthy", 376], ["volunteers", 384], ["received", 395], ["3", 404], ["single", 406], ["doses", 413], ["of", 419], ["empagliflozin", 422], ["in", 436], ["a", 439], ["randomized", 441], ["sequence", 452], ["(", 461], ["25", 462], ["mg", 465], ["empagliflozin", 468], ["under", 482], ["fasted", 488], ["conditions", 495], [",", 505], ["25", 507], ["mg", 510], ["empagliflozin", 513], ["after", 527], ["a", 533], ["high", 535], ["-", 539], ["fat", 540], [",", 543], ["high", 545], ["-", 549], ["calorie", 550], ["breakfast", 558], ["and", 568], ["10", 572], ["mg", 575], ["empagliflozin", 578], ["under", 592], ["fasted", 598], ["conditions", 605], [")", 615], [",", 616], ["each", 618], ["separated", 623], ["by", 633], ["a", 636], ["washout", 638], ["period", 646], ["of", 653], ["at", 656], ["least", 659], ["7", 665], ["days", 667], [".", 671], ["Serial", 673], ["plasma", 680], ["samples", 687], ["were", 695], ["collected", 700], ["at", 710], ["selected", 713], ["time", 722], ["points", 727], ["over", 734], ["a", 739], ["period", 741], ["of", 748], ["72", 751], ["hours", 754], [".", 759], ["Administration", 761], ["with", 776], ["food", 781], ["had", 786], ["no", 790], ["clinically", 793], ["relevant", 804], ["effect", 813], ["on", 820], ["the", 823], ["area", 827], ["under", 832], ["the", 838], ["plasma", 842], ["concentration", 849], ["-", 862], ["time", 863], ["curve", 868], ["(", 874], ["AUC0-\u221e", 875], [")", 881], ["of", 883], ["empagliflozin", 886], ["(", 900], ["geometric", 901], ["mean", 911], ["ratio", 916], ["(", 922], ["GMR", 923], [")", 926], [":", 927], ["84.04", 929], [",", 934], ["90", 936], ["%", 938], ["confidence", 940], ["interval", 951], ["(", 960], ["CI", 961], [")", 963], [":", 964], ["80.86", 966], ["-", 972], ["87.34", 974], [")", 979], [".", 980], ["The", 982], ["decrease", 986], ["observed", 995], ["in", 1004], ["the", 1007], ["maximum", 1011], ["plasma", 1019], ["concentrations", 1026], ["(", 1041], ["Cmax", 1042], [")", 1046], ["of", 1048], ["empagliflozin", 1051], ["(", 1065], ["GMR", 1066], [":", 1069], ["63.22", 1071], [",", 1076], ["90", 1078], ["%", 1080], ["CI", 1082], [":", 1084], ["56.74", 1086], ["-", 1092], ["70.44", 1094], [")", 1099], ["when", 1101], ["administered", 1106], ["with", 1119], ["food", 1124], ["was", 1129], ["not", 1133], ["considered", 1137], ["clinically", 1148], ["meaningful", 1159], [".", 1169], ["The", 1171], ["increases", 1175], ["in", 1185], ["AUC0-\u221e", 1188], ["and", 1195], ["Cmax", 1199], ["for", 1204], ["10", 1208], ["mg", 1211], ["vs.", 1214], ["25", 1218], ["mg", 1221], ["empagliflozin", 1224], ["administered", 1238], ["under", 1251], ["fasting", 1257], ["conditions", 1265], ["were", 1276], ["roughly", 1281], ["dose", 1289], ["-", 1293], ["proportional", 1294], [",", 1306], ["as", 1308], ["demonstrated", 1311], ["by", 1324], ["the", 1327], ["slope", 1331], ["\u03b2", 1337], ["of", 1339], ["the", 1342], ["regression", 1346], ["lines", 1357], ["being", 1363], ["slightly", 1369], ["less", 1378], ["than", 1383], ["1", 1388], ["(", 1390], ["slope", 1391], ["\u03b2", 1397], ["for", 1399], ["AUC0-\u221e", 1403], [":", 1409], ["0.94", 1411], [",", 1415], ["95", 1417], ["%", 1419], ["CI", 1421], [":", 1423], ["0.90", 1425], ["-", 1430], ["0.97", 1432], [";", 1436], ["slope", 1438], ["\u03b2", 1444], ["for", 1446], ["Cmax", 1450], [":", 1454], ["0.91", 1456], [",", 1460], ["95", 1462], ["%", 1464], ["CI", 1466], [":", 1468], ["0.80", 1470], ["-", 1475], ["1.01", 1477], [")", 1481], [".", 1482], ["Empagliflozin", 1484], ["was", 1498], ["well", 1502], ["tolerated", 1507], ["under", 1517], ["fed", 1523], ["and", 1527], ["fasting", 1531], ["conditions", 1539], [".", 1549], ["The", 1551], ["results", 1555], ["support", 1563], ["administration", 1571], ["of", 1586], ["empagliflozin", 1589], ["tablets", 1603], ["independently", 1611], ["of", 1625], ["food", 1628], [".", 1632], ["Increases", 1634], ["in", 1644], ["empagliflozin", 1647], ["exposure", 1661], ["under", 1670], ["fasting", 1676], ["conditions", 1684], ["were", 1695], ["roughly", 1700], ["dose", 1708], ["-", 1712], ["proportional", 1713], ["between", 1726], ["10", 1734], ["mg", 1737], ["and", 1740], ["25", 1744], ["mg", 1747], ["empagliflozin", 1750], [".", 1763]]}
{"context": "Cancer cells frequently induce aberrant centrosomes, which have been implicated in cancer initiation and progression. Human colorectal cancer cells, HCT116, contain aberrant centrioles composed of disorganized cylindrical microtubules and displaced appendages. These cells also express unique centrosome-related structures associated with a subset of centrosomal components, including gamma-tubulin, centrin and PCM1. During hydroxyurea treatment, these abnormal structures become more abundant and undergo a change in shape from small dots to elongated fibers. Although gamma-tubulin seems to exist as a ring complex, the abnormal structures do not support microtubule nucleation. Several lines of evidence suggest that the fibers correspond to a disorganized form of centriolar microtubules. Plk4, a mammalian homolog of ZYG-1 essential for initiation of centriole biogenesis, is not associated with the gamma-tubulin-specific abnormal centrosomes. The amount of Plk4 at each centrosome was less in cells with abnormal centrosomes than cells without gamma-tubulin-specific abnormal centrosomes. In addition, the formation of abnormal structures was abolished by expression of exogenous Plk4, but not SAS6 and Cep135/Bld10p, which are downstream regulators required for the organization of nine-triplet microtubules. These results suggest that HCT116 cells fail to organize the ninefold symmetry of centrioles due to insufficient Plk4.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edef18590b2a40aea0dfe32bad4780ea", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[156, 156], [41, 41]], "char_spans": [[978, 987], [293, 302]]}]}], "context_tokens": [["Cancer", 0], ["cells", 7], ["frequently", 13], ["induce", 24], ["aberrant", 31], ["centrosomes", 40], [",", 51], ["which", 53], ["have", 59], ["been", 64], ["implicated", 69], ["in", 80], ["cancer", 83], ["initiation", 90], ["and", 101], ["progression", 105], [".", 116], ["Human", 118], ["colorectal", 124], ["cancer", 135], ["cells", 142], [",", 147], ["HCT116", 149], [",", 155], ["contain", 157], ["aberrant", 165], ["centrioles", 174], ["composed", 185], ["of", 194], ["disorganized", 197], ["cylindrical", 210], ["microtubules", 222], ["and", 235], ["displaced", 239], ["appendages", 249], [".", 259], ["These", 261], ["cells", 267], ["also", 273], ["express", 278], ["unique", 286], ["centrosome", 293], ["-", 303], ["related", 304], ["structures", 312], ["associated", 323], ["with", 334], ["a", 339], ["subset", 341], ["of", 348], ["centrosomal", 351], ["components", 363], [",", 373], ["including", 375], ["gamma", 385], ["-", 390], ["tubulin", 391], [",", 398], ["centrin", 400], ["and", 408], ["PCM1", 412], [".", 416], ["During", 418], ["hydroxyurea", 425], ["treatment", 437], [",", 446], ["these", 448], ["abnormal", 454], ["structures", 463], ["become", 474], ["more", 481], ["abundant", 486], ["and", 495], ["undergo", 499], ["a", 507], ["change", 509], ["in", 516], ["shape", 519], ["from", 525], ["small", 530], ["dots", 536], ["to", 541], ["elongated", 544], ["fibers", 554], [".", 560], ["Although", 562], ["gamma", 571], ["-", 576], ["tubulin", 577], ["seems", 585], ["to", 591], ["exist", 594], ["as", 600], ["a", 603], ["ring", 605], ["complex", 610], [",", 617], ["the", 619], ["abnormal", 623], ["structures", 632], ["do", 643], ["not", 646], ["support", 650], ["microtubule", 658], ["nucleation", 670], [".", 680], ["Several", 682], ["lines", 690], ["of", 696], ["evidence", 699], ["suggest", 708], ["that", 716], ["the", 721], ["fibers", 725], ["correspond", 732], ["to", 743], ["a", 746], ["disorganized", 748], ["form", 761], ["of", 766], ["centriolar", 769], ["microtubules", 780], [".", 792], ["Plk4", 794], [",", 798], ["a", 800], ["mammalian", 802], ["homolog", 812], ["of", 820], ["ZYG-1", 823], ["essential", 829], ["for", 839], ["initiation", 843], ["of", 854], ["centriole", 857], ["biogenesis", 867], [",", 877], ["is", 879], ["not", 882], ["associated", 886], ["with", 897], ["the", 902], ["gamma", 906], ["-", 911], ["tubulin", 912], ["-", 919], ["specific", 920], ["abnormal", 929], ["centrosomes", 938], [".", 949], ["The", 951], ["amount", 955], ["of", 962], ["Plk4", 965], ["at", 970], ["each", 973], ["centrosome", 978], ["was", 989], ["less", 993], ["in", 998], ["cells", 1001], ["with", 1007], ["abnormal", 1012], ["centrosomes", 1021], ["than", 1033], ["cells", 1038], ["without", 1044], ["gamma", 1052], ["-", 1057], ["tubulin", 1058], ["-", 1065], ["specific", 1066], ["abnormal", 1075], ["centrosomes", 1084], [".", 1095], ["In", 1097], ["addition", 1100], [",", 1108], ["the", 1110], ["formation", 1114], ["of", 1124], ["abnormal", 1127], ["structures", 1136], ["was", 1147], ["abolished", 1151], ["by", 1161], ["expression", 1164], ["of", 1175], ["exogenous", 1178], ["Plk4", 1188], [",", 1192], ["but", 1194], ["not", 1198], ["SAS6", 1202], ["and", 1207], ["Cep135/Bld10p", 1211], [",", 1224], ["which", 1226], ["are", 1232], ["downstream", 1236], ["regulators", 1247], ["required", 1258], ["for", 1267], ["the", 1271], ["organization", 1275], ["of", 1288], ["nine", 1291], ["-", 1295], ["triplet", 1296], ["microtubules", 1304], [".", 1316], ["These", 1318], ["results", 1324], ["suggest", 1332], ["that", 1340], ["HCT116", 1345], ["cells", 1352], ["fail", 1358], ["to", 1363], ["organize", 1366], ["the", 1375], ["ninefold", 1379], ["symmetry", 1388], ["of", 1397], ["centrioles", 1400], ["due", 1411], ["to", 1415], ["insufficient", 1418], ["Plk4", 1431], [".", 1435]]}
{"context": "A study was performed to determine the utility of the 8-point recognition of stroke in the emergency room (ROSIER) instrument as a diagnostic tool in a large Irish emergency department. Fifty patients had ROSIER scores completed by doctors. Diagnoses achieved using the score were compared with discharge diagnoses. Relations between ROSIER score, impairment and length of stay were assessed. Forty-seven patients (94%) had a ROSIER Score > or =1 indicating a stroke, 44 (94%) of these had stroke confirmed on investigation. Two patients with stroke were missed and three were wrongly identified. Positive predictive value for the ROSIER was 94%. ROSIER correlated with Scandinavian neurological stroke score. (r = -0.414, p = 0.003) and was associated with increasing length of stay in survivors (p = 0.16, one-way ANOVA. F = 3.116, df = 6). The ROSIER is a suitable and useful adjunct in the assessment of stroke patients in Ireland.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "84e440c52ada4da9ab59b02ebf6421e1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[13, 13], [179, 179], [102, 102], [84, 84], [126, 126], [94, 94]], "char_spans": [[77, 82], [908, 913], [543, 548], [460, 465], [696, 701], [490, 495]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["performed", 12], ["to", 22], ["determine", 25], ["the", 35], ["utility", 39], ["of", 47], ["the", 50], ["8-point", 54], ["recognition", 62], ["of", 74], ["stroke", 77], ["in", 84], ["the", 87], ["emergency", 91], ["room", 101], ["(", 106], ["ROSIER", 107], [")", 113], ["instrument", 115], ["as", 126], ["a", 129], ["diagnostic", 131], ["tool", 142], ["in", 147], ["a", 150], ["large", 152], ["Irish", 158], ["emergency", 164], ["department", 174], [".", 184], ["Fifty", 186], ["patients", 192], ["had", 201], ["ROSIER", 205], ["scores", 212], ["completed", 219], ["by", 229], ["doctors", 232], [".", 239], ["Diagnoses", 241], ["achieved", 251], ["using", 260], ["the", 266], ["score", 270], ["were", 276], ["compared", 281], ["with", 290], ["discharge", 295], ["diagnoses", 305], [".", 314], ["Relations", 316], ["between", 326], ["ROSIER", 334], ["score", 341], [",", 346], ["impairment", 348], ["and", 359], ["length", 363], ["of", 370], ["stay", 373], ["were", 378], ["assessed", 383], [".", 391], ["Forty", 393], ["-", 398], ["seven", 399], ["patients", 405], ["(", 414], ["94", 415], ["%", 417], [")", 418], ["had", 420], ["a", 424], ["ROSIER", 426], ["Score", 433], [">", 439], ["or", 441], ["=", 444], ["1", 445], ["indicating", 447], ["a", 458], ["stroke", 460], [",", 466], ["44", 468], ["(", 471], ["94", 472], ["%", 474], [")", 475], ["of", 477], ["these", 480], ["had", 486], ["stroke", 490], ["confirmed", 497], ["on", 507], ["investigation", 510], [".", 523], ["Two", 525], ["patients", 529], ["with", 538], ["stroke", 543], ["were", 550], ["missed", 555], ["and", 562], ["three", 566], ["were", 572], ["wrongly", 577], ["identified", 585], [".", 595], ["Positive", 597], ["predictive", 606], ["value", 617], ["for", 623], ["the", 627], ["ROSIER", 631], ["was", 638], ["94", 642], ["%", 644], [".", 645], ["ROSIER", 647], ["correlated", 654], ["with", 665], ["Scandinavian", 670], ["neurological", 683], ["stroke", 696], ["score", 703], [".", 708], ["(", 710], ["r", 711], ["=", 713], ["-0.414", 715], [",", 721], ["p", 723], ["=", 725], ["0.003", 727], [")", 732], ["and", 734], ["was", 738], ["associated", 742], ["with", 753], ["increasing", 758], ["length", 769], ["of", 776], ["stay", 779], ["in", 784], ["survivors", 787], ["(", 797], ["p", 798], ["=", 800], ["0.16", 802], [",", 806], ["one", 808], ["-", 811], ["way", 812], ["ANOVA", 816], [".", 821], ["F", 823], ["=", 825], ["3.116", 827], [",", 832], ["df", 834], ["=", 837], ["6", 839], [")", 840], [".", 841], ["The", 843], ["ROSIER", 847], ["is", 854], ["a", 857], ["suitable", 859], ["and", 868], ["useful", 872], ["adjunct", 879], ["in", 887], ["the", 890], ["assessment", 894], ["of", 905], ["stroke", 908], ["patients", 915], ["in", 924], ["Ireland", 927], [".", 934]]}
{"context": "Acrokeratosis paraneoplastica (Bazex' syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil. A distinctive series of changes was found on histopathologic examination of biopsy specimens taken from his skin lesions, and direct immunofluorescence microscopy of both lesional and nonlesional skin specimens showed immunoglobulin and complement deposition on the epidermal basement membrane. The skin lesions largely resolved following radiation therapy of the neoplasm and of the presumably involved lymph nodes.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "a9d9940bee7341a8a218451d58740c07", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[3, 5]], "char_spans": [[31, 45]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastica", 14], ["(", 30], ["Bazex", 31], ["'", 36], ["syndrome", 38], [")", 46], ["is", 48], ["a", 51], ["rare", 53], ["but", 58], ["clinically", 62], ["distinctive", 73], ["dermatosis", 85], ["that", 96], ["has", 101], ["been", 105], ["associated", 110], ["in", 121], ["all", 124], ["reported", 128], ["cases", 137], [",", 142], ["to", 144], ["our", 147], ["knowledge", 151], [",", 160], ["with", 162], ["either", 167], ["a", 174], ["primary", 176], ["malignant", 184], ["neoplasm", 194], ["of", 203], ["the", 206], ["upper", 210], ["aerodigestive", 216], ["tract", 230], ["or", 236], ["metastatic", 239], ["cancer", 250], ["to", 257], ["the", 260], ["lymph", 264], ["nodes", 270], ["of", 276], ["the", 279], ["neck", 283], [".", 287], ["Acrokeratosis", 289], ["paraneoplastica", 303], ["was", 319], ["found", 323], ["in", 329], ["a", 332], ["53-year", 334], ["-", 341], ["old", 342], ["black", 346], ["man", 352], ["with", 356], ["squamous", 361], ["cell", 370], ["carcinoma", 375], ["of", 385], ["the", 388], ["tonsil", 392], [".", 398], ["A", 400], ["distinctive", 402], ["series", 414], ["of", 421], ["changes", 424], ["was", 432], ["found", 436], ["on", 442], ["histopathologic", 445], ["examination", 461], ["of", 473], ["biopsy", 476], ["specimens", 483], ["taken", 493], ["from", 499], ["his", 504], ["skin", 508], ["lesions", 513], [",", 520], ["and", 522], ["direct", 526], ["immunofluorescence", 533], ["microscopy", 552], ["of", 563], ["both", 566], ["lesional", 571], ["and", 580], ["nonlesional", 584], ["skin", 596], ["specimens", 601], ["showed", 611], ["immunoglobulin", 618], ["and", 633], ["complement", 637], ["deposition", 648], ["on", 659], ["the", 662], ["epidermal", 666], ["basement", 676], ["membrane", 685], [".", 693], ["The", 695], ["skin", 699], ["lesions", 704], ["largely", 712], ["resolved", 720], ["following", 729], ["radiation", 739], ["therapy", 749], ["of", 757], ["the", 760], ["neoplasm", 764], ["and", 773], ["of", 777], ["the", 780], ["presumably", 784], ["involved", 795], ["lymph", 804], ["nodes", 810], [".", 815]]}
{"context": "The economic impact of Clostridium difficile infection (CDI) on the healthcare system is significant. From May 2013 to May 2014, an outbreak of C.\u00a0difficile ribotype 027 occurred in a Dutch tertiary care hospital, involving 72 patients. The primary aim of this study was to provide insight into the financial burden that this CDI outbreak brought upon this hospital. A retrospective analysis was performed to estimate the costs of a one-year-long C.\u00a0difficile ribotype 027 outbreak. Medical charts were reviewed for patient data. In addition, all costs associated with the outbreak control measures were collected. The attributable costs of the whole outbreak were estimated to be \u20ac1,222,376. The main contributing factor was missed revenue due to increased length of stay of CDI patients and closure of beds to enable contact isolation of CDI patients (36%). A second important cost component was extra surveillance and activities of the Department of Medical Microbiology and Infection Control (25%). To the authors' knowledge, this is the first study to provide insight into the attributable costs of CDI in an outbreak setting, and to delineate the major cost items. It is clear that the economic consequences of CDI are significant. The high costs associated with a CDI outbreak should help to justify the use of additional resources for CDI prevention and control.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "6158805862de438691239d93f7ce71aa", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[29, 30], [84, 85]], "char_spans": [[157, 168], [460, 471]]}]}], "context_tokens": [["The", 0], ["economic", 4], ["impact", 13], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["infection", 45], ["(", 55], ["CDI", 56], [")", 59], ["on", 61], ["the", 64], ["healthcare", 68], ["system", 79], ["is", 86], ["significant", 89], [".", 100], ["From", 102], ["May", 107], ["2013", 111], ["to", 116], ["May", 119], ["2014", 123], [",", 127], ["an", 129], ["outbreak", 132], ["of", 141], ["C.", 144], ["difficile", 147], ["ribotype", 157], ["027", 166], ["occurred", 170], ["in", 179], ["a", 182], ["Dutch", 184], ["tertiary", 190], ["care", 199], ["hospital", 204], [",", 212], ["involving", 214], ["72", 224], ["patients", 227], [".", 235], ["The", 237], ["primary", 241], ["aim", 249], ["of", 253], ["this", 256], ["study", 261], ["was", 267], ["to", 271], ["provide", 274], ["insight", 282], ["into", 290], ["the", 295], ["financial", 299], ["burden", 309], ["that", 316], ["this", 321], ["CDI", 326], ["outbreak", 330], ["brought", 339], ["upon", 347], ["this", 352], ["hospital", 357], [".", 365], ["A", 367], ["retrospective", 369], ["analysis", 383], ["was", 392], ["performed", 396], ["to", 406], ["estimate", 409], ["the", 418], ["costs", 422], ["of", 428], ["a", 431], ["one", 433], ["-", 436], ["year", 437], ["-", 441], ["long", 442], ["C.", 447], ["difficile", 450], ["ribotype", 460], ["027", 469], ["outbreak", 473], [".", 481], ["Medical", 483], ["charts", 491], ["were", 498], ["reviewed", 503], ["for", 512], ["patient", 516], ["data", 524], [".", 528], ["In", 530], ["addition", 533], [",", 541], ["all", 543], ["costs", 547], ["associated", 553], ["with", 564], ["the", 569], ["outbreak", 573], ["control", 582], ["measures", 590], ["were", 599], ["collected", 604], [".", 613], ["The", 615], ["attributable", 619], ["costs", 632], ["of", 638], ["the", 641], ["whole", 645], ["outbreak", 651], ["were", 660], ["estimated", 665], ["to", 675], ["be", 678], ["\u20ac", 681], ["1,222,376", 682], [".", 691], ["The", 693], ["main", 697], ["contributing", 702], ["factor", 715], ["was", 722], ["missed", 726], ["revenue", 733], ["due", 741], ["to", 745], ["increased", 748], ["length", 758], ["of", 765], ["stay", 768], ["of", 773], ["CDI", 776], ["patients", 780], ["and", 789], ["closure", 793], ["of", 801], ["beds", 804], ["to", 809], ["enable", 812], ["contact", 819], ["isolation", 827], ["of", 837], ["CDI", 840], ["patients", 844], ["(", 853], ["36", 854], ["%", 856], [")", 857], [".", 858], ["A", 860], ["second", 862], ["important", 869], ["cost", 879], ["component", 884], ["was", 894], ["extra", 898], ["surveillance", 904], ["and", 917], ["activities", 921], ["of", 932], ["the", 935], ["Department", 939], ["of", 950], ["Medical", 953], ["Microbiology", 961], ["and", 974], ["Infection", 978], ["Control", 988], ["(", 996], ["25", 997], ["%", 999], [")", 1000], [".", 1001], ["To", 1003], ["the", 1006], ["authors", 1010], ["'", 1017], ["knowledge", 1019], [",", 1028], ["this", 1030], ["is", 1035], ["the", 1038], ["first", 1042], ["study", 1048], ["to", 1054], ["provide", 1057], ["insight", 1065], ["into", 1073], ["the", 1078], ["attributable", 1082], ["costs", 1095], ["of", 1101], ["CDI", 1104], ["in", 1108], ["an", 1111], ["outbreak", 1114], ["setting", 1123], [",", 1130], ["and", 1132], ["to", 1136], ["delineate", 1139], ["the", 1149], ["major", 1153], ["cost", 1159], ["items", 1164], [".", 1169], ["It", 1171], ["is", 1174], ["clear", 1177], ["that", 1183], ["the", 1188], ["economic", 1192], ["consequences", 1201], ["of", 1214], ["CDI", 1217], ["are", 1221], ["significant", 1225], [".", 1236], ["The", 1238], ["high", 1242], ["costs", 1247], ["associated", 1253], ["with", 1264], ["a", 1269], ["CDI", 1271], ["outbreak", 1275], ["should", 1284], ["help", 1291], ["to", 1296], ["justify", 1299], ["the", 1307], ["use", 1311], ["of", 1315], ["additional", 1318], ["resources", 1329], ["for", 1339], ["CDI", 1343], ["prevention", 1347], ["and", 1358], ["control", 1362], [".", 1369]]}
